PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Simpson, PJ; Xie, HF; Bolam, DN; Gilbert, HJ; Williamson, MP				Simpson, PJ; Xie, HF; Bolam, DN; Gilbert, HJ; Williamson, MP			The structural basis for the ligand specificity of family 2 carbohydrate-binding modules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULOMONAS-FIMI; TRYPTOPHAN RESIDUES; PROTEIN STRUCTURES; DOMAIN; XYLANASE	The interactions of proteins with polysaccharides play a key role in the microbial hydrolysis of cellulose and xylan, the most abundant organic molecules in the biosphere, and are thus pivotal to the recycling of photosynthetically fixed carbon. Enzymes that attack these recalcitrant polymers have a modular structure comprising catalytic modules and non-catalytic carbohydrate-binding modules (CBMs). The largest prokaryotic CBM: family, CBM2, contains members that bind cellulose (CBM2a) and xylan (CEM2b), respectively. A possible explanation for the different ligand specificity of CBM2b is that one of the surface tryptophans involved in the protein-carbohydrate interaction is rotated by 90 degrees compared with its position in CBM2a (thus matching the structure of the binding site to the helical secondary structure of xylan), which may be promoted by a single amino acid difference between the two families. Here we show that by mutation of this single residue (Arg-262-->Gly), a CBM2b xylan-binding module completely loses its affinity for xylan and becomes a cellulose-binding module. The structural effect of the mutation has been revealed using NMR spectroscopy, which confirms that Trp-259 rotates 90 degrees to lie flat against the protein surface. Except for this one residue, the mutation only results in minor changes to the structure. The mutated protein interacts with cellulose using the same residues that the wild-type CBM2b uses to interact with xylan, suggesting that the recognition is of the secondary structure of the polysaccharide rather than any specific recognition of the absence or presence of functional groups.	Univ Sheffield, Dept Mol Biol & Biotechnol, Krebs Inst, Sheffield S10 2TN, S Yorkshire, England; Newcastle Univ, Dept Biol & Nutr Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	University of Sheffield; Newcastle University - UK	Williamson, MP (corresponding author), Univ Sheffield, Dept Mol Biol & Biotechnol, Krebs Inst, Firth Court,Western Bank, Sheffield S10 2TN, S Yorkshire, England.	m.williamson@sheffield.ac.uk		Bolam, David/0000-0003-0314-3122; Williamson, Mike/0000-0001-5572-1903				Baxter NJ, 1997, J BIOMOL NMR, V9, P359, DOI 10.1023/A:1018334207887; Black GW, 1996, BIOCHEM J, V319, P515, DOI 10.1042/bj3190515; BLACK GW, 1995, BIOCHEM J, V307, P191, DOI 10.1042/bj3070191; Bolam DN, 1998, BIOCHEM J, V331, P775, DOI 10.1042/bj3310775; Boraston AB, 1999, ROY SOC CH, P202; Bray MR, 1996, PROTEIN SCI, V5, P2311, DOI 10.1002/pro.5560051117; Brett C., 1990, PHYSL BIOCH PLANT CE; Coutinho PM, 1999, ROY SOC CH, P3; Creagh AL, 1996, P NATL ACAD SCI USA, V93, P12229, DOI 10.1073/pnas.93.22.12229; DIN N, 1994, P NATL ACAD SCI USA, V91, P11383, DOI 10.1073/pnas.91.24.11383; DIN N, 1994, MOL MICROBIOL, V11, P747, DOI 10.1111/j.1365-2958.1994.tb00352.x; Dupont C, 1998, BIOCHEM J, V330, P41, DOI 10.1042/bj3300041; GARDNER KH, 1974, BIOPOLYMERS, V13, P1975, DOI 10.1002/bip.1974.360131005; GILKES NR, 1992, J BIOL CHEM, V267, P6743; Gill J, 1999, BIOCHEM J, V342, P473, DOI 10.1042/0264-6021:3420473; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LEMIEUX RU, 1989, CHEM SOC REV, V18, P347, DOI 10.1039/cs9891800347; MILLWARDSADLER SJ, 1994, MOL MICROBIOL, V11, P375, DOI 10.1111/j.1365-2958.1994.tb00317.x; Nagy T, 1998, FEBS LETT, V429, P312, DOI 10.1016/S0014-5793(98)00625-5; NIEDUSZYNSKI IA, 1972, BIOPOLYMERS, V11, P1335, DOI 10.1002/bip.1972.360110703; NILGES M, 1995, J MOL BIOL, V245, P645, DOI 10.1006/jmbi.1994.0053; QUIOCHO FA, 1989, PURE APPL CHEM, V61, P1293, DOI 10.1351/pac198961071293; Simpson PJ, 1999, STRUCTURE, V7, P853, DOI 10.1016/S0969-2126(99)80108-7; Southall SM, 1999, FEBS LETT, V447, P58, DOI 10.1016/S0014-5793(99)00263-X; Tomme P, 1996, BIOCHEMISTRY-US, V35, P13885, DOI 10.1021/bi961185i; Tomme P, 1995, Adv Microb Physiol, V37, P1, DOI 10.1016/S0065-2911(08)60143-5; Tormo J, 1996, EMBO J, V15, P5739, DOI 10.1002/j.1460-2075.1996.tb00960.x; XU GY, 1995, BIOCHEMISTRY-US, V34, P6993, DOI 10.1021/bi00021a011	29	120	125	2	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41137	41142		10.1074/jbc.M006948200	http://dx.doi.org/10.1074/jbc.M006948200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10973978	hybrid			2022-12-25	WOS:000166114600065
J	Temple, CA; Rajagopalan, KV				Temple, CA; Rajagopalan, KV			Mechanism of assembly of the bis(molybdopterin guanine dinucleotide)molybdenum cofactor in Rhodobacter sphaeroides dimethyl sulfoxide reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDENUM-COFACTOR; ESCHERICHIA-COLI; NITRATE REDUCTASE; CRYSTAL-STRUCTURE; MOB LOCUS; GENE-PRODUCT; BIOSYNTHESIS; MOLYBDOPTERIN; NARJ; INVOLVEMENT	A fully defined in vitro system has been developed for studying the mechanism of assembly of the bis(molybdopterin guanine dinucleotide)molybdenum cofactor in Rhodobacter sphaeroides dimethyl sulfoxide reductase (DMSOR). R. sphaeroides DMSOR expressed in a mobA(-) Escherichia coli strain lacks molybdopterin and molybdenum but contains a full complement of guanine in the form of GMP and GDP. Escherichia coli MobA, molybdopterin-Mo, GTP, and MgCl2, are required and sufficient for the in vitro activation of purified DMSOR expressed in the absence of MobA High levels of MobA inhibit the in vitro activation. A chaperone is not required for the in vitro activation process. The reconstituted DMSOR can exhibit up to 73% of the activity observed in recombinant DMSOR purified from a wildtype strain. The use of radiolabeled GTP has demonstrated incorporation of the guanine moiety from the GTP into the activated DMSOR. No role was observed for E. coli MobB in the in vitro activation of apo-DMSOR. This work also represents the first time that the MobA-mediated conversion of molybdopterin to molybdopterin guanine dinucleotide has been demonstrated directly without using the activation of a molybdoenzyme as an indicator for cofactor formation.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Rajagopalan, KV (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raj@biochem.duke.edu			NIGMS NIH HHS [GM00091] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blasco F, 1998, MOL MICROBIOL, V28, P435, DOI 10.1046/j.1365-2958.1998.00795.x; BLASCO F, 1992, MOL MICROBIOL, V6, P221, DOI 10.1111/j.1365-2958.1992.tb02003.x; Czjzek M, 1998, J MOL BIOL, V284, P435, DOI 10.1006/jmbi.1998.2156; Dias JM, 1999, STRUCTURE, V7, P65, DOI 10.1016/S0969-2126(99)80010-0; Eaves DJ, 1997, EUR J BIOCHEM, V246, P690, DOI 10.1111/j.1432-1033.1997.t01-1-00690.x; Garton SD, 1997, J AM CHEM SOC, V119, P12906, DOI 10.1021/ja972109l; George GN, 1999, J AM CHEM SOC, V121, P1256, DOI 10.1021/ja982843k; Hanzelmann P, 1998, EUR J BIOCHEM, V255, P755, DOI 10.1046/j.1432-1327.1998.2550755.x; Hilton JC, 1999, J BIOL CHEM, V274, P8428, DOI 10.1074/jbc.274.13.8428; Hilton JC, 1996, ARCH BIOCHEM BIOPHYS, V325, P139, DOI 10.1006/abbi.1996.0017; HUNGKEI L, 2000, J AM CHEM SOC, V122, P7673; IOBBINIVOL C, 1995, MICROBIOL-SGM, V141, P1663; JOHNSON JL, 1991, J BIOL CHEM, V266, P12140; Kisker C, 1997, ANNU REV BIOCHEM, V66, P233, DOI 10.1146/annurev.biochem.66.1.233; Lake MW, 2000, J BIOL CHEM, V275, P40211, DOI 10.1074/jbc.M007406200; McAlpine AS, 1998, J MOL BIOL, V275, P613, DOI 10.1006/jmbi.1997.1513; Mouncey NJ, 1997, J BACTERIOL, V179, P7617, DOI 10.1128/jb.179.24.7617-7624.1997; NGUYEN BT, 1986, BIOCHEM J, V234, P263, DOI 10.1042/bj2340263; Palmer T, 1996, MOL MICROBIOL, V20, P875, DOI 10.1111/j.1365-2958.1996.tb02525.x; Palmer T, 1998, BBA-GENE STRUCT EXPR, V1395, P135, DOI 10.1016/S0167-4781(97)00145-0; PALMER T, 1994, EUR J BIOCHEM, V222, P687, DOI 10.1111/j.1432-1033.1994.tb18913.x; PLUNKETT G, 1993, NUCLEIC ACIDS RES, V21, P3391, DOI 10.1093/nar/21.15.3391; Rajagopalan KV, 1996, ESCHERICHIA COLI SAL, P674; ROTHERY RA, 1995, J BACTERIOL, V177, P2057, DOI 10.1128/jb.177.8.2057-2063.1995; Rothery RA, 1998, J BIOL CHEM, V273, P7462, DOI 10.1074/jbc.273.13.7462; SANTINI CL, 1992, J BACTERIOL, V174, P7934, DOI 10.1128/JB.174.24.7934-7940.1992; Schindelin H, 1996, SCIENCE, V272, P1615, DOI 10.1126/science.272.5268.1615; Schwarz G, 1997, J BIOL CHEM, V272, P26811, DOI 10.1074/jbc.272.43.26811; TEMPLE C, 2000, IN PRESS ARCH BIOCH; Temple CA, 2000, BIOCHEMISTRY-US, V39, P4046, DOI 10.1021/bi9921541; Ujiiye T, 1996, BBA-BIOENERGETICS, V1277, P1, DOI 10.1016/S0005-2728(96)00101-6	31	55	58	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40202	40210		10.1074/jbc.M007407200	http://dx.doi.org/10.1074/jbc.M007407200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10978348	hybrid			2022-12-25	WOS:000166039500057
J	Zhou, JJ; Trueman, LJ; Boorer, KJ; Theodoulou, FL; Forde, BG; Miller, AJ				Zhou, JJ; Trueman, LJ; Boorer, KJ; Theodoulou, FL; Forde, BG; Miller, AJ			A high affinity fungal nitrate carrier with two transport mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPERGILLUS-NIDULANS; CHLAMYDOMONAS-REINHARDTII; XENOPUS-OOCYTES; MEMBRANE VOLTAGE; COTRANSPORTER; SYSTEMS; PH; KINETICS; NITRITE; CLONING	We have expressed the CRNA high affinity nitrate transporter from Emericella (Aspergillus) nidulans in Xenopus oocytes and used electrophysiology to study its properties. This method was used because there are no convenient radiolabeled substrates for the transporter. Oocytes injected with crnA mRNA showed nitrate-, nitrite-, and chlorite-dependent currents. Although the gene was originally identified by chlorate selection there was no evidence for transport of this anion, The gene selection is explained by the high affinity of the transporter for chlorite, and the fact that this ion contaminates solutions of chlorate, The pH-dependence of the anion-elicited currents was consistent with H+-coupled mechanism of transport. At any given voltage, currents showed hyperbolic kinetics with respect to extracellular H+, and these data could be fitted with a Michaelis-Menten relationship. But this equation did not adequately describe transport of the anion substrates, At higher concentrations of the anion substrates and more negative membrane voltages, the currents were decreased, but this effect was independent of changes in external pH, These more complicated kinetics could be fit by an equation containing two Michaelis-Menten terms. The substrate inhibition of the currents could be explained by a transport reaction cycle that included two routes for the transfer of nitrate across the membrane, one on the empty carrier and the other proton coupled. The model predicts that the substrate inhibition of transporter current depends on the cytosolic nitrate concentration. This is the first time a high affinity nitrate transport activity has been characterized in a heterologous system and the measurements show how the properties of the CRNA transporter are modified by changes in the membrane potential, external pH, and nitrate concentration. The physiological significance of these observations is discussed.	IACR, Biochem & Physiol Dept, Harpenden AL5 2JQ, Herts, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research	Miller, AJ (corresponding author), IACR, Biochem & Physiol Dept, Harpenden AL5 2JQ, Herts, England.		Miller, Anthony John/B-5139-2008; Forde, Brian G/C-6554-2009	Miller, Anthony John/0000-0003-0572-7607; Forde, Brian G/0000-0001-7973-7280; Theodoulou, Frederica/0000-0002-8306-0716				Blatt MR, 1997, J MEMBRANE BIOL, V160, P59, DOI 10.1007/s002329900295; BOORER KJ, 1994, J BIOL CHEM, V269, P20417; BROWNLEE AG, 1983, J BACTERIOL, V155, P1138, DOI 10.1128/JB.155.3.1138-1146.1983; Chow CW, 1997, J GEN PHYSIOL, V110, P185, DOI 10.1085/jgp.110.2.185; DOWNEY RJ, 1994, MICROBIOS, V78, P35; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; EDDY AA, 1985, BIOCHEM J, V231, P291, DOI 10.1042/bj2310291; Forde BG, 2000, BBA-BIOMEMBRANES, V1465, P219, DOI 10.1016/S0005-2736(00)00140-1; Galvan A, 1996, J BIOL CHEM, V271, P2088, DOI 10.1074/jbc.271.4.2088; GOLDSMITH J, 1973, PLANT PHYSIOL, V52, P362, DOI 10.1104/pp.52.4.362; MEHARG AA, 1995, J MEMBRANE BIOL, V145, P49; PARENT L, 1992, J MEMBRANE BIOL, V125, P9; PARKER I, 1988, PROC R SOC SER B-BIO, V233, P191, DOI 10.1098/rspb.1988.0018; Perez MD, 1997, BIOCHEM J, V321, P397, DOI 10.1042/bj3210397; POMBEIRO SRC, 1983, GENET RES, V41, P203, DOI 10.1017/S0016672300021224; POMBEIRO SRC, 1992, WORLD J MICROB BIOT, V8, P477, DOI 10.1007/BF01201943; QUESADA A, 1994, PLANT J, V5, P407, DOI 10.1111/j.1365-313X.1994.00407.x; Sambrook J., 2002, MOL CLONING LAB MANU; SANDERS D, 1986, J MEMBRANE BIOL, V90, P67, DOI 10.1007/BF01869687; SCHLOEME.RH, 1974, J BACTERIOL, V118, P259, DOI 10.1128/JB.118.1.259-269.1974; SCHLOEME.RH, 1974, J BACTERIOL, V118, P270, DOI 10.1128/JB.118.1.270-274.1974; SLOAN C. H., 1966, TOBACCO SCI, V10, P121; TOMSETT AB, 1979, GENET RES, V34, P19, DOI 10.1017/S001667230001925X; Trueman LJ, 1996, GENE, V175, P223, DOI 10.1016/0378-1119(96)00154-0; TSAY YF, 1993, CELL, V72, P705, DOI 10.1016/0092-8674(93)90399-B; UNKLES SE, 1991, P NATL ACAD SCI USA, V88, P204, DOI 10.1073/pnas.88.1.204; van der Leij M, 1998, PLANTA, V205, P64, DOI 10.1007/s004250050297; YU L, 1989, J BIOL CHEM, V264, P20847; Zhou JJ, 1998, J BIOL CHEM, V273, P12017, DOI 10.1074/jbc.273.20.12017; Zhou JJ, 1997, J MEMBRANE BIOL, V159, P113, DOI 10.1007/s002329900275; Zhou JJ, 2000, FEBS LETT, V466, P225, DOI 10.1016/S0014-5793(00)01085-1	31	51	56	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39894	39899		10.1074/jbc.M004610200	http://dx.doi.org/10.1074/jbc.M004610200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10984478	hybrid			2022-12-25	WOS:000166039500016
J	Fujise, K; Zhang, D; Liu, JL; Yeh, ETH				Fujise, K; Zhang, D; Liu, JL; Yeh, ETH			Regulation of apoptosis and cell cycle progression by MCL1 - Differential role of proliferating cell nuclear antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE PROTEIN-KINASES; DNA POLYMERASE-DELTA; DEPENDENT KINASES; REPLICATION FORK; HUMAN P53; LIGASE-I; PCNA; GENE; EXPRESSION; BINDING	MCL1 (ML1 myeloid cell leukemia 1), a Bcl-2 (B-cell lymphoma-leukemia 2) homologue, is known to function as an anti-apoptotic protein. Here we show in vitro and in vivo that MCL1 interacts with the cell cycle regulator, proliferating cell nuclear antigen (PCNA). This finding prompted us to investigate whether MCL1, in addition to its anti-apoptotic function, has an effect on cell cycle progression. A bromodeoxyuridine uptake assay showed that the overexpression of MCL1 significantly inhibited the cell cycle progression through the S-phase. The S-phase of the cell cycle is also known to be regulated by PCNA. A mutant of MCL1 that lacks PCNA binding (MCL1(Delta 4A)) could not inhibit cell cycle progression as effectively as wild type MCL1. In contrast, MCL1(Delta 4A) retained its anti-apoptotic function in HeLa cells when challenged by Etoposide. In addition, the intracellular localization of MCL1(Delta 4A) was identical to that of wild type MCL1. An in vitro pull-down assay suggested that MCL1 is the only Bcl-2 family protein to interact with PCNA. In fact, MCL1, not other Bcl-2 family proteins, contained the PCNA-binding motif described previously. Taken together, MCL1 is a regulator of both apoptosis and cell cycle progression, and the cell cycle regulatory function of MCL1 is mediated through its interaction with PCNA.	Univ Texas, MD Anderson Canc Ctr, Res Ctr Cardiovasc Dis, Inst Mol Med Prevent Human Dis, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Internal Med, Div Cardiol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Internal Med, Div Mol Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Fujise, K (corresponding author), 6431 Fannin St,Suite 4200, Houston, TX 77030 USA.				NHLBI NIH HHS [1KO8 HL04015-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004015] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Ausubel FM, 1998, CURRENT PROTOCOLS MO; BAI C, 1994, EMBO J, V13, P6087, DOI 10.1002/j.1460-2075.1994.tb06955.x; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BRAVO R, 1986, EXP CELL RES, V163, P287, DOI 10.1016/0014-4827(86)90059-5; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; *CLONTECH, 1997, YEAST HDB, P30; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DOU QP, 1992, P NATL ACAD SCI USA, V89, P3256, DOI 10.1073/pnas.89.8.3256; Eichinger L, 1998, J BIOL CHEM, V273, P12952, DOI 10.1074/jbc.273.21.12952; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Gary R, 1997, J BIOL CHEM, V272, P24522, DOI 10.1074/jbc.272.39.24522; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; Horne MC, 1996, J BIOL CHEM, V271, P6050, DOI 10.1074/jbc.271.11.6050; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; JIANG YQ, 1995, ARCH BIOCHEM BIOPHYS, V320, P297, DOI 10.1016/0003-9861(95)90013-6; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Liu JL, 1999, J VIROL, V73, P4208, DOI 10.1128/JVI.73.5.4208-4219.1999; MIYASHITA T, 1995, CELL, V80, P293; Montecucco A, 1998, EMBO J, V17, P3786, DOI 10.1093/emboj/17.13.3786; MURO Y, 1994, J BIOL CHEM, V269, P18529; NAKAMURA T, 1995, EXP CELL RES, V221, P534, DOI 10.1006/excr.1995.1406; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Reynolds JE, 1996, EXP CELL RES, V225, P430, DOI 10.1006/excr.1996.0194; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SALA A, 1994, CANCER RES, V54, P1402; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; Zhan QM, 1997, ONCOGENE, V14, P1031, DOI 10.1038/sj.onc.1200927	52	138	149	7	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39458	39465		10.1074/jbc.M006626200	http://dx.doi.org/10.1074/jbc.M006626200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10978339	hybrid			2022-12-25	WOS:000165953100071
J	Leppanen, A; White, SP; Helin, J; McEver, RP; Cummings, RD				Leppanen, A; White, SP; Helin, J; McEver, RP; Cummings, RD			Binding of glycosulfopeptides to P-selectin requires stereospecific contributions of individual tyrosine sulfate and sugar residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLID-PHASE SYNTHESIS; GLYCOPROTEIN LIGAND-1; CARBOHYDRATE INTERACTIONS; AMINO-TERMINUS; GMP-140 BINDS; ADHESION; PSGL-1; NEUTROPHILS; OLIGOSACCHARIDES; COUNTERRECEPTOR	P-selectin glycoprotein ligand-l (PSGL-1) is a mucin on leukocytes that binds to selectins. P-selectin binds to an N-terminal region of PSGL-1 that requires sulfation of at least one of three clustered tyrosines (TyrSO(3)) and an adjacent core-2-based O-glycan expressing sialyl Lewis x (C2-O-sLe(x)). We synthesized glycosulfopeptides (GSPs) modeled after this region of PSGL-1 to explore the roles of individual TyrSO(3) residues, the placement of C2-O-sLe(x) relative to TyrSO(3), the relative contributions of fucose and sialic acid on C2-O-sLe(x), and the function of the peptide sequence for binding to P-selectin. Binding of GSPs to P-selectin was measured by affinity chromatography and equilibrium gel filtration. 2-GSP-6, which has C2-O-sLe(x) at Thr-57 and TyrSO(3) at residues 46, 48, and 51, bound to P-selectin with high affinity (K-d similar to 650 nm), whereas an isomeric trisulfated GSP containing C2-O-sLe(x) at Thr-44 bound much less well. Non-sulfated glycopeptide (2-GP-6) containing C2-O-sLe(x) at Thr-57 bound to P-selectin with similar to 40-fold lower affinity (K(d)similar to 25 mum). Proteolysis of 2-GP-6 abolished detectable binding of the residual C2-O-sLe(x)-Thr to P-selectin, demonstrating that the peptide backbone contributes to binding. Monosulfated and disulfated GSPs bound significantly better than non-sulfated 2-GP-6, but sulfation of Tyr-48 enhanced affinity (K-d similar to 6 mum) more than sulfation of Tyr-46 or Tyr-51. 2-GSP-6 lacking sialic acid bound to P-selectin at similar to 10% that of the level of the parent 2-GSP-6, whereas 2-GSP-6 lacking fucose did not detectably bind; thus, fucose contributes more than sialic acid to binding. Reducing NaCl from 150 to 50 mm markedly enhanced binding of 2-GSP-6 to P-selectin (K-d similar to 75 nm), demonstrating the charge dependence of the interaction. These results reveal a stereospecific interaction of P-selectin with PSGL-1 that includes distinct contributions of each of the three TyrSO(3) residues, adjacent peptide determinants, and fucose/sialic acid on an optimally positioned core-2 O-glycan.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, WK Warren Med Res Inst, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK 73104 USA; Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA; Univ Helsinki, Inst Biotechnol, Helsinki 00014, Finland	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation; Oklahoma State University System; Oklahoma State University - Stillwater; University of Helsinki	Cummings, RD (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, 975 NE 10th St,BRC417, Oklahoma City, OK 73104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054804] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL 54804] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ackers G K, 1973, Methods Enzymol, V27, P441; BAJORATH J, 1994, BIOCHEMISTRY-US, V33, P1332, DOI 10.1021/bi00172a007; Borges E, 1997, BLOOD, V90, P1934, DOI 10.1182/blood.V90.5.1934; Cummings RD, 1999, BRAZ J MED BIOL RES, V32, P519, DOI 10.1590/S0100-879X1999000500004; CUMMINGS RD, 1999, ESSENTIALS GLYCOBIOL, P391; Epperson TR, 2000, J BIOL CHEM, V275, P7839, DOI 10.1074/jbc.275.11.7839; ERBE DV, 1993, J CELL BIOL, V120, P1227, DOI 10.1083/jcb.120.5.1227; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; HOLLENBAUGH D, 1995, BIOCHEMISTRY-US, V34, P5678, DOI 10.1021/bi00016a044; HOLLENBAUGH D, 1993, BIOCHEMISTRY-US, V32, P2960, DOI 10.1021/bi00063a006; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; Jain RK, 1998, GLYCOBIOLOGY, V8, P707, DOI 10.1093/glycob/8.7.707; KITAGAWA K, 1994, INT J PEPT PROT RES, V43, P190; Kitagawa K, 1997, TETRAHEDRON LETT, V38, P599, DOI 10.1016/S0040-4039(96)02401-X; Koenig A, 1998, J CLIN INVEST, V101, P877, DOI 10.1172/JCI1509; Koenig A, 1997, GLYCOBIOLOGY, V7, P79, DOI 10.1093/glycob/7.1.79; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LARSEN GR, 1992, J BIOL CHEM, V267, P11104; Leppanen A, 1999, J BIOL CHEM, V274, P24838, DOI 10.1074/jbc.274.35.24838; Li FG, 1996, J BIOL CHEM, V271, P6342, DOI 10.1074/jbc.271.11.6342; Liu W, 1998, J BIOL CHEM, V273, P7078, DOI 10.1074/jbc.273.12.7078; Liu Y, 2000, J EXP MED, V191, P1105, DOI 10.1084/jem.191.7.1105; McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556; McEver RP, 1997, GLYCOCONJUGATE J, V14, P585, DOI 10.1023/A:1018584425879; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; Mehta P, 1998, J BIOL CHEM, V273, P32506, DOI 10.1074/jbc.273.49.32506; Moore KL, 1998, LEUKEMIA LYMPHOMA, V29, P1, DOI 10.3109/10428199809058377; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; Ng KKS, 1997, BIOCHEMISTRY-US, V36, P979, DOI 10.1021/bi962564e; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; Ramachandran V, 1999, P NATL ACAD SCI USA, V96, P13771, DOI 10.1073/pnas.96.24.13771; Romo GM, 1999, J EXP MED, V190, P803, DOI 10.1084/jem.190.6.803; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; Torgersen D, 1998, J BIOL CHEM, V273, P6254, DOI 10.1074/jbc.273.11.6254; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229; Yang J, 1999, THROMB HAEMOSTASIS, V81, P1; Yang J, 1996, BLOOD, V87, P4176, DOI 10.1182/blood.V87.10.4176.bloodjournal87104176; Yang J, 1999, J EXP MED, V190, P1769, DOI 10.1084/jem.190.12.1769; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	41	172	177	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39569	39578		10.1074/jbc.M005005200	http://dx.doi.org/10.1074/jbc.M005005200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10978329	hybrid			2022-12-25	WOS:000165953100083
J	Bonham, K; Ritchie, SA; Dehm, SM; Snyder, K; Boyd, FM				Bonham, K; Ritchie, SA; Dehm, SM; Snyder, K; Boyd, FM			An alternative, human SRC promoter and its regulation by hepatic nuclear factor-1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; ENRICHED TRANSCRIPTION FACTORS; PP60C-SRC PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; TUMOR-NECROSIS-FACTOR; C-SRC; GENE-EXPRESSION; EARLY EVENT; CELL-LINE; ACTIVATION	The SRC gene encodes the proto-oncogene pp60(c-src), a tyrosine kinase implicated in numerous signal transduction pathways. In addition, the SRC gene is differentially expressed, developmentally regulated, and frequently overexpressed in human neoplasia. However, the mechanisms regulating its expression have not been completely explored. Here we describe the isolation of a new distal SRC promoter and associated exon, designated 1 alpha, which we mapped to a position 1.0 kilobase upstream of the previously described SRC1A housekeeping promoter. Differential use of these promoters and their associated exons coupled with subsequent splicing to a common downstream exon results in c-Src transcripts with different 5' ends but identical coding regions. Promoter analysis following transient transfections into HepG2 cells mapped the minimal 1 alpha promoter to a region 145 bp upstream of the major transcription start site. This region contained a consensus binding site for hepatic nuclear factor-1 (HNF-1), a liver-enriched transcription factor implicated in the regulation of a number of genes in liver, kidney, stomach, intestine, and pancreas. Subsequent mobility shift assays confirmed that HNF-1 alpha isoform was the predominant factor interacting with this region of the promoter. Mutation of the HNF-1 site resulted in a dramatic reduction in SRC promoter activity. Cotransfection studies demonstrated the promoter could be strongly transactivated by the HNF-1 alpha isoform but not by the related HNF-1 beta factor. Consistent with these results, we demonstrated that transcripts originating from the SRC1 alpha promoter display a tissue restricted pattern of expression with highest levels present in stomach, kidney, and pancreas. These results indicate that SRC transcriptional regulation is much more complex than previously realized and implicates HNF-1 in both the tissue-specific regulation of the SRC gene in normal tissues and the overexpression of c-Src in certain human cancers.	Univ Saskatchewan, Hlth Res Div, Canc Res Unit, Saskatchewan Canc Agcy, Saskatoon, SK S7N 4H4, Canada; Univ Saskatchewan, Div Oncol, Saskatoon, SK S7N 4H4, Canada; Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5E5, Canada	University of Saskatchewan; University of Saskatchewan; University of Saskatchewan	Bonham, K (corresponding author), Univ Saskatchewan, Hlth Res Div, Canc Res Unit, Saskatchewan Canc Agcy, 20 Campus Dr, Saskatoon, SK S7N 4H4, Canada.	kbonhamA@scf.sk.ca						AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679; ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; BAUMHUETER S, 1988, EMBO J, V7, P2485, DOI 10.1002/j.1460-2075.1988.tb03095.x; Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; BLUMENFELD M, 1991, DEVELOPMENT, V113, P589; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BONHAM K, 1993, ONCOGENE, V8, P1973; CARTWRIGHT CA, 1993, ONCOGENE, V8, P1033; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; CHAKRABORTY M, 1993, BRAIN RES, V625, P197, DOI 10.1016/0006-8993(93)91059-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coffinier C, 1999, DEVELOPMENT, V126, P4785; Coffinier C, 1999, MECH DEVELOP, V89, P211, DOI 10.1016/S0925-4773(99)00221-X; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; GEE CE, 1986, P NATL ACAD SCI USA, V83, P5131, DOI 10.1073/pnas.83.14.5131; Hayashi Y, 1999, J CLIN PATHOL-MOL PA, V52, P19; Higuchi Y, 1999, BONE, V25, P17, DOI 10.1016/S8756-3282(99)00103-9; Hochman JA, 1997, AM J PHYSIOL-GASTR L, V273, pG833, DOI 10.1152/ajpgi.1997.273.4.G833; Hu CB, 1999, AM J PHYSIOL-GASTR L, V276, pG1181, DOI 10.1152/ajpgi.1999.276.5.G1181; Iravani S, 1998, LAB INVEST, V78, P365; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Lin BC, 1997, BIOCHEMISTRY-US, V36, P14096, DOI 10.1021/bi9703249; LIN PH, 1995, ONCOGENE, V10, P401; Lutz MP, 1998, BIOCHEM BIOPH RES CO, V243, P503, DOI 10.1006/bbrc.1997.8043; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Masaki T, 1998, HEPATOLOGY, V27, P1257, DOI 10.1002/hep.510270511; MAZURENKO NN, 1992, EUR J CANCER, V28A, P372, DOI 10.1016/S0959-8049(05)80056-5; MELLSTROM K, 1987, MOL CELL BIOL, V7, P4178, DOI 10.1128/MCB.7.12.4178; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; OTT MO, 1991, MECH DEVELOP, V36, P47, DOI 10.1016/0925-4773(91)90071-D; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PARK JS, 1993, ONCOGENE, V8, P2627; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; Ritchie S, 2000, J BIOL CHEM, V275, P847, DOI 10.1074/jbc.275.2.847; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; SERFAS MS, 1993, AM J PHYSIOL, V265, pG506, DOI 10.1152/ajpgi.1993.265.3.G506; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SORIO C, 1993, FEBS LETT, V327, P315, DOI 10.1016/0014-5793(93)81012-O; Staley CA, 1997, CELL GROWTH DIFFER, V8, P269; TAKADERA T, 1989, MOL CELL BIOL, V9, P2173, DOI 10.1128/MCB.9.5.2173; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TRONCHE F, 1992, BIOESSAYS, V14, P579, DOI 10.1002/bies.950140902; Tsuganezawa H, 1998, KIDNEY INT, V54, P394, DOI 10.1046/j.1523-1755.1998.00029.x; VALLET V, 1995, EXP CELL RES, V216, P363, DOI 10.1006/excr.1995.1046; Verbeek BS, 1996, J PATHOL, V180, P383, DOI 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N; Visser CJT, 1996, LAB INVEST, V74, P2; Wang WP, 1998, J PATHOL, V184, P272, DOI 10.1002/(SICI)1096-9896(199803)184:3<272::AID-PATH4>3.0.CO;2-K; WEBER TK, 1992, J CLIN INVEST, V90, P815, DOI 10.1172/JCI115956; Wiener JR, 1999, CLIN CANCER RES, V5, P2164	54	35	41	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37604	37611		10.1074/jbc.M004882200	http://dx.doi.org/10.1074/jbc.M004882200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10978326	hybrid			2022-12-25	WOS:000165618700042
J	Fridmann, Y; Ulitzur, S; Horovitz, A				Fridmann, Y; Ulitzur, S; Horovitz, A			In vivo and in vitro function of GroEL mutants with impaired allosteric properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOMERIC CHAPERONIN GROEL; ESCHERICHIA-COLI; MOLECULAR CHAPERONE; CRYSTAL-STRUCTURE; INTERRING COMMUNICATION; VIBRIO-FISCHERI; ATP HYDROLYSIS; PROTEIN; BINDING; HEAD	Escherichia coli cells that produce only plasmid-encoded wild-type or mutant GroEL were generated by bacteriophage P1 transduction. Effects of mutations that affect the allosteric properties of GroEL were characterized in vivo. Cells containing only GroEL(R197A), which has reduced intra-ring positive cooperativity and inter-ring negative cooperativity in ATP binding, grow poorly upon a temperature shift from 25 to 42 degreesC. This strain supports the growth of phages T4 and T5 but not phage lambda and produces light at 28 degreesC when transformed with a second plasmid containing the lux operon. In contrast, cells containing only GroEL(R13G, A126V) which lacks negative cooperativity between rings but has intact intra-ring positive cooperativity grow normally and support phage growth but do not produce light at 28 degreesC. In vitro refolding of luciferase in the presence of this mutant is found to be less efficient compared with wild-type GroEL or other mutants tested. Our results show that allostery in GroEL is important in vivo in a manner that depends on the physiological conditions and is protein substrate specific.	Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel; Technion Israel Inst Technol, Dept Food Engn & Biotechnol, IL-32000 Haifa, Israel	Weizmann Institute of Science; Technion Israel Institute of Technology	Horovitz, A (corresponding author), Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel.	Amnon.Horovitz@weizmann.ac.il						ADAR YY, 1993, J BIOLUM CHEMILUM, V8, P261, DOI 10.1002/bio.1170080506; Aharoni A, 1996, J MOL BIOL, V258, P732, DOI 10.1006/jmbi.1996.0282; Aharoni A, 1997, P NATL ACAD SCI USA, V94, P1698, DOI 10.1073/pnas.94.5.1698; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Chatellier J, 1998, P NATL ACAD SCI USA, V95, P9861, DOI 10.1073/pnas.95.17.9861; DOLAN KM, 1992, J BACTERIOL, V174, P5132, DOI 10.1128/JB.174.15.5132-5135.1992; Ellis R. John, 1999, Current Opinion in Structural Biology, V9, P102, DOI 10.1016/S0959-440X(99)80013-X; Fedorov AN, 1997, J MOL BIOL, V268, P712, DOI 10.1006/jmbi.1997.1007; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HOROVITZ A, 1993, J BIOL CHEM, V268, P9957; HOROVITZ A, 1993, J MOL BIOL, V231, P58, DOI 10.1006/jmbi.1993.1256; Horovitz A, 1998, CURR OPIN STRUC BIOL, V8, P93, DOI 10.1016/S0959-440X(98)80015-8; Houry WA, 1999, NATURE, V402, P147, DOI 10.1038/45977; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; Inbar E, 1997, BIOCHEMISTRY-US, V36, P12276, DOI 10.1021/bi9714870; Ivic A, 1997, GENE, V194, P1, DOI 10.1016/S0378-1119(97)00087-5; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; LAEMMLI UK, 1970, J MOL BIOL, V47, P69, DOI 10.1016/0022-2836(70)90402-X; Llorca O, 1997, J BIOL CHEM, V272, P32925, DOI 10.1074/jbc.272.52.32925; MEIGHEN EA, 1971, J BIOL CHEM, V246, P7666; Ranson NA, 1998, BIOCHEM J, V333, P233, DOI 10.1042/bj3330233; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; STERNBERG N, 1973, J MOL BIOL, V76, P25, DOI 10.1016/0022-2836(73)90079-X; ULITZUR S, 1995, PHOTOCHEM PHOTOBIOL, V62, P625, DOI 10.1111/j.1751-1097.1995.tb08709.x; ULITZUR S, 1987, BIOLUMINESCENCE CHEM, P381; VANDERVIES SM, 1994, NATURE, V368, P654, DOI 10.1038/368654a0; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; Wang JD, 1998, P NATL ACAD SCI USA, V95, P12163, DOI 10.1073/pnas.95.21.12163; Weber F, 1998, NAT STRUCT BIOL, V5, P977, DOI 10.1038/2952; WHITE ZW, 1995, J BIOL CHEM, V270, P20404, DOI 10.1074/jbc.270.35.20404; YIFRACH O, 1994, J MOL BIOL, V243, P397, DOI 10.1006/jmbi.1994.1667; YIFRACH O, 1995, BIOCHEMISTRY-US, V34, P5303, DOI 10.1021/bi00016a001; Yifrach O, 2000, P NATL ACAD SCI USA, V97, P1521, DOI 10.1073/pnas.040449997; ZWEIG M, 1973, J MOL BIOL, V80, P505, DOI 10.1016/0022-2836(73)90418-X	40	12	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37951	37956		10.1074/jbc.M007594200	http://dx.doi.org/10.1074/jbc.M007594200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10973985	hybrid			2022-12-25	WOS:000165618700087
J	Hahn, A; Heusinger-Ribeiro, J; Lanz, T; Zenkel, S; Goppelt-Struebe, M				Hahn, A; Heusinger-Ribeiro, J; Lanz, T; Zenkel, S; Goppelt-Struebe, M			Induction of connective tissue growth factor by activation of heptahelical receptors - Modulation by Rho proteins and the actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT MESANGIAL CELLS; PROSTAGLANDIN G/H SYNTHASE-2; LYSOPHOSPHATIDIC ACID; ENDOTHELIAL-CELLS; FACTOR GENE; EXPRESSION; KINASE; SEROTONIN; FAMILY; IDENTIFICATION	Expression of connective tissue growth factor (CTGF) was induced in renal mesangial cells by activation of heptahelical receptors by serotonin (5-HT) and lysophosphatidic acid (LPA), Induction of CTGF mRNA was transient with maximal expression after I to 2 h, whereas induction of CTGF by transforming growth factor beta (TGF-beta) increased over time, In contrast to the induction of other early response genes (Egr-1 and cyclooxygenase-2), LPA-mediated induction of CTGF was pertussis toxin-insensitive and independent of p42/44 MAP kinase activation. B-HT-mediated CTGF induction was due to activation of 5-HT2A receptors and likewise independent of p42/44 MAP kinase activation. Upon stimulation, enhanced levels of CTGF protein were detected in cellular homogenates, whereas no protein was detectable in cell culture supernatants, Inhibition of proteins of the Rho family by toxin B abrogated basal as well as CTGF expression stimulated by LPA, 5-HT, and TGF-beta. Inhibition of the downstream mediator of RhoA, the Rho kinase by Y-27632 partially reduced induction of CTGF by LPA and TGF-beta. Toxin B not only affected gene expression, but disrupted the actin cytoskeleton similarly as observed after treatment with cytochalasin D, Disassembly of actin stress fibers by cytochalasin D partially reduced basal and stimulated CTGF expression. These data indicate that an intact actin cytoskeleton is critical for the expression of CTGF, Elimination of the input of Rho proteins by toxin B, however, was significantly more effective and their effect on CTGF expression thus goes beyond disruption of the cytoskeleton. These findings thus establish activation of heptahelical receptors coupled to pertussis toxin-insensitive G:proteins as a novel signaling pathway to induce CTGF. Proteins of the Rho family and an intact cytoskeleton were identified as critical determinants of CTGF expression induced by LPA and 5-HT, and also by TGF-beta.	Univ Erlangen Nurnberg, Med Klin 4, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Goppelt-Struebe, M (corresponding author), Univ Erlangen Nurnberg, Med Klin 4, Loschgestr 8, D-91054 Erlangen, Germany.	Goppelt-Struebe@rzmail.uni-erlangen.de						Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Boes M, 1999, ENDOCRINOLOGY, V140, P1575, DOI 10.1210/en.140.4.1575; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brigstock DR, 1997, J BIOL CHEM, V272, P20275, DOI 10.1074/jbc.272.32.20275; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cook SJ, 1999, MOL CELL BIOL, V19, P330; Dammeier J, 1998, J BIOL CHEM, V273, P18185, DOI 10.1074/jbc.273.29.18185; Dammeier J, 1998, INT J BIOCHEM CELL B, V30, P909, DOI 10.1016/S1357-2725(98)00046-6; DEWITT DL, 1993, ARCH BIOCHEM BIOPHYS, V306, P94, DOI 10.1006/abbi.1993.1485; Dong JM, 1998, J BIOL CHEM, V273, P22554, DOI 10.1074/jbc.273.35.22554; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Essig M, 1998, CIRC RES, V83, P683, DOI 10.1161/01.RES.83.7.683; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Gaits F, 1997, KIDNEY INT, V51, P1022, DOI 10.1038/ki.1997.143; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; GOOPELSTRUEBE M, 2000, BIOCH J 1, V349, P217; Goppelt-Struebe M, 1998, J CELL PHYSIOL, V175, P341, DOI 10.1002/(SICI)1097-4652(199806)175:3<341::AID-JCP12>3.0.CO;2-8; Goppelt-Struebe M, 1999, BIOCHEM J, V339, P329, DOI 10.1042/0264-6021:3390329; GoppeltStruebe M, 1997, N-S ARCH PHARMACOL, V356, P240, DOI 10.1007/PL00005047; GOPPELTSTRUEBE M, 1995, PROSTAG LEUKOTR ESS, V52, P213, DOI 10.1016/0952-3278(95)90039-X; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Hishikawa K, 1999, CIRCULATION, V100, P2108, DOI 10.1161/01.CIR.100.20.2108; Hishikawa K, 1999, J BIOL CHEM, V274, P37461, DOI 10.1074/jbc.274.52.37461; Igarashi A, 1996, J INVEST DERMATOL, V106, P729, DOI 10.1111/1523-1747.ep12345771; Inoue CN, 1999, CLIN SCI, V96, P431, DOI 10.1042/CS19980248; INOUE CN, 1995, CIRC RES, V77, P888, DOI 10.1161/01.RES.77.5.888; Inoue CN, 1997, P SOC EXP BIOL MED, V216, P370; Ito Y, 1998, KIDNEY INT, V53, P853, DOI 10.1046/j.1523-1755.1998.00820.x; Kasho M, 1998, KIDNEY INT, V54, P1083, DOI 10.1046/j.1523-1755.1998.00114.x; Kim HS, 1997, P NATL ACAD SCI USA, V94, P12981, DOI 10.1073/pnas.94.24.12981; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; LOVETT DH, 1983, J IMMUNOL, V131, P2830; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; Mason R.M., 1997, J AM SOC NEPHROL, V8, p642A; Murphy M, 1999, J BIOL CHEM, V274, P5830, DOI 10.1074/jbc.274.9.5830; NEBIGIL CG, 1995, AM J PHYSIOL-RENAL, V268, pF122, DOI 10.1152/ajprenal.1995.268.1.F122; Oemar BS, 1997, CIRCULATION, V95, P831; Pendurthi UR, 2000, J BIOL CHEM, V275, P14632, DOI 10.1074/jbc.275.19.14632; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Reiser COA, 1998, BIOCHEM J, V330, P1107; Ricupero DA, 2000, J BIOL CHEM, V275, P12475, DOI 10.1074/jbc.275.17.12475; Riser BL, 2000, J AM SOC NEPHROL, V11, P25, DOI 10.1681/ASN.V11125; Sauzeau V, 2000, J BIOL CHEM, V275, P21722, DOI 10.1074/jbc.M000753200; Seasholtz TM, 1999, MOL PHARMACOL, V55, P949, DOI 10.1124/mol.55.6.949; Steffen CL, 1998, GROWTH FACTORS, V15, P199, DOI 10.3109/08977199809002117; STROEBEL M, 1994, J BIOL CHEM, V269, P22952; Verbeke M, 1996, J AM SOC NEPHROL, V7, P621	54	96	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37429	37435		10.1074/jbc.M000976200	http://dx.doi.org/10.1074/jbc.M000976200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10976101	hybrid			2022-12-25	WOS:000165618700018
J	Pedersen, PA; Jorgensen, JR; Jorgensen, PL				Pedersen, PA; Jorgensen, JR; Jorgensen, PL			Importance of conserved alpha-subunit segment (709)GDGVND for Mg2+ binding, phosphorylation, and energy transduction in Na,K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA-2+-ATPASE; P-TYPE ATPASE; AMINO-ACIDS; CONFORMATIONAL TRANSITIONS; BETA-UNITS; SITE; (NA,K)-ATPASE; CONSEQUENCES; SUPERFAMILY; PHOSPHATASE	The segment (708)TGDGVNDSPALKK(720) in the cu subunit P domain of Na,K-ATPase is highly conserved among cation pumps, but little is known about its role in binding of Mg2+ or ATP and energy transduction. Here, 11 mutations of polar residues are expressed at reduced temperature in yeast with preserved capacities for high affinity binding of ouabain and ATP, whereas the Thr(708) --> Ser mutation and alterations of Asp(714) abolish all catalytic reactions. In mutations of Asp(710) and Asn(713) ATP affinity is preserved or increased, whereas Na,K-ATPase activity is severely reduced. Assay of phosphorylation from ATP in the presence of oligomycin shows that Asp710 contributes to coordination of Mg2+ during transfer of gamma -phosphate to Asp(369) in the high energy (MgE1P)-E-.[3Na] intermediate and that Asn(713) is involved in these processes. In contrast, Asp(710) and Asp(713) do not contribute to Mg2+ binding in the E(2)P(.)ouabain complex. Transition to E2P thus involves a shift of Mg2+ coordination away from Asp(710) and Asn(713), and the two residues become more important for hydrolysis of the acyl phosphate bond at Asp(369). Th, Asp(710), Ala mutation blocks interaction with vanadate, whereas Asn(713) --> Ala interferes with phosphorylation from Pi of the E(2)(.)ouabain complex, showing that the GDGVND segment is required for stabilization of the transition state and for the phosphorylation reaction. The Asp(710), Ala mutation also interferes with transmission of structural changes to the ouabain site and reduces the affinity for binding of T1(+) 2- to 3-fold, suggesting a role in transmission of KC stimulation of phospho-enzyme hydrolysis from transmembrane segment 5 to the P domain.	Univ Copenhagen, August Krogh Inst, Biomembrane Res Ctr, DK-2100 Copenhagen OE, Denmark	University of Copenhagen	Jorgensen, PL (corresponding author), Univ Copenhagen, August Krogh Inst, Biomembrane Res Ctr, Universitetsparken 13, DK-2100 Copenhagen OE, Denmark.	pljorgensen@aki.ku.dk	Pedersen, Per Amstrup/M-4592-2014	Pedersen, Per Amstrup/0000-0001-8648-9748				ANDERSEN JP, 1982, J BIOL CHEM, V257, P8300; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; Collet JF, 1999, J BIOL CHEM, V274, P33985, DOI 10.1074/jbc.274.48.33985; Farley RA, 1997, BIOCHEMISTRY-US, V36, P941, DOI 10.1021/bi962153y; FERSHT A, 1999, STRUCTURE MECH PROTE, P129; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIRARDET JL, 1993, EUR J BIOCHEM, V217, P225, DOI 10.1111/j.1432-1033.1993.tb18237.x; Goldshleger R, 1999, J BIOL CHEM, V274, P16213, DOI 10.1074/jbc.274.23.16213; Haldane J. B. S., 1965, ENZYMES; HANSEN O, 1984, PHARMACOL REV, V36, P143; HANSEN O, 1973, BIOCHIM BIOPHYS ACTA, V233, P122; HELMICHDEJONG ML, 1985, 4 INT C NA K ATP CO, P379; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jorgensen PL, 1997, ANN NY ACAD SCI, V834, P161, DOI 10.1111/j.1749-6632.1997.tb52248.x; JORGENSEN PL, 1986, BIOCHEMISTRY-US, V25, P2889; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; JORGENSEN PL, 1992, MOL ASPECTS TRANSPOR, P1; LANE LK, 1993, J BIOL CHEM, V268, P17930; LAUGER P, 1991, ELECTROGENIC ION PUM, P177; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; MARKS PW, 1991, ANAL BIOCHEM, V193, P61, DOI 10.1016/0003-2697(91)90044-T; OHTA T, 1986, P NATL ACAD SCI USA, V83, P2071, DOI 10.1073/pnas.83.7.2071; OVCHINNIKOV YA, 1987, FEBS LETT, V217, P111, DOI 10.1016/0014-5793(87)81253-X; Pauling L., 1946, CHEM ENG NEWS, V24, P1375, DOI [10.1021/cen-v024n010.p1375, DOI 10.1021/CEN-V024N010.P1375]; Pedersen PA, 1996, J BIOL CHEM, V271, P2514, DOI 10.1074/jbc.271.5.2514; Pedersen PA, 1996, BIOCHEMISTRY-US, V35, P16085, DOI 10.1021/bi961614c; Pedersen PA, 1998, BIOCHEMISTRY-US, V37, P17818, DOI 10.1021/bi981898w; RICHARDS DE, 1988, J PHYSIOL-LONDON, V404, P497, DOI 10.1113/jphysiol.1988.sp017302; Ridder IS, 1999, BIOCHEM J, V339, P223, DOI 10.1042/0264-6021:3390223; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; VILSEN B, 1987, J BIOL CHEM, V262, P10511	34	54	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37588	37595		10.1074/jbc.M005610200	http://dx.doi.org/10.1074/jbc.M005610200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10982798	hybrid			2022-12-25	WOS:000165618700040
J	Roduit, R; Morin, J; Masse, F; Segall, L; Roche, E; Newgard, CB; Assimacopoulos-Jeannet, F; Prentki, M				Roduit, R; Morin, J; Masse, F; Segall, L; Roche, E; Newgard, CB; Assimacopoulos-Jeannet, F; Prentki, M			Glucose down-regulates the expression of the peroxisome proliferator-activated receptor-alpha gene in the pancreatic beta-cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PALMITOYLTRANSFERASE-I GENE; OBESE PREDIABETIC RATS; DIABETIC FATTY RATS; INSULIN-SECRETION; LINE INS-1; RESPONSE ELEMENT; MALONYL-COA; ISLET CELLS; C-FOS; ACIDS	To better understand the action of glucose on fatty acid metabolism in the beta -cell and the link between chronically elevated glucose or fatty acids and beta -cell decompensation in adipogenic diabetes, we investigated whether glucose regulates peroxisomal proliferator-activated receptor (PPAR) gene expression in the beta -cell, Islets or INS(832/13) beta -cells exposed to high glucose show a 60-80% reduction in PPAR alpha mRNA expression. Oleate, either in the absence or presence of glucose, has no effect. The action of glucose is dose-dependent in the 6-20 mill range and maximal after 6 h, Glucose also causes quantitatively similar reductions in PPARa! protein and DNA binding activity of this transcription factor. The effect of glucose is blocked by the glucokinase inhibitor mannoheptulose, is partially mimicked by a-deoxyglucose, and is not blocked by the 3-O-methyl or the 6-deoxy analogues of the sugar that are not phosphorylated. Chronic elevated glucose reduces the expression levels of the PPAR target genes, uncoupling protein 2 and acyl-CoA oxidase, which are involved in fat oxidation and lipid detoxification. A 3-day exposure of INS-1 cells to elevated glucose results in a permanent rise in malonyl-CoA, the inhibition of fat oxidation, and the promotion of fatty acid esterification processes and causes elevated insulin secretion at low glucose. The results suggest that a reduction in PPAR alpha gene expression together with a rise in malonyl-CoA plays a role in the coordinated adaptation of beta -cell glucose and lipid metabolism to hyperglycemia and may be implicated in the mechanism of beta -cell "glucolipotoxicity."	Univ Montreal, Mol Nutr Unit, Dept Nutr, Montreal, PQ H2L 4M1, Canada; Ctr Hosp Univ Montreal, Montreal, PQ H2L 4M1, Canada; Inst Canc, Montreal, PQ H2L 4M1, Canada; Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, Dept Biochem & Int Med, Dallas, TX 75235 USA; Univ Geneva, Ctr Med, Dept Biochem Med, CH-1211 Geneva, Switzerland	Universite de Montreal; Universite de Montreal; Universite de Montreal; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Geneva	Prentki, M (corresponding author), CR CHUM, Pavillon de Seve 4,1560 Sherbrooke Est, Montreal, PQ H2L 4M1, Canada.		Roduit, Raphael/AAC-3890-2021; Roche, Enrique/V-5738-2017	Roduit, Raphael/0000-0001-7440-2799; Roche, Enrique/0000-0001-5128-1672				ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; AssimacopoulosJeannet F, 1997, J BIOL CHEM, V272, P1659, DOI 10.1074/jbc.272.3.1659; Auwerx J, 1999, DIABETOLOGIA, V42, P1033, DOI 10.1007/s001250051268; Bollheimer LC, 1998, J CLIN INVEST, V101, P1094, DOI 10.1172/JCI420; BONNY C, 1995, MOL ENDOCRINOL, V9, P1413, DOI 10.1210/me.9.10.1413; Boss O, 2000, DIABETES, V49, P143, DOI 10.2337/diabetes.49.2.143; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; Brun T, 1997, DIABETES, V46, P393, DOI 10.2337/diabetes.46.3.393; BRUN T, 1993, J BIOL CHEM, V268, P18905; Buteau J, 1999, DIABETOLOGIA, V42, P856, DOI 10.1007/s001250051238; Chen GX, 1996, P NATL ACAD SCI USA, V93, P14795, DOI 10.1073/pnas.93.25.14795; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cournarie F, 1999, FEBS LETT, V460, P527, DOI 10.1016/S0014-5793(99)01407-6; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Doiron B, 1996, J BIOL CHEM, V271, P5321, DOI 10.1074/jbc.271.10.5321; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; Foufelle F, 1998, Curr Opin Clin Nutr Metab Care, V1, P323, DOI 10.1097/00075197-199807000-00002; GERMAN MS, 1990, J BIOL CHEM, V265, P22063; GOTOH M, 1987, TRANSPLANTATION, V43, P725, DOI 10.1097/00007890-198705000-00024; Gremlich S, 1997, J BIOL CHEM, V272, P30261, DOI 10.1074/jbc.272.48.30261; Higa M, 1999, P NATL ACAD SCI USA, V96, P11513, DOI 10.1073/pnas.96.20.11513; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; Jonas JC, 1999, J BIOL CHEM, V274, P14112, DOI 10.1074/jbc.274.20.14112; Lee Y, 1997, DIABETES, V46, P408, DOI 10.2337/diabetes.46.3.408; MARIE S, 1993, J BIOL CHEM, V268, P23881; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; McGarry JD, 1999, DIABETOLOGIA, V42, P128, DOI 10.1007/s001250051130; MCGARRY JD, 1976, J LIPID RES, V17, P277; Meyer K, 1999, ARCH TOXICOL, V73, P440, DOI 10.1007/s002040050633; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; OHNEDA M, 1995, DIABETOLOGIA, V38, P173, DOI 10.1007/BF00400091; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; Prentki M, 1996, DIABETES, V45, P273, DOI 10.2337/diabetes.45.3.273; Prentki M, 1996, EUR J ENDOCRINOL, V134, P272, DOI 10.1530/eje.0.1340272; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; Rieusset J, 1999, BIOCHEM BIOPH RES CO, V265, P265, DOI 10.1006/bbrc.1999.1657; Roche E, 1999, DIABETES, V48, P2007, DOI 10.2337/diabetes.48.10.2007; Roche E, 1998, DIABETES, V47, P1086, DOI 10.2337/diabetes.47.7.1086; Roche E, 1997, J BIOL CHEM, V272, P3091, DOI 10.1074/jbc.272.5.3091; Schuit F, 1997, J BIOL CHEM, V272, P18572, DOI 10.1074/jbc.272.30.18572; Segall L, 1999, AM J PHYSIOL-ENDOC M, V277, pE521, DOI 10.1152/ajpendo.1999.277.3.E521; SHARMA A, 1995, MOL ENDOCRINOL, V9, P1127, DOI 10.1210/me.9.9.1127; SHARP GW, 1996, AM J PHYSIOL, V271, pC1731; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Shimabukuro M, 1997, BIOCHEM BIOPH RES CO, V237, P359, DOI 10.1006/bbrc.1997.7140; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; Shimabukuro M, 1998, J BIOL CHEM, V273, P3547, DOI 10.1074/jbc.273.6.3547; Susini S, 2000, FASEB J, V14, P128, DOI 10.1096/fasebj.14.1.128; Susini S, 1998, FASEB J, V12, P1173, DOI 10.1096/fasebj.12.12.1173; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; Towle HC, 1997, ANNU REV NUTR, V17, P405, DOI 10.1146/annurev.nutr.17.1.405; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; Velho G, 1998, EUR J ENDOCRINOL, V138, P233, DOI 10.1530/eje.0.1380233; WITSELL AL, 1990, BIOTECHNIQUES, V9, P318; Zhou YT, 1998, P NATL ACAD SCI USA, V95, P8898, DOI 10.1073/pnas.95.15.8898	57	141	146	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35799	35806		10.1074/jbc.M006001200	http://dx.doi.org/10.1074/jbc.M006001200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10967113	hybrid			2022-12-25	WOS:000165382000024
J	Sakamoto, H; Kitamura, T; Yoshimura, A				Sakamoto, H; Kitamura, T; Yoshimura, A			Mitogen-activated protein kinase plays an essential role in the erythropoietin-dependent proliferation of CTLL-2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; JAK-3 JANUS KINASE; TYROSINE PHOSPHORYLATION; CYTOPLASMIC DOMAINS; HEMATOPOIETIC-CELLS; GENE-EXPRESSION; INDUCIBLE GENE; BETA-SUBUNIT; RECEPTOR; STAT5	Erythropoietin (EPO) and its receptor (EPOR) are required for development of erythrocytes. It has been shown that the ectopic expression of EPOR confers EPO-dependent proliferation on an interleukin 3 (IL3)-dependent cell line, Ba/F3, whereas the IL2-dependent T cell line, CTLL-2 expressing the EPOR (T-ER), fails to proliferate in response to EPO. However, the molecular basis of the EPO unresponsiveness in CTLL-8 has not been clarified. We found that the expression level of JAK2 in T-ER cells was much lower than that in Ba/F3 cells. Therefore, we examined the effects of forced expression of JAK2 in T ER cells. In T-ER transformants expressing JAK2 (T-JER), EPO induced tyrosine phosphorylation of the EPOR, JAK2, and STATE, and consequently STAT5-responsive genes including bcl-X and cis1 were normally induced. Furthermore, T-JER cells were resistant to apoptosis until at least 72 h after switching from IL2 to EPO. Although T-JER cells could not continuously proliferate in the presence of EPO, additional expression of JAK2 in T-JER (T-JJER) to a level similar to that in Ba/F3 cells supported long term proliferation in response to EPO. JAK2 was equally coimmunoprecipitated with the EPOR among T-JER, T-JJER, and Ba/F3 cells expressing the EPOR (BF-ER), However, EPO-dependent mitogen-activated protein (MAP) kinase activation was observed in T-JJER and BF-ER cells but not in T-JER cells. EPO dependent long term proliferation of T-JER cells was conferred by expression of the constitutively activated form of MEK1. Our results suggest that MAP kinase activation is, at least in part, an important component for mitotic signal from the EPOR, and CTLL-2 cells probably lack signaling molecule(s) in JAK2 and the Ras-MAP kinase pathway.	Kurume Univ, Inst Life Sci, Kurume, Fukuoka 8390861, Japan; Univ Tokyo, Inst Med Sci, Dept Hemopoiet Factors, Minato Ku, Tokyo 1088639, Japan	Kurume University; University of Tokyo	Yoshimura, A (corresponding author), Kurume Univ, Inst Life Sci, Aikawa Machi 2432-3, Kurume, Fukuoka 8390861, Japan.	yosimura@lsi.kurume-u.ac.jp	Kitamura, Toshio/AAA-2071-2021; Wilson, Matthew H/K-3193-2013; Yoshimura, Akihiko/K-5515-2013					BARBER DL, 1994, MOL CELL BIOL, V14, P6506, DOI 10.1128/MCB.14.10.6506; BOUSSIOTIS VA, 1994, SCIENCE, V266, P1039, DOI 10.1126/science.7973657; Chin H, 1998, BLOOD, V91, P3734; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; Gaffen SL, 1999, BLOOD, V94, P74, DOI 10.1182/blood.V94.1.74.413k36_74_86; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Jenkins BJ, 1998, BLOOD, V92, P1989, DOI 10.1182/blood.V92.6.1989; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; Kieslinger M, 2000, GENE DEV, V14, P232; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; MIGLIACCIO AR, 1991, P NATL ACAD SCI USA, V88, P11086, DOI 10.1073/pnas.88.24.11086; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIURA O, 1994, BLOOD, V84, P1501; MIURA Y, 1994, J BIOL CHEM, V269, P29962; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; QUELLE DE, 1991, P NATL ACAD SCI USA, V88, P4801, DOI 10.1073/pnas.88.11.4801; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; Sakamoto H, 1998, BLOOD, V92, P1668, DOI 10.1182/blood.V92.5.1668.417k09_1668_1676; SHOWERS MO, 1992, BLOOD, V80, P3070; Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; YAMAMURA Y, 1992, EMBO J, V11, P4909, DOI 10.1002/j.1460-2075.1992.tb05597.x; YAMAMURA Y, 1994, P NATL ACAD SCI USA, V91, P8866, DOI 10.1073/pnas.91.19.8866; YOSHIMURA A, 1992, J BIOL CHEM, V267, P11619; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	48	21	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35857	35862		10.1074/jbc.M006317200	http://dx.doi.org/10.1074/jbc.M006317200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10960479	hybrid			2022-12-25	WOS:000165382000032
J	Sedova, M; Blatter, LA				Sedova, M; Blatter, LA			Intracellular sodium modulates mitochondrial calcium signaling in vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; NITRIC-OXIDE; OXIDATIVE-PHOSPHORYLATION; INOSITOL TRISPHOSPHATE; LIVER-MITOCHONDRIA; HEART-MITOCHONDRIA; STORE DEPLETION; CA2+; OSCILLATIONS; TRANSPORT	We have investigated the role of extramitochondrial Na+ for the regulation of mitochondrial Ca2+ concentration ([Ca2+](m)) in permeabilized single vascular endothelial cells. [Ca2+], was measured by loading the cells with the membrane-permeant Ca2+ indicator fluo-3/AM: and subsequent removal of cytoplasmic fluo-3 by surface membrane permeabilization with digitonin. An elevation of extramitochondrial Ca2+ resulted in a dose-dependent increase in the rate of Ca2+ accumulation into mitochondria (k(0.5) = 3 muM) via the mitochondrial Ca2+ uniporter. In the presence of 10 mM extramitochondrial Na+ ([Na+](em)), repetitive application of brief pulses of high Ca2' (2-10 muM) to simulate cytoplasmic [Ca2+] oscillations caused transient increases of [Ca2+], characterized by a fast rising phase that was followed by a slow decay. Removal of extramitochondrial Naf or inhibition of mitochondrial Na+/Ca2+ exchange with clonazepam blocked mitochondrial Ca2+ efflux and resulted in a net accumulation of Ca2+ by the mitochondria. Half-maximal activation of mitochondrial Na+/Ca2+ exchange occurred at [Na+](em) = 4.4 mM, which is well within the physiological range of cytoplasmic [Na+]. This study provides evidence that Ca2+ efflux from the mitochondria in vascular endothelial cells occurs solely via Na+/Ca2+ exchange and emphasizes the important role of intracellular Nat for mitochondrial Ca2+ regulation.	Loyola Univ, Stritch Sch Med, Dept Physiol, Maywood, IL 60153 USA	Loyola University Chicago	Blatter, LA (corresponding author), Loyola Univ, Stritch Sch Med, Dept Physiol, 2160 S 1st Ave, Maywood, IL 60153 USA.	LBLATTE@LUMC.EDU	Blatter, Lothar/AAC-8431-2020		NHLBI NIH HHS [HL-62231, HL-51941] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL051941, R01HL062231] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Babcock DF, 1998, CURR OPIN NEUROBIOL, V8, P398, DOI 10.1016/S0959-4388(98)80067-6; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; BLATTER LA, 1991, J GEN PHYSIOL, V98, P1141, DOI 10.1085/jgp.98.6.1141; BLATTER LA, 1995, AM J PHYSIOL-CELL PH, V268, pC503, DOI 10.1152/ajpcell.1995.268.2.C503; BLATTER LA, 1995, CIRC RES, V76, P922, DOI 10.1161/01.RES.76.5.922; CARTER TD, 1991, BIOCHEM J, V278, P697, DOI 10.1042/bj2780697; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COX DA, 1993, J BIOL CHEM, V268, P938; CROMPTON M, 1977, EUR J BIOCHEM, V79, P549, DOI 10.1111/j.1432-1033.1977.tb11839.x; CROMPTON M, 1976, EUR J BIOCHEM, V69, P453, DOI 10.1111/j.1432-1033.1976.tb10930.x; CROMPTON M, 1978, EUR J BIOCHEM, V82, P25, DOI 10.1111/j.1432-1033.1978.tb11993.x; Csordas G, 1999, EMBO J, V18, P96, DOI 10.1093/emboj/18.1.96; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Donnadieu E, 1996, CELL CALCIUM, V20, P53, DOI 10.1016/S0143-4160(96)90050-0; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; GRIFFITH TM, 1986, CARDIOVASC RES, V20, P7, DOI 10.1093/cvr/20.1.7; Gunter TE, 1998, BBA-BIOENERGETICS, V1366, P5, DOI 10.1016/S0005-2728(98)00117-0; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Hajnoczky G, 1997, EMBO J, V16, P3533, DOI 10.1093/emboj/16.12.3533; HANSFORD RG, 1994, J BIOENERG BIOMEMBR, V26, P495, DOI 10.1007/BF00762734; HAROOTUNIAN AT, 1989, J BIOL CHEM, V264, P19458; HAWORTH RA, 1980, FEBS LETT, V110, P216, DOI 10.1016/0014-5793(80)80076-7; HEFFRON JJA, 1981, BIOCHEM J, V194, P925, DOI 10.1042/bj1940925; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; Huser J, 1998, BIOPHYS J, V74, P2129, DOI 10.1016/S0006-3495(98)77920-2; JACOB R, 1991, CELL CALCIUM, V12, P127, DOI 10.1016/0143-4160(91)90014-6; Jornot L, 1999, J CELL SCI, V112, P1013; Jou MJ, 1996, J PHYSIOL-LONDON, V497, P299, DOI 10.1113/jphysiol.1996.sp021769; Jouaville LS, 1999, P NATL ACAD SCI USA, V96, P13807, DOI 10.1073/pnas.96.24.13807; JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0; Lawrie AM, 1996, J BIOL CHEM, V271, P10753, DOI 10.1074/jbc.271.18.10753; LI WH, 1992, J BIOL CHEM, V267, P17983; LIDOFSKY SD, 1993, J BIOL CHEM, V268, P14632; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; Montero M, 2000, NAT CELL BIOL, V2, P57, DOI 10.1038/35000001; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Paltauf-Doburzynska J, 2000, J PHYSIOL-LONDON, V524, P701, DOI 10.1111/j.1469-7793.2000.00701.x; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; RIZZUTO R, 1987, BIOCHEM J, V246, P271, DOI 10.1042/bj2460271; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Robb-Gaspers LD, 1998, EMBO J, V17, P4987, DOI 10.1093/emboj/17.17.4987; Rutter GA, 1996, P NATL ACAD SCI USA, V93, P5489, DOI 10.1073/pnas.93.11.5489; SAGE SO, 1991, J PHYSIOL-LONDON, V441, P559, DOI 10.1113/jphysiol.1991.sp018767; Scaduto RC, 1999, BIOPHYS J, V76, P469, DOI 10.1016/S0006-3495(99)77214-0; Sedova M, 2000, J PHYSIOL-LONDON, V523, P549, DOI 10.1111/j.1469-7793.2000.t01-3-00549.x; Sedova M, 2000, BIOPHYS J, V78, p70A; SPARAGNA GC, 1995, J BIOL CHEM, V270, P27510, DOI 10.1074/jbc.270.46.27510; Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349; Teubl M, 1999, J BIOL CHEM, V274, P29529, DOI 10.1074/jbc.274.41.29529; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; Tinel H, 1999, EMBO J, V18, P4999, DOI 10.1093/emboj/18.18.4999; WINGROVE DE, 1986, J BIOL CHEM, V261, P5166	61	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35402	35407		10.1074/jbc.M006058200	http://dx.doi.org/10.1074/jbc.M006058200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10958797	hybrid			2022-12-25	WOS:000165422800076
J	Kreienkamp, HJ; Zitzer, H; Gundelfinger, ED; Richter, D; Bockers, TM				Kreienkamp, HJ; Zitzer, H; Gundelfinger, ED; Richter, D; Bockers, TM			The calcium-independent receptor for alpha-latrotoxin from human and rodent brains interacts with members of the ProSAP/SSTRIP/Shank family of multidomain proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							90/POSTSYNAPTIC DENSITY-95-ASSOCIATED PROTEIN; POSTSYNAPTIC DENSITY PROTEINS; COUPLED RECEPTORS; BINDING-PROTEIN; DOMAIN; PSD-95; CORTACTIN; EXOCYTOSIS; DEFINES; SHANK	Subtypes of the calcium-independent receptors for alpha -latrotoxin (CIRL1-3) define a distinct subgroup within the large family of the seven-transmembrane region cell surface receptors, The physiological function of CIRLs is unknown because neither extracellular ligands nor intracellular coupling proteins (G-proteins) have been identified. Using yeast two-hybrid screening, we identified a novel interaction between the C termini of CIRL1 and -2 and the PSD-95/discs large/ZO-1 (PDZ) domain of a recently discovered multidomain protein family (ProSAP/SSTRIP/Shank) present in human and rat brain. In vitro, CIRL1 and CIRL2 interacted strongly with the PDZ domain of ProSAP1, The specificity of this interaction has been verified by in vivo experiments using solubilized rat brain membrane fractions and ProSAP1 antibodies; only CIRL1, but not CIRL2, was coimmunoprecipitated with ProSAP1. In situ hybridization revealed that ProSAP1 and CIRL1 are co-expressed in the cortex, hippocampus, and cerebellum. Colocalization was also observed at the subcellular level, as both CIRL1 and ProSAP1 are enriched in the postsynaptic density fraction from rat brain. Expression of all three CIRL isoforms is highly regulated during postnatal brain development, with CIRL3 exhibiting its highest expression levels immediately after birth, followed by CIRL2 and finally CIRL1 in aged rats.	Univ Hamburg, Inst Zellbiochem & Klin Neurobiol, D-20246 Hamburg, Germany; Leibnitz Inst Neurobiol, D-39118 Magdeburg, Germany; Univ Munster, Inst Anat, D-48149 Munster, Germany	University of Hamburg; Leibniz Institut fur Neurobiologie (LIN); University of Munster	Richter, D (corresponding author), Univ Hamburg, Inst Zellbiochem & Klin Neurobiol, Martinistr 52, D-20246 Hamburg, Germany.							Boeckers TM, 1999, BIOCHEM BIOPH RES CO, V264, P247, DOI 10.1006/bbrc.1999.1489; Boeckers TM, 1999, J NEUROSCI, V19, P6506; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; Du YR, 1998, MOL CELL BIOL, V18, P5838, DOI 10.1128/MCB.18.10.5838; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Hlubek MD, 2000, MOL PHARMACOL, V57, P519, DOI 10.1124/mol.57.3.519; Ichtchenko K, 1999, J BIOL CHEM, V274, P5491, DOI 10.1074/jbc.274.9.5491; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Kawabe H, 1999, J BIOL CHEM, V274, P30914, DOI 10.1074/jbc.274.43.30914; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Krasnoperov V, 1999, J BIOL CHEM, V274, P3590, DOI 10.1074/jbc.274.6.3590; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Matsushita H, 1999, FEBS LETT, V443, P348, DOI 10.1016/S0014-5793(99)00005-8; Naisbitt S, 1997, J NEUROSCI, V17, P5687; Naisbitt S, 1999, NEURON, V23, P569, DOI 10.1016/S0896-6273(00)80809-0; Orlova EV, 2000, NAT STRUCT BIOL, V7, P48, DOI 10.1038/71247; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; Shiratsuchi T, 1997, CYTOGENET CELL GENET, V79, P103, DOI 10.1159/000134693; Sugita S, 1998, J BIOL CHEM, V273, P32715, DOI 10.1074/jbc.273.49.32715; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; White GRM, 1998, ONCOGENE, V17, P3513, DOI 10.1038/sj.onc.1202487; Yao I, 1999, J BIOL CHEM, V274, P27463, DOI 10.1074/jbc.274.39.27463; Zitzer H, 1999, J BIOL CHEM, V274, P18153, DOI 10.1074/jbc.274.26.18153; Zitzer H, 1999, J BIOL CHEM, V274, P32997, DOI 10.1074/jbc.274.46.32997	27	70	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32387	32390		10.1074/jbc.C000490200	http://dx.doi.org/10.1074/jbc.C000490200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10964907	hybrid			2022-12-25	WOS:000090003800003
J	Elliott, DE; Urban, JF; Argo, CK; Weinstock, JV				Elliott, DE; Urban, JF; Argo, CK; Weinstock, JV			Does the failure to acquire helminthic parasites predispose to Crohn's disease?	FASEB JOURNAL			English	Article						ulcerative colitis; helminths; Th1/Th2 response; CD	INFLAMMATORY BOWEL-DISEASE; CYTOKINE-MEDIATED REGULATION; T-CELLS; ULCERATIVE-COLITIS; IMMUNE-RESPONSES; PROTECTIVE IMMUNITY; JEWISH POPULATION; TRICHURIS-MURIS; UNITED-STATES; SCHISTOSOMA-MANSONI	Two polarized patterns (Th1 and Th2) of cytokines regulate inflammatory responses. Each cytokine pattern inhibits production of the opposing pattern. Lymphocytes from inflamed intestine due to Crohn's disease secrete a Th1 pattern of cytokines. Crohn's disease is most prevalent in highly industrialized countries with temperate climates. It occurs rarely in tropical third world countries with poor sanitation. We propose that exposure to an environmental agent predisposes individuals to Crohn's disease. Parasitic worms (helminths) are common in tropical climates and in populations subject to crowding and poor sanitation. Children are most subject to helminthic colonization. Many helminths live within or migrate through the human gut where they interact with the mucosal immune system. The host mounts a mucosal response that includes Th2 cytokine production limiting helminthic colonization. Helminths and their eggs probably are the most potent stimulators of mucosal Th2 responses. The Th2 response provoked by parasitic worms can modulate immune reactions to unrelated parasitic, bacterial, and viral infections. Many people in developed countries now live in increasingly hygienic environments, avoiding exposure to helminths. Perhaps failure to acquire these parasites and experience mucosal Th2 conditioning predisposes to Crohn's disease, which is an overly active Th1 inflammation.	Univ Iowa, Dept Internal Med, Div Gastroenterol Hepatol, Iowa City, IA 52242 USA; USDA, Immunol & Dis Resistance Lab, Beltsville, MD 20705 USA	University of Iowa; United States Department of Agriculture (USDA)	Elliott, DE (corresponding author), Univ Hosp 4611 JCP, Div Gastroenterol Hepatol, 200 Hawkins Dr, Iowa City, IA 52242 USA.	david-elliott@uiowa.edu; joel-weinstock@uiowa.edu		Urban, Joseph/0000-0002-1590-8869; Elliott, David/0000-0002-5359-7125	NIADDK NIH HHS [AM38327] Funding Source: Medline; NIDDK NIH HHS [DK02428] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002428] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON RM, 1982, PARASITOLOGY, V85, P373, DOI 10.1017/S0031182000055347; ASANO K, 1992, EXPERIENTIA, V48, P67, DOI 10.1007/BF01923611; BANCROFT AJ, 1994, EUR J IMMUNOL, V24, P3113, DOI 10.1002/eji.1830241230; Bentwich Z, 1996, CLIN EXP IMMUNOL, V103, P239, DOI 10.1046/j.1365-2249.1996.d01-612.x; Berg DJ, 1996, J CLIN INVEST, V98, P1010, DOI 10.1172/JCI118861; BERGMAN L, 1975, SCAND J GASTROENTERO, V10, P725; BETZ M, 1990, J IMMUNOL, V145, P1046; BLUMENTHAL DS, 1977, NEW ENGL J MED, V297, P1437, DOI 10.1056/NEJM197712292972605; Bortoletti G., 1992, Parassitologia (Rome), V34, P17; BRAHME F, 1975, GASTROENTEROLOGY, V69, P342; Ehrhardt RO, 1997, J IMMUNOL, V158, P566; Elliott DE, 1998, AUTOIMMUNE DISEASES, THIRD EDITION, P477; Elliott DE, 1996, GASTROENTEROL CLIN N, V25, P599, DOI 10.1016/S0889-8553(05)70265-X; Elliott DE, 1999, GASTROENTEROLOGY, V116, pA706; ELSE KJ, 1992, IMMUNOLOGY, V75, P232; ELSE KJ, 1994, J EXP MED, V179, P347, DOI 10.1084/jem.179.1.347; ELSON CO, 1995, GASTROENTEROLOGY, V109, P1344, DOI 10.1016/0016-5085(95)90599-5; ERICKSON RV, 1980, AM J PUBLIC HEALTH, V70, P1003, DOI 10.2105/AJPH.70.9.1003; FELLOWS IW, 1990, GUT, V31, P1262, DOI 10.1136/gut.31.11.1262; FINKELMAN FD, 1994, J EXP MED, V179, P1563, DOI 10.1084/jem.179.5.1563; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; FIREMAN Z, 1989, AM J GASTROENTEROL, V84, P255; FULMER HS, 1965, AM J TROP MED HYG, V14, P269, DOI 10.4269/ajtmh.1965.14.269; Fuss IJ, 1996, J IMMUNOL, V157, P1261; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; Gollob JA, 1997, EUR J IMMUNOL, V27, P647, DOI 10.1002/eji.1830270311; GOLLOP JH, 1988, GUT, V29, P49, DOI 10.1136/gut.29.1.49; GRENCIS RK, 1993, ANN TROP MED PARASIT, V87, P643, DOI 10.1080/00034983.1993.11812823; GROSSMAN A, 1989, HEPATO-GASTROENTEROL, V36, P193; Gusella JF, 1998, GASTROENTEROLOGY, V115, P1286, DOI 10.1016/S0016-5085(98)70103-9; HEALY GR, 1969, PUBLIC HEALTH REP, V84, P907, DOI 10.2307/4593709; HUBBARD DW, 1974, PEDIATR RES, V8, P652, DOI 10.1203/00006450-197406000-00006; Hugot JP, 1996, NATURE, V379, P821, DOI 10.1038/379821a0; HUTT MSR, 1979, ISRAEL J MED SCI, V15, P314; JAYANTHI V, 1992, Q J MED, V82, P125; JEFFERY GM, 1963, PUBLIC HEALTH REP, V78, P45, DOI 10.2307/4591726; JJUMBAMUKASA OR, 1971, AM J TROP MED HYG, V20, P109, DOI 10.4269/ajtmh.1971.20.109; JUNG RC, 1951, PEDIATRICS, V8, P548; KRAWIEC J, 1984, ISRAEL J MED SCI, V20, P16; KUBIN M, 1994, BLOOD, V83, P1847; KULLBERG MC, 1992, J IMMUNOL, V148, P3264; KURATA JH, 1992, GASTROENTEROLOGY, V102, P1940, DOI 10.1016/0016-5085(92)90317-R; KYLE J, 1992, GASTROENTEROLOGY, V103, P392, DOI 10.1016/0016-5085(92)90826-K; Lapidus A, 1997, GUT, V41, P480, DOI 10.1136/gut.41.4.480; LASHNER BA, 1986, GASTROENTEROLOGY, V91, P1396, DOI 10.1016/0016-5085(86)90193-9; Lederer JA, 1996, J EXP MED, V184, P397, DOI 10.1084/jem.184.2.397; Ledingham DL, 1996, TRANSPLANTATION, V61, P184, DOI 10.1097/00007890-199601270-00003; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; LICHTMAN AH, 1987, P NATL ACAD SCI USA, V84, P824, DOI 10.1073/pnas.84.3.824; LINDBERG E, 1991, SCAND J GASTROENTERO, V26, P495, DOI 10.3109/00365529108998572; MALEFYT RD, 1993, J IMMUNOL, V151, P6370; MANSFIELD LS, 1999, EFFECTS MICROBES IMM; Metwali A, 1996, J IMMUNOL, V157, P4546; MEUCCI G, 1992, GASTROENTEROLOGY, V103, P514, DOI 10.1016/0016-5085(92)90841-L; MILLER DS, 1974, LANCET, V2, P691; Mizoguchi A, 1996, J EXP MED, V183, P847, DOI 10.1084/jem.183.3.847; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MUNKHOLM P, 1992, SCAND J GASTROENTERO, V27, P609, DOI 10.3109/00365529209000127; NEURATH MF, 1995, J EXP MED, V182, P1281, DOI 10.1084/jem.182.5.1281; NIESSNER M, 1995, CLIN EXP IMMUNOL, V101, P428; NIV Y, 1990, AM J GASTROENTEROL, V85, P1580; NOVIS BH, 1975, S AFR MED J, V49, P693; ODES HS, 1991, GUT, V32, P1024, DOI 10.1136/gut.32.9.1024; ODES HS, 1989, SCAND J GASTROENTERO, V24, P36, DOI 10.3109/00365528909091348; ODES HS, 1994, AM J GASTROENTEROL, V89, P1859; ORHOLM M, 1991, NEW ENGL J MED, V324, P84, DOI 10.1056/NEJM199101103240203; PEARLMAN E, 1993, J IMMUNOL, V151, P4857; POWRIE F, 1994, IMMUNITY, V1, P553, DOI 10.1016/1074-7613(94)90045-0; Ramaswamy K, 1996, J IMMUNOL, V156, P4328; ROLON PA, 1979, ISRAEL J MED SCI, V15, P318; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; ROSE JDR, 1988, GUT, V29, P346, DOI 10.1136/gut.29.3.346; ROTH MP, 1989, GASTROENTEROLOGY, V96, P1016, DOI 10.1016/0016-5085(89)91618-1; Sabin EA, 1996, J INFECT DIS, V173, P269, DOI 10.1093/infdis/173.1.269; SALAS SD, 1990, ARCH INTERN MED, V150, P1514, DOI 10.1001/archinte.150.7.1514; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SEGAL I, 1988, INT J COLORECTAL DIS, V3, P222, DOI 10.1007/BF01660719; SHAPIRA M, 1994, EUR J EPIDEMIOL, V10, P231, DOI 10.1007/BF01730377; SHAPIRA M, 1992, J CLIN GASTROENTEROL, V15, P278; Shi HN, 1998, J IMMUNOL, V160, P2449; Shivananda S, 1996, GUT, V39, P690, DOI 10.1136/gut.39.5.690; SINGER HC, 1971, GASTROENTEROLOGY, V61, P423; SONNENBERG A, 1990, GUT, V31, P1037, DOI 10.1136/gut.31.9.1037; SONNENBERG A, 1991, GASTROENTEROLOGY, V101, P122, DOI 10.1016/0016-5085(91)90468-Z; SWAIN SL, 1990, J IMMUNOL, V145, P3796; TAN CC, 1992, J GASTROEN HEPATOL, V7, P360, DOI 10.1111/j.1440-1746.1992.tb00997.x; THOMAS GAO, 1995, EUR J GASTROEN HEPAT, V7, P401; TYSK C, 1988, GUT, V29, P990, DOI 10.1136/gut.29.7.990; URBAN JF, 1993, J IMMUNOL, V151, P7086; URBAN JF, 1991, EXP PARASITOL, V73, P500, DOI 10.1016/0014-4894(91)90074-7; URBAN JF, 1995, J IMMUNOL, V154, P4675; URBAN JF, 1992, IMMUNOL REV, V127, P205, DOI 10.1111/j.1600-065X.1992.tb01415.x; Weinstock JV, 1996, GASTROENTEROL CLIN N, V25, pR11, DOI 10.1016/S0889-8553(05)70256-9; WRIGHT JP, 1983, S AFR MED J, V63, P226; Wright WH, 1955, PUBLIC HEALTH REP, V70, P966, DOI 10.2307/4589255; ZIMMERMANN WJ, 1968, PUBLIC HEALTH REP, V83, P957, DOI 10.2307/4593456	97	187	202	0	35	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2000	14	12					1848	1855		10.1096/fj.99-0885hyp	http://dx.doi.org/10.1096/fj.99-0885hyp			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973934				2022-12-25	WOS:000089212400024
J	Zhou, J; Ng, S; Adesanya-Famuiya, O; Anderson, K; Bondy, CA				Zhou, J; Ng, S; Adesanya-Famuiya, O; Anderson, K; Bondy, CA			Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression	FASEB JOURNAL			English	Article						breast cancer; androgen; tamoxifen; monkey	BREAST-CANCER RISK; POSTMENOPAUSAL WOMEN; MENSTRUAL-CYCLE; HORMONE LEVELS; PRIMATE OVARY; ANDROGEN; TAMOXIFEN; SERUM; THERAPY; GROWTH	This study investigated the effect of sex steroids and tamoxifen on primate mammary epithelial proliferation and steroid receptor gene expression. Ovariectomized rhesus monkeys were treated with placebo, 17 beta estradiol (E2) alone or in combination with progesterone (E2/P) or testosterone (E2/T), or tamoxifen for 3 days. E2 alone increased mammary epithelial proliferation by similar to six-fold (P<0.0001) and increased mammary epithelial estrogen receptor (ER alpha) mRNA expression by similar to 50% (P<0.0001; ER beta mRNA was not detected in the primate mammary gland). Progesterone did not alter E2's proliferative effects, but testosterone reduced E2-induced proliferation by similar to 40% (P<0.002) and entirely abolished E2-induced augmentation of ER alpha expression. Tamoxifen had a significant agonist effect in the ovariectomized monkey, producing a similar to threefold increase in mammary epithelial proliferation (P<0.01), but tamoxifen also reduced ER alpha expression below placebo level.. Androgen receptor (AR) mRNA was detected in mammary epithelium by in situ hybridization. AR mRNA levels were not altered by E2 alone but were significantly reduced by E2/T and tamoxifen treatment. Because combined E2/T and tamoxifen had similar effects on mammary epithelium, we investigated the regulation of known sex steroid-responsive mRNAs in the primate mammary epithelium. E2 alone had no effect on apolipoprotein D (ApoD) or IGF binding protein 5 (IGFBP5) expression, but E2/T and tamoxifen treatment groups both demonstrated identical alterations in these mRNAs (ApoD was decreased and IGFBP5 was increased). These observations showing androgen-induced down-regulation of mammary epithelial proliferation and ER expression suggest that combined estrogen/androgen hormone replacement therapy might reduce the risk of breast cancer associated with estrogen replacement. In addition, these novel findings on tamoxifen's androgen-like effects on primate mammary epithelial sex steroid receptor expression suggest that tamoxifen's protective action on mammary gland may involve androgenic effects.	NICHHD, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Bondy, CA (corresponding author), NICHHD, Dev Endocrinol Branch, NIH, Bldg 10,Rm 10N262, Bethesda, MD 20892 USA.	bondyc@exchange.nih.gov			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000628] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000628] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ayoub JPM, 1997, ANN INTERN MED, V126, P745, DOI 10.7326/0003-4819-126-9-199705010-00033; Berrino F, 1996, JNCI-J NATL CANCER I, V88, P291, DOI 10.1093/jnci/88.5.291; BRYAN RM, 1984, CANCER, V54, P2436, DOI 10.1002/1097-0142(19841201)54:11<2436::AID-CNCR2820541121>3.0.CO;2-H; Cauley JA, 1999, ANN INTERN MED, V130, P270, DOI 10.7326/0003-4819-130-4_Part_1-199902160-00004; DAUVOIS S, 1991, CANCER RES, V51, P3131; Dorgan JF, 1996, CANCER EPIDEM BIOMAR, V5, P533; ENCARNACION CA, 1993, BREAST CANCER RES TR, V26, P237, DOI 10.1007/BF00665801; GERDES J, 1991, AM J PATHOL, V138, P867; GOING JJ, 1988, AM J PATHOL, P130; Hankinson SE, 1998, JNCI-J NATL CANCER I, V90, P1292, DOI 10.1093/jnci/90.17.1292; KEY TJA, 1988, EUR J CANCER CLIN ON, V24, P29, DOI 10.1016/0277-5379(88)90173-3; LABRIE F, 1992, CANCER DETECT PREV, V16, P31; LONGACRE TA, 1986, AM J SURG PATHOL, V10, P382, DOI 10.1097/00000478-198606000-00003; MacGregor JI, 1998, PHARMACOL REV, V50, P151; MELCHOR JC, 1990, ONCOLOGY-BASEL, V47, P467; POTTEN CS, 1988, BRIT J CANCER, V58, P163, DOI 10.1038/bjc.1988.185; Rebbeck TR, 1999, AM J HUM GENET, V64, P1371, DOI 10.1086/302366; SECRETO G, 1991, CANCER RES, V51, P2572; Service RF, 1998, SCIENCE, V279, P1631, DOI 10.1126/science.279.5357.1631; Sfikakis PP, 1998, INT J IMMUNOPHARMACO, V20, P305, DOI 10.1016/S0192-0561(98)00034-4; Shyamala G, 1997, TRENDS ENDOCRIN MET, V8, P34, DOI 10.1016/S1043-2760(96)00207-X; SIMARD J, 1992, ENDOCRINOLOGY, V130, P1115, DOI 10.1210/en.130.3.1115; Simon J, 1999, MENOPAUSE, V6, P138; Staiman VR, 1997, UROLOGY, V50, P929, DOI 10.1016/S0090-4295(97)00457-3; Stomati M, 1996, J ENDOCRINOL INVEST, V19, P535, DOI 10.1007/BF03349013; Vendola KA, 1998, J CLIN INVEST, V101, P2622, DOI 10.1172/JCI2081; Weil SJ, 1998, J CLIN ENDOCR METAB, V83, P2479, DOI 10.1210/jc.83.7.2479; YU H, 1994, BREAST CANCER RES TR, V32, P291, DOI 10.1007/BF00666006; ZHOU J, 2000, IN PRESS J INVEST ME	29	156	163	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2000	14	12					1725	1730		10.1096/fj.99-0863com	http://dx.doi.org/10.1096/fj.99-0863com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973921	Green Submitted			2022-12-25	WOS:000089212400011
J	Rahman, N; Teare, MD; Seal, S; Renard, H; Mangion, J; Cour, C; Thompson, D; Shugart, Y; Eccles, D; Devilee, P; Meijers, H; Nathanson, KL; Neuhausen, SL; Weber, B; Chang-Claude, J; Easton, DF; Goldgar, D; Stratton, MR				Rahman, N; Teare, MD; Seal, S; Renard, H; Mangion, J; Cour, C; Thompson, D; Shugart, Y; Eccles, D; Devilee, P; Meijers, H; Nathanson, KL; Neuhausen, SL; Weber, B; Chang-Claude, J; Easton, DF; Goldgar, D; Stratton, MR			Absence of evidence for a familial breast cancer susceptibility gene at chromosome 8p12-p22	ONCOGENE			English	Article						boast cancer; BRCA1; BRCA2; familial; chromosome 8p	LINKAGE ANALYSIS; SHORT ARM; OVARIAN-CANCER; BRCA1; MUTATIONS; HETEROZYGOSITY; REGION	Several recent studies indicate that the majority of families with five or fen er cases of breast cancer and no cases of ovarian cancer are not due to BRCA1 or BRCA2. It has been proposed that a further breast cancer susceptibility gene that may account for some of these families is located on chromosome 8p12-p22, We have identified 31 site-specific breast cancer families that have a greater than 80% posterior probability of being due to genes other than BRCA1 or BRCA2. These families have been examined for linkage to 8p12-p22 using markers flanking the putative location of the gene. The overall multi-point LOD score is strongly negative across the whole 44 cM. The individual multi-point LOD score is negative in 23 families and only exceeds 0.5 in a single family (with a multi-point LOD score of 1.22). The maximum heterogeneity LOD score was 0.03 at marker D8S136 with estimated proportion linked (alpha) of 3% (95% CI 0-30%), These data do not lend support to the hypothesis that chromosome 8p12-p22 harbours a familial breast cancer susceptibility gene.	Inst Canc Res, Sect Canc Genet, Sutton SM2 5NG, Surrey, England; Strangeways Res Lab, CRC, Genet Epidemiol Unit, Cambridge, England; IARC, Lyon, France; Princess Anne Hosp, Wessex Clin Genet Serv, Southampton, Hants, England; Leiden Univ, Dept Human Genet, NL-2300 RA Leiden, Netherlands; Erasmus Univ, Dept Clin Genet, NL-3000 DR Rotterdam, Netherlands; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Genet, Philadelphia, PA 19104 USA; Univ Utah, Sch Med, Div Genet Epidemiol, Salt Lake City, UT USA; Deutsch Krebsforschungszentrum, Div Genet Epidemiol, D-6900 Heidelberg, Germany	University of London; Institute of Cancer Research - UK; World Health Organization; International Agency for Research on Cancer (IARC); Leiden University; Leiden University - Excl LUMC; Erasmus University Rotterdam; University of Pennsylvania; University of Pennsylvania; Utah System of Higher Education; University of Utah; Helmholtz Association; German Cancer Research Center (DKFZ)	Rahman, N (corresponding author), Univ Wales Hosp, Heath Pk, Cardiff CF4 4XW, S Glam, Wales.		Eccles, Diana/K-6327-2019; Rahman, Nazneen/B-8890-2012; DEVILEE, PETER/ABR-2140-2022; Rahman, Nazneen/D-2802-2013	Eccles, Diana/0000-0002-9935-3169; Teare, Marion Dawn/0000-0003-3994-0051; Rahman, Nazneen/0000-0003-4376-0440; Nathanson, Katherine/0000-0002-6740-0901				CLAUS EB, 1991, AM J HUM GENET, V48, P232; EASTON DF, 1993, AM J HUM GENET, V52, P678; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Hakansson S, 1997, AM J HUM GENET, V60, P1068; Imbert A, 1996, GENOMICS, V32, P29, DOI 10.1006/geno.1996.0073; KERANGUEVEN F, 1995, ONCOGENE, V10, P1023; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; Malone KE, 1998, JAMA-J AM MED ASSOC, V279, P922, DOI 10.1001/jama.279.12.922; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; OCONNELL JR, 1995, NAT GENET, V11, P402, DOI 10.1038/ng1295-402; Peto J, 1999, J NATL CANCER I, V91, P943, DOI 10.1093/jnci/91.11.943; PetrijBosch A, 1997, NAT GENET, V17, P341, DOI 10.1038/ng1197-341; Rahman N, 1998, ANNU REV GENET, V32, P95, DOI 10.1146/annurev.genet.32.1.95; Schubert EK, 1997, AM J HUM GENET, V60, P1031; Seitz S, 1997, BRIT J CANCER, V76, P983, DOI 10.1038/bjc.1997.497; Seitz S, 1997, ONCOGENE, V14, P741, DOI 10.1038/sj.onc.1200881; Serova OM, 1997, AM J HUM GENET, V60, P486; SPURR NK, 1995, CYTOGENET CELL GENET, V68, P148; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; YAREMKO ML, 1995, GENE CHROMOSOME CANC, V13, P186, DOI 10.1002/gcc.2870130308; Yaremko ML, 1996, GENE CHROMOSOME CANC, V16, P189, DOI 10.1002/(SICI)1098-2264(199607)16:3<189::AID-GCC6>3.0.CO;2-V	21	26	27	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2000	19	36					4170	4173		10.1038/sj.onc.1203735	http://dx.doi.org/10.1038/sj.onc.1203735			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962578				2022-12-25	WOS:000088955100011
J	Chen, G; Hitomi, M; Han, JH; Stacey, DW				Chen, G; Hitomi, M; Han, JH; Stacey, DW			The p38 pathway provides negative feedback for Ras proliferative signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NIH 3T3 CELLS; MAP KINASE; C-JUN; TRANSCRIPTIONAL ACTIVATION; CELLULAR-TRANSFORMATION; INCREASING COMPLEXITY; REGULATED KINASE-1/2; TOPOISOMERASE-II; GENE-EXPRESSION	Ras activates three mitogen-activated protein kinases (MAPKs) including ERK, JNK and p38. Whereas the essential roles of ERK and JNK in Ras signaling has been established, the contribution of p38 remains unclear. Here we demonstrate that the p38 pathway functions as a negative regulator of Pas proliferative signaling via a feedback mechanism. Oncogenic Ras activated p38 and two p38-activated protein kinases, MAPK-activated protein kinase 2 (MK2) and p58-related/activated protein kinase (PRAK). MK2 and PRAK in turn suppressed Pas-induced gene expression and cell proliferation, whereas two mutant PRAKs, unresponsive to has, had little effect. Moreover, the constitutive p38 activator MKK6 also suppressed Pas activity in a p38-dependent manner whereas arsenite, a potent chemical inducer of p38, inhibited proliferation only in a tumor cell line that required Pas activity. MEK was required for Ras stimulation of the p38 pathway. The p38 pathway inhibited Pas activity by blocking activation of JNK, without effect upon ERK, as evidenced by the fact that PRAK-mediated suppression of Pas-induced cell proliferation was reversed by coexpression of JNKK2 or JNK1. These studies thus establish a negative feedback mechanism by which Pas proliferative activity is regulated via signaling integrations of MAPK pathways.	Cleveland Clin Fdn, Dept Mol Biol, Cleveland, OH 44195 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Cleveland Clinic Foundation; Scripps Research Institute	Chen, G (corresponding author), Loyola Univ, Med Ctr, Dept Radiat Oncol, 2160 S 1st Ave,Bldg 1,Mail Rte 114B, Maywood, IL 60153 USA.		Han, J/G-4671-2010		NCI NIH HHS [CA91576] Funding Source: Medline; NIGMS NIH HHS [GM51417, GM52271] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA091576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052271] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER V, 1995, P NATL ACAD SCI USA, V92, P10585, DOI 10.1073/pnas.92.23.10585; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Arata S, 1997, J CELL PHYSIOL, V170, P19, DOI 10.1002/(SICI)1097-4652(199701)170:1<19::AID-JCP3>3.0.CO;2-O; Blackburn RV, 1997, INT J CANCER, V72, P871, DOI 10.1002/(SICI)1097-0215(19970904)72:5<871::AID-IJC26>3.0.CO;2-A; BOS JL, 1989, CANCER RES, V49, P4682; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chen G, 1996, J BIOL CHEM, V271, P28259, DOI 10.1074/jbc.271.45.28259; Chen G, 1997, ONCOGENE, V15, P1643, DOI 10.1038/sj.onc.1201347; Chen G, 1999, ONCOGENE, V18, P7149, DOI 10.1038/sj.onc.1203149; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Ellinger-Ziegelbauer H, 1999, MOL CELL BIOL, V19, P3857; ENGEL K, 1995, J BIOL CHEM, V270, P27213, DOI 10.1074/jbc.270.45.27213; Foos G, 1998, J BIOL CHEM, V273, P18871, DOI 10.1074/jbc.273.30.18871; GALANG CK, 1994, ONCOGENE, V9, P2913; Gangarosa LM, 1997, J BIOL CHEM, V272, P18926, DOI 10.1074/jbc.272.30.18926; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Johnson R, 1996, MOL CELL BIOL, V16, P4504; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Klesse LJ, 1999, ONCOGENE, V18, P2055, DOI 10.1038/sj.onc.1202524; Kumar A, 1998, J BIOL CHEM, V273, P15742, DOI 10.1074/jbc.273.25.15742; Larsen CM, 1998, J BIOL CHEM, V273, P15294, DOI 10.1074/jbc.273.24.15294; Larsen JK, 1997, AM J PHYSIOL-LUNG C, V273, pL930, DOI 10.1152/ajplung.1997.273.5.L930; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Miyazawa K, 1998, J BIOL CHEM, V273, P24832, DOI 10.1074/jbc.273.38.24832; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Nemoto S, 1998, MOL CELL BIOL, V18, P3518, DOI 10.1128/MCB.18.6.3518; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rausch O, 1999, J BIOL CHEM, V274, P4096, DOI 10.1074/jbc.274.7.4096; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; Schafer C, 1998, J BIOL CHEM, V273, P24173, DOI 10.1074/jbc.273.37.24173; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; STACEY DW, 1987, EXP CELL RES, V171, P232, DOI 10.1016/0014-4827(87)90266-7; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Verheijen MHG, 1999, ONCOGENE, V18, P4435, DOI 10.1038/sj.onc.1202834; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; WOESSNER RD, 1990, CANCER RES, V50, P2901; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; YAN MH, 1994, J BIOL CHEM, V269, P19067; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232	66	139	145	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					38973	38980		10.1074/jbc.M002856200	http://dx.doi.org/10.1074/jbc.M002856200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10978313	hybrid			2022-12-25	WOS:000165953100006
J	Downey, P; Szabo, I; Ivashikina, N; Negro, A; Guzzo, F; Ache, P; Hedrich, R; Terzi, M; Lo Schiavo, F				Downey, P; Szabo, I; Ivashikina, N; Negro, A; Guzzo, F; Ache, P; Hedrich, R; Terzi, M; Lo Schiavo, F			KDC1, a novel carrot root hair K+ channel - Cloning, characterization, and expression in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; POTASSIUM CHANNEL; APOPLASTIC PH; MEMBRANE; POTATO; GENE; RECTIFIER; MECHANISM; SEQUENCE; SUBUNIT	Potassium is an essential nutrient which plays an important role in many aspects of plant growth and development. Plants have developed a number of highly specific mechanisms to take up potassium from the soil; these include the expression of K+ transporters and potassium channels in root cells. Despite the fact that root epidermal and hair cells are in direct contact with the soil, the role of these tissues in K+ uptake is not well understood. Here we report the molecular cloning and functional characterization of a novel potassium channel KDC1 which forms part of a new subfamily of plant K-in channels. Kdc1 was isolated from carrot root RNA and in situ hybridization experiments show Kdc1 to be highly expressed in root hair cells. Expressing the KDC1 protein in Chinese hamster ovary cells identified it as a voltage and pH-dependent inwardly rectifying potassium channel. An electrophysiological analysis of carrot root hair protoplasts confirmed the biophysical properties of the Kdc1 gene product (KDC1) in the heterologous expression system. KDC1 thus represents a major K+ uptake channel in carrot root hair cells.	Univ Padua, Ctr Biotechnol, Ctr Ric Interdipartimentale Biotechnol Innovat, I-35121 Padua, Italy; Univ Padua, Dipartimento Biol, I-35121 Padua, Italy; Univ Wurzburg, Lehrstuhl Mol Pflanzenphysiol & Biophys, Julius von Sachs Inst Biowissensch, D-97082 Wurzburg, Germany; Univ Verona, Ist Policattedra, I-37134 Verona, Italy	University of Padua; University of Padua; University of Wurzburg; University of Verona	Downey, P (corresponding author), Univ Padua, Ctr Biotechnol, Ctr Ric Interdipartimentale Biotechnol Innovat, Viale G Colombo 3, I-35121 Padua, Italy.	pdowney@civ.bio.unipd.it	Szabo, Ildiko/AAW-5972-2021; Hedrich, Rainer/G-8771-2011; Ache, Peter/AAS-7651-2021; Padova, Ildiko/K-5344-2016	Szabo, Ildiko/0000-0002-3637-3947; Hedrich, Rainer/0000-0003-3224-1362; Ache, Peter/0000-0002-2902-7552; GUZZO, Flavia/0000-0003-2946-1962; NEGRO, ALESSANDRO/0000-0003-3142-7632				Amtmann A, 1999, PLANT PHYSIOL, V120, P331, DOI 10.1104/pp.120.1.331; ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; Bibikova TN, 1998, DEVELOPMENT, V125, P2925; Bruggemann L, 1999, P NATL ACAD SCI USA, V96, P3298, DOI 10.1073/pnas.96.6.3298; CLARKSON DT, 1980, ANNU REV PLANT PHYS, V31, P239, DOI 10.1146/annurev.pp.31.060180.001323; Connor JX, 1998, J BIOL CHEM, V273, P28906, DOI 10.1074/jbc.273.44.28906; COOPER JA, 1984, J BIOL CHEM, V259, P7835; Czempinski K, 1997, EMBO J, V16, P2565, DOI 10.1093/emboj/16.10.2565; Daram P, 1997, EMBO J, V16, P3455, DOI 10.1093/emboj/16.12.3455; DREWS GN, 1998, ARABIDOPSIS PROTOCOL; Ehrhardt T, 1997, FEBS LETT, V409, P166, DOI 10.1016/S0014-5793(97)00502-4; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; Felle HH, 1998, J EXP BOT, V49, P987, DOI 10.1093/jexbot/49.323.987; GASSMANN W, 1994, PLANT PHYSIOL, V105, P1399, DOI 10.1104/pp.105.4.1399; Gaymard F, 1996, J BIOL CHEM, V271, P22863, DOI 10.1074/jbc.271.37.22863; Gaymard F, 1998, CELL, V94, P647, DOI 10.1016/S0092-8674(00)81606-2; GLASS DB, 1986, J BIOL CHEM, V261, P2987; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hartje S, 2000, PLANTA, V210, P723, DOI 10.1007/s004250050673; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; Hirsch RE, 1998, SCIENCE, V280, P918, DOI 10.1126/science.280.5365.918; Hoth S, 1997, P NATL ACAD SCI USA, V94, P4806, DOI 10.1073/pnas.94.9.4806; Hoth S, 1999, J BIOL CHEM, V274, P11599, DOI 10.1074/jbc.274.17.11599; Ketchum KA, 1996, FEBS LETT, V378, P19, DOI 10.1016/0014-5793(95)01417-9; KO CH, 1991, MOL CELL BIOL, V11, P4266, DOI 10.1128/MCB.11.8.4266; KUMPF RA, 1993, SCIENCE, V261, P1708, DOI 10.1126/science.8378771; Lagarde D, 1996, PLANT J, V9, P195, DOI 10.1046/j.1365-313X.1996.09020195.x; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; LUKACS GL, 1993, J BIOL CHEM, V268, P21592; MARSHALL J, 1995, NEURON, V14, P211, DOI 10.1016/0896-6273(95)90279-1; Marten I, 1999, P NATL ACAD SCI USA, V96, P7581, DOI 10.1073/pnas.96.13.7581; MORAN N, 1988, PLANT PHYSIOL, V88, P643, DOI 10.1104/pp.88.3.643; MULLERROBER B, 1995, EMBO J, V14, P2409, DOI 10.1002/j.1460-2075.1995.tb07238.x; NAKAMURA RL, 1995, PLANT PHYSIOL, V109, P371, DOI 10.1104/pp.109.2.371; NEHER E, 1992, METHOD ENZYMOL, V207, P123; Philippar K, 1999, P NATL ACAD SCI USA, V96, P12186, DOI 10.1073/pnas.96.21.12186; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHROEDER JI, 1984, NATURE, V312, P361, DOI 10.1038/312361a0; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; Taylor DP, 1996, PHYSIOL PLANTARUM, V97, P35, DOI 10.1111/j.1399-3054.1996.tb00475.x; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; Yu SP, 1998, J NEUROSCI RES, V52, P612, DOI 10.1002/(SICI)1097-4547(19980601)52:5<612::AID-JNR13>3.0.CO;2-3; Zimmermann S, 1998, PLANT PHYSIOL, V116, P879, DOI 10.1104/pp.116.3.879	48	40	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39420	39426		10.1074/jbc.M002962200	http://dx.doi.org/10.1074/jbc.M002962200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10970888	hybrid			2022-12-25	WOS:000165953100066
J	Einsle, O; Stach, P; Messerschmidt, A; Simon, J; Kroger, A; Huber, R; Kroneck, PMH				Einsle, O; Stach, P; Messerschmidt, A; Simon, J; Kroger, A; Huber, R; Kroneck, PMH			Cytochrome c nitrite reductase from Wolinella succinogenes - Structure at 1.6 angstrom resolution, inhibitor binding, and heme-packing motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESULFOVIBRIO-DESULFURICANS; CRYSTAL-STRUCTURE; PROTEIN; AMMONIA; C(3); PURIFICATION; HYDROGENASE; BIOGENESIS; MOLSCRIPT; SEQUENCE	Cytochrome c nitrite reductase catalyzes the 6-electron reduction of nitrite to ammonia. This second part of the respiratory pathway of nitrate ammonification is a key step in the biological nitrogen cycle. The x-ray structure of the enzyme from the epsilon -proteobacterium Wolinella succinogenes has been solved to a resolution of 1.6 Angstrom It is a pentaheme c-type cytochrome whose heme groups are packed in characteristic motifs that also occur in other multiheme cytochromes. Structures of W. succinogenes nitrite reductase have been obtained with water bound to the active site heme iron as well as complexes with two inhibitors, sulfate and azide, whose binding modes and inhibitory functions differ significantly. Cytochrome c nitrite reductase is part of a highly optimized respiratory system found in a wide range of Gram-negative bacteria. It reduces both anionic and neutral substrates at the distal side of a lysine-coordinated high-spin heme group, which is accessible through two different channels, allowing for a guided flow of reaction educt and product. Based on sequence comparison and secondary structure prediction, we have demonstrated that cytochrome c nitrite reductases constitute a protein family of high structural similarity.	Univ Konstanz, Math Naturwissensch Sekt, Fachbereich Biol, D-78457 Constance, Germany; Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; Goethe Univ Frankfurt, Inst Mikrobiol, D-60439 Frankfurt, Germany	University of Konstanz; Max Planck Society; Goethe University Frankfurt	Einsle, O (corresponding author), Univ Konstanz, Math Naturwissensch Sekt, Fachbereich Biol, Fach M665,Univ Str 10, D-78457 Constance, Germany.	einsle@biochem.mpg.de; Peter.Kroneck@uni-konstanz.de	Messerschmidt, Albrecht/A-8337-2008; Simon, Jörg/F-2355-2016	Simon, Jörg/0000-0003-0214-3745; Einsle, Oliver/0000-0001-8722-2893				Bamford V, 1999, NAT STRUCT BIOL, V6, P1104; Banci L, 1996, P NATL ACAD SCI USA, V93, P14396, DOI 10.1073/pnas.93.25.14396; Barker PD, 1999, STRUCTURE, V7, pR281, DOI 10.1016/S0969-2126(00)88334-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COLE JA, 1980, FEMS MICROBIOL LETT, V7, P65, DOI 10.1111/j.1574-6941.1980.tb01578.x; DARWIN A, 1993, MOL MICROBIOL, V9, P1255, DOI 10.1111/j.1365-2958.1993.tb01255.x; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; Eaves DJ, 1998, MOL MICROBIOL, V28, P205, DOI 10.1046/j.1365-2958.1998.00792.x; Einsle O, 1999, NATURE, V400, P476, DOI 10.1038/22802; EINSLE O, 2000, HDB METALLOPROTEINS; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Guex, 1996, PROTEIN DATA BANK Q, V77, P7; HALADJIAN J, 1987, BIOCHEM BIOPH RES CO, V147, P1289, DOI 10.1016/S0006-291X(87)80210-3; HUSSAIN H, 1994, MOL MICROBIOL, V12, P153, DOI 10.1111/j.1365-2958.1994.tb01004.x; Igarashi N, 1997, NAT STRUCT BIOL, V4, P276, DOI 10.1038/nsb0497-276; Iverson TM, 1998, NAT STRUCT BIOL, V5, P1005, DOI 10.1038/2975; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kranz R, 1998, MOL MICROBIOL, V29, P383, DOI 10.1046/j.1365-2958.1998.00869.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Matias PM, 1997, J BIOL INORG CHEM, V2, P507, DOI 10.1007/s007750050162; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NIVIERE V, 1988, BIOCHIM BIOPHYS ACTA, V935, P34, DOI 10.1016/0005-2728(88)90105-3; Norager S, 1999, J MOL BIOL, V290, P881, DOI 10.1006/jmbi.1999.2917; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Parkhill J, 2000, NATURE, V403, P665, DOI 10.1038/35001088; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rost B, 1996, METHOD ENZYMOL, V266, P525; SCHUMACHER W, 1994, BIOCHEM BIOPH RES CO, V205, P911, DOI 10.1006/bbrc.1994.2751; SCHUMACHER W, 1991, ARCH MICROBIOL, V156, P70, DOI 10.1007/BF00418190; Simon J, 2000, MOL MICROBIOL, V35, P686, DOI 10.1046/j.1365-2958.2000.01742.x; Stach P, 2000, J INORG BIOCHEM, V79, P381, DOI 10.1016/S0162-0134(99)00248-2; STEUBER J, 1994, ARCH MICROBIOL, V162, P255, DOI 10.1007/s002030050134; ThonyMeyer L, 1997, MICROBIOL MOL BIOL R, V61, P337	37	158	161	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39608	39616		10.1074/jbc.M006188200	http://dx.doi.org/10.1074/jbc.M006188200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10984487	hybrid			2022-12-25	WOS:000165953100087
J	Beatrix, B; Sakai, H; Wiedmann, M				Beatrix, B; Sakai, H; Wiedmann, M			The alpha and beta subunit of the nascent polypeptide-associated complex have distinct functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; ENDOPLASMIC-RETICULUM MEMBRANE; BTF3 TRANSCRIPTION FACTOR; MESSENGER-RNA; PROTEIN TRANSLOCATION; MICROSOMAL-MEMBRANES; RIBOSOMES; BINDING; CHAINS; YEAST	Nascent polypeptide-associated complex (NAC) is probably the first cytosolic protein to contact nascent polypeptide chains emerging from ribosomes. In this way NAC prevents inappropriate interactions with other factors. Eventually other factors involved in targeting and folding, like the Signal Recognition Particle or cytosolic chaperones, must gain access to the nascent chain. AU. NAC preparations to date consist of two copurifying polypeptides. Here we rigorously show that these two polypeptides, termed alpha- and beta NAC, form a very stable complex in vivo and in vitro and that a functional complex can be reconstituted from the individual subunits. A dissection of the contributions of the individual subunits to NACs function revealed that both subunits are in direct contact with nascent polypeptide chains on the ribosome and that both contribute to the prevention of inappropriate interactions. However, beta NAC alone directly binds to the ribosome and is sufficient to prevent ribosome binding to the endoplasmic reticulum membrane.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Nagasaki Univ, Sch Dent, Dept Pharmacol, Nagasaki 852, Japan	Memorial Sloan Kettering Cancer Center; Nagasaki University	Wiedmann, M (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.	m-wiedmann@ski.mskcc.org			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050920] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50920-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELMAN MR, 1973, J CELL BIOL, V56, P191, DOI 10.1083/jcb.56.1.191; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BORGESE N, 1974, J MOL BIOL, V88, P559, DOI 10.1016/0022-2836(74)90408-2; BULL AL, 1966, J EXP ZOOL, V161, P221, DOI 10.1002/jez.1401610207; DENG JM, 1995, TRANSGENIC RES, V4, P264, DOI 10.1007/BF01969120; Ellis R. John, 1999, Current Opinion in Structural Biology, V9, P102, DOI 10.1016/S0959-440X(99)80013-X; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; Funfschilling U, 1999, MOL BIOL CELL, V10, P3289, DOI 10.1091/mbc.10.10.3289; George R, 1998, P NATL ACAD SCI USA, V95, P2296, DOI 10.1073/pnas.95.5.2296; GILMORE R, 1991, METHOD CELL BIOL, V34, P223; GORLICH D, 1990, J CELL BIOL, V111, P2283, DOI 10.1083/jcb.111.6.2283; GORLICH D, 1991, METHOD CELL BIOL, V34, P241; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HAUSER S, 1995, EMBO J, V14, P5485, DOI 10.1002/j.1460-2075.1995.tb00235.x; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; KANNO M, 1992, GENE, V117, P219, DOI 10.1016/0378-1119(92)90732-5; Lauring B, 1995, COLD SPRING HARB SYM, V60, P47, DOI 10.1101/SQB.1995.060.01.008; LAURING B, 1995, P NATL ACAD SCI USA, V92, P5411, DOI 10.1073/pnas.92.12.5411; LAURING B, 1995, P NATL ACAD SCI USA, V92, P9435, DOI 10.1073/pnas.92.21.9435; Markesich DC, 2000, DEVELOPMENT, V127, P559; Moller I, 1998, P NATL ACAD SCI USA, V95, P13425, DOI 10.1073/pnas.95.23.13425; Moller I, 1998, FEBS LETT, V441, P1, DOI 10.1016/S0014-5793(98)01440-9; Moreau A, 1998, MOL CELL BIOL, V18, P1312, DOI 10.1128/MCB.18.3.1312; Munz B, 1999, J BIOL CHEM, V274, P13305, DOI 10.1074/jbc.274.19.13305; Netzer WJ, 1998, TRENDS BIOCHEM SCI, V23, P68, DOI 10.1016/S0968-0004(97)01171-7; Neuhof A, 1998, MOL BIOL CELL, V9, P103, DOI 10.1091/mbc.9.1.103; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Prinz A, 2000, EMBO J, V19, P1900, DOI 10.1093/emboj/19.8.1900; Raden D, 1998, MOL BIOL CELL, V9, P117, DOI 10.1091/mbc.9.1.117; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; Reimann B, 1999, YEAST, V15, P397, DOI 10.1002/(SICI)1097-0061(19990330)15:5<397::AID-YEA384>3.3.CO;2-L; Rost B, 1996, METHOD ENZYMOL, V266, P525; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WANG S, 1995, J CELL BIOL, V130, P519, DOI 10.1083/jcb.130.3.519; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; Yotov WV, 1998, MOL CELL BIOL, V18, P1303, DOI 10.1128/MCB.18.3.1303; Yotov WV, 1996, GENE DEV, V10, P1763, DOI 10.1101/gad.10.14.1763	42	77	87	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37838	37845		10.1074/jbc.M006368200	http://dx.doi.org/10.1074/jbc.M006368200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10982809	hybrid			2022-12-25	WOS:000165618700072
J	Gabai, VL; Meriin, AB; Yaglom, JA; Wei, JY; Mosser, DD; Sherman, MY				Gabai, VL; Meriin, AB; Yaglom, JA; Wei, JY; Mosser, DD; Sherman, MY			Suppression of stress kinase JNK is involved in Hsp72-mediated protection of myogenic cells from transient energy deprivation - Hsp72 alleviates the stress-induced inhibition of JNK dephosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; HEAT-SHOCK PROTEINS; MYOCARDIAL-ISCHEMIA; TRANSGENIC MICE; CARDIOVASCULAR BIOLOGY; INDUCED APOPTOSIS; TERMINAL KINASES; GENE-EXPRESSION; CARDIAC-CELLS; INFARCT SIZE	Since protection of cells from stress-induced apoptosis by the heat shock protein Hsp72 involves suppression of stress kinase JNK, we suggested that Hsp72-mediated JNK inhibition might also be critical for myocardial protection from ischemia/reperfusion. Transient energy deprivation of H9c2 myogenic cells, used as an in vitro model of myocardial ischemia, led to cell death that had morphological features of apoptosis and necrosis and was independent of caspases. Surprisingly, this unusual type of cell death was regulated by JNK and ERK kinases, In fact, specific inhibition of JNK increased cell survival; specific inhibition of ERKs enhanced deleterious consequences of energy deprivation, whereas inhibition of p38 kinase had no effect. Hsp72 suppressed activation of JNK and did not increase ERK activity, suggesting that inhibition of JNK is the important component of Hsp72-mediated protection. Upon transient energy deprivation, activation of JNK proceeds via two distinct pathways, stimulation of JNK phosphorylation by a protein kinase SEK1 and inhibition of JNK dephosphorylation. Remarkably, in cells exposed to transient energy deprivation, Hsp72 enhanced the rate of JNK dephosphorylation but did not affect SEK1 activity. Therefore, it appears that Hsp72 specifically down-regulates JNK by accelerating its dephosphorylation, which reduces the susceptibility of cardiac cells to simulated ischemia/reperfusion.	Boston Biomed Res Inst, Watertown, MA 02472 USA; Russian Acad Med Sci, Med Radiol Res Inst, Obninsk 249020, Russia; Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada	Boston Biomedical Research Institute; Russian Academy of Medical Sciences; Harvard University; Beth Israel Deaconess Medical Center; National Research Council Canada	Sherman, MY (corresponding author), Boston Biomed Res Inst, 64 Grove St, Watertown, MA 02472 USA.		Gabai, Vladimir L/I-1650-2013; Mosser, Dick D/A-7391-2008	Gabai, Vladimir L/0000-0003-4505-4718; Meriin, Anatoli/0000-0003-0087-814X; Yaglom, Julia/0000-0002-8723-3506; Mosser, Richard/0000-0002-9183-2288	NATIONAL CANCER INSTITUTE [R01CA081244] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA81244-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Benjamin IJ, 1998, CIRC RES, V83, P117, DOI 10.1161/01.RES.83.2.117; Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; Brar BK, 1999, J MOL CELL CARDIOL, V31, P135, DOI 10.1006/jmcc.1998.0857; Cheng W, 1996, EXP CELL RES, V226, P316, DOI 10.1006/excr.1996.0232; Elsasser A, 2000, J MOL CELL CARDIOL, V32, P711, DOI 10.1006/jmcc.2000.1125; Feige U., 1996, STRESS INDUCIBLE CEL; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; Gabai VL, 1998, FEBS LETT, V438, P1, DOI 10.1016/S0014-5793(98)01242-3; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gottlieb RA, 1999, ANN NY ACAD SCI, V874, P412, DOI 10.1111/j.1749-6632.1999.tb09255.x; HEADS RJ, 1995, J MOL CELL CARDIOL, V27, P1669, DOI 10.1016/S0022-2828(95)90722-X; Hutter JJ, 1996, CIRCULATION, V94, P1408, DOI 10.1161/01.CIR.94.6.1408; Kabakov A. E., 1997, HEAT SHOCK PROTEINS; KABAKOV AE, 1993, EXPERIENTIA, V49, P706, DOI 10.1007/BF01923956; KABAKOV AE, 1994, ARCH BIOCHEM BIOPHYS, V309, P247, DOI 10.1006/abbi.1994.1109; Kajstura J, 1996, LAB INVEST, V74, P86; Karwatowska-Prokopczuk E, 1998, CIRC RES, V82, P1139, DOI 10.1161/01.RES.82.11.1139; Kumar S, 1999, BIOCHEM BIOPH RES CO, V263, P825, DOI 10.1006/bbrc.1999.1454; Ma XL, 1999, CIRCULATION, V99, P1685, DOI 10.1161/01.CIR.99.13.1685; Mackay K, 1999, J BIOL CHEM, V274, P6272, DOI 10.1074/jbc.274.10.6272; MacLellan WR, 1997, CIRC RES, V81, P137, DOI 10.1161/01.RES.81.2.137; Massie B, 1998, CYTOTECHNOLOGY, V28, P53, DOI 10.1023/A:1008013211222; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; MESTRIL R, 1995, J MOL CELL CARDIOL, V27, P45, DOI 10.1016/S0022-2828(08)80006-5; Mestril R, 1996, J MOL CELL CARDIOL, V28, P2351, DOI 10.1006/jmcc.1996.0228; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Mosser DD, 1997, BIOTECHNIQUES, V22, P150, DOI 10.2144/97221rr02; Nayeem MA, 1997, AM J PHYSIOL-HEART C, V273, pH861, DOI 10.1152/ajpheart.1997.273.2.H861; Ovelgonne JH, 1996, J MOL CELL CARDIOL, V28, P1617, DOI 10.1006/jmcc.1996.0152; Piper HM, 1998, CARDIOVASC RES, V38, P291, DOI 10.1016/S0008-6363(98)00033-9; PLUMIER JCL, 1995, J CLIN INVEST, V95, P1854, DOI 10.1172/JCI117865; POMBO CM, 1994, J BIOL CHEM, V269, P26546; Radford NB, 1996, P NATL ACAD SCI USA, V93, P2339, DOI 10.1073/pnas.93.6.2339; Rieger D, 1997, ANAL BIOCHEM, V246, P67, DOI 10.1006/abio.1996.9978; Stephanou A, 1998, J MOL CELL CARDIOL, V30, P849, DOI 10.1006/jmcc.1998.0651; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Turner NA, 1998, J MOL CELL CARDIOL, V30, P1789, DOI 10.1006/jmcc.1998.0743; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang CC, 1998, J ELECTROCERAM, V2, P273, DOI 10.1023/A:1009978607621; Webb S J, 1997, Adv Pharmacol, V41, P1, DOI 10.1016/S1054-3589(08)61052-2; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yin TG, 1997, J BIOL CHEM, V272, P19943, DOI 10.1074/jbc.272.32.19943; Yue TL, 2000, CIRC RES, V86, P692, DOI 10.1161/01.RES.86.6.692; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115	46	95	100	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					38088	38094		10.1074/jbc.M006632200	http://dx.doi.org/10.1074/jbc.M006632200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10978340	hybrid			2022-12-25	WOS:000165618700104
J	Kar, S; Soong, L; Colmenares, M; Goldsmith-Pestana, K; McMahon-Pratt, D				Kar, S; Soong, L; Colmenares, M; Goldsmith-Pestana, K; McMahon-Pratt, D			The immunologically protective P-4 antigen of Leishmania amastigotes - A developmentally regulated single strand-specific nuclease associated with the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; MESSENGER-RNA; CUTANEOUS LEISHMANIASIS; EXCISION-REPAIR; CHAGASI PROMASTIGOTES; TRYPANOSOMA-BRUCEI; MEMBRANE-PROTEINS; GOLGI-APPARATUS; SIGNAL PEPTIDE; L AMAZONENSIS	The purified membrane-associated Leishmania pifanoi amastigote protein P-4 has been shown to induce protective immunity against infection and to elicit preferentially a T helper 1-like response in peripheral blood mononuclear cells of patients with American cutaneous leishmaniasis. As this molecule is potentially important for future vaccine studies, the L. pifanoi gene encoding the P-4 membrane protein was cloned and sequenced. Southern blot analyses indicate the presence of six tandemly arrayed copies of the P-4 gene in L. pifanoi; homologues of the P-4 gene are found in all other species of the genus Leishmania examined. DNA-derived protein sequence data indicated an identity to the Pi zinc-dependent nuclease of Penicillium citrinum (20.8%) and the C-terminal domain of the 3' nucleotidase of Leishmania donovani (33.7%), Consistent with these sequence analyses, purified L. pifanoi P-4 protein possesses single strand nuclease (DNA and RNA) and phosphomonoesterase activity, with a preference for UMP > TMP > AMP >> CMP, Double-labeling immunofluorescence microscopic analyses employing anti-binding protein antibodies revealed that the P-4 protein is localized in the endoplasmic reticulum of the amastigote. Northern blot analyses indicated that the gene is selectively expressed in the intracellular amastigote stage (mammalian host) but not in the promastigote stage (insect) of the parasite. Based upon its subcellular localization and single-stranded specific nuclease activity, possible roles of the P-4 nuclease in the amastigote in RNA stability (gene expression) or DNA repair are discussed.	Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA	Yale University	McMahon-Pratt, D (corresponding author), Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, POB 208034,60 Coll St, New Haven, CT 06510 USA.	diane.mcmahon-pratt@yale.edu	Colmenares, Maria Isabel/H-2848-2017	Colmenares, Maria Isabel/0000-0003-4114-277X				Al-Qahtani A, 1998, BIOCHEM J, V331, P521, DOI 10.1042/bj3310521; Bangs JD, 1996, J BIOL CHEM, V271, P18387, DOI 10.1074/jbc.271.31.18387; BANYOPADHYAY R, 1990, MOL CELL BIOL, V10, P2060; Beetham JK, 1997, J BIOL CHEM, V272, P17360, DOI 10.1074/jbc.272.28.17360; BEVERLEY SM, 1988, NUCLEIC ACIDS RES, V16, P925, DOI 10.1093/nar/16.3.925; BISHOP RP, 1990, MOL BIOCHEM PARASIT, V18, P127; BLAINEAU C, 1991, MOL BIOCHEM PARASIT, V46, P293, DOI 10.1016/0166-6851(91)90053-9; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; CAMPOSNETO A, 1995, J EXP MED, V182, P1423, DOI 10.1084/jem.182.5.1423; Charest H, 1996, J BIOL CHEM, V271, P17081, DOI 10.1074/jbc.271.29.17081; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; Coutinho SG, 1996, EXP PARASITOL, V84, P144, DOI 10.1006/expr.1996.0100; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; DEBRABANT A, 1995, MOL BIOCHEM PARASIT, V71, P51, DOI 10.1016/0166-6851(95)00035-Y; DOMPENCIEL RE, 1995, J BIOL CHEM, V270, P6108, DOI 10.1074/jbc.270.11.6108; DUBOISE SM, 1994, THESIS YALE U NEW HA; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GERBER LD, 1992, J BIOL CHEM, V267, P12168; GLASER TA, 1988, P NATL ACAD SCI USA, V85, P7602, DOI 10.1073/pnas.85.20.7602; Gomord V, 1999, BIOCHIMIE, V81, P607, DOI 10.1016/S0300-9084(99)80118-7; GOTTLIEB M, 1983, MOL BIOCHEM PARASIT, V7, P303, DOI 10.1016/0166-6851(83)90013-0; GRIMALDI G, 1993, CLIN MICROBIOL REV, V6, P230, DOI 10.1128/CMR.6.3.230-250.1993; HAMMOND DJ, 1984, MOL BIOCHEM PARASIT, V13, P243, DOI 10.1016/0166-6851(84)90117-8; Handman E, 1997, PARASITOL TODAY, V13, P236, DOI 10.1016/S0169-4758(97)01060-0; HART DT, 1982, EXP PARASITOL, V54, P397, DOI 10.1016/0014-4894(82)90049-2; Hodgkinson VH, 1996, EXP PARASITOL, V83, P94, DOI 10.1006/expr.1996.0053; Kawahara T, 1997, MOL BIOL CELL, V8, P1845, DOI 10.1091/mbc.8.10.1845; Kim PK, 1999, J BIOL CHEM, V274, P36876, DOI 10.1074/jbc.274.52.36876; LANDFORD CK, 1992, EXP PARASITOL, V74, P360; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; McCoy JJ, 1998, MOL BIOCHEM PARASIT, V95, P251, DOI 10.1016/S0166-6851(98)00112-1; MCMAHONPRATT D, 1993, INFECT IMMUN, V61, P3351, DOI 10.1128/IAI.61.8.3351-3359.1993; MODABBER F, 1990, SCAND J INFECT DIS, P72; Mosser David M., 1993, Seminars in Cell Biology, V4, P315, DOI 10.1006/scel.1993.1038; MOUGNEAU E, 1995, SCIENCE, V268, P563, DOI 10.1126/science.7725103; Mziaut H, 1999, J BIOL CHEM, V274, P14122, DOI 10.1074/jbc.274.20.14122; Odermatt A, 1999, J BIOL CHEM, V274, P28762, DOI 10.1074/jbc.274.40.28762; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; Ouzzine M, 1999, J BIOL CHEM, V274, P31401, DOI 10.1074/jbc.274.44.31401; PAN AA, 1988, J IMMUNOL, V140, P2406; Paramchuk WJ, 1997, MOL BIOCHEM PARASIT, V90, P203, DOI 10.1016/S0166-6851(97)00141-2; Parikh SS, 1997, STRUCTURE, V5, P1543, DOI 10.1016/S0969-2126(97)00303-1; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; Peters C, 1997, INFECT IMMUN, V65, P783, DOI 10.1128/IAI.65.2.783-786.1997; PETERSEN EA, 1984, J IMMUNOL, V132, P2603; RAINEY PM, 1991, MOL BIOCHEM PARASIT, V45, P307, DOI 10.1016/0166-6851(91)90099-R; RAMAMOORTHY R, 1995, J BIOL CHEM, V270, P12133, DOI 10.1074/jbc.270.20.12133; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; RUSSELL DG, 1988, J IMMUNOL, V140, P1274; RUSSELL DG, 1989, IMMUNOL TODAY, V10, P328, DOI 10.1016/0167-5699(89)90188-6; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; Shamu CE, 1998, CURR BIOL, V8, pR121, DOI 10.1016/S0960-9822(98)70986-8; SHISHIDO K, 1986, BIOCHIM BIOPHYS ACTA, V884, P215, DOI 10.1016/0304-4165(86)90247-3; SIRAKOVA TD, 1994, INFECT IMMUN, V62, P4208, DOI 10.1128/IAI.62.10.4208-4218.1994; SOONG L, 1995, INFECT IMMUN, V63, P3559, DOI 10.1128/IAI.63.9.3559-3566.1995; STRAUS AH, 1993, J BIOL CHEM, V268, P13723; Straus AH, 1997, BRAZ J MED BIOL RES, V30, P395, DOI 10.1590/S0100-879X1997000300014; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; VOGT VM, 1973, EUR J BIOCHEM, V33, P192, DOI 10.1111/j.1432-1033.1973.tb02669.x; VOLBEDA A, 1991, EMBO J, V10, P1607, DOI 10.1002/j.1460-2075.1991.tb07683.x; YANG DM, 1990, J IMMUNOL, V145, P2281; Zhang WW, 1997, P NATL ACAD SCI USA, V94, P8807, DOI 10.1073/pnas.94.16.8807; ZILBERSTEIN D, 1993, MOL BIOCHEM PARASIT, V61, P197, DOI 10.1016/0166-6851(93)90066-7; ZLOTNICK GW, 1987, COMP BIOCHEM PHYS B, V87, P629, DOI 10.1016/0305-0491(87)90063-0; ZLOTNICK GW, 1986, ANAL BIOCHEM, V153, P121, DOI 10.1016/0003-2697(86)90069-2	65	28	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37789	37797		10.1074/jbc.M002149200	http://dx.doi.org/10.1074/jbc.M002149200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10969068	hybrid			2022-12-25	WOS:000165618700066
J	Lee, KN; Lee, CS; Tae, WC; Jackson, KW; Christiansen, VJ; McKee, PA				Lee, KN; Lee, CS; Tae, WC; Jackson, KW; Christiansen, VJ; McKee, PA			Cross-linking of wild-type and mutant alpha(2)-antiplasmins to fibrin by activated factor XIII and by a tissue transglutaminase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE TRANSGLUTAMINASE; PIG LIVER TRANSGLUTAMINASE; COAGULATION FACTOR-XIII; PLASMA FACTOR-XIIIA; ALPHA2-PLASMIN INHIBITOR; STRUCTURAL FEATURES; COLORIMETRIC ASSAY; PURIFICATION; IDENTIFICATION; EXPRESSION	Human alpha (2)-antiplasmin (alpha (2)AP), the main inhibitor of plasmin-mediated fibrinolysis, is a substrate for plasma transglutaminase, also termed activated factor XIII (FXIIIa). Of 452 amino acids in alpha (2)AP, only Gln(2) is believed to be a fibrin-cross-linking (or FXIIIa-reactive) site. Kinetic efficiencies (k(cat)/K-m(app)) of FXIIIa and the guinea pig liver tissue transglutaminase (tTG;) and reactivities of Gin substrate sites were compared for recombinant wild-type alpha (2)AP (WT-alpha (2)AP) and Q2A mutant alpha (2)AP (Q2A-alpha (2)AP), [C-14]Methylamine incorporation showed the k(cat)/K-m(app) of FXIIIa to be 3-fold greater than that of tTG for WT-alpha (2)AP, With FXIIIa or tTG catalysis, [C-14]methylamine was incorporated into Q2A-alpha (2)AP, indicating that WT-alpha (2)AP has more than one Gin cross-linking site. To identify transglutaminase-reactive sites in WT-alpha (2)AP or Q2A-alpha (2)AP, each was labeled with 5-(biotinamido)pentylamine by FXIIIa or tTG catalysis, After each labeled alpha (2)AP was digested by trypsin, sequence and mass analyses of each labeled peptide showed that 4 of 35 Gin residues were labeled with the following reactivities: Gln(2) > Gln(21) > Gln(419) > Gln(447). Q(2)A-alpha (2)AP was also labeled at Gln(21) > Gln(419) > Gln(447), but became cross-linked to fibrin;by FXIIIa or tTG at approximately one-tenth the rate for WT-alpha (2)AP, These results show that alpha (2)AP is a better substrate for FXIIIa than for this particular tTG, but that either enzyme involves the same Gin substrate sites in alpha (2)AP and yields the same order of reactivities.	Univ Oklahoma, Hlth Sci Ctr, William K Warren Med Res Inst, Oklahoma City, OK 73190 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Lee, KN (corresponding author), Univ Oklahoma, Hlth Sci Ctr, William K Warren Med Res Inst, POB 26901,BSEB 306, Oklahoma City, OK 73190 USA.	kyung-lee@ouhsc.edu						AESCHLIMANN D, 1992, J BIOL CHEM, V267, P11316; BRENNER SC, 1978, BIOCHIM BIOPHYS ACTA, V522, P74, DOI 10.1016/0005-2744(78)90323-6; CARMINES PK, 1983, RENAL PHYSIOL BIOCH, V6, P281; CHUNG SI, 1974, J BIOL CHEM, V249, P940; COLLEN D, 1976, EUR J BIOCHEM, V69, P209, DOI 10.1111/j.1432-1033.1976.tb10875.x; CURTIS CG, 1973, BIOCHEM BIOPH RES CO, V52, P51, DOI 10.1016/0006-291X(73)90952-2; FOLK JE, 1985, METHOD ENZYMOL, V113, P358; FOLK JE, 1966, J BIOL CHEM, V241, P5518; FOLK JE, 1969, J BIOL CHEM, V244, P3707; GORMAN JJ, 1980, J BIOL CHEM, V255, P419; GORMAN JJ, 1981, J BIOL CHEM, V256, P2712; GREENBERG CS, 1987, BLOOD, V70, P702; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; Haroon ZA, 1999, FASEB J, V13, P1787, DOI 10.1096/fasebj.13.13.1787; HORTIN G, 1987, J BIOL CHEM, V262, P3082; JENSEN PH, 1994, J BIOL CHEM, V269, P15394; JEON WM, 1989, ANAL BIOCHEM, V182, P170, DOI 10.1016/0003-2697(89)90737-9; KWON KS, 1995, BBA-PROTEIN STRUCT M, V1247, P179, DOI 10.1016/0167-4838(94)00224-5; LEE KN, 1986, PREP BIOCHEM, V16, P321, DOI 10.1080/00327488608068752; LEE KN, 1992, BIOCHIM BIOPHYS ACTA, V1136, P12, DOI 10.1016/0167-4889(92)90078-P; Lee KN, 1998, THROMB HAEMOSTASIS, V80, P637; LEE KN, 1989, BIOCHEM BIOPH RES CO, V162, P1370, DOI 10.1016/0006-291X(89)90825-5; LEE KN, 1988, CLIN CHEM, V34, P906; LEE KN, 1985, J BIOL CHEM, V260, P4689; Lee KN, 1999, BLOOD, V94, P164, DOI 10.1182/blood.V94.1.164.413k16_164_171; Lee SC, 1997, PREP BIOCHEM BIOTECH, V27, P227, DOI 10.1080/10826069708001281; LIJNEN HR, 1987, EUR J BIOCHEM, V166, P565, DOI 10.1111/j.1432-1033.1987.tb13551.x; LIN XL, 1989, J BIOL CHEM, V264, P4482; MIESCHENDAHL M, 1986, BIO-TECHNOL, V4, P802, DOI 10.1038/nbt0986-802; MIMURO J, 1986, J CLIN INVEST, V77, P1006, DOI 10.1172/JCI112352; MOROI M, 1976, J BIOL CHEM, V251, P5956; Rashtchian Ayoub, 1995, Current Opinion in Biotechnology, V6, P30, DOI 10.1016/0958-1669(95)80006-9; Reed GL, 1999, CIRCULATION, V99, P299, DOI 10.1161/01.CIR.99.2.299; RUBIN H, 1990, J BIOL CHEM, V265, P1199; Schaefer BM, 1996, ARCH DERMATOL RES, V288, P122, DOI 10.1007/BF02505820; SCHWARTZ ML, 1973, J BIOL CHEM, V248, P1395; SHAINOFF JR, 1991, J BIOL CHEM, V266, P6429; TAMAKI T, 1981, BIOCHIM BIOPHYS ACTA, V661, P280, DOI 10.1016/0005-2744(81)90016-4; TAMAKI T, 1982, J BIOL CHEM, V257, P4767; VALENZUELA R, 1992, AM J PATHOL, V141, P861; Valnickova Z, 1998, J BIOL CHEM, V273, P27220, DOI 10.1074/jbc.273.42.27220; WEITZ JI, 1993, J CLIN INVEST, V91, P1343, DOI 10.1172/JCI116335; WIMAN B, 1977, EUR J BIOCHEM, V78, P19, DOI 10.1111/j.1432-1033.1977.tb11709.x	43	36	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37382	37389		10.1074/jbc.M003375200	http://dx.doi.org/10.1074/jbc.M003375200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10958788	hybrid			2022-12-25	WOS:000165618700012
J	Reyland, ME; Evans, RM; White, EK				Reyland, ME; Evans, RM; White, EK			Lipoproteins regulate expression of the steroidogenic acute regulatory protein (StAR) in mouse adrenocortical cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAMITOCHONDRIAL CHOLESTEROL TRANSFER; LIPOID ADRENAL-HYPERPLASIA; PROMOTER ACTIVITY; SCAVENGER RECEPTOR; GENE-TRANSCRIPTION; BINDING PROTEIN; CDNA CLONING; SR-BI; FACTOR-1; GLAND	The steroidogenic acute regulatory protein (StAR) is required for the movement of cholesterol from the outer to the inner mitochondrial membrane, the site of cholesterol side chain cleavage. Here we describe a novel form of regulation of StAR gene expression in steroidogenic cells. Treatment of Y-1 BS1 adrenocortical cells with either low density lipoprotein (LDL) or high density lipoprotein (HDL) increases expression of endogenous StAR mRNA and protein in a dose dependent manner. Induction of StAR mRNA by lipoprotein requires basal cAMP-dependent protein kinase, since the inhibitor, R-p-8-Br-cAMP, inhibited induction of StAR protein by LDL, Likewise, basal StAR expression or LDL induction of StAR protein was not detectable in Y-1 kin-8 cells which are deficient in cAMP-dependent protein kinase, Aminoglutethimide and ketoconazole were used to determine if side chain cleavage of lipoprotein-derived cholesterol is required for induction of StAR mRNA. Treatment with either drug alone induced StAR mRNA expression 1.5-3-fold, while induction of StAR in cells treated with either drug plus LDL, was equal to, or greater than, induction seen with either agent alone, suggesting that lipoprotein does not regulate StAR via generation of an oxysterol intermediate. Both LDL and HDL increased expression of a mouse -966 StAR promoter-reporter construct 1.5-2.5-fold, indicating that regulation occurs at the level of transcription. In contrast, neither lipoprotein was able to induce transcription from a -966 StAR promoter in which the steroidogenic factor-1 site at -135 was abolished, indicating that regulation of StAR transcription by lipoproteins requires steroidogenic factor-1. The regulation of StAR gene expression by lipoproteins may represent a positive feedback circuit which links cholesterol availability with steroidogenic output.	Univ Colorado, Hlth Sci Ctr, Sch Dent, Dept Basic Sci & Oral Res, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Pathol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Reyland, ME (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Dent, Dept Basic Sci & Oral Res, 4200 E 9th Ave,Box C286, Denver, CO 80262 USA.				NIDDK NIH HHS [DK050690] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050690] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Accad M, 1998, CURR BIOL, V8, pR601, DOI 10.1016/S0960-9822(98)70386-0; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Arakane F, 1997, J BIOL CHEM, V272, P32656, DOI 10.1074/jbc.272.51.32656; Caron KM, 1997, MOL ENDOCRINOL, V11, P138, DOI 10.1210/me.11.2.138; Caron KM, 1997, P NATL ACAD SCI USA, V94, P11540, DOI 10.1073/pnas.94.21.11540; Cherradi N, 1998, MOL ENDOCRINOL, V12, P962, DOI 10.1210/me.12.7.962; Christenson LK, 1998, J BIOL CHEM, V273, P30729, DOI 10.1074/jbc.273.46.30729; CLARK BJ, 1995, MOL ENDOCRINOL, V9, P1346, DOI 10.1210/me.9.10.1346; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; DAWSON PA, 1989, J BIOL CHEM, V264, P16798; Estabrook RW, 1996, P NATL ACAD SCI USA, V93, P13552, DOI 10.1073/pnas.93.24.13552; GWYNNE JT, 1989, J BIOL CHEM, V264, P8141; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; JEFCOATE CR, 1986, ENDOCR RES, V12, P315, DOI 10.3109/07435808609035444; Kallen CB, 1998, J BIOL CHEM, V273, P26285, DOI 10.1074/jbc.273.41.26285; KOVANEN PT, 1980, J BIOL CHEM, V255, P5591; Lala DS, 1997, P NATL ACAD SCI USA, V94, P4895, DOI 10.1073/pnas.94.10.4895; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; Lund EG, 1998, J BIOL CHEM, V273, P34316, DOI 10.1074/jbc.273.51.34316; Miller WL, 1997, J MOL ENDOCRINOL, V19, P227, DOI 10.1677/jme.0.0190227; ORMEJOHNSON NR, 1990, BIOCHIM BIOPHYS ACTA, V1020, P213, DOI 10.1016/0005-2728(90)90151-S; PON LA, 1986, J BIOL CHEM, V261, P3309; PRIVALLE CT, 1983, P NATL ACAD SCI-BIOL, V80, P702, DOI 10.1073/pnas.80.3.702; RAE PA, 1979, P NATL ACAD SCI USA, V76, P1896, DOI 10.1073/pnas.76.4.1896; Reinhart AJ, 1999, MOL ENDOCRINOL, V13, P729, DOI 10.1210/me.13.5.729; Reyland ME, 1998, AM J PHYSIOL-CELL PH, V275, pC780, DOI 10.1152/ajpcell.1998.275.3.C780; REYLAND ME, 1993, MOL ENDOCRINOL, V7, P1021, DOI 10.1210/me.7.8.1021; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; Sandhoff TW, 1998, ENDOCRINOLOGY, V139, P4820, DOI 10.1210/en.139.12.4820; Schimmer B P, 1979, Methods Enzymol, V58, P570; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; Sugawara T, 1997, BIOCHEMISTRY-US, V36, P7249, DOI 10.1021/bi9628984; Sugawara T, 1996, BIOCHEMISTRY-US, V35, P9052, DOI 10.1021/bi960057r; SUGAWARA T, 1995, P NATL ACAD SCI USA, V92, P4778, DOI 10.1073/pnas.92.11.4778; TAKAGI K, 1989, J BIOL CHEM, V264, P12352; Tamasawa N, 1997, ATHEROSCLEROSIS, V131, P237, DOI 10.1016/S0021-9150(97)00055-5; VANDENBOSSCHE H, 1992, J STEROID BIOCHEM, V43, P1003, DOI 10.1016/0960-0760(92)90328-G; Wang XJ, 1998, ENDOCRINOLOGY, V139, P3903, DOI 10.1210/en.139.9.3903	39	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36637	36644		10.1074/jbc.M006456200	http://dx.doi.org/10.1074/jbc.M006456200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10960482	hybrid			2022-12-25	WOS:000165577700027
J	Chakravarthy, MV; Abraha, TW; Schwartz, RJ; Fiorotto, ML; Booth, FW				Chakravarthy, MV; Abraha, TW; Schwartz, RJ; Fiorotto, ML; Booth, FW			Insulin-like growth factor-I extends in vitro replicative life span of skeletal muscle satellite cells by enhancing G(1)/S cell cycle progression via the activation of phosphatidylinositol 3 '-kinase/Akt signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; RETINOBLASTOMA GENE-PRODUCT; HUMAN-DIPLOID FIBROBLASTS; PROTEIN-KINASE; TUMOR SUPPRESSION; MICE LACKING; SENESCENCE; P27(KIP1); 3-KINASE; ACCUMULATION	Interest is growing in methods to extend replicative life span of non-immortalized stem cells. Using the insulin-like growth factor I (IGF-I) transgenic mouse in which the IG;F-I transgene is expressed during skeletal muscle development and maturation prior to isolation and during culture of satellite cells (the myogenic stem cells of mature skeletal muscle fibers) as a model system, we elucidated the underlying molecular mechanisms of IGF-I-mediated enhancement of proliferative potential of these cells. Satellite cells from IGF-I transgenic muscles achieved at least five additional population doublings above the maximum that was attained by wild type satellite cells. This IGF-I-induced increase in proliferative potential was mediated via activation of the phosphatidylinositol 3'-kinase/Akt pathway, independent of mitogen-activated protein kinase activity, facilitating G(1)/S cell cycle progression via a down-regulation of p27(Kip1). Adenovirally mediated ectopic overexpression of p27(Kip1) i, exponentially growing IGF-I transgenic satellite cells reversed the increase in cyclin E-cdk2 kinase activity, pRb phosphorylation, and cyclin A protein abundance, thereby implicating an important role for p27(Kip1) i, promoting satellite cell senescence. These observations provide a more complete dissection of molecular events by which increased local expression of a growth factor in mature skeletal muscle fibers extends replicative life span of primary stem cells than previously known.	Univ Missouri, Dept Vet Biomed Sci, Coll Vet Med, Columbia, MO 65211 USA; Univ Missouri, Dept Physiol, Coll Vet Med, Columbia, MO 65211 USA; Univ Missouri, Dalton Cardiovasc Inst, Coll Vet Med, Columbia, MO 65211 USA; Univ Texas, Sch Med, Dept Integrat Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; USDA, Dept Pediat, Agr Res Stn, Childrens Nutr Res Ctr, Houston, TX 77030 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Texas System; Baylor College of Medicine; United States Department of Agriculture (USDA)	Booth, FW (corresponding author), Univ Missouri, Dept Vet Biomed Sci, Coll Vet Med, E102 Vet Med Bldg,1600 E Rollins Rd, Columbia, MO 65211 USA.		Chakravarthy, Manu/AAD-7553-2021	Chakravarthy, Manu/0000-0002-3699-150X	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR019393, R01AR019393] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018780] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 19393] Funding Source: Medline; NIA NIH HHS [AG18780] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adams GR, 1998, J APPL PHYSIOL, V84, P1716, DOI 10.1152/jappl.1998.84.5.1716; Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; ANGELLO JC, 1992, MECH AGEING DEV, V62, P1, DOI 10.1016/0047-6374(92)90139-5; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; Barton-Davis ER, 1998, P NATL ACAD SCI USA, V95, P15603, DOI 10.1073/pnas.95.26.15603; Bischoff R, 1994, MYOLOGY, P97; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; Butler AA, 1998, COMP BIOCHEM PHYS B, V121, P19, DOI 10.1016/S0305-0491(98)10106-2; Chakravarthy MV, 2000, J APPL PHYSIOL, V89, P1365, DOI 10.1152/jappl.2000.89.4.1365; Chen DH, 1997, J CLIN INVEST, V99, P2334, DOI 10.1172/JCI119414; Chen J, 1996, J CLIN INVEST, V97, P1983, DOI 10.1172/JCI118631; COHICK WS, 1993, ANNU REV PHYSIOL, V55, P131, DOI 10.1146/annurev.ph.55.030193.001023; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Criswell DS, 1998, AM J PHYSIOL-ENDOC M, V275, pE373; DANTO SI, 1984, J CELL BIOL, V98, P2179, DOI 10.1083/jcb.98.6.2179; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Decary S, 1997, HUM GENE THER, V8, P1429, DOI 10.1089/hum.1997.8.12-1429; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; GOLDSTEIN S, 1993, J CELL PHYSIOL, V156, P294, DOI 10.1002/jcp.1041560211; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; KAUFMAN SJ, 1988, P NATL ACAD SCI USA, V85, P9606, DOI 10.1073/pnas.85.24.9606; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Liu JL, 2000, P SOC EXP BIOL MED, V223, P344, DOI 10.1046/j.1525-1373.2000.22349.x; Milasincic DJ, 1996, MOL CELL BIOL, V16, P5964; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NEVINS JR, 1992, SCIENCE, V258, P424; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; RHEINWALD JG, 1977, NATURE, V265, P421, DOI 10.1038/265421a0; RITTLING SR, 1986, P NATL ACAD SCI USA, V83, P3316, DOI 10.1073/pnas.83.10.3316; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; Schulze A, 1996, MOL CELL BIOL, V16, P4632; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SMITH JR, 1980, MECH AGEING DEV, V12, P355, DOI 10.1016/0047-6374(80)90068-8; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; STOCKDALE F, 1961, EXP CELL RES, V24, P508, DOI 10.1016/0014-4827(61)90450-5; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tu WW, 1999, BRIT J HAEMATOL, V104, P785, DOI 10.1046/j.1365-2141.1999.01272.x; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Watanabe Y, 1997, ONCOGENE, V14, P2025, DOI 10.1038/sj.onc.1201033; Wong H, 1996, EXP GERONTOL, V31, P311, DOI 10.1016/0531-5565(95)00025-9; WRIGHT WE, 1985, EXP CELL RES, V157, P343, DOI 10.1016/0014-4827(85)90119-3	57	177	182	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35942	35952		10.1074/jbc.M005832200	http://dx.doi.org/10.1074/jbc.M005832200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10962000	hybrid			2022-12-25	WOS:000165382000044
J	Delage-Mourroux, R; Martini, PGV; Choi, I; Kraichely, DM; Hoeksema, J; Katzenellenbogen, BS				Delage-Mourroux, R; Martini, PGV; Choi, I; Kraichely, DM; Hoeksema, J; Katzenellenbogen, BS			Analysis of estrogen receptor interaction with a repressor of estrogen receptor activity (REA) and the regulation of estrogen receptor transcriptional activity by REA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE RECEPTORS; ER-ALPHA; DEPENDENT TRANSCRIPTION; PEPTIDE ANTAGONISTS; COACTIVATOR-1 SRC-1; CO-REPRESSOR; ACTIVATION; BINDING; BETA; ANTIESTROGENS	The transcriptional activity of nuclear hormone receptors is known to be modulated by coregulator proteins. We found that the repressor of estrogen receptor activity (REA), a protein recruited to the hormone-occupied estrogen receptor (ER), decreased the transcriptional activity of ER, both when ER was acting directly through DNA response elements as well as when it was tethered to other transcription factors. Administration of antisense REA resulted in a 2-4-fold increase in ER transactivation, implying that endogenous REA normally dampens the stimulatory response to estradiol, To define the interaction regions between ER and REA, we used glutathione S-transferase pull-down assays. We found that REA bound to the ligand-binding domain (E domain) of ER, but not to other regions of ER, and that REA interaction with ER involved a region in the C-terminal half of REA, REA and the coactivator SRC-1 were involved in a functional competition for regulation of ER transcriptional activity, which we show results from competition between these two coregulators for interaction with ER, REA contains an LXXLL motif near its N terminus, but this motif was not involved in its binding to ER, Rather, this sequence was required for the competitive binding of REA and SRC-1 to ER and thus: for optimal repression of ER activity. Our findings show that the regions of REA required for its interaction with ER and for its repression of ER activity are different.	Univ Illinois, Dept Mol & Integrat Physiol, Coll Med, Urbana, IL 61801 USA; Univ Illinois, Dept Cell & Struct Biol, Coll Med, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Katzenellenbogen, BS (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, Coll Med, Urbana, IL 61801 USA.		DELAGE-MOURROUX, Régis/ABE-1424-2021	DELAGE-MOURROUX, Régis/0000-0002-7145-5948	NCI NIH HHS [5T32 CA09067, CA18119, CA60514] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060514, R01CA018119, T32CA009067, R37CA018119] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Carlson KE, 1997, BIOCHEMISTRY-US, V36, P14897, DOI 10.1021/bi971746l; Chang CY, 1999, MOL CELL BIOL, V19, P8226; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; INCE BA, 1995, ENDOCRINOLOGY, V136, P3194, DOI 10.1210/en.136.8.3194; INCE BA, 1993, J BIOL CHEM, V268, P14026; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; Katzenellenbogen JA, 1996, CHEM BIOL, V3, P529, DOI 10.1016/S1074-5521(96)90143-X; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Liu Z, 1999, P NATL ACAD SCI USA, V96, P9485, DOI 10.1073/pnas.96.17.9485; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McInerney EM, 1998, ENDOCRINOLOGY, V139, P4513, DOI 10.1210/en.139.11.4513; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; MONTANO MM, 1995, MOL ENDOCRINOL, V9, P814, DOI 10.1210/me.9.7.814; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Norris JD, 1996, MOL ENDOCRINOL, V10, P1605, DOI 10.1210/mend.10.12.8961270; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; ONATE SA, 1995, SCIENCE, V270, P1354; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Schodin DJ, 1995, J BIOL CHEM, V270, P31163, DOI 10.1074/jbc.270.52.31163; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Sun J, 1999, ENDOCRINOLOGY, V140, P800, DOI 10.1210/en.140.2.800; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040; Yang NN, 1996, SCIENCE, V273, P1222, DOI 10.1126/science.273.5279.1222; Zamir I, 1996, MOL CELL BIOL, V16, P5458	48	114	118	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35848	35856		10.1074/jbc.M001327200	http://dx.doi.org/10.1074/jbc.M001327200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10960470	hybrid			2022-12-25	WOS:000165382000031
J	Krieger-Brauer, HI; Medda, P; Kather, H				Krieger-Brauer, HI; Medda, P; Kather, H			Basic fibroblast growth factor utilizes both types of component subunits of G(s) for dual signaling in human adipocytes - Stimulation of adenylyl cyclase via G alpha(s) and inhibition of NADPH oxidase by G beta gamma(s)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT H2O2 GENERATION; HETEROTRIMERIC G-PROTEINS; BETA-GAMMA-SUBUNITS; ALPHA-SUBUNIT; H2O2-GENERATING SYSTEM; HYDROGEN-PEROXIDE; PLASMA-MEMBRANES; RECEPTOR KINASE; BINDING; ACTIVATION	Basic fibroblast growth factor (bFGF), a ligand of receptor protein-tyrosine kinases, promoted the dissociation of G(s) and had antagonistic stimulatory and inhibitory effects on adenylyl cyclase and NADPH oxidase in human fat cell plasma membranes. The bFGF-induced activation of adenylyl cyclase was blocked by COOH-terminal anti-Ca,, indicating that it was mediated by Ga,. The inhibitory action of bFGF was mimicked by exogenously supplied G beta gamma -subunits and was reversed by anti-G beta (1/2), or beta ARK-CT, a COOH-terminal beta -adrenergic receptor kinase fragment that specifically binds free G beta gamma, indicating that it was transduced by G beta gamma complexes. The bFGF-induced inhibition of NADPH-dependent H2O2 generation was also reversed by peptide 100-119, an inhibitor of G(s) activation by ligand-occupied beta -adrenergic receptors, indicating that the G beta gamma complexes mediating the inhibitory action of the growth factor are derived from G(s). The findings suggest a direct, non-kinase-dependent, coupling of bFGF receptor(s) to and G(s) provide the first example of a ligand of receptor protein-tyrosine kinases that is capable of utilizing both types of component subunits of a single heterotrimeric G protein for dual signaling in a single cell type.	Univ Heidelberg, Klin Inst Herzinfarktforsch, Med Klin, D-69115 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Krieger-Brauer, HI (corresponding author), Univ Heidelberg, Klin Inst Herzinfarktforsch, Med Klin, Bergheimerstr 58, D-69115 Heidelberg, Germany.							Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Bayewitch ML, 1998, J BIOL CHEM, V273, P2273, DOI 10.1074/jbc.273.4.2273; BOMSEL M, 1993, J BIOL CHEM, V268, P25824; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; Burke D, 1998, TRENDS BIOCHEM SCI, V23, P59, DOI 10.1016/S0968-0004(97)01170-5; BURRUS LW, 1992, MOL CELL BIOL, V12, P5600, DOI 10.1128/MCB.12.12.5600; Degtiar VE, 1997, J PHYSIOL-LONDON, V502, P321, DOI 10.1111/j.1469-7793.1997.321bk.x; Fedorov YV, 1998, MOL CELL BIOL, V18, P5780, DOI 10.1128/MCB.18.10.5780; Fernig David G., 1994, Progress in Growth Factor Research, V5, P353, DOI 10.1016/0955-2235(94)00007-8; Hallak H, 2000, J BIOL CHEM, V275, P2255, DOI 10.1074/jbc.275.4.2255; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; JO H, 1992, ENDOCRINOLOGY, V131, P2855, DOI 10.1210/en.131.6.2855; Kanzaki M, 1997, J BIOL CHEM, V272, P14733, DOI 10.1074/jbc.272.23.14733; KATADA T, 1982, J BIOL CHEM, V257, P3739; KATADA T, 1984, J BIOL CHEM, V259, P3586; KATAOKA R, 1993, J BIOL CHEM, V268, P19851; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; Krieger-Brauer HI, 2000, J BIOL CHEM, V275, P2486, DOI 10.1074/jbc.275.4.2486; Krieger-Brauer HI, 1999, J BIOL CHEM, V274, P28308, DOI 10.1074/jbc.274.40.28308; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P549, DOI 10.1042/bj3070549; KRIEGERBRAUER HI, 1992, J CLIN INVEST, V89, P1006, DOI 10.1172/JCI115641; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P543, DOI 10.1042/bj3070543; KriegerBrauer HI, 1997, J BIOL CHEM, V272, P10135; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Macrez N, 1997, J BIOL CHEM, V272, P23180, DOI 10.1074/jbc.272.37.23180; MAGNALDO I, 1989, CELL SIGNAL, V1, P507, DOI 10.1016/0898-6568(89)90035-1; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; Murthy KS, 1996, J BIOL CHEM, V271, P23458, DOI 10.1074/jbc.271.38.23458; NAIR BG, 1990, J BIOL CHEM, V265, P21317; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; ORLY J, 1975, P NATL ACAD SCI USA, V72, P3433, DOI 10.1073/pnas.72.9.3433; Pursiheimo JP, 2000, P NATL ACAD SCI USA, V97, P168, DOI 10.1073/pnas.97.1.168; RODBELL M, 1964, J BIOL CHEM, V239, P375; SA G, 1994, J BIOL CHEM, V269, P3219; STEHNOBITTEL L, 1995, J BIOL CHEM, V270, P30068; StryjekKaminska D, 1996, BIOCHEM J, V316, P87, DOI 10.1042/bj3160087; Szebenyi G, 1999, INT REV CYTOL, V185, P45; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; TEICHERTKULISZEWSKA K, 1992, J CLIN INVEST, V90, P1226, DOI 10.1172/JCI115984; TOYOSHIGE M, 1994, BIOCHEMISTRY-US, V33, P4865, DOI 10.1021/bi00182a014; Toyoshige M, 1996, J BIOL CHEM, V271, P8791, DOI 10.1074/jbc.271.15.8791; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; YAMASHITA H, 1995, CELL GROWTH DIFFER, V6, P1457; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	46	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35920	35925		10.1074/jbc.M002490200	http://dx.doi.org/10.1074/jbc.M002490200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10969069	hybrid			2022-12-25	WOS:000165382000041
J	Schmoll, D; Walker, KS; Alessi, DR; Grempler, R; Burchell, A; Guo, SD; Walther, R; Unterman, TG				Schmoll, D; Walker, KS; Alessi, DR; Grempler, R; Burchell, A; Guo, SD; Walther, R; Unterman, TG			Regulation of glucose-6-phosphatase gene expression by protein kinase B alpha and the forkhead transcription factor FKHR - Evidence for insulin response unit-dependent and -independent effects of insulin on promoter activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; PHOSPHATIDYLINOSITOL 3-KINASE; CAENORHABDITIS-ELEGANS; CATALYTIC SUBUNIT; HEPATOMA-CELLS; CAMP INDUCTION; FAMILY MEMBER; BINDING-SITES; ACTIVATION; PHOSPHORYLATION	Glucose-6-phosphatase plays an important role in the regulation of hepatic glucose production, and insulin suppresses glucose-6-phosphatase gene expression. Recent Studies indicate that protein kinase B and Forkhead proteins contribute to insulin-regulated gene expression in the liver. Here, we examined the role of protein kinase B and Forkhead proteins in mediating effects of insulin on glucose-6-phosphatase promoter activity. Transient transfection studies with reporter gene constructs demonstrate that insulin suppresses both basal and dexamethasone/cAMP-induced activity of the glucose-6-phosphatase promoter in H4IIE hepatoma cells. Both effects are partially mimicked by coexpression bf protein kinase B alpha. Coexpression of the Forkhead transcription factor FKHR stimulates the glucose-6-phosphatase promoter activity via interaction with an insulin response unit (IRU), and this activation is suppressed by protein kinase B, Coexpression of a mutated form of FKHR that cannot be phosphorylated by protein kinase B abolishes the regulation of the glucose-6-phosphatase promoter by protein kinase B and disrupts the ability of insulin to regulate the glucose-6-phosphatase promoter via the IRU, Mutation of the insulin response unit of the glucose-6-phosphatase promoter also prevents the regulation of promoter activity by FKHR and protein kinase B but only partially impairs the ability of insulin: to suppress both basal and dexamethasone/cAMP-stimulated promoter function. Taken together, these results indicate that signaling by protein kinase B to Forkhead proteins can account for the ability of insulin to regulate glucose-6-phosphatase promoter activity via the IRU and that other mechanisms that are independent of the IRU, protein kinase B, and Forkhead proteins also are important in mediating effects of in insulin-on glucose-6-phosphatase gene expression.	Univ Greifswald, Klinikum Sauerbruchstr, Dept Biochem, D-17487 Greifswald, Germany; Univ Dundee, MRC, Prot Phosphorylat Unit, Dundee DD1 4HN, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Tayside Inst Child Hlth, Dundee DD1 9SY, Scotland; Univ Illinois, Coll Med, Dept Med, Chicago, IL 60612 USA; Chicago Area Vet Affairs Hlth Care Syst, W Side Div, Chicago, IL 60612 USA	Ernst Moritz Arndt Universitat Greifswald; University of Dundee; University of Dundee; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Schmoll, D (corresponding author), Univ Greifswald, Klinikum Sauerbruchstr, Dept Biochem, D-17487 Greifswald, Germany.		Burchell, Ann/B-7475-2008	Schmoll, Dieter/0000-0003-2578-3366; Alessi, Dario/0000-0002-2140-9185	NIDDK NIH HHS [DK41430] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041430, R29DK041430] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agati JM, 1998, J BIOL CHEM, V273, P18751, DOI 10.1074/jbc.273.30.18751; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Ayala JE, 1999, DIABETES, V48, P1885, DOI 10.2337/diabetes.48.9.1885; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cha JY, 2000, J BIOL CHEM, V275, P18358, DOI 10.1074/jbc.M909536199; Chou JY, 1999, TRENDS ENDOCRIN MET, V10, P104; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Dickens M, 1998, J BIOL CHEM, V273, P20144, DOI 10.1074/jbc.273.32.20144; Durham SK, 1999, ENDOCRINOLOGY, V140, P3140, DOI 10.1210/en.140.7.3140; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; LANGE AJ, 1994, BIOCHEM BIOPH RES CO, V201, P302, DOI 10.1006/bbrc.1994.1702; Liao JF, 1998, J BIOL CHEM, V273, P27320, DOI 10.1074/jbc.273.42.27320; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakae J, 2000, EMBO J, V19, P989, DOI 10.1093/emboj/19.5.989; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Nordlie RC, 1999, ANNU REV NUTR, V19, P379, DOI 10.1146/annurev.nutr.19.1.379; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Schmoll D, 1999, BIOCHEM J, V338, P457, DOI 10.1042/0264-6021:3380457; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Streeper RS, 1998, P NATL ACAD SCI USA, V95, P9208, DOI 10.1073/pnas.95.16.9208; Streeper RS, 1997, J BIOL CHEM, V272, P11698, DOI 10.1074/jbc.272.18.11698; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; Wang D, 1998, J BIOL CHEM, V273, P25420, DOI 10.1074/jbc.273.39.25420; Wang JC, 1999, MOL ENDOCRINOL, V13, P604, DOI 10.1210/me.13.4.604; Yeagley D, 2000, J BIOL CHEM, V275, P17814, DOI 10.1074/jbc.M909842199; Yeagley D, 1998, J BIOL CHEM, V273, P18743, DOI 10.1074/jbc.273.30.18743	38	290	299	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36324	36333		10.1074/jbc.M003616200	http://dx.doi.org/10.1074/jbc.M003616200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10960473	hybrid			2022-12-25	WOS:000165382000096
J	Nakatogawa, H; Mori, H; Ito, K				Nakatogawa, H; Mori, H; Ito, K			Two independent mechanisms down-regulate the intrinsic SecA ATPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEIN TRANSLOCATION; MEMBRANE INSERTION; PREPROTEIN; BINDING; DOMAINS; HYDROLYSIS; MUTANTS; SUBUNIT; SECYEG	SecA initiates protein translocation by interacting with ATP, preprotein, and the SecYEG membrane components. Under such conditions, it undergoes a conformational change characterized as membrane insertion, which is then followed by hydrolysis of ATP, enabling the release of the preprotein and deinsertion of SecA itself for the next cycle of reactions. Without ongoing translocation, the ATPase activity of SecA is kept very low. Previously, it was shown that the C-terminal 34-kDa domain of SecA interacts with the N-terminal 68-kDa ATPase domain to down-regulate the ATPase, Here, we show, using a deregulated SecA mutant, that the intrinsic ATPase activity is subject to dual inhibitory mechanisms. Thus, the proposed second ATP-binding domain down-regulates the ATPase activity executed by the primary ATPase domain. This regulation, within the N-terminal ATPase domain, operates independently of the C-terminal domain-mediated regulation. The absence of both the mechanisms resulted in a 50-fold elevation of translocation-uncoupled ATP hydrolysis.	Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Ito, K (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan.	kito@virus.kyoto-u.ac.jp	Nakatogawa, Hitoshi/D-5155-2015	Nakatogawa, Hitoshi/0000-0002-5828-0741				BABA T, 1990, J BACTERIOL, V172, P7005, DOI 10.1128/jb.172.12.7005-7010.1990; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Eichler J, 1997, P NATL ACAD SCI USA, V94, P5574, DOI 10.1073/pnas.94.11.5574; Karamanou S, 1999, MOL MICROBIOL, V34, P1133, DOI 10.1046/j.1365-2958.1999.01686.x; KIHARA A, 1995, P NATL ACAD SCI USA, V92, P4532, DOI 10.1073/pnas.92.10.4532; KIM YJ, 1994, CELL, V78, P845; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; Matsumoto G, 1997, EMBO J, V16, P6384, DOI 10.1093/emboj/16.21.6384; MATSUMOTO G, 2000, IN PRESS GENES CELLS; MCFARLAND L, 1993, J BACTERIOL, V175, P2255, DOI 10.1128/JB.175.8.2255-2262.1993; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; Nakatogawa H, 2000, J BIOCHEM-TOKYO, V127, P1071, DOI 10.1093/oxfordjournals.jbchem.a022700; OLIVER DB, 1982, J BACTERIOL, V150, P686, DOI 10.1128/JB.150.2.686-691.1982; Price A, 1996, J BIOL CHEM, V271, P31580, DOI 10.1074/jbc.271.49.31580; Ramamurthy V, 1997, J BIOL CHEM, V272, P23239, DOI 10.1074/jbc.272.37.23239; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; Song M, 1997, J BIOCHEM-TOKYO, V122, P1010; Taura T, 1997, BIOCHIMIE, V79, P517, DOI 10.1016/S0300-9084(97)82744-7; TOKUDA H, 1993, BIOCHEM BIOPH RES CO, V195, P1415, DOI 10.1006/bbrc.1993.2201	20	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33209	33212		10.1074/jbc.C000550200	http://dx.doi.org/10.1074/jbc.C000550200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10982786	hybrid			2022-12-25	WOS:000090104600007
J	Sitterlin, D; Bergametti, F; Transy, C				Sitterlin, D; Bergametti, F; Transy, C			UVDDB p127-binding modulates activities and intracellular distribution of hepatitis B virus X protein	ONCOGENE			English	Article						hepatitis B virus; X protein; UV-damaged DNA-binding protein; transactivation; apoptosis; nuclear import	NF-KAPPA-B; CELLULAR DNA-REPAIR; HBX PROTEIN; NUCLEAR IMPORT; GENE PRODUCT; DAMAGED DNA; TRANSACTIVATION FUNCTION; TRANSCRIPTION MACHINERY; BINDING; ACTIVATION	Mammalian hepatitis B, viruses encode a unique regulatory protein termed X, which is essential for infection and likely plays a role in the carcinogenic process associated with hepadnaviral infection. Among the numerous properties ascribed to X protein, two have been widely documented: promiscuous transcriptional transactivation and proapoptosis. However, full understanding of the mechanisms underlying these activities requires the identification of the genuine X partners among the multiple X-binding: host proteins. Here we show that (i) mutations in X protein, which markedly alter affinity for the host protein UVDDBp127, inactivate both transactivation and proapoptosis; (ii) ectopic fusion of a functional UVDDB-binding domain to a deficient binding;X mutant restored its activity; (iii) in contrast to the loss-of-binding mutants, a mutant with a strong gain-of-binding exerted trans-dominant negative effects on wt X activity and localized in the nucleus and (iv) increase in intracellular UVDDB concentration enhanced both wt X-mediated transactivation and apoptosis, Taken together, our data provide strong evidence for a common upstream step in X mode of action, consisting of its productive interaction with UVDDB, via a structurally and functionally autonomous module. In addition, they underscore a nuclear location step of the viral protein that depends on its ability to bind UVDDB.	Inst Pasteur, Unite Recombinais & Express Genet, INSERM, U163, F-75724 Paris 15, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Transy, C (corresponding author), Inst Pasteur, Unite Recombinais & Express Genet, INSERM, U163, 28 Rue Dr Roux, F-75724 Paris 15, France.							BEASLEY RP, 1981, LANCET, V2, P1129; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; Benning H, 1995, Ger J Ophthalmol, V4, P11; Bergametti F, 1999, ONCOGENE, V18, P2860, DOI 10.1038/sj.onc.1202643; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; COLGROVE R, 1989, J VIROL, V63, P4019, DOI 10.1128/JVI.63.9.4019-4026.1989; Dandri M, 1998, J VIROL, V72, P9359, DOI 10.1128/JVI.72.11.9359-9364.1998; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; GIRONES R, 1989, P NATL ACAD SCI USA, V86, P1846, DOI 10.1073/pnas.86.6.1846; Haviv I, 1996, EMBO J, V15, P3413, DOI 10.1002/j.1460-2075.1996.tb00707.x; Henkler F, 1998, J GEN VIROL, V79, P2737, DOI 10.1099/0022-1317-79-11-2737; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HWANG BJ, 1993, BIOCHEMISTRY-US, V32, P1657, DOI 10.1021/bi00057a033; Kane MA, 1998, VACCINE, V16, pS104, DOI 10.1016/S0264-410X(98)00308-9; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; Kumar V, 1996, P NATL ACAD SCI USA, V93, P5647, DOI 10.1073/pnas.93.11.5647; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Lee YH, 1998, J BIOL CHEM, V273, P25510, DOI 10.1074/jbc.273.39.25510; Lin Y, 1998, J BIOL CHEM, V273, P27097, DOI 10.1074/jbc.273.42.27097; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; RUNKEL L, 1993, VIROLOGY, V197, P529, DOI 10.1006/viro.1993.1626; SCHODEL F, 1989, ADV VIRAL ONCOL, V8, P73; Shiyanov P, 1999, MOL CELL BIOL, V19, P4935; Sitterlin D, 2000, ONCOGENE, V19, P4427, DOI 10.1038/sj.onc.1203770; Sitterlin D, 1997, J VIROL, V71, P6194, DOI 10.1128/JVI.71.8.6194-6199.1997; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Su Q, 1998, HEPATOLOGY, V27, P1109, DOI 10.1002/hep.510270428; TAKAO M, 1993, NUCLEIC ACIDS RES, V21, P4111, DOI 10.1093/nar/21.17.4111; TRANSY C, 1995, MOL BIOL REP, V21, P119, DOI 10.1007/BF00986502; Turpin P, 1999, J BIOL CHEM, V274, P6804, DOI 10.1074/jbc.274.10.6804; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Weil R, 1999, MOL CELL BIOL, V19, P6345; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20	41	44	45	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2000	19	38					4417	4426		10.1038/sj.onc.1203771	http://dx.doi.org/10.1038/sj.onc.1203771			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980617				2022-12-25	WOS:000089271900012
J	Patel, NM; Nozaki, S; Shortle, NH; Bhat-Nakshatri, P; Newton, TR; Rice, S; Gelfanov, V; Boswell, SH; Goulet, RJ; Sledge, GW; Nakshatri, H				Patel, NM; Nozaki, S; Shortle, NH; Bhat-Nakshatri, P; Newton, TR; Rice, S; Gelfanov, V; Boswell, SH; Goulet, RJ; Sledge, GW; Nakshatri, H			Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappa B is enhanced by I kappa B alpha super-repressor and parthenolide	ONCOGENE			English	Article						breast cancer; parthenolide; paclitaxel; NF-kB	TUMOR-NECROSIS-FACTOR; INDUCED APOPTOSIS; SESQUITERPENE LACTONE; NEGATIVE REGULATION; DRUG-RESISTANCE; KINASE COMPLEX; CYCLIN D1; ACTIVATION; EXPRESSION; INHIBITION	The transcription factor nuclear factor-kappa B (NF-KB) regulates genes important for tumor invasion, metastasis and chemoresistance. Normally, NF-kappa B remains sequestered in an inactive state by cytoplasmic inhibitor-of-kappa B (I kappa B) proteins, NF-kappa B translocates to nucleus and activates gene expression upon exposure of cells to growth factors and cytokines, We and others have shown previously that NF-kappa B is constitutively active in a subset of breast cancers. In this study, we show that constitutive activation of NF-kappa B leads to overexpression of the antiapoptotic genes c-inhibitor of apoptosis 2 (c-IAP2) and manganese superoxide dismutase (Mn-SOD) in breast cancer cells, Furthermore, expression of the antiapoptotic tumor necrosis factor receptor associated factor 1 (TRAF1) and defender-against cell death (DAD-1) is regulated by NF-kappa B in certain breast cancer cells. We also demonstrate that NF-kappa B-inducible genes protect cancer cells against paclitaxel as MDA-MB-231 breast cancer cells modified to overexpress I kappa B alpha required lower concentrations of paclitaxel to arrest at the G2/M phase of the cell cycle and undergo apoptosis when compared to parental cells. The effect of NF-kappa B on paclitaxel-sensitivity appears to be specific to cancer cells because normal fibroblasts derived from embryos lacking p65 subunit of NF-kappa B and wild type littermate embryos were insensitive to paclitaxel-induced G2/M cell cycle arrest. Parthenolide, an active ingredient of herbal remedies such as feverfew (tanacetum parthenium), mimicked the effects of I kappa B alpha by inhibiting NF-kappa B DNA binding activity and Mn-SOD expression, and increasing paclitaxel-induced apoptosis of breast cancer cells. These results suggest that active ingredients of herbs with anti-inflammatory properties may be useful in increasing the sensitivity of cancers with constitutively active NF-kappa B to chemotherapeutic drugs.	Indiana Univ, Sch Med, Dept Surg, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pathol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Nakshatri, H (corresponding author), Indiana Canc Res Inst, 1044 W Walnut St,R4-202, Indianapolis, IN 46202 USA.			Gelfanov, Vasily/0000-0001-5216-5227; Nakshatri, Harikrishna/0000-0001-8876-0052				Amato SF, 1998, CANCER RES, V58, P241; Ambrosone CB, 1999, CANCER RES, V59, P602; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldini N, 1997, NAT MED, V3, P378, DOI 10.1038/nm0497-378; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Bargou RC, 1996, J CLIN INVEST, V97, P2651, DOI 10.1172/JCI118715; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bentires-Alj M, 1999, CANCER RES, V59, P811; BERENBAUM MC, 1981, ADV CANCER RES, V35, P269, DOI 10.1016/S0065-230X(08)60912-4; Bhat-Nakshatri P, 1998, P NATL ACAD SCI USA, V95, P6971, DOI 10.1073/pnas.95.12.6971; BISWAS DK, 1993, J ACQ IMMUN DEF SYND, V6, P778; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Bork PM, 1997, FEBS LETT, V402, P85, DOI 10.1016/S0014-5793(96)01502-5; Cassimeris L, 1999, CURR OPIN CELL BIOL, V11, P134, DOI 10.1016/S0955-0674(99)80017-9; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dong G, 1999, CANCER RES, V59, P3495; Ferlini C, 1997, BRIT J CANCER, V75, P884, DOI 10.1038/bjc.1997.156; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Fukuda K, 1999, PLANTA MED, V65, P381, DOI 10.1055/s-2006-960795; Galien R, 1997, NUCLEIC ACIDS RES, V25, P2424, DOI 10.1093/nar/25.12.2424; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Habtemariam S, 1998, PLANTA MED, V64, P683, DOI 10.1055/s-2006-957558; Hehner SP, 1999, J IMMUNOL, V163, P5617; Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Jiang F, 1998, J PATHOL, V185, P382; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; Kelleher DJ, 1997, P NATL ACAD SCI USA, V94, P4994, DOI 10.1073/pnas.94.10.4994; Kumar A, 1998, BIOCHEM PHARMACOL, V55, P775, DOI 10.1016/S0006-2952(97)00557-1; Kumar R, 1996, CLIN CANCER RES, V2, P1215; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Legrand O, 1998, BLOOD, V91, P4480, DOI 10.1182/blood.V91.12.4480.412k28_4480_4488; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Lin ZP, 1998, CANCER RES, V58, P3059; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Lyss G, 1998, J BIOL CHEM, V273, P33508, DOI 10.1074/jbc.273.50.33508; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER AD, 1989, BIOTECHNIQUES, V7, P984; MILLER AD, 1989, BIOTECHNIQUES, V7, P989; Miyake H, 2000, CANCER RES, V60, P170; MURPHY JJ, 1988, LANCET, V2, P189; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Newton TR, 1999, J BIOL CHEM, V274, P18827, DOI 10.1074/jbc.274.26.18827; Oberley TD, 1997, HISTOL HISTOPATHOL, V12, P525; Panvichian R, 1998, CANCER RES, V58, P4667; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; PRICE JE, 1990, CANCER RES, V50, P717; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; Shen SC, 1998, CELL GROWTH DIFFER, V9, P23; SOMMERS CL, 1994, BREAST CANCER RES TR, V31, P325, DOI 10.1007/BF00666165; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Torres K, 1998, CANCER RES, V58, P3620; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang FJ, 1998, J NUTR, V128, P2334, DOI 10.1093/jn/128.12.2334; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zandi E, 1999, MOL CELL BIOL, V19, P4547; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	76	256	275	1	18	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2000	19	36					4159	4169		10.1038/sj.onc.1203768	http://dx.doi.org/10.1038/sj.onc.1203768			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962577				2022-12-25	WOS:000088955100010
J	Faulkner, G; Pallavicini, A; Comelli, A; Salamon, M; Bortoletto, G; Ievolella, C; Trevisan, S; Kojic, S; Dalla Vecchia, F; Laveder, P; Valle, G; Lanfranchi, G				Faulkner, G; Pallavicini, A; Comelli, A; Salamon, M; Bortoletto, G; Ievolella, C; Trevisan, S; Kojic, S; Dalla Vecchia, F; Laveder, P; Valle, G; Lanfranchi, G			FATZ, a filamin-, actinin-, and telethonin-binding protein of the Z-disc of skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOMERIC PROTEIN; DOMAIN; TITIN; IDENTIFICATION; REPEAT; PDZ; ACTIVATION; INTERACTS; SEQUENCE; CLONING	We report the identification and characterization of a novel 32-kDa protein expressed in skeletal muscle and located in the Z-disc of the sarcomere. We found that this protein binds to three other Z-disc proteins; therefore, we have-named it FATZ, gamma -filamin/ABP-L, alpha -actinin and telethonin binding protein of the Z-disc. From yeast two-hybrid experiments we are able to show that the SR3-SR4 domains of alpha -actinin 2 are required to bind the COOH-terminal region of the FATZ as does gamma -filamin/ABP-L, Furthermore, by using a glutathione S-transferase overlay assay we find that FATZ also binds telethonin. The level of FATZ protein in muscle cells increases during differentiation, being clearly detectable before the onset of myosin, Although FATZ has no known interaction domains, it would appear to be involved in a complex network of interactions with other Z-band components. On the basis of the information known about its binding partners, we could envisage a central role for FATZ in the: myofibrillogenesis, After screening our muscle expressed sequence tag data base and the public expressed sequence tag data bases, we were able to assemble two other muscle transcripts that show a high level of identity with FATZ in two different domains. Therefore, FATZ may be the first member of a small family of novel muscle proteins.	Univ Padua, CRIBI, Ctr Biotechnol, I-35121 Padua, Italy; Univ Padua, Dipartimento Biol, I-35121 Padua, Italy; Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	University of Padua; University of Padua; International Center for Genetic Engineering & Biotechnology (ICGEB)	Lanfranchi, G (corresponding author), Univ Padua, CRIBI, Ctr Biotechnol, Via Ugo Bassi 58B, I-35121 Padua, Italy.	lanfra@eos.bio.unipd.it	Pallavicini, Alberto/J-4158-2012; Kojic, Snezana/AAF-4873-2019; Pallavicini, Alberto/H-9281-2019	Pallavicini, Alberto/0000-0001-7174-4603; Pallavicini, Alberto/0000-0001-7174-4603; VALLE, GIORGIO/0000-0003-4377-5685; Kojic, Snezana/0000-0001-5090-1278	Telethon [1023, B.57] Funding Source: Medline	Telethon(Fondazione Telethon)		Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; BEGGS AH, 1992, J BIOL CHEM, V267, P9281; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; CASTRESANA J, 1995, FEBS LETT, V374, P149, DOI 10.1016/0014-5793(95)01098-Y; Chan YM, 1998, BIOCHEM BIOPH RES CO, V248, P134, DOI 10.1006/bbrc.1998.8920; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; DAVISON MD, 1988, CELL, V52, P159, DOI 10.1016/0092-8674(88)90503-X; DIJOVNOVIAECARU.K, 1999, CELL, V98, P537; Faulkner G, 1999, J CELL BIOL, V146, P465, DOI 10.1083/jcb.146.2.465; FLOOD G, 1995, J MOL BIOL, V252, P227, DOI 10.1006/jmbi.1995.0490; Gautel M, 1996, J CELL SCI, V109, P2747; GORLIN JB, 1993, GENOMICS, V17, P496, DOI 10.1006/geno.1993.1354; GREGORIO CC, 1999, CELL BIOL, V11, P8; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Lanfranchi G, 1996, GENOME RES, V6, P35, DOI 10.1101/gr.6.1.35; MAESTRINI E, 1993, HUM MOL GENET, V2, P761, DOI 10.1093/hmg/2.6.761; Mayans O, 1998, NATURE, V395, P863, DOI 10.1038/27603; MILLAKE DB, 1989, NUCLEIC ACIDS RES, V17, P6725, DOI 10.1093/nar/17.16.6725; MIMURA N, 1986, J BIOL CHEM, V261, P680; Moreira ES, 2000, NAT GENET, V24, P163, DOI 10.1038/72822; Mues A, 1998, FEBS LETT, V428, P111, DOI 10.1016/S0014-5793(98)00501-8; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Ohtsuka H, 1997, BIOCHEM BIOPH RES CO, V235, P1, DOI 10.1006/bbrc.1997.6534; POLLARD TD, 1981, J CELL BIOL, V91, pS156, DOI 10.1083/jcb.91.3.156s; Pomies P, 1997, J CELL BIOL, V139, P157, DOI 10.1083/jcb.139.1.157; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; Salmikangas P, 1999, HUM MOL GENET, V8, P1329, DOI 10.1093/hmg/8.7.1329; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Sorimachi H, 1997, J MOL BIOL, V270, P688, DOI 10.1006/jmbi.1997.1145; Takafuta T, 1998, J BIOL CHEM, V273, P17531, DOI 10.1074/jbc.273.28.17531; Thompson TG, 2000, J CELL BIOL, V148, P115, DOI 10.1083/jcb.148.1.115; Valle G, 1997, FEBS LETT, V415, P163, DOI 10.1016/S0014-5793(97)01108-3; van der Ven PFM, 2000, CELL MOTIL CYTOSKEL, V45, P149, DOI 10.1002/(SICI)1097-0169(200002)45:2<149::AID-CM6>3.0.CO;2-G; WACHSSTOCK DH, 1987, BIOCHEM BIOPH RES CO, V146, P554, DOI 10.1016/0006-291X(87)90564-X; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; Xia HH, 1997, J CELL BIOL, V139, P507, DOI 10.1083/jcb.139.2.507; Xie ZW, 1998, BIOCHEM BIOPH RES CO, V251, P914, DOI 10.1006/bbrc.1998.9506; Young P, 1998, EMBO J, V17, P1614, DOI 10.1093/emboj/17.6.1614; Zhou Q, 1999, J BIOL CHEM, V274, P19807, DOI 10.1074/jbc.274.28.19807; [No title captured]	42	131	146	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41234	41242		10.1074/jbc.M007493200	http://dx.doi.org/10.1074/jbc.M007493200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10984498	hybrid, Green Published			2022-12-25	WOS:000166114600077
J	Bhakta, S; Bartes, A; Bowman, KG; Kao, WM; Polsky, I; Lee, JK; Cook, BN; Bruehl, RE; Rosen, SD; Bertozzi, CR; Hemmerich, S				Bhakta, S; Bartes, A; Bowman, KG; Kao, WM; Polsky, I; Lee, JK; Cook, BN; Bruehl, RE; Rosen, SD; Bertozzi, CR; Hemmerich, S			Sulfation of N-acetylglucosamine by chondroitin 6-sulfotransferase 2 (GST-5)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-SELECTIN LIGAND; SIALYL-LEWIS-X; MOLECULAR-CLONING; CARBOHYDRATE SULFOTRANSFERASES; RESPIRATORY MUCINS; KERATAN SULFATE; EXPRESSION; OLIGOSACCHARIDES; ROLES; IDENTIFICATION	Based on sequence homology with a previously cloned human GlcNAc 6-O-sulfotransferase, we have identified an open reading frame (ORF) encoding a novel member of the Gal/GalNAc/GlcNAc 6-O-sulfotransferase (GST) family termed GST-5 on the human X chromosome (band Xp11). GST-5 has recently been characterized as a novel GalNAc 6-O-sulfotransferase termed chondroitin 6-sulfotransferase-2 (Kitagawa, H., Fujita, M,, Itio, N., and Sugahara K, (2000) J. Biol Chem. 275, 21075-21080), We have coexpressed a human GST-5 cDNA with a GlyCAM-1/IgG fusion protein in COS-7 cells and observed fourfold enhanced [S-35]sulfate incorporation into this mucin acceptor. All mucin-associated [S-35]sulfate was incorporated as GlcNAc-6-sulfate or Gal beta1-->4GlcNAc-6-sulfate. GST-5 was also expressed in soluble epitope-tagged form and found to catalyze 6-O-sulfation of GlcNAc residues in synthetic acceptor structures. In particular, GST-B was found to catalyze 6-O-sulfation of beta -benzyl GlcNAc but not alpha- or beta -benzyl GalNAc, In the mouse genome we have found a homologous ORF that predicts a novel murine GlcNAc 6-O-sulfotransferase with 88% identity to the human enzyme. This gene was mapped to mouse chromosome X at band XA3.1-3.2. GST-5 is the newest member of an emerging family of carbohydrate 6-O-sulfotransferases that includes chondroitin g-sulfotransferase (GST-0), keratan-sulfate galactose 6-O-sulfotransferase (GST-1), the ubiquitously expressed GlcNAc 6-O-sulfotransferase (GST-S), high endothelial cell GlcNAc 6-O-sulfotransferase (GST-3), and intestinal GlcNAc 6-O-sulfotransferase (GST-4),	Roche Biosci, Dept Resp Dis, Palo Alto, CA 94304 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Immunol, San Francisco, CA 94143 USA	Roche Holding; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Hemmerich, S (corresponding author), Thios Biotechnol, 828 Clayton St, San Francisco, CA 94117 USA.	stefan@thiosbiotech.com		Bowman, Kendra/0000-0002-0562-589X; Rosen, Steven/0000-0002-6245-701X	NIGMS NIH HHS [R01GM5741, R01GM59907-01, R37GM23547] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059907, R37GM023547] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Amado M, 1998, J BIOL CHEM, V273, P12770, DOI 10.1074/jbc.273.21.12770; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; Blake JA, 2000, NUCLEIC ACIDS RES, V28, P108, DOI 10.1093/nar/28.1.108; Bowman KG, 1999, CHEM BIOL, V6, pR9, DOI 10.1016/S1074-5521(99)80014-3; Bowman KG, 1998, CHEM BIOL, V5, P447, DOI 10.1016/S1074-5521(98)90161-2; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Carrel L, 1999, P NATL ACAD SCI USA, V96, P14440, DOI 10.1073/pnas.96.25.14440; Cook BN, 2000, J AM CHEM SOC, V122, P8612, DOI 10.1021/ja001224k; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Fukuda M, 1999, J CELL BIOL, V147, P467, DOI 10.1083/jcb.147.3.467; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; Fukuta M, 1998, BBA-GENE STRUCT EXPR, V1399, P57, DOI 10.1016/S0167-4781(98)00089-X; Fukuta M, 1997, J BIOL CHEM, V272, P32321, DOI 10.1074/jbc.272.51.32321; GERSTEN KM, 1995, J BIOL CHEM, V270, P25047, DOI 10.1074/jbc.270.42.25047; Gleeson PA, 1998, HISTOCHEM CELL BIOL, V109, P517, DOI 10.1007/s004180050252; Grabenhorst E, 1999, J BIOL CHEM, V274, P36107, DOI 10.1074/jbc.274.51.36107; Habuchi O, 1996, GLYCOBIOLOGY, V6, P51, DOI 10.1093/glycob/6.1.51; Habuchi O, 1997, GLYCOBIOLOGY, V7, P405, DOI 10.1093/glycob/7.3.405; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; Hemmerich S, 2000, GLYCOBIOLOGY, V10, P849, DOI 10.1093/glycob/10.9.849; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; Hooper LV, 1996, FASEB J, V10, P1137, DOI 10.1096/fasebj.10.10.8751716; IOANNOU PA, 1999, CURRENT PROTOCOLS HU; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; Kimura N, 1999, P NATL ACAD SCI USA, V96, P4530, DOI 10.1073/pnas.96.8.4530; Kitagawa H, 2000, J BIOL CHEM, V275, P21075, DOI 10.1074/jbc.M002101200; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Lee JK, 1999, BIOCHEM BIOPH RES CO, V263, P543, DOI 10.1006/bbrc.1999.1324; Li XA, 1999, GENOMICS, V55, P345, DOI 10.1006/geno.1998.5653; LOGUIDICE JM, 1994, J BIOL CHEM, V269, P18794; LoGuidice JM, 1997, GLYCOCONJUGATE J, V14, P113, DOI 10.1023/A:1018525318185; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; Nelson RM, 1995, ANNU REV CELL DEV BI, V11, P601, DOI 10.1146/annurev.cellbio.11.1.601; Rosen SD, 1996, CURR BIOL, V6, P261, DOI 10.1016/S0960-9822(02)00473-6; ROSEN SD, 1999, OLIGOSACCHARIDES CHE, V2, P245; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Spiro RG, 1996, BIOCHEM J, V319, P209, DOI 10.1042/bj3190209; Uchimura K, 2000, BIOCHEM BIOPH RES CO, V274, P291, DOI 10.1006/bbrc.2000.3141; Uchimura K, 1998, GLYCOBIOLOGY, V8, P489, DOI 10.1093/glycob/8.5.489; Uchimura K, 1998, J BIOCHEM-TOKYO, V124, P670, DOI 10.1093/oxfordjournals.jbchem.a022164; Uchimura K, 1998, J BIOL CHEM, V273, P22577, DOI 10.1074/jbc.273.35.22577; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181	43	31	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40226	40234		10.1074/jbc.M006414200	http://dx.doi.org/10.1074/jbc.M006414200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10956661	hybrid			2022-12-25	WOS:000166039500060
J	Yu, R; Chen, C; Mo, YY; Hebbar, V; Owuor, ED; Tann, TH; Kong, ANT				Yu, R; Chen, C; Mo, YY; Hebbar, V; Owuor, ED; Tann, TH; Kong, ANT			Activation of mitogen-activated protein kinase pathways induces antioxidant response element-mediated gene expression via a Nrf2-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; YA SUBUNIT GENE; TRANSCRIPTION FACTOR NRF2; BETA SIGNAL-TRANSDUCTION; MAP KINASE; PHENOLIC ANTIOXIDANTS; OXIDOREDUCTASE GENE; CELL-DEATH; INDUCTION; JUN	Antioxidant response element (ARE) regulates the induction of a number of cellular antioxidant and detoxifying enzymes. However, the signaling pathways that lead to ARE activation remain unknown. Here, we report that the expression of mitogen-activated protein (MAP) kinase/extracellular signal-regulated kinase kinase kinase 1 (MEKK1), transforming growth factor-beta -activated kinase (TAK1), and apoptosis signal-regulating kinase (ASK1) in HepG2 cells activated the ARE reporter gene, whereas the expression of their dominant-negative mutants impaired ARE activation by the chemicals sodium arsenite and mercury chloride. Coexpression of downstream kinases, MAP kinase kinase 4, MAP kinase kinase 6, and c-Jun NH(2)-terminal kinase-1, but not MAP kinase kinase 3 and p38, augmented ARE activation by MEKK1, TAK1, and ASK1. The coexpression of a basic leucine zipper transcription factor Nrf2 but not c-Jun also greatly enhanced the activation of reporter gene by MEKK1, TAK1, and ASK1; however, a dominant-negative mutant of Nrf2 (NF-ES-related factor 2) blocked this event. Furthermore, when overexpressed, MEKK1, TAK1, and ASK1 induced the expression of heme oxygenase-l, a gene regulated by ARE, and the cotransfection with the dominant-negative mutant of Nrf2 abolished the induction. Taken together, these results suggest that MAP kinase pathways that are activated by MEKK1, TAK1, and ASK1 may link chemical signals to Nrf2, leading to the activation of ARE-dependent genes.	Univ Illinois, Coll Pharm, Dept Pharmaceut & Pharmacodynam, Chicago, IL 60612 USA; Univ Illinois, Coll Pharm, Ctr Pharmaceut Biotechnol, Chicago, IL 60612 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Baylor College of Medicine	Kong, ANT (corresponding author), Univ Illinois, Coll Pharm, Ctr Pharmaceut Biotechnol, Dept Pharmaceut & Pharmacodynam, MC870,900 S Ashland Ave,MBRB Rm 3102, Chicago, IL 60607 USA.	KongT@uic.edu	Mo, Yin-Yuan/R-8255-2019; Mo, Yin-Yuan/B-6141-2011; Chen, Chi/AAF-5343-2020; Tan, Tse-Hua/E-3983-2010; Tan, Tse-Hua/ABD-7080-2021; Kong, Ah-Ng Tony/AAX-2828-2020	Chen, Chi/0000-0001-9703-604X; Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170; 	NCI NIH HHS [R01CA73647] Funding Source: Medline; NIAID NIH HHS [R01AI42532, R01AI38649] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038649, R01AI042532] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hayes JD, 1999, BIOCHEM SOC SYMP, P141; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; JAISWAL AK, 1994, PHARMACOGENETICS, V4, P1, DOI 10.1097/00008571-199402000-00001; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; NGUYEN T, 1994, J BIOL CHEM, V269, P13656; PEZZUTO JM, 1995, RECENT ADV PHYTOCHEM, V29, P19; PROCHASKA HJ, 1985, P NATL ACAD SCI USA, V82, P8232, DOI 10.1073/pnas.82.23.8232; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; SAMBROOK J, 1989, MOL CLONING LABORATO, V2, P16; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; WANG B, 1994, BBA-GENE STRUCT EXPR, V1219, P645, DOI 10.1016/0167-4781(94)90223-2; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; WATTENBERG LW, 1972, JNCI-J NATL CANCER I, V48, P1425; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yu R, 1999, J BIOL CHEM, V274, P27545, DOI 10.1074/jbc.274.39.27545; Yu R, 2000, J BIOL CHEM, V275, P9612, DOI 10.1074/jbc.275.13.9612; Yu R, 2000, J BIOL CHEM, V275, P2322, DOI 10.1074/jbc.275.4.2322	40	299	304	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39907	39913		10.1074/jbc.M004037200	http://dx.doi.org/10.1074/jbc.M004037200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10986282	hybrid			2022-12-25	WOS:000166039500018
J	Du, BH; Fu, CZ; Kent, KC; Bush, H; Schulick, AH; Kreiger, K; Collins, T; McCaffrey, TA				Du, BH; Fu, CZ; Kent, KC; Bush, H; Schulick, AH; Kreiger, K; Collins, T; McCaffrey, TA			Elevated Egr-1 in human atherosclerotic cells transcriptionally represses the transforming growth factor-beta type II receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; TGF-BETA; GENE-EXPRESSION; REGULATORY ELEMENT; IN-VITRO; PROMOTER; SP1; INDUCTION; BINDING; GROWTH-FACTOR-BETA-1	Atherosclerotic lesions may progress due to a "failure to die" by vascular repair cells. Egr-1, a zinc finger transcription factor, is elevated more than 5-fold in human carotid lesions relative to the adjacent tunica media. Lesion cells in vitro also express 2-3-fold higher Egr-1 mRNA and protein levels but express much lower levels of the transforming growth factor-beta (TGF-beta) Type II receptor (T betaR-2) and are functionally resistant to the antiproliferative effects of TGF-beta. Lesion cells fail to express a T betaR-2 promoter/chloramphenicol acetyltransferase (CAT) construct but overexpress an Egr-1-inducible platelet-derived growth factor-A promoter/CAT construct. Transfection of Egr-1 cDNA represses T betaR-2/CAT constructs but induces PDGF-A/CAT, Egr-1 transfection reduces the levels of T betaR-2 and confers resistance to the antiproliferative effect of TGF-beta1, Egr-1 can interact directly with both the -143 Spl site and the positive regulatory element 2 (PRE2) (ERT/ets) region of the T betaR-2 promoter. Thus, although activating a family of stress-responsive genes, Egr-1 also transcriptionally represses one of the major inhibitory pathways that restrains vascular repair.	Cornell Univ, Weill Med Coll, Dept Med, Div Hematol Oncol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Surg, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Div Vasc Surg, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Cardiothorac Surg, New York, NY 10021 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA	Cornell University; Cornell University; Cornell University; Cornell University; Harvard University; Brigham & Women's Hospital; Harvard Medical School	McCaffrey, TA (corresponding author), Cornell Univ, Weill Med Coll, Dept Med, Div Hematol Oncol, 1300 York Ave,C-608, New York, NY 10021 USA.	tamccaf@med.cornell.edu			NHLBI NIH HHS [HL56987, HL56985] Funding Source: Medline; NIA NIH HHS [AG12712] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056987, P50HL056985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012712, R37AG012712] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; Aicher WK, 1999, RHEUMATOL INT, V18, P207, DOI 10.1007/s002960050086; Akuzawa N, 2000, ARTERIOSCL THROM VAS, V20, P377, DOI 10.1161/01.ATV.20.2.377; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; BENNETT MR, 1995, J CLIN INVEST, V95, P2266, DOI 10.1172/JCI117917; Bobik A, 1999, CIRCULATION, V99, P2883, DOI 10.1161/01.CIR.99.22.2883; Bray PJ, 1999, ARTERIOSCL THROM VAS, V19, P1180, DOI 10.1161/01.ATV.19.5.1180; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; Cui MZ, 1999, J BIOL CHEM, V274, P32795, DOI 10.1074/jbc.274.46.32795; Day FL, 1999, J BIOL CHEM, V274, P23726, DOI 10.1074/jbc.274.34.23726; Dinkel A, 1997, J IMMUNOL, V159, P2678; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GRAINGER DJ, 1995, NAT MED, V1, P74, DOI 10.1038/nm0195-74; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hougaard S, 1999, BRIT J CANCER, V79, P1005, DOI 10.1038/sj.bjc.6690161; Houston P, 1999, ARTERIOSCL THROM VAS, V19, P281, DOI 10.1161/01.ATV.19.2.281; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Kim SJ, 2000, CYTOKINE GROWTH F R, V11, P159, DOI 10.1016/S1359-6101(99)00039-8; KIM SJ, 1994, J BIOL CHEM, V269, P3739; KIM SK, 1995, J PHARMACOL EXP THER, V273, P509; Li-Weber M, 1999, EUR J IMMUNOL, V29, P3017, DOI 10.1002/(SICI)1521-4141(199909)29:09<3017::AID-IMMU3017>3.0.CO;2-R; Liu CT, 2000, J BIOL CHEM, V275, P20315, DOI 10.1074/jbc.M909046199; Maltzman JS, 1996, J EXP MED, V183, P1747, DOI 10.1084/jem.183.4.1747; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; McCaffrey TA, 2000, CYTOKINE GROWTH F R, V11, P103, DOI 10.1016/S1359-6101(99)00034-9; McCaffrey TA, 1995, J CLIN INVEST, V96, P2667, DOI 10.1172/JCI118333; McCaffrey TA, 1999, J MOL CELL CARDIOL, V31, P1627, DOI 10.1006/jmcc.1999.0999; McCaffrey TA, 1997, J CLIN INVEST, V100, P2182, DOI 10.1172/JCI119754; MCCAFFREY TA, 1993, MOL BIOL CELL, V4, P315, DOI 10.1091/mbc.4.3.315; McCaffrey TA, 2000, J CLIN INVEST, V105, P653, DOI 10.1172/JCI8592; McKay S, 1998, AM J RESP CELL MOL, V18, P823, DOI 10.1165/ajrcmb.18.6.2924; Minc E, 1999, J BIOL CHEM, V274, P503, DOI 10.1074/jbc.274.1.503; Miyazono K, 2000, CYTOKINE GROWTH F R, V11, P15, DOI 10.1016/S1359-6101(99)00025-8; MOLNAR G, 1994, MOL CELL BIOL, V14, P5242, DOI 10.1128/MCB.14.8.5242; Reiss M, 1999, MICROBES INFECT, V1, P1327, DOI 10.1016/S1286-4579(99)00251-8; Rembold C, 1996, PERSPECT BIOL MED, V39, P405; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Santiago FS, 1999, NAT MED, V5, P1264, DOI 10.1038/15215; Santiago FS, 1999, AM J PATHOL, V155, P897, DOI 10.1016/S0002-9440(10)65189-9; Sato K, 1999, MOL BRAIN RES, V74, P182, DOI 10.1016/S0169-328X(99)00279-X; SCHMITTGRAFF A, 1994, VIRCHOWS ARCH, V425, P3, DOI 10.1007/BF00193944; SHIMIZU N, 1992, J BIOCHEM-TOKYO, V111, P272, DOI 10.1093/oxfordjournals.jbchem.a123748; Silverman ES, 1998, AM J RESP CELL MOL, V19, P316, DOI 10.1165/ajrcmb.19.2.3154; Silverman ES, 1997, AM J PHYSIOL-HEART C, V273, pH1415, DOI 10.1152/ajpheart.1997.273.3.H1415; SKERKA C, 1995, J BIOL CHEM, V270, P22500, DOI 10.1074/jbc.270.38.22500; Srivastava S, 1998, J CLIN INVEST, V102, P1850, DOI 10.1172/JCI4561; Thottassery JV, 1999, J BIOL CHEM, V274, P3199, DOI 10.1074/jbc.274.5.3199; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030; Yan YX, 1997, J BIOL CHEM, V272, P33181, DOI 10.1074/jbc.272.52.33181; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795	53	49	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39039	39047		10.1074/jbc.M005159200	http://dx.doi.org/10.1074/jbc.M005159200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10982796	hybrid			2022-12-25	WOS:000165953100015
J	Fowler, SJ; Jose, S; Zhang, XM; Deutzmann, R; Sarras, MP; Boot-Handford, RP				Fowler, SJ; Jose, S; Zhang, XM; Deutzmann, R; Sarras, MP; Boot-Handford, RP			Characterization of hydra type IV collagen - Type IV collagen is essential for head regeneration and its expression is up-regulated upon exposure to glucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE COLLAGEN; EXTRACELLULAR-MATRIX MESOGLEA; AMINO-ACID SEQUENCE; STRUCTURAL ORGANIZATION; CAENORHABDITIS-ELEGANS; ALPHA-2(IV) COLLAGEN; CHAIN; GENE; LAMININ; IDENTIFICATION	Hydra vulgaris mesoglea is a primitive basement membrane that also exhibits some features of an interstitial matrix. We have characterized cDNAs that encode the full-length hydra alpha1(IV) chain. The 5169-base pair transcript encodes a protein of 1723 amino acids, including an interrupted 1455-residue collagenous domain and a 228-residue C-terminal noncollagenous domain. N-terminal sequence analyses of collagen IV peptides suggest the molecule is homotrimeric. Denatured hydra type IV collagen protein occurs as dimers and higher order aggregates held together by nonreducible cross-links. Hydra collagen TV exhibits no functional evidence for the presence of a 7 S domain. Type TV collagen is expressed by the ectoderm along the entire longitudinal axis of the animal but is most intense at the base of the tentacles at the site of battery cell transdifferentiation. Antisense studies show that inhibition of collagen IV translation causes a blockage in head regeneration, indicating its importance in normal hydra development. Exposure of adult hydra to 15 mm glucose resulted in up-regulation of type IV collagen mRNA levels within 48 h and significant thickening of the mesoglea within 14 days, suggesting that basement membrane thickening seen in diabetes may be, in evolutionary terms, an ancient glucose-mediated response.	Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66160 USA; Univ Regensburg, Inst Biochem 1, D-8400 Regensburg, Germany; SW Missouri State Univ, Dept Biomed Sci, Springfield, MO 65804 USA	University of Manchester; University of Kansas; University of Kansas Medical Center; University of Regensburg; Missouri State University	Boot-Handford, RP (corresponding author), Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Sch Biol Sci, 2-205 Stopford, Manchester M13 9PT, Lancs, England.			Boot-Handford, Raymond/0000-0002-6167-8419	NIDDK NIH HHS [DK47840] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047840] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGOSTI CG, 1991, CELL MOTIL CYTOSKEL, V20, P215, DOI 10.1002/cm.970200305; BARZANSKY B, 1974, AM ZOOL, V14, P575; BLUMBERG B, 1988, J BIOL CHEM, V263, P18328; BOOTHANDFORD RP, 1987, J BIOL CHEM, V262, P12475; Boute N, 1996, BIOL CELL, V88, P37, DOI 10.1016/S0248-4900(97)86829-3; BRAZEL D, 1987, EUR J BIOCHEM, V168, P529, DOI 10.1111/j.1432-1033.1987.tb13450.x; BURNETT AL, 1969, J EXP ZOOL, V171, P15, DOI 10.1002/jez.1401710104; DAY RM, 1981, SCIENCE, V211, P291, DOI 10.1126/science.7444468; Deutzmann R, 2000, DEVELOPMENT, V127, P4669; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; EXPOSITO JY, 1993, J BIOL CHEM, V268, P5249; EXPOSITO JY, 1994, J BIOL CHEM, V269, P13167; FAWCETT DW, 1961, BIOL HYDRA SOME OTHE, P65; Flanagan WM, 1996, NUCLEIC ACIDS RES, V24, P2936, DOI 10.1093/nar/24.15.2936; Graham PL, 1997, J CELL BIOL, V137, P1171, DOI 10.1083/jcb.137.5.1171; Grens A, 1999, DEVELOPMENT, V126, P517; Grens A, 1995, DEVELOPMENT, V121, P4027; GUO XD, 1991, NATURE, V349, P707, DOI 10.1038/349707a0; HAUSMAN RE, 1971, J EXP ZOOL, V177, P435, DOI 10.1002/jez.1401770405; HOSTIKKA SL, 1988, J BIOL CHEM, V263, P19488; JOHANSSON C, 1992, J BIOL CHEM, V267, P24533; KUHN K, 1994, MATRIX BIOL, V14, P439; LEINONEN A, 1994, J BIOL CHEM, V269, P26172; Leontovich AA, 2000, DEVELOPMENT, V127, P907; NOELKEN ME, 1986, J BIOL CHEM, V261, P4706; OBERBAUMER I, 1985, EUR J BIOCHEM, V147, P217, DOI 10.1111/j.1432-1033.1985.tb08739.x; PETTITT J, 1991, J BIOL CHEM, V266, P16149; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; SARRAS MP, 1991, DEV BIOL, V148, P495, DOI 10.1016/0012-1606(91)90267-7; SARRAS MP, 1991, DEV BIOL, V148, P481, DOI 10.1016/0012-1606(91)90266-6; SARRAS MP, 1994, DEV BIOL, V164, P312, DOI 10.1006/dbio.1994.1201; SHOSTAK S, 1965, DEV BIOL, V12, P434, DOI 10.1016/0012-1606(65)90008-4; SIBLEY MH, 1993, J CELL BIOL, V123, P255, DOI 10.1083/jcb.123.1.255; SIMONASSMANN P, 1995, EXPERIENTIA, V51, P883, DOI 10.1007/BF01921739; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WAGNER RW, 1995, NAT MED, V1, P1116, DOI 10.1038/nm1195-1116; Yan L, 2000, DEV BIOL, V219, P115, DOI 10.1006/dbio.1999.9568; Yan L, 2000, DEVELOPMENT, V127, P129; YURCHENCO PD, 1990, ANN NY ACAD SCI, V580, P195, DOI 10.1111/j.1749-6632.1990.tb17929.x; ZHANG X, 1990, DIABETOLOGIA, V33, P704, DOI 10.1007/BF00400573; ZHANG XM, 1994, DEVELOPMENT, V120, P425	41	53	55	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39589	39599		10.1074/jbc.M005871200	http://dx.doi.org/10.1074/jbc.M005871200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10956657	hybrid			2022-12-25	WOS:000165953100085
J	Dutta, R; Yoshida, T; Inouye, M				Dutta, R; Yoshida, T; Inouye, M			The critical role of the conserved Thr(247) residue in the functioning of the osmosensor EnvZ, a histidine kinase/phosphatase, in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 REGULATORY PROTEINS; PORIN GENE-EXPRESSION; SIGNAL-TRANSDUCTION; PHOSPHATASE-ACTIVITIES; OMPC GENES; OSMOREGULATORY EXPRESSION; TRANSCRIPTIONAL ACTIVATOR; TRANSMEMBRANE RECEPTOR; BACTERIAL CHEMOTAXIS; PHOSPHORYLATION	The histidine kinase/phosphatase EnvZ helps Escherichia coli adapt to osmotic-shock by controlling the phosphorylation state of the transcription factor OmpR, which regulates the levels of the outer membrane porin proteins OmpF and OmpC. We examined the effects of mutating the highly conserved Thr(247) residue in EnvZ, Using purified C-terminal domains of wild-type and mutant EnvZ proteins, we demonstrate that Thr(247) plays a vital role in EnvZ function, variously affecting its autokinase and phosphotransferase activities, but mostly its function as a phosphatase, The cytoplasmic domain of EnvZ (EnvZc) is composed of three segments: the Linker domain (residues 180-222), domain A (residues 223-289), and domain B (residues 290-450), It has been shown that the isolated domain A itself can dephosphorylate phosphorylated OmpR. Here we show that mutating Thr247 to Arg in domain A abolishes its phosphatase activity. Furthermore, using an in vivo beta -galactosidase activity assay of Taz1-1 (hybrid of the aspartate receptor Tar and EnvZ) constructs of the Thr(247) mutants in RU1012 cells expressing ompC-lacZ, we demonstrate that the external signal primarily down-regulates the phosphatase activity of EnvZ, Of the nine EnvZc(T247X) mutants (X = Ser, Ale, Cys, Lys, Asn, Glu, Gin, Tyr, or Arg) analyzed, only Ser functionally substituted for Thr at this position, whereas all the others displayed constitutive expression of beta -galactosidase.	Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Inouye, M (corresponding author), Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.			Yoshida, Takeshi/0000-0003-0133-5067	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019043, R01GM019043] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19043] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIBA H, 1989, J BIOL CHEM, V264, P14090; AIBA H, 1989, J BIOL CHEM, V264, P8563; Arnez JG, 1998, PROTEINS, V32, P362; DELGADO J, 1993, MOL MICROBIOL, V10, P1037, DOI 10.1111/j.1365-2958.1993.tb00974.x; Dutta R, 1996, J BIOL CHEM, V271, P1424, DOI 10.1074/jbc.271.3.1424; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; Dutta R, 1999, MOL MICROBIOL, V34, P633, DOI 10.1046/j.1365-2958.1999.01646.x; Egger LA, 1997, GENES CELLS, V2, P167, DOI 10.1046/j.1365-2443.1997.d01-311.x; FENG JL, 1992, J BACTERIOL, V174, P6061, DOI 10.1128/JB.174.19.6061-6070.1992; FERSHT A, 1999, STRUCTURE EMCH PROTE, P84; FORST S, 1988, J BACTERIOL, V170, P5080, DOI 10.1128/jb.170.11.5080-5085.1988; FORST S, 1989, P NATL ACAD SCI USA, V86, P6052, DOI 10.1073/pnas.86.16.6052; FORST SA, 1994, RES MICROBIOL, V145, P363, DOI 10.1016/0923-2508(94)90083-3; Grebe TW, 1999, ADV MICROB PHYSIOL, V41, P139, DOI 10.1016/S0065-2911(08)60167-8; HALL MN, 1981, J MOL BIOL, V151, P1, DOI 10.1016/0022-2836(81)90218-7; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; Hoch JA, 1995, 2 COMPONENT SIGNAL T; Hsing WH, 1998, J BACTERIOL, V180, P4538, DOI 10.1128/JB.180.17.4538-4546.1998; IGO MM, 1988, J BACTERIOL, V170, P5971, DOI 10.1128/jb.170.12.5971-5973.1988; IGO MM, 1989, GENE DEV, V3, P1725, DOI 10.1101/gad.3.11.1725; Jiang P, 2000, BIOCHEMISTRY-US, V39, P5057, DOI 10.1021/bi992921w; JIN T, 1993, J MOL BIOL, V232, P484, DOI 10.1006/jmbi.1993.1404; Kramer G, 1999, P NATL ACAD SCI USA, V96, P604, DOI 10.1073/pnas.96.2.604; Loomis WF, 1998, CURR OPIN MICROBIOL, V1, P643, DOI 10.1016/S1369-5274(98)80109-4; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; MATSUYAMA SI, 1986, J BACTERIOL, V168, P1309, DOI 10.1128/jb.168.3.1309-1314.1986; MILLER F, 1972, IMMUNOCHEMISTRY, V9, P217, DOI 10.1016/0019-2791(72)90087-0; MIZUNO T, 1987, J BIOCHEM-TOKYO, V101, P387, DOI 10.1093/oxfordjournals.jbchem.a121923; Park H, 1997, J BACTERIOL, V179, P4382, DOI 10.1128/jb.179.13.4382-4390.1997; Park H, 1998, P NATL ACAD SCI USA, V95, P6728, DOI 10.1073/pnas.95.12.6728; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; Pratt L., 1995, 2 COMPONENT SIGNAL T, P105; RAMPERSAUD A, 1991, J BIOL CHEM, V266, P7633; ROBERTS DL, 1994, J BIOL CHEM, V269, P8728; RUSSO FD, 1991, J MOL BIOL, V222, P567, DOI 10.1016/0022-2836(91)90497-T; SARMA V, 1977, J BACTERIOL, V132, P23, DOI 10.1128/JB.132.1.23-27.1977; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Skarphol K, 1997, J BACTERIOL, V179, P1413, DOI 10.1128/jb.179.4.1413-1416.1997; SLAUCH JM, 1989, J MOL BIOL, V210, P281, DOI 10.1016/0022-2836(89)90330-6; STOCK A, 1988, P NATL ACAD SCI USA, V85, P1403, DOI 10.1073/pnas.85.5.1403; STOCK AM, 1993, BIOCHEMISTRY-US, V32, P13375, DOI 10.1021/bi00212a001; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; Tanaka T, 1998, NATURE, V396, P88, DOI 10.1038/23968; Tomomori C, 1999, NAT STRUCT BIOL, V6, P729; UTSUMI R, 1989, SCIENCE, V245, P1246, DOI 10.1126/science.2476847; WANDERSMAN C, 1980, J BACTERIOL, V143, P1374, DOI 10.1128/JB.143.3.1374-1383.1980; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919; YANG Y, 1993, J MOL BIOL, V231, P335, DOI 10.1006/jmbi.1993.1286; YANG Y, 1991, P NATL ACAD SCI USA, V88, P11057, DOI 10.1073/pnas.88.24.11057; Zhu Y, 2000, P NATL ACAD SCI USA, V97, P7808, DOI 10.1073/pnas.97.14.7808	52	58	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38645	38653		10.1074/jbc.M005872200	http://dx.doi.org/10.1074/jbc.M005872200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10973966	hybrid			2022-12-25	WOS:000165739800069
J	Fraaije, MW; van den Heuvel, RHH; van Berkel, WJH; Mattevi, A				Fraaije, MW; van den Heuvel, RHH; van Berkel, WJH; Mattevi, A			Structural analysis of flavinylation in vanillyl-alcohol oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-HYDROXYBENZOATE HYDROXYLASE; L-ASPARTATE OXIDASE; OXIDOREDUCTASE FAMILY; CRYSTAL-STRUCTURES; PROTEIN MODELS; ACTIVE-SITE; BINDING; FLAVOPROTEIN; FAD; REFINEMENT	Vanillyl-alcohol oxidase (VAO) is member of a newly recognized flavoprotein family of structurally related oxidoreductases. The enzyme contains a covalently linked FAD cofactor. To study the mechanism of flavinylation we have created a design point mutation (His-61 --> Thr). In the mutant enzyme the covalent His-C8 alpha -flavin linkage is not formed, while the enzyme is still able to bind FAD and perform catalysis. The H61T mutant displays a similar affinity for FAD and ADP (K-d = 1.8 and 2.1 muM, respectively) but does not interact with FMN. H61T is about 10-fold less active with 4-(methoxymethyl)phenol) (k(cat) = 0.24 s(-1), K-m = 40 muM) than the wild-type enzyme. The crystal structures of both the hole and apo form of H61T are highly similar to the structure of wild-type VAO, indicating that binding of FAD to the apoprotein does not require major structural rearrangements. These results show that covalent flavinylation is an autocatalytical process in which His-BI plays a crucial role by activating His-422. Furthermore, our studies clearly demonstrate that in VAO, the FAD binds via a typical lock-and-key approach to a preorganized binding site.	Univ Wageningen & Res Ctr, Biochem Lab, Dept Biomol Sci, NL-6703 HA Wageningen, Netherlands; Univ Pavia, Dept Genet & Microbiol, I-27100 Pavia, Italy	Wageningen University & Research; University of Pavia	Fraaije, MW (corresponding author), Univ Groningen, Biochem Lab, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.		Fraaije, Marco/E-8421-2014; mattevi, andrea/K-5464-2012; Mattevi, Andrea/R-4469-2019; van Berkel, Willem J.H./O-2431-2014	mattevi, andrea/0000-0002-9523-7128; Mattevi, Andrea/0000-0002-9523-7128; van Berkel, Willem J.H./0000-0002-6551-2782; Fraaije, Marco/0000-0001-6346-5014				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; *DINO, 1999, VIS STRUCT BIOL; Dobbek H, 1999, P NATL ACAD SCI USA, V96, P8884, DOI 10.1073/pnas.96.16.8884; Fraaije MW, 2000, TRENDS BIOCHEM SCI, V25, P126, DOI 10.1016/S0968-0004(99)01533-9; Fraaije MW, 1999, J BIOL CHEM, V274, P35514, DOI 10.1074/jbc.274.50.35514; Fraaije MW, 1997, J BIOL CHEM, V272, P18111, DOI 10.1074/jbc.272.29.18111; Fraaije MW, 1998, TRENDS BIOCHEM SCI, V23, P206, DOI 10.1016/S0968-0004(98)01210-9; GHISLA S, 1989, EUR J BIOCHEM, V181, P1, DOI 10.1111/j.1432-1033.1989.tb14688.x; Guenther BD, 1999, NAT STRUCT BIOL, V6, P359, DOI 10.1038/7594; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Mattevi A, 1997, STRUCTURE, V5, P907, DOI 10.1016/S0969-2126(97)00245-1; Mattevi A, 1997, PROTEINS, V27, P601, DOI 10.1002/(SICI)1097-0134(199704)27:4<601::AID-PROT12>3.0.CO;2-O; Mattevi A, 1999, STRUCTURE, V7, P745, DOI 10.1016/S0969-2126(99)80099-9; Mewies M, 1998, PROTEIN SCI, V7, P7, DOI 10.1002/pro.5560070102; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; MULLER F, 1982, EUR J BIOCHEM, V128, P21; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; SANDALOVA T, 1993, FEBS LETT, V327, P361, DOI 10.1016/0014-5793(93)81021-Q; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; SATO K, 1992, J BIOCHEM-TOKYO, V112, P804, DOI 10.1093/oxfordjournals.jbchem.a123980; SCHREUDER HA, 1994, BIOCHEMISTRY-US, V33, P10161, DOI 10.1021/bi00199a044; Steensma E, 1998, J MOL BIOL, V282, P653, DOI 10.1006/jmbi.1998.2045; Tedeschi G, 1999, EUR J BIOCHEM, V260, P896, DOI 10.1046/j.1432-1327.1999.00234.x; Trickey P, 1999, STRUCTURE, V7, P331, DOI 10.1016/S0969-2126(99)80043-4; Van Berkel WJH, 2000, PROTEIN SCI, V9, P435; VANDERLAAN JM, 1989, BIOCHEMISTRY-US, V28, P7199, DOI 10.1021/bi00444a011	28	52	54	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38654	38658		10.1074/jbc.M004753200	http://dx.doi.org/10.1074/jbc.M004753200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10984479	hybrid, Green Published			2022-12-25	WOS:000165739800070
J	Stephenson, K; Yamaguchi, Y; Hoch, JA				Stephenson, K; Yamaguchi, Y; Hoch, JA			The mechanism of action of inhibitors of bacterial two-component signal transduction systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SYSTEMS; BACILLUS-SUBTILIS; SPORULATION; DOMAIN; GENE	Two-component signal transduction systems allow bacteria to sense and respond rapidly to changes in their environment leading to specific gene activation or repression. These two-component systems are integral in the ability of pathogenic bacteria to mount and establish a successful infection within the host and, consequently, have been recognized as targets for new antimicrobial agents. In this paper, we define the site and mechanism of action of several previously identified inhibitors of bacterial two-component systems. We show that the most potent inhibitors target the carboxyl-terminal catalytic domain of the sensor kinase and exert their affect by causing structural alterations of the kinase leading to aggregation. Recognition of this phenomenon has important implications for the development of novel inhibitors of two-component systems and should facilitate the rapid identification and elimination of compounds with nonspecific affects from medicinal chemistry drug discovery programs.	Scripps Res Inst, Dept Mol & Expt Med, Div Cellular Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Hoch, JA (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, Div Cellular Biol, MEM-116,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	hoch@scripps.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019416, R37GM019416] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19416] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barrett J. F., 1995, ANNU REP MED CHEM, P111; Barrett JF, 1998, ANTIMICROB AGENTS CH, V42, P1529, DOI 10.1128/AAC.42.7.1529; Barrett JF, 1998, P NATL ACAD SCI USA, V95, P5317, DOI 10.1073/pnas.95.9.5317; Bilwes AM, 1999, CELL, V96, P131, DOI 10.1016/S0092-8674(00)80966-6; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; Domagala JM, 1998, ADV EXP MED BIOL, V456, P269; Grimshaw CE, 1998, BIOCHEMISTRY-US, V37, P1365, DOI 10.1021/bi971917m; Hilliard JJ, 1995, ADV EXP MED BIOL, V390, P59; Hilliard JJ, 1999, ANTIMICROB AGENTS CH, V43, P1693, DOI 10.1128/AAC.43.7.1693; Hlasta DJ, 1998, BIOORG MED CHEM LETT, V8, P1923, DOI 10.1016/S0960-894X(98)00326-6; Hoch JA, 1995, 2 COMPONENT SIGNAL T; Macielag MJ, 1998, J MED CHEM, V41, P2939, DOI 10.1021/jm9803572; NINFA AJ, 1986, J BACTERIOL, V168, P1002, DOI 10.1128/jb.168.2.1002-1004.1986; Ninfa AJ, 1995, 2 COMPONENT SIGNAL T, P67; ROYCHOUDHURY S, 1993, P NATL ACAD SCI USA, V90, P965, DOI 10.1073/pnas.90.3.965; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Sui ZH, 1998, BIOORG MED CHEM LETT, V8, P1929, DOI 10.1016/S0960-894X(98)00325-4; Tanaka T, 1998, NATURE, V396, P88, DOI 10.1038/23968; Throup JP, 2000, MOL MICROBIOL, V35, P566, DOI 10.1046/j.1365-2958.2000.01725.x; Tomomori C, 1999, NAT STRUCT BIOL, V6, P729; Varughese KI, 1998, MOL CELL, V2, P485, DOI 10.1016/S1097-2765(00)80148-3; Wang L, 1997, GENE DEV, V11, P2569, DOI 10.1101/gad.11.19.2569; Zapf JW, 1996, BIOCHEMISTRY-US, V35, P2926, DOI 10.1021/bi9519361	23	79	93	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38900	38904		10.1074/jbc.M006633200	http://dx.doi.org/10.1074/jbc.M006633200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10978341	hybrid			2022-12-25	WOS:000165739800103
J	Hefner, Y; Borsch-Haubold, AG; Murakami, M; Wilde, JI; Pasquet, S; Schieltz, D; Ghomashchi, F; Yates, JR; Armstrong, CG; Paterson, A; Cohen, P; Fukunaga, R; Hunter, T; Kudo, I; Watson, SP; Gelb, MH				Hefner, Y; Borsch-Haubold, AG; Murakami, M; Wilde, JI; Pasquet, S; Schieltz, D; Ghomashchi, F; Yates, JR; Armstrong, CG; Paterson, A; Cohen, P; Fukunaga, R; Hunter, T; Kudo, I; Watson, SP; Gelb, MH			Serine 727 phosphorylation and activation of cytosolic phospholipase A(2) by MNK1-related protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RELAXATION MAGNETIC-RESONANCE; STIMULATED HUMAN PLATELETS; MAP KINASE; ARACHIDONIC-ACID; SUBSTRATE-SPECIFICITY; CRYSTAL-STRUCTURE; NUCLEAR-ENVELOPE; BINDING DOMAIN; IN-VIVO; STRESS	We have previously reported that in thrombin-stimulated human platelets, cytosolic phospholipase A, (cPLA2) is phosphorylated on Ser-505 by p38 protein kinase and on Ser-727 by an unknown kinase. Pharmacological inhibition of p38 leads to inhibition of cPLA2 phosphorylation at both Ser-505 and Ser-727 suggesting that the kinase responsible for phosphorylation on Ser727 is activated in a p38-dependent pathway. By using Chinese hamster ovary, HeLa, and HEK293 cells stably transfected with wild type and phosphorylation site mutant forms of cPLA2, we show that phosphorylation of cPLA2 at both Ser-505 and Ser-727 and elevation of Ca2+ leads to its activation in agonist-stimulated cells. The p38-activated protein kinases MNK1, MSK1, and PRAK1 phosphorylate cPLA2 in vitro uniquely on Ser-727 as shown by mass spectrometry. Furthermore, MNK1 and PRAK1, but not MSK1, is present in platelets and undergo modest activation in response to thrombin. Expression of a dominant negative form of MNK1 in HFK293 cells leads to significant inhibition of cPLA2-mediated arachidonate release. The results suggest that MNK1 or a closely related kinase is responsible for in vivo phosphorylation of cPLA2 on Ser-727.	Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England; Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, Tokyo 142, Japan; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA; Univ Dundee, Dept Biochem, Div Signal Transduct, Dundee DD1 5EH, Scotland; Osaka Univ, Sch Med, Dept Genet, Suita, Osaka 565, Japan; Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Oxford; Showa University; University of Washington; University of Washington Seattle; University of Dundee; Osaka University; Salk Institute	Gelb, MH (corresponding author), Univ Washington, Dept Chem, Seattle, WA 98195 USA.		Fukunaga, Rikiro/CAG-2891-2022; Watson, Stephen P/Q-6292-2016	Watson, Stephen P/0000-0002-7846-7423; gelb, michael/0000-0001-7000-5219	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050040] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50040] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ball A, 1999, P NATL ACAD SCI USA, V96, P6637, DOI 10.1073/pnas.96.12.6637; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; Bayburt T, 1997, BIOCHEMISTRY-US, V36, P3216, DOI 10.1021/bi961659d; Borsch-Haubold AG, 1999, EUR J BIOCHEM, V265, P195, DOI 10.1046/j.1432-1327.1999.00722.x; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P4449, DOI 10.1074/jbc.273.8.4449; BorschHaubold AG, 1996, BIOCHEM J, V318, P207; BorschHaubold AG, 1997, EUR J BIOCHEM, V245, P751, DOI 10.1111/j.1432-1033.1997.t01-1-00751.x; BORSCHHAUBOLD AG, 1995, J BIOL CHEM, V270, P25855; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; Clifton AD, 1996, FEBS LETT, V392, P209, DOI 10.1016/0014-5793(96)00816-2; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; Dessen A, 1999, CELL, V97, P349, DOI 10.1016/S0092-8674(00)80744-8; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Flati V, 1996, EMBO J, V15, P1566, DOI 10.1002/j.1460-2075.1996.tb00501.x; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Gatlin CL, 1998, ANAL BIOCHEM, V263, P93, DOI 10.1006/abio.1998.2809; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Hixon MS, 1998, BIOCHEMISTRY-US, V37, P8516, DOI 10.1021/bi980416d; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; Kramer RM, 1997, FEBS LETT, V410, P49, DOI 10.1016/S0014-5793(97)00322-0; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Lin Y, 1998, SCIENCE, V279, P1925, DOI 10.1126/science.279.5358.1925; LUDWIG S, 1998, MOL CELL BIOL, V12, P6687; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SHARP JD, 1991, J BIOL CHEM, V266, P14850; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; YATES I, 1994, CELL BIOL LAB HDB, P380	41	185	188	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37542	37551		10.1074/jbc.M003395200	http://dx.doi.org/10.1074/jbc.M003395200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10978317	hybrid			2022-12-25	WOS:000165618700034
J	Harada, A; Furuta, B; Takeuchi, K; Itakura, M; Takahashi, M; Umeda, M				Harada, A; Furuta, B; Takeuchi, K; Itakura, M; Takahashi, M; Umeda, M			Nadrin, a novel neuron-specific GTPase-activating protein involved in regulated exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILIZED MAST-CELLS; CHROMAFFIN CELLS; BINDING PROTEINS; PC12 CELLS; CA2+-DEPENDENT EXOCYTOSIS; ACTIN CYTOSKELETON; SYNAPTIC VESICLES; RHO-GDI; ORGANIZATION; DOMAIN	It has been proposed that the cortical actin filament networks act as a cortical barrier that must be reorganized to enable docking and fusion of the synaptic vesicles with the plasma membranes, We identified a novel neuron-associated developmentally regulated protein, designated as Nadrin, Expression of Nadrin is restricted to neurons and correlates well with the differentiation of neurons, Nadrin has a unique structure; it contains a GTPase-activating protein (GAP) domain for Rho family GTPases, a potential coiled-coil domain, and a succession of 29 glutamines, In vitro the GAP domain activates RhoA, Rac1, and Cdc42 GTPases, Expression of Nadrin in NIH3T3 cells markedly reduced the number of the actin stress fibers and the formation of the ruffled membranes, suggesting that Nadrin regulates actin filament reorganization. In PC12 cells, Nadrin colocalized with synaptotagmin in the neurite termini and also with cortical actin filaments in the subplasmalemmal regions, Expression of Nadrin or its mutant composed of the coiled-coil and GAP domain enhanced Ca2+-dependent exocytosis of PC12 cells, but a mutant lacking the GAP domain inhibited exocytosis, These results suggest that Nadrin plays a role in regulating Ca2+-dependent exocytosis, most likely by catalyzing GTPase activity of Rho family proteins and by inducing the reorganization of the cortical actin filaments.	Tokyo Metropolitan Inst Med Sci, Dept Mol Biodynam, Bunkyo Ku, Tokyo 1138613, Japan; Ochanomizu Univ, Fac Sci, Dept Biol, Bunkyo Ku, Tokyo 1128610, Japan; Mitsubishi Kasei Inst Life Sci, Machida, Tokyo 1948511, Japan	Tokyo Metropolitan Institute of Medical Science; Ochanomizu University	Umeda, M (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Mol Biodynam, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P40; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; Bernstein BW, 1998, MOL BRAIN RES, V53, P236, DOI 10.1016/S0169-328X(97)00319-7; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Brown AM, 1998, MOL BIOL CELL, V9, P1053, DOI 10.1091/mbc.9.5.1053; BURGOYNE RD, 1982, PROC R SOC SER B-BIO, V216, P111, DOI 10.1098/rspb.1982.0064; Calakos N, 1996, PHYSIOL REV, V76, P1; CASTICAS S, 1991, P NATL ACAD SCI U S, V88, P785; Chasserot-Golaz S, 1998, J NEUROCHEM, V70, P2347; CICCHETTI P, 1995, EMBO J, V14, P3127, DOI 10.1002/j.1460-2075.1995.tb07315.x; Daly C, 1997, J NEUROSCI, V17, P2365; Emoto K, 1996, P NATL ACAD SCI USA, V93, P12867, DOI 10.1073/pnas.93.23.12867; Fernandez-Chacon R, 1999, ANNU REV PHYSIOL, V61, P753, DOI 10.1146/annurev.physiol.61.1.753; Gasman S, 1997, J BIOL CHEM, V272, P20564, DOI 10.1074/jbc.272.33.20564; Gasman S, 1998, J BIOL CHEM, V273, P16913, DOI 10.1074/jbc.273.27.16913; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Harada A, 1999, J BIOCHEM, V125, P443, DOI 10.1093/oxfordjournals.jbchem.a022306; HEISTERKAMP N, 1993, J BIOL CHEM, V268, P16903; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Ikonomov OC, 1998, J NEUROSCI, V18, P6331; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; Itakura M, 1999, BIOCHEM BIOPH RES CO, V265, P691, DOI 10.1006/bbrc.1999.1756; Kaneda M, 1997, J BIOCHEM-TOKYO, V122, P1233; Komuro R, 1996, GENES CELLS, V1, P943, DOI 10.1046/j.1365-2443.1996.760276.x; Kozma R, 1996, MOL CELL BIOL, V16, P5069; LACASSE EC, 1995, NUCLEIC ACIDS RES, V23, P1647, DOI 10.1093/nar/23.10.1647; LANDIS DMD, 1988, NEURON, V1, P201, DOI 10.1016/0896-6273(88)90140-7; LEE RWH, 1981, NEUROSCIENCE, V6, P2087, DOI 10.1016/0306-4522(81)90048-8; LEUNG T, 1993, J BIOL CHEM, V268, P3813; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; LOU XJ, 1995, MOL CELL NEUROSCI, V6, P252, DOI 10.1006/mcne.1995.1020; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MIYAMOTO S, 1995, BIOCHIM BIOPHYS ACTA, V11, P85; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; Muller RT, 1997, MOL BIOL CELL, V8, P2039, DOI 10.1091/mbc.8.10.2039; NORMAN JC, 1994, J CELL BIOL, V126, P1005, DOI 10.1083/jcb.126.4.1005; Norman JC, 1996, MOL BIOL CELL, V7, P1429, DOI 10.1091/mbc.7.9.1429; Orita S, 1996, J BIOL CHEM, V271, P7257, DOI 10.1074/jbc.271.13.7257; OSullivan AJ, 1996, MOL BIOL CELL, V7, P397, DOI 10.1091/mbc.7.3.397; Paulson HL, 1996, ANNU REV NEUROSCI, V19, P79; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; REINHARD J, 1995, EMBO J, V14, P697, DOI 10.1002/j.1460-2075.1995.tb07048.x; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Sasaki T, 1998, BIOCHEM BIOPH RES CO, V245, P641, DOI 10.1006/bbrc.1998.8253; Seastone DJ, 1998, MOL BIOL CELL, V9, P2891, DOI 10.1091/mbc.9.10.2891; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; TAKAHASHI M, 1991, BRAIN RES, V551, P279, DOI 10.1016/0006-8993(91)90942-O; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Tatsis N, 1998, J BIOL CHEM, V273, P34631, DOI 10.1074/jbc.273.51.34631; Trifaro JM, 1997, NEUROCHEM RES, V22, P831, DOI 10.1023/A:1022087910902; TRIFARO JM, 1993, TRENDS NEUROSCI, V16, P466, DOI 10.1016/0166-2236(93)90079-2; VITALE ML, 1991, J CELL BIOL, V113, P1057, DOI 10.1083/jcb.113.5.1057; VITALE ML, 1995, NEURON, V14, P353, DOI 10.1016/0896-6273(95)90291-0; WICK PF, 1993, J BIOL CHEM, V268, P10983; Zhang L, 1996, NEURON, V17, P287, DOI 10.1016/S0896-6273(00)80160-9; ZHENG Y, 1993, J BIOL CHEM, V268, P24629	60	51	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36885	36891		10.1074/jbc.M004069200	http://dx.doi.org/10.1074/jbc.M004069200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10967100	hybrid			2022-12-25	WOS:000165577700063
J	Reddy, MA; Prasadarao, NV; Wass, CA; Kim, KS				Reddy, MA; Prasadarao, NV; Wass, CA; Kim, KS			Phosphatidylinositol 3-kinase activation and interaction with focal adhesion kinase in Escherichia coli K1 invasion of human brain microvascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE PROTEIN-A; SIGNAL-TRANSDUCTION; PHOSPHOINOSITIDE 3-KINASE; LISTERIA-MONOCYTOGENES; INDUCED APOPTOSIS; COMMON THEMES; GENE LOCUS; CONTRIBUTES; OVEREXPRESSION; IDENTIFICATION	Invasion of brain microvascular endothelial cells (BMEC) is a prerequisite for successful crossing of the blood-brain barrier by Escherichia coli K1. We have previously demonstrated the requirement of cytoskeletal rearrangements and activation of focal adhesion kinase (FAK) in E. coli K1 invasion of human BMEC (HBMEC), The current study investigated the role of phosphatidylinositol S-kinase (PI3K) activation and PI3K interaction with FAR in E. coli invasion of HBMEC. PI3K inhibitor LY294002 blocked E. coli K1 invasion of HBMEC in a dose-dependent manner, whereas an inactive analogue LYS03511 had no such effect. In HBMEC, E, coli K1 increased phosphorylation of Akt, a downstream effector of PI3K, which was completely blocked by LY294002. In contrast, non-invasive E. coli failed to activate PI3K Overexpression of PI3K mutants Delta p85 and catalytically inactive p110 in HBMEC significantly inhibited both PI3K/Akt activation and E. coli gl invasion of HBMEC, Stimulation of HBMEC with E. coli K1 increased PI3K association with FAK. Furthermore, PI3K/Akt activation was blocked in HBMEC-overexpressing FAK dominant-negative mutants (FRNK and Phe397FAK). These results demonstrated the involvement of PI3K signaling in E. coli K1 invasion of HBMEC and identified a novel role for PI3K interaction with FAR in the pathogenesis off. coli meningitis.	Childrens Hosp Los Angeles, Div Infect Dis, Los Angeles, CA 90027 USA; Univ So Calif, Sch Med, Dept Pediat, Los Angeles, CA 90027 USA; Univ So Calif, Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles; University of Southern California; University of Southern California	Kim, KS (corresponding author), Johns Hopkins Univ, Sch Med, Ped Infect Dis Div, 600 N Wolfe St,Pk 256, Baltimore, MD 21287 USA.			Reddy, Marpadga A/0000-0001-9259-7243	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061951] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047225] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026310] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-61951] Funding Source: Medline; NIAID NIH HHS [AI-47225] Funding Source: Medline; NINDS NIH HHS [R01-NS-26310] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Badger JL, 1999, INFECT IMMUN, V67, P4208, DOI 10.1128/IAI.67.8.4208-4215.1999; BRIGITTE MJ, 1995, ANNU REV CELL DEV BI, V11, P379; Carpenter CL, 1997, ADV ENZYME REGUL, V37, P377, DOI 10.1016/S0065-2571(96)00005-2; Chan PC, 1999, J BIOL CHEM, V274, P26901, DOI 10.1074/jbc.274.38.26901; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Greiffenberg L, 1998, INFECT IMMUN, V66, P5260, DOI 10.1128/IAI.66.11.5260-5267.1998; Guan JL, 1996, INT REV CYTOL, V168, P81, DOI 10.1016/S0074-7696(08)60883-9; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HUANG SH, 1995, INFECT IMMUN, V63, P4470, DOI 10.1128/IAI.63.11.4470-4475.1995; Huang SH, 1999, INFECT IMMUN, V67, P2103, DOI 10.1128/IAI.67.5.2103-2109.1999; Ireton K, 1999, J BIOL CHEM, V274, P17025, DOI 10.1074/jbc.274.24.17025; Ireton K, 1996, SCIENCE, V274, P780, DOI 10.1126/science.274.5288.780; Kim K S, 2000, Subcell Biochem, V33, P47; Leib SL, 1999, INFECT DIS CLIN N AM, V13, P527, DOI 10.1016/S0891-5520(05)70093-3; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Martinez JJ, 2000, EMBO J, V19, P2803, DOI 10.1093/emboj/19.12.2803; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Nielsen E, 1999, NAT CELL BIOL, V1, P376, DOI 10.1038/14075; Nizet V, 1997, INFECT IMMUN, V65, P5074, DOI 10.1128/IAI.65.12.5074-5081.1997; Prasadarao NV, 1999, INFECT IMMUN, V67, P5775, DOI 10.1128/IAI.67.11.5775-5783.1999; Prasadarao NV, 1999, INFECT IMMUN, V67, P1131, DOI 10.1128/IAI.67.3.1131-1138.1999; Prasadarao NV, 1996, INFECT IMMUN, V64, P154, DOI 10.1128/IAI.64.1.154-160.1996; Prasadarao NV, 1996, INFECT IMMUN, V64, P146, DOI 10.1128/IAI.64.1.146-153.1996; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Reddy MA, 2000, INFECT IMMUN, V68, P6423, DOI 10.1128/IAI.68.11.6423-6430.2000; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; Stins MF, 1997, J NEUROIMMUNOL, V76, P81, DOI 10.1016/S0165-5728(97)00036-2; Wang Y, 1999, INFECT IMMUN, V67, P4751, DOI 10.1128/IAI.67.9.4751-4756.1999; WANG Y, 2000, 100 AM SOC MICR GEN, P65; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413	42	88	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36769	36774		10.1074/jbc.M007382200	http://dx.doi.org/10.1074/jbc.M007382200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973983	hybrid			2022-12-25	WOS:000165577700047
J	Titus, SA; Moran, RG				Titus, SA; Moran, RG			Retrovirally mediated complementation of the glyB phenotype - Cloning of a human gene encoding the carrier for entry of folates into mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMATE SYNTHETASE; ONE-CARBON METABOLISM; RAT-LIVER MITOCHONDRIA; ADP ATP CARRIER; BROWN FAT MITOCHONDRIA; SERINE HYDROXYMETHYLTRANSFERASE; STRUCTURAL RELATIONSHIP; THIAMINE TRANSPORTER; UNCOUPLING PROTEIN; HIGH-TITER	The transduction of a human placental cDNA retroviral library into glyB cells, a Chinese hamster ovary RI subline that is deficient in the transport of folates into mitochondria, resulted in the complementation of glycine auxotrophy of these cells. A 2.6-kilobase pair cDNA insert flanked by retroviral sequences had integrated into genomic DNA in rescued cells. An open reading frame in this cDNA encoded a 35-kDa protein homologous to several inner mitochondrial wall transporters for intermediate metabolites. The subcloned cDNA complemented the glycine auxotrophy of glyB cells and reinstated folate accumulation in the mitochondria of transfected cells, The human origin, chromosomal location, and intron-exon organization of the isolated mitochondrial folate transporter gene were deduced from the expressed sequence tag database and human genome project data.	Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University	Moran, RG (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, 1101 E Marshall St,Box 980230, Richmond, VA 23298 USA.	rmoran@hsc.vcu.edu			NCI NIH HHS [CA-27605] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA027605] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; AQUILA H, 1982, H-S Z PHYSIOL CHEM, V363, P345; AQUILA H, 1985, EMBO J, V4, P2369, DOI 10.1002/j.1460-2075.1985.tb03941.x; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BRIGLE KE, 1994, BIOCHEM PHARMACOL, V47, P337, DOI 10.1016/0006-2952(94)90025-6; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; CHASIN LA, 1974, P NATL ACAD SCI USA, V71, P718, DOI 10.1073/pnas.71.3.718; Chen L, 1996, J BIOL CHEM, V271, P13077, DOI 10.1074/jbc.271.22.13077; COOK RJ, 1979, BIOCHEM J, V178, P651, DOI 10.1042/bj1780651; CYBULSKI RL, 1981, BIOCHIM BIOPHYS ACTA, V646, P329, DOI 10.1016/0005-2736(81)90339-4; Diaz GA, 1999, NAT GENET, V22, P309, DOI 10.1038/10385; DIXON KH, 1994, J BIOL CHEM, V269, P17; Endres M, 1999, EMBO J, V18, P3214, DOI 10.1093/emboj/18.12.3214; Fleming JC, 1999, NAT GENET, V22, P305, DOI 10.1038/10379; FREEMANTLE SJ, 1995, J BIOL CHEM, V270, P9579, DOI 10.1074/jbc.270.16.9579; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOLDMAN ID, 1968, J BIOL CHEM, V243, P5007; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HENDERSON GB, 1990, CANCER RES, V50, P1709; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HORNE DW, 1992, J NUTR, V122, P2204, DOI 10.1093/jn/122.11.2204; JONES C, 1981, SOMAT CELL GENET, V7, P399, DOI 10.1007/BF01542985; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KAO FT, 1984, CYTOGENET CELL GENET, V37, P504; KAO FT, 1975, GENETICS, V79, P343; KAO FT, 1969, P NATL ACAD SCI USA, V64, P1284, DOI 10.1073/pnas.64.4.1284; Kastanos EK, 1997, BIOCHEMISTRY-US, V36, P14956, DOI 10.1021/bi971610n; KLINGENBERG M, 1981, NATURE, V290, P449, DOI 10.1038/290449a0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUAN J, 1993, CRIT REV BIOCHEM MOL, V28, P209, DOI 10.3109/10409239309086795; LIN BF, 1993, J BIOL CHEM, V268, P21674; Nelson DR, 1998, J MOL BIOL, V277, P285, DOI 10.1006/jmbi.1997.1594; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Qi H, 1999, ADV ENZYME REGUL, V39, P263, DOI 10.1016/S0065-2571(98)00023-5; RUNSWICK MJ, 1987, EMBO J, V6, P1367, DOI 10.1002/j.1460-2075.1987.tb02377.x; RUNSWICK MJ, 1990, BIOCHEMISTRY-US, V29, P11033, DOI 10.1021/bi00502a004; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SARASTE M, 1982, FEBS LETT, V144, P250, DOI 10.1016/0014-5793(82)80648-0; Scharfe C, 2000, NUCLEIC ACIDS RES, V28, P155, DOI 10.1093/nar/28.1.155; SCHIRCH L, 1980, J BIOL CHEM, V255, P7801; SHANE B, 1989, VITAM HORM, V45, P263; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; TAYLOR RT, 1982, ARCH BIOCHEM BIOPHYS, V217, P609, DOI 10.1016/0003-9861(82)90543-4; Turner FB, 1999, CANCER RES, V59, P6074; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WANG FK, 1967, BIOCHEM Z, V346, P458	48	102	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36811	36817		10.1074/jbc.M005163200	http://dx.doi.org/10.1074/jbc.M005163200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10978331	Green Submitted, hybrid			2022-12-25	WOS:000165577700053
J	White, JR; Lee, JM; Dede, K; Imburgia, CS; Jurewicz, AJ; Chan, G; Fornwald, JA; Dhanak, D; Christmann, LT; Darcy, MG; Widdowson, KL; Foley, JJ; Schmidt, DB; Sarau, HM				White, JR; Lee, JM; Dede, K; Imburgia, CS; Jurewicz, AJ; Chan, G; Fornwald, JA; Dhanak, D; Christmann, LT; Darcy, MG; Widdowson, KL; Foley, JJ; Schmidt, DB; Sarau, HM			Identification of potent, selective non-peptide CC chemokine receptor-3 antagonist that inhibits eotaxin-, eotaxin-2-, and monocyte chemotactic protein-4-induced eosinophil migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALLERGIC INFLAMMATION; MOLECULAR-CLONING; GUINEA-PIG; FUNCTIONAL-CHARACTERIZATION; CHEMOATTRACTANT CYTOKINE; BIOLOGICAL-ACTIVITY; C5A RECEPTOR; EXPRESSION; RANTES; MCP-4	Eosinophils have been implicated in the pathogenesis of asthma and other allergic diseases. Several CC chemokines including eotaxin (CCL-11), eotaxin-2 (CCL-24), RANTES (CCL-5), and monocyte chemotactic protein-3 (MCP-3, CCL-7) and 4 (MCP-4 CCL-13) are potent eosinophil chemotactic and activating peptides acting through CC chemokine receptor-3 (CCR3). Thus, antagonism of CCR3 could have a therapeutic role in asthma and other eosinophil-mediated diseases. A high throughput, cellular functional screen was configured using RBL-2H3 cells stably expressing CCR3 (RBL-2H3-CCR3) to identify non-peptide receptor antagonists. A small molecule CCR3 antagonist was identified, SK&F 45523, and chemical optimization led to the generation of a number of highly potent, selective CCR3 antagonists including SB-297006 and SB-328437, These compounds were further characterized in vitro and demonstrated high affinity, competitive inhibition of I-125-eotaxin and I-125-MCP-4 binding to human eosinophils. The compounds were potent inhibitors of eotaxin- and MCP-P induced Ca2+ mobilization in RBL-2H3-CCR3 cells and eosinophils. Additionally, SB-328437 inhibited eosinophil chemotaxis induced by three ligands that activate CCR3 with similar potencies. Selectivity was affirmed using a panel of 10 seven-transmembrane receptors. This is the first description of a non-peptide CCR3 antagonist, which should be useful in further elucidating the pathophysioiogical role of CCR3 in allergic inflammatory diseases.	SmithKline Beecham Pharmaceut, Dept Biomol Discovery, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Pulm Biol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Gene Express Sci, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Med Chem, King Of Prussia, PA 19406 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	White, JR (corresponding author), SmithKline Beecham Pharmaceut, Dept Immunol, 709 Swedeland Rd, King Of Prussia, PA 19406 USA.			White, John R/0000-0003-2998-1626				Baba M, 1999, P NATL ACAD SCI USA, V96, P5698, DOI 10.1073/pnas.96.10.5698; Baggiolini M, 1996, J CLIN INVEST, V97, P587, DOI 10.1172/JCI118451; BAGGIOLINI M, 1994, CHEST, V105, P95; BARLUENGA J, 1990, J ORG CHEM, V55, P3104, DOI 10.1021/jo00297a027; Berkhout TA, 1997, J BIOL CHEM, V272, P16404, DOI 10.1074/jbc.272.26.16404; Bischoff SC, 1999, AM J GASTROENTEROL, V94, P3521, DOI 10.1111/j.1572-0241.1999.01641.x; BROOKS DP, 1991, PHARMACOLOGY, V43, P90, DOI 10.1159/000138833; Chambers J, 1999, NATURE, V400, P261, DOI 10.1038/22313; CLOZEL M, 1993, NATURE, V365, P759, DOI 10.1038/365759a0; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; Donzella GA, 1998, NAT MED, V4, P72, DOI 10.1038/nm0198-072; Durham SR, 1998, CLIN EXP ALLERGY, V28, P20; Elsner J, 1997, EUR J IMMUNOL, V27, P2892, DOI 10.1002/eji.1830271122; EMONDSALT X, 1992, LIFE SCI, V50, pPL101, DOI 10.1016/0024-3205(92)90352-P; Forssmann U, 1997, J EXP MED, V185, P2171, DOI 10.1084/jem.185.12.2171; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; HAY DWP, 1991, PULM PHARMACOL THER, V4, P177, DOI 10.1016/0952-0600(91)90009-R; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; Hesselgesser J, 1998, J BIOL CHEM, V273, P15687, DOI 10.1074/jbc.273.25.15687; Howard AD, 2000, NATURE, V406, P70, DOI 10.1038/35017610; JOSE PJ, 1994, BIOCHEM BIOPH RES CO, V205, P788, DOI 10.1006/bbrc.1994.2734; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Kita H, 1996, J EXP MED, V183, P2421, DOI 10.1084/jem.183.6.2421; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656; KROEGEL C, 1994, J ALLERGY CLIN IMMUN, V93, P725, DOI 10.1016/0091-6749(94)90252-6; LANZA TJ, 1992, J MED CHEM, V35, P252, DOI 10.1021/jm00080a008; Leung DYM, 1999, J ALLERGY CLIN IMMUN, V104, pS99, DOI 10.1016/S0091-6749(99)70051-5; Mackay CR, 1997, CURR BIOL, V7, pR384, DOI 10.1016/S0960-9822(06)00181-3; Mackay CR, 1996, J EXP MED, V184, P799, DOI 10.1084/jem.184.3.799; Macphee CH, 1998, J IMMUNOL, V161, P6273; Martin U, 1997, J EXP MED, V186, P199, DOI 10.1084/jem.186.2.199; Medhurst AD, 1999, BRIT J PHARMACOL, V128, P627, DOI 10.1038/sj.bjp.0702854; Nibbs RJB, 2000, J IMMUNOL, V164, P1488, DOI 10.4049/jimmunol.164.3.1488; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; Proudfoot AEI, 1999, J BIOL CHEM, V274, P32478, DOI 10.1074/jbc.274.45.32478; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; PROUDFOOT AEI, 1995, FEBS LETT, V376, P19, DOI 10.1016/0014-5793(95)01235-X; ROLLINS TE, 1988, J BIOL CHEM, V263, P520; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; Sabroe I, 2000, J BIOL CHEM, V275, P25985, DOI 10.1074/jbc.M908864199; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; SCHALL TJ, 1994, CYTOKINE HDB, P419; Smart D, 1999, BRIT J PHARMACOL, V128, P1, DOI 10.1038/sj.bjp.0702780; Stellato C, 1999, J IMMUNOL, V163, P5624; Stellato C, 1997, J CLIN INVEST, V99, P926, DOI 10.1172/JCI119257; Sullivan E, 1999, METH MOL B, V114, P125; White JR, 1998, J BIOL CHEM, V273, P10095, DOI 10.1074/jbc.273.17.10095; White JR, 1997, J LEUKOCYTE BIOL, V62, P667, DOI 10.1002/jlb.62.5.667; Yang Y, 1998, BLOOD, V92, P3912, DOI 10.1182/blood.V92.10.3912.422k23_3912_3923; Ying S, 1999, J IMMUNOL, V163, P6321	55	97	109	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36626	36631		10.1074/jbc.M006613200	http://dx.doi.org/10.1074/jbc.M006613200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10969084	hybrid			2022-12-25	WOS:000165577700025
J	Yang, Q; Manicone, A; Coursen, JD; Linke, SP; Nagashima, M; Forgues, M; Wang, XW				Yang, Q; Manicone, A; Coursen, JD; Linke, SP; Nagashima, M; Forgues, M; Wang, XW			Identification of a functional domain in a GADD45-mediated G(2)/M checkpoint	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53-REGULATED PROTEIN GADD45; CELL-CYCLE CHECKPOINTS; DNA-DAMAGING AGENTS; GROWTH ARREST; RAN/TC4 GTPASE; P53; INDUCTION; MITOSIS; YEAST; GENES	Cell cycle checkpoints are essential for the maintenance of genomic stability in response to DNA damage. We demonstrated recently that GADD45, a DNA damage-inducible protein, activates a G(2)/M checkpoint induced by either UV radiation or alkylating agents. GADD45 can interact in vivo with the G(2) cell cycle-specific kinase, Cdc2, proliferating cell nuclear antigen (PCNA), and the cell cycle kinase inhibitor p21(waf1). The ability of GADD45 to induce a G2/M arrest may be caused in part by the inhibition of Cdc2 kinase activity. Here, we report the identification of a region of GADD45 that is involved in this G(2)/M checkpoint. Mutants of GADD45 that lacked either the first 35 or the last 80 residues still retained an ability to induce G(2)/M arrest. A mutant with a deletion of the central region (residues 50-76), which is conserved in the family members GADD45 beta and GADD45 gamma, lacked such activity. This mutant also lacked an ability to bind to Cdc2, PCNA, and p21(waf1) in vivo. Consistently, either GADD45 beta or GADD45 gamma bind to Cdc2 in vivo. However, unlike GADD45, neither GADD45 beta nor GADD45 gamma inhibited the Cdc2 kinase or induced G2/M arrest. The unique effect of GADD45 may be caused by the presence of a region containing DEDDDR residues. Alanine substitutions in the region abolished GADD45 induction of a G(2)/M arrest and its inactivation of the Cdc2 kinase but not its binding to Cdc2, PCNA, or p21(waf1). Therefore, the binding of GADD45 to Cdc2 was insufficient to induce a G2/M arrest, and additional activity contributed by the DEDDDR residues may be necessary to regulate the G(2)/M checkpoint.	NCI, Human Carcinogenesis Lab, DBS, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wang, XW (corresponding author), NCI, Human Carcinogenesis Lab, DBS, NIH, 37 Convent Dr,MSC 4255,Bldg 37,Rm 2C08, Bethesda, MD 20892 USA.		Wang, Xin Wei/B-6162-2009	Wang, Xin Wei/0000-0001-9735-606X; Linke, Steven/0000-0001-8584-4947	DIVISION OF BASIC SCIENCES - NCI [Z01BC010421] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; CHEN IT, 1995, ONCOGENE, V11, P1931; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GUILLOUF C, 1995, ONCOGENE, V10, P2263; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; Lounsbury KM, 1996, J BIOL CHEM, V271, P32834, DOI 10.1074/jbc.271.51.32834; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; O'Connor P M, 1996, Prog Cell Cycle Res, V2, P165; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; POWELL SN, 1995, CANCER RES, V55, P1643; REN MD, 1994, MOL CELL BIOL, V14, P4216, DOI 10.1128/MCB.14.6.4216; RICHARDS SA, 1995, J BIOL CHEM, V270, P14405, DOI 10.1074/jbc.270.24.14405; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STEWART N, 1995, ONCOGENE, V10, P109; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	35	74	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36892	36898		10.1074/jbc.M005319200	http://dx.doi.org/10.1074/jbc.M005319200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973963	hybrid			2022-12-25	WOS:000165577700064
J	Adler, CE; Miyoshi-Akiyama, TS; Aleman, LM; Tanaka, M; Smith, JM; Mayer, BJ				Adler, CE; Miyoshi-Akiyama, TS; Aleman, LM; Tanaka, M; Smith, JM; Mayer, BJ			Abl family kinases and Cbl cooperate with the Nck adaptor to modulate Xenopus development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; PROTEIN-TYROSINE KINASE; SRC HOMOLOGY-3 DOMAINS; C-ABL; SIGNAL-TRANSDUCTION; SH3 DOMAINS; RING FINGER; ACTIVATION; PROTOONCOGENE; LOCALIZATION	We previously showed that overexpression of the Nck Src homology (SH) 2/SH3 adaptor in Xenopus embryos induced developmental defects including anterior truncation and mesoderm ventralization. Mutagenic analysis indicated that this was due to relocalization of endogenous proteins that bind the first two SH3 domains of Nck. We therefore screened a Xenopus expression library with Nck SH3 domains to identify Nck-interacting proteins, and evaluated candidate binding proteins for a potential,role in Nck-induced anterior truncation/ventralization. Of 39 binding proteins analyzed, only the Abl-related kinase Arg and the Cbl proto-oncogene product bound preferentially to the first two SH3 domains in tandem:compared with the individual domains, consistent with a role in the developmental phenotype, High level overexpression of c-Abl or Arg alone induced anterior truncation, as did lower levels of an activated form of Abl; Cbl alone had no effect. In a sensitized system where subthreshold amounts of a ventralizing Nck mutant were expressed, co-expression of the combination of Abl:or Arg and Cbl at modest levels strongly potentiated anterior truncation, while Arg, Abl, or Cbl alone were without effect. These results suggest a role for both Cbl and Abl family kinases in patterning the Xenopus embryo.	Harvard Univ, Childrens Hosp, Sch Med, Mol Med Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Mayer, BJ (corresponding author), Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, 263 Farmington Ave, Farmington, CT 06030 USA.	bmayer@neuron.uchc.edu			NATIONAL CANCER INSTITUTE [R01CA082258] Funding Source: NIH RePORTER; NCI NIH HHS [CA82258] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMAYA E, 1993, DEVELOPMENT, V118, P477; ATALIOTIS P, 1995, DEVELOPMENT, V121, P3099; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Frischknecht F, 1999, NATURE, V401, P926, DOI 10.1038/44860; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; Gupta RW, 1998, ONCOGENE, V17, P2155, DOI 10.1038/sj.onc.1202158; Heasman J, 1997, DEVELOPMENT, V124, P4179; Isaacs HV, 1997, CELL MOL LIFE SCI, V53, P350, DOI 10.1007/PL00000611; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; McCarty JH, 1998, BIOESSAYS, V20, P913, DOI 10.1002/(SICI)1521-1878(199811)20:11<913::AID-BIES6>3.0.CO;2-T; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Mysliwiec T, 1996, ONCOGENE, V12, P631; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Raitano AB, 1997, BBA-REV CANCER, V1333, pF201, DOI 10.1016/S0304-419X(97)00023-1; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Ryan PJ, 1998, BIOCHEM BIOPH RES CO, V244, P763, DOI 10.1006/bbrc.1998.8326; Slack JMW, 1996, BIOCHEM SOC SYMP, P1; Smith JM, 1999, J BIOL CHEM, V274, P27956, DOI 10.1074/jbc.274.39.27956; Symes K, 1996, P NATL ACAD SCI USA, V93, P9641, DOI 10.1073/pnas.93.18.9641; Tanaka M, 1997, P NATL ACAD SCI USA, V94, P4493, DOI 10.1073/pnas.94.9.4493; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; Wang BL, 1996, ONCOGENE, V13, P193; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Wunderlich L, 1999, CELL SIGNAL, V11, P253, DOI 10.1016/S0898-6568(98)00054-0; Yablonski D, 1998, EMBO J, V17, P5647, DOI 10.1093/emboj/17.19.5647; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	43	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36472	36478		10.1074/jbc.M005424200	http://dx.doi.org/10.1074/jbc.M005424200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10967110	hybrid			2022-12-25	WOS:000165382000115
J	Lancaster, MK; Dibb, KM; Quinn, CC; Leach, R; Lee, JK; Findlay, JBC; Boyett, MR				Lancaster, MK; Dibb, KM; Quinn, CC; Leach, R; Lee, JK; Findlay, JBC; Boyett, MR			Residues and mechanisms for slow activation and Ba2+ block of the cardiac muscarinic K+ channel, Kir3.1/Kir3.4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFIER POTASSIUM CHANNELS; NEGATIVELY CHARGED RESIDUE; INWARD-RECTIFIER; XENOPUS OOCYTES; I-KACH; GATING PROPERTIES; RECTIFICATION; KIR2.1; MEMBRANE; SPERMINE	Mechanisms and residues responsible for slow activation and Ba2+ block of the cardiac muscarinic K+ channel, Kir3.1/Kir3.4, were investigated using site-directed mutagenesis. Mutagenesis of negatively charged residues located throughout the pore of the channel (in H5, M2, and proximal C terminus) reduced or abolished slow activation. The strongest effects resulted from mutagenesis of residues in H5 close to the selectivity filter; mutagenesis of residues in M2 and proximal C terminus equivalent to those identified as important determinants of the activation kinetics of Kir2.1 was less effective. In giant patches, slow activation was present in cell-attached patches, lost on excision of the patch, and restored on perfusion with polyamine, Mutagenesis of residues in H5 and M2 close to the selectivity filter also decreased Ba2+ block of the channel. A critical residue for Ba2+ block was identified in Kir3.4. Mutagenesis of the equivalent residue in Kir3.1 failed to have as pronounced an effect on Ba2+ block, suggesting an asymmetry of the channel pore. It is concluded that slow activation is principally the result of unbinding of polyamines from negatively charged residues close to the selectivity filter of the channel and not an intrinsic gating mechanism. Ba2+ block involves an interaction with the same residues.	Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England; Nagoya Univ, Environm Med Res Inst, Nagoya, Aichi 46401, Japan	University of Leeds; Nagoya University	Lancaster, MK (corresponding author), Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England.		Lancaster, Matthew/L-2396-2013; Dibb, Katharine/G-8764-2015	Lancaster, Matthew/0000-0002-3976-736X; Dibb, Katharine/0000-0002-9309-3853; Boyett, Mark/0000-0003-3931-2020				COHEN IS, 1989, BIOPHYS J, V55, P197, DOI 10.1016/S0006-3495(89)82792-4; Corey S, 1998, J BIOL CHEM, V273, P5271, DOI 10.1074/jbc.273.9.5271; DASCAL N, 1995, P NATL ACAD SCI USA, V92, P6758, DOI 10.1073/pnas.92.15.6758; Dibb KM, 2000, PFLUG ARCH EUR J PHY, V440, P740, DOI 10.1007/s004240000344; DOUPNIK CA, 1995, J GEN PHYSIOL, V106, P1, DOI 10.1085/jgp.106.1.1; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; Hilgemann DW, 1998, METHOD ENZYMOL, V293, P267; ISHIHARA K, 1989, J PHYSIOL-LONDON, V419, P297, DOI 10.1113/jphysiol.1989.sp017874; Jiang YX, 2000, J GEN PHYSIOL, V115, P269, DOI 10.1085/jgp.115.3.269; Kofuji P, 1996, J PHYSIOL-LONDON, V490, P633, DOI 10.1113/jphysiol.1996.sp021173; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KURACHI Y, 1985, J PHYSIOL-LONDON, V366, P365, DOI 10.1113/jphysiol.1985.sp015803; Lee JK, 1999, J GEN PHYSIOL, V113, P555, DOI 10.1085/jgp.113.4.555; LIM NF, 1995, J GEN PHYSIOL, V105, P421, DOI 10.1085/jgp.105.3.421; Lopatin AN, 1996, J GEN PHYSIOL, V108, P105, DOI 10.1085/jgp.108.2.105; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; Luchian T, 1997, J PHYSIOL-LONDON, V505, P13, DOI 10.1111/j.1469-7793.1997.013bc.x; Owen JM, 1999, EXP PHYSIOL, V84, P471, DOI 10.1017/S0958067099018060; PESSIA M, 1995, NEURON, V14, P1039, DOI 10.1016/0896-6273(95)90342-9; Reuveny E, 1996, BIOPHYS J, V70, P754, DOI 10.1016/S0006-3495(96)79615-7; Shieh RC, 1998, BIOPHYS J, V75, P2313, DOI 10.1016/S0006-3495(98)77675-1; Shyng SL, 1996, P NATL ACAD SCI USA, V93, P12014, DOI 10.1073/pnas.93.21.12014; SIMMONS MA, 1987, PFLUG ARCH EUR J PHY, V409, P454, DOI 10.1007/BF00583801; STANFIELD PR, 1994, J PHYSIOL-LONDON, V478, P1; TAGLIALATELA M, 1994, SCIENCE, V264, P844, DOI 10.1126/science.8171340; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0; Wischmeyer E, 1997, MOL CELL NEUROSCI, V9, P194, DOI 10.1006/mcne.1997.0614; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687; YAMADA M, 1995, J BIOL CHEM, V270, P9289, DOI 10.1074/jbc.270.16.9289; YANG J, 1995, NEURON, V14, P1047, DOI 10.1016/0896-6273(95)90343-7; Yang J, 1997, P NATL ACAD SCI USA, V94, P1568, DOI 10.1073/pnas.94.4.1568; ZANG WJ, 1995, PFLUG ARCH EUR J PHY, V430, P348, DOI 10.1007/BF00373909; Zhou H, 1996, AM J PHYSIOL-CELL PH, V271, pC1949, DOI 10.1152/ajpcell.1996.271.6.C1949	35	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35831	35839		10.1074/jbc.M006565200	http://dx.doi.org/10.1074/jbc.M006565200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10956662	hybrid			2022-12-25	WOS:000165382000029
J	Vignal, E; De Toledo, M; Comunale, F; Ladopoulou, A; Gauthier-Rouviere, C; Blangy, A; Fort, P				Vignal, E; De Toledo, M; Comunale, F; Ladopoulou, A; Gauthier-Rouviere, C; Blangy, A; Fort, P			Characterization of TCL, a new GTPase of the Rho family related to TC10 and Cdc42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SEQUENCE ALIGNMENT; RAS; CELLS; MORPHOLOGY; PROTEINS; PATHWAY; GROWTH; RAC1	GTPases of the Rho family control a wide variety of cellular processes such as cell morphology, motility, proliferation, differentiation, and apoptosis, We report here the characterization of a new Rho member, which shares 85% and 78% amino acid similarity to TC10 and Cdc42, respectively. This GTPase, termed as TC10-like (TCL) is encoded by an unexpectedly large locus, made of five exons spanning over 85 kilobases on human chromosome 14, TCL mRNA is 2.5 kilobases long and is mainly expressed in heart. In vitro, TCL shows rapid GDP/GTP exchange and displays higher GTP dissociation and hydolysis rates than TC10, Using the yeast two-hybrid system and GST pull-down assays, we show that GTP-bound but not GDP-bound TCL protein directly interacts with Cdc42/Rac interacting binding domains, such as those found in PAK and WASP. Despite its overall similarity to TC10 and Cdc42, the constitutively active TCL mutant displays distinct morphogenic activity in REF-52 fibroblasts, producing large and dynamic F-actin-rich ruffles on the dorsal cell membrane. Interestingly, TCL morphogenic activity is blocked by dominant negative Rad and Cdc42 mutants, suggesting a crosstalk between these three Rho GTPases.	Ctr Rech Biochim Macromol, CNRS UPR 1086, F-34293 Montpellier 5, France; Demokritos Natl Ctr Sci Res, Inst Radioisotopes & Radiodiagnost Prod, Mol Diagnost Lab, Athens 15310, Greece	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; National Centre of Scientific Research "Demokritos"	Fort, P (corresponding author), Ctr Rech Biochim Macromol, CNRS UPR 1086, 1919 Route Mende, F-34293 Montpellier 5, France.	fort@crbm.cnrs-mop.fr	Fort, Philippe/M-9498-2015; Vignal, Emmanuel/B-6985-2009	Fort, Philippe/0000-0001-5997-8722; Comunale, Franck/0000-0001-8838-2151; GAUTHIER-ROUVIERE, Cecile/0000-0002-8364-3882; Vignal, Emmanuel/0000-0002-2585-119X; BLANGY, Anne/0000-0001-7043-0784				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Aronheim A, 1998, CURR BIOL, V8, P1125, DOI 10.1016/S0960-9822(98)70468-3; Aspenstrom P, 1999, EXP CELL RES, V246, P20, DOI 10.1006/excr.1998.4300; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Blangy A, 2000, J CELL SCI, V113, P729; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRUNK U, 1981, J MICROSC-OXFORD, V123, P121, DOI 10.1111/j.1365-2818.1981.tb01288.x; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Courjal F, 1997, GENOMICS, V44, P242, DOI 10.1006/geno.1997.4871; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Fort P, 1999, Prog Mol Subcell Biol, V22, P159; Gallo G, 1998, CURR BIOL, V8, pR80, DOI 10.1016/S0960-9822(98)70051-X; Gauthier-Rouviere C, 1998, MOL BIOL CELL, V9, P1379, DOI 10.1091/mbc.9.6.1379; Gomez J, 1998, IMMUNOL CELL BIOL, V76, P125, DOI 10.1046/j.1440-1711.1998.00723.x; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Keely P, 1998, TRENDS CELL BIOL, V8, P101, DOI 10.1016/S0962-8924(97)01219-1; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; LeGallic L, 1997, GENOMICS, V42, P157; Moorman JP, 1999, ONCOGENE, V18, P47, DOI 10.1038/sj.onc.1202262; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; Murphy GA, 1999, ONCOGENE, V18, P3831, DOI 10.1038/sj.onc.1202758; Neudauer CL, 1998, CURR BIOL, V8, P1151, DOI 10.1016/S0960-9822(07)00486-1; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Reif K, 1998, IMMUNITY, V8, P395, DOI 10.1016/S1074-7613(00)80545-2; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, BIOESSAYS, V16, P321, DOI 10.1002/bies.950160506; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Stam J C, 1999, Prog Mol Subcell Biol, V22, P51; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; van der Voort H. T. M., 1993, Bioimaging, V1, P20, DOI 10.1002/1361-6374(199303)1:1<20::AID-BIO5>3.3.CO;2-U; VANDERVOORT HTM, 1995, J MICROSC-OXFORD, V178, P165, DOI 10.1111/j.1365-2818.1995.tb03593.x	35	95	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36457	36464		10.1074/jbc.M003487200	http://dx.doi.org/10.1074/jbc.M003487200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10967094	Green Published, hybrid			2022-12-25	WOS:000165382000113
J	Doong, H; Price, J; Kim, YS; Gasbarre, C; Probst, J; Liotta, LA; Blanchette, J; Rizzo, K; Kohn, E				Doong, H; Price, J; Kim, YS; Gasbarre, C; Probst, J; Liotta, LA; Blanchette, J; Rizzo, K; Kohn, E			CAIR-1/BAG-3 forms an EGF-regulated ternary complex with phospholipase C-gamma and Hsp70/Hsc70	ONCOGENE			English	Article						calcium; EGF; phospholipase C; Hsp70/Hsc70; signal transduction	SIGNAL-TRANSDUCTION; BCL-2-BINDING PROTEIN; MOLECULAR CHAPERONES; CALCIUM INFLUX; SH3 DOMAINS; CELL-DEATH; RECEPTOR; ACTIVATION; INHIBITION; C-GAMMA-1	CAIR-1/BAG-3 forms an EGF-regulated ternary complex with Hsp70/Hsc70 and latent phospholipase C-gamma (PLC-gamma). The expression of CAIR-1, CAI stressed-1, was induced in A2058 human melanoma cells by continuous exposure to CAI, an inhibitor of non voltage-gated calcium influx. CAIR-1 sequence is identical, save 2 amino acids, to BAG-3 also cloned recently as Bis, a member of the bcl-2-associated athanogene family. We show that CAIR-I/BAG-3 binds to Hsp70/Hsc70 in intact cells and this binding is increased by short term exposure to CAI (P<0.007). CAIR-1/BAG-3 is phosphorylated in vivo in the absence of stimulation. Basal phosphorylation is inhibited by treatment with d-erythrosphingosine (d-ES), a broad inhibitor of the protein kinase C family. CAIR-1/BAG-3 contains several PXXP SH3 binding domains leading to the hypothesis that it is a partner protein of phospholipase C-gamma. PLC-gamma is bound to CAIR-1/BAG-3 in unstimulated cells, It is increased by CAI or d-ES (P=0.05) treatment, and abrogated by EGF (r(2)=0.99); d-ES treatment blocks the EGF-mediated dissociation, We show that CAIR-1/BAG-3 binds to PLC-gamma and Hsp701/Hsc70 through separate and distinct domains. Hsp70/Hsc70 binds to the BAG domain of BAGs-1 and -3, CAIR-1/BAG-3 from control and EGF-treated cell lysates bound selectively to the SH3 domain of PLC-gamma, but not its N-SH2 or C-SH2 domains, Confirming the SH3 interaction, PLC-gamma was pulled down by CAIR-1/BAG-3 PXXP-GST fusions, but GST-PXXP constructs confronted with lysates from EGF-treated cells did not bind PLC-gamma as was seen in intact cells. Hsp70/Hsc70 was brought down by the PLC-gamma SH3 construct equally from native and EGF-treated cells, but did not bind the PXXP construct under either condition. We propose that CAIR-1/BAG-3 may act as a multifunctional signaling protein linking the Hsp70/Hsc70 pathway with those necessary for activation of the EGF receptor tyrosine kinase signaling pathways.	NCI, Mol Signaling Sect, Pathol Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kohn, E (corresponding author), 10 Ctr Dr,10-2A33, Bethesda, MD 20892 USA.			Price, John/0000-0002-8244-1023				BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Chang JS, 1997, CANCER RES, V57, P5465; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; FELDER CC, 1991, J PHARMACOL EXP THER, V257, P967; GUSOVSKY F, 1993, J BIOL CHEM, V268, P7768; HAMPSON IN, 1992, NUCLEIC ACIDS RES, V20, P2899, DOI 10.1093/nar/20.11.2899; HATA A, 1993, J BIOL CHEM, V268, P9122; Hu YL, 1996, ONCOGENE, V12, P1865; Khoshyomn S, 1999, NEUROSURGERY, V44, P568, DOI 10.1097/00006123-199903000-00073; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOHN EC, 1992, CANCER RES, V52, P3208; KOHN EC, 1994, CANCER RES, V54, P935; KOHN EC, 1995, P NATL ACAD SCI USA, V92, P1307, DOI 10.1073/pnas.92.5.1307; KOHN EC, 1990, J NATL CANCER I, V82, P54, DOI 10.1093/jnci/82.1.54; KOHN EC, 1994, J BIOL CHEM, V269, P21505; Lee JH, 1999, ONCOGENE, V18, P6183, DOI 10.1038/sj.onc.1203043; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pilon M, 1999, CELL, V97, P679, DOI 10.1016/S0092-8674(00)80780-1; SCHLIEF R, 1994, ADV ECHO AGENTS, V4, P5; Smith MR, 1998, CARCINOGENESIS, V19, P177, DOI 10.1093/carcin/19.1.177; Stuart JK, 1998, J BIOL CHEM, V273, P22506, DOI 10.1074/jbc.273.35.22506; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Turner T, 1997, CLIN CANCER RES, V3, P2275; Turner T, 1996, CLIN EXP METASTAS, V14, P409, DOI 10.1007/BF00123400; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; Yang H, 1998, ANTICANCER RES, V18, P1399; YANG LJ, 1994, J BIOL CHEM, V269, P7156; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	34	122	128	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4385	4395		10.1038/sj.onc.1203797	http://dx.doi.org/10.1038/sj.onc.1203797			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980614				2022-12-25	WOS:000089271900009
J	Belmant, C; Espinosa, E; Halary, F; Tang, Y; Peyrat, MA; Sicard, H; Kozikowski, A; Buelow, R; Poupot, R; Bonneville, M; Fournie, JJ				Belmant, C; Espinosa, E; Halary, F; Tang, Y; Peyrat, MA; Sicard, H; Kozikowski, A; Buelow, R; Poupot, R; Bonneville, M; Fournie, JJ			A chemical basis for selective recognition of nonpeptide antigens by human delta T cells	FASEB JOURNAL			English	Article									CHU Purpan, INSERM, U395, F-31024 Toulouse, France; Inst Biol, INSERM, U463, F-44035 Nantes, France; Georgetown Univ, GICS, Washington, DC USA; Sang Stat Med Corp, Menlo Pk, CA USA; Innate Pharma, F-13009 Marseille, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Georgetown University	Fournie, JJ (corresponding author), CHU Purpan, INSERM, U395, BP3028, F-31024 Toulouse, France.	fournie@purpan.inserm.fr	Halary, Franck/B-3782-2017; Fournie, Jean-Jacques/J-7805-2013; espinosa, eric/E-4872-2013; halary, franck/AAR-9437-2020	Halary, Franck/0000-0003-0336-9615; Fournie, Jean-Jacques/0000-0001-6542-6908; espinosa, eric/0000-0002-3512-0921; halary, franck/0000-0003-0336-9615					0	68	69	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2000	14	12					1669	1670		10.1096/fj.99-0909fje	http://dx.doi.org/10.1096/fj.99-0909fje			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973912	Bronze			2022-12-25	WOS:000089212400002
J	Merienne, K; Jacquot, S; Zeniou, M; Pannetier, S; Sassone-Corsi, P; Hanauer, A				Merienne, K; Jacquot, S; Zeniou, M; Pannetier, S; Sassone-Corsi, P; Hanauer, A			Activation of RSK by UV-light: phosphorylation dynamics and involvement of the MAPK pathway	ONCOGENE			English	Article						RSK; phosphorylation; UV radiation	RIBOSOMAL S6 KINASE; COFFIN-LOWRY-SYNDROME; SIGNAL-TRANSDUCTION PATHWAYS; KAPPA-B-ALPHA; PROTEIN-KINASE; MENTAL-RETARDATION; DOCKING SITE; CREB KINASE; HEAT-SHOCK; HISTONE H3	Ribosomal S6 kinases (RSKs) are serine/threonine kinases activated by mitogenic signals through the Mitogen-Activated Protein Kinases/Extracellular Signal-Regulated Kinases (MAPK/ERK), RSKs contain two heterologous complete protein kinase domains. Phosphorylation by ERK of the C-terminal kinase domain allows activation of the N-terminal kinase domain, which mediates substrate phosphorylation, In human, there are three isoforms of RSK (RSK1, RSK2, RSK3), whose functional specificity remains undefined. Importantly, we have shown that mutations in the RSK2 gene lead to the Coffin-Lowry syndrome (CLS), In this study, we characterize two monoclonal antibodies raised against phosphorylated forms of the N- and C-terminal domain of RSK2 (P-S227 and P-T577, respectively). Using these two antibodies, we show that stress signals, such as UV light, induce phosphorylation and activation of the three RSKs to an extent which is comparable to Epidermal Growth Factor (EGF)-mediated activation. The use of specific kinase inhibitors indicates that UV-induced phosphorylation and activation of RSK2 is mediated by the MAPK/ERK pathway, but that the Stress-Activated Protein Kinase 2 (SAPK2)/p38 pathway is also involved. These results modify the view of RSKs as kinases restricted to the mitogenic response and reveal a previously unappreciated role of MAPKs in stress induced signaling.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Hanauer, A (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, BP 163, F-67404 Strasbourg, France.			Merienne, Karine/0000-0003-2549-2315				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Huang CS, 1999, ONCOGENE, V18, P2828, DOI 10.1038/sj.onc.1202639; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; Jacquot S, 1998, AM J HUM GENET, V63, P1631, DOI 10.1086/302153; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Karin M, 1996, PHILOS T ROY SOC B, V351, P127, DOI 10.1098/rstb.1996.0008; KHARBANDA S, 1994, P NATL ACAD SCI USA, V91, P5416, DOI 10.1073/pnas.91.12.5416; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Merienne K, 1999, NAT GENET, V22, P13, DOI 10.1038/8719; Merienne K, 1998, J MED GENET, V35, P890, DOI 10.1136/jmg.35.11.890; MOHIT AA, 1995, NEURON, V14, P67, DOI 10.1016/0896-6273(95)90241-4; MOLLER DE, 1994, AM J PHYSIOL, V266, pC351, DOI 10.1152/ajpcell.1994.266.2.C351; New L, 1999, J BIOL CHEM, V274, P1026, DOI 10.1074/jbc.274.2.1026; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; Richards SA, 1999, CURR BIOL, V9, P810, DOI 10.1016/S0960-9822(99)80364-9; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; Swanson KD, 1999, J BIOL CHEM, V274, P3385, DOI 10.1074/jbc.274.6.3385; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Trivier E, 1996, NATURE, V384, P567, DOI 10.1038/384567a0; Waring P, 1997, J BIOL CHEM, V272, P17929, DOI 10.1074/jbc.272.29.17929; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; XIA Z, 1995, SCIENCE, V269, P403; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YOUNG ID, 1988, J MED GENET, V25, P344, DOI 10.1136/jmg.25.5.344; ZHAO Y, 1995, MOL CELL BIOL, V15, P4353; ZHAO Y, 1996, J BIOL CHEM, V271, P29778	57	41	42	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 31	2000	19	37					4221	4229		10.1038/sj.onc.1203712	http://dx.doi.org/10.1038/sj.onc.1203712			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980595				2022-12-25	WOS:000089032900004
J	Burmeister, WP; Cottaz, S; Rollin, P; Vasella, A; Henrissat, B				Burmeister, WP; Cottaz, S; Rollin, P; Vasella, A; Henrissat, B			High resolution x-ray crystallography shows that ascorbate is a cofactor for myrosinase and substitutes for the function of the catalytic base	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYL HYDROLASES; GLYCOSIDASE INHIBITORS; CRYSTAL-STRUCTURES; BETA-GLUCOSIDASE; SINAPIS-ALBA; MECHANISM; ACID; COMPARTMENTATION; CLASSIFICATION; INTERMEDIATE	Myrosinase, an S-glycosidase, hydrolyzes plant anionic 1-thio beta -D-glucosides (glucosinolates) considered part of the plant defense system. Although O-glycosidases are ubiquitous, myrosinase is the only known S-glycosidase. Its active site is very similar to that of retaining O-glycosidases, but one of the catalytic residues in O-glycosidases, a carboxylate residue functioning as the general base, is replaced by a glutamine residue. Myrosinase is strongly activated by ascorbic acid. Several binary and ternary complexes of myrosinase with different transition state analogues and ascorbic acid have been analyzed at high resolution by x-ray crystallography along with a 2-deoxy-2-fluoro-glucosyl enzyme intermediate. One of the inhibitors, D-gluconhydroximo-1,5-lactam, binds simultaneously with a sulfate ion to form a mimic of the enzyme-substrate complex, Ascorbate binds to a site distinct from the glucose binding site but overlapping with the aglycon binding site, suggesting that activation occurs at the second step of catalysis, i.e. hydrolysis of the glycosyl enzyme, A water molecule is placed perfectly for activation by ascorbate and for nucleophilic attack on the covalently trapped S-fluoroglucosyl-moiety, Activation of the hydrolysis of the glucosyl enzyme intermediate is further evidenced by the observation that ascorbate enhances the rate of reactivation of the 2-fluoro-glycosyl enzyme, leading to the conclusion that ascorbic acid substitutes for the catalytic base in myrosinase.	European Synchrotron Radiat Facil, F-38043 Grenoble, France; Forschungszentrum Julich, F-38043 Grenoble, France; CNRS, Ctr Rech Macromol Vegetales, F-38041 Grenoble, France; Univ Orleans, Inst Chim Organ & Analyt, F-45067 Orleans 2, France; ETH Zentrum, Organ Chem Lab, CH-8092 Zurich, Switzerland; CNRS, IFR1, F-13402 Marseille 20, France	European Synchrotron Radiation Facility (ESRF); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Universite de Orleans; Swiss Federal Institutes of Technology Domain; ETH Zurich; Centre National de la Recherche Scientifique (CNRS)	Burmeister, WP (corresponding author), European Mol Biol Lab, BP 156, F-38042 Grenoble, France.		Henrissat, Bernard/J-2475-2012	Henrissat, Bernard/0000-0002-3434-8588; Burmeister, Wim/0000-0003-0876-6118; cottaz, sylvain/0000-0001-8674-0162				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Aucagne V, 2000, TETRAHEDRON, V56, P2647, DOI 10.1016/S0040-4020(00)00153-8; BARRETT T, 1995, STRUCTURE, V3, P951, DOI 10.1016/S0969-2126(01)00229-5; BJORKMAN R, 1973, BIOCHIM BIOPHYS ACTA, V327, P121, DOI 10.1016/0005-2744(73)90109-5; BONES AM, 1996, PHYSIOL PLANTARUM, V97, P1194; BOTTI MG, 1995, J BIOL CHEM, V270, P20530, DOI 10.1074/jbc.270.35.20530; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, XPLOR VERSION 3 1; Burmeister WP, 1997, STRUCTURE, V5, P663, DOI 10.1016/S0969-2126(97)00221-9; CONCHIE J, 1967, BIOCHEM J, V103, P609, DOI 10.1042/bj1030609; Cottaz S, 1996, BIOCHEMISTRY-US, V35, P15256, DOI 10.1021/bi9622480; Cottaz S, 1997, CARBOHYD RES, V298, P127, DOI 10.1016/S0008-6215(96)00294-7; Cutfield SM, 1999, J MOL BIOL, V294, P771, DOI 10.1006/jmbi.1999.3287; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Davies GJ, 1998, BIOCHEMISTRY-US, V37, P11707, DOI 10.1021/bi981315i; Dixon M., 1964, ENZYMES, p[63, 92]; ERMERT P, 1993, CARBOHYD RES, V250, P113, DOI 10.1016/0008-6215(93)84160-8; ERMERT P, 1991, HELV CHIM ACTA, V74, P2043, DOI 10.1002/hlca.19910740839; ETTLINGER MG, 1961, P NATL ACAD SCI USA, V47, P1875, DOI 10.1073/pnas.47.12.1875; FENWICK GR, 1983, CRC CR REV FOOD SCI, V18, P123, DOI 10.1080/10408398209527361; GMELIN R, 1961, ANN ACAD SCI FENN A, V11, P3; GROB K, 1980, Z PFLANZENPHYSIOL, V98, P235, DOI 10.1016/S0044-328X(80)80273-X; Heightman TD, 1999, ANGEW CHEM INT EDIT, V38, P750, DOI 10.1002/(SICI)1521-3773(19990315)38:6<750::AID-ANIE750>3.0.CO;2-6; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HOOS R, 1993, HELV CHIM ACTA, V76, P2666, DOI 10.1002/hlca.19930760723; Iori R, 1996, FEBS LETT, V385, P87, DOI 10.1016/0014-5793(96)00335-3; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KISS G, 1966, MITT GEB LEBENSM HYG, V57, P443; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESLIE AGW, 1992, JOINT CCP4 ESF EADBM; LEVVY GA, 1972, ADV ENZYMOL RAMB, V36, P151; MATILE P, 1980, BIOCHEM PHYSIOL PFL, V175, P722, DOI 10.1016/S0015-3796(80)80059-X; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; McCarter JD, 1997, J AM CHEM SOC, V119, P5792, DOI 10.1021/ja9627454; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; NAGASHIMA Z, 1959, J AGR CHEM SOC JAPAN, V33, P980; OHTSURU M, 1979, BIOCHIM BIOPHYS ACTA, V567, P384, DOI 10.1016/0005-2744(79)90124-4; PALMIERI S, 1982, ANAL BIOCHEM, V123, P320, DOI 10.1016/0003-2697(82)90452-3; Shikita M, 1999, BIOCHEM J, V341, P725, DOI 10.1042/0264-6021:3410725; TSURUO I, 1967, AGR BIOL CHEM TOKYO, V31, P27; White A, 1996, NAT STRUCT BIOL, V3, P149, DOI 10.1038/nsb0296-149; WILKINSON AP, 1984, ANAL BIOCHEM, V139, P284, DOI 10.1016/0003-2697(84)90004-6; WITHERS SG, 1988, J BIOL CHEM, V263, P7929; WITHERS SG, 1990, J AM CHEM SOC, V112, P5887, DOI 10.1021/ja00171a043	45	154	161	1	51	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39385	39393		10.1074/jbc.M006796200	http://dx.doi.org/10.1074/jbc.M006796200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10978344	hybrid			2022-12-25	WOS:000165953100062
J	Svaren, J; Ehrig, T; Abdulkadir, SA; Ehrengruber, MU; Watson, MK; Milbrandt, J				Svaren, J; Ehrig, T; Abdulkadir, SA; Ehrengruber, MU; Watson, MK; Milbrandt, J			EGR1 target genes in prostate carcinoma cells identified by microarray analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II GENE; POLYMERASE CHAIN-REACTION; TUMOR SUPPRESSOR WT1; GROWTH-FACTOR-A; BECKWITH-WIEDEMANN-SYNDROME; MESSENGER-RIBONUCLEIC-ACID; PROTEIN NGFI-A; IGF-II; TRANSFORMING GROWTH-FACTOR-BETA-1; NEUROENDOCRINE DIFFERENTIATION	The EGR1 transactivator is overexpressed in prostate cancer, and its expression pattern suggests that EGR1 could potentially regulate a number of steps involved in initiation and progression of prostate cancer, such as mitogenesis, invasiveness, angiogenesis, and metastasis. To identify potential EGR1 target genes in an unbiased manner, we have utilized adenovirus-mediated expression of EGR1 in a prostate cancer cell line to identify specific genes that are induced by EGR1. Using oligonucleotide arrays, a number of EGR1-regulated genes were identified and their regulation was confirmed by quantitative reverse transcription-polymerase chain reaction analysis. One of the largest gene classes identified in this screen includes several neuroendocrine-associated genes (neuron-specific enolase, neurogranin), suggesting that EGR1 overexpression may contribute to the neuroendocrine differentiation that often accompanies prostate cancer progression. This screen also identified several growth factors such as insulin-like growth factor-II, platelet-derived growth factor-A, and transforming growth factor-beta1, which have previously been implicated in enhancing tumor progression. The insulin-like growth factor-II gene lies within the 11p15.5 chromosomal locus, which contains a number of other imprinted genes, and EGR1 expression was found to induce at least two other genes in this locus (IPL, p57(KIP2)). Based on our results, coupling adenoviral overexpression with microarray and quantitative reverse transcription-polymerase chain reaction analyses could be a versatile strategy for identifying target genes of transactivators.	Washington Univ, Sch Med, Dept Pathol, Div Lab Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Internal Med, Div Lab Med, St Louis, MO 63110 USA; Univ Zurich, Inst Brain Res, CH-8057 Zurich, Switzerland	Washington University (WUSTL); Washington University (WUSTL); University of Zurich	Milbrandt, J (corresponding author), Washington Univ, Sch Med, Dept Pathol, Div Lab Med, 660 S Euclid Ave, St Louis, MO 63110 USA.		Svaren, John/A-1605-2010	Svaren, John/0000-0003-2963-7921; Milbrandt, Jeffrey/0000-0002-5477-7689	NCI NIH HHS [5P01CA49712-08] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abrahamsson PA, 1999, PROSTATE, V39, P135, DOI 10.1002/(SICI)1097-0045(19990501)39:2<135::AID-PROS9>3.0.CO;2-S; Bae SK, 1999, CANCER RES, V59, P5989; Barrack ER, 1997, PROSTATE, V31, P61; BATTEGAY EJ, 1995, J MOL MED, V73, P333; Becker A, 1996, ANAL BIOCHEM, V237, P204, DOI 10.1006/abio.1996.0230; BOSTWICK DG, 1997, UROLOGIC SURG PATHOL, P343; Caspary T, 1999, GENE DEV, V13, P3115, DOI 10.1101/gad.13.23.3115; CHRISTOFORI G, 1995, NAT GENET, V10, P196, DOI 10.1038/ng0695-196; Culig Z, 1996, PROSTATE, V28, P392, DOI 10.1002/(SICI)1097-0045(199606)28:6<392::AID-PROS9>3.0.CO;2-C; Dang CV, 1999, MOL CELL BIOL, V19, P1; DAY ML, 1990, J BIOL CHEM, V265, P15253; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DISANTAGNESE PA, 1994, J UROLOGY, V152, P1927, DOI 10.1016/S0022-5347(17)32417-5; Dong GY, 1997, J CLIN ENDOCR METAB, V82, P2198, DOI 10.1210/jc.82.7.2198; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; Eggenschwiler J, 1997, GENE DEV, V11, P3128, DOI 10.1101/gad.11.23.3128; Ehrengruber MU, 1998, METHOD ENZYMOL, V293, P483; Eid MA, 1998, CANCER RES, V58, P2461; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; FEINBERG AP, 1999, CANCER RES, V59, P1743; FUDGE K, 1994, MODERN PATHOL, V7, P549; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; Garabedian EM, 1998, P NATL ACAD SCI USA, V95, P15382, DOI 10.1073/pnas.95.26.15382; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Holthuizen PE, 1999, CONT ENDOCRINOL, V17, P37; IKEJIRI K, 1991, BIOCHEM J, V280, P439, DOI 10.1042/bj2800439; Jarrard DF, 1995, CLIN CANCER RES, V1, P1471; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Lee SL, 1996, MOL CELL BIOL, V16, P4566; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; Lee YI, 1996, DNA CELL BIOL, V15, P99, DOI 10.1089/dna.1996.15.99; Li SL, 1998, CELL TISSUE RES, V291, P469, DOI 10.1007/s004410051016; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Liu AY, 1997, PROSTATE, V30, P145, DOI 10.1002/(SICI)1097-0045(19970215)30:3<145::AID-PROS1>3.0.CO;2-L; Liu CT, 1996, CRIT REV ONCOGENESIS, V7, P101, DOI 10.1615/CritRevOncog.v7.i1-2.70; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Morrison TB, 1998, BIOTECHNIQUES, V24, P954; Namba K, 2000, ONCOGENE, V19, P106, DOI 10.1038/sj.onc.1203257; Qu ZC, 1998, J CELL BIOL, V142, P1075, DOI 10.1083/jcb.142.4.1075; Reik W, 1997, TRENDS GENET, V13, P330, DOI 10.1016/S0168-9525(97)01200-6; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; Ririe KM, 1997, ANAL BIOCHEM, V245, P154, DOI 10.1006/abio.1996.9916; ROGLER CE, 1994, J BIOL CHEM, V269, P13779; Rotwein P, 1999, CONT ENDOCRINOL, V17, P19; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; RUSSO MW, 1995, P NATL ACAD SCI USA, V92, P6873, DOI 10.1073/pnas.92.15.6873; Santelli G, 1999, AM J PATHOL, V155, P799, DOI 10.1016/S0002-9440(10)65178-4; SCHNEEBERGER C, 1995, PCR METH APPL, V4, P234; Silverman ES, 1999, AM J PATHOL, V154, P665, DOI 10.1016/S0002-9440(10)65312-6; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; Sun FL, 1997, NATURE, V389, P809, DOI 10.1038/39797; Svaren J, 1996, MOL CELL BIOL, V16, P3545; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; TADOKORO K, 1991, NUCLEIC ACIDS RES, V19, P6967, DOI 10.1093/nar/19.24.6967; TAKIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P1686, DOI 10.1073/pnas.88.5.1686; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Tennant MK, 1996, J CLIN ENDOCR METAB, V81, P3774, DOI 10.1210/jc.81.10.3774; Thigpen AE, 1996, J UROLOGY, V155, P975, DOI 10.1016/S0022-5347(01)66361-4; Toretsky JA, 1996, J ENDOCRINOL, V149, P367, DOI 10.1677/joe.0.1490367; VANDIJK MA, 1991, MOL CELL ENDOCRINOL, V81, P81, DOI 10.1016/0303-7207(91)90207-9; Watanabe H, 1996, CANCER RES, V56, P2960; Wittwer CT, 1997, BIOTECHNIQUES, V22, P130, DOI 10.2144/97221bi01; Xu ZD, 1999, ENDOCRINOLOGY, V140, P2134, DOI 10.1210/en.140.5.2134; Yan SF, 1998, P NATL ACAD SCI USA, V95, P8298, DOI 10.1073/pnas.95.14.8298; ZHAN SL, 1995, J BIOL CHEM, V270, P27983; Zhu JH, 1999, P NATL ACAD SCI USA, V96, P14911, DOI 10.1073/pnas.96.26.14911	71	156	162	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38524	38531		10.1074/jbc.M005220200	http://dx.doi.org/10.1074/jbc.M005220200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10984481	hybrid			2022-12-25	WOS:000165739800053
J	Ives, EB; Nichols, J; Wente, SR; York, JD				Ives, EB; Nichols, J; Wente, SR; York, JD			Biochemical and functional characterization of inositol 1,3,4,5,6-pentakisphosphate 2-kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE ENDOCYTOSIS; ASSEMBLY PROTEIN AP-2; SACCHAROMYCES-CEREVISIAE; RNA-EXPORT; ARGININE METABOLISM; ACTIN CYTOSKELETON; YEAST-CELLS; SH3 DOMAIN; AMPHIPHYSIN; BINDING	Synthesis of inositol 1,2,3,4,5,6-hexakisphosphate (IP6), also known as phytate, is integral to cellular function in all eukaryotes. Production of IP6 predominately occurs through phosphorylation of inositol 1,3,4,5,6-pentakisphosphate (IP5) by a 2-kinase. Recent cloning of the gene encoding this kinase from Saccharomyces cerevisiae, designated scIpk1, has identified a cellular role for IP6 production in the regulation of mRNA export from the nucleus. In this report, we characterize the biochemical and functional parameters of recombinant scIpk1. Purified recombinant scIpk1 kinase activity is highly selective for IP5 substrate and exhibits apparent Ii, values of 644 nM and 62.8 muM for IP5 and ATP, respectively. The observed apparent catalytic efficiency (k(cat)/ K-m) of scIpk1 is 31,610 s(-1) M-1. A sequence similarity search was used to identify an IP5 2-kinase from the fission yeast Schizosaccharomyces pombe. Recombinant spIpk1 has similar substrate selectivity and catalytic efficiency to its budding yeast counterpart, despite sharing only 24% sequence identity. Cells lacking scIPk1 are deficient in IP6 production and exhibit lethality in combination with a gle1 mutant allele. Both of these phenotypes are complemented by expression of the spIPK1 gene in the sc-ipk1 cells. Analysis of several inactive mutants and multiple sequence alignment of scIpk1, spIpk1, and a putative Candida albicans Ipk1 have identified residues involved in catalysis. This includes two conserved motifs: E(i/l/m)KPKWL(t/y) and LXMTLRDV(t/g) (l/c)(f/y)I. Our data suggest that the mechanism for IP6 production is conserved across species.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA	Washington University (WUSTL); Duke University; Duke University; Duke University; Duke University; Howard Hughes Medical Institute	Wente, SR (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Box 8228,660 S Euclid Ave, St Louis, MO 63110 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051219, R37GM051219] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55672] Funding Source: Medline; NIGMS NIH HHS [GM51219] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Balguerie A, 1999, J CELL SCI, V112, P2529; BAUER F, 1993, MOL CELL BIOL, V13, P5070, DOI 10.1128/MCB.13.8.5070; BECK KA, 1991, J BIOL CHEM, V266, P4442; Biswas S, 1996, Subcell Biochem, V26, P287; Colwill K, 1999, GENETICS, V152, P881; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DESFARGES L, 1993, YEAST, V9, P267, DOI 10.1002/yea.320090306; DROBAK BK, 1992, BIOCHEM J, V288, P697, DOI 10.1042/bj2880697; DUBOIS E, 1994, MOL GEN GENET, V243, P315, DOI 10.1007/BF00301067; Gadd GM, 1997, MICROBIOL-SGM, V143, P437, DOI 10.1099/00221287-143-2-437; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; HUANG XQ, 1994, COMPUT APPL BIOSCI, V10, P227; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Lee J, 1998, CURR BIOL, V8, P1310, DOI 10.1016/S0960-9822(07)00561-1; Lila T, 1997, MOL BIOL CELL, V8, P367, DOI 10.1091/mbc.8.2.367; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; Majerus PW, 1999, J BIOL CHEM, V274, P10669, DOI 10.1074/jbc.274.16.10669; McMahon HT, 1997, FEBS LETT, V413, P319, DOI 10.1016/S0014-5793(97)00928-9; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; MESSENGUY F, 1993, MOL CELL BIOL, V13, P2586, DOI 10.1128/MCB.13.4.2586; Mizutani A, 1997, BIOCHEM BIOPH RES CO, V240, P128, DOI 10.1006/bbrc.1997.7578; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; Murphy R, 1996, NATURE, V383, P357, DOI 10.1038/383357a0; Navarro P, 1997, BBA-PROTEIN STRUCT M, V1343, P187, DOI 10.1016/S0167-4838(97)00108-8; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; Ongusaha PP, 1998, BIOCHEM J, V335, P671, DOI 10.1042/bj3350671; PHILLIPPY BQ, 1994, J BIOL CHEM, V269, P28393; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; Saiardi A, 2000, J BIOL CHEM, V275, P24686, DOI 10.1074/jbc.M002750200; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Saiardi A, 2000, FEBS LETT, V468, P28, DOI 10.1016/S0014-5793(00)01194-7; Sambrook J., 2002, MOL CLONING LAB MANU; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Shears SB, 1998, BBA-MOL CELL BIOL L, V1436, P49, DOI 10.1016/S0005-2760(98)00131-3; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Stolz LE, 1998, J BIOL CHEM, V273, P11852, DOI 10.1074/jbc.273.19.11852; TIMERMAN AP, 1992, P NATL ACAD SCI USA, V89, P8976, DOI 10.1073/pnas.89.19.8976; VOGLMAIER SM, 1992, BIOCHEM BIOPH RES CO, V187, P158, DOI 10.1016/S0006-291X(05)81473-1; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Watkins JL, 1998, P NATL ACAD SCI USA, V95, P6779, DOI 10.1073/pnas.95.12.6779; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96	49	64	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36575	36583		10.1074/jbc.M007586200	http://dx.doi.org/10.1074/jbc.M007586200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10960485	hybrid			2022-12-25	WOS:000165577700018
J	Kunz, J; Schneider, U; Howald, I; Schmidt, A; Hall, MN				Kunz, J; Schneider, U; Howald, I; Schmidt, A; Hall, MN			HEAT repeats mediate plasma membrane localization of Tor2p in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL KINASE HOMOLOG; GTP-BINDING PROTEIN; EXCHANGE FACTOR ROM2; P70 S6 KINASE; SACCHAROMYCES-CEREVISIAE; SIGNALING PATHWAY; CELL-GROWTH; AMINO-ACID; ACTIN CYTOSKELETON; SERINE RESIDUE	The subcellular distribution of Tor1p and Tor2p, two phosphatidylinositol kinase homologs and targets of the immunosuppressive drug rapamycin in Saccharomyces cerevisiae, was analyzed. We found that Tor protein is peripherally associated with membranes. Subcellular fractionation and immunofluorescence studies showed that Tor1p and Tor2p associate with the plasma membrane and a second fraction that is distinct from Golgi, vacuoles, mitochondria, and nucleus and may represent vesicular structures. Pulse-chase experiments showed that association of Tor protein with plasma membrane and the second compartment is fast, does not appear to involve components of endocytic, secretory, or Golgi to vacuole transport pathways, and is not affected by the immunosuppressive drag rapamycin. Deletion analysis reveals that two domains within Tor2p independently mediate localization to both compartments. These domains are composed of HEAT repeats that are thought to act as protein-protein interaction surfaces. Our studies therefore place Tor proteins at the site of action of their known downstream effecters and suggest that they may be part of a multiprotein complex.	Univ Basel, Biozentrum, Dept Biochem, CH-4056 Basel, Switzerland	University of Basel	Hall, MN (corresponding author), Univ Basel, Biozentrum, Dept Biochem, Klingelbergstr 70, CH-4056 Basel, Switzerland.			Hall, Michael N/0000-0002-2998-0757				Alarcon CM, 1999, MOL BIOL CELL, V10, P2531, DOI 10.1091/mbc.10.8.2531; ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bickle M, 1998, EMBO J, V17, P2235, DOI 10.1093/emboj/17.8.2235; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; CARDENAS ME, 1995, EMBO J, V14, P5892, DOI 10.1002/j.1460-2075.1995.tb00277.x; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; Desrivieres S, 1998, J BIOL CHEM, V273, P15787, DOI 10.1074/jbc.273.25.15787; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Fiorentino DF, 1997, MOL BIOL CELL, V8, P2519, DOI 10.1091/mbc.8.12.2519; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Gusella JF, 1998, CURR OPIN NEUROBIOL, V8, P425, DOI 10.1016/S0959-4388(98)80071-8; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Helliwell SB, 1998, GENETICS, V148, P99; Homma K, 1998, J BIOL CHEM, V273, P15779, DOI 10.1074/jbc.273.25.15779; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; Iiboshi Y, 1999, J BIOL CHEM, V274, P1092, DOI 10.1074/jbc.274.2.1092; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Lim DS, 1998, P NATL ACAD SCI USA, V95, P10146, DOI 10.1073/pnas.95.17.10146; MAGEE AI, 1985, EMBO J, V4, P1137, DOI 10.1002/j.1460-2075.1985.tb03751.x; Manning BD, 1997, MOL BIOL CELL, V8, P1829, DOI 10.1091/mbc.8.10.1829; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; MCCAFFREY M, 1991, J CELL BIOL, V115, P309, DOI 10.1083/jcb.115.2.309; Murata K, 1997, P NATL ACAD SCI USA, V94, P10624, DOI 10.1073/pnas.94.20.10624; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; PATTON JL, 1991, J BACTERIOL, V173, P3101, DOI 10.1128/JB.173.10.3101-3108.1991; Powers T, 1999, MOL BIOL CELL, V10, P987, DOI 10.1091/mbc.10.4.987; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Schmidt A, 1996, P NATL ACAD SCI USA, V93, P13780, DOI 10.1073/pnas.93.24.13780; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; Schmidt A, 1998, EMBO J, V17, P6924, DOI 10.1093/emboj/17.23.6924; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SHERMAN F, 1991, P3; Shigemitsu K, 1999, J BIOL CHEM, V274, P1058, DOI 10.1074/jbc.274.2.1058; STAN R, 1994, J BIOL CHEM, V269, P32027; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Vetter IR, 1999, CELL, V97, P635, DOI 10.1016/S0092-8674(00)80774-6; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077	53	106	112	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37011	37020		10.1074/jbc.M007296200	http://dx.doi.org/10.1074/jbc.M007296200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973982	Green Accepted, hybrid			2022-12-25	WOS:000165577700079
J	Morii, H; Nishihara, M; Koga, Y				Morii, H; Nishihara, M; Koga, Y			CTP : 2,3-di-O-geranylgeranyl-sn-glycero-1-phosphate cytidyltransferase in the methanogenic archaeon Methanothermobacter thermoautotrophicus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENANTIOMERIC GLYCEROPHOSPHATE BACKBONE; METHANOBACTERIUM-THERMOAUTOTROPHICUM; SN-GLYCEROL-1-PHOSPHATE DEHYDROGENASE; ARCHAEBACTERIAL MEMBRANES; ETHER LIPIDS; BIOSYNTHESIS; PURIFICATION; ENZYME; ACID; PHOSPHOLIPIDS	CDP-S, 3-di-O-geranylgeranyl-sn-glycerol synthase (CDP-archaeol synthase) activity was discovered in the membrane fraction of the methanoarchaeon Methano-thennobacter thermoautotrophicus cells. It catalyzed the formation of CDP-2,3-di-O-geranylgeranyl-sn-glycerol from CTP and 2,3-di-O-geranylgeranyl-sn-glycero-1-phosphate (unsaturated archaetidic acid). The identity of the reaction product was confirmed by thin layer chromatography, fast atom bombardment-mass spectroscopy, chemical analysis, and by UV spectroscopy. One mole of the product was formed hom approximately 1 mol of each of the reactants. The enzyme showed maximal. activity at pH 8.5 and 55 degreesC in the presence of Mg2+ and K+ ions. By in vivo pulse labeling of phospholipids with P-32(i), CDP-archaeol was found to be an intracellular intermediate. A cell-free homogenate of Bf. thermoautotrophicus, when incubated with L-serine, converted the product of CDP-archaeol synthase reaction to a product with the same chromatographic mobility as archaetidylserine. It was concluded from these results that both CDP-archaeol and CDP-archaeol synthase were involved in cellular phospholipid biosynthesis. Among various synthetic substrate analogs, both enantiomers of unsaturated archaetidic acid possessing geranylgeranyl chains showed similar levels of activity, while archaetidic acid with saturated or monounsaturated isoprenoid or straight chains was a poor substrate, despite having the same stereostructure as the fully active substrate. The ester analogs with geranylgeranioyl chains showed significant activities. These results suggest that the enzyme dose not recognize ether or ester bonds between glycerophosphate and hydrocarbon chains nor the stereostructure of the glycerophosphate backbone but mainly targets substrates with geranylgeranyl chains.	Univ Occupat & Environm Hlth, Sch Med, Dept Chem, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan; Univ Occupat & Environm Hlth, Sch Hlth Sci, Dept Environm Management, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan	University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan	Koga, Y (corresponding author), Univ Occupat & Environm Hlth, Sch Med, Dept Chem, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.							BAER E, 1951, J BIOL CHEM, V189, P235; BALCH WE, 1979, MICROBIOL REV, V43, P260, DOI 10.1128/MMBR.43.2.260-296.1979; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BITTMAN R, 1984, CHEM PHYS LIPIDS, V34, P201, DOI 10.1016/0009-3084(84)90044-6; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CARTER JR, 1968, J LIPID RES, V9, P748; CHEN AJ, 1993, J BIOL CHEM, V268, P21701; Dowhan W, 1997, BBA-LIPID LIPID MET, V1348, P157, DOI 10.1016/S0005-2760(97)00111-2; ISOBE M, 1987, TETRAHEDRON, V43, P4767, DOI 10.1016/S0040-4020(01)86918-0; KATES M, 1971, CAN J BIOCHEM CELL B, V49, P275, DOI 10.1139/o71-040; KATES M, 1978, Progress in the Chemistry of Fats and Other Lipids, V15, P301; KATES M, 1972, TECHNIQUES LIPIDOLOG, P558; MENGER FM, 1993, J AM CHEM SOC, V115, P6600, DOI 10.1021/ja00068a017; NISHIHARA M, 1995, J BIOCHEM-TOKYO, V117, P933, DOI 10.1093/oxfordjournals.jbchem.a124822; NISHIHARA M, 1990, BIOCHEM CELL BIOL, V68, P91, DOI 10.1139/o90-011; Nishihara M, 1997, J BIOCHEM-TOKYO, V122, P572; NISHIHARA M, 1989, BIOCHEMISTRY-US, V28, P95, DOI 10.1021/bi00427a014; NISHIHARA M, 1987, J BIOCHEM-TOKYO, V101, P1007, DOI 10.1093/oxfordjournals.jbchem.a121942; POULTER CD, 1988, J AM CHEM SOC, V110, P2620, DOI 10.1021/ja00216a041; Rosenthal A F, 1975, Methods Enzymol, V35, P429, DOI 10.1016/0076-6879(75)35179-3; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPARROW CP, 1992, METHOD ENZYMOL, V209, P237; SPARROW CP, 1985, J BIOL CHEM, V260, P2084; Wasserfallen A, 2000, INT J SYST EVOL MICR, V50, P43, DOI 10.1099/00207713-50-1-43; ZHANG DL, 1990, J AM CHEM SOC, V112, P1264, DOI 10.1021/ja00159a067; ZHANG DL, 1993, J AM CHEM SOC, V115, P1270, DOI 10.1021/ja00057a008	27	36	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36568	36574		10.1074/jbc.M005925200	http://dx.doi.org/10.1074/jbc.M005925200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10960477	hybrid			2022-12-25	WOS:000165577700017
J	Perugini, MA; Schuck, P; Howlett, GJ				Perugini, MA; Schuck, P; Howlett, GJ			Self-association of human apolipoprotein E3 and E4 in the presence and absence of phospholipid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; LOW-DENSITY LIPOPROTEINS; RECEPTOR-BINDING DOMAIN; AMINO-ACID-SEQUENCE; E ISOFORMS; ALZHEIMERS-DISEASE; AQUEOUS-SOLUTIONS; NMR-SPECTROSCOPY; LAMM EQUATION; SEDIMENTATION	Human apolipoprotein E (apoE) exists as three main isoforms, differing by single amino acid substitutions, with the apoE4 isoform strongly linked to the incidence of late onset Alzheimer's disease. We have expressed and purified apoE3 and apoE4 from Escherichia coli and compared their hydrodynamic properties by gel permeation liquid chromatography, capillary electrophoresis, circular dichroism, and sedimentation methods. Sedimentation velocity experiments, employing a new method for determining the size distribution of polydisperse macromolecules in solution (Schuck, P. (2000) Biophys. J. 78, 1606-1619), provide direct evidence for the heterogeneous solution structures of apoE3 and apoE4. In a lipid-free environment, apoE3 and apoE4 exist as a slow equilibrium mixture of monomer, tetramer, octamer, and a small proportion of higher oligomers. Both sedimentation velocity and equilibrium experiments indicate that apoE4 has a greater propensity to self-associate. We also demonstrate that apoE3 and apoE4 oligomers dissociate significantly in the presence of dihexanoylphosphatidylcholine micelles (20 mM) and to a lesser extent at submicellar concentrations (4 mM). The ct-helical content for both isoforms was almost identical (50%) in the presence and absence of dihexanoylphosphatidylcholine. These results reveal that apoE oligomers undergo phospholipid-induced dissociation to folded monomers, suggesting the monomeric form prevails on the lipoprotein surface in vivo.	Univ Melbourne, Russel Grimwade Sch Biochem & Mol biol, Parkville, Vic 3052, Australia; NIH, Div Bioengn & Phys Sci, Off Res Serv, Bethesda, MD 20892 USA	University of Melbourne; National Institutes of Health (NIH) - USA	Howlett, GJ (corresponding author), Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia.	g.howlett@biochemistry.unimelb.edu.au	Schuck, Peter/AAA-6888-2020	Schuck, Peter/0000-0002-8859-6966; Perugini, Matthew/0000-0001-8052-5584	OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [Z01OD010485] Funding Source: NIH RePORTER	OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; Buchko GW, 1998, BBA-LIPID LIPID MET, V1392, P101, DOI 10.1016/S0005-2760(98)00028-9; BURNS RA, 1980, BIOCHEMISTRY-US, V19, P3100, DOI 10.1021/bi00554a041; Chan W, 1996, BIOCHEMISTRY-US, V35, P7123, DOI 10.1021/bi952852v; CLAVERIE JM, 1976, BIOPOLYMERS, V15, P843, DOI 10.1002/bip.1976.360150504; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; COX DJ, 1969, ARCH BIOCHEM BIOPHYS, V129, P106, DOI 10.1016/0003-9861(69)90157-X; DERGUNOV AD, 1992, BIOL CHEM H-S, V373, P323, DOI 10.1515/bchm3.1992.373.1.323; DONG LM, 1994, J BIOL CHEM, V269, P22358; EISENBERG S, 1984, J LIPID RES, V25, P1017; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; Forstner M, 1999, PROTEIN EXPRES PURIF, V17, P267, DOI 10.1006/prep.1999.1144; Golabek AA, 1996, J BIOL CHEM, V271, P10602, DOI 10.1074/jbc.271.18.10602; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; LADU MJ, 1994, J BIOL CHEM, V269, P23403; Lamm O., 1929, ARK MAT ASTR FYS, V21B, P1; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; MacPhee CE, 1997, FEBS LETT, V416, P265, DOI 10.1016/S0014-5793(97)01224-6; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Minton AP, 1997, CURR OPIN BIOTECH, V8, P65, DOI 10.1016/S0958-1669(97)80159-0; Morrow JA, 1999, PROTEIN EXPRES PURIF, V16, P224, DOI 10.1006/prep.1999.1069; OSBORNE JC, 1986, METHOD ENZYMOL, V128, P375; RALL SC, 1982, J BIOL CHEM, V257, P4171; ROZEK A, 1995, BIOCHEMISTRY-US, V34, P7401, DOI 10.1021/bi00022a013; Schuck P, 1998, BIOPHYS J, V75, P1503, DOI 10.1016/S0006-3495(98)74069-X; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; SHORE VG, 1973, BIOCHEMISTRY-US, V12, P502, DOI 10.1021/bi00727a022; SPARROW JT, 1992, BIOCHEMISTRY-US, V31, P1065, DOI 10.1021/bi00119a015; TAUSK RJM, 1974, BIOPHYS CHEM, V2, P175, DOI 10.1016/0301-4622(74)80004-9; UTERMANN G, 1975, FEBS LETT, V56, P352, DOI 10.1016/0014-5793(75)81125-2; Wang GS, 1996, BIOCHEMISTRY-US, V35, P10358, DOI 10.1021/bi960934t; WEISGRABER KH, 1981, J BIOL CHEM, V256, P9077; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WESTERLUND JA, 1993, J BIOL CHEM, V268, P15745; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; Wood SJ, 1996, BIOCHEMISTRY-US, V35, P12623, DOI 10.1021/bi961074j; YOKOYAMA S, 1985, J BIOL CHEM, V260, P6375; ZANNIS VI, 1982, J LIPID RES, V23, P911; ZIMMERMAN SB, 1993, BIOCHIM BIOPHYS ACTA, V1216, P175, DOI 10.1016/0167-4781(93)90142-Z	40	101	102	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36758	36765		10.1074/jbc.M005565200	http://dx.doi.org/10.1074/jbc.M005565200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10970893	hybrid			2022-12-25	WOS:000165577700045
J	Tullai, JW; Cummins, PM; Pabon, A; Roberts, JL; Lopingeo, MC; Shrimpton, CN; Smith, AI; Martignetti, JA; Ferro, ES; Glucksman, MJ				Tullai, JW; Cummins, PM; Pabon, A; Roberts, JL; Lopingeo, MC; Shrimpton, CN; Smith, AI; Martignetti, JA; Ferro, ES; Glucksman, MJ			The neuropeptide processing enzyme EC 3.4.24.15 is modulated by protein kinase A phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENKEPHALIN-CONTAINING PEPTIDES; HORMONE-RELEASING HORMONE; ENDOPEPTIDASE 24.15; LUTEINIZING-HORMONE; METALLOENDOPEPTIDASE EC-3.4.24.15; SECRETORY GRANULES; GROWTH-FACTOR; RAT TESTES; CELLS; INHIBITION	The metalloendopeptidase EC 3.4.24.15 (EP24.15) is a neuropeptide-metabolizing enzyme expressed predominantly in brain, pituitary, and testis, and is implicated in several physiological processes and diseases. Multiple putative phosphorylation sites in the primary sequence led us to investigate whether phosphorylation effects the specificity and/or the kinetics of substrate cleavage. Only protein kinase A (PICA) treatment resulted in serine phosphorylation with a stoichiometry of 1.11 +/- 0.12 mol of phosphate/mol of recombinant rat EP24.15. Mutation analysis of each putative PICA site, in vitro phosphorylation, and phosphopeptide mapping indicated serine 644 as the phosphorylation site. Phosphorylation effects on catalytic activity were assessed using physiological (GnRH, GnRH(1-9) bradykinin, and neurotensin) and fluorimetric (MCA-PLGPDL-Dnp and orthoaminobenzoyl-GGFLRRV-Dnp-edn) substrates. The most dramatic change upon PICA phosphorylation was a substrate-specific, 7-fold increase in both K-m and k(cat) for GnRH. In both rat PC12 and mouse AtT-20 cells, EP24.15 was serine-phosphorylated, and EP24.15 phosphate incorporation was enhanced by forskolin treatment, and attenuated by H89, consistent with PICA-mediated phosphorylation. Cloning of the full-length mouse EP24.15 cDNA revealed 96.7% amino acid identity to the rat sequence, and conservation at serine 644, consistent with its putative functional role. Therefore, PICA phosphorylation is suggested to play a regulatory role in EP24.15 enzyme activity.	CUNY Mt Sinai Sch Med, Fishberg Res Ctr Neurobiol, Struct Neurol & Proteom Lab, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; Baker Med Res Inst, Peptide Biol Lab, Melbourne, Vic 8008, Australia	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Baker Heart and Diabetes Institute	Glucksman, MJ (corresponding author), CUNY Mt Sinai Sch Med, Fishberg Res Ctr Neurobiol, Struct Neurol & Proteom Lab, Box 1065,1425 Madison Ave, New York, NY 10029 USA.	glux@msvax.mssm.edu	Ferro, Emer S/D-3908-2012	Ferro, Emer S/0000-0003-1651-9192; Smith, Ian/0000-0002-4143-2892	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028822] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007135] Funding Source: NIH RePORTER; NICHD NIH HHS [P30-HD28822] Funding Source: Medline; NIDA NIH HHS [2T32-DA7135-16] Funding Source: Medline; NIDDK NIH HHS [T32-DK07645] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asara JM, 1999, J AM SOC MASS SPECTR, V10, P35, DOI 10.1016/S1044-0305(98)00129-9; CACACE AM, 1993, ONCOGENE, V8, P2095; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHU TG, 1985, ENDOCRINOLOGY, V116, P1418, DOI 10.1210/endo-116-4-1418; Crack PJ, 1999, BRAIN RES, V835, P113, DOI 10.1016/S0006-8993(99)01494-8; Cummins PM, 1999, J BIOL CHEM, V274, P16003, DOI 10.1074/jbc.274.23.16003; DAHMS P, 1992, EUR J BIOCHEM, V208, P145, DOI 10.1111/j.1432-1033.1992.tb17168.x; DIXON M, 1959, BIOCHEM J, V55, P170; FERRO ES, 1995, J CELL BIOCHEM, V57, P311, DOI 10.1002/jcb.240570215; Ferro ES, 1999, DNA CELL BIOL, V18, P781, DOI 10.1089/104454999314926; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Ganju RK, 1996, BLOOD, V88, P4159; GARVEY EP, 1989, BIOCHEMISTRY-US, V28, P2083, DOI 10.1021/bi00431a018; GLUCKSMAN MJ, 1992, BIOPHYS J, V62, P119, DOI 10.1016/S0006-3495(92)81798-8; GLUCKSMAN MJ, 1995, METH NEUROSCI, V23, P296; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HARDIE DG, 1992, BIOCH MESSENGERS HOR; HEALY DP, 1992, BRAIN RES, V571, P121, DOI 10.1016/0006-8993(92)90517-D; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HUTTON JC, 1983, BIOCHEM J, V210, P297, DOI 10.1042/bj2100297; JULIANO L, 1990, BIOCHEM BIOPH RES CO, V173, P647, DOI 10.1016/S0006-291X(05)80084-1; KAMTEKAR S, 1995, FASEB J, V9, P1013, DOI 10.1096/fasebj.9.11.7649401; KEST B, 1992, PSYCHOPHARMACOLOGY, V106, P408, DOI 10.1007/BF02245427; KRAUSS RS, 1992, MOL CELL BIOL, V12, P3117, DOI 10.1128/MCB.12.7.3117; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASDUN A, 1989, J PHARMACOL EXP THER, V251, P439; LASDUN A, 1990, J PHARMACOL EXP THER, V253, P1265; LEVINE JE, 1999, ENCY REPROD, V2, P478; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; MAINS RE, 1987, ANN NY ACAD SCI, V493, P278, DOI 10.1111/j.1749-6632.1987.tb27213.x; Martins LM, 1998, BLOOD, V92, P3042, DOI 10.1182/blood.V92.9.3042.421k55_3042_3049; Mason GGF, 1996, EUR J BIOCHEM, V238, P453, DOI 10.1111/j.1432-1033.1996.0453z.x; Montiel JL, 1997, J NEUROCHEM, V68, P354; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NESTLER EJ, 1983, NATURE, V305, P583, DOI 10.1038/305583a0; NEUFELD E, 1989, ANAL BIOCHEM, V177, P138, DOI 10.1016/0003-2697(89)90028-6; NIEDBALSKI JS, 1986, ANAL BIOCHEM, V158, P138, DOI 10.1016/0003-2697(86)90601-9; ORLOWSKI M, 1983, EUR J BIOCHEM, V135, P81, DOI 10.1111/j.1432-1033.1983.tb07620.x; ORLOWSKI M, 1988, BIOCHEMISTRY-US, V27, P597, DOI 10.1021/bi00402a015; ORLOWSKI M, 1989, BIOCHEM J, V261, P951, DOI 10.1042/bj2610951; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PIEROTTI A, 1990, BIOCHEMISTRY-US, V29, P10323, DOI 10.1021/bi00497a006; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; Shrimpton CN, 1997, J BIOL CHEM, V272, P17395, DOI 10.1074/jbc.272.28.17395; Smith B J, 1994, Methods Mol Biol, V32, P297; VANDERGEER P, 1993, PROTEIN PHOSPHORYLAT, P32; Vincent B, 1997, EUR J PHARMACOL, V334, P49, DOI 10.1016/S0014-2999(97)01209-0; Wilkins MR, 1997, ELECTROPHORESIS, V18, P403, DOI 10.1002/elps.1150180314; WILKINS MR, 1998, 2 D PROTEOME ANAL PR, P531; Wu TJ, 1997, J NEUROENDOCRINOL, V9, P813, DOI 10.1046/j.1365-2826.1997.00637.x; Yamin R, 1999, J BIOL CHEM, V274, P18777, DOI 10.1074/jbc.274.26.18777	52	41	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36514	36522		10.1074/jbc.M001843200	http://dx.doi.org/10.1074/jbc.M001843200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10969067	hybrid			2022-12-25	WOS:000165577700010
J	Bourbon, NA; Yun, J; Kester, M				Bourbon, NA; Yun, J; Kester, M			Ceramide directly activates protein kinase C zeta to regulate a stress-activated protein kinase signaling complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ARACHIDONIC-ACID; MESANGIAL CELLS; INDUCED TRANSLOCATION; INDUCED APOPTOSIS; PKC-ZETA; PATHWAY; BINDING; DIFFERENTIATION; TRANSDUCTION	We have previously shown that interleukin 1 (IL-1)receptor-generated ceramide induces growth arrest in smooth muscle pericytes by activating an upstream kinase in the stress-activated protein kinase (SAPK) cascade. We now report the mechanism by which ceramide activates the SAPK signaling pathway in human embryonic kidney cells (HEK-293). We demonstrate that ceramide activation of protein kinase C zeta (PKC zeta) mediates SAPK signal complex formation and subsequent growth suppression. Ceramide directly activates both immunoprecipitated and recombinant human PKC zeta in vitro. Additionally, ceramide activates SAPK activity, which is blocked with a dominant-negative mutant of PKC zeta Coimmunoprecipitation studies reveal that ceramide induces the association of SAPK with PKC zeta, but not with PKC epsilon. In addition, ceramide treatment induces PKC zeta association with phosphorylated SEK and MEKK1, elements of the SAPK signaling complex. The biological role of ceramide to induce cell cycle arrest is mimicked by overexpression of a constitutively active PKC zeta. Together, these studies demonstrate that ceramide induces cell cycle arrest by enhancing the ability of PKC zeta to form a signaling complex with MEKK1, SEK, and SAPK.	Penn State Univ, Milton S Hershey Med Ctr, Dept Pharmacol, Coll Med, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Kester, M (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Dept Pharmacol, Coll Med, POB 850, Hershey, PA 17033 USA.				NIDDK NIH HHS [DK53715] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053715] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; Bieberich E, 2000, J BIOL CHEM, V275, P177, DOI 10.1074/jbc.275.1.177; BISWAS P, 1995, FEBS LETT, V373, P146, DOI 10.1016/0014-5793(95)01025-A; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Cacace AM, 1996, ONCOGENE, V13, P2517; Carpio LC, 1999, PROSTAG LEUKOTR ESS, V61, P267, DOI 10.1054/plef.1999.0100; Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313; Coroneos E, 1996, BIOCHEM J, V316, P13, DOI 10.1042/bj3160013; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Esteve P, 1998, ONCOGENE, V17, P1855, DOI 10.1038/sj.onc.1202082; GalveRoperh I, 1997, FEBS LETT, V415, P271, DOI 10.1016/S0014-5793(97)00985-X; Hurley JH, 1997, PROTEIN SCI, V6, P477; Huwiler A, 1998, BIOCHEMISTRY-US, V37, P14556, DOI 10.1021/bi981401i; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Kieser A, 1996, GENE DEV, V10, P1455, DOI 10.1101/gad.10.12.1455; KIM MY, 1991, J BIOL CHEM, V266, P484; Liu Q, 1998, J IMMUNOL, V160, P1393; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Mandal A, 1997, J BIOL CHEM, V272, P20306, DOI 10.1074/jbc.272.32.20306; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MONTANER S, 1995, ONCOGENE, V10, P2213; Muller G, 1998, EMBO J, V17, P732, DOI 10.1093/emboj/17.3.732; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; MUSIAL A, 1995, J BIOL CHEM, V270, P21632, DOI 10.1074/jbc.270.37.21632; Sawai H, 1997, J BIOL CHEM, V272, P2452; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Shin EA, 1999, FEBS LETT, V452, P355, DOI 10.1016/S0014-5793(99)00657-2; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; SOZERI O, 1992, ONCOGENE, V7, P2259; Spiegel S, 1999, J LEUKOCYTE BIOL, V65, P341, DOI 10.1002/jlb.65.3.341; Stewart S, 1999, MOL CELL BIOL, V19, P5523; Uberall F, 1999, J CELL BIOL, V144, P413, DOI 10.1083/jcb.144.3.413; van Blitterswijk WJ, 1998, BIOCHEM J, V331, P679; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang YM, 1999, J NEUROSCI RES, V55, P293, DOI 10.1002/(SICI)1097-4547(19990201)55:3<293::AID-JNR4>3.3.CO;2-0; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671	42	188	192	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35617	35623		10.1074/jbc.M007346200	http://dx.doi.org/10.1074/jbc.M007346200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10962008	hybrid			2022-12-25	WOS:000165422800104
J	Lagane, B; Gaibelet, G; Meilhoc, E; Masson, JM; Cezanne, L; Lopez, A				Lagane, B; Gaibelet, G; Meilhoc, E; Masson, JM; Cezanne, L; Lopez, A			Role of sterols in modulating the human mu-opioid receptor function in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; RESPONSE PATHWAY; BINDING-SITES; CHOLESTEROL; MEMBRANES; GENE; MODEL	This study provides evidence that the differences in membrane composition found from one cell type to another can represent a limiting factor to recovering the functionality of transmembrane proteins when expressed in heterologous systems. Restoring the properties of the human mu -opioid receptor in yeast (Saccharomyces cerevisiae), similar to those observed in native cells, was achieved by replacing ergosterol from yeast by cholesterol, which is normally found in mammalian plasma membranes. The results suggest that these two sterols have opposite effects with respect to the ligand binding function of the receptor. Ergosterol was found to constrain the Cr-opioid receptor in an inactive state in yeast plasma membranes and cannot replace cholesterol in activating it. These data differ from previous works dealing with the function of related G-protein-coupled receptors (GPCR) in ergosterol-enriched membranes. This suggests that structural requirements of GPCR with respect to their modulation by lipid components differ from one protein to another. As a consequence, we assume that the presence of appropriate lipids around transmembrane proteins determines their function. This highlights the functional significance of lateral heterogeneities of membrane components within biological membranes.	Inst Natl Sci Appl, CNRS, UMR 5089, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite Federale Toulouse Midi-Pyrenees (ComUE); Institut National des Sciences Appliquees de Toulouse	Lopez, A (corresponding author), Inst Natl Sci Appl, CNRS, UMR 5089, Inst Pharmacol & Biol Struct, 205 Route Narbonne, F-31077 Toulouse, France.		meilhoc, eliane/AAG-4396-2020; Lagane, Bernard/K-8446-2016; Lagane, Bernard/AAA-2205-2019	Lagane, Bernard/0000-0002-3459-7867				[Anonymous], 1993, CHOLESTEROL MEMBRANE; Baenziger JE, 2000, J BIOL CHEM, V275, P777, DOI 10.1074/jbc.275.2.777; Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; BLUMER KJ, 1988, J BIOL CHEM, V263, P10836; Bogdanov M, 1999, J BIOL CHEM, V274, P36827, DOI 10.1074/jbc.274.52.36827; Bogdanov M, 1999, J BIOL CHEM, V274, P12339, DOI 10.1074/jbc.274.18.12339; Brown AJ, 2000, YEAST, V16, P11, DOI 10.1002/(SICI)1097-0061(20000115)16:1<11::AID-YEA502>3.0.CO;2-K; Christian AE, 1997, J LIPID RES, V38, P2264; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; Dumas F, 1999, FEBS LETT, V458, P271, DOI 10.1016/S0014-5793(99)01148-5; Emmerson PJ, 1999, J NEUROCHEM, V73, P289, DOI 10.1046/j.1471-4159.1999.0730289.x; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Gaibelet G, 1999, EUR J BIOCHEM, V261, P517, DOI 10.1046/j.1432-1327.1999.00301.x; Gimpl G, 1997, BIOCHEMISTRY-US, V36, P10959, DOI 10.1021/bi963138w; JONES OT, 1988, BIOCHEMISTRY-US, V27, P2364, DOI 10.1021/bi00407a018; LITMAN BJ, 1996, LIPIDS S, V31, P193; LONDON E, 1981, BIOCHEMISTRY-US, V20, P1939, DOI 10.1021/bi00510a033; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; PRICE LA, 1995, MOL CELL BIOL, V15, P6188; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Schroeder F, 1996, P SOC EXP BIOL MED, V213, P150, DOI 10.3181/00379727-213-44047; SCHULER I, 1990, BIOCHIM BIOPHYS ACTA, V1028, P82, DOI 10.1016/0005-2736(90)90268-S; SIMMONDS AC, 1982, BIOCHIM BIOPHYS ACTA, V693, P398, DOI 10.1016/0005-2736(82)90447-3; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Stanasila L, 1998, BIOCHIMIE, V80, P563, DOI 10.1016/S0300-9084(00)80021-8; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; YEAGLE PL, 1991, BIOCHIMIE, V73, P1303, DOI 10.1016/0300-9084(91)90093-G; Yun CW, 1998, BIOCHEM BIOPH RES CO, V252, P29, DOI 10.1006/bbrc.1998.9600; ZINSER E, 1993, J BACTERIOL, V175, P2853, DOI 10.1128/JB.175.10.2853-2858.1993	31	83	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33197	33200		10.1074/jbc.C000576200	http://dx.doi.org/10.1074/jbc.C000576200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10973945	hybrid			2022-12-25	WOS:000090104600004
J	Jin, SQ; Zhao, HC; Fan, FY; Blanck, P; Fan, WH; Colchagie, AB; Fornace, AJ; Zhan, QM				Jin, SQ; Zhao, HC; Fan, FY; Blanck, P; Fan, WH; Colchagie, AB; Fornace, AJ; Zhan, QM			BRCA1 activation of the GADD45 promoter	ONCOGENE			English	Article						GADD45; BRCA1; p53; gene regulation	P53-REGULATED PROTEIN GADD45; MAMMARY EPITHELIAL-CELLS; DNA-DAMAGE; OVARIAN-CANCER; CYCLE CHECKPOINT; GENE-EXPRESSION; BREAST; P53; INDUCTION; GROWTH	Breast cancer susceptibility gene BRCA1 has been implicated in the control of gene regulation and such regulated genes are thought to mediate the biological role of BRCA1. Overexpression of BRCA1 induces GADD45, a p53-regulated and stress-inducible gene. However, the molecular mechanism by which BRCA1 induces the expression GADD45 remains unclear. In this report, we have shown that the GADD45 promoter is strongly activated following expression of wild-type BRCA1, In contrast, both the tumor-derived BRCA1 mutants (p1749R and Y1853insA) and truncated BRCA1 mutant protein (Delta 500-1863 BRCA1), which lack transactivation activity, were unable to activate the GADD45 promoter, indicating that the BRCA1-mediated activation of the GADD45 promoter requires normal transcriptional properties of BRCA1. BRCA1 did not induce the c-Jun and c-fos promoters, which rules out a general effect of BRCA1 on other immediate-responsive genes. Expression of the human papillomavirus E6 and the dominant-negative mutant p53 proteins had no effect on the induction of the GADD45 promoter by BRCA1, suggesting that activation of the GADD45 promoter by BRCA1 is independent of cellular p53 function. With the 5'-deletion analysis, the BRCA1-responsive element of the GADD45 promoter was mapped at the region from -121 to -75. Disruption of this region resulted in the abrogation of BRCA1 activation of the GADD45 promoter. Taken together, these results demonstrate that the mechanism by which BRCA1 induces GADD45 is mainly through the transactivation of the GADD45 promoter, further demonstrating the evidence that GADD45 acts as one of the BRCA1-regulated genes.	Univ Pittsburgh, Sch Med, Inst Canc, Dept Radiat Oncol, Pittsburgh, PA 15213 USA; NCI, Gene Response Sect, DBS, NIH, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Zhan, QM (corresponding author), Univ Pittsburgh, Sch Med, Inst Canc, Dept Radiat Oncol, BST W-945,200 Lothrop St, Pittsburgh, PA 15213 USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X	DIVISION OF BASIC SCIENCES - NCI [Z01BC007184] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Carrier F, 1999, MOL CELL BIOL, V19, P1673; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; EASTON DF, 1995, AM J HUM GENET, V56, P265; FORD D, 1995, BRIT J CANCER, V72, P805, DOI 10.1038/bjc.1995.417; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Larson JS, 1997, CANCER RES, V57, P3351; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Rao VN, 1996, ONCOGENE, V12, P523; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Smith ML, 1996, ONCOGENE, V13, P2255; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	38	82	86	2	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 17	2000	19	35					4050	4057		10.1038/sj.onc.1203759	http://dx.doi.org/10.1038/sj.onc.1203759			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962562				2022-12-25	WOS:000088825300011
J	Chi, YH; Kumar, TKS; Chiu, IM; Yu, C				Chi, YH; Kumar, TKS; Chiu, IM; Yu, C			N-15 NMR relaxation studies of free and ligand-bound human acidic fibroblast growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE RELAXATION; FGF RECEPTOR DIMERIZATION; MODEL-FREE APPROACH; BACKBONE DYNAMICS; 3-DIMENSIONAL STRUCTURE; BINDING; SPECTROSCOPY; POLYANIONS; DOMAIN; OLIGOMERIZATION	N-15 NMR relaxation data have been used to characterize the backbone dynamics of the human acidic fibroblast growth factor (hFGF-1) in its free and sucrose octasulfate (SOS)-bound states. N-15 longitudinal (R-1), transverse (R-2) relaxation rates and {H-1}-N-15 steady-state nuclear Overhauser effects were obtained at 500 and 600 MHz (at 25 degreesC) for all resolved backbone amide groups using H-1- detected two-dimensional NMR experiments. Relaxation data were fit to the extended model free dynamics for each NH group. The overall correlation time (tau (m)) for the free and SOS-bound forms were estimated to be 10.4 +/- 1.07 and 11.1 +/- 1.35 ns, respectively. Titration experiments with SOS reveals that the Ligand binds specifically to the C-terminal domain of the protein in a 1:1 ratio. Binding of SOS to hFGF-1 is found to induce a subtle conformational change in the protein. Significant conformational exchange (R-ex) is observed for several residues in the free form of the protein. How ever, in the SOS-bound form only three residues exhibit significant R-ex values, suggesting that the dynamics on the micro- to millisecond time scale in the free form is coupled to the cts-trans-proline isomerization. hFGF-1 is a rigid molecule with an average generalized parameter (S-2) value of 0.89 +/- 0.03. Upon binding to SOS, there is a marked decrease in the overall flexibility (S-2 = 0.94 +/- 0.02) of the hFGF-1 molecule. However, the segment comprising residues 103-111 shows increased flexibility in the presence of SOS. Significant correlation is found between residues that show high flexibility and the putative receptor binding sites on the protein.	Natl Tsing Hua Univ, Dept Chem, Hsinchu 30043, Taiwan; Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA	National Tsing Hua University; University System of Ohio; Ohio State University	Yu, C (corresponding author), Natl Tsing Hua Univ, Dept Chem, Hsinchu 30043, Taiwan.		Chi, Ya-Hui/ABE-8550-2020; Kumar, Dr Suresh/HHZ-2615-2022; Chiu, Ing-Ming/B-1534-2008; Kumar, Suresh Thallapuranam/R-5606-2016; Chi, Ya-Hui/B-1080-2010; KUMAR, P. SURESH/AAT-8951-2020	Chi, Ya-Hui/0000-0002-9216-0938; Kumar, Dr Suresh/0000-0002-2539-6553; Kumar, Suresh Thallapuranam/0000-0001-7262-1373; KUMAR, P. SURESH/0000-0003-3222-2604				BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; BASCILICO C, 1992, ADV CANCER RES, V59, P115; Blaber SI, 1999, BIOPHYS J, V77, P470, DOI 10.1016/S0006-3495(99)76904-3; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; BURKE CJ, 1993, BIOCHEMISTRY-US, V32, P6419, DOI 10.1021/bi00076a015; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P7387, DOI 10.1021/bi00484a006; DABORA JM, 1991, J BIOL CHEM, V266, P23637; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; Faham S, 1998, CURR OPIN STRUC BIOL, V8, P578, DOI 10.1016/S0959-440X(98)80147-4; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; GASPODAROWICZ D, 1986, J CELL PHYSL, V128, P475; Herr AB, 1997, J BIOL CHEM, V272, P16382, DOI 10.1074/jbc.272.26.16382; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; LEATHERBARROW RJ, 1992, GRAFT VERSION 3 0; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; MACH H, 1994, ARCH BIOCHEM BIOPHYS, V309, P36, DOI 10.1006/abbi.1994.1080; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; Moy FJ, 1998, BIOCHEMISTRY-US, V37, P1495, DOI 10.1021/bi972181w; Ogura K, 1999, J BIOMOL NMR, V13, P11, DOI 10.1023/A:1008330622467; PALMER AG, 1991, J AM CHEM SOC, V113, P4371, DOI 10.1021/ja00012a001; PASCAL SM, 1995, BIOCHEMISTRY-US, V34, P11353, DOI 10.1021/bi00036a008; PinedaLucena A, 1996, J MOL BIOL, V264, P162, DOI 10.1006/jmbi.1996.0631; PINEDALUCENA A, 1994, J MOL BIOL, V242, P81, DOI 10.1006/jmbi.1994.1558; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; PRESS WH, 1992, NUMERICAL RECIPES FO, P48; Sanz JM, 1997, EUR J BIOCHEM, V246, P328, DOI 10.1111/j.1432-1033.1997.00328.x; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; Stivers JT, 1996, BIOCHEMISTRY-US, V35, P16036, DOI 10.1021/bi961834q; STONE MJ, 1993, BIOCHEMISTRY-US, V32, P426, DOI 10.1021/bi00053a007; VOLKIN DB, 1993, BIOCHIM BIOPHYS ACTA, V1203, P18, DOI 10.1016/0167-4838(93)90031-L; Ye JQ, 1999, J BIOMOL NMR, V15, P115, DOI 10.1023/A:1008376728947; Zhu HY, 1997, PROTEIN ENG, V10, P417, DOI 10.1093/protein/10.4.417; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	37	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39444	39450		10.1074/jbc.M007205200	http://dx.doi.org/10.1074/jbc.M007205200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10982816	hybrid			2022-12-25	WOS:000165953100069
J	Gerner, C; Frohwein, U; Gotzmann, J; Bayer, E; Gelbmann, D; Bursch, W; Schulte-Hermann, R				Gerner, C; Frohwein, U; Gotzmann, J; Bayer, E; Gelbmann, D; Bursch, W; Schulte-Hermann, R			The Fas-induced apoptosis analyzed by high throughput proteome analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MATRIX PROTEINS; DEATH; IDENTIFICATION; ACTIVATION; CELLS; MECHANISMS; RESISTANCE; CASPASES; CALCIUM; FAMILY	The fate of cytosolic proteins was studied during Fas-induced cell death of Jurkat T-lymphocytes by proteome analysis. Among 1000 spots resolved in two-dimensional gels, comparison of control versus apoptotic cells revealed that the signal intensity of 19 spots decreased or even disappeared, whereas 38 novel spots emerged. These proteins were further analyzed with respect to de novo protein synthesis, phosphorylation status, and intracellular localization by metabolic labeling and analysis of subcellular protein fractions in combination with two-dimensional Western blots and mass spectrometry analysis of tryptic digests. We found that ag. hsp27, hsp70B, calmodulin, and H-ras synthesis was induced upon Fas signaling. 34 proteins were affected by dephosphorylation (e.g. endoplasmin) and phosphorylation (e.g. hsc70, hsp57, and hsp90). Nuclear annexin IV translocated to the cytosol, whereas decreasing cytosolic TCP-lar became detectable in the nucleus. In addition, degradation of 12 proteins was observed; among them myosin heavy chain was identified as a novel caspase target. Fas-induced proteome alterations were compared with those of other cell death inducers, indicating specific physiological characteristics of different cell death mechanisms, consequent to as well as independent of caspase activation. Characteristic proteome alterations of apoptotic cells at early time points were found reminiscent of those of malignant cells in vivo.	Univ Vienna, Canc Res Inst, A-1090 Vienna, Austria	University of Vienna	Gerner, C (corresponding author), Univ Vienna, Canc Res Inst, Borschkegasse 8A, A-1090 Vienna, Austria.	Christopher.Gerner@univie.ac.at		Gotzmann, Josef/0000-0001-6392-2115; Gerner, Christopher/0000-0003-4964-0642				Anderson NL, 1998, ELECTROPHORESIS, V19, P1853, DOI 10.1002/elps.1150191103; BJELLQVIST B, 1993, ELECTROPHORESIS, V14, P1023, DOI 10.1002/elps.11501401163; Brockstedt E, 1998, J BIOL CHEM, V273, P28057, DOI 10.1074/jbc.273.43.28057; CharriautMarlangue C, 1996, ELECTROPHORESIS, V17, P1781, DOI 10.1002/elps.1150171117; CSERMELY P, 1995, J BIOL CHEM, V270, P6381, DOI 10.1074/jbc.270.11.6381; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Egerton M, 1996, BIOCHEM BIOPH RES CO, V224, P666, DOI 10.1006/bbrc.1996.1082; Evan G, 1997, INT J CANCER, V71, P709, DOI 10.1002/(SICI)1097-0215(19970529)71:5<709::AID-IJC2>3.0.CO;2-V; Fountoulakis M, 1997, ANAL BIOCHEM, V250, P153, DOI 10.1006/abio.1997.2213; Frame S, 2000, CURR OPIN GENET DEV, V10, P106, DOI 10.1016/S0959-437X(99)00052-0; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Gerner C, 1999, J CELL BIOCHEM, V72, P470, DOI 10.1002/(SICI)1097-4644(19990315)72:4<470::AID-JCB3>3.0.CO;2-V; Gerner C, 1998, J CELL BIOCHEM, V71, P363, DOI 10.1002/(SICI)1097-4644(19981201)71:3<363::AID-JCB5>3.0.CO;2-W; Gerner C, 1998, EXP CELL RES, V238, P472, DOI 10.1006/excr.1997.3866; Gerner C, 1999, J CELL BIOCHEM, V74, P145, DOI 10.1002/(SICI)1097-4644(19990801)74:2<145::AID-JCB1>3.0.CO;2-#; Glinsky GV, 1996, CANCER LETT, V101, P43, DOI 10.1016/0304-3835(96)04112-2; Gotzmann J, 2000, CELL DEATH DIFFER, V7, P425, DOI 10.1038/sj.cdd.4400668; Gotzmann J, 2000, ELECTROPHORESIS, V21, P523, DOI 10.1002/(SICI)1522-2683(20000201)21:3<523::AID-ELPS523>3.0.CO;2-L; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HOCHSTRASSER DF, 1988, ANAL BIOCHEM, V173, P424, DOI 10.1016/0003-2697(88)90209-6; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Levy-Strumpf N, 1998, ONCOGENE, V17, P3331, DOI 10.1038/sj.onc.1202588; Ma H, 1999, J CELL BIOL, V146, P531, DOI 10.1083/jcb.146.3.531; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; McCormick TS, 1997, J BIOL CHEM, V272, P6087, DOI 10.1074/jbc.272.9.6087; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Prasad SC, 1999, ELECTROPHORESIS, V20, P1065, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<1065::AID-ELPS1065>3.3.CO;2-D; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Schulte-Hermann R, 1999, IARC SCI PUBL, P273; SchulteHermann R, 1997, CELL BIOL TOXICOL, V13, P339, DOI 10.1023/A:1007495626864; Scoltock AB, 2000, J BIOL CHEM, V275, P30586, DOI 10.1074/jbc.M004058200; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; Takayama S, 1998, CANCER RES, V58, P3116; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Uozaki H, 1997, CANCER-AM CANCER SOC, V79, P2336, DOI 10.1002/(SICI)1097-0142(19970615)79:12<2336::AID-CNCR7>3.0.CO;2-J; Waterhouse NJ, 1998, CELL DEATH DIFFER, V5, P1051, DOI 10.1038/sj.cdd.4400425; Wilkins MR, 1997, J THEOR BIOL, V186, P7, DOI 10.1006/jtbi.1996.0346; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	48	143	147	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39018	39026		10.1074/jbc.M006495200	http://dx.doi.org/10.1074/jbc.M006495200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10978337	hybrid			2022-12-25	WOS:000165953100012
J	Mills, JS; Miettinen, HM; Cummings, D; Jesaitis, AJ				Mills, JS; Miettinen, HM; Cummings, D; Jesaitis, AJ			Characterization of the binding site on the formyl peptide receptor using three receptor mutants and analogs of Met-Leu-Phe and Met-Met-Trp-Leu-Leu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-FORMYLPEPTIDE RECEPTOR; G-PROTEIN; SIGNAL-TRANSDUCTION; IDENTIFICATION; LIGAND; ACTIVATION; CDNA; RHODOPSIN; MODEL; CHEMOATTRACTANTS	The formyl peptide receptor (FPR) is a chemotactic G protein-coupled receptor found on the surface of phagocytes. We have previously shown that the formyl peptide binding site maps to the membrane-spanning region (Miettinen, H. R., Mills, J. S., Gripentrog, J. M., Dratz, E. A., Granger, E. L., and Jesaitis, A. J. (1997) J. Immunol, 159, 4045-4054). Recent reports have indicated that nonformylated peptides, such as MMWLL can also activate this receptor (Chen, J., Bernstein, H. S., Chen, M.,Wang, L., Ishi, M., Turck, C. W., and Coughlin, S. R. (1995) J, Biol. Chem. 270, 23398-23401.) Here we show that the selectivity for the binding of different NH2-terminal analogs of MMWLL or MLF can be markedly altered by mutating Asp-106 to asparagine or Arg-201 to alanine. Both D106N and R201A produced a similar change in ligand specificity, including an enhanced ability to bind the HIV-I peptide DP178. In contrast, the mutation R205A exhibited altered specificity at the COOH terminus of fMLF, with R205A binding fMLF-O-butyl > fMLF-O-methyl > fiMLF, whereas wt FPR bound fMLF > fMLF-O-methyl similar to fMLF-O-butyl. These data, taken together with our previous finding that the leucine side chain of fMLF is probably bound to FPR near FPR (VRK95)-V-93 (Mills, J. S., Miettinen, H. M., Barnidge, D., Vlases, M. J., Wimer-Mackin, S., Dratz, E. A., and Jesaitis, A. J. (1998) J. Biol. Chem. 273, 10428-10435.), indicate that the most Likely positioning of fMLF in the binding pocket of EPR is approximately parallel to the fifth transmembrane helix with the formamide group of fMLF hydrogen-bonded to both Asp-106 and Arg-201, the leucine side chain pointing toward the second transmembrane region, and the COOH-terminal carboxyl group of fMLF ion-paired with Arg-205.	Montana State Univ, Dept Microbiol, Bozeman, MT 59717 USA	Montana State University System; Montana State University Bozeman	Mills, JS (corresponding author), Montana State Univ, Dept Microbiol, 109 Lewis Hall, Bozeman, MT 59717 USA.	umbmj@mantana.edu		Jesaitis, Algirdas/0000-0001-9001-5617	PHS HHS [2RO1A40108-4] Funding Source: Medline; SAMHSA HHS [2ROAI22735-14] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); SAMHSA HHS		Alvarez V, 1996, IMMUNOGENETICS, V44, P446, DOI 10.1007/BF02602806; Beck M, 1998, BIOCHEMISTRY-US, V37, P7630, DOI 10.1021/bi9801560; BELLEAU B, 1989, INT J IMMUNOPHARMACO, V11, P467, DOI 10.1016/0192-0561(89)90175-6; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; BROOM MF, 1989, EXPERIENTIA, V45, P1097, DOI 10.1007/BF01950167; CHEN J, 1995, J BIOL CHEM, V270, P23398, DOI 10.1074/jbc.270.40.23398; Dahlgren C, 2000, BLOOD, V95, P1810, DOI 10.1182/blood.V95.5.1810.005k06_1810_1818; DEMARTINO JA, 1995, J BIOL CHEM, V270, P15966, DOI 10.1074/jbc.270.27.15966; Derian CK, 1996, BIOCHEMISTRY-US, V35, P1265, DOI 10.1021/bi952087k; Eilers M, 1999, P NATL ACAD SCI USA, V96, P487, DOI 10.1073/pnas.96.2.487; FIORE S, 1994, J EXP MED, V180, P253, DOI 10.1084/jem.180.1.253; FREER RJ, 1982, BIOCHEMISTRY-US, V21, P257, DOI 10.1021/bi00531a009; FREER RJ, 1980, BIOCHEMISTRY-US, V19, P2404, DOI 10.1021/bi00552a019; GAO JL, 1994, J EXP MED, V180, P2191, DOI 10.1084/jem.180.6.2191; GAO JL, 1993, J BIOL CHEM, V268, P25395; Gao JL, 1998, GENOMICS, V51, P270, DOI 10.1006/geno.1998.5376; Gao JL, 1999, J EXP MED, V189, P657, DOI 10.1084/jem.189.4.657; GIERSCHIK P, 1989, EUR J PHARM-MOLEC PH, V172, P481, DOI 10.1016/0922-4106(89)90031-X; HAN BM, 1995, BIOCHEMISTRY-US, V34, P13412, DOI 10.1021/bi00041a019; HEDNER J, 1983, ACTA PHYSIOL SCAND, V117, P427, DOI 10.1111/j.1748-1716.1983.tb00017.x; Higgins JD, 1996, J MED CHEM, V39, P1013, DOI 10.1021/jm950908d; Klein C, 1998, NAT BIOTECHNOL, V16, P1334, DOI 10.1038/4310; Laakkonen LJ, 1996, BIOCHEMISTRY-US, V35, P7651, DOI 10.1021/bi952203j; Le YY, 1999, J IMMUNOL, V163, P6777; MARASCO WA, 1984, J BIOL CHEM, V259, P5430; Miettinen HM, 1998, J CELL SCI, V111, P1921; Miettinen HM, 1997, J IMMUNOL, V159, P4045; Mills JS, 1999, CURR INFLAMMAT RES, P215; Mills JS, 1998, J BIOL CHEM, V273, P10428, DOI 10.1074/jbc.273.17.10428; MURPHY PM, 1992, J BIOL CHEM, V267, P7637; NODA K, 1995, J BIOL CHEM, V270, P2284, DOI 10.1074/jbc.270.5.2284; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PERLMAN JH, 1994, J BIOL CHEM, V269, P1610; SCHIFFMANN E, 1975, P NATL ACAD SCI USA, V72, P1059, DOI 10.1073/pnas.72.3.1059; Su SB, 1999, BLOOD, V93, P3885, DOI 10.1182/blood.V93.11.3885.411k19_3885_3892; Su SB, 1999, J EXP MED, V189, P395, DOI 10.1084/jem.189.2.395; Su SB, 1999, J IMMUNOL, V162, P5924; WEITZ CJ, 1993, BIOCHEMISTRY-US, V32, P14176, DOI 10.1021/bi00214a016; Wenzel-Seifert K, 1998, J BIOL CHEM, V273, P24181, DOI 10.1074/jbc.273.37.24181; YE RD, 1992, BIOCHEM BIOPH RES CO, V184, P582, DOI 10.1016/0006-291X(92)90629-Y; YE RD, 1993, J IMMUNOL, V150, P1383	41	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39012	39017		10.1074/jbc.M003081200	http://dx.doi.org/10.1074/jbc.M003081200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10960471	hybrid			2022-12-25	WOS:000165953100011
J	Wrisch, A; Grissmer, S				Wrisch, A; Grissmer, S			Structural differences of bacterial and mammalian K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; CHARYBDOTOXIN BLOCK; BINDING-SITES; MUTANT CYCLES; KALIOTOXIN; VESTIBULE; INHIBITOR; KV1.3; PORE; SELECTIVITY	Using a peptide toxin, kaliotoxin (KTX), we gained new insight into the topology of the pore region of a voltage-gated potassium channel, mKv1.1. In order to find new interactions between mHv1.1 and KTX, we investigated the pH dependence of KTX block which was stronger at pH, 6.2 compared with pH(o) 7.4. Using site-directed mutagenesis on the channel and the toxin, we found that protonation of His(34) in KTX caused the pH(o) dependence of KTX block. Glu(350) and Glu(353) in mKv1.1, which interact with His(34) in KTX, were calculated to be 4 and 7 Angstrom away from His(34)/KTX, respectively. Docking of KTX into a homology model of mHv1.1 based on the KcsA crystal structure using this and other known interactions as constraints showed structural differences between mKv1.1 and KcsA within the turret (amino acids 348-357). To satisfy our data, we would have to modify the KcsA crystal structure for the mKv1.1 channel orienting Glu(350) 7 Angstrom and Glu(353) 4 Angstrom more toward the center of the pore compared with KcsA. This would place Glu(350) 15 Angstrom and Glu(353) 11 Angstrom away from the center of the pore instead of the distances for the equivalent KcsA residues with 22 Angstrom for Gly(53) and 15 Angstrom for Gly(56), respectively. Bacterial and mammalian potassium channels may have structural differences regarding the turret of the outer pore vestibule. This topological difference between both channel types may have substantial influence on structure-guided development of new drugs for mammalian potassium channels by rational drug design.	Univ Ulm, Dept Appl Physiol, D-89081 Ulm, Germany	Ulm University	Grissmer, S (corresponding author), Univ Ulm, Dept Appl Physiol, Albert Einstein Allee 11, D-89081 Ulm, Germany.							AIYAR J, 1995, NEURON, V15, P1169, DOI 10.1016/0896-6273(95)90104-3; Aiyar J, 1996, J BIOL CHEM, V271, P31013, DOI 10.1074/jbc.271.49.31013; Bretschneider F, 1999, BIOPHYS J, V76, P2351, DOI 10.1016/S0006-3495(99)77392-3; CHANDY KG, 1990, SCIENCE, V247, P973, DOI 10.1126/science.2305265; CREST M, 1992, J BIOL CHEM, V267, P1640; DEUTSCH C, 1991, J BIOL CHEM, V266, P3668; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Dudlak CS, 2000, BIOPHYS J, V78, p97A; ECCLESTON E, 1973, NATURE-NEW BIOL, V244, P73, DOI 10.1038/newbio244073b0; Gairi M, 1997, J PEPT SCI, V3, P314, DOI 10.1002/(SICI)1099-1387(199707)3:4<314::AID-PSC117>3.0.CO;2-E; Garcia M L, 1999, Methods Enzymol, V294, P624; GARCIA ML, 1994, BIOCHEMISTRY-US, V33, P6834, DOI 10.1021/bi00188a012; GOLDSTEIN SAN, 1993, BIOPHYS J, V65, P1613, DOI 10.1016/S0006-3495(93)81200-1; GRISSMER S, 1984, PFLUG ARCH EUR J PHY, V402, P353, DOI 10.1007/BF00583935; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; Hille B., 1992, IONIC CHANNELS EXCIT; Kalman K, 1998, J BIOL CHEM, V273, P32697, DOI 10.1074/jbc.273.49.32697; Legros C, 2000, J BIOL CHEM, V275, P16918, DOI 10.1074/jbc.275.22.16918; LOEWENTHAL R, 1992, J MOL BIOL, V224, P759, DOI 10.1016/0022-2836(92)90560-7; MACKINNON R, 1988, J GEN PHYSIOL, V91, P335, DOI 10.1085/jgp.91.3.335; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; Mourre C, 1999, J PHARMACOL EXP THER, V291, P943; Perez-Cornejo P, 1998, J GEN PHYSIOL, V111, P441, DOI 10.1085/jgp.111.3.441; Rauer H, 2000, J BIOL CHEM, V275, P1201, DOI 10.1074/jbc.275.2.1201; Rauer H, 1996, MOL PHARMACOL, V50, P1625; Rehwald M, 1999, FEBS LETT, V443, P357, DOI 10.1016/S0014-5793(99)00007-1; Rodriguez R, 1998, BIOINFORMATICS, V14, P523, DOI 10.1093/bioinformatics/14.6.523; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; SHAPIRO R, 1989, BIOCHEMISTRY-US, V28, P7401, DOI 10.1021/bi00444a038; STOCKER M, 1994, P NATL ACAD SCI USA, V91, P9509, DOI 10.1073/pnas.91.20.9509; ULBRICHT W, 1975, PHILOS T ROY SOC B, V270, P353, DOI 10.1098/rstb.1975.0015	35	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39345	39353		10.1074/jbc.M006827200	http://dx.doi.org/10.1074/jbc.M006827200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10962004	hybrid			2022-12-25	WOS:000165953100057
J	Boskovic, DS; Krishnaswamy, S				Boskovic, DS; Krishnaswamy, S			Exosite binding tethers the macromolecular substrate to the prothrombinase complex and directs cleavage at two spatially distinct sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE CHLOROMETHYL KETONES; DEPENDENT ENZYME COMPLEXES; FACTOR-VA; ACTIVE-SITE; FACTOR-XA; CATALYZED ACTIVATION; BLOOD-COAGULATION; PHOSPHOLIPID-VESICLES; SPECTROSCOPIC PROBES; CRYSTAL-STRUCTURE	The prothrombinase complex, composed of the proteinase, factor Xa, bound to factor Va on membranes, catalyzes thrombin formation by the specific and ordered proteolysis of prothrombin at Arg(323)-Ile(324), followed by cleavage at Arg(274)-Thr(275). We have used a fluorescent derivative of meizothrombin des fragment I (mIIa Delta F1) as a substrate analog to assess the mechanism of substrate recognition in the second half-reaction of bovine prothrombin activation. Cleavage of mIIa Delta F1 exhibits pseudo-first order kinetics regardless of the substrate concentration relative to K-m. This phenomenon arises from competitive product inhibition by thrombin, which binds to prothrombinase with exactly the same affinity as mIIa Delta F1. As thrombin is known to bind to an exosite on prothrombinase, initial interactions at an exosite likely play a role in the enzyme-substrate interaction. Occupation of the active site of prothrombinase by a reversible inhibitor does not exclude the binding of mIIa Delta F1 to the enzyme. Specific recognition of mIIa Delta FI is achieved through an initial bimolecular reaction with an enzymic exosite, followed by an active site docking step in an intramolecular reaction prior to bond cleavage. By alternate substrate studies, we have resolved the contributions of the individual binding steps to substrate affinity and catalysis, This pathway for substrate binding is identical to that previously determined with a substrate analog for the first half-reaction of prothrombin activation. We show that differences in the observed kinetic constants for the two cleavage reactions arise entirely from differences in the inferred equilibrium constant for the intramolecular binding step that permits elements surrounding the scissile bond to dock at the active site of prothrombinase. Therefore, substrate specificity is achieved by binding interactions with an enzymic exosite that tethers the protein substrate to prothrombinase and directs cleavage at two spatially distinct scissile bonds.	Childrens Hosp Philadelphia, Joseph Stokes Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Krishnaswamy, S (corresponding author), Childrens Hosp Philadelphia, Joseph Stokes Res Inst, 310 Abramson,3516 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	skrishna@mail.med.upenn.edu	Boskovic, Danilo/D-4670-2012; Krishnaswamy, Sriram/Z-4380-2019	Boskovic, Danilo/0000-0001-6919-3726; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062523, R01HL052883] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62523, HL52883] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson PJ, 2000, J BIOL CHEM, V275, P16435, DOI 10.1074/jbc.M001255200; ARMSTRONG SA, 1990, J BIOL CHEM, V265, P6210; BAJAJ SP, 1975, J BIOL CHEM, V250, P2150; Baugh RJ, 2000, J BIOL CHEM, V275, P28826, DOI 10.1074/jbc.M005266200; Betz A, 1997, BIOCHEMISTRY-US, V36, P181, DOI 10.1021/bi962060g; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; Bevington PR., 2002, DATA REDUCTION ERROR; BOCK PE, 1993, METHOD ENZYMOL, V222, P478; Bock PE, 1997, J BIOL CHEM, V272, P19837, DOI 10.1074/jbc.272.32.19837; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; BOCK PE, 1992, J BIOL CHEM, V267, P14974; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; CARLISLE TL, 1990, J BIOL CHEM, V265, P22044; DOWNING MR, 1975, J BIOL CHEM, V250, P8897; DOYLE MF, 1993, METHOD ENZYMOL, V222, P299; ESMON CT, 1974, J BIOL CHEM, V249, P7791; EVANS SA, 1982, J BIOL CHEM, V257, P3014; Fredenburgh JC, 1997, J BIOL CHEM, V272, P25493, DOI 10.1074/jbc.272.41.25493; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P5290, DOI 10.1021/bi00723a006; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JACKSON CM, 1968, BIOCHEMISTRY-US, V7, P4492, DOI 10.1021/bi00852a046; KALAFATIS M, 1993, METHOD ENZYMOL, V222, P224; KALAFATIS M, 1994, BBA-MOL BASIS DIS, V1227, P113, DOI 10.1016/0925-4439(94)90086-8; KOSOW DP, 1979, J BIOL CHEM, V254, P9448; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; KRISHNASWAMY S, 1993, METHOD ENZYMOL, V222, P260; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P3319, DOI 10.1021/bi9623993; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P12080, DOI 10.1021/bi970979+; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUE TM, 1984, BIOCHEMISTRY-US, V23, P1339, DOI 10.1021/bi00302a001; LIU LW, 1991, J BIOL CHEM, V266, P23632; LOTTENBERG R, 1986, BIOCHIM BIOPHYS ACTA, V874, P326, DOI 10.1016/0167-4838(86)90032-4; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; Lu YF, 1996, BIOCHEMISTRY-US, V35, P8201, DOI 10.1021/bi960281g; Lundblad R L, 1976, Methods Enzymol, V45, P156; Mann K G, 1976, Methods Enzymol, V45, P123; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1990, BLOOD, V76, P1; Martin PD, 1997, STRUCTURE, V5, P1681, DOI 10.1016/S0969-2126(97)00314-6; MIHALYI E, 1988, BIOCHEMISTRY-US, V27, P976, DOI 10.1021/bi00403a021; MYRMEL KH, 1976, BIOCHEMISTRY-US, V15, P1767, DOI 10.1021/bi00653a027; Nelsestuen GL, 1997, BIOCHEMISTRY-US, V36, P9081, DOI 10.1021/bi970720r; NESHEIM ME, 1983, J BIOL CHEM, V258, P5386; NISHIDA S, 1995, BIOCHEMISTRY-US, V34, P1771, DOI 10.1021/bi00005a034; OWEN WG, 1974, J BIOL CHEM, V249, P594; PEI G, 1992, BIOCHEMISTRY-US, V31, P6990, DOI 10.1021/bi00145a017; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Segel IH, 1975, ENZYME KINETICS BEHA; Stanley TB, 1998, BIOCHEMISTRY-US, V37, P13262, DOI 10.1021/bi981031y; STRAUME M, 1992, METHOD ENZYMOL, V210, P87; VANDEGRIFF KD, 1994, METHOD ENZYMOL, V232, P460; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; WALKER RK, 1993, J BIOL CHEM, V268, P13920; WALKER RK, 1994, J BIOL CHEM, V269, P27441	61	38	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38561	38570		10.1074/jbc.M006637200	http://dx.doi.org/10.1074/jbc.M006637200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10984491	hybrid			2022-12-25	WOS:000165739800058
J	Somasundaram, R; Ruehl, M; Tiling, N; Ackermann, R; Schmid, M; Riecken, EO; Schuppan, D				Somasundaram, R; Ruehl, M; Tiling, N; Ackermann, R; Schmid, M; Riecken, EO; Schuppan, D			Collagens serve as an extracellular store of bioactive interleukin 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; CELL-PROLIFERATION; RECEPTOR COMPLEX; TYROSINE KINASES; MATRIX PROTEINS; BINDING DOMAINS; T-LYMPHOCYTES; I COLLAGEN; TGF-BETA; PDGF-A	The binding of certain growth factors and cytokines to components of the extracellular matrix can regulate their local availability and modulate their biological activities. We show that interleukin 2 (IL-2), an important stimulator of T cell growth, preferentially binds to collagen types I, III, and VI and to a lesser degree to collagen types II, IV, and V, immobilized on polystyrene or nitrocellulose. These interactions are inhibited by denatured, single collagen chains or a subset of their cyanogen bromide peptides in a dose-dependent manner. Cross-inhibition experiments and ligand blotting of collagen-derived peptides point to a limited set of collagenous consensus sequences mediating the binding of IL-2. This interaction is saturable, with dissociation constants of similar to 10(-8) M, and estimated molar ratios of 4-6 molecules of IL-2 bound to one molecule of triple helical collagen. Furthermore, collagen-bound IL-2 stimulates proliferation of mouse lymphocytes. We conclude that its specific binding to the abundant interstitial collagens leads to a spatial pattern of bioavailable IL-2 which is dictated by the local organization of the collagenous extracellular matrix. This interaction may contribute to the particular phenotype of stromal lymphocytes and could be exploited for devising collagenous peptide analogues that modulate IL-2 bioactivity.	Univ Erlangen Nurnberg, Med Klin 1, Dept Med 1, D-91054 Erlangen, Germany; Free Univ Berlin, Klinikum Benjamin Franklin, Dept Gastroenterol & Hepatol, D-12200 Berlin, Germany	University of Erlangen Nuremberg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schuppan, D (corresponding author), Univ Erlangen Nurnberg, Med Klin 1, Dept Med 1, Krankenhausstr 12, D-91054 Erlangen, Germany.	detlef.schuppan@med1.imed.uni-erlangen.de		Somasundaram, Rajan/0000-0003-3461-3326				ALON R, 1994, J IMMUNOL, V152, P1304; Ariel A, 1997, EUR J IMMUNOL, V27, P2562, DOI 10.1002/eji.1830271015; Atkinson JC, 1996, EXP CELL RES, V228, P283, DOI 10.1006/excr.1996.0328; BOTTOMLY K, 1999, CURRENT PROTOCOLS IM; Dai ZH, 1999, CURR OPIN IMMUNOL, V11, P504, DOI 10.1016/S0952-7915(99)00008-4; Geginat J, 1999, J IMMUNOL, V162, P5085; HERSHKOVIZ R, 1994, J IMMUNOL, V153, P554; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Kafienah W, 1998, BIOCHEM J, V330, P897, DOI 10.1042/bj3300897; KELLY JL, 1993, J CELL BIOL, V121, P1153, DOI 10.1083/jcb.121.5.1153; KHACHIGIAN LM, 1994, PEPTIDES, V15, P133, DOI 10.1016/0196-9781(94)90181-3; Kitson RP, 1998, J IMMUNOL, V160, P4248; LORTAT-JACOB H, 1991, J CLIN INVEST, V87, P878, DOI 10.1172/JCI115093; Mangasser-Stephan K, 1999, CELL TISSUE RES, V297, P363, DOI 10.1007/s004410051364; Martino G, 1998, ANN NEUROL, V43, P340, DOI 10.1002/ana.410430312; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Miyazaki T, 1996, CANCER SURV, V27, P25; MOORADIAN DL, 1989, J CELL BIOCHEM, V41, P189, DOI 10.1002/jcb.240410404; MOSER TL, 1993, J BIOL CHEM, V268, P18917; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; PACKARD BZ, 1995, BBA-MOL CELL RES, V1269, P51, DOI 10.1016/0167-4889(95)00114-8; Panayi GS, 1999, RHEUMATOLOGY, V38, P8; PARALKAR VM, 1991, DEV BIOL, V143, P303, DOI 10.1016/0012-1606(91)90081-D; Pollock RA, 1992, GROWTH FACTORS, V7, P267, DOI 10.3109/08977199209046409; RAINES EW, 1992, P NATL ACAD SCI USA, V89, P1281, DOI 10.1073/pnas.89.4.1281; RAMSDEN L, 1992, EUR J IMMUNOL, V22, P3027, DOI 10.1002/eji.1830221139; Rees C, 1998, J CELL BIOCHEM, V71, P375, DOI 10.1002/(SICI)1097-4644(19981201)71:3<375::AID-JCB6>3.0.CO;2-M; Roberts AI, 1999, IMMUNOLOGY, V97, P679; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Saharinen J, 1999, CYTOKINE GROWTH F R, V10, P99, DOI 10.1016/S1359-6101(99)00010-6; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Schonherr E, 1998, ARCH BIOCHEM BIOPHYS, V355, P241, DOI 10.1006/abbi.1998.0720; SCHUPPAN D, 1990, J BIOL CHEM, V265, P8823; Schuppan D, 2000, GUT, V47, P12, DOI 10.1136/gut.47.1.12; Schuppan D, 1998, GASTROENTEROLOGY, V114, P139, DOI 10.1016/S0016-5085(98)70642-0; Somasundaram R, 1996, J BIOL CHEM, V271, P26884, DOI 10.1074/jbc.271.43.26884; Streuli C, 1999, CURR OPIN CELL BIOL, V11, P634, DOI 10.1016/S0955-0674(99)00026-5; Taipale J, 1998, ADV CANCER RES, V75, P87, DOI 10.1016/S0065-230X(08)60740-X; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; Tschoetschel U, 1997, INT IMMUNOL, V9, P147, DOI 10.1093/intimm/9.1.147; Vaday GG, 2000, J LEUKOCYTE BIOL, V67, P149, DOI 10.1002/jlb.67.2.149; Van Parijs L, 1999, IMMUNITY, V11, P281, DOI 10.1016/S1074-7613(00)80103-X; WALZOG B, 1995, EXP CELL RES, V218, P28, DOI 10.1006/excr.1995.1127; Wettreich A, 1999, J BIOL CHEM, V274, P31468, DOI 10.1074/jbc.274.44.31468; WONG P, 1995, J BIOL CHEM, V270, P25805, DOI 10.1074/jbc.270.43.25805; Yan Q, 1999, J HISTOCHEM CYTOCHEM, V47, P1495, DOI 10.1177/002215549904701201; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	49	45	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38170	38175		10.1074/jbc.M006616200	http://dx.doi.org/10.1074/jbc.M006616200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10982811	hybrid			2022-12-25	WOS:000165739800007
J	Watanabe, K; Mie, T; Ichihara, A; Oikawa, H; Honma, M				Watanabe, K; Mie, T; Ichihara, A; Oikawa, H; Honma, M			Detailed reaction mechanism of macrophomate synthase - Extraordinary enzyme catalyzing five-step transformation from 2-pyrones to benzoates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIELS-ALDER REACTION; DEHYDROQUINATE SYNTHASE; BIOSYNTHESIS; DECARBOXYLATION; ANTIBIOTICS; OXALACETATE; CATALYSIS; PROBE; NMR	Macrophomate synthase from the fungus Macrophoma commelinae IFO 9570 is a Mg(II)-dependent dimeric enzyme that catalyzes an extraordinary, complex five-step chemical transformation from a-pyrone and oxalacetate to benzoate involving decarboxylation, C-C bond formation, and dehydration. The catalytic mechanism of the whole pathway was investigated in three separate chemical steps. In the first decarboxylation step, the enzyme loses oxalacetate decarboxylation activity upon incubation with EDTA. Activity is fully restored by addition of Mg(II) and is not restored with other divalent metal cations, The dissociation constant of 0.93 x 10(-7) for Mg(II) and atomic absorption analysis established a 1:1 stoichiometric complex, Inhibition of pyruvate formation with 2-pyrone revealed that the actual product in the first step is a pyruvate enolate, which undergoes C-C bond formation in the presence of S-pyrone, Incubation of substrate analogs provided aberrant adducts that were produced via C-C bond formation and rearrangement, This strongly indicates that the second step is two C-C bond formations, affording a bicyclic intermediate, Based on the stereospecificity, involvement of a Diels-Alder reaction at the second step is proposed. Incubation of the stereospecifically deuterium-labeled malate with 2-pyrones in the presence of malate dehydrogenase provided information for the stereochemical course of the reaction catalyzed by macrophomate synthase, indicating that the first decarboxylation provides pyruvate (Z)-[3-H-2]enolate and that dehydration at the final step occurs with anti elimination accompanied by concomitant decarboxylation, Examination of kinetic parameters in the individual steps suggests that the third step is the rate determining step of the overall transformation.	Hokkaido Univ, Grad Sch Agr, Dept Appl Biosci, Kita Ku, Sapporo, Hokkaido 0608589, Japan	Hokkaido University	Oikawa, H (corresponding author), Hokkaido Univ, Grad Sch Agr, Dept Appl Biosci, Kita Ku, Kita 9 Nishi 9, Sapporo, Hokkaido 0608589, Japan.		Watanabe, Kenji/N-2012-2015; Oikawa, Hideaki/F-9128-2012	Watanabe, Kenji/0000-0002-0463-4831; Oikawa, Hideaki/0000-0002-6947-3397				AFARINKIA K, 1992, TETRAHEDRON, V48, P9111, DOI 10.1016/S0040-4020(01)85607-6; Babbitt PC, 1996, BIOCHEMISTRY-US, V35, P16489, DOI 10.1021/bi9616413; BARTLETT PA, 1988, J AM CHEM SOC, V110, P1628, DOI 10.1021/ja00213a049; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BENDER SL, 1989, BIOCHEMISTRY-US, V28, P7560, DOI 10.1021/bi00445a010; BENZIMAN M, 1978, J BACTERIOL, V134, P1; BREWER JM, 1966, J BIOL CHEM, V241, P2550; FUKUSHI Y, 1994, TETRAHEDRON LETT, V35, P599, DOI 10.1016/S0040-4039(00)75848-5; HILVERT D, 1989, J AM CHEM SOC, V111, P9261, DOI 10.1021/ja00208a037; Kudo F, 1999, J ANTIBIOT, V52, P559, DOI 10.7164/antibiotics.52.559; Kudo F, 1999, J ANTIBIOT, V52, P81, DOI 10.7164/antibiotics.52.81; MAGGIO ET, 1975, BIOCHEMISTRY-US, V14, P1131, DOI 10.1021/bi00677a006; OIKAWA H, 1994, J AM CHEM SOC, V116, P3605, DOI 10.1021/ja00087a059; OIKAWA H, 1995, J CHEM SOC CHEM COMM, P1321, DOI 10.1039/c39950001321; Oikawa H, 1999, TETRAHEDRON LETT, V40, P6983, DOI 10.1016/S0040-4039(99)01441-0; Oikawa H., 1997, J CHEM SOC CHEM COMM, P97; PARK SH, 1986, BIOCHEMISTRY-US, V25, P3752, DOI 10.1021/bi00361a004; ROSE IA, 1969, J BIOL CHEM, V244, P6130; SAKURAI I, 1988, CHEM PHARM BULL, V36, P2003; SAKURAI I, 1985, CHEM PHARM BULL, V33, P5141; SAKURAI I, 1988, CHEM PHARM BULL, V36, P1328; SATO H, 1981, AGR BIOL CHEM TOKYO, V45, P1675, DOI 10.1080/00021369.1981.10864745; SATO H, 1981, AGR BIOL CHEM TOKYO, V45, P795, DOI 10.1080/00021369.1981.10864607; SATO H, 1979, AGR BIOL CHEM TOKYO, V43, P2409, DOI 10.1080/00021369.1979.10863831; WALDROP GL, 1994, BIOCHEMISTRY-US, V33, P5262, DOI 10.1021/bi00183a032; Watanabe K, 2000, J BIOCHEM-TOKYO, V127, P467, DOI 10.1093/oxfordjournals.jbchem.a022629; Watanabe K, 2000, BIOSCI BIOTECH BIOCH, V64, P530, DOI 10.1271/bbb.64.530; Watanabe K, 2000, TETRAHEDRON LETT, V41, P1443, DOI 10.1016/S0040-4039(99)02311-4; Xu JA, 1999, SCIENCE, V286, P2345, DOI 10.1126/science.286.5448.2345; YAMADA K, 1962, B CHEM SOC JPN, V35, P1323, DOI 10.1246/bcsj.35.1323	30	74	74	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38393	38401		10.1074/jbc.M003119200	http://dx.doi.org/10.1074/jbc.M003119200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10984474	hybrid			2022-12-25	WOS:000165739800036
J	Ales, E; Gabilan, NH; Cano-Abad, MF; Garcia, AG; Lopez, MG				Ales, E; Gabilan, NH; Cano-Abad, MF; Garcia, AG; Lopez, MG			The sea anemone toxin Bc2 induces continuous or transient exocytosis, in the presence of sustained levels of high cytosolic Ca2+ in chromaffin cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MODEL LIPID-MEMBRANES; MOUSE ADRENAL SLICES; PROTEIN-KINASE-C; ALPHA-LATROTOXIN; EQUINATOXIN-II; NEUROTRANSMITTER RELEASE; STICHODACTYLA-HELIANTHUS; TRANSMITTER RELEASE; QUANTAL RELEASE; ACTINIA-EQUINA	We have isolated and characterized a new excitatory toxin from the venom of the sea anemone Bunodosoma caissarum, named Bc2. We investigated the mechanism of action of the toxin on Ca2+-regulated exocytosis in single bovine adrenal chromaffin cells, monitoring simultaneously fura-a fluorescence measurements and electrochemical recordings using a carbon fiber microelectrode. Bc2 induced quantal release of catecholamines in a calcium-dependent manner. This release was associated with a sustained rise in cytosolic Ca2+ and displayed two different patterns of response: a continuous discharge of prolonged duration that changed to a transient burst as the toxin concentration (Or incubation time) increased. Continuous secretion was dependent on the activity of native voltage-dependent Ca2+ channels and showed a pattern similar to that of alpha -latrotoxin; however, its kinetics adjusted better to that of continuous cell depolarization with high Kf concentration. In contrast, transient secretion was independent of Ca2+ entry through native voltage dependent Ca2+ channels and showed inhibition of late vesicle fusion that was accompanied by "freezing" of F-actin disassembly. These new features make Bc2 a promising new tool for studying the machinery of neurotransmitter release.	Univ Autonoma Madrid, Dept Farmacol, Inst Farmacol Teofilo Hernando, Madrid 28029, Spain; Hosp Princesa, Serv Farmacol Clin, Madrid 28006, Spain; Hosp Princesa, Inst Gerontol, Madrid 28006, Spain; Univ Fed Santa Catarina, Dept Bioquim, BR-88049 Florianopolis, SC, Brazil	Autonomous University of Madrid; Hospital de La Princesa; Hospital de La Princesa; Universidade Federal de Santa Catarina (UFSC)	Ales, E (corresponding author), Univ Autonoma Madrid, Dept Farmacol, Inst Farmacol Teofilo Hernando, C Arzobispo Morcillo 4, Madrid 28029, Spain.		GARCIA, ANTONIO G/E-9961-2018; Lopez, Manuela G/D-2164-2015; Ales, Eva/E-6315-2010	GARCIA, ANTONIO G/0000-0002-6517-3565; Lopez, Manuela G/0000-0003-4461-8788; Ales, Eva/0000-0002-5536-4616; Cano-Abad, Maria F./0000-0002-2602-6626				ALMERS W, 1985, FEBS LETT, V192, P13, DOI 10.1016/0014-5793(85)80033-8; Anderluh G, 1999, EUR J BIOCHEM, V263, P128, DOI 10.1046/j.1432-1327.1999.00477.x; Anderluh G, 2000, J MEMBRANE BIOL, V173, P47, DOI 10.1007/s002320001006; ARTALEJO CR, 1986, BIOCHEM BIOPH RES CO, V134, P1, DOI 10.1016/0006-291X(86)90518-8; BELMONTE G, 1993, J MEMBRANE BIOL, V131, P11, DOI 10.1007/BF02258530; Betz A, 1998, NEURON, V21, P123, DOI 10.1016/S0896-6273(00)80520-6; BURGOYNE RD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P174, DOI 10.1016/0304-4157(91)90024-Q; BURGOYNE RD, 1995, J PHYSIOL PHARMACOL, V46, P273; Chik CL, 1999, ENDOCRINOLOGY, V140, P5682, DOI 10.1210/en.140.12.5682; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; COPOGNA M, 1996, J NEUROPHYSIOL, V76, P3149; Cuchillo-Ibanez I, 1999, FEBS LETT, V459, P22, DOI 10.1016/S0014-5793(99)01115-1; David D, 1998, J CELL BIOL, V143, P1167, DOI 10.1083/jcb.143.5.1167; Davletov BA, 1998, EMBO J, V17, P3909, DOI 10.1093/emboj/17.14.3909; de los Rios V, 1999, FEBS LETT, V455, P27, DOI 10.1016/S0014-5793(99)00846-7; DETOLEDO A, 1993, NATURE, V373, P554; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; Drevensek G, 2000, PFLUG ARCH EUR J PHY, V439, pR150, DOI 10.1007/s004240000126; Frangez R, 2000, PFLUG ARCH EUR J PHY, V439, pR100, DOI 10.1007/s004240000105; GANDFA L, 1993, J PHYSIOL-LONDON, V244, P253; Gil A, 1998, EUR J NEUROSCI, V10, P3369, DOI 10.1046/j.1460-9568.1998.00341.x; GODA Y, 1994, P NATL ACAD SCI USA, V91, P12942, DOI 10.1073/pnas.91.26.12942; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3450; HEINEMANN C, 1993, PFLUG ARCH EUR J PHY, V424, P105, DOI 10.1007/BF00374600; HEINEMANN C, 1994, BIOPHYS J, V70, P1069; HORRIGAN FT, 1994, NEURON, V13, P1119, DOI 10.1016/0896-6273(94)90050-7; HURLBUT WP, 1994, J MEMBRANE BIOL, V138, P91, DOI 10.1007/BF00211072; Katz B., 1969, RELEASE NEURAL TRANS; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; Liu J, 1998, J NEUROSCI, V18, P6113; Liu J, 1998, BRAIN RES, V799, P55, DOI 10.1016/S0006-8993(98)00467-3; LIVETT BG, 1984, PHYSIOL REV, V64, P1103, DOI 10.1152/physrev.1984.64.4.1103; MACEK P, 1994, TOXICOLOGY, V87, P205, DOI 10.1016/0300-483X(94)90252-6; Malovrh P, 2000, BIOCHEM J, V346, P223, DOI 10.1042/0264-6021:3460223; Martin-Benito J, 2000, BIOPHYS J, V78, P3186, DOI 10.1016/S0006-3495(00)76855-X; MELDOLESI J, 1984, P NATL ACAD SCI-BIOL, V81, P620, DOI 10.1073/pnas.81.2.620; Menestrina G, 1999, BIOCHEM BIOPH RES CO, V254, P174, DOI 10.1006/bbrc.1998.9898; Meunier FA, 2000, TOXICON, V38, P1547, DOI 10.1016/S0041-0101(00)00088-X; MICHELENA P, 1993, P NATL ACAD SCI USA, V90, P3284, DOI 10.1073/pnas.90.8.3284; Michelena P, 1997, J PHYSIOL-LONDON, V502, P481, DOI 10.1111/j.1469-7793.1997.481bj.x; Migues PV, 1999, NEUROREPORT, V10, P67, DOI 10.1097/00001756-199901180-00013; MOLLAY C, 1976, FEBS LETT, V64, P65, DOI 10.1016/0014-5793(76)80250-5; Montero M, 2000, NAT CELL BIOL, V2, P57, DOI 10.1038/35000001; MORO MA, 1990, ANAL BIOCHEM, V185, P243, DOI 10.1016/0003-2697(90)90287-J; Moser T, 1997, J NEUROSCI, V17, P2314; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; Neher E, 1998, NEURON, V20, P389, DOI 10.1016/S0896-6273(00)80983-6; NICHOLLS DG, 1982, P NATL ACAD SCI-BIOL, V79, P7924, DOI 10.1073/pnas.79.24.7924; PARSONS TD, 1995, NEURON, V15, P1085, DOI 10.1016/0896-6273(95)90097-7; Plattner H, 1997, J CELL BIOL, V139, P1709, DOI 10.1083/jcb.139.7.1709; Poklar N, 1999, BIOCHEMISTRY-US, V38, P14999, DOI 10.1021/bi9916022; RAYA SA, 1994, NAT TOXINS, V1, P263; ROSARIO LM, 1989, NEUROSCIENCE, V29, P735, DOI 10.1016/0306-4522(89)90145-0; ROSENTHAL L, 1990, MOL PHARMACOL, V38, P917; ROSENTHAL L, 1989, PHARMACOL THERAPEUT, V42, P115, DOI 10.1016/0163-7258(89)90024-7; Sakaba T, 1997, NEUROSCI RES, V27, P357, DOI 10.1016/S0168-0102(97)01168-1; SARAFIAN T, 1991, J CELL BIOL, V114, P1135, DOI 10.1083/jcb.114.6.1135; Smith C, 1998, NEURON, V20, P1243, DOI 10.1016/S0896-6273(00)80504-8; Steyer JA, 1997, NATURE, V388, P474, DOI 10.1038/41329; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sullivan R, 1999, J BIOL CHEM, V274, P38140, DOI 10.1074/jbc.274.53.38140; Tejuca M, 1996, BIOCHEMISTRY-US, V35, P14947, DOI 10.1021/bi960787z; THELESTAM M, 1988, TOXICON, V26, P51, DOI 10.1016/0041-0101(88)90137-7; THOMAS P, 1993, NEURON, V11, P93, DOI 10.1016/0896-6273(93)90274-U; VITALE ML, 1991, J CELL BIOL, V113, P1057, DOI 10.1083/jcb.113.5.1057; VITALE ML, 1995, NEURON, V14, P353, DOI 10.1016/0896-6273(95)90291-0; Voets T, 1999, NEURON, V23, P607, DOI 10.1016/S0896-6273(00)80812-0; Xu T, 1998, NAT NEUROSCI, V1, P192, DOI 10.1038/642; YOUNES A, 1992, J BIOL CHEM, V267, P842; ZOREC R, 1990, J MEMBRANE BIOL, V118, P243, DOI 10.1007/BF01868608	70	16	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37488	37495		10.1074/jbc.M007388200	http://dx.doi.org/10.1074/jbc.M007388200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10980205	hybrid			2022-12-25	WOS:000165618700027
J	Bendahan, A; Armon, A; Madani, N; Kavanaugh, MP; Kanner, BI				Bendahan, A; Armon, A; Madani, N; Kavanaugh, MP; Kanner, BI			Arginine 447 plays a pivotal role in substrate interactions in a neuronal glutamate transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTER; RAT-BRAIN; ESCHERICHIA-COLI; FUNCTIONAL-CHARACTERIZATION; MEMBRANE-VESICLES; LIGAND-BINDING; HIGH-AFFINITY; EXPRESSION; CLONING; GLT-1	Glutamate transporters from the central nervous system play a crucial role in the clearance of the transmitter from the synaptic cleft. Glutamate is cotransported with sodium ions, and the electrogenic translocation cycle is completed by countertransport of potassium. Mutants that cannot interact with potassium are only capable of catalyzing electroneutral exchange. Here we identify a residue involved in controlling substrate recognition in the neuronal transporter EAAC-1 that transports acidic amino acids as well as cysteine, When arginine 447, a residue conserved in all glutamate transporters, is replaced by cysteine, transport of glutamate or aspartate is abolished, but sodium-dependent cysteine transport is left intact. Analysis of other substitution mutants shows that the replacement of arginine rather than the introduced cysteine is responsible for the observed phenotype, In further contrast to wild type, acidic amino acids are unable to inhibit cysteine transport in R447C-EAAC-1, indicating that the selectivity change is manifested at the binding step, Electrophysiological analysis shows that in the mutant cysteine, transport has become electroneutral, and its interaction with the countertransported potassium is impaired. Thus arginine 447 plays a pivotal role in the sequential interaction of acidic amino acids and potassium with the transporter and, thereby, constitutes one of the molecular determinants of coupling their fluxes.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel; Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97201 USA	Hebrew University of Jerusalem; Oregon Health & Science University	Kanner, BI (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel.	kannerb@cc.huji.ac.il						Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; CONRADT M, 1995, J BIOL CHEM, V270, P25207, DOI 10.1074/jbc.270.42.25207; DANBOLT NC, 1992, NEUROSCIENCE, V51, P295, DOI 10.1016/0306-4522(92)90316-T; DANBOLT NC, 1990, BIOCHEMISTRY-US, V29, P6734, DOI 10.1021/bi00480a025; Diamond JS, 1997, J NEUROSCI, V17, P4672; Edgar R, 1999, EMBO J, V18, P822, DOI 10.1093/emboj/18.4.822; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Grunewald M, 1998, NEURON, V21, P623, DOI 10.1016/S0896-6273(00)80572-3; Grunewald M, 2000, J BIOL CHEM, V275, P9684, DOI 10.1074/jbc.275.13.9684; HAMA H, 1993, J BIOL CHEM, V268, P10060; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KANNER BI, 1982, BIOCHEMISTRY-US, V21, P6327, DOI 10.1021/bi00267a044; Kavanaugh MP, 1997, J BIOL CHEM, V272, P1703, DOI 10.1074/jbc.272.3.1703; Kekuda R, 1996, J BIOL CHEM, V271, P18657, DOI 10.1074/jbc.271.31.18657; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MENNERICK S, 1994, NATURE, V368, P59, DOI 10.1038/368059a0; Muth TR, 2000, EMBO J, V19, P234, DOI 10.1093/emboj/19.2.234; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; Ogawa W, 1998, J BACTERIOL, V180, P6749, DOI 10.1128/JB.180.24.6749-6752.1998; Otis TS, 1996, J NEUROSCI, V16, P1634, DOI 10.1523/jneurosci.16-05-01634.1996; PINES G, 1995, J BIOL CHEM, V270, P17093, DOI 10.1074/jbc.270.29.17093; PINES G, 1990, BIOCHEMISTRY-US, V29, P11209, DOI 10.1021/bi00503a008; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Seal RP, 2000, NEURON, V25, P695, DOI 10.1016/S0896-6273(00)81071-5; SHAFQAT S, 1993, J BIOL CHEM, V268, P15351; Slotboom DJ, 1999, P NATL ACAD SCI USA, V96, P14282, DOI 10.1073/pnas.96.25.14282; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; Sun JZ, 1998, BIOCHEMISTRY-US, V37, P8020, DOI 10.1021/bi973192s; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; TONG G, 1994, NEURON, V13, P1195, DOI 10.1016/0896-6273(94)90057-4; UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883, DOI 10.1074/jbc.271.25.14883; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; Yerushalmi H, 2000, J BIOL CHEM, V275, P5264, DOI 10.1074/jbc.275.8.5264; Zarbiv R, 1998, J BIOL CHEM, V273, P14231, DOI 10.1074/jbc.273.23.14231; Zerangue N, 1996, J BIOL CHEM, V271, P27991, DOI 10.1074/jbc.271.45.27991; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0; Zerangue N, 1996, J PHYSIOL-LONDON, V493, P419, DOI 10.1113/jphysiol.1996.sp021393; Zhang YM, 1999, P NATL ACAD SCI USA, V96, P1710, DOI 10.1073/pnas.96.4.1710; Zhang YM, 1998, P NATL ACAD SCI USA, V95, P751, DOI 10.1073/pnas.95.2.751	49	131	132	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37436	37442		10.1074/jbc.M006536200	http://dx.doi.org/10.1074/jbc.M006536200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10978338	Green Published, hybrid			2022-12-25	WOS:000165618700019
J	Galbiati, F; Volonte, D; Minetti, C; Bregman, DB; Lisanti, MP				Galbiati, F; Volonte, D; Minetti, C; Bregman, DB; Lisanti, MP			Limb-girdle muscular dystrophy (LGMD-1C) mutants of caveolin-3 undergo ubiquitination and proteasomal degradation - Treatment with proteasomal inhibitors blocks the dominant negative effect of LGMD-1C mutants and rescues wild-type caveolin-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICH MEMBRANE DOMAINS; NITRIC-OXIDE SYNTHASE; ROUS-SARCOMA VIRUS; RNA-POLYMERASE-II; PLASMA-MEMBRANE; GENE FAMILY; SMOOTH-MUSCLE; SUBCELLULAR-DISTRIBUTION; INTEGRAL COMPONENT; TRANSPORT VESICLES	Caveolin-3 is the principal structural protein of caveolae in striated muscle. Autosomal dominant limb-girdle muscular dystrophy (LGMD-1C) in humans is due to mutations (Delta TFT and Pro --> Leu) within the CAV3 gene. We have shown that LGMD-1C mutations lead to formation of unstable aggregates of caveolin-3 that are retained intracellularly and are rapidly degraded. The mechanism by which LGMD-1C mutants of caveolin-3 are degraded remains unknown. Here, we show that LGMD-1C mutants of caveolin-3 undergo ubiquitination-proteasomal degradation. Treatment with proteasomal inhibitors (MG-132, MG-115, lactacystin, or proteasome inhibitor I), but not lysosomal inhibitors, prevented degradation of LGMD-1C caveolin-3 mutants. In the presence of MG-132, LGMD-1C caveolin-3 mutants accumulated within the endoplasmic reticulum and did not reach the plasma membrane. LGMD-1C mutants of caveolin-3 behave in a dominant negative fashion, causing intracellular retention and degradation of wild-type caveolin-3, Interestingly, in cells co-expressing wildtype and mutant forms of caveolin-3, MG-132 treatment rescued wild-type caveolin-3; wild-type caveolin-3 was not degraded and reached the plasma membrane. These results may have clinical implications for treatment of patients with LGMD-1C.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; Univ Genoa, Ist Giannina Gaslini, Serv Malattie Neuro Muscolari, I-16147 Genoa, Italy; Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Genoa; IRCCS Istituto Giannina Gaslini; Yeshiva University; Albert Einstein College of Medicine	Lisanti, MP (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	lisanti@aecom.yu.edu	Minetti, Carlo/K-4666-2018; Lisanti, Michael/B-6131-2018; Galbiati, Ferruccio/AAF-3527-2020; Lisanti, Michael P/C-6866-2013	Minetti, Carlo/0000-0002-0640-1804; Lisanti, Michael/0000-0003-2034-1382; 	Telethon [1111] Funding Source: Medline	Telethon(Fondazione Telethon)		Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; BONILLA E, 1981, AM J PATHOL, V104, P167; Bregman DB, 1996, P NATL ACAD SCI USA, V93, P11586, DOI 10.1073/pnas.93.21.11586; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CORLEYMASTICK C, 1995, J CELL BIOL, V129, P1523; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Crosbie RH, 1998, FEBS LETT, V427, P279, DOI 10.1016/S0014-5793(98)00442-6; Engelman JA, 1998, AM J HUM GENET, V63, P1578, DOI 10.1086/302172; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; Galbiati F, 1999, J BIOL CHEM, V274, P25632, DOI 10.1074/jbc.274.36.25632; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; Herrmann JM, 1999, TRENDS CELL BIOL, V9, P5, DOI 10.1016/S0962-8924(98)01414-7; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Kagan A, 2000, J BIOL CHEM, V275, P11241, DOI 10.1074/jbc.275.15.11241; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Minetti C, 1998, NAT GENET, V18, P365, DOI 10.1038/ng0498-365; MOLDOVAN NI, 1995, EXP CELL RES, V219, P309, DOI 10.1006/excr.1995.1233; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; NORTH AJ, 1993, J CELL BIOL, V120, P1159, DOI 10.1083/jcb.120.5.1159; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; Ratner JN, 1998, J BIOL CHEM, V273, P5184, DOI 10.1074/jbc.273.9.5184; Razani B, 2000, J CELL SCI, V113, P2103; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SARGIACOMO M, 1994, ONCOGENE, V9, P2589; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; SEVERS NJ, 1988, J CELL SCI, V90, P341; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SIFERS RN, 1995, NAT STRUCT BIOL, V2, P355, DOI 10.1038/nsb0595-355; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Song KS, 1997, J BIOL CHEM, V272, P4398, DOI 10.1074/jbc.272.7.4398; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Tang ZL, 1997, J BIOL CHEM, V272, P2437, DOI 10.1074/jbc.272.4.2437; THOMAS PJ, 1992, FEBS LETT, V312, P7, DOI 10.1016/0014-5793(92)81399-7; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Volonte D, 1999, FEBS LETT, V445, P431, DOI 10.1016/S0014-5793(99)00164-7; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Welihinda AA, 1999, GENE EXPRESSION, V7, P293	65	81	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37702	37711		10.1074/jbc.M006657200	http://dx.doi.org/10.1074/jbc.M006657200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10973975	hybrid			2022-12-25	WOS:000165618700055
J	Liapakis, G; Ballesteros, JA; Papachristou, S; Chan, WC; Chen, X; Javitch, JA				Liapakis, G; Ballesteros, JA; Papachristou, S; Chan, WC; Chen, X; Javitch, JA			The forgotten serine - A critical role for Ser-203(5.42) in ligand binding to and activation of the beta(2)-adrenergic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2) ADRENERGIC-RECEPTOR; SITE-DIRECTED MUTAGENESIS; CONSTITUTIVE ACTIVATION; DOPAMINE-RECEPTOR; AGONIST BINDING; AMINO-ACIDS; RESIDUES; IDENTIFICATION; MECHANISM; SEGMENT	Previous work in the beta (2)-adrenergic receptor demonstrated critical interactions between Ser-204 and Ser-207 in the fifth membrane-spanning segment and the meta-OH and para-Os, respectively, of catecholamine agonists (Strader, C. D., Candelore, M, R., Hill, W. S., Sigal, I. S., and Dixon, R, A. (1989) J. Biol. Chem. 264, 13572-13578). Using the substituted cysteine accessibility method in the beta (2)-adrenergic receptor, we have found that in addition to Ser-204 and Ser-207, Ser-203 is also accessible on the surface of the binding-site crevice and is occluded by bound agonist. Mutation of Ser-203 to Ala, Val, or Cys reduced the binding affinity and adenylyl cyclase-activating potency of agonists containing a meta-OH, whereas their affinities and potencies were largely preserved by mutation of Ser-203 to Thr, which maintained an OH at this position. Thus both Ser-203 and Ser-204 appear to interact with the meta-OH of catecholamines, perhaps through a bifurcated H bond. Furthermore, the removal of the OH at position 203 led to a significant loss of affinity of antagonists with nitrogen in their heterocyclic ring structure. The greatest effect was seen with pindolol, a partial agonist, suggesting that a H bond between the heterocyclic ring and Ser-203 may play a role in partial agonism. In contrast, the affinities of antagonists such as propranolol or alprenolol, which have cyclic structures without H-bonding capability, were unaltered after mutation of Ser-203.	Columbia Univ Coll Phys & Surg, Ctr Mol Recognit, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA; New York State Psychiat Inst & Hosp, New York, NY 10032 USA; CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA	Columbia University; Columbia University; Columbia University; New York State Psychiatry Institute; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Javitch, JA (corresponding author), Columbia Univ Coll Phys & Surg, Ctr Mol Recognit, 630 W 168th St,P&S 11-401, New York, NY 10032 USA.	jaj2@columbia.edu		Javitch, Jonathan/0000-0001-7395-2967	NIMH NIH HHS [MH57324, MH54137] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH054137] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Ambrosio C, 2000, MOL PHARMACOL, V57, P198; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; BALLESTEROS JA, 2000, IN PRESS BIOPHYS J; BELLEAU B, 1969, BIOCHEM PHARMACOL, V18, P1039, DOI 10.1016/0006-2952(69)90107-5; Cavalli A, 1996, FEBS LETT, V399, P9, DOI 10.1016/S0014-5793(96)01286-0; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; COX BA, 1992, J NEUROCHEM, V59, P627, DOI 10.1111/j.1471-4159.1992.tb09416.x; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; GRAY TM, 1984, J MOL BIOL, V175, P75, DOI 10.1016/0022-2836(84)90446-7; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; HO BY, 1992, FEBS LETT, V312, P259, DOI 10.1016/0014-5793(92)80948-G; Hwa J, 1996, J BIOL CHEM, V271, P6322, DOI 10.1074/jbc.271.11.6322; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; Javitch JA, 1995, BIOCHEMISTRY-US, V34, P16433, DOI 10.1021/bi00050a026; JAVITCH JA, 1999, REC BIOCH M, P21; KOBILKA BK, 1995, ANAL BIOCHEM, V231, P269, DOI 10.1006/abio.1995.1533; NEVE KA, 1986, MOL PHARMACOL, V30, P104; NORDSTEDT C, 1990, ANAL BIOCHEM, V189, P231, DOI 10.1016/0003-2697(90)90113-N; POLLOCK NJ, 1992, J BIOL CHEM, V267, P17780; PREISSNER R, 1991, FEBS LETT, V288, P192, DOI 10.1016/0014-5793(91)81032-4; Rasmussen SGF, 1999, MOL PHARMACOL, V56, P175, DOI 10.1124/mol.56.1.175; Rees S, 1996, BIOTECHNIQUES, V20, P102; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; Rudling JE, 1999, BRIT J PHARMACOL, V127, P877, DOI 10.1038/sj.bjp.0702614; Sartania N, 1999, J NEUROCHEM, V72, P2621, DOI 10.1046/j.1471-4159.1999.0722621.x; STRADER CD, 1991, J BIOL CHEM, V266, P5; STRADER CD, 1989, J BIOL CHEM, V264, P13572; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; WANG CD, 1991, MOL PHARMACOL, V40, P168; Watts VJ, 1998, J NEUROSCI, V18, P8692; Wiens BL, 1998, MOL PHARMACOL, V54, P435, DOI 10.1124/mol.54.2.435; Woodward R, 1996, J NEUROCHEM, V66, P394, DOI 10.1046/j.1471-4159.1996.66010394.x	34	161	165	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37779	37788		10.1074/jbc.M002092200	http://dx.doi.org/10.1074/jbc.M002092200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10964911	hybrid			2022-12-25	WOS:000165618700065
J	Meyer, RK; Lustig, A; Oesch, B; Fatzer, R; Zurbriggen, A; Vandevelde, M				Meyer, RK; Lustig, A; Oesch, B; Fatzer, R; Zurbriggen, A; Vandevelde, M			A monomer-dimer equilibrium of a cellular prion protein (PrPC) not observed with recombinant PrP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB-DISEASE; SCRAPIE PRION; N-TERMINUS; FORM; BINDING; ISOFORM; GENE; PURIFICATION; INFECTIVITY; PROPAGATION	Both the purified normal (protease-sensitive) isoform of the prion protein (PrPC) (Pergami, P., Jaffe, Il., and Safar, J. (1996) Anal. Biochem. 236, 63-73) and recombinant prion protein (PrP) have been found to be in monomeric form (Mehlhorn, I., Groth, D., Stockel, J., Moffat, B., Reilly, D., Yansura, D., Willet, W. S., Baldwin, Ri., Fletterick, R., Cohen, F. E., Vandlen, R., Henner, D., and Prusiner, S. B. (1996) Biochemistry 35, 5528-5537; and this paper), and therefore PrPC-PrPC interactions were previously unknown. In this report we confirm recombinant PrP to be a monomer by analytical ultracentrifugation. However, by three lines of evidence (enzyme-linked immunosorbent assay (ELISA), cross-linking experiments, and size exclusion chromatography) we could also demonstrate that, under native conditions, at least part of the native bovine PrPC exists as a monomer-dimer equilibrium. A bovine PrPC-specific immunosandwich ELISA was developed and calibrated with recombinant PrP (Meyer, R. It., Oesch, B., Fatter, R., Zurbriggen, A., and Vandevelde, M. (1999) J. Virol. 73, 9386-9392). By this ELISA we identified a distinct PrPC fraction and partially purified this protein. When serial dilutions of brain homogenate or partially purified PrPC were measured, using the peptide antibody C15S, a nonlinear dose-response curve was obtained. This nonlinearity was shown not to be due to an artifact of the procedure but to a monomer-dimer equilibrium of PrPC with preferential binding of the antibody to the dimer. From the curvature we could deduce the association constant (3.9 x 10(8) M-1 at 37 degreesC). Accordingly, DeltaG degrees of the reaction was calculated (-48.6 kJ M-1), and DeltaH degrees (9.5 kJ M-1) as well as DeltaS degrees (0.2 kJ K-1 M-1) were extrapolated from the van't Hoff plot. When serial dilutions of monomeric recombinant PrP were tested, only a straight line was obtained, supporting our hypothesis. Additional evidence of dimer formation was revealed by Western blotting of partially purified PrPC cross-linked by the homobifunctional cross-linker BS3. Finally, size exclusion chromatography of partially purified PrPC fractions revealed an additional shoulder not observed with recombinant PrP. The difference in respect of dimer formation between native PrPC and recombinant PrP could be explained by the lack of glycosylation of the latter.	Univ Bern, Inst Anim Neurol, TSE Reference Ctr, CH-3012 Bern, Switzerland; Univ Basel, Bioctr, CH-4056 Basel, Switzerland; Univ Zurich, Prionics Ltd, CH-8057 Zurich, Switzerland	University of Bern; University of Basel; University of Zurich	Meyer, RK (corresponding author), Univ Bern, Inst Anim Neurol, TSE Reference Ctr, Bremgartenstr 109A, CH-3012 Bern, Switzerland.							Aguzzi A, 1997, NATURE, V389, P795, DOI 10.1038/39758; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BOLTON DC, 1985, J VIROL, V53, P596, DOI 10.1128/JVI.53.2.596-606.1985; BORCHELT DR, 1993, GLYCOBIOLOGY, V3, P319, DOI 10.1093/glycob/3.4.319; BORCHELT DR, 1990, J CELL BIOL, V110, P754; Brown DR, 1999, BIOCHEM J, V344, P1, DOI 10.1042/0264-6021:3440001; BROWN P, 1982, J INFECT DIS, V145, P683, DOI 10.1093/infdis/145.2.683; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; GABIZON R, 1993, AM J HUM GENET, V53, P828; GOLDMANN W, 1991, J GEN VIROL, V72, P201, DOI 10.1099/0022-1317-72-1-201; HARAGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V274, P1, DOI 10.1016/0003-9861(89)90409-8; HAY B, 1987, BIOCHEMISTRY-US, V26, P8110, DOI 10.1021/bi00399a014; Horiuchi M, 1999, EMBO J, V18, P3193, DOI 10.1093/emboj/18.12.3193; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; KANEKO K, 1995, P NATL ACAD SCI USA, V92, P11160, DOI 10.1073/pnas.92.24.11160; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Korth C, 1997, NATURE, V390, P74, DOI 10.1038/36337; LUGARESI E, 1986, NEW ENGL J MED, V315, P997, DOI 10.1056/NEJM198610163151605; Mehlhorn I, 1996, BIOCHEMISTRY-US, V35, P5528, DOI 10.1021/bi952965e; Meyer RK, 1999, J VIROL, V73, P9386, DOI 10.1128/JVI.73.11.9386-9392.1999; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; Morillas M, 1999, J BIOL CHEM, V274, P36859, DOI 10.1074/jbc.274.52.36859; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PAN KM, 1992, PROTEIN SCI, V1, P1343, DOI 10.1002/pro.5560011014; Peretz D, 1997, J MOL BIOL, V273, P614, DOI 10.1006/jmbi.1997.1328; Pergami P, 1996, ANAL BIOCHEM, V236, P63, DOI 10.1006/abio.1996.0132; PRIOLA SA, 1995, J BIOL CHEM, V270, P3299, DOI 10.1074/jbc.270.7.3299; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1984, CELL, V38, P127, DOI 10.1016/0092-8674(84)90533-6; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Prusiner SB, 1998, BRAIN PATHOL, V8, P499; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; ROGERS M, 1990, Glycobiology, V1, P101, DOI 10.1093/glycob/1.1.101; SAFAR J, 1993, PROTEIN SCI, V2, P2206, DOI 10.1002/pro.5560021220; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; TAGLIAVINI F, 1992, BIOCHEM BIOPH RES CO, V184, P1398, DOI 10.1016/S0006-291X(05)80038-5; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Viles JH, 1999, P NATL ACAD SCI USA, V96, P2042, DOI 10.1073/pnas.96.5.2042	43	78	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					38081	38087		10.1074/jbc.M007114200	http://dx.doi.org/10.1074/jbc.M007114200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10967124	hybrid			2022-12-25	WOS:000165618700103
J	Patel, CV; Handy, I; Goldsmith, T; Patel, RC				Patel, CV; Handy, I; Goldsmith, T; Patel, RC			PACT, a stress-modulated cellular activator of interferon-induced double-stranded RNA-activated protein kinase, PKR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; EUKARYOTIC TRANSLATION INITIATION-FACTOR-2; DEPENDENT EIF-2-ALPHA KINASE; TUMOR-SUPPRESSOR P53; U937 CELLS; INDUCED APOPTOSIS; BINDING DOMAIN; SUBUNIT; PATHWAY; DEATH	The interferon (IFN)-induced, double-stranded (ds)RNA-activated serine-threonine protein kinase, PKR, is a key mediator of the antiviral activities of IFNs. In addition, PKR activity is also involved in regulation of cell proliferation, apoptosis, and signal transduction. In virally infected cells, dsRNA has been shown to bind and activate PKR kinase function. Implication of PKR activity in normal cellular processes has invoked activators other than dsRNA because RNAs with perfectly duplexed regions of sufficient length that are able to activate PKR are absent in cellular RNAs. We have recently reported cloning of PACT, a novel protein activator of PKR. PACT heterodimerizes with PKR and activates it by direct protein-protein interaction. Overexpression of PACT in mammalian cells leads to phosphorylation of the alpha subunit of the eukaryotic initiation factor 2 (eIF2 alpha), the cellular substrate for PKR, and leads to inhibition of protein synthesis. Here, we present evidence that endogenous PACT acts as a protein activator of PKR in response to diverse stress signals such as serum starvation, and peroxide or arsenite treatment. Following exposure of cells to these stress agents, PACT is phosphorylated and associates with PKR with increased affinity. PACT-mediated activation of PKR leads to enhanced eIF2 alpha phosphorylation followed by apoptosis. Based on the results presented here, we propose that PACT is a novel stress-modulated physiological activator of PKR.	Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Patel, RC (corresponding author), Univ S Carolina, Dept Biol Sci, 700 Sumter St, Columbia, SC 29208 USA.		Patel, Rekha/M-7123-2015	Patel, Rekha/0000-0001-9434-4880				Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; BARBER GN, 1991, BIOCHEMISTRY-US, V30, P10356, DOI 10.1021/bi00106a038; Berlanga JJ, 1999, EUR J BIOCHEM, V265, P754, DOI 10.1046/j.1432-1327.1999.00780.x; Brostrom CO, 1998, PROG NUCLEIC ACID RE, V58, P79; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; COLTHURST DR, 1987, EUR J BIOCHEM, V166, P357, DOI 10.1111/j.1432-1033.1987.tb13523.x; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; Dever TE, 1999, TRENDS BIOCHEM SCI, V24, P398, DOI 10.1016/S0968-0004(99)01457-7; Fierro-Monti I, 2000, TRENDS BIOCHEM SCI, V25, P241, DOI 10.1016/S0968-0004(00)01580-2; Gil J, 2000, ONCOGENE, V19, P1369, DOI 10.1038/sj.onc.1203448; Gil J, 1999, MOL CELL BIOL, V19, P4653; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; JUDWARE R, 1991, MOL CELL BIOL, V11, P3259, DOI 10.1128/MCB.11.6.3259; Katze Michael G., 1995, Trends in Microbiology, V3, P75, DOI 10.1016/S0966-842X(00)88880-0; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; Kibler KV, 1997, J VIROL, V71, P1992, DOI 10.1128/JVI.71.3.1992-2003.1997; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Lee SB, 1997, VIROLOGY, V231, P81, DOI 10.1006/viro.1997.8494; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MONTINE KS, 1989, BIOCHIM BIOPHYS ACTA, V1014, P282, DOI 10.1016/0167-4889(89)90224-3; PATEL RC, 1992, J BIOL CHEM, V267, P7671; PATEL RC, 1994, J BIOL CHEM, V269, P18593; PATEL RC, 1995, P NATL ACAD SCI USA, V92, P8283, DOI 10.1073/pnas.92.18.8283; Patel RC, 1998, MOL CELL BIOL, V18, P7009, DOI 10.1128/MCB.18.12.7009; Patel RC, 1996, J BIOL CHEM, V271, P25657, DOI 10.1074/jbc.271.41.25657; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; Ramana CV, 2000, EMBO J, V19, P263, DOI 10.1093/emboj/19.2.263; SALZBERG S, 1995, EXP CELL RES, V219, P223, DOI 10.1006/excr.1995.1222; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; WILLIAMS BRG, 1995, SEMIN VIROL, V6, P191, DOI 10.1006/smvy.1995.0024; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Yeung MC, 1999, P NATL ACAD SCI USA, V96, P11860, DOI 10.1073/pnas.96.21.11860; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451; Yeung MC, 1998, J BIOL CHEM, V273, P25198, DOI 10.1074/jbc.273.39.25198	49	188	193	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37993	37998		10.1074/jbc.M004762200	http://dx.doi.org/10.1074/jbc.M004762200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10988289	hybrid			2022-12-25	WOS:000165618700092
J	Pulvermuller, A; Schroder, K; Fischer, T; Hofmann, KP				Pulvermuller, A; Schroder, K; Fischer, T; Hofmann, KP			Interactions of metarhodopsin II - Arrestin peptides compete with arrestin and transducin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; VISUAL ARRESTIN; G-PROTEIN; PHOSPHORYLATED RHODOPSIN; CRYSTAL-STRUCTURE; BINDING-PROTEIN; 48-KDA PROTEIN; KINETICS; COMPLEX; REGENERATION	Arrestin blocks the interaction of rhodopsin with the G protein transducin (G(t)). To characterize the sites of arrestin that interact with rhodopsin, we have utilized a spectrophotometric peptide competition assay. It is based on the stabilization of the active intermediates metarhodopsin II (MII) and phosphorylated MII by G(t) and arrestin, respectively (extra MII monitor). The protocol involves native disc membranes and three sets of peptides 10-30 amino acids in length spanning the arrestin sequence, In the absence of arrestin, not one of the peptides by itself had an effect on the amount of MII formed. However, inhibition of arrestin-dependent extra MII was found for the peptides at residues 11-30 and 51-70 (IC50 < 100 <mu>M) and residues 231-260 (IC50 < 200 <mu>M) A similar pattern of inhibition by arrestin peptides was seen when arrestin was replaced by G(t) or the farnesylated G(t)gamma C-terminal peptide. Only arrestin-(11-30) inhibited MII.G(t) less (IC50 = 300 muM) than phosphorylated MII.arrestin. We interpreted the data by competition of the arrestin peptides for interaction sites at rhodopsin, exposed in the MPI conformation and specific for both arrestin and G(t). The arrestin sites are located in both the C- and N-terminal domains of the arrestin structure.	Humboldt Univ, Klinikum Charite, Inst Med Phys & Biophys, D-10098 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Pulvermuller, A (corresponding author), Humboldt Univ, Klinikum Charite, Inst Med Phys & Biophys, Schumannstr 20-21, D-10098 Berlin, Germany.							BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; Bartl F, 2000, FEBS LETT, V473, P259, DOI 10.1016/S0014-5793(00)01544-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRAFT CM, 1995, FEBS LETT, V362, P247, DOI 10.1016/0014-5793(95)00213-S; Ernst OP, 2000, METHOD ENZYMOL, V315, P471; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; Gibson SK, 2000, BIOCHEMISTRY-US, V39, P5738, DOI 10.1021/bi991857f; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; GrayKeller MP, 1997, BIOCHEMISTRY-US, V36, P7058, DOI 10.1021/bi963110k; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; GUREVICH VV, 1994, J BIOL CHEM, V269, P8721; Gurevich VV, 1997, MOL PHARMACOL, V51, P161, DOI 10.1124/mol.51.1.161; GUREVICH VV, 1995, J BIOL CHEM, V270, P6010, DOI 10.1074/jbc.270.11.6010; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; Heck M, 2000, METHOD ENZYMOL, V315, P329; HECK M, 1993, BIOCHEMISTRY-US, V32, P8220, DOI 10.1021/bi00083a024; Helmreich EJM, 1996, BBA-REV BIOMEMBRANES, V1286, P285, DOI 10.1016/S0304-4157(96)00013-5; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; HOFMANN KP, 1992, J BIOL CHEM, V267, P15701; HOFMANN LP, 1985, BIOCHIM BIOPHYS ACTA, V810, P278; Kisselev OG, 1999, P NATL ACAD SCI USA, V96, P4898, DOI 10.1073/pnas.96.9.4898; KRUPNICK JG, 1994, J BIOL CHEM, V269, P3226; KUHN H, 1982, METHOD ENZYMOL, V81, P556; OHGURO H, 1994, PROTEIN SCI, V3, P2428, DOI 10.1002/pro.5560031226; PALCZEWSKI K, 1994, PROTEIN SCI, V3, P314; PALCZEWSKI K, 1992, BIOCHEMISTRY-US, V31, P3902, DOI 10.1021/bi00131a003; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P18649; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P15334; Palczewski K, 1999, BIOCHEMISTRY-US, V38, P12012, DOI 10.1021/bi990504d; Palczewski K, 1997, EUR J BIOCHEM, V248, P261, DOI 10.1111/j.1432-1033.1997.00261.x; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; Parkes JH, 1999, BIOCHEMISTRY-US, V38, P6862, DOI 10.1021/bi9827666; PUIG J, 1995, FEBS LETT, V362, P185, DOI 10.1016/0014-5793(95)00225-X; PULVERMULLER A, 1993, BIOCHEMISTRY-US, V32, P14082, DOI 10.1021/bi00214a002; Pulvermuller A, 1997, BIOCHEMISTRY-US, V36, P9253, DOI 10.1021/bi970772g; Sachs K, 2000, METHOD ENZYMOL, V315, P238; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; Smith WC, 1999, BIOCHEMISTRY-US, V38, P2752, DOI 10.1021/bi982643l; Vishnivetskiy SK, 1999, J BIOL CHEM, V274, P11451, DOI 10.1074/jbc.274.17.11451; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; Wilson CJ, 1997, J PROTEIN CHEM, V16, P755, DOI 10.1023/A:1026311832660; Xu J, 1997, NATURE, V389, P505, DOI 10.1038/39068	46	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37679	37685		10.1074/jbc.M006776200	http://dx.doi.org/10.1074/jbc.M006776200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10969086	hybrid			2022-12-25	WOS:000165618700052
J	Scherer, SJ; Maier, SM; Seifert, M; Hanselmann, RG; Zang, KD; Muller-Hermelink, HK; Angel, P; Welter, C; Schartl, M				Scherer, SJ; Maier, SM; Seifert, M; Hanselmann, RG; Zang, KD; Muller-Hermelink, HK; Angel, P; Welter, C; Schartl, M			p53 and c-Jun functionally synergize in the regulation of the DNA repair gene hMSH2 in response to UV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; HUMAN MISMATCH REPAIR; WILD-TYPE P53; NONPOLYPOSIS COLON-CANCER; LI-FRAUMENI SYNDROME; ULTRAVIOLET-LIGHT; PROMOTER REGION; TUMOR-CELLS; APOPTOSIS; MUTATIONS	The tumor suppresser protein p53 is critical for guarding the genome from incorporation of damaged DNA (Lane, D. P. (1992) Nature 358, 15-16). A relevant stress that activates p53 function is UV light (Noda, A, Toma-Aiba, Y., and Fujiwara, Y. (2000) Oncogene 19, 21-31). Another well known component of the mammalian UV response is the transcription factor c-Jun (Angel, P., and Karin, M. (1991) Biochim. Biophys. Acta 1072, 129-157). We show here that upon UV irradiation p53 activates transcription of the human mismatch repair gene MSH2. Interestingly, this up-regulation critically depends on functional interaction with c-Jun. Hence, the synergistic interaction of a proto-oncogene with a tumor suppresser gene is required for the regulation of the mammalian stress response through activation of expression of MSH2.	Univ Wurzburg, Bioctr, Dept Physiol Chem 1, D-97074 Wurzburg, Germany; Univ Saarlandes, Dept Human Genet, D-66421 Homburg, Germany; Univ Saarland, Dept Expt Phys, D-68111 Saarbrucken, Germany; Univ Wurzburg, Dept Pathol, D-97080 Wurzburg, Germany; Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control, D-69120 Heidelberg, Germany	University of Wurzburg; Saarland University; Saarland University; University of Wurzburg; Helmholtz Association; German Cancer Research Center (DKFZ)	Schartl, M (corresponding author), Univ Wurzburg, Bioctr, Dept Physiol Chem 1, Hubland, D-97074 Wurzburg, Germany.		Piris, Miguel A/AAP-1445-2020	Piris, Miguel A/0000-0001-5839-3634; Schartl, Manfred/0000-0001-9882-5948				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; Fishel R, 1999, NAT MED, V5, P1239, DOI 10.1038/15191; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; HAVRE PA, 1995, CANCER RES, V55, P4420; Henseleit U, 1997, J INVEST DERMATOL, V109, P722, DOI 10.1111/1523-1747.ep12340708; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li G, 1998, BRIT J DERMATOL, V139, P3; Li G, 1996, AM J PATHOL, V148, P1113; Li G, 1997, AM J PATHOL, V150, P1457; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; McKay BC, 1997, CARCINOGENESIS, V18, P245, DOI 10.1093/carcin/18.2.245; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Mirzayans R, 1996, CARCINOGENESIS, V17, P691, DOI 10.1093/carcin/17.4.691; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; Noda A, 2000, ONCOGENE, V19, P21, DOI 10.1038/sj.onc.1203230; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Scherer SJ, 1996, BIOCHEM BIOPH RES CO, V221, P722, DOI 10.1006/bbrc.1996.0663; Scherer SJ, 1996, HUM GENET, V97, P114; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; SMITH ML, 1995, ONCOGENE, V10, P1053; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; UMAR A, 1994, J BIOL CHEM, V269, P14367; VOGELSTEIN B, 1998, GENETIC BASIS HUMAN, P241; Wang HX, 1999, J BIOL CHEM, V274, P16894, DOI 10.1074/jbc.274.24.16894; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang Y, 1998, J INVEST DERMATOL, V111, P380, DOI 10.1046/j.1523-1747.1998.00319.x; Yamagishi N, 1997, MUTAGENESIS, V12, P191, DOI 10.1093/mutage/12.3.191; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YUAN JL, 1995, CARCINOGENESIS, V16, P2295, DOI 10.1093/carcin/16.10.2295; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	49	78	81	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37469	37473		10.1074/jbc.M006990200	http://dx.doi.org/10.1074/jbc.M006990200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10984493	hybrid			2022-12-25	WOS:000165618700024
J	Shirakawa, H; Herrera, JE; Bustin, M; Postnikov, Y				Shirakawa, H; Herrera, JE; Bustin, M; Postnikov, Y			Targeting of high mobility group-14/-17 proteins in chromatin is independent of DNA sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP CHROMOSOMAL-PROTEINS; NUCLEOSOME CORES; HMG-17; HISTONE-H1; NUCLEUS; BINDING; GENE	Chromosomal proteins high mobility group (HMG)-14 and HMG-17 are nucleosomal-binding proteins that unfold the chromatin fiber and enhance transcription from chromatin templates. Their intracellular organization is dynamic and related to both cell cycle and transcription. Here we examine possible mechanisms for targeting HMG-14/-17 to specific regions in chromatin. Chromatin immunoprecipitation assays indicate that HMG-17 protein is not preferentially associated with chromatin regions containing transcriptionally active genes, or any type of specific DNA. We used a modification of the random amplified polymorphic DNA method to analyze DNA in various HMG-14/-17 nucleosome complexes. We found that although HMG-14 or HMG-17 proteins preferentially associate with core particles in which the DNA has a low frequency of CG dinucleotides, the genome does not contain consensus sequences that serve as specific targeting sites for the binding of either HMG-14 or HMG-17 proteins to nucleosomes. We used size exclusion and ion exchange chromatography to demonstrate that nuclei contain a large portion of HMG-17 associated with other proteins in a multiprotein complex. We suggest that these complexes regulate the dynamic organization of HMG-14/-17 in the nucleus and serve to target the proteins to specific sites in chromatin.	NCI, Prot Sect, Div Basic Sci, Nihon Univ, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Postnikov, Y (corresponding author), NCI, Prot Sect, Div Basic Sci, Nihon Univ, Bldg 37,Rm 3D-20,9000 Rockville Pike, Bethesda, MD 20892 USA.	yupo@helix.nih.gov	Shirakawa, Hitoshi/D-1406-2009; Bustin, Michael/G-6155-2015	Bustin, Michael/0000-0002-5147-7242; SHIRAKAWA, HITOSHI/0000-0002-4828-5274				AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; Dimitrov SI, 1997, METHODS, V12, P57, DOI 10.1006/meth.1997.0447; DRUCKMANN S, 1986, EXP CELL RES, V166, P486, DOI 10.1016/0014-4827(86)90493-3; Hayes JJ, 1997, METHODS, V12, P2, DOI 10.1006/meth.1997.0441; Hock R, 1998, EMBO J, V17, P6992, DOI 10.1093/emboj/17.23.6992; Hock R, 1998, J CELL BIOL, V143, P1427, DOI 10.1083/jcb.143.6.1427; JONES EW, 1982, HMG CHROMOSOMAL PROT; Karlin S, 1997, P NATL ACAD SCI USA, V94, P10227, DOI 10.1073/pnas.94.19.10227; Munteanu MG, 1998, TRENDS BIOCHEM SCI, V23, P341, DOI 10.1016/S0968-0004(98)01265-1; NIGHTINGALE K, 1995, J BIOL CHEM, V270, P4197, DOI 10.1074/jbc.270.9.4197; ONEILL TE, 1992, J MOL BIOL, V223, P67, DOI 10.1016/0022-2836(92)90716-W; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; POSTNIKOV YV, 1995, J MOL BIOL, V252, P423, DOI 10.1006/jmbi.1995.0508; POSTNIKOV YV, 1994, NUCLEIC ACIDS RES, V22, P4520, DOI 10.1093/nar/22.21.4520; POSTNIKOV YV, 1991, NUCLEIC ACIDS RES, V19, P717, DOI 10.1093/nar/19.4.717; Postnikov YV, 1997, J MOL BIOL, V274, P454, DOI 10.1006/jmbi.1997.1391; SANDEEN G, 1980, NUCLEIC ACIDS RES, V8, P3757, DOI 10.1093/nar/8.17.3757; Ulyanov NB, 1995, METHOD ENZYMOL, V261, P90; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WILLIAMS JGK, 1990, NUCLEIC ACIDS RES, V18, P6531, DOI 10.1093/nar/18.22.6531; YOUNG PR, 1982, NUCLEIC ACIDS RES, V10, P3099, DOI 10.1093/nar/10.10.3099	24	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37937	37944		10.1074/jbc.M000989200	http://dx.doi.org/10.1074/jbc.M000989200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10973947	hybrid			2022-12-25	WOS:000165618700085
J	Wower, J; Kirillov, SV; Wower, IK; Guven, S; Hixson, SS; Zimmermann, RA				Wower, J; Kirillov, SV; Wower, IK; Guven, S; Hixson, SS; Zimmermann, RA			Transit of tRNA through the Escherichia coli ribosome - Cross-linking of the 3 ' end of tRNA to specific nucleotides of the 23 S ribosomal RNA at the A, P, and E sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYL TRANSFERASE CENTER; CODON-ANTICODON INTERACTION; DEACYLATED TRANSFER-RNA; A-SITE; ELONGATION CYCLE; PEPTIDYLTRANSFERASE CENTER; CRYOELECTRON MICROSCOPY; BINDING-SITES; SUBUNITS; LOOP	When bound to Escherichia coli ribosomes and irradiated with near-UV light, various derivatives of yeast tRNA(Phe) containing 2-azidoadenosine at the 3' terminus form cross-links to 23 S rRNA and 50 S subunit proteins in a site-dependent manner. A and P site-bound tRNAs, whose 3' termini reside in the peptidyl transferase center, label primarily nucleotides U2506 and U2585 and protein L27. In contrast, E site-bound tRNA labels nucleotide C2422 and protein L33. The cross-linking patterns confirm the topographical separation of the peptidyl transferase center from the E site domain. The relative amounts of label incorporated into the universally conserved residues U2506 and U2585 depend on the occupancy of the A and P sites by different tRNA ligands and indicates that these nucleotides play a pivotal role in peptide transfer. In particular, the S'-adenosine of the peptidyl-tRNA analogue, AcPhe-tRNA(Phe), remains,in close contact with U2506 regardless of whether its anticodon is located in the A site or P site. Our findings, therefore, modify and extend the hybrid state model of tRNA-ribosome interaction. We show that the S'-end of the deacylated tRNA that is formed after transpeptidation does not immediately progress to the E site but remains temporarily in the peptidyl transferase center. In addition, we demonstrate that the E site, defined by the labeling of nucleotide C2422 and protein L33, represents an intermediate state of binding that precedes the entry of deacylated tRNA into the F (final) site from which it dissociates into the cytoplasm.	Auburn Univ, Dept Anim & Dairy Sci, Program Cell & Mol Biosci, Auburn, AL 36849 USA; Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA; Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA; Russian Acad Sci, Petersburg Nucl Phys Inst, Gatchina 188350, Leningrad Reg, Russia	Auburn University System; Auburn University; University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst; National Research Centre - Kurchatov Institute; Petersburg Nuclear Physics Institute; Russian Academy of Sciences	Wower, J (corresponding author), Auburn Univ, Dept Anim & Dairy Sci, Program Cell & Mol Biosci, Auburn, AL 36849 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058267, R01GM022807] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22807, GM58267] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal RK, 1999, J BIOL CHEM, V274, P8723, DOI 10.1074/jbc.274.13.8723; Agrawal RK, 1996, SCIENCE, V271, P1000, DOI 10.1126/science.271.5251.1000; BEAUCLERK AAD, 1988, EMBO J, V7, P3589, DOI 10.1002/j.1460-2075.1988.tb03236.x; BOCCHETTA M, 2000, IN PRESS RNA; BOON K, 1992, EUR J BIOCHEM, V210, P177, DOI 10.1111/j.1432-1033.1992.tb17406.x; BRIMACOMBE R, 1990, RIBOSOMES PROTEIN SY, P131; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; CHRISTIANSEN J, 1990, RIBOSOMES PROTEIN SY, P229; DONTSOVA O, 1994, P NATL ACAD SCI USA, V91, P4125, DOI 10.1073/pnas.91.10.4125; DORING T, 1994, EMBO J, V13, P2677, DOI 10.1002/j.1460-2075.1994.tb06558.x; Frank J, 1998, J STRUCT BIOL, V124, P142, DOI 10.1006/jsbi.1998.4071; GRAJEVSKAJA RA, 1982, EUR J BIOCHEM, V128, P47; Green R, 1997, J MOL BIOL, V266, P40, DOI 10.1006/jmbi.1996.0780; Green R, 1998, SCIENCE, V280, P286, DOI 10.1126/science.280.5361.286; KIRILLOV SV, 1978, EUR J BIOCHEM, V89, P297, DOI 10.1111/j.1432-1033.1978.tb20927.x; KIRILLOV SV, 1982, FEBS LETT, V148, P235, DOI 10.1016/0014-5793(82)80814-4; Kirillov SV, 1999, RNA, V5, P1003, DOI 10.1017/S1355838299990568; KIRILLOV SV, 1983, FEBS LETT, V157, P91, DOI 10.1016/0014-5793(83)81122-3; LAKE JA, 1977, P NATL ACAD SCI USA, V74, P1903, DOI 10.1073/pnas.74.5.1903; LILL R, 1987, J MOL BIOL, V196, P137, DOI 10.1016/0022-2836(87)90516-X; LILL R, 1984, BIOCHEMISTRY-US, V23, P6710, DOI 10.1021/bi00321a066; MAKHNO VI, 1988, MOL BIOL+, V22, P528; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MOAZED D, 1986, J MOL BIOL, V187, P399, DOI 10.1016/0022-2836(86)90441-9; Muth GW, 2000, SCIENCE, V289, P947, DOI 10.1126/science.289.5481.947; NIRENBERG MW, 1964, SCIENCE, V145, P1399, DOI 10.1126/science.145.3639.1399; NISSEN P, 1995, BIOCHIMIE PARIS, V78, P921; NOLLER HF, 1990, RIBOSOME, P73; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; OSSWALD M, 1990, NUCLEIC ACIDS RES, V18, P6755; Porse BT, 1996, J MOL BIOL, V264, P472, DOI 10.1006/jmbi.1996.0655; PORSE BT, 1995, J MOL BIOL, V249, P1, DOI 10.1006/jmbi.1995.0276; Puglisi EV, 1997, NAT STRUCT BIOL, V4, P775; Rappoport S, 1974, Methods Enzymol, V29, P685; RHEINBERGER HJ, 1981, P NATL ACAD SCI-BIOL, V78, P5310, DOI 10.1073/pnas.78.9.5310; ROBERTSON JM, 1981, J MOL BIOL, V151, P57, DOI 10.1016/0022-2836(81)90221-7; RODRIGUEZFONSECA C, 1995, J MOL BIOL, V247, P224, DOI 10.1006/jmbi.1994.0135; ROSEN KV, 1993, BIOCHEMISTRY-US, V32, P12802, DOI 10.1021/bi00210a032; SAMAHA RR, 1995, NATURE, V377, P309, DOI 10.1038/377309a0; SEMENKOV Y, 1992, FEBS LETT, V296, P207, DOI 10.1016/0014-5793(92)80380-Y; SEMENKOV YP, 1985, BIOPOLYM KLETKA KIEV, V1, P183; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; STIEGE W, 1983, NUCLEIC ACIDS RES, V11, P1687, DOI 10.1093/nar/11.6.1687; SYLVERS LA, 1993, BIOCONJUGATE CHEM, V4, P411, DOI 10.1021/bc00024a001; SYLVERS LA, 1989, FEBS LETT, V245, P9, DOI 10.1016/0014-5793(89)80180-2; TAMURA K, 1994, FEBS LETT, V353, P173, DOI 10.1016/0014-5793(94)01038-2; WOWER J, 1988, BIOCHEMISTRY-US, V27, P8114, DOI 10.1021/bi00421a021; WOWER J, 1991, BIOCHIMIE, V73, P961, DOI 10.1016/0300-9084(91)90137-P; Wower J, 1995, BIOCHEM CELL BIOL, V73, P1041, DOI 10.1139/o95-111; WOWER J, 1993, EMBO J, V12, P617, DOI 10.1002/j.1460-2075.1993.tb05694.x; WOWER J, 1989, P NATL ACAD SCI USA, V86, P5232, DOI 10.1073/pnas.86.14.5232; WOWER J, 1999, NUCL ACIDS S, V41, P187; Yarus Michael, 1995, P443; Zimmermann R. A., 1980, RIBOSOMES STRUCTURE, P135	54	35	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37887	37894		10.1074/jbc.M005031200	http://dx.doi.org/10.1074/jbc.M005031200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10961994	hybrid			2022-12-25	WOS:000165618700078
J	Munagala, N; Sarver, AE; Wang, CC				Munagala, N; Sarver, AE; Wang, CC			Converting the guanine phosphoribosyltransferase from Giardia lamblia to a hypoxanthine-guanine phosphoribosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEADY-STATE KINETICS; XANTHINE PHOSPHORIBOSYLTRANSFERASE; TRITRICHOMONAS-FETUS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; OROTATE PHOSPHORIBOSYLTRANSFERASE; POINT MUTATIONS; FLEXIBLE LOOP; BINDING; SPECIFICITY	Guanine phosphoribosyltransferase from Giardia lamblia a key enzyme in the purine salvage pathway, is a potential target for anti-giardiasis chemotherapy. Recent structural determination of GPRTase (Shi, W., Munagala, N. R., Wang, C. C., Li, C. M, Tyler, P. C,, Furneaux, R I., Grubmeyer, C., Schramm, V. L., and Alno, S. C. (2000) Biochemistry 39, 6781-6790) showed distinctive features, which could be responsible for its singular guanine specificity. Through characterizing specifically designed site-specific mutants of GPRTase, we identified essential moieties in the active site for substrate binding. Mutating the unusual Tyr-127 of GPRTase to the highly conserved De results in B-fold lower K-m for guanine, A L186F mutation in GPRTase increased the affinity toward guanine by 3.3-fold, whereas the corresponding human HGPRTase mutant L192F showed a 33-fold increase in K-m for guanine. A double mutant (Y127I/K152R) of GPRTase retained the improved binding of guanine and also enabled the enzyme to utilize hypoxanthine as a substrate with a K-m, of 54 +/- 15.5 muM A triple mutant (Y127I/K152/L186F) resulted in further increased binding affinity with both guanine and hypoxanthine with the latter showing a lowered K-m of 29.8 +/- 4.1 muM. Dissociation constants measured by fluorescence quenching showed 6-fold tighter binding of GMP with the triple mutant compared with wild type. Thus, by increasing the binding affinity of 6-oxopurine, we were able to convert the GPRTase to a HGPRTase.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Wang, CC (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, 513 Parnassus, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019391] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-19391] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAM RD, 1991, MICROBIOL REV, V55, P706, DOI 10.1128/MMBR.55.4.706-732.1991; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; CRAIG SP, 1991, P NATL ACAD SCI USA, V88, P2500, DOI 10.1073/pnas.88.6.2500; EADS JC, 1994, CELL, V78, P325, DOI 10.1016/0092-8674(94)90301-8; Henriksen A, 1996, BIOCHEMISTRY-US, V35, P3803, DOI 10.1021/bi952226y; Heroux A, 1999, BIOCHEMISTRY-US, V38, P14485, DOI 10.1021/bi990507q; JOCHIMSEN B, 1975, MOL GEN GENET, V143, P85, DOI 10.1007/BF00269424; KANNAANEH J, 1994, EUR J BIOCHEM, V223, P595; Lee CC, 1998, BIOCHEMISTRY-US, V37, P3491, DOI 10.1021/bi9720179; Munagala NR, 1998, BIOCHEMISTRY-US, V37, P4045, DOI 10.1021/bi972515h; Munagala NR, 1998, BIOCHEMISTRY-US, V37, P16612, DOI 10.1021/bi9818974; Page JP, 1999, EUR J BIOCHEM, V259, P565, DOI 10.1046/j.1432-1327.1999.00020.x; SCAPIN G, 1995, BIOCHEMISTRY-US, V34, P10744, DOI 10.1021/bi00034a006; Schumacher MA, 1996, NAT STRUCT BIOL, V3, P881, DOI 10.1038/nsb1096-881; Shi WX, 2000, BIOCHEMISTRY-US, V39, P6781, DOI 10.1021/bi000128t; Shi WX, 1999, BIOCHEMISTRY-US, V38, P9872, DOI 10.1021/bi990664p; Sommer JM, 1996, MOL BIOCHEM PARASIT, V78, P185, DOI 10.1016/S0166-6851(96)02623-0; Somoza JR, 1996, BIOCHEMISTRY-US, V35, P7032, DOI 10.1021/bi953072p; WANG CC, 1983, J EXP MED, V158, P1703, DOI 10.1084/jem.158.5.1703; WANG CC, 1984, J MED CHEM, V27, P1, DOI 10.1021/jm00367a001; Wang CC, 1997, PARASITOLOGY, V114, pS31; YU Y, 1997, BIOCHEMISTRY-US, V36, P3700; YUAN L, 1992, BIOCHEMISTRY-US, V31, P806, DOI 10.1021/bi00118a024	23	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37072	37077		10.1074/jbc.M007239200	http://dx.doi.org/10.1074/jbc.M007239200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10976110	hybrid			2022-12-25	WOS:000165577700086
J	Ryabova, LA; Pooggin, MM; Dominguez, DI; Hohn, T				Ryabova, LA; Pooggin, MM; Dominguez, DI; Hohn, T			Continuous and discontinuous ribosome scanning on the cauliflower mosaic virus 35 S RNA leader is controlled by short open reading frames	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCISTRONIC MESSENGER-RNA; EUKARYOTIC RIBOSOMES; TRANSLATIONAL REGULATION; SECONDARY STRUCTURE; STABLE HAIRPIN; INITIATION; PROTEIN; PHOSPHORYLATION; REINITIATION; EFFICIENCY	The pathways of scanning ribosome migration controlled by the cauliflower mosaic virus 35 S RNA leader were investigated in vitro and in vivo. This long (600 nucleotides) leader contains several short open reading frames (sORFs) and folds into an extended hairpin structure with three main stable stem sections. Translation initiation downstream of the leader is cap-dependent and occurs via ribosomal shunt under the control of two cis elements, a short open reading frame A (sORF A) followed by stem section 1. Here we show that a second similar configuration comprising sORF B followed by stem section 2 also allows shunting. The efficiency of the secondary shunt was greatly increased when stem section 1 was destabilized. In addition, we present evidence that a significant fi action of reinitiation-competent ribosomes that escape both shunt events migrate linearly via the structured central region but are intercepted by internal AUG start codons. Thus, expression downstream of the 35 S RNA leader is largely controlled by its multiple sORFs.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Hohn, T (corresponding author), Friedrich Miescher Inst, POB 2543, CH-4002 Basel, Switzerland.	Hohn@fmi.ch		Pooggin, Mikhail/0000-0003-2308-393X; Ryabova, Lyubov/0000-0003-1989-203X				Belsham GJ, 2000, COLD SPRING HARBOR M, V39, P869; BONNEVILLE JM, 1989, CELL, V59, P1135, DOI 10.1016/0092-8674(89)90769-1; CURRAN J, 1988, EMBO J, V7, P2869, DOI 10.1002/j.1460-2075.1988.tb03143.x; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; Dominguez DI, 1998, J BIOL CHEM, V273, P3669, DOI 10.1074/jbc.273.6.3669; FRANCK A, 1980, CELL, V21, P285, DOI 10.1016/0092-8674(80)90136-1; FUTTERER J, 1990, EMBO J, V9, P1697, DOI 10.1002/j.1460-2075.1990.tb08293.x; FUTTERER J, 1992, NUCLEIC ACIDS RES, V20, P3851, DOI 10.1093/nar/20.15.3851; FUTTERER J, 1991, EMBO J, V10, P3887, DOI 10.1002/j.1460-2075.1991.tb04958.x; FUTTERER J, 1993, CELL, V73, P789, DOI 10.1016/0092-8674(93)90257-Q; Futterer J, 1996, J VIROL, V70, P2999; Guerra-Peraza O, 2000, J VIROL, V74, P2067, DOI 10.1128/JVI.74.5.2067-2072.2000; Gurevich VV, 1996, METHOD ENZYMOL, V275, P382; Hemmings-Mieszczak M, 1999, RNA, V5, P1149, DOI 10.1017/S1355838299990325; Hemmings-Mieszczak M, 1998, RNA, V4, P101; HemmingsMieszczak M, 1997, J MOL BIOL, V267, P1075, DOI 10.1006/jmbi.1997.0929; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Hohn T, 1998, LOOK BEYOND TRANSCRIPTION, P84; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; KOZAK M, 1978, CELL, V15, P1109, DOI 10.1016/0092-8674(78)90039-9; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Latorre P, 1998, MOL CELL BIOL, V18, P5021, DOI 10.1128/MCB.18.9.5021; LUUKKONEN BGM, 1995, J VIROL, V69, P4086, DOI 10.1128/JVI.69.7.4086-4094.1995; MERRICK WC, 1990, ENZYME, V44, P7, DOI 10.1159/000468743; Paraskeva E, 1999, MOL CELL BIOL, V19, P807; Pestova TV, 1999, TRENDS BIOCHEM SCI, V24, P85, DOI 10.1016/S0968-0004(99)01356-0; Pestova TV, 1998, NATURE, V394, P854, DOI 10.1038/29703; Pooggin MM, 2000, J BIOL CHEM, V275, P17288, DOI 10.1074/jbc.M001143200; Pooggin MM, 1998, J VIROL, V72, P4157, DOI 10.1128/JVI.72.5.4157-4169.1998; RAMAIAH KVA, 1992, P NATL ACAD SCI USA, V89, P12063, DOI 10.1073/pnas.89.24.12063; Remm M, 1999, J VIROL, V73, P3062, DOI 10.1128/JVI.73.4.3062-3070.1999; ROBERTS BE, 1973, P NATL ACAD SCI USA, V70, P2330, DOI 10.1073/pnas.70.8.2330; Ryabova LA, 2000, GENE DEV, V14, P817; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SchmidtPuchta W, 1997, NUCLEIC ACIDS RES, V25, P2854, DOI 10.1093/nar/25.14.2854; Yueh A, 2000, GENE DEV, V14, P414; Yueh A, 1996, GENE DEV, V10, P1557, DOI 10.1101/gad.10.12.1557; ZUKER M, 1989, METHOD ENZYMOL, V180, P262	40	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37278	37284		10.1074/jbc.M004909200	http://dx.doi.org/10.1074/jbc.M004909200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973961	hybrid			2022-12-25	WOS:000165577700113
J	Agani, FH; Pichiule, P; Chavez, JC; LaManna, JC				Agani, FH; Pichiule, P; Chavez, JC; LaManna, JC			The role of mitochondria in the regulation of hypoxia-inducible factor 1 expression during hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR 1-ALPHA; XENOMITOCHONDRIAL CYBRIDS; ERYTHROPOIETIN GENE; OXIDATIVE STRESS; PROTEIN; BINDING; TRANSCRIPTION; CELLS; MPTP; STABILIZATION	Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric transcription factor that regulates transcriptional activation of several genes responsive to the lack of oxygen, including erythropoietin, vascular endothelial growth factor, glycolytic enzymes, and glucose transporters. Because the involvement of mitochondria in the regulation of HIF-1 has been postulated, we tested the effects of mitochondrial electron transport chain deficiency on HIF-1 protein expression and DNA binding in hypoxic cells. The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) inhibits electron transport chain at the level of complex I. MPTP is first converted to a pharmacologically active metabolite 1-methyl-4-phenylpyridinum (MPP+). MPP+ effectively inhibited both complex I activity and hypoxic accumulation of HIF-1 alpha protein in dopaminergic cell lines PC12 and CATH.a, In C57BL/6 mice, a single dose of MPTP (15 mg/kg, intraperitoneal) inhibited complex I activity and HIF-1 alpha protein accumulation in the striatum in response to a subsequent hypoxic challenge (8% O-2, 4 h). In a genetic model system, 40% complex I-inhibited human-ape xe-nomitochondrial cybrids, hypoxic induction of HIF-1 alpha was severely reduced, and HIF-1 DNA binding was diminished. However, succinate, the mitochondrial complex II substrate, restored the hypoxic response in cybrid cells, suggesting that electron transport chain activity is required for activation of HIF-1. A partial complex I deficiency and a mild reduction in intact cell oxygen consumption effectively prevented hypoxic induction of HIF-1 alpha protein.	Case Western Reserve Univ, Sch Med, Dept Anat, Cleveland, OH 44106 USA	Case Western Reserve University	LaManna, JC (corresponding author), Case Western Reserve Univ, Sch Med, Dept Anat, 10900 Euclid Ave, Cleveland, OH 44106 USA.		LaManna, Joseph/D-3860-2013; LaManna, Joseph C/C-3347-2012	LaManna, Joseph/0000-0002-0159-4512; LaManna, Joseph C/0000-0002-0159-4512	NHLBI NIH HHS [HL 56470] Funding Source: Medline; NINDS NIH HHS [NS37111, NS 38632] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056470] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037111, R01NS038632] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bai JX, 1999, J BIOL CHEM, V274, P26217, DOI 10.1074/jbc.274.37.26217; Barrientos A, 1998, J BIOL CHEM, V273, P14210, DOI 10.1074/jbc.273.23.14210; Beal MF, 1998, BBA-BIOENERGETICS, V1366, P211, DOI 10.1124/jpet.112.192138; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; de la Torre JC, 1999, ACTA NEUROPATHOL, V98, P1, DOI 10.1007/s004010051044; FANDREY J, 1994, BIOCHEM J, V303, P507, DOI 10.1042/bj3030507; Feldser D, 1999, CANCER RES, V59, P3915; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Kenyon L, 1997, P NATL ACAD SCI USA, V94, P9131, DOI 10.1073/pnas.94.17.9131; MARONGIU ME, 1988, NEUROSCI LETT, V94, P349, DOI 10.1016/0304-3940(88)90043-2; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MILLER WG, 1999, TRENDS NEUROSCI, V10, P424; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; Przedborski S, 1998, MOVEMENT DISORD, V13, P35; RAMSAY RR, 1991, J NEUROCHEM, V56, P1184, DOI 10.1111/j.1471-4159.1991.tb11409.x; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Schapira AHV, 1998, BBA-BIOENERGETICS, V1366, P225, DOI 10.1016/S0005-2728(98)00115-7; Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2000, BIOCHEM PHARMACOL, V59, P47, DOI 10.1016/S0006-2952(99)00292-0; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Spooren WPJM, 1998, NEUROSCIENCE, V85, P649; Sriram K, 1997, BRAIN RES, V749, P44, DOI 10.1016/S0006-8993(96)01271-1; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Zaman K, 1999, J NEUROSCI, V19, P9821; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085	32	155	163	3	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35863	35867		10.1074/jbc.M005643200	http://dx.doi.org/10.1074/jbc.M005643200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10961998	hybrid			2022-12-25	WOS:000165382000033
J	Boschi-Muller, S; Azza, S; Sanglier-Cianferani, S; Talfournier, F; Van Dorsselear, A; Branlant, G				Boschi-Muller, S; Azza, S; Sanglier-Cianferani, S; Talfournier, F; Van Dorsselear, A; Branlant, G			A sulfenic acid enzyme intermediate is involved in the catalytic mechanism of peptide methionine sulfoxide reductase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYL HYDROPEROXIDE REDUCTASE; GLUTATHIONE-PEROXIDASE; THIOREDOXIN REDUCTASE; IN-VIVO; EXPRESSION; PROTEINS; RESIDUES; GENE; RESOLUTION; KINETICS	Methionine oxidation into methionine sulfoxide is known to be involved in many pathologies and to exert regulatory effects on proteins. This oxidation can be reversed by a ubiquitous monomeric enzyme, the peptide methionine sulfoxide reductase (MsrA), whose activity in vivo requires the thioredoxin-regenerating system. The proposed chemical mechanism of Escherichia coli MsrA involves three Cys residues (positions 51, 198, and 206), A fourth Cys (position 86) is not important for catalysis, In the absence of a reducing system, 2 mol of methionine are formed per mole of enzyme for wild type and Cys->86 Ser mutant MsrA, whereas only 1 mol is formed for mutants in which either Cys-198 or Cys-206 is mutated, Reduction of methionine sulfoxide is shown to proceed through the formation of a sulfenic acid intermediate, This intermediate has been characterized by chemical probes and mass spectrometry analyses. Together, the results support a three-step chemical mechanism in vivo: 1) Cys-51 attacks the sulfur atom of the sulfoxide substrate leading, via a rearrangement, to the formation of a sulfenic acid intermediate on Cys-BI and release of 1 mol of methionine/mol of enzyme; 2) the sulfenic acid is then reduced via a double displacement mechanism involving formation of a disulfide bond between Cys-51 and Cys-198, followed by formation of a disulfide bond between Cys-198 and Cys-206, which liberates Cys-51, and 3) the disulfide bond between Cys-198 and Cys-206 is reduced by thioredoxin-dependent recycling system process.	Fac Sci, UMR CNRS UHP 7567, F-54506 Vandoeuvre Les Nancy, France; Univ Strasbourg, UMR CNRS ULP 7509, Lab Spectrometrie Masse Bioorgan, F-67087 Strasbourg, France	Universite de Lorraine; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Branlant, G (corresponding author), Fac Sci, UMR CNRS UHP 7567, Bld des Aiguillettes,BP 239, F-54506 Vandoeuvre Les Nancy, France.	Guy.Branlant@maem.uhp-nancy.fr		Cianferani, Sarah/0000-0003-4013-4129; Boschi, Sandrine/0000-0001-8962-4749				ABRAMS WR, 1981, P NATL ACAD SCI-BIOL, V78, P7483, DOI 10.1073/pnas.78.12.7483; ALLISON WS, 1976, ACCOUNTS CHEM RES, V9, P293, DOI 10.1021/ar50104a003; BENITEZ LV, 1974, J BIOL CHEM, V249, P6234; Carsol MA, 1997, EUR J BIOCHEM, V247, P248, DOI 10.1111/j.1432-1033.1997.00248.x; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; Crane EJ, 1997, BIOCHEMISTRY-US, V36, P8611, DOI 10.1021/bi9707990; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P15013, DOI 10.1021/bi972191x; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P13349, DOI 10.1021/bi9713658; EPP O, 1983, EUR J BIOCHEM, V133, P51, DOI 10.1111/j.1432-1033.1983.tb07429.x; JACQUOT JP, 1994, J MOL BIOL, V235, P1357, DOI 10.1006/jmbi.1994.1091; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; Lin TY, 1999, BIOCHEMISTRY-US, V38, P15508, DOI 10.1021/bi9907678; Lowther WT, 2000, P NATL ACAD SCI USA, V97, P6463, DOI 10.1073/pnas.97.12.6463; Moskovitz J, 1997, P NATL ACAD SCI USA, V94, P9585, DOI 10.1073/pnas.94.18.9585; Moskovitz J, 1998, P NATL ACAD SCI USA, V95, P14071, DOI 10.1073/pnas.95.24.14071; Moskovitz J, 2000, J BIOL CHEM, V275, P14167, DOI 10.1074/jbc.275.19.14167; MOSKOVITZ J, 1995, J BACTERIOL, V177, P502, DOI 10.1128/jb.177.3.502-507.1995; Moskovitz J, 1996, P NATL ACAD SCI USA, V93, P3205, DOI 10.1073/pnas.93.8.3205; Mossner E, 1999, J BIOL CHEM, V274, P25254, DOI 10.1074/jbc.274.36.25254; RAHMAN MA, 1992, J BIOL CHEM, V267, P15549; Ren B, 1997, J MOL BIOL, V268, P869, DOI 10.1006/jmbi.1997.1005; RUSSEL M, 1986, J BIOL CHEM, V261, P4997; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; Silver M, 1979, Methods Enzymol, V62, P135, DOI 10.1016/0076-6879(79)62208-5; STEIN M, 1995, PLANT MOL BIOL, V28, P487, DOI 10.1007/BF00020396; Sun HY, 1999, BIOCHEMISTRY-US, V38, P105, DOI 10.1021/bi981295k; Tete-Favier F, 2000, ACTA CRYSTALLOGR D, V56, P1194, DOI 10.1107/S0907444900009483; URSINI F, 1995, METHOD ENZYMOL, V252, P38; VOGT W, 1995, FREE RADICAL BIO MED, V18, P93, DOI 10.1016/0891-5849(94)00158-G; WALLACE TJ, 1964, J AM CHEM SOC, V86, P4099, DOI 10.1021/ja01073a039; WALLACE TJ, 1965, J ORG CHEM, V30, P1502, DOI 10.1021/jo01016a039	32	158	166	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35908	35913		10.1074/jbc.M006137200	http://dx.doi.org/10.1074/jbc.M006137200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10964927	hybrid, Green Published			2022-12-25	WOS:000165382000039
J	Dupont, J; Karas, M; LeRoith, D				Dupont, J; Karas, M; LeRoith, D			The potentiation of estrogen on insulin-like growth factor I action in MCF-7 human breast cancer cells includes cell cycle components	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; IGF-BINDING-PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASE; RETINOBLASTOMA PROTEIN; RECEPTOR SUBSTRATE-1; SIGNALING PATHWAYS; DEPENDENT KINASES; RIBONUCLEIC-ACID; CDK INHIBITORS; EXPRESSION	To gain insight into the mechanisms involved in the cross-talk between IGF-1 receptor (IGF-1R) and estrogen receptor signaling pathways, we used MCF-7-derived cells (SX13), which exhibit a 50% reduction in IGF-1R expression. Growth of NEO cells (control MCF-7 cells) was stimulated by both IGF-1 and estradiol (E2), and the addition of both mitogens resulted in a synergistic response. Estrogen enhanced IGF-1R signaling in NEO cells, but this effect was markedly diminished in SX13 cells. Estrogen was also able to potentiate the IGF-1 effect on the expression of cyclin D1 and cyclin E and on the phosphorylation of retinoblastoma protein in control but not in SX13 cells. IGF-1 increased the protein level of p21 and the luciferase activity of the p21 promoter, whereas it only reduced the protein level of p27 without affecting p27 promoter activity. Estrogen did not affect the p21 inhibitor, but it decreased the protein level of p27 and the p27 promoter luciferase activity. These effects of both mitogens were also observed at the level of association of both cyclin-dependent kinase inhibitors with CDK2 suggesting that IGF-1 and E2 affect the activity of both p21 and p27. Taken together, these data suggest that in MCF-7 cells, estrogen potentiates the IGF-1 effect on IGF-1R signaling as well as on the cell cycle components. Moreover, IGF-I and E2 regulate the expression of p21 and p27 and their association with CDK2 differently.	NIDDK, Sect Cellular & Mol Physiol, Clin Endocrinol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	LeRoith, D (corresponding author), NIDDK, Sect Cellular & Mol Physiol, Clin Endocrinol Branch, NIH, Rm 8D12,Bldg 10, Bethesda, MD 20892 USA.							Ahmad S, 1999, BIOCHEM PHARMACOL, V58, P425, DOI 10.1016/S0006-2952(99)00125-2; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Dupont J, 1998, BIOCHEM J, V335, P293, DOI 10.1042/bj3350293; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; Guvakova MA, 1997, EXP CELL RES, V231, P149, DOI 10.1006/excr.1996.3457; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Huynh H, 1996, J BIOL CHEM, V271, P1016, DOI 10.1074/jbc.271.2.1016; Huynh H, 1996, CLIN CANCER RES, V2, P2037; Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309; Jackson JG, 1998, J BIOL CHEM, V273, P9994, DOI 10.1074/jbc.273.16.9994; Johannessen LE, 1999, BIOCHEM J, V337, P599, DOI 10.1042/0264-6021:3370599; Johnson MR, 1998, ONCOGENE, V16, P2647, DOI 10.1038/sj.onc.1201789; Kahlert S, 2000, J BIOL CHEM, V275, P18447, DOI 10.1074/jbc.M910345199; Kleinman D, 1996, ENDOCRINOLOGY, V137, P1089, DOI 10.1210/en.137.3.1089; KLEINMAN D, 1995, ENDOCRINOLOGY, V136, P2531, DOI 10.1210/en.136.6.2531; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lalli E, 1996, EMBO J, V15, P528, DOI 10.1002/j.1460-2075.1996.tb00385.x; Lee AV, 1999, MOL ENDOCRINOL, V13, P787, DOI 10.1210/me.13.5.787; Lee AV, 1995, BIOMED PHARMACOTHER, V49, P415, DOI 10.1016/0753-3322(96)82678-3; Liu Y, 1996, CANCER RES, V56, P31; Molloy CA, 2000, J BIOL CHEM, V275, P12565, DOI 10.1074/jbc.275.17.12565; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Moro A, 2000, BIOCHEM BIOPH RES CO, V269, P31, DOI 10.1006/bbrc.2000.2256; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; NEUENSCHWANDER S, 1995, ENDOCRINOLOGY, V136, P4298, DOI 10.1210/en.136.10.4298; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Petley T, 1999, HORM METAB RES, V31, P70, DOI 10.1055/s-2007-978701; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Richards RG, 1998, J BIOL CHEM, V273, P11962, DOI 10.1074/jbc.273.19.11962; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; RUAN WF, 1995, ENDOCRINOLOGY, V136, P1296, DOI 10.1210/en.136.3.1296; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STEWART AJ, 1990, J BIOL CHEM, V265, P21172; Stoica A, 2000, J CELL BIOCHEM, V76, P605, DOI 10.1002/(SICI)1097-4644(20000315)76:4<605::AID-JCB9>3.0.CO;2-T; Surmacz E, 1995, CLIN CANCER RES, V1, P1429; Teruel T, 1996, BIOCHEM J, V319, P627, DOI 10.1042/bj3190627; Valverde AM, 1997, MOL ENDOCRINOL, V11, P595, DOI 10.1210/me.11.5.595; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; White MF, 1998, CURR TOP MICROBIOL, V228, P179; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	48	126	130	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35893	35901		10.1074/jbc.M006741200	http://dx.doi.org/10.1074/jbc.M006741200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10967123	hybrid, Green Submitted			2022-12-25	WOS:000165382000037
J	Gorman, L; Mercatante, DR; Kole, R				Gorman, L; Mercatante, DR; Kole, R			Restoration of correct splicing of thalassemic beta-globin pre-mRNA by modified U1 snRNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SMALL NUCLEAR RNAS; ICAM-1 ANTISENSE OLIGONUCLEOTIDE; SITE-SPECIFIC MUTAGENESIS; EXTERNAL GUIDE SEQUENCES; MESSENGER-RNA; MAMMALIAN-CELLS; PREMESSENGER RNA; IN-VIVO; GENE-EXPRESSION	The T-->G mutation at nucleotide 705 in the second intron of the p-globin gene creates an aberrant 5' splice site and activates a 3' cryptic splice site upstream from the mutation. As a result, the IVS2-705 pre-mRNA is spliced via the aberrant splice sites leading to a deficiency of P-globin mRNA and protein and to the genetic blood disorder thalassemia. We have shown previously that in cell culture models of thalassemia, aberrant splicing of P-thalassemic IVS2-705 pre-mRNA was permanently corrected by a modified murine U7 snRNA that incorporated sequences antisense to the splice sites activated by the mutation. To explore the possibility of using other snRNAs as vectors for antisense sequences, U1 snRNA was modified in a similar manner. Replacement of the U1 9-nucleotide 5' splice site recognition sequence with nucleotides complementary to the aberrant 5' splice site failed to correct splicing of IVS2-705 pre-mRNA In contrast, U1 snRNA targeted to the cryptic 3' splice site was effective. A hybrid with a modified U7 snRNA gene under the control of the U1 promoter and terminator sequences resulted in the highest levels of correction (up to 70%) in transiently and stably transfected target cells.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Kole, R (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, CB 7295, Chapel Hill, NC 27599 USA.	kole@med.unc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051940] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-51940] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baserga S., 1993, RNA WORLD, P359; Bennett CF, 1997, J PHARMACOL EXP THER, V280, P988; BENZ EJ, 1996, T AM CLIN CLIMAT ASS, V108, P78; Bertrand E, 1997, RNA, V3, P75; Biasolo MA, 1996, J VIROL, V70, P2154, DOI 10.1128/JVI.70.4.2154-2161.1996; BOND UM, 1991, GENE DEV, V5, P1709, DOI 10.1101/gad.5.9.1709; BRINGMANN P, 1984, EMBO J, V3, P1357, DOI 10.1002/j.1460-2075.1984.tb01977.x; Cantor GH, 1996, ANTISENSE NUCLEIC A, V6, P301, DOI 10.1089/oli.1.1996.6.301; CHEN IT, 1993, MOL CELL BIOL, V13, P289, DOI 10.1128/MCB.13.1.289; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; COHEN JB, 1993, MOL CELL BIOL, V13, P2666, DOI 10.1128/MCB.13.5.2666; COHEN JB, 1994, P NATL ACAD SCI USA, V91, P10470, DOI 10.1073/pnas.91.22.10470; Crooke ST, 1998, ANTISENSE NUCLEIC A, V8, P133, DOI 10.1089/oli.1.1998.8.133; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; DOMINSKI Z, 1993, P NATL ACAD SCI USA, V90, P8673, DOI 10.1073/pnas.90.18.8673; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; Friedman KJ, 1999, J BIOL CHEM, V274, P36193, DOI 10.1074/jbc.274.51.36193; Good PD, 1997, GENE THER, V4, P45, DOI 10.1038/sj.gt.3300354; Gorman L, 1998, P NATL ACAD SCI USA, V95, P4929, DOI 10.1073/pnas.95.9.4929; GRIMM C, 1993, EMBO J, V12, P1229, DOI 10.1002/j.1460-2075.1993.tb05764.x; GRUBER A, 1991, BIOCHIM BIOPHYS ACTA, V1088, P151, DOI 10.1016/0167-4781(91)90167-K; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HASHIMOTO C, 1984, NUCLEIC ACIDS RES, V12, P3283, DOI 10.1093/nar/12.7.3283; Hashiramoto A, 1999, ARTHRITIS RHEUM, V42, P954, DOI 10.1002/1529-0131(199905)42:5<954::AID-ANR14>3.0.CO;2-J; He JK, 1997, CANCER RES, V57, P3993; He YK, 1998, JNCI-J NATL CANCER I, V90, P1080, DOI 10.1093/jnci/90.14.1080; JACOB A, 1993, EUR J BIOCHEM, V216, P19, DOI 10.1111/j.1432-1033.1993.tb18111.x; Jiang ZH, 1999, P SOC EXP BIOL MED, V220, P64, DOI 10.1046/j.1525-1373.1999.d01-11.x; JONES DH, 1991, BIOTECHNIQUES, V10, P62; JONES DH, 1992, BIOTECHNIQUES, V12, P528; KEAN JM, 1995, BIOCHEMISTRY-US, V34, P14617, DOI 10.1021/bi00045a001; Kenney JL, 1998, BLOOD, V92, P1721, DOI 10.1182/blood.V92.5.1721.417a08_1721_1727; KRAWCZAK M, 1992, HUM GENET, V90, P41; Li B, 1997, NEUROCHEM INT, V31, P393, DOI 10.1016/S0197-0186(96)00109-X; Liu DK, 1997, J VIROL, V71, P4079, DOI 10.1128/JVI.71.5.4079-4085.1997; Ma MYX, 1998, ANTISENSE NUCLEIC A, V8, P415; Michienzi A, 1998, HUM GENE THER, V9, P621, DOI 10.1089/hum.1998.9.5-621; Michienzi A, 1996, P NATL ACAD SCI USA, V93, P7219, DOI 10.1073/pnas.93.14.7219; Mirochnitchenko O, 1993, Antisense Res Dev, V3, P171; Montgomery RA, 1997, HUM MOL GENET, V6, P519, DOI 10.1093/hmg/6.4.519; Moore M., 1993, RNA WORLD, P303; NOONBERG SB, 1994, NUCLEIC ACIDS RES, V22, P2830, DOI 10.1093/nar/22.14.2830; Offensperger WB, 1998, MOL BIOTECHNOL, V9, P161, DOI 10.1007/BF02760817; Perez-Ruiz M, 1999, ANTISENSE NUCLEIC A, V9, P33, DOI 10.1089/oli.1.1999.9.33; RINKE J, 1985, J MOL BIOL, V185, P721, DOI 10.1016/0022-2836(85)90057-9; Roh H, 1998, J SURG RES, V77, P85, DOI 10.1006/jsre.1998.5353; Rubenstein M, 1998, METHOD FIND EXP CLIN, V20, P825, DOI 10.1358/mf.1998.20.10.487534; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAUFELE F, 1986, NATURE, V323, P777, DOI 10.1038/323777a0; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; Schmajuk G, 1999, J BIOL CHEM, V274, P21783, DOI 10.1074/jbc.274.31.21783; SCHWARTZ E, 1991, HEMATOLOGY BASIC PRI, P586; Sierakowska H, 1999, RNA, V5, P369, DOI 10.1017/S135583829998130X; Sierakowska H, 1997, NUCLEOS NUCLEOT NUCL, V16, P1173, DOI 10.1080/07328319708006154; Sierakowska H, 1996, P NATL ACAD SCI USA, V93, P12840, DOI 10.1073/pnas.93.23.12840; SMITH CC, 1986, P NATL ACAD SCI USA, V83, P2787, DOI 10.1073/pnas.83.9.2787; SPYCHER C, 1994, NUCLEIC ACIDS RES, V22, P4023, DOI 10.1093/nar/22.20.4023; STRUB K, 1984, EMBO J, V3, P2801, DOI 10.1002/j.1460-2075.1984.tb02212.x; Suter D, 1999, HUM MOL GENET, V8, P2415, DOI 10.1093/hmg/8.13.2415; Taylor JK, 1999, NAT BIOTECHNOL, V17, P1097, DOI 10.1038/15079; Werner M, 1998, RNA, V4, P847, DOI 10.1017/S1355838298980323; Werner M, 1999, ANTISENSE NUCLEIC A, V9, P81, DOI 10.1089/oli.1.1999.9.81; Wilton SD, 1999, NEUROMUSCULAR DISORD, V9, P330, DOI 10.1016/S0960-8966(99)00010-3; Yacyshyn BR, 1998, GASTROENTEROLOGY, V114, P1133, DOI 10.1016/S0016-5085(98)70418-4; Zhang H, 1999, ANTIMICROB AGENTS CH, V43, P347, DOI 10.1128/AAC.43.2.347; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	66	27	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35914	35919		10.1074/jbc.M006259200	http://dx.doi.org/10.1074/jbc.M006259200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10969081	hybrid, Green Published			2022-12-25	WOS:000165382000040
J	King, TR; Fang, Y; Mahon, ES; Anderson, DH				King, TR; Fang, Y; Mahon, ES; Anderson, DH			Using a phage display library to identify basic residues in A-Raf required to mediate binding to the Src homology 2 domains of the p85 subunit of phosphatidylinositol 3 '-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL SH2 DOMAIN; PHOSPHOTYROSINE-DEPENDENT MANNER; GROWTH-FACTOR RECEPTORS; HIGH-AFFINITY; PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; P85-ALPHA SUBUNIT; PEPTIDE LIGANDS; BETA RECEPTOR; ABL ONCOGENE	Src homology 2 (SH2) domains are found in a variety of cytoplasmic proteins involved in mediating signals from cell surface receptors to various intracellular pathways. They fold as modular units and are capable of recognizing and binding to short linear peptide sequences containing a phosphorylated tyrosine residue. Here we show that each of the SH2 domains of the p85 subunit of phosphatidylinositol 3-kinase selects phage displayed peptide sequences containing the core (L/I)-A-(R/K)-I-R. The serine/threonine kinase A-Raf, containing the sequence LQRIRS, is associated with the p85 protein in both quiescent and growth factor stimulated cells. This suggests:that p85 and A-Raf exist in a protein complex in cells and that complex formation does not require growth factor stimulation. We also show that p85 and A-Raf can bind directly to each other in vitro and that this interaction is mediated in part by the p85 SH2 domains. Further, the p85 SH2 domains require at least one df four distinct basic-X-basic sequence motifs within A-Raf for binding. This is the first description of a phosphotyrosine-independent SH2 domain interaction that requires basic residues on the SH2 ligand.	Saskatchewan Canc Agcy, Hlth Res Div, Dept Oncol, Saskatoon, SK S7N 4H4, Canada; Saskatchewan Canc Agcy, Hlth Res Div, Canc Res Unit, Saskatoon, SK S7N 4H4, Canada; Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5E5, Canada	University of Saskatchewan; University of Saskatchewan; University of Saskatchewan	Anderson, DH (corresponding author), Saskatchewan Canc Agcy, Hlth Res Div, Dept Oncol, 20 Campus Dr, Saskatoon, SK S7N 4H4, Canada.	danderson@scf.sk.ca						ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; Anderson DH, 1998, ONCOGENE, V16, P2321, DOI 10.1038/sj.onc.1201780; Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; Breeze AL, 1996, EMBO J, V15, P3579, DOI 10.1002/j.1460-2075.1996.tb00727.x; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHAREST A, 1995, BIOCHEM J, V308, P425, DOI 10.1042/bj3080425; CHEADLE C, 1994, J BIOL CHEM, V269, P24034; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Dutartre H, 1998, VIROLOGY, V247, P200, DOI 10.1006/viro.1998.9244; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; LETWIN K, 1988, ONCOGENE, V3, P621; Li SC, 1999, CURR BIOL, V9, P1355, DOI 10.1016/S0960-9822(00)80080-9; MALEK SN, 1994, J BIOL CHEM, V269, P33009; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; Park I, 1995, P NATL ACAD SCI USA, V92, P12338, DOI 10.1073/pnas.92.26.12338; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; Raffel GD, 1996, J BIOL CHEM, V271, P4640; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; Schmandt R, 1999, ONCOGENE, V18, P1867, DOI 10.1038/sj.onc.1202507; SCOTT JK, 1992, TRENDS BIOCHEM SCI, V17, P241, DOI 10.1016/0968-0004(92)90401-T; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; Siegal G, 1998, J MOL BIOL, V276, P461, DOI 10.1006/jmbi.1997.1562; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WANG JYJ, 1985, J BIOL CHEM, V260, P64; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; Wu XY, 1996, J BIOL CHEM, V271, P3265, DOI 10.1074/jbc.271.6.3265; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Yuryev A, 2000, MOL CELL BIOL, V20, P4870, DOI 10.1128/MCB.20.13.4870-4878.2000; ZHOU MM, 1995, P NATL ACAD SCI USA, V92, P7784, DOI 10.1073/pnas.92.17.7784; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	51	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36450	36456		10.1074/jbc.M004720200	http://dx.doi.org/10.1074/jbc.M004720200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10967104	hybrid			2022-12-25	WOS:000165382000112
J	Minty, A; Dumont, X; Kaghad, M; Caput, D				Minty, A; Dumont, X; Kaghad, M; Caput, D			Covalent modification of p73 alpha by SUMO-1 - Two-hybrid screening with p73 identifies novel SUMO-1-interacting proteins and a SUMO-1 interaction motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; NUCLEAR-BODIES; CONJUGATING ENZYME; ANDROGEN RECEPTOR; S-PHASE; P53; PML; KINASE; FAMILY; DEATH	Two-hybrid screening in yeast with p73 alpha isolated SUMO-1 (small ubiquitin-like modifier (1) over bar), the enzyme responsible for its conjugation, Ubc-9, and a number of novel SUMO-l-interacting proteins, including thymine DNA glycosylase, PM-Sc175, PIASx, PKY, and CHD3/ZFH, A subset: of these proteins contain a common motif, hhX-SXS/Taaa, where h is a hydrophobic amino acid and a is an acidic amino acid, that is shown to interact with SUMO-1 in the two-hybrid system. We show here that p73 alpha, but not p73 beta, can be covalently modified by SUMO-I, The major SUMO-l-modified residue in p73 alpha is the C-terminal lysine (Lys(627)). The sequence surrounding this lysine:conforms to a consensus SUMO-1 modification:site b(X)XXhKXE, where b is a basic amino acid. SUMO-l-modified p73 is more rapidly degraded by the proteasme than unmodified p73, although SUMO-1 modification:is not required for p73 degradation. SUMO-I modification does not affect the transcriptional activity of p73 alpha on an RGC-luciferase reporter gene in SK-N-AS cells. Instead, SUMO-1 modification may alter the subcellular localization of p73, because SUMO-1-modified p73 is preferentially found in detergent-insoluble fractions, Alternatively, it may modulate the interaction of p73 with other proteins that are substrates for SUMO-1 modification or which interact with SUMO-1, such as those identified here.	Sanofi Synthelabo Rech, Mol & Funct Genom Dept, F-31676 Labege, France	Sanofi-Aventis; Sanofi France	Minty, A (corresponding author), Sanofi Synthelabo Rech, Mol & Funct Genom Dept, F-31676 Labege, France.	adrian.minty@sanofi-synthelabo.com						ALDERUCCIO F, 1991, J EXP MED, V173, P941, DOI 10.1084/jem.173.4.941; Aubry F, 1998, EUR J BIOCHEM, V254, P558, DOI 10.1046/j.1432-1327.1998.2540558.x; Begley DA, 1997, GENE, V200, P35, DOI 10.1016/S0378-1119(97)00350-8; BRODY MN, 1996, ONCOGENE, V13, P971; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Chelbi-Alix MK, 1999, ONCOGENE, V18, P935, DOI 10.1038/sj.onc.1202366; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Everett RD, 1998, J VIROL, V72, P6581, DOI 10.1128/JVI.72.8.6581-6591.1998; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Gottlicher M, 1996, STEROIDS, V61, P257, DOI 10.1016/0039-128X(96)00032-3; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hochstrasser M, 1998, GENE DEV, V12, P901, DOI 10.1101/gad.12.7.901; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Hofmann H, 2000, J VIROL, V74, P2510, DOI 10.1128/JVI.74.6.2510-2524.2000; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; KIPPERT F, 1995, FEMS MICROBIOL LETT, V128, P201, DOI 10.1016/0378-1097(95)00113-J; Koipally J, 1999, EMBO J, V18, P3090, DOI 10.1093/emboj/18.11.3090; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Lehembre F, 2000, MOL CELL BIOL, V20, P1072, DOI 10.1128/MCB.20.3.1072-1082.2000; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Liou ML, 1999, J BIOL CHEM, V274, P10145, DOI 10.1074/jbc.274.15.10145; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; Meluh PB, 1997, GENE DEV, V11, P3401, DOI 10.1101/gad.11.24.3401; Million K, 1999, J CELL SCI, V112, P4357; Moilanen AM, 1999, J BIOL CHEM, V274, P3700, DOI 10.1074/jbc.274.6.3700; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; Okura T, 1996, J IMMUNOL, V157, P4277; Ozaki T, 1999, CANCER RES, V59, P5902; Poukka H, 1999, J BIOL CHEM, V274, P19441, DOI 10.1074/jbc.274.27.19441; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Seeler JS, 1999, CURR OPIN GENET DEV, V9, P362, DOI 10.1016/S0959-437X(99)80054-9; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Shen ZY, 1996, GENOMICS, V37, P183, DOI 10.1006/geno.1996.0540; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; SUGIMOTO T, 1984, J NATL CANCER I, V73, P51; SUSUKI T, 1999, J BIOL CHEM, V274, P31181; Tanaka K, 1999, MOL CELL BIOL, V19, P8660; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Trost M, 2000, J BIOL CHEM, V275, P7373, DOI 10.1074/jbc.275.10.7373; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; Um S, 1998, J BIOL CHEM, V273, P20728, DOI 10.1074/jbc.273.33.20728; Vikhanskaya F, 2000, NUCLEIC ACIDS RES, V28, P513, DOI 10.1093/nar/28.2.513; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; White E, 1999, NATURE, V399, P734, DOI 10.1038/21539; Woodage T, 1997, P NATL ACAD SCI USA, V94, P11472, DOI 10.1073/pnas.94.21.11472; Wu L, 1997, MECH DEVELOP, V65, P3, DOI 10.1016/S0925-4773(97)00032-4; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583	80	325	335	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36316	36323		10.1074/jbc.M004293200	http://dx.doi.org/10.1074/jbc.M004293200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10961991	hybrid			2022-12-25	WOS:000165382000095
J	Persons, DL; Yazlovitskaya, EM; Pelling, JC				Persons, DL; Yazlovitskaya, EM; Pelling, JC			Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; DAMAGE-INDUCED PHOSPHORYLATION; DNA-DAMAGE; SERINE 15; RADIOSENSITIZING AGENT; INHIBITOR; TRANSDUCTION; EXPRESSION; CELLS; ATM	The p53 tumor suppressor protein is a transcription factor that plays a major role in the DNA damage response. After DNA damage, p53 levels increase due primarily to stabilization of the protein. The molecular mechanisms leading to stabilization of p53 after DNA damage have not been completely elucidated. Recently we reported that cisplatin treatment activated extracellular signal-regulated kinase 1 and 2 (ERK1/2) and that inhibition of ERK1/2 resulted in enhanced sensitivity to cisplatin. In the present study, we examined the potential role of ERK1/2 activation in regulation of the p53 response to cisplatin. In the ovarian carcinoma cell line A2780, inhibition of ERK1/2 activation with the mitogen-activated protein kinase/ERK kinase 1 (MEK1) inhibitor PD98059 resulted in decreased p53 protein half-life and diminished accumulation of p53 protein during exposure to cisplatin. We also demonstrated that p53 protein co-immunoprecipitated with ERK1/2 protein and was phosphorylated by activated recombinant murine ERK2 in vitro. Furthermore, PD98059 decreased the phosphorylation of p53 at serine 15 during cisplatin exposure, suggesting that ERK1/2 mediates in part phosphorylation of p53 during the cisplatin DNA response. These results strongly suggest that cisplatin-induced ERK activation is an up-stream regulator of the p53 response to DNA damage caused by cisplatin.	Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Clin Lab 1213, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Persons, DL (corresponding author), Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Clin Lab 1213, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.	dpersons@kumc.edu			NATIONAL CANCER INSTITUTE [R01CA072987] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR011825] Funding Source: NIH RePORTER; NCI NIH HHS [CA72987] Funding Source: Medline; NCRR NIH HHS [P20RR11825] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Anderson P, 1997, MICROBIOL MOL BIOL R, V61, P33, DOI 10.1128/.61.1.33-46.1997; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chernikova SB, 1999, RADIAT RES, V151, P159, DOI 10.2307/3579766; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Delmastro DA, 1997, CANCER CHEMOTH PHARM, V39, P245; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; EASTMAN A, 1995, SEMIN CANCER BIOL, V6, P45, DOI 10.1006/scbi.1995.0006; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRITSCHE M, 1993, ONCOGENE, V8, P307; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Harlow E, 1988, ANTIBODIES LABORATOR, P521; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Keller D, 1999, BIOCHEM BIOPH RES CO, V261, P464, DOI 10.1006/bbrc.1999.1023; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Mayo LD, 1997, CANCER RES, V57, P5013; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Persons DL, 1999, CLIN CANCER RES, V5, P1007; Prives C, 1999, J PATHOL, V187, P112; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sarkaria JN, 1998, CANCER RES, V58, P4375; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	57	230	234	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35778	35785		10.1074/jbc.M004267200	http://dx.doi.org/10.1074/jbc.M004267200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10958792	hybrid			2022-12-25	WOS:000165382000021
J	Tran, TT; Dai, WX; Sarkar, HK				Tran, TT; Dai, WX; Sarkar, HK			Cyclosporin A inhibits creatine uptake by altering surface expression of the creatine transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYL-PROLYL ISOMERASE; SKELETAL-MUSCLE; NERVOUS-SYSTEM; MOLECULAR CHARACTERIZATION; IMMUNOSUPPRESSANT FK506; FUNCTIONAL EXPRESSION; DOWN-REGULATION; IN-SITU; IMMUNOPHILINS; LOCALIZATION	The immunosuppressive drug cyclosporin A (CsA) inhibited the hCRT-1 cDNA-induced creatine uptake in Xenopus oocytes and the endogenous creatine uptake in cultured C2C12 muscle cells in a dose- and time-dependent manner, FK506, another potent immunosuppressant, was unable to mimic the effect of CsA suggesting that the inhibitory effect of CsA was specific. To delineate the mechanism underlying, we investigated the effect of CsA on the K-m and V-max of creatine transport and also on the cell surface distribution of the creatine transporter, Although CsA treatment did not affect the K-m (20-24 muM) for creatine, it significantly decreased the V-max of creatine uptake in both oocytes and muscle cells. CsA treatment reduced the cell surface expression level of the creatine transporter in the muscle cells by similar to 60% without significantly altering its total expression level, and the reduction in the cell surface expression paralleled the decrease in creatine uptake, Taken together, our results suggest that CsA inhibited creatine uptake by altering the surface abundance of the creatine transporter. We propose that CsA impairs the targeting of the creatine transporter by inhibiting the function of an associated cyclophilin, resulting in an apparent loss in surface expression of the creatine transporter. Our results also suggest that prolonged exposure to CsA may result in chronically creatine-depleted muscle, which may be a cause for the development of CsA-associated clinical myopathies in organ transplant patients.	Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA	Baylor College of Medicine	Sarkar, HK (corresponding author), Baylor Coll Med, Dept Mol Physiol & Biophys, 1 Baylor Plaza, Houston, TX 77030 USA.	hsarkar@bcm.tmc.edu						Abbott KL, 1998, MOL BIOL CELL, V9, P2905, DOI 10.1091/mbc.9.10.2905; ARELLANO F, 1991, LANCET, V337, P915, DOI 10.1016/0140-6736(91)90245-K; BEIS I, 1975, BIOCHEM J, V152, P23, DOI 10.1042/bj1520023; BENNETT WM, 1994, MINER ELECTROL METAB, V20, P214; BESSMAN SP, 1981, SCIENCE, V211, P448, DOI 10.1126/science.6450446; Biring MS, 1998, J APPL PHYSIOL, V84, P1967, DOI 10.1152/jappl.1998.84.6.1967; BOREL JF, 1989, PHARMACOL REV, V41, P259; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; Budak-Alpdogan T, 1998, BONE MARROW TRANSPL, V22, P115, DOI 10.1038/sj.bmt.1701285; Dai WX, 1999, ARCH BIOCHEM BIOPHYS, V361, P75, DOI 10.1006/abbi.1998.0959; DALY MM, 1980, ARCH BIOCHEM BIOPHYS, V203, P317, DOI 10.1016/0003-9861(80)90182-4; Daniels GM, 1998, METHOD ENZYMOL, V296, P307; FERNANDEZSOLA J, 1990, LANCET, V335, P362; FITCH CD, 1974, J BIOL CHEM, V249, P1060; GALAT A, 1993, EUR J BIOCHEM, V216, P689, DOI 10.1111/j.1432-1033.1993.tb18189.x; GARCIAESCRIG M, 1994, CLIN NEUROPHARMACOL, V17, P298, DOI 10.1097/00002826-199406000-00010; GOY JJ, 1989, LANCET, V1, P1446; Guerrero-Ontiveros ML, 1998, MOL CELL BIOCHEM, V184, P427, DOI 10.1023/A:1006895414925; GUIMBAL C, 1993, J BIOL CHEM, V268, P8418; HARDIMAN O, 1993, NEUROLOGY, V43, P1432, DOI 10.1212/WNL.43.7.1432; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HELEKAR SA, 1994, NEURON, V12, P179, DOI 10.1016/0896-6273(94)90162-7; Ho S, 1996, CLIN IMMUNOL IMMUNOP, V80, pS40, DOI 10.1006/clin.1996.0140; Hoyer P F, 1995, Contrib Nephrol, V114, P111; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LODISH HF, 1991, J BIOL CHEM, V266, P14835; Marks AR, 1996, PHYSIOL REV, V76, P631, DOI 10.1152/physrev.1996.76.3.631; MAYSER W, 1992, FEBS LETT, V305, P31, DOI 10.1016/0014-5793(92)80649-2; MEKHFI H, 1990, AM J PHYSIOL, V258, pH1151, DOI 10.1152/ajpheart.1990.258.4.H1151; NASH SR, 1994, RECEPTOR CHANNEL, V2, P165; Neubauer S, 1999, CIRCULATION, V100, P1847, DOI 10.1161/01.CIR.100.18.1847; OCHIAI T, 1987, TRANSPLANT P, V19, P1284; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; RAMAMOORTHY S, 1992, PEDIATR RES, V32, P125, DOI 10.1203/00006450-199207000-00024; RUIZ M, 1994, INVEST OPHTH VIS SCI, V35, P4039; Saltarelli MD, 1996, DEV NEUROSCI-BASEL, V18, P524, DOI 10.1159/000111450; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SHAW LM, 1990, CLIN CHEM, V36, P1841; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SNYDER SH, 1995, NAT MED, V1, P32, DOI 10.1038/nm0195-32; SORA I, 1994, BIOCHEM BIOPH RES CO, V204, P419, DOI 10.1006/bbrc.1994.2475; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; Stephan MM, 1997, BIOCHEMISTRY-US, V36, P1322, DOI 10.1021/bi962150l; TEGZESS AM, 1988, TRANSPLANT P, V20, P530; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vinnakota S, 1997, J NEUROCHEM, V69, P2238; Walker J B, 1979, Adv Enzymol Relat Areas Mol Biol, V50, P177; WALSH CT, 1992, J BIOL CHEM, V267, P13115; WYSS M, 1994, MOL CELL BIOCHEM, V133, P51, DOI 10.1007/BF01267947	49	42	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35708	35714		10.1074/jbc.M005636200	http://dx.doi.org/10.1074/jbc.M005636200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10964923	hybrid			2022-12-25	WOS:000165382000011
J	Korsisaari, N; Makela, TP				Korsisaari, N; Makela, TP			Interactions of Cdk7 and Kin28 with Hint/PKCI-1 and Hnt1 histidine triad proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXY-TERMINAL DOMAIN; ACTIVATING KINASE CAK; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVITY; FACTOR TFIIH; BINDING; CLONING; CYCLIN; YEAST	Cyclin-dependent kinase 7 (Cdk7) forms a trimeric complex with cyclin H and Mat1 to form the mammalian Cdk-activating kinase, CAK, as well as a part of the basal transcription factor TFIIH, where Cdk7 phosphorylates the C-terminal domain (CTD) of the large subunit of RNA polymerase II. Here, we report a novel interaction between Cdk7 and a histidine triad (HIT) family protein, Hint/PKCI-1. This interaction was initially observed in a yeast two hybrid study and subsequently verified by co-immunoprecipitation and subcellular localization studies, where overexpression of Cdk7 leads to partial relocalization of Hint to the nucleus. The physical association is independent of cyclin H binding or Cdk7 kinase activity and is conserved between the related Sacharomyces cerevisiae CTD kinase Kin28 and the HIT protein Hnt1. Furthermore, combination of a disruption of HNT1 and a KIN28 temperature-sensitive allele in S. cerevisae led to highly elongated cell morphology and reduced colony formation, indicating a genetic interaction between KIN28 and HNT1. The physical and genetic interactions of Hint and Hnt1 with Cdk7 and Kin28 suggest a role for this class of histidine triad proteins in the regulation of Cdk7 and Kin28 functions.	Univ Helsinki, Haartman Inst, FIN-00014 Helsinki, Finland; Univ Helsinki, Biocentrum Helsinki, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Diagnost Lab, Helsinki 00029, Finland	University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Makela, TP (corresponding author), Univ Helsinki, Haartman Inst, POB 21, FIN-00014 Helsinki, Finland.	tomi.makela@helsinki.fi	makela, tomi/B-3734-2009	makela, tomi/0000-0002-4869-8044				Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; Bastien J, 2000, J BIOL CHEM, V275, P21896, DOI 10.1074/jbc.M001985200; Brenner C, 1997, NAT STRUCT BIOL, V4, P231, DOI 10.1038/nsb0397-231; BREVET A, 1991, J BACTERIOL, V173, P5275, DOI 10.1128/jb.173.17.5275-5279.1991; Brzoska PM, 1996, GENOMICS, V36, P151, DOI 10.1006/geno.1996.0435; BRZOSKA PM, 1995, P NATL ACAD SCI USA, V92, P7824, DOI 10.1073/pnas.92.17.7824; Busso D, 2000, J BIOL CHEM, V275, P22815, DOI 10.1074/jbc.M002578200; Chen J, 1998, J BACTERIOL, V180, P2345, DOI 10.1128/JB.180.9.2345-2349.1998; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Cujec TP, 1997, GENE DEV, V11, P2645, DOI 10.1101/gad.11.20.2645; Damagnez V, 1995, EMBO J, V14, P6164, DOI 10.1002/j.1460-2075.1995.tb00307.x; Drapkin R, 1996, P NATL ACAD SCI USA, V93, P6488, DOI 10.1073/pnas.93.13.6488; FRASER ED, 1991, FEBS LETT, V294, P285, DOI 10.1016/0014-5793(91)81450-M; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; Fusco C, 1998, GENOMICS, V51, P351, DOI 10.1006/geno.1998.5368; Gilmour J, 1997, BIOCHEM J, V326, P471, DOI 10.1042/bj3260471; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Huang Y, 1995, BIOCHEM J, V312, P925, DOI 10.1042/bj3120925; Inamoto S, 1997, J BIOL CHEM, V272, P29852, DOI 10.1074/jbc.272.47.29852; Kaldis P, 1999, CELL MOL LIFE SCI, V55, P284, DOI 10.1007/s000180050290; Klein MG, 1998, EXP CELL RES, V244, P26, DOI 10.1006/excr.1998.4153; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Lima CD, 1996, P NATL ACAD SCI USA, V93, P5357, DOI 10.1073/pnas.93.11.5357; Lima CD, 1997, SCIENCE, V278, P286, DOI 10.1126/science.278.5336.286; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MAKELA TP, 1995, P NATL ACAD SCI USA, V92, P5174, DOI 10.1073/pnas.92.11.5174; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; PEARSON JD, 1990, J BIOL CHEM, V265, P4583; Razin E, 1999, J BIOL CHEM, V274, P34272, DOI 10.1074/jbc.274.48.34272; Reardon JT, 1996, P NATL ACAD SCI USA, V93, P6482, DOI 10.1073/pnas.93.13.6482; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; Rodriguez CR, 2000, MOL CELL BIOL, V20, P104, DOI 10.1128/MCB.20.1.104-112.2000; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; Sambrook J, 1989, MOL CLONING; Stanhill A, 1999, MOL CELL BIOL, V19, P7529; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; VALAY JG, 1993, J MOL BIOL, V234, P307, DOI 10.1006/jmbi.1993.1587	40	55	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34837	34840		10.1074/jbc.C000505200	http://dx.doi.org/10.1074/jbc.C000505200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10958787	hybrid			2022-12-25	WOS:000165422800002
J	Suh, JR; Oppenheim, EW; Girgis, S; Stover, PJ				Suh, JR; Oppenheim, EW; Girgis, S; Stover, PJ			Purification and properties of a folate-catabolizing enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDASE-GENERATED SUPEROXIDE; INDUCED INSULIN RELEASE; ONE-CARBON METABOLISM; FERRITIN-H-CHAIN; RAT-LIVER; IRON MOBILIZATION; PLACENTAL ISOFERRITIN; SIDEROSOMAL FERRITIN; ANTICONVULSANT DRUGS; PANCREATIC-ISLETS	We have identified and purified to homogeneity an enzyme from rat liver that catalyzes the oxidative catabolism of 5-formyltetrahydrofolate to p-aminobenzoylglutamate and a pterin derivative. Purification of the enzyme utilized six column matrices, including a pterin-6-carboxylic acid affinity column. Treatment of crude rat liver extracts with EDTA or heat decreased the specific activity of the enzyme by up to 85%. Peptides generated from-the purified protein were sequenced and found to be identical to primary sequences present within rat light chain or heavy chain ferritin. Commercial rat ferritin did not display catabolic activity, but activity could be acquired with iron loading. The purified enzyme contained 2000 atoms of iron/ferritin 24-mer and displayed similar electrophoretic properties as commercial rat liver ferritin. The ferritin-catalyzed reaction displayed burst kinetics, and the enzyme catalyzed only a single turnover In vitro. Expression of rat heavy chain ferritin cDNA resulted in increased rates of folate turnover in cultured Chinese hamster ovary cells and human mammary carcinoma cells and reduced intracellular folate concentrations in Chinese hamster ovary cells. These results indicate that ferritin catalyzes folate turnover in vitro: and in vivo and may be an important factor in regulating intracellular folate concentrations.	Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA	Cornell University	Stover, PJ (corresponding author), Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA.	PJS13@cornell.edu			NICHD NIH HHS [HD35678] Funding Source: Medline; NIDDK NIH HHS [DK07158-21] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007158] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS SC, 1992, J INORG BIOCHEM, V47, P161, DOI 10.1016/0162-0134(92)84062-R; ANDREWS SC, 1987, BIOCHEM J, V245, P439, DOI 10.1042/bj2450439; ANDREWS SC, 1987, BIOCHEM J, V245, P447, DOI 10.1042/bj2450447; APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; ARCHER MC, 1972, CAN J BIOCHEM CELL B, V50, P1174, DOI 10.1139/o72-160; AROSIO P, 1978, J BIOL CHEM, V253, P4451; Beljanski M, 1996, INT J ONCOL, V8, P1143; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BOMFORD A, 1981, J BIOL CHEM, V256, P948; Bratton AC, 1939, J BIOL CHEM, V128, P537; Caudill MA, 1998, J NUTR, V128, P204, DOI 10.1093/jn/128.2.204; Chasteen ND, 1999, J STRUCT BIOL, V126, P182, DOI 10.1006/jsbi.1999.4118; CRAGG SJ, 1981, BIOCHEM J, V199, P565, DOI 10.1042/bj1990565; CRICHTON RR, 1980, J INORG BIOCHEM, V13, P305, DOI 10.1016/S0162-0134(00)80251-2; DAVIS MD, 1989, J BIOL CHEM, V264, P8585; DENIS MG, 1992, INT J CANCER, V50, P930, DOI 10.1002/ijc.2910500619; Einstein RS, 1998, J NUTR, V128, P2295, DOI 10.1093/jn/128.12.2295; GEOGHEGAN FL, 1995, J NUTR, V125, P2563; GRADY JK, 1990, IRON BIOMINERALS, P315; Gregory J F 3rd, 1996, Adv Food Nutr Res, V40, P81, DOI 10.1016/S1043-4526(08)60021-2; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; HARRISON PM, 1975, PROTEINS IRON STORAG, P269; HAZARD JT, 1977, BLOOD, V49, P139; Higgy NA, 1997, MOL CARCINOGEN, V20, P332, DOI 10.1002/(SICI)1098-2744(199712)20:4<332::AID-MC2>3.0.CO;2-L; HOOGSTRATEN B, 1965, CANCER RES, V25, P1933; Horne DW, 1997, METHOD ENZYMOL, V281, P38; IHARA K, 1984, J BIOL CHEM, V259, P278; Johnson JL, 1999, BIOCHEMISTRY-US, V38, P4089, DOI 10.1021/bi982690d; JONES T, 1978, BIOCHEMISTRY-US, V17, P4011, DOI 10.1021/bi00612a021; Juan SH, 1999, ARCH BIOCHEM BIOPHYS, V361, P295, DOI 10.1006/abbi.1998.0998; KELLY D, 1979, J CLIN INVEST, V64, P1089, DOI 10.1172/JCI109547; KELLY DA, 1983, CLIN SCI, V65, P303, DOI 10.1042/cs0650303; KIRKALI Z, 1995, EUR UROL, V28, P131; LAVOIE DJ, 1979, BIOCHIM BIOPHYS ACTA, V579, P359, DOI 10.1016/0005-2795(79)90063-1; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; LEIBOLD EA, 1984, J BIOL CHEM, V259, P4327; LEWIS GP, 1979, ANAL BIOCHEM, V93, P91, DOI 10.1016/S0003-2697(79)80121-9; LIAU G, 1991, J BIOL CHEM, V266, P18819; Liu ZD, 1999, BIOCHEM PHARMACOL, V57, P559, DOI 10.1016/S0006-2952(98)00319-0; MACDONALD MJ, 1991, J BIOL CHEM, V266, P1335; MACDONALD MJ, 1994, FASEB J, V8, P777, DOI 10.1096/fasebj.8.10.8050678; MACDONALD MJ, 1991, J BIOL CHEM, V266, P22392; MAGNUS EM, 1963, LANCET, V2, P302; MARAS B, 1994, J BIOL CHEM, V269, P18429; MARCUS DM, 1979, J NATL CANCER I, V55, P791; MARUYAMA T, 1978, ANAL BIOCHEM, V84, P277, DOI 10.1016/0003-2697(78)90511-0; MATZNER Y, 1979, BRIT J HAEMATOL, V42, P345, DOI 10.1111/j.1365-2141.1979.tb01142.x; MAXWELL JD, 1972, BRIT MED J, V1, P297, DOI 10.1136/bmj.1.5795.297; Maymon R, 1996, BRIT J OBSTET GYNAEC, V103, P301, DOI 10.1111/j.1471-0528.1996.tb09732.x; MAYMON R, 1989, OBSTET GYNECOL, V74, P597; MCNULTY H, 1993, J NUTR, V123, P1089; MCNULTY H, 1995, J NUTR, V125, P99; MCPARTLIN J, 1993, LANCET, V341, P148, DOI 10.1016/0140-6736(93)90007-4; MILLER LL, 1991, P NATL ACAD SCI USA, V88, P4946, DOI 10.1073/pnas.88.11.4946; MOAD G, 1978, TETRAHEDRON LETT, P2271; Oppenheim EW, 2000, J BIOL CHEM, V275, P19268, DOI 10.1074/jbc.M001610200; Picard V, 1996, BLOOD, V87, P2057; Picard V, 1998, J BIOL CHEM, V273, P15382, DOI 10.1074/jbc.273.25.15382; RAO BPR, 1963, LANCET, V1, P1192; ROBERTSON EF, 1987, ANAL BIOCHEM, V167, P290, DOI 10.1016/0003-2697(87)90166-7; SCHIRCH V, 1989, ARCH BIOCHEM BIOPHYS, V269, P371, DOI 10.1016/0003-9861(89)90120-3; Scott J. M., 1984, FOLATES PTERINS, P307; SHANE B, 1989, VITAM HORM, V45, P263; SHAW S, 1989, BIOCHEM J, V257, P277, DOI 10.1042/bj2570277; SHAW S, 1990, FREE RADICAL BIO MED, V9, P11, DOI 10.1016/0891-5849(90)90044-J; STOVER P, 1993, TRENDS BIOCHEM SCI, V18, P102, DOI 10.1016/0968-0004(93)90162-G; STOVER P, 1991, J BIOL CHEM, V266, P1543; TAHER MM, 1987, ARCH BIOCHEM BIOPHYS, V257, P100, DOI 10.1016/0003-9861(87)90547-9; VONDERPORTEN AE, 1992, J NUTR, V122, P1293, DOI 10.1093/jn/122.6.1293; WANG CZ, 1994, NUTR RES, V14, P875, DOI 10.1016/S0271-5317(05)80488-9; WEINSTEIN RE, 1982, CANCER, V50, P2406, DOI 10.1002/1097-0142(19821201)50:11<2406::AID-CNCR2820501127>3.0.CO;2-S; WORWOOD M, 1990, BLOOD REV, V4, P259, DOI 10.1016/0268-960X(90)90006-E; Wu CG, 1997, INT J ONCOL, V11, P187; ZAKRZEWSKI SF, 1966, J BIOL CHEM, V241, P2957; ZAMIEROWSKI MM, 1977, J NUTR, V107, P1937, DOI 10.1093/jn/107.10.1937; ZHU LJ, 1995, ENDOCRINOLOGY, V136, P4106, DOI 10.1210/en.136.9.4106	76	53	56	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35646	35655		10.1074/jbc.M005864200	http://dx.doi.org/10.1074/jbc.M005864200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10978335	hybrid			2022-12-25	WOS:000165422800108
J	Salloukh, HF; Vowles, I; Heisterkamp, N; Groffen, J; Laneuville, P				Salloukh, HF; Vowles, I; Heisterkamp, N; Groffen, J; Laneuville, P			Early events in leukemogenesis in P190Bcr-abl transgenic mice	ONCOGENE			English	Article						oncogenesis; acute leukemia; P190Bcr-abl; cell cycle; apoptosis	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; DNA-POLYMERASE-BETA; BCR-ABL ONCOPROTEIN; TYROSINE PHOSPHORYLATION; EXPRESSING P210(BCR/ABL); PHILADELPHIA-CHROMOSOME; HEMATOPOIETIC-CELLS; ADAPTER PROTEIN; C-ABL	The activated tyrosine kinase, Bcr-abl, is implicated in a number of hematopoietic malignancies. The exact biological mechanism by which the kinases transforms cells is still not well delineated. Previous data has suggested that the inhibition of apoptosis and the deregulation of cell cycle progression as the result of P210Bcr-abl expression might contribute to leukemogenesis, In vitro systems in which Bcr-Abl is over-expressed have concluded that similar growth regulatory pathways are affected as a result of the expression of both P210 and P190Bcr-abl. Here, we utilized an in vitro P190Bcr-abl leukemia mouse model to dissect the early events that contribute to transformation by this isoform of Bcr-Abl. In this mouse model P190Bcr-abl is expressed as a low but physiologically relevant level in that all mice develop pre-B leukemia lymphomas, We show that cell cycle and apoptotic responses to DNA damage are intact in bone marrow and spleen cells of such animals. We also demonstrate a normal induction of p21(WAF-1/CIP1) in both hematopoietic and non-hematopoietic tissue as a result of genotoxic stress, We suggest that P190Bcr-abl induced transformation is different than that of P210Bcr-abl.	Royal Victoria Hosp, Dept Med, Div Expt Med, Montreal, PQ H3A 1A1, Canada; Royal Victoria Hosp, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; Childrens Hosp Los Angeles, Sect Mol Diag, Div Hematol Oncol, Los Angeles, CA 90027 USA	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; Children's Hospital Los Angeles	Laneuville, P (corresponding author), Royal Victoria Hosp, Dept Med, Div Expt Med, Hersey Pavil,H5-21, 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.		Heisterkamp, Nora/C-1698-2012; Laneuville, Pierre/AAH-2293-2021	Heisterkamp, Nora/0000-0003-2769-2273; 	NATIONAL CANCER INSTITUTE [R01CA050248, R55CA047456, R01CA047456] Funding Source: NIH RePORTER; NCI NIH HHS [CA47456, CA50248] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; BEDI A, 1994, BLOOD, V83, P2038; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; BERGER R, 1993, LEUKEMIA LYMPHOMA, V11, P235, DOI 10.3109/10428199309047892; BLOOMFIELD CD, 1989, ACUTE LYMPHOBLASTIC, P101; Cambier N, 1998, ONCOGENE, V16, P335, DOI 10.1038/sj.onc.1201490; Canitrot Y, 1999, ONCOGENE, V18, P2676, DOI 10.1038/sj.onc.1202619; Cortez D, 1997, ONCOGENE, V15, P2333, DOI 10.1038/sj.onc.1201400; Cox LS, 1997, J PATHOL, V183, P134, DOI 10.1002/(SICI)1096-9896(199710)183:2<134::AID-PATH960>3.0.CO;2-D; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; de Jong R, 1997, J BIOL CHEM, V272, P32649, DOI 10.1074/jbc.272.51.32649; DEJONG R, 1995, ONCOGENE, V11, P1469; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; GOTOH A, 1995, EXP HEMATOL, V23, P1153; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HEISTERKAMP N, 1991, HEMATOL PATHOL, V5, P1; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Honda H, 1998, BLOOD, V91, P2067, DOI 10.1182/blood.V91.6.2067.2067_2067_2075; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; LANEUVILLE P, 1994, CANCER RES, V54, P1360; LI X, 1994, LEUKEMIA LYMPHOMA, V13, P65, DOI 10.3109/10428199409052678; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SALGIA R, 1995, ONCOGENE, V11, P1149; Sattler M, 1996, ONCOGENE, V12, P839; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; TENHOEVE J, 1994, CANCER RES, V54, P2563; VONCKEN JW, 1992, BLOOD, V79, P1029; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603; VONCKEN JW, 1992, CANCER RES, V52, P4534; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	36	8	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2000	19	38					4362	4374		10.1038/sj.onc.1203804	http://dx.doi.org/10.1038/sj.onc.1203804			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980612				2022-12-25	WOS:000089271900007
J	Zhang, CL; Tada, M; Kobayashi, H; Nozaki, M; Moriuchi, T; Abe, H				Zhang, CL; Tada, M; Kobayashi, H; Nozaki, M; Moriuchi, T; Abe, H			Detection of PTEN nonsense mutation and psi PTEN expression in central nervous system high-grade astrocytic tumors by a yeast-based stop codon assay	ONCOGENE			English	Article						astrocytoma; glioblastoma; PTEN/MMAC1; psi PTEN; pseudogene	P53 FUNCTIONAL ASSAY; BANNAYAN-ZONANA-SYNDROME; SUPPRESSOR GENE; GLIOBLASTOMA-MULTIFORME; HUMAN GLIOMAS; CELL-LINES; PTEN/MMAC1 MUTATIONS; GERMLINE MUTATIONS; MALIGNANT GLIOMAS; COWDEN-DISEASE	We have developed a new yeast-based assay for the detection of PTEN nonsense mutation, and applied it to a total of 42 astrocytic tumors, The assay utilizes homologous recombination of PCR-amplified PTEN cDNA samples to a yeast vector which expresses an in-frame PTEN::ADE2 chimera protein. An allele of nonsense mutation in the sample PTEN mRNA gives a truncated chimera protein in a yeast cell, resulting in the formation of a red colony, The assay and subsequent sequence analysis demonstrated nonsense mutations as red colonies of more than 10% in one of 10 anaplastic astrocytomas and six of 18 glioblastomas, but none in six pilocytic astrocytomas or in eight astrocytomas, Sequence analysis of white colonies showed one missense mutation in a glioblastoma. Interestingly, four of seven nonsense mutations were frame-shifts due to exon skipping, In addition, pink colonies were found in one of six pilocytic astrocytomas, three of eight astrocytomas, two of 10 anaplastic astrocytomas, and 10 of 18 glioblastomas, Sequence analysis of the pink colonies revealed a sequence similar to those reported as psi PTEN/PTH2. By testing mRNA and genomic DNA, it was found to be a processed pseudogene which was transcribed, The psi PTEN expression was complementary to PTEN mutation, for 14 of 18 glioblastomas showed either PTEN mutation or psi PTEN expression and only one case showed both PTEN mutation and psi PTEN expression (P<0.046), suggesting a pathological role of psi PTEN expression as an alternative to PTEN mutation in glioblastomas.	Hokkaido Univ, Grad Sch Med, Inst Canc, Div Cell Biol, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ, Grad Sch Med, Neurosurg Sect, Dept Neuropathophysiol, Sapporo, Hokkaido 0608638, Japan	Hokkaido University; Hokkaido University	Tada, M (corresponding author), Hokkaido Univ, Grad Sch Med, Inst Canc, Div Cell Biol, Sapporo, Hokkaido 0608638, Japan.		KOBAYASHI, Hiroyuki/G-8990-2012					AndreuttiZaugg C, 1997, CANCER RES, V57, P3288; AYALA FJ, 1995, SCIENCE, V270, P1930, DOI 10.1126/science.270.5244.1930; BELLO MJ, 1994, INT J CANCER, V57, P172, DOI 10.1002/ijc.2910570207; Bostrom J, 1998, CANCER RES, V58, P29; Cheney IW, 1998, CANCER RES, V58, P2331; Chiariello E, 1998, ONCOGENE, V16, P541, DOI 10.1038/sj.onc.1201689; Dahia PLM, 1998, ONCOGENE, V16, P2403, DOI 10.1038/sj.onc.1201762; Davies MA, 1999, CANCER RES, V59, P2551; Davies MA, 1998, CANCER RES, V58, P5285; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Hayashi Y, 1997, BRAIN PATHOL, V7, P871, DOI 10.1111/j.1750-3639.1997.tb00890.x; Ishii N, 1998, INT J CANCER, V76, P797, DOI 10.1002/(SICI)1097-0215(19980610)76:6<797::AID-IJC5>3.3.CO;2-1; Kim SK, 1998, ONCOGENE, V16, P89, DOI 10.1038/sj.onc.1201512; Kleihues P, 1993, HISTOLOGICAL TYPING; Kon H, 1998, ONCOGENE, V16, P257, DOI 10.1038/sj.onc.1201488; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; LI WH, 1981, NATURE, V292, P237, DOI 10.1038/292237a0; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Liu WG, 1997, CANCER RES, V57, P5254; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; MAQUAT LE, 1995, RNA, V1, P453; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Matsumoto R, 1998, CANCER RES, V58, P609; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nakamura H, 1998, ONCOGENE, V16, P1009, DOI 10.1038/sj.onc.1201618; Olschwang S, 1998, NAT GENET, V18, P12, DOI 10.1038/ng0198-12; Rasheed BKA, 1997, CANCER RES, V57, P4187; REIFENBERGER G, 1994, CANCER RES, V54, P4299; Scala S, 1998, INT J ONCOL, V13, P665; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tada M, 1997, NEUROSURGERY, V40, P393, DOI 10.1097/00006123-199702000-00034; Tada M, 1997, MOL CARCINOGEN, V18, P171, DOI 10.1002/(SICI)1098-2744(199703)18:3<171::AID-MC6>3.3.CO;2-2; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Teng DHF, 1997, CANCER RES, V57, P5221; Tohma Y, 1998, J NEUROPATH EXP NEUR, V57, P684, DOI 10.1097/00005072-199807000-00005; Tsou HC, 1998, HUM GENET, V102, P467, DOI 10.1007/s004390050723; VONDEIMLING A, 1992, J NEUROSURG, V77, P295, DOI 10.3171/jns.1992.77.2.0295; VONDEIMLING A, 1994, INT J CANCER, V57, P676, DOI 10.1002/ijc.2910570511; Wang SI, 1997, CANCER RES, V57, P4183; WEISMAN LS, 1987, J CELL BIOL, V105, P1539, DOI 10.1083/jcb.105.4.1539	48	17	18	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4346	4353		10.1038/sj.onc.1203795	http://dx.doi.org/10.1038/sj.onc.1203795			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980610				2022-12-25	WOS:000089271900005
J	Reznikov, K; Kolesnikova, L; Pramanik, A; Tan-no, K; Gileva, I; Yakovleva, T; Rigler, R; Terenius, L; Bakalkin, G				Reznikov, K; Kolesnikova, L; Pramanik, A; Tan-no, K; Gileva, I; Yakovleva, T; Rigler, R; Terenius, L; Bakalkin, G			Clustering of apoptotic cells via bystander killing by peroxides	FASEB JOURNAL			English	Article						intercellular communications; cell death; reactive oxygen species	HYDROGEN-PEROXIDE; NITRIC-OXIDE; IN-VITRO; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; OXIDATIVE STRESS; INDUCED P53; EXPRESSION; GROWTH; DEATH	Clustering of apoptotic cells is a characteristic of many developing or renewing systems, suggesting that apoptotic cells kill bystanders. Bystander killing can be triggered experimentally by inducing apoptosis in single cells and may be based on the exchange of as yet unidentified chemical cell death signals between nearby cells without the need for cell-to-cell communication via gap junctions. Here we demonstrate that apoptotic cell clusters occurred spontaneously, after serum deprivation or p53 transfection in cell monolayers in vitro. Clustering was apparently induced through bystander killing by primary apoptotic cells. Catalase, a peroxide scavenger, suppressed bystander killing, suggesting that hydrogen peroxide generated by apoptotic cells is the death signal. Although p53 expression increased the number of apoptoses, clustering was found to be similar around apoptotic cells whether or not p53 was expressed, indicating that there is no specific p53 contribution to bystander killing. Bystander killing through peroxides emitted by apoptotic cells may propagate tissue injury in different pathological situations and be relevant in chemo-, gamma-ray, and gene therapy of cancer.	Karolinska Inst, Dept Clin Neurosci, Expt Alcohol & Drug Addict Res Sect, S-17176 Stockholm, Sweden; Karolinska Inst, Dept Med Biochem & Biophys, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Bakalkin, G (corresponding author), Karolinska Inst, Dept Clin Neurosci, Sect Alcohol & Drug Addict Res, CMM L8-01, S-17176 Stockholm, Sweden.	Gregory.Bakalkin@cmm.ki.se		Bakalkin, Georgy/0000-0002-8074-9833; Tan-No, Koichi/0000-0001-6724-848X				Bedner E, 1999, CYTOMETRY, V35, P181, DOI 10.1002/(SICI)1097-0320(19990301)35:3<181::AID-CYTO1>3.0.CO;2-5; Boonen G, 2000, PLANTA MED, V66, P7, DOI 10.1055/s-2000-11112; Booth C, 1995, CELL PROLIFERAT, V28, P581, DOI 10.1111/j.1365-2184.1995.tb00046.x; Bouvet M, 1998, CANCER RES, V58, P2288; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CIVITELLI R, 1993, J CLIN INVEST, V91, P1888, DOI 10.1172/JCI116406; CLARK PJ, 1954, ECOLOGY, V35, P445, DOI 10.2307/1931034; Collins JA, 1997, J HISTOCHEM CYTOCHEM, V45, P923, DOI 10.1177/002215549704500702; Davies KJA, 1999, IUBMB LIFE, V48, P41, DOI 10.1080/152165499307404; Dilber MS, 1997, GENE THER, V4, P273, DOI 10.1038/sj.gt.3300389; DONAHUE HJ, 1995, J BONE MINER RES, V10, P881; Dumont A, 1999, ONCOGENE, V18, P747, DOI 10.1038/sj.onc.1202325; EDELSTEINKESHET L, 1990, DIFFERENTIATION, V45, P147, DOI 10.1111/j.1432-0436.1990.tb00468.x; Favrot M, 1998, GENE THER, V5, P728, DOI 10.1038/sj.gt.3300661; Frank DK, 1998, CLIN CANCER RES, V4, P2521; Goldkorn T, 1998, J CELL SCI, V111, P3209; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; Haugland R.P., 1996, HDB FLUORESCENT PROB, P491; Hendry JH, 1998, INT J RADIAT BIOL, V73, P575; HICKMAN AW, 1994, CANCER RES, V54, P5797; Hiraoka W, 1998, J CLIN INVEST, V102, P1961, DOI 10.1172/JCI3437; Ijiri K., 1987, P326; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Kaneko K, 1997, B MATH BIOL, V59, P139, DOI 10.1016/S0092-8240(96)00044-4; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Komarova EA, 1998, ONCOGENE, V17, P1089, DOI 10.1038/sj.onc.1202303; Kravtsov VD, 1999, AM J PATHOL, V155, P1327, DOI 10.1016/S0002-9440(10)65235-2; Kuzin B, 1996, CELL, V87, P639, DOI 10.1016/S0092-8674(00)81384-7; LANG R, 1994, DEVELOPMENT, V120, P3395; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; Lin JHC, 1998, NAT NEUROSCI, V1, P494, DOI 10.1038/2210; Matsumoto H, 1999, CANCER RES, V59, P3239; Maxeiner H, 1998, J EXP MED, V188, P2257, DOI 10.1084/jem.188.12.2257; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; Milan M, 1997, P NATL ACAD SCI USA, V94, P5691, DOI 10.1073/pnas.94.11.5691; MORITA I, 1995, BIOCHEMISTRY-US, V34, P7194, DOI 10.1021/bi00021a034; Mothersill C, 1998, RADIAT RES, V149, P256, DOI 10.2307/3579958; Narayanan PK, 1997, CANCER RES, V57, P3963; NATHAN CF, 1987, J CLIN INVEST, V80, P1550, DOI 10.1172/JCI113241; NIKOTERA P, 1997, ADV NEUROIMMUNOL, V5, P411; Ogino T, 1997, FREE RADICAL BIO MED, V23, P445, DOI 10.1016/S0891-5849(97)00115-9; Olejnicka BT, 1999, APMIS, V107, P747, DOI 10.1111/j.1699-0463.1999.tb01469.x; PAILLARD F, 1997, GENE THER, V4, P273; Peunova N, 1996, COLD SPRING HARB SYM, V61, P417; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Potten C S, 1981, Int Rev Cytol, V69, P271; Pramanik A., 1999, Biomedical Chromatography, V13, P119, DOI 10.1002/(SICI)1099-0801(199904)13:2<119::AID-BMC835>3.0.CO;2-P; Prise KM, 1998, INT J RADIAT BIOL, V74, P793, DOI 10.1080/095530098141087; QUI XB, 1997, FREE RADICAL BIO MED, V24, P848; REZNIKOV K, 1995, J COMP NEUROL, V360, P536, DOI 10.1002/cne.903600313; REZNIKOV KY, 1991, ADV ANAT EMBRYOL CEL, V122, P1; REZNIKOV KY, 1984, ANAT EMBRYOL, V170, P99, DOI 10.1007/BF00319464; Rigler R, 1999, P NATL ACAD SCI USA, V96, P13318, DOI 10.1073/pnas.96.23.13318; RIGLER R, 1995, J BIOTECHNOL, V41, P177, DOI 10.1016/0168-1656(95)00054-T; Rollet-Labelle E, 1998, FREE RADICAL BIO MED, V24, P563, DOI 10.1016/S0891-5849(97)00292-X; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Simizu S, 1998, J BIOL CHEM, V273, P26900, DOI 10.1074/jbc.273.41.26900; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012; VANDISSEL JT, 1987, J IMMUNOL, V138, P4428; Wilson JW, 1998, AM J PATHOL, V153, P899, DOI 10.1016/S0002-9440(10)65631-3	62	31	34	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2000	14	12					1754	1764		10.1096/fj.99-0890com	http://dx.doi.org/10.1096/fj.99-0890com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973925				2022-12-25	WOS:000089212400015
J	Herr, I; Posovszky, C; Di Marzio, L; Cifone, MG; Boehler, T; Debatin, KM				Herr, I; Posovszky, C; Di Marzio, L; Cifone, MG; Boehler, T; Debatin, KM			Autoamplification of apoptosis following ligation of CD95-L, TRAIL and TNF-alpha	ONCOGENE			English	Article						FADD; JNK/SAPKs; ATF-2; cJun; APO-1/Fas	TUMOR-NECROSIS-FACTOR; APO-1/FAS LIGAND EXPRESSION; THERAPY-INDUCED APOPTOSIS; HUMAN T-CELLS; FAS LIGAND; SIGNAL-TRANSDUCTION; JNK/SAPK ACTIVITY; ACTIVATION; PROTEIN; STRESS	CD95-L, TNP-alpha and TRAIL are death-inducing ligands (DILs) which may signal apoptosis via crosslinking of their cognate receptors, The present study shows that treatment of cells with agonistic mAB alpha APO-1 (CD95), recombinant TRAIL or TNF-alpha leads to enhanced mRNA and protein expression of each DIL with concomitant death in target cells, Immunoprecipitation of CD95-L protein from supernatant as well as neutralizing antibodies suggest DIL proteins to be cooperatively acting mediators of these cytotoxic activity, Antoamplification of the death signal was blocked in cells with a defect in apoptosis signaling either due to a dysfunctional FADD molecule or to the failure to activate JNK/SAPKs, Phosphorylation and enhanced binding of cJun and ATF-2 to DIL promoters suggest JNK/SAPKs as activators of these transcription factors following death receptor triggering, In consequence, autocrine production of DILs allows the spread of death signals to sensitive target cells.	German Canc Res Ctr, Div Pediat Oncol, D-6900 Heidelberg, Germany; Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy; Univ Ulm, Childrens Hosp, Ulm, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); University of L'Aquila; Ulm University	Debatin, KM (corresponding author), Univ Kinderklin, Prittwitzstr 43, D-89075 Ulm, Germany.		Böhler, Thomas/AAS-3986-2021; Di Marzio, Luisa/AAF-8052-2021; Cifone, Maria Grazia/ABH-1984-2021; Debatin, Klaus-Michael/J-9704-2014; Cifone, Maria Grazia/I-3750-2019; Posovszky, Carsten/J-5966-2018; Di Marzio, Luisa/H-9969-2012	Di Marzio, Luisa/0000-0002-2518-7188; Debatin, Klaus-Michael/0000-0002-8397-1886; Cifone, Maria Grazia/0000-0002-9923-5445; Posovszky, Carsten/0000-0002-9487-8812; 				Afford SC, 1999, J EXP MED, V189, P441, DOI 10.1084/jem.189.2.441; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Basu S, 1998, ONCOGENE, V17, P3277, DOI 10.1038/sj.onc.1202570; Cahill MA, 1996, ONCOGENE, V13, P2087; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; Grell M, 1999, EMBO J, V18, P3034, DOI 10.1093/emboj/18.11.3034; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Herr I, 1996, CELL DEATH DIFFER, V3, P299; Herr I, 1999, CELL DEATH DIFFER, V6, P130, DOI 10.1038/sj.cdd.4400467; HERR I, 1994, CARCINOGENESIS, V15, P1105, DOI 10.1093/carcin/15.6.1105; Herr I, 1999, INT J CANCER, V80, P417, DOI 10.1002/(SICI)1097-0215(19990129)80:3<417::AID-IJC14>3.3.CO;2-2; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Jeremias I, 1998, EUR J IMMUNOL, V28, P143, DOI 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KIERNER PA, 1997, J IMMUNOL, V159, P1594; Krammer P H, 1999, Adv Immunol, V71, P163; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MILLERGRAZIANO CL, 1994, SHOCK, V1, P317, DOI 10.1097/00024382-199405000-00001; PIGUET PF, 1991, J EXP MED, V173, P673, DOI 10.1084/jem.173.3.673; Sheikh MS, 1998, CANCER RES, V58, P1593; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Suda T, 1997, J EXP MED, V186, P2045, DOI 10.1084/jem.186.12.2045; Tanaka M, 1998, NAT MED, V4, P31, DOI 10.1038/nm0198-031; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsai EY, 1996, MOL CELL BIOL, V16, P459; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Vogt M, 1998, FEBS LETT, V429, P67, DOI 10.1016/S0014-5793(98)00562-6; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9	36	36	39	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 31	2000	19	37					4255	4262		10.1038/sj.onc.1203776	http://dx.doi.org/10.1038/sj.onc.1203776			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980599				2022-12-25	WOS:000089032900008
J	Bartkova, J; Thullberg, M; Rajpert-De Meyts, E; Skakkebaek, NE; Bartek, J				Bartkova, J; Thullberg, M; Rajpert-De Meyts, E; Skakkebaek, NE; Bartek, J			Lack of p19(INK4d) in human testicular germ-cell tumours contrasts with high expression during normal spermatogenesis	ONCOGENE			English	Article						p19(INK4d); RB pathway; spermatogenesis; carcinoma in situ; testicular germ cell tumours	RETINOBLASTOMA PROTEIN PATHWAY; CARCINOMA IN-SITU; CDK INHIBITORS; DEPENDENT KINASES; TUMORS; CANCER; TESTIS; DIFFERENTIATION; PROLIFERATION; TUMORIGENESIS	p19(INK4d) a member of the INK4 family of cyclin-dependent kinase inhibitors, negatively regulates the proto-oncogenic cyclin D/CDK4(6) complexes whose ability to phosphorylate the retinoblastoma tumour suppressor (RB) promotes G1/S transition. In contrast to the related p16(INK4a) tumour suppressor, expression patterns of 19(INK4d) in human tissues and tumours remain unknown. As the RE pathway is commonly targeted in cancer, and mouse models suggest a role for p19(INK4d) in spermatogenesis, ne examined the abundance and localization of p19(INK4d) in the human testis, both during normal development and at various stages of germ-cell tumour pathogenesis. Our data show that the p19(INK4d) protein is abundant in spermatocytes of normal human adult testes, whereas virtually no p19(INK4d) is detectable in testicular cancer, including the preinvasive carcinoma ill situ stage. Together with the lack of p19(INK4d) in human foetal germ cells, these results support the concept of foetal origin of the testicular germ-cell tumours, and help better understand the emerging role of the RE pathway in spermatogenesis and tumorigenesis in the human testis.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen O, Denmark; Univ Copenhagen, Dept Growth & Reprod, Rigshosp, Copenhagen, Denmark	Danish Cancer Society; Rigshospitalet; University of Copenhagen	Bartek, J (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen O, Denmark.		Rajpert-De Meyts, Ewa/H-6526-2019; Bartek, Jiri/G-5870-2014	Rajpert-De Meyts, Ewa/0000-0002-5946-7559; 				Andrews PW, 1998, APMIS, V106, P158, DOI 10.1111/j.1699-0463.1998.tb01331.x; BARKOVA J, 2000, INT J CANCER, V85, P370; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Bartkova J, 1998, ONCOGENE, V17, P1027, DOI 10.1038/sj.onc.1202016; Bartkova J, 1999, J PATHOL, V187, P573, DOI 10.1002/(SICI)1096-9896(199904)187:5<573::AID-PATH289>3.0.CO;2-H; BERNARDS R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P33; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; Chaubert P, 1997, AM J PATHOL, V151, P859; Dieckmann KP, 1999, INT J CANCER, V83, P815, DOI 10.1002/(SICI)1097-0215(19991210)83:6<815::AID-IJC21>3.3.CO;2-Q; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; GRIGOR KM, 1993, EUR UROL, V23, P93; Grigor KM, 1998, APMIS, V106, P221, DOI 10.1111/j.1699-0463.1998.tb01339.x; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Heidenreich A, 1998, J UROLOGY, V159, P1725, DOI 10.1097/00005392-199805000-00101; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Houldsworth J, 1997, CELL GROWTH DIFFER, V8, P293; HUSTIN J, 1987, INT J ANDROL, V10, P29, DOI 10.1111/j.1365-2605.1987.tb00162.x; JORGENSEN N, 1995, LAB INVEST, V72, P223; MOSTOFI FK, 1986, GERM CELL TUMOURS, V2, P1; OOSTERHUIS JW, 1993, EUR UROL, V23, P245; Rajpert-De Meyts E, 1998, APMIS, V106, P198; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; STROHMEYER T, 1991, P NATL ACAD SCI USA, V88, P6662, DOI 10.1073/pnas.88.15.6662; Thullberg M, 2000, HYBRIDOMA, V19, P63, DOI 10.1089/027245700315806; Zindy F, 2000, MOL CELL BIOL, V20, P372, DOI 10.1128/MCB.20.1.372-378.2000; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	36	46	48	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2000	19	36					4146	4150		10.1038/sj.onc.1203769	http://dx.doi.org/10.1038/sj.onc.1203769			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962575				2022-12-25	WOS:000088955100008
J	Ge, NL; Rudikoff, S				Ge, NL; Rudikoff, S			Expression of PTEN in PTEN-deficient multiple mgeloma cells abolishes tumor growth in vivo	ONCOGENE			English	Article						multiple myeloma; PTEN; AKT; OPM-2 cells	SUPPRESSOR GENE; FACTOR-I; GERMLINE MUTATIONS; CARCINOMA-CELLS; MYELOMA; INSULIN; BREAST; CANCER; APOPTOSIS; LINES	Biochemical abnormalities associated with the development of multiple myeloma hale been difficult to define especially in terms of demonstrating an irt vivo effect of suspected lesions. Herein, we have identified such a defect associated with lack of expression of PTEN, a cellular phosphatase involved in the regulation of phosphatidylinositol phosphates (PIP's), In myeloma cells, PIP's are required for phosphorylation of Akt, a key event leading to inhibition of apoptosis, Loss of PTEN results in a failure to de-phosphorylate PIP's and a corresponding increase in Akt phosphorylation. OPM-2 cells lacking PTEN expression have the highest level of Akt phosphorylation of eight lines examined. Loss of PTEN was found to be associated with a 630 bp deletion corresponding to amino acids 56-267, Ectopic expression of wild type PTEN in OPM-2 cells inhibited Akt phosphorylation which was correlated with an increase in apoptosis, The in vivo relevance of loss of PTEN expression was demonstrated by injecting control and wild type PTEN transfected OPM-2 cells into SCID mice. Tumors arose at an incidence of 100% in controls, but only 50% (and of smaller size and longer latency) in lon PTEN expressing clones. Importantly, clones expressing high le,els of PTEN failed to produce tumors even at five times the latency period of controls. These results demonstrate that PTEN deletion/mutation is responsible for in vivo growth of this tumor and suggests that PTEN regulation may play an important role in turner development in a subset of multiple myeloma patients.	NCI, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rudikoff, S (corresponding author), NCI, Cellular & Mol Biol Lab, NIH, Bldg 37, Bethesda, MD 20892 USA.				DIVISION OF BASIC SCIENCES - NCI [Z01BC005553] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson KC, 1999, SEMIN HEMATOL, V36, P3; Bergsagel PL, 1996, P NATL ACAD SCI USA, V93, P13931, DOI 10.1073/pnas.93.24.13931; Boni R, 1998, MELANOMA RES, V8, P300; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Davies MA, 1999, CANCER RES, V59, P2551; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; FREUND GG, 1994, CANCER RES, V54, P3179; Gabrea A, 1999, MOL CELL, V3, P119, DOI 10.1016/S1097-2765(00)80180-X; GE NL, 2000, IN PRESS BLOOD; GeorgiiHemming P, 1996, BLOOD, V88, P2250, DOI 10.1182/blood.V88.6.2250.bloodjournal8862250; Ghosh AK, 1999, GENE, V235, P85, DOI 10.1016/S0378-1119(99)00206-1; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Jelinek DF, 1997, J IMMUNOL, V159, P487; KLEIN B, 1992, HEMATOL ONCOL CLIN N, V6, P273, DOI 10.1016/S0889-8588(18)30344-7; Klein B, 1990, Eur Cytokine Netw, V1, P193; KYLE RA, 1992, HEMATOL ONCOL CLIN N, V6, P347, DOI 10.1016/S0889-8588(18)30348-4; LADANYI M, 1992, AM J PATHOL, V141, P949; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Munshi NC, 1999, SEMIN ONCOL, V26, P28; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; PORTIER M, 1992, ONCOGENE, V7, P2539; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; Risinger JI, 1997, CANCER RES, V57, P4736; Seiden Michael V., 1994, Current Opinion in Oncology, V6, P41, DOI 10.1097/00001622-199401000-00006; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Uddin S, 1996, EXP HEMATOL, V24, P622; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YASUGA Y, 1995, INT J HEMATOL, V62, P91	32	45	47	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2000	19	36					4091	4095		10.1038/sj.onc.1203801	http://dx.doi.org/10.1038/sj.onc.1203801			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962569				2022-12-25	WOS:000088955100002
J	Garcia-Guzman, M; Larsen, E; Vuori, K				Garcia-Guzman, M; Larsen, E; Vuori, K			The proto-oncogene c-Cbl is a positive regulator of Met-induced MAP kinase activation: a role for the adaptor protein Crk	ONCOGENE			English	Article						kinase; oncogenesis; signal transduction; tyrosine phosphorylation	GROWTH-FACTOR RECEPTOR; UBIQUITIN-PROTEASOME PATHWAY; SIGNALING COMPLEX-FORMATION; PAPILLARY RENAL CARCINOMAS; SRC-FAMILY KINASES; GRB2 BINDING-SITE; TYROSINE KINASE; T-CELL; PROTOONCOGENE PRODUCT; EGF-RECEPTOR	Hepatocyte growth factor triggers a complex biological program leading to invasive cell growth by activating the c-Met receptor tyrosine kinase. Following activation, Met signaling is elicited via its interactions with SH2- containing proteins, or via the phosphorylation of the docking protein Gab1, and the subsequent interaction of Gab1 with additional SH2-containing effector molecules. We have previously shown that the interaction between phosphorylated Gab1 and the adaptor protein Crk mediates activation of the JNK pathway downstream of Met. We report here that c-Cbl, which is a Gab1-like docking protein, also becomes tyrosine-phosphorylated in response to Met activation and serves as a docking molecule for various SH2-containing molecules, including Crk. We further show that Cbl is similarly capable of enhancing Met-induced JNK activation, and several lines of experimentation suggests that it does so by interacting with Crk. We also show that both Cbl and Gab1 enhance Met-induced activation of another MAP kinase cascade, the ERK pathway, in a Crk-independent manner. Taken together, our studies demonstrate a previously unidentified functional role for Cbl in Met signaling and suggest that Met utilizes at least two docking proteins, Gab1 and Cbl, to activate downstream signaling pathways.	Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Vuori, K (corresponding author), Burnham Inst, Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NCI NIH HHS [CA71560, CA76037] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071560, R01CA076037] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; Bustelo XR, 1997, ONCOGENE, V15, P2511, DOI 10.1038/sj.onc.1201430; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Ettenberg SA, 1999, ONCOGENE, V18, P1855, DOI 10.1038/sj.onc.1202499; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; Feshchenko EA, 1999, ONCOGENE, V18, P3703, DOI 10.1038/sj.onc.1202672; Fischer J, 1998, ONCOGENE, V17, P733, DOI 10.1038/sj.onc.1201983; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; Garcia-Guzman M, 1999, ONCOGENE, V18, P7775, DOI 10.1038/sj.onc.1203198; Grishin A, 2000, ONCOGENE, V19, P97, DOI 10.1038/sj.onc.1203254; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Jeffers M, 1998, ONCOGENE, V17, P2691, DOI 10.1038/sj.onc.1202209; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lupher ML, 1998, INT J BIOCHEM CELL B, V30, P439, DOI 10.1016/S1357-2725(97)00075-7; Matsuda M, 1996, CELL SIGNAL, V8, P335, DOI 10.1016/0898-6568(96)00067-8; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Sakkab D, 2000, J BIOL CHEM, V275, P10772, DOI 10.1074/jbc.275.15.10772; Sawasdikosol S, 1996, J IMMUNOL, V157, P110; Scaife RM, 2000, J CELL SCI, V113, P215; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; Thien CBF, 1997, ONCOGENE, V15, P2909, DOI 10.1038/sj.onc.1201468; Ueno H, 1998, BLOOD, V91, P46, DOI 10.1182/blood.V91.1.46.46_46_53; Ueno H, 1997, J BIOL CHEM, V272, P8739, DOI 10.1074/jbc.272.13.8739; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; VANDEWOUDE GF, 1997, CIBA F SYMP, V212, P130; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Zell T, 1998, CURR BIOL, V8, P814, DOI 10.1016/S0960-9822(98)70323-9; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU H, 1994, J BIOL CHEM, V269, P29943; Zhuang ZP, 1998, NAT GENET, V20, P66, DOI 10.1038/1727	69	42	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2000	19	35					4058	4065		10.1038/sj.onc.1203750	http://dx.doi.org/10.1038/sj.onc.1203750			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962563				2022-12-25	WOS:000088825300012
J	Thomas, M; Langley, B; Berry, C; Sharma, M; Kirk, S; Bass, J; Kambadur, R				Thomas, M; Langley, B; Berry, C; Sharma, M; Kirk, S; Bass, J; Kambadur, R			Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; BETA SUPERFAMILY MEMBER; TGF-BETA; CDK INHIBITORS; MYOGENIC LINEAGE; SKELETAL-MUSCLE; GENE MYF-5; MICE; DIFFERENTIATION; PROGRESSION	Myostatin, a member of the transforming growth factor-beta (TGF-beta) superfamily, has been shown to be a negative regulator of myogenesis. Here we show that myostatin functions by controlling the proliferation of muscle precursor cells. When C2C12 myoblasts were incubated with myostatin, proliferation of myoblasts decreased with increasing levels of myostatin. Fluorescence-activated cell sorting analysis revealed that myostatin prevented the progression of myoblasts from the G(1)- to S-phase of the cell cycle. Western analysis indicated that myostatin specifically up-regulated p21(Waf1,Cip1).a cyclin-dependent kinase inhibitor, and decreased the levels and activity of Cdk2 protein in myoblasts, Furthermore, we also observed that in myoblasts treated with myostatin protein, Rb was predominately present in the hypophosphorylated form. These results suggests that, in response to myostatin signaling, there is an increase in p21 expression and a decrease in Cdk2 protein and activity thus resulting in an accumulation of hypophosphorylated Rb protein. This, in turn, leads to the arrest of myoblasts in G(1)-phase of cell cycle, Thus, we propose that the generalized muscular hyperplasia phenotype observed in animals that lack functional myostatin could be as a result of deregulated myoblast proliferation.	AgRes, Anim Genom, Hamilton 2001, New Zealand	AgResearch - New Zealand	Kambadur, R (corresponding author), AgRes, Anim Genom, Private Bag 3123, Hamilton 2001, New Zealand.		Oliffe, John Lindsay/F-3436-2011; Langley, Brett C/P-7207-2017	Oliffe, John Lindsay/0000-0001-9029-4003; Langley, Brett C/0000-0003-4009-2109				BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Gonzalez-Cadavid NF, 1998, P NATL ACAD SCI USA, V95, P14938, DOI 10.1073/pnas.95.25.14938; Grobet L, 1997, NAT GENET, V17, P71, DOI 10.1038/ng0997-71; Guo K, 1997, J BIOL CHEM, V272, P791, DOI 10.1074/jbc.272.2.791; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; Ji SQ, 1998, AM J PHYSIOL-REG I, V275, pR1265, DOI 10.1152/ajpregu.1998.275.4.R1265; Kambadur R, 1997, GENOME RES, V7, P910, DOI 10.1101/gr.7.9.910; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LaThangue NB, 1996, BIOCHEM SOC T, V24, P54; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC, 1997, P NATL ACAD SCI USA, V94, P12457, DOI 10.1073/pnas.94.23.12457; McPherron AC., 1996, GROWTH FACTORS CYTOK, P357, DOI [10.1016/s1874-5687(96)80016-4, DOI 10.1016/S1874-5687(96)80016-4]; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; O'Malley J. P., 1996, Methods in Cell Science, V18, P19, DOI 10.1007/BF00123519; OLIVER MH, 1989, J CELL SCI, V92, P513; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; QUINN LS, 1983, DIFFERENTIATION, V24, P111, DOI 10.1111/j.1432-0436.1983.tb01310.x; Rawls A, 1998, DEVELOPMENT, V125, P2349; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; Saltis J, 1996, MOL CELL ENDOCRINOL, V116, P227, DOI 10.1016/0303-7207(95)03721-7; Sharma M, 1999, J CELL PHYSIOL, V180, P1; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	35	701	803	2	79	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40235	40243		10.1074/jbc.M004356200	http://dx.doi.org/10.1074/jbc.M004356200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10976104	hybrid			2022-12-25	WOS:000166039500061
J	Costa, ET; Olivera, DS; Meyer, DA; Ferreira, VMM; Soto, EE; Frausto, S; Savage, DD; Browning, MD; Valenzuela, CF				Costa, ET; Olivera, DS; Meyer, DA; Ferreira, VMM; Soto, EE; Frausto, S; Savage, DD; Browning, MD; Valenzuela, CF			Fetal alcohol exposure alters neurosteroid modulation of hippocampal N-methyl-D-aspartate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRENATAL ETHANOL EXPOSURE; NEUROACTIVE STEROID ALLOPREGNANOLONE; BINDING-SITE DENSITY; NMDA RECEPTOR; PREGNENOLONE-SULFATE; ULTRASONIC VOCALIZATIONS; TARGETED DISRUPTION; MEMORY; CALCIUM; NEURONS	The actions of ethanol on brain ligand-gated ion channels have important roles in the pathophysiology of alcohol-related neurodevelopmental disorders and fetal alcohol syndrome. Studies have shown that N-methyl-D-aspartate (NMDA) receptors are among the ligand-gated ion channels affected by prenatal ethanol exposure, We exposed pregnant dams to an ethanol-containing liquid diet that results in blood ethanol levels near the legal intoxication limit in most states (0.08%). Primary cultures of hippocampal neurons were prepared from the neonatal offspring of these dams, and NMDA receptor function was assessed by patch clamp electrophysiological techniques after 6-7 days in culture in ethanol-free media. Unexpectedly, we did not detect any changes in hippocampal NMDA receptor function at either the whole-cell or single-channel levels. However, we determined that fetal alcohol exposure alters the actions of the neurosteroids pregnenolone sulfate and pregnenolone hemisuccinate, which potentiate NMDA receptor function. Western immunoblot analyses demonstrated that this alteration is not due to a change in the expression levels of NMDA receptor subunits. Importantly, in utero ethanol exposure did not affect the actions of neurosteroids that inhibit NMDA receptor function, Moreover, the actions of pregnenolone sulfate on type A gamma -aminobutyric acid and non-NMDA receptor function were unaltered by ethanol exposure in utero, which suggests that the alteration is specific to NMDA receptors. These findings are significant because they provide, at least in part, a plausible mechanistic explanation for the alterations in the behavioral responses to neurosteroids found in neonatal rats prenatally exposed to ethanol and to other forms of maternal stress (Zimmerberg, B,, and McDonald, B, C. (1996) Pharmacol. Biochem. Behav. 55, 541-547).	Univ New Mexico, Hlth Sci Ctr, Dept Neurosci, Albuquerque, NM 87131 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	University of New Mexico; University of New Mexico's Health Sciences Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Valenzuela, CF (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Neurosci, Basic Med Sci Bldg,Rm 145, Albuquerque, NM 87131 USA.				NIAAA NIH HHS [AA06548, AA00227] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006548] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ABDOLLAH S, 1995, ALCOHOL, V12, P369, DOI 10.1016/0741-8329(95)00020-R; Allan AM, 1998, J PHARMACOL EXP THER, V284, P250; Bergeron R, 1996, J NEUROSCI, V16, P1193; Calton JL, 2000, J NEUROPHYSIOL, V83, P685, DOI 10.1152/jn.2000.83.2.685; Compagnone NA, 1998, P NATL ACAD SCI USA, V95, P4678, DOI 10.1073/pnas.95.8.4678; Costa ET, 2000, ALCOHOL CLIN EXP RES, V24, P706, DOI 10.1097/00000374-200005000-00016; DiazGranados JL, 1997, ALCOHOL CLIN EXP RES, V21, P874, DOI 10.1097/00000374-199708000-00016; Ebralidze AK, 1996, J NEUROSCI, V16, P5014; Emptage N, 1999, NEURON, V22, P115, DOI 10.1016/S0896-6273(00)80683-2; FFRENCHMULLEN JMH, 1994, J NEUROSCI, V14, P1963; FLOOD JF, 1995, P NATL ACAD SCI USA, V92, P10806, DOI 10.1073/pnas.92.23.10806; FORREST D, 1994, NEURON, V13, P325, DOI 10.1016/0896-6273(94)90350-6; FRANCISK A, 2000, J NEUROSCI, V20, P3067; Gruol DL, 1998, BRAIN RES, V793, P12, DOI 10.1016/S0006-8993(98)00014-6; Hughes PD, 1998, ALCOHOL CLIN EXP RES, V22, P1255, DOI 10.1111/j.1530-0277.1998.tb03906.x; IRWIN RP, 1992, NEUROSCI LETT, V141, P30, DOI 10.1016/0304-3940(92)90327-4; Iwasato T, 1997, NEURON, V19, P1201, DOI 10.1016/S0896-6273(00)80412-2; Kadotani H, 1996, J NEUROSCI, V16, P7859; Kishimoto Y, 1997, NEUROREPORT, V8, P3717, DOI 10.1097/00001756-199712010-00012; Larkby C, 1997, ALCOHOL HEALTH RES W, V21, P192; LEE YH, 1994, J PHARMACOL EXP THER, V271, P1291; LIEBER CS, 1982, ALCOHOL CLIN EXP RES, V6, P523, DOI 10.1111/j.1530-0277.1982.tb05017.x; MAJEWSKA MD, 1987, BRAIN RES, V404, P355; MATHIS C, 1994, PSYCHOPHARMACOLOGY, V116, P201, DOI 10.1007/BF02245063; Mathis C, 1996, NEUROPHARMACOLOGY, V35, P1057, DOI 10.1016/S0028-3908(96)00041-X; Mattson SN, 1996, ALCOHOL CLIN EXP RES, V20, P810, DOI 10.1111/j.1530-0277.1996.tb05256.x; McHugh TJ, 1996, CELL, V87, P1339, DOI 10.1016/S0092-8674(00)81828-0; MORRISETT RA, 1989, ALCOHOL, V6, P415, DOI 10.1016/0741-8329(89)90013-X; Okabe S, 1998, J NEUROSCI, V18, P4177; Park-Chung M, 1997, MOL PHARMACOL, V52, P1113, DOI 10.1124/mol.52.6.1113; RABOW LE, 1995, SYNAPSE, V21, P189, DOI 10.1002/syn.890210302; SAVAGE DD, 1992, ALCOHOL, V9, P37, DOI 10.1016/0741-8329(92)90007-W; SAVAGE DD, 1991, ALCOHOL, V8, P193, DOI 10.1016/0741-8329(91)90806-8; Sprengel R, 1998, CELL, V92, P279, DOI 10.1016/S0092-8674(00)80921-6; SpuhlerPhillips K, 1997, ALCOHOL CLIN EXP RES, V21, P68; STREISSGUTH AP, 1989, NEUROTOXICOL TERATOL, V11, P493, DOI 10.1016/0892-0362(89)90026-3; Uecker A, 1998, AM J MENT RETARD, V103, P12, DOI 10.1352/0895-8017(1998)103<0012:SBNOMI>2.0.CO;2; Uecker A, 1996, NEUROPSYCHOLOGIA, V34, P209, DOI 10.1016/0028-3932(95)00096-8; Vallee M, 1997, P NATL ACAD SCI USA, V94, P14865, DOI 10.1073/pnas.94.26.14865; WEAVER MS, 1993, ALCOHOL CLIN EXP RES, V17, P643, DOI 10.1111/j.1530-0277.1993.tb00812.x; WU FS, 1991, MOL PHARMACOL, V40, P333; Yaghoubi N, 1998, BRAIN RES, V803, P153, DOI 10.1016/S0006-8993(98)00644-1; ZIMMERBERG B, 1995, PHARMACOL BIOCHEM BE, V51, P463, DOI 10.1016/0091-3057(95)00008-K; Zimmerberg B, 1996, PHARMACOL BIOCHEM BE, V55, P541, DOI 10.1016/S0091-3057(96)00281-X; ZIMMERBERG B, 1994, PHARMACOL BIOCHEM BE, V47, P735, DOI 10.1016/0091-3057(94)90181-3	45	38	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38268	38274		10.1074/jbc.M004136200	http://dx.doi.org/10.1074/jbc.M004136200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10988286	hybrid			2022-12-25	WOS:000165739800020
J	Bonten, EJ; d'Azzo, A				Bonten, EJ; d'Azzo, A			Lysosomal neuraminidase - Catalytic activation in insect cells is controlled by the protective protein/cathepsin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMBINED BETA-GALACTOSIDASE; PROTEIN CATHEPSIN-A; BACTERIAL SIALIDASE; EXPRESSION VECTORS; CRYSTAL-STRUCTURE; HUMAN-PLACENTA; COMPLEX; PURIFICATION; ASSOCIATION; DEFICIENCY	Lysosomal N-Acetyl-alpha -neuraminidase is active in complex with the protective protein/cathepsin A (PPCA) and beta -galactosidase, The interaction with PPCA is essential for the correct intracellular routing and lysosomal localization of neuraminidase, but the mechanism of its catalytic activation is unclear. To investigate this process, we have used the baculovirus expression system to co-express neuraminidase and PPCA precursors in in sect cells, which resulted in high enzymatic activity of neuraminidase, Both the 34- and 20-kDa PPCA subunits were required for the activation. We further demonstrated that when expressed alone, the neuraminidase precursor remained dimeric (114 kDa) and had low enzymatic activity, but when co-expressed with PPCA and beta -galactosidase, it multimerized in a complex of similar to 1350 kDa, together with the other two proteins. The fully active neuraminidase co-precipitated with full-length PPCA and beta -galactosidase precursors. However, when co-expressed with the individual PPCA subunits, neuraminidase co-precipitated only with the small 20-kDa polypeptide, which therefore must contain a neuraminidase-binding site. Our finding suggests a model of activation of neuraminidase dependent on its oligomerization at acidic pH that is mediated by interaction with PPCA.	St Jude Childrens Res Hosp, Dept Genet, Memphis, TN 38105 USA	St Jude Children's Research Hospital	d'Azzo, A (corresponding author), St Jude Childrens Res Hosp, Dept Genet, 332 N Lauderdale, Memphis, TN 38105 USA.				NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060950] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765] Funding Source: Medline; NIGMS NIH HHS [R01GM60950] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRIA G, 1981, SIALIDASES SIALIDOSE, P379; Bonten E, 1996, GENE DEV, V10, P3156, DOI 10.1101/gad.10.24.3156; BONTEN EJ, 1995, J BIOL CHEM, V270, P26441, DOI 10.1074/jbc.270.44.26441; Braulke T, 1996, Subcell Biochem, V27, P15; CRENNELL S, 1994, STRUCTURE, V2, P535, DOI 10.1016/S0969-2126(00)00053-8; Crennell SJ, 1996, J MOL BIOL, V259, P264, DOI 10.1006/jmbi.1996.0318; CRENNELL SJ, 1993, P NATL ACAD SCI USA, V90, P9852, DOI 10.1073/pnas.90.21.9852; D'Azzo A, 1995, METABOLIC MOL BASES, V2, P2825; DAZZO A, 1982, P NATL ACAD SCI-BIOL, V79, P4535, DOI 10.1073/pnas.79.15.4535; GALJAARD H, 1980, GENETIC METABOLIC DI, P817; GALJART NJ, 1991, J BIOL CHEM, V266, P14754; GALJART NJ, 1990, J BIOL CHEM, V265, P4678; GASKELL A, 1995, STRUCTURE, V3, P1197, DOI 10.1016/S0969-2126(01)00255-6; HINK WF, 1970, NATURE, V226, P466, DOI 10.1038/226466b0; Hiraiwa M, 1997, BBA-PROTEIN STRUCT M, V1341, P189, DOI 10.1016/S0167-4838(97)00060-5; HIRAIWA M, 1991, BIOCHEM BIOPH RES CO, V177, P1211, DOI 10.1016/0006-291X(91)90670-3; Hiraiwa M, 1996, SEIKAGAKU, V68, P464; HOOGEVEEN AT, 1983, J BIOL CHEM, V258, P2143; HUBBES M, 1992, BIOCHEM J, V285, P827, DOI 10.1042/bj2850827; Kaufman R. J., 1999, BIOCHIM BIOPHYS ACTA, V1423, P13; LUCKOW VA, 1988, VIROLOGY, V167, P56, DOI 10.1016/0042-6822(88)90054-2; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MORREAU H, 1989, J BIOL CHEM, V264, P20655; POTIER M, 1990, BIOCHEM J, V267, P197, DOI 10.1042/bj2670197; PROIA RL, 1984, J BIOL CHEM, V259, P3350; Pshezhetsky AV, 1996, J BIOL CHEM, V271, P28359, DOI 10.1074/jbc.271.45.28359; Pshezhetsky AV, 1997, NAT GENET, V15, P316, DOI 10.1038/ng0397-316; PSHEZHETSKY AV, 1994, ARCH BIOCHEM BIOPHYS, V313, P64, DOI 10.1006/abbi.1994.1359; Rottier RJ, 1998, HUM MOL GENET, V7, P313, DOI 10.1093/hmg/7.2.313; RUDENKO G, 1995, STRUCTURE, V3, P1249, DOI 10.1016/S0969-2126(01)00260-X; SCHEIBE R, 1990, BIOMED BIOCHIM ACTA, V49, P547; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; Taylor G, 1996, CURR OPIN STRUC BIOL, V6, P830, DOI 10.1016/S0959-440X(96)80014-5; van der Spoel A, 2000, J BIOL CHEM, V275, P10035, DOI 10.1074/jbc.275.14.10035; van der Spoel A, 1998, EMBO J, V17, P1588, DOI 10.1093/emboj/17.6.1588; VANDERHORST GTJ, 1989, J BIOL CHEM, V264, P1317; VANDIGGELEN OP, 1982, BIOCHIM BIOPHYS ACTA, V703, P69, DOI 10.1016/0167-4838(82)90012-7; VERHEIJEN F, 1982, BIOCHEM BIOPH RES CO, V108, P868, DOI 10.1016/0006-291X(82)90911-1; VERHEIJEN FW, 1987, EUR J BIOCHEM, V162, P63, DOI 10.1111/j.1432-1033.1987.tb10542.x; VERHEIJEN FW, 1985, EUR J BIOCHEM, V149, P315, DOI 10.1111/j.1432-1033.1985.tb08928.x; Vinogradova MV, 1998, BIOCHEM J, V330, P641; WENGER DA, 1978, BIOCHEM BIOPH RES CO, V82, P589, DOI 10.1016/0006-291X(78)90915-4; YAMAMOTO Y, 1987, INT J BIOCHEM, V19, P435, DOI 10.1016/0020-711X(87)90064-4; ZHOU XY, 1995, GENE DEV, V9, P2623, DOI 10.1101/gad.9.21.2623	44	45	48	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37657	37663		10.1074/jbc.M007380200	http://dx.doi.org/10.1074/jbc.M007380200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10982818	Green Submitted, hybrid			2022-12-25	WOS:000165618700049
J	Knauer, DJ; Majumdar, D; Fong, PC; Knauer, MF				Knauer, DJ; Majumdar, D; Fong, PC; Knauer, MF			SERPIN regulation of factor XIa - The novel observation that protease nexin 1 in the presence of heparin is a more potent inhibitor of factor XIa than C1 inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-BETA-PROTEIN; RECEPTOR-RELATED PROTEIN; PLASMA THROMBOPLASTIN ANTECEDENT; BLOOD-COAGULATION FACTOR; ACTIVATED HAGEMAN-FACTOR; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; ALPHA(2)-MACROGLOBULIN RECEPTOR; APOLIPOPROTEIN-E; MECHANISM	In the present studies we have made the novel observation that protease nexin 1 (PN1), a member of the serine protease inhibitor (SERPIN) superfamily, is a potent inhibitor of the blood coagulation Factor Ma (FXIa). The inhibitory complexes formed between PN1 and FXIa are stable when subjected to reducing agents, SDS, and boiling, a characteristic of the acyl linkage formed between SERPINs and their cognate proteases. Using a sensitive fluorescence-quenched peptide substrate, the K-assoc of PN1 for FXIa was determined to be 7.9 x 10(4) M-1 s(-1) in the absence of heparin. In the presence of heparin, this rate was accelerated to 1.7 x 10(6), M-1 s(-1), making PN1 a far better inhibitor of FXIa than C1 inhibitor, which is the only other SERPIN known to significantly inhibit FXIa. FXIa-PN1 complexes are shown to be internalized and degraded by human fibroblasts, most likely via the low density lipoprotein receptor-related protein (LRP), since degradation was strongly inhibited by the LRP agonist, receptor associated protein. Since FXIa proteolytically modifies the amyloid precursor protein, this observation may suggest an accessory role for PN1 in the pathobiogenesis of Alzheimer's disease.	Univ Calif Irvine, Sch Biol Sci, Dept Dev & Cell Biol, Irvine, CA 92627 USA	University of California System; University of California Irvine	Knauer, MF (corresponding author), Univ Calif Irvine, Sch Biol Sci, Dept Dev & Cell Biol, Irvine, CA 92627 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034001] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM34001-12] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baglia FA, 2000, J BIOL CHEM, V275, P20514, DOI 10.1074/jbc.M000464200; BOUMA BN, 1983, BLOOD, V62, P1123; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; CONESE M, 1994, J BIOL CHEM, V269, P17886; DAMUS PS, 1973, NATURE, V246, P355, DOI 10.1038/246355a0; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DONOVAN FM, 1994, J BIOL CHEM, V269, P17199; FORBES CD, 1970, J LAB CLIN MED, V76, P809; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; GRONKE RS, 1989, BLOOD, V73, P472; GRONKE RS, 1987, J BIOL CHEM, V262, P3030; HECK LW, 1974, J EXP MED, V140, P1615, DOI 10.1084/jem.140.6.1615; HERZ J, 1991, J BIOL CHEM, V266, P21232; HOWARD EW, 1986, J BIOL CHEM, V261, P684; HOWARD EW, 1987, J CELL PHYSIOL, V131, P276, DOI 10.1002/jcp.1041310219; KITCHENS CS, 1991, SEMIN THROMB HEMOST, V17, P55, DOI 10.1055/s-2007-1002590; Knauer MF, 1999, J BIOL CHEM, V274, P275, DOI 10.1074/jbc.274.1.275; Knauer MF, 1997, J BIOL CHEM, V272, P29039, DOI 10.1074/jbc.272.46.29039; KOMIYAMA Y, 1988, THROMB RES, V50, P329, DOI 10.1016/0049-3848(88)90234-4; Kridel SJ, 1996, J BIOL CHEM, V271, P20935, DOI 10.1074/jbc.271.34.20935; KURACHI K, 1977, BIOCHEMISTRY-US, V16, P5831, DOI 10.1021/bi00645a030; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; ORLANDO RA, 1992, P NATL ACAD SCI USA, V89, P6698, DOI 10.1073/pnas.89.15.6698; REBECK GW, 1995, ANN NEUROL, V37, P211, DOI 10.1002/ana.410370212; SAITO H, 1977, BLOOD, V50, P377; SAITO H, 1979, P NATL ACAD SCI USA, V76, P2013, DOI 10.1073/pnas.76.4.2013; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; SAPORITOIRWIN SM, 1995, J BIOL CHEM, V270, P26265, DOI 10.1074/jbc.270.44.26265; SCHUBERT D, 1989, BIOCHEM BIOPH RES CO, V162, P83, DOI 10.1016/0006-291X(89)91965-7; SCOTT RW, 1985, J BIOL CHEM, V260, P7029; SMALL DH, 1994, J NEUROSCI, V14, P2117; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Van Uden E, 1999, MOL CELL NEUROSCI, V14, P129, DOI 10.1006/mcne.1999.0772; VANDERGRAAF F, 1983, J BIOL CHEM, V258, P9669; VANNOSTRAND WE, 1995, THROMB RES, V78, P43, DOI 10.1016/0049-3848(95)00033-X; VANNOSTRAND WE, 1990, SCIENCE, V248, P745, DOI 10.1126/science.2110384; VANNOSTRAND WE, 1990, J BIOL CHEM, V265, P9591; Wuillemin WA, 1996, J BIOL CHEM, V271, P12913, DOI 10.1074/jbc.271.22.12913; YANG AJ, 1995, J BIOL CHEM, V270, P14786, DOI 10.1074/jbc.270.24.14786; Zhang Y, 1997, J BIOL CHEM, V272, P26139, DOI 10.1074/jbc.272.42.26139	41	47	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37340	37346		10.1074/jbc.M003909200	http://dx.doi.org/10.1074/jbc.M003909200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10973954	hybrid			2022-12-25	WOS:000165618700007
J	Phippen, TM; Sweigart, AL; Moniwa, M; Krumm, A; Davie, JR; Parkhurst, SM				Phippen, TM; Sweigart, AL; Moniwa, M; Krumm, A; Davie, JR; Parkhurst, SM			Drosophila C-terminal binding protein functions as a context-dependent transcriptional co-factor and interferes with both Mad and Groucho transcriptional repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE; ADENOVIRUS E1A; CELLULAR PHOSPHOPROTEIN; NEGATIVE MODULATION; COREPRESSOR GROUCHO; DOMAIN; INTERACTS; HAIRY; CTBP; EMBRYO	Drosophila C-terminal binding protein (dCtBP) and Groucho have been identified as Hairy-interacting proteins required for embryonic segmentation and Hairy-mediated transcriptional repression. While both dCtBP and Groucho are required for proper Hairy function, their properties are very different. As would be expected for a co-repressor, reduced Groucho activity enhances the hairy mutant phenotype, In contrast, reduced dCtBP activity suppresses it. We show here that dCtBP can function as either a co-activator or co-repressor of transcription in a context-dependent manner. The regions of dCtBP required for activation and repression are separable. We find that mSin3A-histone deacetylase complexes are altered in the presence of dCtBP and that dCtBP interferes with both Groucho and Mad transcriptional repression. Similar to CtBP's role in attenuating E1A's oncogenicity, we propose that dCtBP can interfere with corepressor-histone deacetylase complexes, thereby attenuating transcriptional repression. Hairy defines a new class of proteins that requires both CtBP and Groucho co-factors for proper function.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Program Dev Biol, Seattle, WA 98109 USA; Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98195 USA; Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Parkhurst, SM (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, A1-162,1100 Fairview Ave N, Seattle, WA 98109 USA.			Davie, James/0000-0002-0420-6888	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007183] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM047852, R01GM047852] Funding Source: NIH RePORTER; NICHD NIH HHS [5T32HD07183] Funding Source: Medline; NIGMS NIH HHS [GM47852] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; AUSUBEL FM, 1996, CURRENT PROTOCOLS MO, V2; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Berg A, 1998, EUR J BIOCHEM, V252, P45, DOI 10.1046/j.1432-1327.1998.2520045.x; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Brannon M, 1999, DEVELOPMENT, V126, P3159; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Cai HN, 1996, P NATL ACAD SCI USA, V93, P9309, DOI 10.1073/pnas.93.18.9309; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; CHINNADURAI G, 1992, ONCOGENE, V7, P1255; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Dang CV, 1997, J BIOENERG BIOMEMBR, V29, P345, DOI 10.1023/A:1022446730452; Dubnicoff T, 1997, GENE DEV, V11, P2952, DOI 10.1101/gad.11.22.2952; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; Goodman RH, 1998, CURR OPIN NEUROBIOL, V8, P413, DOI 10.1016/S0959-4388(98)80069-X; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Gray S, 1996, CURR OPIN CELL BIOL, V8, P358; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; Hassig CA, 1997, CURR OPIN CHEM BIOL, V1, P300, DOI 10.1016/S1367-5931(97)80066-X; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; INGHAM PW, 1985, GENETICS, V111, P463; Jimenez G, 1997, GENE DEV, V11, P3072, DOI 10.1101/gad.11.22.3072; Kiermaier A, 1997, CURR BIOL, V7, pR505, DOI 10.1016/S0960-9822(06)00249-1; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Koipally J, 2000, J BIOL CHEM, V275, P19594, DOI 10.1074/jbc.M000254200; Krumm A, 1998, P NATL ACAD SCI USA, V95, P13501, DOI 10.1073/pnas.95.23.13501; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Laherty CD, 1998, MOL CELL, V2, P33, DOI 10.1016/S1097-2765(00)80111-2; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Mannervik M, 1999, P NATL ACAD SCI USA, V96, P6797, DOI 10.1073/pnas.96.12.6797; Mannervik M, 1999, SCIENCE, V284, P606, DOI 10.1126/science.284.5414.606; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Mymryk JS, 1996, ONCOGENE, V13, P1581; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Nibu Y, 1998, EMBO J, V17, P7009, DOI 10.1093/emboj/17.23.7009; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; Parkhurst SM, 1998, TRENDS GENET, V14, P130, DOI 10.1016/S0168-9525(98)01407-3; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; ROTH SY, 1995, CURR OPIN GENET DEV, V5, P168, DOI 10.1016/0959-437X(95)80004-2; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Sollerbrant K, 1996, NUCLEIC ACIDS RES, V24, P2578, DOI 10.1093/nar/24.13.2578; Sundqvist A, 1998, FEBS LETT, V429, P183, DOI 10.1016/S0014-5793(98)00588-2; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; Wieschaus E., 1986, P199; Zhang HL, 1999, P NATL ACAD SCI USA, V96, P535, DOI 10.1073/pnas.96.2.535	62	66	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37628	37637		10.1074/jbc.M004234200	http://dx.doi.org/10.1074/jbc.M004234200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10973955	hybrid			2022-12-25	WOS:000165618700045
J	Suzuki, T; Suzuki, J; Mitome, N; Ueno, H; Yoshida, M				Suzuki, T; Suzuki, J; Mitome, N; Ueno, H; Yoshida, M			Second stalk of ATP synthase - Cross-linking of gamma subunit in F-1 to truncated F(o)b subunit prevents ATP hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1F0-ATPASE; DELTA-SUBUNIT; B-SUBUNIT; 2ND STALK; DOMAIN; ROTATION; F1-ATPASE; EPSILON; COMPLEX; PARTS	ATP synthase consists of two portions, F-1 and F-o, connected by two stalks: a central rotor stalk containing gamma and epsilon subunits and a peripheral, second stalk formed by delta and two copies of F(o)b subunits. The second stalk is expected to keep the stator subunits from spinning along with the rotor. We isolated a TF1-b'(2) complex (alpha (3)beta (3)gamma delta epsilonb'(2)) of a thermophilic Bacillus PS3, in which b' was a truncated cytoplasmic fragment of F(o)b subunit, and introduced a cysteine at its N terminus (bc'). Association of b'(2) or bc'(2) with TF1 did not have significant effect on ATPase activity. A disulfide bond between the introduced cysteine of bc' and cysteine 109 of gamma subunit was readily formed, and this cross-link caused inactivation of ATPase. This implies that F(o)b subunit bound to stator subunits of F-1 with enough strength to resist rotation of gamma subunit and to prevent catalysis. Contrary to this apparent tight binding, some detergents such as lauryldodecylamine oxide tend to cause release of b'(2) from TF1.	Tokyo Inst Technol, Chem Resources Lab, Midori Ku, Yokohama, Kanagawa 2268503, Japan	Tokyo Institute of Technology	Yoshida, M (corresponding author), Tokyo Inst Technol, Chem Resources Lab, Midori Ku, Nagatsuta 4259, Yokohama, Kanagawa 2268503, Japan.							Aggeler R, 1997, J BIOL CHEM, V272, P19621, DOI 10.1074/jbc.272.31.19621; Bottcher B, 2000, J MOL BIOL, V296, P449, DOI 10.1006/jmbi.1999.3435; Bottcher B, 1998, J MOL BIOL, V281, P757, DOI 10.1006/jmbi.1998.1957; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Cross RL, 2000, BBA-BIOENERGETICS, V1458, P270, DOI 10.1016/S0005-2728(00)00079-7; Dmitriev O, 1999, J BIOL CHEM, V274, P15598, DOI 10.1074/jbc.274.22.15598; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Dunn SD, 2000, BBA-BIOENERGETICS, V1458, P356, DOI 10.1016/S0005-2728(00)00086-4; DUNN SD, 1992, J BIOL CHEM, V267, P7630; Dunn SD, 1998, J BIOL CHEM, V273, P8646, DOI 10.1074/jbc.273.15.8646; Fillingame RH, 2000, J EXP BIOL, V203, P9; Garcia JJ, 1998, J BIOL CHEM, V273, P15940, DOI 10.1074/jbc.273.26.15940; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lill H, 1996, J BIOL CHEM, V271, P32737, DOI 10.1074/jbc.271.51.32737; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; Matsui T, 1997, J BIOL CHEM, V272, P8215, DOI 10.1074/jbc.272.13.8215; McLachlin DT, 2000, BIOCHEMISTRY-US, V39, P3486, DOI 10.1021/bi992586b; McLachlin DT, 1998, J BIOL CHEM, V273, P15162, DOI 10.1074/jbc.273.24.15162; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; OHTA S, 1988, BIOCHIM BIOPHYS ACTA, V933, P141, DOI 10.1016/0005-2728(88)90064-3; Revington M, 1999, J BIOL CHEM, V274, P31094, DOI 10.1074/jbc.274.43.31094; Rodgers AJW, 1997, J BIOL CHEM, V272, P31058, DOI 10.1074/jbc.272.49.31058; Rodgers AJW, 1998, J BIOL CHEM, V273, P29406, DOI 10.1074/jbc.273.45.29406; Sambrook J., 2002, MOL CLONING LAB MANU; Schulenberg B, 1997, EUR J BIOCHEM, V249, P134, DOI 10.1111/j.1432-1033.1997.t01-1-00134.x; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; Sorgen PL, 1999, J BIOL CHEM, V274, P36261, DOI 10.1074/jbc.274.51.36261; Sorgen PL, 1998, J BIOL CHEM, V273, P27873, DOI 10.1074/jbc.273.43.27873; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Wilkens S, 2000, J MOL BIOL, V295, P387, DOI 10.1006/jmbi.1999.3381; Wilkens S, 1998, BBA-BIOENERGETICS, V1365, P93, DOI 10.1016/S0005-2728(98)00048-6; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; YOSHIDA M, 1984, H PLUS ATPASE ATP SY, P147	34	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37902	37906		10.1074/jbc.M007075200	http://dx.doi.org/10.1074/jbc.M007075200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10970900	hybrid			2022-12-25	WOS:000165618700080
J	Wilson, KF; Wu, WJ; Cerione, RA				Wilson, KF; Wu, WJ; Cerione, RA			Cdc42 stimulates RNA splicing via the S6 kinase and a novel S6 kinase target, the nuclear cap-binding complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SIGNALING PATHWAY; MAMMALIAN TARGET; LOCALIZATION; TRANSLATION; RAPAMYCIN; EXPORT; RAC1	Cdc42 is a low molecular weight GTP-binding protein that plays a key regulatory role in a variety of cellular activities. The importance of the coordination of different cell functions by Cdc42 is underscored by the fact that a constitutively active Cdc42 mutant induces cellular transformation. In this study, we describe a novel function for Cdc42: its ability to stimulate pre-messenger RNA splicing. This activity is dependent on cysteine 37 in the effector loop of Cdc42 but is not dependent on cell growth. A likely candidate protein for mediating the Cdc42 effects on pre-mRNA splicing is the nuclear RNA cap-binding complex (CBC), which plays a key role in an early step of cap dependent RNA splicing. Activation of the CBC by Cdc42 can be inhibited by rapamycin, Additionally, phosphatidylinositol 3-kinase and the Cdc42 effector, pp70 Se kinase, stimulate the RNA cap-binding activity of the CBC, S6 kinase may directly target the CBC in vivo as it can phosphorylate the 80-kDa subunit of the CBC, CBP80, at residues that are subject to a growth factor-dependent and rapamycin-sensitive phosphorylation in vivo. Together these data suggest the involvement of a Cdc42-S6 kinase pathway in the regulation of RNA splicing, mediated by an increase in capped RNA binding by the CBC, as well as raise the possibility that the effects of Cdc42 on cell growth may be due in part to its regulation of RNA processing.	Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA; Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA	Cornell University; Cornell University	Cerione, RA (corresponding author), Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040654] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40654] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; COFFER PJ, 1994, BIOCHEM BIOPH RES CO, V198, P780, DOI 10.1006/bbrc.1994.1112; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DEGROOT RP, 1994, CELL, V79, P81, DOI 10.1016/0092-8674(94)90402-2; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Flaherty SM, 1997, P NATL ACAD SCI USA, V94, P11893, DOI 10.1073/pnas.94.22.11893; HARA K, 1997, J BIOL CHEM, V272, P26547; Izaurralde E, 1995, COLD SPRING HARB SYM, V60, P669, DOI 10.1101/SQB.1995.060.01.072; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; IZAURRALDE E, 1995, NATURE, V376, P709, DOI 10.1038/376709a0; Koh H, 1999, ONCOGENE, V18, P5115, DOI 10.1038/sj.onc.1202895; Lewis JD, 1996, GENE DEV, V10, P1683, DOI 10.1101/gad.10.13.1683; Lewis JD, 1996, NUCLEIC ACIDS RES, V24, P3332, DOI 10.1093/nar/24.17.3332; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; OHNO M, 1987, P NATL ACAD SCI USA, V84, P5187, DOI 10.1073/pnas.84.15.5187; OLSON ME, 1995, SCIENCE, V269, P53; Peterson RT, 1998, CURR BIOL, V8, pR248, DOI 10.1016/S0960-9822(98)70152-6; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; Tang T, 1996, J NEUROCHEM, V66, P1198; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; VAN AL, 1997, GENE DEV, V11, P2295; Visa N, 1996, J CELL BIOL, V133, P5, DOI 10.1083/jcb.133.1.5; Wilson KF, 1999, J BIOL CHEM, V274, P4166, DOI 10.1074/jbc.274.7.4166; Wu WJ, 2000, NATURE, V405, P800, DOI 10.1038/35015585; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	32	59	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37307	37310		10.1074/jbc.C000482200	http://dx.doi.org/10.1074/jbc.C000482200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10973943	hybrid			2022-12-25	WOS:000165618700002
J	Yang, L; Chansky, HA; Hickstein, DD				Yang, L; Chansky, HA; Hickstein, DD			EWS center dot Fli-1 fusion protein interacts with hyperphosphorylated RNA polymerase II and interferes with serine-arginine protein-mediated RNA splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; EWINGS-SARCOMA TRANSLOCATION; ROUND-CELL TUMOR; BINDING PROTEIN; DNA-BINDING; CHROMOSOME-TRANSLOCATION; TRANSCRIPTION FACTOR; EWS GENE; MYXOID LIPOSARCOMA; MALIGNANT-MELANOMA	Ewing's sarcoma displays a characteristic chromosomal translocation that results in fusion of the N-terminal domain of the Ewing's sarcoma protein (EWS) to the C-terminal DNA-binding domain of the ETS family transcription factor Fli-1 (Friend leukemia integration-1). EWS possesses structural motifs suggesting a role in transactivation as well as RNA binding. We demonstrate that wild-type EWS protein functions as an adapter molecule coupling transcription to RNA splicing by binding to hyperphosphorylated RNA polymerase II through the N-terminal domain of EWS and recruiting serine-arginine (SR) splicing factors through the C-terminal domain of EWS. The oncogenic EWS Fli-1 fusion protein retains the ability to bind to hyperphosphorylated RNA polymerase II but lacks the ability to recruit SR proteins because of replacement of the C-terminal domain of EWS by Fli-1. In an in vivo splicing assay, the EWS.Fli-1 fusion protein inhibits SR protein-mediated E1A pre-mRNA splicing in a dominant-negative manner. These results indicate that EWS Fli-1 interferes with the normal function of EWS and implicate uncoupling of gene transcription from RNA splicing in the pathogenesis of Ewing's sarcoma.	Univ Washington, Sch Med, Dept Med Oncol, Seattle, WA 98108 USA; Univ Washington, Sch Med, Dept Orthoped, Seattle, WA 98108 USA; Vet Affairs Puget Sound Hlth Care Syst, Med Res Serv, Seattle, WA 98108 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System	Hickstein, DD (corresponding author), Univ Washington, Sch Med, Dept Med Oncol, Box 358280,1660 S Columbian Way,GMR 151, Seattle, WA 98108 USA.							BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Barr FG, 1999, CANCER RES, V59, P5443; Bentley D, 1999, CURR OPIN CELL BIOL, V11, P347, DOI 10.1016/S0955-0674(99)80048-9; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; BREGMAN DB, 1995, J CELL BIOL, V129, P287, DOI 10.1083/jcb.129.2.287; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; Hinohara S, 1998, JPN J CANCER RES, V89, P887, DOI 10.1111/j.1349-7006.1998.tb00645.x; Hirose Y, 1999, GENE DEV, V13, P1234, DOI 10.1101/gad.13.10.1234; Jaishankar S, 1999, ONCOGENE, V18, P5592, DOI 10.1038/sj.onc.1202940; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; Knoop LL, 2000, J BIOL CHEM, V275, P24865, DOI 10.1074/jbc.M001661200; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; LADANYI M, 1994, CANCER RES, V54, P2837; LESSNICK SL, 1995, ONCOGENE, V10, P423; MAO XH, 1994, J BIOL CHEM, V269, P18216; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; Nawa G, 1999, BRIT J CANCER, V80, P1185, DOI 10.1038/sj.bjc.6690484; OHNO T, 1994, ONCOGENE, V9, P3087; Panagopoulos I, 1996, ONCOGENE, V12, P489; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RAUSCHER FJ, 1994, COLD SPRING HARB SYM, V59, P137, DOI 10.1101/SQB.1994.059.01.017; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; WANG J, 1995, RNA, V1, P335; Yang L, 2000, MOL CELL BIOL, V20, P3345, DOI 10.1128/MCB.20.10.3345-3354.2000; Yang L, 1998, J BIOL CHEM, V273, P27761, DOI 10.1074/jbc.273.43.27761; Zhang D, 1998, J BIOL CHEM, V273, P18086, DOI 10.1074/jbc.273.29.18086; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	43	116	126	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37612	37618		10.1074/jbc.M005739200	http://dx.doi.org/10.1074/jbc.M005739200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10982800	hybrid			2022-12-25	WOS:000165618700043
J	Cong, YS; Bacchetti, S				Cong, YS; Bacchetti, S			Histone deacetylation is involved in the transcriptional repression of hTERT in normal human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TELOMERASE ACTIVITY; IMMORTAL CELLS; LIFE-SPAN; RECONSTITUTION; GENE; MAD; MYC; PROMOTER; CANCER; LEADS	Trancriptional regulation of the human telomerase reverse transcriptase (hTERT) gene, encoding the catalytic protein of human telomerase, plays a critical role in the activation of the enzyme during cell immortalization and tumorigenesis. However, the molecular mechanisms involved in the regulation of hTERT expression are still not fully understood. We have previously cloned and characterized the genomic sequences and promoter of the hTERT gene. Here, we provide evidence that histone deacetylation is involved in the repression of hTERT in human cells. Inhibition of histone deacetylases by trichostatin A in telomerase-negative cells resulted in activation of telomerase activity and upregulation of hTERT mRNA. Transient transfection experiments with a reporter under control of the hTERT promoter indicated that this promoter can be activated by trichostatin A. Finally, our results show that repression of the hTERT promoter by the Mad protein requires histone deacetylase activity, whereas de-repression by trichostatin A is independent of the E-boxes located in its core region.	McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada	McMaster University	Bacchetti, S (corresponding author), McMaster Univ, Dept Pathol & Mol Med, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	bacchett@fhs.mcmaster.ca						Avilion AA, 1996, CANCER RES, V56, P645; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Davie JR, 1999, J CELL BIOCHEM, P141; Dessain SK, 2000, CANCER RES, V60, P537; DEVEREUX TR, 1999, CANCER RES, V59, P6078; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Gunes C, 2000, CANCER RES, V60, P2116; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Horikawa I, 1999, CANCER RES, V59, P826; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Kyo S, 1999, CANCER RES, V59, P5917; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lingner J, 1998, CURR OPIN GENET DEV, V8, P226, DOI 10.1016/S0959-437X(98)80145-7; Liu JP, 1999, FASEB J, V13, P2091, DOI 10.1096/fasebj.13.15.2091; Misiti S, 2000, MOL CELL BIOL, V20, P3764, DOI 10.1128/MCB.20.11.3764-3771.2000; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Oulton R, 2000, CURR OPIN ONCOL, V12, P74, DOI 10.1097/00001622-200001000-00013; Price CM, 1999, CURR OPIN GENET DEV, V9, P218, DOI 10.1016/S0959-437X(99)80032-X; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Shay JW, 1999, J NATL CANCER I, V91, P4, DOI 10.1093/jnci/91.1.4; TAKAKURA M, 1999, CANCER RES, P551; Ulaner GA, 1998, CANCER RES, V58, P4168; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	36	136	146	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35665	35668		10.1074/jbc.C000637200	http://dx.doi.org/10.1074/jbc.C000637200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10986277	hybrid			2022-12-25	WOS:000165382000003
J	Edwards, TK; Saleem, A; Shaman, JA; Dennis, T; Gerigk, C; Oliveros, E; Gartenberg, MR; Rubin, EH				Edwards, TK; Saleem, A; Shaman, JA; Dennis, T; Gerigk, C; Oliveros, E; Gartenberg, MR; Rubin, EH			Role for nucleolin/Nsr1 in the cellular localization of topoisomerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE T-ANTIGEN; ANTITUMOR DRUG CAMPTOTHECIN; YEAST NSR1 PROTEIN; RNA-POLYMERASE-I; RIBOSOMAL-RNA; SACCHAROMYCES-CEREVISIAE; DNA TOPOISOMERASES; NUCLEOLAR PROTEIN; MESSENGER-RNA; CLEAVABLE COMPLEXES	Nucleolin functions in ribosome biogenesis and contains an acidic N terminus that binds nuclear localization sequences. In previous work we showed that human nucleolin associates with the N-terminal region of human topoisomerase I (Top1), We have now mapped the topoisomerase I interaction domain of nucleolin to the N-terminal 225 amino acids. We also show that the Saccharomyces cerevisiae nucleolin ortholog, Nsr1p, physically interacts with yeast topoisomerase I, yTop1p. Studies of isogenic NSR1(+) and Delta nsr1 strains indicate that NSR1 is important in determining the cellular localization of yTop1p. Moreover, deletion of NSR1 reduces sensitivity to camptothecin, an antineoplastic topoisomerase I inhibitor. By contrast, Delta nsr1 cells are hypersensitive to the topoisomerase II-targeting drug amsacrine. These findings indicate that nucleolin/Nsr1 is involved in the cellular localization of Top1 and that this localization may be important in determining sensitivity to drugs that target topoisomerases.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst NEw JErsey, Dept Med, New Brunswick, NJ 08901 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst NEw JErsey, Dept Pharmacol, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Rubin, EH (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst NEw JErsey, Dept Med, New Brunswick, NJ 08901 USA.			Gartenberg, Marc/0000-0003-0713-7993; Shaman, Jeffrey/0000-0001-7397-5755	NATIONAL CANCER INSTITUTE [R29CA070981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051402, R55GM051402, R01GM059170] Funding Source: NIH RePORTER; NCI NIH HHS [CA70981] Funding Source: Medline; NIGMS NIH HHS [GM59170, GM51402] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELSON HT, 1972, NATURE-NEW BIOL, V237, P144, DOI 10.1038/newbio237144a0; Albor A, 1998, CANCER RES, V58, P2091; ALSNER J, 1992, J BIOL CHEM, V267, P12408; Beidler DR, 1996, CANCER RES, V56, P345; BEIDLER DR, 1995, MOL PHARMACOL, V47, P907; BENDIXEN C, 1990, BIOCHEMISTRY-US, V29, P5613, DOI 10.1021/bi00475a028; Bharti AK, 1996, J BIOL CHEM, V271, P1993, DOI 10.1074/jbc.271.4.1993; BJORNSTI MA, 1989, CANCER RES, V49, P6318; BONVEN BJ, 1985, CELL, V41, P541, DOI 10.1016/S0092-8674(85)80027-1; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BOUCHE G, 1984, NUCLEIC ACIDS RES, V12, P3025, DOI 10.1093/nar/12.7.3025; BRILL SJ, 1987, NATURE, V326, P414, DOI 10.1038/326414a0; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; Buckwalter CA, 1996, CANCER RES, V56, P1674; BUGLER B, 1987, J BIOL CHEM, V262, P10922; CHANG JY, 1992, BIOCHEM PHARMACOL, V43, P2443, DOI 10.1016/0006-2952(92)90325-D; CHEN A, 1994, ANN REV PHARM TOXICO, V84, P191; Cheng TH, 1998, P NATL ACAD SCI USA, V95, P5521, DOI 10.1073/pnas.95.10.5521; CHRISTMAN MF, 1988, CELL, V55, P413, DOI 10.1016/0092-8674(88)90027-X; Daniely Y, 2000, J CELL BIOL, V149, P799, DOI 10.1083/jcb.149.4.799; Danks MK, 1996, CANCER RES, V56, P1664; David-Pfeuty T, 1999, ONCOGENE, V18, P7409, DOI 10.1038/sj.onc.1203103; Desai SD, 1997, J BIOL CHEM, V272, P24159, DOI 10.1074/jbc.272.39.24159; Duguet M, 1997, J CELL SCI, V110, P1345; EGYHAZI E, 1987, MOL CELL BIOL, V7, P4308, DOI 10.1128/MCB.7.12.4308; ENG WK, 1988, MOL PHARMACOL, V34, P755; Fan Y, 1998, J MED CHEM, V41, P2216, DOI 10.1021/jm9605445; FANG SH, 1993, EXP CELL RES, V208, P48, DOI 10.1006/excr.1993.1221; FELDHOFF PW, 1994, CANCER RES, V54, P756; Gadal O, 1997, MOL CELL BIOL, V17, P1787, DOI 10.1128/MCB.17.4.1787; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GARTENBERG MR, 1992, P NATL ACAD SCI USA, V89, P11461, DOI 10.1073/pnas.89.23.11461; Ginisty H, 1999, J CELL SCI, V112, P761; Ginisty H, 1998, EMBO J, V17, P1476, DOI 10.1093/emboj/17.5.1476; Gobert C, 1996, BIOCHEMISTRY-US, V35, P5778, DOI 10.1021/bi952327w; GOLDWASSER F, 1995, CANCER RES, V55, P2116; Haluska P, 1998, NUCLEIC ACIDS RES, V26, P1841, DOI 10.1093/nar/26.7.1841; Haluska P, 1999, NUCLEIC ACIDS RES, V27, P2538, DOI 10.1093/nar/27.12.2538; Hanakahi LA, 1999, J BIOL CHEM, V274, P15908, DOI 10.1074/jbc.274.22.15908; HARKER WG, 1995, CANCER RES, V55, P4962; HENRIQUEZ R, 1990, J BIOL CHEM, V265, P2209; HSIANG YH, 1989, CANCER RES, V49, P5077; JAVAHERIAN K, 1983, NUCLEIC ACIDS RES, V11, P461, DOI 10.1093/nar/11.2.461; KIM RA, 1989, CELL, V57, P975, DOI 10.1016/0092-8674(89)90336-X; KONDO K, 1992, J BIOL CHEM, V267, P16259; KONDO K, 1992, J BIOL CHEM, V267, P16252; KORDIYAK GJ, 1994, BIOCHEMISTRY-US, V33, P13484, DOI 10.1021/bi00249a037; LEE WC, 1992, MOL CELL BIOL, V12, P3865, DOI 10.1128/MCB.12.9.3865; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; Mirabella A, 1997, EMBO J, V16, P523, DOI 10.1093/emboj/16.3.523; MIRSKI SEL, 1995, CANCER RES, V55, P2129; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; Mo YY, 2000, EXP CELL RES, V256, P480, DOI 10.1006/excr.2000.4864; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; OHTAKE Y, 1995, MOL CELL BIOL, V15, P2772; Pantazis P, 1995, ANTICANCER RES, V15, P1873; Park H, 1999, YEAST, V15, P35, DOI 10.1002/(SICI)1097-0061(19990115)15:1<35::AID-YEA340>3.0.CO;2-R; Pommier Y, 1998, BIOCHEMISTRY-US, V37, P3818, DOI 10.1021/bi972067d; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Reid RJD, 1998, BBA-GENE STRUCT EXPR, V1400, P289, DOI 10.1016/S0167-4781(98)00142-0; Reid RJD, 1997, J BIOL CHEM, V272, P12091, DOI 10.1074/jbc.272.18.12091; ROSE KM, 1988, CHROMOSOMA, V96, P411, DOI 10.1007/BF00303034; Rossi F, 1996, NATURE, V381, P80, DOI 10.1038/381080a0; RUBIN E, 1994, J BIOL CHEM, V269, P2433; SANTIAGO TC, 1986, NUCLEIC ACIDS RES, V14, P8347, DOI 10.1093/nar/14.21.8347; SAPP M, 1989, EUR J BIOCHEM, V179, P541, DOI 10.1111/j.1432-1033.1989.tb14581.x; SCHULTZ MC, 1992, GENE DEV, V6, P1332, DOI 10.1101/gad.6.7.1332; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Simmons DT, 1996, VIROLOGY, V222, P365, DOI 10.1006/viro.1996.0433; Sorensen M, 1998, BRIT J CANCER, V77, P2152, DOI 10.1038/bjc.1998.360; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Straight AF, 1999, CELL, V97, P245, DOI 10.1016/S0092-8674(00)80734-5; Straub T, 1998, J BIOL CHEM, V273, P26261, DOI 10.1074/jbc.273.41.26261; THRASH C, 1985, P NATL ACAD SCI USA, V82, P4374, DOI 10.1073/pnas.82.13.4374; Tsalik EL, 1998, YEAST, V14, P847, DOI 10.1002/(SICI)1097-0061(19980630)14:9<847::AID-YEA285>3.0.CO;2-9; TUTEJA N, 1995, GENE, V160, P143, DOI 10.1016/0378-1119(95)00207-M; Wadkins RM, 1998, EXP CELL RES, V241, P332, DOI 10.1006/excr.1998.4033; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Wessel I, 1997, CANCER RES, V57, P4451; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Wu JX, 1997, NUCLEIC ACIDS RES, V25, P4181, DOI 10.1093/nar/25.21.4181; WU RS, 1971, P NATL ACAD SCI USA, V68, P3009, DOI 10.1073/pnas.68.12.3009; Xue Zhixiong, 1994, Trends in Cell Biology, V4, P414, DOI 10.1016/0962-8924(94)90095-7; XUE ZX, 1993, EUR J CELL BIOL, V62, P13; ZHANG H, 1988, P NATL ACAD SCI USA, V85, P1060, DOI 10.1073/pnas.85.4.1060	87	42	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36181	36188		10.1074/jbc.M006628200	http://dx.doi.org/10.1074/jbc.M006628200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10967121	hybrid			2022-12-25	WOS:000165382000076
J	Davani, B; Khan, A; Hult, M; Martensson, E; Okret, SE; Efendic, S; Jornvall, H; Oppermann, UCT				Davani, B; Khan, A; Hult, M; Martensson, E; Okret, SE; Efendic, S; Jornvall, H; Oppermann, UCT			Type 1 11 beta-hydroxysteroid dehydrogenase mediates glucocorticoid activation and insulin release in pancreatic islets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CELLS; GLUCAGON-SECRETION; RAT; INHIBITION; REDUCTASE; CORTICOSTERONE; LOCALIZATION; SENSITIVITY; EXPRESSION; STEROIDS	Metabolic transformation of glucocorticoid hormones constitutes a determinant of their cell-specific effects. The most important reaction for this class of steroids is the reversible C11 keto/beta -hydroxyl conversion between receptor-binding 11 beta -OH steroids and the nonbinding 11-oxo compounds, carried out by 11 beta -hydroxysteroid dehydrogenases (11 beta -HSDs). In this study, we determined the role of glucocorticoid conversion by 11 beta -HSD in pancreatic islets and its function in the regulation of insulin release. Pancreatic islets isolated from ob/ob mice display type 1 11 beta -hydroxysteroid dehydrogenase activity, i.e. in intact cells the reductive reaction prevails, leading from dehydrocorticosterone to corticosterone. Expression of type 1 11 beta -HSD mRNA was detected by reverse transcriptase-polymerase chain reaction in islets isolated from ob/ob mice and also from human tissue. Incubation of beta -cells in the presence of 11-dehydrocorticosterone leads to a dose-dependent inhibition of insulin release, indicating cellular activation of 11-dehydrocorticosterone to the receptor ligand, further confirmed by reporter gene assays. Inhibition of 11 beta -HSD activity by carbenoxolone reverses inhibition of insulin release. The presence of 11 beta -HSD in islets supports the concept that reactivation of inert circulating hormone precursors in a cell-specific manner plays a major role in glucocorticoid physiology in rodents and man.	Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Huddinge Univ Hosp, Novum, Dept Med Nutr, S-14186 Huddinge, Sweden; Karolinska Hosp, Dept Mol Med, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Oppermann, UCT (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.							AGARWAL AK, 1995, GENOMICS, V29, P195, DOI 10.1006/geno.1995.1231; Barnes PJ, 1995, BIOCHEM SOC T, V23, P940, DOI 10.1042/bst0230940; BARSEGHIAN G, 1980, ENDOCRINOLOGY, V106, P547, DOI 10.1210/endo-106-2-547; BARSEGHIAN G, 1982, ENDOCRINOLOGY, V111, P1648, DOI 10.1210/endo-111-5-1648; BILLAUDEL B, 1979, HORM METAB RES, V11, P555, DOI 10.1055/s-0028-1092779; Bujalska IJ, 1997, LANCET, V349, P1210, DOI 10.1016/S0140-6736(96)11222-8; Delaunay F, 1997, J CLIN INVEST, V100, P2094, DOI 10.1172/JCI119743; Delaunay F, 1996, EUR J BIOCHEM, V242, P839, DOI 10.1111/j.1432-1033.1996.0839r.x; DINNEEN S, 1993, J CLIN INVEST, V92, P2283, DOI 10.1172/JCI116832; Gremlich S, 1997, J BIOL CHEM, V272, P3216, DOI 10.1074/jbc.272.6.3216; Hult M, 1998, FEBS LETT, V441, P25, DOI 10.1016/S0014-5793(98)01515-4; KHAN A, 1992, AM J PHYSIOL, V263, pE663, DOI 10.1152/ajpendo.1992.263.4.E663; Kotelevtsev Y, 1997, P NATL ACAD SCI USA, V94, P14924, DOI 10.1073/pnas.94.26.14924; Krozowski Z, 1995, J STEROID BIOCHEM, V55, P457, DOI 10.1016/0960-0760(95)00194-8; LAKSHMI V, 1988, ENDOCRINOLOGY, V123, P2390, DOI 10.1210/endo-123-5-2390; Lambillotte C, 1997, J CLIN INVEST, V99, P414, DOI 10.1172/JCI119175; Leckie CM, 1998, J ENDOCRINOL, V159, P233, DOI 10.1677/joe.0.1590233; LENZEN S, 1984, ENDOCR REV, V5, P411, DOI 10.1210/edrv-5-3-411; Ling ZC, 1998, DIABETOLOGIA, V41, P634, DOI 10.1007/s001250050961; LOW SC, 1994, J MOL ENDOCRINOL, V13, P167, DOI 10.1677/jme.0.0130167; Lowe WL, 1998, PRINCIPLES MOL MED, P433; MARANDICI A, 1993, STEROIDS, V58, P153, DOI 10.1016/0039-128X(93)90062-R; MCMAHON M, 1988, DIABETES METAB REV, V4, P17, DOI 10.1002/dmr.5610040105; Michael AE, 1997, MOL CELL ENDOCRINOL, V132, P43, DOI 10.1016/S0303-7207(97)00118-4; MONDER C, 1993, VITAM HORM, V47, P187, DOI 10.1016/S0083-6729(08)60447-1; MUNE T, 1995, NAT GENET, V10, P394, DOI 10.1038/ng0895-394; Napolitano A, 1998, J STEROID BIOCHEM, V64, P251, DOI 10.1016/S0960-0760(97)00200-8; OPPERMANN UCT, 1995, EUR J BIOCHEM, V227, P202, DOI 10.1111/j.1432-1033.1995.tb20377.x; Oppermann UCT, 1997, EUR J BIOCHEM, V249, P355, DOI 10.1111/j.1432-1033.1997.t01-1-00355.x; Plat L, 1996, AM J PHYSIOL-ENDOC M, V270, pE36, DOI 10.1152/ajpendo.1996.270.1.E36; Reichardt HM, 2000, ADV PHARMACOL, V47, P1; Ricketts ML, 1998, J ENDOCRINOL, V156, P159, DOI 10.1677/joe.0.1560159; Stewart PM, 1999, VITAM HORM, V57, P249; SURWIT RS, 1992, DIABETES CARE, V15, P1413, DOI 10.2337/diacare.15.10.1413; vanderBurg B, 1997, TRENDS ENDOCRIN MET, V8, P152, DOI 10.1016/S1043-2760(97)00006-4; Voice MW, 1996, BIOCHEM J, V317, P621, DOI 10.1042/bj3170621; WALKER BR, 1995, J CLIN ENDOCR METAB, V80, P3155, DOI 10.1210/jc.80.11.3155	37	95	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34841	34844		10.1074/jbc.C000600200	http://dx.doi.org/10.1074/jbc.C000600200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10973946	hybrid			2022-12-25	WOS:000165422800003
J	Goldfinger, LE; Jiang, LH; Hopkinson, SB; Stack, MS; Jones, JCR				Goldfinger, LE; Jiang, LH; Hopkinson, SB; Stack, MS; Jones, JCR			Spatial regulation and activity modulation of plasmin by high affinity binding to the G domain of the alpha(3) subunit of laminin-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX PROTEINS; ENDOTHELIAL-CELL RECEPTOR; ANNEXIN-II TETRAMER; HEPARIN-BINDING; A-CHAIN; T-PA; ACTIVATOR; EXPRESSION; CLONING; ADHESION	Cells in complex tissues contact extracellular matrix that interacts with integrin receptors to influence gene expression, proliferation, apoptosis, adhesion, and motility, During development, tissue remodeling, and tumorigenesis, matrix components are modified by enzymatic digestion with subsequent effects on integrin binding and signaling. We are interested in understanding the mechanisms by which broad spectrum proteinases such as plasmin are targeted to their extracellular matrix protein substrates, We have utilized plasmin-mediated cleavage of the epithelial basement membrane glycoprotein laminin-5 as a model to evaluate molecular events that direct plasmin activity to specific structural domains. We report that plasminogen and tissue plasminogen activator (tPA) exhibit high affinity, specific binding to the G(1) subdomain of the N terminus of the laminin-5 alpha (3) subunit, with equilibrium dissociation constants of 50 nM for plasminogen and 80 nM for tPA, No high affinity binding to the G(2), G(3), and G(4) subdomains was observed. As a result of binding to the G(1) subdomain, the catalytic efficiency of tPA-catalyzed plasminogen activation is enhanced 32-fold, leading to increased matrix-associated plasmin that is positioned favorably for cleavage within the G(4) subdomain as we have reported previously (Goldfinger, L. E,, Stack, M. S,, and Jones, J, C, R, (1998) J, Cell Biol, 141, 255-265), Thus, physical constraints dictated by interaction of proteinase and matrix macromolecule control not only enzymatic activity but may regulate substrate targeting of proteinases.	Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Obstet & Gynecol, Chicago, IL 60611 USA	Northwestern University; Northwestern University	Jones, JCR (corresponding author), Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Morton 4-616,303 E Chicago Ave, Chicago, IL 60611 USA.		Jones, Jonathan C R/T-9467-2017	Jones, Jonathan C R/0000-0002-1496-4922	NCI NIH HHS [T32 CA09560] Funding Source: Medline; NIDCR NIH HHS [P01 DE12328] Funding Source: Medline; NIGMS NIH HHS [R01 GM38470] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009560] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038470] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andac Z, 1999, J MOL BIOL, V287, P253, DOI 10.1006/jmbi.1999.2606; Ashkenas J, 1996, DEV BIOL, V180, P433, DOI 10.1006/dbio.1996.0317; Baker SE, 1996, J CELL SCI, V109, P2509; BLASCHKE RJ, 1994, METHOD ENZYMOL, V245, P535; Boudreau N, 1998, CURR OPIN CELL BIOL, V10, P640, DOI 10.1016/S0955-0674(98)80040-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTELLINO FJ, 1981, CHEM REV, V81, P431, DOI 10.1021/cr00045a001; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; Frieser M, 1997, EUR J BIOCHEM, V246, P727, DOI 10.1111/j.1432-1033.1997.t01-1-00727.x; Gase K, 1996, EUR J BIOCHEM, V239, P42, DOI 10.1111/j.1432-1033.1996.0042u.x; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; Hajjar KA, 1998, J BIOL CHEM, V273, P9987, DOI 10.1074/jbc.273.16.9987; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; HARLOW E, 1988, ANTIBODIES LAB MANUA, P92; HIGHSMITH RF, 1981, J BIOL CHEM, V256, P6788; IIVANAINEN A, 1995, FEBS LETT, V365, P183, DOI 10.1016/0014-5793(95)00462-I; Jonsson U., 1992, ADV BIOSENSOR, P291; Kassam G, 1998, BIOCHEMISTRY-US, V37, P16958, DOI 10.1021/bi981713l; Kassam G, 1998, J BIOL CHEM, V273, P4790, DOI 10.1074/jbc.273.8.4790; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; MANGEL WF, 1990, SCIENCE, V248, P69, DOI 10.1126/science.2108500; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Mizushima H, 1997, CELL GROWTH DIFFER, V8, P979; MOSER TL, 1993, J BIOL CHEM, V268, P18917; OSSOWSKI L, 1978, BIOL MARKERS NEOPLAS, P473; REICH E, 1978, BIOL MARKERS NEOPLAS, P506; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; RYAN MC, 1994, J BIOL CHEM, V269, P22779; SASAKI M, 1988, J BIOL CHEM, V263, P16536; STACK MS, 1995, MOL BASIS THROMBOSIS, P479; STACK MS, 1990, BIOCHEMISTRY-US, V30, P2073; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; Sung U, 1997, EUR J BIOCHEM, V250, P138, DOI 10.1111/j.1432-1033.1997.00138.x; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; VUOLTEENAHO R, 1994, J CELL BIOL, V124, P381, DOI 10.1083/jcb.124.3.381; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; YAMAGUCHI H, 1995, AMYLOID, V2, P7, DOI 10.3109/13506129509031882; YURCHENCO PD, 1993, J BIOL CHEM, V268, P8356; Zhang K, 1996, EXP CELL RES, V227, P309, DOI 10.1006/excr.1996.0280	40	37	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34887	34893		10.1074/jbc.M006652200	http://dx.doi.org/10.1074/jbc.M006652200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10956663	hybrid			2022-12-25	WOS:000165422800011
J	Roeb, E; Behrmann, I; Grotzinger, J; Breuer, B; Matern, S				Roeb, E; Behrmann, I; Grotzinger, J; Breuer, B; Matern, S			An MMP-9 mutant without gelatinolytic activity as a novel TIMP-1-antagonist	FASEB JOURNAL			English	Article									Rhein Westfal TH Aachen, Med Klin 3, D-52057 Aachen, Germany; Inst Biochem, D-52057 Aachen, Germany	RWTH Aachen University	Roeb, E (corresponding author), Rhein Westfal TH Aachen, Med Klin 3, Pauwelsstr 30, D-52057 Aachen, Germany.			Behrmann, Iris/0000-0003-3688-3645					0	34	36	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2000	14	12					1671	1673						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973913				2022-12-25	WOS:000089212400003
J	Chatterjee, D; Pantazis, P; Li, G; Bremner, TA; Hendrickson, EA; Wyche, JH				Chatterjee, D; Pantazis, P; Li, G; Bremner, TA; Hendrickson, EA; Wyche, JH			Susceptibility to apoptosis is restored in human leukemia HCW-2 cells following induction and stabilization of the apoptotic effector Bak	ONCOGENE			English	Article						apoptosis; Bak; leukemia cells; differentiation	ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; BCL-2 HOMOLOG BAK; CYTOCHROME-C; MYELOID-LEUKEMIA; HL-60 CELLS; TERMINAL DIFFERENTIATION; INHIBITS APOPTOSIS; MESSENGER-RNA; LINE HL-60	We demonstrate that treatment of HCW-2 cells, an apoptotic resistant variant of the human HL-60 promyelocytic leukemia cell line with phorbol-12-myristate acetate (PMA), induced differentiation along the monocytic lineage. During this process there was a dramatic increase in the mitochondrial levels of the apoptosis effector, Bail, due to the stabilization of bak mRNA, which was correlated with the sensitization of HCW-2 cells to respond to the apoptotic effect of staurosporine (STS), Treatment of PMA-differentiated, but not undifferentiated, HCW-2 cells induced processing of Bid, substantial efflux of cytochrome c from mitochondria to the cytosol, activation of caspase-3 and apoptosis, The biological significance of the increased mitochondrial Bak in differentiated HCW-2 cells mas supported by the finding that transient transfection of a bak cDNA into HCW-2 cells conferred sensitivity to STS-triggered apoptosis, as determined ba pro-caspase-3 processing, cytochrome c efflux and DNA fragmentation. Our results suggest that the induction of Bak, upon monocytic differentiation, may he a critical event that regulates the apoptotic sensitivity of differentiated HCW-2 cells.	Brown Univ, Dept Mol Biol Cell Biol & Biochem, Providence, RI 02912 USA; Howard Univ, Dept Biol, Washington, DC 20059 USA	Brown University; Howard University	Chatterjee, D (corresponding author), Brown Univ, Dept Mol Biol Cell Biol & Biochem, 69 Brown St, Providence, RI 02912 USA.							BENITO A, 1995, AM J PATHOL, V146, P481; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYD JM, 1995, ONCOGENE, V11, P1921; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; BREITMAN TR, 1990, METHOD ENZYMOL, V190, P118; CAMPANA D, 1993, BLOOD, V81, P1025; CASTAIGNE S, 1990, BLOOD, V76, P1704; Chang TC, 1997, FEBS LETT, V415, P11, DOI 10.1016/S0014-5793(97)01083-1; Chatterjee D, 1997, CELL GROWTH DIFFER, V8, P1083; CHATTERJEE D, 1989, CANCER RES, V49, P3910; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; DELIA D, 1992, BLOOD, V79, P1291, DOI 10.1182/blood.V79.5.1291.bloodjournal7951291; DELIA D, 1995, BLOOD, V85, P359, DOI 10.1182/blood.V85.2.359.bloodjournal852359; DEXTER DL, 1979, CANCER RES, V39, P1020; Doyle GAR, 1997, BIOCHEMISTRY-US, V36, P2492, DOI 10.1021/bi962161e; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FRANKEL SR, 1992, ANN INTERN MED, V117, P292, DOI 10.7326/0003-4819-117-4-292; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; Han ZT, 1998, P NATL ACAD SCI USA, V95, P5357, DOI 10.1073/pnas.95.9.5357; HAN ZY, 1994, AM J PATHOL, V145, P423; Han ZY, 1998, CELL DEATH DIFFER, V5, P469, DOI 10.1038/sj.cdd.4400367; Han ZY, 1999, MOL CELL BIOL, V19, P1381; Han ZY, 1996, CANCER RES, V56, P1621; Hegde R, 1998, J BIOL CHEM, V273, P7783, DOI 10.1074/jbc.273.14.7783; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Holinger EP, 1999, J BIOL CHEM, V274, P13298, DOI 10.1074/jbc.274.19.13298; HSU SY, 1997, P NATL ACAD SCI USA, V95, P4997; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Inohara N, 1998, J BIOL CHEM, V273, P8705, DOI 10.1074/jbc.273.15.8705; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Krajewski S, 1996, CANCER RES, V56, P2849; Kren BT, 1996, CELL GROWTH DIFFER, V7, P1633; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; MINN AJ, 1997, NATURE, V385, P853; MIYASHITA T, 1993, BLOOD, V81, P151; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; NAUMOVSKI L, 1994, BLOOD, V83, P2261; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Olsson I, 1996, EUR J HAEMATOL, V57, P1; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PANTAZIS P, 1994, EUR J HAEMATOL, V53, P135; Pantazis Panayotis, 1999, Neoplasia (New York), V1, P231, DOI 10.1038/sj.neo.7900025; PARK JR, 1994, BLOOD, V84, P440; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Rokhlin OW, 1997, CANCER RES, V57, P1758; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; ROVERA G, 1979, SCIENCE, V204, P868, DOI 10.1126/science.286421; Sanz C, 1997, BLOOD, V89, P3199, DOI 10.1182/blood.V89.9.3199; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Simonian PL, 1997, ONCOGENE, V15, P1871, DOI 10.1038/sj.onc.1201350; SOLARY E, 1993, BLOOD, V81, P1359; Sordet O, 1999, CELL DEATH DIFFER, V6, P351, DOI 10.1038/sj.cdd.4400499; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	71	4	4	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2000	19	36					4108	4116		10.1038/sj.onc.1203757	http://dx.doi.org/10.1038/sj.onc.1203757			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962571				2022-12-25	WOS:000088955100004
J	Kostic, C; Shaw, PH				Kostic, C; Shaw, PH			Isolation and characterization of sixteen novel p53 response genes	ONCOGENE			English	Article						p53; transcription; inducible; apoptosis	WILD-TYPE P53; TUMOR-SUPPRESSOR P53; PROGRAMMED CELL-DEATH; SUBTRACTIVE HYBRIDIZATION; P53-INDUCIBLE GENE; TYROSINE KINASE; BINDING-PROTEIN; CANCER-CELLS; DNA-BINDING; G(1) ARREST	The EB-1 cell line is a stable transfectant of EB, a p53 null colon carcinoma cell line, with an inducible promoter controlling expression of a wild type p53 cDNA. The induced p53 is transcriptionally active and gives rise to apoptosis in these cells. Using this cellular model for presence or absence of the transcription factor p53 and transactivated genes, the Suppression Subtractive Hybridization (SSH) technique permitted the isolation of 17 mRNA candidates (GIPs-(G) under bar enes (i) under bar nduced by (p) under bar 53), whose expression appears to be p53-dependent. Identity has been established for nine of the 17 isolated candidates. These are HGFL/MSP, Zap-70, APOBEC2, Ponsin/ SH3P12/CAP/FLAF2, CDCreI2b/H5/PrutI2, Igc, lats 2, cytokeratin 15 and PIG-3 (quinone oxidoreductase). The latter gene is the only GIP previously demonstrated to be p53 regulated. Of the eight remaining GIPs, sis correspond to Unigene clusters. One candidate, GIP #1, is significantly homologous (72% identity) to a chicken zinc finger protein, CTCF, which binds to insulator elements and thus attenuates enhancer cross-talk between physically adjacent promoters. The p53-dependent expression of GIPs was confirmed by dependence of expression upon induction of wt p53 expression in the EB-1 cellular model and by up-regulation following activation of an endogenous wt p53 by treatment with adriamycin.	Univ Lausanne, Inst Pathol, Lausanne, Switzerland	University of Lausanne	Shaw, PH (corresponding author), Univ Lausanne, Inst Pathol, Lausanne, Switzerland.			Kostic, Corinne/0000-0003-1006-9733				ALMON E, 1993, DEV BIOL, V156, P107, DOI 10.1006/dbio.1993.1062; ALONIGRINSTEIN R, 1993, ONCOGENE, V8, P3297; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Arah IN, 1998, ANTICANCER RES, V18, P1845; Bacus SS, 1996, ONCOGENE, V12, P2535; Beites CL, 1999, NAT NEUROSCI, V2, P434, DOI 10.1038/8100; Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Church DM, 1997, GENOME RES, V7, P787, DOI 10.1101/gr.7.8.787; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Collavin L, 1999, ONCOGENE, V18, P5879, DOI 10.1038/sj.onc.1202970; Comer KA, 1998, ONCOGENE, V16, P1299, DOI 10.1038/sj.onc.1201645; Diatchenko L, 1999, METHOD ENZYMOL, V303, P349; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gloushankova N, 1997, ONCOGENE, V15, P2985, DOI 10.1038/sj.onc.1201483; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Han S, 1993, EXS, V65, P81; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HODGSON CP, 1987, NUCLEIC ACIDS RES, V15, P6295, DOI 10.1093/nar/15.15.6295; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOSONO S, 1991, ONCOGENE, V6, P237; ISHIJIMA SA, 1995, CELL IMMUNOL, V165, P278, DOI 10.1006/cimm.1995.1214; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612; Klotzsche O, 1998, ONCOGENE, V16, P3423, DOI 10.1038/sj.onc.1202155; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEUBE RE, 1988, J CELL BIOL, V106, P1249, DOI 10.1083/jcb.106.4.1249; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li S, 1999, J ORTHOP RES, V17, P891, DOI 10.1002/jor.1100170614; Liao W, 1999, BIOCHEM BIOPH RES CO, V260, P398, DOI 10.1006/bbrc.1999.0925; LITTLE JB, 1995, J BIOL CHEM, V270, P11033, DOI 10.1074/jbc.270.19.11033; Maas S, 1997, CURR OPIN CELL BIOL, V9, P343, DOI 10.1016/S0955-0674(97)80006-3; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; Mehta A, 1996, J BIOL CHEM, V271, P28294, DOI 10.1074/jbc.271.45.28294; MIYASHITA T, 1995, CELL, V80, P293; MUKHOPADHYAY T, 1996, ANTICANCER RES, V16, P99; Nagase T, 1999, DNA Res, V6, P337, DOI 10.1093/dnares/6.5.337; NOBLE JR, 1992, EXP CELL RES, V203, P297, DOI 10.1016/0014-4827(92)90002-P; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Paavola P, 1999, GENOMICS, V55, P122, DOI 10.1006/geno.1998.5612; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Renzing J, 1996, J CELL SCI, V109, P1105; Ribon V, 1998, MOL CELL BIOL, V18, P872, DOI 10.1128/MCB.18.2.872; Ribon V, 1998, J BIOL CHEM, V273, P4073, DOI 10.1074/jbc.273.7.4073; Rubtsova SN, 1998, FEBS LETT, V430, P353, DOI 10.1016/S0014-5793(98)00692-9; Sambrook J., 2002, MOL CLONING LAB MANU; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Shaw P, 1996, ONCOGENE, V12, P921; SIEBERT PD, 1995, NUCLEIC ACIDS RES, V23, P1087, DOI 10.1093/nar/23.6.1087; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Stahlhut M, 2000, MOL BIOL CELL, V11, P325, DOI 10.1091/mbc.11.1.325; Take Y, 1996, BIOCHEM BIOPH RES CO, V221, P207, DOI 10.1006/bbrc.1996.0575; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; TISHLER RB, 1995, CANCER RES, V55, P6021; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Trepel M, 1998, J NEURO-ONCOL, V39, P19, DOI 10.1023/A:1005910323338; Utrera R, 1998, EMBO J, V17, P5015, DOI 10.1093/emboj/17.17.5015; WALDMAN T, 1995, CANCER RES, V55, P5187; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Xia F, 1997, MUTAT RES-FUND MOL M, V373, P87, DOI 10.1016/S0027-5107(96)00193-5; Xie H, 1999, CELL MOTIL CYTOSKEL, V43, P52, DOI 10.1002/(SICI)1097-0169(1999)43:1<52::AID-CM6>3.0.CO;2-5; XU TA, 1995, DEVELOPMENT, V121, P1053; Yabuta N, 2000, GENOMICS, V63, P263, DOI 10.1006/geno.1999.6065; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhang JS, 1999, CURR BIOL, V9, P1458, DOI 10.1016/S0960-9822(00)80115-3	80	35	39	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 17	2000	19	35					3978	3987		10.1038/sj.onc.1203747	http://dx.doi.org/10.1038/sj.onc.1203747			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962554				2022-12-25	WOS:000088825300003
J	Becker, NA; O'Neill, HA; Zimmerman, JM; Maher, LJ				Becker, NA; O'Neill, HA; Zimmerman, JM; Maher, LJ			In vitro and in vivo ligation-mediated polymerase chain reaction analysis of a polypurine/polypyrimidine sequence upstream of the mouse metallothionein-1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPERCOILED PLASMID DNA; ESCHERICHIA-COLI-CELLS; TRIPLE-HELIX FORMATION; H-DNA; HALOBACTERIUM-HALOBIUM; DIETHYL PYROCARBONATE; IN-VIVO; B-DNA; TRANSCRIPTION; BINDING	The mouse metallothionein-1 homopurine/homopyrimidine (MT-I R/Y) sequence is a 128-base pair element located similar to1.2 kilobase pairs upstream of the MT-I gene. Previous in vitro studies of this sequence in purified plasmids indicated the formation of a non-B DNA structure stabilized by acidic pH and negative supercoiling. We now present a detailed in vitro and in vivo analysis of the MT-I R/Y sequence using chemical probes of DNA structure and ligation-mediated polymerase chain reaction. In vivo analysis suggests neither profound base unpairing nor protein binding within the MT-I R/Y sequence before or after metal induction of MT-I. We conclude for this element that the propensity to adopt an unusual DNA structure in vitro does not imply the occurrence of such a structure in vive. We were able to show both in purified genomic DNA and in vive that only isolated thymines and the 3' terminal thymine in strings of consecutive thymines are modified significantly by KMnO4, indicating an altered thymine accessibility pattern within the R/Y sequence. This KMnO4, reactivity pattern is more consistent and predictable within the R/Y sequence when compared with flanking sequences. We propose a simple steric interference model to explain the observed pattern of KMnO4, modification of thymines.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Maher, LJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.	maher@mayo.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047814, R01GM054411] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47814, GM54411] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agazie YM, 1996, BIOCHEM J, V316, P461, DOI 10.1042/bj3160461; ANDERSEN RD, 1987, MOL CELL BIOL, V7, P3574, DOI 10.1128/MCB.7.10.3574; Backer NA, 1998, NUCLEIC ACIDS RES, V26, P1951, DOI 10.1093/nar/26.8.1951; BACOLLA A, 1991, NUCLEIC ACIDS RES, V19, P1639, DOI 10.1093/nar/19.7.1639; COLLIER DA, 1990, J BIOL CHEM, V265, P10652; CULOTTA VC, 1989, MOL CELL BIOL, V9, P1376, DOI 10.1128/MCB.9.3.1376; DURNAM DM, 1981, J BIOL CHEM, V256, P5712; FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433; FRAPPIER L, 1987, J MOL BIOL, V193, P751, DOI 10.1016/0022-2836(87)90356-1; FREEMAN F, 1976, BIOCHIM BIOPHYS ACTA, V447, P238, DOI 10.1016/0005-2787(76)90346-4; HAMER D H, 1982, Journal of Molecular and Applied Genetics, V1, P273; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HANVEY JC, 1988, J BIOL CHEM, V263, P7386; HANVEY JC, 1988, P NATL ACAD SCI USA, V85, P6292, DOI 10.1073/pnas.85.17.6292; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; HTUN H, 1989, SCIENCE, V243, P1571, DOI 10.1126/science.2648571; Hunter CA, 1997, J MOL BIOL, V265, P603, DOI 10.1006/jmbi.1996.0755; IIDA S, 1970, BIOCHIM BIOPHYS ACTA, V213, P1, DOI 10.1016/0005-2787(70)90002-X; JOHNSTON BH, 1988, SCIENCE, V241, P1800, DOI 10.1126/science.2845572; KARLOVSKY P, 1990, FEBS LETT, V274, P39, DOI 10.1016/0014-5793(90)81324-H; Kelm RJ, 1996, J BIOL CHEM, V271, P24278, DOI 10.1074/jbc.271.39.24278; Kim J, 1996, J BIOL CHEM, V271, P9340, DOI 10.1074/jbc.271.16.9340; Kim JM, 1996, J BIOL CHEM, V271, P19724, DOI 10.1074/jbc.271.33.19724; KOHWI Y, 1993, GENE DEV, V7, P1766, DOI 10.1101/gad.7.9.1766; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KOHWI Y, 1992, J MOL BIOL, V223, P817, DOI 10.1016/0022-2836(92)90242-C; KOHWISHIGEMATSU T, 1992, METHOD ENZYMOL, V212, P155; Krasilnikov AS, 1999, J MOL BIOL, V292, P1149, DOI 10.1006/jmbi.1999.3117; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LYAMICHEV VI, 1986, J BIOMOL STRUCT DYN, V3, P667, DOI 10.1080/07391102.1986.10508454; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCARTHY JG, 1990, BIOCHEMISTRY-US, V29, P6071, DOI 10.1021/bi00477a027; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MURCHIE AIH, 1992, METHOD ENZYMOL, V211, P158; Nejedly K, 1998, BIOPHYS CHEM, V73, P205, DOI 10.1016/S0301-4622(98)00145-8; PALECEK E, 1993, J CELL SCI, V104, P653; PALECEK E, 1988, BIOCHEM BIOPH RES CO, V150, P731, DOI 10.1016/0006-291X(88)90452-4; PESTOV DG, 1991, NUCLEIC ACIDS RES, V19, P6527, DOI 10.1093/nar/19.23.6527; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; SPIRO C, 1995, J BIOL CHEM, V270, P27702, DOI 10.1074/jbc.270.46.27702; SPIRO C, 1999, TRANSCRIPTION FACTOR, P27; STEINMETZER K, 1995, J MOL BIOL, V254, P29, DOI 10.1006/jmbi.1995.0596; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; Suzuki M, 1997, J MOL BIOL, V274, P421, DOI 10.1006/jmbi.1997.1406; THIELE DJ, 1992, NUCLEIC ACIDS RES, V20, P1183, DOI 10.1093/nar/20.6.1183; WANG AHJ, 1979, NATURE, V282, P680, DOI 10.1038/282680a0; WELLS RD, 1988, J BIOL CHEM, V263, P1095; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307	54	1	1	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40218	40225		10.1074/jbc.M909658199	http://dx.doi.org/10.1074/jbc.M909658199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10986295	hybrid			2022-12-25	WOS:000166039500059
J	Liou, JS; Chen, CY; Chen, JS; Faller, DV				Liou, JS; Chen, CY; Chen, JS; Faller, DV			Oncogenic Ras mediates apoptosis in response to protein kinase C inhibition through the generation of reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; NF-KAPPA-B; ALKYL-PHOSPHOLIPID ANALOGS; GROWTH-FACTOR; HUMAN FIBROBLASTS; NADPH OXIDASE; PC12 CELLS; P53-INDEPENDENT APOPTOSIS; SIGNAL-TRANSDUCTION; CYTO-TOXICITY	Ras is a well established modulator of apoptosis. Suppression of protein kinase C (PKC) activity can selectively induce apoptosis in cells expressing a constitutively activated Ras protein. We wished to determine whether reactive oxygen species serve as an effector of Ras-mediated apoptosis. Ras-transformed NIH/3T3 cells contained higher basal levels of intracellular H2O2 compared with normal NIH/3T3 cells, and PKC inhibition up-regulated ROS to 5-fold greater levels in Ras-transformed cells than in normal cells. Treatment with N-acetyl-L-cysteine reduced both the basal and inducible levels of intracellular H2O2 in NIH/3T3-Ras cells and antagonized the induction of apoptosis by PKC inhibition. Culturing NIH/3T3-Ras cells in low oxygen conditions, which prevents ROS generation, also inhibited the apoptotic response to PKC inhibition. These results suggest that reactive oxygen species are necessary as downstream effecters of the Ras-mediated apoptotic response to PKC inhibition. However, the generation of ROS alone is not sufficient to induce apoptosis in Ras-transformed cells because inhibition of cell cycle progression prevented the induction of apoptosis in NIH/3T3-Ras cells without inhibiting the generation of intracellular H2O2 observed after PKC inhibition. These findings suggest that continued cell cycle progression of Ras-transformed cells during PKC inhibition is also necessary for the induction of apoptosis.	Boston Univ, Sch Med, Canc Res Ctr, Boston, MA 02118 USA	Boston University	Faller, DV (corresponding author), Boston Univ, Sch Med, Canc Res Ctr, 715 Albany St,Rm K-701, Boston, MA 02118 USA.				NCPDCID CDC HHS [NCI 50459] Funding Source: Medline	NCPDCID CDC HHS		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Anderson KM, 1999, MED HYPOTHESES, V52, P451, DOI 10.1054/mehy.1997.0521; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Chen CY, 1998, CELL DEATH DIFFER, V5, P984, DOI 10.1038/sj.cdd.4400448; CHEN CY, 1995, ONCOGENE, V11, P1487; Chen CY, 1998, J BIOL CHEM, V273, P16700, DOI 10.1074/jbc.273.27.16700; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; Coopersmith CM, 1997, J CELL BIOL, V138, P167, DOI 10.1083/jcb.138.1.167; DANIEL LW, 1987, LIPIDS, V22, P851, DOI 10.1007/BF02535543; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; FERRARI G, 1994, EMBO J, V13, P5922, DOI 10.1002/j.1460-2075.1994.tb06937.x; Foo SY, 1999, TRENDS GENET, V15, P229; FRENKEL K, 1987, CARCINOGENESIS, V8, P455, DOI 10.1093/carcin/8.3.455; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOFFMAN DR, 1986, CANCER RES, V46, P5803; HOFFMAN DR, 1984, BLOOD, V63, P545; Irani K, 1998, BIOCHEM PHARMACOL, V55, P1339; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JANSSEN JWG, 1985, CANCER RES, V45, P3262; JANSSEN YMW, 1993, LAB INVEST, V69, P261; JONES SA, 1994, FEBS LETT, V355, P178, DOI 10.1016/0014-5793(94)01201-6; Joneson T, 1999, MOL CELL BIOL, V19, P5892; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; King KL, 1998, ANNU REV PHYSIOL, V60, P601, DOI 10.1146/annurev.physiol.60.1.601; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; KOUREMBANAS S, 1990, J CLIN INVEST, V86, P670, DOI 10.1172/JCI114759; KRAMER IM, 1989, J BIOL CHEM, V264, P5876; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; LU Y, 1994, J IMMUNOL, V153, P1495; LUCAS M, 1995, GEN PHARMACOL, V26, P881, DOI 10.1016/0306-3623(94)00295-X; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MEIER B, 1991, BIOCHEM J, V275, P241, DOI 10.1042/bj2750241; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; Mills EM, 1998, J BIOL CHEM, V273, P22165, DOI 10.1074/jbc.273.35.22165; MOLLINEDO F, 1993, BIOCHEM BIOPH RES CO, V192, P603, DOI 10.1006/bbrc.1993.1458; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; Nalca A, 1999, J BIOL CHEM, V274, P29976, DOI 10.1074/jbc.274.42.29976; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Ohmori M, 1997, CANCER RES, V57, P4714; Parrizas M, 1997, BIOCHEM BIOPH RES CO, V234, P616, DOI 10.1006/bbrc.1997.6641; Parrizas M, 1997, J BIOL CHEM, V272, P154; PERRINE SP, 1994, BRIT J HAEMATOL, V88, P555, DOI 10.1111/j.1365-2141.1994.tb05073.x; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TIDWELL T, 1981, BLOOD, V57, P794; VANBLITTERSWIJK WJ, 1987, LIPIDS, V22, P820, DOI 10.1007/BF02535537; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10344; VANBLITTERSWIJK WJ, 1987, LIPIDS, V22, P842, DOI 10.1007/BF02535541; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; Wagner BA, 1998, CANCER RES, V58, P2809; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; ZULLO JN, 1988, MOL CELL BIOL, V8, P5080, DOI 10.1128/MCB.8.12.5080	72	44	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39001	39011		10.1074/jbc.M007154200	http://dx.doi.org/10.1074/jbc.M007154200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10967125	hybrid			2022-12-25	WOS:000165953100010
J	Parrill, AL; Wang, DA; Bautista, DL; Van Brocklyn, JR; Lorincz, Z; Fischer, DJ; Baker, DL; Liliom, K; Spiegel, S; Tigyi, G				Parrill, AL; Wang, DA; Bautista, DL; Van Brocklyn, JR; Lorincz, Z; Fischer, DJ; Baker, DL; Liliom, K; Spiegel, S; Tigyi, G			Identification of Edg1 receptor residues that recognize sphingosine 1-phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SPHINGOSINE-1-PHOSPHATE; LIGAND; PROLIFERATION; CONSTRUCTION; ACTIVATION	Originating from its DNA sequence, a computational model of the Edg1 receptor has been developed that predicts critical interactions with its ligand, sphingosine I-phosphate. The basic amino acids Arg(120) and Arg(292) ion pair with the phosphate, whereas the acidic Glu(121) residue ion pairs with the ammonium moiety of sphingosine l-phosphate. The requirement of these interactions for specific ligand recognition has been confirmed through examination of site-directed mutants by radioligand binding, ligand-induced [S-35]GTP gammaS binding, and receptor internalization assays. These ion-pairing interactions explain the ligand specificity of the Edg1 receptor and provide insight into ligand specificity differences within the Edg receptor family. This computational map of the ligand binding pocket provides information necessary for understanding the molecular pharmacology of this receptor, thus underlining the potential of the computational method in predicting ligand-receptor interactions.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA; Univ Memphis, Dept Chem, Memphis, TN 38152 USA; Univ Memphis, Computat Res Mat Inst, Memphis, TN 38152 USA; Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; Georgetown Univ, Dept Biochem, Washington, DC 20007 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Memphis; University of Memphis; University System of Ohio; Ohio State University; Georgetown University	Tigyi, G (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol & Biophys, 894 Union Ave, Memphis, TN 38163 USA.	gtigyi@physio1.utmem.edu	Liliom, Karoly/A-6563-2011; Van Brocklyn, Jim/A-9733-2010	Liliom, Karoly/0000-0002-7177-6872; Parrill, Abby/0000-0003-1658-8497; Baker, Daniel/0000-0003-1482-0416	NHLBI NIH HHS [HL07641, HL61469] Funding Source: Medline; NIGMS NIH HHS [GM43880] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061469] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043880, R37GM043880] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An SZ, 2000, J BIOL CHEM, V275, P288, DOI 10.1074/jbc.275.1.288; An SZ, 1997, FEBS LETT, V417, P279, DOI 10.1016/S0014-5793(97)01301-X; An SZ, 1998, MOL PHARMACOL, V54, P881, DOI 10.1124/mol.54.5.881; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Bautista DL, 2000, J MOL STRUC-THEOCHEM, V529, P219, DOI 10.1016/S0166-1280(00)00549-2; BRAMBLETT RD, 1995, LIFE SCI, V56, P1971, DOI 10.1016/0024-3205(95)00178-9; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; DEWAR MJS, 1985, J AM CHEM SOC, V107, P3902, DOI 10.1021/ja00299a024; Finney DJ., 1977, PROBIT ANAL; Fischer DJ, 1998, MOL PHARMACOL, V54, P979, DOI 10.1124/mol.54.6.979; Gonda K, 1999, BIOCHEM J, V337, P67, DOI 10.1042/0264-6021:3370067; Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281; Im DS, 2000, MOL PHARMACOL, V57, P753, DOI 10.1124/mol.57.4.753; Konvicka K, 1998, BIOPHYS J, V75, P601, DOI 10.1016/S0006-3495(98)77551-4; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1998, J BIOL CHEM, V273, P22105, DOI 10.1074/jbc.273.34.22105; Lefkowitz RJ, 2000, NAT CELL BIOL, V2, pE133, DOI 10.1038/35017152; Liu CH, 1999, MOL BIOL CELL, V10, P1179, DOI 10.1091/mbc.10.4.1179; Okamoto H, 1998, J BIOL CHEM, V273, P27104, DOI 10.1074/jbc.273.42.27104; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parrill AL, 2000, ANN NY ACAD SCI, V905, P330; Pogozheva ID, 1997, BIOPHYS J, V72, P1963, DOI 10.1016/S0006-3495(97)78842-8; SADAHIRA Y, 1992, P NATL ACAD SCI USA, V89, P9686, DOI 10.1073/pnas.89.20.9686; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SPIEGEL S, 1994, BREAST CANCER RES TR, V31, P337, DOI 10.1007/BF00666166; Tao Q, 1999, MOL PHARMACOL, V55, P605; Van Brocklyn JR, 2000, BLOOD, V95, P2624; Van Brocklyn JR, 1999, J BIOL CHEM, V274, P4626, DOI 10.1074/jbc.274.8.4626; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; vanRhee AM, 1996, DRUG DEVELOP RES, V37, P1, DOI 10.1002/(SICI)1098-2299(199601)37:1<1::AID-DDR1>3.0.CO;2-S; ZHANG DQ, 1994, FEBS LETT, V337, P207, DOI 10.1016/0014-5793(94)80274-2; Zhang GF, 1999, GENE, V227, P89, DOI 10.1016/S0378-1119(98)00589-7	32	133	150	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39379	39384		10.1074/jbc.M007680200	http://dx.doi.org/10.1074/jbc.M007680200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10982820	hybrid			2022-12-25	WOS:000165953100061
J	Nakamura, H; Fujii, Y; Inoki, I; Sugimoto, K; Tanzawa, K; Matsuki, H; Miura, R; Yamaguchi, Y; Okada, Y				Nakamura, H; Fujii, Y; Inoki, I; Sugimoto, K; Tanzawa, K; Matsuki, H; Miura, R; Yamaguchi, Y; Okada, Y			Brevican is degraded by matrix metalloproteinases and aggrecanase-1 (ADAMTS4) at different sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHEUMATOID SYNOVIAL FIBROBLASTS; EXTRACELLULAR-MATRIX; ENZYMATIC-PROPERTIES; INTERGLOBULAR DOMAIN; CARTILAGE AGGRECAN; NEURITE OUTGROWTH; CLEAVAGE-SITE; ACTIVATION; PRECURSOR; PURIFICATION	Brevican is a member of the lectican family of chondroitin sulfate proteoglycans that is predominantly expressed in the central nervous system. The susceptibility of brevican to digestion by matrix metalloproteinases (MMP-1, -2, -3, -7, -8, -9, -10, and -13 and membrane type 1 and 3 MMPs) and aggrecanase-1 (ADAMTS4) was examined. MMP-1, -2, -3, -7, -8, -10, and -13 degraded brevican into a few fragments with similar molecular masses, whereas the degradation products of aggrecanase-1 had apparently different sizes. NH2-terminal sequence analyses of the digestion fragments revealed that cleavages of the brevican core protein by these metalloproteinases occurred commonly within the central non-homologous domain. MMP-1, -2, -3, -7, -8, -10, and -13 preferentially attacked the Ala(360)-Phe(361) bond, whereas aggrecanase-1 cleaved the Glu(395)-Ser(396) bond, which are similar to the cleavage sites observed with cartilage proteoglycan (aggrecan) for the MMPs and aggrecanase-1, respectively. These data demonstrate that MMP-1, -2, -3, -7, -8, -10, and -13 and aggrecanase-1 digest brevican in a similar pattern to aggrecan and suggest that they may be responsible for the physiological turnover and pathological degradation of brevican.	Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, Tokyo 1600016, Japan; Fukui Med Univ, Dept Chem, Fukui 9101193, Japan; Sankyo Co Ltd, Biol Res Labs, Shinagawa Ku, Tokyo 1408710, Japan; Fuji Chem Ind Co Ltd, Biopharmaceut Dept, Takaoka, Toyama 9338511, Japan; Burnham Inst, La Jolla, CA 92037 USA	Keio University; University of Fukui; Daiichi Sankyo Company Limited; Sanford Burnham Prebys Medical Discovery Institute	Okada, Y (corresponding author), Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1600016, Japan.	okada@med.keio.ac.jp	Okada, Yasunori/B-5550-2014; nakamura, hiroyuki/A-2953-2013	Okada, Yasunori/0000-0001-9208-4755; nakamura, hiroyuki/0000-0002-2524-3063; Fujii, Yutaka/0000-0001-6357-3795				BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; FOSANG AJ, 1995, BIOCHEM J, V310, P337, DOI 10.1042/bj3100337; FOSANG AJ, 1992, J BIOL CHEM, V267, P19470; Fosang AJ, 1996, J CLIN INVEST, V98, P2292, DOI 10.1172/JCI119040; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; Gary SC, 1998, CURR OPIN NEUROBIOL, V8, P576, DOI 10.1016/S0959-4388(98)80083-4; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; Imai K, 1997, BIOCHEM J, V322, P809, DOI 10.1042/bj3220809; IMAI K, 1995, J BIOL CHEM, V270, P6691, DOI 10.1074/jbc.270.12.6691; IMAI K, 1994, FEBS LETT, V352, P216, DOI 10.1016/0014-5793(94)00960-0; Jaworski DM, 1996, CANCER RES, V56, P2293; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; Matsuki H, 1996, CLIN CHIM ACTA, V244, P129, DOI 10.1016/0009-8981(95)06197-5; Matthews RT, 2000, J BIOL CHEM, V275, P22695, DOI 10.1074/jbc.M909764199; Merzak A, 1997, CANCER METAST REV, V16, P155, DOI 10.1023/A:1005760726850; Miura R, 1999, J BIOL CHEM, V274, P11431, DOI 10.1074/jbc.274.16.11431; Nakada M, 1999, AM J PATHOL, V154, P417, DOI 10.1016/S0002-9440(10)65288-1; Nakamura H, 1998, EUR J BIOCHEM, V253, P67, DOI 10.1046/j.1432-1327.1998.2530067.x; NAKANO A, 1995, J NEUROSURG, V83, P298, DOI 10.3171/jns.1995.83.2.0298; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OKADA Y, 1988, BIOCHEM J, V254, P731, DOI 10.1042/bj2540731; OKADA Y, 1992, J BIOL CHEM, V267, P21712; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OKADA Y, 2000, TXB RHEUMATOLOGY; Ruoslahti E, 1996, GLYCOBIOLOGY, V6, P489, DOI 10.1093/glycob/6.5.489; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; Shimada T, 1999, EUR J BIOCHEM, V262, P907, DOI 10.1046/j.1432-1327.1999.00459.x; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; Sugimoto K, 1999, J BIOCHEM, V126, P449, DOI 10.1093/oxfordjournals.jbchem.a022471; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; YAMADA H, 1995, BIOCHEM BIOPH RES CO, V216, P957, DOI 10.1006/bbrc.1995.2713; Yamada H, 1997, J NEUROSCI, V17, P7784; YAMADA H, 1994, J BIOL CHEM, V269, P10119; Yamaguchi Y, 2000, CELL MOL LIFE SCI, V57, P276, DOI 10.1007/PL00000690; Zhang H, 1998, J NEUROSCI, V18, P2370	36	134	138	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38885	38890		10.1074/jbc.M003875200	http://dx.doi.org/10.1074/jbc.M003875200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10986281	hybrid			2022-12-25	WOS:000165739800101
J	Stanhope-Baker, P; Williams, BRG				Stanhope-Baker, P; Williams, BRG			Identification of connective tissue growth factor as a target of WT1 transcriptional regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR SUPPRESSOR WT1; DENYS-DRASH SYNDROME; FACTOR BINDING-PROTEINS; IMMEDIATE-EARLY GENE; I RECEPTOR GENE; WILMS-TUMOR; DNA-BINDING; OLIGONUCLEOTIDE ARRAYS; NOV PROTOONCOGENE; SELF-ASSOCIATION	The Wilms tumor suppressor WT1 has transcription-activating and -suppressing capabilities. WT1-responsive promoters have been described; however, in large part, it remains unclear which potential downstream genes are physiologically relevant and mediate the function of WT1 in tumorigenesis and development. To identify genes regulated by WT1 in vivo, we used a dominant-negative version of WT1 to modulate WT1 activity in a Wilms tumor cell line. Screening oligonucleotide arrays with RNA from these cells uncovered a number of genes whose expression was altered by abrogation of WT1 function. Several of the genes encode members of the CCN family of growth regulators. The promoter of one of these genes, connective tissue growth factor (CTGF), is suppressed by WT1 both in its endogenous location and in reporter constructs. WT1 regulation of CTGF expression is not mediated by previously identified WT1 recognition elements and may therefore involve a novel mechanism. Our results indicate that CTGF is a bona fide target of WT1 transcriptional suppression and likely plays a role in Wilms tumorigenesis and associated disease syndromes.	Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Williams, BRG (corresponding author), Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, Mail Code NB40,9500 Euclid Ave, Cleveland, OH 44195 USA.	williab@ccf.org	Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151				Babic AM, 1999, MOL CELL BIOL, V19, P2958; BONETTA L, 1990, SCIENCE, V250, P994, DOI 10.1126/science.2173146; Borel F, 1996, BIOCHEMISTRY-US, V35, P12070, DOI 10.1021/bi960758o; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; COPPES MJ, 1995, WILMS TUMOR CLIN MOL; DEPLAEN E, 1994, IMMUNOGENETICS, V40, P360, DOI 10.1007/BF01246677; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; DROP SLS, 1992, GROWTH REGULAT, V2, P69; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; Duarte A, 1998, BRIT J CANCER, V77, P253, DOI 10.1038/bjc.1998.41; Englert C, 1998, TRENDS BIOCHEM SCI, V23, P389, DOI 10.1016/S0968-0004(98)01277-8; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; GAUGLER B, 1994, J EXP MED, V179, P921, DOI 10.1084/jem.179.3.921; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Haque SJ, 2000, J BIOL CHEM, V275, P26500, DOI 10.1074/jbc.275.34.26500; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hashimoto Y, 1998, J EXP MED, V187, P289, DOI 10.1084/jem.187.3.289; Hastie Nicholas D., 1992, Human Molecular Genetics, V1, P293; Holmes G, 1997, BIOCHEM BIOPH RES CO, V233, P723, DOI 10.1006/bbrc.1997.6545; Hosono S, 2000, J BIOL CHEM, V275, P10943, DOI 10.1074/jbc.275.15.10943; Ito Y, 1998, KIDNEY INT, V53, P853, DOI 10.1046/j.1523-1755.1998.00820.x; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; Kato MV, 1996, ONCOGENE, V12, P1361; Kim HS, 1997, P NATL ACAD SCI USA, V94, P12981, DOI 10.1073/pnas.94.24.12981; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; LITTLE M, 1995, HUM MOL GENET, V4, P351, DOI 10.1093/hmg/4.3.351; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; Martinerie C, 1996, ONCOGENE, V12, P1479; MARTINERIE C, 1994, ONCOGENE, V9, P2729; MARTINERIE C, 1992, ONCOGENE, V7, P2529; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOFFETT P, 1995, P NATL ACAD SCI USA, V92, P11105, DOI 10.1073/pnas.92.24.11105; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; Murphy M, 1999, J BIOL CHEM, V274, P5830, DOI 10.1074/jbc.274.9.5830; MURPHY M, 1993, CELL GROWTH DIFFER, V4, P715; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322; *PE APPL BIOS, 1997, ABI PRISM 7700 SEQ D; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REDDY JC, 1995, J BIOL CHEM, V270, P10878, DOI 10.1074/jbc.270.18.10878; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; Sakamoto Y, 1997, ONCOGENE, V15, P2001, DOI 10.1038/sj.onc.1201391; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; WERNER H, 1995, MOL CELL BIOL, V15, P3516; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Yamanaka Y, 1997, J BIOL CHEM, V272, P30729, DOI 10.1074/jbc.272.49.30729; Ye Y, 1996, EMBO J, V15, P5606, DOI 10.1002/j.1460-2075.1996.tb00945.x	57	33	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38139	38150		10.1074/jbc.M004901200	http://dx.doi.org/10.1074/jbc.M004901200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10973960	hybrid			2022-12-25	WOS:000165739800004
J	Pekkari, K; Gurunath, R; Arner, ESJ; Holmgren, A				Pekkari, K; Gurunath, R; Arner, ESJ; Holmgren, A			Truncated thioredoxin is a mitogenic cytokine for resting human peripheral blood mononuclear cells and is present in human plasma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-DERIVED FACTOR; CYTOTOXICITY-ENHANCING FACTOR; LYMPHOCYTE-PROLIFERATION; HUMAN EOSINOPHILS; KAPPA-B; GROWTH; INVOLVEMENT; ACTIVATION; EXPRESSION; MECHANISM	Human thioredoxin (Trx) catalyzes intracellular disulfide reductions but has also co-cytokine activity with interleukins after leaderless secretion. A recombinant truncated form of thioredoxin with the 80 N-terminal residues (Trx80) was purified to homogeneity, We discovered that Trx80 by itself is a potent mitogenic cytokine stimulating growth of resting human peripheral blood mononuclear cells. No effect was seen by Trx, but Trx80 at 50-100 nm induced cell proliferation of human peripheral blood mononuclear cells in serum-free synthetic medium, measured as [H-3]thymidine incorporation after 72 h, with a maximum effect being comparable with that of 5 units/ml of interleukin-a. Trx80 lacked redox activity, but CD spectra suggested a secondary structure similar to Trx. Reduced Trx80 had an M-r of 25,000, indicating that it is a dimer in solution. We also developed two different sandwich enzyme-linked immunosorbent assays that distinguish between full-length Trx and Trx80 and determined plasma levels of Trx and Trx80 in blood donors. The levels of Trx80 varied from 2 to 175 ng/ml; in comparison levels of Trx varied from 16 to 55 ng/ml without correlation to Trx80, In conclusion, the naturally occurring Trx80 is a novel mitogenic cytokine for normal resting human blood mononuclear cells.	Karolinska Inst, Dept Biochem & Biophys, Med Nobel Inst Biochem, S-17177 Stockholm, Sweden	Karolinska Institutet	Holmgren, A (corresponding author), Karolinska Inst, Dept Biochem & Biophys, Med Nobel Inst Biochem, S-17177 Stockholm, Sweden.	Arne.Holmgren@mbb.ki.se	Ramanathan, Gurunath/B-4757-2011; Arnér, Elias/K-6737-2019; Arnér, Elias S.J./J-5832-2012; Ramanathan, Gurunath/AAR-3650-2020; Pekkari, Klas/AAA-5124-2022	Ramanathan, Gurunath/0000-0003-4627-1677; Arnér, Elias/0000-0002-4807-6114; Arnér, Elias S.J./0000-0002-4807-6114; Ramanathan, Gurunath/0000-0003-4627-1677; 				Aitken Alastair, 1996, P3, DOI 10.1007/978-1-60327-259-9_1; ARNER ESJ, 1992, J BIOL CHEM, V267, P10968; ARNER ESJ, 1993, ANAL BIOCHEM, V210, P102, DOI 10.1006/abio.1993.1157; BALCEWICZSABLINSKA MK, 1991, J IMMUNOL, V147, P2170; Bertini R, 1999, J EXP MED, V189, P1783, DOI 10.1084/jem.189.11.1783; BIGUET C, 1994, J BIOL CHEM, V269, P28865; BODYCOTE J, 1986, P NATL ACAD SCI USA, V83, P4749, DOI 10.1073/pnas.83.13.4749; DESSEIN AJ, 1984, CELL IMMUNOL, V85, P100, DOI 10.1016/0008-8749(84)90282-X; Di Trapani G, 1998, MOL HUM REPROD, V4, P369, DOI 10.1093/molehr/4.4.369; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; ERICSON ML, 1992, LYMPHOKINE CYTOK RES, V11, P201; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; HOLMGREN A, 1978, BIOCHEMISTRY-US, V17, P4071, DOI 10.1021/bi00612a031; HOLMGREN A, 1979, J BIOL CHEM, V254, P9113; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; IWATA S, 1994, J IMMUNOL, V152, P5633; Jiang XM, 1999, J BIOL CHEM, V274, P2416, DOI 10.1074/jbc.274.4.2416; KRAVTSOV VD, 1994, EUR J CANCER, V30A, P1564, DOI 10.1016/0959-8049(94)00291-C; LENZI HL, 1985, CELL IMMUNOL, V94, P333, DOI 10.1016/0008-8749(85)90257-6; LUNDSTROM J, 1992, J BIOL CHEM, V267, P9047; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; Nakamura H, 1996, INT IMMUNOL, V8, P603, DOI 10.1093/intimm/8.4.603; NAKAMURA H, 1992, CANCER-AM CANCER SOC, V69, P2091, DOI 10.1002/1097-0142(19920415)69:8<2091::AID-CNCR2820690814>3.0.CO;2-X; NEWMAN GW, 1994, J EXP MED, V180, P359, DOI 10.1084/jem.180.1.359; Powis G, 1997, Adv Pharmacol, V38, P329; QIN J, 1994, STRUCTURE, V2, P503, DOI 10.1016/S0969-2126(00)00051-4; REN XL, 1993, BIOCHEMISTRY-US, V32, P9701, DOI 10.1021/bi00088a023; ROSEN A, 1995, INT IMMUNOL, V7, P625, DOI 10.1093/intimm/7.4.625; RUBARTELLI A, 1992, J BIOL CHEM, V267, P24161; Sahaf B, 1997, EXP CELL RES, V236, P181, DOI 10.1006/excr.1997.3699; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SILBERSTEIN DS, 1993, J BIOL CHEM, V268, P9138; SILBERSTEIN DS, 1995, CRIT REV ONCOL HEMAT, V19, P47, DOI 10.1016/1040-8428(94)00127-F; SILBERSTEIN DS, 1987, J IMMUNOL, V138, P3042; SILBERSTEIN DS, 1989, J IMMUNOL, V143, P979; SLABY I, 1975, J BIOL CHEM, V250, P1340; WAKASUGI N, 1990, P NATL ACAD SCI USA, V87, P8282, DOI 10.1073/pnas.87.21.8282; Weichsel A, 1996, STRUCTURE, V4, P735, DOI 10.1016/S0969-2126(96)00079-2; YODOI J, 1991, ADV CANCER RES, V57, P381	45	85	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37474	37480		10.1074/jbc.M001012200	http://dx.doi.org/10.1074/jbc.M001012200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10982790	hybrid			2022-12-25	WOS:000165618700025
J	Yue, TL; Gu, JL; Wang, CL; Reith, AD; Lee, JC; Mirabile, RC; Kreutz, R; Wang, YB; Maleeff, B; Parsons, AA; Ohlstein, EH				Yue, TL; Gu, JL; Wang, CL; Reith, AD; Lee, JC; Mirabile, RC; Kreutz, R; Wang, YB; Maleeff, B; Parsons, AA; Ohlstein, EH			Extracellular signal-regulated kinase plays an essential role in hypertrophic agonists, endothelin-1 and phenylephrine-induced cardiomyocyte hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RAT VENTRICULAR MYOCYTES; GENE-EXPRESSION; CARDIAC-HYPERTROPHY; MUSCLE-CELLS; MITOGEN; STIMULATE; INVOLVEMENT; MECHANISMS; PATHWAYS	The extracellular signal-regulated kinase (ERK) pathway is activated by hypertrophic stimuli in cardiomyocytes, However, whether ERK plays an essential role or is implicated in all major components of cardiac hypertrophy remains controversial, Using a selective MEK inhibitor, U0126, and a selective Raf inhibitor, SB-386023, to block the ERK signaling pathway at two different levels and adenovirus-mediated transfection of dominant-negative Raf, we studied the role of ERK signaling in response of cultured rat cardiomyocytes to hypertrophic agonists, endothelin-l (ET-1), and phenylephrine (PE). U0126 and SB-386023 blocked ET I and PE-induced ERK but not p38 and JNK activation in cardiomyocytes. Both compounds inhibited ET-1 and PE-induced protein synthesis and increased cell size, sarcomeric reorganization, and expression of P-myosin heavy chain in myocytes with IC,, values of 1-2 muM. Furthermore, both inhibitors significantly reduced ET-1- and PE-induced expression of atrial natriuretic factor. In cardiomyocytes transfected with a dominant-negative Raf, ET-1- and PE-induced increase in cell size, sarcomeric reorganization, and atrial natriuretic factor production were remarkably attenuated compared with the cells infected with an adenovirus-expressing green fluorescence protein. Taken together, our data strongly support the notion that the ERK signal pathway plays an essential role in ET-1- and PE-induced cardiomyocyte hypertrophy.	SmithKline Beecham Pharmaceut, Dept Cardiovasc Pharmacol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Neurosci, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Bone & Cartilage Biol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Safety Assessment, King Of Prussia, PA 19406 USA; Univ Maryland, Dept Physiol, Baltimore, MD 21201 USA; Free Univ Berlin, Dept Clin Pharmacol & Toxicol, D-12200 Berlin, Germany	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; University System of Maryland; University of Maryland Baltimore; Free University of Berlin	Yue, TL (corresponding author), SmithKline Beecham Pharmaceut, Dept Cardiovasc Pharmacol, 709 Swedeland Rd,POB 1539,UW2510, King Of Prussia, PA 19406 USA.		Kreutz, Reinhold/AEV-0507-2022	Kreutz, Reinhold/0000-0002-4818-211X; Wang, Yibin/0000-0003-0852-0767				Aoki H, 2000, NAT MED, V6, P183, DOI 10.1038/72287; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P26303, DOI 10.1074/jbc.270.44.26303; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; Choukroun G, 1998, J CLIN INVEST, V102, P1311, DOI 10.1172/JCI3512; Clerk A, 2000, CIRC RES, V86, P1019, DOI 10.1161/01.RES.86.10.1019; Clerk A, 1998, J CELL BIOL, V142, P523, DOI 10.1083/jcb.142.2.523; Colucci WS., 1997, HEART DIS TXB CARDIO, P394; Eble DM, 1998, J MOL CELL CARDIOL, V30, P55, DOI 10.1006/jmcc.1997.0571; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fuller SJ, 1998, J BIOL CHEM, V273, P18146, DOI 10.1074/jbc.273.29.18146; GILLESPIEBROWN J, 1995, J BIOL CHEM, V270, P28092; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Hertig CM, 1999, J BIOL CHEM, V274, P37362, DOI 10.1074/jbc.274.52.37362; Hoshijima M, 1998, J BIOL CHEM, V273, P7725, DOI 10.1074/jbc.273.13.7725; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; HUGHES JP, 2000, BIOCH MOL BIOL INT; HUNTER JJ, 1995, J BIOL CHEM, V270, P23173, DOI 10.1074/jbc.270.39.23173; Jette C, 2000, FEBS LETT, V467, P1, DOI 10.1016/S0014-5793(00)01114-5; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Kreutz R, 1997, HYPERTENSION, V29, P131, DOI 10.1161/01.HYP.29.1.131; Miyata S, 2000, CIRC RES, V86, P386, DOI 10.1161/01.RES.86.4.386; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Sekiguchi K, 1999, CIRC RES, V85, P1000; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Sugden PH, 1998, J MOL MED, V76, P725, DOI 10.1007/s001090050275; Sugden PH, 1999, CIRC RES, V84, P633, DOI 10.1161/01.RES.84.6.633; Swynghedauw B, 1999, PHYSIOL REV, V79, P215, DOI 10.1152/physrev.1999.79.1.215; THORBURN A, 1993, J BIOL CHEM, V268, P2244; THORBURN J, 1994, J BIOL CHEM, V269, P30580; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; Yue TL, 1999, J BIOL CHEM, V274, P1479, DOI 10.1074/jbc.274.3.1479; Yue TL, 2000, CIRC RES, V86, P692, DOI 10.1161/01.RES.86.6.692; YUE TL, 1994, CIRC RES, V75, P1, DOI 10.1161/01.RES.75.1.1	34	162	175	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37895	37901		10.1074/jbc.M007037200	http://dx.doi.org/10.1074/jbc.M007037200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10984495	hybrid			2022-12-25	WOS:000165618700079
J	Atlante, A; Calissano, P; Bobba, A; Azzariti, A; Marra, E; Passarella, S				Atlante, A; Calissano, P; Bobba, A; Azzariti, A; Marra, E; Passarella, S			Cytochrome c is released from mitochondria in a reactive oxygen species (ROS)-dependent fashion and can operate as a ROS scavenger and as a respiratory substrate in cerebellar neurons undergoing excitotoxic death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	Keystone Symposia on Mitochondrial Dysfunction in Pathogenesis	JAN 15-20, 2000	SANTA FE, NM				GRANULE CELLS; GLUTAMATE NEUROTOXICITY; PERMEABILITY TRANSITION; CALPAIN INHIBITORS; APOPTOSIS; CULTURES; DEPOLARIZATION; ACTIVATION; PROTEASE; HYPOXIA	In rat cerebellar granule cells both reactive oxygen species production and release of cytochrome c take place during glutamate toxicity. This investigation was aimed (i) to ascertain whether and how these two processes are related and (ii) to gain insight into the role played by the released cytochrome c in the onset of neurotoxicity. Cytochrome c release takes place owing to the generation of reactive oxygen species both in glutamate-treated cerebellar granule cells and in sister control cultures incubated in the presence of the reactive oxygen species generating system consisting of xanthine plus xanthine oxidase. In the early phase of neurotoxicity (30-min glutamate exposure) about 40% of the maximum las measured at 3 h of glutamate exposure) cytochrome c release was found to occur in cerebellar granule cells from mitochondria that were essentially coupled and intact and that had a negligible production of oxygen free radicals. Contrarily, mitochondria from cells treated with glutamate for 3 h were mostly uncoupled and produced reactive oxygen species at a high rate. The cytosolic fraction containing the released cytochrome c was able to transfer electrons from superoxide anion to molecular oxygen via the respiratory chain and was found to partially prevent glutamate toxicity when added externally to cerebellar neurons undergoing necrosis. In the light of these findings, we propose that in the early phase of neurotoxicity, cytochrome c release can be part of a cellular and mitochondrial defense mechanism against oxidative stress.	Univ Molise, Dipartimento Sci Anim Vegetali & Ambiente, I-86100 Campobasso, Italy; CNR, Ctr Studio Mitocondri & Metab Energet, I-70126 Bari, Italy; CNR, Inst Neurobiol, I-00137 Rome, Italy; Univ Bari, Dipartmento Biochim & Biol Mol, I-70126 Bari, Italy	University of Molise; Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR); Universita degli Studi di Bari Aldo Moro	Passarella, S (corresponding author), Univ Molise, Dipartimento Sci Anim Vegetali & Ambiente, Via De Sanctis, I-86100 Campobasso, Italy.	csmmaa08@area.ba.cnr.it	Azzariti, Amalia/K-4498-2016; atlante, anna/AAK-7041-2021; Bobba, ANTONELLA/AAC-9382-2021; atlante, anna/AAT-7764-2021	Azzariti, Amalia/0000-0002-6149-5049; atlante, anna/0000-0001-6577-6414; 				Almeida A, 1998, BRAIN RES PROTOC, V2, P209, DOI 10.1016/S1385-299X(97)00044-5; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; ARAI A, 1990, BRAIN RES, V532, P63, DOI 10.1016/0006-8993(90)91742-Y; ARDAIL D, 1990, J BIOL CHEM, V265, P18797; Atlante A, 1997, J NEUROCHEM, V68, P2038, DOI 10.1046/j.1471-4159.1997.68052038.x; Atlante A, 1996, NEUROREPORT, V7, P2519, DOI 10.1097/00001756-199611040-00023; Atlante A, 1999, BRAIN RES PROTOC, V4, P266, DOI 10.1016/S1385-299X(99)00028-8; Atlante A, 1999, J NEUROCHEM, V73, P237, DOI 10.1046/j.1471-4159.1999.0730237.x; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BERRY MN, 1991, LAB TECHNIQUES BIOCH, P83; Bobba A, 1999, FEBS LETT, V457, P126, DOI 10.1016/S0014-5793(99)01018-2; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Budd SL, 1996, J NEUROCHEM, V67, P2282; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1994, PROG BRAIN RES, V100, P47; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Du YS, 1997, J NEUROCHEM, V69, P1382; DUGAN LL, 1995, J NEUROSCI, V15, P6377; ELNOUE FK, 1984, BIOENERGETICS, P221; Errede B, 1978, Methods Enzymol, V53, P40; FLOWER RJ, 1985, PHARMACOL BASIS THER, P674; FORMAN HJ, 1973, ARCH BIOCHEM BIOPHYS, V158, P396, DOI 10.1016/0003-9861(73)90636-X; Fujimura M, 2000, J NEUROSCI, V20, P2817; Gorman AM, 1999, EUR J NEUROSCI, V11, P1067, DOI 10.1046/j.1460-9568.1999.00512.x; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kantrow SP, 1997, BIOCHEM BIOPH RES CO, V232, P669, DOI 10.1006/bbrc.1997.6353; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Korshunov SS, 1999, FEBS LETT, V462, P192, DOI 10.1016/S0014-5793(99)01525-2; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; LEVI G, 1984, BRAIN RES, V290, P77, DOI 10.1016/0006-8993(84)90737-6; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Minervini M, 1997, BRAIN RES, V768, P57, DOI 10.1016/S0006-8993(97)00547-7; MISRA HP, 1972, J BIOL CHEM, V247, P3170; NICHOLLS D, 1982, BIOENERGETICS; Nicholls DG, 1998, BBA-BIOENERGETICS, V1366, P97, DOI 10.1016/S0005-2728(98)00123-6; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; Petit PX, 1998, FEBS LETT, V426, P111, DOI 10.1016/S0014-5793(98)00318-4; RAMI A, 1993, BRAIN RES, V609, P67, DOI 10.1016/0006-8993(93)90856-I; Schinder AF, 1996, J NEUROSCI, V16, P6125; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Single B, 1998, CELL DEATH DIFFER, V5, P1001, DOI 10.1038/sj.cdd.4400462; VOLONTE C, 1994, CYTOMETRY, V17, P274, DOI 10.1002/cyto.990170311; WADDELL WJ, 1956, J LAB CLIN MED, V48, P311	44	167	177	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37159	37166		10.1074/jbc.M002361200	http://dx.doi.org/10.1074/jbc.M002361200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	378GY	10980192	hybrid			2022-12-25	WOS:000165577700096
J	Baillet, L; Mullur, RS; Esser, V; McGarry, JD				Baillet, L; Mullur, RS; Esser, V; McGarry, JD			Elucidation of the mechanism by which (+)-acylcarnitines inhibit mitochondrial fatty acid transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARNITINE PALMITOYLTRANSFERASE-I; ACYLCARNITINE TRANSLOCASE SYSTEM; MALONYL-COA; RAT-LIVER; KETOGENESIS; METABOLISM	It is well established that medium and long chain (+)-acylcarnitines (ie. fatty acid esters of the unnatural D-isomer of carnitine) inhibit the oxidation of long chain fatty acids in mammalian tissues by interfering with some component(s) of the mitochondrial carnitine palmitoyltransferase (CPT) system. However, whether their site of action is at the level of CPT I (outer membrane), CPT II (inner membrane), carnitine-acylcarnitine translocase (CACT, inner membrane), or some combination of these elements has never been resolved. Ne chose to readdress this question using rat liver mitochondria and employing a variety of assays that distinguish between the three enzyme activities. The effect on each of (+)-acetylcarnitine, (+)-hexanoylcarnitine, (+)octanoylcarnitine, (+)-decanoylcarnitine, and (+)-palmitoylcarnitine was examined. Contrary to longstanding belief, none of these agents was found to impact significantly upon the activity of CPT I or CPT II. Whereas (+)-acetylcarnitine also failed to influence CACT, both (+) octanoylcarnitine and (+)-palmitoylcarnitine strongly inhibited this enzyme with a similar IC50 value (similar to 35 muM) under the assay conditions employed. Remarkably, (+)-decanoylcarnitine was even more potent (IC50 similar to5 muM), whereas (+)-hexanoylcarnitine was far less potent (IC50 >200 muM). These findings resolve a 35-year-old puzzle by establishing unambiguously that medium and long chain (+)-acylcarnitines suppress mitochondrial fatty acid transport solely through the inhibition of the CACT component. They also reveal a surprising rank order of potency among the various (+)-acylcarnitines in this respect and should prove useful in the design of future experiments in which selective blockade of CACT is desired.	Univ Texas, Hlth Sci Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas System; University of Texas Dallas	McGarry, JD (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Internal Med, Dallas, TX 75390 USA.				NIDDK NIH HHS [DK 18573] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018573, R37DK018573] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		DELISLE G, 1967, P NATL ACAD SCI USA, V58, P790, DOI 10.1073/pnas.58.2.790; Esser V, 1996, J BIOL CHEM, V271, P6972, DOI 10.1074/jbc.271.12.6972; FRITZ IB, 1965, P NATL ACAD SCI USA, V54, P1226, DOI 10.1073/pnas.54.4.1226; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGARRY JD, 1974, DIABETES, V23, P485, DOI 10.2337/diab.23.6.485; MCGARRY JD, 1973, J BIOL CHEM, V248, P270; MCGARRY JD, 1973, J CLIN INVEST, V52, P877, DOI 10.1172/JCI107252; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; MCGARRY JD, 1974, J BIOL CHEM, V249, P7984; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; MCGARRY JD, 1992, NEW DEV FATTY ACID O, V375, P47; PANDE SV, 1976, J BIOL CHEM, V251, P6683; PANDE SV, 1975, P NATL ACAD SCI USA, V72, P883, DOI 10.1073/pnas.72.3.883; WILLIAMSON JR, 1969, J BIOL CHEM, V244, P5055; WILLIAMSON JR, 1968, DIABETES, V17, P194, DOI 10.2337/diab.17.4.194; WOELTJE KF, 1987, J BIOL CHEM, V262, P9822; ZAMMIT VA, 1984, BIOCHEM J, V222, P335, DOI 10.1042/bj2220335	17	24	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36766	36768		10.1074/jbc.M008265200	http://dx.doi.org/10.1074/jbc.M008265200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10986294	hybrid			2022-12-25	WOS:000165577700046
J	Casolaro, V; Keane-Myers, AM; Swendeman, SL; Steindler, C; Zhong, FM; Sheffery, M; Georas, SN; Ono, SJ				Casolaro, V; Keane-Myers, AM; Swendeman, SL; Steindler, C; Zhong, FM; Sheffery, M; Georas, SN; Ono, SJ			Identification and characterization of a critical CP2-binding element in the human interleukin-4 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR CP2; HELPER CELL SUBSETS; STAGE SELECTOR PROTEIN; IL-4 GENE-EXPRESSION; SIMPLEX VIRUS TYPE-1; LONG TERMINAL REPEAT; ACTIVATED T-CELLS; DNA-BINDING; NUCLEAR FACTOR; IN-VITRO	Expression of cytokine genes in T cells is thought to result from a complex network of antigen- and mitogen-activated transcriptional regulators. CP2, a factor homologous to Drosophila Elf-1 and previously found to be a critical regulator of several viral and cellular genes in response to developmental signals, is rapidly activated in T helper (Th) cells in response to mitogenic stimulation. Here we show that overexpression of CP2 enhances interleukin (IL)-4 promoter-driven chloramphenicol acetyltransferase expression, while repressing IL-2 promoter activity, in transiently transfected Jurkat cells. A CP2-protected element, partially overlapping the nuclear factor of activated T cell-binding P2 sequence, was required for IL-4 promoter activation in CPS-overexpressing Jurkat cells. This CPS-response element is the site of a cooperative interaction between CP2 and an inducible heteromeric co-factor(s). Mutation of conserved nucleotide contacts within the CPa-response element prevented CP2 binding and significantly reduced constitutive and induced IL-4 promoter activity. Expression of a CP2 mutant lacking the Elf-l-homology region of the DNA-binding domain inhibited IL-4 promoter activity in a dominant negative fashion in transiently transfected Jurkat cells. Moreover, overexpressed CP2 markedly enhanced, while its dominant negative mutant consistently suppressed, expression of the endogenous IL-4 gene in the murine Th2 cell line DIG. Taken together, these findings point to CP2 as a critical IL-4 transactivator in Th cells.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21224 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Comm Immunol, Boston, MA 02114 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02114 USA; Cornell Univ, Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Cornell Univ, Mem Sloan Kettering Canc Ctr, Grad Sch Med Sci, New York, NY 10021 USA	Johns Hopkins University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Schepens Eye Research Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center	Casolaro, V (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21224 USA.	casolaro@mail.jhmi.edu	Casolaro, Vincenzo/E-9144-2010	Casolaro, Vincenzo/0000-0001-9810-0488	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K11AI001152, R29AI041463, Z01AI000888, R01AI041463] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049661] Funding Source: NIH RePORTER; NIAID NIH HHS [AI41463, AI01152] Funding Source: Medline; NIGMS NIH HHS [GM49661] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI N, 1989, J IMMUNOL, V142, P274; Belichon S, 1996, ACTA OECOL, V17, P503; Bird JJ, 1998, IMMUNITY, V9, P229, DOI 10.1016/S1074-7613(00)80605-6; BOULAY JL, 1992, J BIOL CHEM, V267, P20525; CASOLARO V, 1995, P NATL ACAD SCI USA, V92, P11623, DOI 10.1073/pnas.92.25.11623; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; Cron RQ, 1999, J IMMUNOL, V162, P860; CUNNINGHAM JM, 1995, GENOMICS, V30, P398; Cunningham JM, 1995, BLOOD, V86, P4; DABROWSKI CE, 1994, MOL CELL BIOL, V14, P2545, DOI 10.1128/MCB.14.4.2545; FITCH FW, 1993, ANNU REV IMMUNOL, V11, P29, DOI 10.1146/annurev.immunol.11.1.29; Georas S, 2000, LEUKEMIA, V14, P629, DOI 10.1038/sj.leu.2401712; Georas SN, 1998, BLOOD, V92, P4529, DOI 10.1182/blood.V92.12.4529.424k39_4529_4538; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; Ikuta T, 1998, ANN NY ACAD SCI, V850, P87, DOI 10.1111/j.1749-6632.1998.tb10466.x; JANE SM, 1995, EMBO J, V14, P97, DOI 10.1002/j.1460-2075.1995.tb06979.x; KIM CG, 1990, MOL CELL BIOL, V10, P5958, DOI 10.1128/MCB.10.11.5958; KleinHessling S, 1996, P NATL ACAD SCI USA, V93, P15311, DOI 10.1073/pnas.93.26.15311; LEDERER JA, 1994, J IMMUNOL, V152, P77; Lederer JA, 1996, J EXP MED, V184, P397, DOI 10.1084/jem.184.2.397; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; LI YC, 1991, MOL CELL BIOL, V11, P1883, DOI 10.1128/MCB.11.4.1883; LIM LC, 1993, J BIOL CHEM, V268, P18008; LIM LC, 1992, MOL CELL BIOL, V12, P828, DOI 10.1128/MCB.12.2.828; LIWEBER M, 1994, J IMMUNOL, V153, P4122; MIN LW, 1992, J IMMUNOL, V148, P1913; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; PARADA CA, 1995, J BIOL CHEM, V270, P2274, DOI 10.1074/jbc.270.5.2274; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SHIRRA MK, 1994, MOL CELL BIOL, V14, P5076, DOI 10.1128/MCB.14.8.5076; Shirra MK, 1998, J BIOL CHEM, V273, P19260, DOI 10.1074/jbc.273.30.19260; SIGMAN DS, 1990, BIOCHEMISTRY-US, V29, P9097, DOI 10.1021/bi00491a001; SONG ZM, 1994, J EXP MED, V180, P1763, DOI 10.1084/jem.180.5.1763; SUEYOSHI T, 1995, MOL CELL BIOL, V15, P4158; Takemoto N, 1997, INT IMMUNOL, V9, P1329, DOI 10.1093/intimm/9.9.1329; UV AE, 1994, MOL CELL BIOL, V14, P4020, DOI 10.1128/MCB.14.6.4020; Volker JL, 1997, GENE DEV, V11, P1435, DOI 10.1101/gad.11.11.1435; WEINBERG AD, 1990, J IMMUNOL, V144, P1800; YOON JB, 1994, MOL CELL BIOL, V14, P1776, DOI 10.1128/MCB.14.3.1776; ZHONG FM, 1994, J BIOL CHEM, V269, P21269	41	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36605	36611		10.1074/jbc.M007086200	http://dx.doi.org/10.1074/jbc.M007086200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973979	hybrid			2022-12-25	WOS:000165577700022
J	Yap, DBS; Hsieh, JK; Lu, X				Yap, DBS; Hsieh, JK; Lu, X			Mdm2 inhibits the apoptotic function of p53 mainly by targeting it for degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; TUMOR-SUPPRESSOR P53; TRANSCRIPTIONAL REPRESSION; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; DNA-BINDING; IN-VIVO; PROTEIN; TRANSACTIVATION; STABILITY	The ability of Mdm2 to inhibit the activities of a C-terminal truncated p53 mutant, p53-Delta 30, which can bind Mdm2 but is resistant to Mdm2-mediated protein degradation was investigated. The inhibitory function of an Mdm2, mutant, Mdm2-Delta (222-437), which can bind p53 but is defective in targeting p53 for degradation was also studied. Ne have demonstrated that targeting p53 for degradation is the most effective way for Mdm2 to inhibit the apoptotic function of p53. However, we have also shown that Mdm2 can inhibit the transactivation function of p53 without targeting it for degradation, although Mdm2 releases the transrepression ability of p53 mainly by targeting it for degradation. The ability of Mdm2 to inhibit the apoptotic function of p53 was linked to its ability to inhibit the transrepression but not the transactivation function of p53. Furthermore, we have demonstrated that the transrepression function of p53 was specific to p53-induced apoptosis and was not simply a result of cell death.	Univ London Imperial Coll Sci Technol & Med, Ludwig Inst Canc Res, London W2 1PG, England	Imperial College London; Ludwig Institute for Cancer Research	Lu, X (corresponding author), Univ London Imperial Coll Sci Technol & Med, Ludwig Inst Canc Res, St Marys Campus,Norfolk Pl, London W2 1PG, England.			Yap, Damian/0000-0002-5370-4592; Lu, Xin/0000-0002-6587-1152				Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FUCHS B, 1995, ONCOGENE, V10, P789; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUNA RMD, 1995, NATURE, V378, P203; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668	34	18	30	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37296	37302		10.1074/jbc.M004359200	http://dx.doi.org/10.1074/jbc.M004359200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10980197	hybrid			2022-12-25	WOS:000165577700116
J	Roshak, AK; Capper, EA; Stevenson, C; Eichman, C; Marshall, LA				Roshak, AK; Capper, EA; Stevenson, C; Eichman, C; Marshall, LA			Human calcium-independent phospholipase A(2) mediates lymphocyte proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID MOBILIZATION; CYTOSOLIC PHOSPHOLIPASE-A2; RECOMBINANT EXPRESSION; P388D(1) MACROPHAGES; ANTISENSE INHIBITION; BROMOENOL LACTONE; GENE-EXPRESSION; SYNOVIAL-FLUID; CELL-CYCLE; METABOLISM	Activation of lymphocytes induces blastogenesis and cell division which is accompanied by membrane lipid metabolism such as increased fatty acid turnover. To date little is known about the enzymatic mechanism(s) regulating this process. Release of fatty acids such as arachidonic acid requires sn-2-deacylation catalyzed by a class of enzymes known as phospholipases A, (PLA,, EC 3.1.1.4), Herein, we confirm that human peripheral blood B or T lymphocytes (PBL) do not possess measurable levels of 85-kDa PLA(2) as assessed by Western immunoblot, Low levels of 14-kDa PLA(2) protein and activity were detectable in the particulate fraction of PBL and Jurkat cells. Western immunoblot analysis indicates that PBLs possess the calcium-independent PLA, (iPLA(2)) protein. Calcium-independent sn-2-acylhydrolytic activity was measurable in PBL cytosols and could be inhibited by the selective iPLA(2) inhibitor bromoenol lactone, Mitogen activation of PBLs resulted in maintenance of activity levels which remained constant over 72 h suggesting an important role for iPLA(2) in this proliferative process. Indeed, evaluation of iPLA(2) activity in cell cycle-arrested Jurkat T cell fractions revealed the highest iPLA(2) levels occurring at the G(2)/M phase. Addition of the iPLA(2) inhibitors, bromoenol lactone, or arachidonyl trifluoromethyl ketone (AAOCF(3)), inhibited both mitogen-induced PBL as well as Jurkat T cell proliferation. Moreover, specific depletion of iPLA(2) protein by antisense treatment also resulted in marked suppression of cell division. Inhibition of Jurkat cell proliferation was not associated with arrest at a particular phase of the cell cycle nor was it associated with apoptosis as assessed by flow cytometry, These findings provide the first evidence that iPLA(2) plays a key role in the lymphocyte proliferative response.	SmithKline Beecham Pharmaceut, Dept Immunol, King Of Prussia, PA 19406 USA	GlaxoSmithKline	Roshak, AK (corresponding author), SmithKline Beecham Pharmaceut, Dept Immunol, 709 Swedeland Rd, King Of Prussia, PA 19406 USA.			Spudich, Elizabeth/0000-0002-6223-8271				ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; Akiba S, 1998, FEBS LETT, V437, P225, DOI 10.1016/S0014-5793(98)01236-8; Anderson KM, 1997, J BIOL CHEM, V272, P30504, DOI 10.1074/jbc.272.48.30504; Balboa MA, 1998, J BIOL CHEM, V273, P7684, DOI 10.1074/jbc.273.13.7684; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8531; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BARTOLI F, 1994, J BIOL CHEM, V269, P15625; BROOKS R, 1993, CELL CYCLE PRACTICAL, P1; CHEN J, 1994, J BIOL CHEM, V269, P2365; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CROWL RM, 1991, J BIOL CHEM, V266, P2647; Gilbert JJ, 1996, J IMMUNOL, V156, P2054; GOPPELT M, 1985, BIOCHIM BIOPHYS ACTA, V833, P463, DOI 10.1016/0005-2760(85)90104-3; GROSS RW, 1995, J BIOL CHEM, V270, P14855, DOI 10.1074/jbc.270.25.14855; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; Jackowski S, 1996, J BIOL CHEM, V271, P20219, DOI 10.1074/jbc.271.34.20219; KANDA A, 1989, BIOCHEM BIOPH RES CO, V163, P42, DOI 10.1016/0006-291X(89)92096-2; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; LAI CY, 1988, BIOCHEM BIOPH RES CO, V157, P488, DOI 10.1016/S0006-291X(88)80275-4; Larsson PKA, 1998, J BIOL CHEM, V273, P207, DOI 10.1074/jbc.273.1.207; MARSHALL LA, 1994, J PHARMACOL EXP THER, V268, P709; MARSHALL LA, 1995, J PHARMACOL EXP THER, V274, P1254; Marshall LA, 1997, J BIOL CHEM, V272, P759, DOI 10.1074/jbc.272.2.759; MARSHALL LA, 1993, BIOCHEM CELL BIOL, V71, P331, DOI 10.1139/o93-050; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; OKA S, 1991, J BIOL CHEM, V266, P9956; PONTUS KA, 1998, FEBS LETT, V434, P295; Ramanadham S, 1999, J BIOL CHEM, V274, P13915, DOI 10.1074/jbc.274.20.13915; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; RESCH K, 1981, EUR J BIOCHEM, V115, P247, DOI 10.1111/j.1432-1033.1981.tb05230.x; RESCH K, 1972, EUR J BIOCHEM, V27, P153, DOI 10.1111/j.1432-1033.1972.tb01821.x; RODE HN, 1982, BIOCHIM BIOPHYS ACTA, V688, P66, DOI 10.1016/0005-2736(82)90579-X; ROSHAK A, 1994, J BIOL CHEM, V269, P25999; Roshak A, 1996, J RHEUMATOL, V23, P420; Roshak AK, 1999, J LEUKOCYTE BIOL, V65, P43, DOI 10.1002/jlb.65.1.43; SCHALKWIJK CG, 1992, EUR J BIOCHEM, V248, P1; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; TRAMPOSCH KM, 1994, J PHARMACOL EXP THER, V271, P852	45	79	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35692	35698		10.1074/jbc.M002273200	http://dx.doi.org/10.1074/jbc.M002273200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10964913	hybrid			2022-12-25	WOS:000165382000009
J	Wang, HY; Maechler, P; Antinozzi, PA; Hagenfeldt, KA; Wollheim, CB				Wang, HY; Maechler, P; Antinozzi, PA; Hagenfeldt, KA; Wollheim, CB			Hepatocyte nuclear factor 4 alpha regulates the expression of pancreatic beta-cell genes implicated in glucose metabolism and nutrient-induced insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; HNF-4 GENE; FACTOR-I; MUTATION; ACTIVATION; YOUNG; ARGININE	Mutations in the HNF4 alpha gene are associated with the subtype 1 of maturity-onset diabetes of the young (MODY1), which is characterized by impaired insulin secretory response to glucose in pancreatic beta -cells. Hepatocyte nuclear factor 4 alpha (HNF4 alpha) is a transcription factor critical for liver development and hepatocyte-specific gene expression. However, the role of HNF4 alpha in the regulation of pancreatic beta -cell gene expression and its correlation with metabolism secretion coupling have not been previously investigated. The tetracycline-inducible system was employed to achieve tightly controlled expression of both wild type (WT) and dominant-negative mutant (DN) of HNF4 alpha in INS-1 cells. The induction of WT-HNF4 alpha resulted in a left shift in glucose-stimulated insulin secretion, whereas DN-HNPF4 alpha selectively impaired nutrient-stimulated insulin release, Induction of DN-HNF4 alpha also caused defective mitochondrial function substantiated by reduced [C-14]pyruvate oxidation, attenuated substrate-evoked mitochondrial membrane hyperpolarization, and blunted nutrient-generated cellular ATP production. Quantitative evaluation of HNF4 alpha -regulated pancreatic p-cell gene expression revealed altered mRNA levels of insulin, glucose transporter-2, L-pyruvate kinase, aldolase B, 2-oxoglutarate dehydrogenase El subunit, and mitochondrial uncoupling protein-2, The patterns of HNF4a-regulated gene expression are strikingly similar to that of its downstream transcription factor HNF1 alpha, Indeed, HNF4a changed the HNF1 alpha mRNA levels and HNF1 alpha promoter luciferase activity through altered HNF4 alpha binding. These results demonstrate the importance of HNF4 alpha in beta -cell metabolism-secretion coupling.	Ctr Med Univ Geneva, Div Biochim Clin, Dept Med Interne, CH-1211 Geneva 4, Switzerland	University of Geneva	Wollheim, CB (corresponding author), Ctr Med Univ Geneva, Div Biochim Clin, Dept Med Interne, CH-1211 Geneva 4, Switzerland.	Claes.Wollheim@medicine.unige.ch		Maechler, Pierre/0000-0002-2005-1433				Antinozzi PA, 1998, J BIOL CHEM, V273, P16146, DOI 10.1074/jbc.273.26.16146; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BYNE MM, 1995, DIABETES, V44, P699; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; Fraser JD, 1997, J BIOL CHEM, V272, P13892, DOI 10.1074/jbc.272.21.13892; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Gragnoli C, 1997, DIABETES, V46, P1648, DOI 10.2337/diabetes.46.10.1648; HadzopoulouCladaras M, 1997, J BIOL CHEM, V272, P539; Hani E, 1998, J CLIN INVEST, V101, P521, DOI 10.1172/JCI1403; Hattersley AT, 1998, DIABETIC MED, V15, P15, DOI 10.1002/(SICI)1096-9136(199801)15:1<15::AID-DIA562>3.0.CO;2-M; Herman WH, 1997, DIABETES, V46, P1749, DOI 10.2337/diabetes.46.11.1749; Ilag LL, 2000, DIABETES, V49, P961, DOI 10.2337/diabetes.49.6.961; Kennedy ED, 1998, DIABETES METAB, V24, P15; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; Lausen J, 2000, NUCLEIC ACIDS RES, V28, P430, DOI 10.1093/nar/28.2.430; Lehto M, 1999, DIABETES, V48, P423, DOI 10.2337/diabetes.48.2.423; Li JX, 2000, GENE DEV, V14, P464; Lindner T, 1997, J CLIN INVEST, V100, P1400, DOI 10.1172/JCI119660; Maechler P, 1997, EMBO J, V16, P3833, DOI 10.1093/emboj/16.13.3833; MIQUEROL L, 1994, J BIOL CHEM, V269, P8944; MUIRA N, 1993, NUCLEIC ACIDS RES, V21, P3731; Noel RJ, 1997, J BIOL CHEM, V272, P18621, DOI 10.1074/jbc.272.30.18621; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Sladek FM, 1999, MOL CELL BIOL, V19, P6509; SLADEK FM, 1994, LIVER GENE EXPRESSIO, P207; Stoffel M, 1997, P NATL ACAD SCI USA, V94, P13209, DOI 10.1073/pnas.94.24.13209; TARAVIRAS S, 1994, MECH DEVELOP, V48, P67, DOI 10.1016/0925-4773(94)90017-5; TIAN JM, 1991, GENE DEV, V5, P2225, DOI 10.1101/gad.5.12a.2225; Wang HY, 1997, P NATL ACAD SCI USA, V94, P4372, DOI 10.1073/pnas.94.9.4372; Wang HY, 1998, EMBO J, V17, P6701, DOI 10.1093/emboj/17.22.6701; Ware TL, 2000, EMBO J, V19, P3119, DOI 10.1093/emboj/19.12.3119; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Wollheim CB, 2000, DIABETOLOGIA, V43, P265, DOI 10.1007/s001250050044; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0	37	167	170	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35953	35959		10.1074/jbc.M006612200	http://dx.doi.org/10.1074/jbc.M006612200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10967120	hybrid, Green Published			2022-12-25	WOS:000165382000045
J	Wu, K; Jiang, SW; Thangaraju, M; Wu, G; Couch, FJ				Wu, K; Jiang, SW; Thangaraju, M; Wu, G; Couch, FJ			Induction of the BRCA2 promoter by nuclear factor-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER SUSCEPTIBILITY GENE; TRANSCRIPTION FACTOR USF; SPORADIC BREAST-TUMORS; OVARIAN CANCERS; DNA-REPAIR; TATA BOX; RAD51; MUTATIONS; INVOLVEMENT; EXPRESSION	BRCA2 is a tumor suppressor gene that has been implicated in response to DNA damage, cell cycle control, and transcription. BRCA2 has been found to be overexpressed in-many breast tumors, suggesting that altered expression of the BRCA2 gene may contribute to breast tumbrigenesis.( To determine how BRCA2 is overexpressed in tumors, we investigated the transcriptional regulation of the BRCA2 promoter, Deletion mapping of the BRCA2 promoter identified three regions associated with 3-fold activation or repression and one upstream stimulatory factor binding site associated with 20-fold activation Gel shift and cotransfection studies verified the role of USF in regulation of BRCA2 transcription, Analysis df the:-144 to -59 region associated with 3-fold activation identified a putative NF kappaB binding site. Cotransfection of the p65 and p50 subunits of NF kappaB upregulated the BRCA2 promoter 16-fold in a luciferase reporter assay, whereas mutations in the binding site ablated:the effect. Gel shift and supershift assays with anti-p65 and -p50 antibodies demonstrated that NF kappaB binds specifically to the NF kappaB site. In addition, ectopic expression of NF kappaB resulted in increased levels of endogeneous BRCA2 expression. Thus, NF kappaB and USF regulate BRCA2 expression through the BRCA2 promoter.	Mayo Clin & Mayo Fdn, Dept Pathol & Lab Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Endocrinol Res Unit, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Couch, FJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Pathol & Lab Med, 200 1st St SW,1001 Guggenheim Bldg, Rochester, MN 55905 USA.							Bertwistle D, 1997, CANCER RES, V57, P5485; Bieche I, 1999, ONCOGENE, V18, P5232, DOI 10.1038/sj.onc.1202903; Bieche I, 1997, BRIT J CANCER, V76, P1416, DOI 10.1038/bjc.1997.572; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; Collins N, 1997, BRIT J CANCER, V76, P1150, DOI 10.1038/bjc.1997.526; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Couch FJ, 1996, GENOMICS, V36, P86, DOI 10.1006/geno.1996.0428; Davis PL, 1999, ONCOGENE, V18, P6000, DOI 10.1038/sj.onc.1202990; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Easton D, 1997, NAT GENET, V16, P210, DOI 10.1038/ng0797-210; Gretarsdottir S, 1998, CANCER RES, V58, P859; Hamann U, 1996, CANCER RES, V56, P1988; Ismail PM, 1999, ONCOGENE, V18, P5582, DOI 10.1038/sj.onc.1202932; KERANGUEVEN F, 1995, GENE CHROMOSOME CANC, V13, P291, DOI 10.1002/gcc.2870130410; Lancaster JM, 1996, NAT GENET, V13, P238, DOI 10.1038/ng0696-238; Lee H, 1999, MOL CELL, V4, P1, DOI 10.1016/S1097-2765(00)80182-3; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Luo X, 1996, MOL CELL BIOL, V16, P1367; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; MEIER JL, 1994, MOL CELL BIOL, V14, P6896, DOI 10.1128/MCB.14.10.6896; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526; Raziuddin A, 1997, J BIOL CHEM, V272, P15715, DOI 10.1074/jbc.272.25.15715; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; Scholtz B, 1996, J BIOL CHEM, V271, P32375, DOI 10.1074/jbc.271.50.32375; Sharan C, 1999, BIOCHEM BIOPH RES CO, V265, P285, DOI 10.1006/bbrc.1999.1652; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Siddique H, 1998, ONCOGENE, V16, P2283, DOI 10.1038/sj.onc.1202003; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Spillman MA, 1996, ONCOGENE, V13, P1639; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Teng DHF, 1996, NAT GENET, V13, P241, DOI 10.1038/ng0696-241; Thorlacius S, 1998, LANCET, V352, P1337, DOI 10.1016/S0140-6736(98)03300-5; Vaughn JP, 1996, CANCER RES, V56, P4590; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Yuan SSF, 1999, CANCER RES, V59, P3547	42	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35548	35556		10.1074/jbc.M004390200	http://dx.doi.org/10.1074/jbc.M004390200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10961992	hybrid			2022-12-25	WOS:000165422800094
J	Zhu, XY; Price-Schiavi, SA; Carraway, KL				Zhu, XY; Price-Schiavi, SA; Carraway, KL			Extracellular regulated kinase (ERK)-dependent regulation of sialomucin complex/rat Muc4 in mammary epithelial cells	ONCOGENE			English	Article						Muc4; ERK; ErbB2; mammary; epithelial; transcript; regulation	GROWTH-FACTOR-I; RECEPTOR TYROSINE KINASE; ADENOCARCINOMA CELLS; MOLECULAR-CLONING; PROTEIN-KINASE; MAP KINASE; DUCTAL MORPHOGENESIS; GLYCOPROTEIN COMPLEX; SIGNAL-TRANSDUCTION; CASEIN GENE	Sialomucin complex (SMC, rat Muc4) is a membrane mucin implicated in the protection of epithelia and the metastasis of some tumors. It is a heterodimeric complex, containing a mucin subunit with anti-adhesive activity and a transmembrane subunit with epidermal growth factor-like domains, one of which acts as an intramembrane ligand for ErbB2, Serum, insulin and insulin-like growth factor, but not epidermal growth factor, induce the expression of sialomucin complex in mammary epithelial cells, Induction correlates,vith sustained, but not transient, activation of extracellular-regulated protein kinase (ERK), MEK inhibitor U0126 blocked the induction, while activated MEK-1 transfected into a rat mammary adenocarcinoma cell line induced a sustained activation of ERK and up-regulated SMC/Muc4 expression, Northern and Western blotting indicated that up-regulation occurred concomitantly at the transcript and protein levels, both of which could be blocked by U0126. These results suggest that expression of SMC/Muc4 in mammary epithelial cells is regulated by selected growth factors through an ERK-dependent pathway at the transcript level.	Univ Miami, Sch Med, Dept Cell Biol & Anat R 124, Miami, FL 33101 USA	University of Miami	Carraway, KL (corresponding author), Univ Miami, Sch Med, Dept Cell Biol & Anat R 124, POB 016960, Miami, FL 33101 USA.				NCI NIH HHS [CA52498] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052498] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1987, J CELL SCI, V99, P407; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CAHILL AL, 1991, J NEUROCHEM, V57, P1832, DOI 10.1111/j.1471-4159.1991.tb06392.x; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; CHEN QM, 1994, J BIOL CHEM, V269, P26602; COLEMAN S, 1990, DEV BIOL, V137, P425, DOI 10.1016/0012-1606(90)90267-M; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Hadsell DL, 1996, ENDOCRINOLOGY, V137, P321, DOI 10.1210/en.137.1.321; HULL SR, 1990, BIOCHEM J, V265, P121, DOI 10.1042/bj2650121; Juang SH, 1996, ONCOGENE, V12, P1033; Kleinberg DL, 1998, BREAST CANCER RES TR, V47, P201, DOI 10.1023/A:1005998832636; Komatsu M, 1997, J BIOL CHEM, V272, P33245, DOI 10.1074/jbc.272.52.33245; Komatsu M, 1999, CANCER RES, V59, P2229; Komatsu M, 2000, INT J CANCER, V87, P480, DOI 10.1002/1097-0215(20000815)87:4<480::AID-IJC4>3.0.CO;2-6; LEVITZKI A, 1991, METHOD ENZYMOL, V201, P347; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; McNeer RR, 1998, J CELL PHYSIOL, V176, P110, DOI 10.1002/(SICI)1097-4652(199807)176:1<110::AID-JCP13>3.3.CO;2-U; McNeer RR, 1998, BIOCHEM J, V330, P737, DOI 10.1042/bj3300737; MCNEER RR, 1997, FRONT BIOSCI, V2, P449; Merlo GR, 1996, EUR J CELL BIOL, V70, P97; Moniaux N, 1999, BIOCHEM J, V338, P325, DOI 10.1042/0264-6021:3380325; Neuenschwander S, 1996, J CLIN INVEST, V97, P2225, DOI 10.1172/JCI118663; NICHOLAS KR, 1983, BIOCHIM BIOPHYS ACTA, V763, P309, DOI 10.1016/0167-4889(83)90139-8; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; Price-Schiavi SA, 1998, J BIOL CHEM, V273, P35228, DOI 10.1074/jbc.273.52.35228; Price-Schiavi SA, 2000, J BIOL CHEM, V275, P17800, DOI 10.1074/jbc.275.23.17800; Price-Schiavi SA, 2000, BIOCHEM J, V349, P641, DOI 10.1042/0264-6021:3490641; PROSSER CG, 1987, ENDOCRINOLOGY, V120, P1411, DOI 10.1210/endo-120-4-1411; Rossi EA, 1996, J BIOL CHEM, V271, P33476, DOI 10.1074/jbc.271.52.33476; Ruan WF, 1999, ENDOCRINOLOGY, V140, P5075, DOI 10.1210/en.140.11.5075; RUAN WF, 1992, P NATL ACAD SCI USA, V89, P10872, DOI 10.1073/pnas.89.22.10872; RUAN WF, 1995, ENDOCRINOLOGY, V136, P1296, DOI 10.1210/en.136.3.1296; SHENG Z, 1990, J BIOL CHEM, V265, P8505; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; SHERBLOM AP, 1980, J BIOL CHEM, V255, P2051; SHERBLOM AP, 1980, J BIOL CHEM, V255, P783; SPITZER E, 1995, J CELL BIOCHEM, V57, P495, DOI 10.1002/jcb.240570315; Swantek JL, 1999, ENDOCRINOLOGY, V140, P3163, DOI 10.1210/en.140.7.3163; TAKETANI Y, 1983, P NATL ACAD SCI-BIOL, V80, P2647, DOI 10.1073/pnas.80.9.2647; TAKETANI Y, 1983, FEBS LETT, V152, P256, DOI 10.1016/0014-5793(83)80391-3; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; VOYTOVICH AE, 1969, P NATL ACAD SCI USA, V63, P213, DOI 10.1073/pnas.63.1.213; Wartmann M, 1996, J BIOL CHEM, V271, P31863, DOI 10.1074/jbc.271.50.31863; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; WU K, 1994, J BIOL CHEM, V269, P11950; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	50	24	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2000	19	38					4354	4361		10.1038/sj.onc.1203781	http://dx.doi.org/10.1038/sj.onc.1203781			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980611				2022-12-25	WOS:000089271900006
J	Nieborowska-Skorska, M; Slupianek, A; Skorski, T				Nieborowska-Skorska, M; Slupianek, A; Skorski, T			Progressive changes in the leukemogenic signaling in BCR/ABL-transformed cells	ONCOGENE			English	Article						BCR/ABL; signaling; Akt; STAT5	CHRONIC MYELOGENOUS LEUKEMIA; BCR-ABL ONCOGENE; DNA-BINDING ACTIVITY; HEMATOPOIETIC-CELLS; TYROSINE KINASE; ANTISENSE OLIGODEOXYNUCLEOTIDES; PHILADELPHIA-CHROMOSOME; PHOSPHATIDYLINOSITOL 3-KINASE; MEDIATED TRANSFORMATION; CONSTITUTIVE ACTIVATION	Our previous study indicated that BCR/ABL SH2 domain and BCR/ABL SH3 domain+SH2 domain complex are required for immediate activation of the phosphatidylinositol-3 kinase PI-3k) --> Akt serine/threonine kinase pathway and of the signal transducer and activator of transcription 5 (STAT5), respectively, in hematopoietic cells. We show here that the defect in activation of PI-3k/Akt by BCR/ABL Delta SH2 mutant (SH2 domain deleted) and of STAT5 by BCR/ABL Delta SH3 + Delta SH2 mutant (SH3 and SH2 domains deleted) is not permanent and both Akt and STAT5 could be 'reactivated' by in vitro culture. This phenomenon was responsible for increased resistance to apoptosis, growth factor-independent proliferation and leukemogenesis in SCID mice. Incubation of cells with BCR/ABL tyrosine kinase inhibitor STI571 abrogated the 're-activation' of Akt or STAT5 by BCR/ABL SH3+SH2 mutants in some clones, in the others Akt and STAT5 activation became independent on BCR/ABL kinase activity. The immediate upstream activators of Akt and STAT5 such as PI-3k and Jak-2 were also activated. In addition, the common beta subunit of IL-3/IL-5/GM-CSF receptor was tyrosine phosphorylated in the clones in which 'reactivation' was dependent on the BCR/ABL kinase activity, These results suggested that 're-activation' of Akt and STAT5, in the absence of functional BCR/ABL SH3+SH2 domains, may be achieved by two different mechanisms: (i) BCR/ABL kinase-dependent activation of alternative pathway(s) and (ii) additional genetic changes stimulating Akt and STAT5 independently of BCR/ABL.	Temple Univ, Ctr Biotechnol, Coll Sci & Technol, Philadelphia, PA 19122 USA; Poznan Tech Univ, Dept Canc Immunol, Sch Med Sci, Great Poland Canc Ctr, PL-60965 Poznan, Poland	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Poznan University of Technology; Wielkopolskie Centrum Onkologii	Skorski, T (corresponding author), Temple Univ, Ctr Biotechnol, Coll Sci & Technol, Philadelphia, PA 19122 USA.							AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; Anderson SM, 1996, BLOOD, V87, P238; BEDI A, 1994, BLOOD, V83, P2038; Bhat A, 1997, J BIOL CHEM, V272, P16170, DOI 10.1074/jbc.272.26.16170; Burton EA, 1997, J BIOL CHEM, V272, P16189, DOI 10.1074/jbc.272.26.16189; Canitrot Y, 1999, ONCOGENE, V18, P2676, DOI 10.1038/sj.onc.1202619; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Chai SK, 1997, J IMMUNOL, V159, P4720; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Feng SH, 1999, MOL CELL BIOL, V19, P7995; Frank DA, 1996, LEUKEMIA, V10, P1724; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Honda H, 2000, BLOOD, V95, P1144, DOI 10.1182/blood.V95.4.1144.004k04_1144_1150; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; Majewski M, 1999, CANCER RES, V59, P2815; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; MATULONIS U, 1993, EXP HEMATOL, V21, P1460; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; Nakamura N, 1996, J BIOL CHEM, V271, P19483, DOI 10.1074/jbc.271.32.19483; Neshat MS, 2000, MOL CELL BIOL, V20, P1179, DOI 10.1128/MCB.20.4.1179-1186.2000; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Raitano A. B., 1997, BIOCHIM BIOPHYS ACTA, V1333, P201, DOI 10.1016/S0304-419X(97)00023-1; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Salomoni P, 1998, J EXP MED, V187, P1995, DOI 10.1084/jem.187.12.1995; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; Shuai K, 1996, ONCOGENE, V13, P247; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; SIRARD C, 1994, BLOOD, V83, P1575; Skorski T, 1996, P NATL ACAD SCI USA, V93, P13137, DOI 10.1073/pnas.93.23.13137; SKORSKI T, 1995, CANCER RES, V55, P2275; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; SKORSKI T, 1995, J EXP MED, V182, P1645, DOI 10.1084/jem.182.6.1645; Skorski T, 1998, P NATL ACAD SCI USA, V95, P11858, DOI 10.1073/pnas.95.20.11858; SKORSKI T, 1994, J EXP MED, V179, P1855, DOI 10.1084/jem.179.6.1855; Skorski T, 1998, BLOOD, V91, P406, DOI 10.1182/blood.V91.2.406.406_406_418; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; SKORSKI T, 1993, J CLIN INVEST, V92, P194, DOI 10.1172/JCI116549; Skorski T, 1997, J NATL CANCER I, V89, P124, DOI 10.1093/jnci/89.2.124; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VERFAILLIE CM, 1992, J CLIN INVEST, V90, P1232, DOI 10.1172/JCI115985; WilsonRawls J, 1996, CANCER RES, V56, P3426	57	19	19	1	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2000	19	36					4117	4124		10.1038/sj.onc.1203754	http://dx.doi.org/10.1038/sj.onc.1203754			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962572				2022-12-25	WOS:000088955100005
J	Piehler, J; Roisman, LC; Schreiber, G				Piehler, J; Roisman, LC; Schreiber, G			New structural and functional aspects of the type I interferon-receptor interaction revealed by comprehensive mutational analysis of the binding interface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; ALPHA; BETA; PROTEIN; RESOLUTION; COMPLEX; MODEL; COMPONENTS; AFFINITY	Type I interferons bind to two cell surface receptors, ifnar1 and ifnar2, as the first step in the activation of several signal transduction pathways that elicit an antiviral state and an anti-proliferative response. Here, we quantitatively mapped the complete binding region of ifnar2 on interferon (IFN)alpha2 by 35 individual mutations to alanine and isosteric residues. Of the six "hot-spot" residues identified (Leu-30, Arg-33, Arg-144, Ala-145, Met-148, and Arg-149), four are located on the E-helix, which is located at the center of the binding site flanked by residues on the A-helix and the AD-loop. The contribution of residues of the D-helix, which have been previously implicated in binding, proved to be marginal for the interaction with the extracellular domain of ifnar2. Interestingly, the ifnar2 binding site overlaps the largest continuous hydrophobic patch on IFN alpha2. Thus, hydrophobic interactions seem to play a significant role stabilizing this interaction, with the charged residues contributing toward the rapid association of the complex. Relating the anti-viral and anti-proliferative activity of the various interferon mutants with their affinity toward ifnar2 results in linear function over the whole range of affinities investigated, suggesting that ifnar2 binding is the rate-determining step in cellular activation. Dose-time analysis of the anti-viral response revealed that shortening the incubation time of low-level activation cannot be compensated by higher IFN doses. Considering the strict dependence of the cellular response on affinity, these results suggest that for maintaining transcription of IFN-responsive genes over a longer time period, low but continuous signaling through the IFN receptor is essential.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Piehler, J (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.		Roisman, Laila/D-1827-2010; Roisman, Laila C./P-9129-2019; Schreiber, Gideon/C-7332-2008	Roisman, Laila/0000-0001-8455-9327; Roisman, Laila C./0000-0001-8455-9327; Piehler, Jacob/0000-0002-2143-2270				Albeck S, 1999, BIOCHEMISTRY-US, V38, P11, DOI 10.1021/bi981772z; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; BRECHT A, 1993, BIOSENS BIOELECTRON, V8, P387, DOI 10.1016/0956-5663(93)80078-4; CHANG NT, 1983, ARCH BIOCHEM BIOPHYS, V221, P585, DOI 10.1016/0003-9861(83)90179-0; CHEETHAM BF, 1991, ANTIVIR RES, V15, P27, DOI 10.1016/0166-3542(91)90038-S; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; COHEN B, 1995, MOL CELL BIOL, V15, P4208; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; GAUGLITZ G, 1993, SENSOR ACTUAT B-CHEM, V11, P21, DOI 10.1016/0925-4005(93)85234-2; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Karpusas M, 1997, P NATL ACAD SCI USA, V94, P11813, DOI 10.1073/pnas.94.22.11813; Klaus W, 1997, J MOL BIOL, V274, P661, DOI 10.1006/jmbi.1997.1396; KORN AP, 1994, J INTERFERON RES, V14, P1, DOI 10.1089/jir.1994.14.1; Lee CK, 1997, J BIOL CHEM, V272, P21872, DOI 10.1074/jbc.272.35.21872; Lewerenz M, 1998, J MOL BIOL, V282, P585, DOI 10.1006/jmbi.1998.2026; Lijnzaad P, 1996, PROTEINS, V26, P192; MITSUI Y, 1993, PHARMACOL THERAPEUT, V58, P93, DOI 10.1016/0163-7258(93)90068-O; Mogensen KE, 1999, J INTERF CYTOK RES, V19, P1069, DOI 10.1089/107999099313019; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; Pearce KH, 1999, BIOCHEMISTRY-US, V38, P81, DOI 10.1021/bi9817008; Piehler J, 1999, J MOL BIOL, V289, P57, DOI 10.1006/jmbi.1999.2726; Piehler J, 1999, J MOL BIOL, V294, P223, DOI 10.1006/jmbi.1999.3230; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; Radhakrishnan R, 1996, STRUCTURE, V4, P1453, DOI 10.1016/S0969-2126(96)00152-9; Radhakrishnan R, 1999, J MOL BIOL, V286, P151, DOI 10.1006/jmbi.1998.2480; Rani MRS, 1996, J BIOL CHEM, V271, P22878, DOI 10.1074/jbc.271.37.22878; RUBINSTEIN S, 1981, J VIROL, V37, P755, DOI 10.1128/JVI.37.2.755-758.1981; Runkel L, 2000, BIOCHEMISTRY-US, V39, P2538, DOI 10.1021/bi991631c; Schmitt HM, 1997, BIOSENS BIOELECTRON, V12, P809, DOI 10.1016/S0956-5663(97)00046-8; Selzer T, 2000, NAT STRUCT BIOL, V7, P537; Selzer T, 1999, J MOL BIOL, V287, P409, DOI 10.1006/jmbi.1999.2615; SENDA T, 1992, EMBO J, V11, P3193, DOI 10.1002/j.1460-2075.1992.tb05396.x; SETO MH, 1995, PROTEIN SCI, V4, P655; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; UZE G, 1995, J INTERF CYTOK RES, V15, P3, DOI 10.1089/jir.1995.15.3; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0	37	130	156	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40425	40433		10.1074/jbc.M006854200	http://dx.doi.org/10.1074/jbc.M006854200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10984492	hybrid			2022-12-25	WOS:000166039500085
J	Balaji, RA; Ohtake, A; Sato, K; Gopalakrishnakone, P; Kini, RM; Seow, KT; Bay, BH				Balaji, RA; Ohtake, A; Sato, K; Gopalakrishnakone, P; Kini, RM; Seow, KT; Bay, BH			lambda-conotoxins, a new family of conotoxins with unique disulfide pattern and protein folding - Isolation and characterization from the venom of Conus marmoreus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-CONOTOXIN; PEPTIDE; TEXTILE; GI	Conotoxins are multiple disulfide-bonded peptides isolated fk om marine cone snail venom. These toxins have been classified into several families based on their disulfide pattern and biological properties. Here, we report a new family of Conus peptides, which have a novel cysteine motif. Three peptides of this family (CMrVIA, CMrVIB, and CMrX) have been purified from Conus marmoreus venom, and their structures have been determined. Their amino acid sequences are VCCGYKLCHOC (CMrVIA), NGVCCGYKLCHOC (CMrVIB), and GICCGVSFCYOC (CMrX), where O represents 4-transhydroxyproline. Two of these peptides (CMrVIA and CMrX) have been chemically synthesized Using a selective protection and deprotection strategy during disulfide bond formation, peptides with both feasible cysteine-pairing combinations were generated. The disulfide pattern (C-1-C-4, C-2-C-3) in native toxins was identified by their co-elution with the synthetic disulfide-isomeric peptides on reverse-phase high pressure liquid chromatography. Although cysteine residues were found in comparable positions with those of alpha -conotoxins, these toxins exhibited a distinctly different disulfide bonding pattern; we have named this new family "lambda -conotoxins." CMrVIA and CMrX induced different biological effects when injected intra-cerebroventricularly in mice; CMrVIA induces seizures, whereas CMrX induces flaccid paralysis. The synthetic peptide with lambda -conotoxin folding is about 1150-fold more potent in inducing seizures than the mispaired isomer with alpha -conotoxin folding Thus it appears that the unique disulfide pattern, and hence the "ribbon" conformation, in lambda -conotoxins is important for their biological activity.	Natl Univ Singapore, Fac Med, Dept Anat, Venom & Toxin Res Programme, Singapore 117597, Singapore; Natl Univ Singapore, Fac Sci, Dept Sci Biol, Singapore 117597, Singapore; Mitsubishi Kasei Inst Life Sci, Machida, Tokyo 1948511, Japan	National University of Singapore; National University of Singapore	Gopalakrishnakone, P (corresponding author), Natl Univ Singapore, Fac Med, Dept Anat, Venom & Toxin Res Programme, 4 Med Dr,MD10, Singapore 117597, Singapore.	antgopal@nus.edu.sg	Kini, Manjunatha/H-8029-2012	Kini, Manjunatha/0000-0002-6100-3251				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Balaji RA, 2000, FEBS LETT, V474, P208, DOI 10.1016/S0014-5793(00)01593-3; Cartier GE, 1996, J BIOL CHEM, V271, P7522, DOI 10.1074/jbc.271.13.7522; Drakopoulou E, 2000, J PEPT SCI, V6, P175; Duda TF, 1999, P NATL ACAD SCI USA, V96, P6820, DOI 10.1073/pnas.96.12.6820; FAINZILBER M, 1991, EUR J BIOCHEM, V202, P589, DOI 10.1111/j.1432-1033.1991.tb16412.x; FAINZILBER M, 1995, BIOCHEMISTRY-US, V34, P5364, DOI 10.1021/bi00016a007; Favreau P, 1999, BIOCHEMISTRY-US, V38, P6317, DOI 10.1021/bi982817z; Gehrmann J, 1998, J MOL BIOL, V278, P401, DOI 10.1006/jmbi.1998.1701; Hill JM, 1997, STRUCTURE, V5, P571, DOI 10.1016/S0969-2126(97)00212-8; Jones R M, 2000, Curr Opin Drug Discov Devel, V3, P141; McIntosh J M, 1999, Methods Enzymol, V294, P605; MCINTOSH JM, 1984, J BIOL CHEM, V259, P4343; McIntosh JM, 1999, ANNU REV BIOCHEM, V68, P59, DOI 10.1146/annurev.biochem.68.1.59; Mezo G, 2000, J PEPT RES, V55, P7, DOI 10.1034/j.1399-3011.2000.00140.x; NISHIUCHI Y, 1982, FEBS LETT, V148, P260, DOI 10.1016/0014-5793(82)80820-X; OLIVERA BM, 1987, BIOCHEMISTRY-US, V26, P2086, DOI 10.1021/bi00382a004; OLIVERA BM, 1985, SCIENCE, V230, P1338, DOI 10.1126/science.4071055; Rigby AC, 1999, P NATL ACAD SCI USA, V96, P5758, DOI 10.1073/pnas.96.10.5758; Shon KJ, 1998, J BIOL CHEM, V273, P33, DOI 10.1074/jbc.273.1.33; ZHANG RM, 1991, BIOCHEMISTRY-US, V30, P11343, DOI 10.1021/bi00111a021	21	71	76	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39516	39522		10.1074/jbc.M006354200	http://dx.doi.org/10.1074/jbc.M006354200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10988292	hybrid			2022-12-25	WOS:000165953100078
J	Hill, KL; Hutchings, NR; Grandgenett, PM; Donelson, JE				Hill, KL; Hutchings, NR; Grandgenett, PM; Donelson, JE			T lymphocyte-triggering factor of African trypanosomes is associated with the flagellar fraction of the cytoskeleton and represents a new family of proteins that are present in several divergent eukaryotes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; BRUCEI-BRUCEI; MOLECULAR-CLONING; PARAFLAGELLAR ROD; ALPHA-TUBULIN; CELL-DIVISION; POCKET; GENE; LOCALIZATION; CLIP-170	The trypanosome cytoskeleton consists almost entirely of microtubule-based structures. Although alpha- and beta -tubulin from Trypanosoma brucei have been well characterized, much less is known about other cytoskeleton-associated proteins in trypanosomes. Using biochemical fractionation, we demonstrate here that T lymphocyte-triggering factor (TLTF) from T, brucei is a component of the detergent-resistant and Ca2+-resistant fraction of the parasite cytoskeleton. This fraction contains the flagellar apparatus and a subset of cytoskeletal protein complexes that together function in cell motility,cytokinesis, and organelle inheritance. We also show that TLTF-related genes are present in several highly divergent eukaryotic organisms. Although the function of the corresponding proteins is not known, the mammalian TLTF-like gene (GAS11; growth arrest-specific gene 11) is up-regulated in growth-arrested cells and is a candidate tumor suppressor (Whitmore, S. A, Settasatian, C., Crawford, J., Lower, K. M., McCallum, B., Seshadri, R., Cornelisse, C. J., Moerland, E. W., Cleton-Jansen, A. M., Tipping; A. J., Mathew, C. G., Savnio, M., Savoia, A, Verlander, P., Auerbach, A. D., Van Berkel, C., Pronk, J. C., Doggett, N. A, and Callen, D. F. (1998) Genomics 52, 325-331), suggestive of a role in coordinating cytoskeleton activities. Consistent with this possibility, we show that the human GAS11 protein contains a 144-amino acid domain that co-localizes with microtubules when fused to the green fluorescent protein and expressed in mammalian cells. These findings suggest that TLTF represents a newly defined protein family, whose members contribute to cytoskeleton function in species as diverse as protozoa and mammals.	Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Univ Iowa, Interdept Genet PhD Program, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Hill, KL (corresponding author), Univ Calif Los Angeles, Dept Microbiol & Immunol, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.	kenthill@mednet.ucla.edu	Donelson, John E/F-5795-2010		NIAID NIH HHS [AI07511, AI40591] Funding Source: Medline; NIDDK NIH HHS [DK25295] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040591] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BALABAN N, 1989, CELL MOTIL CYTOSKEL, V14, P393, DOI 10.1002/cm.970140309; BALBER AE, 1990, CRIT REV IMMUNOL, V10, P177; BANGS JD, 1993, J CELL SCI, V105, P1101; Bangs JD, 1996, J BIOL CHEM, V271, P18387, DOI 10.1074/jbc.271.31.18387; Bastin P, 1996, PARASITOL TODAY, V12, P302, DOI 10.1016/0169-4758(96)10031-4; Bastin P, 1998, NATURE, V391, P548, DOI 10.1038/35300; Biebinger S, 1996, NUCLEIC ACIDS RES, V24, P1202, DOI 10.1093/nar/24.7.1202; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CHU DTW, 1989, DEV BIOL, V136, P104, DOI 10.1016/0012-1606(89)90134-6; COLIGAN JE, 1995, CURRENT PROTOCOLS IM, V2; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; Diamantopoulos GS, 1999, J CELL BIOL, V144, P99, DOI 10.1083/jcb.144.1.99; Dilbeck V, 1999, J CELL SCI, V112, P4687; Gull K, 1999, ANNU REV MICROBIOL, V53, P629, DOI 10.1146/annurev.micro.53.1.629; HEMPHILL A, 1991, J PARASITOL, V77, P603, DOI 10.2307/3283167; Hill KL, 1999, J CELL SCI, V112, P3091; HILL KL, 1991, J BIOL CHEM, V266, P15060; Hill KL, 1996, J CELL BIOL, V135, P1535, DOI 10.1083/jcb.135.6.1535; Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1; Kim KS, 1997, J BIOL CHEM, V272, P24637, DOI 10.1074/jbc.272.39.24637; Kohl L, 1998, MOL BIOCHEM PARASIT, V93, P1, DOI 10.1016/S0166-6851(98)00014-0; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; LEE MGS, 1990, MOL CELL BIOL, V10, P4506, DOI 10.1128/MCB.10.9.4506; Ludin B, 1996, GENE, V173, P107, DOI 10.1016/0378-1119(95)00899-3; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MACRAE TH, 1990, BIOCHEM J, V265, P87, DOI 10.1042/bj2650087; McDowell MA, 1998, BIOCHEM J, V335, P681, DOI 10.1042/bj3350681; MULLER N, 1993, PARASITOLOGY, V107, P411, DOI 10.1017/S0031182000067767; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; OLSSON T, 1993, CELL, V72, P715, DOI 10.1016/0092-8674(93)90400-K; Perez F, 1999, CELL, V96, P517, DOI 10.1016/S0092-8674(00)80656-X; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; RICKARD JE, 1990, J CELL BIOL, V110, P1623, DOI 10.1083/jcb.110.5.1623; ROBINSON D, 1991, METHOD ENZYMOL, V196, P285; ROBINSON DR, 1995, J CELL BIOL, V128, P1163, DOI 10.1083/jcb.128.6.1163; ROBINSON DR, 1991, NATURE, V352, P731, DOI 10.1038/352731a0; Roggy JL, 1999, MOL BIOCHEM PARASIT, V98, P1, DOI 10.1016/S0166-6851(98)00114-5; Schneider A, 1997, J CELL SCI, V110, P431; SCHNEIDER A, 1987, J CELL BIOL, V104, P431, DOI 10.1083/jcb.104.3.431; SCHNEIDER A, 1988, SCIENCE, V241, P459, DOI 10.1126/science.3393912; Scott V, 1997, J CELL SCI, V110, P157; SEEBECK T, 1990, PARASITOL TODAY, V6, P49, DOI 10.1016/0169-4758(90)90069-G; SHERWIN T, 1989, PHILOS T R SOC B, V323, P573, DOI 10.1098/rstb.1989.0037; Tellam JT, 1997, J BIOL CHEM, V272, P6187, DOI 10.1074/jbc.272.10.6187; Vaidya T, 1997, J EXP MED, V186, P433, DOI 10.1084/jem.186.3.433; Vickerman K, 1976, BIOL KINETOPLASTIDA, P35; WEBSTER P, 1993, PARASITOL TODAY, V9, P201, DOI 10.1016/0169-4758(93)90008-4; Whitmore SA, 1998, GENOMICS, V52, P325, DOI 10.1006/geno.1998.5457; WOODS A, 1989, J CELL SCI, V93, P491	51	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39369	39378		10.1074/jbc.M006907200	http://dx.doi.org/10.1074/jbc.M006907200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10969087	hybrid			2022-12-25	WOS:000165953100060
J	Verzijl, N; DeGroot, J; Thorpe, SR; Bank, RA; Shaw, JN; Lyons, TJ; Bijlsma, JWJ; Lafeber, FPJG; Baynes, JW; TeKoppele, JM				Verzijl, N; DeGroot, J; Thorpe, SR; Bank, RA; Shaw, JN; Lyons, TJ; Bijlsma, JWJ; Lafeber, FPJG; Baynes, JW; TeKoppele, JM			Effect of collagen turnover on the accumulation of advanced glycation end products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTIC-ACID RACEMIZATION; HUMAN ARTICULAR-CARTILAGE; PERFORMANCE LIQUID-CHROMATOGRAPHY; AGE-DEPENDENT ACCUMULATION; HUMAN SKIN COLLAGEN; AMINO-ACID; NONENZYMATIC GLYCATION; EXTRACELLULAR-MATRIX; DIABETES-MELLITUS; LENS PROTEINS	Collagen molecules in articular cartilage have an exceptionally long lifetime, which makes them susceptible to the accumulation of advanced glycation end products (AGEs). In fact, in comparison to other collagen-rich tissues, articular cartilage contains relatively high amounts of the AGE pentosidine. To test the hypothesis that this higher AGE accumulation is primarily the result of the slow turnover of cartilage collagen, AGE levels in cartilage and skin collagen were compared with the degree of racemization of aspartic acid (% D-Asp, a measure of the residence time of a protein). AGE (N-epsilon-(carboxymethyl)lysine, N-epsilon-(carboxyethyl)lysine, and pentosidine) and % D-Asp concentrations increased linearly with age in both cartilage and skin collagen (p < 0.0001), The rate of increase in AGEs was greater in cartilage collagen than in skin collagen (p < 0.0001). % D-Asp was also higher in cartilage collagen than in skin collagen (p < 0.0001), indicating that cartilage collagen has a longer residence time in the tissue, and thus a slower turnover, than skin collagen. In both types of collagen, AGE concentrations increased linearly with % D-Asp (p < 0.0005). Interestingly, the slopes of the curves of AGEs versus % D-Asp, i.e. the rates of accumulation of AGEs corrected for turnover, were identical for cartilage and skin collagen. The present study thus provides the first experimental evidence that protein turnover is a major determinant in AGE accumulation in different collagen types. From the age-related increases in % D-Asp the half-life of cartilage collagen was calculated to be 117 years and that of skin collagen 15 years, thereby providing the first reasonable estimates of the half-lives of these collagens.	TNO, Prevent & Hlth, Gaubius Lab, NL-2301 CE Leiden, Netherlands; Univ Utrecht, Med Ctr, Dept Rheumatol & Clin Immunol, NL-3508 GA Utrecht, Netherlands; Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA	Netherlands Organization Applied Science Research; Utrecht University; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Medical University of South Carolina	TeKoppele, JM (corresponding author), TNO, Prevent & Hlth, Gaubius Lab, POB 2215, NL-2301 CE Leiden, Netherlands.	JM.teKoppele@pg.tno.nl	DeGroot, Jeroen/C-4585-2012; YAMAMOTO, MASAHIRO/F-9094-2011	YAMAMOTO, MASAHIRO/0000-0003-3859-0125; Lyons, Timothy/0000-0003-2106-1622	NATIONAL EYE INSTITUTE [R29EY010697] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019971, R37DK019971] Funding Source: NIH RePORTER; NEI NIH HHS [EY 10697] Funding Source: Medline; NIDDK NIH HHS [DK 19971] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmed MU, 1997, BIOCHEM J, V324, P565, DOI 10.1042/bj3240565; Arrhenius S., 1889, Z PHYS CHEM, V4U, P226, DOI [10.1515/zpch-1889-0416, DOI 10.1515/ZPCH-1889-0416]; ASWAD DW, 1984, ANAL BIOCHEM, V137, P405, DOI 10.1016/0003-2697(84)90106-4; BADA JL, 1973, P NATL ACAD SCI USA, V70, P1331, DOI 10.1073/pnas.70.5.1331; Bank RA, 1997, J CHROMATOGR B, V703, P37, DOI 10.1016/S0378-4347(97)00391-5; Bank RA, 1998, BIOCHEM J, V330, P345, DOI 10.1042/bj3300345; Bank RA, 1996, ANAL BIOCHEM, V240, P167, DOI 10.1006/abio.1996.0346; BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223; Choi JK, 1997, INT J BIOMETEOROL, V41, P68, DOI 10.1007/s004840050056; Cloos PAC, 2000, BIOCHEM J, V345, P473, DOI 10.1042/0264-6021:3450473; DeGroot J, 1999, ARTHRITIS RHEUM, V42, P1003, DOI 10.1002/1529-0131(199905)42:5<1003::AID-ANR20>3.0.CO;2-K; DUNN JA, 1989, BIOCHEMISTRY-US, V28, P9464, DOI 10.1021/bi00450a033; DUNN JA, 1991, BIOCHEMISTRY-US, V30, P1205, DOI 10.1021/bi00219a007; DYER DG, 1991, J BIOL CHEM, V266, P11654; EYRE DR, 1980, BIOCHEM J, V188, P823, DOI 10.1042/bj1880823; Freeman MAR, 1999, J ORTHOP RES, V17, P3, DOI 10.1002/jor.1100170103; Gineyts E, 2000, BIOCHEM J, V345, P481, DOI 10.1042/0264-6021:3450481; Haimovici N, 1982, Prog Clin Biol Res, V107, P453; HELFMAN PM, 1976, NATURE, V262, P279, DOI 10.1038/262279b0; HELFMAN PM, 1975, P NATL ACAD SCI USA, V72, P2891, DOI 10.1073/pnas.72.8.2891; HORVATH SM, 1949, J CLIN INVEST, V28, P469, DOI 10.1172/JCI102092; KIM YJ, 1988, ANAL BIOCHEM, V174, P168, DOI 10.1016/0003-2697(88)90532-5; LIBBY WF, 1964, SCIENCE, V146, P1171; LYONS TJ, 1991, J CLIN INVEST, V87, P1910, DOI 10.1172/JCI115216; MAN EH, 1983, SCIENCE, V220, P1407, DOI 10.1126/science.6857259; Maroudas A, 1998, ARCH BIOCHEM BIOPHYS, V350, P61, DOI 10.1006/abbi.1997.0492; MAROUDAS A, 1992, CONNECT TISSUE RES, V28, P161, DOI 10.3109/03008209209015033; MAROUDAS A, 1980, STUDIES JOINT DISEAS, V1, P59; MASTERS PM, 1977, NATURE, V268, P71, DOI 10.1038/268071a0; MONNIER VM, 1992, DIABETES, V41, P36, DOI 10.2337/diab.41.2.S36; OHTANI S, 1991, J FORENSIC SCI, V36, P792; Ohtani S, 1998, J FORENSIC SCI, V43, P949; Ohtani S, 1996, GROWTH DEVELOP AGING, V60, P1; Ohtani S, 1998, AM J FOREN MED PATH, V19, P284, DOI 10.1097/00000433-199809000-00017; PFEIFFER H, 1995, INT J LEGAL MED, V108, P19, DOI 10.1007/BF01845611; PFEIFFER H, 1995, INT J LEGAL MED, V108, P24, DOI 10.1007/BF01845612; RITZ S, 1993, J FORENSIC SCI, V38, P633; SCHMIDT MB, 1990, J ORTHOPAED RES, V8, P353, DOI 10.1002/jor.1100080307; SELL DR, 1989, J BIOL CHEM, V264, P21597; SMITH GG, 1978, J ORG CHEM, V43, P1, DOI 10.1021/jo00395a001; UCHIYAMA A, 1991, J BIOCHEM, V110, P714, DOI 10.1093/oxfordjournals.jbchem.a123646; VANBOEKEL MAM, 1991, MOL BIOL REP, V15, P57, DOI 10.1007/BF00364840; Verzijl N, 2000, BIOCHEM J, V350, P381, DOI 10.1042/0264-6021:3500381; WellsKnecht MC, 1997, J CLIN INVEST, V100, P839, DOI 10.1172/JCI119599	44	601	614	3	45	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39027	39031		10.1074/jbc.M006700200	http://dx.doi.org/10.1074/jbc.M006700200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10976109	Green Published, hybrid			2022-12-25	WOS:000165953100013
J	Dowland, LK; Luyckx, VA; Enck, AH; Leclercq, B; Yu, ASL				Dowland, LK; Luyckx, VA; Enck, AH; Leclercq, B; Yu, ASL			Molecular cloning and characterization of an intracellular chloride channel in the proximal tubule cell line, LLC-PK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED HEREDITARY NEPHROLITHIASIS; TRANS-GOLGI NETWORK; DENTS-DISEASE; ENDOCYTIC PATHWAY; HUMAN KIDNEY; SUBCELLULAR-DISTRIBUTION; CYSTIC-FIBROSIS; RENAL-FAILURE; PROTON PUMP; PIG-KIDNEY	CLC5 is an intracellular chloride channel of unknown function, expressed in the renal proximal tubule, The subcellular localization and function of CLC5 were investigated in the UC-PK1 porcine proximal tubule cell line. We cloned a cDNA for the porcine CLC5 ortholog (pCLC5) that is predicted to encode an 83-kDa protein with 97% amino acid sequence identity to rat and human CLC5, By immunofluorescence, pCLC5 was localized to early endosomes of the apical membrane fluid-phase endocytotic pathway and to the Golgi complex. Xenopus oocytes injected with pCLC5 cRNA exhibited outwardly rectifying whole cell currents with a relative conductance profile (nitrate >> Cl- approximate to Br- > I- > acetate > gluconate) different from that of control oocytes. Acidification of the extracellular medium reversibly inhibited this outward current with a pK(a) of 6.0 and a Hill coefficient of 1. Overexpression of CLC5 in LLC-PK1 cells resulted in morphological changes, including loss of cell-cell contacts and the appearance of multiple prominent vesicles. These findings are consistent with a potential role for CLC5 in the acidification of membrane compartments of both the endocytic and the exocytic pathway and suggest that its function may be important for normal intercellular adhesion and vesicular trafficking.	Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Membrane Biol Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Yu, ASL (corresponding author), Brigham & Womens Hosp, Div Renal, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	ayu@rics.bwh.harvard.edu	Luyckx, Valerie/J-9747-2019; Yu, Alan/AID-7467-2022	Luyckx, Valerie/0000-0001-7066-8135; Yu, Alan/0000-0002-1776-2533				Alami M, 1997, CELL BIOL INT, V21, P145, DOI 10.1006/cbir.1996.0120; ALAWQATI Q, 1995, CURR OPIN CELL BIOL, V7, P504, DOI 10.1016/0955-0674(95)80006-9; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; Bolino A., 1993, European Journal of Human Genetics, V1, P269; Branten AJW, 1999, NEPHRON, V81, P329, DOI 10.1159/000045301; Buyse G, 1998, BIOCHEM J, V330, P1015, DOI 10.1042/bj3301015; Buyse G, 1997, J BIOL CHEM, V272, P3615, DOI 10.1074/jbc.272.6.3615; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHAPMAN RE, 1994, EMBO J, V13, P2305, DOI 10.1002/j.1460-2075.1994.tb06514.x; Chillaron J, 1997, J BIOL CHEM, V272, P9543; Christensen EI, 1999, J AM SOC NEPHROL, V10, P685; CONDAMINE L, 1994, J CLIN INVEST, V94, P1673, DOI 10.1172/JCI117512; Devuyst O, 1999, HUM MOL GENET, V8, P247, DOI 10.1093/hmg/8.2.247; FISHER SE, 1995, GENOMICS, V29, P598, DOI 10.1006/geno.1995.9960; FISHER SE, 1994, HUM MOL GENET, V3, P2053; Friedrich T, 1999, J BIOL CHEM, V274, P896, DOI 10.1074/jbc.274.2.896; FRYMOYER PA, 1991, NEW ENGL J MED, V325, P681, DOI 10.1056/NEJM199109053251003; GEKLE M, 1995, AM J PHYSIOL-RENAL, V268, pF899, DOI 10.1152/ajprenal.1995.268.5.F899; Gunther W, 1998, P NATL ACAD SCI USA, V95, P8075, DOI 10.1073/pnas.95.14.8075; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; KIEFERLE S, 1994, P NATL ACAD SCI USA, V91, P6943, DOI 10.1073/pnas.91.15.6943; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LENCER WI, 1990, AM J PHYSIOL, V258, pC309, DOI 10.1152/ajpcell.1990.258.2.C309; LINDENTHAL S, 1997, AM J PHYSIOL, V273, pC1173; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; Londono I, 1999, KIDNEY INT, V55, P1407, DOI 10.1046/j.1523-1755.1999.00365.x; Lorenz L, 1996, P NATL ACAD SCI USA, V93, P13362, DOI 10.1073/pnas.93.23.13362; Luyckx VA, 1999, P NATL ACAD SCI USA, V96, P12174, DOI 10.1073/pnas.96.21.12174; Luyckx VA, 1998, AM J PHYSIOL-RENAL, V275, pF761, DOI 10.1152/ajprenal.1998.275.5.F761; Marshansky V, 1997, ELECTROPHORESIS, V18, P538, DOI 10.1002/elps.1150180334; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Mo L, 1999, J MEMBRANE BIOL, V168, P253, DOI 10.1007/s002329900514; Nielsen R, 1998, J AM SOC NEPHROL, V9, P1767; Nykjaer A, 1999, CELL, V96, P507, DOI 10.1016/S0092-8674(00)80655-8; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; Presley JF, 1997, J BIOL CHEM, V272, P13929, DOI 10.1074/jbc.272.21.13929; PRINCE LS, 1994, P NATL ACAD SCI USA, V91, P5192, DOI 10.1073/pnas.91.11.5192; Redhead C, 1997, MOL BIOL CELL, V8, P691, DOI 10.1091/mbc.8.4.691; RODMAN JS, 1991, EXP CELL RES, V192, P445, DOI 10.1016/0014-4827(91)90063-Z; Sakamoto H, 1999, AM J PHYSIOL-RENAL, V277, pF957, DOI 10.1152/ajprenal.1999.277.6.F957; Schapiro FB, 2000, J BIOL CHEM, V275, P21025, DOI 10.1074/jbc.M002386200; SchmidtRose T, 1997, P NATL ACAD SCI USA, V94, P7633, DOI 10.1073/pnas.94.14.7633; Shugrue CA, 1999, J AM SOC NEPHROL, V10, P1649; Steinmeyer K, 1995, J BIOL CHEM, V270, P31172, DOI 10.1074/jbc.270.52.31172; SUMPIO BE, 1985, Q J MED, V57, P611; SUMPIO BE, 1982, AM J PHYSIOL, V243, pF379, DOI 10.1152/ajprenal.1982.243.4.F379; SUNDIN DP, 1994, AM J PHYSIOL, V267, pF380, DOI 10.1152/ajprenal.1994.267.3.F380; Thakkar H, 1998, KIDNEY INT, V54, P1197, DOI 10.1046/j.1523-1755.1998.00098.x; Tulk BM, 1998, AM J PHYSIOL-RENAL, V274, pF1140, DOI 10.1152/ajprenal.1998.274.6.F1140; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; WRONG OM, 1994, Q J MED, V87, P473; XU HX, 1994, J BIOL CHEM, V269, P22875; YET SF, 1994, J CELL PHYSIOL, V158, P506, DOI 10.1002/jcp.1041580315; YU ASL, 1992, AM J PHYSIOL, V263, pF680, DOI 10.1152/ajprenal.1992.263.4.F680	55	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37765	37773		10.1074/jbc.M004840200	http://dx.doi.org/10.1074/jbc.M004840200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10978325	hybrid			2022-12-25	WOS:000165618700063
J	Reagan, JM; Hubbert, ML; Shelness, GS				Reagan, JM; Hubbert, ML; Shelness, GS			Posttranslational regulation of acid sphingomyelinase in Niemann-Pick type C1 fibroblasts and free cholesterol-enriched Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLEAVAGE-ACTIVATING PROTEIN; CULTURED FIBROBLASTS; ENDOPLASMIC-RETICULUM; LIPOPROTEIN FRACTION; SKIN FIBROBLASTS; PLASMA-MEMBRANES; DEFICIENT MICE; SAPOSIN-D; DISEASE; LOCALIZATION	Niemann-Pick type C disease is characterized by the accumulation of cholesterol and other lipids within the lysosomal compartment, a process that is often accompanied by a reduction in acid sphingomyelinase activity. These studies demonstrate that a CHO cell mutant (CT 60), which accumulates lysosomal cholesterol because of a defective NP-C1 protein, has approximately 5-10% of the acid sphingomyelinase activity of its parental cell line (25-RA) or wild type (CHO-K1) cells. The cholesterol-induced reduction in acid sphingomyelinase activity can be reproduced in CHO-K1 cells by incubation in the presence of low density lipoprotein (LDL) and progesterone, which impairs the normal egress of LDL derived cholesterol from the lysosomal compartment. Kinetic analysis of sphingomyelin hydrolysis in cell extracts suggests that the CT60 cells have a reduced amount of functional acid sphingomyelinase as indicated by a 10-fold reduction in the apparent V-max. Western blot analysis using antibodies generated to synthetic peptides corresponding to segments within the carboxyl-terminal region of acid sphingomyelinase demonstrate that both the CT60 and the LDL/progesterone-treated CHO-K1 cells possess near normal levels of acid sphingomyelinase protein. Likewise, Niemann-Pick type C fibroblasts also displayed normal acid sphingomyelinase protein but negligible levels of acid sphingomyelinase activity. These data suggest that cholesterol-induced inhibition is a posttranslational event, perhaps involving cofactor mediated modulation of enzymatic activity or alterations in acid sphingomyelinase protein trafficking and maturation.	Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center	Reagan, JM (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.	jreagan@wfubmc.edu						BARNHOLZ Y, 1966, J BIOL CHEM, V241, P3731; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brown RE, 1998, J CELL SCI, V111, P1; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; CADIGAN KM, 1990, J CELL BIOL, V110, P295, DOI 10.1083/jcb.110.2.295; CARRE JB, 1989, J NEUROCHEM, V52, P1294, DOI 10.1111/j.1471-4159.1989.tb01878.x; Coleman P S, 1997, Subcell Biochem, V28, P363; Cruz JC, 2000, J BIOL CHEM, V275, P4013, DOI 10.1074/jbc.275.6.4013; DEMEL RA, 1977, BIOCHIM BIOPHYS ACTA, V465, P1, DOI 10.1016/0005-2736(77)90350-9; FERLINZ K, 1994, BIOCHEM J, V301, P855, DOI 10.1042/bj3010855; Ferlinz K, 1997, EUR J BIOCHEM, V243, P511, DOI 10.1111/j.1432-1033.1997.511_1a.x; FINDLAY J, 1958, BIOCHEM J, V69, P467, DOI 10.1042/bj0690467; FOWLER S, 1969, BIOCHIM BIOPHYS ACTA, V191, P481, DOI 10.1016/0005-2744(69)90271-X; GATT S, 1980, J BIOL CHEM, V255, P3371; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HASILIK A, 1992, EXPERIENTIA, V48, P130, DOI 10.1007/BF01923507; Heinrich M, 1999, EMBO J, V18, P5252, DOI 10.1093/emboj/18.19.5252; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; HURWITZ R, 1994, J BIOL CHEM, V269, P5440; KLANSEK JJ, 1995, J LIPID RES, V36, P2261; Kusuda S, 1998, J INVEST DERMATOL, V111, P733, DOI 10.1046/j.1523-1747.1998.00370.x; LANGE Y, 1989, J BIOL CHEM, V264, P3786; Lansmann S, 1996, FEBS LETT, V399, P227, DOI 10.1016/S0014-5793(96)01331-2; Leppimaki P, 1998, BIOCHEM J, V335, P285, DOI 10.1042/bj3350285; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAZIERE JC, 1981, BIOCHEM BIOPH RES CO, V100, P1299, DOI 10.1016/0006-291X(81)91965-3; MUNFORD RS, 1995, J LIPID RES, V36, P1653; NEWRZELLA D, 1992, BIOL CHEM H-S, V373, P1233, DOI 10.1515/bchm3.1992.373.2.1233; Newrzella D, 1996, J BIOL CHEM, V271, P32089, DOI 10.1074/jbc.271.50.32089; Nohturfft A, 1999, P NATL ACAD SCI USA, V96, P11235, DOI 10.1073/pnas.96.20.11235; NOVAK EK, 1991, J BIOL CHEM, V266, P6377; Ohvo H, 1997, BBA-LIPID LIPID MET, V1349, P131, DOI 10.1016/S0005-2760(97)00126-4; OTTERBACH B, 1995, CELL, V81, P1053, DOI 10.1016/S0092-8674(05)80010-8; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; PONTING CP, 1994, PROTEIN SCI, V3, P359; RIDGWAY ND, 1995, J LIPID RES, V36, P1345; SCHNEIDER PB, 1967, J LIPID RES, V8, P202; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; SONDERFELDFRESKO S, 1988, J BIOL CHEM, V263, P13463; SPENCE MW, 1989, METABOLIC BASIS INHE, P1655; Storey MK, 1998, BIOCHEM J, V336, P247, DOI 10.1042/bj3360247; Tatti M, 1999, EUR J BIOCHEM, V263, P486, DOI 10.1046/j.1432-1327.1999.00521.x; THOMAS GH, 1989, J INHERIT METAB DIS, V12, P139, DOI 10.1007/BF01800716; van der Spoel A, 1998, EMBO J, V17, P1588, DOI 10.1093/emboj/17.6.1588; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; WATTENBERG BW, 1983, J BIOL CHEM, V258, P2284; Yamamoto T, 1999, HUM GENET, V105, P10, DOI 10.1007/s004390051057; YOSHIKAWA H, 1992, J INHERIT METAB DIS, V15, P155, DOI 10.1007/BF01800359	50	44	46	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					38104	38110		10.1074/jbc.M005296200	http://dx.doi.org/10.1074/jbc.M005296200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10978332	hybrid			2022-12-25	WOS:000165618700106
J	Tang, Y; Tang, J; Chen, ZG; Trost, C; Flockerzi, V; Lin, M; Ramesh, V; Zhu, MX				Tang, Y; Tang, J; Chen, ZG; Trost, C; Flockerzi, V; Lin, M; Ramesh, V; Zhu, MX			Association of mammalian Trp4 and phospholipase C isozymes with a PDZ domain-containing protein, NHERF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; EXCHANGER REGULATORY FACTOR; CA2+-PERMEABLE CATION CHANNEL; ACTIVATED CA2+ INFLUX; NA+/H+-EXCHANGER; STORE DEPLETION; DROSOPHILA TRP; BETA(2)-ADRENERGIC RECEPTOR; FUNCTIONAL-CHARACTERIZATION; SIGNALING COMPLEXES	Mammalian homologues of Drosophila Trp have been implicated to form channels that are activated following the depletion of Ca2+ from internal stores. Recent studies indicate that actin redistribution is required for the activation of these channels. Here we show that murine Trp4 and Trp5, as well as phospholipase C beta1 and beta2 interact with the first PDZ domain of NHERF, regulatory factor of the Na+/H+ exchanger. We demonstrated the association of Trp4 and phospholipase C-beta1 with NHERF in vivo in an HEK293 cell line expressing Trp4 and in adult mouse brain by immuno-coprecipitation. NIIERF is a two PDZ domain-containing protein that associates with the actin cytoskeleton via interactions with members of ezrin/radixin/moesin family. Thus, store-operated channels involving Trp4 and Trp5 can form signaling complexes with phospholipase C isozymes via interactions with NHERF and thereby linking the lipase and the channels to the actin cytoskeleton. The interaction with the PDZ protein may constitute an important mechanism for distribution and regulation of store-operated channels.	Ohio State Univ, Neurobiotechnol Ctr, Columbus, OH 43210 USA; Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; Univ Saarlandes, Inst Pharmakil & Toxikol, D-66421 Homburg, Germany; Johns Hopkins Univ, Sch Med, Dept Physiol & Neurosci, Baltimore, MD 21205 USA; Massachusetts Gen Hosp, Mol Neurogenet Unit, Charlestown, MA 02129 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Saarland University; Johns Hopkins University; Harvard University; Massachusetts General Hospital	Zhu, MX (corresponding author), Ohio State Univ, Neurobiotechnol Ctr, 168 Rightmire Hall,1060 Carmack Rd, Columbus, OH 43210 USA.		Chen, Zhangguo/AAW-2032-2021	Chen, Zhangguo/0000-0002-2741-0080	NIGMS NIH HHS [GM54235] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054235] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bahner M, 2000, J BIOL CHEM, V275, P2901, DOI 10.1074/jbc.275.4.2901; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Breton S, 2000, J BIOL CHEM, V275, P18219, DOI 10.1074/jbc.M909857199; Bretscher A, 1997, J CELL SCI, V110, P3011; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Dare E, 1998, J MOL ENDOCRINOL, V21, P7, DOI 10.1677/jme.0.0210007; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; Fouassier L, 2000, J BIOL CHEM, V275, P25039, DOI 10.1074/jbc.C000092200; Gillo B, 1996, P NATL ACAD SCI USA, V93, P14146, DOI 10.1073/pnas.93.24.14146; Gonzalez-Agosti C, 1999, J BIOL CHEM, V274, P34438, DOI 10.1074/jbc.274.48.34438; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; HU YF, 1994, BIOCHEM BIOPH RES CO, V201, P1050, DOI 10.1006/bbrc.1994.1808; Huber A, 1998, FEBS LETT, V425, P317, DOI 10.1016/S0014-5793(98)00248-8; Kondo T, 1997, J CELL BIOL, V139, P749, DOI 10.1083/jcb.139.3.749; Kurschner C, 1998, MOL CELL NEUROSCI, V11, P161, DOI 10.1006/mcne.1998.0679; LEVY FO, 1993, P NATL ACAD SCI USA, V90, P10798, DOI 10.1073/pnas.90.22.10798; Liu MY, 2000, J BIOL CHEM, V275, P12194, DOI 10.1074/jbc.275.16.12194; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Minkoff C, 1999, CURR OPIN NEPHROL HY, V8, P603, DOI 10.1097/00041552-199909000-00012; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Okada T, 1998, J BIOL CHEM, V273, P10279, DOI 10.1074/jbc.273.17.10279; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PETERSEN CCH, 1995, BIOCHEM J, V311, P41, DOI 10.1042/bj3110041; Philipp S, 2000, J BIOL CHEM, V275, P23965, DOI 10.1074/jbc.M003408200; Philipp S, 1997, FEBS LETT, V413, P243, DOI 10.1016/S0014-5793(97)00877-6; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; Pietromonaco SF, 1998, J BIOL CHEM, V273, P7594, DOI 10.1074/jbc.273.13.7594; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; SANFORD J, 1991, J BIOL CHEM, V266, P9570; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Ullmer C, 1998, FEBS LETT, V424, P63, DOI 10.1016/S0014-5793(98)00141-0; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC1501, DOI 10.1152/ajpcell.1994.267.5.C1501; van Huizen R, 1998, EMBO J, V17, P2285, DOI 10.1093/emboj/17.8.2285; Vannier B, 1999, P NATL ACAD SCI USA, V96, P2060, DOI 10.1073/pnas.96.5.2060; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Weinman EJ, 2000, BIOCHEMISTRY-US, V39, P6123, DOI 10.1021/bi000064m; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333	59	199	211	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37559	37564		10.1074/jbc.M006635200	http://dx.doi.org/10.1074/jbc.M006635200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10980202	hybrid			2022-12-25	WOS:000165618700036
J	Cameron, A; Appel, J; Houghten, RA; Lindberg, I				Cameron, A; Appel, J; Houghten, RA; Lindberg, I			Polyarginines are potent furin inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUENCHED FLUOROGENIC SUBSTRATE; SUBTILISIN-LIKE ENDOPROTEASE; PROHORMONE CONVERTASES; PROPROTEIN CONVERTASES; ALPHA-1-ANTITRYPSIN PORTLAND; PROCESSING ENDOPROTEASE; COMBINATORIAL LIBRARIES; MOLECULAR MECHANISMS; IN-VITRO; SPECIFICITY	The ubiquitous serine endoprotease furin has been implicated in the activation of bacterial toxins and viral glycoproteins as well as in the metastatic progression of certain tumors, Although high molecular mass bioengineered serpin inhibitors have been well characterized, no small nontoxic nanomolar inhibitors have been reported to date. Here we describe the identification of such inhibitors using positional scanning amidated and acetylated synthetic L- and D hexapeptide combinatorial libraries, The results indicated that L-Arg or L-Lys in all positions generated the most potent inhibitors. However, further investigation revealed that the peptide terminating groups hindered inhibition. Consequently, a series of non-amidated and acetylated polyarginines was synthesized. The most potent inhibitor identified, nona-L-arginine, had a K-i for furin of 40 nM. The K-i, values for the related convertases PACE4 and prohormone con vertase-1 (PC1) were 110 nM and 2.5 muM respectively. Although nona-L-arginine was cleaved by furin, the major products after a 6-h incubation at 37 degreesC were hexa-and hepta-L-arginines, both of which retained the great majority of their potency and specificity against furin, Hexa-D-arginine was as potent and specific a furin inhibitor as hexa-L-arginine (K-i values of hexa-D-arginine: 106 nM, 580 nM, and 13.2 muM for furin, PACE4, and PC1, respectively). PC2 was not inhibited by any polyarginine tested; indeed, PC2 showed an increase in activity of up to 140% of the control in the presence of L-polyarginines, Data are also presented that show extended subsite recognition by furin and PC2, Whereas N-terminal acetylation was found to reduce the inhibitory potency of the L-hexapeptide LLRVKR against furin 8-fold, C-terminal amidation reduced the potency <2-fold. Conversely, N-terminal acetylation increased the potency against PC2 nearly 8-fold, whereas C-terminal amidation of the same peptide increased the potency by a factor of 1,6, Our data indicate that non-acetylated, poly-D-arginine-derived molecules may represent excellent lead compounds for the development of therapeutically useful furin inhibitors.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Torrey Pines Inst Mol Studies, San Diego, CA 92121 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Torrey Pines Institute for Molecular Studies, California	Lindberg, I (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1901 Perdido St, New Orleans, LA 70112 USA.		Lindberg, Iris/Q-3825-2019		NIDA NIH HHS [DA05084, R56 DA005084, R01 DA005084] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA005084, R56DA005084] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; ANGLIKER H, 1995, ANAL BIOCHEM, V224, P409, DOI 10.1006/abio.1995.1058; ANGLIKER H, 1995, J MED CHEM, V38, P4014, DOI 10.1021/jm00020a016; ANGLIKER H, 1993, BIOCHEM J, V293, P75, DOI 10.1042/bj2930075; Apletalina E, 1998, J BIOL CHEM, V273, P26589, DOI 10.1074/jbc.273.41.26589; BASAK A, 1994, INT J PEPT PROT RES, V44, P253; Bergeron F, 2000, J MOL ENDOCRINOL, V24, P1, DOI 10.1677/jme.0.0240001; Berman Y, 1999, J NEUROCHEM, V72, P2120, DOI 10.1046/j.1471-4159.1999.0722120.x; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; Cameron A, 2000, FEBS LETT, V473, P135, DOI 10.1016/S0014-5793(00)01511-8; Cieplik M, 1998, BIOL CHEM, V379, P1433, DOI 10.1515/bchm.1998.379.12.1433; COYLE AJ, 1994, AM J RESP CRIT CARE, V150, pS63, DOI 10.1164/ajrccm/150.5_Pt_2.S63; Dahlen JR, 1998, J BIOL CHEM, V273, P1851, DOI 10.1074/jbc.273.4.1851; Dufour EK, 1998, FEBS LETT, V426, P41, DOI 10.1016/S0014-5793(98)00307-X; Frenette G, 1997, BBA-GEN SUBJECTS, V1334, P109, DOI 10.1016/S0304-4165(96)00080-3; Fricker LD, 2000, J NEUROSCI, V20, P639, DOI 10.1523/JNEUROSCI.20-02-00639.2000; FRIGAS E, 1981, MAYO CLIN P, V56, P245; Fujisawa T, 1999, INT ARCH ALLERGY IMM, V120, P65, DOI 10.1159/000053598; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HATSUZAWA K, 1992, J BIOCHEM-TOKYO, V111, P296, DOI 10.1093/oxfordjournals.jbchem.a123753; HOUGHTEN RA, 1986, INT J PEPT PROT RES, V27, P673; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; Houghten RA, 1999, J MED CHEM, V42, P3743, DOI 10.1021/jm990174v; Jean F, 2000, P NATL ACAD SCI USA, V97, P2864, DOI 10.1073/pnas.050504297; JEAN F, 1995, BIOCHEM J, V307, P689, DOI 10.1042/bj3070689; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; JEAN F, 1995, J BIOL CHEM, V270, P19225, DOI 10.1074/jbc.270.33.19225; Khan AR, 1998, PROTEIN SCI, V7, P815; KO KH, 1999, AM J PHYSIOL, V277, P6811; Krysan DJ, 1999, J BIOL CHEM, V274, P23229, DOI 10.1074/jbc.274.33.23229; Lazure C, 1998, J BIOL CHEM, V273, P8572, DOI 10.1074/jbc.273.15.8572; Lindberg I., 1995, METH NEUROSCI, V23, P94; LU WY, 1993, J BIOL CHEM, V268, P14583; Mains RE, 1997, BIOCHEM J, V321, P587, DOI 10.1042/bj3210587; Maquoi E, 1998, FEBS LETT, V424, P262, DOI 10.1016/S0014-5793(98)00187-2; MATTHEWS DJ, 1994, PROTEIN SCI, V3, P1197, DOI 10.1002/pro.5560030805; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Oliva AA, 2000, BBA-PROTEIN STRUCT M, V1477, P338, DOI 10.1016/S0167-4838(99)00283-6; PINILLA C, 1992, BIOTECHNIQUES, V13, P901; Polette M, 1998, INT J BIOCHEM CELL B, V30, P1195, DOI 10.1016/S1357-2725(98)00083-1; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; Santavicca M, 1996, BIOCHEM J, V315, P953, DOI 10.1042/bj3150953; Schwingshackl A, 1999, J ALLERGY CLIN IMMUN, V104, P983, DOI 10.1016/S0091-6749(99)70079-5; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Shinde U, 2000, SEMIN CELL DEV BIOL, V11, P35, DOI 10.1006/scdb.1999.0349; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; Stroh A, 1999, EUR J CELL BIOL, V78, P151, DOI 10.1016/S0171-9335(99)80094-6; Teuchert M, 1999, J BIOL CHEM, V274, P8199, DOI 10.1074/jbc.274.12.8199; Teuchert M, 1999, J BIOL CHEM, V274, P36781, DOI 10.1074/jbc.274.51.36781; Tsuji A, 1999, J BIOCHEM, V126, P591, DOI 10.1093/oxfordjournals.jbchem.a022491; VanRompaey L, 1997, BIOCHEM J, V326, P507; Vepa S, 1997, AM J PHYSIOL-LUNG C, V272, pL608, DOI 10.1152/ajplung.1997.272.4.L608; Zhong M, 1999, J BIOL CHEM, V274, P33913, DOI 10.1074/jbc.274.48.33913; ZHOU A, 1995, J BIOL CHEM, V270, P21509, DOI 10.1074/jbc.270.37.21509	57	162	182	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36741	36749		10.1074/jbc.M003848200	http://dx.doi.org/10.1074/jbc.M003848200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10958789	hybrid, Green Submitted			2022-12-25	WOS:000165577700043
J	Delerive, P; Gervois, P; Fruchart, JC; Staels, B				Delerive, P; Gervois, P; Fruchart, JC; Staels, B			Induction of I kappa B alpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; TRANSCRIPTION FACTOR; ENDOTHELIAL-CELLS; GENE-EXPRESSION; INHIBITOR; COMPLEX; KINASE; IMMUNOSUPPRESSION; ATHEROSCLEROSIS; MACROPHAGES	Chronic inflammation is a hallmark of degenerative diseases such as atherosclerosis. Peroxisome proliferator-activated receptors (PPARs) are transcription factors belonging to the nuclear receptor superfamily, which are expressed in the cells of the atherosclerosic lesion PPAR alpha ligands have been reported to exert anti-inflammatory activities in different cell types by antagonizing the transcriptional activity of NF-kappaB. In the present study, the influence of PPAR alpha activators on the NF-kappaB signaling pathway was investigated. Our results show that fibrates, synthetic PPAR alpha activators, induced the expression of the inhibitory protein I kappaB alpha in human aortic smooth muscle cells as well as in primary human hepatocytes, whereas neither I kappaB-kinase activity nor the degradation rate of I kappaB alpha: were affected. Using PPAR alpha -null mice, we demonstrated that fibrates induced I kappaB alpha in liver in vivo and that this action required PPAR alpha. Furthermore, fibrate treatment induced I kappaB alpha protein expression in the cytoplasm and also enhanced IL-1 beta induced accumulation of I kappaB alpha protein in the nucleus. These actions of fibrates on I kappaB alpha expression were accompanied by a decrease in NF-kappaB DNA binding activity as demonstrated by electrophoretic mobility shift assays. Taken together, these data provide an additional molecular mechanism for the anti-inflammatory activity of PPAR alpha agonists and reinforce their potential use in the treatment of inflammatory diseases.	Inst Pasteur, Dept Atherosclerose, INSERM, U325, F-59019 Lille, France; Univ Lille 2, Fac Pharm, F-59000 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; Universite de Lille	Staels, B (corresponding author), Inst Pasteur, Dept Atherosclerose, INSERM, U325, 1 Rue Pr Calmette, F-59019 Lille, France.	Bart.Staels@pasteur-lille.fr	Staels, Bart/N-9497-2016	Staels, Bart/0000-0002-3784-1503				ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BELLAS RE, 1995, J CLIN INVEST, V96, P2521, DOI 10.1172/JCI118313; Brand K, 1996, J CLIN INVEST, V97, P1715, DOI 10.1172/JCI118598; Chinetti G, 2000, CIRCULATION, V101, P2411, DOI 10.1161/01.CIR.101.20.2411; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; Delerive P, 1999, CIRC RES, V85, P394, DOI 10.1161/01.RES.85.5.394; Delerive P, 1999, J BIOL CHEM, V274, P32048, DOI 10.1074/jbc.274.45.32048; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Gervois P, 1999, MOL ENDOCRINOL, V13, P1535, DOI 10.1210/me.13.9.1535; Han YQ, 1997, J BIOL CHEM, V272, P9825; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; KLUCIS E, 1984, MOL CELL BIOCHEM, V65, P73; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Marx N, 1999, CIRCULATION, V99, P3125, DOI 10.1161/01.CIR.99.24.3125; Marx N, 1998, CIRC RES, V83, P1097, DOI 10.1161/01.RES.83.11.1097; Marx N, 1999, ARTERIOSCL THROM VAS, V19, P546, DOI 10.1161/01.ATV.19.3.546; Marx N, 1998, AM J PATHOL, V153, P17, DOI 10.1016/S0002-9440(10)65540-X; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Palmer CNA, 1998, MOL PHARMACOL, V53, P14, DOI 10.1124/mol.53.1.14; Poynter ME, 1998, J BIOL CHEM, V273, P32833, DOI 10.1074/jbc.273.49.32833; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Soliman MS, 1997, BIOCHEM PHARMACOL, V53, P1369, DOI 10.1016/S0006-2952(97)87956-7; STAELS B, 1992, ARTERIOSCLER THROMB, V12, P286, DOI 10.1161/01.ATV.12.3.286; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Vu-Dac N, 1998, J CLIN INVEST, V102, P625, DOI 10.1172/JCI1581; Xin XH, 1999, J BIOL CHEM, V274, P9116, DOI 10.1074/jbc.274.13.9116; Yamaoka K, 1998, J IMMUNOL, V160, P838; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	46	385	414	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36703	36707		10.1074/jbc.M004045200	http://dx.doi.org/10.1074/jbc.M004045200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10980195	hybrid			2022-12-25	WOS:000165577700037
J	Jung, YS; Bonagura, CA; Tilley, GJ; Gao-Sheridan, HS; Armstrong, FA; Stout, CD; Burgess, BK				Jung, YS; Bonagura, CA; Tilley, GJ; Gao-Sheridan, HS; Armstrong, FA; Stout, CD; Burgess, BK			Structure of C42D Azotobacter vinelandii FdI - A Cys-X-X-Asp-X-X-Cys motif ligates an air-stable [4Fe-4S](2+/+) cluster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTERS; PYROCOCCUS-FURIOSUS FERREDOXIN; SITE-DIRECTED MUTAGENESIS; AMINO-ACID-SEQUENCE; DESULFOVIBRIO-AFRICANUS FERREDOXIN; PUTIDA 7-IRON FERREDOXINS; LIGAND 4FE-4S CLUSTER; F-A; SPECTROSCOPIC CHARACTERIZATION; CLOSTRIDIUM-PASTEURIANUM	All naturally occurring ferredoxins that have Cys-XX-Asp-X-X-Cys motifs contain [4Fe-4S]2(+/+) clusters that can be easily and reversibly converted to [3Fe-4S](+/0) clusters. In contrast, ferredoxins with unmodified Cys-X-X-Cyss-X-X-Cys motifs assemble [4Fe-4S]2(+/+) clusters that cannot be easily interconverted with [3Fe-4S](+/0) clusters. In this study we changed the central cysteine of the Cys(39)-X-X-Cys(42)-X-X-Cys(45) of Azotobacter vinelandii FdI, which coordinates its [4Fe-4S]2(+/+) cluster, into an aspartate. UV-visible, EPR, and CD spectroscopies, metal analysis, and x-ray crystallography show that, Like native FdI, aerobically purified C42D FdI is a seven-iron protein retaining its [4Fe-4S]2(+/+) cluster with monodentate aspartate ligation to one iron. Unlike known clusters of this type the reduced [4Fe-4S](+) cluster of C42D FdI exhibits only an S = 1/2 EPR with no higher spin signals detected. The cluster shows only a minor change in reduction potential relative to the native protein. All attempts to convert the cluster to a 3Fe cluster using conventional methods of oxygen or ferricyanide oxidation or thiol exchange were not successful. The cluster conversion was ultimately accomplished using a new electrochemical method. Hydrophobic and electrostatic interaction and the lack of Gly residues adjacent to the Asp Ligand explain the remarkable stability of this cluster.	Univ Calif Irvine, Dept Biochem & Mol Biol, Irvine, CA 92697 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Univ Oxford, Dept Chem, Oxford OX1 3QR, England	University of California System; University of California Irvine; Scripps Research Institute; University of Oxford	Burgess, BK (corresponding author), Univ Calif Irvine, Dept Biochem & Mol Biol, Irvine, CA 92697 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036325, R01GM045209] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-45209, GM-36325] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; Aono S, 1996, J BIOL INORG CHEM, V1, P523, DOI 10.1007/s007750050087; Aono S, 1998, BIOCHEMISTRY-US, V37, P9812, DOI 10.1021/bi972818b; AONO S, 1989, J BACTERIOL, V171, P3433, DOI 10.1128/jb.171.6.3433-3439.1989; ARMSTRONG FA, 1993, METHOD ENZYMOL, V227, P479, DOI 10.1016/0076-6879(93)27020-H; BEINERT H, 1990, FASEB J, V4, P2483, DOI 10.1096/fasebj.4.8.2185975; BEINERT H, 1989, EUR J BIOCHEM, V186, P5, DOI 10.1111/j.1432-1033.1989.tb15170.x; Beinert H, 2000, J BIOL INORG CHEM, V5, P2, DOI 10.1007/s007750050002; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; BELL SH, 1982, FEBS LETT, V142, P143, DOI 10.1016/0014-5793(82)80238-X; BERTINI I, 1993, FEBS LETT, V332, P268, DOI 10.1016/0014-5793(93)80647-D; Bian SM, 1998, J AM CHEM SOC, V120, P3532, DOI 10.1021/ja974296t; Boll M, 2000, BIOCHEMISTRY-US, V39, P4929, DOI 10.1021/bi9927890; BOVIERLAPIERRE G, 1987, BIOCHIM BIOPHYS ACTA, V913, P20, DOI 10.1016/0167-4838(87)90227-5; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; Burgess BK, 1996, CHEM REV, V96, P2983, DOI 10.1021/cr950055x; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; Busch JLH, 2000, BIOCHEM J, V346, P375, DOI 10.1042/0264-6021:3460375; Busch JLH, 1996, BIOCHEM J, V314, P63, DOI 10.1042/bj3140063; Busch JLH, 1997, BIOCHEM J, V323, P95, DOI 10.1042/bj3230095; BUTT JN, 1991, J AM CHEM SOC, V113, P6663, DOI 10.1021/ja00017a045; BUTT JN, 1993, J AM CHEM SOC, V115, P1413, DOI 10.1021/ja00057a026; Calzolai L, 1996, J AM CHEM SOC, V118, P2513, DOI 10.1021/ja953744z; CALZOLAI L, 1995, BIOCHEMISTRY-US, V34, P11373, DOI 10.1021/bi00036a010; Camba R, 2000, BIOCHEMISTRY-US, V39, P10587, DOI 10.1021/bi000832+; CAMMACK R, 1992, ADV INORG CHEM, V38, P281, DOI 10.1016/S0898-8838(08)60066-5; CARNEY MJ, 1988, J AM CHEM SOC, V110, P6084, DOI 10.1021/ja00226a025; CHENG H, 1990, J BIOL CHEM, V265, P12388; CHENG H, 1992, J BIOL CHEM, V267, P8073; Coldren CD, 1997, P NATL ACAD SCI USA, V94, P6635, DOI 10.1073/pnas.94.13.6635; CONOVER RC, 1990, J BIOL CHEM, V265, P8533; Duderstadt RE, 1999, FEBS LETT, V454, P21, DOI 10.1016/S0014-5793(99)00766-8; Duff JLC, 1996, J AM CHEM SOC, V118, P8593, DOI 10.1021/ja961465l; EMPTAGE MH, 1983, J BIOL CHEM, V258, P1106; Fawcett SEJ, 1998, BIOCHEM J, V335, P357, DOI 10.1042/bj3350357; FLINT DH, 1993, J BIOL CHEM, V268, P14732; Gao-Sheridan HS, 1998, J BIOL CHEM, V273, P5514, DOI 10.1074/jbc.273.10.5514; GAOSHERIDAN HS, 1998, THESIS U CALIFORNIA; GEORGE SJ, 1989, BIOCHEM J, V264, P275, DOI 10.1042/bj2640275; GIBNEY BR, 1996, P NATL ACAD SCI U S, V93, P1541; GORST CM, 1995, BIOCHEMISTRY-US, V34, P600, DOI 10.1021/bi00002a027; GRAVES MC, 1985, P NATL ACAD SCI USA, V82, P1653, DOI 10.1073/pnas.82.6.1653; HAGEN WR, 1985, FEBS LETT, V189, P250, DOI 10.1016/0014-5793(85)81033-4; HERRING HA, 1998, J AM CHEM SOC, V120, P11628; Holm RH, 1996, CHEM REV, V96, P2239, DOI 10.1021/cr9500390; HOWARD JB, 1991, ADV PROTEIN CHEM, V42, P199; IISMAA SE, 1991, J BIOL CHEM, V266, P21563; ISAS JM, 1994, J BIOL CHEM, V269, P19404; ISAS JM, 1995, J BIOL CHEM, V270, P21258, DOI 10.1074/jbc.270.36.21258; JOHNSON MK, 1994, ENCY INORGANIC CHEM, V4, P1896; Jordan PA, 1997, FEBS LETT, V416, P349, DOI 10.1016/S0014-5793(97)01219-2; Jung YS, 1997, J BIOL INORG CHEM, V2, P209, DOI 10.1007/s007750050126; Jung YS, 1999, J BIOL CHEM, V274, P2978, DOI 10.1074/jbc.274.5.2978; Jung YS, 1999, J BIOL CHEM, V274, P32402, DOI 10.1074/jbc.274.45.32402; Jung YS, 1996, J BIOL CHEM, V271, P31135, DOI 10.1074/jbc.271.49.31135; Jung YS, 1997, J BIOL CHEM, V272, P8040, DOI 10.1074/jbc.272.12.8040; KENNEDY MC, 1988, J BIOL CHEM, V263, P8194; KENT TA, 1985, J BIOL CHEM, V260, P6871; Khoroshilova N, 1997, P NATL ACAD SCI USA, V94, P6087, DOI 10.1073/pnas.94.12.6087; KISSINGER CR, 1991, J MOL BIOL, V219, P693, DOI 10.1016/0022-2836(91)90665-S; LINDAHL PA, 1990, J CLUST SCI, V1, P29; MANDORI A, 1992, BIOCHEMISTRY-US, V31, P2703; MARTIN AE, 1989, J BACTERIOL, V171, P3162, DOI 10.1128/jb.171.6.3162-3167.1989; MARTIN AE, 1990, P NATL ACAD SCI USA, V87, P598, DOI 10.1073/pnas.87.2.598; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MINAMI Y, 1985, J BIOCHEM-TOKYO, V97, P745, DOI 10.1093/oxfordjournals.jbchem.a135114; MORGAN TV, 1985, FEBS LETT, V183, P206, DOI 10.1016/0014-5793(85)80777-8; MORGAN TV, 1984, P NATL ACAD SCI-BIOL, V81, P1931, DOI 10.1073/pnas.81.7.1931; MORGAN TV, 1988, J BIOL CHEM, V263, P1370; MOURA JJG, 1984, EUR J BIOCHEM, V141, P319, DOI 10.1111/j.1432-1033.1984.tb08194.x; MOURA JJG, 1982, J BIOL CHEM, V257, P6259; OKAWARA N, 1988, J BIOCHEM-TOKYO, V104, P196, DOI 10.1093/oxfordjournals.jbchem.a122441; ONATE YA, 1989, J BIOL CHEM, V264, P18386; REGSTROM K, 1999, P NATL ACAD SCI U S, V96, P12389; Reyntjens B, 1997, J BIOL INORG CHEM, V2, P595, DOI 10.1007/s007750050174; ROBBINS AH, 1989, P NATL ACAD SCI USA, V86, P3639, DOI 10.1073/pnas.86.10.3639; ROBBINS AH, 1989, PROTEINS, V5, P289, DOI 10.1002/prot.340050406; ROTH EKH, 1992, INORG CHEM, V31, P240, DOI 10.1021/ic00028a022; SHEN B, 1995, P NATL ACAD SCI USA, V92, P10064, DOI 10.1073/pnas.92.22.10064; SHEN BH, 1994, J BIOL CHEM, V269, P8564; SHEN BH, 1993, J BIOL CHEM, V268, P25928; Sridhar V, 1998, J BIOL INORG CHEM, V3, P140; STOUT CD, 1988, J BIOL CHEM, V263, P9256; STOUT CD, 1989, J MOL BIOL, V205, P545, DOI 10.1016/0022-2836(89)90225-8; STOUT GH, 1988, P NATL ACAD SCI USA, V85, P1020, DOI 10.1073/pnas.85.4.1020; THOMSON AJ, 1981, BIOCHIM BIOPHYS ACTA, V637, P423, DOI 10.1016/0005-2728(81)90047-5; THOMSON AJ, 1992, J INORG BIOCHEM, V47, P197, DOI 10.1016/0162-0134(92)84065-U; TONG JJ, 1994, J BIOL CHEM, V269, P24920; VAZQUEZ A, 1994, PROTEIN EXPRES PURIF, V5, P96, DOI 10.1006/prep.1994.1014; WAKABAYASHI S, 1983, FEBS LETT, V162, P21, DOI 10.1016/0014-5793(83)81041-2; Wakagi T, 1996, BIOCHEM BIOPH RES CO, V225, P489, DOI 10.1006/bbrc.1996.1200; WEIGEL JA, 1991, J AM CHEM SOC, V113, P4184, DOI 10.1021/ja00011a020; Yannone SM, 1998, J BIOL INORG CHEM, V3, P253, DOI 10.1007/s007750050229; Yannone SM, 1997, J BIOL CHEM, V272, P14454, DOI 10.1074/jbc.272.22.14454; YU L, 1995, BIOCHEMISTRY-US, V34, P7861, DOI 10.1021/bi00024a010; YU LA, 1995, J BIOL CHEM, V270, P28118; Zhou J, 1996, J AM CHEM SOC, V118, P1966, DOI 10.1021/ja9537843; Zhou ZH, 1997, BIOCHEMISTRY-US, V36, P10892, DOI 10.1021/bi9708141	98	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36974	36983		10.1074/jbc.M004947200	http://dx.doi.org/10.1074/jbc.M004947200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10961993	hybrid			2022-12-25	WOS:000165577700074
J	Underwood, MC; Zhong, DG; Mathur, A; Heyduk, T; Bajaj, SP				Underwood, MC; Zhong, DG; Mathur, A; Heyduk, T; Bajaj, SP			Thermodynamic linkage between the S1 site, the Na+ site, and the Ca2+ site in the protease domain of human coagulation factor Xa - Studies on catalytic efficiency and inhibitor binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONO-VALENT CATIONS; FACTOR-VA; RESIDUE 225; FACTOR-IX; ACTIVATION; STIMULATION; PROTHROMBIN; THROMBIN; CLEAVAGE; AMIDASE	The serine protease domain of factor Xa (FXa) contains a sodium as well as a calcium-binding site. Here, we investigated the functional significance of these two cation-binding sites and their thermodynamic links to the S1 site. Kinetic data reveal that Na+ binds to the substrate bound FXa with K-d similar to 39 mM in the absence and similar to9.5 mM in the presence of Ca2+. Sodium-bound FXa (sodium-Xa) has similar to 18-fold increased catalytic efficiency (similar to4.5-fold decrease in K-m and similar to4-fold increase in k(cat)) in hydrolyzing S-2222 (benzoyl-Ile-Glu-Gly-Arg-p-nitroanilide), and Ca2+ further increases this k(cat) similar to1.4-fold. Ca2+ binds to the protease domain of substrate bound FXa with K-d similar to 705 par in the absence and similar to 175 muM in the presence of Na+. Ca2+ binding to the protease domain of FXa (Xa-calcium) has no effect on the K-m but increases the k(cat) similar to4-fold in hydrolyzing S-2222, and Na+ further increases this k(cat) similar to1.4-fold. In agreement with the K-m data, sodium-Xa has similar to5-fold increased affinity in its interaction with p-aminobenzamidine (S1 site probe) and similar to4-fold increased rate in binding to the two-domain tissue factor pathway inhibitor; Ca2+ (+/-Na+) has no effect on these interactions. Antithrombin binds to Xa-calcium with a similar to4-fold faster rate, to sodium-Xa with a similar to 24-fold faster rate and to sodium-Xa-calcium with a similar to 28-fold faster rate. Thus, Ca2+ and Na+ together increase the catalytic efficiency of FXa similar to 28-fold. Na+ enhances Ca2+ binding, and Ca2+ enhances Na+ binding. Further, Na+ enhances S1 site occupancy, and S1 site occupancy enhances Na+ binding. Therefore, Na+ site is thermodynamically linked to the S1 site as well as to the protease domain Ca2+ site, whereas Ca2+ site is only linked to the Na+ site. The significance of these findings is that during physiologic coagulation, most of the FXa formed will exist as sodium-Xa-calcium, which has maximum biologic activity.	St Louis Univ, Sch Med, Hlth Sci Ctr, Dept Biochem & Mol Biol,Div Hematol & Oncol, St Louis, MO 63110 USA; St Louis Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; St Louis Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	Saint Louis University; Saint Louis University; Saint Louis University	Bajaj, SP (corresponding author), St Louis Univ, Sch Med, Hlth Sci Ctr, Dept Biochem & Mol Biol,Div Hematol & Oncol, 3635 Vista Ave,POB 15250, St Louis, MO 63110 USA.	BajajPS@slu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036365, R55HL036365, R56HL036365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM050514, R01GM050514] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36365] Funding Source: Medline; NIGMS NIH HHS [GM50514] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; Bajaj SP, 1999, SEMIN THROMB HEMOST, V25, P407, DOI 10.1055/s-2007-994943; BAJAJ SP, 1990, J BIOL CHEM, V265, P2956; Bajaj SP, 1999, THROMB HAEMOSTASIS, V82, P218; Betz A, 1997, BIOCHEMISTRY-US, V36, P181, DOI 10.1021/bi962060g; Brandstetter H, 1996, J BIOL CHEM, V271, P29988, DOI 10.1074/jbc.271.47.29988; BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; COPELAND RA, 1996, ENZYMES PRACTICAL IN, P225; Dang QD, 1996, P NATL ACAD SCI USA, V93, P10653, DOI 10.1073/pnas.93.20.10653; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P5253, DOI 10.1021/bi00643a015; FERSHT A, 1998, STRUCTURE MECH PROTE, P125; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; Guinto ER, 1999, P NATL ACAD SCI USA, V96, P1852, DOI 10.1073/pnas.96.5.1852; He XH, 1999, J BIOL CHEM, V274, P4970, DOI 10.1074/jbc.274.8.4970; HILL KAW, 1986, J BIOL CHEM, V261, P4991; HILL KAW, 1987, J BIOL CHEM, V262, P140; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; JESTY J, 1990, J BIOL CHEM, V265, P17539; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J. R., 1999, PRINCIPLES FLUORESCE, P52; LEACH RD, 1991, THROMB RES, V62, P635, DOI 10.1016/0049-3848(91)90368-7; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P5098, DOI 10.1021/bi00366a018; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; MANN KG, 1990, BLOOD, V76, P1; MARQUART M, 1983, ACTA CRYSTALLOGR B, V39, P480, DOI 10.1107/S010876818300275X; Mathur A, 1997, J BIOL CHEM, V272, P23418, DOI 10.1074/jbc.272.37.23418; Mathur A, 1998, BLOOD, V92, p40A; MONROE DM, 1988, ANAL BIOCHEM, V172, P427, DOI 10.1016/0003-2697(88)90465-4; MORITA T, 1986, J BIOL CHEM, V261, P4015; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; ORTHNER CL, 1978, ARCH BIOCHEM BIOPHYS, V185, P400, DOI 10.1016/0003-9861(78)90182-0; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PERSSON E, 1993, J BIOL CHEM, V268, P22531; PETERSEN JGL, 1993, J BIOL CHEM, V268, P13344; Pryzdial ELG, 1996, J BIOL CHEM, V271, P16614, DOI 10.1074/jbc.271.28.16614; Rezaie AR, 2000, BIOCHEMISTRY-US, V39, P1817, DOI 10.1021/bi992006a; Rezaie AR, 1999, THROMB HAEMOSTASIS, P36; REZAIE AR, 1994, J BIOL CHEM, V269, P21495; ROBERTS PS, 1974, THROMB DIATH HAEMOST, V31, P309, DOI 10.1055/s-0038-1649165; Rosenberg I.M., 1996, PROTEIN ANAL PURIFIC, V1996, P153; Rudolph AE, 2000, BIOCHEMISTRY-US, V39, P2861, DOI 10.1021/bi992379b; Sabharwal AK, 1997, J BIOL CHEM, V272, P22037, DOI 10.1074/jbc.272.35.22037; STEINER SA, 1980, BIOCHEM BIOPH RES CO, V94, P340, DOI 10.1016/S0006-291X(80)80226-9; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; Zhang EL, 1997, BIOPHYS CHEM, V63, P185, DOI 10.1016/S0301-4622(96)02227-2	47	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36876	36884		10.1074/jbc.M001386200	http://dx.doi.org/10.1074/jbc.M001386200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973949	hybrid			2022-12-25	WOS:000165577700062
J	Wu, G; MacKenzie, R; Durda, PJ; Tsang, P				Wu, G; MacKenzie, R; Durda, PJ; Tsang, P			The binding of a glycoprotein 120 V3 loop peptide to HIV-1 neutralizing antibodies - Structural implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PANCREATIC TRYPSIN-INHIBITOR; NUCLEAR-MAGNETIC-RESONANCE; 2-DIMENSIONAL NMR-SPECTROSCOPY; SURFACE-PLASMON RESONANCE; C-13 RELAXATION-TIMES; SOLUTION CONFORMATIONS; SYNTHETIC PEPTIDES; ENVELOPE PROTEIN; MONOCLONAL-ANTIBODIES	The structural and antigenic properties of a peptide ("CRK") derived from the V3 loop of HIV-1 gp120 protein were studied using NMR and SPR techniques. The sequence of CRK corresponds to the central portion of the V3 loop containing the highly conserved ''GPGR'' residue sequence. Although the biological significance of this conserved sequence is unknown, the adoption of conserved secondary structure (type II beta -turn) in this region has been proposed. The tendency of CRK (while free or conjugated to protein), to adopt such structure and the influence of such structure upon CRK antigenicity were investigated by NMR and SPR, respectively. Regardless of conjugation, CRK is conformationally averaged in solution but a weak tendency of the CRK "GPGR'' residues to adopt a beta -turn conformation was observed after conjugation. The influence of GPGR structure upon CRK antigenicity was investigated by measuring the affinities of two cognate antibodies: "5023A" and "5025A," for CRK, protein-conjugated CRK and gp120 protein. Each antibody bound to all the antigens with nearly the same affinity. From these data, it appears that: (a) antibody binding most likely involves an induced fit of the peptide and (b) the gp120 V3 loop is probably conformationally heterogeneous. Since 5023A and 5025A are HIV-1 neutralizing antibodies, neutralization in these cases appears to be independent of adopted GPGR beta -turn structure.	Univ Cincinnati, Dept Chem, Cincinnati, OH 45221 USA; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA	University System of Ohio; University of Cincinnati; National Research Council Canada; Harvard University; Massachusetts General Hospital	Tsang, P (corresponding author), Univ Cincinnati, Dept Chem, Cincinnati, OH 45221 USA.	pearl.tsang@uc.edu			NIGMS NIH HHS [GM-47013] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALASUBRAMANIAN S, 1994, J MAGN RESON SER B, V104, P240, DOI 10.1006/jmrb.1994.1081; Beeser SA, 1998, J MOL BIOL, V284, P1581, DOI 10.1006/jmbi.1998.2240; BERNDT KD, 1992, J MOL BIOL, V227, P757, DOI 10.1016/0022-2836(92)90222-6; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BROWN LR, 1978, EUR J BIOCHEM, V88, P87, DOI 10.1111/j.1432-1033.1978.tb12425.x; CATASTI P, 1995, J BIOL CHEM, V270, P2224, DOI 10.1074/jbc.270.5.2224; Catasti P, 1996, J BIOL CHEM, V271, P8236, DOI 10.1074/jbc.271.14.8236; CHANDRASEKHAR K, 1991, BIOCHEMISTRY-US, V30, P9187, DOI 10.1021/bi00102a009; CLEMENTS GJ, 1991, AIDS RES HUM RETROV, V7, P3, DOI 10.1089/aid.1991.7.3; DELORIMIER R, 1994, BIOCHEMISTRY-US, V33, P2055, DOI 10.1021/bi00174a011; DETTIN M, 1993, BIOCHEM BIOPH RES CO, V191, P364, DOI 10.1006/bbrc.1993.1226; DURDA PJ, 1990, AIDS RES HUM RETROV, V6, P1115, DOI 10.1089/aid.1990.6.1115; DYSON HJ, 1985, NATURE, V318, P480; DYSON HJ, 1991, ANNU REV BIOPHYS BIO, V20, P519; DYSON HJ, 1995, IMMUNOLOGICAL RECOGN, P133; EBINA S, 1989, J BIOL CHEM, V264, P7882; Ghiara JB, 1997, J MOL BIOL, V266, P31, DOI 10.1006/jmbi.1996.0768; GHIARA JB, 1994, SCIENCE, V264, P82, DOI 10.1126/science.7511253; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; GUPTA G, 1993, J BIOMOL STRUCT DYN, V11, P345, DOI 10.1080/07391102.1993.10508731; Hansen JE, 1996, PROTEINS, V25, P1, DOI 10.1002/(SICI)1097-0134(199605)25:1<1::AID-PROT1>3.0.CO;2-N; Harlow E., 1988, ANTIBODIES LABORATOR, P628; HATTORI T, 1989, FEBS LETT, V248, P48, DOI 10.1016/0014-5793(89)80429-6; Huang XL, 1997, BIOCHEMISTRY-US, V36, P10846, DOI 10.1021/bi9703655; Huang XL, 1996, FEBS LETT, V393, P280, DOI 10.1016/0014-5793(96)00912-X; JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Jelinek R, 1997, J MAGN RESON, V125, P185, DOI 10.1006/jmre.1996.1099; Jelinek R, 1997, J MOL BIOL, V266, P649, DOI 10.1006/jmbi.1996.0821; JEMMERSON R, 1987, P NATL ACAD SCI USA, V84, P9180, DOI 10.1073/pnas.84.24.9180; Jemmerson R., 1995, IMMUNOLOGICAL RECOGN, P213; JOHNSON ME, 1994, FEBS LETT, V337, P4, DOI 10.1016/0014-5793(94)80618-7; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KIM PS, 1988, BIOPHYS CHEM, V31, P107, DOI 10.1016/0301-4622(88)80014-0; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LANGEDIJK JPM, 1991, J GEN VIROL, V72, P2519, DOI 10.1099/0022-1317-72-10-2519; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; Markert RLM, 1996, EUR J BIOCHEM, V237, P188, DOI 10.1111/j.1432-1033.1996.0188n.x; NIRMALA NR, 1988, J AM CHEM SOC, V110, P7557, DOI 10.1021/ja00230a057; Niwa Y, 1996, EUR J BIOCHEM, V237, P64, DOI 10.1111/j.1432-1033.1996.0064n.x; OTTING G, 1986, J MAGN RESON, V66, P187, DOI 10.1016/0022-2364(86)90122-8; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932; PORTER R, 1986, CIB FDN S, V119, P70; RANCE M, 1989, METHOD ENZYMOL, V176, P114; RANCE M, 1986, J MAGN RESON, V66, P372, DOI 10.1016/0022-2364(86)90043-0; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; SCHWAB C, 1993, PROTEIN SCI, V2, P175; SPANGLER BD, 1991, J IMMUNOL, V146, P1591; Speck RF, 1997, J VIROL, V71, P7136, DOI 10.1128/JVI.71.9.7136-7139.1997; Stanfield RL, 1999, STRUCTURE, V7, P131, DOI 10.1016/S0969-2126(99)80020-3; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Tsang P, 1997, J MOL RECOGNIT, V10, P256; Tugarinov V, 1999, NAT STRUCT BIOL, V6, P331; Ugolini S, 1997, J EXP MED, V186, P1287, DOI 10.1084/jem.186.8.1287; VANGEET AL, 1970, ANAL CHEM, V42, P679, DOI 10.1021/ac60288a022; Vranken WF, 1996, EUR J BIOCHEM, V236, P100, DOI 10.1111/j.1432-1033.1996.00100.x; Vu HM, 1996, BIOCHEMISTRY-US, V35, P5158, DOI 10.1021/bi952665x; Vu HM, 1999, J VIROL, V73, P746, DOI 10.1128/JVI.73.1.746-750.1999; WAGNER G, 1982, J MOL BIOL, V155, P347, DOI 10.1016/0022-2836(82)90009-2; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; Weliky DP, 1999, NAT STRUCT BIOL, V6, P141; WLODAWER A, 1987, J MOL BIOL, V198, P469, DOI 10.1016/0022-2836(87)90294-4; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; WUTHRICH K, 1986, NMR PROTEINS NUUCL A; ZVI A, 1992, BIOCHEMISTRY-US, V31, P6972, DOI 10.1021/bi00145a015	68	23	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36645	36652		10.1074/jbc.M005369200	http://dx.doi.org/10.1074/jbc.M005369200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10967109	hybrid			2022-12-25	WOS:000165577700028
J	Goicoechea, S; Orr, AW; Pallero, MA; Eggleton, P; Murphy-Ullrich, JE				Goicoechea, S; Orr, AW; Pallero, MA; Eggleton, P; Murphy-Ullrich, JE			Thrombospondin mediates focal adhesion disassembly through interactions with cell surface calreticulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; RECEPTOR-RELATED PROTEIN; CALCIUM-BINDING PROTEIN; RO/SS-A-ANTIGEN; ENDOTHELIAL-CELLS; EXTRACELLULAR-MATRIX; HEAT-SHOCK; NG108-15 CELLS; UP-REGULATION; EXPRESSION	Thrombospondin induces reorganization of the actin cytoskeleton and restructuring of focal adhesions. This activity is localized to amino acids 17-35 in the N-terminal heparin-binding domain of thrombospondin and can be replicated by a peptide (hep I) with this sequence. Thrombospondin/hep I stimulate focal adhesion disassembly through a mechanism involving phosphoinositide 3-kinase, activation. However, the receptor for this thrombospondin sequence is unknown. We now report that calreticulin on the cell surface mediates focal adhesion disassembly by thrombospondin/hep I. A 60-kDa protein from endothelial cell detergent extracts has homology and-immunoreactivity to calreticulin, binds a hep I affinity column, and neutralizes thrombospondin/hep I-mediated focal adhesion disassembly, Calreticulin on the cell Surface was confirmed by biotinylation, confocal microscopy, and by fluorescence-activated cell sorting analyses, Thrombospondin and calreticulin potentially bind through the hep I sequence, since thrombospondin-calreticulin complex formation can be blocked specifically by hep I peptide. Antibodies to calreticulin and preincubation of thrombospondin/hep I with glutathione S-transferase-calreticulin block thrombospondin/hep I-mediated focal adhesion disassembly and :phosphoinositide 3-kinase activation, suggesting that calreticulin is a component of the thrombospondin-induced signaling cascade that regulates cytoskeletal organization. These data identify both a novel receptor for the N terminus of thrombospondin and a distinct role for cell surface calreticulin in cell adhesion.	Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Cell Adhes & Matrix Res Ctr, Birmingham, AL 35294 USA; Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3RE, England	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Oxford	Murphy-Ullrich, JE (corresponding author), Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, G038 Volker Hall,1670 Univ Blvd, Birmingham, AL 35294 USA.	murphy@uab.edu	Orr, Anthony/P-8927-2015	Orr, Anthony/0000-0002-2377-213X; Eggleton, Paul/0000-0001-8244-2125; Goicoechea, Silvia/0000-0003-1107-389X	NHLBI NIH HHS [HL44575] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044575] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams J. C., 1995, THROMBOSPONDIN GENE; Arosa FA, 1999, J BIOL CHEM, V274, P16917, DOI 10.1074/jbc.274.24.16917; BAKSH S, 1991, J BIOL CHEM, V266, P21458; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; Cho JH, 1999, EUR J BIOCHEM, V266, P878, DOI 10.1046/j.1432-1327.1999.00920.x; Chung CY, 1996, MOL BIOL CELL, V7, P883, DOI 10.1091/mbc.7.6.883; CONWAY EM, 1995, J BIOL CHEM, V270, P17011, DOI 10.1074/jbc.270.28.17011; COPPOLINO M, 1995, J BIOL CHEM, V270, P23132, DOI 10.1074/jbc.270.39.23132; Coppolino MG, 2000, INT J BIOCHEM CELL B, V32, P171, DOI 10.1016/S1357-2725(99)00043-6; Coppolino MG, 1999, BIOCHEM J, V340, P41, DOI 10.1042/0264-6021:3400041; Coppolino MG, 1997, NATURE, V386, P843, DOI 10.1038/386843a0; DEDHAR S, 1994, TRENDS BIOCHEM SCI, V19, P269, DOI 10.1016/0968-0004(94)90001-9; Denning GM, 1997, BLOOD, V90, P372; DiPietro LA, 1996, AM J PATHOL, V148, P1851; EGGLETON P, 1994, CLIN IMMUNOL IMMUNOP, V72, P405, DOI 10.1006/clin.1994.1160; Fadel MP, 1999, J BIOL CHEM, V274, P15085, DOI 10.1074/jbc.274.21.15085; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; GODYNA S, 1995, J CELL BIOL, V129, P1403, DOI 10.1083/jcb.129.5.1403; GRAY AJ, 1995, J BIOL CHEM, V270, P26602, DOI 10.1074/jbc.270.44.26602; Greenwood JA, 1998, J BIOL CHEM, V273, P1755, DOI 10.1074/jbc.273.3.1755; Greenwood JA, 1998, MICROSC RES TECHNIQ, V43, P420, DOI 10.1002/(SICI)1097-0029(19981201)43:5<420::AID-JEMT8>3.0.CO;2-B; Guo WX, 1999, J LAB CLIN MED, V133, P541, DOI 10.1016/S0022-2143(99)90183-X; HOWE SR, 1995, AM J PATHOL, V146, P1568; KAWASHIMA T, 1994, LUPUS, V3, P493, DOI 10.1177/096120339400300612; KETIS NV, 1990, J CELL SCI, V96, P263; Kishore U, 1997, BIOCHEM J, V322, P543, DOI 10.1042/bj3220543; Krutzsch HC, 1999, J BIOL CHEM, V274, P24080, DOI 10.1074/jbc.274.34.24080; KUWABARA K, 1995, J BIOL CHEM, V270, P8179, DOI 10.1074/jbc.270.14.8179; Kwon MS, 2000, MOL BIOL CELL, V11, P1433, DOI 10.1091/mbc.11.4.1433; LEUNGHAGESTEIJN CY, 1994, J CELL SCI, V107, P589; LIEU TS, 1988, J CLIN INVEST, V82, P96, DOI 10.1172/JCI113607; McDonnell JM, 1996, J BIOL CHEM, V271, P7891, DOI 10.1074/jbc.271.14.7891; Mesaeli N, 1999, J CELL BIOL, V144, P857, DOI 10.1083/jcb.144.5.857; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; Mikhailenko I, 1997, J BIOL CHEM, V272, P6784, DOI 10.1074/jbc.272.10.6784; MILNER RE, 1991, J BIOL CHEM, V266, P7155; MurphyUllrich JE, 1996, J CELL SCI, V109, P2499; MURPHYULLRICH JE, 1989, J CELL BIOL, V109, P1309, DOI 10.1083/jcb.109.3.1309; MURPHYULLRICH JE, 1988, J BIOL CHEM, V263, P6400; MURPHYULLRICH JE, 1995, J CELL BIOCHEM, V57, P341, DOI 10.1002/jcb.240570218; MURPHYULLRICH JE, 1991, J CELL BIOL, V115, P1127, DOI 10.1083/jcb.115.4.1127; MURPHYULLRICH JE, 1993, J BIOL CHEM, V268, P26784; MURPHYULLRICH JE, 1995, TRENDS GLYCOSCI GLYC, V7, P89; Nguyen TQ, 1996, MOL IMMUNOL, V33, P379, DOI 10.1016/0161-5890(95)00149-2; Opas M, 1996, J CELL BIOL, V135, P1913, DOI 10.1083/jcb.135.6.1913; PEERSCHKE EIB, 1993, J LEUKOCYTE BIOL, V53, P179, DOI 10.1002/jlb.53.2.179; Phelan MW, 1998, J LAB CLIN MED, V132, P519, DOI 10.1016/S0022-2143(98)90131-7; Pike SE, 1999, BLOOD, V94, P2461, DOI 10.1182/blood.V94.7.2461.419a26_2461_2468; Pike SE, 1998, J EXP MED, V188, P2349, DOI 10.1084/jem.188.12.2349; RAUGI GJ, 1987, J INVEST DERMATOL, V89, P551, DOI 10.1111/1523-1747.ep12461198; ROBERTS DD, 1988, CANCER RES, V48, P6785; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; SUN XJ, 1989, J BIOL CHEM, V264, P11288; Szewczenko-Pawlikowski M, 1997, MOL CELL BIOCHEM, V177, P145, DOI 10.1023/A:1006874019070; van den Berg RH, 1998, J IMMUNOL, V161, P6924; VANDENBERG RH, 1995, EUR J IMMUNOL, V25, P2206, DOI 10.1002/eji.1830250814; WHITE TK, 1995, J BIOL CHEM, V270, P15926, DOI 10.1074/jbc.270.27.15926; Xiao GQ, 1999, MOL BRAIN RES, V72, P121, DOI 10.1016/S0169-328X(99)00188-6; Xiao GQ, 1999, J NEUROSCI RES, V58, P652, DOI 10.1002/(SICI)1097-4547(19991201)58:5<652::AID-JNR6>3.0.CO;2-H; Zhu J, 1996, CLIN EXP IMMUNOL, V103, P47, DOI 10.1046/j.1365-2249.1996.00912.x; Zhu Q, 1997, BIOCHEM BIOPH RES CO, V232, P354, DOI 10.1006/bbrc.1997.6195	64	131	134	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36358	36368		10.1074/jbc.M005951200	http://dx.doi.org/10.1074/jbc.M005951200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10964924	hybrid			2022-12-25	WOS:000165382000100
J	Kamashev, DE; Balandina, AV; Karpov, VL				Kamashev, DE; Balandina, AV; Karpov, VL			Tramtrack protein-DNA interactions - A cross-linking study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PEPTIDE; CRYSTAL-STRUCTURE; BINDING DOMAIN; YEAST ADR1; SEQUENCE; RECOGNITION; REGION; ORIENTATION; EXPRESSION; EXTENSION	Interaction of the Tramtrack protein from Drosophila melanogaster with DNA was analyzed by a cross-linking method. Tramtrack, residues cross-linkable to the partially, depurinated DNA were identified by direct sequencing. The N-terminal alpha -amino group of the protein DNA-binding domain was found to be the major product of cross-linking. The location of the N terminus on the DNA was determined by identification of the DNA bases that were cross-linked to the protein cy-amino group. We conclude that accessory N-terminal peptide preceding the first zinc finger of Tramtrack directly interacts with DNA, both in specific and nonspecific DNA-protein complexes. Our finding explains the role in the protein binding of the DNA bases outside of the direct interaction with the zinc fingers.	Russian Acad Sci, W Engelhardt Inst Mol Biol, Lab Chromatin Struct & Funct, Moscow 117984, Russia	Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Kamashev, DE (corresponding author), Russian Acad Sci, W Engelhardt Inst Mol Biol, Lab Chromatin Struct & Funct, 32 Vavilov Str, Moscow 117984, Russia.	kamashev@imb.imb.ac.ru	Karpov, Vadim/G-7932-2014; Kamashev, Dmitri/K-6560-2017	Kamashev, Dmitri/0000-0003-4158-5300				BROWN JL, 1991, EMBO J, V10, P665, DOI 10.1002/j.1460-2075.1991.tb07995.x; Dutnall RN, 1996, STRUCTURE, V4, P599, DOI 10.1016/S0969-2126(96)00064-0; EBRALIDSE KK, 1988, NATURE, V331, P365, DOI 10.1038/331365a0; FAIRALL L, 1992, J MOL BIOL, V226, P349, DOI 10.1016/0022-2836(92)90952-G; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; Hyre DE, 1998, J MOL BIOL, V279, P929, DOI 10.1006/jmbi.1998.1811; JACOBS GH, 1992, EMBO J, V11, P4507, DOI 10.1002/j.1460-2075.1992.tb05552.x; KAMASHEV DE, 1995, FEBS LETT, V375, P27, DOI 10.1016/0014-5793(95)01153-6; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MIRZABEKOV AD, 1989, METHOD ENZYMOL, V170, P386; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; NAKASEKO Y, 1992, J MOL BIOL, V228, P619, DOI 10.1016/0022-2836(92)90845-B; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Schmiedeskamp M, 1997, BIOCHEMISTRY-US, V36, P14003, DOI 10.1021/bi971364f; THUKRAL SK, 1991, MOL CELL BIOL, V11, P1566, DOI 10.1128/MCB.11.3.1566; Wuttke DS, 1997, J MOL BIOL, V273, P183, DOI 10.1006/jmbi.1997.1291	17	5	5	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36056	36061		10.1074/jbc.M001691200	http://dx.doi.org/10.1074/jbc.M001691200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10964908	hybrid			2022-12-25	WOS:000165382000059
J	Lai, CF; Feng, X; Nishimura, R; Teitelbaum, SL; Avioli, LV; Ross, FP; Cheng, SL				Lai, CF; Feng, X; Nishimura, R; Teitelbaum, SL; Avioli, LV; Ross, FP; Cheng, SL			Transforming growth factor-beta up-regulates the beta(5) integrin subunit expression via Sp1 and Smad signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLAST-LIKE CELLS; TGF-BETA; VITRONECTIN RECEPTOR; ALPHA-V; CHEMOTACTIC RESPONSE; FUNCTIONAL-ANALYSIS; BONE SIALOPROTEIN; GENE-EXPRESSION; DIFFERENTIATION; PROMOTER	Integrin-mediated cell-matrix interactions play important:roles in regulating cell function. Since transforming growth factor-beta (TGF-beta) modulates many osteoblast activities, we hypothesized that the growth factor acts in part by modulating integrin expression. TGF-beta increased cell adhesion to vitronectin and up-regulated the surface level of alpha (v)beta (5) via increasing beta (5) protein synthesis,by a transcriptional mechanism. Promoter activity analysis demonstrated that a TGF-beta -responsive element resides between nucleotides -63 and -44. Electrophoretic mobility shift assay and immunoprecipitation/Western studies indicated that the nuclear complex formed using the -66/-42 oligonucleotide contained both Sp1/Sp3 and Smad proteins. Since nuclear Sp1/Sp3 levels were not altered, whereas Smad levels were increased by TGF-beta, we investigated the roles of Smad proteins in the up-regulation of beta (5) gene activation. Co-transfection of cells with beta (5) promoter reporter construct and expression vectors for Smad3, Smad4, and Spl increased the stimulatory effect of TGF-beta. Furthermore, expression of dominant negative Smad3 or Smad4 in cells decreased or abolished the stimulation of beta (5) promoter activity by TGF-beta. Smad4 mutant also inhibited the up-regulation of surface beta (5) level by TGF-beta. Thus, TGF-beta increases expression of the integrin beta (5) gene by mechanisms involving Sp1/Sp3 and Smad transcription factors.	Washington Univ, Sch Med, Dept Internal Med, Div Bone & Mineral Dis, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Osaka Univ, Fac Dent, Dept Biochem, Suita, Osaka 565, Japan	Washington University (WUSTL); Washington University (WUSTL); Osaka University	Cheng, SL (corresponding author), Washington Univ, Barnes Jewish Hosp, Sch Med, Div Bone & Mineral Dis, 216 S Kingshighway Blvd, St Louis, MO 63110 USA.	scheng@imgate.wustl.edu		Teitelbaum, Steven/0000-0002-4054-6679; Nishimura, Riko/0000-0001-7279-8363	NIAMS NIH HHS [AR32087, AR07033, AR42404] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR032087, T32AR007033, R01AR042404] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Albert ML, 1998, J EXP MED, V188, P1359, DOI 10.1084/jem.188.7.1359; AMARNANI S, 1993, J BONE MINER RES, V8, P157; Bostrom MPG, 1998, CLIN ORTHOP RELAT R, pS124, DOI 10.1097/00003086-199810001-00014; CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27; Cheng SL, 2000, J CELL BIOCHEM, V77, P265, DOI 10.1002/(SICI)1097-4644(20000501)77:2<265::AID-JCB9>3.0.CO;2-6; Choi JY, 1996, J CELL BIOCHEM, V61, P609, DOI 10.1002/(SICI)1097-4644(19960616)61:4<609::AID-JCB15>3.3.CO;2-Q; CLOVER J, 1992, J CELL SCI, V103, P267; Cohen MM, 1997, J BONE MINER RES, V12, P322, DOI 10.1359/jbmr.1997.12.3.322; CONFORTI G, 1994, CELL ADHES COMMUN, V1, P279, DOI 10.3109/15419069409097260; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; De Deyne PG, 1998, J CELL SCI, V111, P2729; Erlebacher A, 1998, MOL BIOL CELL, V9, P1903, DOI 10.1091/mbc.9.7.1903; Feng X, 1999, J BIOL CHEM, V274, P1366, DOI 10.1074/jbc.274.3.1366; Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932; FREED E, 1989, EMBO J, V8, P2955, DOI 10.1002/j.1460-2075.1989.tb08445.x; GRONOWICZ GA, 1995, ENDOCRINOLOGY, V136, P598, DOI 10.1210/en.136.2.598; Gronthos S, 1997, J BONE MINER RES, V12, P1189, DOI 10.1359/jbmr.1997.12.8.1189; GRZESIK WJ, 1994, J BONE MINER RES, V9, P487, DOI 10.1002/jbmr.5650090408; HEINO J, 1989, J BIOL CHEM, V264, P21806; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HU DD, 1995, J BIOL CHEM, V270, P26232, DOI 10.1074/jbc.270.44.26232; Hu PPC, 1998, ENDOCR REV, V19, P349, DOI 10.1210/er.19.3.349; HUGHES DE, 1993, J BONE MINER RES, V8, P527; HUGHES FJ, 1992, BONE MINER, V19, P63, DOI 10.1016/0169-6009(92)90844-4; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGNOTZ RA, 1989, J BIOL CHEM, V264, P389; Jikko A, 1999, J BONE MINER RES, V14, P1075, DOI 10.1359/jbmr.1999.14.7.1075; JIMENEZ SA, 1994, J BIOL CHEM, V269, P12684; JOYCE ME, 1990, J CELL BIOL, V110, P2195, DOI 10.1083/jcb.110.6.2195; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; KIM JP, 1994, J BIOL CHEM, V269, P26926; Kim LT, 1997, P SOC EXP BIOL MED, V214, P123; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; LIND M, 1995, APMIS, V103, P140, DOI 10.1111/j.1699-0463.1995.tb01089.x; Liu YK, 1997, FEBS LETT, V420, P112, DOI 10.1016/S0014-5793(97)01498-1; LUCAS PA, 1989, BONE, V10, P459, DOI 10.1016/8756-3282(89)90079-3; MARCELLI C, 1990, J BONE MINER RES, V5, P1087; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; McCann TJ, 1997, MATRIX BIOL, V16, P273, DOI 10.1016/S0945-053X(97)90015-9; Memmo LM, 1998, J CELL SCI, V111, P425; Moses HL, 1996, CURR OPIN GENET DEV, V6, P581, DOI 10.1016/S0959-437X(96)80087-6; Moursi AM, 1997, J CELL SCI, V110, P2187; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; NODA M, 1989, ENDOCRINOLOGY, V124, P2991, DOI 10.1210/endo-124-6-2991; Opperman LA, 1997, J BONE MINER RES, V12, P301, DOI 10.1359/jbmr.1997.12.3.301; OREFFO ROC, 1989, BIOCHEM BIOPH RES CO, V158, P817, DOI 10.1016/0006-291X(89)92795-2; OURSLER MJ, 1994, J BONE MINER RES, V9, P443; Padgett RW, 1998, PHARMACOL THERAPEUT, V78, P47, DOI 10.1016/S0163-7258(97)00166-6; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; PFEILSCHIFTER J, 1990, J BONE MINER RES, V5, P825; PROETZEL G, 1995, NAT GENET, V11, P409, DOI 10.1038/ng1295-409; QU Q, 1998, BONE NY, V23, pS529; Roberts AB, 1998, MINER ELECTROL METAB, V24, P111, DOI 10.1159/000057358; ROSIER RN, 1998, CLIN ORTHOP S, V335, pS294; Roth DA, 1997, J BONE MINER RES, V12, P311, DOI 10.1359/jbmr.1997.12.3.311; SAITO T, 1994, J ORTHOP RES, V12, P384, DOI 10.1002/jor.1100120311; Sanford LP, 1997, DEVELOPMENT, V124, P2659; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SMITH JW, 1990, J BIOL CHEM, V265, P11008; Srivastava S, 1998, J CLIN INVEST, V102, P1850, DOI 10.1172/JCI4561; Sung V, 1998, J CELL PHYSIOL, V176, P482, DOI 10.1002/(SICI)1097-4652(199809)176:3<482::AID-JCP5>3.0.CO;2-K; TAKAHASHI T, 1986, CELL TISSUE RES, V245, P9; TAKAHASHI T, 1986, ARCH ORAL BIOL, V31, P703, DOI 10.1016/0003-9969(86)90101-9; WERGEDAL JE, 1990, J BONE MINER RES, V5, P179, DOI 10.1002/jbmr.5650050212; Xiao GZ, 1998, J BIOL CHEM, V273, P32988, DOI 10.1074/jbc.273.49.32988; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yebra M, 1996, J BIOL CHEM, V271, P29393, DOI 10.1074/jbc.271.46.29393; ZAMBRUNO G, 1995, J CELL BIOL, V129, P853, DOI 10.1083/jcb.129.3.853; ZHOU HY, 1995, CALCIFIED TISSUE INT, V56, P403, DOI 10.1007/BF00301610	72	87	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36400	36406		10.1074/jbc.M002131200	http://dx.doi.org/10.1074/jbc.M002131200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10964912	hybrid			2022-12-25	WOS:000165382000105
J	Takaku, K; Sonoshita, M; Sasaki, N; Uozumi, N; Doi, Y; Shimizu, T; Taketo, MM				Takaku, K; Sonoshita, M; Sasaki, N; Uozumi, N; Doi, Y; Shimizu, T; Taketo, MM			Suppression of intestinal polyposis in Apc(Delta 716) knockout mice by an additional mutation in the cytosolic phospholipase A(2) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; MAST-CELLS; GROUP-II; PROSTAGLANDIN PRODUCTION; P388D(1) MACROPHAGES; DEPENDENT INCREASE; MAJOR MODIFIER; COLON-CANCER; CYCLOOXYGENASE-2; GENERATION	Arachidonic acid is a precursor for biosynthesis of eicosanoids, including prostaglandins, thromboxanes, leukotrienes, and lipoxins. Cytosolic phospholipase A, (cPLA(2)) plays a key role in the release of arachidonic acid as the substrate of cyclooxygenase-l (COX-1) or COX-2. We found that the level of cPLA(2) mRNA was markedly elevated in the polyps and correlated with the polyp size in the small intestine of the Apc(Delta 716) knockout mouse, a model for human familial adenomatous polyposis. To determine the role of cPLA(2) in intestinal tumorigenesis, we then introduced a cPLA(2) gene mutation into Apc(Delta 716) mice. In the compound mutant mice, the size of the small intestinal polyps was reduced significantly, although the numbers remained unchanged. These results provide direct genetic evidence that cPLA(2) plays a key role in the expansion of polyps in the small intestine rather than in the initiation process. In contrast, colonic polyps were not affected in either size or number. Interestingly, group X sPLA(2) was constitutively expressed in the colon at much higher levels than in the small intestine. These results suggest that in the colon, group X sPLA(2) supplies arachidonic acid in both the normal epithelium and the polyps even in the absence of cPLA(2).	Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Biomed Genet, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Med, Dept Biochem & Mol Biol, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Taketo, MM (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Biomed Genet, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.		SONOSHITA, MASAHIRO/Q-1571-2019; Sasaki, Nobuya/F-6579-2012; Sonoshita, Masahiro/AAE-5516-2019; Uozumi, Nobuyuki/AAG-3252-2019	SONOSHITA, MASAHIRO/0000-0003-2890-336X; 				Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; Bingham CO, 1996, J BIOL CHEM, V271, P25936, DOI 10.1074/jbc.271.42.25936; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Chen QR, 1997, J BIOL CHEM, V272, P5952, DOI 10.1074/jbc.272.9.5952; Dennis EA, 2000, AM J RESP CRIT CARE, V161, pS32, DOI 10.1164/ajrccm.161.supplement_1.ltta-7; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; Dimberg J, 1998, ANTICANCER RES, V18, P3283; Fujishima H, 1999, P NATL ACAD SCI USA, V96, P4803, DOI 10.1073/pnas.96.9.4803; Fujita T, 1998, CANCER RES, V58, P4823; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; Gould KA, 1996, GENETICS, V144, P1769; HOLTZMAN MJ, 1991, AM REV RESPIR DIS, V143, P188, DOI 10.1164/ajrccm/143.1.188; Hull MA, 1999, BRIT J CANCER, V79, P1399, DOI 10.1038/sj.bjc.6690224; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 1999, J BIOL CHEM, V274, P31435, DOI 10.1074/jbc.274.44.31435; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Reddy ST, 1997, J BIOL CHEM, V272, P3231, DOI 10.1074/jbc.272.6.3231; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; RIGAS B, 1993, J LAB CLIN MED, V122, P518; Sawada H, 1999, EUR J BIOCHEM, V263, P826, DOI 10.1046/j.1432-1327.1999.00565.x; Shattuck-Brandt RL, 2000, GASTROENTEROLOGY, V118, P337, DOI 10.1016/S0016-5085(00)70216-2; Shindou H, 2000, BIOCHEM BIOPH RES CO, V271, P812, DOI 10.1006/bbrc.2000.2723; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; Soydan AS, 1997, EUR J CANCER, V33, P1508, DOI 10.1016/S0959-8049(97)00168-8; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Taketo MM, 1998, CLINICAL SIGNIFICANCE AND POTENTIAL OF SELECTIVE COX-2 INHIBITORS, P129; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; Yang VW, 1998, CANCER RES, V58, P1750	41	124	127	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34013	34016		10.1074/jbc.C000586200	http://dx.doi.org/10.1074/jbc.C000586200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10969066	hybrid			2022-12-25	WOS:000165095300002
J	Biessen, EAL; Valentijn, ARPM; De Vrueh, RLA; Van de Bilt, E; Sliedregt, LAJM; Prince, P; Bijsterbosch, MK; Van Boom, JH; Van der Marel, GA; Abrahams, PJ; Van Berkel, TJC				Biessen, EAL; Valentijn, ARPM; De Vrueh, RLA; Van de Bilt, E; Sliedregt, LAJM; Prince, P; Bijsterbosch, MK; Van Boom, JH; Van der Marel, GA; Abrahams, PJ; Van Berkel, TJC			Novel hepatotrophic prodrugs of the antiviral nucleoside 9-(2-phosphonylmethoxyethyl)adenine with improved pharmacokinetics and antiviral activity	FASEB JOURNAL			English	Article						asialoglycoprotein; HBV; HSV-1; drug targeting; liver	CHRONIC HEPATITIS-B; LOW-DENSITY-LIPOPROTEIN; HERPES-SIMPLEX VIRUS; POLY-L-LYSINE; ASIALOGLYCOPROTEIN RECEPTOR; LIVER-CELLS; HIGH-AFFINITY; LAMIVUDINE RESISTANCE; CLUSTER GALACTOSIDES; LIPOPHILIC PRODRUG	The device of new hepatotrophic prodrugs of the antiviral nucleoside 9-(2-phosphonylmethoxyethyl)adenine (PMEA) with specificity for the asialoglycoprotein receptor on parenchymal liver cells is described. PMEA was conjugated to bi- and trivalent cluster glycosides (K(GN)(2) and K-2 (GN)(3), respectively) with nanomolar affinity for the asialoglycoprotein receptor. The liver uptake of the PMEA prodrugs was more than 10-fold higher than that of the parent drug (52+/-6% and 62+/-3% vs. 4.8+/-0.7% of the injected dose for PMEA) and could be attributed for 90% to parenchymal cells. Accumulation of the PMEA prodrugs in extrahepatic tissue (e.g., kidney, skin) was substantially reduced. The ratio of parenchymal liver cell-to-kidney uptake-a measure of the prodrugs therapeutic window-was increased from 0.058 +/- 0.01 for PMEA to 1.86 +/- 0.57 for K(GN)(2)-PMEA and even 2.69 +/- 0.24 for K-2 (GN)(3)-PMEA. Apparently both glycosides have a similar capacity to redirect (antiviral) drugs to the liver. After cellular uptake, both PMEA prodrugs were converted into the parent drug, PMEA, during acidification of the lysosomal milieu (t(1/2) approximate to 100 min), and the released PMEA was rapidly translocated into the cytosol. The antiviral activity of the prodrugs in vitro was dramatically enhanced as compared to the parent drug (5- and 52-fold for K(GN)(2)-PMEA and K-2 (GN)(3)-PMEA, respectively). Given the 15-fold enhanced liver uptake of the prodrugs, we anticipate that the potency in vivo will be similarly increased. We conclude that PMEA prodrugs have been developed with greatly improved pharmacokinetics and therapeutic activity against viral infections that implicate the liver parenchyma (e.g., HBV). In addition, the significance of the above prodrug concept also extends to drugs that intervene in other liver disorders such as cholestasis and dyslipidemia.	Leiden Amsterdam Ctr Drug Res, Sylvius Labs, Div Biopharmaceut, Leiden, Netherlands; Leiden Univ, LIC, Dept Bioorgan Chem, Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Radiat Genet & Chem Mutagenesis, Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Biessen, EAL (corresponding author), Leiden Amsterdam Ctr Drug Res, Sylvius Labs, Div Biopharmaceut, Wassenaarseweg 72, Leiden, Netherlands.	biessen@lacdr.leidenuniv.nl	Van Berkel, Theo/ABD-7677-2021; de Vrueh, Remco/ABE-3053-2020					ABRAHAMS PJ, 1984, MOL CELL BIOL, V4, P2341, DOI 10.1128/MCB.4.11.2341; Angus PW, 1997, J GASTROEN HEPATOL, V12, P217, DOI 10.1111/j.1440-1746.1997.tb00411.x; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; Atkins M, 1998, J HEPATOL, V28, P169, DOI 10.1016/S0168-8278(98)80219-5; BIESSEN EAL, 1995, J MED CHEM, V38, P1538, DOI 10.1021/jm00009a014; BIESSEN EAL, 1994, J HEPATOL, V21, P806, DOI 10.1016/S0168-8278(94)80243-2; Bijsterbosch MK, 1996, BIOCHEM PHARMACOL, V52, P113, DOI 10.1016/0006-2952(96)00170-0; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BISCHOFBERGER N, 1994, ANTIMICROB AGENTS CH, V38, P2387, DOI 10.1128/AAC.38.10.2387; BURGESS JB, 1992, HEPATOLOGY, V15, P702, DOI 10.1002/hep.1840150425; CASTER WO, 1955, AM J PHYSIOL, V183, P317, DOI 10.1152/ajplegacy.1955.183.2.317; Cerenzia MT, 1996, HEPATOLOGY, V23, P657, DOI 10.1002/hep.510230401; CIHLAR T, 1995, ANTIMICROB AGENTS CH, V39, P117, DOI 10.1128/AAC.39.1.117; de Vrueh RLA, 1999, PHARMACEUT RES, V16, P1179, DOI 10.1023/A:1018933126885; DECLERCQ E, 1993, ADV VIRUS RES, V42, P1, DOI 10.1016/S0065-3527(08)60082-2; DIENSTAG JL, 1995, NEW ENGL J MED, V333, P1657, DOI 10.1056/NEJM199512213332501; EISENBERG C, 1991, J HEPATOL, V13, P305, DOI 10.1016/0168-8278(91)90073-K; ENRIQUEZ PM, 1995, BIOCONJUGATE CHEM, V6, P195, DOI 10.1021/bc00032a007; FIUME L, 1995, HEPATOLOGY, V22, P1072, DOI 10.1002/hep.1840220409; Fiume L, 1997, J VIRAL HEPATITIS, V4, P363, DOI 10.1046/j.1365-2893.1997.00067.x; FIUME L, 1986, BIOCHEM PHARMACOL, V35, P967, DOI 10.1016/0006-2952(86)90084-5; FOSTER SA, 1991, J BIOL CHEM, V266, P238; Hangeland JJ, 1997, ANTISENSE NUCLEIC A, V7, P141, DOI 10.1089/oli.1.1997.7.141; HOLY A, 1987, COLLECT CZECH CHEM C, V52, P2801, DOI 10.1135/cccc19872801; Honkoop P, 1997, J HEPATOL, V26, P1393, DOI 10.1016/S0168-8278(97)80476-X; Hoofnagle JH, 1997, J VIRAL HEPATITIS, V4, P41, DOI 10.1111/j.1365-2893.1997.tb00159.x; JANSEN RW, 1993, HEPATOLOGY, V18, P146, DOI 10.1016/0270-9139(93)90518-R; KROGSGAARD K, 1994, J HEPATOL, V21, P646, DOI 10.1016/S0168-8278(94)80114-2; KRUINING J, 1995, J HEPATOL, V22, P263, DOI 10.1016/0168-8278(95)80277-0; Kuznetsova E V, 1995, Mol Biol (Mosk), V29, P415; Lee RT, 1997, BIOCONJUGATE CHEM, V8, P762, DOI 10.1021/bc9700796; Ling R, 1996, HEPATOLOGY, V24, P711, DOI 10.1053/jhep.1996.v24.pm0008781347; MIDOUX P, 1990, BIOCHEM BIOPH RES CO, V167, P1044, DOI 10.1016/0006-291X(90)90628-Z; MYERS BM, 1995, HEPATOLOGY, V22, P1519, DOI 10.1016/0270-9139(95)90160-4; Naesens L, 1997, ANTIVIR CHEM CHEMOTH, V8, P1; NAESENS L, 1992, DRUG METAB DISPOS, V20, P747; NAGELKERKE JF, 1983, J BIOL CHEM, V258, P2221; Nevens F, 1997, GASTROENTEROLOGY, V113, P1258, DOI 10.1053/gast.1997.v113.pm9322520; RAHIL J, 1981, J AM CHEM SOC, V103, P1723, DOI 10.1021/ja00397a024; RENSEN PCN, 1995, NAT MED, V1, P221, DOI 10.1038/nm0395-221; SCHALM SW, 1995, J HEPATOL, V22, P52; Smeijsters LJJW, 1996, ANTIMICROB AGENTS CH, V40, P1584, DOI 10.1128/AAC.40.7.1584; Valentijn ARPM, 1997, TETRAHEDRON, V53, P759, DOI 10.1016/S0040-4020(96)01018-6; Van Berkel Theo J. C., 1994, Current Opinion in Lipidology, V5, P331, DOI 10.1097/00041433-199410000-00004; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282; VANBERKEL TJC, 1987, BIOCHEM J, V243, P715, DOI 10.1042/bj2430715; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011	47	15	31	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2000	14	12					1784	1792		10.1096/fj.99-0887com	http://dx.doi.org/10.1096/fj.99-0887com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973928	Bronze			2022-12-25	WOS:000089212400018
J	von Lintig, FC; Pilz, RB; Boss, GR				von Lintig, FC; Pilz, RB; Boss, GR			Quantitative determination of Rap 1 activation in cyclic nucleotide-treated HL-60 leukemic cells: lack of Rap 1 activation in variant cells	ONCOGENE			English	Article						Rap 1; HL-60; cells; cAMP; cGMP	DEPENDENT PROTEIN-KINASE; CGMP-INDUCED DIFFERENTIATION; HUMAN NEUTROPHILS; BINDING PROTEINS; GENE-EXPRESSION; GROWTH-FACTOR; PHASE-SEPARATION; EXCHANGE PROTEIN; HUMAN-PLATELETS; TRITON X-114	We have previously isolated variant HL-60 cells that are resistant to cGMP-induced differentiation and showed that they are deficient in proteolytic cleavage and/or carboxyl methylation of Rap 1A (J. Biol. Chem. 269, 32155-32161, 1994 and Oncogene 17, 2211-2233, 1998). We have now developed an enzyme-based method for assessing Rap 1 activation which is quantitative and provides a measurement of the per cent of Rap molecules in the active GTP-bound state. Using this method, we show that cAMP and cGMP analogs activate Rap 1 in parental HL-60 cells but not in the variant cells and that H-89, a cAMP-dependent protein kinase inhibitor, has no effect on cAMP-induced Rap 1 activation in parental cells. Thus, cAMP activation of Rap 1 in HL-60 cells is likely through a cAMP-regulated guanine nucleotide exchange factor (cAMP-GEF) and since cAMP does not activate Rap 1 in the variant cells, the data suggest that full post-translational processing of Rap 1 is necessary for cAMP-GEF activation of Rap 1. Activation of Rap 1 by cGMP analogs has not been previously found and suggests possible cross-talk between the NO/cGMP signal transduction pathway and Rap 1 signaling.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Boss, GR (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.			Boss, Gerry/0000-0002-9758-8714	NATIONAL CANCER INSTITUTE [R21CA081115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055586] Funding Source: NIH RePORTER; NCI NIH HHS [R21 CA81115] Funding Source: Medline; NIGMS NIH HHS [R01GM055586] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI M, 1992, ONCOGENE, V7, P323; ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; Asha H, 1999, EMBO J, V18, P605, DOI 10.1093/emboj/18.3.605; BOKOCH GM, 1990, BIOCHEM J, V267, P407, DOI 10.1042/bj2670407; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Bos JL, 1997, FEBS LETT, V410, P59, DOI 10.1016/S0014-5793(97)00324-4; BOSS GR, 1989, P NATL ACAD SCI USA, V86, P7174, DOI 10.1073/pnas.86.18.7174; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; CHAPLINSKI TJ, 1982, J CLIN INVEST, V70, P953, DOI 10.1172/JCI110707; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Egawa K, 1999, J BIOL CHEM, V274, P14306, DOI 10.1074/jbc.274.20.14306; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; GANONG BR, 1991, ANAL BIOCHEM, V193, P35, DOI 10.1016/0003-2697(91)90039-V; Gudi T, 1996, J BIOL CHEM, V271, P4597; Guha A, 1996, ONCOGENE, V12, P507; Guha A, 1997, ONCOGENE, V15, P2755, DOI 10.1038/sj.onc.1201455; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; HART PA, 1990, ONCOGENE, V5, P1099; HATA Y, 1991, J BIOL CHEM, V266, P6571; HATTORI S, 1987, MOL CELL BIOL, V7, P1999, DOI 10.1128/MCB.7.5.1999; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kurachi H, 1997, J BIOL CHEM, V272, P28081, DOI 10.1074/jbc.272.44.28081; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; Liu ML, 1998, ONCOGENE, V17, P2403, DOI 10.1038/sj.onc.1202456; M'Rabet L, 1998, BLOOD, V92, P2133, DOI 10.1182/blood.V92.6.2133.418k19_2133_2140; MURRAY MJ, 1983, CELL, V33, P749, DOI 10.1016/0092-8674(83)90017-X; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; ORITA S, 1993, J BIOL CHEM, V268, P25542; Pham N, 2000, CURR BIOL, V10, P555, DOI 10.1016/S0960-9822(00)00473-5; Pilz RB, 1997, CELL GROWTH DIFFER, V8, P53; PILZ RB, 1994, J BIOL CHEM, V269, P32155; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; Prigent SA, 1996, J BIOL CHEM, V271, P25639, DOI 10.1074/jbc.271.41.25639; QUILLIAM LA, 1991, J IMMUNOL, V147, P1628; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SCHEELE JS, 1994, J BIOL CHEM, V269, P18599; SCHEELE JS, 1995, P NATL ACAD SCI USA, V92, P1097, DOI 10.1073/pnas.92.4.1097; Scheele JS, 1998, ONCOGENE, V17, P2211, DOI 10.1038/sj.onc.1202137; Scheele JS, 1998, MOL CELL BIOCHEM, V185, P111, DOI 10.1023/A:1006834324419; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; SHIRATAKI H, 1991, J BIOL CHEM, V266, P20672; Suhasini M, 1998, MOL CELL BIOL, V18, P6983, DOI 10.1128/MCB.18.12.6983; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; YAMASHIRO S, 1993, LEUKEMIA RES, V17, P129, DOI 10.1016/0145-2126(93)90057-R; Yao H, 1998, J BIOL CHEM, V273, P8240, DOI 10.1074/jbc.273.14.8240; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	54	20	20	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 17	2000	19	35					4029	4034		10.1038/sj.onc.1203741	http://dx.doi.org/10.1038/sj.onc.1203741			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962559				2022-12-25	WOS:000088825300008
J	Pece, S; Gutkind, JS				Pece, S; Gutkind, JS			Signaling from E-cadherins to the MAPK pathway by the recruitment and activation of epidermal growth factor receptors upon cell-cell contact formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATENIN COMPLEX; PROTEIN INTERACTIONS; ADHESION; JUNCTIONS; INTEGRINS; SURVIVAL; LINE	E-cadherins are well characterized cell surface molecules expressed in epithelial cells, which play a major role in cell adhesion through the establishment of calcium-dependent hemophilic interactions at sites of cell-cell contacts. They are also integral components of morphogenetic programs controlling the maintenance of the structural and functional integrity of epithelia, Accumulated evidence indicates that the E-cadherin-mediated cell adhesion system is highly regulated from inside the cells by a number of intracellular signaling pathways. Recently available information suggests that E-cadherins may also play a role in the transduction of signals from the outside of the cell to the cytoplasm. However, the nature of the biochemical routes regulated by E-cadherins is still largely unknown. In this study, we set out to explore the possibility that E-cadherins may regulate the activity of MAPK, a key signaling pathway involved in cell fate decisions, upon the formation of cell-cell contacts among neighboring cells. By using an immortalized non-tumorigenic keratinocyte cell line, HaCat, as a model system, we provide evidence that the assembly of calcium-dependent adherens junctions leads to a rapid and remarkable increase in the state of activation of MAPK and that this event is mediated by E-cadherins. Furthermore, we found that E-cadherins stimulate the MAPK pathway through the ligand-independent activation of epidermal growth factor receptors and the consequent activation of a biochemical route leading to the stimulation of MAPKs. These findings suggest that E-cadherins can initiate outside-in signal transducing pathways through the engagement of tyrosine kinase receptors for epidermal growth factor, thus providing a novel molecular mechanism whereby these cell adhesion molecules may ultimately control the fate of normal and transformed epithelial cells.	NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Gutkind, JS (corresponding author), NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bldg 30,Rm 211,9000 Rockville Pike, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/A-1053-2009; Pece, Salvatore/B-9609-2013; Gutkind, J. Silvio/J-1201-2016	Pece, Salvatore/0000-0003-1764-3929; Gutkind, J. Silvio/0000-0002-5150-4482	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551, ZIADE000558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551, Z01DE000558] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Braga VMM, 1999, J CLIN PATHOL-MOL PA, V52, P197, DOI 10.1136/mp.52.4.197; Breitkreutz D, 1998, EUR J CELL BIOL, V75, P273, DOI 10.1016/S0171-9335(98)80123-4; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; KARTENBECK J, 1991, J CELL BIOL, V113, P881, DOI 10.1083/jcb.113.4.881; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kinch M S, 1997, Cell Adhes Commun, V4, P425, DOI 10.3109/15419069709004459; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHIOZAKI H, 1995, BRIT J CANCER, V71, P250, DOI 10.1038/bjc.1995.52; Steinberg MS, 1999, CURR OPIN CELL BIOL, V11, P554, DOI 10.1016/S0955-0674(99)00027-7; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; VOLBERG T, 1986, J CELL BIOL, V102, P1832, DOI 10.1083/jcb.102.5.1832; Zhu AJ, 1999, P NATL ACAD SCI USA, V96, P6728, DOI 10.1073/pnas.96.12.6728	26	277	290	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41227	41233		10.1074/jbc.M006578200	http://dx.doi.org/10.1074/jbc.M006578200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10969083	hybrid			2022-12-25	WOS:000166114600076
J	Yap, CL; Hughan, SC; Cranmer, SL; Nesbitt, WS; Rooney, MM; Giuliano, S; Kulkarni, S; Dopheide, SM; Yuan, YP; Salem, HH; Jackson, SP				Yap, CL; Hughan, SC; Cranmer, SL; Nesbitt, WS; Rooney, MM; Giuliano, S; Kulkarni, S; Dopheide, SM; Yuan, YP; Salem, HH; Jackson, SP			Synergistic adhesive interactions and signaling mechanisms operating between platelet glycoprotein Ib/IX and integrin alpha(IIB)beta(3) - Studies in human platelets and transfected Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; VONWILLEBRAND-FACTOR-BINDING; IIB-IIIA; SHEAR-STRESS; TYROSINE PHOSPHORYLATION; THROMBUS FORMATION; IIB/IIIA COMPLEX; FLOW CONDITIONS; MOLECULAR-BASIS; DISTINCT ROLES	This study investigates three aspects of the adhesive interaction operating between platelet glycoprotein Ib/IX and integrin alpha (IIb)beta (3). These include the following: 1) examining the sufficiency of GPIb/IX and integrin alpha (IIb)beta (3) to mediate irreversible cell adhesion on immobilized von Willebrand factor (vWf) under flow; 2) the ability of the vWf-GPIb interaction to induce integrin alpha (IIb)beta (3) activation independent of endogenous platelet stimuli; and 3) the identification of key second messengers linking the vWf-GPIb/IX interaction to integrin alpha (IIb)beta (3) activation. By using Chinese hamster ovary cells transfected with GPIb/IX and integrin alpha (IIb)beta (3), we demonstrate that these receptors are both necessary and sufficient to mediate irreversible cell adhesion under flow, wherein GPIb/M mediates cell tethering and rolling on immobilized vWf, and integrin alpha (IIb)beta (3) mediates cell arrest, Moreover, we demonstrate direct signaling between GPIb/M and integrin alpha (IIb)beta (3). Studies on human platelets demonstrated that vWf binding to GPIb/M is able to induce integrin alpha (IIb)beta (3) activation independent of endogenous platelet stimuli under both static and physiological flow conditions (150-1800 s(-1)). Analysis of the key second messengers linking the vWf-GPIb interaction to integrin alpha (IIb)beta (3) activation demonstrated that the first step in the activation process involves calcium release from internal stores, whereas transmembrane calcium influx is a secondary event potentiating integrin alpha (IIb)beta (3) activation.	Box HIll Hosp, Monash Med Sch, Dept Med, Australian Ctr Blood Dis, Box Hill, Vic 3128, Australia	Box Hill Hospital; Monash University	Jackson, SP (corresponding author), Box HIll Hosp, Monash Med Sch, Dept Med, Australian Ctr Blood Dis, Arnold St, Box Hill, Vic 3128, Australia.	Shaun.Jackson@med.monash.edu.au		Jackson, Shaun/0000-0002-4750-1991; Nesbitt, Warwick/0000-0001-5644-7053				Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; CHEN YP, 1995, BLOOD, V86, P2606, DOI 10.1182/blood.V86.7.2606.bloodjournal8672606; CHOW TW, 1992, BLOOD, V80, P113; COOKE BM, 1993, MICROVASC RES, V45, P33, DOI 10.1006/mvre.1993.1004; Cranmer SL, 1999, J BIOL CHEM, V274, P6097, DOI 10.1074/jbc.274.10.6097; Daniel JL, 1998, J BIOL CHEM, V273, P2024, DOI 10.1074/jbc.273.4.2024; DAVIS PD, 1992, J MED CHEM, V35, P994, DOI 10.1021/jm00084a004; DEMARCO L, 1985, J CLIN INVEST, V75, P1198, DOI 10.1172/JCI111816; FRANCESCONI M, 1995, BIOCHEM BIOPH RES CO, V214, P102, DOI 10.1006/bbrc.1995.2262; FRANCESCONI MA, 1993, THROMB HAEMOSTASIS, V70, P697; Gachet C, 1997, THROMB HAEMOSTASIS, V78, P271; GRALNICK HR, 1985, J CLIN INVEST, V75, P19; Gu MY, 1999, J CELL BIOL, V147, P1085, DOI 10.1083/jcb.147.5.1085; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; HANDA M, 1986, J BIOL CHEM, V261, P2579; Hechler B, 1998, BLOOD, V92, P152, DOI 10.1182/blood.V92.1.152.413k27_152_159; Heraud JM, 1998, J BIOL CHEM, V273, P17817, DOI 10.1074/jbc.273.28.17817; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; IKEDA Y, 1993, THROMB HAEMOSTASIS, V69, P496; Ingall AH, 1999, J MED CHEM, V42, P213, DOI 10.1021/jm981072s; JACKSON SP, 1994, J BIOL CHEM, V269, P27093; Jin JG, 1998, J BIOL CHEM, V273, P2030, DOI 10.1074/jbc.273.4.2030; Kermode JC, 1996, BLOOD CELL MOL DIS, V22, P238, DOI 10.1006/bcmd.1996.0104; KROLL MH, 1991, J CLIN INVEST, V88, P1568, DOI 10.1172/JCI115468; Kulkarni S, 2000, J CLIN INVEST, V105, P783, DOI 10.1172/JCI7569; Kuwahara M, 1999, BLOOD, V94, P1149, DOI 10.1182/blood.V94.4.1149.416k18_1149_1155; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEY K, 1991, BLOOD, V77, P2553; MacKenzie AB, 1996, J BIOL CHEM, V271, P2879, DOI 10.1074/jbc.271.6.2879; MOAKE JL, 1988, BLOOD, V71, P1366; MOLNAR J, 1961, ARCH BIOCHEM BIOPHYS, V93, P353, DOI 10.1016/0003-9861(61)90278-8; MONTGOMERY RR, 1978, J CLIN INVEST, V61, P1498, DOI 10.1172/JCI109070; MORITZ MW, 1983, J LAB CLIN MED, V101, P537; NIIYA K, 1987, BLOOD, V70, P475; ODA A, 1995, THROMB HAEMOSTASIS, V74, P736; Ruggeri ZM, 1993, CURR OPIN CELL BIOL, V5, P898, DOI 10.1016/0955-0674(93)90041-N; RUGGERI ZM, 1985, SEMIN HEMATOL, V22, P203; Ruggeri ZM, 1999, BLOOD, V94, P172, DOI 10.1182/blood.V94.1.172.413k17_172_178; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAGE SO, 1987, J BIOL CHEM, V262, P16364; SAKARIASSEN KS, 1986, BRIT J HAEMATOL, V63, P681, DOI 10.1111/j.1365-2141.1986.tb07552.x; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; Schaffner-Reckinger E, 1998, J BIOL CHEM, V273, P12623, DOI 10.1074/jbc.273.20.12623; Shattil SJ, 1999, THROMB HAEMOSTASIS, V82, P318; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WEISS HJ, 1991, ANN NY ACAD SCI, V614, P125, DOI 10.1111/j.1749-6632.1991.tb43698.x; WEISS HJ, 1986, BLOOD, V67, P322; WEISS HJ, 1971, NEW ENGL J MED, V285, P369, DOI 10.1056/NEJM197108122850703; Yuan YP, 1997, J BIOL CHEM, V272, P21847, DOI 10.1074/jbc.272.35.21847; Yuan YP, 1999, J BIOL CHEM, V274, P36241, DOI 10.1074/jbc.274.51.36241; Zaffran Y, 2000, J BIOL CHEM, V275, P16779, DOI 10.1074/jbc.275.22.16779	55	91	93	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41377	41388		10.1074/jbc.M005590200	http://dx.doi.org/10.1074/jbc.M005590200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10967111	hybrid			2022-12-25	WOS:000166114600095
J	Inoue, S; Tanaka, K; Arisaka, F; Kimura, S; Ohtomo, K; Mizuno, S				Inoue, S; Tanaka, K; Arisaka, F; Kimura, S; Ohtomo, K; Mizuno, S			Silk fibroin of Bombyx mori is secreted, assembling a high molecular mass elementary unit consisting of H-chain, L-chain, and P25, with a 6 : 6 : 1 molar ratio	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; AMINO-ACID-SEQUENCE; ENDOPLASMIC-RETICULUM; SUBUNIT COMBINATION; IGM POLYMERIZATION; LIGHT-CHAINS; CELL-SURFACE; TRANSPORT; PROTEIN; IDENTIFICATION	Silk fibroin produced by the silkworm Bombyx mori consists of a heavy chain, a light chain, and a glycoprotein, P25. The heavy and light chains are linked by a disulfide bond, and P25 associates with disulfide-linked heavy and light chains by noncovalent interactions. Quantitative enzyme-linked immunosorbent assay revealed that molar ratios of the heavy chain, light chain, and P25 were 6:6:1, both in cocoons and in fibroin secreted into the lumen of posterior silk gland. Trace amounts of fibroin produced by three "naked pupa" mutants of B. mori lacked the light chain, but the molar ratio of heavy chain and P25 was also 6:1. Gel filtration chromatography and sedimentation equilibrium analysis demonstrated that a large protein complex of approximately 2.3 MDa, designated an elementary unit of fibroin having 6:6:1 molar ratios of the heavy chain, light chain, and P25, existed in posterior silk gland cells. Inaccessibility of biotinylated concanavalin A to the native elementary unit and partial dissociation of the elementary unit after incubation with excess N-glycosidase F or endoglycosidase H suggest that a single molecule of P25 is located internally and plays an important role in maintaining integrity of the complex.	Tohoku Univ, Grad Sch Agr Sci, Dept Mol & Cell Biol, Mol Biol Lab,Aoba Ku, Sendai, Miyagi 9818555, Japan; Tokyo Inst Technol, Dept Life Sci, Fac Biosci & Bioengn, Yokohama, Kanagawa 2268501, Japan; Chiba Univ, Fac Sci, Dept Biol, Chiba 2638522, Japan	Tohoku University; Tokyo Institute of Technology; Chiba University	Mizuno, S (corresponding author), Nihon Univ, Coll Bioresource Sci, Dept Agr & Biol Chem, 1866 Kameino, Fujisawa, Kanagawa, Japan.	s-mizuno@brs.nihon-u.ac.jp						AKAI H, 1971, EXP CELL RES, V69, P219, DOI 10.1016/0014-4827(71)90329-6; *APPL BIOS INC, 1985, APPL BIOS US B, V14, P23; BORNEMANN KD, 1995, P NATL ACAD SCI USA, V92, P4912, DOI 10.1073/pnas.92.11.4912; BRENCKLE R, 1980, ARCH BIOCHEM BIOPHYS, V201, P160, DOI 10.1016/0003-9861(80)90499-3; Cals MM, 1996, MOL IMMUNOL, V33, P15, DOI 10.1016/0161-5890(95)00132-8; CHEVILLARD M, 1986, NUCLEIC ACIDS RES, V14, P6341, DOI 10.1093/nar/14.15.6341; Chevillard M., 1986, SERICOLOGIA, V26, P435; COPELAND CS, 1986, J CELL BIOL, V103, P1179, DOI 10.1083/jcb.103.4.1179; COPELAND CS, 1988, CELL, V53, P197, DOI 10.1016/0092-8674(88)90381-9; COUBLE P, 1987, DEV BIOL, V124, P431, DOI 10.1016/0012-1606(87)90496-9; de Lalla C, 1998, MOL IMMUNOL, V35, P837, DOI 10.1016/S0161-5890(98)00073-X; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; FAYE L, 1986, EUR J BIOCHEM, V158, P655, DOI 10.1111/j.1432-1033.1986.tb09803.x; GAMO T, 1985, Journal of Sericultural Science of Japan, V54, P412; GARFIN DE, 1990, METHOD ENZYMOL, V182, P425; HYODO A, 1980, JPN J GENET, V55, P297, DOI 10.1266/jjg.55.297; Isidoro C, 1996, J BIOL CHEM, V271, P26138, DOI 10.1074/jbc.271.42.26138; KALB AJ, 1968, BIOCHIM BIOPHYS ACTA, V168, P366, DOI 10.1016/0005-2795(68)90161-X; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; MACHAMER CE, 1985, MOL CELL BIOL, V5, P3074, DOI 10.1128/MCB.5.11.3074; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MARUYAMA K, 1984, J BIOCHEM, V95, P1423, DOI 10.1093/oxfordjournals.jbchem.a134750; MORI K, 1995, J MOL BIOL, V251, P217, DOI 10.1006/jmbi.1995.0429; OSAWA T, 1987, ANNU REV BIOCHEM, V56, P21, DOI 10.1146/annurev.biochem.56.1.21; OYAMA F, 1984, J BIOCHEM, V96, P1689, DOI 10.1093/oxfordjournals.jbchem.a135001; Reddy PS, 1998, BIOESSAYS, V20, P546, DOI 10.1002/(SICI)1521-1878(199807)20:7<546::AID-BIES5>3.0.CO;2-I; ROBBINS PW, 1984, J BIOL CHEM, V259, P7577; SHIMURA K, 1982, Journal of Sericultural Science of Japan, V51, P20; SHIMURA K, 1983, EXPERIENTIA, V39, P455, DOI 10.1007/BF01965160; TAKEI F, 1984, JPN J GENET, V59, P307, DOI 10.1266/jjg.59.307; TAKEI F, 1984, J CELL BIOL, V99, P2005, DOI 10.1083/jcb.99.6.2005; TAKEI F, 1987, J CELL BIOL, V105, P175, DOI 10.1083/jcb.105.1.175; TANAKA K, 1993, J BIOCHEM-TOKYO, V114, P1; Tanaka K, 1999, BBA-PROTEIN STRUCT M, V1432, P92, DOI 10.1016/S0167-4838(99)00088-6; Tanaka K, 1999, INSECT BIOCHEM MOLEC, V29, P269, DOI 10.1016/S0965-1748(98)00135-0; TARENTINO AL, 1990, J BIOL CHEM, V265, P6961; WANG JL, 1971, P NATL ACAD SCI USA, V68, P1130, DOI 10.1073/pnas.68.6.1130; WORMALD MR, 1991, EUR J BIOCHEM, V198, P131, DOI 10.1111/j.1432-1033.1991.tb15995.x; YAMAGUCHI K, 1989, J MOL BIOL, V210, P127, DOI 10.1016/0022-2836(89)90295-7; Yamamoto K, 1998, METH MOL B, V76, P35; YAMAMOTO K, 1981, BIOCHEMISTRY-US, V20, P5894, DOI 10.1021/bi00523a037; Zurovec M, 1998, J BIOL CHEM, V273, P15423, DOI 10.1074/jbc.273.25.15423	43	477	532	5	128	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40517	40528		10.1074/jbc.M006897200	http://dx.doi.org/10.1074/jbc.M006897200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10986287	hybrid			2022-12-25	WOS:000166039500097
J	Filipenko, NR; Waisman, DM				Filipenko, NR; Waisman, DM			Characterization of the Ca2+-binding sites of annexin II tetramer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-BINDING PROTEIN; DIRECTED MUTAGENESIS; PLASMINOGEN; ACTIVATION; CALPACTIN; CALCIUM; ACTIN	Annexin II heterotetramer (AIIt) is a multifunctional Ca2+-binding protein composed of two 11-kDa subunits and two annexin II subunits, The annexin II subunit contains three type II and two type III Ca2+-binding sites which are thought to regulate the interaction of AIIt with anionic phospholipid, F-actin, and heparin, In the present study we utilized site-directed mutagenesis to create AIIt mutants with inactive type III (TM AIIt), type II (CM AIIt), and both type II and III Ca2+-binding sites (TCM AIIt), Surprisingly, we found that in the presence of Ca2+, the TM, CM, and TCM AIIt bound phospholipid and F-actin with similar affinity to the wild type AIIt (WT AIIt). Furthermore, the TCM mutant, and to a lesser extent the TM and CM AIIt displayed dose-dependent Ca2+-independent phospholipid aggregation and binding. While the TM and CM AIIt demonstrated Ca2+-dependent binding to F-actin, the binding of the TCM AIIt was Ca2+-independent. These results suggest that the type II or type III Ca2+-binding sites do not directly participate in anionic phospholipid or F-actin binding, We therefore propose that in the absence of Ca2+, the type II and type III Ca2+-binding sites of AIIt stabilize a conformation of AIIt that is unfavorable for binding phospholipid and F-actin, Ca2+ binding to these sites, or the inactivation of these Ca2+-binding sites by site-directed mutagenesis, results in a conformational change that promotes binding to anionic phospholipid and F-actin. Since the TM, CM, and TCM AIIt require Ca2+ for binding to heparin, we also propose that novel Ca2+-binding sites regulate this binding event.	Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Oncol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary	Waisman, DM (corresponding author), Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Canc Biol Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.			Waisman, David/0000-0002-5097-9662	NATIONAL CANCER INSTITUTE [R01CA078639] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA78639] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Donnelly SR, 1997, CELL MOL LIFE SCI, V53, P533, DOI 10.1007/s000180050068; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; FOLLENIUSWUND A, 1993, BIOCHEM MOL BIOL INT, V29, P653; GEISOW MJ, 1986, NATURE, V320, P636, DOI 10.1038/320636a0; Gerke V, 1997, BBA-MOL CELL RES, V1357, P129, DOI 10.1016/S0167-4889(97)00038-4; GLENNEY J, 1986, J BIOL CHEM, V261, P7247; IKEBUCHI NW, 1990, J BIOL CHEM, V265, P3392; JOST M, 1992, EUR J BIOCHEM, V207, P923, DOI 10.1111/j.1432-1033.1992.tb17125.x; JOST M, 1994, BIOCHEM J, V298, P553, DOI 10.1042/bj2980553; Kang HM, 1997, BIOCHEMISTRY-US, V36, P2041, DOI 10.1021/bi962569b; Kassam G, 1997, J BIOL CHEM, V272, P15093, DOI 10.1074/jbc.272.24.15093; Kassam G, 1998, BIOCHEMISTRY-US, V37, P16958, DOI 10.1021/bi981713l; Kassam G, 1998, J BIOL CHEM, V273, P4790, DOI 10.1074/jbc.273.8.4790; MOSS SE, 1995, NATURE, V378, P446, DOI 10.1038/378446a0; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; REGNOUF F, 1991, J NEUROCHEM, V56, P1985, DOI 10.1111/j.1471-4159.1991.tb03457.x; Siever DA, 1997, INT J BIOCHEM CELL B, V29, P1219, DOI 10.1016/S1357-2725(97)00057-5; SWAIRJO MA, 1995, NAT STRUCT BIOL, V2, P968, DOI 10.1038/nsb1195-968; SWAIRJO MA, 1994, ANNU REV BIOPH BIOM, V23, P193, DOI 10.1146/annurev.bb.23.060194.001205; THIEL C, 1991, J BIOL CHEM, V266, P14732; THIEL C, 1991, FEBS LETT, V285, P59, DOI 10.1016/0014-5793(91)80724-H; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; WENG XW, 1993, PROTEIN SCI, V2, P448	24	14	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38877	38884		10.1074/jbc.M004125200	http://dx.doi.org/10.1074/jbc.M004125200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10980196	hybrid			2022-12-25	WOS:000165739800100
J	Vujcic, S; Halmekyto, M; Diegelman, P; Gan, G; Kramer, DL; Janne, J; Porter, CW				Vujcic, S; Halmekyto, M; Diegelman, P; Gan, G; Kramer, DL; Janne, J; Porter, CW			Effects of conditional overexpression of spermidine/spermine N-1-acetyltransferase on polyamine pool dynamics, cell growth, and sensitivity to polyamine analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE DECARBOXYLASE; SPERMINE N-1-ACETYLTRANSFERASE; IRREVERSIBLE INHIBITION; ORNITHINE DECARBOXYLASE; INDUCED INCREASES; GENE-EXPRESSION; MELANOMA-CELLS; L1210 CELLS; N1-ACETYLTRANSFERASE; DERIVATIVES	Acetylation of polyamines by spermidine/spermine N-1-acetyltransferase (SSAT) has been implicated in their degradation and/or export out of the cell, The relationship of SSAT to polyamine pool dynamics and cell growth is not yet clearly understood. MCF-7 human breast carcinoma cells were transfected with tetracycline-regulated (Tet-off) SSAT human cDNA or murine gene. Doxycycline removal for >2 days caused a similar to 20-fold increase in SSAT RNA and a similar to 10-fold increase in enzyme activity. After 4 days, intracellular putrescine and spermidine pools were markedly lowered, and cell growth was inhibited, Growth inhibition could not be prevented with exogenous polyamines due to a previously unrecognized ability of SSAT to rapidly acetylate influxing polyamines and thereby prevent restoration of the endogenous pools. Instead, cells accumulated high levels of N-1-acetylspermidine, N-1-acetylspermine, and N-1,N-12-diacetylspermine, a metabolite not previously reported in mammalian cells. Doxycycline deprivation before treatment with N-1,N-11-diethylnorspermine markedly increased analog induction of SSAT mRNA and activity and enhanced growth sensitivity to the analog by similar to 100-fold. Overall, the findings demonstrate that conditional overexpression of SSAT lowers polyamine pools, inhibits cell growth and markedly enhances growth sensitivity to certain analogs, The enzyme also plays a remarkably efficient role in maintaining polyamine pool homeostasis during challenges with exogenous polyamines.	Roswell Pk Canc Inst, Grace Canc Drug Ctr, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Porter, CW (corresponding author), Roswell Pk Canc Inst, Grace Canc Drug Ctr, Elm & Carlton Sts, Buffalo, NY 14263 USA.				NCI NIH HHS [CA16056, CA76428, CA22153] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076428, R01CA022153, P30CA016056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alhonen L, 1998, J BIOL CHEM, V273, P1964, DOI 10.1074/jbc.273.4.1964; ALHONENHONGISTO L, 1982, FEBS LETT, V145, P82; BERGERON RJ, 1994, J MED CHEM, V37, P3464, DOI 10.1021/jm00047a004; Bergeron RJ, 1997, J MED CHEM, V40, P1475, DOI 10.1021/jm960849j; BEY P, 1985, J MED CHEM, V28, P1, DOI 10.1021/jm00379a001; BOLKENIUS FN, 1981, INT J BIOCHEM, V13, P287, DOI 10.1016/0020-711X(81)90080-X; CASERO RA, 1990, BIOCHEM J, V270, P615, DOI 10.1042/bj2700615; CASERO RA, 1989, CANCER RES, V49, P3829; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; COLEMAN CS, 1995, BIOCHEMISTRY-US, V34, P13423, DOI 10.1021/bi00041a020; DANZIN C, 1990, BIOCHEM PHARMACOL, V40, P1499, DOI 10.1016/0006-2952(90)90446-R; ERWIN BG, 1986, BIOCHEM J, V238, P581, DOI 10.1042/bj2380581; FogelPetrovic M, 1996, BIOCHEMISTRY-US, V35, P14436, DOI 10.1021/bi9612273; FOGELPETROVIC M, 1993, BIOCHIM BIOPHYS ACTA, V1216, P255, DOI 10.1016/0167-4781(93)90152-4; FogelPetrovic M, 1996, FEBS LETT, V391, P89, DOI 10.1016/0014-5793(96)00710-7; FOGELPETROVIC M, 1993, J BIOL CHEM, V268, P19118; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; HESSELS J, 1990, BIOCHEM J, V266, P843; HIRAMATSU K, 1995, J BIOCHEM-TOKYO, V117, P107, DOI 10.1093/oxfordjournals.jbchem.a124694; KABRA PM, 1986, J CHROMATOGR, V380, P19, DOI 10.1016/S0378-4347(00)83621-X; KRAMER DL, 1989, BIOCHEM J, V259, P325, DOI 10.1042/bj2590325; LIBBY PR, 1991, ARCH BIOCHEM BIOPHYS, V284, P238, DOI 10.1016/0003-9861(91)90291-P; LIBBY PR, 1987, BIOCHEM BIOPH RES CO, V144, P528, DOI 10.1016/S0006-291X(87)80541-7; LIBBY PR, 1989, BIOCHEM PHARMACOL, V38, P1435, DOI 10.1016/0006-2952(89)90182-2; LIBBY PR, 1989, CANCER RES, V49, P6226; MAMONT PS, 1978, BIOCHEM BIOPH RES CO, V81, P58, DOI 10.1016/0006-291X(78)91630-3; McCloskey DE, 1999, J BIOL CHEM, V274, P6175, DOI 10.1074/jbc.274.10.6175; McCloskey DE, 2000, J BIOL CHEM, V275, P28708, DOI 10.1074/jbc.M004120200; NOTARANGELO A, 1997, FOCUS, V19, P58; PARRY L, 1995, BIOCHEMISTRY-US, V34, P2701, DOI 10.1021/bi00008a038; PARRY L, 1995, BIOCHEM J, V305, P451, DOI 10.1042/bj3050451; PEGG AE, 1989, J BIOL CHEM, V264, P11744; Pietila M, 1997, J BIOL CHEM, V272, P18746, DOI 10.1074/jbc.272.30.18746; Porter C. W., 1992, V62, P301; PORTER CW, 1991, CANCER RES, V51, P3715; QUEMENER V, 1992, ANTICANCER RES, V12, P1447; REGENASS U, 1994, CANCER RES, V54, P3210; SEILER N, 1987, CAN J PHYSIOL PHARM, V65, P2024, DOI 10.1139/y87-317; SHAPPELL NW, 1992, ANTICANCER RES, V12, P1083; TAMARA A, 1995, CANCER RES, V55, P3500; VARGIU C, 1994, FEBS LETT, V355, P163, DOI 10.1016/0014-5793(94)01183-4; Woolridge DP, 1999, BIOCHEM J, V340, P753, DOI 10.1042/0264-6021:3400753; XIAO L, 1991, BIOCHEM BIOPH RES CO, V179, P407, DOI 10.1016/0006-291X(91)91385-P	44	107	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38319	38328		10.1074/jbc.M003270200	http://dx.doi.org/10.1074/jbc.M003270200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10978316	hybrid			2022-12-25	WOS:000165739800027
J	Dobson, AW; Xu, Y; Kelley, MR; LeDoux, SP; Wilson, GL				Dobson, AW; Xu, Y; Kelley, MR; LeDoux, SP; Wilson, GL			Enhanced mitochondrial DNA repair and cellular survival after oxidative stress by targeting the human 8-oxoguanine glycosylase repair enzyme to mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSONS-DISEASE; ALZHEIMER-DISEASE; NUCLEAR-DNA; HUMAN-CELLS; DAMAGE; ALKYLATION; EXPRESSION; MUTATIONS; APOPTOSIS; SEQUENCE	Oxidative damage to mitochondrial DNA (mtDNA) has been implicated as a causative factor in many disease processes and in aging. We have recently discovered that different cell types vary in their capacity to repair this damage, and this variability correlates with their ability to withstand oxidative stress. To explore strategies to enhance repair of oxidative lesions in mtDNA, we have constructed a vector containing a mitochondrial transport sequence upstream of the sequence for human 8-oxoguanine DNA glycosylase. This enzyme is the glycosylase/AP lyase that participates in repair of purine lesions, such as 8-oxoguanine. Western blot analysis confirmed that this recombinant protein was targeted to mitochondria, Enzyme activity assays showed that mitochondrial extracts from cells transfected with the construct had increased enzyme activity compared with cells transfected with vector only, whereas nuclear enzyme activity was not changed. Repair assays showed that there was enhanced repair of oxidative lesions in mtDNA, Additional studies revealed that this augmented repair led to enhanced cellular viability as determined by reduction of the tetrazolium compound to formazan, trypan blue dye exclusion, and clonogenic assays. Therefore, targeting of DNA repair enzymes to mitochondria may be a viable approach for the protection of cells against some of the deleterious effects of oxidative stress.	Univ S Alabama, Coll Med, Dept Cell Biol & Neurosci, Mobile, AL 36688 USA; Indiana Univ, Sch Med, Wells Ctr Pediat Res, Dept Pediat, Indianapolis, IN 46202 USA	University of South Alabama; Indiana University System; Indiana University-Purdue University Indianapolis	Wilson, GL (corresponding author), Univ S Alabama, Coll Med, Dept Cell Biol & Neurosci, Mobile, AL 36688 USA.			Kelley, Mark/0000-0002-6120-9532	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003456] Funding Source: NIH RePORTER; NIA NIH HHS [AG12422] Funding Source: Medline; NIEHS NIH HHS [ES05865, ES03456] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bandmann O, 1997, J NEUROL, V244, P262, DOI 10.1007/s004150050082; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; CORRALDEBRINSKI M, 1994, GENOMICS, V23, P471, DOI 10.1006/geno.1994.1525; Croteau DL, 1997, J BIOL CHEM, V272, P25409, DOI 10.1074/jbc.272.41.25409; Davis RE, 1997, P NATL ACAD SCI USA, V94, P4526, DOI 10.1073/pnas.94.9.4526; DRIGGERS WJ, 1993, J BIOL CHEM, V268, P22042; Driggers WJ, 1997, NUCLEIC ACIDS RES, V25, P4362, DOI 10.1093/nar/25.21.4362; FREI B, 1986, BIOCHEMISTRY-US, V25, P4438, DOI 10.1021/bi00363a040; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Hollensworth SB, 2000, FREE RADICAL BIO MED, V28, P1161, DOI 10.1016/S0891-5849(00)00214-8; Hudson EK, 1998, FREE RADICAL RES, V29, P573, DOI 10.1080/10715769800300611; HUTCHIN T, 1995, P NATL ACAD SCI USA, V92, P6892, DOI 10.1073/pnas.92.15.6892; LeDoux SP, 1998, GLIA, V24, P304, DOI 10.1002/(SICI)1098-1136(199811)24:3<304::AID-GLIA4>3.3.CO;2-J; LeDoux SP, 1999, MUTAT RES-DNA REPAIR, V434, P149, DOI 10.1016/S0921-8777(99)00026-9; MECOCCI P, 1994, ANN NEUROL, V36, P747, DOI 10.1002/ana.410360510; Nishioka K, 1999, MOL BIOL CELL, V10, P1637, DOI 10.1091/mbc.10.5.1637; Ozawa T, 1997, PHYSIOL REV, V77, P425, DOI 10.1152/physrev.1997.77.2.425; Papa S, 1997, MOL CELL BIOCHEM, V174, P305, DOI 10.1023/A:1006873518427; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; Rotig A, 1996, DIABETES METAB, V22, P291; Schapira AHV, 1999, BBA-BIOENERGETICS, V1410, P159, DOI 10.1016/S0005-2728(98)00164-9; Schnopp NM, 1996, CLIN NEUROPATHOL, V15, P348; Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755; SHEN CC, 1995, MUTAT RES-DNA REPAIR, V337, P19, DOI 10.1016/0921-8777(95)00008-8; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; ShimodaMatsubayashi S, 1996, BIOCHEM BIOPH RES CO, V226, P561, DOI 10.1006/bbrc.1996.1394; Singh KK, 1999, ONCOGENE, V18, P6641, DOI 10.1038/sj.onc.1203056; SLUPPHAUG G, 1993, NUCLEIC ACIDS RES, V21, P2579, DOI 10.1093/nar/21.11.2579; Souza-Pinto NC, 1999, NUCLEIC ACIDS RES, V27, P1935, DOI 10.1093/nar/27.8.1935; Takao M, 1998, NUCLEIC ACIDS RES, V26, P2917, DOI 10.1093/nar/26.12.2917; Tamura T, 1996, BIOCHEM BIOPH RES CO, V222, P659, DOI 10.1006/bbrc.1996.0800; TANHAUSER SM, 1995, J BIOL CHEM, V270, P24769, DOI 10.1074/jbc.270.42.24769; THOR H, 1982, J BIOL CHEM, V257, P2419; Vialettes B, 1997, DIABETES METAB, V23, P52; Wei YH, 1998, ANN NY ACAD SCI, V854, P155, DOI 10.1111/j.1749-6632.1998.tb09899.x; Wilson GL, 1997, DIABETES, V46, P1291, DOI 10.2337/diabetes.46.8.1291; Wooten GF, 1997, ANN NEUROL, V41, P265, DOI 10.1002/ana.410410218; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; Zastawny TH, 1998, FREE RADICAL BIO MED, V24, P722, DOI 10.1016/S0891-5849(97)00331-6; Zharkov DO, 2000, J BIOL CHEM, V275, P28607, DOI 10.1074/jbc.M002441200	42	115	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37518	37523		10.1074/jbc.M000831200	http://dx.doi.org/10.1074/jbc.M000831200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10982789	hybrid			2022-12-25	WOS:000165618700031
J	Dupraz, P; Cottet, S; Hamburger, F; Dolci, W; Felley-Bosco, E; Thorens, B				Dupraz, P; Cottet, S; Hamburger, F; Dolci, W; Felley-Bosco, E; Thorens, B			Dominant negative MyD88 proteins inhibit interleukin-1 beta/interferon-gamma-mediated induction of nuclear factor kappa B-dependent nitrite production and apoptosis in beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIVO GENE DELIVERY; OXIDE SYNTHASE; INSULIN-SECRETION; DIABETES-MELLITUS; FATTY-ACIDS; EXPRESSION; CYTOKINES; INTERLEUKIN-1; DESTRUCTION; MEDIATORS	Insulin-dependent diabetes mellitus is an autoimmune disease in which pancreatic islet beta cells are destroyed by a combination of immunological and inflammatory mechanisms. In particular, cytokine-induced production of nitric oxide has been shown to correlate with beta cell apoptosis and/or inhibition of insulin secretion. In the present study, we investigated whether the interleukin (IL)-1 beta intracellular signal transduction pathway could be blocked by overexpression of dominant negative forms of the IL-1 receptor interacting protein MyD88, We show that overexpression of the Toll domain or the 1pr mutant of MyD88 in beta Tc-Tet cells decreased nuclear factor kappaB (NF-kappaB) activation upon IL-1 beta and IL-1 beta /interferon (IFN)-gamma stimulation, Inducible nitric oxide synthase mRNA accumulation and nitrite production, which required the simultaneous presence of IL-1 beta and IFN-gamma, were also suppressed by similar to 70%, and these cells were more resistant to cytokine-induced apoptosis as compared with parental cells. The decrease in glucose-stimulated insulin secretion induced by IL-1 beta and IFN-gamma was however not prevented. This was because these dysfunctions were induced by IFN-gamma alone, which decreased cellular insulin content and stimulated insulin exocytosis, These results demonstrate that IL-1 beta is involved in inducible nitric oxide synthase gene expression and induction of apoptosis in mouse beta cells but does not contribute to impaired glucose stimulated insulin secretion. Furthermore, our data show that IL-1 beta cellular actions can be blocked by expression of MyD88 dominant negative proteins and, finally, that cytokine-induced beta cell secretory dysfunctions are due to the action of IFN-gamma.	Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	University of Lausanne	Thorens, B (corresponding author), Univ Lausanne, Inst Pharmacol & Toxicol, 27 Rue Bugnon, CH-1005 Lausanne, Switzerland.		Felley-Bosco, Emanuela/E-7484-2017	Felley-Bosco, Emanuela/0000-0002-3408-0294				Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Auron PE, 1998, CYTOKINE GROWTH F R, V9, P221, DOI 10.1016/S1359-6101(98)00018-5; Benoist C, 1997, CELL, V89, P1, DOI 10.1016/S0092-8674(00)80174-9; Bonny C, 2000, J BIOL CHEM, V275, P16466, DOI 10.1074/jbc.M908297199; Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; CHARNEAU P, 1994, J MOL BIOL, V241, P561; Darville MI, 1998, DIABETOLOGIA, V41, P1101, DOI 10.1007/s001250051036; Delaney CA, 1997, ENDOCRINOLOGY, V138, P2610, DOI 10.1210/en.138.6.2610; Dupraz P, 1999, GENE THER, V6, P1160, DOI 10.1038/sj.gt.3300922; Efrat S, 1998, EUR J ENDOCRINOL, V138, P129, DOI 10.1530/eje.0.1380129; EFRAT S, 1995, P NATL ACAD SCI USA, V92, P3576, DOI 10.1073/pnas.92.8.3576; EIZIRIK DL, 1994, J CLIN INVEST, V93, P1968, DOI 10.1172/JCI117188; Eizirik DL, 1996, DIABETOLOGIA, V39, P875; Eizirik DL, 1997, DIABETES METAB REV, V13, P293, DOI 10.1002/(SICI)1099-0895(199712)13:4<293::AID-DMR195>3.0.CO;2-4; Fleischer N, 1998, DIABETES, V47, P1419, DOI 10.2337/diabetes.47.9.1419; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Gremlich S, 1997, J BIOL CHEM, V272, P3216, DOI 10.1074/jbc.272.6.3216; Gremlich S, 1997, J BIOL CHEM, V272, P30261, DOI 10.1074/jbc.272.48.30261; Guillam MT, 1997, NAT GENET, V17, P327, DOI 10.1038/ng1197-327; Hoorens A, 1996, J CLIN INVEST, V98, P1568, DOI 10.1172/JCI118950; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; KWON G, 1995, ENDOCRINOLOGY, V136, P4790, DOI 10.1210/en.136.11.4790; Ling ZD, 2000, DIABETES, V49, P340, DOI 10.2337/diabetes.49.3.340; MandrupPoulsen T, 1996, DIABETOLOGIA, V39, P1005, DOI 10.1007/BF00400649; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Pakala SV, 1999, J EXP MED, V189, P1053, DOI 10.1084/jem.189.7.1053; Pavlovic D, 1999, EUR CYTOKINE NETW, V10, P403; RABINOVITCH A, 1994, J CLIN ENDOCR METAB, V79, P1058, DOI 10.1210/jc.79.4.1058; Rabinovitch A, 1998, BIOCHEM PHARMACOL, V55, P1139, DOI 10.1016/S0006-2952(97)00492-9; RAGO R, 1990, ANAL BIOCHEM, V191, P31; SUAREZPINZON WL, 1994, ENDOCRINOLOGY, V134, P1006, DOI 10.1210/en.134.3.1006; Takamura T, 1998, J BIOL CHEM, V273, P2493, DOI 10.1074/jbc.273.5.2493; Underhill DM, 1999, P NATL ACAD SCI USA, V96, P14459, DOI 10.1073/pnas.96.25.14459; Waeber G, 2000, NAT GENET, V24, P291, DOI 10.1038/73523; Welsh N, 1996, J BIOL CHEM, V271, P8307, DOI 10.1074/jbc.271.14.8307; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998; Zufferey R, 1999, J VIROL, V73, P2886, DOI 10.1128/JVI.73.4.2886-2892.1999; Zumsteg U, 2000, DIABETES, V49, P39, DOI 10.2337/diabetes.49.1.39	43	66	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37672	37678		10.1074/jbc.M005150200	http://dx.doi.org/10.1074/jbc.M005150200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10967106	hybrid			2022-12-25	WOS:000165618700051
J	Liszewski, MK; Leung, M; Cui, WY; Subramanian, VB; Parkinson, J; Barlow, PN; Manchester, M; Atkinson, JP				Liszewski, MK; Leung, M; Cui, WY; Subramanian, VB; Parkinson, J; Barlow, PN; Manchester, M; Atkinson, JP			Dissecting sites important for complement regulatory activity in membrane cofactor protein (MCP; CD46)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEASLES-VIRUS RECEPTOR; CRYSTAL-STRUCTURE; FACTOR-H; COMPONENT C3; MONOCLONAL-ANTIBODY; SECONDARY STRUCTURE; MULTIPLE ISOFORMS; N-GLYCANS; BINDING; MODULES	Membrane cofactor protein (MCP; CD46), a widely distributed regulator of complement activation, is a cofactor for the factor I-mediated degradation of C3b and C4b deposited on host cells. MCP possesses four extracellular, contiguous complement control protein modules (CCPs) important for this inhibitory activity. The goal of the present study was to delineate functional sites within these modules. We employed multiple approaches including mutagenesis, epitope mapping, and comparisons to primate MCP to make the following observations. First, functional sites were located to each of the four CCPs. Second, some residues were important for both C3b and C4b interactions while others were specific for one or the other. Third, while a reduction in ligand binding was invariably accompanied by a parallel reduction in cofactor activity (CA), other mutants lost or had reduced CA but retained ligand binding. Fourth, two C4b-regulatory domains overlapped measles virus interactive regions, indicating that the hemagglutinin docks to a site important for complement inhibition. Fifth, several MCP regulatory areas corresponded to functionally critical, homologous positions in other CCP-bearing C3b/C4b-binding proteins. Based on these data and the recently derived crystal structure of repeats one and two, computer modeling was employed to predict MCP structure and examine active sites.	Washington Univ, Sch Med, Div Rheumatol, Dept Med, St Louis, MO 63110 USA; Scripps Res Inst, Dept Neuropharmacol, Div Virol, La Jolla, CA 92037 USA; Edinburgh Ctr Prot Technol, Edinburgh EH9 3JJ, Midlothian, Scotland	Washington University (WUSTL); Scripps Research Institute; University of Edinburgh	Atkinson, JP (corresponding author), Washington Univ, Sch Med, Div Rheumatol, Dept Med, 660 S Euclid Ave,Box 8045, St Louis, MO 63110 USA.		Barlow, Paul N/G-2853-2011; Parkinson, John/A-4424-2008	Parkinson, John/0000-0001-9815-1189; Atkinson, John/0000-0002-2514-3441; Manchester, Marianne/0000-0002-7143-5744	NIAID NIH HHS [R01AI37618] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037618] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Accardo P, 1996, J IMMUNOL, V157, P4935; ADAMS EM, 1991, J IMMUNOL, V147, P3005; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDERSON DJ, 1989, BIOL REPROD, V41, P285, DOI 10.1095/biolreprod41.2.285; ANDERSON DJ, 1993, P NATL ACAD SCI USA, V90, P10051, DOI 10.1073/pnas.90.21.10051; ANDREWS PW, 1985, ANN HUM GENET, V49, P31, DOI 10.1111/j.1469-1809.1985.tb01673.x; BARLOW PN, 1992, BIOCHEMISTRY-US, V31, P3626, DOI 10.1021/bi00129a011; BARLOW PN, 1993, J MOL BIOL, V232, P268, DOI 10.1006/jmbi.1993.1381; BARLOW PN, 1991, BIOCHEMISTRY-US, V30, P997, DOI 10.1021/bi00218a016; BARON M, 1991, TRENDS BIOCHEM SCI, V16, P13, DOI 10.1016/0968-0004(91)90009-K; Bouma B, 1999, EMBO J, V18, P5166, DOI 10.1093/emboj/18.19.5166; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; Buchholz CJ, 1997, J BIOL CHEM, V272, P22072, DOI 10.1074/jbc.272.35.22072; Casasnovas JM, 1999, EMBO J, V18, P2911, DOI 10.1093/emboj/18.11.2911; CERVONI F, 1992, J IMMUNOL, V148, P1431; COLE JL, 1985, P NATL ACAD SCI USA, V82, P859, DOI 10.1073/pnas.82.3.859; COYNE KE, 1992, J IMMUNOL, V149, P2906; COZZI E, 1995, NAT MED, V1, P964, DOI 10.1038/nm0995-964; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; DYKMAN TR, 1983, P NATL ACAD SCI-BIOL, V80, P1698, DOI 10.1073/pnas.80.6.1698; Higgins PJ, 1997, J IMMUNOL, V158, P2872; Howard J, 1998, J LEUKOCYTE BIOL, V64, P68, DOI 10.1002/jlb.64.1.68; HSI BL, 1988, AM J REPROD IMMUNOL, V18, P21; Hsu EC, 1999, VIROLOGY, V258, P314, DOI 10.1006/viro.1999.9712; Hsu EC, 1997, J VIROL, V71, P6144, DOI 10.1128/JVI.71.8.6144-6154.1997; IWATA K, 1995, J BIOL CHEM, V270, P15148, DOI 10.1074/jbc.270.25.15148; Kallstrom H, 1997, MOL MICROBIOL, V25, P639, DOI 10.1046/j.1365-2958.1997.4841857.x; Kirkitadze MD, 1999, BIOCHEMISTRY-US, V38, P7019, DOI 10.1021/bi982453a; Kirkitadze MD, 1999, BIOCHEM J, V344, P167, DOI 10.1042/0264-6021:3440167; Kirkitadze MD, 1999, FEBS LETT, V459, P133, DOI 10.1016/S0014-5793(99)01205-3; Kirkitadze MD, 1999, PROG COLL POL SCI S, V113, P164; Kitamura M, 1997, J REPROD IMMUNOL, V33, P83, DOI 10.1016/S0165-0378(97)01017-6; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krych M, 1998, J BIOL CHEM, V273, P8623, DOI 10.1074/jbc.273.15.8623; Krych-Goldberg M, 1999, J BIOL CHEM, V274, P31160, DOI 10.1074/jbc.274.44.31160; Lambris JD, 1996, J IMMUNOL, V156, P4821; Liszewski MK, 1996, ADV IMMUNOL, V61, P201; Liszewski MK, 1998, J IMMUNOL, V161, P3711; Liszewski MK, 1996, J IMMUNOL, V156, P4415; LISZEWSKI MK, 1998, COMPLEMENT SYSTEM, P146; Lozahic S, 2000, EUR J IMMUNOL, V30, P900, DOI 10.1002/1521-4141(200003)30:3<900::AID-IMMU900>3.0.CO;2-X; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Maisner A, 1996, J VIROL, V70, P4973, DOI 10.1128/JVI.70.8.4973-4977.1996; MAISNER A, 1995, VIROLOGY, V210, P479, DOI 10.1006/viro.1995.1365; MAISNER A, 1994, J VIROL, V68, P6299, DOI 10.1128/JVI.68.10.6299-6304.1994; Manchester M, 1997, VIROLOGY, V233, P174, DOI 10.1006/viro.1997.8581; MANCHESTER M, 1995, P NATL ACAD SCI USA, V92, P2303, DOI 10.1073/pnas.92.6.2303; MANCHESTER M, 1994, P NATL ACAD SCI USA, V91, P2161, DOI 10.1073/pnas.91.6.2161; Mumenthaler C, 1997, PROTEIN SCI, V6, P588; Nagar B, 1998, SCIENCE, V280, P1277, DOI 10.1126/science.280.5367.1277; NANICHE D, 1993, J VIROL, V67, P6025, DOI 10.1128/JVI.67.10.6025-6032.1993; NICKELLS MW, 1990, J IMMUNOL, V144, P4262; NICKELLS MW, 1995, J IMMUNOL, V154, P2829; Ogata RT, 1998, J IMMUNOL, V161, P4785; OKADA N, 1995, P NATL ACAD SCI USA, V92, P2489, DOI 10.1073/pnas.92.7.2489; Oran AE, 1999, J BIOL CHEM, V274, P5120, DOI 10.1074/jbc.274.8.5120; PERKINS SJ, 1988, BIOCHEMISTRY-US, V27, P4004, DOI 10.1021/bi00411a017; POST TW, 1991, J EXP MED, V174, P93, DOI 10.1084/jem.174.1.93; ROONEY IA, 1993, XENOBIOTICA, V1, P29; RUSSELL SM, 1992, EUR J IMMUNOL, V22, P1513, DOI 10.1002/eji.1830220625; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Santoro F, 1999, CELL, V99, P817, DOI 10.1016/S0092-8674(00)81678-5; Schwarzenbacher R, 1999, EMBO J, V18, P6228, DOI 10.1093/emboj/18.22.6228; SEYA T, 1993, EUR J IMMUNOL, V23, P1322, DOI 10.1002/eji.1830230620; TANIGUCHISIDLE A, 1994, J IMMUNOL, V153, P5285; Wiles AP, 1997, J MOL BIOL, V272, P253, DOI 10.1006/jmbi.1997.1241; Xu CG, 2000, SCIENCE, V287, P498, DOI 10.1126/science.287.5452.498	67	117	122	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37692	37701		10.1074/jbc.M004650200	http://dx.doi.org/10.1074/jbc.M004650200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10960475	hybrid			2022-12-25	WOS:000165618700054
J	Mikitani, K; Sugasaki, T; Shimada, T; Kobayashi, N; Gustafsson, JA				Mikitani, K; Sugasaki, T; Shimada, T; Kobayashi, N; Gustafsson, JA			The chitinase gene of the silkworm, Bombyx mori, contains a novel Tc-like transposable element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHITINOLYTIC ENZYMES; SEQUENCE; CHITOTRIOSIDASE; INTEGUMENT; HORMONE; CLONING; CDNA	We have determined the cDNA sequence and the genomic organization of the chitinase gene of the silkworm, Bombyx mori. The cDNA encodes 544 amino acids having 83% amino acid homology to the chitinase of the tobacoo hornworm, Manduca sexta. The total length of the gene is larger than 25 kilobase pairs, and it is separated into 11 exons. The intron-exon boundaries are all in accordance with the GT-AG rule. Also, the TATA box sequence was found in the 5' upstream region of the gene, and the gene is mapped on the seventh chromosome. A novel DNA type transposon that shows similarity to the Tc-like element was found in the third intron in some strains of B. mori; other strains, however, lack this element in the same intron. This element has long terminal inverted repeats, presumably encodes a transposase of about 340 amino acids with a DDE motif, and has an amino-terminal domain with a strong nuclear localization function. Seven other transposable elements with homologous but distinct sequences were isolated from the B. mori genome. Together with plaque hybridization results, our findings suggest that these novel elements exist in multiple copies constituting a new Tc-like transposable element family in the silkworm genome.	Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden; Univ Tokyo, Dept Agr & Environm Biol, Bunkyo Ku, Tokyo 113, Japan; Karolinska Inst, Dept Med Nutr, S-14157 Huddinge, Sweden	Karolinska Institutet; University of Tokyo; Karolinska Institutet	Mikitani, K (corresponding author), Karolinska Inst, Ctr Biotechnol, S-14157 Huddinge, Sweden.	kenichi.mikitani@csb.ki.se	Shimada, Toru/A-2033-2011; Shimada, Toru/AAZ-2703-2021	Shimada, Toru/0000-0002-5791-0000; Shimada, Toru/0000-0002-5791-0000				ARATAKE Y, 1961, B SERICUL EXP STA, V17, P155; BOOT RG, 1995, J BIOL CHEM, V270, P26252, DOI 10.1074/jbc.270.44.26252; Boot RG, 1998, J BIOL CHEM, V273, P25680, DOI 10.1074/jbc.273.40.25680; BUTENANDT A, 1954, Z NATURFORSCH B, V9, P389; Capy P, 1996, J MOL EVOL, V42, P359, DOI 10.1007/BF02337546; CHERBAS L, 1993, INSECT BIOCHEM MOLEC, V23, P81, DOI 10.1016/0965-1748(93)90085-7; Choi HK, 1997, INSECT BIOCHEM MOLEC, V27, P37, DOI 10.1016/S0965-1748(96)00066-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; de la Vega H, 1998, INSECT MOL BIOL, V7, P233, DOI 10.1111/j.1365-2583.1998.00065.x; FRANZ G, 1994, P NATL ACAD SCI USA, V91, P4746, DOI 10.1073/pnas.91.11.4746; Fukuda S., 1940, P IMP ACAD TOKYO, V16, P417; FUKUDA SOICHI, 1944, JOUR FAC SCI IMP UNIV TOKYO SECT IV, V6, P477; GAGE LP, 1974, J MOL BIOL, V86, P97; Garel A, 1997, INSECT BIOCHEM MOLEC, V27, P469, DOI 10.1016/S0965-1748(97)00022-2; Hart DL, 1997, ANNU REV GENET, V31, P337, DOI 10.1146/annurev.genet.31.1.337; Hawtin RE, 1997, VIROLOGY, V238, P243, DOI 10.1006/viro.1997.8816; Hoekstra R, 1999, MOL BIOCHEM PARASIT, V102, P157, DOI 10.1016/S0166-6851(99)00094-8; Ivics Z, 1997, CELL, V91, P501, DOI 10.1016/S0092-8674(00)80436-5; KATAOKA H, 1987, AGR BIOL CHEM TOKYO, V51, P1067, DOI 10.1080/00021369.1987.10868149; KAZNOWSKI CE, 1986, J INSECT PHYSIOL, V32, P133, DOI 10.1016/0022-1910(86)90132-0; Kim MG, 1998, INSECT BIOCHEM MOLEC, V28, P163, DOI 10.1016/S0965-1748(97)00112-4; KIMURA S, 1973, J INSECT PHYSIOL, V19, P115, DOI 10.1016/0022-1910(73)90227-8; KOBAYASHI M, 1958, NATURE, V181, P1217, DOI 10.1038/1811217a0; KOGA D, 1989, INSECT BIOCHEM, V19, P123, DOI 10.1016/0020-1790(89)90082-6; KOGA D, 1992, INSECT BIOCHEM MOLEC, V22, P305, DOI 10.1016/0965-1748(92)90068-P; Koga D, 1997, INSECT BIOCHEM MOLEC, V27, P757, DOI 10.1016/S0965-1748(97)00058-1; KRAMER KJ, 1993, INSECT BIOCHEM MOLEC, V23, P691, DOI 10.1016/0965-1748(93)90043-R; KRAMER KJ, 1986, INSECT BIOCHEM, V16, P851, DOI 10.1016/0020-1790(86)90059-4; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; MAEDA S, 1985, NATURE, V315, P592, DOI 10.1038/315592a0; OKAZAKI S, 1993, MOL CELL BIOL, V13, P1424, DOI 10.1128/MCB.13.3.1424; Overdijk B, 1999, MICROBIOL-UK, V145, P259, DOI 10.1099/13500872-145-1-259; Plasterk RHA, 1996, CURR TOP MICROBIOL, V204, P125; Promboon Amornrat, 1995, Genetical Research, V66, P1, DOI 10.1017/S0016672300034339; RASCH EM, 1974, CHROMOSOMA, V45, P1; Robertson HM, 1996, INSECT BIOCHEM MOLEC, V26, P945, DOI 10.1016/S0965-1748(96)00061-6; SURHOLT B, 1975, J COMP PHYSIOL, V102, P135, DOI 10.1007/BF00691299; Yamao M, 1999, GENE DEV, V13, P511, DOI 10.1101/gad.13.5.511; YOSHITAK.N, 1966, JPN J GENET, V41, P259, DOI 10.1266/jjg.41.259	39	23	24	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37725	37732		10.1074/jbc.M005271200	http://dx.doi.org/10.1074/jbc.M005271200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10984482	hybrid			2022-12-25	WOS:000165618700058
J	Webb, P; Nguyen, P; Valentine, C; Weatherman, RV; Scanlan, TS; Kushner, PJ				Webb, P; Nguyen, P; Valentine, C; Weatherman, RV; Scanlan, TS; Kushner, PJ			An antiestrogen-responsive estrogen receptor-alpha mutant (D351Y) shows weak AF-2 activity in the presence of tamoxifen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; PEPTIDE ANTAGONISTS; ER ALPHA; COACTIVATOR; ACTIVATION; CELL; MECHANISMS; IDENTIFICATION; RALOXIFENE; ASPARTATE	Antiestrogens, including tamoxifen and raloxifene, block estrogen receptor (ER) action by blocking the interactions of an estrogen-dependent activation function (AF-2) with p160 coactivators. Although tamoxifen does show some agonist activity in the presence of ER alpha, this stems from a distinct constitutive activation function (AF-1) that lies within the ER alpha N terminus. Previous studies identified a naturally occurring mutation (D351Y) that allows ER alpha to perceive tamoxifen and raloxifene as estrogens. Here, we examine the contributions of ER alpha activation functions to the D351Y phenotype. We find that the AF-2 function of ER alpha D351Y lacks detectable tamoxifen-dependent activity when tested in isolation but does synergize with AF-1 to allow enhanced tamoxifen response. Weak tamoxifen-dependent interactions between the ER alpha D351Y AF-2 function and GRIP1, a representative p160, can be detected in glutathione S-transferase binding assays and mammalian two-hybrid assays. Furthermore, tamoxifen-dependent AF-2 activity can be detected in the presence of ER alpha D351Y and high levels of overexpressed GRIP1, We therefore propose that the D351Y mutation allows weak tamoxifen-dependent AF-2 activity but that this activity is only detectable when AF-1 is strong, and AF-1 and AF-2 synergize, or when p160s are overexpressed. We discuss the possible structural basis of this effect.	Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Cellular & Mol Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Webb, P (corresponding author), Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA.	webbp@itsa.ucsf.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057574, R01DK051083] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK51083, DK57574] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anghel SI, 2000, J BIOL CHEM, V275, P20867, DOI 10.1074/jbc.M002098200; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Aumais JP, 1997, J BIOL CHEM, V272, P12229, DOI 10.1074/jbc.272.18.12229; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Chang CY, 1999, MOL CELL BIOL, V19, P8226; Chen SC, 2000, J BIOL CHEM, V275, P15039, DOI 10.1074/jbc.275.20.15039; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Glass CK, 2000, GENE DEV, V14, P121; GRONEMEYER H, 1992, J STEROID BIOCHEM, V41, P217, DOI 10.1016/0960-0760(92)90347-L; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Jordan VC, 1998, SCI AM, V279, P60, DOI 10.1038/scientificamerican1098-60; Katzenellenbogen BS, 1996, BIOL REPROD, V54, P287, DOI 10.1095/biolreprod54.2.287; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; Knutti D, 2000, MOL CELL BIOL, V20, P2411, DOI 10.1128/MCB.20.7.2411-2422.2000; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; LEES JA, 1989, J STEROID BIOCHEM, V34, P33, DOI 10.1016/0022-4731(89)90063-0; Levenson AS, 1998, CANCER RES, V58, P1872; Levenson AS, 1997, J STEROID BIOCHEM, V60, P261, DOI 10.1016/S0960-0760(96)00184-7; Lopez GN, 1999, MOL ENDOCRINOL, V13, P897, DOI 10.1210/me.13.6.897; MCDONNELL DP, 1995, ANN NY ACAD SCI, V761, P121, DOI 10.1111/j.1749-6632.1995.tb31374.x; McInerney EM, 1996, J BIOL CHEM, V271, P24172, DOI 10.1074/jbc.271.39.24172; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; PARKER MG, 1993, ANN NY ACAD SCI, V684, P119, DOI 10.1111/j.1749-6632.1993.tb32276.x; Parker MG, 1998, BIOCHEM SOC SYMP, P45; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; Rachez C, 2000, MOL CELL BIOL, V20, P2718, DOI 10.1128/MCB.20.8.2718-2726.2000; RIBEIRO RCJ, 1995, ANNU REV MED, V46, P443, DOI 10.1146/annurev.med.46.1.443; Saatcioglu F, 1997, MOL CELL BIOL, V17, P4687, DOI 10.1128/MCB.17.8.4687; SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554; Schafer JIM, 1999, CANCER RES, V59, P4308; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; WEBB P, 1992, MOL ENDOCRINOL, V6, P157, DOI 10.1210/me.6.2.157; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443	47	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37552	37558		10.1074/jbc.M007435200	http://dx.doi.org/10.1074/jbc.M007435200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10986290	hybrid			2022-12-25	WOS:000165618700035
J	Asoh, S; Ohtsu, T; Ohta, S				Asoh, S; Ohtsu, T; Ohta, S			The super anti-apoptotic factor Bcl-xFNK constructed by disturbing intramolecular polar interactions in rat Bcl-x(L)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C ACCUMULATION; CELL-DEATH; HYDROGEN-PEROXIDE; PROTEIN; MITOCHONDRIA; CHANNEL; RELEASE; INVOLVEMENT; INHIBITORS; DEPENDENCE	A powerful artificial anti-apoptotic factor will be useful for medical applications of the future therapies for many diseases by prolonging survival of sick cells. For constructing it, we designed the super anti-apoptotic factor by disturbing three intramolecular polar interactions among alpha -helix structures of Ecl-x,. The resultant mutant Bcl-x(L), named Bcl-xFNK was expected to make the pore-forming domain more mobile and flexible than the wild-type, When overexpressed in Jurkat cells, Bcl-xFNK was markedly more potent in prolonging survival following apoptosis-inducing treatment with a kind of cell death cytokines (anti-Fas), a protein kinase inhibitor (staurosporine), cell cycle inhibitors (TN-16, camptothecin, hydroxyurea, and trichostatin A), or oxidative stress (hydrogen peroxide and paraquat) than wild-type Bcl-x(L), Furthermore, the transfectants of bcl-xFNK became more resistant against a calcium ionophore and even a heat treatment than wild-type Bcl-x(L). In addition, Bcl-xFNK showed marked anti-apoptotic activity in Chinese hamster ovary and Jurkat cells deprived of serum. Thus, Bcl-xFNK may be the first mutant generated by site-directed mutagenesis of Bcl-x(L) with a gain-of-function phenotype, Interestingly, Bcl-xFNK was found to allow interleukin-3-dependent FDC-P1 to grow without interleukin-3, but not BaF/3. In Bcl-xFNK transfectants of FDC-P1 and Jurkat, the p42/p44 mitogen-activated protein kinase was activated by 2 to 5 times, but not in those of BaF/3 and Chinese hamster ovary. Bcl-xFNK might gain a new function to activate the mitogen-activated protein kinase in a cell-type specific manner. The findings of this study suggest that the central alpha5-alpha6 pore-forming region of anti-apoptotic factor Bcl-x(L) has a pivotal role in suppressing apoptosis.	Nippon Med Sch, Inst Gerontol, Dept Biochem & Cell Biol, Nakahara Ku, Kawasaki, Kanagawa 2118533, Japan	Nippon Medical School	Ohta, S (corresponding author), Nippon Med Sch, Inst Gerontol, Dept Biochem & Cell Biol, Nakahara Ku, 1-396 Kosuhicho, Kawasaki, Kanagawa 2118533, Japan.							Aritomi M, 1997, J BIOL CHEM, V272, P27886, DOI 10.1074/jbc.272.44.27886; Asoh S, 1999, NEUROSCI LETT, V272, P62, DOI 10.1016/S0304-3940(99)00485-1; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Clevenger CV, 1997, MOL ENDOCRINOL, V11, P608, DOI 10.1210/me.11.5.608; Deng XM, 2000, P NATL ACAD SCI USA, V97, P1578, DOI 10.1073/pnas.97.4.1578; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; Ishibashi Y, 1998, BIOCHEM BIOPH RES CO, V243, P609, DOI 10.1006/bbrc.1998.8145; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Marzo I, 1998, BIOMED PHARMACOTHER, V52, P248, DOI 10.1016/S0753-3322(98)80009-7; Mastrangelo AJ, 2000, BIOTECHNOL BIOENG, V67, P555, DOI 10.1002/(SICI)1097-0290(20000305)67:5<555::AID-BIT6>3.0.CO;2-T; Matsuyama S, 1998, J BIOL CHEM, V273, P30995, DOI 10.1074/jbc.273.47.30995; Medina V, 1997, CANCER RES, V57, P3697; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nouraini S, 2000, MOL CELL BIOL, V20, P1604, DOI 10.1128/MCB.20.5.1604-1615.2000; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Samali A, 1999, FEBS LETT, V461, P306, DOI 10.1016/S0014-5793(99)01486-6; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu T, 1997, LEUKEMIA, V11, P1238, DOI 10.1038/sj.leu.2400734; Shiraiwa N, 1996, J BIOL CHEM, V271, P13258, DOI 10.1074/jbc.271.22.13258; Stridh H, 1998, FEBS LETT, V429, P351, DOI 10.1016/S0014-5793(98)00630-9; Takadera T, 1997, EUR J BIOCHEM, V249, P8, DOI 10.1111/j.1432-1033.1997.00008.x; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Tang DG, 1998, BIOCHEM BIOPH RES CO, V242, P380, DOI 10.1006/bbrc.1997.7969; Tey BT, 2000, BIOTECHNOL BIOENG, V68, P31, DOI 10.1002/(SICI)1097-0290(20000405)68:1<31::AID-BIT4>3.0.CO;2-L; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	33	37	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37240	37245		10.1074/jbc.M005841200	http://dx.doi.org/10.1074/jbc.M005841200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10970895	hybrid			2022-12-25	WOS:000165577700107
J	Hsieh, CM; Fukumoto, S; Layne, MD; Maemura, K; Charles, H; Patel, A; Perrella, MA; Lee, ME				Hsieh, CM; Fukumoto, S; Layne, MD; Maemura, K; Charles, H; Patel, A; Perrella, MA; Lee, ME			Striated muscle preferentially expressed genes alpha and beta are two serine/threonine protein kinases derived from the same gene as the aortic preferentially expressed gene-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; CONSERVED FEATURES; RAT HEARTS; SMOOTH; TELOKIN; FAMILY; IDENTIFICATION; ISOFORMS; DATABASE; DOMAIN	Aortic preferentially expressed gene (APEG)-1 is a 1.4-kilobase pair (kb) mRNA expressed in vascular smooth muscle cells and is down-regulated by vascular injury. An APEG-1 5'-end cDNA probe identified three additional isoforms. The 9-kb striated preferentially expressed gene (SPEG)alpha and the 11-kb SPEG beta were found in skeletal muscle and heart. The 4-kb brain preferentially expressed gene was detected in the brain and aorta. We report here cloning of the Il-kb SPEG beta cDNA SPEG beta encodes a 355-kDa protein that contains two serine/threonine kinase domains and is homologous to proteins of the myosin light chain kinase family. At least one Kinase domain is active and capable of autophosphorylation. In the genome, all four isoforms share the middle three of the five exons of APEG-1, and they differ from each other by using different 5'- and S'-ends and alternative splicing. We show that the expression of SPEG alpha and SPEG beta is developmentally regulated in the striated muscle during C2C12 myoblast to myotube differentiation in vitro and cardiomyocyte maturation in vivo. This developmental regulation suggests that both SPEG alpha and SPEG beta can serve as sensitive markers for striated muscle differentiation and that they may be important for adult striated muscle function.	Brigham & Womens Hosp, Div Cardiovasc, Program Dev Cardiovasc Biol, Boston, MA 02115 USA; Brigham & Womens Hosp, Pulm & Crit Care Div, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Perrella, MA (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, Program Dev Cardiovasc Biol, 75 Francis St, Boston, MA 02115 USA.	mperrella@rics.bwh.harvard.edu		Layne, Matthew/0000-0003-0007-4870	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060788, F32HL010113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053249] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60788, HL10113] Funding Source: Medline; NIGMS NIH HHS [GM53249] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON PAW, 1995, CIRC RES, V76, P681, DOI 10.1161/01.RES.76.4.681; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Chin MT, 2000, J BIOL CHEM, V275, P6381, DOI 10.1074/jbc.275.9.6381; Chin MT, 1999, J MOL CELL CARDIOL, V31, P2199, DOI 10.1006/jmcc.1999.1054; CLAYCOMB WC, 1992, TRENDS CARDIOVAS MED, V2, P231, DOI 10.1016/1050-1738(92)90030-V; Corpet F, 2000, NUCLEIC ACIDS RES, V28, P267, DOI 10.1093/nar/28.1.267; EPSTEIN HF, 1991, SCIENCE, V251, P1039, DOI 10.1126/science.1998120; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23945; Gittenberger-de Groot AC, 1999, ARTERIOSCL THROM VAS, V19, P1589; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; HOLDEN HM, 1992, J MOL BIOL, V227, P840, DOI 10.1016/0022-2836(92)90226-A; Hsieh CM, 1999, J BIOL CHEM, V274, P14344, DOI 10.1074/jbc.274.20.14344; Hsieh CM, 1996, J BIOL CHEM, V271, P17354, DOI 10.1074/jbc.271.29.17354; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; KEMP BE, 1994, PROTEIN KINASES, P30; Maruyama K, 1997, FASEB J, V11, P341, DOI 10.1096/fasebj.11.5.9141500; Mende U, 1998, P NATL ACAD SCI USA, V95, P13893, DOI 10.1073/pnas.95.23.13893; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; Nagase T, 2000, DNA RES, V7, P65, DOI 10.1093/dnares/7.1.65; NAUMANN K, 1994, DIFFERENTIATION, V55, P203, DOI 10.1046/j.1432-0436.1994.5530203.x; Nieznanski K, 1997, BIOCHEM J, V322, P65, DOI 10.1042/bj3220065; Ota S, 2000, J BIOL CHEM, V275, P414, DOI 10.1074/jbc.275.1.414; OWENS GK, 1995, PHYSIOL REV, V75, P487; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; RUDNICKI MA, 1995, BIOESSAYS, V17, P203, DOI 10.1002/bies.950170306; Rumyantsev P P, 1977, Int Rev Cytol, V51, P186; Sanjo H, 1998, J BIOL CHEM, V273, P29066, DOI 10.1074/jbc.273.44.29066; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; Wu XQ, 1998, J BIOL CHEM, V273, P11362, DOI 10.1074/jbc.273.18.11362; YOSHIZUMI M, 1995, J CLIN INVEST, V95, P2275, DOI 10.1172/JCI117918	37	47	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36966	36973		10.1074/jbc.M006028200	http://dx.doi.org/10.1074/jbc.M006028200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973969	hybrid			2022-12-25	WOS:000165577700073
J	Nillni, EA; Vaslet, C; Harris, M; Hollenberg, A; Bjorbaek, C; Flier, JS				Nillni, EA; Vaslet, C; Harris, M; Hollenberg, A; Bjorbaek, C; Flier, JS			Leptin regulates prothyrotropin-releasing hormone biosynthesis - Evidence for direct and indirect pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; AGOUTI-RELATED PROTEIN; MESSENGER-RIBONUCLEIC-ACID; OBESE GENE-PRODUCT; NEUROPEPTIDE-Y; OB/OB MICE; FRAMESHIFT MUTATION; INDUCED SUPPRESSION; RESPONSE ELEMENTS; THYROID-FUNCTION	The hypothalamic-pituitary-thyroid axis is down-regulated during starvation, and falling levels of leptin are a critical signal for this adaptation, acting to suppress preprothyrbtropin-releasing hormone (prepro-TRH) mRNA expression in the paraventricular nucleus of the hypothalamus, This study addresses the mechanism for this regulation, using primary cultures of fetal rat hypothalamic neurons as a model system. Leptin dose-dependently stimulated a 10-fold increase in pro-TRH biosynthesis, with a maximum response at 10 nM, TRH release was quantified using immunoprecipitation, followed by isoelectric focusing gel electrophoresis and specific TRH, radioimmunoassay, Leptin stimulated TRH release by 7-fold. Immunocytochemistry revealed that a substantial population of cells expressed TRH or leptin receptors and that 8-13% of those expressing leptin receptors coexpressed TRH. Leptin produced a 5-fold induction of luciferase activity in CV-1 cells transfected with a TRH promoter and the long form of the leptin receptor cDNA, Although the above data are consistent with a direct ability of leptin to promote TRH biosynthesis through actions on TRH neurons, addition of alpha -melanocyte-stimulating hormone produced a 3.5-fold increase in TRH biosynthesis and release, whereas neuropeptide Y treatment suppressed pro-TRH biosynthesis similar to3-fold. Furthermore, the melanocortin-4 receptor antagonist SHU9119 partially inhibited leptin-stimulated TRH release from the neuronal culture, Consequently, our data suggest that leptin regulates the TRH neurons through both direct and indirect pathways.	Brown Univ, Rhode Isl Hosp, Sch Med, Div Endocrinol, Providence, RI 02903 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Endocrinol, Boston, MA 02215 USA	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Nillni, EA (corresponding author), Brown Univ, Rhode Isl Hosp, Sch Med, Div Endocrinol, 55 Claverick St, Providence, RI 02903 USA.	Eduardo_Nillni@Brown.edu	Bjorbaek, Christian/S-4727-2019; Harris, Mark/A-5858-2011; Flier, jeffrey/AAG-6223-2019	Harris, Mark/0000-0003-2461-6603; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058148] Funding Source: NIH RePORTER; NIDDK NIH HHS [1 RO1 DK58148-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahima RS, 1999, ENDOCRINOLOGY, V140, P4923, DOI 10.1210/en.140.11.4923; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; Bjorbaek C, 1998, ENDOCRINOLOGY, V139, P3485, DOI 10.1210/en.139.8.3485; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; BLAKE NG, 1991, ENDOCRINOLOGY, V129, P2714, DOI 10.1210/endo-129-5-2714; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Cheung CC, 1997, ENDOCRINOLOGY, V138, P4489, DOI 10.1210/en.138.10.4489; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Cohen RN, 1998, MOL ENDOCRINOL, V12, P1567, DOI 10.1210/me.12.10.1567; Elias CF, 1999, NEURON, V23, P775, DOI 10.1016/S0896-6273(01)80035-0; Elmquist JK, 1998, J COMP NEUROL, V395, P535; Fekete C, 2000, J NEUROSCI, V20, P1550; Flier JS, 1998, CELL, V92, P437, DOI 10.1016/S0092-8674(00)80937-X; FREAKE HC, 1995, ANNU REV NUTR, V15, P263, DOI 10.1146/annurev.nu.15.070195.001403; GANTZ I, 1993, J BIOL CHEM, V268, P15174; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Hileman SM, 2000, ENDOCRINOLOGY, V141, P1955, DOI 10.1210/en.141.6.1955; HOLLENBERG AN, 1995, MOL ENDOCRINOL, V9, P540, DOI 10.1210/me.9.5.540; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Kask A, 1999, NEUROREPORT, V10, P707, DOI 10.1097/00001756-199903170-00009; Kim MS, 2000, J CLIN INVEST, V105, P1005, DOI 10.1172/JCI8857; Kristensen P, 1998, NATURE, V393, P72, DOI 10.1038/29993; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Legradi G, 1999, ENDOCRINOLOGY, V140, P3643, DOI 10.1210/en.140.8.3643; Legradi G, 1997, ENDOCRINOLOGY, V138, P2569, DOI 10.1210/en.138.6.2569; Legradi G, 1998, ENDOCRINOLOGY, V139, P3262, DOI 10.1210/en.139.7.3262; Legradi G, 1998, NEUROENDOCRINOLOGY, V68, P89, DOI 10.1159/000054354; Marsh DJ, 1999, NAT GENET, V21, P119, DOI 10.1038/5070; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; MUENZER J, 1979, J BIOL CHEM, V254, P5623; NILLNI EA, 1993, ENDOCRINOLOGY, V132, P1260, DOI 10.1210/en.132.3.1260; NILLNI EA, 1993, ENDOCRINOLOGY, V132, P1271, DOI 10.1210/en.132.3.1271; Nillni EA, 1999, ENDOCRINE, V10, P185, DOI 10.1007/BF02738618; Nillni EA, 1999, ENDOCR REV, V20, P599, DOI 10.1210/er.20.5.599; NILLNI EA, 1995, J NEUROCHEM, V65, P2462; Nillni EA, 1996, ENDOCRINOLOGY, V137, P5651, DOI 10.1210/en.137.12.5651; NILLNI EA, 1991, METHODS NEUROSCIENCE, V6, P51; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; RONDEEL JMM, 1992, NEUROENDOCRINOLOGY, V56, P348, DOI 10.1159/000126248; Rosenfeld RD, 1998, BIOCHEMISTRY-US, V37, P16041, DOI 10.1021/bi981027m; SASAKI S, 1982, J DENT RES, V61, P1479; Schaner P, 1997, J BIOL CHEM, V272, P19958, DOI 10.1074/jbc.272.32.19958; Schwartz MW, 1996, DIABETES, V45, P531, DOI 10.2337/diabetes.45.4.531; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Thornton JE, 1997, ENDOCRINOLOGY, V138, P5063, DOI 10.1210/en.138.11.5063; TONI R, 1993, J ENDOCRINOL INVEST, V16, P715, DOI 10.1007/BF03348918; Vaisse C, 1998, NAT GENET, V20, P113, DOI 10.1038/2407; Yeo GSH, 1998, NAT GENET, V20, P111, DOI 10.1038/2404; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	53	174	179	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36124	36133		10.1074/jbc.M003549200	http://dx.doi.org/10.1074/jbc.M003549200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10967095	hybrid			2022-12-25	WOS:000165382000069
J	Peterson, YK; Bernard, ML; Ma, HZ; Hazard, S; Graber, SG; Lanier, SM				Peterson, YK; Bernard, ML; Ma, HZ; Hazard, S; Graber, SG; Lanier, SM			Stabilization of the GDP-bound conformation of Gi alpha by a peptide derived from the G-protein regulatory motif of AGS3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; BETA; MEMBRANES; SUBUNITS; BINDING	The G-protein regulatory (GPR) motif in AGS3 was recently identified as a region for protein binding to heterotrimeric G-protein alpha subunits. To define the properties of this similar to 20-amino acid motif, we designed a GPR consensus peptide and determined its influence on the activation state of G-protein and receptor coupling to G-protein. The GPR peptide sequence (28 amino acids) encompassed the consensus sequence defined by the four GPR motifs conserved in the family of AGS3 proteins. The GPR consensus peptide effectively prevented the binding of AGS3 to Gi alpha1,2 in protein interaction assays, inhibited guanosine 5'-O-(3-thiotriphosphate) binding to Gi alpha, and stabilized the GDP-bound conformation of Gi alpha, The GPR peptide had little effect on nucleotide binding to Go alpha and brain G-protein indicating selective regulation of Gia. Thus, the GPR peptide functions as a guanine nucleotide dissociation inhibitor for Gi alpha. The GPR consensus peptide also blocked receptor coupling to Gi alpha beta gamma indicating that although the AGS3-GPR peptide stabilized the GDP-bound conformation of Gi alpha, this conformation of Gi alpha (GDP) was not recognized by a G-protein coupled receptor. The AGS3-GPR motif presents an opportunity for selective control of Gi alpha- and G beta gamma -regulated effector systems, and the GPR motif allows for alternative modes of signal input to G-protein signaling systems.	Med Univ S Carolina, Dept Pharmacol, Charleston, SC 29403 USA; Med Univ S Carolina, Dept Lib & Informat, Charleston, SC 29403 USA; W Virginia Univ, Sch Med, Dept Pharmacol & Toxicol, Morgantown, WV 26506 USA	Medical University of South Carolina; Medical University of South Carolina; West Virginia University	Lanier, SM (corresponding author), Med Univ S Carolina, Dept Pharmacol, 173 Ashley Ave, Charleston, SC 29403 USA.		Bernard, Michael/AAW-3944-2021	Lanier, Stephen/0000-0002-2740-7607	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008716] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS024821, R01NS024821] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32-GM08716] Funding Source: Medline; NIMH NIH HHS [MH5993] Funding Source: Medline; NINDS NIH HHS [NS24821] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bae H, 1997, J BIOL CHEM, V272, P32071, DOI 10.1074/jbc.272.51.32071; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Cismowski MJ, 2000, J BIOL CHEM, V275, P23421, DOI 10.1074/jbc.C000322200; Cismowski MJ, 1999, NAT BIOTECHNOL, V17, P878, DOI 10.1038/12867; Clawges HM, 1997, BIOCHEMISTRY-US, V36, P12930, DOI 10.1021/bi970112b; DINGUS J, 1994, METHOD ENZYMOL, V237, P457; Hildebrandt JD, 1997, BIOCHEM PHARMACOL, V54, P325, DOI 10.1016/S0006-2952(97)00269-4; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; Luo Y, 1999, J BIOL CHEM, V274, P10685, DOI 10.1074/jbc.274.16.10685; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; Nanoff C, 1997, PHYSIOL RES, V46, P79; Richardson M, 1999, J BIOL CHEM, V274, P13525, DOI 10.1074/jbc.274.19.13525; ROSS EM, 1994, METHOD ENZYMOL, V237, P26; Schaefer M, 2000, CURR BIOL, V10, P353, DOI 10.1016/S0960-9822(00)00401-2; Siderovski DP, 1999, TRENDS BIOCHEM SCI, V24, P340, DOI 10.1016/S0968-0004(99)01441-3; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; TAYLOR JM, 1994, J BIOL CHEM, V269, P27618; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wu GY, 1998, J BIOL CHEM, V273, P7197, DOI 10.1074/jbc.273.13.7197; Yu FW, 2000, CELL, V100, P399, DOI 10.1016/S0092-8674(00)80676-5	21	114	117	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33193	33196		10.1074/jbc.C000509200	http://dx.doi.org/10.1074/jbc.C000509200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10969064	hybrid			2022-12-25	WOS:000090104600003
J	Machwe, A; Orren, DK; Bohr, VA				Machwe, A; Orren, DK; Bohr, VA			Accelerated methylation of ribosomal RNA genes during the cellular senescence of Werner syndrome fibroblasts	FASEB JOURNAL			English	Article						life span; aging; population doubling; rDNA	REPLICATIVE LIFE-SPAN; AGE-DEPENDENT LOSS; DNA METHYLATION; HUMAN-CELLS; RESTRICTION ENDONUCLEASE; SYNDROME PROTEIN; HELICASE; SEQUENCES; SGS1; RDNA	Ribosomal DNA (rDNA) metabolism has been implicated in cellular and organismal aging. The role of rDNA in premature and normal human aging was investigated by measuring rDNA gene copy number, the level of rDNA methylation, and rRNA expression during the in vitro senescence of primary fibroblasts from normal (young and old) donors and from Werner syndrome (WS) patients, In comparison to their normal counterparts, WS fibroblasts grew slowly and reached senescence after fewer doublings. The rDNA copy number did not change significantly throughout the life span of both normal and WS fibroblasts, However, in senescent WS and normal old fibroblasts, we detected rDNA species with unusually slow electrophoretic mobility, Cellular aging in Saccharomyces cerevisiae is accompanied by the formation and accumulation of rDNA circles. Our analysis revealed that the rDNA species observed in this study were longer, linear rDNA molecules attributable to the inhibition of EcoRI cleavage by methylation. Furthermore, isoschizomeric restriction analysis confirmed that in vitro senescence of fibroblasts is accompanied by significant increases in cytosine methylation within rDNA genes, This increased methylation is maximal during the abbreviated life span of WS fibroblasts. Despite increased methylation of rDNA in senescent cells, the steady-state levels of 28S rRNA remained constant over the life span of both normal and WS fibroblasts.	NIA, Mol Genet Lab, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Bohr, VA (corresponding author), NIA, Mol Genet Lab, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Bohr, Vilhelm/AAP-5931-2020					ALVES J, 1984, EUR J BIOCHEM, V140, P83, DOI 10.1111/j.1432-1033.1984.tb08069.x; ARKING R, 1998, BIOL AGING, P415; Battey, 1986, BASIC METHODS MOL BI; Bennett RJ, 1998, J BIOL CHEM, V273, P9644, DOI 10.1074/jbc.273.16.9644; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BRENNAN CA, 1986, J BIOL CHEM, V261, P7270; BROWN TC, 1987, CELL, V50, P945, DOI 10.1016/0092-8674(87)90521-6; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; CHIKARAISHI DM, 1983, NUCLEIC ACIDS RES, V11, P6437, DOI 10.1093/nar/11.18.6437; Cristofalo Vincent J., 1995, P53; Cristofalo VJ, 1998, P NATL ACAD SCI USA, V95, P10614, DOI 10.1073/pnas.95.18.10614; Epstein CJ, 1996, BIOESSAYS, V18, P1025, DOI 10.1002/bies.950181214; Finch CE, 1990, LONGEVITY SENESCENCE; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GAUBATZ JW, 1978, GERONTOLOGY, V24, P179, DOI 10.1159/000212250; Goto M, 1997, MECH AGEING DEV, V98, P239, DOI 10.1016/S0047-6374(97)00111-5; Gray MD, 1998, EXP CELL RES, V242, P487, DOI 10.1006/excr.1998.4124; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Guarente L, 1997, GENE DEV, V11, P2449, DOI 10.1101/gad.11.19.2449; Halle JP, 1997, EUR J CELL BIOL, V74, P281; HO L, 1989, MOL CELL BIOL, V9, P1594, DOI 10.1128/MCB.9.4.1594; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; JOHNSON R, 1972, NATURE, V240, P412, DOI 10.1038/240412a0; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; Kochanek S, 1996, FEBS LETT, V388, P192, DOI 10.1016/0014-5793(96)00506-6; MACLEOD D, 1983, NATURE, V306, P200, DOI 10.1038/306200a0; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; Martin GM, 1996, EXP GERONTOL, V31, P49, DOI 10.1016/0531-5565(95)02021-7; MARTIN GM, 1970, LAB INVEST, V23, P86; MCCLELLAND M, 1992, NUCLEIC ACIDS RES, V20, P2145, DOI 10.1093/nar/20.suppl.2145; Moser MJ, 1999, HUM MUTAT, V13, P271, DOI 10.1002/(SICI)1098-1004(1999)13:4<271::AID-HUMU2>3.0.CO;2-Q; PENNOCK DG, 1984, NUCLEIC ACIDS RES, V12, P2225, DOI 10.1093/nar/12.4.2225; PETERSON CRD, 1984, ARCH GERONTOL GERIAT, V3, P115, DOI 10.1016/0167-4943(84)90004-9; Rattan SIS, 1996, EXP GERONTOL, V31, P33, DOI 10.1016/0531-5565(95)02022-5; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; SALK D, 1981, CYTOGENET CELL GENET, V30, P108, DOI 10.1159/000131597; Sambrook J., 2002, MOL CLONING LAB MANU; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STREHLER BL, 1979, MECH AGEING DEV, V11, P379, DOI 10.1016/0047-6374(79)90013-7; STREHLER BL, 1979, MECH AGEING DEV, V11, P371, DOI 10.1016/0047-6374(79)90012-5; SWISSHELM K, 1990, MUTAT RES, V237, P131, DOI 10.1016/0921-8734(90)90019-N; TASSERONDEJONG JG, 1988, GENE, V74, P147, DOI 10.1016/0378-1119(88)90272-7; Van Remmen Holly, 1995, P171; VERTINO PM, 1994, CELL GROWTH DIFFER, V5, P1395; WANG RYH, 1982, BIOCHIM BIOPHYS ACTA, V697, P371, DOI 10.1016/0167-4781(82)90101-4; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; WILSON V L, 1983, Science (Washington D C), V220, P1055, DOI 10.1126/science.6844925; WILSON VL, 1987, J BIOL CHEM, V262, P9948; Yan H, 1998, NAT GENET, V19, P375, DOI 10.1038/1263; YANG JK, 1984, J MOL BIOL, V176, P169, DOI 10.1016/0022-2836(84)90419-4; Yu CE, 1997, AM J HUM GENET, V60, P330; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	56	38	41	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2000	14	12					1715	1724		10.1096/fj.99-0926com	http://dx.doi.org/10.1096/fj.99-0926com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973920				2022-12-25	WOS:000089212400010
J	Nakano, K; Balint, E; Ashcroft, M; Vousden, KH				Nakano, K; Balint, E; Ashcroft, M; Vousden, KH			A ribonucleotide reductase gene is a transcriptional target of p53 and p73	ONCOGENE			English	Article						p53; p73; DNA damage; ribonucleotide reductase; p53R2	CELL-CYCLE ARREST; KINASE C-ABL; DNA-DAMAGE; APOPTOTIC RESPONSE; TUMOR SUPPRESSION; INDUCE APOPTOSIS; ENDOREDUPLICATION; PROLIFERATION; MUTANTS; CANCER	Many p53-inducible genes have been identified that might play a role in mediating the various downstream activities of p53, We have identified a close relative of ribonucleotide reductase, recently named p53R2, as a p53-inducible gene, and show that this gene is activated by several stress signals that activate a p53 response, including DNA damaging agents and p14(ARF), p53R2 expression was induced by p53 mutants that are defective for the activation of apoptosis, but retain cell cycle arrest function, although no induction of p53R2 was seen in response to p21(WAF1/CIP1)-mediated cell cycle arrest. Several isoforms of the p53 family member p73 were also shown to induce p53R2 expression. Transient ectopic expression of either wild type p53R2 or p53R2 targeted to the nucleus, did not significantly alter cell cycle progression in unstressed cells, The identification of this gene as a p53 target supports a direct role for p53 in DNA repair, in addition to inhibition of growth of damaged cells.	NCI, Frederick Canc Res & Dev Ctr, Regulat Cell Growth Lab, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Vousden, KH (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Regulat Cell Growth Lab, Bldg 560,Room 22-96,W 7th St, Frederick, MD 21702 USA.		Balint, Eva/B-8695-2008	Balint, Eva/0000-0002-1258-6892				Agami R, 1999, NATURE, V399, P809; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Attardi LD, 1999, CELL MOL LIFE SCI, V55, P48, DOI 10.1007/s000180050269; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; BATES S, 1996, CURRENT OPIN GENET D, V6, P1; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evans SC, 1997, MOL MED TODAY, V3, P390, DOI 10.1016/S1357-4310(97)01105-2; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Gong JG, 1999, NATURE, V399, P806; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hollstein M, 1999, MUTAT RES-FUND MOL M, V431, P199, DOI 10.1016/S0027-5107(99)00162-1; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Lohrum MAE, 1999, CELL DEATH DIFFER, V6, P1162, DOI 10.1038/sj.cdd.4400625; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; WALDMAN T, 1995, CANCER RES, V55, P5187; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	32	191	199	0	13	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 31	2000	19	37					4283	4289		10.1038/sj.onc.1203774	http://dx.doi.org/10.1038/sj.onc.1203774			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980602				2022-12-25	WOS:000089032900011
J	Gaitonde, SV; Riley, JR; Qiao, DH; Martinez, JD				Gaitonde, SV; Riley, JR; Qiao, DH; Martinez, JD			Conformational phenotype of p53 is linked to nuclear translocation	ONCOGENE			English	Article						p53; conformation; subcellular localization	WILD-TYPE P53; CELL-CYCLE; CYTOPLASMIC SEQUESTRATION; MONOCLONAL-ANTIBODY; HUMAN NEUROBLASTOMA; DNA-BINDING; PROTEIN; LOCALIZATION; SUPPRESSOR; GENE	P53 is inactivated in tumors by mechanisms other than mutations in the p53 gene itself, To gain insight into the mechanisms by which this inactivation occurs, we chemically mutagenized A1-5 cells expressing high levels of temperature sensitive p53(val135) (tsp53) and selected for clones that were capable of growth at the permissive temperature for p53 activation. We expanded 22 clones (ALTR cells for (A) under bar 1-5 (L) under bar ow (T) under bar emperature (R) under bar esistant) that could grow at the permissive temperature. Most exhibited cytoplasmic sequestration as the mechanism by which p53 was inactivated. We show here that this cytoplasmically sequestered tsp53 protein is maintained in a mutant conformation. Only in clones with nuclear localized p53 is it also expressed in the wild-type conformation suggesting that subcellular localization of tsp53 is important in determining the conformation of the protein. Consistent with this, we show that the changes in conformation of p53 in A1-5 and SK-N-SH cells induced by ionizing radiation also correlate with nuclear translocation of p53, We suggest that nuclear translocation of p53 can result in a change in the conformation from mutant to wild-type but that these may be two separable events.	Univ Arizona, Dept Radiat Oncol, Arizona Canc Ctr, Tucson, AZ 85724 USA; Univ Arizona, Canc Biol Interdisciplinary Program, Grad Program, Tucson, AZ 85724 USA	Arizona Center Cancer Care; University of Arizona; University of Arizona	Martinez, JD (corresponding author), Univ Arizona, Dept Radiat Oncol, Arizona Canc Ctr, POB 245024,1515 N Campbell Ave, Tucson, AZ 85724 USA.				NCI NIH HHS [CA64842] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064842] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOSARI S, 1995, AM J PATHOL, V147, P790; BROWN JP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DAVIDOFF AM, 1992, ONCOGENE, V7, P127; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Goldman SC, 1996, AM J PATHOL, V148, P1381; HAINAUT P, 1993, CANCER RES, V53, P1739; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; LEVINE AJ, 1994, J LAB CLIN MED, V123, P817; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; McLure KG, 1996, ONCOGENE, V13, P1297; McLure KG, 1999, EMBO J, V18, P763, DOI 10.1093/emboj/18.3.763; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1994, SEMIN CANCER BIOL, V5, P211; MILNER J, 1987, ONCOGENE, V1, P453; MILNER J, 1990, ONCOGENE, V5, P1683; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHAULSKY G, 1991, CELL GROWTH DIFFER, V2, P661; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; Wolkowicz R, 1998, CANCER DETECT PREV, V22, P1, DOI 10.1046/j.1525-1500.1998.00003.x; Zaika A, 1999, J BIOL CHEM, V274, P27474, DOI 10.1074/jbc.274.39.27474; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZERRAHN J, 1992, ONCOGENE, V7, P1371	42	21	21	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 17	2000	19	35					4042	4049		10.1038/sj.onc.1203756	http://dx.doi.org/10.1038/sj.onc.1203756			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962561	Bronze			2022-12-25	WOS:000088825300010
J	Carlos, JL; Paetzel, M; Brubaker, G; Karla, A; Ashwell, CM; Lively, MO; Cao, GQ; Bullinger, P; Dalbey, RE				Carlos, JL; Paetzel, M; Brubaker, G; Karla, A; Ashwell, CM; Lively, MO; Cao, GQ; Bullinger, P; Dalbey, RE			The role of the membrane-spanning domain of type I signal peptidases in substrate cleavage site selection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI LEADER PEPTIDASE; ESCHERICHIA-COLI; DIRECTED MUTAGENESIS; SECRETORY PRECURSOR; FUNCTIONAL LIMITS; BACILLUS-SUBTILIS; ACTIVE-SITE; NUCLEASE-A; FACTOR-XA; SEQUENCE	Type I signal peptidase (SPase I) catalyzes the cleavage of the amino-terminal signal sequences from preproteins destined for cell export. Preproteins contain a signal sequence with a positively charged n-region, a hydrophobic h-region, and a neutral but polar c-region, Despite having no distinct consensus sequence other than a commonly found c-region "Ala-X-Ala" motif preceding the cleavage site, signal sequences are recognized by SPase I with high fidelity, Remarkably, other potential Ala-X-Ala sites are not cleaved within the preprotein. One hypothesis is that the source of this fidelity is due to the anchoring of both the SPase I enzyme (by way of its transmembrane segment) and the preprotein substrate (by the h-region in the signal sequence) in the membrane, This limits the enzyme-substrate interactions such that cleavage occurs at only one site, In this work we have, for the first time, successfully isolated Bacillus subtilis type I signal peptidase (SipS) and a truncated version lacking the transmembrane domain (SipS-P2), With purified full-length as well. as truncated constructs of both B. subtilis and Escherichia coli (Lep) SPase I, in vitro specificity studies indicate that the transmembrane domains of either enzyme are not important determinants of in vitro cleavage fidelity, since enzyme constructs lacking them reveal no alternate site processing of pro-OmpA nuclease A substrate. In addition, experiments with mutant pro-OmpA nuclease A substrate constructs indicate that the h-region of the signal peptide is also not critical for substrate specificity. In contrast, certain mutants in the c-region of the signal peptide result in alternate site cleavage by both Lep and SipS enzymes.	Ohio State Univ, Dept Chem, Columbus, OH 43210 USA; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Wake Forest Univ, Sch Med, Winston Salem, NC 27157 USA	University System of Ohio; Ohio State University; University of British Columbia; Wake Forest University	Dalbey, RE (corresponding author), Ohio State Univ, Dept Chem, 120 W 18Th Ave, Columbus, OH 43210 USA.	dalbey@chemistry.ohio-state.edu	; Ashwell, Christopher/N-1332-2016	Paetzel, Mark/0000-0002-7408-5487; Ashwell, Christopher/0000-0002-8190-1147	NIGMS NIH HHS [GM32861, GM08512, GM48805] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM048805, R01GM032861, T32GM008512, R15GM132861] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHATTERJEE S, 1995, J MOL BIOL, V245, P311, DOI 10.1006/jmbi.1994.0025; Cregg KM, 1996, J BACTERIOL, V178, P5712, DOI 10.1128/jb.178.19.5712-5718.1996; Dalbey RE, 1997, PROTEIN SCI, V6, P1129, DOI 10.1002/pro.5560060601; DATE T, 1983, J BACTERIOL, V154, P76, DOI 10.1128/JB.154.1.76-83.1983; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FIKES JD, 1990, J BIOL CHEM, V265, P3417; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; JAIN RG, 1994, J BIOL CHEM, V269, P16305; Karamyshev AL, 1998, J MOL BIOL, V277, P859, DOI 10.1006/jmbi.1997.1617; Klenotic PA, 2000, J BIOL CHEM, V275, P6490, DOI 10.1074/jbc.275.9.6490; Klug G, 1997, MOL GEN GENET, V253, P666, DOI 10.1007/s004380050370; KUHN A, 1985, J BIOL CHEM, V260, P5914; LAFORET GA, 1991, J BIOL CHEM, V266, P1326; Maniatis T., 1982, MOL CLONING LAB MANU; NAGAI K, 1985, P NATL ACAD SCI USA, V82, P7252, DOI 10.1073/pnas.82.21.7252; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; Nielsen H, 1997, Int J Neural Syst, V8, P581, DOI 10.1142/S0129065797000537; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NILSSON IM, 1991, J BIOL CHEM, V266, P3408; Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196; Paetzel M, 1997, TRENDS BIOCHEM SCI, V22, P28, DOI 10.1016/S0968-0004(96)10065-7; PATTERSON WR, 1994, J BIOL CHEM, V269, P17020; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; ROSENBLATT M, 1980, P NATL ACAD SCI-BIOL, V77, P3983, DOI 10.1073/pnas.77.7.3983; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SHEN LM, 1991, BIOCHEMISTRY-US, V30, P11775, DOI 10.1021/bi00115a006; Stein RL, 2000, BIOCHEMISTRY-US, V39, P7973, DOI 10.1021/bi000352i; TAKAHARA M, 1985, J BIOL CHEM, V260, P2670; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tjalsma H, 1998, GENE DEV, V12, P2318, DOI 10.1101/gad.12.15.2318; TSCHANTZ WR, 1995, BIOCHEMISTRY-US, V34, P3935, DOI 10.1021/bi00012a010; VANDIJL JM, 1995, J BIOL CHEM, V270, P3611, DOI 10.1074/jbc.270.8.3611; VONHEIJNE G, 1989, FEBS LETT, V244, P439, DOI 10.1016/0014-5793(89)80579-4; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1986, J MOL BIOL, V192, P287, DOI 10.1016/0022-2836(86)90365-7; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WEARNE SJ, 1990, FEBS LETT, V263, P23, DOI 10.1016/0014-5793(90)80696-G; Zhang YB, 1997, GENE, V194, P249, DOI 10.1016/S0378-1119(97)00198-4; Zhong WY, 1998, ANAL BIOCHEM, V255, P66, DOI 10.1006/abio.1997.2471	40	50	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38813	38822		10.1074/jbc.M007093200	http://dx.doi.org/10.1074/jbc.M007093200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10982814	Green Published, hybrid			2022-12-25	WOS:000165739800092
J	Egas, C; Lavoura, N; Resende, R; Brito, RMM; Pires, E; de Lima, MCP; Faro, C				Egas, C; Lavoura, N; Resende, R; Brito, RMM; Pires, E; de Lima, MCP; Faro, C			The saposin-like domain of the plant aspartic proteinase precursor is a potent inducer of vesicle leakage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYNARA-CARDUNCULUS L; NK-LYSIN; PHOSPHOLIPID-MEMBRANES; CRYSTAL-STRUCTURE; BARLEY; GRANULYSIN; PEPTIDES; CARDOSIN; BINDING; FUSION	A unique feature of plant aspartic proteinase precursors is the presence of an internal domain, known as plant-specific insert, whose function is not completely understood. The three-dimensional structure of the plant-specific insert resembles that of saposin-like proteins, a group of lipid-binding proteins involved in a variety of physiological processes. Here we show that recombinant plant-specific insert is able to interact with phospholipid vesicles and to induce leakage of their contents in a pH- and lipid-dependent manner. The leakage activity is higher at pH 4.5 and requires the presence of acidic phospholipids such as phosphatidylserine. To determine whether the same effect could be observed when the plant-specific insert is part of the precursor form, procardosin A and a mutant form lacking this specific domain were produced and characterized. Procardosin A displays a similar activity profile, whereas the mutant without the plant-specific insert shows only residual activity. These findings indicate that the plant-specific insert domain of plant aspartic proteinases mediates an interaction of their precursors with phospholipid membranes and induces membrane permeabilization. It is therefore possible that the plant-specific insert, alone or in conjunction with the proteolytic activity of plant aspartic proteinases, may function either as a defensive weapon against pathogens or in late autolysis of plant cells.	Univ Coimbra, Ctr Neurociencias Coimbra, P-3004517 Coimbra, Portugal; Univ Coimbra, Dept Bioquim, Fac Ciencias & Tecnol, P-3001401 Coimbra, Portugal; Univ Coimbra, Dept Quim, Fac Ciencias & Tecnol, P-3004535 Coimbra, Portugal	Universidade de Coimbra; Universidade de Coimbra; Universidade de Coimbra	Egas, C (corresponding author), Ctr Neurociencias Coimbra, Dept Biol Mol & Biotecnol, Inst Biomed Invest Luz & Imagem, Azinhaga Santa Comba, P-3000 Coimbra, Portugal.	cve@imagem.ibili.uc.pt	Resende, Rosa/F-4610-2010; de Lima, Maria da Conceição Monteiro/AAS-5602-2021; Resende, Rosa/AFU-7705-2022; Egas, Conceição/K-4866-2014	Resende, Rosa/0000-0002-0504-5756; de Lima, Maria da Conceição Monteiro/0000-0003-1844-5027; Egas, Conceição/0000-0002-2307-5414; Brito, Rui/0000-0001-9128-2557; Faro, Carlos/0000-0002-0480-8379; Pires, Euclides/0000-0002-5853-0165				Andreu D, 1999, BIOCHEM J, V344, P845, DOI 10.1042/0264-6021:3440845; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Beck DC, 2000, J BIOL CHEM, V275, P3365, DOI 10.1074/jbc.275.5.3365; Chang R, 1998, BBA-BIOMEMBRANES, V1371, P254, DOI 10.1016/S0005-2736(98)00031-5; Chen FQ, 1997, PLANT MOL BIOL, V35, P821, DOI 10.1023/A:1005833207707; DEKRUIJFF B, 1994, FEBS LETT, V346, P78, DOI 10.1016/0014-5793(94)00404-8; Faro C, 1999, J BIOL CHEM, V274, P28724, DOI 10.1074/jbc.274.40.28724; Faro C, 1998, ADV EXP MED BIOL, V436, P423; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Frazao C, 1999, J BIOL CHEM, V274, P27694, DOI 10.1074/jbc.274.39.27694; Gamen S, 1998, J IMMUNOL, V161, P1758; Glathe S, 1998, J BIOL CHEM, V273, P31230, DOI 10.1074/jbc.273.47.31230; GURUPRASAD K, 1994, FEBS LETT, V352, P131, DOI 10.1016/0014-5793(94)00935-X; HEELEE I, 1997, FEBS LETT, V400, P158; James MNG, 1998, ASPARTIC PROTEINASES; Kervinen J, 1999, EMBO J, V18, P3947, DOI 10.1093/emboj/18.14.3947; Lehrer RI, 1999, CURR OPIN IMMUNOL, V11, P23, DOI 10.1016/S0952-7915(99)80005-3; Leippe M, 1997, PARASITOL TODAY, V13, P178, DOI 10.1016/S0169-4758(97)01038-7; Liepinsh E, 1997, NAT STRUCT BIOL, V4, P793, DOI 10.1038/nsb1097-793; MagetDana R, 1997, BIOPHYS J, V73, P2527, DOI 10.1016/S0006-3495(97)78281-X; Matsuzaki K, 1998, BIOCHEMISTRY-US, V37, P11856, DOI 10.1021/bi980539y; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P6521, DOI 10.1021/bi00019a033; Nir S, 1999, MOL MEMBR BIOL, V16, P95, DOI 10.1080/096876899294814; OSTOLAZA H, 1993, BIOCHIM BIOPHYS ACTA, V1147, P81, DOI 10.1016/0005-2736(93)90318-T; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P179, DOI 10.1016/S0968-0004(00)89003-9; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P213, DOI 10.1016/0010-4655(82)90173-4; RAFALSKI M, 1991, BIOCHEMISTRY-US, V30, P10211, DOI 10.1021/bi00106a020; Ramalho-Santos M, 1998, EUR J BIOCHEM, V255, P133, DOI 10.1046/j.1432-1327.1998.2550133.x; RamalhoSantos M, 1997, PLANTA, V203, P204, DOI 10.1007/s004250050183; Runeberg-Roos P, 1998, PLANT J, V15, P139, DOI 10.1046/j.1365-313X.1998.00187.x; Ruysschaert JM, 1998, FEBS LETT, V425, P341, DOI 10.1016/S0014-5793(98)00261-0; Stenger S, 1998, SCIENCE, V282, P121, DOI 10.1126/science.282.5386.121; Tatti M, 1999, EUR J BIOCHEM, V263, P486, DOI 10.1046/j.1432-1327.1999.00521.x; Vaccaro AM, 1999, NEUROCHEM RES, V24, P307, DOI 10.1023/A:1022530508763; Vaccaro AM, 1995, J BIOL CHEM, V270, P30576, DOI 10.1074/jbc.270.51.30576; Verissimo P, 1996, EUR J BIOCHEM, V235, P762, DOI 10.1111/j.1432-1033.1996.00762.x; White PC, 1999, J BIOL CHEM, V274, P16685, DOI 10.1074/jbc.274.24.16685	37	50	53	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38190	38196		10.1074/jbc.M006093200	http://dx.doi.org/10.1074/jbc.M006093200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10982803	hybrid			2022-12-25	WOS:000165739800010
J	Lebrun, P; Baron, V; Hauck, CR; Schlaepfer, DD; Van Obberghen, E				Lebrun, P; Baron, V; Hauck, CR; Schlaepfer, DD; Van Obberghen, E			Cell adhesion and focal adhesion kinase regulate insulin receptor substrate-1 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; PHOSPHATIDYLINOSITOL 3-KINASE; MUSCLE CELLS; C-JUN; INTEGRIN; BINDING; GROWTH; ACTIVATION	Integrins are transmembrane receptors involved in interactions between cells and extracellular matrix proteins. Here we show that cell adhesion regulates insulin receptor substrate-1 (IRS-1) mRNA synthesis, When fibroblasts are held in suspension, lower levels of IRS-1 mRNA, but not of IRS-2 mRNA, are detected, and this effect is due to the negative regulation of IRS-1 transcription rather than to decreased mRNA stability. Upon fibronectin- or vitronectin-mediated integrin stimulation, the level of IRS-1 mRNA was restored within 4 h, The focal adhesion kinase (FAK) is known to be activated upon integrin stimulation, and we found that IRS-1 was not expressed in FAK(-/-) cells. Stable re-expression of epitope-tagged FAK in FAK(-/-) fibroblasts (DA2 cells) restored normal levels of IRS-1 expression, confirming that IRS-1 mRNA expression is regulated by FAK, It is known that integrins activate the JNK pathway. However, in adherent FAK(-/-) cells, we failed to detect activation of JNK, whereas JNK was stimulated in DA2 cells, This confirms the role of FAK in integrin-induced JNK stimulation. FAR-independent stimulation of JNK with anisomycin treatment both in FAK(-/-) cells and in suspended FAK(-/-) cells confirmed that IRS-1 mRNA transcription can be partially regulated by JNK, We suggest that integrins can modulate insulin and insulin-like growth factor-1 signaling pathways by regulating the levels of IRS-1 in cells and that FAR-mediated signaling to JNK is one pathway involved in this process.	INSERM, U145, Inst Federatif Rech, F-06107 Nice 2, France; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Scripps Research Institute	Baron, V (corresponding author), INSERM, U145, Inst Federatif Rech, 50 Ave Valombrose, F-06107 Nice 2, France.		LEBRUN, Patricia/O-5765-2016					Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; ARAKI E, 1995, MOL ENDOCRINOL, V9, P1367, DOI 10.1210/me.9.10.1367; Boudreau J, 1999, BIOCHEM J, V339, P481, DOI 10.1042/0264-6021:3390481; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Echtermeyer F, 1996, J BIOL CHEM, V271, P2071, DOI 10.1074/jbc.271.4.2071; Edwards GM, 1998, J BIOL CHEM, V273, P9495, DOI 10.1074/jbc.273.16.9495; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Guilherme A, 1998, J BIOL CHEM, V273, P22899, DOI 10.1074/jbc.273.36.22899; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KAHN R, 1997, INT TXB DIABETES MEL, P437; Keely P, 1998, TRENDS CELL BIOL, V8, P101, DOI 10.1016/S0962-8924(97)01219-1; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lebrun P, 1998, J BIOL CHEM, V273, P32244, DOI 10.1074/jbc.273.48.32244; Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; Matsuda K, 1997, DIABETES, V46, P354, DOI 10.2337/diabetes.46.3.354; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Miele C, 1999, J BIOL CHEM, V274, P3094, DOI 10.1074/jbc.274.5.3094; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Pabla R, 1999, J CELL BIOL, V144, P175, DOI 10.1083/jcb.144.1.175; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; SHAW RJ, 1990, J CELL BIOL, V111, P2139, DOI 10.1083/jcb.111.5.2139; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; Walzog B, 1999, FASEB J, V13, P1855, DOI 10.1096/fasebj.13.13.1855; Waters SB, 1996, TRENDS CELL BIOL, V6, P1, DOI 10.1016/0962-8924(96)81024-5; Xiao GZ, 1998, J BIOL CHEM, V273, P32988, DOI 10.1074/jbc.273.49.32988; Xu JH, 1996, J CELL BIOL, V132, P239, DOI 10.1083/jcb.132.1.239; Zheng B, 1998, J BIOL CHEM, V273, P8994, DOI 10.1074/jbc.273.15.8994; Zheng B, 1998, P NATL ACAD SCI USA, V95, P11217, DOI 10.1073/pnas.95.19.11217; Zhu T, 1998, J BIOL CHEM, V273, P33864, DOI 10.1074/jbc.273.50.33864	51	53	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38371	38377		10.1074/jbc.M006162200	http://dx.doi.org/10.1074/jbc.M006162200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10967115	hybrid, Green Published			2022-12-25	WOS:000165739800033
J	Millard, EE; Srivastava, K; Traub, LM; Schaffer, JE; Ory, DS				Millard, EE; Srivastava, K; Traub, LM; Schaffer, JE; Ory, DS			Niemann-Pick type C1 (NPC1) overexpression alters cellular cholesterol homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; HAMSTER OVARY CELLS; HUMAN FIBROBLASTS; PROTEIN; TRANSPORT; DISEASE; TRAFFICKING; METABOLISM; MEMBRANE; MUTATION	The Niemann-Pick type C1 (NPC1) protein is a key participant in intracellular trafficking of low density lipoprotein cholesterol, but its role in regulation of sterol homeostasis is not well understood. To characterize further the function of NPC1, we generated stable Chinese hamster ovary (CHO) cell lines overexpressing the human NPC1 protein (CHO/NPC1). NPC1 overexpression increases the rate of trafficking of low density lipoprotein cholesterol to the endoplasmic reticulum and the rate of delivery of endosomal cholesterol to the plasma membrane (PM). CHO/NPC1 cells exhibit a 1.5-fold increase in total cellular cholesterol and up to a 2.9-fold increase in PM cholesterol. This increase in PM cholesterol is closely paralleled by a 3-fold increase in de novo cholesterol synthesis. Inhibition of cholesterol synthesis results in marked redistribution of PM cholesterol to intracellular sites, suggesting an unsuspected role for NPC1 in internalization of PM cholesterol, Despite elevated total cellular cholesterol, CHO/NPC1 cells exhibit increased cholesterol synthesis, which may be attributable to both resistance to oxysterol suppression of sterol-regulated gene expression and to reduced endoplasmic reticulum cholesterol levels under basal conditions. Taken together, these studies provide important new insights into the role of NPC1 in the determination of the levels and distribution of cellular cholesterol.	Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Washington University (WUSTL); Washington University (WUSTL); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Ory, DS (corresponding author), Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Internal Med, Box 8086,660 S Euclid Ave, St Louis, MO 63110 USA.	dory@imgate.wustl.edu		Traub, Linton/0000-0002-1303-0298				BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BROWN MS, 1973, P NATL ACAD SCI USA, V70, P2162, DOI 10.1073/pnas.70.7.2162; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CADIGAN KM, 1990, J CELL BIOL, V110, P295, DOI 10.1083/jcb.110.2.295; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Cruz JC, 2000, J BIOL CHEM, V275, P4013, DOI 10.1074/jbc.275.6.4013; Davies JP, 2000, J BIOL CHEM, V275, P24367, DOI 10.1074/jbc.M002184200; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; KRIEGER M, 1978, J BIOL CHEM, V253, P4093; Lange Y, 1997, J BIOL CHEM, V272, P13103, DOI 10.1074/jbc.272.20.13103; LISCUM L, 1987, J BIOL CHEM, V262, P17002; LISCUM L, 1989, J BIOL CHEM, V264, P11796; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Patel SC, 1999, P NATL ACAD SCI USA, V96, P1657, DOI 10.1073/pnas.96.4.1657; PENTCHEV PG, 1985, P NATL ACAD SCI USA, V82, P8247, DOI 10.1073/pnas.82.23.8247; Rawson RB, 1998, J BIOL CHEM, V273, P28261, DOI 10.1074/jbc.273.43.28261; SLOTTE JP, 1989, BIOCHIM BIOPHYS ACTA, V985, P90, DOI 10.1016/0005-2736(89)90108-9; Stuhlsatz-Krouper SM, 1998, J BIOL CHEM, V273, P28642, DOI 10.1074/jbc.273.44.28642; Underwood KW, 1998, J BIOL CHEM, V273, P4266, DOI 10.1074/jbc.273.7.4266; Watari H, 1999, P NATL ACAD SCI USA, V96, P805, DOI 10.1073/pnas.96.3.805; Worgall TS, 1998, J BIOL CHEM, V273, P25537, DOI 10.1074/jbc.273.40.25537; Yang T, 2000, J BIOL CHEM, V275, P29881, DOI 10.1074/jbc.M005439200	27	94	98	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38445	38451		10.1074/jbc.M003180200	http://dx.doi.org/10.1074/jbc.M003180200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10964915	hybrid			2022-12-25	WOS:000165739800042
J	Han, X; Sterling, H; Chen, YM; Saginario, C; Brown, EJ; Frazier, WA; Lindberg, FP; Vignery, A				Han, X; Sterling, H; Chen, YM; Saginario, C; Brown, EJ; Frazier, WA; Lindberg, FP; Vignery, A			CD47, a ligand for the macrophage fusion receptor, participates in macrophage multinucleation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-ASSOCIATED PROTEIN; NEURAL ADHESION MOLECULE; MEMBRANE-PROTEIN; EXPRESSION; ANTIGEN; FAMILY; CELLS; OVEREXPRESSION; GLYCOPROTEIN; RETROVIRUS	The macrophage fusion receptor (MFR), also called P84/BIT/SIRP alpha /SHPS-1, is a transmembrane glycoprotein that belongs to the superfamily of immunoglobulins. Previously, we showed that MFR expression is highly induced at the onset of fusion in macrophages, and that MFR appears to play a role in macrophage-macrophage adhesion/fusion leading to multinucleation. The recent finding that I4P/CD47 acts as a ligand for MFR led us to hypothesize that it interacts with CD47 at the onset of cell-cell fusion. CD47 is a transmembrane glycoprotein, which, like MFR, belongs to the superfamily of immunoglobulins. We show that macrophages express the hemopoietic form of CD47, the expression of which is induced at the onset of fusion, but to a lower level than MFR. A glutathione S-transferase CD47 fusion protein engineered to contain the extracellular domain of CD47, binds macrophages, associates with MFR, and prevents multinucleation. CD47 and MFR associate via their amino-terminal immunoglobulin variable domain. Of the nine monoclonal antibodies raised against the extracellular domain of CD47, three block fusion, as well as MFR-CD47 interaction, whereas the others have no effect. Together, these data suggest that CD47 is involved in macrophage multinucleation by virtue of interacting with MFR during adhesion/fusion.	Yale Univ, Sch Med, Dept Orthopaed & Rehabil, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Washington Univ, Sch Med, Div Infect Dis, St Louis, MO 63110 USA; Univ Calif San Francisco, Ctr Host Pathogen Interact, San Francisco, CA 94143 USA; Washington Univ, Sch Med, Dept Biochem, St Louis, MO 63110 USA	Yale University; Yale University; Washington University (WUSTL); University of California System; University of California San Francisco; Washington University (WUSTL)	Vignery, A (corresponding author), Yale Univ, Sch Med, Dept Orthopaed & Rehabil, 333 Cedar St, New Haven, CT 06510 USA.	agnes.vignery@yale.edu			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057573] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE12110] Funding Source: Medline; NIGMS NIH HHS [GM57573-01] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Babic I, 2000, J IMMUNOL, V164, P3652, DOI 10.4049/jimmunol.164.7.3652; Baron R, 1995, ACTA ORTHOP SCAND, V66, P66, DOI 10.3109/17453679509157650; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; CHUANG W, 1990, DEV BIOL, V137, P219, DOI 10.1016/0012-1606(90)90249-I; Comu S, 1997, J NEUROSCI, V17, P8702; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Gao AG, 1996, J CELL BIOL, V135, P533, DOI 10.1083/jcb.135.2.533; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; Jiang PH, 1999, J BIOL CHEM, V274, P559, DOI 10.1074/jbc.274.2.559; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kirby JE, 1998, MOL MICROBIOL, V27, P323, DOI 10.1046/j.1365-2958.1998.00680.x; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; Le Naour F, 2000, SCIENCE, V287, P319, DOI 10.1126/science.287.5451.319; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; MAWBY WJ, 1994, BIOCHEM J, V304, P525, DOI 10.1042/bj3040525; Miyado K, 2000, SCIENCE, V287, P321, DOI 10.1126/science.287.5451.321; Nishiyama Y, 1997, JPN J CANCER RES, V88, P120, DOI 10.1111/j.1349-7006.1997.tb00356.x; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; PARKINSON JE, 1995, VIROLOGY, V214, P177, DOI 10.1006/viro.1995.9942; REINHOLD MI, 1995, J CELL SCI, V108, P3419; Saginario C, 1995, P NATL ACAD SCI USA, V92, P12210, DOI 10.1073/pnas.92.26.12210; Saginario C, 1998, MOL CELL BIOL, V18, P6213, DOI 10.1128/MCB.18.11.6213; Sanderson CM, 1996, J VIROL, V70, P905, DOI 10.1128/JVI.70.2.905-914.1996; Sano S, 1999, BIOCHEM J, V344, P667, DOI 10.1042/0264-6021:3440667; Sano S, 1997, FEBS LETT, V411, P327, DOI 10.1016/S0014-5793(97)00724-2; Seiffert M, 1999, BLOOD, V94, P3633, DOI 10.1182/blood.V94.11.3633.423k01_3633_3643; Sterling H, 1998, J CELL BIOL, V143, P837, DOI 10.1083/jcb.143.3.837; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; Veillette A, 1998, J BIOL CHEM, V273, P22719, DOI 10.1074/jbc.273.35.22719; VIGNERY A, 1989, AM J PATHOL, V135, P565; VIGNERY A, 1989, J HISTOCHEM CYTOCHEM, V37, P1265, DOI 10.1177/37.8.2546991; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0	36	168	184	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37984	37992		10.1074/jbc.M002334200	http://dx.doi.org/10.1074/jbc.M002334200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10964914	hybrid			2022-12-25	WOS:000165618700091
J	Chou, CL; Yip, KP; Michea, L; Kador, K; Ferraris, JD; Wade, JB; Knepper, MA				Chou, CL; Yip, KP; Michea, L; Kador, K; Ferraris, JD; Wade, JB; Knepper, MA			Regulation of aquaporin-2 trafficking by vasopressin in the renal collecting duct - Roles of ryanodine-sensitive Ca2+ stores and calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; WATER PERMEABILITY; INTRACELLULAR CA2+; RAT; ACTIVATION; RECEPTOR; CALCIUM; EXPRESSION; CHANNELS; HORMONE	In the renal collecting duct, vasopressin increases osmotic water permeability (P-f) by triggering trafficking of aquaporin-2 vesicles to the apical plasma membrane. We investigated the role of vasopressin-induced intracellular Ca2+ mobilization in this process. In isolated inner medullary collecting ducts (IMCDs), vasopressin (0.1 nM) and 8-(4-chlorophenylthio)-cAMP (0.1 mM) elicited marked increases in [Ca2+](i) (fluo-4), Vasopressin-induced Ca2+ mobilization was completely blocked by preloading with the Ca2+ chelator BAPTA, In parallel experiments, BAPTA completely blocked the vasopressin-induced increase in P-f without affecting adenosine 3',5'-cyclic monophosphate (cAMP) production. Previously, we demonstrated the lack of activation of the phosphoinositide-signaIing pathway by vasopressin in IMCD, suggesting an inositol 1,4,5-trisphosphate-independent mechanism of Ca2+ release. Evidence for expression of the type I ryanodine receptor (RyR1) in IMCD was obtained by immunofluorescence, immunoblotting, and reverse transcription-polymerase chain reaction, Ryanodine (100 muM), a ryanodine receptor antagonist, blocked the arginine vasopressin-mediated increase in P-f and blocked vasopressin-stimulated redistribution of aquaporin-2 to the plasma membrane domain in primary cultures of IMCD cells, as assessed by immunofluorescence immunocytochemistry. Calmodulin inhibitors (W7 and trifluoperazine) blocked the P-f response to vasopressin and the vasopressin-stimulated redistribution of aquaporin-2. The results suggest that Ca2+ release from ryanodine-sensitive stores plays an essential role in vasopressin-mediated aquaporin-2 trafficking via a calmodulin-dependent mechanism.	NHLBI, Kidney & Electrolyte Metab Lab, NIH, Bethesda, MD 20892 USA; Univ S Florida, Coll Med, Dept Physiol & Biophys, Tampa, FL 33612 USA; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); State University System of Florida; University of South Florida; University System of Maryland; University of Maryland Baltimore	Knepper, MA (corresponding author), NHLBI, Kidney & Electrolyte Metab Lab, NIH, 10 Ctr Dr,MSC 1603,Bldg 10,Rm 6N260, Bethesda, MD 20892 USA.		Yip, Kay-Pong D/H-4639-2012; Knepper, Mark/AAF-8412-2020	Yip, Kay-Pong D/0000-0003-4364-6701; 	Intramural NIH HHS [Z01 HL001285-21, Z99 HL999999] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL001285] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agre P, 1998, J BIOL CHEM, V273, P14659, DOI 10.1074/jbc.273.24.14659; ALZAHID G, 1977, J MEMBRANE BIOL, V31, P103, DOI 10.1007/BF01869401; BAJJALIEH SM, 1995, J BIOL CHEM, V270, P1971, DOI 10.1074/jbc.270.5.1971; BOKVIST K, 1995, EMBO J, V14, P50, DOI 10.1002/j.1460-2075.1995.tb06974.x; Brown D, 1998, AM J PHYSIOL-RENAL, V275, pF328, DOI 10.1152/ajprenal.1998.275.3.F328; BURG M, 1966, AM J PHYSIOL, V210, P1293, DOI 10.1152/ajplegacy.1966.210.6.1293; Burgoyne RD, 1998, CELL CALCIUM, V24, P367, DOI 10.1016/S0143-4160(98)90060-4; BURGOYNE RD, 1995, TRENDS NEUROSCI, V18, P191, DOI 10.1016/0166-2236(95)93900-I; Chabardes D, 1996, J BIOL CHEM, V271, P19264, DOI 10.1074/jbc.271.32.19264; CHAMPIGNEULLE A, 1993, AM J PHYSIOL, V265, pF35, DOI 10.1152/ajprenal.1993.265.1.F35; Cheng H, 1996, CELL CALCIUM, V20, P129, DOI 10.1016/S0143-4160(96)90102-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU CL, 1995, AM J PHYSIOL-RENAL, V269, pF78, DOI 10.1152/ajprenal.1995.269.1.F78; Chou CL, 1998, AM J PHYSIOL-RENAL, V274, pF564, DOI 10.1152/ajprenal.1998.274.3.F564; DIGIOVANNI SR, 1994, P NATL ACAD SCI USA, V91, P8984, DOI 10.1073/pnas.91.19.8984; DILLINGHAM MA, 1986, J PHYSIOL-LONDON, V372, P41, DOI 10.1113/jphysiol.1986.sp015995; Ecelbarger CA, 1996, AM J PHYSIOL-RENAL, V270, pF623, DOI 10.1152/ajprenal.1996.270.4.F623; GROMADA J, 1995, FEBS LETT, V373, P182, DOI 10.1016/0014-5793(95)01070-U; Gustafson CE, 2000, AM J PHYSIOL-RENAL, V278, pF317, DOI 10.1152/ajprenal.2000.278.2.F317; Holz GG, 1999, J BIOL CHEM, V274, P14147, DOI 10.1074/jbc.274.20.14147; Islam MS, 1998, P NATL ACAD SCI USA, V95, P6145, DOI 10.1073/pnas.95.11.6145; Jaggar JH, 2000, AM J PHYSIOL-CELL PH, V278, pC235, DOI 10.1152/ajpcell.2000.278.2.C235; Katsura T, 1997, Am J Physiol, V272, pF817; Knepper MA, 1997, AM J PHYSIOL-RENAL, V272, pF3, DOI 10.1152/ajprenal.1997.272.1.F3; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; LEVINE SD, 1981, J CLIN INVEST, V67, P662, DOI 10.1172/JCI110081; MAEDA Y, 1993, AM J PHYSIOL, V265, pF15, DOI 10.1152/ajprenal.1993.265.1.F15; MAEDA Y, 1992, AM J PHYSIOL, V263, pF319, DOI 10.1152/ajprenal.1992.263.2.F319; NEYLON CB, 1995, BIOCHEM BIOPH RES CO, V215, P814, DOI 10.1006/bbrc.1995.2536; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; Ozawa T, 1998, BIOCHEM BIOPH RES CO, V246, P422, DOI 10.1006/bbrc.1998.8636; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; Querfurth HW, 1998, BIOCHEM J, V334, P79, DOI 10.1042/bj3340079; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; STAR RA, 1988, J CLIN INVEST, V81, P1879, DOI 10.1172/JCI113534; Terris J, 1996, AM J PHYSIOL-RENAL, V271, pF414, DOI 10.1152/ajprenal.1996.271.2.F414; Tunwell REA, 1996, J BIOL CHEM, V271, P29583, DOI 10.1074/jbc.271.47.29583; Wade JB, 2000, AM J PHYSIOL-RENAL, V278, pF52, DOI 10.1152/ajprenal.2000.278.1.F52; WALL SM, 1992, AM J PHYSIOL, V262, pF989, DOI 10.1152/ajprenal.1992.262.6.F989; Yip KP, 1996, AM J PHYSIOL-RENAL, V271, pF1004, DOI 10.1152/ajprenal.1996.271.5.F1004; Zhang MJ, 1998, BIOCHEM CELL BIOL, V76, P313, DOI 10.1139/bcb-76-2-3-313	41	170	176	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36839	36846		10.1074/jbc.M005552200	http://dx.doi.org/10.1074/jbc.M005552200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973964	hybrid			2022-12-25	WOS:000165577700057
J	Lindsay, H; Beaumont, E; Richards, SD; Kelly, SM; Sanderson, SJ; Price, NC; Lindsay, JG				Lindsay, H; Beaumont, E; Richards, SD; Kelly, SM; Sanderson, SJ; Price, NC; Lindsay, JG			FAD insertion is essential for attaining the assembly competence of the dihydrolipoamide dehydrogenase (E3) monomer from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REFINED CRYSTAL-STRUCTURE; LIPOAMIDE DEHYDROGENASE; LIPOYL DOMAIN; 3-DIMENSIONAL STRUCTURE; NUCLEOTIDE-SEQUENCE; AZOTOBACTER-VINELANDII; MULTIENZYME COMPLEX; BINDING DOMAIN; ACID; RESOLUTION	Dihydrolipoamide dehydrogenase (E3) from Escherichia coli, an FAD-linked homodimer, can be fully reconstituted in. vitro following denaturation in 6 M guanidinium chloride. Complete restoration of activity occurs within 1-2 h in the presence of FAD, dithiothreitol, and bovine serum albumin. In the absence of FAD, the dihydrolipoamide dehydrogenase monomer forms a stable folding intermediate, which is incapable of dimerization, This intermediate displays a similar tryptic resistance to the native enzyme but is less heat-stable, because its ability to form native E3 is lost after incubation at 65 degreesC for 15 min, The presence of FAD promotes slow, additional conformational rearrangements of the E3 subunit as observed by cofactor-dependent decreases in intrinsic tryptophan fluorescence. However, after 2 h, the tryptophan fluorescence spectrum and far UV CD spectrum of E3, refolded in the absence of FAD, are similar to that of the native enzyme, and full activity can still be recovered on addition of FAD, Cross-linking studies show that FAD insertion is necessary for the monomeric folding intermediate to attain an assembly competent state leading to dimerization. Thus cofactor insertion represents a key step in the assembly of this enzyme, although its initial presence appears not to be required to promote the correct folding pathway.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland; Univ Stirling, Dept Biol Sci, Stirling FK9 4LA, Scotland	University of Glasgow; University of Stirling	Lindsay, JG (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	G.Lindsay@bio.gla.ac.uk	Kelly, Sharon/K-4611-2013	Kelly, Sharon/0000-0002-3516-1387				Berg A, 1997, EUR J BIOCHEM, V244, P352, DOI 10.1111/j.1432-1033.1997.00352.x; DANSON MJ, 1987, BIOCHEM J, V243, P661, DOI 10.1042/bj2430661; DARDEL F, 1993, J MOL BIOL, V229, P1037, DOI 10.1006/jmbi.1993.1103; delaSierra IL, 1997, J MOL BIOL, V269, P129, DOI 10.1006/jmbi.1997.1009; ELSE AJ, 1994, MOL BIOCHEM PARASIT, V64, P233, DOI 10.1016/0166-6851(93)00016-3; Engels A, 1997, BBA-PROTEIN STRUCT M, V1340, P33, DOI 10.1016/S0167-4838(97)00025-3; Harris RA, 1997, ADV ENZYME REGUL, V37, P271, DOI 10.1016/S0065-2571(96)00009-X; HOPKINS N, 1995, BIOCHEMISTRY-US, V34, P11757, DOI 10.1021/bi00037a013; JACKMAN SA, 1990, EUR J BIOCHEM, V193, P91, DOI 10.1111/j.1432-1033.1990.tb19308.x; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; KALIA YN, 1993, J MOL BIOL, V230, P323, DOI 10.1006/jmbi.1993.1145; KALSE JF, 1968, BIOCHIM BIOPHYS ACTA, V159, P244, DOI 10.1016/0005-2744(68)90073-9; KOCHI H, 1976, ARCH BIOCHEM BIOPHYS, V173, P71, DOI 10.1016/0003-9861(76)90236-8; Mande SS, 1996, STRUCTURE, V4, P277, DOI 10.1016/S0969-2126(96)00032-9; MATTEVI A, 1992, SCIENCE, V255, P1544, DOI 10.1126/science.1549782; MATTEVI A, 1991, J MOL BIOL, V220, P975, DOI 10.1016/0022-2836(91)90367-F; MATTEVI A, 1992, PROTEINS, V13, P336, DOI 10.1002/prot.340130406; MATTEVI A, 1993, J MOL BIOL, V230, P1183, DOI 10.1006/jmbi.1993.1235; MATTEVI A, 1993, J MOL BIOL, V230, P1200, DOI 10.1006/jmbi.1993.1236; MAYER A, 1995, J BIOL CHEM, V270, P12390, DOI 10.1074/jbc.270.21.12390; McCartney RG, 1997, BIOCHEMISTRY-US, V36, P6819, DOI 10.1021/bi9630016; PATEL MS, 1995, FASEB J, V9, P1164, DOI 10.1096/fasebj.9.12.7672509; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; RUSSELL GC, 1992, BIOCHEM J, V1076, P225; SAIJO T, 1995, BIOCHEM J, V261, P189; STEPHENS PE, 1983, EUR J BIOCHEM, V133, P155, DOI 10.1111/j.1432-1033.1983.tb07441.x; STEPHENS PE, 1983, EUR J BIOCHEM, V135, P519, DOI 10.1111/j.1432-1033.1983.tb07683.x; STEPHENS PE, 1983, EUR J BIOCHEM, V133, P481, DOI 10.1111/j.1432-1033.1983.tb07490.x; THORPE C, 1974, BIOCHEMISTRY-US, V13, P3263, DOI 10.1021/bi00713a013; Toyoda T, 1998, J BIOCHEM-TOKYO, V123, P668; VISSER J, 1968, BIOCHIM BIOPHYS ACTA, V159, P257, DOI 10.1016/0005-2744(68)90074-0; Wallis NG, 1996, J MOL BIOL, V263, P463, DOI 10.1006/jmbi.1996.0589; WALLIS NG, 1994, J MOL BIOL, V236, P209, DOI 10.1006/jmbi.1994.1130; WEST SM, 1995, BIOCHEM J, V308, P1025, DOI 10.1042/bj3081025; WEST SM, 1989, BIOCHEM J, V171, P609; WHITE MF, 1993, BIOCHEM J, V291, P479, DOI 10.1042/bj2910479; Williams Jr C.H., 1989, ANN N Y ACAD SCI, V573, P55	37	16	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36665	36670		10.1074/jbc.M004777200	http://dx.doi.org/10.1074/jbc.M004777200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10970889	hybrid			2022-12-25	WOS:000165577700031
J	Narouz-Ott, L; Maurer, P; Nitsche, DP; Smyth, N; Paulsson, M				Narouz-Ott, L; Maurer, P; Nitsche, DP; Smyth, N; Paulsson, M			Thrombospondin-4 binds specifically to both collagenous and non-collagenous extracellular matrix proteins via its C-terminal domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-MICROSCOPY; NERVOUS-SYSTEM; GENE FAMILY; CARTILAGE; COMP; EXPRESSION; TISSUES; FIBRONECTIN; LAMININ; TENDON	Full-length and truncated forms of rat thrombospondin-4 (TSP-4) were expressed recombinantly in a mammalian cell line and purified to homogeneity. Biochemical analysis revealed a limited proteolytic processing, which detaches the N-terminal heparin-binding domain from the rest of the molecule and confirmed the importance of the heptad-repeat domain for pentamerization. In electron microscopy the uncleaved TSP-4 was seen as a large central particle to which five smaller globules are attached by elongated Linker regions. Binding of TSP-4 to collagens and to non-collagenous proteins could be detected in enzyme-linked immunosorbent assay-style ligand binding assays, by surface plasmon resonance spectroscopy, and in rotary shadowing electron microscopy. Although the binding of TSP-4 to solid-phase collagens was enhanced by Zn2+, that to non-collagenous proteins was not. The interactions of TSP-4 with both classes of proteins are mediated by C-terminal domains of the TSP-4 subunits but do not require an oligomeric structure. Major binding sites for TSP-4 are located in or close to the N- and C-terminal telopeptides in collagen I, but additional sites are detected in more central regions of the molecule.	Univ Cologne, Fac Med, Inst Biochem, D-50931 Cologne, Germany	University of Cologne	Paulsson, M (corresponding author), Univ Cologne, Fac Med, Inst Biochem, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.			Smyth, Neil/0000-0002-3734-2149				Adams JC, 1997, INT J BIOCHEM CELL B, V29, P861, DOI 10.1016/S1357-2725(96)00171-9; ARBER S, 1995, J CELL BIOL, V131, P1083, DOI 10.1083/jcb.131.4.1083; BAENZIGE.NL, 1971, P NATL ACAD SCI USA, V68, P240, DOI 10.1073/pnas.68.1.240; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; DICESARE P, 1994, FEBS LETT, V354, P237, DOI 10.1016/0014-5793(94)01134-6; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; GALVIN NJ, 1987, J CELL BIOL, V104, P1413, DOI 10.1083/jcb.104.5.1413; HAUSER N, 1995, FEBS LETT, V368, P307, DOI 10.1016/0014-5793(95)00675-Y; Hecht JT, 1998, MATRIX BIOL, V17, P269, DOI 10.1016/S0945-053X(98)90080-4; HEDBOM E, 1992, J BIOL CHEM, V267, P6132; HENNESSY SW, 1989, J CELL BIOL, V108, P729, DOI 10.1083/jcb.108.2.729; IRUELAARISPE ML, 1993, DEV DYNAM, V197, P40, DOI 10.1002/aja.1001970105; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; Kyriakides TR, 1998, J CELL BIOL, V140, P419, DOI 10.1083/jcb.140.2.419; Kyriakides TR, 1998, J HISTOCHEM CYTOCHEM, V46, P1007, DOI 10.1177/002215549804600904; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWLER J, 1993, J CELL BIOL, V120, P1059, DOI 10.1083/jcb.120.4.1059; LAWLER J, 1995, J BIOL CHEM, V270, P2809, DOI 10.1074/jbc.270.6.2809; Lawler J, 1998, J CLIN INVEST, V101, P982, DOI 10.1172/JCI1684; LAWLER J, 1992, BIOCHEMISTRY-US, V31, P1173, DOI 10.1021/bi00119a029; LAWLER JW, 1978, J BIOL CHEM, V253, P8609; MEIER T, 1992, ANAL BIOCHEM, V204, P220, DOI 10.1016/0003-2697(92)90165-4; MIEKKA SI, 1982, THROMB RES, V27, P1, DOI 10.1016/0049-3848(82)90272-9; MORGELIN M, 1992, J BIOL CHEM, V267, P6137; OLDBERG A, 1992, J BIOL CHEM, V267, P22346; PAULSSON M, 1988, J BIOL CHEM, V263, P5425; Piecha D, 1999, J BIOL CHEM, V274, P13353, DOI 10.1074/jbc.274.19.13353; QABAR AN, 1994, J BIOL CHEM, V269, P1262; Rosenberg K, 1998, J BIOL CHEM, V273, P20397, DOI 10.1074/jbc.273.32.20397; TUCKER RP, 1995, DEV DYNAM, V203, P477, DOI 10.1002/aja.1002030410; Urry LA, 1998, DEV DYNAM, V211, P390, DOI 10.1002/(SICI)1097-0177(199804)211:4<390::AID-AJA10>3.0.CO;2-8; VOS HL, 1992, J BIOL CHEM, V267, P12192	32	80	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37110	37117		10.1074/jbc.M007223200	http://dx.doi.org/10.1074/jbc.M007223200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10956668	hybrid			2022-12-25	WOS:000165577700091
J	MacRae, IJ; Hanna, E; Ho, JD; Fisher, AJ; Segel, IH				MacRae, IJ; Hanna, E; Ho, JD; Fisher, AJ; Segel, IH			Induction of positive cooperativity by amino acid replacements within the C-terminal domain of Penicillium chrysogenum ATP sulfurylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE 5'-PHOSPHOSULFATE KINASE; SULFATE-ACTIVATING ENZYMES; SITE-DIRECTED MUTAGENESIS; KINETIC CHARACTERIZATION; FILAMENTOUS FUNGI; SULFHYDRYL-GROUP; HIGHER-PLANTS; RAT-LIVER; PURIFICATION; INHIBITION	ATP sulfurylase from Penicillium chrysogenum is an allosteric enzyme in which Cys-509 is critical for maintaining the R state. Cys-509 is located in a C-terminal domain that is 42% identical to the conserved core of adenosine 5'-phosphosulfate (adenylylsulfate) (APS) kinase, This domain is believed to provide the binding site for the allosteric effector, 3'-phosphoadenosine 5'-phosphosulfate (PAPS), Replacement of Cys-509 with either Tyr or Ser destabilizes the R state, resulting in an enzyme that is intrinsically cooperative at pH 8 in the absence of PAPS. The kinetics of C509Y resemble those of the wild type enzyme in which Cys-509 has been covalently modified. The kinetics of C509S resemble those of the wild type enzyme in the presence of PAPS. It is likely that the negative charge on the Cys-509 side chain helps to stabilize the R state. Treatment of the enzyme with a low level of trypsin results in cleavage at Lys-527, a residue that lies in a region analogous to a PAPS motif-containing mobile loop of true APS kinase, Both mutant enzymes were cleaved more rapidly than the wild type enzyme, suggesting that movement of the mobile loop occurs during the R to T transition.	Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; Univ Calif Davis, Dept Chem, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Segel, IH (corresponding author), Univ Calif Davis, Sect Mol & Cellular Biol, 1 Shields Ave, Davis, CA 95616 USA.		Hanna, Ehab Y/B-1593-2017	Hanna, Ehab Y/0000-0003-3241-2440; Fisher, Andrew/0000-0003-3488-6594; Ho, Joseph/0000-0002-9636-5527				BALLIO A, 1959, SSPISS, V2, P343; Deyrup AT, 1999, J BIOL CHEM, V274, P28929, DOI 10.1074/jbc.274.41.28929; FOSTER BA, 1994, J BIOL CHEM, V269, P19777; HANSON AD, 1991, PLANT PHYSIOL, V97, P1199, DOI 10.1104/pp.97.3.1199; ITAHASHI M, 1961, J BIOCHEM, V50, P52, DOI 10.1093/oxfordjournals.jbchem.a127408; MacRae I, 1997, ARCH BIOCHEM BIOPHYS, V337, P17, DOI 10.1006/abbi.1996.9751; MacRae IJ, 1998, J BIOL CHEM, V273, P28583, DOI 10.1074/jbc.273.44.28583; MacRae IJ, 2000, BIOCHEMISTRY-US, V39, P1613, DOI 10.1021/bi9924157; MARTIN RL, 1989, J BIOL CHEM, V264, P11768; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; OSSLUND T, 1982, PLANT PHYSIOL, V70, P39, DOI 10.1104/pp.70.1.39; PETTIGREW DW, 1977, J BIOL CHEM, V252, P4546; RENOSTO F, 1985, J BIOL CHEM, V260, P1535; RENOSTO F, 1987, J BIOL CHEM, V262, P16279; RENOSTO F, 1977, ARCH BIOCHEM BIOPHYS, V180, P416, DOI 10.1016/0003-9861(77)90056-X; RENOSTO F, 1985, J BACTERIOL, V164, P674, DOI 10.1128/JB.164.2.674-683.1985; RENOSTO F, 1991, ARCH BIOCHEM BIOPHYS, V290, P66, DOI 10.1016/0003-9861(91)90592-7; RENOSTO F, 1990, J BIOL CHEM, V265, P10300; RENOSTO F, 1984, J BIOL CHEM, V259, P2113; RENOSTO F, 1993, ARCH BIOCHEM BIOPHYS, V307, P272, DOI 10.1006/abbi.1993.1590; RUBIN MM, 1966, J MOL BIOL, V21, P265, DOI 10.1016/0022-2836(66)90097-0; RYAN LD, 1974, ARCH BIOCHEM BIOPHYS, V160, P279, DOI 10.1016/S0003-9861(74)80035-4; SATISHCHANDRAN C, 1992, BIOCHEMISTRY-US, V31, P11684, DOI 10.1021/bi00162a003; SEGEL IH, 1987, METHOD ENZYMOL, V143, P334; SEGEL IH, 1993, ENZYME KINETICS BEHA, P421; SEUBERT PA, 1983, ARCH BIOCHEM BIOPHYS, V225, P679, DOI 10.1016/0003-9861(83)90079-6; STORER AC, 1976, BIOCHEM J, V159, P1; TWEEDIE JW, 1971, PREP BIOCHEM, V1, P91, DOI 10.1080/00327487108081932; Venkatachalam KV, 1999, J BIOL CHEM, V274, P2601, DOI 10.1074/jbc.274.5.2601; WOOD HG, 1966, J BIOL CHEM, V241, P5692; YU M, 1989, ARCH BIOCHEM BIOPHYS, V269, P156, DOI 10.1016/0003-9861(89)90096-9	31	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36303	36310		10.1074/jbc.M005992200	http://dx.doi.org/10.1074/jbc.M005992200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10956658	hybrid			2022-12-25	WOS:000165382000093
J	Liu, TM; Guo, ZW; Yang, QL; Sad, S; Jennings, HJ				Liu, TM; Guo, ZW; Yang, QL; Sad, S; Jennings, HJ			Biochemical engineering of surface alpha 2-8 polysialic acid for immunotargeting tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B NEISSERIA-MENINGITIDIS; ESCHERICHIA-COLI K1; SIALIC-ACID; ADHESION MOLECULE; EPITOPE; GLYCOPROTEINS; MENINGOCOCCI; ANTIBODIES; RECEPTOR; ANALOGS	To target tumor cells for immunotherapy, we evaluated the feasibility of altering the epitopes on the surface polysialic acid of tumor cells. A precursor (N-propionylmannosamine), when incubated with leukemic cells, RBL-2H3 and RMA, resulted in substitution of the N-acetyl groups of surface alpha2-8 polysialic acid with N-propionyl groups. Expression of the altered alpha2-8 N-propionylpolysialic acid on the surface of tumor cells induced their susceptibility to cell death mediated by monoclonal antibody 13D9 (mAb 13D9), which specifically recognizes alpha2-8 N-propionylated polysialic acid. The expression of alpha2-8 N-propionylated polysialic acid and the lysis of tumor cells by antibody-dependent cytotoxicity depended on the time and dose of incorporation of N-propionylated mannosamine, In vivo, mAb 13D9 effectively controlled metastasis of leukemic cells RIMA when mice were administered the precursor N-propionylated mannosamine.	Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	National Research Council Canada	Jennings, HJ (corresponding author), Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada.		Guo, Zhong-wu/C-7322-2011	Sad, Subash/0000-0002-2462-7137				BAUMANN H, 1993, BIOCHEMISTRY-US, V32, P4007, DOI 10.1021/bi00066a022; FINNE J, 1987, J IMMUNOL, V138, P4402; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; Fusco PC, 1997, J INFECT DIS, V175, P364, DOI 10.1093/infdis/175.2.364; Herrmann M, 1997, J VIROL, V71, P5922, DOI 10.1128/JVI.71.8.5922-5931.1997; JARVIS GA, 1987, INFECT IMMUN, V55, P174, DOI 10.1128/IAI.55.1.174-180.1987; JENNINGS HJ, 1989, J IMMUNOL, V142, P3585; JENNINGS HJ, 1986, J IMMUNOL, V137, P1708; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; KAYSER H, 1992, J BIOL CHEM, V267, P16934; KEPPLER OT, 1995, J BIOL CHEM, V270, P1308, DOI 10.1074/jbc.270.3.1308; KOSA RE, 1993, BIOCHEM BIOPH RES CO, V190, P914, DOI 10.1006/bbrc.1993.1136; LIN CH, 1992, J AM CHEM SOC, V114, P10138, DOI 10.1021/ja00052a008; Mahal LK, 1997, SCIENCE, V276, P1125, DOI 10.1126/science.276.5315.1125; Martersteck CM, 1996, GLYCOBIOLOGY, V6, P289, DOI 10.1093/glycob/6.3.289; Pon RA, 1997, J EXP MED, V185, P1929, DOI 10.1084/jem.185.11.1929; ROBBINS JB, 1974, NEW ENGL J MED, V290, P1216, DOI 10.1056/NEJM197405302902202; Rosenberg Abraham, 1976, BIOL ROLES SIALIC AC; ROTH J, 1988, P NATL ACAD SCI USA, V85, P2999, DOI 10.1073/pnas.85.9.2999; ROTH J, 1993, POLYSIALIC ACID MICR, P335; SCHEIDEGGER EP, 1994, LAB INVEST, V70, P95; SHAMES S L, 1991, Glycobiology, V1, P187, DOI 10.1093/glycob/1.2.187; Slovin SF, 1999, SEMIN ONCOL, V26, P448; SPARKS MA, 1993, TETRAHEDRON, V49, P1, DOI 10.1016/S0040-4020(01)80502-0; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; VIRAG L, 1995, J IMMUNOL METHODS, V185, P199, DOI 10.1016/0022-1759(95)00115-Q	26	86	95	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32832	32836		10.1074/jbc.C000573200	http://dx.doi.org/10.1074/jbc.C000573200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10976100	hybrid			2022-12-25	WOS:000090003800063
J	Brown, MD; Trounce, IA; Jun, AS; Allen, JC; Wallace, DC				Brown, MD; Trounce, IA; Jun, AS; Allen, JC; Wallace, DC			Functional analysis of lymphoblast and cybrid mitochondria containing the 3460, 11778, or 14484 Leber's hereditary optic neuropathy mitochondrial DNA mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEX-I; NUCLEOTIDE PAIR-14459; PHYLOGENETIC ANALYSIS; POINT MUTATION; CELL-LINES; PEDIGREES; DYSTONIA; NADH; 11778-MUTATION; DEFICIENCY	Leber's hereditary optic neuropathy (LHON) is a form of blindness caused by mitochondrial DNA (mtDNA) mutations in complex I genes. We report an extensive biochemical analysis of the mitochondrial defects in lymphoblasts and transmitochondrial cybrids harboring the three most common LHON mutations: 3460A, 11778A, and 14484C. Respiration studies revealed that the 3460A mutation reduced the maximal respiration rate 20-28%, the 11778A mutation 30-36%, and the 14484C mutation 10-15%. The respiration defects of the 3460A and 11778A mutations transferred in cybrid experiments linking these defects to the mtDNA. Complex I enzymatic assays revealed that the 3460A mutation resulted in a 79% reduction in specific activity and the 11778A mutation resulted in a 20% reduction, while the 14484C mutation did not affect the complex I activity. The enzyme defect of the 3460A mutation transferred with the mtDNA in cybrids. Overall, these data support the conclusion that the 3460A and 11778A mutants result in complex I defects and that the 14484C mutation causes a much milder biochemical defect. These studies represent the first direct comparison of oxidative phosphorylation defects among all of the primary LHON mtDNA mutations, thus permitting insight into the underlying pathophysiological mechanism of the disease.	Emory Univ, Sch Med, Ctr Mol Med, Atlanta, GA 30322 USA; St Vincents Hosp, Mutat Res Ctr, Fitzroy, Vic 3065, Australia	Emory University; St Vincent's Hospital Melbourne	Brown, MD (corresponding author), Emory Univ, Sch Med, Ctr Mol Med, 1462 Clifton Rd,Rm 420, Atlanta, GA 30322 USA.		Trounce, Ian A/F-8338-2010	Trounce, Ian A/0000-0002-1070-8892; Allen, Jeffrey/0000-0001-9957-6664	NATIONAL EYE INSTITUTE [R29EY011305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021328] Funding Source: NIH RePORTER; NEI NIH HHS [EY11305] Funding Source: Medline; NINDS NIH HHS [NS21328] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BROWN MD, 1994, CLIN NEUROSCI, V2, P138; Brown MD, 1997, AM J HUM GENET, V60, P381; BROWN MD, 1995, HUM MUTAT, V6, P311, DOI 10.1002/humu.1380060405; Carelli V, 1999, ANN NEUROL, V45, P320, DOI 10.1002/1531-8249(199903)45:3<320::AID-ANA7>3.0.CO;2-L; Carelli V, 1997, NEUROLOGY, V48, P1623, DOI 10.1212/WNL.48.6.1623; Cock HR, 1999, J NEUROL SCI, V165, P10, DOI 10.1016/S0022-510X(99)00088-X; COCK HR, 1995, AM J HUM GENET, V57, P1501; ESPOSTI MD, 1994, FEBS LETT, V352, P375, DOI 10.1016/0014-5793(94)00971-6; Hofhaus G, 1996, J BIOL CHEM, V271, P13155, DOI 10.1074/jbc.271.22.13155; Howell N, 1997, VISION RES, V37, P3495, DOI 10.1016/S0042-6989(96)00167-8; HOWELL N, 1995, GENETICS, V140, P285; HOWELL N, 1991, AM J HUM GENET, V49, P939; JOHNS DR, 1993, ARCH OPHTHALMOL-CHIC, V111, P495, DOI 10.1001/archopht.1993.01090040087038; Jun AS, 1996, MOL CELL BIOL, V16, P771; JUN AS, 1994, P NATL ACAD SCI USA, V91, P6206, DOI 10.1073/pnas.91.13.6206; LARSSON NG, 1991, ANN NEUROL, V30, P701, DOI 10.1002/ana.410300511; Majander A, 1996, EUR J BIOCHEM, V239, P201, DOI 10.1111/j.1432-1033.1996.0201u.x; MAJANDER A, 1991, FEBS LETT, V292, P289, DOI 10.1016/0014-5793(91)80886-8; NEWMAN NJ, 1991, AM J OPHTHALMOL, V111, P750, DOI 10.1016/S0002-9394(14)76784-4; OOSTRA RJ, 1995, BIOCHEM BIOPH RES CO, V215, P1001, DOI 10.1006/bbrc.1995.2563; RIORDANEVA P, 1995, BRAIN, V118, P319, DOI 10.1093/brain/118.2.319; SHOFFNER JM, 1995, ANN NEUROL, V38, P163, DOI 10.1002/ana.410380207; SMITH PR, 1994, J NEUROL SCI, V122, P80, DOI 10.1016/0022-510X(94)90055-8; Torroni A, 1997, AM J HUM GENET, V60, P1107; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; VERGANI L, 1995, BIOCHEM BIOPH RES CO, V210, P880, DOI 10.1006/bbrc.1995.1740; WALLACE DC, 1996, EMERY RIMOINS PRINCI, V1, P277	27	198	215	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39831	39836		10.1074/jbc.M006476200	http://dx.doi.org/10.1074/jbc.M006476200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10976107	hybrid			2022-12-25	WOS:000166039500008
J	Lin, XY; Choi, MSK; Porter, AG				Lin, XY; Choi, MSK; Porter, AG			Expression analysis of the human caspase-1 subfamily reveals specific regulation of the CASP5 gene by lipopolysaccharide and interferon-gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOTIC CELL-DEATH; INTERLEUKIN-1-BETA-CONVERTING ENZYME; CYSTEINE PROTEASES; FAMILY; ICE; IDENTIFICATION; PATHWAY; ACTIVATION; MEMBERS	Based on high sequence homology, there are six members in the caspase-1 subfamily: caspases 1, 4, 5, and 13 in humans and caspases 1, 11, and 12 in mice. Only caspase-1 is known to activate interleukin-1 beta and interleukin-18, and caspase-11 activates pro-caspase-1 in vivo. Almost nothing is known about caspases 4, 5, and 13. Here we report a sensitive and specific polymerase chain reaction system to analyze closely related genes. We employed this system to analyze the gene expression and regulation of human caspases 1, 4, 5, and 13, demonstrating that they have different expression patterns in normal tissues and cell lines, Interferon-gamma strongly induced CASP1 and CASP5 but not CASP4 or CASP13 gene expression in HT-29 colon carcinoma cells. In contrast to the mRNA, interferon-gamma up-regulated caspase-1 but not caspase-5 protein. In the monocytic cell line THP-1, CASP1 mRNA and caspase-1 protein are expressed constitutively, and their levels were not increased by lipopolysaccharide, whereas both GASPS mRNA and caspase-5 protein were induced by lipopolysaccharide. Caspase-1 subfamily members displayed different in vitro activities toward pro-caspases 1 and 3 and pro-interleukin-1 beta. Our results demonstrate that caspase-1 and caspase-5 levels are modulated by interferon-gamma and lipopolysaccharide, respectively, and suggest that caspase-1 subfamily members are differentially regulated and may have distinct functions.	Inst Mol & Cell Biol, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Porter, AG (corresponding author), Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.							Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Fantuzzi G, 1999, J CLIN IMMUNOL, V19, P1, DOI 10.1023/A:1020506300324; Fassy F, 1998, EUR J BIOCHEM, V253, P76, DOI 10.1046/j.1432-1327.1998.2530076.x; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; Faucheu C, 1996, EUR J BIOCHEM, V236, P207, DOI 10.1111/j.1432-1033.1996.t01-1-00207.x; FENTON MJ, 1987, J IMMUNOL, V138, P3972; Friedlander RM, 1998, CELL DEATH DIFFER, V5, P823, DOI 10.1038/sj.cdd.4400433; Garcia-Calvo M, 1999, CELL DEATH DIFFER, V6, P362, DOI 10.1038/sj.cdd.4400497; Humke EW, 1998, J BIOL CHEM, V273, P15702, DOI 10.1074/jbc.273.25.15702; Janicke RU, 1996, MOL CELL BIOL, V16, P5245; Kamada S, 1997, ONCOGENE, V15, P285, DOI 10.1038/sj.onc.1201192; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; Kang SJ, 2000, J CELL BIOL, V149, P613, DOI 10.1083/jcb.149.3.613; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; Schwartz S, 1999, CANCER RES, V59, P2995; Tamura T, 1996, BIOCHEM BIOPH RES CO, V229, P21, DOI 10.1006/bbrc.1996.1752; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Wang SY, 1996, J BIOL CHEM, V271, P20580, DOI 10.1074/jbc.271.34.20580; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Zheng TS, 1999, CELL DEATH DIFFER, V6, P1043, DOI 10.1038/sj.cdd.4400593	23	159	167	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39920	39926		10.1074/jbc.M007255200	http://dx.doi.org/10.1074/jbc.M007255200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10986288	hybrid			2022-12-25	WOS:000166039500020
J	Masure, S; Cik, M; Hoefnagel, E; Nosrat, CA; Van der Linden, I; Scott, R; Van Gompel, P; Lesage, ASJ; Verhasselt, P; Ibanez, CF; Gordon, RD				Masure, S; Cik, M; Hoefnagel, E; Nosrat, CA; Van der Linden, I; Scott, R; Van Gompel, P; Lesage, ASJ; Verhasselt, P; Ibanez, CF; Gordon, RD			Mammalian GFR alpha-4, a divergent member of the GFR alpha family of coreceptors for glial cell line-derived neurotrophic factor family ligands, is a receptor for the neurotrophic factor persephin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-RET PROTOONCOGENE; TYROSINE KINASE; GDNF FAMILY; FUNCTIONAL RECEPTOR; NEURTURIN; ACTIVATION; EXPRESSION; COMPLEX; MECHANISMS; NEURONS	Four members of the glial cell line-derived neurotrophic factor family have been identified (GDNF, neurturin, persephin, and enovin/artemin). They bind to a specific membrane-anchored GDNF family receptor as follows: GFR alpha -1 for GDNF, GFR alpha -2 for neurturin, GFR alpha -3 for enovin/artemin, and (chicken) GFR alpha -4 for persephin. Subsequent signaling occurs through activation of a common transmembrane tyrosine kinase, cRET. GFR alpha -4, the coreceptor for persephin, was previously identified in chicken only. We describe the cloning and characterization of a mammalian persephin receptor GFR alpha -4 The novel GFR alpha receptor is substantially different in sequence from all known GFR alphas, including chicken GFR alpha -4, and lacks the first cysteine-rich domain present in all previously characterized GFR alphas. At least two different GFR alpha -4 splice variants exist in rat tissues, differing at their respective COOH termini. GFR alpha -4 mRNA is expressed at low levels in different brain areas in the adult as well as in some peripheral tissues including testis and heart. Recombinant rat GFR alpha -4 variants were expressed in mammalian cells and shown to be at least partially secreted from the cells. Persephin binds specifically and with high affinity (K-D = 6 nm) to the rat GFR alpha -4 receptor, but no cRET activation could be demonstrated. Although the newly characterized mammalian GFR alpha -4 receptor is structurally divergent from previously characterized GFR alpha family members, we suggest that it is a mammalian orthologue of the chicken persephin receptor. This discovery will allow a more detailed investigation of the biological targets of persephin action and its potential involvement in diseases of the nervous system.	Janssen Res Fdn, Dept Biotechnol, B-2340 Beerse, Belgium; Janssen Res Fdn, Dept High Throughput Screening, B-2340 Beerse, Belgium; Janssen Res Fdn, Dept Biochem Pharmacol, B-2340 Beerse, Belgium; Karolinska Inst, Dept Neurosci, S-17177 Stockholm, Sweden	Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Karolinska Institutet	Masure, S (corresponding author), Janssen Res Fdn, Dept Biotechnol, Turnhoutseweg 30, B-2340 Beerse, Belgium.	smasure@janbe.jnj.com	Scott, Rizaldy/AAC-5264-2020	Scott, Rizaldy/0000-0002-0288-8862				Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Angrist M, 1998, GENOMICS, V48, P354, DOI 10.1006/geno.1997.5191; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; Baloh RH, 1998, NEURON, V21, P1291, DOI 10.1016/S0896-6273(00)80649-2; BujBello A, 1997, NATURE, V387, P721, DOI 10.1038/42729; Cik M, 2000, J BIOL CHEM, V275, P27505; Creedon DJ, 1997, P NATL ACAD SCI USA, V94, P7018, DOI 10.1073/pnas.94.13.7018; Davies AM, 1997, NEURON, V19, P485; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Eketjall S, 1999, EMBO J, V18, P5901, DOI 10.1093/emboj/18.21.5901; Enokido Y, 1998, CURR BIOL, V8, P1019, DOI 10.1016/S0960-9822(07)00422-8; GERBER LD, 1992, J BIOL CHEM, V267, P12168; Gunn TM, 1999, NATURE, V398, P152, DOI 10.1038/18217; Helou K, 1998, IMMUNOGENETICS, V47, P166, DOI 10.1007/s002510050342; Ibanez CF, 1998, TRENDS NEUROSCI, V21, P438, DOI 10.1016/S0166-2236(98)01266-1; ISLAM MQ, 1987, HEREDITAS, V107, P127, DOI 10.1111/j.1601-5223.1987.tb00277.x; Jaszai J, 1998, J NEUROSCI RES, V53, P494, DOI 10.1002/(SICI)1097-4547(19980815)53:4<494::AID-JNR12>3.0.CO;2-2; Jing SQ, 1997, J BIOL CHEM, V272, P33111, DOI 10.1074/jbc.272.52.33111; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Lindahl M, 2000, MOL CELL NEUROSCI, V15, P522, DOI 10.1006/mcne.2000.0845; Masure S, 1999, EUR J BIOCHEM, V266, P892, DOI 10.1046/j.1432-1327.1999.00925.x; Masure S, 1998, EUR J BIOCHEM, V251, P622, DOI 10.1046/j.1432-1327.1998.2510622.x; Milbrandt J, 1998, NEURON, V20, P245, DOI 10.1016/S0896-6273(00)80453-5; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Naveilhan P, 1998, P NATL ACAD SCI USA, V95, P1295, DOI 10.1073/pnas.95.3.1295; Nishino J, 1999, NEURON, V23, P725, DOI 10.1016/S0896-6273(01)80031-3; Poteryaev D, 1999, FEBS LETT, V463, P63, DOI 10.1016/S0014-5793(99)01590-2; Rosenthal A, 1999, NEURON, V22, P201, DOI 10.1016/S0896-6273(00)81077-6; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; Thompson J, 1998, MOL CELL NEUROSCI, V11, P117, DOI 10.1006/mcne.1998.0682; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Trupp M, 1998, MOL CELL NEUROSCI, V11, P47, DOI 10.1006/mcne.1998.0667; Trupp M, 1997, J NEUROSCI, V17, P3554; Worby CA, 1998, J BIOL CHEM, V273, P3502, DOI 10.1074/jbc.273.6.3502; Yu T, 1998, J NEUROSCI, V18, P4684	43	45	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39427	39434		10.1074/jbc.M003867200	http://dx.doi.org/10.1074/jbc.M003867200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10958791	hybrid			2022-12-25	WOS:000165953100067
J	Taboy, CH; Faulkner, KM; Kraiter, D; Bonaventura, C; Crumbliss, AL				Taboy, CH; Faulkner, KM; Kraiter, D; Bonaventura, C; Crumbliss, AL			Concentration-dependent effects of anions on the anaerobic oxidation of hemoglobin and myoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CHLORIDE-BINDING SITES; REDOX POTENTIALS; ELECTRON-TRANSFER; SPECTROELECTROCHEMICAL METHOD; APLYSIA MYOGLOBIN; OXYGEN-AFFINITY; HEME-PROTEINS; MECHANISM; AUTOXIDATION	The redox potentials of hemoglobin and myoglobin and the shapes of their anaerobic oxidation curves are sensitive indicators of globin alterations surrounding the active site. This report documents concentration-dependent effects of anions on the ease of anaerobic oxidation of representative hemoglobins and myoglobins. Hemoglobin (Hb) oxidation curves reflect the cooperative transition from the T state of deoxyHb to the more readily oxidized R-like conformation of metHb. Shifts in the oxidation curves for Hb A(0) as Cl- concentrations are increased to 0.2 M at pH 7.1 indicate preferential anion binding to the T state and destabilization of the R-like state of metHb, leading to reduced cooperativity in the oxidation process. A dramatic reversal of trend occurs above 0.2 M Cl- as anions bind to lower affinity sites and shift the conformational equilibrium toward the R state. This pattern has been observed for various hemoglobins with a variety of small anions. Steric rather than electronic effects are invoked to explain the fact that no comparable reversal of oxygen affinity is observed under identical conditions. Evidence is presented to show that increases in hydrophilicity in the distal heme pocket can decrease oxygen affinity via steric hindrance effects while increasing the ease of anaerobic oxidation.	Duke Univ, Dept Chem, Durham, NC 27708 USA; Duke Univ, Marine Lab, Nicholas Sch Environm, Beaufort, NC 28516 USA	Duke University; Duke University	Crumbliss, AL (corresponding author), Duke Univ, Dept Chem, Durham, NC 27708 USA.				NHLBI NIH HHS [HL-58248] Funding Source: Medline; NIEHS NIH HHS [ESO 1908] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P50ES001908, P30ES001908] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANTONINI E, 1964, J BIOL CHEM, V239, P907; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; ARNONE A, 1974, NATURE, V249, P34, DOI 10.1038/249034a0; BELLELLI A, 1994, METHOD ENZYMOL, V232, P56; BENESCH R, 1969, NATURE, V221, P618, DOI 10.1038/221618a0; BENESCH RE, 1969, BIOCHEMISTRY-US, V8, P2567, DOI 10.1021/bi00834a046; BOLOGNESI M, 1989, J MOL BIOL, V205, P529, DOI 10.1016/0022-2836(89)90224-6; BONAVENTURA C, 1991, J BIOL CHEM, V266, P23033; Bonaventura C, 1998, BIOCHEMISTRY-US, V37, P496, DOI 10.1021/bi971574s; BONAVENTURA C, 1980, HEMOGLOBIN, V4, P275; BONAVENTURA C, 1976, J BIOL CHEM, V251, P1871; BONAVENTURA C, 1994, J MOL BIOL, V239, P561, DOI 10.1006/jmbi.1994.1395; BONAVENTURA C, 1978, BIOCH CLIN ASPECTS H, P647; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; BRUNORI M, 1971, BIOCHEMISTRY-US, V10, P1604, DOI 10.1021/bi00785a016; CHIANCONE E, 1975, EUR J BIOCHEM, V55, P385, DOI 10.1111/j.1432-1033.1975.tb02173.x; CHIANCONE E, 1975, BIOPHYS CHEM, V3, P56, DOI 10.1016/0301-4622(75)80037-8; CHIANCONE E, 1972, J MOL BIOL, V70, P675, DOI 10.1016/0022-2836(72)90566-9; COLLMAN JP, 1975, J AM CHEM SOC, V97, P1427, DOI 10.1021/ja00839a026; DESBOIS A, 1975, J MOL BIOL, V92, P479, DOI 10.1016/0022-2836(75)90293-4; Di Cera E, 1998, CHEM REV, V98, P1563, DOI 10.1021/cr960135g; DICKERSON LD, 1993, J AM CHEM SOC, V115, P3623, DOI 10.1021/ja00062a028; FAULKNER KM, 1994, INORG CHIM ACTA, V226, P187, DOI 10.1016/0020-1693(94)04086-9; FAULKNER KM, 1995, J BIOL CHEM, V270, P13604, DOI 10.1074/jbc.270.23.13604; FONTICELLI C, 1994, J BIOL CHEM, V269, P23965; Gunner MR, 1997, J BIOL INORG CHEM, V2, P126, DOI 10.1007/s007750050116; Hu XH, 1997, BIOCHEMISTRY-US, V36, P15701, DOI 10.1021/bi971136l; KASSNER RJ, 1972, P NATL ACAD SCI USA, V69, P2263, DOI 10.1073/pnas.69.8.2263; KASSNER RJ, 1973, J AM CHEM SOC, V95, P2674, DOI 10.1021/ja00789a044; KLEINSCHMIDT T, 1983, BIOMED BIOCHIM ACTA, V42, P685; KRISTENSEN EW, 1991, J ELECTROANAL CHEM, V309, P61, DOI 10.1016/0022-0728(91)87004-N; LopezCastillo JM, 1997, J AM CHEM SOC, V119, P1978, DOI 10.1021/ja961978s; Mathews J.B., 1979, BIOCHEMISTRY-US, V18, P1928; Mauk AG, 1997, J BIOL INORG CHEM, V2, P119, DOI 10.1007/s007750050115; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MOOPENN WF, 1978, FEBS LETT, V92, P53, DOI 10.1016/0014-5793(78)80720-0; MOORE GR, 1986, P NATL ACAD SCI USA, V83, P4998, DOI 10.1073/pnas.83.14.4998; Mylvaganam SE, 1996, NAT STRUCT BIOL, V3, P275, DOI 10.1038/nsb0396-275; PERELLA M, 1994, BIOCHEMISTRY-US, V33, P10358; PERUTZ M, 1997, SCI NOT QUIET LIFE; PERUTZ MF, 1993, J MOL BIOL, V233, P536, DOI 10.1006/jmbi.1993.1530; PERUTZ MF, 1960, NATURE, V185, P491; ROLLEMA HS, 1975, J BIOL CHEM, V250, P1333; RUSSU IM, 1986, BIOCHEMISTRY-US, V25, P1706, DOI 10.1021/bi00355a040; Shikama K, 1998, CHEM REV, V98, P1357, DOI 10.1021/cr970042e; SMERDON SJ, 1995, BIOCHEMISTRY-US, V34, P8715, DOI 10.1021/bi00027a022; SZABO A, 1972, J MOL BIOL, V72, P163, DOI 10.1016/0022-2836(72)90077-0; Taboy CH, 1999, BIOELECTROCH BIOENER, V48, P79, DOI 10.1016/S0302-4598(98)00236-0; Tezcan FA, 1998, J AM CHEM SOC, V120, P13383, DOI 10.1021/ja982536e; VALLONE B, 1993, FEBS LETT, V324, P117, DOI 10.1016/0014-5793(93)81375-A; VANDEGRIFF KD, 1995, BLOOD SUBSTITUTES PH, P134; WALLACE WJ, 1982, J BIOL CHEM, V257, P4966; WALLACE WJ, 1974, FEBS LETT, V43, P33, DOI 10.1016/0014-5793(74)81099-9; Warshel A, 1997, J BIOL INORG CHEM, V2, P143, DOI 10.1007/s007750050119; Zhou HX, 1997, J BIOL INORG CHEM, V2, P109, DOI 10.1007/s007750050113	55	32	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39048	39054		10.1074/jbc.M004547200	http://dx.doi.org/10.1074/jbc.M004547200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10984477	hybrid			2022-12-25	WOS:000165953100016
J	Goode, BL; Chau, M; Denis, PE; Feinstein, SC				Goode, BL; Chau, M; Denis, PE; Feinstein, SC			Structural and functional differences between 3-repeat and 4-repeat tau isoforms - Implications for normal tau function and the onset of neurodegenerative disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-BINDING DOMAINS; PERIPHERAL NERVOUS-SYSTEM; PAIRED HELICAL FILAMENTS; MOLECULAR-WEIGHT TAU; PROTEIN-TAU; DYNAMIC INSTABILITY; KINETIC STABILIZATION; BIG-TAU; EXPRESSION; PHOSPHORYLATION	Tau, MAP2, and MAP4 are members of a microtubule-associated protein (MAP) family that are each expressed as "3-repeat" and "4-repeat" isoforms. These isoforms arise from tightly controlled tissue-specific and/or developmentally regulated alternative splicing of a 31-amino acid long "inter-repeat:repeat module," raising the possibility that different MAP isoforms may possess some distinct functional capabilities. Consistent with this hypothesis, regulatory mutations in the human tau gene that disrupt the normal balance between 3-repeat and 4-repeat tau isoform expression lead to a collection of neurodegenerative diseases known as FTDP-17 (fronto-temporal dementias and Parkinsonism Linked to chromosome 17), which are characterized by the formation of pathological tau filaments and neuronal cell death. Unfortunately, very little is known regarding structural and functional differences between the isoforms. In our previous analyses, we focused on 4-repeat tau structure and function. Here, we investigate 3-repeat tau, generating a series of truncations, amino acid substitutions, and internal deletions and examining the functional consequences. 3-Repeat tau possesses a "core microtubule binding domain" composed of its first two repeats and the intervening inter-repeat. This observation is in marked contrast to the widely held notion that tau possesses multiple independent tubulin-binding sites aligned in sequence along the length of the protein. In addition, we observed that the carboxyl-terminal sequences downstream of the repeat region make a strong but indirect contribution to microtubule binding activity in 5-repeat tan, which is in contrast to the negligible effect of these same sequences in 4-repeat tau. Taken together with previous work, these data suggest that 3-repeat and 4-repeat tau assume complex and distinct structures that are regulated differentially, which in turn suggests that they may possess isoform-specific functional capabilities. The relevance of isoform-specific structure and function to normal tan action and the onset of neurodegenerative disease are discussed.	Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Feinstein, SC (corresponding author), Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA.				NINDS NIH HHS [R01NS35010] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035010] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ackmann M, 2000, J BIOL CHEM, V275, P30335, DOI 10.1074/jbc.M002590200; BOYNE LJ, 1995, J COMP NEUROL, V358, P279, DOI 10.1002/cne.903580209; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; BULINSKI JC, 1994, MICROTUBULES, P145; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; Clark LN, 1998, P NATL ACAD SCI USA, V95, P13103, DOI 10.1073/pnas.95.22.13103; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; COUCHIE D, 1992, P NATL ACAD SCI USA, V89, P4378, DOI 10.1073/pnas.89.10.4378; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; GEORGIEFF IS, 1993, J CELL SCI, V105, P729; GOEDERT M, 1992, P NATL ACAD SCI USA, V89, P1983, DOI 10.1073/pnas.89.5.1983; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Goedert M., 1994, V13, P183; Goode BL, 1997, MOL BIOL CELL, V8, P353, DOI 10.1091/mbc.8.2.353; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; HIMMLER A, 1989, MOL CELL BIOL, V9, P1381, DOI 10.1128/MCB.9.4.1381; HIMMLER A, 1989, MOL CELL BIOL, V9, P1389, DOI 10.1128/MCB.9.4.1389; HIROKAWA N, 1988, J CELL BIOL, V107, P1449, DOI 10.1083/jcb.107.4.1449; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; JOLY JC, 1990, BIOCHEMISTRY-US, V29, P8916, DOI 10.1021/bi00490a006; Jordan MA, 1996, CANCER RES, V56, P816; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98; Koshland DE, 1998, NAT MED, V4, P1112, DOI 10.1038/2605; KOSIK KS, 1989, NEURON, V2, P1389, DOI 10.1016/0896-6273(89)90077-9; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LEE VM, 1995, PATHOLOGY ALZHEIMERS; Lee VMY, 1999, NEURON, V24, P507, DOI 10.1016/S0896-6273(00)81106-X; LICHTENBERGKRAAG B, 1992, P NATL ACAD SCI USA, V89, P5384, DOI 10.1073/pnas.89.12.5384; LINDWALL G, 1984, J BIOL CHEM, V259, P2241; Lo Matthew M. S., 1993, Molecular Brain Research, V20, P209, DOI 10.1016/0169-328X(93)90043-O; Lovestone S, 1997, NEUROSCIENCE, V78, P309; Matus Andrew, 1994, V13, P155; PANDA D, 1995, BIOCHEMISTRY-US, V34, P11117, DOI 10.1021/bi00035a017; SACKETT DL, 1994, BIOCHEMISTRY-US, V33, P12868, DOI 10.1021/bi00209a019; Sahara N, 2000, J NEUROSCI RES, V60, P380, DOI 10.1002/(SICI)1097-4547(20000501)60:3<380::AID-JNR13>3.0.CO;2-5; SCHWEERS O, 1994, J BIOL CHEM, V269, P24290; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; TOSO RJ, 1993, BIOCHEMISTRY-US, V32, P1285, DOI 10.1021/bi00056a013; TRINCZEK B, 1995, MOL BIOL CELL, V6, P1887, DOI 10.1091/mbc.6.12.1887; WANG DS, 1988, NUCLEIC ACIDS RES, V16, P11369, DOI 10.1093/nar/16.23.11369; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573	48	170	175	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38182	38189		10.1074/jbc.M007489200	http://dx.doi.org/10.1074/jbc.M007489200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10984497	hybrid			2022-12-25	WOS:000165739800009
J	Jackson, VN; Zammit, VA; Price, NT				Jackson, VN; Zammit, VA; Price, NT			Identification of positive and negative determinants of malonyl-CoA sensitivity and carnitine affinity within the amino termini of rat liver- and muscle-type carnitine palmitoyltransferase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL OUTER-MEMBRANE; EXPRESSION; TOPOLOGY; BINDING; ACYLTRANSFERASE; INHIBITION; RESIDUES; SYSTEM	The extreme amino terminus and, in particular, residue Glu-3 in rat liver (L) carnitine palmitoyltransferase I (CPT I) have previously been shown to be essential for the sensitivity of the enzyme to inhibition by malonyl-CoA. Using the Pichia pastoris expression system, we now observe that, although mutants E3A (GIu-3 --> Ala) or Delta (3-18) of L-CPT I have markedly lowered sensitivity to malonyl-CoA compared with the wild-type protein, the mutant Delta (1-82) generated an enzyme that had regained much of the sensitivity of wild-type CPT I. This suggests that a region antagonistic to malonyl-CoA sensitivity is present within residues 19-82 of the enzyme. This was confirmed in the construct Delta (19-30), which was found to be 50-fold more sensitive than wild-type L-CPT I, Indeed, this mutant was >4-fold more sensitive than even the native muscle (M)-CPT I isoform expressed and assayed under identical conditions. This behavior was dependent on the presence of Glu-3, with the mutant E3A-Delta (19-30) having kinetic characteristics similar to those of the E3A mutant. The increase in the sensitivity of the L-CPT I-Delta (19-30) mutant was not due to a change in the mechanism of inhibition with respect to palmitoyl-CoA, nor to any marked change of the K-0.5 for this substrate. Conversely, for M-CPT I, a decrease in malonyl-CoA sensitivity was invariably observed with increasing deletions from Delta (3-18) to Delta (1-80). However, deletion of residues 3-18 hom M-CPT I affected the II;, for carnitine of this isoform, but not of L-CPT I, These observations (i) provide the first evidence for negative determinants of malonyl-CoA sensitivity within the amino-terminal segment of L-CPT I and (ii) suggest a mechanism for the inverse relationship between affinity for malonyl-CoA and for carnitine of the two isoforms of the enzyme.	Hannah Res Inst, Dept Cell Biochem, Ayr KA6 5HL, Scotland		Zammit, VA (corresponding author), Hannah Res Inst, Dept Cell Biochem, Ayr KA6 5HL, Scotland.							Broadway NM, 1997, BIOCHEM J, V322, P435, DOI 10.1042/bj3220435; CORNISHBOWDEN A, 1995, FUNDAMENTALS ENZYME, P115; DECLERCQ PE, 1987, J BIOL CHEM, V262, P9812; deVries Y, 1997, BIOCHEMISTRY-US, V36, P5285, DOI 10.1021/bi962875p; ESSER V, 1993, J BIOL CHEM, V268, P5817; Fraser F, 1997, BIOCHEM J, V323, P711, DOI 10.1042/bj3230711; Fraser F, 1998, BIOCHEM J, V329, P225, DOI 10.1042/bj3290225; Jackson VN, 1999, BIOCHEM J, V341, P483, DOI 10.1042/0264-6021:3410483; Jackson VN, 2000, J BIOL CHEM, V275, P19560, DOI 10.1074/jbc.M002177200; KOLODZIEJ MP, 1990, BIOCHEM J, V267, P85, DOI 10.1042/bj2670085; KOLODZIEJ MP, 1993, FEBS LETT, V327, P294, DOI 10.1016/0014-5793(93)81007-M; KOLODZIEJ MP, 1990, BIOCHEM J, V272, P421, DOI 10.1042/bj2720421; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; LLOYD AC, 1986, BIOCHEM J, V237, P289, DOI 10.1042/bj2370289; McGarry JD, 2000, BIOCHEM J, V349, P179, DOI 10.1042/0264-6021:3490179; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; MURTHY MSR, 1987, P NATL ACAD SCI USA, V84, P378, DOI 10.1073/pnas.84.2.378; MYNATT RL, 1992, BIOCHIM BIOPHYS ACTA, V1128, P105, DOI 10.1016/0005-2760(92)90263-U; MYNATT RL, 1994, BIOCHEM J, V248, P727; SAGGERSON ED, 1982, BIOCHEM J, V202, P397, DOI 10.1042/bj2020397; Shi JY, 2000, BIOCHEMISTRY-US, V39, P712, DOI 10.1021/bi9918700; Shi JY, 1999, J BIOL CHEM, V274, P9421, DOI 10.1074/jbc.274.14.9421; Shi JY, 1998, BIOCHEMISTRY-US, V37, P11033, DOI 10.1021/bi9803426; Swanson ST, 1998, BIOCHEM J, V335, P513, DOI 10.1042/bj3350513; Zammit VA, 1999, PROG LIPID RES, V38, P199, DOI 10.1016/S0163-7827(99)00002-8; Zammit VA, 1998, LIPIDS, V33, P371, DOI 10.1007/s11745-998-0217-7; Zammit VA, 1999, BIOCHEM J, V343, P505, DOI 10.1042/0264-6021:3430505; Zammit VA, 1997, ADV ENZYME REGUL, V37, P295, DOI 10.1016/S0065-2571(96)00015-5; Zammit VA, 1996, BIOCHEM J, V314, P1, DOI 10.1042/bj3140001; Zhu HF, 1997, BIOCHEM BIOPH RES CO, V239, P498, DOI 10.1006/bbrc.1997.7494; Zhu HF, 1997, ARCH BIOCHEM BIOPHYS, V347, P53, DOI 10.1006/abbi.1997.0314	31	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38410	38416		10.1074/jbc.M007722200	http://dx.doi.org/10.1074/jbc.M007722200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10969089	hybrid			2022-12-25	WOS:000165739800038
J	Chiarugi, P; Taddei, ML; Cirri, P; Talini, D; Buricchi, F; Camici, G; Manao, G; Raugei, G; Ramponi, G				Chiarugi, P; Taddei, ML; Cirri, P; Talini, D; Buricchi, F; Camici, G; Manao, G; Raugei, G; Ramponi, G			Low molecular weight protein-tyrosine phosphatase controls the rate and the strength of NIH-3T3 cells adhesion through its phosphorylation on tyrosine 131 or 132	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; UP-REGULATION; KAPPA-B; C-SRC; TRANSCRIPTION; FIBROBLASTS; EXPRESSION; GENE; MECHANISMS; COLLAGENASE	The low molecular weight protein-tyrosine phosphatase (LMW-PTP) is an enzyme involved in platelet-derived growth factor (PDGF)-induced mitogenesis and cytoskeleton rearrangement. Our previous results demonstrated that LMW-PTP is able to bind and dephosphorylate activated PDGF receptor, thus inhibiting cell proliferation. Recently we have shown that LMW-PTP is specifically phosphorylated by c-Src in a cytoskeleton-associated fraction in response to PDGF, and this phosphorylation increases LMW-PTP activity about 20-fold. LMW-PTP strongly influences cell adhesion, spreading, and chemotaxis induced by PDGF stimulation, by regulating the phosphorylation level of p190Rho-GAP, a protein that is able to regulate Rho activity and hence cytoskeleton rearrangement. In the present study we investigate the physiological role of the two LMW-PTP tyrosine phosphorylation sites, using LMW-PTP mutants on tyrosine 131 or 132, We demonstrate that each tyrosine residue is involved in specific LMW-PTP functions. Both of them are phosphorylated during PDGF signaling, Phosphorylation on tyrosine 131 influences mitogenesis, dephosphorylating activated PDGF-R and cytoskeleton rearrangement, acting on p190RhoGAP. Phosphorylation on tyrosine 132 leads to an increase in the strength of cell substrate adhesion, down-regulating matrix metalloproteases expression, through the inhibition of Grb2/MAPK pathway, In conclusion, LMW-PTP tyrosine phosphorylation on both Tyr(131) Or Tyr(132) cooperate to determine a faster and stronger adhesion to extracellular matrix, although these two events may diverge in timing and relative amount.	Univ Florence, Dipartimento Sci Biochim, I-50134 Florence, Italy	University of Florence	Ramponi, G (corresponding author), Univ Florence, Dipartimento Sci Biochim, Viale Morgagni 50, I-50134 Florence, Italy.		Chiarugi, Paola/CDD-7988-2022; Camici, Giovanni/H-1631-2018	Chiarugi, Paola/0000-0001-7655-2969; Camici, Giovanni/0000-0002-0523-0695; raugei, giovanni/0000-0003-1294-786X				Benbow U, 1997, MATRIX BIOL, V15, P519, DOI 10.1016/S0945-053X(97)90026-3; Besser D, 1997, ONCOGENE, V14, P705, DOI 10.1038/sj.onc.1200879; Blanchetot C, 2000, J BIOL CHEM, V275, P12446, DOI 10.1074/jbc.275.17.12446; Bond M, 1999, BIOCHEM BIOPH RES CO, V264, P561, DOI 10.1006/bbrc.1999.1551; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Bucciantini M, 1999, FEBS LETT, V456, P73, DOI 10.1016/S0014-5793(99)00828-5; CHANG JH, 1995, J CELL BIOL, V130, P335; Chiarugi P, 1998, J BIOL CHEM, V273, P6776, DOI 10.1074/jbc.273.12.6776; Chiarugi P, 2000, J BIOL CHEM, V275, P4640, DOI 10.1074/jbc.275.7.4640; CHIARUGI P, 1995, FEBS LETT, V372, P49, DOI 10.1016/0014-5793(95)00947-8; Cirri P, 1998, J BIOL CHEM, V273, P32522, DOI 10.1074/jbc.273.49.32522; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; Fibbi G, 1999, HEPATOLOGY, V29, P868, DOI 10.1002/hep.510290343; Ganju RK, 2000, J BIOL CHEM, V275, P17263, DOI 10.1074/jbc.M000689200; Inagaki K, 2000, ONCOGENE, V19, P75, DOI 10.1038/sj.onc.1203204; Janulis M, 1999, J BIOL CHEM, V274, P801, DOI 10.1074/jbc.274.2.801; Johnsen M, 1998, CURR OPIN CELL BIOL, V10, P667, DOI 10.1016/S0955-0674(98)80044-6; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Lau HKF, 1999, CARDIOVASC RES, V43, P1049, DOI 10.1016/S0008-6363(99)00136-4; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Liu Y, 1999, CHEM BIOL, V6, P671, DOI 10.1016/S1074-5521(99)80118-5; Mott JD, 2000, J BIOL CHEM, V275, P1384, DOI 10.1074/jbc.275.2.1384; RAMPONI G, 1994, ADV PROT PHOSPHATASE, V8, P1; Reddy KB, 1999, INT J CANCER, V82, P268, DOI 10.1002/(SICI)1097-0215(19990719)82:2<268::AID-IJC18>3.3.CO;2-W; Ried S, 1999, J BIOL CHEM, V274, P16377, DOI 10.1074/jbc.274.23.16377; Rigacci S, 1996, J BIOL CHEM, V271, P1278, DOI 10.1074/jbc.271.3.1278; Roof RW, 1998, MOL CELL BIOL, V18, P7052, DOI 10.1128/MCB.18.12.7052; Sieuwerts AM, 1999, BREAST CANCER RES TR, V55, P9, DOI 10.1023/A:1006190729866; Singer CF, 1999, EUR J BIOCHEM, V259, P40, DOI 10.1046/j.1432-1327.1999.00001.x; Tailor P, 1997, J BIOL CHEM, V272, P5371, DOI 10.1074/jbc.272.9.5371; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vincenti MP, 1996, CRIT REV EUKAR GENE, V6, P391, DOI 10.1615/CritRevEukarGeneExpr.v6.i4.40; Westermarck J, 1997, ONCOGENE, V14, P2651, DOI 10.1038/sj.onc.1201111; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271	36	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37619	37627		10.1074/jbc.M006375200	http://dx.doi.org/10.1074/jbc.M006375200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10980198	hybrid			2022-12-25	WOS:000165618700044
J	Seo, BB; Wang, JM; Flotte, TR; Yagi, T; Matsuno-Yagi, A				Seo, BB; Wang, JM; Flotte, TR; Yagi, T; Matsuno-Yagi, A			Use of the NADH-quinone oxidoreductase (NDI1) gene of Saccharomyces cerevisiae as a possible cure for complex I defects in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOASSOCIATED VIRUS VECTORS; ROTENONE-INSENSITIVE NADH; DNA POLYMERASE-ALPHA; OXIDATIVE-PHOSPHORYLATION; VIRAL VECTORS; ELECTRON-TRANSPORT; MITOCHONDRIA; DELIVERY; DISEASES; THERAPY	The Ndi1 enzyme of Saccharomyces cerevisiae is a single subunit rotenone-insensitive NADH-quinone oxidoreductase that is located on the matrix side of the inner mitochondrial membrane. We have shown previously that the NDI1 gene can be functionally expressed in Chinese hamster cells (Seo, B. B., Kitajima-Ihara, T., Chan, E. K., Scheffler, I. E., Matsuno-Yagi, A., and Yagi, T. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 9167-9171) and human embryonal kidney 293 (HEK 293) cells (Seo, B. B., Matsuno-Yagi, A., and Yagi, T. (1999) Biochim. Biochem. Acta 1412, 56-65) and that the Ndi1 protein is capable of compensating respiratory deficiencies caused by defects in the host NADH-quinone oxidoreductase (complex I). To extend the potential use of this enzyme to repair complex I deficiencies in vivo, we constructed a recombinant adeno-associated virus vector carrying the NDI1 gene (rAAV-NDI1). With rAAV-NDI1 as the gene delivery method, we were able to achieve high transduction efficiencies (nearly 100%) even in 143B cells that are difficult to transfect by lipofection or calcium phosphate precipitation methods. The NDI1 gene was successfully introduced into non-proliferating human cells using rAAV-NDI1. The expressed Ndi1 protein was shown to be functionally active just as seen for proliferating cells. Furthermore, when cells were cultured under the conditions where energy has to be provided by respiration, the NDI1-transduced cells were able to grow even in the presence of added complex I inhibitor such as rotenone and 1-methyl-4-phenylpyridinium ion. In contrast, control cells that did not receive the NDI1 gene failed to survive as anticipated. The Ndi1 protein has a great potential as a molecular remedy for complex I defects, and it is highly likely that the same strategy can be extended to correction of other mitochondrial disorders.	Scripps Res Inst, Dept Mol & Expt Med, Div Biochem, La Jolla, CA 92037 USA; Univ Florida, Inst Genet, Powell Gene Therapy Ctr, Gainesville, FL 32610 USA	Scripps Research Institute; State University System of Florida; University of Florida	Matsuno-Yagi, A (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, Div Biochem, La Jolla, CA 92037 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053244, R01DK051809] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK53244, R01DK51809] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS JD, 1993, FREE RADICAL BIO MED, V15, P181, DOI 10.1016/0891-5849(93)90057-2; Au HC, 1999, P NATL ACAD SCI USA, V96, P4354, DOI 10.1073/pnas.96.8.4354; Beck SE, 1999, J VIROL, V73, P9446, DOI 10.1128/JVI.73.11.9446-9455.1999; Bueler H, 1999, BIOL CHEM, V380, P613, DOI 10.1515/BC.1999.078; BYRNES JJ, 1984, MOL CELL BIOCHEM, V62, P13; CHAN EKL, 1987, J EXP MED, V166, P1627, DOI 10.1084/jem.166.6.1627; CHOMYN A, 1986, SCIENCE, V234, P614, DOI 10.1126/science.3764430; CHOMYN A, 1985, NATURE, V314, P591; de Grey ADNJ, 2000, TRENDS BIOTECHNOL, V18, P394, DOI 10.1016/S0167-7799(00)01476-1; Desai VG, 1996, BRAIN RES, V715, P1, DOI 10.1016/0006-8993(95)01255-9; DEVRIES S, 1988, EUR J BIOCHEM, V176, P377; FLOTTE TR, 1993, P NATL ACAD SCI USA, V90, P10613, DOI 10.1073/pnas.90.22.10613; FLOTTE TR, 1995, GENE THER, V2, P357; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; HATEFI Y, 1985, ENZYMES BIOL MEMBR, P1; Hernandez YJ, 1999, J VIROL, V73, P8549, DOI 10.1128/JVI.73.10.8549-8558.1999; HUBERMAN JA, 1981, CELL, V23, P647, DOI 10.1016/0092-8674(81)90426-8; Jooss K, 1998, J VIROL, V72, P4212, DOI 10.1128/JVI.72.5.4212-4223.1998; Kitajima-Ihara T, 1998, FEBS LETT, V421, P37, DOI 10.1016/S0014-5793(97)01533-0; Klimatcheva Ekaterina, 1999, Frontiers in Bioscience, V4, pD481, DOI 10.2741/Klimatcheva; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Monahan PE, 2000, GENE THER, V7, P24, DOI 10.1038/sj.gt.3301109; MUZYCZKA N, 1994, J CLIN INVEST, V94, P1351, DOI 10.1172/JCI117468; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Owen R, 2000, HUM GENE THER, V11, P2067, DOI 10.1089/104303400750001381; Rabinowitz JE, 1998, CURR OPIN BIOTECH, V9, P470, DOI 10.1016/S0958-1669(98)80031-1; RAMSAY RR, 1992, BIOCHEM BIOPH RES CO, V189, P47, DOI 10.1016/0006-291X(92)91523-S; Robbins PD, 1998, PHARMACOL THERAPEUT, V80, P35, DOI 10.1016/S0163-7258(98)00020-5; Robinson BH, 1998, BBA-BIOENERGETICS, V1364, P271, DOI 10.1016/S0005-2728(98)00033-4; Schapira AHV, 1998, BBA-BIOENERGETICS, V1364, P261, DOI 10.1016/S0005-2728(98)00032-2; SCHEFFLER IE, 1986, CARBOHYD METABOL, P77; Seo BB, 1998, P NATL ACAD SCI USA, V95, P9167, DOI 10.1073/pnas.95.16.9167; Seo BB, 1999, BBA-BIOENERGETICS, V1412, P56, DOI 10.1016/S0005-2728(99)00051-1; SHOFFNER JM, 1994, ANNU REV NUTR, V14, P535, DOI 10.1146/annurev.nu.14.070194.002535; Skehel JM, 1998, FEBS LETT, V438, P301, DOI 10.1016/S0014-5793(98)01317-9; Snyder RO, 1999, J GENE MED, V1, P166; Todd S, 2000, BBA-PROTEIN STRUCT M, V1477, P168, DOI 10.1016/S0167-4838(99)00272-1; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Wu NX, 2000, CURR OPIN BIOTECH, V11, P205, DOI 10.1016/S0958-1669(00)00080-X; Yagi T, 1998, BBA-BIOENERGETICS, V1364, P125, DOI 10.1016/S0005-2728(98)00023-1; ZIMMERMANN W, 1980, J BIOL CHEM, V255, P1847; Zolotukhin S, 1999, GENE THER, V6, P973, DOI 10.1038/sj.gt.3300938	42	66	68	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37774	37778		10.1074/jbc.M007033200	http://dx.doi.org/10.1074/jbc.M007033200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10982813	hybrid			2022-12-25	WOS:000165618700064
J	Bakin, AV; Tomlinson, AK; Bhowmick, NA; Moses, HL; Arteaga, CL				Bakin, AV; Tomlinson, AK; Bhowmick, NA; Moses, HL; Arteaga, CL			Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; PHOSPHOINOSITIDE 3-KINASE; ACTIVATION; PROTEIN; RHO; TRANSCRIPTION; INVASIVENESS; RECEPTOR; BINDING; INSULIN	We have studied the role of phosphatidylinositol 3-OH kinase (PI3K)-Akt signaling in transforming growth factor beta (TGF beta)-mediated epithelial to mesenchymal transition (EMT). In NMuMG mammary epithelial cells, exogenous TGF beta1 induced phosphorylation of Akt at Ser-473 and Akt in vitro kinase activity against GrSK-3 beta within 30 min. These responses were temporally correlated with delocalization of E-cadherin, ZO-1, and integrin beta (1) from cell junctions and the acquisition of spindle cell morphology. LY294002, an inhibitor of the p110 catalytic subunit of PI3K, and a dominant-negative mutant of Akt blocked the delocalization of ZO-1 induced by TGF beta1, whereas transfection of constitutively active p110 induced loss of ZO-1 from tight junctions. In addition, LY294002 blocked TGF beta -mediated C-terminal phosphorylation of Smad2. Consistent with these data, TGF beta -induced p3TP-Lux and p(CAGA)(12). Lux reporter activities were inhibited by LY294002 and transiently expressed dominant-negative p85 and Akt mutants in NMuMG and 4T1 cells. Dominant-negative RhoA inhibited TGF beta -induced phosphorylation of Akt at Ser-473, whereas constitutively active RhoA increased the basal phosphorylation of Akt, suggesting that RhoA in involved in TGF beta -induced EMT. Finally, LY294002 and neutralizing TGF beta1 antibodies inhibited ligand-independent constitutively active Akt as well as basal and TGF beta -stimulated migration in 4T1 and EMT6 breast tumor cells. Taken together, these data suggest that PI3K-Akt signaling is required for TGF beta -induced transcriptional responses, EMT, and cell migration.	Vanderbilt Univ, Sch Med, Div Hematol Oncol, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA; Dept Vet Affairs Med Ctr, Nashville, TN 37232 USA; Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University	Arteaga, CL (corresponding author), Vanderbilt Univ, Sch Med, Div Hematol Oncol, Dept Med, 22nd Ave S,1956 TVC, Nashville, TN 37232 USA.	carlos.arteaga@mcmail.vanderbilt.edu	Bhowmick, Neil/AAA-7302-2019	Bhowmick, Neil/0000-0001-8747-5989; Bakin, Andrei/0000-0002-7728-1969	NCI NIH HHS [R35 CA42572, CA09592, R01 CA62212] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA062212, T32CA009592, R35CA042572] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Bandyopadhyay A, 1999, CANCER RES, V59, P5041; Barbieri MA, 1998, J BIOL CHEM, V273, P19367, DOI 10.1074/jbc.273.31.19367; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Fruman DA, 1999, CELL, V97, P817, DOI 10.1016/S0092-8674(00)80792-8; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; GUNDERSEN GG, 1994, J CELL SCI, V107, P645; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Higaki M, 1999, ARTERIOSCL THROM VAS, V19, P2127, DOI 10.1161/01.ATV.19.9.2127; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Hojo M, 1999, NATURE, V397, P530, DOI 10.1038/17401; Kamei T, 1999, ONCOGENE, V18, P6776, DOI 10.1038/sj.onc.1203114; KAPELLER R, 1995, J BIOL CHEM, V270, P25985, DOI 10.1074/jbc.270.43.25985; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; Kobayashi M, 1997, J BIOL CHEM, V272, P16089, DOI 10.1074/jbc.272.26.16089; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; Krymskaya VP, 1997, AM J PHYSIOL-LUNG C, V273, pL1220, DOI 10.1152/ajplung.1997.273.6.L1220; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; LUCAS C, 1990, J IMMUNOL, V145, P1415; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; NOBES CD, 1995, J CELL SCI, V108, P225; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Piek E, 1999, J CELL SCI, V112, P4557; POSTLETHWAITE AE, 1987, J EXP MED, V165, P251, DOI 10.1084/jem.165.1.251; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; Ren XD, 1998, CURR OPIN GENET DEV, V8, P63, DOI 10.1016/S0959-437X(98)80063-4; Roberts AB, 1999, MICROBES INFECT, V1, P1265, DOI 10.1016/S1286-4579(99)00258-0; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Shpetner H, 1996, J CELL BIOL, V132, P595, DOI 10.1083/jcb.132.4.595; Tang WL, 1998, J BIOL CHEM, V273, P5506, DOI 10.1074/jbc.273.10.5506; Thelen M, 1995, BIOCHEM BIOPH RES CO, V217, P1255, DOI 10.1006/bbrc.1995.2903; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Waterman-Storer CM, 1999, CURR OPIN CELL BIOL, V11, P61, DOI 10.1016/S0955-0674(99)80008-8; Wong C, 1999, MOL CELL BIOL, V19, P1821; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	50	799	839	3	59	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36803	36810		10.1074/jbc.M005912200	http://dx.doi.org/10.1074/jbc.M005912200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10969078	hybrid			2022-12-25	WOS:000165577700052
J	Morimura, T; Goitsuka, R; Zhang, Y; Saito, I; Reth, M; Kitamura, D				Morimura, T; Goitsuka, R; Zhang, Y; Saito, I; Reth, M; Kitamura, D			Cell cycle arrest and apoptosis induced by Notch1 in B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; ANKYRIN REPEATS; HUMAN HOMOLOG; NEURONAL DIFFERENTIATION; IMMUNOGLOBULIN GENES; EMBRYONIC LETHALITY; DROSOPHILA HOMOLOG; TYROSINE KINASE; CRE RECOMBINASE; CHICKEN BURSA	Notch receptors play various roles for cell fate decisions in developing organs, although their functions at the cell level are poorly understood. Recently, we found that Notch1 and its ligand are each expressed in juxta-posed cell compartments in the follicles of the bursa of Fabricius, the central organ for chicken B cell development. To examine the function of Notch1 in B cells, a constitutively active form of chicken Notch1 was expressed in a chicken B cell line, DT40, by a Cre/loxP-mediated inducible expression system. Remarkably, the active Notch1 caused growth suppression of the cells, accompanied by a cell cycle inhibition at the G(1) phase and apoptosis. The expression of Hairy1, a gene product up-regulated by the Notch1 signaling, also induced the apoptosis, but no cell cycle inhibition. Thus, Notch1 signaling induces apoptosis of the B cells through Hairy1, and the G(1) cell cycle arrest through other pathways. This novel function of Notch1 may account for the recent observations indicating the selective inhibition of early B cell development in mice by Notch1.	Tokyo Univ Sci, Biosci Res Inst, Div Mol Biol, Noda, Chiba 2780022, Japan; Japan Sci & Technol Corp, PRESTO, Noda, Chiba 2780022, Japan; Univ Freiburg, Dept Mol Immunol, D-79108 Freiburg, Germany; Max Planck Inst Immunobiol, D-79108 Freiburg, Germany; Univ Tokyo, Inst Med Sci, Genet Mol Lab, Minato Ku, Tokyo 1088639, Japan	Tokyo University of Science; Japan Science & Technology Agency (JST); University of Freiburg; Max Planck Society; University of Tokyo	Kitamura, D (corresponding author), Tokyo Univ Sci, Biosci Res Inst, Div Mol Biol, Noda, Chiba 2780022, Japan.	kitamura@rs.noda.sut.ac.jp						ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BUERSTEDDE JM, 1990, EMBO J, V9, P921, DOI 10.1002/j.1460-2075.1990.tb08190.x; Choi JK, 1996, EMBO J, V15, P5014, DOI 10.1002/j.1460-2075.1996.tb00881.x; Christensen S, 1996, DEVELOPMENT, V122, P1373; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; CONLON RA, 1995, DEVELOPMENT, V121, P1533; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Felli MP, 1999, INT IMMUNOL, V11, P1017, DOI 10.1093/intimm/11.7.1017; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; FUKUDA T, 1995, P NATL ACAD SCI USA, V92, P7302, DOI 10.1073/pnas.92.16.7302; FURUKAWA T, 1992, CELL, V69, P1191, DOI 10.1016/0092-8674(92)90640-X; Goitsuka R, 1997, J IMMUNOL, V159, P3126; Hamada T, 1998, BRIT J HAEMATOL, V102, P691; Hamada Y, 1999, DEVELOPMENT, V126, P3415; Hasserjian RP, 1996, BLOOD, V88, P970, DOI 10.1182/blood.V88.3.970.bloodjournal883970; Honjo T, 1996, GENES CELLS, V1, P1, DOI 10.1046/j.1365-2443.1996.10010.x; HOUSSAINT E, 1983, EUR J IMMUNOL, V13, P590, DOI 10.1002/eji.1830130715; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jehn BM, 1999, J IMMUNOL, V162, P635; Jiang RL, 1998, GENE DEV, V12, P1046, DOI 10.1101/gad.12.7.1046; Kanegae Y, 1996, GENE, V181, P207, DOI 10.1016/S0378-1119(96)00516-1; Katsuta H, 1998, J IMMUNOL, V160, P1547; Kidd S, 1998, GENE DEV, V12, P3728, DOI 10.1101/gad.12.23.3728; Kurooka H, 1998, NUCLEIC ACIDS RES, V26, P5448, DOI 10.1093/nar/26.23.5448; LASSILA O, 1989, EUR J IMMUNOL, V19, P955, DOI 10.1002/eji.1830190527; Li LH, 1998, IMMUNITY, V8, P43, DOI 10.1016/S1074-7613(00)80457-4; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; Masteller E L, 1997, Int Rev Immunol, V15, P185, DOI 10.3109/08830189709068176; MATSUNAMI N, 1989, NATURE, V342, P934, DOI 10.1038/342934a0; MATSUNO K, 1995, DEVELOPMENT, V121, P2633; Matsuno K, 1998, NAT GENET, V19, P74, DOI 10.1038/ng0598-74; MILNER LA, 1994, BLOOD, V83, P2057; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MORIMURA T, 1995, J GEN VIROL, V76, P2979, DOI 10.1099/0022-1317-76-12-2979; Morrison AM, 1998, BLOOD, V92, P3865, DOI 10.1182/blood.V92.10.3865.422k01_3865_3878; MOTYKA B, 1991, EUR J IMMUNOL, V21, P1951, DOI 10.1002/eji.1830210825; Nakamura Y, 2000, J NEUROSCI, V20, P283, DOI 10.1523/JNEUROSCI.20-01-00283.2000; Nofziger D, 1999, DEVELOPMENT, V126, P1689; Nutt SL, 1997, IMMUNOBIOLOGY, V198, P227, DOI 10.1016/S0171-2985(97)80043-5; O'Riordan M, 1999, IMMUNITY, V11, P21, DOI 10.1016/S1074-7613(00)80078-3; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Ordentlich P, 1998, MOL CELL BIOL, V18, P2230, DOI 10.1128/MCB.18.4.2230; Oswald F, 1998, MOL CELL BIOL, V18, P2077, DOI 10.1128/MCB.18.4.2077; Palmeirim I, 1997, CELL, V91, P639, DOI 10.1016/S0092-8674(00)80451-1; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; PINK JRL, 1985, EUR J IMMUNOL, V15, P617, DOI 10.1002/eji.1830150616; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; RATCLIFFE MJH, 1986, EUR J IMMUNOL, V16, P129, DOI 10.1002/eji.1830160204; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; REYNAUD CA, 1989, CELL, V59, P171, DOI 10.1016/0092-8674(89)90879-9; REYNAUD CA, 1987, CELL, V48, P379, DOI 10.1016/0092-8674(87)90189-9; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; Sakai K, 1995, BIOCHEM BIOPH RES CO, V217, P393, DOI 10.1006/bbrc.1995.2789; Schroeder T, 2000, EMBO J, V19, P2558, DOI 10.1093/emboj/19.11.2558; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; SCHWEISGUTH F, 1992, CELL, V69, P1199, DOI 10.1016/0092-8674(92)90641-O; Sigvardsson M, 1997, IMMUNITY, V7, P25, DOI 10.1016/S1074-7613(00)80507-5; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; Tomita K, 1999, GENE DEV, V13, P1203, DOI 10.1101/gad.13.9.1203; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; Varnum-Finney B, 1998, BLOOD, V91, P4084, DOI 10.1182/blood.V91.11.4084.411k05_4084_4091; Wakamatsu Y, 1999, NEURON, V23, P71, DOI 10.1016/S0896-6273(00)80754-0; WAKATSUKI Y, 1994, J EXP MED, V179, P1099, DOI 10.1084/jem.179.4.1099; Washburn T, 1997, CELL, V88, P833, DOI 10.1016/S0092-8674(00)81929-7; WEILL JC, 1986, P NATL ACAD SCI USA, V83, P3336, DOI 10.1073/pnas.83.10.3336; Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723; Zhang Y, 1996, NUCLEIC ACIDS RES, V24, P543, DOI 10.1093/nar/24.4.543; Zhang Y, 1998, EMBO J, V17, P7304, DOI 10.1093/emboj/17.24.7304	74	118	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36523	36531		10.1074/jbc.M006415200	http://dx.doi.org/10.1074/jbc.M006415200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10967117	hybrid			2022-12-25	WOS:000165577700011
J	Ward, RA; Nakamura, M; McLeish, KR				Ward, RA; Nakamura, M; McLeish, KR			Priming of the neutrophil respiratory burst involves p38 mitogen-activated protein kinase-dependent exocytosis of flavocytochrome b(558)-containing granules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; COLONY-STIMULATING FACTOR; CHRONIC GRANULOMATOUS-DISEASE; SIGNAL-TRANSDUCTION PATHWAYS; SUPEROXIDE ANION GENERATION; CELL-SURFACE; FACTOR-ALPHA; TNF-ALPHA; SUBCELLULAR-LOCALIZATION; TYROSINE PHOSPHORYLATION	The respiratory burst of human neutrophils is primed by a number of pro-inflammatory stimuli, including tumor necrosis factor-alpha (TNF alpha) and lipopolysaccharide (LPS); however, the mechanism of priming remains unknown. LPS has been shown previously to increase membrane expression of flavocytochrome b(558), a component of the NADPH oxidase. This study shows that TNF alpha also increases membrane expression of flavocytochrome b(558). Mitogen-activated protein kinase (MAPK) modules have been implicated in the action of priming agents. Pharmacologic inhibitors of MAPKs, SB203580 and PD098059, revealed that priming of the respiratory burst and up-regulation of flavocytochrome b(558) are dependent on p38 MAPK but not on extracellular-signal regulated kinase (ERK). TNF alpha and LPS primed respiratory burst activity and increased membrane expression of CD35 and CD66b, specific markers of secretory vesicles and specific granules that contain flavocytochrome b(558) with similar time courses and concentration dependences. These processes also required p38 MAPK but were independent of ERK. TNF alpha failed to prime respiratory burst activity or to increase membrane CD35 expression in enucleated neutrophil cytoplasts. These data suggest that one mechanism by which TNF alpha and LPS prime neutrophil respiratory burst activity is by increasing membrane expression of flavocytochrome b(558) through exocytosis of intracellular granules in a process regulated by p38 MAPK.	Univ Louisville, Dept Med, Mol Signaling Grp, Louisville, KY 40202 USA; Univ Louisville, Dept Biochem & Mol Biol, Louisville, KY 40202 USA; Nagasaki Univ, Inst Trop Med, Dept Host Def Biochem, Nagasaki 8528523, Japan; Vet Affairs Med Ctr, Louisville, KY 40204 USA	University of Louisville; University of Louisville; Nagasaki University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Ward, RA (corresponding author), Univ Louisville, Dept Med, Mol Signaling Grp, 615 S Preston St, Louisville, KY 40202 USA.	richard.ward@louisville.edu	McLeish, Kenneth R./B-9819-2013	McLeish, Kenneth R./0000-0002-7816-3286				Absolom D R, 1986, Methods Enzymol, V132, P95; ATKINSON YH, 1988, J CLIN INVEST, V81, P759, DOI 10.1172/JCI113381; Avdi NJ, 1996, J BIOL CHEM, V271, P33598, DOI 10.1074/jbc.271.52.33598; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; BAJAJ MS, 1992, INFLAMMATION, V16, P241, DOI 10.1007/BF00918813; BASS DA, 1986, J IMMUNOL, V136, P860; BORREGAARD N, 1994, J LEUKOCYTE BIOL, V56, P80, DOI 10.1002/jlb.56.1.80; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; Clerk A, 1998, FEBS LETT, V426, P93, DOI 10.1016/S0014-5793(98)00324-X; Coxon PY, 2000, J IMMUNOL, V164, P6530, DOI 10.4049/jimmunol.164.12.6530; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DeLeo FR, 1998, J CLIN INVEST, V101, P455, DOI 10.1172/JCI949; Detmers PA, 1998, J IMMUNOL, V161, P1921; Downey GP, 1998, J IMMUNOL, V160, P434; DURSTIN M, 1993, BIOCHEM J, V292, P183, DOI 10.1042/bj2920183; ElBenna J, 1996, ARCH BIOCHEM BIOPHYS, V334, P395; ENGLISH D, 1986, BLOOD, V67, P1314; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Hale KK, 1999, J IMMUNOL, V162, P4246; HASLETT C, 1985, AM J PATHOL, V119, P101; JOHNSTON RB, 1975, J CLIN INVEST, V55, P1357, DOI 10.1172/JCI108055; KLEBANOFF SJ, 1986, J IMMUNOL, V136, P4220; KLEIN JB, 1990, INFLAMMATION, V14, P599, DOI 10.1007/BF00914279; KLEIN JB, 1995, J LEUKOCYTE BIOL, V57, P500, DOI 10.1002/jlb.57.3.500; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; Lali FV, 2000, J BIOL CHEM, V275, P7395, DOI 10.1074/jbc.275.10.7395; LINAS SL, 1992, KIDNEY INT, V42, P610, DOI 10.1038/ki.1992.325; Mansfield PJ, 2000, BLOOD, V95, P2407, DOI 10.1182/blood.V95.7.2407.007k02_2407_2412; MCCOLL SR, 1990, J IMMUNOL, V145, P3047; McLeish KR, 1998, J LEUKOCYTE BIOL, V64, P835, DOI 10.1002/jlb.64.6.835; McLeish KR, 1998, J LEUKOCYTE BIOL, V64, P537, DOI 10.1002/jlb.64.4.537; MEGE JL, 1989, J LEUKOCYTE BIOL, V46, P161, DOI 10.1002/jlb.46.2.161; Mocsai A, 2000, J IMMUNOL, V164, P4321, DOI 10.4049/jimmunol.164.8.4321; Nahas N, 1996, BIOCHEM J, V318, P247, DOI 10.1042/bj3180247; NAKAMURA M, 1987, BLOOD, V69, P1404; Nick JA, 1997, J CLIN INVEST, V99, P975, DOI 10.1172/JCI119263; Nick JA, 1996, J IMMUNOL, V156, P4867; Nick JA, 1999, J CLIN INVEST, V103, P851, DOI 10.1172/JCI5257; OZAKI Y, 1988, INFLAMMATION, V12, P297, DOI 10.1007/BF00915767; PETREQUIN PR, 1986, BLOOD, V67, P1119; Pugin J, 1999, AM J RESP CELL MOL, V20, P458, DOI 10.1165/ajrcmb.20.3.3311; Rane MJ, 1997, J IMMUNOL, V159, P5070; REED D, 1988, ARCH SURG-CHICAGO, V123, P1333; ROOS D, 1983, J CELL BIOL, V97, P368, DOI 10.1083/jcb.97.2.368; Smolen JE, 2000, J BIOL CHEM, V275, P15876, DOI 10.1074/jbc.M906232199; Tandon R, 2000, BIOCHEM BIOPH RES CO, V270, P858, DOI 10.1006/bbrc.2000.2540; TRINKLE LS, 1987, DIAGN CLIN IMMUNOL, V5, P62; VOSBECK K, 1990, J LEUKOCYTE BIOL, V47, P97, DOI 10.1002/jlb.47.2.97; WARD RA, 1995, J AM SOC NEPHROL, V5, P1697; WATERMAN WH, 1995, BIOCHEM J, V307, P39, DOI 10.1042/bj3070039; WEISBART RH, 1987, BLOOD, V69, P18; WEISBART RH, 1986, J IMMUNOL, V137, P3584; WEWERS MD, 1990, AM J PHYSIOL, V259, pL276, DOI 10.1152/ajplung.1990.259.4.L276; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; WORTHEN GS, 1987, AM REV RESPIR DIS, V136, P19, DOI 10.1164/ajrccm/136.1.19; YASUI K, 1992, BIOCHEM BIOPH RES CO, V183, P1280, DOI 10.1016/S0006-291X(05)80329-8; YOU A, 1997, BIOCHEM BIOPH RES CO, V235, P42; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zu YL, 1998, J IMMUNOL, V160, P1982	63	130	134	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36713	36719		10.1074/jbc.M003017200	http://dx.doi.org/10.1074/jbc.M003017200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10976103	hybrid			2022-12-25	WOS:000165577700039
J	Yancey, PG; de la Llera-Moya, M; Swarnakar, S; Monzo, P; Klein, SM; Connelly, MA; Johnson, WJ; Williams, DL; Rothblat, GH				Yancey, PG; de la Llera-Moya, M; Swarnakar, S; Monzo, P; Klein, SM; Connelly, MA; Johnson, WJ; Williams, DL; Rothblat, GH			High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SR-BI; SELECTIVE UPTAKE; HUMAN-SERUM; FU5AH CELLS; EFFLUX; HDL; MECHANISM; TRANSPORT; MEMBRANE; PROMOTES	The role of high density lipoprotein (HDL) phospholipid in scavenger receptor BI (SR-BI)-mediated free cholesterol flux was examined by manipulating HDL, phosphatidylcholine and sphingomyelin content. Both phosphatidylcholine and sphingomyelin enrichment of HDL enhanced the net efflux of cholesterol from SR-BI-expressing COS-7 cells but by two different mechanisms. Phosphatidylcholine enrichment of HDL increased efflux, whereas sphingomyelin enrichment decreased influx of HDL cholesterol. Although similar trends were observed in control (vector-transfected) COS-7 cells, SR-BI overexpression amplified the effects of phosphatidylcholine and sphingomyelin enrichment of HDL 25-and 2.8-fold, respectively. By using both phosphatidylcholine-enriched and phospholipase A(2)-treated HDL to obtain HDL with a graded phosphatidylcholine content, we showed that SR-BI-mediated cholesterol efflux was highly correlated (r(2) = 0.985) with HDL phosphatidylcholine content. The effects of varying HDL phospholipid composition on SR-BI-mediated free cholesterol flux were not correlated with changes in either the K-d or B-max values for high affinity binding to SR-BI. We conclude that SR-BI-mediated free cholesterol flux is highly sensitive to HDL phospholipid composition. Thus, factors that regulate cellular SR-BI expression and the local modification of HDL phospholipid composition will have a large impact on reverse cholesterol transport.	SUNY Stony Brook, Med Ctr, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; Childrens Hosp Philadelphia, Dept Pediat, Div Gastroenterol & Nutr, Philadelphia, PA 19104 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Williams, DL (corresponding author), SUNY Stony Brook, Med Ctr, Dept Pharmacol Sci, Stony Brook, NY 11794 USA.		Eckhardt, Erik/G-1567-2010; Yancey, Patricia/ABB-5856-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063768, R01HL058012, P01HL022633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL22633, HL58012, HL63768] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Atger V, 1995, J CLIN INVEST, V96, P2613, DOI 10.1172/JCI118326; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; BAMBERGER M, 1985, BIOCHEMISTRY-US, V24, P3693, DOI 10.1021/bi00335a044; BITTMAN R, 1994, BIOCHEMISTRY-US, V33, P11776, DOI 10.1021/bi00205a013; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Calvo D, 1998, J LIPID RES, V39, P777; Chen WG, 2000, J BIOL CHEM, V275, P30794, DOI 10.1074/jbc.M004552200; Connelly MA, 1999, J BIOL CHEM, V274, P41, DOI 10.1074/jbc.274.1.41; DAVIDSON WS, 1994, J BIOL CHEM, V269, P22975; DAVIDSON WS, 1995, J BIOL CHEM, V270, P17106, DOI 10.1074/jbc.270.29.17106; DAVIDSON WS, 1995, J BIOL CHEM, V270, P5882, DOI 10.1074/jbc.270.11.5882; Davit-Spraul A, 1999, J LIPID RES, V40, P328; de la Llera-Moya M, 1999, J LIPID RES, V40, P575; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; EISENBERG S, 1984, J LIPID RES, V25, P1017; FIELDING CJ, 1995, J LIPID RES, V36, P211; FIELDING CJ, 1991, CURR OPIN LIPIDOL, V2, P376; Fournier N, 1996, J LIPID RES, V37, P1704; Fournier N, 1997, ARTERIOSCL THROM VAS, V17, P2685, DOI 10.1161/01.ATV.17.11.2685; FRANCESCHINI G, 1991, ATHEROSCLEROSIS, V88, P99, DOI 10.1016/0021-9150(91)90073-C; Fukasawa M, 1996, EXP CELL RES, V222, P246, DOI 10.1006/excr.1996.0030; GLOMSET JA, 1964, BIOCHIM BIOPHYS ACTA, V89, P266, DOI 10.1016/0926-6569(64)90215-9; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Graf GA, 1999, J BIOL CHEM, V274, P12043, DOI 10.1074/jbc.274.17.12043; Gu XJ, 2000, J BIOL CHEM, V275, P29993, DOI 10.1074/jbc.275.39.29993; Hatch F T, 1968, Adv Lipid Res, V6, P1; Haynes MP, 2000, BIOCHEMISTRY-US, V39, P4508, DOI 10.1021/bi992125q; Hirano K, 1999, CIRC RES, V85, P108; Jaye M, 1999, NAT GENET, V21, P424, DOI 10.1038/7766; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Ji Y, 1999, J BIOL CHEM, V274, P33398, DOI 10.1074/jbc.274.47.33398; Jian B, 1997, J LIPID RES, V38, P734; Jian B, 1998, J BIOL CHEM, V273, P5599, DOI 10.1074/jbc.273.10.5599; JOHNSON WJ, 1986, J BIOL CHEM, V261, P5766; Kellner-Weibel G, 2000, BIOCHEMISTRY-US, V39, P221, DOI 10.1021/bi991666c; KLANSEK JJ, 1995, J LIPID RES, V36, P2261; Krieger M, 1999, CURR OPIN LIPIDOL, V10, P491, DOI 10.1097/00041433-199912000-00003; KUNZ F, 1994, ARTERIOSCLER THROMB, V14, P1146, DOI 10.1161/01.ATV.14.7.1146; LAGROST L, 1995, J BIOL CHEM, V270, P13004, DOI 10.1074/jbc.270.22.13004; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; PATTNAIK NM, 1976, J BIOL CHEM, V251, P1984; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; Pilon A, 2000, ARTERIOSCL THROM VAS, V20, P1074, DOI 10.1161/01.ATV.20.4.1074; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; ROTHBLAT GH, 1982, J BIOL CHEM, V257, P4775; Rothblat GH, 1999, J LIPID RES, V40, P781; Schroeder F, 1996, P SOC EXP BIOL MED, V213, P150, DOI 10.3181/00379727-213-44047; Slotte JP, 1999, CHEM PHYS LIPIDS, V102, P13, DOI 10.1016/S0009-3084(99)00071-7; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; Tabas I, 1999, CHEM PHYS LIPIDS, V102, P123, DOI 10.1016/S0009-3084(99)00080-8; TALL AR, 1992, J INTERN MED, V231, P661, DOI 10.1111/j.1365-2796.1992.tb01255.x; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; Williams DL, 2000, J BIOL CHEM, V275, P18897, DOI 10.1074/jbc.M002411200; Williams DL, 1999, CURR OPIN LIPIDOL, V10, P329, DOI 10.1097/00041433-199908000-00007	58	252	264	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36596	36604		10.1074/jbc.M006924200	http://dx.doi.org/10.1074/jbc.M006924200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10964930	hybrid			2022-12-25	WOS:000165577700021
J	Kikyo, M; Matozaki, T; Kodama, A; Kawabe, H; Nakanishi, H; Takai, Y				Kikyo, M; Matozaki, T; Kodama, A; Kawabe, H; Nakanishi, H; Takai, Y			Cell-cell adhesion-mediated tyrosine phosphorylation of nectin-2 delta, an immunoglobulin-like cell adhesion molecule at adherens junctions	ONCOGENE			English	Article						cell-cell adhesion; cadherin; nectin; Src; tyrosine phosphorylation	POLIOVIRUS RECEPTOR GENE; CADHERIN-CATENIN COMPLEX; EPIDERMAL GROWTH-FACTOR; SIMPLEX VIRUS TYPE-1; SRC FAMILY KINASES; BETA-CATENIN; BINDING PROTEIN; COMPLEMENTARY-DNA; N-CADHERIN; PHOSPHATASE	We have recently found a novel functional unit of cell-cell adhesion at cadherin-based adherens junctions, consisting of at least nectin, an immunoglobulin-like cell adhesion molecule, and afadin, an actin filament-binding protein which connects nectin to the actin cytoskeleton. Among the members of the nectin family, we have found here that nectin-2 delta is tyrosine-phosphorylated in response to cell-cell adhesion. Expression of E-cadherin induced tyrosine phosphorylation of nectin-2 delta, while disruption of cell-cell adhesion by an anti-E-cadherin antibody reduced the tyrosine phosphorylation of nectin-2 delta. An inhibitor specific for Src family kinase or expression of Csk reduced tyrosine phosphorylation of nectin-2 delta. In addition, Src kinase tyrosine phosphorylates the recombinant cytoplasmic region of nectin-2 delta in vitro. The major tyrosine phosphorylation site of nectin-2 delta was Tyr(505) in the cytoplasmic region, because the mutant nectin-2 delta, of which Tyr(505) was replaced by Phe, showed a loss of tyrosine phosphorylation in vivo and in vitro. These results, together with our recent observations, indicate that the cadherin-catenin system and the nectin-afadin system are closely connected to each other. The cadherin-mediated cell-cell adhesion system may link to the activation of a Src family kinase, that is, at least in part, responsible for the tyrosine phosphorylation of the cytoplasmic region of nectin-2 delta.	Osaka Univ, Grad Sch Med, Fac Med, Dept Biochem & Mol Biol, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Biochem & Mol Biol, Suita, Osaka 5650871, Japan.		Kawabe, Hiroshi/U-7325-2018	Nakanishi, Hiroyuki/0000-0002-9765-0266; Kawabe, Hiroshi/0000-0001-5650-8696				Aoki J, 1997, EXP CELL RES, V235, P374, DOI 10.1006/excr.1997.3685; Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Bouchard MJ, 2000, MOL CELL BIOL, V20, P2865, DOI 10.1128/MCB.20.8.2865-2873.2000; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; Calautti E, 1998, J CELL BIOL, V141, P1449, DOI 10.1083/jcb.141.6.1449; Cocchi F, 1998, J VIROL, V72, P9992, DOI 10.1128/JVI.72.12.9992-10002.1998; Cocchi F, 2000, J VIROL, V74, P3909, DOI 10.1128/JVI.74.8.3909-3917.2000; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; Kamei T, 1999, ONCOGENE, V18, P6776, DOI 10.1038/sj.onc.1203114; KARTENBECK J, 1991, J CELL BIOL, V113, P881, DOI 10.1083/jcb.113.4.881; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; Lampugnani MG, 1997, J CELL SCI, V110, P2065; Lopez M, 1998, BLOOD, V92, P4602, DOI 10.1182/blood.V92.12.4602.424k21_4602_4611; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; Miyahara M, 2000, J BIOL CHEM, V275, P613, DOI 10.1074/jbc.275.1.613; MORRISON ME, 1992, J VIROL, V66, P2807, DOI 10.1128/JVI.66.5.2807-2813.1992; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; Noguchi T, 1999, EMBO J, V18, P1748, DOI 10.1093/emboj/18.7.1748; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; OCHIAI A, 1994, BIOCHEM BIOPH RES CO, V205, P73, DOI 10.1006/bbrc.1994.2631; OKADA M, 1991, J BIOL CHEM, V266, P24249; Pertz O, 1999, EMBO J, V18, P1738, DOI 10.1093/emboj/18.7.1738; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; TAKAISHI K, 1994, ONCOGENE, V9, P273; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tomschy A, 1996, EMBO J, V15, P3507, DOI 10.1002/j.1460-2075.1996.tb00719.x; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; Warner MS, 1998, VIROLOGY, V246, P179, DOI 10.1006/viro.1998.9218; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	49	11	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2000	19	35					4022	4028		10.1038/sj.onc.1203744	http://dx.doi.org/10.1038/sj.onc.1203744			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962558				2022-12-25	WOS:000088825300007
J	Zoumpourlis, V; Papassava, P; Linardopoulos, S; Gillespie, D; Balmain, A; Pintzas, A				Zoumpourlis, V; Papassava, P; Linardopoulos, S; Gillespie, D; Balmain, A; Pintzas, A			High levels of phosphorylated c-Jun, Fra-1, Fra-2 and ATF-2 proteins correlate with malignant phenotypes in the multistage mouse skin carcinogenesis model	ONCOGENE			English	Article						jun; fos; ATF-2; mouse skin; AP-1; carcinogenesis	DNA-BINDING ACTIVITY; HA-RAS; CYCLIN D1; V-JUN; TRANSCRIPTIONAL ACTIVATION; CHEMICAL CARCINOGENESIS; CELLULAR-TRANSFORMATION; HETERODIMER FORMATION; ONCOGENE ACTIVATION; IN-VITRO	Analysis of the functions of AP-1 transcription factor in cellular systems has shown its key role as a mediator of oncogenic signals. The employment of suitable animal model systems greatly facilitates the study of changes in the composition and activity of the AP-1 complex. Here, we have analysed the quantitative and qualitative changes of AP-1 at different stages of carcinogenesis in mouse skin cell lines, derived from tumours induced by chemical mutagens. The findings of this study suggest that elevated AP-1 DNA binding and transactivation activity characterize the carcinoma cell lines, most notably the highly malignant spindle carcinomas. In addition, increased amounts and post-translational modifications of c-Jun, Fra-1, Fra-2 and ATF-2 proteins account for a high percentage of the increased AP-1 activity. Remarkably, high levels of phosphorylated ATF-2 protein were detected in malignant cell lines, indicating a novel role of ATF-2 in tumour progression. c-Jun and ATF-2 proteins are phosphorylated by highly active JNK kinases present in tumour cells. Finally, our results indicate distinct functions for different AP-1 components in the promotion and progression of mouse skin tumours.	Natl Hellen Res Fdn, Inst Biol Res & Biotechnol, GR-11635 Athens, Greece; Onyx Pharmaceut, Richmond, CA 94806 USA; CRC Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Univ Calif San Francisco, Ctr Canc, San Francisco, CA 94143 USA	National Hellenic Research Foundation; Beatson Institute; University of California System; University of California San Francisco	Pintzas, A (corresponding author), Natl Hellen Res Fdn, Inst Biol Res & Biotechnol, 48 Vas Constantinou Ave, GR-11635 Athens, Greece.			Gillespie, David/0000-0002-6338-0544; Linardopoulos, Spiros/0000-0002-6600-400X				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BENBROOK DM, 1990, ONCOGENE, V5, P295; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BIANCHI AB, 1993, ONCOGENE, V8, P1127; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLACK EJ, 1994, ONCOGENE, V9, P2363; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOWDEN GT, 1994, CANCER RES, V54, pS1882; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BUCHMANN A, 1991, CANCER RES, V51, P4097; BURLEY SK, 1994, CURR OPIN STRUC BIOL, V4, P3, DOI 10.1016/S0959-440X(94)90053-1; BURNS PA, 1991, ONCOGENE, V6, P2363; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOMANN FE, 1994, MOL CARCINOGEN, V9, P61, DOI 10.1002/mc.2940090202; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FILMUS J, 1994, ONCOGENE, V9, P3627; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GRUDA MC, 1994, ONCOGENE, V9, P2537; HANKINS WD, 1981, CELL, V26, P91, DOI 10.1016/0092-8674(81)90036-2; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Lallemand D, 1998, EMBO J, V17, P5615, DOI 10.1093/emboj/17.19.5615; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OEHLER T, 1993, ONCOGENE, V8, P1141; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; QUINTANILLA M, 1991, CARCINOGENESIS, V12, P1875, DOI 10.1093/carcin/12.10.1875; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STOLER AB, 1993, J CELL BIOL, V122, P1103, DOI 10.1083/jcb.122.5.1103; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Vandel L, 1996, MOL CELL BIOL, V16, P1881; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; YUSPA SH, 1988, ADV CANCER RES, V50, P25, DOI 10.1016/S0065-230X(08)60434-0; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	65	85	92	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2000	19	35					4011	4021		10.1038/sj.onc.1203732	http://dx.doi.org/10.1038/sj.onc.1203732			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962557				2022-12-25	WOS:000088825300006
J	Wendt, CH; Gick, G; Sharma, R; Zhuang, Y; Deng, WL; Ingbar, DH				Wendt, CH; Gick, G; Sharma, R; Zhuang, Y; Deng, WL; Ingbar, DH			Up-regulation of Na,K-ATPase beta(1) transcription by hyperoxia is mediated by SP1/SP3 binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MDCK EPITHELIAL-CELLS; NF-KAPPA-B; SUBUNIT GENE; PROTEINS SP1; SP FAMILY; ACTIVATION; LUNG; GROWTH; EXPRESSION; PROMOTER	The sodium pump, Na,K-ATPase, is an important protein for maintaining intracellular ion concentration, cellular volume, and ion transport and is regulated both transcriptionally and post-transcriptionally. We previously-demonstrated that hyperoxia increased Na,K-ATPase beta (1) gene expression in Madin-Darby canine kidney (MDCK) cells. In this study, we identify a DNA element necessary for up-regulation of the Na,K-ATPase beta (1) transcription by hyperoxia and evaluate the nuclear proteins responsible for this up-regulation. Transient transfection experiments in MOCK cells using sequential 5'-deletions of the rat Na,K-ATPase beta (1) promoter-luciferase fusion gene demonstrated promoter activation by hyperoxia between -102 and +151. The hyperoxia response was localized to a 7-base pair region between -62 and -55, which contained a GC-rich region consistent with a consensus sequence for the SP1 family, that was sufficient for up-regulation by hyperoxia. This GC element exhibited both basal and hyperoxia-induced promoter activity and bound both transcription factors SP1 and SP3 in electrophoretic mobility shift assays. In addition, electrophoretic mobility shift assays demonstrated increased binding of SP1/SP3 in cells exposed to hyperoxia while mutation of this element eliminated protein binding. Other GC sites within the proximal promoter also demonstrated up-regulation of transcription by hyperoxia, however, the site at -55 had higher affinity for SP proteins.	Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; SUNY Hlth Sci Ctr, Dept Biochem, Brooklyn, NY 11203 USA	University of Minnesota System; University of Minnesota Twin Cities; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Wendt, CH (corresponding author), Univ Minnesota, Dept Med, Box 276 Mayo Mail Code,420 Delaware St SE, Minneapolis, MN 55455 USA.	wendt005@tc.umn.edu	Wendt, Chris/C-6823-2012	Ingbar, David H./0000-0003-1695-4493				Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; Carter EP, 1997, AM J PHYSIOL-LUNG C, V272, pL542, DOI 10.1152/ajplung.1997.272.3.L542; Chalaka S, 1999, AM J PHYSIOL-LUNG C, V277, pL197, DOI 10.1152/ajplung.1999.277.1.L197; Chu SJ, 1999, AM J PHYSIOL-LUNG C, V276, pL614, DOI 10.1152/ajplung.1999.276.4.L614; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; Discher DJ, 1998, J BIOL CHEM, V273, P26087, DOI 10.1074/jbc.273.40.26087; DREHER D, 1992, AM J PHYSIOL, V262, pC358, DOI 10.1152/ajpcell.1992.262.2.C358; Factor P, 1998, J CLIN INVEST, V102, P1421, DOI 10.1172/JCI3214; GEERING K, 1991, FEBS LETT, V285, P189, DOI 10.1016/0014-5793(91)80801-9; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HammKunzelmann B, 1997, FEBS LETT, V403, P87, DOI 10.1016/S0014-5793(97)00029-X; Harris ZL, 1996, EUR RESPIR J, V9, P472, DOI 10.1183/09031936.96.09030472; Hata Y, 1998, J BIOL CHEM, V273, P19294, DOI 10.1074/jbc.273.30.19294; HORISBERGER JD, 1991, ANNU REV PHYSIOL, V53, P565, DOI 10.1146/annurev.physiol.53.1.565; Jiang JG, 1997, ONCOGENE, V14, P3039, DOI 10.1038/sj.onc.1201152; Jyonouchi H, 1997, NUTR CANCER, V28, P115, DOI 10.1080/01635589709514562; Kumar AP, 1997, NUCLEIC ACIDS RES, V25, P2012, DOI 10.1093/nar/25.10.2012; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LIU B, 1993, CELL MOL BIOL RES, V39, P221; LIU B, 1992, BIOCHIM BIOPHYS ACTA, V1130, P336, DOI 10.1016/0167-4781(92)90449-A; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; MEYER M, 1994, CHEM-BIOL INTERACT, V91, P91, DOI 10.1016/0009-2797(94)90029-9; Murakami Y, 1997, BBA-GENE STRUCT EXPR, V1352, P311, DOI 10.1016/S0167-4781(97)00032-8; Netzker R, 1997, EUR J BIOCHEM, V245, P174, DOI 10.1111/j.1432-1033.1997.00174.x; NICI L, 1994, AM J PHYSIOL, V261, pL307; OLIVERA W, 1994, AM J PHYSIOL, V266, pL577, DOI 10.1152/ajplung.1994.266.5.L577; Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422; Rajakumar RA, 1998, J BIOL CHEM, V273, P27474, DOI 10.1074/jbc.273.42.27474; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; Schanke JT, 1998, MOL ENDOCRINOL, V12, P405, DOI 10.1210/me.12.3.405; SKOU JC, 1988, METHOD ENZYMOL, V156, P1; Toonen RFG, 1996, BIOCHEM J, V316, P467, DOI 10.1042/bj3160467; Wendt CH, 1999, CHEST, V116, p87S, DOI 10.1378/chest.116.suppl_1.87S; Wendt CH, 1998, AM J PHYSIOL-CELL PH, V274, pC356, DOI 10.1152/ajpcell.1998.274.2.C356; Wu XS, 1996, MOL CELL BIOL, V16, P1035; Wu YX, 1998, BIOCHEM J, V330, P1469, DOI 10.1042/bj3301469	37	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41396	41404		10.1074/jbc.M004759200	http://dx.doi.org/10.1074/jbc.M004759200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10988288	hybrid			2022-12-25	WOS:000166114600097
J	Goswami, PC; Sheren, J; Albee, LD; Parsian, A; Sim, JE; Ridnour, LA; Higashikubo, R; Gius, D; Hunt, CR; Spitz, DR				Goswami, PC; Sheren, J; Albee, LD; Parsian, A; Sim, JE; Ridnour, LA; Higashikubo, R; Gius, D; Hunt, CR; Spitz, DR			Cell cycle-coupled variation in topoisomerase II alpha mRNA is regulated by the 3 '-untranslated region - Possible role of redox-sensitive protein binding in mRNA accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; AU-RICH ELEMENTS; DNA TOPOISOMERASES; PHOSPHATASE-ACTIVITY; GENE-EXPRESSION; MAMMALIAN-CELLS; HEAT-SHOCK; DEGRADATION; CLONING; PHOSPHORYLATION	Mammalian topoisomerase II alpha (Topo II) is a highly regulated enzyme essential for many cellular processes including the G(2) cell cycle checkpoint. Because Topo II gene expression is regulated posttranscriptionally during the cell cycle, we investigated the possible role of the 3'-untranslated region (3'-UTR) in controlling Topo II mRNA accumulation. Reporter assays in stably transfected cells demonstrated that, similar to endogenous Topo II mRNA levels, the mRNA levels of reporter genes containing the Topo II 3'-UTR varied during the cell cycle and were maximal in S and G(2)/M relative to G(1). Topo II 3'-UTR sequence analysis and RNA-protein binding assays identified a 177-nucleotide (base pairs 4772-4949) region containing an AUUUUUA motif sufficient for protein binding. Multiple proteins (84, 70, 44, and 37 kDa) bound this region, and the binding of 84- and 37-kDa (tentatively identified as the adenosine- or uridine-rich element-binding factor AUF1) proteins was enhanced in G(1), correlating with decreased Topo II mRNA levels. The binding activity was enhanced in cellular extracts or cells treated with thiol-reducing agents, and increased binding correlated with decreased Topo II mRNA levels. These results support the hypothesis that cell cycle-coupled Topo II gene expression is regulated by interaction of the 3'-UTR with redox-sensitive protein complexes.	Univ Iowa, Dept Radiol, Free Radical & Radiat Biol Program, Iowa City, IA 52242 USA; Washington Univ, Sch Med, Radiat Oncol Ctr, MIR, St Louis, MO 63108 USA	University of Iowa; Washington University (WUSTL)	Goswami, PC (corresponding author), Univ Iowa, Dept Radiol, Free Radical & Radiat Biol Program, B180 Med Labs, Iowa City, IA 52242 USA.			Ridnour, Lisa A./0000-0001-9446-8349; Spitz, Douglas/0000-0002-1254-8765; Goswami, Prabhat/0000-0002-5700-2096	NATIONAL CANCER INSTITUTE [R29CA069593] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051469] Funding Source: NIH RePORTER; NCI NIH HHS [CA50950, R29CA69593] Funding Source: Medline; NHLBI NIH HHS [R01HL51469] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson ME, 1985, HDB METHODS OXYGEN R, P317; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; Blackburn RV, 1999, FREE RADICAL BIO MED, V26, P419, DOI 10.1016/S0891-5849(98)00217-2; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; DETOLEDO SM, 1995, INT J RADIAT BIOL, V67, P135, DOI 10.1080/09553009514550171; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Duret L, 1997, CURR OPIN STRUC BIOL, V7, P399, DOI 10.1016/S0959-440X(97)80058-9; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; EARNSHAW WC, 1988, CELL CYCLE CONTROL E, P176; ELDIERY WS, 1993, CELL, V75, P817; Falck J, 1999, J BIOL CHEM, V274, P18753, DOI 10.1074/jbc.274.26.18753; GIACCONE G, 1992, CANCER RES, V52, P1666; GILLIS P, 1991, J BIOL CHEM, V266, P3172; Goswami PC, 1996, MOL CELL BIOL, V16, P1500; GOSWAMI PC, 1992, RADIAT RES, V132, P162, DOI 10.2307/3578522; HECK MMS, 1988, P NATL ACAD SCI USA, V85, P1086, DOI 10.1073/pnas.85.4.1086; HENTZ MW, 1991, SCIENCE, V244, P357; HOCHHAUSER D, 1992, J BIOL CHEM, V267, P18961; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Jarvinen TAH, 1996, AM J PATHOL, V148, P2073; KALWINSKY DK, 1983, CANCER RES, V43, P1592; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; Li N, 1998, J CELL PHYSIOL, V177, P148, DOI 10.1002/(SICI)1097-4652(199810)177:1<148::AID-JCP16>3.0.CO;2-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; MALTER JS, 1991, J BIOL CHEM, V266, P3167; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; McPherson JP, 1998, CANCER RES, V58, P4519; NAKAGAWA J, 1995, P NATL ACAD SCI USA, V92, P2051, DOI 10.1073/pnas.92.6.2051; RAJAGOPALAN LE, 1994, J BIOL CHEM, V269, P23882; Ridnour LA, 1999, METHOD ENZYMOL, V299, P258; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; ROSS J, 1994, RNA PROCESSING PRACT, V2, P107; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	47	65	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38384	38392		10.1074/jbc.M005298200	http://dx.doi.org/10.1074/jbc.M005298200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10986283	hybrid			2022-12-25	WOS:000165739800035
J	Scheidegger, KJ; Cenni, B; Picard, D; Delafontaine, P				Scheidegger, KJ; Cenni, B; Picard, D; Delafontaine, P			Estradiol decreases IGF-1 and IGF-1 receptor expression in rat aortic smooth muscle cells - Mechanisms for its atheroprotective effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; HORMONE-REPLACEMENT THERAPY; BREAST-CANCER CELLS; CORONARY HEART-DISEASE; NF-KAPPA-B; ESTROGEN-RECEPTOR; GENE-EXPRESSION; POSTMENOPAUSAL WOMEN; RESPONSIVE ELEMENT; MESSENGER-RNA	Insulin-like growth factor (IGF-1) is a potent mitogen for vascular smooth muscle cells, Both IGF-1 and its receptor have been shown to be highly expressed in atherosclerotic lesions. Here we investigated whether part of the vasculoprotective properties of E-2 may be mediated by its negative regulation of the IGF-1 system. HeLa cells, which do not contain endogenous estrogen receptors (ER), were transiently 'transfected with IGF-1R promoter constructs with or without a plasmid encoding human ER alpha or ER beta and treated with 100 nM 17 beta -estradiol (E-2) for 24 h. E-2 treatment decreased basal luciferase activity by 51%, and this effect was dependent on co-expression of ER alpha, whereas no repression was observed with ER beta. A mutation within the DNA binding domain of the ER alpha abolished the repressor function of the ER receptor. Similarly, E-2 decreased IGF-1R transcription by 21% in rat aortic smooth muscle cells (RASMC), which express endogenous ER, This effect was specific for E-2, because it was inhibited by an antiestrogen and because progesterone did not have any effect on IGF-1R expression in HeLa or RASMC transfected with progesterone receptor. Accordingly, E-2 decreased IGF-1R and IGF-1 mRNA in RASMC by 47% and 33%, Western blot analysis and radioligand binding studies showed that E-2 also dose-dependently decreased IGF-1R protein expression in RASMC by 40% and 30%, respectively, and that IGF-1 protein was reduced by 43%. Repression of IGF-1R promoter activity by a combination of ER alpha and E-2 did not appear to be mediated via direct binding of ER to the IGP-1R promoter but rather by inhibition of SP1 binding to the IGF-1R promoter. Thus, E-2 down-regulates IGF-1R and IGF-1 expression in vascular smooth muscle cells, This may have important implications for the understanding of the beneficial effects of estrogen in the cardiovascular system.	Univ Hosp Geneva, Div Cardiol, CH-1211 Geneva 14, Switzerland; Univ Geneva, Dept Cell Biol, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva	Delafontaine, P (corresponding author), Univ Hosp Geneva, Div Cardiol, Rue Micheli du Crest 24, CH-1211 Geneva 14, Switzerland.			Cenni, Bruno/0000-0002-8603-2032; Delafontaine, Patrice/0000-0003-3744-3617	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL045317, R01HL047035, R01HL045317] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47035, HL45317] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLER S, 1988, CELL, V52, P685, DOI 10.1016/0092-8674(88)90406-0; An JP, 1999, P NATL ACAD SCI USA, V96, P15161, DOI 10.1073/pnas.96.26.15161; Anwar A, 2000, ARTERIOSCL THROM VAS, V20, P370, DOI 10.1161/01.ATV.20.2.370; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; BAYARD F, 1995, ENDOCRINOLOGY, V136, P1523, DOI 10.1210/en.136.4.1523; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BEITNERJOHNSON D, 1995, MOL ENDOCRINOL, V9, P1147, DOI 10.1210/me.9.9.1147; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Bhalla RC, 1997, AM J PHYSIOL-HEART C, V272, pH1996, DOI 10.1152/ajpheart.1997.272.4.H1996; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; BORNFELDT KE, 1992, DIABETOLOGIA, V35, P104, DOI 10.1007/BF00402540; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; CAULEY JA, 1983, ATHEROSCLEROSIS, V49, P31, DOI 10.1016/0021-9150(83)90005-9; Cenni B, 1999, TRENDS ENDOCRIN MET, V10, P41, DOI 10.1016/S1043-2760(98)00121-0; CERCEK B, 1990, CIRC RES, V66, P1755, DOI 10.1161/01.RES.66.6.1755; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; Chen ZG, 1999, MOL CELL ENDOCRINOL, V158, P131, DOI 10.1016/S0303-7207(99)00172-0; CLEMMONS DR, 1985, J CLIN INVEST, V75, P1914, DOI 10.1172/JCI111906; CLEMMONS DR, 1980, P NATL ACAD SCI-BIOL, V77, P6644, DOI 10.1073/pnas.77.11.6644; COHICK WS, 1993, J CELL PHYSIOL, V157, P52, DOI 10.1002/jcp.1041570107; COLLINS P, 1994, CIRCULATION, V90, P1964, DOI 10.1161/01.CIR.90.4.1964; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; Couse JF, 1999, SCIENCE, V286, P2328, DOI 10.1126/science.286.5448.2328; DELAFONTAINE P, 1995, J BIOL CHEM, V270, P14383, DOI 10.1074/jbc.270.24.14383; DELAFONTAINE P, 1991, HYPERTENSION, V17, P693, DOI 10.1161/01.HYP.17.5.693; DELAFONTAINE P, 1994, J MOL CELL CARDIOL, V26, P1659, DOI 10.1006/jmcc.1994.1185; Delafontaine P, 1996, J CLIN INVEST, V97, P139, DOI 10.1172/JCI118381; deMedeiros SRB, 1997, J BIOL CHEM, V272, P18250, DOI 10.1074/jbc.272.29.18250; DU J, 1995, CIRC RES, V76, P963, DOI 10.1161/01.RES.76.6.963; ERNST M, 1991, MOL ENDOCRINOL, V5, P1081, DOI 10.1210/mend-5-8-1081; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Galien R, 1997, NUCLEIC ACIDS RES, V25, P2424, DOI 10.1093/nar/25.12.2424; Garnero P, 1999, J CLIN ENDOCR METAB, V84, P2390, DOI 10.1210/jc.84.7.2390; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Guetta V, 1996, CIRCULATION, V93, P1928, DOI 10.1161/01.CIR.93.10.1928; Homma H, 2000, J BIOL CHEM, V275, P11404, DOI 10.1074/jbc.275.15.11404; HONG MK, 1992, AM J CARDIOL, V69, P176, DOI 10.1016/0002-9149(92)91300-S; HORWITZ KB, 1978, CANCER RES, V38, P2434; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Huynh H, 1996, CLIN CANCER RES, V2, P2037; JIANG CW, 1992, AM J PHYSIOL, V263, pH271, DOI 10.1152/ajpheart.1992.263.1.H271; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Koike H, 1996, J VASC SURG, V23, P477, DOI 10.1016/S0741-5214(96)80014-0; Kolodgie FD, 1996, AM J PATHOL, V148, P969; Krege JH, 1998, P NATL ACAD SCI USA, V95, P15677, DOI 10.1073/pnas.95.26.15677; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; Li GH, 1999, CIRCULATION, V100, P1639, DOI 10.1161/01.CIR.100.15.1639; Lindner V, 1998, CIRC RES, V83, P224, DOI 10.1161/01.RES.83.2.224; Lou H, 1998, CIRC RES, V83, P947; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; Makela S, 1999, P NATL ACAD SCI USA, V96, P7077, DOI 10.1073/pnas.96.12.7077; MATHIEU M, 1991, MOL ENDOCRINOL, V5, P815, DOI 10.1210/mend-5-6-815; McCarthy TL, 1997, J BIOL CHEM, V272, P18132, DOI 10.1074/jbc.272.29.18132; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; MENDELSON ME, 1994, CURR OPIN CARDIOL, V9, P619, DOI 10.1097/00001573-199409000-00018; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; MURPHY LJ, 1988, ENDOCRINOLOGY, V122, P325, DOI 10.1210/endo-122-1-325; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NABULSI AA, 1993, NEW ENGL J MED, V328, P1069, DOI 10.1056/NEJM199304153281501; Nickenig G, 1998, CIRCULATION, V97, P2197, DOI 10.1161/01.CIR.97.22.2197; ORIMO A, 1993, BIOCHEM BIOPH RES CO, V195, P730, DOI 10.1006/bbrc.1993.2106; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; PFEIFLE B, 1982, HORM METAB RES, V14, P409, DOI 10.1055/s-2007-1019031; POLANCO JI, 1995, BIOCHEM BIOPH RES CO, V209, P182, DOI 10.1006/bbrc.1995.1487; Porter W, 1997, MOL ENDOCRINOL, V11, P1569, DOI 10.1210/me.11.11.1569; PROUDLER AJ, 1995, LANCET, V346, P89, DOI 10.1016/S0140-6736(95)92114-1; RAY A, 1994, J BIOL CHEM, V269, P12940; REDMOND EM, 1994, CIRCULATION, V90, P2519, DOI 10.1161/01.CIR.90.5.2519; RUBINI M, 1994, EXP CELL RES, V211, P374, DOI 10.1006/excr.1994.1101; SAHLIN L, 1994, STEROIDS, V59, P421, DOI 10.1016/0039-128X(94)90011-6; Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379; Scheidegger KJ, 1999, J BIOL CHEM, V274, P3522, DOI 10.1074/jbc.274.6.3522; SHEWMON DA, 1994, ARTERIOSCLER THROMB, V14, P1586, DOI 10.1161/01.ATV.14.10.1586; SIDAWY AN, 1990, SURGERY, V108, P165; Somjen D, 1998, HYPERTENSION, V32, P39, DOI 10.1161/01.HYP.32.1.39; STEIN B, 1995, MOL CELL BIOL, V15, P4971; STEVENSON JC, 1994, DRUGS, V47, P35, DOI 10.2165/00003495-199400472-00007; STEWART AJ, 1990, J BIOL CHEM, V265, P21172; Sun GL, 1998, MOL ENDOCRINOL, V12, P882, DOI 10.1210/me.12.6.882; TORA L, 1988, EMBO J, V7, P3771, DOI 10.1002/j.1460-2075.1988.tb03261.x; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; VERVERIS J, 1994, AM J MED SCI, V307, P77, DOI 10.1097/00000441-199402000-00001; VERVERIS JJ, 1993, CIRC RES, V72, P1285, DOI 10.1161/01.RES.72.6.1285; Wang F, 1998, NUCLEIC ACIDS RES, V26, P3044, DOI 10.1093/nar/26.12.3044; Watanabe T, 1997, BIOCHEM BIOPH RES CO, V236, P140, DOI 10.1006/bbrc.1997.6915; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; WERNER H, 1994, J BIOL CHEM, V269, P12577; WERNER H, 1992, MOL ENDOCRINOL, V6, P1545, DOI 10.1210/me.6.10.1545; WERNER H, 1990, BIOCH CELL BIOL, V19, P1021; WHITE RE, 1995, CIRC RES, V77, P936, DOI 10.1161/01.RES.77.5.936; Xie W, 1999, ENDOCRINOLOGY, V140, P219, DOI 10.1210/en.140.1.219; YAMAMOTO M, 1994, EXP CELL RES, V212, P62, DOI 10.1006/excr.1994.1118; ZHANG F, 1994, AM J PHYSIOL, V266, P975	99	44	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38921	38928		10.1074/jbc.M004691200	http://dx.doi.org/10.1074/jbc.M004691200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10982795	hybrid			2022-12-25	WOS:000165739800106
J	Hoffman, GA; Garrison, TR; Dohlman, HG				Hoffman, GA; Garrison, TR; Dohlman, HG			Endoproteolytic processing of Sst2, a multidomain regulator of G protein signaling in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; PHEROMONE RESPONSE PATHWAY; SACCHAROMYCES-CEREVISIAE; ALPHA-SUBUNIT; TRANSITION-STATE; POINT MUTATION; GAMMA-SUBUNIT; RGS PROTEINS; P115 RHOGEF; IN-VITRO	Regulators of G protein signaling (RGS proteins) constitute a large family of G protein-binding proteins. All RGS proteins contain a conserved core domain that can accelerate Gr protein GTPase activity. In addition, many family members contain a unique N-terminal domain of unknown function. Here, we demonstrate that the RGS protein in yeast, Sst2, is proteolytically processed in vivo to yield separate but functional N-terminal and RGS core domain fragments. In whole cell lysates, the full-length SST2 product (82 kDa) as well as a prominent 36 kDa species are specifically recognized by antibodies against the C terminus of the Sst2 protein. Purification and chemical sequencing of the 36-kDa species revealed cleavage sites after Ser-414 and Ser-416, just preceding the region of RGS homology. Expression of a mutationally truncated form of the protein (C-Sst2) could not restore function to an sst2 Delta mutant strain. In contrast, co-expression of C-Sst2 with the N-terminal domain (N-Sst2) partially restored the ability to regulate the growth arrest response but not the transcription induction response. Whereas the full-length protein was localized to the microsomal and plasma membrane fractions, the N-Sst2 species was predominantly in the microsomal fraction, and C-Sst2 was in the soluble fraction. Mutations that block proteasome or vacuolar protease function, or mutations in the cleavage site Ser residues of Sst2, did not alter processing. However, Sst2 processing did require expression of other components of the pheromone response pathway, including the receptor and the G protein. These results indicate that Sst2 is proteolytically processed, that this event is regulated by the signaling pathway, and that processing can profoundly alter the function and subcellular localization of the protein.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, New Haven, CT 06536 USA; Yale Univ, Sch Med, Interdepartmental Neurosci Program, New Haven, CT 06536 USA	Yale University; Yale University	Dohlman, HG (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, 295 Congress Ave,Rm 436,POB 9812, New Haven, CT 06536 USA.	henrik.dohlman@yale.edu		Dohlman, Henrik/0000-0003-2443-0729	NIGMS NIH HHS [GM59167, R01 GM055316, GM55316, R01 GM059167] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059167, R01GM055316, R29GM055316] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apanovitch DM, 1998, BIOCHEMISTRY-US, V37, P4815, DOI 10.1021/bi9729965; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; AZARIAN SM, 1995, J BIOL CHEM, V270, P24375, DOI 10.1074/jbc.270.41.24375; BAUM P, 1978, P NATL ACAD SCI USA, V75, P4962, DOI 10.1073/pnas.75.10.4962; Benzing T, 2000, J BIOL CHEM, V275, P28167; Benzing T, 1999, NAT MED, V5, P913, DOI 10.1038/11354; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; De Vries L, 1998, P NATL ACAD SCI USA, V95, P12340, DOI 10.1073/pnas.95.21.12340; De Vries L, 1999, TRENDS CELL BIOL, V9, P138, DOI 10.1016/S0962-8924(99)01515-9; DiBello PR, 1998, J BIOL CHEM, V273, P5780, DOI 10.1074/jbc.273.10.5780; DIETZEL C, 1987, MOL CELL BIOL, V7, P4169, DOI 10.1128/MCB.7.12.4169; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; Dohlman HG, 1998, SEMIN CELL DEV BIOL, V9, P135, DOI 10.1006/scdb.1998.0218; Druey KM, 1999, J BIOL CHEM, V274, P18836, DOI 10.1074/jbc.274.26.18836; Dulin NO, 2000, J BIOL CHEM, V275, P21317, DOI 10.1074/jbc.M910079199; Dulin NO, 1999, MOL CELL BIOL, V19, P714; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; Fischer T, 2000, P NATL ACAD SCI USA, V97, P4040, DOI 10.1073/pnas.97.8.4040; Flanary PL, 2000, J BIOL CHEM, V275, P18462, DOI 10.1074/jbc.M002163200; Garrison TR, 1999, J BIOL CHEM, V274, P36387, DOI 10.1074/jbc.274.51.36387; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HASSON MS, 1994, MOL CELL BIOL, V14, P1054, DOI 10.1128/MCB.14.2.1054; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; JACKSON CL, 1991, CELL, V67, P389, DOI 10.1016/0092-8674(91)90190-A; Khan AR, 1998, PROTEIN SCI, V7, P815; Kim E, 1999, P NATL ACAD SCI USA, V96, P6371, DOI 10.1073/pnas.96.11.6371; KLEIN BG, 1991, J AM COLL TOXICOL, V10, P555, DOI 10.3109/10915819109078652; Kobe B, 1999, NATURE, V402, P373, DOI 10.1038/46478; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lan KL, 1998, J BIOL CHEM, V273, P12794, DOI 10.1074/jbc.273.21.12794; MA D, 1995, MOL BIOL CELL, V6, P889, DOI 10.1091/mbc.6.7.889; McEntaffer RL, 1999, BIOCHEMISTRY-US, V38, P4931, DOI 10.1021/bi982636x; Moy FJ, 2000, BIOCHEMISTRY-US, V39, P7063, DOI 10.1021/bi992760w; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Pedram A, 2000, J BIOL CHEM, V275, P7365, DOI 10.1074/jbc.275.10.7365; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Popov SG, 2000, J BIOL CHEM, V275, P18962, DOI 10.1074/jbc.M001128200; Rahman Z, 1999, J NEUROSCI, V19, P2016; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; Sato-Kusubata K, 2000, BIOCHEM J, V347, P733, DOI 10.1042/0264-6021:3470733; Schauber C, 1998, GENES CELLS, V3, P307, DOI 10.1046/j.1365-2443.1998.00192.x; Siderovski DP, 1999, TRENDS BIOCHEM SCI, V24, P340, DOI 10.1016/S0968-0004(99)01441-3; SIKORSKI RS, 1989, GENETICS, V122, P19; Skiba NP, 1999, J BIOL CHEM, V274, P8770, DOI 10.1074/jbc.274.13.8770; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Sommers CM, 1997, J MOL BIOL, V266, P559, DOI 10.1006/jmbi.1996.0816; Song JP, 1996, J BIOL CHEM, V271, P20273, DOI 10.1074/jbc.271.34.20273; Song JP, 1996, BIOCHEMISTRY-US, V35, P14806, DOI 10.1021/bi961846b; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tu YP, 1999, J BIOL CHEM, V274, P38260, DOI 10.1074/jbc.274.53.38260; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687	65	33	33	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37533	37541		10.1074/jbc.M005751200	http://dx.doi.org/10.1074/jbc.M005751200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10982801	hybrid			2022-12-25	WOS:000165618700033
J	Pombo, PMG; Barettino, D; Espliguero, G; Metsis, M; Iglesias, T; Rodriguez-Pena, A				Pombo, PMG; Barettino, D; Espliguero, G; Metsis, M; Iglesias, T; Rodriguez-Pena, A			Transcriptional repression of neurotrophin receptor trkB by thyroid hormone in the developing rat brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; CELL-ADHESION MOLECULE; NEGATIVE REGULATION; NERVOUS-SYSTEM; DEPENDENT TRANSACTIVATION; NEUROBLASTOMA-CELLS; NEURAL DEVELOPMENT; RESPONSE ELEMENTS; NUCLEAR RECEPTORS; GENE PROMOTER	Expression of the neurotrophin receptor trkB is regulated by thyroid hormone (T3) during development of the rat brain. trkB mRNA levels, coding for the full-length and the truncated isoforms, are increased in the cerebral cortex of neonatal experimental hypothyroid animals. Run-on transcription assays with nuclei from postnatal day 15, hypothyroid, and control cerebral cortices demonstrated that an increase in the transcription rate of the trkB gene accounts for the observed effect, Transient transfection experiments using a reporter plasmid containing a 7-kilobase pair DNA fragment upstream of the mouse trkB gene showed that unliganded thyroid hormone receptor (T3R) increases promoter activity, whereas addition of T3 reverses that activity below basal levels. Deletion analysis shows that the TS-dependent repression requires binding of the T3R to a specific region located downstream of the transcription start site. This region, at nucleotide position -465/-432, contains an array of thyroid hormone response half-sites that bind preferentially T3R as heterodimers with retinoid X receptor and whose deletion causes loss of the TS-dependent repression. These half-sites are able to confer negative regulation by T3 to a heterologous promoter, thus indicating the functionality of these sequences. These results demonstrate that, in the developing rat brain, T3 down-regulates the expression of the trkB gene through the active repression of a novel negative response element located downstream of its transcription initiation site.	CSIC, Inst Invest Biomed Alberto Sols, E-28029 Madrid, Spain; Univ Autonoma Madrid, E-28029 Madrid, Spain; Karolinska Inst, Mol Neurobiol Lab, S-17177 Stockholm, Sweden	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; Karolinska Institutet	Rodriguez-Pena, A (corresponding author), CSIC, Inst Invest Biomed Alberto Sols, Arturo Duperier 4, E-28029 Madrid, Spain.	arodriguez@iib.uam.es	Metsis, Madis/F-7080-2016; Vacas, Teresa Iglesias/ABF-8663-2020	Metsis, Madis/0000-0003-1667-677X; Vacas, Teresa Iglesias/0000-0002-4326-9005; Rodriguez-Pena, Angeles/0000-0002-2515-4626				Awad TA, 1999, J BIOL CHEM, V274, P27092, DOI 10.1074/jbc.274.38.27092; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARDE YA, 1994, J NEUROBIOL, V25, P1329, DOI 10.1002/neu.480251102; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BARETTINO D, 1993, EMBO J, V12, P1343, DOI 10.1002/j.1460-2075.1993.tb05779.x; BARETTINO D, 1999, BIOCHIM BIOPHYS ACTA, V1146, P24; Baxter GT, 1997, J NEUROSCI, V17, P2683; Belandia B, 1998, J BIOL CHEM, V273, P30366, DOI 10.1074/jbc.273.46.30366; BIGLER J, 1995, EMBO J, V14, P5710, DOI 10.1002/j.1460-2075.1995.tb00258.x; CARR FE, 1994, J BIOL CHEM, V269, P4175; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHEN O, 1995, J BIOL CHEM, V270, P13899, DOI 10.1074/jbc.270.23.13899; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; Dowling ALS, 2000, J NEUROSCI, V20, P2255; HOLLENBERG AN, 1995, MOL ENDOCRINOL, V9, P540, DOI 10.1210/me.9.5.540; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Ibarrola N, 1997, BRAIN RES, V752, P285, DOI 10.1016/S0006-8993(96)01480-1; Iglesias T, 1996, EMBO J, V15, P4307, DOI 10.1002/j.1460-2075.1996.tb00805.x; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; LAI C, 1987, P NATL ACAD SCI USA, V84, P4337, DOI 10.1073/pnas.84.12.4337; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEGRAND C, 1991, DEV NEUROSCI-BASEL, V13, P382, DOI 10.1159/000112189; MADISON LD, 1993, MOL CELL ENDOCRINOL, V94, P129, DOI 10.1016/0303-7207(93)90060-W; Neveu I, 1996, J CELL BIOL, V133, P631, DOI 10.1083/jcb.133.3.631; PASTOR R, 1994, ONCOGENE, V9, P1081; PORTERFIELD SP, 1993, ENDOCR REV, V14, P94, DOI 10.1210/er.14.1.94; RODRIGUEZPENA A, 1993, J CLIN INVEST, V91, P812, DOI 10.1172/JCI116301; SAATCIOGLU F, 1994, SEMIN CANCER BIOL, V5, P347; Sasaki S, 1999, EMBO J, V18, P5389, DOI 10.1093/emboj/18.19.5389; Satoh T, 1996, J BIOL CHEM, V271, P27919, DOI 10.1074/jbc.271.44.27919; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; WOOD WM, 1989, J BIOL CHEM, V264, P14840	42	21	21	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37510	37517		10.1074/jbc.M006440200	http://dx.doi.org/10.1074/jbc.M006440200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10978336	hybrid			2022-12-25	WOS:000165618700030
J	Carruthers, LM; Hansen, JC				Carruthers, LM; Hansen, JC			The core histone N termini function independently of linker histones during chromatin condensation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGAROSE-GEL ELECTROPHORESIS; SCANNING FORCE MICROSCOPY; HIGHER-ORDER STRUCTURE; TRANSCRIPTION IN-VIVO; RIBOSOMAL-RNA GENE; GLOBULAR DOMAIN; NUCLEOSOMAL ARRAYS; SELF-ASSOCIATION; MOLECULAR-MODEL; TAIL DOMAINS	The relationships between the core histone N termini and linker histones during chromatin assembly and salt-dependent chromatin condensation were investigated using defined chromatin model systems reconstituted from tandemly repeated 5 S rDNA, histone H5, and either native "intact" core histone octamers or "tailless" histone octamers lacking their N-terminal domains. Nuclease digestion and sedimentation studies indicate that H5 binding and the resulting constraint of entering and exiting nucleosomal DNA occur to the same extent in both tailless and intact chromatin arrays. However, despite possessing a normal chromatosomal structure, tailless chromatin arrays can neither condense into extensively folded structures nor cooperatively oligomerize in MgCl2. Tailless nucleosomal arrays lacking linker histones also are unable to either fold extensively or oligomerize, demonstrating that the core histone N termini perform the same functions during salt-dependent condensation regardless of whether linker histones are components of the array. Our results further indicate that disruption of core histone N termini function in vitro allows a linker histone-containing chromatin fiber to exist in a decondensed state under conditions that normally would promote extensive fiber condensation. These findings have key implications for both the mechanism of chromatin condensation, and the regulation of genomic function by chromatin.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Hansen, JC (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	hansen@biochem.uthscsa.edu			NIGMS NIH HHS [GM45916] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045916, R29GM045916] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN J, 1981, J CELL BIOL, V90, P279, DOI 10.1083/jcb.90.2.279; ALLAN J, 1982, J CELL BIOL, V93, P285, DOI 10.1083/jcb.93.2.285; An WJ, 1999, BIOCHIMIE, V81, P727, DOI 10.1016/S0300-9084(99)80130-8; ANNUNZIATO AT, 1988, CHROMOSOMA, V96, P132, DOI 10.1007/BF00331045; BATES DL, 1981, NUCLEIC ACIDS RES, V9, P5883, DOI 10.1093/nar/9.22.5883; Bednar J, 1998, P NATL ACAD SCI USA, V95, P14173, DOI 10.1073/pnas.95.24.14173; BOHM L, 1984, BIOSCIENCE REP, V4, P365, DOI 10.1007/BF01122502; BOUVET P, 1994, GENE DEV, V8, P1147, DOI 10.1101/gad.8.10.1147; Brown DT, 1996, NUCLEIC ACIDS RES, V24, P486, DOI 10.1093/nar/24.3.486; Brown DT, 1997, NUCLEIC ACIDS RES, V25, P5003, DOI 10.1093/nar/25.24.5003; Carruthers LM, 1999, METHOD ENZYMOL, V304, P19; Carruthers LM, 1998, BIOCHEMISTRY-US, V37, P14776, DOI 10.1021/bi981684e; Carruthers LM, 2000, METHOD ENZYMOL, V321, P66; Carter GJ, 1998, BIOCHEMISTRY-US, V37, P12477, DOI 10.1021/bi980716v; CLARK DJ, 1990, J MOL BIOL, V211, P883, DOI 10.1016/0022-2836(90)90081-V; DIMITROV S, 1986, FEBS LETT, V197, P217, DOI 10.1016/0014-5793(86)80329-5; FLETCHER TM, 1994, BIOCHEMISTRY-US, V33, P10859, DOI 10.1021/bi00202a002; FLETCHER TM, 1994, BIOCHEMISTRY-US, V33, P2226, DOI 10.1021/bi00174a032; FLETCHER TM, 1995, J BIOL CHEM, V270, P25359, DOI 10.1074/jbc.270.43.25359; Fletcher TM, 1996, CRIT REV EUKAR GENE, V6, P149, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.40; GARCIA-RAMIREZ M, 1990, Protein Expression and Purification, V1, P40, DOI 10.1016/1046-5928(90)90043-X; GARCIARAMIREZ M, 1992, J BIOL CHEM, V267, P19587; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; GEORGEL P, 1993, J BIOL CHEM, V268, P1947; Georgel PT, 1997, EMBO J, V16, P4717, DOI 10.1093/emboj/16.15.4717; GRIESS GA, 1989, BIOPOLYMERS, V28, P1475, DOI 10.1002/bip.360280811; Grunstein M, 1997, CURR OPIN CELL BIOL, V9, P383, DOI 10.1016/S0955-0674(97)80011-7; HACQUES MF, 1990, J BIOMOL STRUCT DYN, V8, P619, DOI 10.1080/07391102.1990.10507832; Hamiche A, 1996, J MOL BIOL, V257, P30, DOI 10.1006/jmbi.1996.0144; HANSEN JC, 1989, BIOCHEMISTRY-US, V28, P9129, DOI 10.1021/bi00449a026; HANSEN JC, 1993, J BIOL CHEM, V268, P5840; Hansen JC, 1997, METHODS, V12, P62, DOI 10.1006/meth.1997.0448; Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v; HANSEN JC, 1997, METHOD MOL BIOL, V119, P113; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Herrera JE, 2000, MOL CELL BIOL, V20, P523, DOI 10.1128/MCB.20.2.523-529.2000; Howe L, 1998, J BIOL CHEM, V273, P20693, DOI 10.1074/jbc.273.33.20693; KANDOLF H, 1994, P NATL ACAD SCI USA, V91, P7257, DOI 10.1073/pnas.91.15.7257; KRIEG PA, 1983, NUCLEIC ACIDS RES, V11, P619, DOI 10.1093/nar/11.3.619; Leuba SH, 1998, BIOPHYS J, V74, P2830, DOI 10.1016/S0006-3495(98)77990-1; Leuba SH, 1998, BIOPHYS J, V74, P2823, DOI 10.1016/S0006-3495(98)77989-5; MAMAN JD, 1994, BIOCHEMISTRY-US, V33, P1300, DOI 10.1021/bi00172a003; MCGHEE JD, 1983, NUCLEIC ACIDS RES, V11, P4065, DOI 10.1093/nar/11.12.4065; MEERSSEMAN G, 1991, J MOL BIOL, V220, P89, DOI 10.1016/0022-2836(91)90383-H; Moore SC, 1997, BIOCHEM BIOPH RES CO, V230, P136, DOI 10.1006/bbrc.1996.5903; Ramakrishnan V, 1997, CRIT REV EUKAR GENE, V7, P215, DOI 10.1615/CritRevEukarGeneExpr.v7.i3.20; ROSE GD, 1994, PROTEINS, V19, P1, DOI 10.1002/prot.340190102; ROTH SY, 1995, CURR OPIN GENET DEV, V5, P168, DOI 10.1016/0959-437X(95)80004-2; Schwarz PM, 1996, BIOCHEMISTRY-US, V35, P4009, DOI 10.1021/bi9525684; SCHWARZ PM, 1994, J BIOL CHEM, V269, P16284; SEGERS A, 1991, J BIOL CHEM, V266, P1502; SHAW OJ, 1969, ELECTROPHORESIS, P5; Shen XT, 1996, CELL, V86, P475, DOI 10.1016/S0092-8674(00)80120-8; Shibahara K, 2000, P NATL ACAD SCI USA, V97, P7766, DOI 10.1073/pnas.97.14.7766; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SIMPSON RT, 1978, BIOCHEMISTRY-US, V17, P5524, DOI 10.1021/bi00618a030; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; Trieschmann L, 1998, P NATL ACAD SCI USA, V95, P5468, DOI 10.1073/pnas.95.10.5468; Tse C, 1997, BIOCHEMISTRY-US, V36, P11381, DOI 10.1021/bi970801n; Tse C, 1998, P NATL ACAD SCI USA, V95, P12169, DOI 10.1073/pnas.95.21.12169; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; URA K, 1994, J BIOL CHEM, V269, P27171; van Holde K.E., 1988, CHROMATIN; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; WIDOM J, 1989, ANNU REV BIOPHYS BIO, V18, P365, DOI 10.1146/annurev.biophys.18.1.365; Wolffe A., 1998, CHROMATIN STRUCTURE; WOLFFE AP, 1989, EMBO J, V8, P527, DOI 10.1002/j.1460-2075.1989.tb03407.x; Zlatanova J, 1998, BIOPHYS J, V74, P2554, DOI 10.1016/S0006-3495(98)77963-9	69	95	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37285	37290		10.1074/jbc.M006801200	http://dx.doi.org/10.1074/jbc.M006801200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10970897	hybrid			2022-12-25	WOS:000165577700114
J	Festa, M; Ricciardelli, G; Mele, G; Pietropaolo, C; Ruffo, A; Colonna, A				Festa, M; Ricciardelli, G; Mele, G; Pietropaolo, C; Ruffo, A; Colonna, A			Overexpression of H ferritin and up-regulation of iron regulatory protein genes during differentiation of 3T3-L1 pre-adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING; TRANSCRIPTIONAL REGULATION; MESSENGER-RNA; EXPRESSION; ACONITASE; OXIDATION; SEQUENCE; SUBUNIT; INVITRO; LIVER	The role of iron-dependent oxidative metabolism in protecting the oxidable substrates contained in mature adipocytes is still unclear. Because differentiation increases ferritin formation in several cell types, thereby leading to an accumulation of H-rich isoferritins, we investigated whether differentiation affects iron metabolism in 3T3-L1 pre-adipocytes. To this aim, we evaluated the expression of the genes coding for the H and L ferritin subunits and for cytoplasmic iron regulatory protein (IRP) during the differentiation of 3T3-L1 cells in adipocytes induced by the addition of isobutylmethylxanthine, insulin, and dexamethasone, Differentiation enhanced ferritin formation and caused overexpression of the H subunit, thus altering the Hn subunit ratio. Northern blot analysis showed increased levels of H subunit mRNA A gel retardation assay of cytoplasmic extract from differentiated cells, using an iron-responsive element as a probe, revealed enhanced an RNA binding capacity of IRP1, which correlated with the increase of IRP1 mRNA The observed correlation between differentiation and iron metabolism in adipocytes suggests that an accumulation of H-rich isoferritin may limit the toxicity of iron in adipose tissue, thus exerting an antioxidant function.	Univ Naples Federico II, Dipartimento Farmacol Sperimentale, I-80131 Naples, Italy; Univ Naples Federico II, Dipartimento Chim Sostanze Nat, I-80131 Naples, Italy; Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy	University of Naples Federico II; University of Naples Federico II; University of Naples Federico II	Colonna, A (corresponding author), Univ Naples Federico II, Dipartimento Farmacol Sperimentale, Via Domenico Montesano 49, I-80131 Naples, Italy.	alfcolon@unina.it						BALLA G, 1992, J BIOL CHEM, V267, P18148; BEAUMONT C, 1989, J BIOL CHEM, V264, P7498; CHOU CC, 1986, MOL CELL BIOL, V6, P566, DOI 10.1128/MCB.6.2.566; COCCIA EM, 1995, BLOOD, V86, P1570, DOI 10.1182/blood.V86.4.1570.bloodjournal8641570; Eisenstein RS, 2000, ANNU REV NUTR, V20, P627, DOI 10.1146/annurev.nutr.20.1.627; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; Festa M, 2000, BIOCHEM J, V348, P315, DOI 10.1042/0264-6021:3480315; GRAY NK, 1994, EMBO J, V13, P3882, DOI 10.1002/j.1460-2075.1994.tb06699.x; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; Hanson ES, 1999, GENE EXPRESSION, V7, P367; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KIM HY, 1995, J BIOL CHEM, V270, P4983, DOI 10.1074/jbc.270.10.4983; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P549, DOI 10.1042/bj3070549; Kuhn LC, 1998, NUTR REV, V56, pS11; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MIN HY, 1986, NUCLEIC ACIDS RES, V14, P8879; Pantopoulos K, 1996, MOL CELL BIOL, V16, P3781; PHILPOTT CC, 1991, NUCLEIC ACIDS RES, V19, P6333, DOI 10.1093/nar/19.22.6333; Recalcati S, 1999, EUR J BIOCHEM, V259, P304, DOI 10.1046/j.1432-1327.1999.00038.x; REED BC, 1980, P NATL ACAD SCI-BIOL, V77, P285, DOI 10.1073/pnas.77.1.285; Sambrook J., 1989, MOL CLONING LAB MANU, V2; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; Theil EC, 2000, BIOCHEM PHARMACOL, V59, P87, DOI 10.1016/S0006-2952(99)00300-7; TORTI SV, 1988, J BIOL CHEM, V263, P12638; UCHIYAMA M, 1978, ANAL BIOCHEM, V86, P271, DOI 10.1016/0003-2697(78)90342-1	30	59	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36708	36712		10.1074/jbc.M004988200	http://dx.doi.org/10.1074/jbc.M004988200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10978328	hybrid			2022-12-25	WOS:000165577700038
J	Ghanshani, S; Wulff, H; Miller, MJ; Rohm, H; Neben, A; Gutman, GA; Cahalan, MD; Chandy, KG				Ghanshani, S; Wulff, H; Miller, MJ; Rohm, H; Neben, A; Gutman, GA; Cahalan, MD; Chandy, KG			Up-regulation of the IKCa1 potassium channel during T-cell activation - Molecular mechanism and functional consequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-CA CHANNEL; KEY SIGNALING ENZYME; HUMAN LYMPHOCYTE-T; ION CHANNELS; CALCIUM; CONDUCTANCE; GENE; EXPRESSION; KV1.3; TRANSCRIPTION	We used whole cell recording to evaluate functional expression of the intermediate conductance Ca2+-activated KC channel, IKCa1, in response to various mitogenic stimuli. One to two days following engagement of T-cell receptors to trigger both PKC- and Ca2+-dependent events, IKCa1 expression increased from an average of 8 to 300-800 channels/cell. Selective stimulation of the PKC pathway resulted in equivalent up-regulation, whereas a calcium ionophore was relatively ineffective. Enhancement in IKCa1 mRNA levels paralleled the increased channel number. The genomic organization of IKCa1, SKCa2, and SRCa3 were defined, and IKCa and SKCa genes were found to have a remarkably similar intron-exon structure, Mitogens enhanced IKCa1 promoter activity proportional to the increase in IKCa1 mRNA suggesting that transcriptional mechanisms underlie channel up-regulation. Mutation of motifs for AP1 and Ikaros-2 in the promoter abolished this induction. Selective Kv1.3 inhibitors ShK-Dap(22), margatoxin, and correolide suppressed mitogenesis of resting T-cells but not preactivated T-cells with up-regulated IKCa1 channel expression. Selectively blocking IKCa1 channels with clotrimazole or TRAM-34 suppressed mitogenesis of preactivated lymphocytes, whereas resting T-cells were less sensitive. Thus, Kv1.3 channels are essential for activation of quiescent cells, but signaling through the PKC pathway enhances expression of IKCa1 channels that are required for continued proliferation.	Univ Calif Irvine, Sch Med, Dept Phys & Biophys, Irvine, CA 92697 USA; Univ Calif Irvine, Sch Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Wulff, H (corresponding author), Univ Calif Irvine, Sch Med, Dept Phys & Biophys, Rm 291,Joan Irvine Smith Hall, Irvine, CA 92697 USA.	hwulff@uci.edu	wulff, Heike/Z-2056-2019	Miller, Mark/0000-0001-5676-389X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054221] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS014609, R37NS014609] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54221] Funding Source: Medline; NINDS NIH HHS [NS14609] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKASHI M, 1994, BLOOD, V83, P3182; Alizadeh AA, 2000, CURR OPIN IMMUNOL, V12, P219, DOI 10.1016/S0952-7915(99)00078-3; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; Avitahl N, 1999, IMMUNITY, V10, P333, DOI 10.1016/S1074-7613(00)80033-3; Cahalan MD, 1997, CURR OPIN BIOTECH, V8, P749, DOI 10.1016/S0958-1669(97)80130-9; CARLSSON P, 1993, GENE DEV, V7, P2418, DOI 10.1101/gad.7.12a.2418; CHANDY KG, 1984, J EXP MED, V160, P369, DOI 10.1084/jem.160.2.369; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CLIPSTONE NA, 1993, ANN NY ACAD SCI, V696, P20; COLOMER J, 1993, CELL CALCIUM, V14, P609, DOI 10.1016/0143-4160(93)90061-A; Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097; Cron RQ, 1997, J IMMUNOL METHODS, V205, P145, DOI 10.1016/S0022-1759(97)00065-3; DECOURSEY TE, 1984, NATURE, V307, P465, DOI 10.1038/307465a0; DECOURSEY TE, 1987, J GEN PHYSIOL, V89, P405, DOI 10.1085/jgp.89.3.405; DEUTSCH C, 1986, J PHYSIOL-LONDON, V372, P405, DOI 10.1113/jphysiol.1986.sp016016; Dror V, 1999, MOL PSYCHIATR, V4, P254, DOI 10.1038/sj.mp.4000508; Fanger CM, 1999, J BIOL CHEM, V274, P5746, DOI 10.1074/jbc.274.9.5746; Fanger CM, 2000, J IMMUNOL, V164, P1153, DOI 10.4049/jimmunol.164.3.1153; Fomina AF, 2000, J CELL BIOL, V150, P1435, DOI 10.1083/jcb.150.6.1435; Gan L, 1996, J BIOL CHEM, V271, P5859, DOI 10.1074/jbc.271.10.5859; Ghanshani S, 1998, GENOMICS, V51, P160, DOI 10.1006/geno.1998.5333; GRISSMER S, 1993, J GEN PHYSIOL, V102, P601, DOI 10.1085/jgp.102.4.601; Hanson DC, 1999, BRIT J PHARMACOL, V126, P1707, DOI 10.1038/sj.bjp.0702480; HUANG Y, 1994, J BIOL CHEM, V269, P31183; HUGHES CCW, 1993, J IMMUNOL, V150, P3148; Hughes CCW, 1996, J BIOL CHEM, V271, P5369, DOI 10.1074/jbc.271.10.5369; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; Jager H, 2000, FEBS LETT, V469, P196, DOI 10.1016/S0014-5793(00)01236-9; Jensen BS, 1998, AM J PHYSIOL-CELL PH, V275, pC848, DOI 10.1152/ajpcell.1998.275.3.C848; Jensen BS, 1999, P NATL ACAD SCI USA, V96, P10917, DOI 10.1073/pnas.96.19.10917; Joiner WJ, 1997, P NATL ACAD SCI USA, V94, P11013, DOI 10.1073/pnas.94.20.11013; Kalman K, 1998, J BIOL CHEM, V273, P32697, DOI 10.1074/jbc.273.49.32697; Khanna R, 1999, J BIOL CHEM, V274, P14838, DOI 10.1074/jbc.274.21.14838; Koo GC, 1997, J IMMUNOL, V158, P5120; Koo GC, 1999, CELL IMMUNOL, V197, P99, DOI 10.1006/cimm.1999.1569; Litt M, 1999, CYTOGENET CELL GENET, V86, P70, DOI 10.1159/000015415; Logsdon NJ, 1997, J BIOL CHEM, V272, P32723, DOI 10.1074/jbc.272.52.32723; Nguyen A, 1996, MOL PHARMACOL, V50, P1672; PARTISETI M, 1993, J IMMUNOL, V151, P2462; PARTISETI M, 1992, J IMMUNOL, V148, P3361; Pena TL, 1999, J MEMBRANE BIOL, V172, P249, DOI 10.1007/s002329900601; PRICE M, 1989, P NATL ACAD SCI USA, V86, P10171, DOI 10.1073/pnas.86.24.10171; Rauer H, 2000, J BIOL CHEM, V275, P1201, DOI 10.1074/jbc.275.2.1201; Rauer H, 2000, BIOPHYS J, V78, p73A; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Simon M, 1997, CELL PHYSIOL BIOCHEM, V7, P243, DOI 10.1159/000154879; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; VERHEUGEN JAH, 1995, J GEN PHYSIOL, V105, P765, DOI 10.1085/jgp.105.6.765; VERHEUGEN JAH, 1995, CELL CALCIUM, V17, P287, DOI 10.1016/0143-4160(95)90075-6; Wulff H, 2000, P NATL ACAD SCI USA, V97, P8151, DOI 10.1073/pnas.97.14.8151; Wymore RS, 1996, J BIOL CHEM, V271, P15629, DOI 10.1074/jbc.271.26.15629	53	336	355	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37137	37149		10.1074/jbc.M003941200	http://dx.doi.org/10.1074/jbc.M003941200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10961988	hybrid			2022-12-25	WOS:000165577700094
J	Ha, TU; Segev, DL; Barbie, D; Masiakos, PT; Tran, TT; Dombkowski, D; Glander, M; Clarke, TR; Lorenzo, HK; Donahue, PK; Maheswaran, S				Ha, TU; Segev, DL; Barbie, D; Masiakos, PT; Tran, TT; Dombkowski, D; Glander, M; Clarke, TR; Lorenzo, HK; Donahue, PK; Maheswaran, S			Mullerian inhibiting substance inhibits ovarian cell growth through an Rb-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR E2F-1; U343 ASTROCYTOMA-CELLS; D-DEPENDENT KINASES; RETINOBLASTOMA PROTEIN; CYCLE ARREST; II RECEPTOR; P16 GENE; RECOMBINANT ADENOVIRUS; SEXUAL DEVELOPMENT; TGF-BETA	Mullerian inhibiting substance (MIS), a transforming growth factor-beta family member, causes regression of the Mullerian duct in male embryos. MIS overexpression in transgenic mice ablates the ovary, and MIS inhibits the growth of ovarian cancer cell lines in vitro, suggesting a key role for this hormone in postnatal development of the ovary. This report describes a mechanism for MIS-mediated growth inhibition in both a human epithelial ovarian cancer cell line and a cell line derived from normal ovarian surface epithelium, which is the origin of human epithelial ovarian cancers, MIS-treated cells accumulated in the G(1) phase of the cell cycle and subsequently underwent apoptosis. MIS up-regulated the cyclin-dependent kinase inhibitor pie through an MIS type II receptor-mediated mechanism and inhibited growth in the absence of detectable or inactive Rb protein, Prolonged treatment with MIS down-regulated the Rb-related protein p130 and increased the Rb family-regulated transcription factor E2F1, overexpression of which inhibited growth. These findings demonstrate that pig is required for MIS-mediated growth inhibition in ovarian epithelial cells and tumor cells and suggest that up-regulation of E2F1 also plays a role in this process.	Massachusetts Gen Hosp, Pediat Surg Res Lab, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Maheswaran, S (corresponding author), Massachusetts Gen Hosp, Pediat Surg Res Lab, WRN 1024,55 Fruit St, Boston, MA 02114 USA.	maheswaran@helix.mgh.harvard.edu	Lorenzo, Hans-Kristian/GLR-5785-2022	Lorenzo, Hans Kristian/0000-0002-7921-177X	NCI NIH HHS [CA17393, T32-CA-71345] Funding Source: Medline; NICHD NIH HHS [HD32112] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032112] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA017393, T32CA071345] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAARENDS WM, 1994, DEVELOPMENT, V120, P189; BEHRINGER RR, 1990, NATURE, V345, P167, DOI 10.1038/345167a0; BEHRINGER RR, 1994, CELL, V79, P415, DOI 10.1016/0092-8674(94)90251-8; Catlin EA, 1997, ENDOCRINOLOGY, V138, P790, DOI 10.1210/en.138.2.790; CHIN TW, 1991, CANCER RES, V51, P2101; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DICLEMENTE N, 1994, MOL ENDOCRINOL, V8, P1006, DOI 10.1210/me.8.8.1006; DIETL J, 1993, GYNECOL OBSTET INVES, V35, P129, DOI 10.1159/000292682; Dirks PB, 1998, ONCOGENE, V17, P867, DOI 10.1038/sj.onc.1202008; Dirks PB, 1997, ONCOGENE, V15, P2037, DOI 10.1038/sj.onc.1201392; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Fueyo J, 1998, NAT MED, V4, P685, DOI 10.1038/nm0698-685; FULLER AF, 1985, GYNECOL ONCOL, V22, P135, DOI 10.1016/0090-8258(85)90019-8; Furukawa Y, 1999, ONCOGENE, V18, P2003, DOI 10.1038/sj.onc.1202500; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Hama S, 1998, INT J CANCER, V77, P47, DOI 10.1002/(SICI)1097-0215(19980703)77:1<47::AID-IJC9>3.3.CO;2-E; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harvat BL, 1998, J CELL SCI, V111, P1185; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; HUDSON PL, 1990, J CLIN ENDOCR METAB, V70, P16, DOI 10.1210/jcem-70-1-16; Hunt KK, 1997, CANCER RES, V57, P4722; Imbeaud S, 1996, HUM MOL GENET, V5, P1269, DOI 10.1093/hmg/5.9.1269; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kanuma T, 1997, MOL CARCINOGEN, V18, P134, DOI 10.1002/(SICI)1098-2744(199703)18:3<134::AID-MC2>3.0.CO;2-F; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Lee MM, 1996, J CLIN ENDOCR METAB, V81, P571, DOI 10.1210/jc.81.2.571; Marchini S, 1997, BRIT J CANCER, V76, P146, DOI 10.1038/bjc.1997.355; Masiakos PT, 1999, CLIN CANCER RES, V5, P3488; Mayol X, 1996, ONCOGENE, V13, P237; MAYOL X, 1995, ONCOGENE, V11, P801; Milde-Langosch K, 1998, INT J CANCER, V79, P61, DOI 10.1002/(SICI)1097-0215(19980220)79:1<61::AID-IJC12>3.0.CO;2-K; Naruse I, 1998, ANTICANCER RES, V18, P4275; OKUDA T, 1995, GENOMICS, V29, P623, DOI 10.1006/geno.1995.9957; Pedram A, 1998, J BIOL CHEM, V273, P13966, DOI 10.1074/jbc.273.22.13966; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; QUELLE DE, 1995, CELL, V83, P993; RAGIN RC, 1992, PROTEIN EXPRES PURIF, V3, P236, DOI 10.1016/1046-5928(92)90020-W; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Schreiber M, 1999, ONCOGENE, V18, P1663, DOI 10.1038/sj.onc.1202466; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; Scully R E, 1970, Hum Pathol, V1, P73, DOI 10.1016/S0046-8177(70)80005-3; Scully RE, 1995, J CELL BIOCHEM, P208; Segev DL, 2000, J BIOL CHEM, V275, P28371, DOI 10.1074/jbc.M004554200; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; TAKAHASHI M, 1986, BIOL REPROD, V35, P447, DOI 10.1095/biolreprod35.2.447; Teixeira J, 1996, ENDOCRINOLOGY, V137, P160, DOI 10.1210/en.137.1.160; Teixeira J, 1996, J ANDROL, V17, P336; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; UENO S, 1988, ENDOCRINOLOGY, V123, P1652, DOI 10.1210/endo-123-3-1652; Urashima M, 1997, BLOOD, V90, P4106, DOI 10.1182/blood.V90.10.4106; Wolf JK, 1999, GYNECOL ONCOL, V73, P27, DOI 10.1006/gyno.1998.5259; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	63	76	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37101	37109		10.1074/jbc.M005701200	http://dx.doi.org/10.1074/jbc.M005701200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10958795	hybrid			2022-12-25	WOS:000165577700090
J	Brasher, BB; Van Etten, RA				Brasher, BB; Van Etten, RA			c-Ab1 has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABL TRANSFORMING ACTIVITY; C-ABL; PROTEIN-BINDING; IN-VIVO; INTERMOLECULAR AUTOPHOSPHORYLATION; CRYSTAL-STRUCTURE; GENE-PRODUCT; CELL-CYCLE; V-ABL; ACTIVATION	Using the specific Abl tyrosine kinase inhibitor STI 571, we purified unphosphorylated murine type IV c-Abl and measured the kinetic parameters of c-Abl tyrosine kinase activity in a solution with a peptide-based assay. Unphosphorylated c-Abl exhibited substantial peptide kinase activity with K-m of 204 muM and V-max of 33 pmol min(-1). Contrary to previous observations using immune complex kinase assays, we found that a transforming c-Abl mutant with a Src homology 3 domain point mutation (P131L) had significantly (about 6-fold) higher intrinsic kinase activity than wild-type c-Abl (K-m = 91 muM, V-max = 112 pmol min(-1)). Autophosphorylation stimulated the activity of wild-type c-Abl about 18-fold and c-Abl P131L about 3.6-fold, resulting in highly active kinases with similar catalytic rates, The autophosphorylation rate was dependent on Abl protein concentration consistent with an intermolecular reaction, A tyrosine to phenylalanine mutation (Y412F) at the c-Abl residue homologous to the c-Src catalytic domain autophosphorylation site impaired the activation of wildtype c-Abl by 90% but reduced activation of c-Abl P131L by only 45%. Mutation of a tyrosine (Tyr-245) in the linker region between the Src homology 2 and catalytic domains that is conserved among the Abl family inhibited the autophosphorylation-induced activation of wild-type c-Abl by 50%, whereas the c-Abl Y245F/Y412F double mutant was minimally activated by autophosphorylation, These results support a model where c-Abl is inhibited in part through an intramolecular Src homology 3-linker interaction and stimulated to full catalytic activity by sequential phosphorylation at Tyr-412 and Tyr-245.	Harvard Univ, Sch Med, Ctr Blood Res, Dept Genet, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Van Etten, RA (corresponding author), Harvard Univ, Sch Med, Ctr Blood Res, Dept Genet, 200 Longwood Ave, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA072465] Funding Source: NIH RePORTER; NCI NIH HHS [CA72465] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1998, ONCOGENE, V16, P1779, DOI 10.1038/sj.onc.1201708; Allen PB, 1996, J BIOL CHEM, V271, P19585, DOI 10.1074/jbc.271.32.19585; Barila D, 2000, EMBO J, V19, P273, DOI 10.1093/emboj/19.2.273; Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Boerner RJ, 1996, BIOCHEMISTRY-US, V35, P9519, DOI 10.1021/bi960248u; Buchdunger E, 1996, CANCER RES, V56, P100; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; Dorey K, 1999, BIOL CHEM, V380, P223; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; Gonfloni S, 1999, NAT STRUCT BIOL, V6, P760; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JACKSON PK, 1993, ONCOGENE, V8, P1943; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PIWINICAWORMS H, 1987, CELL, V49, P75; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Porter M, 2000, J BIOL CHEM, V275, P2721, DOI 10.1074/jbc.275.4.2721; REYNOLDS FH, 1982, J VIROL, V44, P1097, DOI 10.1128/JVI.44.3.1097-1101.1982; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Smith JM, 1999, J BIOL CHEM, V274, P27956, DOI 10.1074/jbc.274.39.27956; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1995, ONCOGENE, V10, P1977; Walkenhorst J, 1996, ONCOGENE, V12, P1513; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Zhu JY, 1996, MOL CELL BIOL, V16, P7054	46	219	233	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35631	35637		10.1074/jbc.M005401200	http://dx.doi.org/10.1074/jbc.M005401200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10964922	Green Published, hybrid			2022-12-25	WOS:000165422800106
J	Gil-Henn, H; Volohonsky, G; Toledano-Katchalski, H; Gandre, S; Elson, A				Gil-Henn, H; Volohonsky, G; Toledano-Katchalski, H; Gandre, S; Elson, A			Generation of novel cytoplasmic forms of protein tyrosine phosphatase epsilon by proteolytic processing and translational control	ONCOGENE			English	Article						phosphatase; tyrosine; proteolysis; MG132; translational regulation; cleavage	V-HA-RAS; TRANSGENIC MICE; MAMMARY-TUMORS; PTP-SIGMA; PROTEASOME; STEP; INITIATION; ISOFORM; CALPAIN; AUG	Two protein forms of tyrosine phosphatase epsilon (PTP epsilon) are known - receptor-like (tm-PTP epsilon) and non receptor-like (cyt-PTP epsilon), with each form possessing unique tissue-specific expression patterns, subcellular localization, and physiological functions. We describe two additional forms of PTP epsilon: protein - p67 and p65, p67 is produced by initiation of translation at an internal initiation codon of PTP epsilon mRNA molecules, while p65 is produced by specific proteolytic cleavage of larger PTP epsilon proteins. Cleavage is inhibited by MG132, but is proteasome-independent. In contrast with full-length tm-PTP epsilon and cyt-PTP epsilon, p67 and p65 are exclusively cytoplasmic, are not phosphorylated by Neu, and do not associate with Grb2 in unstimulated cells. p67 and p65 are catalytically active and can reduce Src-mediated phosphorylation of the Kv2.1 voltage-gated potassium channel, albeit with reduced efficiency which most likely results from their cytoplasmic localization. We also show that full-length cyt-PTP epsilon protein can be found at the cell membrane and in the nucleus and that it is the first 27 residues of cyt-PTP epsilon which determine this localization. p67 and p65 provide mechanisms for removing PTP epsilon activity from the cell membrane, possibly serving to down-regulate PTP epsilon activity there. PTP epsilon emerges as a family of four related proteins whose expression, subcellular localization and most likely physiological roles are subject to complex regulation at the transcriptional, translational and post-translational levels.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Elson, A (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.		Toledano, Hila/AGY-6574-2022	Toledano, Hila/0000-0001-9409-7728; Elson, Ari/0000-0001-9808-9135				ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; Blanchetot C, 2000, J BIOL CHEM, V275, P12446, DOI 10.1074/jbc.275.17.12446; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; Elson A, 1996, GENOMICS, V31, P373, DOI 10.1006/geno.1996.0061; Elson A, 1999, ONCOGENE, V18, P7535, DOI 10.1038/sj.onc.1203098; ELSON A, 1995, J BIOL CHEM, V270, P26116, DOI 10.1074/jbc.270.44.26116; Elson A, 1995, P NATL ACAD SCI USA, V92, P12235, DOI 10.1073/pnas.92.26.12235; Fischer EH, 1999, ADV ENZYME REGUL, V39, P359, DOI 10.1016/S0065-2571(98)00014-4; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; Gu MX, 1996, J BIOL CHEM, V271, P27751, DOI 10.1074/jbc.271.44.27751; Gurd JW, 1999, J NEUROCHEM, V73, P1990; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Nakamura K, 1996, BIOCHEM BIOPH RES CO, V218, P726, DOI 10.1006/bbrc.1996.0129; Nguyen TH, 1999, J NEUROCHEM, V73, P1995; PERETZ A, IN PRESS EMBO J; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; Rock MT, 1997, J BIOL CHEM, V272, P33377, DOI 10.1074/jbc.272.52.33377; Stein-Gerlach M, 1998, INT J BIOCHEM CELL B, V30, P559, DOI 10.1016/S1357-2725(98)00002-8; Tanuma N, 1999, EUR J BIOCHEM, V259, P46, DOI 10.1046/j.1432-1327.1999.00004.x; Toledano-Katchalski H, 1999, ONCOGENE, V18, P5024, DOI 10.1038/sj.onc.1202883; Wallace MJ, 1998, MOL CELL BIOL, V18, P2608, DOI 10.1128/MCB.18.5.2608; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6	38	43	47	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4375	4384		10.1038/sj.onc.1203790	http://dx.doi.org/10.1038/sj.onc.1203790			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980613				2022-12-25	WOS:000089271900008
J	Canitrot, Y; Hoffmann, JS; Calsou, P; Hayakawa, H; Salles, B; Cazaux, C				Canitrot, Y; Hoffmann, JS; Calsou, P; Hayakawa, H; Salles, B; Cazaux, C			Nucleotide excision repair DNA synthesis by excess DNA polymerase beta: a potential source of genetic instability in cancer cells	FASEB JOURNAL			English	Article						cell variants; DNA repair; mutagenesis	IN-VITRO; MUTATOR PHENOTYPE; MAMMALIAN-CELLS; FREE-EXTRACTS; LINEAR DNA; LIGASE-I; PROTEIN; REPLICATION; EXPRESSION; COMPLEX	The nucleotide excision repair pathway contributes to genetic stability by removing a wide range of DNA damage through an error-free reaction. When the lesion is located, the altered strand is incised on both sides of the lesion and a damaged oligonucleotide excised, A repair patch is then synthesized and the repaired strand is ligated. It is assumed that only DNA polymerases delta and/or epsilon participate to the repair DNA synthesis step. Using UV and cisplatin-modified DNA templates, we measured in vitro that extracts from cells overexpressing the error-prone DNA polymerase beta exhibited a five- to sixfold increase of the ultimate DNA synthesis activity compared with control extracts and demonstrated the specific involvement of Pol beta in this step, By using a 28 nt gapped, double-stranded DNA substrate mimicking the product of the incision step, we showed that pol beta is able to catalyze strand displacement downstream of the gap, We discuss these data within the scope of a hypothesis previously presented proposing that excess error-prone Pol beta in cancer cells could perturb the well-defined specific functions of DNA polymerases during error-free DNA transactions.	Inst Pharmacol & Biol Struct, Grp Instabil Genet & Canc, CNRS, UMR 5089, F-31077 Toulouse 4, France; Inst Pharmacol & Biol Struct, Grp Toxicoresistance, CNRS, UMR 5089, F-31077 Toulouse, France; Kyushu Univ, Sch Med, Dept Biochem, Fukuoka 8128582, Japan	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Kyushu University	Salles, B (corresponding author), Inst Pharmacol & Biol Struct, Grp Instabil Genet & Canc, CNRS, UMR 5089, 205 Route Narbonne, F-31077 Toulouse 4, France.		salles, bernard/B-8531-2008; calsou, patrick/AAB-5123-2020; Hoffmann, Jean-Sebastien/O-9183-2014	Hoffmann, Jean-Sebastien/0000-0003-2222-354X; Calsou, Patrick/0000-0001-7951-9806				APPLEGREN N, 1995, J CELL BIOCHEM, V59, P91, DOI 10.1002/jcb.240590111; Araujo SJ, 1999, MUTAT RES-DNA REPAIR, V435, P23, DOI 10.1016/S0921-8777(99)00042-7; BARBOULE N, 1995, INT J CANCER, V63, P611, DOI 10.1002/ijc.2910630502; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; BIGGERSTAFF M, 1991, MUTAT RES, V254, P217, DOI 10.1016/0921-8777(91)90059-X; Bouayadi K, 1997, CANCER RES, V57, P110; CALSOU P, 1994, NUCLEIC ACIDS RES, V22, P4937, DOI 10.1093/nar/22.23.4937; CALSOU P, 1992, NUCLEIC ACIDS RES, V20, P6363, DOI 10.1093/nar/20.23.6363; CALSOU P, 1994, BIOCHEM BIOPH RES CO, V202, P788, DOI 10.1006/bbrc.1994.1999; Canitrot Y, 1999, FASEB J, V13, P1107, DOI 10.1096/fasebj.13.9.1107; Canitrot Y, 1999, ONCOGENE, V18, P2676, DOI 10.1038/sj.onc.1202619; Canitrot Y, 1998, P NATL ACAD SCI USA, V95, P12586, DOI 10.1073/pnas.95.21.12586; COPELAND WC, 1992, J BIOL CHEM, V267, P21459; DACOSTA LT, 1995, NAT GENET, V9, P10, DOI 10.1038/ng0195-10; DeMott MS, 1998, J BIOL CHEM, V273, P27492, DOI 10.1074/jbc.273.42.27492; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; Dimitriadis EK, 1998, J BIOL CHEM, V273, P20540, DOI 10.1074/jbc.273.32.20540; Flohr T, 1999, INT J CANCER, V80, P919, DOI 10.1002/(SICI)1097-0215(19990315)80:6<919::AID-IJC19>3.0.CO;2-U; FORNACE AJ, 1989, MOL CELL BIOL, V9, P851, DOI 10.1128/MCB.9.2.851; Frit P, 1998, J MOL BIOL, V284, P963, DOI 10.1006/jmbi.1998.2257; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Gomi A, 1996, BIOCHEM BIOPH RES CO, V227, P558, DOI 10.1006/bbrc.1996.1545; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; HANSSON J, 1989, NUCLEIC ACIDS RES, V17, P8073, DOI 10.1093/nar/17.20.8073; HAUSER J, 1986, MOL CELL BIOL, V6, P277, DOI 10.1128/MCB.6.1.277; HOFFMANN J, 1997, INT J ONCOL, V12, P377; Hoffmann JS, 1996, P NATL ACAD SCI USA, V93, P13766, DOI 10.1073/pnas.93.24.13766; HOFFMANN JS, 1995, P NATL ACAD SCI USA, V92, P5356, DOI 10.1073/pnas.92.12.5356; JOZAN S, 1992, IN VITRO CELL DEV-AN, V28A, P687; KamathLoeb AS, 1997, J BIOL CHEM, V272, P5892, DOI 10.1074/jbc.272.9.5892; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kornberg A., 1992, DNA REPLICATION; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; KUMAR A, 1990, J BIOL CHEM, V265, P2124; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; KUNKEL TA, 1986, J BIOL CHEM, V261, P3581; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LOEB L, 1997, CANC SURVEYS, V28, P329; Macdonald F., 1997, MOL BIOL CANC; Marintchev A, 1999, NAT STRUCT BIOL, V6, P884; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; Narayan S, 1996, J BIOL CHEM, V271, P18508, DOI 10.1074/jbc.271.31.18508; Osheroff WP, 1999, J BIOL CHEM, V274, P3642, DOI 10.1074/jbc.274.6.3642; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; Plug AW, 1997, P NATL ACAD SCI USA, V94, P1327, DOI 10.1073/pnas.94.4.1327; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; Radman M, 1999, NATURE, V401, P866, DOI 10.1038/44738; SCANLON KJ, 1989, CANCER INVEST, V7, P581, DOI 10.3109/07357908909017533; SHIJVI MKK, 1992, CELL, V69, P367; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1999, CARCINOGENESIS, V20, P1049, DOI 10.1093/carcin/20.6.1049; Torkelson J, 1997, EMBO J, V16, P3303, DOI 10.1093/emboj/16.11.3303; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; Wood RD, 1997, CARCINOGENESIS, V18, P605, DOI 10.1093/carcin/18.4.605; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036; Yoon JH, 1999, BIOCHEMISTRY-US, V38, P4809, DOI 10.1021/bi990105i; ZMUDZKA BZ, 1988, NUCLEIC ACIDS RES, V16, P9589	62	54	60	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2000	14	12					1765	1774		10.1096/fj.99-1063com	http://dx.doi.org/10.1096/fj.99-1063com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973926				2022-12-25	WOS:000089212400016
J	Taraboletti, G; Morbidelli, L; Donnini, S; Parenti, A; Granger, HJ; Giavazzi, R; Ziche, M				Taraboletti, G; Morbidelli, L; Donnini, S; Parenti, A; Granger, HJ; Giavazzi, R; Ziche, M			The heparin binding 25 kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinase and TIMP-2 production in endothelial cells	FASEB JOURNAL			English	Article									Univ Siena, Inst Pharmacol Sci, I-53100 Siena, Italy; Univ Florence, Dept Pharmacol, Florence, Italy; Mario Negri Inst Pharmacol Res, Dept Oncol, Bergamo, Italy; Texas A&M Univ, Hlth Sci Ctr, Microcirculat Res Inst, College Stn, TX USA; Texas A&M Univ, Hlth Sci Ctr, Dept Physiol, College Stn, TX USA	University of Siena; University of Florence; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Ziche, M (corresponding author), Univ Siena, Inst Pharmacol Sci, Vial Piccolomini 140, I-53100 Siena, Italy.		Morbidelli, Lucia/AAC-7858-2020; Morbidelli, Lucia/K-4053-2016; Giavazzi, Raffaella/ABB-9768-2020; Donnini, Sandra/K-9252-2019; Taraboletti, Giulia/J-4089-2018; Giavazzi, Raffaella/J-7424-2018	Morbidelli, Lucia/0000-0001-8148-7049; Giavazzi, Raffaella/0000-0001-5249-8208; Donnini, Sandra/0000-0001-6617-1644; Taraboletti, Giulia/0000-0001-8780-5001; Parenti, Astrid/0000-0002-7980-6853					0	117	123	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2000	14	12					1674	1676						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973914				2022-12-25	WOS:000089212400004
J	Blostein, MD; Rigby, AC; Jacobs, M; Furie, B; Furie, BC				Blostein, MD; Rigby, AC; Jacobs, M; Furie, B; Furie, BC			The Gla domain of human prothrombin has a binding site for factor Va	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; CONFORMATION-SPECIFIC ANTIBODIES; ACTIVATED PROTEIN-C; BLOOD-COAGULATION; MEMBRANE-BINDING; FACTOR VIIA; FACTOR-X; PHOSPHOLIPID-VESICLES; BOVINE PROTHROMBIN; KRINGLE DOMAIN	The role of the Gla domain of human prothrombin in interaction with the prothrombinase complex was studied using a peptide with the sequence of the first 46 residues of human prothrombin, PT-(1-46). Intrinsic fluorescence measurements showed that PT-(1-46) undergoes a conformational alteration upon binding calcium; this conclusion is supported by one-dimensional H-1 NMR spectroscopy, which identifies a change in the chemical environment of tryptophan 41. PT-(1-46) binds phospholipid membranes in a calcium dependent manner with a K-d Of 0.5 muM and inhibits thrombin generation by the prothrombinase complex with a K-i of 0.8 muM. In the absence of phospholipid membranes, PT-(1-46) inhibits thrombin generation by factor Xa in the presence but not absence of factor Va, suggesting that PT-(1-46) inhibits prothrombin-factor Va binding. The addition of factor Va to PT-(1-46) labeled with the fluorophore sulfosuccinimidyl-7-amino-4-methylcoumarin-3-acetic acid (PT-(1-46)AMCA) caused a concentration-dependent quenching of AMCA fluorescence, providing direct evidence of a PT-(1-46)-factor Va interaction. The K-d for this interaction was 1.3 muM. These results indicate that the N-terminal Gla domain of human prothrombin is a functional unit that has a binding site for factor Va. The prothrombin Gla domain is important for interaction of the substrate with the prothrombinase complex.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Ctr Hemostasis & Thrombosis Res, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Furie, BC (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Ctr Hemostasis & Thrombosis Res, Res E Rm 319,POB 15732, Boston, MA 02215 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL018834, P01HL042443, R01HL018834] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL18834, HL42443] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BOROWSKI M, 1985, J BIOL CHEM, V260, P9258; BOROWSKI M, 1986, J BIOL CHEM, V261, P4969; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; COLPITTS TL, 1994, BIOCHEMISTRY-US, V33, P3501, DOI 10.1021/bi00178a006; Croce K, 1998, BIOCHEMISTRY-US, V37, P16472, DOI 10.1021/bi981341g; Deguchi H, 1997, BIOCHEM J, V321, P729, DOI 10.1042/bj3210729; Dixon M., 1964, ENZYMES, V2nd; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Freedman SJ, 1996, J BIOL CHEM, V271, P16227, DOI 10.1074/jbc.271.27.16227; FURIE B, 1979, J BIOL CHEM, V254, P9766; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; FURIE B, 1992, NEW ENGL J MED, V326, P800; GILBERT GE, 1990, J BIOL CHEM, V265, P815; Hof M, 1996, PROTEINS, V24, P485, DOI 10.1002/(SICI)1097-0134(199604)24:4<485::AID-PROT7>3.0.CO;2-D; Huang QL, 1996, J BIOL CHEM, V271, P21752, DOI 10.1074/jbc.271.36.21752; JACOBS M, 1994, J BIOL CHEM, V269, P25494; KOTKOW KJ, 1993, J BIOL CHEM, V268, P15633; KOTKOW KJ, 1995, J BIOL CHEM, V270, P4551, DOI 10.1074/jbc.270.9.4551; Larson PJ, 1996, J BIOL CHEM, V271, P3869; LUCKOW EA, 1989, BIOCHEMISTRY-US, V28, P2348, DOI 10.1021/bi00431a055; MARTIN DMA, 1993, BIOCHEMISTRY-US, V32, P13949, DOI 10.1021/bi00213a026; NELSESTUEN GL, 1975, BIOCHEM BIOPH RES CO, V65, P233, DOI 10.1016/S0006-291X(75)80084-2; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4164, DOI 10.1021/bi00638a005; PRENDERGAST FG, 1977, J BIOL CHEM, V252, P840; RATCLIFFE JV, 1993, J BIOL CHEM, V268, P24339; ROSING J, 1980, J BIOL CHEM, V255, P274; Ruf W, 1999, BIOCHEMISTRY-US, V38, P1957, DOI 10.1021/bi982254r; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHWALBE RA, 1989, J BIOL CHEM, V264, P20288; SESHADRI TP, 1991, J MOL BIOL, V220, P481, DOI 10.1016/0022-2836(91)90025-2; Smirnov MD, 1998, J BIOL CHEM, V273, P9031, DOI 10.1074/jbc.273.15.9031; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; Sunnerhagen M, 1996, HAEMOSTASIS, V26, P45; WELSCH DJ, 1988, BIOCHEMISTRY-US, V27, P4939, DOI 10.1021/bi00413a052; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yegneswaran S, 1999, J BIOL CHEM, V274, P5462, DOI 10.1074/jbc.274.9.5462	40	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					38120	38126		10.1074/jbc.M007174200	http://dx.doi.org/10.1074/jbc.M007174200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10973980	hybrid			2022-12-25	WOS:000165618700108
J	Li, Y; Li, M; Xing, GC; Hu, ZY; Wang, QM; Dong, CN; Wei, HD; Fan, GC; Chen, JZ; Yang, XM; Zhao, SF; Chen, HP; Guan, KL; Wu, CS; Zhang, CG; He, FC				Li, Y; Li, M; Xing, GC; Hu, ZY; Wang, QM; Dong, CN; Wei, HD; Fan, GC; Chen, JZ; Yang, XM; Zhao, SF; Chen, HP; Guan, KL; Wu, CS; Zhang, CG; He, FC			Stimulation of the mitogen-activated protein kinase cascade and tyrosine phosphorylation of the epidermal growth factor receptor by hepatopoietin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE-1; REGENERATION ALR GENE; LIVER-REGENERATION; EGF RECEPTOR; CELLS; EXPRESSION; RAT; AUGMENTOR; SUBSTANCE; HEPATOMA	Hepatopoietin (HPO) is a novel human hepatotrophic growth factor, which specifically stimulates proliferation of cultured primary hepatocytes in vitro and liver regeneration after liver partial hepatectomy in vivo. Recently, the identification of the mitogenic effect of HPO on hepatoma cell lines and the existence of HPO-specific receptors indicate that HPO acts via its specific cell surface receptor, However, the molecular mechanism of HPO action is not fully elucidated. In this report, we examined the signal transduction events induced by HPO in hepatoma cell line (HepG2), Our results demonstrated that HPO induces phosphorylation of mitogen-activated protein kinase kinase and mitogen-activated protein kinase (MAPK) in a rapid and transient manner. HPO stimulates tyrosine phosphorylation of epidermal growth factor receptor (EGFR). Furthermore, we observed that both MAPK activation and the mitogenic effect of HPO on HepG2 cells were completely blocked by AG1478, a specific inhibitor of EGFR tyrosine kinase activity. However, the effects of HPO were not antagonized by an EGFR-blocking antibody, mAb528, which blocks the interaction between epidermal growth factor and EGFR, indicating that stimulation of tyrosine phosphorylation of EGFR by HPO was not mediated by epidermal growth factor. In contrast, genistein, a general tyrosine kinase inhibitor, significantly attenuated the tyrosine phosphorylation of EGFR in response to HPO, In conclusion, our results suggest that tyrosine phosphorylation of EGFR may play a critical role in MAPK activation and mitogenic stimulation by HPO.	Beijing Inst Radiat Med, Chinese Natl Human Genome Ctr, Dept Genomics & Proteom, Beijing 100850, Peoples R China; Acad Sinica, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China	Academy of Military Medical Sciences - China; Chinese Academy of Sciences; Institute of Biophysics, CAS	He, FC (corresponding author), Beijing Inst Radiat Med, Chinese Natl Human Genome Ctr, Dept Genomics & Proteom, 27 Taiping Rd, Beijing 100850, Peoples R China.		Zhang, Chenggang/B-1480-2009	Zhang, Chenggang/0000-0002-4521-3304				Chaudhary LR, 1997, BIOCHEM BIOPH RES CO, V238, P134, DOI 10.1006/bbrc.1997.7256; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; Dabrowski A, 1997, AM J PHYSIOL-CELL PH, V273, pC1472, DOI 10.1152/ajpcell.1997.273.5.C1472; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Diehl AM, 1996, FASEB J, V10, P215, DOI 10.1096/fasebj.10.2.8641555; Fausto N, 1995, FASEB J, V9, P1527, DOI 10.1096/fasebj.9.15.8529831; GABELMAN BM, 1992, EXP CELL RES, V201, P113, DOI 10.1016/0014-4827(92)90354-B; Giorda R, 1996, MOL MED, V2, P97, DOI 10.1007/BF03402206; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; HAGIYA M, 1994, P NATL ACAD SCI USA, V91, P8142, DOI 10.1073/pnas.91.17.8142; He FC, 1997, CHINESE SCI BULL, V42, P1505; LABRECQUE DR, 1991, DIGEST DIS SCI, V36, P669, DOI 10.1007/BF01297036; LABRECQUE DR, 1975, J PHYSIOL-LONDON, V248, P273, DOI 10.1113/jphysiol.1975.sp010973; LABRECQUE DR, 1994, AM J GASTROENTEROL S, V89, P90; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LISOWSKY T, 1995, GENOMICS, V29, P690, DOI 10.1006/geno.1995.9950; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Putz T, 1999, CANCER RES, V59, P227; Wang G, 1999, J BIOL CHEM, V274, P11469, DOI 10.1074/jbc.274.17.11469; YAMAGUCHI K, 1995, J SURG ONCOL, V58, P240; Yang EB, 1996, BIOCHEM MOL BIOL INT, V38, P813; Yang XM, 1997, SCI CHINA SER C, V40, P642, DOI 10.1007/BF02882695; YANG XM, 1997, ACTA BIOCH BIOPH SIN, V29, P72; YANG XM, 1997, ACTA PHYSL SINICA, V49, P557; Zanella CL, 1996, CANCER RES, V56, P5334	25	57	68	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37443	37447		10.1074/jbc.M004373200	http://dx.doi.org/10.1074/jbc.M004373200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10982794	hybrid			2022-12-25	WOS:000165618700020
J	Xu, Q; Wu, ZG				Xu, Q; Wu, ZG			The insulin-like growth factor-phosphatidylinositol 3-kinase-Akt signaling pathway regulates myogenin expression in normal myogenic cells but not in Rhabdomyosarcoma-derived RD cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE DIFFERENTIATION; PROTEIN-KINASE-B; GENE-EXPRESSION; IGF-I; TRANSCRIPTIONAL ACTIVATION; FACTOR MEF-2; MYOD; SITE; EMBRYOGENESIS; DEFICIENCY	Insulin-like growth factors (IGFs) can stimulate skeletal muscle differentiation. One of the molecular mechanisms underlying IGF-stimulated myogenesis is transcriptional induction of myogenin. The current work is aimed to elucidate the signaling pathways mediating the IGF effect on myogenin promoter in mouse C2C12 myogenic cells. We show that phosphatidylinositol 3-kinase (PI3K)/Akt and p70(S6K) are crucial signaling molecules mediating the stimulatory effect of IGFs on myogenin expression. We have identified three cis-elements, namely the E box, MEF2, and MEF3 sites, within the 133-base pair mouse proximal myogenin promoter that are under the control of the IGF/PI3K/Akt pathway. Simultaneous mutation of all three elements completely abolishes activation of the myogenin promoter by PI3K/ Akt. We demonstrate that PI3K/Akt can increase both the MyoD and the MEF2-dependent reporter activity by enhancing the transcriptional activity of MyoD and MEF2. Interestingly, IGF1 does not enhance myogenin expression in Rhabdomyosarcoma-derived RD cells. Consistently, the constitutively active PI3K/Akt fail to activate the myogenic reporters, suggesting the IGF/ PI3K/Akt pathway is defective in RD cells and the defect(s) is downstream to PI3K/Akt. This is the first time that a defect in the IGF/PI3K/Akt pathway has been revealed in RD cells which provides another clue to future therapeutic treatment of Rhabdomyosarcoma.	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Wu, ZG (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Clear Water Bay, Kowloon, Hong Kong, Peoples R China.		Wu, Zhenguo/B-8144-2013	Wu, Zhenguo/0000-0003-3049-8324				Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Anderson J, 1999, GENE CHROMOSOME CANC, V26, P275, DOI 10.1002/(SICI)1098-2264(199912)26:4<275::AID-GCC1>3.0.CO;2-3; Arnold HH, 1998, CURR OPIN GENET DEV, V8, P539, DOI 10.1016/S0959-437X(98)80008-7; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Black BL, 1998, MOL CELL BIOL, V18, P69, DOI 10.1128/MCB.18.1.69; BOUCHE M, 1993, EXP CELL RES, V208, P209, DOI 10.1006/excr.1993.1239; BUCHBERGER A, 1994, J BIOL CHEM, V269, P17289; CHENG TC, 1992, J CELL BIOL, V119, P1649, DOI 10.1083/jcb.119.6.1649; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; Engert JC, 1996, J CELL BIOL, V135, P431, DOI 10.1083/jcb.135.2.431; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; FLORINI JR, 1991, MOL ENDOCRINOL, V5, P718, DOI 10.1210/mend-5-5-718; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; Heanue TA, 1999, GENE DEV, V13, P3231, DOI 10.1101/gad.13.24.3231; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Jiang BH, 1998, P NATL ACAD SCI USA, V95, P14179, DOI 10.1073/pnas.95.24.14179; Johanson M, 1999, BIOCHEM BIOPH RES CO, V265, P222, DOI 10.1006/bbrc.1999.1390; Kaliman P, 1998, MOL ENDOCRINOL, V12, P66, DOI 10.1210/mend.12.1.0047; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; MALIK S, 1995, EUR J BIOCHEM, V230, P88, DOI 10.1111/j.1432-1033.1995.tb20537.x; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; Ohto H, 1999, MOL CELL BIOL, V19, P6815; Ornatsky OI, 1996, J BIOL CHEM, V271, P24927, DOI 10.1074/jbc.271.40.24927; Petley T, 1999, HORM METAB RES, V31, P70, DOI 10.1055/s-2007-978701; POWELLBRAXTON L, 1993, GENE DEV, V7, P2609, DOI 10.1101/gad.7.12b.2609; Puri PL, 2000, GENE DEV, V14, P574; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Relaix F, 1999, GENE DEV, V13, P3171, DOI 10.1101/gad.13.24.3171; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; ROSENTHAL SM, 1995, P NATL ACAD SCI USA, V92, P10307, DOI 10.1073/pnas.92.22.10307; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Spitz F, 1998, P NATL ACAD SCI USA, V95, P14220, DOI 10.1073/pnas.95.24.14220; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193	48	139	146	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36750	36757		10.1074/jbc.M005030200	http://dx.doi.org/10.1074/jbc.M005030200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973962	hybrid			2022-12-25	WOS:000165577700044
J	Carreno, S; Gouze, ME; Schaak, S; Emorine, LJ; Maridonneau-Parini, I				Carreno, S; Gouze, ME; Schaak, S; Emorine, LJ; Maridonneau-Parini, I			Lack of palmitoylation redirects p59(Hck) from the plasma membrane to p61(Hck)-positive lysosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; SRC FAMILY KINASES; HUMAN NEUTROPHILS; SUBCELLULAR-LOCALIZATION; SIGNAL-TRANSDUCTION; HEMATOPOIETIC-CELLS; GENE HCK; ASSOCIATION; RECEPTOR; ACTIVATION	Hck, a protein-tyrosine kinase of phagocytes, is the unique member of the Src family expressed under two alternatively translated isoforms differing in their N-terminal site of acylation: p61(Hck) has an additional 21-amino acid sequence comprising a single myristoylation motif, whereas p59(Hck) N terminus has myristoylation and palmitoylation sites. To identify the molecular determinants involved in the targeting of each isoform, they were fused to GFP and expressed in HeLa and CHO cells. p61(Hck) was associated with lysosomal vesicles, whereas p59(Hck) was found at the plasma membrane and to a low extent associated with lysosomes. Their unique N-terminal domains were sufficient to target GFP to the corresponding intracellular compartments. Mutation of the palmitoylation site of p59(Hck) redirected this isoform to lysosomes, indicating that the palmitoylation state governs the association of p59(Hck) with the plasma membrane or with lysosomes. In addition, both isoforms and the nonpalmitoylated p59(Hck) mutant were found on the Golgi apparatus, suggesting a role of this organelle in the subcellular sorting of Hck isoforms. Regarding their subcellular localizations, we propose that bi-acylated p59(Hck) might transduce plasma membrane receptor signals, whereas p61(Hck) and the nonpalmitoylated p59(Hck) might control the biogenesis of phagolysosomes, two functions yet proposed for Hck in phagocytes.	CNRS, IPBS, Unite Mixte Rech 5089, F-31077 Toulouse, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Maridonneau-Parini, I (corresponding author), CNRS, IPBS, Unite Mixte Rech 5089, 205 Route Narbonne, F-31077 Toulouse, France.		Maridonneau-Parini, Isabelle/F-1985-2011	Maridonneau-Parini, Isabelle/0000-0003-0189-0976; Carreno, Sebastien/0000-0002-5839-2102				AbuAmer Y, 1997, J CELL BIOL, V137, P247, DOI 10.1083/jcb.137.1.247; Astarie-Dequeker C, 2000, INFECT IMMUN, V68, P4827, DOI 10.1128/IAI.68.8.4827-4830.2000; Astarie-Dequeker C, 1999, INFECT IMMUN, V67, P469, DOI 10.1128/IAI.67.2.469-477.1999; Bijlmakers MJJE, 1997, J CELL BIOL, V137, P1029, DOI 10.1083/jcb.137.5.1029; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Chiaradonna F, 1999, EMBO J, V18, P3013, DOI 10.1093/emboj/18.11.3013; Dunphy JT, 1996, J BIOL CHEM, V271, P7154, DOI 10.1074/jbc.271.12.7154; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; Foster-Barber A, 1998, P NATL ACAD SCI USA, V95, P4673, DOI 10.1073/pnas.95.8.4673; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; Horejsi V, 1999, IMMUNOL TODAY, V20, P356, DOI 10.1016/S0167-5699(99)01489-9; JASMIN BJ, 1989, P NATL ACAD SCI USA, V86, P7218, DOI 10.1073/pnas.86.18.7218; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JS, 1979, J BIOL CHEM, V254, P8015; LINSTEDT AD, 1992, J CELL BIOL, V117, P1077, DOI 10.1083/jcb.117.5.1077; Liu SH, 1998, J CELL BIOL, V140, P1023, DOI 10.1083/jcb.140.5.1023; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; Lowell CA, 1996, J CELL BIOL, V133, P895, DOI 10.1083/jcb.133.4.895; MARIDONNEAUPARINI I, 1992, J BIOL CHEM, V267, P6396; McCabe JB, 1999, MOL BIOL CELL, V10, P3771, DOI 10.1091/mbc.10.11.3771; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; Mocsai A, 1999, J IMMUNOL, V162, P1120; MOHN H, 1995, BIOCHEM J, V309, P657; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; Murray EW, 1998, J BIOL CHEM, V273, P25279, DOI 10.1074/jbc.273.39.25279; N'Diaye EN, 1998, J IMMUNOL, V161, P4983; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RESH MD, 1999, BIOCHIM BIOPHYS ACTA, V12, P1; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; SCHMIDT JW, 1987, J BIOL CHEM, V262, P13713; Skubitz KM, 1998, FEBS LETT, V439, P97, DOI 10.1016/S0014-5793(98)01347-7; Skubitz KM, 1998, J LEUKOCYTE BIOL, V64, P800, DOI 10.1002/jlb.64.6.800; Suen PW, 1999, J CELL SCI, V112, P4067; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; van't Hof W, 1999, J CELL BIOL, V145, P377, DOI 10.1083/jcb.145.2.377; vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023; Ward AC, 1998, BIOCHEM BIOPH RES CO, V251, P117, DOI 10.1006/bbrc.1998.9441; Welch H, 1997, J BIOL CHEM, V272, P102; Wolven A, 1997, MOL BIOL CELL, V8, P1159, DOI 10.1091/mbc.8.6.1159; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; YURCHAK LK, 1995, MOL CELL BIOL, V15, P6914, DOI 10.1128/mcb.15.12.6914; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276; Zlatkine P, 1997, J CELL SCI, V110, P673	50	55	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36223	36229		10.1074/jbc.M003901200	http://dx.doi.org/10.1074/jbc.M003901200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10967098	hybrid			2022-12-25	WOS:000165382000082
J	Kupriyanova, TA; Kandror, KV				Kupriyanova, TA; Kandror, KV			Cellugyrin is a marker for a distinct population of intracellular Glut4-containing vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE-CELLS; GLUT4 GLUCOSE-TRANSPORTER; 3T3-L1 ADIPOCYTES; SUBCELLULAR TRAFFICKING; GLUT4-ENRICHED VESICLES; MAJOR PROTEIN; INSULIN; TRANSLOCATION; SYNAPTOGYRIN; COMPARTMENT	Although Glut4 traffic is routinely described as translocation from an "intracellular storage pool" to the plasma membrane, it has been long realized that Glut4 travels through at least two functionally distinct intracellular membrane compartments on the way to and from the cell surface. Biochemical separation and systematic studies of the individual Glut4-containing compartments have been limited by the lack of appropriate reagents. We have prepared a monoclonal antibody against a novel component protein of Glut4 vesicles and have identified this protein as cellugyrin, a ubiquitously expressed homologue of a major synaptic vesicle protein, synaptogyrin. By means of sucrose gradient centrifugation, immunoadsorption, and confocal microscopy, we have shown that virtually all cellugyrin is colocalized with Glut4 in the same vesicles. However, unlike Glut4, cellugyrin is not re-distributed to the plasma membrane in response to insulin stimulation, and at least 40-50% of the total population of Glut4 vesicles do not contain this protein. We suggest that cellugyrin represents a specific marker of a functionally distinct population of Glut4 vesicles that permanently maintains its intracellular localization and is not recruited to the plasma membrane by insulin.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Kandror, KV (corresponding author), Boston Univ, Sch Med, Dept Biochem, K121 715 Albany St, Boston, MA 02118 USA.			Kandror, Konstantin/0000-0002-8601-9313	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK046200, R01DK052057, R01DK056736, R56DK052057] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52057, DK56736, P30 DK46200] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDINI G, 1991, J BIOL CHEM, V266, P4037; BIRNBAUM MJ, 1992, INT REV CYTOL, V137A, P239; Bogan JS, 1999, J CELL BIOL, V146, P609, DOI 10.1083/jcb.146.3.609; CZECH MP, 1993, J BIOL CHEM, V268, P9187; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Fleischer S, 1974, Methods Enzymol, V31, P3; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; Hashiramoto M, 2000, MOL CELL BIOL, V20, P416, DOI 10.1128/MCB.20.1.416-427.2000; HOLMAN GD, 1994, J BIOL CHEM, V269, P17516; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; Janz R, 1999, NEURON, V24, P687, DOI 10.1016/S0896-6273(00)81122-8; Janz R, 1998, J BIOL CHEM, V273, P2851, DOI 10.1074/jbc.273.5.2851; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KAHN BB, 1992, J CLIN INVEST, V89, P1367, DOI 10.1172/JCI115724; KANDROR K, 1994, J BIOL CHEM, V269, P138; KANDROR KV, 1994, J BIOL CHEM, V269, P30777; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; Kandror KV, 1998, BIOCHEM J, V331, P829, DOI 10.1042/bj3310829; Kedra D, 1998, HUM GENET, V103, P131, DOI 10.1007/s004390050795; Kupriyanova TA, 1999, J BIOL CHEM, V274, P1458, DOI 10.1074/jbc.274.3.1458; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee W, 1999, J BIOL CHEM, V274, P37755, DOI 10.1074/jbc.274.53.37755; Lin BZ, 1997, J BIOL CHEM, V272, P24145, DOI 10.1074/jbc.272.39.24145; Livingstone C, 1996, BIOCHEM J, V315, P487, DOI 10.1042/bj3150487; Malide D, 1997, J HISTOCHEM CYTOCHEM, V45, P1083, DOI 10.1177/002215549704500806; Martin LB, 1998, J BIOL CHEM, V273, P1444, DOI 10.1074/jbc.273.3.1444; MARTIN S, 1994, BIOCHEM J, V300, P743, DOI 10.1042/bj3000743; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; Randhawa VK, 2000, MOL BIOL CELL, V11, P2403, DOI 10.1091/mbc.11.7.2403; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; SATOH S, 1993, J BIOL CHEM, V268, P17820; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; Stenius K, 1995, J CELL BIOL, V131, P1801, DOI 10.1083/jcb.131.6.1801; Sugita S, 1999, J BIOL CHEM, V274, P18893, DOI 10.1074/jbc.274.27.18893; THOIDIS G, 1993, J BIOL CHEM, V268, P11691; VERHEY KJ, 1995, J CELL BIOL, V130, P1071, DOI 10.1083/jcb.130.5.1071; VOLCHUK A, 1995, J BIOL CHEM, V270, P8233, DOI 10.1074/jbc.270.14.8233	41	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36263	36268		10.1074/jbc.M002797200	http://dx.doi.org/10.1074/jbc.M002797200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10967091	hybrid			2022-12-25	WOS:000165382000088
J	Lee, SJ; Beckingham, K; Stull, JT				Lee, SJ; Beckingham, K; Stull, JT			Mutations at lysine 525 of inducible nitric-oxide synthase affect its Ca2+-independent activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAIN; ELECTRON-TRANSFER; MOLECULAR-CLONING; CATALYTIC ACTIVITY; OXYGENASE DOMAIN; NO SYNTHASE; CELL-LINE; EXPRESSION; PURIFICATION; CDNA	Calmodulin binding to inducible nitric-oxide synthase may play an important role in its Ca2+-independent activity. Studies of inducible nitric-oxide synthase chimeras containing the calmodulin binding sequence of neuronal or endothelial nitric-oxide synthases show that the calmodulin binding sequence of inducible nitric-oxide synthase is necessary but not sufficient for the Ca2+- independent activity. The mutations at lysine 525 located at the C terminus of the calmodulin binding sequence of inducible nitric-oxide synthase were examined for the effects on the Ca2+-independent activity with chimeras containing the oxygenase or reductase domains of inducible or neuronal nitric-oxide synthases. Results show that the Ca2+-independent binding of calmodulin is not solely responsible for maximal Ca2+-independent activity of inducible nitric-oxide synthase, Lysine 525 of inducible nitric-oxide synthase may also play an important role in coordinating the maximal Ca2+-independent activity.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Rice University	Lee, SJ (corresponding author), Res Genet Inc, Dept Res & Dev, 2130 Mem Pkwy, Huntsville, AL 35801 USA.		Lee, Shiow-Ju/C-1380-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL026043, R01HL026043] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL06296, HL26043] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHARLES IG, 1993, P NATL ACAD SCI USA, V90, P11419, DOI 10.1073/pnas.90.23.11419; Chen PF, 1996, J BIOL CHEM, V271, P14631, DOI 10.1074/jbc.271.24.14631; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; EVANS T, 1992, P NATL ACAD SCI USA, V89, P5361, DOI 10.1073/pnas.89.12.5361; Gachhui R, 1998, J BIOL CHEM, V273, P5451, DOI 10.1074/jbc.273.10.5451; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; GAO ZH, 1993, J BIOL CHEM, V268, P20096; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; IIDA S, 1992, J BIOL CHEM, V267, P25385; Lee SJ, 1998, J BIOL CHEM, V273, P27430, DOI 10.1074/jbc.273.42.27430; Lin AW, 1996, J BIOL CHEM, V271, P11911, DOI 10.1074/jbc.271.20.11911; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MAIER R, 1994, BBA-PROTEIN STRUCT M, V1208, P145, DOI 10.1016/0167-4838(94)90171-6; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Martasek P, 1998, J BIOL CHEM, V273, P34799, DOI 10.1074/jbc.273.52.34799; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Nishida CR, 1998, J BIOL CHEM, V273, P5566, DOI 10.1074/jbc.273.10.5566; NUNOKAWA Y, 1993, BIOCHEM BIOPH RES CO, V191, P89, DOI 10.1006/bbrc.1993.1188; Perry JM, 1998, P NATL ACAD SCI USA, V95, P11101, DOI 10.1073/pnas.95.19.11101; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; REGULSKI M, 1995, P NATL ACAD SCI USA, V92, P9072, DOI 10.1073/pnas.92.20.9072; Ruan J, 1996, J BIOL CHEM, V271, P22679, DOI 10.1074/jbc.271.37.22679; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SHERMAN PA, 1993, BIOCHEMISTRY-US, V32, P11600, DOI 10.1021/bi00094a017; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; StevensTruss R, 1997, BIOCHEMISTRY-US, V36, P12337, DOI 10.1021/bi970973k; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; SU ZZ, 1995, J BIOL CHEM, V270, P29117, DOI 10.1074/jbc.270.49.29117; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435; Watanabe Y, 1997, FEBS LETT, V403, P75, DOI 10.1016/S0014-5793(97)00012-4; YUI Y, 1991, J BIOL CHEM, V266, P12544; Zoche M, 1997, BIOL CHEM, V378, P851, DOI 10.1515/bchm.1997.378.8.851	42	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36067	36072		10.1074/jbc.M003935200	http://dx.doi.org/10.1074/jbc.M003935200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10978319	hybrid			2022-12-25	WOS:000165382000061
J	Ravid, T; Doolman, R; Avner, R; Harats, D; Roitelman, J				Ravid, T; Doolman, R; Avner, R; Harats, D; Roitelman, J			The ubiquitin-proteasome pathway mediates the regulated degradation of mammalian 3-hydroxy-3-methylglutaryl-coenzyme A reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; HMG-COA REDUCTASE; RETICULUM MEMBRANE-PROTEIN; MEVALONATE-DERIVED PRODUCT; LOW-DENSITY LIPOPROTEIN; ENDOPLASMIC-RETICULUM; MESSENGER-RNA; RAT-LIVER; IN-VIVO; TRANSLATIONAL CONTROL	3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR), the key regulatory enzyme in the mevalonate (MVA) pathway, is rapidly degraded in mammalian cells supplemented with sterols or MVA This accelerated turnover was blocked by N-acetyl-leucyl-leucyl-nor-leucinal (ALLN), MG-132, and lactacystin, and to a lesser extent by N-acetyl-leucyl-leucyl-methional (ALLM), indicating the involvement of the 26 S proteasome. Proteasome inhibition led to enhanced accumulation of high:molecular weight polyubiquitin conjugates of HMGR and of HMGal, a chimera between the membrane domain of HMGR and beta -galactosidase. Importantly, increased amounts of polyubiquitinated HMGR and HMGal were observed upon treating cells with sterols or MVA. Cycloheximide inhibited the sterol-stimulated degradation of HMGR concomitantly with a marked reduction in polyubiquitination of the enzyme, Inhibition of squalene synthase with zaragozic acid blocked the MVA- but not sterol-stimulated ubiquitination and degradation of HMGR, Thus, similar to yeast, the ubiquitin-proteasome pathway is involved in the metabolically regulated turnover of mammalian HMGR, Yet, the data indicate divergence between yeast and mammals and suggest distinct roles for sterol and nonsterol metabolic signals in the regulated ubiquitination and degradation of mammalian HMGR.	Chaim Sheba Med Ctr, Inst Lipid & Atherosclerosis Res, IL-52621 Tel Hashomer, Israel; Tel Aviv Univ, Sackler Sch Med, Dept Clin Biochem, IL-69978 Tel Aviv, Israel	Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Roitelman, J (corresponding author), Chaim Sheba Med Ctr, Inst Lipid & Atherosclerosis Res, IL-52621 Tel Hashomer, Israel.							BASSON ME, 1988, MOL CELL BIOL, V8, P3797, DOI 10.1128/MCB.8.9.3797; Bordallo J, 1999, FEBS LETT, V448, P244, DOI 10.1016/S0014-5793(99)00362-2; Bordallo J, 1998, MOL BIOL CELL, V9, P209, DOI 10.1091/mbc.9.1.209; BRADFUTE DL, 1994, J BIOL CHEM, V269, P6645; CHIN DJ, 1982, P NATL ACAD SCI-BIOL, V79, P7704, DOI 10.1073/pnas.79.24.7704; CHIN DJ, 1985, MOL CELL BIOL, V5, P634, DOI 10.1128/MCB.5.4.634; CHOI JW, 1993, BIOCHEM J, V296, P859, DOI 10.1042/bj2960859; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CHUN KT, 1992, J BIOL CHEM, V267, P4236; CLARKE CF, 1985, J BIOL CHEM, V260, P4363; CORRELL CC, 1994, J BIOL CHEM, V269, P633; CORRELL CC, 1994, J BIOL CHEM, V269, P17390; Du EZ, 1999, J BIOL CHEM, V274, P1856, DOI 10.1074/jbc.274.3.1856; EDWARDS PA, 1983, J BIOL CHEM, V258, P219; Edwards PA, 1999, ANNU REV BIOCHEM, V68, P157, DOI 10.1146/annurev.biochem.68.1.157; FAUST JR, 1982, P NATL ACAD SCI-BIOL, V79, P5205, DOI 10.1073/pnas.79.17.5205; Gardner R, 1998, MOL BIOL CELL, V9, P2611, DOI 10.1091/mbc.9.9.2611; Gardner RG, 1999, EMBO J, V18, P5994, DOI 10.1093/emboj/18.21.5994; Gardner RG, 1999, J BIOL CHEM, V274, P31671, DOI 10.1074/jbc.274.44.31671; GAYEN AK, 1995, ARCH BIOCHEM BIOPHYS, V322, P475, DOI 10.1006/abbi.1995.1491; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Hampton RY, 1998, CURR OPIN LIPIDOL, V9, P93, DOI 10.1097/00041433-199804000-00003; Hampton RY, 1996, P NATL ACAD SCI USA, V93, P828, DOI 10.1073/pnas.93.2.828; Hampton RY, 1997, P NATL ACAD SCI USA, V94, P12944, DOI 10.1073/pnas.94.24.12944; HAMPTON RY, 1994, J CELL BIOL, V125, P299, DOI 10.1083/jcb.125.2.299; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; INOUE S, 1992, J BIOL CHEM, V267, P9080; INOUE S, 1991, J BIOL CHEM, V266, P13311; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; LISCUM L, 1983, P NATL ACAD SCI-BIOL, V80, P7165, DOI 10.1073/pnas.80.23.7165; LISCUM L, 1985, J BIOL CHEM, V260, P522; LISCUM L, 1983, J BIOL CHEM, V258, P8450; McGee TP, 1996, J BIOL CHEM, V271, P25630, DOI 10.1074/jbc.271.41.25630; Meigs TE, 1997, ARCH BIOCHEM BIOPHYS, V345, P1, DOI 10.1006/abbi.1997.0200; Meigs TE, 1996, J BIOL CHEM, V271, P7916, DOI 10.1074/jbc.271.14.7916; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; OSBORNE TF, 1985, CELL, V42, P203, DOI 10.1016/S0092-8674(85)80116-1; PEFFLEY D, 1985, J BIOL CHEM, V260, P9949; PEFFLEY DM, 1995, SOMAT CELL MOLEC GEN, V21, P189, DOI 10.1007/BF02254770; Plemper RK, 1999, J CELL SCI, V112, P4123; PLEMPER RK, 1999, MOL BIOL REP, V26; Ravid T, 1999, J BIOL CHEM, V274, P29341, DOI 10.1074/jbc.274.41.29341; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; ROITELMAN J, 1992, J BIOL CHEM, V267, P25264; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; TANAKA RD, 1986, J LIPID RES, V27, P261; Wigley WC, 1999, J CELL BIOL, V145, P481	53	119	123	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35840	35847		10.1074/jbc.M004793200	http://dx.doi.org/10.1074/jbc.M004793200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10964918	hybrid			2022-12-25	WOS:000165382000030
J	Martin, M; Macias, M; Escames, G; Leon, J; Acuna-Castroviejo, D				Martin, M; Macias, M; Escames, G; Leon, J; Acuna-Castroviejo, D			Melatonin but not vitamins C and E maintains glutathione homeostasis in t-butyl hydroperoxide-induced mitochondrial oxidative stress	FASEB JOURNAL			English	Article									Univ Granada, Inst Biotecnol, Dept Fisiol, E-18012 Granada, Spain	University of Granada	Acuna-Castroviejo, D (corresponding author), Fac Med, Dept Fisiol, Avda Madrid 11, E-18012 Granada, Spain.		Leon, Pepi/K-8972-2014; Acuña-Castroviejo, Dario/N-7456-2016; Escames, Germaine/N-7501-2016	Leon, Pepi/0000-0002-0543-4823; Acuña-Castroviejo, Dario/0000-0002-9680-1560; Escames, Germaine/0000-0003-1256-7656					0	287	298	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2000	14	12					1677	1679						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973915				2022-12-25	WOS:000089212400005
J	Tan, NS; Ng, MLP; Yau, YH; Chong, PKW; Ho, B; Ding, JL				Tan, NS; Ng, MLP; Yau, YH; Chong, PKW; Ho, B; Ding, JL			Definition of endotoxin binding sites in horseshoe crab Factor C recombinant sushi proteins and neutralization of endotoxin by sushi peptides	FASEB JOURNAL			English	Article						Limulus ameboclyte lysate; lipid A; Drosophila S2 cells; LPS	SERINE-PROTEASE ZYMOGEN; LIPOPOLYSACCHARIDE (LPS)-BINDING PROTEIN; GRAM-NEGATIVE BACTERIA; INCREASING PROTEIN; LIPID-A; LIMULUS; HEMOCYTES; LPS; PERMEABILITY; PURIFICATION	Three truncated fragments, harboring different sushi domains, namely, sushi123, sushi1, and sushi3 domains, of Factor C were produced as biologically active secreted recombinant proteins. Sushil and 3 each has a high-affinity LPS binding site with K-d of 10(-9) to 10(-10) M. Positive cooperativity in sushi123 resulted in a 1000-fold increase in K(d)2. The core LPS binding region of sushi and 3 reside in two 34-mer peptides, S1 and S3. A rigidly held disulfide-bonded structure is not essential but is important for LPS binding, as confirmed by a 100- to 10000-fold decrease in affinity. Both SI and S3 can inhibit LAL reaction and LPS-induced hTNF-alpha secretion with different potency. LAL assay revealed that at least two molecules of S1 bind cooperatively to one LPS molecule, with Hill's coefficient of 2.42. The LPS binding by S3 is independent and noncooperative. The modified S Delta 1 and S Delta 3 peptides exhibited increased LPS neutralization potential although its LPS binding affinities indicated only a 10-fold improvement. Hence, the structural difference of the four sushi peptides conferred different efficiencies in LPS neutralization without altering their binding affinity for LPS. Circular dichroism spectrometry revealed that the four peptides underwent conformational change in the presence of lipid A, transitioning from a random coil to either an cu-helical or P-sheet structure. Two factors are critical for the sensitivity of Factor C to LPS: 1) the presence of multiple binding sites for LPS on a single Factor C molecule; and 2) high positive cooperativity in LPS binding. The results showed that in the design of an improved LPS binding and neutralizing peptide, charge balance of the peptide is a critical parameter in addition to its structure.	Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore; Natl Univ Singapore, Dept Microbiol, Singapore 117543, Singapore	National University of Singapore; National University of Singapore	Ding, JL (corresponding author), Natl Univ Singapore, Dept Biol Sci, 10 Kent Ridge Crescent, Singapore 117543, Singapore.		Hoe, YAU Yin/A-2817-2011; Ng, Patricia ML/B-3939-2008; Tan, Nguan Soon/A-2220-2011; Ding, Jeak/H-8057-2012	Hoe, YAU Yin/0000-0001-8136-2393; Ng, Patricia ML/0000-0001-5043-5596; Tan, Nguan Soon/0000-0003-0136-7341; 				CHEN CP, 1995, FEBS LETT, V370, P46, DOI 10.1016/0014-5793(95)00792-8; CORY AH, 1991, CANCER COMMUN, V3, P207, DOI 10.3727/095535491820873191; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; de Haas CJC, 1998, BIOCHEM BIOPH RES CO, V252, P492, DOI 10.1006/bbrc.1998.9675; Ding Jeak L., 1995, Molecular Marine Biology and Biotechnology, V4, P90; GALANOS C, 1979, P NATL ACAD SCI USA, V76, P5939, DOI 10.1073/pnas.76.11.5939; GAZZANOSANTORO H, 1994, INFECT IMMUN, V62, P1185, DOI 10.1128/IAI.62.4.1185-1191.1994; GRAY PW, 1989, J BIOL CHEM, V264, P9505; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; HAN JH, 1994, J BIOL CHEM, V269, P8172; Heinrichs DE, 1998, MOL MICROBIOL, V30, P221, DOI 10.1046/j.1365-2958.1998.01063.x; Hill A.V, 1910, J PHYSL, V40, piv, DOI DOI 10.1113/JPHYSIOL.1910.SP001386; Hong SY, 1998, ANTIMICROB AGENTS CH, V42, P2534, DOI 10.1128/AAC.42.10.2534; IWANAGA S, 1993, CURR OPIN IMMUNOL, V5, P74, DOI 10.1016/0952-7915(93)90084-6; IWANAGA S, 1992, THROMB RES, V68, P1, DOI 10.1016/0049-3848(92)90124-S; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Karima R, 1999, MOL MED TODAY, V5, P123, DOI 10.1016/S1357-4310(98)01430-0; MANNION BA, 1989, J IMMUNOL, V142, P2807; MINETTI CASA, 1991, J BIOL CHEM, V266, P20773; MORITA T, 1985, J BIOCHEM, V97, P1611, DOI 10.1093/oxfordjournals.jbchem.a135218; Muta T., 1996, Progress in Molecular and Subcellular Biology, V15, P154; MUTA T, 1991, J BIOL CHEM, V266, P6554; Myszka DG, 1998, TRENDS BIOCHEM SCI, V23, P149, DOI 10.1016/S0968-0004(98)01183-9; NAKAMURA T, 1988, J BIOCHEM, V103, P370, DOI 10.1093/oxfordjournals.jbchem.a122276; NAKAMURA T, 1986, EUR J BIOCHEM, V154, P511, DOI 10.1111/j.1432-1033.1986.tb09427.x; NAKAMURA T, 1988, EUR J BIOCHEM, V176, P89, DOI 10.1111/j.1432-1033.1988.tb14254.x; RISS TL, 1992, MOL BIOL CELL, V3, pA184; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Tan NS, 2000, FASEB J, V14, P859, DOI 10.1096/fasebj.14.7.859; TOBIAS PS, 1995, J BIOL CHEM, V270, P10482, DOI 10.1074/jbc.270.18.10482; TSUCHIYA S, 1982, CANCER RES, V42, P1530; VAARA M, 1985, ANTIMICROB AGENTS CH, V27, P548, DOI 10.1128/AAC.27.4.548; VAARA M, 1992, MICROBIOL REV, V56, P395, DOI 10.1128/MMBR.56.3.395-411.1992; ZAHRINGER U, 1994, ADV CARBOHYD CHEM BI, V50, P211, DOI 10.1016/S0065-2318(08)60152-3	35	88	105	1	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2000	14	12					1801	1813		10.1096/fj.99-0866com	http://dx.doi.org/10.1096/fj.99-0866com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973930				2022-12-25	WOS:000089212400020
J	Ekman, N; Arighi, E; Rajantie, I; Saharinen, P; Ristimaki, A; Silvennoinen, O; Alitalo, K				Ekman, N; Arighi, E; Rajantie, I; Saharinen, P; Ristimaki, A; Silvennoinen, O; Alitalo, K			The Bmx tyrosine kinase is activated by IL-3 and G-CSF in a PI-3K dependent manner	ONCOGENE			English	Article						Bmx; IL-3; G-CSF; PI-3K; differentiation; apoptosis	PLECKSTRIN HOMOLOGY DOMAIN; BRUTON TYROSINE; PHOSPHOINOSITIDE 3-KINASE; B-LYMPHOCYTES; PH-DOMAIN; RECEPTOR; TEC; BTK; CELLS; FAMILY	Cytoplasmic protein tyrosine kinases play crucial roles in signaling, ia a variety of cell surface receptors, The Bmx tyrosine kinase, a member of the Tec family, is expressed in hematopoietic cells of the granulocytic and monocytic lineages. Here we show that Bmx is catalytically activated by interleukin-3 (IL-3) and granulocyte-colony stimulating factor (G-CSF) receptors, Activation of Ems required phosphatidylinositol 3-kinase (PI-3K) as demonstrated by the ability of PI-3K inhibitors to block the activation signal. A green fluorescent protein (GFP) tagged Bmx nas translocated to cellular membranes upon co-expression of a constitutively active form of PI-3K, further indicating a role for PI-3K in signaling upstream of Ems. The expression of wild type Bmx in 32D myeloid progenitor cells resulted in apoptosis in the presence of G-CSF, while cells expressing a kinase dead mutant of Bmx differentiated into mature granulocytes. However, Bmx did not modulate IL-3-dependent proliferation of the cells. These results demonstrate distinct effects of Ems in cytokine induced proliferation and differentiation of myeloid cells, and suggest that the stage specific expression of Ems is critical for the differentiation of myeloid cells.	Univ Helsinki, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Ludwig Inst Canc Res, Haartman Inst, FIN-00014 Helsinki, Finland; Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Univ Helsinki, Haartman Inst, Dept Virol, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Obstet & Gynecol, Helsinki 00029, Finland; Tampere Univ, Tampere 33014, Finland	University of Helsinki; Ludwig Institute for Cancer Research; University of Helsinki; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Tampere University	Alitalo, K (corresponding author), Univ Helsinki, Mol Canc Biol Lab, POB 21,Haartmaninkatu 3, FIN-00014 Helsinki, Finland.		Saharinen, Pipsa I/C-9601-2016; Alitalo, Kari K/J-5013-2014	Saharinen, Pipsa I/0000-0003-2652-0584; Alitalo, Kari K/0000-0002-7331-0902				Anderson JS, 1996, P NATL ACAD SCI USA, V93, P10966, DOI 10.1073/pnas.93.20.10966; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; BOGGS DANE R., 1967, SEMINAR HEMATOL, V4, P359; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; de Groot RP, 1998, CELL SIGNAL, V10, P619, DOI 10.1016/S0898-6568(98)00023-0; Deng JB, 1998, J BIOL CHEM, V273, P16787, DOI 10.1074/jbc.273.27.16787; Dentelli P, 1999, J IMMUNOL, V163, P2151; DEWEERS M, 1993, EUR J IMMUNOL, V23, P3109, DOI 10.1002/eji.1830231210; Ekman N, 1997, CIRCULATION, V96, P1729, DOI 10.1161/01.CIR.96.6.1729; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; GIBSON S, 1993, BLOOD, V82, P1561; Hamazaki Y, 1998, ONCOGENE, V16, P2773, DOI 10.1038/sj.onc.1201799; Hunter MG, 1998, J IMMUNOL, V160, P4979; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Kaukonen J, 1996, BRIT J HAEMATOL, V94, P455; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; Kawakami Y, 1997, P NATL ACAD SCI USA, V94, P3938, DOI 10.1073/pnas.94.8.3938; Kojima T, 1997, BIOCHEM BIOPH RES CO, V236, P333, DOI 10.1006/bbrc.1997.6947; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; MANO H, 1990, ONCOGENE, V5, P1781; MANO H, 1993, ONCOGENE, V8, P417; Mano H, 1999, CYTOKINE GROWTH F R, V10, P267, DOI 10.1016/S1359-6101(99)00019-2; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; Migone TS, 1998, MOL CELL BIOL, V18, P6416, DOI 10.1128/MCB.18.11.6416; Miyajima A, 1999, INT J HEMATOL, V69, P137; Mohamed AJ, 1999, SCAND J IMMUNOL, V49, P113; MORISHITA K, 1987, J BIOL CHEM, V262, P3844; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nore BF, 2000, EUR J IMMUNOL, V30, P145, DOI 10.1002/1521-4141(200001)30:1<145::AID-IMMU145>3.0.CO;2-0; Okoh MP, 1999, BIOCHEM BIOPH RES CO, V265, P151, DOI 10.1006/bbrc.1999.1407; QUI Y, 1998, P NATL ACAD SCI USA, V95, P3644; Saharinen P, 1997, BLOOD, V90, P4341; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; Schaeffer EM, 1999, SCIENCE, V284, P638, DOI 10.1126/science.284.5414.638; SOMMERS CL, 1995, ONCOGENE, V11, P245; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; Tomlinson MG, 1999, J BIOL CHEM, V274, P13577, DOI 10.1074/jbc.274.19.13577; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; VALTIERI M, 1987, J IMMUNOL, V138, P3829; Varnai P, 1999, J BIOL CHEM, V274, P10983, DOI 10.1074/jbc.274.16.10983; Vassilev A, 1999, J BIOL CHEM, V274, P1646, DOI 10.1074/jbc.274.3.1646; Venkataraman C, 1998, J IMMUNOL, V160, P3322; Weil D, 1997, BLOOD, V90, P4332, DOI 10.1182/blood.V90.11.4332.4332_4332_4340; Wen X, 1999, J BIOL CHEM, V274, P38204, DOI 10.1074/jbc.274.53.38204; Xue LY, 1999, ONCOGENE, V18, P3391, DOI 10.1038/sj.onc.1202687	51	36	36	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2000	19	36					4151	4158		10.1038/sj.onc.1203763	http://dx.doi.org/10.1038/sj.onc.1203763			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962576				2022-12-25	WOS:000088955100009
J	Ladoux, A; Frelin, C				Ladoux, A; Frelin, C			Coordinated up-regulation by hypoxia of adrenomedullin and one of its putative receptors (RDC-1) in cells of the rat blood-brain barrier	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; HUMAN ERYTHROPOIETIN GENE; CYCLIC-AMP FORMATION; ADENYLATE-CYCLASE; TRANSCRIPTIONAL ACTIVATION; INDUCIBLE FACTOR-1; RESPONSE ELEMENTS; MESSENGER-RNA; BINDING-SITES; EXPRESSION	Adrenomedullin (ADM) is a potent hypotensive peptide, which is produced during sepsis and ischemia. We demonstrate here that hypoxia induced a time-dependent increase of both ADM mRNA and protein expressions in cultured astrocytes and endothelial cells from rat brain microvessels. Gene reporter analyses showed a 2-fold increase in ADM gene transcription which was suppressed when the ADM promoter was deleted of its hypoxia responsive element. Hypoxia increased 7-fold the stability of pre-formed ADM mRNAs. Rat brain microvessels expressed mRNAs coding for the different putative ADM receptors but they did not respond to exogenous ADM and calcitonin gene-related peptide by the formation of cAMP. In contrast, ADM and calcitonin gene-related peptide increased the formation of cAMP in astrocytes and their actions were potentiated about 2-fold after hypoxia. Messenger RNA species coding for three putative ADM receptors (the L1 orphan receptor, RDC-1, and calcitonin receptor-like receptor) and accessory proteins (receptor-activity modifying proteins) were present in astrocytes. Hypoxia selectively up-regulated expression of RDC-1 receptor mRNAs. The results indicate that ADM and RDC-1 are hypoxia-sensitive genes and that RDC-1 receptors may mediate some actions of ADM in hypoxic astrocytes.	CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Ladoux, A (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, 660 Route Lucioles, F-06560 Valbonne, France.		LADOUX, ANNIE/S-2077-2019; LADOUX, ANNIE/O-4267-2016	LADOUX, ANNIE/0000-0003-3857-2621; LADOUX, ANNIE/0000-0003-3857-2621				BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; BOZOU JC, 1986, MOL PHARMACOL, V29, P489; Chakravarty P, 2000, BRIT J PHARMACOL, V130, P189, DOI 10.1038/sj.bjp.0702975; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cormier-Regard S, 1998, J BIOL CHEM, V273, P17787, DOI 10.1074/jbc.273.28.17787; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; D'Angelo G, 2000, BIOCHEM BIOPH RES CO, V267, P334, DOI 10.1006/bbrc.1999.1947; DEHOUCK MP, 1990, J NEUROCHEM, V54, P1798, DOI 10.1111/j.1471-4159.1990.tb01236.x; Frayon S, 2000, BIOCHEM BIOPH RES CO, V270, P1063, DOI 10.1006/bbrc.2000.2552; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; Hinson JP, 2000, ENDOCR REV, V21, P138, DOI 10.1210/er.21.2.138; Hofbauer KH, 2000, AM J PHYSIOL-REG I, V278, pR513, DOI 10.1152/ajpregu.2000.278.2.R513; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; ISHIZAKA Y, 1994, BIOCHEM BIOPH RES CO, V200, P642, DOI 10.1006/bbrc.1994.1496; Kapas S, 1995, BIOCHEM BIOPH RES CO, V217, P832, DOI 10.1006/bbrc.1995.2847; KAPAS S, 1995, J BIOL CHEM, V270, P25344, DOI 10.1074/jbc.270.43.25344; Kennedy SP, 1998, BIOCHEM BIOPH RES CO, V244, P832, DOI 10.1006/bbrc.1998.8349; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; LADOUX A, 1991, BIOCHEM BIOPH RES CO, V180, P169, DOI 10.1016/S0006-291X(05)81271-9; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Moreno MJ, 1999, J CEREBR BLOOD F MET, V19, P1270, DOI 10.1097/00004647-199911000-00012; Nagata D, 1999, KIDNEY INT, V55, P1259, DOI 10.1046/j.1523-1755.1999.00361.x; Nakayama M, 1999, PEPTIDES, V20, P769, DOI 10.1016/S0196-9781(99)00061-3; Nakayama M, 1998, BIOCHEM BIOPH RES CO, V243, P514, DOI 10.1006/bbrc.1998.8131; Oliver KR, 1998, MOL BRAIN RES, V57, P149, DOI 10.1016/S0169-328X(98)00052-7; Ono Y, 1998, SHOCK, V10, P243, DOI 10.1097/00024382-199810000-00003; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; SHIMEKAKE Y, 1995, J BIOL CHEM, V270, P4412, DOI 10.1074/jbc.270.9.4412; Upton PD, 1997, ENDOCRINOLOGY, V138, P2508, DOI 10.1210/en.138.6.2508; VIGNE P, 1989, J BIOL CHEM, V264, P7663; VIGNE P, 1994, J NEUROCHEM, V62, P2269; Wang G L, 1996, Curr Opin Hematol, V3, P156; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WANG XK, 1995, P NATL ACAD SCI USA, V92, P11480, DOI 10.1073/pnas.92.25.11480; Webb TE, 1996, BRIT J PHARMACOL, V119, P1385, DOI 10.1111/j.1476-5381.1996.tb16050.x; Yoshitomi Y, 1998, CLIN SCI, V94, P135, DOI 10.1042/cs0940135; Zhou M, 1999, BBA-MOL BASIS DIS, V1453, P273, DOI 10.1016/S0925-4439(98)00111-2; Zimmermann U, 1996, BRAIN RES, V724, P238, DOI 10.1016/0006-8993(96)00337-X	44	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39914	39919		10.1074/jbc.M006512200	http://dx.doi.org/10.1074/jbc.M006512200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10980200				2022-12-25	WOS:000166039500019
J	Abdulaev, NG; Ngo, T; Chen, RW; Lu, ZJ; Ridge, KD				Abdulaev, NG; Ngo, T; Chen, RW; Lu, ZJ; Ridge, KD			Functionally discrete mimics of light-activated rhodopsin identified through expression of soluble cytoplasmic domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; C-TERMINAL PEPTIDES; CONNECTING HELIX-C; F LOOP REGION; ESCHERICHIA-COLI; BOVINE RHODOPSIN; DEPENDENT PHOSPHORYLATION; CONSTITUTIVE ACTIVATION; CONFORMATIONAL-CHANGES; TRANSDUCIN ACTIVATION	Numerous studies on the seven-helix receptor rhodopsin have implicated the cytoplasmic loops and carboxyl-terminal region in the binding and activation of proteins involved in visual transduction and desensitization. In our continuing studies on rhodopsin folding, assembly, and structure, we have attempted to reconstruct the interacting surface(s) for these proteins by inserting fragments corresponding to the cytoplasmic loops and/or the carboxyl-terminal tail of bovine opsin either singly, or in combination, onto a surface loop in thioredoxin. The purpose of the thioredoxin fusion is to provide a soluble scaffold for the cytoplasmic fragments thereby allowing them sufficient conformational freedom to fold to a structure that mimics the protein-binding sites on light-activated rhodopsin. All of the fusion proteins are expressed to relatively high levels in Escherichia coli and can be purified using a two- or three-step chromatography procedure. Biochemical studies show that some of the fusion proteins effectively mimic the activated conformation(s) of rhodopsin in stimulating G-protein or competing with the light-activated rhodopsin/G-protein interaction, in supporting phosphorylation of the carboxyl-terminal opsin fragment by rhodopsin kinase, and/or phosphopeptide-stimulated arrestin binding. These results suggest that specific segments of the cytoplasmic surface of rhodopsin can adopt functionally discrete conformations in the absence of the connecting transmembrane helices and retinal chromophore.	NIST, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; Univ Maryland, Inst Biotechnol, Rockville, MD 20850 USA; Genet Inst Inc, Cambridge, MA 02140 USA	National Institute of Standards & Technology (NIST) - USA; University System of Maryland; University of Maryland Baltimore	Ridge, KD (corresponding author), NIST, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA.				NATIONAL EYE INSTITUTE [R55EY011112, R29EY011112] Funding Source: NIH RePORTER; NEI NIH HHS [EY11112] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abdulaev NG, 1998, P NATL ACAD SCI USA, V95, P12854, DOI 10.1073/pnas.95.22.12854; Acharya S, 1997, J BIOL CHEM, V272, P6519, DOI 10.1074/jbc.272.10.6519; Acharya S, 1996, J BIOL CHEM, V271, P25406, DOI 10.1074/jbc.271.41.25406; Altenbach C, 1999, BIOCHEMISTRY-US, V38, P7931, DOI 10.1021/bi9900121; Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; Altenbach C, 1999, BIOCHEMISTRY-US, V38, P7945, DOI 10.1021/bi990014l; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; BHATTACHARYA S, 1992, J BIOL CHEM, V267, P6763; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BROWN NG, 1992, EUR J BIOCHEM, V208, P659, DOI 10.1111/j.1432-1033.1992.tb17232.x; Cai KW, 1999, BIOCHEMISTRY-US, V38, P7925, DOI 10.1021/bi9900119; Chen GQ, 1998, PROTEIN SCI, V7, P2623, DOI 10.1002/pro.5560071216; CHEUNG AH, 1991, FEBS LETT, V279, P277, DOI 10.1016/0014-5793(91)80167-2; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; DONOSO LA, 1990, CURR EYE RES, V9, P343, DOI 10.3109/02713689008999622; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; FARAHBAKHSH ZT, 1993, SCIENCE, V262, P1416, DOI 10.1126/science.8248781; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; Frayser M, 1999, PROTEIN EXPRES PURIF, V15, P105, DOI 10.1006/prep.1998.0987; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; GUY PM, 1990, BIOCHEMISTRY-US, V29, P6954, DOI 10.1021/bi00482a003; Han M, 1998, BIOCHEMISTRY-US, V37, P8253, DOI 10.1021/bi980147r; HAWES BE, 1994, J BIOL CHEM, V269, P15776; Herzyk P, 1998, J MOL BIOL, V281, P741, DOI 10.1006/jmbi.1998.1981; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HOFMANN KP, 1999, RHODOPSINS PHOTOTRAN, P158; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; KELLEHER DJ, 1990, J BIOL CHEM, V265, P2632; Kim JM, 1997, P NATL ACAD SCI USA, V94, P14273, DOI 10.1073/pnas.94.26.14273; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KRUPNICK JG, 1994, J BIOL CHEM, V269, P3226; KUHN H, 1982, BIOCHIM BIOPHYS ACTA, V679, P95, DOI 10.1016/0005-2728(82)90259-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; LI TS, 1995, P NATL ACAD SCI USA, V92, P3551, DOI 10.1073/pnas.92.8.3551; Lu ZJ, 1996, J BIOL CHEM, V271, P5059; MAO QC, 1995, J BIOL CHEM, V270, P18295, DOI 10.1074/jbc.270.31.18295; Marin EP, 2000, J BIOL CHEM, V275, P1930, DOI 10.1074/jbc.275.3.1930; McDowell JH, 1999, BIOCHEMISTRY-US, V38, P6119, DOI 10.1021/bi990175p; Melia TJ, 1997, BIOPHYS J, V73, P3182, DOI 10.1016/S0006-3495(97)78344-9; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MIN KC, 1993, J BIOL CHEM, V268, P9400; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1988, BIOCHEMISTRY-US, V27, P2306, DOI 10.1021/bi00407a010; PAULSEN R, 1983, NATURE, V302, P417, DOI 10.1038/302417a0; PELLICONE C, 1985, BIOCHEM BIOPH RES CO, V127, P816, DOI 10.1016/S0006-291X(85)80016-4; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Pogozheva ID, 1997, BIOPHYS J, V72, P1963, DOI 10.1016/S0006-3495(97)78842-8; PUIG J, 1995, FEBS LETT, V362, P185, DOI 10.1016/0014-5793(95)00225-X; Raman D, 1999, BIOCHEMISTRY-US, V38, P5117, DOI 10.1021/bi9824588; Rao VR, 1996, ANNU REV BIOPH BIOM, V25, P287; RESEK JF, 1993, BIOCHEMISTRY-US, V32, P12025, DOI 10.1021/bi00096a012; RIDGE KD, 1995, BIOCHEMISTRY-US, V34, P8804, DOI 10.1021/bi00027a032; Ridge KD, 1996, J BIOL CHEM, V271, P7860, DOI 10.1074/jbc.271.13.7860; RIDGE KD, 1995, P NATL ACAD SCI USA, V92, P3204, DOI 10.1073/pnas.92.8.3204; Ridge KD, 1999, J BIOL CHEM, V274, P21437, DOI 10.1074/jbc.274.30.21437; RIM J, 1995, BIOCHEMISTRY-US, V34, P11938, DOI 10.1021/bi00037a035; Rim J, 1997, BIOCHEMISTRY-US, V36, P7064, DOI 10.1021/bi970470e; ROBINSON PR, 1994, P NATL ACAD SCI USA, V91, P5411, DOI 10.1073/pnas.91.12.5411; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5467; SHI W, 1995, J BIOL CHEM, V270, P2112, DOI 10.1074/jbc.270.5.2112; Shi W, 1998, BIOCHEMISTRY-US, V37, P4869, DOI 10.1021/bi9731100; Struthers M, 1999, BIOCHEMISTRY-US, V38, P6597, DOI 10.1021/bi9902384; SURYA A, 1995, J BIOL CHEM, V270, P5024, DOI 10.1074/jbc.270.10.5024; TAKEMOTO DJ, 1986, BIOCHEM J, V235, P309, DOI 10.1042/bj2350309; Thurmond RL, 1997, P NATL ACAD SCI USA, V94, P1715, DOI 10.1073/pnas.94.5.1715; WAKAMATSU K, 1992, BIOCHEMISTRY-US, V31, P5654, DOI 10.1021/bi00139a032; WEISS ER, 1988, J BIOL CHEM, V263, P6150; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3967; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; Yang K, 1996, BIOCHEMISTRY-US, V35, P12464, DOI 10.1021/bi960848t; Yeagle PL, 1997, BIOCHEMISTRY-US, V36, P9649, DOI 10.1021/bi970908a; YEAGLE PL, 1995, BIOCHEMISTRY-US, V34, P14621, DOI 10.1021/bi00045a002; YEAGLE PL, 1995, NAT STRUCT BIOL, V2, P832, DOI 10.1038/nsb1095-832; Yeagle PL, 1997, BIOCHEMISTRY-US, V36, P3864, DOI 10.1021/bi962403a; YEAGLE PL, 1996, MOL VISION, V2; Yu HB, 1999, BIOCHEMISTRY-US, V38, P12033, DOI 10.1021/bi9909492; YU HB, 1995, BIOCHEMISTRY-US, V34, P14963, DOI 10.1021/bi00046a002	89	36	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39354	39363		10.1074/jbc.M005642200	http://dx.doi.org/10.1074/jbc.M005642200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10988291	hybrid			2022-12-25	WOS:000165953100058
J	Dinchuk, JE; Henderson, NL; Burn, TC; Huber, R; Ho, SP; Link, J; O'Neil, KT; Focht, RJ; Scully, MS; Hollis, JM; Hollis, GF; Friedman, PA				Dinchuk, JE; Henderson, NL; Burn, TC; Huber, R; Ho, SP; Link, J; O'Neil, KT; Focht, RJ; Scully, MS; Hollis, JM; Hollis, GF; Friedman, PA			Aspartyl beta-hydroxylase (Asph) and an evolutionarily conserved isoform of Asph missing the catalytic domain share exons with junctin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-LIKE MODULES; SARCOPLASMIC-RETICULUM; CALCIUM-BINDING; SPLICE VARIANT; FACTOR-IX; GROWTH; RECEPTOR; PROTEIN; IDENTIFICATION; CLONING	The mouse aspartyl beta -hydroxylase gene (Asph, BAH) has been cloned and characterized, The mouse BAH gene spans 200 kilobase pairs of genomic DNA and contains 24 exons. Of three major BAH-related transcripts, the two largest (6,629 and 4,419 base pairs) encode full-length protein and differ only in the use of alternative polyadenylation signals. The smallest BAH-related transcript (2,789 base pairs) uses an alternative 3' terminal exon, resulting in a protein lacking a catalytic domain. Evolutionary conservation of this noncatalytic isoform of BAH (humbug) is demonstrated in mouse, man, and Drosophila, Monoclonal antibody reagents were generated, epitope-mapped, and used to definitively correlate RNA bands on Northern blots with protein species on Western blots, The gene for mouse junctin, a calsequestrin-binding protein, was cloned and characterized and shown to be encoded from the same locus, When expressed in heart tissue, BAH/humbug; preferably use the first exon and often the fourth exon of junctin while preserving the reading frame. Thus, three individual genes share common exons and open reading frames and use separate promoters to achieve differential expression, splicing, and function in a variety of tissues, This unusual form of exon sharing suggests that the functions of junctin, BAH, and humbug may be linked.	Dupont Merck Pharmaceut Co, Expt Stn, Dept Appl Biotechnol, Wilmington, DE 19880 USA; Dupont Merck Pharmaceut Co, Expt Stn, Dept Cent Nervous Syst Dis Res, Wilmington, DE 19880 USA; Dupont Merck Pharmaceut Co, Expt Stn, DuPont Pharmaceut Res Labs, Wilmington, DE 19880 USA	DuPont; DuPont; DuPont	Dinchuk, JE (corresponding author), Dupont Merck Pharmaceut Co, Expt Stn, Dept Appl Biotechnol, E400-5446, Wilmington, DE 19880 USA.	joseph.e.dinchuk@dupontpharma.com		Burn, Timothy/0000-0001-6648-4333				Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; DAVIS C G, 1990, New Biologist, V2, P410; Doherty JK, 1999, P NATL ACAD SCI USA, V96, P10869, DOI 10.1073/pnas.96.19.10869; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Goruppi S, 1997, FEBS LETT, V415, P59, DOI 10.1016/S0014-5793(97)01093-4; Harlow E., 1988, ANTIBODIES LAB MANUA; Ho SP, 1996, NUCLEIC ACIDS RES, V24, P1901, DOI 10.1093/nar/24.10.1901; Ince N, 2000, CANCER RES, V60, P1261; JIA S, 1994, P NATL ACAD SCI USA, V91, P7227, DOI 10.1073/pnas.91.15.7227; JIA S, 1992, J BIOL CHEM, V267, P14322; Jones LR, 1995, J BIOL CHEM, V270, P30787, DOI 10.1074/jbc.270.51.30787; KORIOTH F, 1994, GENE, V150, P395, DOI 10.1016/0378-1119(94)90460-X; Lavaissiere L, 1996, J CLIN INVEST, V98, P1313, DOI 10.1172/JCI118918; McGinnis K, 1996, BIOCHEMISTRY-US, V35, P3957, DOI 10.1021/bi951520n; MONKOVIC DD, 1992, BIOCHEM BIOPH RES CO, V189, P233, DOI 10.1016/0006-291X(92)91549-6; Nagano K, 1999, J BIOL CHEM, V274, P2872, DOI 10.1074/jbc.274.5.2872; Nakamura T, 1999, J BIOL CHEM, V274, P22476, DOI 10.1074/jbc.274.32.22476; ONEIL KT, 1992, PROTEINS, V14, P509, DOI 10.1002/prot.340140411; POVINELLI CM, 1993, ANAL BIOCHEM, V210, P16, DOI 10.1006/abio.1993.1144; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; Ross RJM, 1997, MOL ENDOCRINOL, V11, P265, DOI 10.1210/me.11.3.265; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCOTT GK, 1993, MOL CELL BIOL, V13, P2247, DOI 10.1128/MCB.13.4.2247; STENFLO J, 1991, BLOOD, V78, P1637; Sun BS, 1998, HEPATOLOGY, V27, P228, DOI 10.1002/hep.510270135; SUNNERHAGEN MS, 1993, J BIOL CHEM, V268, P23339; WANG QP, 1991, J BIOL CHEM, V266, P14004; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389	31	80	92	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39543	39554		10.1074/jbc.M006753200	http://dx.doi.org/10.1074/jbc.M006753200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10956665	hybrid			2022-12-25	WOS:000165953100081
J	Hatley, ME; Benton, BK; Xu, J; Manfredi, JP; Gilman, AG; Sunahara, RK				Hatley, ME; Benton, BK; Xu, J; Manfredi, JP; Gilman, AG; Sunahara, RK			Isolation and characterization of constitutively active mutants of mammalian adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC MECHANISM; GUANYLYL CYCLASES; CYTOSOLIC DOMAINS; CRYSTAL-STRUCTURE; POLYMERASE-I; FORSKOLIN; COMPLEX; CONSTRUCTION; G(S-ALPHA)	A genetic screen in Saccharomyces cerevisiae identified mutations in mammalian adenylyl cyclase that activate the enzyme in the absence of G(s)alpha. Thirteen of these mutant proteins were characterized biochemically in an assay system that depends on a mixture of the two cytosolic domains (C-1 and C-2) of mammalian adenylyl cyclases. Three mutations, I1010M, K1014N, and P1015Q located in the beta4-beta5 loop of the C-2 domain of type Il adenylyl cyclase, increase enzymatic activity in the absence of activators. The K1014N mutation displays both increased maximal activity and apparent affinity for the C-2 domain of type II adenylyl cyclase in the absence of activators of the enzyme. The increased affinity of the mutant C-2 domain of adenylyl cyclase for the wild type C-1 domain was exploited to isolate a complex containing VC1, IIC2, and G(s)alpha -guanosine 5'-3-O-(thio)triphosphate (GTP gammaS) in the absence of forskolin and a complex of VC1, IIC2, forskolin, and P-site inhibitor in the absence of G(s)alpha -GTP gammaS. The isolation of these complexes should facilitate solution of crystal structures of low activity states of adenylyl cyclase and thus determination of the mechanism of activation of the enzyme by forskolin and G(s)alpha.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Cadus Pharmaceut Corp, New York, NY 10153 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gilman, AG (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Sunahara, Roger/AAJ-8667-2020; Hatley, Mark Edward/G-8764-2018	Hatley, Mark Edward/0000-0001-7147-3946	NIGMS NIH HHS [GM34497] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Artymiuk PJ, 1997, NATURE, V388, P33, DOI 10.1038/40310; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CLARKE L, 1980, NATURE, V287, P504, DOI 10.1038/287504a0; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LEE E, 1994, METHOD ENZYMOL, V237, P146; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Liu Y, 1997, P NATL ACAD SCI USA, V94, P13414, DOI 10.1073/pnas.94.25.13414; LONDOS C, 1977, P NATL ACAD SCI USA, V74, P5482, DOI 10.1073/pnas.74.12.5482; Rose MD., 1990, METHODS YEAST GENETI; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; Smit Martine J., 1998, Advances in Second Messenger and Phosphoprotein Research, V32, P1; Sunahara RK, 1998, J BIOL CHEM, V273, P16332, DOI 10.1074/jbc.273.26.16332; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941; Yan SZ, 1997, J BIOL CHEM, V272, P12342, DOI 10.1074/jbc.272.19.12342; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0; Zimmermann G, 1999, MOL PHARMACOL, V56, P895, DOI 10.1124/mol.56.5.895; Zimmermann G, 1998, J BIOL CHEM, V273, P6968, DOI 10.1074/jbc.273.12.6968; Zimmermann G, 1998, J BIOL CHEM, V273, P19650, DOI 10.1074/jbc.273.31.19650	29	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38626	38632		10.1074/jbc.M007148200	http://dx.doi.org/10.1074/jbc.M007148200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10982815	hybrid			2022-12-25	WOS:000165739800066
J	Morikawa, W; Yamamoto, K; Ishikawa, S; Takemoto, S; Ono, M; Fukushi, J; Naito, S; Nozaki, C; Iwanaga, S; Kuwano, M				Morikawa, W; Yamamoto, K; Ishikawa, S; Takemoto, S; Ono, M; Fukushi, J; Naito, S; Nozaki, C; Iwanaga, S; Kuwano, M			Angiostatin generation by cathepsin D secreted by human prostate carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; PROCATHEPSIN-D ACTIVATION; LEWIS-LUNG-CARCINOMA; ANGIOGENESIS INHIBITOR; PROTON-PUMP; ENDOTHELIAL-CELLS; HUMAN PLASMINOGEN; BONE-RESORPTION; TUMOR-GROWTH; PROTEOLYSIS	Angiostatin, a potent endogenous inhibitor of angiogenesis, is generated by cancer-mediated proteolysis of plasminogen. The culture medium of human prostate carcinoma cells, when incubated with plasminogen at a variety of pH values, generated angiostatic peptides and miniplasminogen. The enzyme(s) responsible for this reaction was purified and identified as procathepsin D. The purified procathepsin D, as well as cathepsin D, generated two angiostatic peptides having the same NH2-terminal amino acid sequences and comprising kringles 1-4 of plasminogen in the pH range of 3.0-6.8, most strongly at pH 4.0 in vitro. This reaction required the concomitant conversion of procathepsin D to catalytically active pseudocathepsin D. The conversion of pseudocathepsin D to the mature cathepsin D was not observed by the prolonged incubation. The affinity-purified angiostatic peptides inhibited angiogenesis both in vitro and in vivo. Importantly, procathepsin D secreted by human breast carcinoma cells showed a significantly lower angiostatin-generating activity than that by human prostate carcinoma cells. Since deglycosylated procathepsin D from both prostate and breast carcinoma cells exhibited a similar low angiostatin-generating activity, this discrepancy appeared to be attributed to the difference in carbohydrate structures of procathepsin D molecules between the two cell types. The seminal vesicle fluid from patients with prostate carcinoma contained the mature cathepsin D and procathepsin D, but not pseudocathepsin D, suggesting that pseudocathepsin D is not a normal intermediate of procathepsin D processing in vivo. The present study provides evidence for the first time that cathepsin D secreted by human prostate carcinoma cells is responsible for angiostatin generation, thereby causing the prevention of tumor growth and angiogenesis-dependent growth of metastases.	Kyushu Univ, Fac Dent, Dept Pharmacol, Higashi Ku, Fukuoka 8128582, Japan; Kikuchi Res Ctr, Chemoserotherapeut Res Inst, Kumamoto 8691298, Japan; Kyushu Univ, Dept Biochem Med, Grad Sch Med Sci, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Dept Urol, Grad Sch Med Sci, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University; Kyushu University; Kyushu University	Yamamoto, K (corresponding author), Kyushu Univ, Fac Dent, Dept Pharmacol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	kyama@dent.kyushu-u.ac.jp						AKISAKA T, 1986, CELL TISSUE RES, V245, P507; BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; BRIOZZO P, 1988, CANCER RES, V48, P3688; Cao YH, 1997, J BIOL CHEM, V272, P22924, DOI 10.1074/jbc.272.36.22924; Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; CAPONY F, 1989, CANCER RES, V49, P3904; CAVAILLES V, 1993, P NATL ACAD SCI USA, V90, P203, DOI 10.1073/pnas.90.1.203; CHEN C, 1995, CANCER RES, V55, P4230; CONNER GE, 1992, BIOCHEMISTRY-US, V31, P1142, DOI 10.1021/bi00119a024; CONNER GE, 1989, BIOCHEM J, V263, P601, DOI 10.1042/bj2630601; DAS B, 1994, J EXP MED, V180, P273, DOI 10.1084/jem.180.1.273; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; EMMERTBUCK MR, 1994, AM J PATHOL, V145, P1285; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; FOLKMAN J, 1971, J EXP MED, V133, P275, DOI 10.1084/jem.133.2.275; FRIBERGER P, 1978, HAEMOSTASIS, V7, P138; Gately S, 1996, CANCER RES, V56, P4887; Gately S, 1997, P NATL ACAD SCI USA, V94, P10868, DOI 10.1073/pnas.94.20.10868; HASILIK A, 1982, EUR J BIOCHEM, V125, P317, DOI 10.1111/j.1432-1033.1982.tb06685.x; Ji WR, 1998, BIOCHEM BIOPH RES CO, V247, P414, DOI 10.1006/bbrc.1998.8825; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; KWAAN HC, 1992, CANCER METAST REV, V11, P291, DOI 10.1007/BF01307184; LARSEN LB, 1993, FEBS LETT, V319, P54, DOI 10.1016/0014-5793(93)80036-T; Lijnen HR, 1998, BIOCHEMISTRY-US, V37, P4699, DOI 10.1021/bi9731798; MacDonald N., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P46; Martinez-Zaguilan R, 1998, J CELL PHYSIOL, V176, P196, DOI 10.1002/(SICI)1097-4652(199807)176:1<196::AID-JCP21>3.0.CO;2-4; MAWATARI M, 1989, J IMMUNOL, V143, P1619; Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811; O'Reilly MS, 1999, J BIOL CHEM, V274, P29568, DOI 10.1074/jbc.274.41.29568; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Patterson BC, 1997, J BIOL CHEM, V272, P28823, DOI 10.1074/jbc.272.46.28823; RICHO GR, 1994, J BIOL CHEM, V269, P14806; SAMAREL AM, 1986, AM J PHYSIOL, V250, pC589, DOI 10.1152/ajpcell.1986.250.4.C589; Sim BKL, 1997, CANCER RES, V57, P1329; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; Stathakis P, 1997, J BIOL CHEM, V272, P20641, DOI 10.1074/jbc.272.33.20641; Stathakis P, 1999, J BIOL CHEM, V274, P8910, DOI 10.1074/jbc.274.13.8910; VAANANEN HK, 1990, J CELL BIOL, V111, P1305, DOI 10.1083/jcb.111.3.1305; VACLAV V, 1995, ARCH BIOCHEM BIOPHYS, V322, P295, DOI 10.1006/abbi.1995.1466; VIGNON F, 1986, ENDOCRINOLOGY, V118, P1537, DOI 10.1210/endo-118-4-1537; WESTLEY BR, 1987, NUCLEIC ACIDS RES, V15, P3773, DOI 10.1093/nar/15.9.3773; Wu ZG, 1997, BIOCHEM BIOPH RES CO, V236, P651, DOI 10.1006/bbrc.1997.7032; YAMAMOTO K, 1984, BIOCHIM BIOPHYS ACTA, V790, P208, DOI 10.1016/0167-4838(84)90024-4	47	73	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38912	38920		10.1074/jbc.M005402200	http://dx.doi.org/10.1074/jbc.M005402200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10986284	hybrid			2022-12-25	WOS:000165739800105
J	Taylor, SW; Craig, AG; Fischer, WH; Park, M; Lehrer, RI				Taylor, SW; Craig, AG; Fischer, WH; Park, M; Lehrer, RI			Styelin D, an extensively modified antimicrobial peptide from ascidian hemocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIONA-INTESTINALIS; BLOOD-CELLS; HALOCYNTHIA-RORETZI; IN-VITRO; TUNICATE HEMOCYTES; CYTOTOXIC ACTIVITY; SOLITARY TUNICATE; ESCHERICHIA-COLI; CARCINUS-MAENAS; MYTILUS-EDULIS	We isolated styelin D, a 32-residue, C-terminally amidated antimicrobial peptide, from the blood cells (hemocytes) of the solitary ascidian, Styela clava, Styelin D had remarkably extensive post-translational modifications, containing two novel amino acids, dihydroxyarginine and dihydroxylysine, and two distinctly unusual ones, 6-bromotryptophan and 3,4-dihydroxyphenylalanine. In addition, the peptide exhibited microheterogeneity because of differential mono- and dihydroxylation of several lysine residues. The primary sequence of one variant was: GW*LR**K**AAK**SVGK**FY*Y*K**HK*Y* Y*IK*AAWQIGKHAL-NH2, where W* is 6-bromotryptophan, R** is dihydroxyarginine, Y* is 3,4-dihydroxyphenylalanine, K* is B-hydroxylysine, and K** is dihydroxylysine, Styelin D exhibited activity against Gram-negative and Gram-positive bacteria, and this activity was retained in 200 mM NaCl, The role of the extensive modifications may be to preserve activity at low pH and/or high salinity because, under these conditions, the native peptide was considerably more active against the Gram-positive bacterial strains than its unmodified synthetic analogue. The peptide was also hemolytic and quite cytotoxic to eukaryotic cells. These broad ranging activities, combined with its relative abundance in ascidian hemocytes, suggest that styelin D plays a significant role in the innate immune mechanisms of S. clava.	Univ Calif San Diego, Scripps Inst Oceanog, Ctr Marine Biotechnol & Biomed, La Jolla, CA 92093 USA; Salk Inst, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90095 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography; Salk Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Taylor, SW (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, Ctr Marine Biotechnol & Biomed, La Jolla, CA 92093 USA.							AGUDELO MI, 1983, COMP BIOCHEM PHYS A, V75, P211, DOI 10.1016/0300-9629(83)90072-5; Arizza V, 1997, J MAR BIOTECHNOL, V5, P31; AZUMI K, 1990, BIOCHEMISTRY-US, V29, P159, DOI 10.1021/bi00453a021; AZUMI K, 1991, DEV COMP IMMUNOL, V15, P1, DOI 10.1016/0145-305X(91)90041-V; AZUMI K, 1990, EXPERIENTIA, V46, P1066, DOI 10.1007/BF01940675; AZUMI K, 1991, DEV COMP IMMUNOL, V15, P9, DOI 10.1016/0145-305X(91)90042-W; BALDWIN JE, 1993, TETRAHEDRON LETT, V34, P5645, DOI 10.1016/S0040-4039(00)73905-0; Ballarin L, 1998, DEV COMP IMMUNOL, V22, P479, DOI 10.1016/S0145-305X(98)00035-4; Beaven AE, 1999, BIOL BULL-US, V196, P26, DOI 10.2307/1543163; Bechinger B, 1997, J MEMBRANE BIOL, V156, P197, DOI 10.1007/s002329900201; Cammarata M, 1997, EUR J CELL BIOL, V74, P302; Charlet M, 1996, J BIOL CHEM, V271, P21808, DOI 10.1074/jbc.271.36.21808; Craig AG, 1997, J BIOL CHEM, V272, P4689, DOI 10.1074/jbc.272.8.4689; DELEO G, 1992, B ZOOL, V59, P195, DOI 10.1080/11250009209386669; DeLeo G, 1997, J INVERTEBR PATHOL, V69, P14, DOI 10.1006/jipa.1996.4621; Destoumieux D, 1997, J BIOL CHEM, V272, P28398, DOI 10.1074/jbc.272.45.28398; DORSETT LC, 1987, BIOCHEMISTRY-US, V26, P8078, DOI 10.1021/bi00399a009; Euli D, 1999, J CHROMATOGR B, V724, P373, DOI 10.1016/S0378-4347(98)00539-8; FRANK H, 1978, J CHROMATOGR, V167, P187, DOI 10.1016/S0021-9673(00)91157-9; Frank P, 1998, J BIOL CHEM, V273, P24498, DOI 10.1074/jbc.273.38.24498; FUKE MT, 1980, BIOL BULL, V158, P305; Hackam DJ, 1997, J BIOL CHEM, V272, P29810, DOI 10.1074/jbc.272.47.29810; Hata S, 1998, COMP BIOCHEM PHYS B, V119, P769, DOI 10.1016/S0305-0491(98)00054-6; HAWKINS CJ, 1983, COMP BIOCHEM PHYS B, V76, P559, DOI 10.1016/0305-0491(83)90293-6; IWANAGA S, 1994, CIBA F SYMP, V186, P160; Jimenez EC, 1997, BIOCHEMISTRY-US, V36, P989, DOI 10.1021/bi962840p; KELLY KL, 1992, J EXP ZOOL, V262, P202, DOI 10.1002/jez.1402620210; Lee IH, 1997, COMP BIOCHEM PHYS B, V118, P515, DOI 10.1016/S0305-0491(97)00109-0; Lee IH, 1997, INFECT IMMUN, V65, P2898, DOI 10.1128/IAI.65.7.2898-2903.1997; Lee IH, 1997, FEBS LETT, V400, P158, DOI 10.1016/S0014-5793(96)01374-9; LEE JY, 1989, P NATL ACAD SCI USA, V86, P9159, DOI 10.1073/pnas.86.23.9159; LEHRER RI, 1988, J IMMUNOL METHODS, V108, P153, DOI 10.1016/0022-1759(88)90414-0; LEHRER RI, 1989, J CLIN INVEST, V84, P553, DOI 10.1172/JCI114198; LEIMER KR, 1977, J CHROMATOGR, V141, P121, DOI 10.1016/S0021-9673(00)99131-3; PAPOV VV, 1995, J BIOL CHEM, V270, P20183, DOI 10.1074/jbc.270.34.20183; Parrinello N, 1996, BIOL BULL, V190, P418, DOI 10.2307/1543035; PEDDIE CM, 1994, J EXP ZOOL, V270, P335, DOI 10.1002/jez.1402700402; PEDDIE CM, 1993, J EXP ZOOL, V267, P616, DOI 10.1002/jez.1402670609; POSTELS HT, 1994, TETRAHEDRON LETT, V35, P535; Raftos DA, 1995, DEV COMP IMMUNOL, V19, P463, DOI 10.1016/0145-305X(95)00028-R; Reddy MVR, 1998, TETRAHEDRON, V54, P10649; Relf JM, 1999, EUR J BIOCHEM, V264, P350, DOI 10.1046/j.1432-1327.1999.00607.x; Schnapp D, 1996, EUR J BIOCHEM, V240, P532, DOI 10.1111/j.1432-1033.1996.0532h.x; SCIPPA S, 1985, ACTA EMBRYOL MORPHOL, V6, P285; Shinnar A.E., 1996, P 14 PEPT AM S COL O, P189; Steinbeg Deborah A., 1997, V78, P169; Taylor SW, 1995, ARCH BIOCHEM BIOPHYS, V324, P228, DOI 10.1006/abbi.1995.0035; Taylor SW, 1997, ARCH BIOCHEM BIOPHYS, V348, P278, DOI 10.1006/abbi.1997.0371; Tincu JA, 2000, BIOCHEM BIOPH RES CO, V270, P421, DOI 10.1006/bbrc.2000.2449; TSUGITA A, 1987, J BIOCH, V102, P1592; Vervoort H, 2000, J ORG CHEM, V65, P782, DOI 10.1021/jo991425a; Watters Diane, 1993, Molecular Marine Biology and Biotechnology, V2, P28; Zhao CQ, 1997, FEBS LETT, V410, P490, DOI 10.1016/S0014-5793(97)00646-7; Zhao CQ, 1997, FEBS LETT, V412, P144, DOI 10.1016/S0014-5793(97)00769-2	54	83	91	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38417	38426		10.1074/jbc.M006762200	http://dx.doi.org/10.1074/jbc.M006762200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10978343	hybrid			2022-12-25	WOS:000165739800039
J	Barrantes, FJ; Antollini, SS; Blanton, MP; Prieto, M				Barrantes, FJ; Antollini, SS; Blanton, MP; Prieto, M			Topography of nicotinic acetylcholine receptor membrane-embedded domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MARMORATA ELECTRIC ORGAN; ACYL CHAIN-LENGTH; ALPHA-SUBUNIT; TORPEDO-MARMORATA; TRANSMEMBRANE SEGMENT; TRANSVERSE LOCATION; SPATIAL STRUCTURE; LIPID BILAYERS; FLUORESCENCE; PROTEIN	The topography of nicotinic acetylcholine receptor (AChR) membrane-embedded domains and the relative affinity of lipids for these protein regions were studied using fluorescence methods. Intact Torpedo californica AChR protein and transmembrane peptides were derivatized with N-(1-pyrenyl)maleimide (PM), purified, and reconstituted into asolectin liposomes, Fluorescence mapped to proteolytic fragments consistent with PM labeling of cysteine residues in alpha M1, alpha M4, gamma M1, and gamma M4. The topography of the pyrene-labeled Cys residues with respect to the membrane and the apparent affinity for representative lipids were determined by differential fluorescence quenching with spin-labeled derivatives of fatty acids, phosphatidylcholine, and the steroids cholestane and androstane, Different spin label lipid analogs exhibit different selectivity for the whole AChR protein and its transmembrane domains. In all cases labeled residues were found to lie in a shallow position, For M4 segments, this is compatible with a linear alpha -helical structure, but not so for M1, for which "classical" models locate Cys residues at the center of the hydrophobic stretch. The transmembrane topography of MI can be rationalized on the basis of the presence of a substantial amount of non-helical structure, and/or of kinks attributable to the occurrence of the evolutionarily conserved proline residues. The latter is a striking feature of M1 in the AChR and all members of the rapid ligand-gated ion channel superfamily.	Inst Invest Bioquim Bahia Blanca, RA-8000 Bahia Blanca, Buenos Aires, Argentina; Texas Tech Univ, Hlth Sci Ctr, Dept Pharmacol, Lubbock, TX 79430 USA; Texas Tech Univ, Hlth Sci Ctr, Dept Anesthesiol, Lubbock, TX 79430 USA; Ctr Quim Fis Mol, P-1049001 Lisbon, Portugal	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Universidade de Lisboa	Barrantes, FJ (corresponding author), Inst Invest Bioquim Bahia Blanca, CC 857, RA-8000 Bahia Blanca, Buenos Aires, Argentina.	rtfjb1@criba.edu.ar	Prieto, Manuel/N-4448-2013; Barrantes, Francisco J./HCH-0258-2022	Prieto, Manuel/0000-0003-3012-6598; Barrantes, Francisco J./0000-0002-4745-681X	FOGARTY INTERNATIONAL CENTER [R03TW001225] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS035786] Funding Source: NIH RePORTER; FIC NIH HHS [1RO3-TW01225-01] Funding Source: Medline; NINDS NIH HHS [R29NS35786] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAMS FS, 1992, BIOCHEMISTRY-US, V31, P5322, DOI 10.1021/bi00138a011; AKABAS MH, 1995, BIOCHEMISTRY-US, V34, P12496, DOI 10.1021/bi00039a002; ARIAS HR, 1990, BIOCHIM BIOPHYS ACTA, V1027, P287, DOI 10.1016/0005-2736(90)90320-N; BAENZIGER JE, 1995, J BIOL CHEM, V270, P29129, DOI 10.1074/jbc.270.49.29129; BARANTES FJ, 1998, NICOTINIC ACETYLCHOL; BARRANTES FJ, 1975, P NATL ACAD SCI USA, V72, P3097, DOI 10.1073/pnas.72.8.3097; BARRANTES FJ, 1978, J MOL BIOL, V124, P1, DOI 10.1016/0022-2836(78)90144-4; BLANTON MP, 1994, BIOCHEMISTRY-US, V33, P2859, DOI 10.1021/bi00176a016; BLANTON MP, 1992, BIOCHEMISTRY-US, V31, P3738, DOI 10.1021/bi00130a003; Blanton MP, 2000, J BIOL CHEM, V275, P3469, DOI 10.1074/jbc.275.5.3469; BLANTON MP, 1991, BIOCHIM BIOPHYS ACTA, V1067, P1, DOI 10.1016/0005-2736(91)90019-5; Blanton MP, 1998, BIOCHEMISTRY-US, V37, P14545, DOI 10.1021/bi981435q; BLATT E, 1984, PHOTOCHEM PHOTOBIOL, V39, P477; Castanho M, 1996, BBA-BIOMEMBRANES, V1279, P164, DOI 10.1016/0005-2736(95)00251-0; Changeux JP, 1998, NEURON, V21, P959, DOI 10.1016/S0896-6273(00)80616-9; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; Chattopadhyay A., 1992, BIOMEMBRANE STRUCTUR, P153; CHAVEZ RA, 1992, J CELL BIOL, V116, P385, DOI 10.1083/jcb.116.2.385; Corbin J, 1998, J BIOL CHEM, V273, P771, DOI 10.1074/jbc.273.2.771; CORNELL BA, 1983, BIOCHIM BIOPHYS ACTA, V733, P189, DOI 10.1016/0005-2736(83)90106-2; del Camino D, 2000, NATURE, V403, P321, DOI 10.1038/35002099; ELLENA JF, 1983, BIOCHEMISTRY-US, V22, P5523, DOI 10.1021/bi00293a012; Grant MA, 1999, BIOCHEMISTRY-US, V38, P10730, DOI 10.1021/bi983007q; GREEN SA, 1990, J AM CHEM SOC, V112, P7337, DOI 10.1021/ja00176a038; JACKSON MB, 1995, ANNU REV PHYSIOL, V57, P447; Kim J, 1998, BIOCHEMISTRY-US, V37, P4680, DOI 10.1021/bi972666k; KUHSE J, 1995, CURR OPIN NEUROBIOL, V5, P318, DOI 10.1016/0959-4388(95)80044-1; Ladokhin AS, 1999, BIOPHYS J, V76, P946, DOI 10.1016/S0006-3495(99)77258-9; Le Novere N, 1999, BIOPHYS J, V76, P2329, DOI 10.1016/S0006-3495(99)77390-X; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; LEWIS BA, 1983, J MOL BIOL, V166, P211, DOI 10.1016/S0022-2836(83)80007-2; Lugovskoy AA, 1998, EUR J BIOCHEM, V255, P455, DOI 10.1046/j.1432-1327.1998.2550455.x; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; MARQUEZ J, 1989, BIOCHEMISTRY-US, V28, P7433, DOI 10.1021/bi00444a042; MARSH D, 1978, P NATL ACAD SCI USA, V75, P4329, DOI 10.1073/pnas.75.9.4329; NARAYANASWAMI V, 1993, BIOCHEMISTRY-US, V32, P12413, DOI 10.1021/bi00097a020; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; Opella SJ, 1999, NAT STRUCT BIOL, V6, P374, DOI 10.1038/7610; Ortells MO, 1996, PROTEIN ENG, V9, P51, DOI 10.1093/protein/9.1.51; ORTELLS MO, 1998, NICOTINIC ACETYLCHOL, P85; Pashkov VS, 1999, FEBS LETT, V457, P117, DOI 10.1016/S0014-5793(99)01023-6; PEDERSEN SE, 1986, J BIOL CHEM, V261, P3735; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHREIERMUCCILLO S, 1976, ARCH BIOCHEM BIOPHYS, V172, P1, DOI 10.1016/0003-9861(76)90041-2; SCHROEDER F, 1991, P SOC EXP BIOL MED, V196, P235; SMITH GB, 1995, TRENDS PHARMACOL SCI, V16, P162, DOI 10.1016/S0165-6147(00)89009-4; SOBEL A, 1977, EUR J BIOCHEM, V80, P215, DOI 10.1111/j.1432-1033.1977.tb11874.x; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; VONHEIJNE G, 1991, J MOL BIOL, V218, P499, DOI 10.1016/0022-2836(91)90695-3; WHITE BH, 1991, J BIOL CHEM, V266, P21595; Williamson PTF, 2000, BIOPHYS J, V78, p147A	52	58	58	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37333	37339		10.1074/jbc.M005246200	http://dx.doi.org/10.1074/jbc.M005246200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10967108	hybrid, Green Published			2022-12-25	WOS:000165618700006
J	Qureshi, SA; Ding, V; Li, ZH; Szalkowski, D; Biazzo-Ashnault, DE; Xie, D; Saperstein, R; Brady, E; Huskey, S; Shen, XL; Liu, K; Xu, LB; Salituro, GM; Heck, JV; Moller, DE; Jones, AB; Zhang, BB				Qureshi, SA; Ding, V; Li, ZH; Szalkowski, D; Biazzo-Ashnault, DE; Xie, D; Saperstein, R; Brady, E; Huskey, S; Shen, XL; Liu, K; Xu, LB; Salituro, GM; Heck, JV; Moller, DE; Jones, AB; Zhang, BB			Activation of insulin signal transduction pathway and anti-diabetic activity of small molecule insulin receptor activators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; KINASE-ACTIVITY; TYROSINE KINASE; PROTEIN-KINASE; OBESE SUBJECTS; PHOSPHOINOSITIDE 3-KINASE; 3T3-L1 ADIPOCYTES; CRYSTAL-STRUCTURE; PHOSPHORYLATION; RESISTANCE	We recently described the identification of a non-peptidyl fungal metabolite (L-783,281, compound I), which induced activation of human insulin receptor (Ht) tyrosine kinase and mediated insulin-like effects in cells, as well as decreased blood glucose levels in murine models of Type 2 diabetes (Zhang, B., Salituro, G., Szalkowski, D., Li, Z., Zhang, Y., Royo, I., Vilella, D., Diet, M T., Pelaez, F., Ruby, C., Kendall, R. L., Mao, X., Griffin, P., Calaycay, J., Zierath, J. R., Heck, J. V., Smith, R, G. & Moller, D. E. (1999) Science 284, 974-977). Here we report the characterization of an active analog (compound 2) with enhanced IR kinase activation potency and selectivity over related receptors (insulin-Like growth factor I receptor, epidermal growth factor receptor, and platelet-derived growth factor receptor). The IR activators stimulated tyrosine kinase activity of partially purified native IR and recombinant IR tyrosine kinase domain. Administration of the IR activators to mice was associated with increased IR tyrosine kinase activity in liver. In vivo oral treatment with compound 2 resulted in significant glucose lowering in several rodent models of diabetes. In db/db mice, oral administration of compound 2 elicited significant correction of hyperglycemia, In a streptozotocin-induced diabetic mouse model, compound 2 potentiated the glucose-lowering effect of insulin. In normal rats, compound 2 improved oral glucose tolerance with significant reduction in insulin release following glucose challenge. A structurally related inactive analog (compound 3) was not effective on insulin receptor activation or glucose lowering in db/db mice. Thus, small molecule IR activators exert insulin mimetic and sensitizing effects in cells and in animal models of diabetes. These results have implications for the future development of new therapies for diabetes mellitus.	Merck Res Labs, Dept Mol Endocrinol, Rahway, NJ 07065 USA; Merck Res Labs, Dept Pharmacol, Rahway, NJ 07065 USA; Merck Res Labs, Dept Drug Metab, Rahway, NJ 07065 USA; Merck Res Labs, Dept Comparat Med, Rahway, NJ 07065 USA; Merck Res Labs, Dept Nat Prod Drug Discovery, Rahway, NJ 07065 USA; Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA	Merck & Company; Merck & Company; Merck & Company; Merck & Company; Merck & Company; Merck & Company	Zhang, BB (corresponding author), Merck Res Labs, Dept Mol Endocrinol, R80W250,POB 2000,126 E Lincoln Ave, Rahway, NJ 07065 USA.							Accili D, 1996, NAT GENET, V12, P106, DOI 10.1038/ng0196-106; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; BLONDEL O, 1989, DIABETES METAB, V15, P382; BLONDEL O, 1989, DIABETOLOGIA, V32, P185, DOI 10.1007/BF00265092; BLONDEL O, 1990, AM J PHYSIOL, V258, pE459, DOI 10.1152/ajpendo.1990.258.3.E459; BONINI JA, 1995, BIOCHEM BIOPH RES CO, V212, P933, DOI 10.1006/bbrc.1995.2059; CARO JF, 1986, J CLIN INVEST, V78, P249, DOI 10.1172/JCI112558; CARO JF, 1987, J CLIN INVEST, V79, P1330, DOI 10.1172/JCI112958; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; ELLIS L, 1987, MOL ENDOCRINOL, V1, P15, DOI 10.1210/mend-1-1-15; FREIDENBERG GR, 1987, J CLIN INVEST, V79, P240, DOI 10.1172/JCI112789; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; HEYDRICK SJ, 1993, J CLIN INVEST, V91, P1358, DOI 10.1172/JCI116337; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Joshi RL, 1996, EMBO J, V15, P1542, DOI 10.1002/j.1460-2075.1996.tb00498.x; KADOWAKI T, 1984, J BIOL CHEM, V259, P4208; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; Kim YB, 1999, DIABETES, V48, P310, DOI 10.2337/diabetes.48.2.310; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOLB H, 1987, DIABETES METAB REV, V3, P751, DOI 10.1002/dmr.5610030308; Krook A, 1998, DIABETES, V47, P1281, DOI 10.2337/diabetes.47.8.1281; Liu K, 2000, J MED CHEM, V43, P3487, DOI 10.1021/jm000285q; Luo RZT, 1999, SCIENCE, V285, P1077, DOI 10.1126/science.285.5430.1077; OLEFSKY JM, 1976, J CLIN INVEST, V57, P1165, DOI 10.1172/JCI108384; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; ROSEN OM, 1989, DIABETES, V38, P1508, DOI 10.2337/diabetes.38.12.1508; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SINHA MK, 1987, DIABETES, V36, P620, DOI 10.2337/diabetes.36.5.620; TAYLOR SI, 1992, DIABETES, V41, P1473, DOI 10.2337/diabetes.41.11.1473; WHITE MF, 1994, J BIOL CHEM, V269, P1; White MF, 1998, CURR TOP MICROBIOL, V228, P179; WHITE MF, 1988, J BIOL CHEM, V263, P2969; YU KT, 1984, J BIOL CHEM, V259, P5277; Zhang B, 1999, SCIENCE, V284, P974, DOI 10.1126/science.284.5416.974; Zhou GC, 1998, MOL ENDOCRINOL, V12, P1594, DOI 10.1210/me.12.10.1594; ZICK Y, 1983, J BIOL CHEM, V258, P75	40	58	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36590	36595		10.1074/jbc.M006287200	http://dx.doi.org/10.1074/jbc.M006287200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10967116	hybrid			2022-12-25	WOS:000165577700020
J	Stocco, CO; Zhong, LP; Sugimoto, Y; Ichikawa, A; Lau, LF; Gibori, G				Stocco, CO; Zhong, LP; Sugimoto, Y; Ichikawa, A; Lau, LF; Gibori, G			Prostaglandin F-2 alpha-induced expression of 20 alpha-hydroxysteroid dehydrogenase involves the transcription factor NUR77	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE RECEPTOR SUPERFAMILY; RAT CORPUS-LUTEUM; RIBONUCLEIC-ACID EXPRESSION; ORPHAN STEROID-RECEPTOR; SERUM GROWTH-FACTORS; NGFI-B NUR77; NUCLEAR RECEPTOR; CORPORA-LUTEA; GENE NUR77; LUTEINIZING-HORMONE	Prostaglandin F(2)alpha (PGF(2)alpha) binding to its receptor on the rat corpus luteum triggers various signal transduction pathways that lead to the activation of a steroidogenic enzyme, 20 alpha -hydroxysteroid dehydrogenase (20 alpha -HSD), which in turn catabolizes progesterone. The molecular mechanism underlying PGF(2)alpha -induced 20 alpha -HSD) enzyme activity has not yet been explored. In this report we show, using mice lacking PGF(2)alpha receptor and pregnant rats, that PGF(2)alpha is responsible for the rapid and massive expression of the 20 alpha -HSD gene at the end of pregnancy leading to a decrease in progesterone secretion. We also present evidence that PGF(2)alpha enhances 20 alpha -HSD promoter activity. We have determined a region upstream of the -1590 position in the 20 alpha -HSD promoter that confers regulation by PGF(2)alpha in ovarian primary cells. This region encompasses a unique transcription factor-binding site with a sequence of a NUR77 response element. Deletion of this motif or overexpression of a NUR77 dominant negative protein caused a complete loss of 20 alpha -HSD promoter activation by PGF(2)alpha. NUR77 also transactivated the 20a-HSD promoter in transient transfection experiments in corpus luteum-derived cells (GG-CL), This induction required the NUR77-transactivating domain. We also show that PGF(2)alpha induces a very rapid expression of NUR77 that binds to a distal response element located at -1599/ -1606 but does not interact with another proximal putative NUR77 response element located downstream in the promoter. A rapid increase in NUR77 mRNA was observed in mice corpora lutea just before parturition at a time when 20 alpha -HSD becomes expressed. This increase in the expression of both genes was not seen in PGF(2)alpha receptor knockout mice. By using cyclosporin A and PGF(2)alpha treatment, we established that inhibition of NUR77 DNA binding in vivo prevents PGF(2)alpha induction of the 20 alpha -HSD gene in the corpus luteum. Taken together, our results demonstrate, for the first time, that PGF(2)alpha induces in the corpus luteum the expression of the nuclear orphan receptor and transcription factor, NUR77, which in turn leads to the transcriptional stimulation of 20 alpha -HSD, triggering the decrease in serum progesterone essential for parturition.	Univ Illinois, Coll Med, Dept Physiol & Biophys MC 901, Chicago, IL 60612 USA; Kyoto Univ, Fac Pharmaceut Sci, Dept Physiol Chem, Kyoto 6068501, Japan; Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Kyoto University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gibori, G (corresponding author), Univ Illinois, Coll Med, Dept Physiol & Biophys MC 901, 835 S Wolcott Ave, Chicago, IL 60612 USA.		Sugimoto, Yukihiko/AAV-6470-2021	Sugimoto, Yukihiko/0000-0001-6973-932X; Lau, Lester/0000-0002-4364-2914	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD011119, R01HD011119, R01HD012356] Funding Source: NIH RePORTER; NICHD NIH HHS [HD12356, HD11119] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBARRACIN CT, 1994, ENDOCRINOLOGY, V134, P2453, DOI 10.1210/en.134.6.2453; ALBARRACIN CT, 1991, ENDOCRINOLOGY, V129, P1821, DOI 10.1210/endo-129-4-1821; BAST JD, 1972, ENDOCRINOLOGY, V91, P1499, DOI 10.1210/endo-91-6-1499; Bertrand JE, 1996, ENDOCRINE, V4, P165, DOI 10.1007/BF02782761; BUSSMANN LE, 1979, J STEROID BIOCHEM, V11, P1485, DOI 10.1016/0022-4731(79)90125-0; CHANG SF, 1995, MOL ENDOCRINOL, V9, P1330, DOI 10.1210/me.9.10.1330; CHIN R, 1988, CELL, V54, P541; CRAWFORD PA, 1995, MOL CELL BIOL, V15, P4331; DAVIS IJ, 1993, MOL ENDOCRINOL, V7, P953, DOI 10.1210/me.7.8.953; DAVIS IJ, 1991, MOL ENDOCRINOL, V5, P854, DOI 10.1210/mend-5-6-854; DEIS RP, 1971, NATURE, V229, P568, DOI 10.1038/229568a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAHMER TJ, 1990, MOL CELL BIOL, V10, P6454; Fiedler EP, 1999, BIOL REPROD, V61, P643, DOI 10.1095/biolreprod61.3.643; FONG HW, 1996, BIOL REPROD S1, V54, P169; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FUCHS AR, 1974, BIOL REPROD, V10, P24, DOI 10.1095/biolreprod10.1.24; Gibori G., 1993, OVARY, P261; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HASHIMOTO I, 1969, ENDOCRINOLOGY, V84, P886, DOI 10.1210/endo-84-4-886; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; Ishida Maho, 1999, Journal of Reproduction and Development, V45, P321, DOI 10.1262/jrd.45.321; Juengel JL, 1996, BIOL REPROD, V54, P1096, DOI 10.1095/biolreprod54.5.1096; JUENGEL JL, 1993, ENDOCRINOLOGY, V132, P249, DOI 10.1210/en.132.1.249; LEE SL, 1995, SCIENCE, V269, P532, DOI 10.1126/science.7624775; LEUNG PCK, 1992, ENDOCR REV, V13, P476, DOI 10.1210/er.13.3.476; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; Mao JF, 1997, ENDOCRINOLOGY, V138, P182, DOI 10.1210/en.138.1.182; MARUYAMA K, 1995, CANCER LETT, V96, P117, DOI 10.1016/0304-3835(95)03921-I; MCLEAN MP, 1995, ENDOCRINOLOGY, V136, P4963, DOI 10.1210/en.136.11.4963; Meinke G, 1999, NAT STRUCT BIOL, V6, P471; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MIURA R, 1994, BIOCHEM J, V299, P561, DOI 10.1042/bj2990561; MORISHIG.WK, 1973, ENDOCRINOLOGY, V92, P1527, DOI 10.1210/endo-92-5-1527; MURDOCH WJ, 1995, J ANIM SCI, V73, P1789; Narko K, 1997, ENDOCRINOLOGY, V138, P3638, DOI 10.1210/en.138.9.3638; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Niswender Gordon D., 1994, P781; Okabe T, 1998, J ENDOCRINOL, V156, P169, DOI 10.1677/joe.0.1560169; Okabe T, 1998, Nihon Rinsho, V56, P1734; OLOFSSON J, 1990, BIOL REPROD, V42, P792, DOI 10.1095/biolreprod42.5.792; OLOFSSON J, 1992, PROSTAG LEUKOTR ESS, V46, P151, DOI 10.1016/0952-3278(92)90222-5; Olofsson JI, 1996, MOL CELL ENDOCRINOL, V123, P45, DOI 10.1016/0303-7207(96)03894-4; PARMER TG, 1994, BIOL REPROD S1, V51, P142; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; PHARRISS BB, 1969, P SOC EXP BIOL MED, V130, P92; Sandhoff TW, 1999, ENDOCRINE, V10, P83, DOI 10.1385/ENDO:10:1:83; SCEARCE LM, 1993, J BIOL CHEM, V268, P8855; Spencer WE, 1999, BIOTECHNIQUES, V27, P1044, DOI 10.2144/99275rr04; STRAUSS JF, 1974, PROSTAG OTH LIPID M, V5, P73, DOI 10.1016/S0090-6980(74)80134-6; Sugimoto Y, 1997, SCIENCE, V277, P681, DOI 10.1126/science.277.5326.681; Sugino N, 1998, ENDOCRINOLOGY, V139, P1936, DOI 10.1210/en.139.4.1936; Telleria CM, 1999, STEROIDS, V64, P760, DOI 10.1016/S0039-128X(99)00061-6; Telleria CM, 1997, ENDOCRINOLOGY, V138, P4812, DOI 10.1210/en.138.11.4812; WIEST WG, 1968, ENDOCRINOLOGY, V82, P844, DOI 10.1210/endo-82-4-844; WILLIAMS GT, 1993, MOL CELL BIOL, V13, P6124, DOI 10.1128/MCB.13.10.6124; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WILSON TE, 1993, MOL CELL BIOL, V13, P861, DOI 10.1128/MCB.13.2.861; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; WORONICZ JD, 1995, MOL CELL BIOL, V15, P6364; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; YAZDANBAKHSH K, 1995, P NATL ACAD SCI USA, V92, P437, DOI 10.1073/pnas.92.2.437; YOON JK, 1994, MOL CELL BIOL, V14, P7731, DOI 10.1128/MCB.14.12.7731; Zhong L, 1998, BIOCHEM BIOPH RES CO, V249, P797, DOI 10.1006/bbrc.1998.9229; Zhong L, 1997, BIOCHEM BIOPH RES CO, V235, P587, DOI 10.1006/bbrc.1997.6833	65	113	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37202	37211		10.1074/jbc.M006016200	http://dx.doi.org/10.1074/jbc.M006016200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973968	hybrid			2022-12-25	WOS:000165577700102
J	Lumb, MJ; Danpure, CJ				Lumb, MJ; Danpure, CJ			Functional synergism between the most common polymorphism in human alanine : glyoxylate aminotransferase and four of the most common disease-causing mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY HYPEROXALURIA TYPE-1; PEROXISOMAL L-ALANINE; HUMAN-LIVER; POINT MUTATION; PYRUVATE AMINOTRANSFERASE; HEPATIC ALANINE; GENE; MITOCHONDRIAL; SERINE; DIAGNOSIS	The autosomal recessive disorder primary hyperoxaluria type 1 (PN1) is caused by a deficiency of the liver-specific pyridoxal-phosphate-dependent enzyme alanine:glyoxylate aminotransferase (AGT), Numerous mutations and polymorphisms in the gene encoding AGT have been identified, but in only a few cases has the causal relationship between genotype and phenotype actually been demonstrated. In this study, we have determined the effects of the most common naturally occurring amino acid substitutions (both normal polymorphisms and disease-causing mutations) on the properties, especially specific catalytic activity, of purified recombinant AGT. The results presented in this paper show the following: 1) normal human His-tagged AGT can be expressed at high levels in Escherichia coli and purified in a correctly folded, dimerized and catalytically active state; 2) presence of the common P11L polymorphism decreases the specific activity of purified recombinant AGT by a factor of three; 3) AGTs containing four of the most common PH1-specific mutations (G41R, F152I, G170R, and I244T) are all soluble and catalytically active in the absence of the P11L polymorphism, but in its presence all lead to protein destabilization and aggregation into inclusion bodies; 4) naturally occurring;and artificial amino acid substitutions that lead to peroxisome-to-mitochondrion AGT mistargeting in mammalian cells also lead to destabilization and aggregation in E. coli; and 5) the PH1-specific G82E mutation abolishes AGT catalytic activity by interfering with cofactor binding, as does the artificial K209R mutation at the putative site of cofactor Shiff base formation. These results are discussed in the light of the high allelic frequency (similar to 20%) of the P11L polymorphism and its importance ill determining the phenotypic manifestations of mutations in PH1.	UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England; UCL, Dept Biol, London WC1E 6BT, England	University of London; University College London; University of London; University College London	Danpure, CJ (corresponding author), UCL, MRC, Mol Cell Biol Lab, Gower St, London WC1E 6BT, England.	c.danpure@ucl.ac.uk						ALLSOP J, 1987, CLIN CHIM ACTA, V170, P187, DOI 10.1016/0009-8981(87)90127-6; BARRATT TM, 1999, PEDIAT NEPHROLOGY, P609; COOPER PJ, 1988, J HISTOCHEM CYTOCHEM, V36, P1285, DOI 10.1177/36.10.3418107; Danpure CJ, 1997, BIOESSAYS, V19, P317, DOI 10.1002/bies.950190409; DANPURE CJ, 1994, J INHERIT METAB DIS, V17, P487, DOI 10.1007/BF00711363; Danpure CJ, 1996, PRENATAL DIAG, V16, P587; DANPURE CJ, 1994, HUM GENET, V94, P55, DOI 10.1007/BF02272842; DANPURE CJ, 1993, AM J HUM GENET, V53, P417; DANPURE CJ, 1988, CLIN SCI, V75, P315, DOI 10.1042/cs0750315; DANPURE CJ, 1986, FEBS LETT, V201, P20, DOI 10.1016/0014-5793(86)80563-4; DANPURE CJ, 1989, J CELL BIOL, V108, P1345, DOI 10.1083/jcb.108.4.1345; Danpure CJ., 1995, CALCIUM OXALATE BIOL, P189; Danpure CJ, 1996, KIDNEY STONES MED SU, P859; DANPURE CJ, 1995, METABOLIC MOL BASES, P2385; Fancy DA, 1999, P NATL ACAD SCI USA, V96, P6020, DOI 10.1073/pnas.96.11.6020; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; Holbrook JD, 2000, MOL BIOL EVOL, V17, P387, DOI 10.1093/oxfordjournals.molbev.a026318; Horvath VAP, 1995, CLIN CHIM ACTA, V243, P105, DOI 10.1016/0009-8981(95)06149-5; Ishikawa K, 1996, J BIOCHEM, V119, P970; KAMODA N, 1980, BIOCHEM MED METAB B, V23, P25, DOI 10.1016/0006-2944(80)90051-4; Ledent P, 1997, FEBS LETT, V413, P194, DOI 10.1016/S0014-5793(97)00908-3; Leiper JM, 1996, J CELL BIOL, V135, P939, DOI 10.1083/jcb.135.4.939; MOTLEY A, 1995, J CELL BIOL, V131, P95, DOI 10.1083/jcb.131.1.95; NISHIYAMA K, 1991, BIOCHEM BIOPH RES CO, V176, P1093, DOI 10.1016/0006-291X(91)90396-O; NISHIYAMA K, 1993, J CELL BIOL, V123, P1237, DOI 10.1083/jcb.123.5.1237; NOGUCHI T, 1979, ARCH BIOCHEM BIOPHYS, V196, P645, DOI 10.1016/0003-9861(79)90319-9; ODA T, 1987, EUR J BIOCHEM, V168, P537, DOI 10.1111/j.1432-1033.1987.tb13451.x; Pirulli D, 1999, HUM GENET, V104, P523, DOI 10.1007/s004390050998; PURDUE PE, 1991, HUM GENET, V87, P394; PURDUE PE, 1991, P NATL ACAD SCI USA, V88, P10900, DOI 10.1073/pnas.88.23.10900; PURDUE PE, 1992, GENOMICS, V13, P215, DOI 10.1016/0888-7543(92)90225-H; PURDUE PE, 1990, J CELL BIOL, V111, P2341, DOI 10.1083/jcb.111.6.2341; PURDUE PE, 1992, EUR J BIOCHEM, V207, P757, DOI 10.1111/j.1432-1033.1992.tb17106.x; ROBERTSON WG, 1980, NEPHRON, V26, P105, DOI 10.1159/000181963; Rumsby G, 1997, ANN CLIN BIOCHEM, V34, P400, DOI 10.1177/000456329703400411; TAKADA Y, 1990, BIOCHEM J, V268, P517, DOI 10.1042/bj2680517; TAKADA Y, 1982, COMP BIOCHEM PHYS B, V72, P597, DOI 10.1016/0305-0491(82)90512-0; Tarn AC, 1997, J INHERIT METAB DIS, V20, P689, DOI 10.1023/A:1005326510239; THOMPSON JS, 1966, ARCH BIOCHEM BIOPHYS, V117, P599, DOI 10.1016/0003-9861(66)90101-9; THOMPSON JS, 1967, J BIOL CHEM, V242, P3614; VANSCHNAKENBURG C, 1998, THESIS U LONDON LOND; vonSchnakenburg C, 1997, J MED GENET, V34, P489, DOI 10.1136/jmg.34.6.489; WANDERS RJA, 1990, CLIN CHIM ACTA, V189, P139, DOI 10.1016/0009-8981(90)90084-6; Xue HH, 1999, J BIOL CHEM, V274, P16028, DOI 10.1074/jbc.274.23.16028; Yendt E R, 1988, Md Med J, V37, P857	45	122	126	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36415	36422		10.1074/jbc.M006693200	http://dx.doi.org/10.1074/jbc.M006693200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10960483	hybrid			2022-12-25	WOS:000165382000107
J	Foehr, ED; Bohuslav, J; Chen, LF; DeNoronha, C; Geleziunas, R; Lin, X; O'Mahony, A; Greene, WC				Foehr, ED; Bohuslav, J; Chen, LF; DeNoronha, C; Geleziunas, R; Lin, X; O'Mahony, A; Greene, WC			The NF-kappa B-inducing kinase induces PC12 cell differentiation and prevents apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; IKK-BETA; ALPHA PROTEOLYSIS; ACTIVATION; PHOSPHORYLATION; NEURONS; SITE; DEATH; TNF; IDENTIFICATION	NF-kappaB has been implicated in the survival and differentiation of PC12 cells. In this study, we examined the effect of the NF-kappaB-inducing kinase (NIK) on these processes. When inducibly expressed in PC12 cells, a kinase-proficient but not -deficient form of NIK promoted neurite process formation and mediated anti-apoptotic signaling. As expected, NIK expression led to I kappaB kinase activation and induced nuclear translocation of NF-kappaB, However, NIK-induced neurite outgrowth was only partially blocked by concomitant expression of a nondegradable form of I kappaB alpha that completely blocks NF-kappaB induction. In search of additional signaling pathways activated by NIX, we now demonstrate that NIR. activates MEK1 phosphorylation and induces the Erk1/Erk2 MAPK pathway. Treatment of PC12 cells with PD98059, a MEK1 inhibitor, potently blocked neurite process formation; however, a dominantly interfering mutant of the upstream Shc adapter failed to alter this response. These findings reveal a new function for MK as a MEK1-dependent activator of the MAPK pathway and implicate both the I kappaB kinase and MAPK signaling cascades in NIK-induced differentiation of PC12 cells.	Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Foehr, ED (corresponding author), Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA.	efoehr@gladstone.ucsf.edu			NIMH NIH HHS [P30MH59037] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH059037] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Aronsson FC, 1998, HUM GENET, V103, P340, DOI 10.1007/s004390050827; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bethea JR, 1998, J NEUROSCI, V18, P3251; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HATTORI A, 1993, J BIOL CHEM, V268, P2577; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; Kaltschmidt B, 1997, P NATL ACAD SCI USA, V94, P2642, DOI 10.1073/pnas.94.6.2642; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; LINDHOLM D, 1987, NATURE, V330, P658, DOI 10.1038/330658a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mattson MP, 2000, J NEUROCHEM, V74, P443, DOI 10.1046/j.1471-4159.2000.740443.x; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MIYAWAKI S, 1994, EUR J IMMUNOL, V24, P429, DOI 10.1002/eji.1830240224; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; RATTNER A, 1993, EMBO J, V12, P4261, DOI 10.1002/j.1460-2075.1993.tb06110.x; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Thomas D, 1997, J BIOL CHEM, V272, P22293, DOI 10.1074/jbc.272.35.22293; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yu ZF, 1999, J NEUROSCI, V19, P8856, DOI 10.1523/JNEUROSCI.19-20-08856.1999; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	42	43	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34021	34024		10.1074/jbc.C000507200	http://dx.doi.org/10.1074/jbc.C000507200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10980190	hybrid			2022-12-25	WOS:000165095300004
J	Kiguchi, K; Bol, D; Carbajal, S; Beltran, L; Moats, S; Chan, K; Jorcano, J; DiGiovanni, J				Kiguchi, K; Bol, D; Carbajal, S; Beltran, L; Moats, S; Chan, K; Jorcano, J; DiGiovanni, J			Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development	ONCOGENE			English	Article						erbB2; EGFr; erbB3; skin; carcinogenesis	GROWTH-FACTOR-RECEPTOR; TREATED MOUSE EPIDERMIS; FACTOR-ALPHA; SIGNAL-TRANSDUCTION; ALTERED EXPRESSION; NEU-ONCOGENE; CELL-LINE; TGF-ALPHA; CANCER; OVEREXPRESSION	The erbB family of receptor tyrosine kinases, which consists of the epidermal growth factor receptor (EGFr/erbB1), erbB2 (neu), erbB3 and erbB4, has been shown to be important for both normal development as well as neoplasia. The expression of rat erbB2 was targeted to the basal layer of mouse epidermis with the bovine keratin 5 promoter. Overexpression of wild type rat erbB2 in the basal layer of epidermis led to alopecia, follicular hyperplasia and sebaceous gland enlargement as well as hyperplasia of the interfollicular epidermis. Spontaneous papillomas, some of which converted to squamous cell carcinomas, arose in homozygous erbB2 transgenic mice as early as 6 weeks of age with >90% incidence by 6 months. Analysis of several proliferationl differentiation markers indicated that erbB2 overexpression led to epidermal hyperproliferation and a possible delay in epidermal differentiation. Transgenic mice were also hypersensitive to the proliferative effects of the skin tumor promoter, 12-0-tetradecanoylphorbol-13-acetate (TPA) and were more sensitive to two-stage carcinogenesis. Elevations in EGFr and erbB2 protein as well as erbB2:EGFr and erbB2:erbB3 heterodimers were observed in skin of the erbB2 transgenic mice. Phosphotyrosine levels of the EGFr, erbB2 and erbB3 proteins were also elevated. These results indicate an important role for erbB2 signaling in epidermal growth, development and neoplasia.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA; Ciemat Inst, Dept Cell & Mol Biol, Madrid 28040, Spain	University of Texas System; UTMD Anderson Cancer Center; Centro de Investigaciones Energeticas, Medioambientales Tecnologicas	DiGiovanni, J (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, POB 389, Smithville, TX 78957 USA.				NCI NIH HHS [CA16672, CA76520] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA076520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ALDAZ CM, 1989, SKIN TUMORS EXPT CLI, V11, P227; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; Bol D, 1998, MOL CARCINOGEN, V21, P2, DOI 10.1002/(SICI)1098-2744(199801)21:1<2::AID-MC2>3.3.CO;2-7; Bol DK, 1997, ONCOGENE, V14, P1725, DOI 10.1038/sj.onc.1201011; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Cohen BM, 1996, J BIOL CHEM, V271, P4813; DiGiovanni J, 2000, CANCER RES, V60, P1561; DOMINEY AM, 1993, CELL GROWTH DIFFER, V4, P1071; DOUGALL WC, 1994, ONCOGENE, V9, P2109; ELDRIDGE SR, 1990, CARCINOGENESIS, V4, P281; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FUKUSHIGE S, 1986, MOL CELL BIOL, V6, P955, DOI 10.1128/MCB.6.3.955; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; Hogan B, 1994, MANIPULATING MOUSE E; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; JHAPPAN C, 1994, CELL GROWTH DIFFER, V5, P385; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kiguchi K, 1998, MOL CARCINOGEN, V22, P73, DOI 10.1002/(SICI)1098-2744(199806)22:2<73::AID-MC2>3.0.CO;2-L; KIGUCHI K, 1995, MOL CARCINOGEN, V12, P225, DOI 10.1002/mc.2940120407; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KIYOKAWA N, 1995, P NATL ACAD SCI USA, V92, P1092, DOI 10.1073/pnas.92.4.1092; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERSCH R, 1988, MOL CELL BIOL, V8, P486, DOI 10.1128/MCB.8.1.486; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MANSBRIDGE JN, 1987, J INVEST DERMATOL, V89, P253, DOI 10.1111/1523-1747.ep12471216; MARCHESE C, 1990, J CELL PHYSIOL, V144, P326, DOI 10.1002/jcp.1041440219; MCCANN A, 1990, CANCER, V65, P88, DOI 10.1002/1097-0142(19900101)65:1<88::AID-CNCR2820650119>3.0.CO;2-Z; MOLLOY CJ, 1987, CANCER RES, V47, P4674; MURILLAS R, 1995, EMBO J, V14, P5216, DOI 10.1002/j.1460-2075.1995.tb00206.x; NAITO M, 1987, CARCINOGENESIS, V8, P1807, DOI 10.1093/carcin/8.12.1807; NELSON WG, 1983, J CELL BIOL, V97, P244, DOI 10.1083/jcb.97.1.244; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; RHO OY, 1994, MOL CARCINOGEN, V11, P19, DOI 10.1002/mc.2940110105; Riese DJ, 1996, ONCOGENE, V12, P345; SAMBROOK J, 1994, MOL CLONING LAB MAN; SCHLESSINGER J, 1992, NEURON, V9, P389; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; TOFTGARD R, 1985, CANCER RES, V45, P5845; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VASSAR R, 1992, MOL CELL BIOL, V12, P4643, DOI 10.1128/MCB.12.10.4643; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WANG XJ, 1994, MOL CARCINOGEN, V10, P15, DOI 10.1002/mc.2940100104; Wang ZX, 1999, MOL BIOL CELL, V10, P1621, DOI 10.1091/mbc.10.5.1621; WOOD DP, 1991, J UROLOGY, V146, P1398, DOI 10.1016/S0022-5347(17)38123-5; Xian WJ, 1997, ONCOGENE, V14, P1435, DOI 10.1038/sj.onc.1200980; Xie W, 1998, CELL GROWTH DIFFER, V9, P313; Xie W, 1999, ONCOGENE, V18, P3593, DOI 10.1038/sj.onc.1202673; YOKOTA J, 1986, LANCET, V1, P765; YUSPA S, 1994, J INVEST DERMATOL, V103, P908; YUSPA SH, 1994, CANCER RES, V54, P1178; [No title captured]	60	76	76	2	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 31	2000	19	37					4243	4254		10.1038/sj.onc.1203778	http://dx.doi.org/10.1038/sj.onc.1203778			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980598				2022-12-25	WOS:000089032900007
J	Wittau, N; Grosse, R; Kalkbrenner, F; Gohla, A; Schultz, G; Gudermann, T				Wittau, N; Grosse, R; Kalkbrenner, F; Gohla, A; Schultz, G; Gudermann, T			The galanin receptor type 2 initiates multiple signaling pathways in small cell lung cancer cells by coupling to G(q), G(i) and G(12) proteins	ONCOGENE			English	Article						G-protein-coupled receptor; mitogenic signaling; multiple signaling; neuropeptides	GROWTH-FACTOR RECEPTOR; STRESS FIBER FORMATION; PHOSPHOLIPASE C-BETA; ACTIVATED G-PROTEINS; SMOOTH-MUSCLE CELLS; TYROSINE KINASE; MEMBRANE DEPOLARIZATION; NEUROENDOCRINE PEPTIDE; LYSOPHOSPHATIDIC ACID; MOLECULAR-CLONING	Neuropeptides like galanin produced and released by small cell lung cancer (SCLC) cells are considered principal mitogens in these tumors. We identified the galanin receptor type 2 (GALR2) as the only galanin receptor expressed in H69 and H510 cells. Photoaffinity labeling of G proteins in H69 cell membranes revealed that GALR2, activates G proteins of three subfamilies: G(q), G(i), and G(12). In H-69 cells, galanin-induced Ca2+ mobilization was pertussis toxin-insensitive. While phorbol ester-induced extracellular signal-regulated kinase (ERK) activation required protein kinase C (PKC) activity, preincubation of 1169 cells with the PKC-inhibitor GF109203X had no effect on galanin-dependent ERK activity. A rise of the intracellular calcium concentration was necessary and sufficient to mediate galanin-induced ERK activation, In support of Gi coupling, stimulation of GALR2 expressed in HEK293 cells inhibited isoproterenol-induced cAMP accumulation and raised cAMP levels in COS-7 cells when coexpressed with a chimeric G alpha(S)-G alpha(i) protein. In 1169 cells, galanin activated the monomeric GTPase RhoA and induced stress fiber formation in Swiss 3T3 cells expressing GALR2, Thus, we provide the first direct evidence that in SCLC the mitogenic neuropeptide galanin, interacting with GALR2, simultaneously activates multiple classes of G proteins and signals through the Gq phospholipase C/calcium sequence and a G(12)/Rho pathway.	Univ Marburg, Fachbereich Humanmed, Inst Pharmakol & Toxikol, D-35033 Marburg, Germany; Univ Klinikum Benjamin Franklin, Inst Pharmakol, D-14195 Berlin, Germany	Philipps University Marburg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Gudermann, T (corresponding author), Univ Marburg, Fachbereich Humanmed, Inst Pharmakol & Toxikol, Karl Von Frisch Str 1, D-35033 Marburg, Germany.			Grosse, Robert/0000-0002-3380-5273; Gohla, Antje/0000-0002-7442-1487				ALLGEIER A, 1994, J BIOL CHEM, V269, P13733; Barr AJ, 1997, J BIOL CHEM, V272, P2223; BARTFAI T, 1993, CRIT REV NEUROBIOL, V7, P229; BEDECS K, 1995, INT J BIOCHEM CELL B, V27, P337, DOI 10.1016/1357-2725(95)00008-D; Beekman A, 1998, CANCER RES, V58, P910; BEPLER G, 1988, J CANCER RES CLIN, V114, P235, DOI 10.1007/BF00405828; BERRIDGE MJ, 1983, BIOCHEM J, V212, P849, DOI 10.1042/bj2120849; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; Bloomquist BT, 1998, BIOCHEM BIOPH RES CO, V243, P474, DOI 10.1006/bbrc.1998.8133; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Dhanasekaran N, 1998, ONCOGENE, V17, P1383, DOI 10.1038/sj.onc.1202242; Eguchi S, 1999, HYPERTENSION, V33, P201, DOI 10.1161/01.HYP.33.1.201; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Gautam N, 1998, CELL SIGNAL, V10, P447, DOI 10.1016/S0898-6568(98)00006-0; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Grosse R, 2000, J BIOL CHEM, V275, P9193, DOI 10.1074/jbc.275.13.9193; Grosse R, 2000, J BIOL CHEM, V275, P12251, DOI 10.1074/jbc.275.16.12251; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; HABERTORTOLI E, 1994, P NATL ACAD SCI USA, V91, P9780, DOI 10.1073/pnas.91.21.9780; Heasley LE, 1996, J BIOL CHEM, V271, P349, DOI 10.1074/jbc.271.1.349; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Herrlich A, 1996, J BIOL CHEM, V271, P16764, DOI 10.1074/jbc.271.28.16764; Jarpe MB, 1998, J BIOL CHEM, V273, P3097, DOI 10.1074/jbc.273.5.3097; KALKBRENNER F, 1995, EMBO J, V14, P4728, DOI 10.1002/j.1460-2075.1995.tb00154.x; KAO JPY, 1994, METHOD CELL BIOL, V40, P155; Kask K, 1995, CELL MOL NEUROBIOL, V15, P653, DOI 10.1007/BF02071130; Komatsuzaki K, 1997, FEBS LETT, V406, P165, DOI 10.1016/S0014-5793(97)00257-3; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Kuhn B, 1996, MOL ENDOCRINOL, V10, P1697, DOI 10.1210/me.10.12.1697; LASSEN U, 1995, J CLIN ONCOL, V13, P1215, DOI 10.1200/JCO.1995.13.5.1215; LAUGWITZ KL, 1994, METHOD ENZYMOL, V237, P283; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; MITCHELL FM, 1995, J BIOL CHEM, V270, P8623, DOI 10.1074/jbc.270.15.8623; MOODY TW, 1985, LIFE SCI, V37, P105, DOI 10.1016/0024-3205(85)90413-8; OFFERMANNS S, 1991, METHOD ENZYMOL, V195, P286; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Pang L, 1998, J NEUROCHEM, V71, P2252; Ravi RK, 1998, J CLIN INVEST, V101, P153, DOI 10.1172/JCI831; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Rozengurt Enrique, 1999, Current Opinion in Oncology, V11, P116; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Schoneberg T, 1999, MOL CELL ENDOCRINOL, V151, P181, DOI 10.1016/S0303-7207(99)00017-9; SETHI T, 1991, CANCER RES, V51, P1674; SETHI T, 1991, CANCER RES, V51, P3621; SETHI T, 1992, CANCER RES, V52, pS2737; Seufferlein T, 1996, CANCER RES, V56, P5758; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Smith KE, 1997, J BIOL CHEM, V272, P24612, DOI 10.1074/jbc.272.39.24612; Smith KE, 1998, J BIOL CHEM, V273, P23321, DOI 10.1074/jbc.273.36.23321; Soltoff SP, 1998, J BIOL CHEM, V273, P23110, DOI 10.1074/jbc.273.36.23110; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Tokman MG, 1997, CANCER RES, V57, P1785; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; VIALLET J, 1990, J CLIN INVEST, V86, P1904, DOI 10.1172/JCI114923; Wang S, 1998, BIOCHEMISTRY-US, V37, P6711, DOI 10.1021/bi9728405; Wang S, 1997, MOL PHARMACOL, V52, P337, DOI 10.1124/mol.52.3.337; Wang SK, 1998, DRUG NEWS PERSPECT, V11, P458; Wang SK, 1997, J BIOL CHEM, V272, P31949, DOI 10.1074/jbc.272.51.31949; WONG YH, 1994, METHOD ENZYMOL, V238, P81; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767	71	94	97	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2000	19	37					4199	4209		10.1038/sj.onc.1203777	http://dx.doi.org/10.1038/sj.onc.1203777			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980593				2022-12-25	WOS:000089032900002
J	Kovar, H; Jug, G; Printz, D; Bartl, S; Schmid, G; Wesierska-Gadek, J				Kovar, H; Jug, G; Printz, D; Bartl, S; Schmid, G; Wesierska-Gadek, J			Characterization of distinct consecutive phases in non-genotoxic p53-induced apoptosis of Ewing tumor cells and the rate-limiting role of caspase 8	ONCOGENE			English	Article						Ewing tumors; p53; caspase S; transcription; early phase; apoptosis; PIG-3; TRAIL	IRRADIATION-INDUCED APOPTOSIS; TEMPERATURE-SENSITIVE MUTANT; ZINC-FINGER PROTEIN; BCL-X-L; CYTOCHROME-C; TRANSCRIPTIONAL ACTIVATION; HUMAN P53; P53-DEPENDENT APOPTOSIS; P53-MEDIATED APOPTOSIS; MEDIATED APOPTOSIS	To dissect the p53-dependent apoptotic pathway events following induction of temperature sensitive (ts) p53val138 were studied in a Ewing tumor cell line. Transcriptional deregulation of p53 targets first observable after 1 h at 32 degrees C preceded activation of caspases and the break-down of mitochondrial respiratory activity. Activation of caspases was first observed 4 h after p53 induction. Using peptide inhibitors we identified activation of caspase 8 upstream of caspases-9 and -3. Although the caspase 8 specific inhibitor z-IETD.fmk did not affect translocation of BAX to the mitochondrial membrane and cytochrome C release it almost completely blocked cleavage of the prototype caspase substrate PARP and DNA fragmentation while enforcing mitochondrial depolarization and production of reactive oxygene species (ROS). Activation of caspase 8 did not involve death-domain receptor signaling. Expression of BCL2 only partially suppressed caspase activation but blocked apoptosis, Replacement of the N-terminus of p53val138 by the related VP16 transactivation domain created a ts p53 with a tanscriptional activity indistinguishable from p53val138 until the time of caspase activation. However, the VP16-p53 fusion failed to trigger caspases and subsequent induction of the ROS producing gene pig3 paralleled by complete loss of apoptotic activity. These results indicate that p53-dependent transcriptional deregulation, triggering of the caspase cascade and the mitochondrial break-down occur in a timely ordered sequence coordinated by the genuine p53 amino terminus and suggest caspase 8 and PIG3 as key regulatory elements in this process.	St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria; Univ Vienna, Canc Res Inst, A-1090 Vienna, Austria	Saint Anna Children's Hospital; University of Vienna	Kovar, H (corresponding author), St Anna Childrens Hosp, Childrens Canc Res Inst, Kinderspitalgasse 6, A-1090 Vienna, Austria.			Kovar, Heinrich/0000-0001-6873-9109				Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Buckbinder L, 1997, P NATL ACAD SCI USA, V94, P7868, DOI 10.1073/pnas.94.15.7868; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FISKUM G, 1980, P NATL ACAD SCI-BIOL, V77, P3430, DOI 10.1073/pnas.77.6.3430; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Fuchs EJ, 1997, CANCER RES, V57, P2550; Fulda S, 1998, CELL DEATH DIFFER, V5, P884, DOI 10.1038/sj.cdd.4400419; Gao CF, 1999, JPN J CANCER RES, V90, P180, DOI 10.1111/j.1349-7006.1999.tb00731.x; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HAUPT Y, 1995, ONCOGENE, V10, P1563; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HIRANO Y, 1995, ONCOGENE, V10, P1879; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOVAR H, 1993, ONCOGENE, V8, P2683; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MIYASHITA T, 1995, CELL, V80, P293; Muller M, 1998, EUR CYTOKINE NETW, V9, P685; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; PRASAD SC, 1990, CANCER RES, V50, P38; Roemer K, 1996, ONCOGENE, V12, P2069; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sabbatini P, 1997, CELL GROWTH DIFFER, V8, P643; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; Sheikh MS, 1998, CANCER RES, V58, P1593; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Song QZ, 1999, EMBO J, V18, P167, DOI 10.1093/emboj/18.1.167; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Theis S, 1997, INT J CANCER, V71, P858; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; VarmehZiaie S, 1997, ONCOGENE, V15, P2699, DOI 10.1038/sj.onc.1201454; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhan QM, 1999, ONCOGENE, V18, P297, DOI 10.1038/sj.onc.1202310; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533	59	32	32	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2000	19	36					4096	4107		10.1038/sj.onc.1203780	http://dx.doi.org/10.1038/sj.onc.1203780			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962570				2022-12-25	WOS:000088955100003
J	Quinn, LM; Dorstyn, L; Mills, K; Colussi, PA; Chen, P; Coombe, M; Abrams, J; Kumar, S; Richardson, H				Quinn, LM; Dorstyn, L; Mills, K; Colussi, PA; Chen, P; Coombe, M; Abrams, J; Kumar, S; Richardson, H			An essential role for the caspase dronc in developmentally programmed cell death in Drosophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EYE IMAGINAL DISC; INDUCED APOPTOSIS; CYCLIN-E; PROTEASE; GENE; INHIBITOR; EXPRESSION; ACTIVATION; PATHWAY; REAPER	Drone is a caspase recruitment domain-containing Drosophila caspase that is expressed in a temporally and spatially restricted fashion during development. Drone is the only fly caspase known to be regulated by the hormone ecdysone. Here we show that ectopic expression of drone in the developing fly eye leads to increased cell death and an ablated eye phenotype that can be suppressed by halving the dosage of the genes in the H99 complex (reaper, hid, and grim) and enhanced by mutations in diap1. In contrast to previous reports, we show that the drone eye ablation phenotype can be suppressed by coexpression of the baculoviral caspase inhibitor p35. Drone also interacts, both genetically and biochemically, with the CED-4/Apaf-1 fly homolog, Dark. Furthermore, extracts made from Dark homozygous mutant flies have reduced ability to process Drone, showing that Dark is required for Drone processing. Finally, using the RNA interference technique, we show that loss of Drone function in early Drosophila embryos results in a dramatic decrease in cell death, indicating that Drone is important for programmed cell death during embryogenesis. These results suggest that Drone is a key caspase mediating programmed cell death in Drosophila.	Inst Med & Vet Sci, Hanson Ctr Canc Res, Adelaide, SA 5000, Australia; Univ Adelaide, Dept Genet, Adelaide, SA 5001, Australia; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75235 USA	Institute Medical & Veterinary Science Australia; University of Adelaide; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Kumar, S (corresponding author), Inst Med & Vet Sci, Hanson Ctr Canc Res, Adelaide, SA 5000, Australia.		Richardson, Helena E/A-8080-2013; Kumar, Sharad/AAX-7787-2020; Dorstyn, Loretta/F-3673-2013	Richardson, Helena E/0000-0003-3852-4953; Kumar, Sharad/0000-0001-7126-9814; Dorstyn, Loretta/0000-0001-9886-0989; Quinn, Leonie/0000-0002-3911-6508				ABRAMS JM, 1993, DEVELOPMENT, V117, P29; Abrams JM, 1999, TRENDS CELL BIOL, V9, P435, DOI 10.1016/S0962-8924(99)01646-3; Bhat MA, 1999, CELL, V96, P833, DOI 10.1016/S0092-8674(00)80593-0; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BRAND AH, 1993, DEVELOPMENT, V118, P401; Butt AJ, 1998, J BIOL CHEM, V273, P6763, DOI 10.1074/jbc.273.12.6763; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Chen P, 1998, DEV BIOL, V201, P202, DOI 10.1006/dbio.1998.9000; Claveria C, 1998, EMBO J, V17, P7199, DOI 10.1093/emboj/17.24.7199; Colussi PA, 2000, J CELL BIOL, V148, P703, DOI 10.1083/jcb.148.4.703; Colussi PA, 1998, J BIOL CHEM, V273, P26566, DOI 10.1074/jbc.273.41.26566; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Dorstyn L, 1999, J BIOL CHEM, V274, P30778, DOI 10.1074/jbc.274.43.30778; ELLIS MC, 1993, DEVELOPMENT, V119, P855; Fraser AG, 1997, EMBO J, V16, P6192, DOI 10.1093/emboj/16.20.6192; Fraser AG, 1997, EMBO J, V16, P2805, DOI 10.1093/emboj/16.10.2805; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Hawkins CJ, 2000, J BIOL CHEM, V275, P27084; Hawkins CJ, 1999, P NATL ACAD SCI USA, V96, P2885, DOI 10.1073/pnas.96.6.2885; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Hunter CP, 1999, CURR BIOL, V9, pR440, DOI 10.1016/S0960-9822(99)80276-0; Igaki T, 2000, P NATL ACAD SCI USA, V97, P662, DOI 10.1073/pnas.97.2.662; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Jones G, 2000, J BIOL CHEM, V275, P22157, DOI 10.1074/jbc.M000369200; Kanuka H, 1999, MOL CELL, V4, P757, DOI 10.1016/S1097-2765(00)80386-X; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; Kumar S, 1999, CELL DEATH DIFFER, V6, P1060, DOI 10.1038/sj.cdd.4400600; Kumar S, 2000, CELL DEATH DIFFER, V7, P1039, DOI 10.1038/sj.cdd.4400756; Kumar S, 1999, TRENDS BIOCHEM SCI, V24, P1, DOI 10.1016/S0968-0004(98)01332-2; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; McCall K, 1998, SCIENCE, V279, P230, DOI 10.1126/science.279.5348.230; Meier P, 2000, EMBO J, V19, P598, DOI 10.1093/emboj/19.4.598; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; Misquitta L, 1999, P NATL ACAD SCI USA, V96, P1451, DOI 10.1073/pnas.96.4.1451; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; RICHARDSON H, 1995, DEVELOPMENT, V121, P3371; Rodriguez A, 1999, NAT CELL BIOL, V1, P272, DOI 10.1038/12984; Secombe J, 1998, GENETICS, V149, P1867; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; Vernooy SY, 2000, J CELL BIOL, V150, pF69, DOI 10.1083/jcb.150.2.F69; Vucic D, 1997, P NATL ACAD SCI USA, V94, P10183, DOI 10.1073/pnas.94.19.10183; Vucic D, 1997, MOL CELL BIOL, V17, P667, DOI 10.1128/MCB.17.2.667; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; Wianny F, 2000, NAT CELL BIOL, V2, P70, DOI 10.1038/35000016; Wing JP, 1998, CELL DEATH DIFFER, V5, P930, DOI 10.1038/sj.cdd.4400423; Zhou L, 1999, MOL CELL, V4, P745, DOI 10.1016/S1097-2765(00)80385-8; ZIPURSKY SL, 1984, CELL, V36, P15, DOI 10.1016/0092-8674(84)90069-2	54	125	132	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40416	40424		10.1074/jbc.M002935200	http://dx.doi.org/10.1074/jbc.M002935200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10984473	hybrid			2022-12-25	WOS:000166039500084
J	Weisz, OA; Wang, JM; Edinger, RS; Johnson, JP				Weisz, OA; Wang, JM; Edinger, RS; Johnson, JP			Non-coordinate regulation of endogenous epithelial sodium channel (ENaC) subunit expression at the apical membrane of A6 cells in response to various transporting conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORTICAL COLLECTING TUBULE; LUNG LIQUID CLEARANCE; SENSITIVE NA+ CHANNEL; BETA-SUBUNIT; SURFACE EXPRESSION; RECEPTOR SUBUNITS; XENOPUS-OOCYTES; ALDOSTERONE; KIDNEY; MICE	In many epithelial tissues in the body (e.g. kidney distal nephron, colon, airways) the rate of Na+ reabsorption is governed by the activity of the epithelial Na+ channel (ENaC), ENaC activity in turn is regulated by a number of factors including hormones, physiological conditions, and other ion channels. To begin to understand the mechanisms by which ENaC is regulated, we have examined the trafficking and turnover of ENaC subunits in A6 cells, a polarized, hormonally responsive Xenopus kidney cell line. As previously observed by others, the half-life of newly synthesized ENaC subunits was universally short (similar to2 h). However, the half-lives of alpha- and gamma -ENaC subunits that reached the apical cell surface were considerably longer (t(1/2) > 24 h), whereas intriguingly, the half-life of cell surface beta -ENaC was only approximately 6 h. We then examined the effects of various modulators of sodium transport on cell surface levels of individual ENaC subunits, Up-regulation of ENaC-mediated sodium conductance by overnight treatment with aldosterone or by short term incubation with vasopressin dramatically increased cell surface levels of beta -ENaC without affecting alpha- or gamma -ENaC levels. Conversely, treatment with brefeldin A selectively decreased the amount of beta -ENaC at the apical membrane. Short term treatment with aldosterone or insulin had no effect on cell surface amounts of any subunits, Subcellular fractionation revealed a selective loss of beta -ENaC from early endosomal pools in response to vasopressin, Our data suggest the possibility that trafficking and turnover of individual ENaC subunits at the apical membrane of A6 cells is non-coordinately regulated. The selective trafficking of beta -ENaC may provide a mechanism for regulating sodium conductance in response to physiological stimuli.	Univ Pittsburgh, Renal Electrolyte Div, Lab Epithelial Cell Biol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Johnson, JP (corresponding author), Univ Pittsburgh, Renal Electrolyte Div, Lab Epithelial Cell Biol, 3550 Terrace St, Pittsburgh, PA 15261 USA.	johnson@msx.dept-med.pitt.edu			NIDDK NIH HHS [R01DK47874] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047874] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams CM, 1997, J BIOL CHEM, V272, P27295, DOI 10.1074/jbc.272.43.27295; Asher C, 1996, AM J PHYSIOL-CELL PH, V271, pC605, DOI 10.1152/ajpcell.1996.271.2.C605; Barker PM, 1998, J CLIN INVEST, V102, P1634, DOI 10.1172/JCI3971; Barnard EA, 1998, PHARMACOL REV, V50, P291; Blazer-Yost BL, 1998, AM J PHYSIOL-CELL PH, V274, pC1373, DOI 10.1152/ajpcell.1998.274.5.C1373; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; BRADLEY J, 1994, P NATL ACAD SCI USA, V91, P8890, DOI 10.1073/pnas.91.19.8890; BURCH LH, 1995, AM J PHYSIOL-CELL PH, V269, pC511, DOI 10.1152/ajpcell.1995.269.2.C511; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; Cheng C, 1998, J BIOL CHEM, V273, P22693, DOI 10.1074/jbc.273.35.22693; de la Rosa DA, 1999, J BIOL CHEM, V274, P37834, DOI 10.1074/jbc.274.53.37834; ERLIJ D, 1994, J PHYSL, V481, P553; Escoubet B, 1997, AM J PHYSIOL-CELL PH, V272, pC1482, DOI 10.1152/ajpcell.1997.272.5.C1482; Eskandari S, 1999, J BIOL CHEM, V274, P27281, DOI 10.1074/jbc.274.38.27281; Farman N, 1997, AM J PHYSIOL-CELL PH, V272, pC131, DOI 10.1152/ajpcell.1997.272.1.C131; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Fisher RS, 1996, AM J PHYSIOL-CELL PH, V270, pC138, DOI 10.1152/ajpcell.1996.270.1.C138; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; HELMAN SI, 1983, J GEN PHYSIOL, V82, P201, DOI 10.1085/jgp.82.2.201; Helman SI, 1998, AM J PHYSIOL-CELL PH, V274, pC947, DOI 10.1152/ajpcell.1998.274.4.C947; Hummler E, 1999, AM J PHYSIOL-GASTR L, V276, pG567, DOI 10.1152/ajpgi.1999.276.3.G567; Hummler E, 1996, NAT GENET, V12, P325, DOI 10.1038/ng0396-325; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; Ismailov II, 1996, J BIOL CHEM, V271, P807, DOI 10.1074/jbc.271.2.807; KELYMAN TR, 1994, AM J PHYSIOL, V266, pF506; KEMENDY AE, 1992, AM J PHYSIOL, V263, pC825, DOI 10.1152/ajpcell.1992.263.4.C825; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; Le KT, 1999, J BIOL CHEM, V274, P15415, DOI 10.1074/jbc.274.22.15415; Le KT, 1998, J NEUROSCI, V18, P7152; Leung SM, 2000, MOL BIOL CELL, V11, P2131, DOI 10.1091/mbc.11.6.2131; LING BN, 1989, AM J PHYSIOL, V256, pF1094, DOI 10.1152/ajprenal.1989.256.6.F1094; MARUNAKA Y, 1991, AM J PHYSIOL, V260, pC1071, DOI 10.1152/ajpcell.1991.260.5.C1071; MARUNAKA Y, 1992, AM J PHYSIOL, V263, pF392, DOI 10.1152/ajprenal.1992.263.3.F392; Masilamani S, 1999, J CLIN INVEST, V104, pR19, DOI 10.1172/JCI7840; MATSUMOTO PS, 1993, AM J PHYSIOL, V264, pC246, DOI 10.1152/ajpcell.1993.264.1.C246; May A, 1997, J AM SOC NEPHROL, V8, P1813; McNicholas CM, 1997, J GEN PHYSIOL, V109, P681, DOI 10.1085/jgp.109.6.681; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; PACHA J, 1993, J GEN PHYSIOL, V102, P25, DOI 10.1085/jgp.102.1.25; PALMER LG, 1983, AM J PHYSIOL, V244, pF195, DOI 10.1152/ajprenal.1983.244.2.F195; Palmer LG, 1996, J GEN PHYSIOL, V107, P35, DOI 10.1085/jgp.107.1.35; PALMER LG, 1988, J GEN PHYSIOL, V92, P121, DOI 10.1085/jgp.92.1.121; PRadervand S, 1999, P NATL ACAD SCI USA, V96, P1732, DOI 10.1073/pnas.96.4.1732; Prince LS, 1998, BIOCHEM J, V336, P705, DOI 10.1042/bj3360705; PUOTI A, 1995, AM J PHYSIOL, V269, pC1868; RENARD S, 1995, PFLUG ARCH EUR J PHY, V430, P299, DOI 10.1007/BF00373903; Rokaw MD, 1998, J BIOL CHEM, V273, P28746, DOI 10.1074/jbc.273.44.28746; Rokaw MD, 1996, AM J PHYSIOL-CELL PH, V270, pC600, DOI 10.1152/ajpcell.1996.270.2.C600; Ruknudin A, 1998, J BIOL CHEM, V273, P14165, DOI 10.1074/jbc.273.23.14165; SARIBANSOHRABY S, 1983, AM J PHYSIOL, V245, pC167, DOI 10.1152/ajpcell.1983.245.3.C167; Schaedel C, 1999, J PEDIATR-US, V135, P739, DOI 10.1016/S0022-3476(99)70094-6; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; STEELE RE, 1986, AM J PHYSIOL, V251, pC186; STEINMAN RM, 1976, J CELL BIOL, V68, P665, DOI 10.1083/jcb.68.3.665; TCHEPICHEV S, 1995, AM J PHYSIOL-CELL PH, V269, pC805, DOI 10.1152/ajpcell.1995.269.3.C805; Torres GE, 1998, MOL PHARMACOL, V54, P989, DOI 10.1124/mol.54.6.989; Torres GE, 1999, J BIOL CHEM, V274, P6653, DOI 10.1074/jbc.274.10.6653; Valentijn JA, 1998, J BIOL CHEM, V273, P30344, DOI 10.1074/jbc.273.46.30344; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411; WEISZ OA, 1993, J CELL BIOL, V122, P1185, DOI 10.1083/jcb.122.6.1185; Yeager M, 1998, CURR OPIN STRUC BIOL, V8, P517, DOI 10.1016/S0959-440X(98)80131-0; Zuckerman JB, 1999, J BIOL CHEM, V274, P23286, DOI 10.1074/jbc.274.33.23286	70	90	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39886	39893		10.1074/jbc.M003822200	http://dx.doi.org/10.1074/jbc.M003822200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10978318	hybrid			2022-12-25	WOS:000166039500015
J	Creemers, JWM; van de Loo, JWHP; Plets, E; Hendershot, LM; Van de Ven, WJM				Creemers, JWM; van de Loo, JWHP; Plets, E; Hendershot, LM; Van de Ven, WJM			Binding of BiP to the processing enzyme lymphoma proprotein convertase prevents aggregation, but slows down maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN HEAVY-CHAIN; MOLECULAR CHAPERONE BIP; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; IN-VITRO; PROHORMONE CONVERTASES; SERINE PROTEASES; QUALITY-CONTROL; ER MEMBRANE; FURIN	Lymphoma proprotein convertase (LPC) is a subtilisin-like serine protease of the mammalian proprotein convertase family. It is synthesized as an inactive precursor protein, and propeptide cleavage occurs via intramolecular cleavage in the endoplasmic reticulum. In contrast to other convertases like furin and proprotein convertase-1, propeptide cleavage occurs slowly, Also, both a glycosylated and an unglycosylated precursor are detected. Here we demonstrate that the unglycosylated precursor form of LPC is localized in the cytosol due to the absence of a signal peptide. Using a reducible cross-linker, we found that glycosylated pro-LPC is associated with the molecular chaperone BiP. In addition, we show that pro-LPC is prone to aggregation and forms large complexes linked via interchain disulfide bonds. BiP is associated mainly with non-aggregated pro-LPC and pro-LPC dimers and trimers, suggesting that BiP prevents aggregation. Overexpression of wild-type Dip or a dominant-negative BiP ATPase mutant resulted in reduced processing of pro-LPC. Taken together, these results suggest that binding of BiP to pro-LPC prevents aggregation, but results in slower maturation.	Katholieke Univ Leuven, Ctr Human Genet, Mol Oncol Lab, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, B-3000 Louvain, Belgium; St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA	KU Leuven; St Jude Children's Research Hospital	Creemers, JWM (corresponding author), Katholieke Univ Leuven, Ctr Human Genet, Mol Oncol Lab, Herestr 49, B-3000 Louvain, Belgium.	john.creemers@med.kuleuven.ac.be	Hendershot, Linda/N-8124-2018	Hendershot, Linda/0000-0002-5473-0274; Plets, Evelyn/0000-0001-7312-8804				Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; BRAKS JAM, 1994, CELL, V78, P263, DOI 10.1016/0092-8674(94)90296-8; Bruzzaniti A, 1996, BIOCHEM J, V314, P727, DOI 10.1042/bj3140727; Constam DB, 1996, J CELL BIOL, V134, P181, DOI 10.1083/jcb.134.1.181; Creemers JWM, 1996, J BIOL CHEM, V271, P25284, DOI 10.1074/jbc.271.41.25284; CREEMERS JWM, 1995, J BIOL CHEM, V270, P2695, DOI 10.1074/jbc.270.6.2695; CREEMERS JWM, 1993, J BIOL CHEM, V268, P21826; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GAUT JR, 1993, J BIOL CHEM, V268, P7248; Gething MJ, 1999, SEMIN CELL DEV BIOL, V10, P465, DOI 10.1006/scdb.1999.0318; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GLUSCHANKOF P, 1994, EMBO J, V13, P2280, DOI 10.1002/j.1460-2075.1994.tb06510.x; GOODMAN LJ, 1994, BIOCHEM BIOPH RES CO, V201, P795, DOI 10.1006/bbrc.1994.1771; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Hellman R, 1999, J CELL BIOL, V144, P21, DOI 10.1083/jcb.144.1.21; Hendershot L, 1996, P NATL ACAD SCI USA, V93, P5269, DOI 10.1073/pnas.93.11.5269; Jackson RS, 1997, NAT GENET, V16, P303, DOI 10.1038/ng0797-303; KIM PS, 1992, J CELL BIOL, V118, P541, DOI 10.1083/jcb.118.3.541; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Lamango NS, 1999, ARCH BIOCHEM BIOPHYS, V362, P275, DOI 10.1006/abbi.1998.1033; LEDUC R, 1992, J BIOL CHEM, V267, P14304; Mains RE, 1997, BIOCHEM J, V321, P587, DOI 10.1042/bj3210587; Matlack KES, 1999, CELL, V97, P553, DOI 10.1016/S0092-8674(00)80767-9; MATTHEWS G, 1994, J BIOL CHEM, V269, P588; Meerabux J, 1996, CANCER RES, V56, P448; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; Muller L, 1997, J CELL BIOL, V139, P625, DOI 10.1083/jcb.139.3.625; Munzer JS, 1997, J BIOL CHEM, V272, P19672, DOI 10.1074/jbc.272.32.19672; Muresan Z, 1998, MOL ENDOCRINOL, V12, P458, DOI 10.1210/me.12.3.458; Nagahama M, 1998, FEBS LETT, V434, P155, DOI 10.1016/S0014-5793(98)00970-3; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; POUYSSEGUR J, 1977, CELL, V11, P941, DOI 10.1016/0092-8674(77)90305-1; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; Siezen RJ, 1997, PROTEIN SCI, V6, P501; SIMONS JF, 1995, J CELL BIOL, V130, P41, DOI 10.1083/jcb.130.1.41; Tatu U, 1997, J CELL BIOL, V136, P555, DOI 10.1083/jcb.136.3.555; Taylor NA, 1998, J MOL ENDOCRINOL, V21, P209, DOI 10.1677/jme.0.0210209; vandeLoo JWHP, 1997, J BIOL CHEM, V272, P27116, DOI 10.1074/jbc.272.43.27116; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; VANDEVEN WJM, 1993, CRIT REV ONCOGENESIS, V4, P115; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; WEI JY, 1995, J BIOL CHEM, V270, P26677, DOI 10.1074/jbc.270.44.26677; Westphal CH, 1999, CELL, V96, P689, DOI 10.1016/S0092-8674(00)80579-6; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wouters S, 1998, BIOCHEM J, V336, P311, DOI 10.1042/bj3360311; YI Z, 1993, J BIOL CHEM, V268, P5615; Zhong M, 1999, J BIOL CHEM, V274, P33913, DOI 10.1074/jbc.274.48.33913; ZHOU A, 1995, J BIOL CHEM, V270, P21509, DOI 10.1074/jbc.270.37.21509	55	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38842	38847		10.1074/jbc.M006758200	http://dx.doi.org/10.1074/jbc.M006758200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10964928	hybrid			2022-12-25	WOS:000165739800095
J	Kumazaki, S; Nakajima, H; Sakaguchi, T; Nakagawa, E; Shinohara, H; Yoshihara, K; Aono, S				Kumazaki, S; Nakajima, H; Sakaguchi, T; Nakagawa, E; Shinohara, H; Yoshihara, K; Aono, S			Dissociation and recombination between ligands and heme in a CO-sensing transcriptional activator CooA - A flash photolysis study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOSPIRILLUM-RUBRUM; RAMAN-SPECTROSCOPY; CARBON-MONOXIDE; HISTIDINE 77; MYOGLOBIN; PROTEIN; PHOTODISSOCIATION; IDENTIFICATION; RELAXATION; ABSORPTION	CooA from Rhodospirillum rubrum is a transcriptional activator in which a heme prosthetic group acts as a CO sensor and regulates the activity of the protein. In this study, the electronic relaxation of the heme, and the concurrent recombination between ligands and the heme at similar to 280 K were examined in an effort to understand the environment around the heme and the dynamics of the ligands, Upon photoexcitation of the reduced CooA at 400 nm, electronic relaxation of the heme occurred with time constants of 0.8 and 1.7 ps, The ligand rebinding was substantially completed with a time constant of 6.5 ps, followed by a slow relaxation process with a time constant of 173 ps, In the case of GO-bound CooA, relaxation of the excited heme occurred with two time constants, 1.1 and 2.4 ps, which were largely similar to those with reduced CooA. The subsequent CO recombination process was remarkably fast compared with that of other GO-bound heme proteins. It was well described as a biphasic geminate recombination process with time constants of 78 ps (60%) and 386 ps (30%). About 10% of the excited heme remained unligated at 1.9 ns, The dynamics of rebinding of CO thus will help us to understand how the physiologically relevant diatomic molecule approaches the heme binding site in CooA with picosecond resolution.	Japan Adv Inst Sci & Technol, Sch Mat Sci, Tatsunokuchi, Ishikawa 9231292, Japan	Japan Advanced Institute of Science & Technology (JAIST)	Kumazaki, S (corresponding author), Japan Adv Inst Sci & Technol, Sch Mat Sci, Tatsunokuchi, Ishikawa 9231292, Japan.	kumazaki@jaist.ac.jp	Aono, Shigetoshi/ABD-7618-2020	Aono, Shigetoshi/0000-0002-2870-3694; Kumazaki, Shigeichi/0000-0003-0008-4200				Aono S, 1997, BIOCHEM BIOPH RES CO, V240, P783, DOI 10.1006/bbrc.1997.7746; Aono S, 1996, BIOCHEM BIOPH RES CO, V228, P752, DOI 10.1006/bbrc.1996.1727; Aono S, 1998, J BIOL CHEM, V273, P25757, DOI 10.1074/jbc.273.40.25757; Fox JD, 1996, J BACTERIOL, V178, P6200, DOI 10.1128/jb.178.21.6200-6208.1996; He YP, 1996, J BIOL CHEM, V271, P120, DOI 10.1074/jbc.271.1.120; HENRY ER, 1983, J MOL BIOL, V166, P443, DOI 10.1016/S0022-2836(83)80094-1; JACKSON TA, 1994, CHEM PHYS, V180, P131, DOI 10.1016/0301-0104(93)E0414-Q; JONGEWARD KA, 1988, J BIOL CHEM, V263, P6027; Kholodenko Y, 1999, BIOCHEMISTRY-US, V38, P5918, DOI 10.1021/bi983022v; Lim MH, 1996, J PHYS CHEM-US, V100, P12043, DOI 10.1021/jp9536458; MARTIN CT, 1985, J BIOL CHEM, V260, P2857; MARTIN JL, 1992, ANNU REV BIOPH BIOM, V21, P199, DOI 10.1146/annurev.bb.21.060192.001215; Mizutani Y, 1997, SCIENCE, V278, P443, DOI 10.1126/science.278.5337.443; Mizutani Y, 1999, INT CONGR SER, V1194, P85; Olson JS, 1996, J BIOL CHEM, V271, P17593, DOI 10.1074/jbc.271.30.17593; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; PETRICH JW, 1989, CHEM PHYS, V131, P31, DOI 10.1016/0301-0104(89)87079-X; QUILLIN ML, 1995, J MOL BIOL, V245, P416, DOI 10.1006/jmbi.1994.0034; SCHELVIS JP, 1997, J AM CHEM SOC, V119, P8400; Shelver D, 1999, BIOCHEMISTRY-US, V38, P2669, DOI 10.1021/bi982658j; Shelver D, 1997, P NATL ACAD SCI USA, V94, P11216, DOI 10.1073/pnas.94.21.11216; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; STOUTLAND PO, 1991, J PHYS CHEM-US, V95, P6406, DOI 10.1021/j100170a004; Uchida T, 1998, J BIOL CHEM, V273, P19988, DOI 10.1074/jbc.273.32.19988; Uchida T, 2000, BIOCHEMISTRY-US, V39, P12747, DOI 10.1021/bi0011476; XIE XL, 1991, BIOCHEMISTRY-US, V30, P3682, DOI 10.1021/bi00229a013	26	43	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38378	38383		10.1074/jbc.M005533200	http://dx.doi.org/10.1074/jbc.M005533200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10978334	hybrid			2022-12-25	WOS:000165739800034
J	Mechanic, LE; Frankel, BA; Matson, SW				Mechanic, LE; Frankel, BA; Matson, SW			Escherichia coli MutL loads DNA helicase II onto DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED MISMATCH REPAIR; BACTERIOPHAGE-T7 DEOXYRIBONUCLEIC-ACID; SINGLE-STRANDED-DNA; GENE-PRODUCT; REPLICATION FIDELITY; GENOME INSTABILITY; UVRD PROTEIN; BINDING; CANCER; HETERODUPLEX	Previous studies have shown that MutL physically interacts with UvrD (DNA helicase II) (Hall, M. C., Jordan, J. R., and Matson, S. W. (1998) EMBO J. 17, 1535-1541) and dramatically stimulates the unwinding reaction catalyzed by UvrD in the presence and absence of the other protein components of the methyl-directed mismatch repair pathway (Yamaguchi, M., Dao, V., and Modrich, P. (1998) J. Biol. Chem. 273, 9197-9201). The mechanism of this stimulation was investigated using DNA binding assays, single-turnover helicase assays, and unwinding assays involving long duplex DNA substrates. The results indicate that MutL binds DNA and loads UvrD onto the DNA substrate, The interaction between MutL and DNA and that between MutL and UvrD are both important for stimulation of UvrD-catalyzed unwinding. MutL does not clamp UvrD onto the substrate; and therefore, the processivity of unwinding is not increased in the presence of MutL. The implications of these results are discussed, and models are presented for the mechanism of MutL stimulation as well as for the role of MutL as a master coordinator in the methyl-directed mismatch repair pathway.	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Prot Engn, Chapel Hill, NC 27599 USA; Univ N Carolina, Mol Genet Training Program, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Matson, SW (corresponding author), Univ N Carolina, Dept Biol, CB 3280,Coker Hall, Chapel Hill, NC 27599 USA.	smatson@tbio.unc.edu			NIGMS NIH HHS [GM33476] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033476] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ail JA, 1999, J MOL BIOL, V293, P815, DOI 10.1006/jmbi.1999.3185; Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; AMARATUNGA M, 1993, BIOCHEMISTRY-US, V32, P6815, DOI 10.1021/bi00078a003; AU KG, 1992, J BIOL CHEM, V267, P12142; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; BENDE SM, 1991, NUCLEIC ACIDS RES, V19, P1549, DOI 10.1093/nar/19.7.1549; BJORNSON KP, 1994, BIOCHEMISTRY-US, V33, P14306, DOI 10.1021/bi00251a044; BROSH RM, 1995, J BACTERIOL, V177, P5612, DOI 10.1128/jb.177.19.5612-5621.1995; Brosh RM, 1996, J BIOL CHEM, V271, P25360, DOI 10.1074/jbc.271.41.25360; COOPER DL, 1993, J BIOL CHEM, V268, P11823; Dao V, 1998, J BIOL CHEM, V273, P9202, DOI 10.1074/jbc.273.15.9202; Drotschmann K, 1998, NUCLEIC ACIDS RES, V26, P948, DOI 10.1093/nar/26.4.948; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; GEORGE JW, 1994, J MOL BIOL, V235, P424, DOI 10.1006/jmbi.1994.1003; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; Hall MC, 1999, J BIOL CHEM, V274, P1306, DOI 10.1074/jbc.274.3.1306; Hall MC, 1998, EMBO J, V17, P1535, DOI 10.1093/emboj/17.5.1535; Hall MC, 1998, J MOL BIOL, V277, P257, DOI 10.1006/jmbi.1997.1614; HALL MH, 1998, THESIS U N CAROLINA; Jiricny J, 1996, CANCER SURV, V28, P47; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; MATSON SW, 1985, J BIOL CHEM, V260, P2281; MATSON SW, 1986, J BIOL CHEM, V261, P169; Mechanic LE, 1999, J BACTERIOL, V181, P2519, DOI 10.1128/JB.181.8.2519-2526.1999; Mechanic LE, 1999, J BIOL CHEM, V274, P12488, DOI 10.1074/jbc.274.18.12488; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MODRICH P, 1987, ANNU REV BIOCHEM, V56, P435, DOI 10.1146/annurev.biochem.56.1.435; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; RUNYON GT, 1989, J BIOL CHEM, V264, P17502; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P602, DOI 10.1021/bi00053a028; RUNYON GT, 1990, P NATL ACAD SCI USA, V87, P6383, DOI 10.1073/pnas.87.16.6383; SANCAR A, 1993, SCIENCE, V259, P1415, DOI 10.1126/science.8451638; Smith J.A., 2000, CURRENT PROTOCOLS MO; Spampinato C, 2000, J BIOL CHEM, V275, P9863, DOI 10.1074/jbc.275.13.9863; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; SU SS, 1988, J BIOL CHEM, V263, P6829; Umar A, 1996, EUR J BIOCHEM, V238, P297, DOI 10.1111/j.1432-1033.1996.0297z.x; WELSH KM, 1987, J BIOL CHEM, V262, P15624; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238; Yamaguchi M, 1998, J BIOL CHEM, V273, P9197, DOI 10.1074/jbc.273.15.9197	48	98	105	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38337	38346		10.1074/jbc.M006268200	http://dx.doi.org/10.1074/jbc.M006268200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10984488	hybrid, Green Published			2022-12-25	WOS:000165739800029
J	Njau, RK; Herndon, CA; Hawes, JW				Njau, RK; Herndon, CA; Hawes, JW			Novel beta-hydroxyacid dehydrogenases in Escherichia coli and Haemophilus influenzae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; 3-HYDROXYISOBUTYRATE DEHYDROGENASE; GENE; 6-PHOSPHOGLUCONATE	Our laboratory has previously reported a structurally and mechanistically related family of beta -hydroxyacid dehydrogenases with significant homology to beta -hydroxyisobutyrate dehydrogenase. A large number of the members of this family are hypothetical proteins of bacterial origin with unknown identity in terms of their substrate specificities and metabolic roles. The Escherichia coli beta -hydroxyacid dehydrogenase homologue corresponding to the AE000157 locus was cloned and expressed with a 6-histidine tag for specific purification. The purified recombinant protein very specifically catalyzed the NAD(+)-dependent oxidation of D-glycerate and the NADH-dependent reduction of tartronate semialdehyde, identifying this protein as a tartronate semialdehyde reductase. Further evidence for identification as tartronate semialdehyde reductase is the observation that the coding region for this protein is directly preceded by genes coding for hydroxypyruvate isomerase and glyoxylate carboligase, two enzymes that synthesize tartronate semialdehyde, producing an operon clearly designed for D-glycerate biosynthesis from tartronate semialdehyde. The single beta -hydroxyacid dehydrogenase homologue from Haemophilus influenzae was also cloned, expressed, and purified with a g-histidine tag. This protein also catalyzed the NAD(+)-dependent oxidation of D-glycerate but was significantly more efficient in the oxidation of four-carbon beta -hydroxyacids like D-hydroxybutyrate and D-threonine. This enzyme differs from all the presently known beta -hydroxybutyrate dehydrogenases which are well established members of the short chain dehydrogenase/reductase superfamily.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Hawes, JW (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.	jhawes@iupui.edu						ADAMS MJ, 1994, STRUCTURE, V2, P651, DOI 10.1016/S0969-2126(00)00066-6; ANDERSON AJ, 1990, MICROBIOL REV, V54, P450, DOI 10.1128/MMBR.54.4.450-472.1990; Aneja P, 1999, J BACTERIOL, V181, P849, DOI 10.1128/JB.181.3.849-857.1999; Ashiuchi M, 1999, BBA-PROTEIN STRUCT M, V1435, P153, DOI 10.1016/S0167-4838(99)00216-2; BERGMEYER HU, 1967, BIOCHEM J, V102, P423, DOI 10.1042/bj1020423; Gamble MV, 1999, J LIPID RES, V40, P2279; HAWES JW, 1995, BIOCHEMISTRY-US, V34, P4231, DOI 10.1021/bi00013a012; Hawes JW, 1996, FEBS LETT, V389, P263, DOI 10.1016/0014-5793(96)00597-2; HAWES JW, 1996, ENZYMOLOGY MOL BIOL, P395; Jia Y, 2000, BIOCHEMISTRY-US, V39, P3927, DOI 10.1021/bi9928086; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; KOHN LD, 1968, J BIOL CHEM, V243, P2465; KOHN LD, 1968, J BIOL CHEM, V243, P4426; Kruger K, 1999, APPL MICROBIOL BIOT, V52, P666, DOI 10.1007/s002530051576; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mirny LA, 1999, J MOL BIOL, V291, P177, DOI 10.1006/jmbi.1999.2911; ROUGRAFF PM, 1988, J BIOL CHEM, V263, P327; STEELE MI, 1992, J BIOL CHEM, V267, P13585; WILLIAMSON DH, 1974, METHODS ENZYMATIC AN; ZHANG L, 1999, BIOCHEMITRY, V18, P11231; ZHAO Y, 1994, J BIOL CHEM, V269, P18583	21	17	19	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38780	38786		10.1074/jbc.M007432200	http://dx.doi.org/10.1074/jbc.M007432200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10978349	hybrid			2022-12-25	WOS:000165739800088
J	Roshick, C; Iliffe-Lee, ER; McClarty, G				Roshick, C; Iliffe-Lee, ER; McClarty, G			Cloning and characterization of ribonucleotide reductase from Chlamydia trachomatis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA SECONDARY STRUCTURE; ESCHERICHIA-COLI; LARGE SUBUNIT; HYDROXYUREA RESISTANCE; TRANSLATION INITIATION; DIPHOSPHATE REDUCTASE; QUANTITATIVE-ANALYSIS; ALLOSTERIC REGULATION; TRYPANOSOMA-BRUCEI; RECOMBINANT MOUSE	In all organisms the deoxyribonucleotide precursors required for DNA synthesis are synthesized from ribonucleotides, a reaction catalyzed by ribonucleotide reductase. In a previous study we showed that Chlamydia trachomatis growth was inhibited by hydroxyurea, an inhibitor of ribonucleotide reductase, and a mutant resistant to the cytotoxic effects of the drug was isolated. Here we report the cloning, expression, and purification of the R1 and R2 subunits of the C. trachomatis ribonucleotide reductase. In comparison with other ribonucleotide reductases, the primary sequence of protein R1 has an extended amino terminus, and the R2 protein has a phenylalanine where the essential tyrosine is normally located. Despite its unusual primary structure, the recombinant enzyme catalyzes the reduction of CDP to dCDP. Results from deletion mutagenesis experiments indicate that while the extended amino terminus of the R1 protein is not required for enzyme activity, it is needed for allosteric inhibition mediated by dATP. Results with site directed mutants of protein R2 suggest that the essential tyrosine is situated two amino acids downstream of its normal location. Finally, Western blot analysis show that the hydroxyurea-resistant mutant C. trachomatis isolate overexpresses both subunits of ribonucleotide reductase. At the genetic level, compared with wild type C. trachomatis, the resistant isolate has a single base mutation just upstream of the ATG start codon of the R2 protein. The possibility that this mutation affects translational efficiency is discussed.	Univ Manitoba, Dept Med Microbiol, Winnipeg, MB R3E 0W3, Canada	University of Manitoba	McClarty, G (corresponding author), Univ Manitoba, Dept Med Microbiol, 730 William Ave, Winnipeg, MB R3E 0W3, Canada.	mcclart@cc.umanitoba.ca						BARRICK D, 1994, NUCLEIC ACIDS RES, V22, P1287, DOI 10.1093/nar/22.7.1287; BERGLUND O, 1972, J BIOL CHEM, V247, P7276; BOOKER S, 1994, BIOCHEMISTRY-US, V33, P12676, DOI 10.1021/bi00208a019; BOOKER S, 1993, P NATL ACAD SCI USA, V90, P8352, DOI 10.1073/pnas.90.18.8352; CALDWELL HD, 1981, INFECT IMMUN, V31, P1161, DOI 10.1128/IAI.31.3.1161-1176.1981; Chabes A, 2000, P NATL ACAD SCI USA, V97, P2474, DOI 10.1073/pnas.97.6.2474; CHOY BK, 1988, CANCER RES, V48, P2029; DAVIS R, 1994, J BIOL CHEM, V269, P23171; Davydov A, 1996, BIOCHEM BIOPH RES CO, V219, P213, DOI 10.1006/bbrc.1996.0207; DESMIT MH, 1994, J MOL BIOL, V244, P144, DOI 10.1006/jmbi.1994.1714; DESMIT MH, 1994, J MOL BIOL, V235, P173, DOI 10.1016/S0022-2836(05)80024-5; EHRENBERG A, 1972, J BIOL CHEM, V247, P3485; Eklund H, 1997, BIOL CHEM, V378, P821; ENGSTROM Y, 1979, BIOCHEMISTRY-US, V18, P2941, DOI 10.1021/bi00581a004; Eriksson M, 1997, STRUCTURE, V5, P1077, DOI 10.1016/S0969-2126(97)00259-1; FAHR MJ, 1995, J BACTERIOL, V177, P4252, DOI 10.1128/jb.177.15.4252-4260.1995; FAN HZ, 1991, J BACTERIOL, V173, P6670, DOI 10.1128/jb.173.21.6670-6677.1991; FLENSBURG J, 1987, EUR J BIOCHEM, V162, P473, DOI 10.1111/j.1432-1033.1987.tb10664.x; FRAIZ J, 1988, ANNU REV MED, V39, P357, DOI 10.1146/annurev.me.39.020188.002041; FUCHS JA, 1976, J BACTERIOL, V128, P810, DOI 10.1128/JB.128.3.810-814.1976; FURLONG J, 1991, VIROLOGY, V182, P846, DOI 10.1016/0042-6822(91)90627-N; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; HANKE PD, 1983, J BACTERIOL, V156, P1192, DOI 10.1128/JB.156.3.1192-1197.1983; Hofer A, 1997, P NATL ACAD SCI USA, V94, P6959, DOI 10.1073/pnas.94.13.6959; Hofer A, 1998, J BIOL CHEM, V273, P34098, DOI 10.1074/jbc.273.51.34098; Iliffe-Lee ER, 1999, MOL MICROBIOL, V33, P177, DOI 10.1046/j.1365-2958.1999.01464.x; Jordan A, 1997, P NATL ACAD SCI USA, V94, P13487, DOI 10.1073/pnas.94.25.13487; Jordan A, 1999, J BACTERIOL, V181, P3974, DOI 10.1128/JB.181.13.3974-3980.1999; JORDAN A, 1994, P NATL ACAD SCI USA, V91, P12892, DOI 10.1073/pnas.91.26.12892; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Kalman S, 1999, NAT GENET, V21, P385, DOI 10.1038/7716; LACY MJ, 1986, J IMMUNOL METHODS, V87, P169, DOI 10.1016/0022-1759(86)90527-2; LARSSON A, 1986, EMBO J, V5, P2037, DOI 10.1002/j.1460-2075.1986.tb04461.x; LESAGE P, 1992, J MOL BIOL, V228, P366, DOI 10.1016/0022-2836(92)90827-7; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; MATHEWS SA, 1994, J BACTERIOL, V176, P3785, DOI 10.1128/JB.176.12.3785-3789.1994; MCCLARTY G, 1991, J BACTERIOL, V173, P4922, DOI 10.1128/jb.173.16.4922-4931.1991; McClarty G, 1999, CHLAMYDIA, P69; MCCLARTY GA, 1987, BIOCHEMISTRY-US, V26, P8004, DOI 10.1021/bi00398a068; MOULDER JW, 1991, MICROBIOL REV, V55, P143, DOI 10.1128/MMBR.55.1.143-190.1991; NILSSON O, 1988, Nucleic Acids Research, V16, P4174, DOI 10.1093/nar/16.9.4174; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; Potsch S, 1999, J BIOL CHEM, V274, P17696, DOI 10.1074/jbc.274.25.17696; Read TD, 2000, NUCLEIC ACIDS RES, V28, P1397, DOI 10.1093/nar/28.6.1397; Riera J, 1997, P NATL ACAD SCI USA, V94, P475, DOI 10.1073/pnas.94.2.475; RINGQUIST S, 1992, MOL MICROBIOL, V6, P1219, DOI 10.1111/j.1365-2958.1992.tb01561.x; Sauge-Merle S, 1999, EUR J BIOCHEM, V266, P62, DOI 10.1046/j.1432-1327.1999.00814.x; Schachter J, 1999, CHLAMYDIA, P139; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SLABAUGH MB, 1986, J VIROL, V60, P506, DOI 10.1128/JVI.60.2.506-514.1986; SLABAUGH MB, 1993, J BIOL CHEM, V268, P17803; Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754; Storz J., 1988, Microbiology of Chlamydia., P167; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; Sun XY, 1996, J BIOL CHEM, V271, P6827, DOI 10.1074/jbc.271.12.6827; SUN XY, 1993, P NATL ACAD SCI USA, V90, P577, DOI 10.1073/pnas.90.2.577; THELANDER L, 1986, MOL CELL BIOL, V6, P3433, DOI 10.1128/MCB.6.10.3433; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; THELANDER M, 1989, EMBO J, V8, P2475, DOI 10.1002/j.1460-2075.1989.tb08383.x; TIPPLES G, 1993, MOL MICROBIOL, V8, P1105, DOI 10.1111/j.1365-2958.1993.tb01655.x; TIPPLES G, 1991, J BACTERIOL, V173, P4932, DOI 10.1128/jb.173.16.4932-4940.1991; TIPPLES G, 1995, J BIOL CHEM, V270, P7908, DOI 10.1074/jbc.270.14.7908; WALKER D, 1992, J MOL BIOL, V228, P265, DOI 10.1016/0022-2836(92)90505-E; Wylie JL, 1996, MOL MICROBIOL, V22, P631, DOI 10.1046/j.1365-2958.1996.d01-1717.x; Zhong GM, 1999, J EXP MED, V189, P1931, DOI 10.1084/jem.189.12.1931	65	63	63	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					38111	38119		10.1074/jbc.M006367200	http://dx.doi.org/10.1074/jbc.M006367200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10984489	hybrid			2022-12-25	WOS:000165618700107
J	Shiffman, D; Mikita, T; Tai, JTN; Wade, DP; Porter, JG; Seilhamer, JJ; Somogyi, R; Liang, SD; Lawn, RM				Shiffman, D; Mikita, T; Tai, JTN; Wade, DP; Porter, JG; Seilhamer, JJ; Somogyi, R; Liang, SD; Lawn, RM			Large scale gene expression analysis of cholesterol-loaded macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; DIFFERENTIATION-RELATED PROTEIN; ACTIVATED RECEPTOR-GAMMA; SMOOTH-MUSCLE CELLS; PPAR-GAMMA; ATHEROSCLEROTIC LESIONS; MESSENGER-RNA; OXIDIZED LDL; SCAVENGER RECEPTOR; ENDOTHELIAL-CELLS	We conducted large scale gene expression analysis of the response of macrophages to exposure to oxidized low density lipoprotein (Ox-LDL), Much of the vessel wall lesion of atherosclerosis is composed of macrophages that have become engorged with cholesterol. These resulting "foam cells" contribute to the progression of vascular disease through several pathways. As a potential model of foam cell formation, we treated THP-1 cells with 12-O-tetradecanoylphorbol 13-acetate to differentiate them into a macrophage-like phenotype and subsequently treated them with oxidized low density lipoprotein for various time periods. RNA from Ox-LDL treated and time-matched control untreated cells was hybridized to microarrays containing 9808 human genes. 268 genes were found to be at least 2-fold regulated at one or more time points. These regulation patterns were classified into seven clusters of expression profiles. The data is discussed in terms of the overall pattern of gene expression, the thematic classification of the responding genes, and the clustering of functional groups in distinct expression patterns. The magnitude and the temporal patterns of gene expression identified known and novel molecular components of the cellular response that are implicated in the growth, survival, migratory, inflammatory, and matrix remodeling activity of vessel wall macrophages. In particular, the role of nuclear receptors in mediating the gene expression modulation by Ox-LDL is highlighted.	CV Therapeut Inc, Palo Alto, CA 94304 USA; Incyte Genomics Inc, Palo Alto, CA 94304 USA	CV Therapeutics, Inc.; Incyte	Lawn, RM (corresponding author), CV Therapeut Inc, 3172 Porter Dr, Palo Alto, CA 94304 USA.	lawn@cvt.com						ACTON SL, 1994, J BIOL CHEM, V269, P21003; Arvilommi AM, 1997, EUR J IMMUNOL, V27, P248, DOI 10.1002/eji.1830270137; AUWERX J, 1991, EXPERIENTIA, V47, P22, DOI 10.1007/BF02041244; Brand K, 1997, ARTERIOSCL THROM VAS, V17, P1901, DOI 10.1161/01.ATV.17.10.1901; Brasaemle DL, 1997, J LIPID RES, V38, P2249; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1983, ANNU REV BIOCHEM, V362, P801; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; Costet P, 2000, J BIOL CHEM, V275, P28240; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DHAESELEER P, 2000, IN PRESS BIOINFORMAT; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eligini S, 1999, ARTERIOSCL THROM VAS, V19, P1719, DOI 10.1161/01.ATV.19.7.1719; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; FONG LG, 1991, J LIPID RES, V32, P1899; FRESHNEY IR, 1994, CULTURE ANIMAL CELLS, P277; Gao J, 1999, J BIOL CHEM, V274, P16825, DOI 10.1074/jbc.274.24.16825; Green DR, 2000, NATURE, V405, P28, DOI 10.1038/35011175; Grey ST, 1996, J IMMUNOL, V156, P2256; HAMMER A, 1995, ARTERIOSCL THROM VAS, V15, P704, DOI 10.1161/01.ATV.15.5.704; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Karsan A, 1996, BLOOD, V87, P3089, DOI 10.1182/blood.V87.8.3089.bloodjournal8783089; Kataoka H, 1999, CIRCULATION, V99, P3110, DOI 10.1161/01.CIR.99.24.3110; KELLEY JL, 1987, EXP MOL PATHOL, V46, P266, DOI 10.1016/0014-4800(87)90049-9; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Lennon PF, 1998, J EXP MED, V188, P1433, DOI 10.1084/jem.188.8.1433; Lilly M, 1999, ONCOGENE, V18, P4022, DOI 10.1038/sj.onc.1202741; Lowell BB, 1999, CELL, V99, P239, DOI 10.1016/S0092-8674(00)81654-2; MATIKAINEN S, 1994, INT J CANCER, V57, P98, DOI 10.1002/ijc.2910570118; MIYAGAWA J, 1995, J CLIN INVEST, V95, P404, DOI 10.1172/JCI117669; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Navab M, 1996, ARTERIOSCL THROM VAS, V16, P831, DOI 10.1161/01.ATV.16.7.831; NODAHEINY H, 1995, ARTERIOSCL THROM VAS, V15, P37, DOI 10.1161/01.ATV.15.1.37; PATAKI M, 1992, ARTERIOSCLER THROMB, V12, P936, DOI 10.1161/01.ATV.12.8.936; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; Ramprasad MP, 1996, P NATL ACAD SCI USA, V93, P14833, DOI 10.1073/pnas.93.25.14833; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; ROSENFELD ME, 1992, AM J PATHOL, V140, P291; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; SAMBRANO GR, 1995, P NATL ACAD SCI USA, V92, P1396, DOI 10.1073/pnas.92.5.1396; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; TSUCHIYA S, 1982, CANCER RES, V42, P1530; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700; Wang N, 1996, J BIOL CHEM, V271, P8837, DOI 10.1074/jbc.271.15.8837; Wang XK, 1999, FEBS LETT, V462, P145, DOI 10.1016/S0014-5793(99)01521-5; Wen XL, 1998, P NATL ACAD SCI USA, V95, P334, DOI 10.1073/pnas.95.1.334; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; Xaus J, 1999, IMMUNITY, V11, P103, DOI 10.1016/S1074-7613(00)80085-0; Xie B, 1998, J BIOL CHEM, V273, P11576, DOI 10.1074/jbc.273.19.11576; Yamashita Y, 1998, EUR J IMMUNOL, V28, P2981, DOI 10.1002/(SICI)1521-4141(199810)28:10<2981::AID-IMMU2981>3.0.CO;2-D; Yoshida H, 1998, ARTERIOSCL THROM VAS, V18, P794, DOI 10.1161/01.ATV.18.5.794	61	112	127	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37324	37332		10.1074/jbc.M004732200	http://dx.doi.org/10.1074/jbc.M004732200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10973959	hybrid			2022-12-25	WOS:000165618700005
J	Sotgia, F; Lee, JK; Das, K; Bedford, M; Petrucci, TC; Macioce, P; Sargiacomo, M; Bricarelli, FD; Minetti, C; Sudol, M; Lisanti, MP				Sotgia, F; Lee, JK; Das, K; Bedford, M; Petrucci, TC; Macioce, P; Sargiacomo, M; Bricarelli, FD; Minetti, C; Sudol, M; Lisanti, MP			Caveolin-3 directly interacts with the C-terminal tail of beta-dystroglycan - Identification of a central WW-like domain within caveolin family members	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-ASSOCIATED GLYCOPROTEINS; RICH MEMBRANE DOMAINS; SCAFFOLDING DOMAIN; INTEGRAL COMPONENT; PLASMA-MEMBRANE; PROTEIN; TYROSINE; EXPRESSION; SEQUENCE; ASSOCIATION	Caveolin-3, the most recently recognized member of the caveolin gene family, is muscle-specific and is found in both cardiac and skeletal muscle, as well as smooth muscle cells. Several independent lines of evidence indicate that caveolin-3 is localized to the sarcolemma, where it associates with the dystrophin-glycoprotein complex. However, it remains unknown which component of the dystrophin complex interacts with caveolin-3. Here, we demonstrate that caveolin-3 directly interacts with beta -dystroglycan, an integral membrane component of the dystrophin complex. Our results indicate that caveolin-3 co-localizes, co-fractionates, and coimmunoprecipitates with a fusion protein containing the cytoplasmic tail of beta -dystroglycan. In addition, we show that a novel WW-like domain within caveolin-3 directly recognizes the extreme C terminus of beta -dystroglycan that contains a PPXY motif. As the WW domain of dystrophin recognizes the same site within beta -dystroglycan, we also demonstrate that caveolin-3 can effectively block the interaction of dystrophin with beta -dystroglycan. In this regard, interaction of caveolin-3 with beta -dystroglycan may competitively regulate the recruitment of dystrophin to the sarcolemma. We discuss the possible implications of our findings in the context of Duchenne muscular dystrophy.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; Univ Genoa, Ist Gaslini, Serv Malattie Neuro Muscolari, I-16147 Genoa, Italy; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Ist Super Sanita, Biol Cellulaire Lab, I-00161 Rome, Italy; Ist Super Sanita, Dept Hematol Oncol, I-00161 Rome, Italy; CUNY Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA; EO Osped Galliera, Lab Genet Umana, I-16128 Genoa, Italy	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Genoa; IRCCS Istituto Giannina Gaslini; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Harvard Medical School; Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Ente Ospedaliero Ospedali Galliera	Lisanti, MP (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	lisanti@aecom.yu.edu	Macioce, Pompeo/H-2142-2016; Minetti, Carlo/K-4666-2018; Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013; Bedford, Mark T/E-7856-2011	Macioce, Pompeo/0000-0002-1829-9448; Minetti, Carlo/0000-0002-0640-1804; Lisanti, Michael/0000-0003-2034-1382; Sotgia, Federica/0000-0003-2826-4529; Sargiacomo, Massimo/0000-0003-4040-706X	Telethon [1111] Funding Source: Medline	Telethon(Fondazione Telethon)		BONILLA E, 1981, AM J PATHOL, V104, P167; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Crosbie RH, 1998, FEBS LETT, V427, P279, DOI 10.1016/S0014-5793(98)00442-6; Das K, 1999, J BIOL CHEM, V274, P18721, DOI 10.1074/jbc.274.26.18721; di Vignano AT, 2000, FEBS LETT, V471, P229, DOI 10.1016/S0014-5793(00)01400-9; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Galbiati F, 2000, P NATL ACAD SCI USA, V97, P9689, DOI 10.1073/pnas.160249097; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Huang X, 2000, NAT STRUCT BIOL, V7, P634, DOI 10.1038/77923; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; Irusta PM, 1998, EMBO J, V17, P6912, DOI 10.1093/emboj/17.23.6912; James M, 2000, J CELL SCI, V113, P1717; JUNG D, 1995, J BIOL CHEM, V270, P27305, DOI 10.1074/jbc.270.45.27305; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MASTICK CC, 1995, J CELL BIOL, V129, P1523, DOI 10.1083/jcb.129.6.1523; MCFARLAND EDC, 1995, J BIOL CHEM, V270, P28103; NORTH AJ, 1993, J CELL BIOL, V120, P1159, DOI 10.1083/jcb.120.5.1159; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; Razani B, 2000, J CELL SCI, V113, P2103; Rentschler S, 1999, BIOL CHEM, V380, P431, DOI 10.1515/BC.1999.057; Repetto S, 1999, BIOCHEM BIOPH RES CO, V261, P547, DOI 10.1006/bbrc.1999.1055; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; Rosa G, 1996, BIOCHEM BIOPH RES CO, V223, P272, DOI 10.1006/bbrc.1996.0883; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SARGIACOMO M, 1994, ONCOGENE, V9, P2589; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Schlegel A, 2000, J BIOL CHEM, V275, P21605, DOI 10.1074/jbc.M002558200; Schlegel A, 1999, J BIOL CHEM, V274, P22660, DOI 10.1074/jbc.274.32.22660; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; SEVERS NJ, 1988, J CELL SCI, V90, P341; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711	60	172	178	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					38048	38058		10.1074/jbc.M005321200	http://dx.doi.org/10.1074/jbc.M005321200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10988290	hybrid			2022-12-25	WOS:000165618700099
J	Verhaegh, GW; van Bokhoven, A; Smit, F; Schalken, JA; Bussemakers, MJG				Verhaegh, GW; van Bokhoven, A; Smit, F; Schalken, JA; Bussemakers, MJG			Isolation and characterization of the promoter of the human prostate cancer-specific DD3 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANDROGEN-REGULATED EXPRESSION; TISSUE-SPECIFIC EXPRESSION; DNA-BINDING; MEMBRANE ANTIGEN; TRANSGENIC MICE; THERAPY; IDENTIFICATION; ENHANCERS; PROTEINS; CLONING	Recently, we have described a novel gene, DD3, which is one of the most prostate cancer-specific genes described to date (Bussemakers, M. J. G., van Bokhoven, A., Verhaegh, G. W,, Smit, F. P., Karthaus, H. F. M., Schalken, J. A, Debruyne, F. M. J., Ru, N., and Isaacs, W. B. (1999) Cancer Res. 59, 5975-5979). The prostate cancer-specific expression of DD3 indicates that the DD3 gene promoter is a promising tool for the treatment of prostate cancer. To identify the promoter elements that are responsible for the prostate cancer-specific expression of DD3, we have isolated and characterized the DD3 promoter. Sequence analysis of the DD3 B'-flanking region was performed and several promoter-human growth hormone reporter constructs were prepared, which were transiently transfected in the DD3-positive cell line LNCaP and several DD3-negative cell lines. Using a 500-base pair DD3 promoter construct, we could detect promoter activity in LNCaP cells, which was not affected by increasing the size of the constructs. Truncated constructs, however, showed an increased transcriptional activity, suggesting the presence of a silencer that negatively regulates the expression of DD3. DNase-I footprint analysis, using nuclear extracts from LNCaP cells, revealed the presence of three DNase-I-protected areas within the DD3 proximal promoter. We show that the high mobility group I(Y) protein binds to one of the DNase-I-protected areas and recruits another, yet unidentified, protein to the DD3 promoter in LNCaP cells.	Catholic Univ Nijmegen, Med Ctr, Urol Res Lab, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Verhaegh, GW (corresponding author), Catholic Univ Nijmegen, Med Ctr, Urol Res Lab, POB 9101, NL-6500 HB Nijmegen, Netherlands.		Verhaegh, Gerald/L-4708-2015; Schalken, Jack A/B-1277-2014; Bussemakers, Marion JG/D-4259-2012	Verhaegh, Gerald/0000-0003-0227-2280; Schalken, Jack A/0000-0001-8274-7797; 				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Boulikas T, 1997, ANTICANCER RES, V17, P1471; Brakebusch C, 1997, J BIOL CHEM, V272, P3674, DOI 10.1074/jbc.272.6.3674; Bussemakers MJG, 1999, CANCER RES, V59, P5975; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P1256, DOI 10.1210/me.11.9.1256; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dubbink HJ, 1996, BIOCHEM J, V315, P901, DOI 10.1042/bj3150901; Gotoh A, 1998, J UROLOGY, V160, P220, DOI 10.1016/S0022-5347(01)63094-5; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; ISRAELI RS, 1993, CANCER RES, V53, P227; Israeli RS, 1997, UROL CLIN N AM, V24, P439, DOI 10.1016/S0094-0143(05)70391-8; Kaluz S, 1999, J BIOL CHEM, V274, P32588, DOI 10.1074/jbc.274.46.32588; LIN MF, 1992, CANCER RES, V52, P4600; Martiniello-Wilks R, 1998, HUM GENE THER, V9, P1617, DOI 10.1089/hum.1998.9.11-1617; MCCORMACK RT, 1995, UROLOGY, V45, P729, DOI 10.1016/S0090-4295(99)80076-4; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Overdier DG, 1997, J BIOL CHEM, V272, P13725, DOI 10.1074/jbc.272.21.13725; Pang S, 1997, CANCER RES, V57, P495; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Reiter RE, 1998, P NATL ACAD SCI USA, V95, P1735, DOI 10.1073/pnas.95.4.1735; Sambrook J., 2002, MOL CLONING LAB MANU; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Sokoll LJ, 1997, UROL CLIN N AM, V24, P253, DOI 10.1016/S0094-0143(05)70370-0; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; TAMIMI Y, 1993, CANCER RES, V53, P5512; TANEJA SS, 1995, CANCER SURV, V23, P247; vanWeerden WM, 1996, AM J PATHOL, V149, P1055; Wei CW, 1997, P NATL ACAD SCI USA, V94, P6369, DOI 10.1073/pnas.94.12.6369; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; YE JP, 1994, J BIOL CHEM, V269, P25728	37	35	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37496	37503		10.1074/jbc.M006293200	http://dx.doi.org/10.1074/jbc.M006293200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10982808	hybrid, Green Published			2022-12-25	WOS:000165618700028
J	Fujiwara, C; Imamura, A; Hashiguchi, N; Shimozawa, N; Suzuki, Y; Kondo, N; Imanaka, T; Tsukamoto, T; Osumi, T				Fujiwara, C; Imamura, A; Hashiguchi, N; Shimozawa, N; Suzuki, Y; Kondo, N; Imanaka, T; Tsukamoto, T; Osumi, T			Catalase-less peroxisomes - Implication in the milder forms of peroxisome biogenesis disorder	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFICIENT ZELLWEGER-SYNDROME; OVARY CELL MUTANTS; COMPLEMENTATION GROUP; FUNCTIONAL COMPLEMENTATION; MEMBRANE-PROTEIN; IN-VIVO; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; COMMON-CAUSE; HUMAN PEX1	We established a Chinese hamster ovary cell line having a temperature-sensitive phenotype in peroxisome biogenesis. This mutant (65TS) was produced by transforming a PEX2-defective mutant, Z65, with a mutant PEX2 gene, pEX2(E55K), derived from a patient with infantile Refsum disease, a milder form of peroxisome biogenesis disorder. In 65TS, catalase was found in the cytosol at a nonpermissive temperature (39 degreesC), but upon the shift to a permissive temperature (33 degreesC), catalase gradually localized to the structures containing a 70-kDa peroxisomal membrane protein, PMP70. In contrast to catalase, other matrix proteins containing typical peroxisome targeting signals, acyl-CoA oxidase and peroxisomal 3-ketoacyl-CoA thiolase, were co-localized with PMP70 in most cells, even at 39 degreesC. We found that these structures are partially functional peroxisomes and named them "catalase-less peroxisomes.'' Catalase-less peroxisomes were also observed in human fibroblasts from patients with milder forms of peroxisome biogenesis disorder, including the one from which the mutant PEX2 gene was derived. We suggest that these structures are the causes of the milder phenotypes of the patients. Temperature-dependent restoration of the peroxisomes in 65TS occurred even in the presence of cycloheximide, a protein synthesis inhibitor. Thus, we conclude that in 65TS, catalase-less peroxisomes are the direct precursors of peroxisomes.	Himeji Inst Technol, Fac Sci, Dept Life Sci, Kamigori, Hyogo 6781297, Japan; Gifu Univ, Sch Med, Dept Pediat, Gifu 5008076, Japan; Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Dept Biol Chem, Toyama 9300194, Japan	University of Hyogo; Gifu University; University of Toyama	Osumi, T (corresponding author), Himeji Inst Technol, Fac Sci, Dept Life Sci, 3-2-1 Koto, Kamigori, Hyogo 6781297, Japan.	osumi@sci.himeji-tech.ac.jp		Shimozawa, Nobuyuki/0000-0003-3040-5458; Imanaka, Tsuneo/0000-0003-4677-1356				Distel B, 1996, J CELL BIOL, V135, P1, DOI 10.1083/jcb.135.1.1; Elgersma Y, 1997, EMBO J, V16, P7326, DOI 10.1093/emboj/16.24.7326; Faber KN, 1998, MOL CELL BIOL, V18, P936, DOI 10.1128/MCB.18.2.936; Fiering S, 2000, BIOESSAYS, V22, P381, DOI 10.1002/(SICI)1521-1878(200004)22:4<381::AID-BIES8>3.0.CO;2-E; Fukuda S, 1996, AM J HUM GENET, V59, P1210; Geisbrecht BV, 1998, P NATL ACAD SCI USA, V95, P8630, DOI 10.1073/pnas.95.15.8630; Hettema EH, 2000, EMBO J, V19, P223, DOI 10.1093/emboj/19.2.223; Honsho M, 1998, AM J HUM GENET, V63, P1622, DOI 10.1086/302161; Imamura A, 1998, HUM MOL GENET, V7, P2089, DOI 10.1093/hmg/7.13.2089; Imamura A, 1998, AM J HUM GENET, V62, P1539, DOI 10.1086/301881; Imamura A, 2000, BRAIN DEV-JPN, V22, P8, DOI 10.1016/S0387-7604(99)00072-8; Imanaka T, 1996, J BIOL CHEM, V271, P3706; Kinoshita N, 1998, J BIOL CHEM, V273, P24122, DOI 10.1074/jbc.273.37.24122; Kunau WH, 1998, CURR BIOL, V8, pR299, DOI 10.1016/S0960-9822(98)70191-5; Lazarow P. B., 1995, METABOLIC MOL BASES, P2287; LAZAROW PB, 1982, ANN NY ACAD SCI, V386, P285, DOI 10.1111/j.1749-6632.1982.tb21423.x; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; Matsuzono Y, 1999, P NATL ACAD SCI USA, V96, P2116, DOI 10.1073/pnas.96.5.2116; MIYAZAWA S, 1989, MOL CELL BIOL, V9, P83, DOI 10.1128/MCB.9.1.83; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V181, P947, DOI 10.1016/0006-291X(91)92028-I; PATARCA R, 1992, FEBS LETT, V312, P1, DOI 10.1016/0014-5793(92)81397-5; Portsteffen H, 1997, NAT GENET, V17, P449, DOI 10.1038/ng1297-449; Purdue PE, 1996, J CELL BIOL, V134, P849, DOI 10.1083/jcb.134.4.849; Reuber BE, 1997, NAT GENET, V17, P445, DOI 10.1038/ng1297-445; SANTOS MJ, 1988, J BIOL CHEM, V263, P10502; SANTOS MJ, 1988, SCIENCE, V239, P1536, DOI 10.1126/science.3281254; Setoyama C, 1995, BIOCHEM BIOPH RES CO, V217, P482, DOI 10.1006/bbrc.1995.2801; Shimozawa N, 1999, HUM MOL GENET, V8, P1077, DOI 10.1093/hmg/8.6.1077; Shimozawa N, 1999, J MED GENET, V36, P779, DOI 10.1136/jmg.36.10.779; Shimozawa N, 1998, AM J HUM GENET, V63, P1898, DOI 10.1086/302142; SHIMOZAWA N, 1988, PEDIATR RES, V24, P723, DOI 10.1203/00006450-198812000-00015; SHIMOZAWA N, 1992, SCIENCE, V255, P1132, DOI 10.1126/science.1546315; South ST, 1999, J CELL BIOL, V144, P255, DOI 10.1083/jcb.144.2.255; SUZUKI Y, 1991, BIOCHEM PHARMACOL, V41, P453, DOI 10.1016/0006-2952(91)90544-F; TAHAK HF, 1999, TRENDS CELL BIOL, V9, P447; Tamura S, 1998, BIOCHEM BIOPH RES CO, V245, P883, DOI 10.1006/bbrc.1998.8522; Tamura S, 1998, P NATL ACAD SCI USA, V95, P4350, DOI 10.1073/pnas.95.8.4350; Titorenko VI, 2000, J CELL BIOL, V148, P29, DOI 10.1083/jcb.148.1.29; Titorenko VI, 1998, MOL CELL BIOL, V18, P2789, DOI 10.1128/MCB.18.5.2789; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; TSUKAMOTO T, 1995, NAT GENET, V11, P395, DOI 10.1038/ng1295-395; TSUKAMOTO T, 1991, NATURE, V350, P77, DOI 10.1038/350077a0; Yahraus T, 1996, EMBO J, V15, P2914, DOI 10.1002/j.1460-2075.1996.tb00654.x; Yamasaki M, 1999, J BIOL CHEM, V274, P35293, DOI 10.1074/jbc.274.50.35293; Yamasaki M., 1998, BIOIMAGES, V6, P1	46	14	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37271	37277		10.1074/jbc.M006347200	http://dx.doi.org/10.1074/jbc.M006347200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10960480	hybrid			2022-12-25	WOS:000165577700112
J	Janulczyk, R; Iannelli, F; Sjoholm, AG; Pozzi, G; Bjorck, L				Janulczyk, R; Iannelli, F; Sjoholm, AG; Pozzi, G; Bjorck, L			Hic, a novel surface protein of Streptococcus pneumoniae that interferes with complement function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-H; NEISSERIA-GONORRHOEAE; SERUM RESISTANCE; BINDING; VIRULENCE; DEGRADATION; SEQUENCE; REGION; TRANSFORMATION; OPSONIZATION	The important human pathogen Streptococcus pneumoniae was found to absorb factor H, an inhibitor of complement, from human plasma. We identified the gene encoding a novel surface protein, factor H-binding inhibitor of complement (Hic), in the pspC locus of type 3 pneumococci, Unlike PspC proteins in other serotypes, Hic is anchored to the cell wall by means of an LPXTG motif, and the overall sequence homology to various PspC proteins is low. However, the NH2-terminal region showed significant homology to the NH2-terminal region of several PspC proteins. A fragment of Hic, covering this homologous region, was expressed as a glutathione S-transferase (GST) fusion protein. GST:Hic(39-261) bound radiolabeled factor H and inhibited binding of factor H to pneumococci of different serotypes. Interaction kinetics between GST:Hic(39-261) and factor H were studied with surface plasmon resonance and showed a high affinity binding (K-A = 5 x 10(7), K-D = 2.3 x 10(-8)). Mutant pneumococci lacking Hic showed no absorption of factor H in human plasma and no binding of radiolabeled factor H, suggesting that Hic is responsible for factor H-binding in type 3 pneumococci, Factor H-dependent inhibition of the alternative pathway was not diminished by the presence of GST:Hic(39-261). I, addition, an intrinsic inhibitory effect of Hic is suggested.	Univ Lund, Sect Mol Pathogenesis, Dept Cell & Mol Biol, S-22100 Lund, Sweden; Univ Lund, Dept Lab Med, Sect MIG, S-22100 Lund, Sweden; Univ Siena, Dept Mol Biol, I-53100 Siena, Italy	Lund University; Lund University; University of Siena	Janulczyk, R (corresponding author), Univ Lund, Sect Mol Pathogenesis, Dept Cell & Mol Biol, Solvegatan 39, S-22100 Lund, Sweden.		Pozzi, Gianni/Q-2713-2018; Iannelli, Francesco/R-1170-2018	Pozzi, Gianni/0000-0002-9557-4714; Iannelli, Francesco/0000-0001-5064-1496				AKESSON P, 1990, MOL IMMUNOL, V27, P523, DOI 10.1016/0161-5890(90)90071-7; ALONSODEVELASCO E, 1995, MICROBIOL REV, V59, P591, DOI 10.1128/MMBR.59.4.591-603.1995; ANGEL CS, 1994, J INFECT DIS, V170, P600, DOI 10.1093/infdis/170.3.600; Avery OT, 1944, J EXP MED, V79, P137, DOI 10.1084/jem.79.2.137; Berry AM, 1996, INFECT IMMUN, V64, P5255, DOI 10.1128/IAI.64.12.5255-5262.1996; BERRY AM, 1989, INFECT IMMUN, V57, P2037, DOI 10.1128/IAI.57.7.2037-2042.1989; Brooks-Walter A, 1999, INFECT IMMUN, V67, P6533; BROWN EJ, 1985, CURR TOP MICROBIOL, V121, P159; BRUYN GAW, 1992, CLIN INFECT DIS, V14, P251, DOI 10.1093/clinids/14.1.251; CHINA B, 1993, INFECT IMMUN, V61, P3129, DOI 10.1128/IAI.61.8.3129-3136.1993; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOMI H, 1990, J IMMUNOL, V144, P4046; GORDON DL, 1988, J INFECT DIS, V157, P697, DOI 10.1093/infdis/157.4.697; Hammerschmidt S, 1997, MOL MICROBIOL, V25, P1113, DOI 10.1046/j.1365-2958.1997.5391899.x; HARBAUGH MP, 1993, MOL MICROBIOL, V8, P981, DOI 10.1111/j.1365-2958.1993.tb01642.x; HOLLINGSHEAD SK, 1986, J BIOL CHEM, V261, P1677; HORSTMANN RD, 1988, P NATL ACAD SCI USA, V85, P1657, DOI 10.1073/pnas.85.5.1657; HORTON RM, 1995, MOL BIOTECHNOL, V3, P93, DOI 10.1007/BF02789105; HOSTETTER MK, 1986, J INFECT DIS, V153, P682, DOI 10.1093/infdis/153.4.682; Iannelli F, 1999, J BACTERIOL, V181, P2652, DOI 10.1128/JB.181.8.2652-2654.1999; Johnsson E, 1998, J IMMUNOL, V161, P4894; Johnsson E, 1996, J IMMUNOL, V157, P3021; KELLY T, 1994, INFECT IMMUN, V62, P1813, DOI 10.1128/IAI.62.5.1813-1819.1994; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCDANIEL LS, 1987, J EXP MED, V165, P381, DOI 10.1084/jem.165.2.381; Morgan BP, 1999, COMPLEMENT REGULATOR, p[59, 121]; Navarre WW, 1999, MICROBIOL MOL BIOL R, V63, P174, DOI 10.1128/MMBR.63.1.174-229.1999; Neeleman C, 1999, INFECT IMMUN, V67, P4517, DOI 10.1128/IAI.67.9.4517-4524.1999; NESBITT SA, 1992, ANAL BIOCHEM, V206, P267, DOI 10.1016/0003-2697(92)90365-E; NYDEGGER UE, 1978, J IMMUNOL, V120, P1404; Pozzi G, 1996, J BACTERIOL, V178, P6087, DOI 10.1128/jb.178.20.6087-6090.1996; Ram S, 1998, J EXP MED, V187, P743, DOI 10.1084/jem.187.5.743; Ram S, 1998, J EXP MED, V188, P671, DOI 10.1084/jem.188.4.671; Rosenow C, 1997, MOL MICROBIOL, V25, P819, DOI 10.1111/j.1365-2958.1997.mmi494.x; SHOEMAKER NB, 1974, MOL GEN GENET, V128, P283, DOI 10.1007/BF00268516; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRUEDSSON L, 1993, J IMMUNOL, V151, P5856; Tu AHT, 1999, INFECT IMMUN, V67, P4720, DOI 10.1128/IAI.67.9.4720-4724.1999; Wurzner R, 1999, MOL IMMUNOL, V36, P249, DOI 10.1016/S0161-5890(99)00049-8; Zipfel PF, 1999, MOL IMMUNOL, V36, P241, DOI 10.1016/S0161-5890(99)00038-3	41	171	180	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37257	37263		10.1074/jbc.M004572200	http://dx.doi.org/10.1074/jbc.M004572200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10967103	hybrid, Green Published			2022-12-25	WOS:000165577700110
J	Studer, S; Narberhaus, F				Studer, S; Narberhaus, F			Chaperone activity and homo- and hetero-oligomer formation of bacterial small heat shock proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-B-CRYSTALLIN; COMPLETE GENOME SEQUENCE; ESCHERICHIA-COLI; QUATERNARY STRUCTURE; LENS ALPHA; EXPRESSION; HSP25; IBPB; COMPLEX; BINDING	Rhizobia are the only bacteria known to induce a multitude of small heat shock proteins (sHsps) upon temperature upshift. The sHsps of Bradyrhizobium japonicum fall into two different classes, class A and class B. Here, we studied the chaperone activity and oligomeric features of two representative members of each class. The purified sHsps were efficient chaperones, as demonstrated by their ability to prevent thermally induced aggregation of citrate synthase in vitro. Homo-oligomer formation of all four sHsps was demonstrated by gel filtration and by two independent co-purification approaches. Mixed oligomers were readily observed between members of the same class, even when these proteins originated from different species such as Escherichia coli and B. japonicum. The chaperone activity of purified hetero oligomers was indistinguishable from the activity of homo-oligomers. Heteromeric complexes were never obtained between class A and class B sHsps, indicating that hetero-oligomer formation is restricted to sHsps of the same class.	Swiss Fed Inst Technol, Inst Microbiol, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Narberhaus, F (corresponding author), Swiss Fed Inst Technol, Inst Microbiol, Schmelzbergstr 7, CH-8092 Zurich, Switzerland.	fnarber@micro.biol.ethz.ch		Narberhaus, Franz/0000-0002-8552-5310				ALLEN SP, 1992, J BACTERIOL, V174, P6938, DOI 10.1128/JB.174.21.6938-6947.1992; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Chang ZY, 1996, J BIOL CHEM, V271, P7218, DOI 10.1074/jbc.271.12.7218; Cobb BA, 2000, J BIOL CHEM, V275, P6664, DOI 10.1074/jbc.275.9.6664; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; Ehrnsperger M, 1999, J BIOL CHEM, V274, P14867, DOI 10.1074/jbc.274.21.14867; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Haley DA, 1998, J MOL BIOL, V277, P27, DOI 10.1006/jmbi.1997.1611; Haley DA, 2000, J MOL BIOL, V298, P261, DOI 10.1006/jmbi.2000.3657; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; Helm KW, 1997, PLANT PHYSIOL, V114, P1477, DOI 10.1104/pp.114.4.1477; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kitagawa M, 2000, FEMS MICROBIOL LETT, V184, P165, DOI 10.1111/j.1574-6968.2000.tb09009.x; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; Lindner RA, 2000, EUR J BIOCHEM, V267, P1923, DOI 10.1046/j.1432-1327.2000.01188.x; MERCK KB, 1993, J BIOL CHEM, V268, P1046; Munchbach M, 1999, J BACTERIOL, V181, P83; Munchbach M, 1999, EUR J BIOCHEM, V264, P39, DOI 10.1046/j.1432-1327.1999.00567.x; Roy SK, 1999, EUR J BIOCHEM, V262, P406, DOI 10.1046/j.1432-1327.1999.00380.x; Shearstone JR, 1999, J BIOL CHEM, V274, P9937, DOI 10.1074/jbc.274.15.9937; Soto A, 1999, PLANT PHYSIOL, V120, P521, DOI 10.1104/pp.120.2.521; Sun TX, 1997, J BIOL CHEM, V272, P6220, DOI 10.1074/jbc.272.10.6220; Thomas JG, 1998, J BACTERIOL, V180, P5165, DOI 10.1128/JB.180.19.5165-5172.1998; van Boekel MAM, 1999, BBA-PROTEIN STRUCT M, V1434, P114, DOI 10.1016/S0167-4838(99)00178-8; van de Klundert FAJM, 1998, EUR J BIOCHEM, V258, P1014, DOI 10.1046/j.1432-1327.1998.2581014.x; Waters ER, 1996, J EXP BOT, V47, P325, DOI 10.1093/jxb/47.3.325; ZANTEMA A, 1992, J BIOL CHEM, V267, P12936	34	75	81	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37212	37218		10.1074/jbc.M004701200	http://dx.doi.org/10.1074/jbc.M004701200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10978322	hybrid			2022-12-25	WOS:000165577700103
J	Whisstock, JC; Romero, S; Gurung, R; Nandurkar, H; Ooms, LM; Bottomley, SP; Mitchell, CA				Whisstock, JC; Romero, S; Gurung, R; Nandurkar, H; Ooms, LM; Bottomley, SP; Mitchell, CA			The inositol polyphosphate 5-phosphatases and the apurinic/apyrimidinic base excision repair endonucleases share a common mechanism for catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN APURINIC ENDONUCLEASE; SITE-DIRECTED MUTAGENESIS; HUMAN-PLATELETS; DNASE-I; IDENTIFICATION; RESIDUES; MEMBRANE; BINDING; 1,4,5-TRISPHOSPHATE; PHOSPHOINOSITIDES	Inositol polyphosphate 5-phosphatases (5-phosphatase) hydrolyze the 5-position phosphate from the inositol ring of phosphatidylinositol-derived signaling molecules; however; the mechanism of catalysis is only partially characterized. These enzymes play critical roles in regulating cell growth, apoptosis, intracellular calcium oscillations, and post-synaptic vesicular trafficking. The UCLA fold recognition server (threader) predicted that the conserved 300-amino acid catalytic domain, common to all 5-phosphatases, adopts the fold of the apurinic/apyrimidinic (AP) base excision repair endonucleases. PSI-BLAST searches of GENPEPT, using the amino acid sequence of AP endonuclease exonuclease III, identified all members of the B-phosphatase family with highly significant scores. A sequence alignment between exonuclease III and all known 5-phosphatases revealed six highly conserved motifs containing residues that corresponded to the catalytic residues in the AP endonucleases. Mutation of each of these residues to alanine in the mammalian 43-kDa, or yeast Inp52p 5-phosphatase, resulted in complete loss of enzyme activity. We predict the 5-phosphatase enzymes share a similar mechanism of catalysis to the AP endonucleases, consistent with other common functional similarities such as an absolute requirement for magnesium for activity. Based on this analysis, functional roles have been assigned to conserved residues in all B-phosphatase enzymes.	Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia	Monash University	Mitchell, CA (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia.		Nandurkar, Harshal/AAO-7443-2020; Ooms, Lisa/AGZ-7420-2022	Mitchell, Christina A/0000-0001-9372-3192; Nandurkar, Harshal/0000-0002-8767-116X; Ooms, Lisa Michelle/0000-0002-8918-9932; Whisstock, James/0000-0003-4200-5611				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; BARZILAY G, 1995, NAT STRUCT BIOL, V2, P561, DOI 10.1038/nsb0795-561; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Communi D, 1996, J BIOL CHEM, V271, P11676, DOI 10.1074/jbc.271.20.11676; Communi D, 1996, BIOCHEM J, V320, P181, DOI 10.1042/bj3200181; CONNOLLY TM, 1985, J BIOL CHEM, V260, P7868; Corvera S, 1999, CURR OPIN CELL BIOL, V11, P460, DOI 10.1016/S0955-0674(99)80066-0; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dlakic M, 2000, TRENDS BIOCHEM SCI, V25, P272, DOI 10.1016/S0968-0004(00)01582-6; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; Erneux C, 1998, BBA-MOL CELL BIOL L, V1436, P185, DOI 10.1016/S0005-2760(98)00132-5; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; Fischer D, 1996, PROTEIN SCI, V5, P947; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Janne PA, 1998, J CLIN INVEST, V101, P2042, DOI 10.1172/JCI2414; Jefferson AB, 1996, BIOCHEMISTRY-US, V35, P7890, DOI 10.1021/bi9602627; JEFFERSON AB, 1995, J BIOL CHEM, V270, P9370, DOI 10.1074/jbc.270.16.9370; Jones SJ, 1996, J MOL BIOL, V264, P1154, DOI 10.1006/jmbi.1996.0703; Majerus PW, 1996, GENE DEV, V10, P1051, DOI 10.1101/gad.10.9.1051; Martin TFJ, 1997, CURR OPIN NEUROBIOL, V7, P331, DOI 10.1016/S0959-4388(97)80060-8; Matsuo Y, 1996, PROTEIN SCI, V5, P2459, DOI 10.1002/pro.5560051208; MATZARIS M, 1994, J BIOL CHEM, V269, P3397; Mitchell CA, 1996, BIOCHEM SOC T, V24, P994, DOI 10.1042/bst0240994; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; Park J, 1998, J MOL BIOL, V284, P1201, DOI 10.1006/jmbi.1998.2221; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sattler M, 1999, MOL CELL BIOL, V19, P7473; Speed CJ, 1999, J CELL SCI, V112, P669; Speed CJ, 1996, EMBO J, V15, P4852, DOI 10.1002/j.1460-2075.1996.tb00866.x; SUCK D, 1986, NATURE, V321, P620, DOI 10.1038/321620a0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; Wilson DM, 1997, NUCLEIC ACIDS RES, V25, P933, DOI 10.1093/nar/25.5.933; Zhang XL, 1998, SEMIN CELL DEV BIOL, V9, P153, DOI 10.1006/scdb.1997.0220	38	59	60	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37055	37061		10.1074/jbc.M006244200	http://dx.doi.org/10.1074/jbc.M006244200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10962003	hybrid			2022-12-25	WOS:000165577700084
J	Xu, W; Longo, FJ; Wintermantel, MR; Jiang, XY; Clark, RA; DeLisle, S				Xu, W; Longo, FJ; Wintermantel, MR; Jiang, XY; Clark, RA; DeLisle, S			Calreticulin modulates capacitative Ca2+ influx by controlling the extent of inositol 1,4,5-trisphosphate-induced Ca2+ store depletion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; INTRACELLULAR CALCIUM; GENE-EXPRESSION; BINDING PROTEIN; RECEPTOR; TRISPHOSPHATE; ACTIVATION; OVEREXPRESSION; MESSENGER; CURRENTS	Calreticulin (CRT) is a highly conserved Ca2+-binding protein that resides in the lumen of the endoplasmic reticulum (ER). We overexpressed CRT in Xenopus oocytes to determine how it could modulate inositol 1,4-5-trisphosphate (InsP(3))-induced Ca2+ influx. Under conditions where it did not affect the spatially complex elevations in free cytosolic Ca2+ concentration ([Ca2+](i)) due to InsP(3)-induced Ca2+ release, overexpressed CRT decreased by 46% the Ca2+-gated Cl- current due to Ca2+ influx. Deletion mutants revealed that CRT requires its high capacity Ca2+-binding domain to reduce the elevations of [Ca2+](i), due to Ca2+ influx. This functional domain was also required for CRT to attenuate the InsP(3)-induced decline in the free Ca2+ concentration within the ER lumen ([Ca2+](ER)), as monitored with a "chameleon" indicator. Our data suggest that by buffering [Ca2+](ER) near resting levels, CRT may prevent InsP(3) from depleting the intracellular stores sufficiently to activate Ca2+ influx.	Univ Maryland, Sch Med, Vet Affairs Med Ctr, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Univ Iowa, Coll Med, Dept Anat, Iowa City, IA 52242 USA; S Texas Vet Hlth Care Syst, Dept Med, San Antonio, TX 78230 USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX 78230 USA	University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Texas System; University of Texas Health San Antonio	DeLisle, S (corresponding author), Univ Maryland, Dept Med, Vet Affairs Med Ctr 3B185, 10 N Greene St, Baltimore, MD 21201 USA.		Clark, Robert/Q-6764-2019	Clark, Robert/0000-0002-4892-3619				BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; BROOKER G, 1990, P NATL ACAD SCI USA, V87, P2813, DOI 10.1073/pnas.87.7.2813; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; Coppolino MG, 1997, NATURE, V386, P843, DOI 10.1038/386843a0; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; DEDHAR S, 1994, TRENDS BIOCHEM SCI, V19, P269, DOI 10.1016/0968-0004(94)90001-9; DeLisle S, 1996, AM J PHYSIOL-CELL PH, V270, pC1255; DELISLE S, 1992, J BIOL CHEM, V267, P7963; DeLisle S, 1997, J BIOL CHEM, V272, P9956; DELISLE S, 1990, J BIOL CHEM, V265, P11726; Denning GM, 1997, BLOOD, V90, P372; Fadel MP, 1999, J BIOL CHEM, V274, P15085, DOI 10.1074/jbc.274.21.15085; Fasolato C, 1998, MOL BIOL CELL, V9, P1513, DOI 10.1091/mbc.9.6.1513; FUJINO I, 1995, CELL TISSUE RES, V280, P201, DOI 10.1007/s004410050345; GILLO B, 1987, J PHYSIOL-LONDON, V392, P349, DOI 10.1113/jphysiol.1987.sp016784; HAN JK, 1990, J CELL BIOL, V110, P1103, DOI 10.1083/jcb.110.4.1103; Hartzell HC, 1996, J GEN PHYSIOL, V108, P157, DOI 10.1085/jgp.108.3.157; John LM, 1998, J CELL BIOL, V142, P963, DOI 10.1083/jcb.142.4.963; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Krause KH, 1997, CELL, V88, P439, DOI 10.1016/S0092-8674(00)81884-X; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LEUNGHAGESTEIJN CY, 1994, J CELL SCI, V107, P589; LIPP P, 1993, CELL CALCIUM, V14, P359, DOI 10.1016/0143-4160(93)90040-D; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; Mesaeli N, 1999, J CELL BIOL, V144, P857, DOI 10.1083/jcb.144.5.857; Michalak M, 1996, J BIOL CHEM, V271, P29436, DOI 10.1074/jbc.271.46.29436; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MILEDI R, 1989, J PHYSIOL-LONDON, V415, P189, DOI 10.1113/jphysiol.1989.sp017718; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MOREAU M, 1980, DEV BIOL, V78, P201, DOI 10.1016/0012-1606(80)90329-2; Nauseef WM, 1998, J BIOL CHEM, V273, P7107, DOI 10.1074/jbc.273.12.7107; OPAS M, 1996, J CELL BIOL, V135, P1, DOI DOI 10.1083/JCB.135.6.1913; OSTWALD TJ, 1974, J BIOL CHEM, V249, P974; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PARKER I, 1986, PROC R SOC SER B-BIO, V228, P307, DOI 10.1098/rspb.1986.0057; PARKER I, 1987, PROC R SOC SER B-BIO, V231, P27, DOI 10.1098/rspb.1987.0033; PARYS JB, 1994, DEV BIOL, V161, P466, DOI 10.1006/dbio.1994.1045; PARYS JB, 1992, J BIOL CHEM, V267, P18776; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Perrone L, 1999, J BIOL CHEM, V274, P4640, DOI 10.1074/jbc.274.8.4640; PETERSEN CCH, 1994, J BIOL CHEM, V269, P32246; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; PICARD A, 1990, SCIENCE, V247, P327, DOI 10.1126/science.2153316; Putney JW, 1997, CELL CALCIUM, V21, P257, DOI 10.1016/S0143-4160(97)90050-6; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; ROBINSON KR, 1985, DEV BIOL, V109, P504, DOI 10.1016/0012-1606(85)90475-0; SNYDER PM, 1988, J BIOL CHEM, V263, P11048; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812; TAKAHASHI T, 1987, P NATL ACAD SCI USA, V84, P5063, DOI 10.1073/pnas.84.14.5063; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; Yao Y, 1997, J GEN PHYSIOL, V109, P703, DOI 10.1085/jgp.109.6.703; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; Zhang JX, 1997, MOL BIOL CELL, V8, P1943, DOI 10.1091/mbc.8.10.1943	55	46	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36676	36682		10.1074/jbc.M002041200	http://dx.doi.org/10.1074/jbc.M002041200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973951	hybrid			2022-12-25	WOS:000165577700033
J	Steinberger, P; Sutton, JK; Rader, C; Elia, M; Barbas, CF				Steinberger, P; Sutton, JK; Rader, C; Elia, M; Barbas, CF			Generation and characterization of a recombinant human CCR5-specific antibody - A phage display approach for rabbit antibody humanization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MONOCLONAL-ANTIBODY; HIV-1 INFECTION; CHEMOKINE RECEPTORS; T-CELLS; CORECEPTOR; THERAPY; GENE; PROGRESSION; LIBRARIES	We describe the isolation of a CCR5-specific antibody, ST6, from an antibody phage display library generated from an immune rabbit. ST6 was previously shown to efficiently prevent; the surface expression of CCR5 when expressed intracellularly (Steinberger, P., Andris-Widhopf, J., Buhler, B., Torbett, B. E., and Barbas, C. F., III (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 805-810). Because ST6 has therapeutic potential in human immunodeficiency virus, type 1 disease, its humanization was desired to minimize the potential for immunogenicity, ST6 was humanized using a phage display-based approach. Like the parental rabbit clone, the humanized version ST6/34 efficiently prevented the surface expression of CCR5. The conserved linear peptide epitope bound by these antibodies was mapped using phage display. Both ST6 as well as the humanized anti-CCR5 antibody ST6/34 were produced as complete IgG antibodies and shown to bind to cell surface CCR5.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Barbas, CF (corresponding author), 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Rader, Christoph/0000-0001-9955-3454; Steinberger, Peter/0000-0001-6848-4097	PHS HHS [A141944] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Baca M, 1997, J BIOL CHEM, V272, P10678; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Chen ZW, 1997, J VIROL, V71, P2705, DOI 10.1128/JVI.71.4.2705-2714.1997; Chun TW, 1999, NAT MED, V5, P651, DOI 10.1038/9498; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Jung S, 1999, CURR OPIN IMMUNOL, V11, P319, DOI 10.1016/S0952-7915(99)80051-X; Karlstrom A, 2000, P NATL ACAD SCI USA, V97, P3878, DOI 10.1073/pnas.97.8.3878; Koenig S, 1996, NAT MED, V2, P165, DOI 10.1038/nm0296-165; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MARASCO WA, 1993, P NATL ACAD SCI USA, V90, P7889, DOI 10.1073/pnas.90.16.7889; McDermott DH, 1998, LANCET, V352, P866, DOI 10.1016/S0140-6736(98)04158-0; Presta LG, 1997, CANCER RES, V57, P4593; Rader C, 2000, J BIOL CHEM, V275, P13668, DOI 10.1074/jbc.275.18.13668; Rader C, 1997, CURR OPIN BIOTECH, V8, P503, DOI 10.1016/S0958-1669(97)80075-4; Rader C, 1998, P NATL ACAD SCI USA, V95, P8910, DOI 10.1073/pnas.95.15.8910; RIDDER R, 1995, BIO-TECHNOL, V13, P255, DOI 10.1038/nbt0395-255; Steinberger P, 2000, P NATL ACAD SCI USA, V97, P805, DOI 10.1073/pnas.97.2.805; Tang Y, 1999, J BIOL CHEM, V274, P27371, DOI 10.1074/jbc.274.39.27371; YAMADA O, 1994, GENE THER, V1, P38; Yang AG, 1997, P NATL ACAD SCI USA, V94, P11567, DOI 10.1073/pnas.94.21.11567; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	22	52	70	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36073	36078		10.1074/jbc.M002765200	http://dx.doi.org/10.1074/jbc.M002765200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10969070	hybrid			2022-12-25	WOS:000165382000062
J	Stros, M; Muselikova, E				Stros, M; Muselikova, E			A role of basic residues and the putative intercalating phenylalanine of the HMG-1 box B in DNA supercoiling and binding to four-way DNA junctions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTICANCER DRUG CISPLATIN; CHROMOSOMAL PROTEIN HMG1; DETERMINING FACTOR SRY; TRANSCRIPTION FACTOR; HISTONE H1; HIGH-MOBILITY-GROUP-1 PROTEIN; NUCLEOPROTEIN STRUCTURES; SEQUENCE SPECIFICITY; DAMAGED DNA; A-DOMAIN	HMG thigh mobility group) 1 is a chromosomal protein with two homologous DNA-binding domains, the HMG boxes A and B. HMG-1, like its individual HMG boxes, can recognize structural distortion of DNA, such as four-way DNA junctions (4WJs), that are very likely to have features common to their natural, yet unknown, cellular binding targets. HMG-1 can also bend/loop DNA and introduce negative supercoils in the presence of topoisomerase I in topologically closed DNAs, Results of our gel shift: assays demonstrate that mutation of Arg(97) within the extended N-terminal strand of the B domain significantly (>50-fold) decreases affinity of the HMG box for 4WJs and alters the mode of binding without changing the structural specificity for 4WJs. Several basic amino acids of the extended N-terminal strand (Lys(96)/Arg(97)) and helix I (Arg(110)/Lys(114)) Of the B domain participate in DNA binding and supercoiling, The putative intercalating hydrophobic Phe(103) of helix I is important for DNA supercoiling but dispensable for binding to supercoiled DNA and 4WJs. We conclude that the B domain of HMG-1 can tolerate substitutions of a number of amino acid residues without abolishing the structure-specific recognition of 4WJs, whereas mutations of most of these residues severely impair the topoisomerase I-mediated DNA supercoiling and change the sign of supercoiling from negative to positive,	Acad Sci Czech Republ, Inst Biophys, CZ-61265 Brno, Czech Republic	Czech Academy of Sciences; Institute of Biophysics of the Czech Academy of Sciences	Stros, M (corresponding author), Acad Sci Czech Republ, Inst Biophys, Kralovopolska 135, CZ-61265 Brno, Czech Republic.							Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; Allain FHT, 1999, EMBO J, V18, P2563, DOI 10.1093/emboj/18.9.2563; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P1019, DOI 10.1093/nar/23.6.1019; BAZETTJONES DP, 1994, SCIENCE, V264, P1134, DOI 10.1126/science.8178172; BIANCHI ME, 1992, EMBO J, V11, P1055, DOI 10.1002/j.1460-2075.1992.tb05144.x; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BILLINGS PC, 1992, BIOCHEM BIOPH RES CO, V188, P1286, DOI 10.1016/0006-291X(92)91371-V; Boonyaratanakornkit V, 1998, MOL CELL BIOL, V18, P4471, DOI 10.1128/MCB.18.8.4471; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Cryer JE, 1996, CANCER CHEMOTH PHARM, V38, P163, DOI 10.1007/s002800050465; FALCIOLA L, 1994, NUCLEIC ACIDS RES, V22, P285, DOI 10.1093/nar/22.3.285; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; Hardman CH, 1995, BIOCHEMISTRY-US, V34, P16596, DOI 10.1021/bi00051a007; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; Hill DA, 1999, NUCLEIC ACIDS RES, V27, P2135, DOI 10.1093/nar/27.10.2135; Hill DA, 1997, NUCLEIC ACIDS RES, V25, P3523, DOI 10.1093/nar/25.17.3523; HU CH, 1994, MOL CELL BIOL, V14, P2871, DOI 10.1128/MCB.14.5.2871; Ivanchenko M, 1997, BIOPHYS J, V72, P1388, DOI 10.1016/S0006-3495(97)78785-X; JAVAHERIAN K, 1978, SCIENCE, V199, P1345, DOI 10.1126/science.628842; JONES DNM, 1994, STRUCTURE, V2, P609, DOI 10.1016/S0969-2126(00)00063-0; LILLEY DMJ, 1993, ANNU REV BIOPH BIOM, V22, P299, DOI 10.1146/annurev.bb.22.060193.001503; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; Murphy FV, 1999, EMBO J, V18, P6610, DOI 10.1093/emboj/18.23.6610; Ohndorf UM, 1999, NATURE, V399, P708, DOI 10.1038/21460; Palecek E, 1997, ONCOGENE, V15, P2201, DOI 10.1038/sj.onc.1201398; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; PIL PM, 1993, P NATL ACAD SCI USA, V90, P9465, DOI 10.1073/pnas.90.20.9465; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; Pohler JRG, 1998, EMBO J, V17, P817, DOI 10.1093/emboj/17.3.817; Ramstein J, 1999, EUR J BIOCHEM, V260, P692, DOI 10.1046/j.1432-1327.1999.00185.x; Read C., 1995, NUCL ACIDS MOL BIOL, P222; READ CM, 1994, EMBO J, V13, P5639, DOI 10.1002/j.1460-2075.1994.tb06902.x; READ CM, 1993, NUCLEIC ACIDS RES, V21, P3427, DOI 10.1093/nar/21.15.3427; Saito K, 1999, PROTEIN ENG, V12, P235, DOI 10.1093/protein/12.3.235; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SELVIN PR, 1992, SCIENCE, V255, P82, DOI 10.1126/science.1553534; SHEFLIN LG, 1993, BIOCHEMISTRY-US, V32, P3238, DOI 10.1021/bi00064a005; SHEFLIN LG, 1989, BIOCHEMISTRY-US, V28, P5658, DOI 10.1021/bi00439a048; Stros M, 1998, EUR J BIOCHEM, V251, P427, DOI 10.1046/j.1432-1327.1998.2510427.x; Stros M, 1998, J BIOL CHEM, V273, P10355; STROS M, 1994, FEBS LETT, V344, P201, DOI 10.1016/0014-5793(94)00364-5; STROS M, 1994, NUCLEIC ACIDS RES, V22, P1044, DOI 10.1093/nar/22.6.1044; STROS M, 1994, EUR J BIOCHEM, V225, P581, DOI 10.1111/j.1432-1033.1994.00581.x; Stros M, 2000, EUR J BIOCHEM, V267, P4088, DOI 10.1046/j.1432-1327.2000.01450.x; TEO SH, 1995, EUR J BIOCHEM, V230, P943, DOI 10.1111/j.1432-1033.1995.tb20640.x; TEO SH, 1995, EMBO J, V14, P3844, DOI 10.1002/j.1460-2075.1995.tb00054.x; Webb M, 1999, J MOL BIOL, V294, P373, DOI 10.1006/jmbi.1999.3150; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; WERNER MH, 1995, BIOCHEMISTRY-US, V34, P11998, DOI 10.1021/bi00037a042; WISNIEWSKI JR, 1994, J BIOL CHEM, V269, P29261; Yen YM, 1998, J BIOL CHEM, V273, P4424, DOI 10.1074/jbc.273.8.4424; Zlatanova J, 1998, FASEB J, V12, P791, DOI 10.1096/fasebj.12.10.791; ZWILLING S, 1995, EMBO J, V14, P1198, DOI 10.1002/j.1460-2075.1995.tb07103.x	54	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35699	35707		10.1074/jbc.M007167200	http://dx.doi.org/10.1074/jbc.M007167200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10962007	hybrid			2022-12-25	WOS:000165382000010
J	Akdis, CA; Joss, A; Akdis, M; Faith, A; Blaser, K				Akdis, CA; Joss, A; Akdis, M; Faith, A; Blaser, K			A molecular basis for T cell suppression by IL-10: CD28-associated IL-10 receptor inhibits CD28 tyrosine phosphorylation and phosphatidylinositol 3-kinase binding	FASEB JOURNAL			English	Article									Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland	Swiss Institute of Allergy & Asthma Research	Akdis, CA (corresponding author), Swiss Inst Allergy & Asthma Res, Obere Str 22, CH-7270 Davos, Switzerland.		Akdis, Cezmi/AAV-4844-2020	Akdis, Cezmi/0000-0001-8020-019X					0	129	133	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2000	14	12					1666	1668						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973911				2022-12-25	WOS:000089212400001
J	Deregnaucourt, C; Schrevel, J				Deregnaucourt, C; Schrevel, J			Bee venom phospholipase A(2) induces stage-specific growth arrest of the intraerythrocytic Plasmodium falciparum via modifications of human serum components	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACIDS; MEMBRANE; LYSOPHOSPHATIDYLCHOLINE; ERYTHROCYTES; ORGANIZATION; INHIBITION; EXPRESSION; CELLS; PUMP; PH	Secreted phospholipases A(2) (sPLA(2)s) from snake and insect venoms and from mammalian pancreas are structurally related enzymes that have been associated with several toxic, pathological, or physiological processes. We addressed the issue of whether toxic sPLA(2)s might exert specific effects on the Plasmodium falciparum intraerythrocytic development. We showed that both toxic and non-toxic sPLA(2)s are lethal to P. falciparum grown in vitro, with large discrepancies between respective IC50 values; IC50 values from toxic PLA(2)s ranged from 1.1 to 200 pM, and IC50 values from non-toxic PLA(2)s ranged from 0.14 to 1 muM. Analysis of the molecular mechanisms responsible for cytotoxicity of bee venom PLA(2) (toxic) and hog pancreas PLA, (non-toxic) demonstrated that, in both cases, enzymatic hydrolysis of serum phospholipids present in the culture medium was responsible for parasite growth arrest. However, bee PLA(2)-lipolyzed serum induced stage-specific inhibition of P. falciparum development, whereas hog PLA(2)-lipolyzed serum killed parasites at either stage. Sensitivity to bee PLA(2)-treated serum appeared restricted to the 19-26-h period of the 48 h parasite cycle. Analysis of the respective role of the different lipoprotein classes as substrates of bee PLA(2) showed that enzyme treatment of high density lipoproteins, low density lipoproteins, and very low density lipoproteins/chylomicrons fractions induces cytotoxicity of either fraction. In conclusion, our results demonstrate that toxic and non-toxic PLA(2)s 1) are cytotoxic to P. falciparum via hydrolysis of lipoprotein phospholipids and 2) display different killing processes presumably involving lipoprotein by-products recognizing different targets on the infected red blood cell.	Museum Natl Hist Nat, Lab Biochem Parasitaire, F-75231 Paris 05, France	Museum National d'Histoire Naturelle (MNHN)	Deregnaucourt, C (corresponding author), Museum Natl Hist Nat, Lab Biochem Parasitaire, IFR 63,61 Rue Buffon, F-75231 Paris 05, France.	schrevel@mnhn.fr	Schrevel, Joseph/AAG-7085-2020					ARITA H, 1991, J BIOL CHEM, V266, P19139; ATKINSON CT, 1990, BLOOD CELLS, V16, P351; Cantrill RC, 1997, ADV EXP MED BIOL, V400, P539; CHWETZOFF S, 1989, J BIOL CHEM, V264, P13289; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DEARAUJO AL, 1987, TOXICON, V25, P1181, DOI 10.1016/0041-0101(87)90136-X; DEMEL RA, 1975, BIOCHIM BIOPHYS ACTA, V406, P97, DOI 10.1016/0005-2736(75)90045-0; DENNIS EA, 1987, BIO-TECHNOL, V5, P1294, DOI 10.1038/nbt1287-1294; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DESJARDINS RE, 1979, ANTIMICROB AGENTS CH, V16, P710, DOI 10.1128/AAC.16.6.710; DIEZ E, 1994, BIOCHEM J, V301, P721, DOI 10.1042/bj3010721; ESTERBAUER H, 1990, CHEM RES TOXICOL, V3, P77, DOI 10.1021/tx00014a001; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Francis GA, 2000, BBA-MOL CELL BIOL L, V1483, P217, DOI 10.1016/S1388-1981(99)00181-X; GHOMASHCHI F, 1991, BIOCHEMISTRY-US, V30, P7318, DOI 10.1021/bi00243a037; GRELLIER P, 1991, J CELL BIOL, V112, P267, DOI 10.1083/jcb.112.2.267; GUTIERREZ JM, 1995, TOXICON, V33, P1405, DOI 10.1016/0041-0101(95)00085-Z; Hawgood B., 1991, HDB NATURAL TOXINS R, V5, P3; HSIAO LL, 1991, BIOCHEM J, V274, P121, DOI 10.1042/bj2740121; JOSHI P, 1987, BIOCHEM J, V246, P103, DOI 10.1042/bj2460103; KISHINO J, 1994, J BIOL CHEM, V269, P5092; KISHINO J, 1995, J BIOCHEM-TOKYO, V117, P420, DOI 10.1093/jb/117.2.420; KRUGLIAK M, 1995, EXP PARASITOL, V81, P97, DOI 10.1006/expr.1995.1097; KUMARATILAKE LM, 1992, J CLIN INVEST, V89, P961, DOI 10.1172/JCI115678; Kundu GC, 1997, J BIOL CHEM, V272, P2346; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; LANGE Y, 1982, J LIPID RES, V23, P1121; Le Bonniec S, 1999, J BIOL CHEM, V274, P14218, DOI 10.1074/jbc.274.20.14218; LIJNEN P, 1990, METHOD FIND EXP CLIN, V12, P281; MOLL GN, 1990, BIOCHIM BIOPHYS ACTA, V1024, P189, DOI 10.1016/0005-2736(90)90224-C; OHARA O, 1995, PROG LIPID RES, V34, P117, DOI 10.1016/0163-7827(94)00009-B; OISHI K, 1990, J BIOL CHEM, V265, P70; PASVOL G, 1978, ANN TROP MED PARASIT, V72, P87, DOI 10.1080/00034983.1978.11719283; ROBERTS MF, 1977, J BIOL CHEM, V252, P2405; ROSSI JPFC, 1995, BIOCHEMISTRY-US, V34, P3802, DOI 10.1021/bi00011a038; SAKATA T, 1989, BIOCHIM BIOPHYS ACTA, V1007, P124, DOI 10.1016/0167-4781(89)90141-3; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; Snitko Y, 1997, BIOCHEM J, V321, P737, DOI 10.1042/bj3210737; Tischfield JA, 1996, GENOMICS, V32, P328, DOI 10.1006/geno.1996.0126; UN D, 1990, NUTRITION, V6, P429; Vadas P, 1997, BBA-LIPID LIPID MET, V1346, P193, DOI 10.1016/S0005-2760(97)00029-5; VANDERSCHAFT PH, 1987, BIOCHIM BIOPHYS ACTA, V901, P1, DOI 10.1016/0005-2736(87)90250-1; *WHO, 1998, WEEKLY EPIDEMIOL REC, V72, P269	46	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39973	39980		10.1074/jbc.M006712200	http://dx.doi.org/10.1074/jbc.M006712200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10988294	hybrid			2022-12-25	WOS:000166039500026
J	Sudhahar, GCP; Balamurugan, K; Chin, DH				Sudhahar, GCP; Balamurugan, K; Chin, DH			Release of the neocarzinostatin chromophore from the holoprotein does not require major conformational change of the tertiary and secondary structures induced by trifluoroethanol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL SOLUTION STRUCTURE; HEME ORIENTATIONAL DISORDER; REVISED PRIMARY STRUCTURE; FAST ATOM BOMBARDMENT; APO-NEOCARZINOSTATIN; ANTITUMOR PROTEIN; STREPTOMYCES-CARZINOSTATICUS; MASS-SPECTROMETRY; NATURAL-ABUNDANCE; CRYSTAL-STRUCTURE	Neocarzinostatin is a potent enediyne antitumor antibiotic complex in which a chromophore is noncovalently bound to a carrier protein. The protein regulates availability of the drug by proper release of the biologically active chromophore, To understand the physiological mechanism of the drug delivery system, we have examined the trifluoroethanol (TFE)-induced conformational changes of the protein with special emphasis on their relation to the release of the chromophore from holoneocarzinostatin. The effect of the (alpha helix-inducing agent, TFE, on all the beta -sheet neocarzinostatin proteins was studied by circular dichroism, fluorescence, and H-1 NMR studies. By using binding of anilinonaphthalene sulfonic acid as a probe, we observed that the protein exists in a stable, partially structured intermediate state around 45-50% TFE, which is consistent with the results from tryptophan fluorescence and circular dichroism studies. The native state is stable until 20% TFE and is half-converted into the intermediate state at 30% TFE, which starts to collapse beyond 50%. High pressure liquid chromatographic analysis of the release of the chromophore caused by TFE treatment at 0 degreesC suggests that the release process, which occurs below 20% TFE, does not result from an observable conformational change in the protein. Kinetic measurements of the release of chromophore at 25 degreesC reveal that TFE does stimulate the rate of release, which increases sharply at 15% and reaches a maximum at 20% TFE, although no major secondary or tertiary structural change of the carrier protein is observed under these same conditions. Our data suggest that chromophore release results from a fluctuation of the protein structure that is stimulated by TFE. Complete release of the chromophore occurs at TFE concentrations where no overall observable unfolding of the apoprotein is seen. Thus, the results suggest that denaturation of the protein by TFE is not a necessary step for release of the tightly bound chromophore.	Natl Changhua Univ Educ, Dept Chem, Changhua 50058, Taiwan	National Changhua University of Education	Chin, DH (corresponding author), Natl Changhua Univ Educ, Dept Chem, Changhua 50058, Taiwan.	chdhchin@cc.ncue.edu.tw		Balamurugan, Prof. Dr. Krishnaswamy/0000-0001-9316-8141				ADJADJ E, 1992, EUR J BIOCHEM, V203, P505, DOI 10.1111/j.1432-1033.1992.tb16576.x; ADJADJ E, 1992, BIOCHIMIE, V74, P853, DOI 10.1016/0300-9084(92)90068-P; ADJADJ E, 1990, EUR J BIOCHEM, V190, P263, DOI 10.1111/j.1432-1033.1990.tb15571.x; ANANTHASAMY TS, 1977, BIOCHEMISTRY-US, V16, P5573, DOI 10.1021/bi00644a029; BLACKWELL LF, 1987, BIOCHEM J, V242, P803, DOI 10.1042/bj2420803; Chin DH, 1997, TETRAHEDRON LETT, V38, P2891, DOI 10.1016/S0040-4039(97)00498-X; Chin DH, 1997, BBA-GEN SUBJECTS, V1336, P43, DOI 10.1016/S0304-4165(97)00008-1; CHIN DH, 1993, J AM CHEM SOC, V115, P9341, DOI 10.1021/ja00073a081; Chin DH, 1999, CHEM-EUR J, V5, P1084, DOI 10.1002/(SICI)1521-3765(19990301)5:3<1084::AID-CHEM1084>3.0.CO;2-K; DEDON PC, 1992, BIOCHEMISTRY-US, V31, P1909, DOI 10.1021/bi00122a003; Digits JA, 1999, BIOCHEMISTRY-US, V38, P2295, DOI 10.1021/bi982305k; EDO K, 1985, TETRAHEDRON LETT, V26, P331, DOI 10.1016/S0040-4039(01)80810-8; GAO XL, 1991, BIOCHEMISTRY-US, V30, P7730, DOI 10.1021/bi00245a009; GAO XL, 1992, J MOL BIOL, V225, P125, DOI 10.1016/0022-2836(92)91030-S; GIBSON BW, 1984, J BIOL CHEM, V259, P801; GOLDBERG IH, 1991, ACCOUNTS CHEM RES, V24, P191, DOI 10.1021/ar00007a001; GOLDBERG IH, 1985, CELLULAR REGULATION, P483; Heyd B, 2000, J BACTERIOL, V182, P1812, DOI 10.1128/JB.182.7.1812-1818.2000; HIRAMA M, 1994, PURE APPL CHEM, V66, P791, DOI 10.1351/pac199466040791; HIRAYAMA K, 1986, B CHEM SOC JPN, V59, P1371, DOI 10.1246/bcsj.59.1371; IMAJO S, 1995, BIOORGAN MED CHEM, V3, P429, DOI 10.1016/0968-0896(95)00032-C; ISHIDA N, 1965, J ANTIBIOT, V18, P68; JOHNSON JP, 1989, J CANCER RES CLIN, V115, P494, DOI 10.1007/BF00393348; JUNG G, 1981, BIOCHEM BIOPH RES CO, V98, P176, DOI 10.1016/0006-291X(81)91885-4; KAPPEN LS, 1978, NUCLEIC ACIDS RES, V5, P2959, DOI 10.1093/nar/5.8.2959; KAPPEN LS, 1979, BIOCHEMISTRY-US, V18, P5647, DOI 10.1021/bi00592a020; KIM KH, 1993, SCIENCE, V262, P1042, DOI 10.1126/science.8235619; KUROMIZU K, 1986, ARCH BIOCHEM BIOPHYS, V246, P199, DOI 10.1016/0003-9861(86)90464-9; LAMAR GN, 1983, J MOL BIOL, V168, P887, DOI 10.1016/S0022-2836(83)80080-1; LECOMTE JTJ, 1985, BIOCHIM BIOPHYS ACTA, V829, P268, DOI 10.1016/0167-4838(85)90197-9; LEFEVRE C, 1994, J BIOMOL NMR, V4, P689, DOI 10.1007/BF00404278; MAEDA H, 1974, ARCH BIOCHEM BIOPHYS, V164, P379, DOI 10.1016/0003-9861(74)90046-0; MAEDA H, 1975, CANCER RES, V35, P554; MEIENHOFER J, 1972, SCIENCE, V178, P875, DOI 10.1126/science.178.4063.875; MISPELTER J, 1995, J BIOMOL NMR, V5, P233; Mizutani K, 2000, BIOCHEMISTRY-US, V39, P3258, DOI 10.1021/bi992574q; Okuno Y, 2000, J AM CHEM SOC, V122, P6848, DOI 10.1021/ja994323a; POSNER RG, 1992, BIOCHEMISTRY-US, V31, P5350, DOI 10.1021/bi00138a015; POVIRK LF, 1980, BIOCHEMISTRY-US, V19, P4773, DOI 10.1021/bi00562a009; Ptitsyn Oleg B., 1992, P243; REMEROWSKI ML, 1990, BIOCHEMISTRY-US, V29, P8401, DOI 10.1021/bi00488a029; SAKATA N, 1993, BIOL PHARM BULL, V16, P26; SIEKER LC, 1976, BIOCHEM BIOPH RES CO, V68, P358, DOI 10.1016/0006-291X(76)91152-9; TAKASHIMA H, 1991, J BIOCHEM-TOKYO, V109, P807, DOI 10.1093/oxfordjournals.jbchem.a123462; TANAKA T, 1991, TETRAHEDRON LETT, V32, P3175, DOI 10.1016/S0040-4039(00)79715-2; TANAKA T, 1993, J CHEM SOC CHEM COMM, P1205, DOI 10.1039/c39930001205; TEPLYAKOV A, 1993, EUR J BIOCHEM, V213, P737, DOI 10.1111/j.1432-1033.1993.tb17814.x; Thorson JS, 1999, BIOORG CHEM, V27, P172, DOI 10.1006/bioo.1998.1122	48	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39900	39906						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10982812				2022-12-25	WOS:000166039500017
J	Klose, R; Fresser, F; Kochl, S; Parson, W; Kapetanopoulos, A; Fruchart-Najib, J; Baier, G; Utermann, G				Klose, R; Fresser, F; Kochl, S; Parson, W; Kapetanopoulos, A; Fruchart-Najib, J; Baier, G; Utermann, G			Mapping of a minimal apolipoprotein(a) interaction motif conserved in fibrin(ogen) beta- and gamma-chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC LESIONS; PLASMINOGEN-BINDING-SITES; LOW-DENSITY-LIPOPROTEIN; GROWTH-FACTOR-BETA; TRANSGENIC MICE; SIZE HETEROGENEITY; FIBRINOGEN BINDING; MOLECULAR-BASIS; LYSINE ANALOGS; KRINGLE IV-10	Lipoprotein(a) (Lp(a)) is a major independent risk factor for atherothrombotic disease in humans. The physiological function(s) of Lp(a) as well as the precise mechanism(s) by which high plasma levels of Lp(a) increase risk are unknown. Binding of apolipoprotein(a) (apo(a)) to fibrin(ogen) and other components of the blood clotting cascade has been demonstrated in vitro, but the domains in fibrin(ogen) critical for interaction are undefined. We used apo(a) kringle IV subtypes to screen a human liver cDNA library by the yeast GAL4 two-hybrid interaction trap system. Among positive clones that emerged from the screen, clones were identified as fibrinogen beta- and gamma -chains. Peptide-based pull-down experiments confirmed that the emerging peptide motif, conserved in the carboxyl-terminal globular domains of the fibrinogen beta- and gamma modules specifically interacts with apo(a)np(a) in human plasma as well as in cell culture supernatants of HepG2 and Chinese hamster ovary cells, ectopically expressing apo(a)/Lp(a). The influence of lysine in the fibrinogen peptides and of lysine binding sites in apo(a) for the interaction was evaluated by binding experiments with apo(a) mutants and a mutated fibrin(ogen) peptid. This confirmed the lysine binding sites in kringle IV type 10 of apo(a) as the major fibrin(ogen) binding site but also demonstrated lysine-independent interactions.	Univ Innsbruck, Inst Med Biol & Human Genet, A-6020 Innsbruck, Austria; Univ Innsbruck, Inst Legal Med, A-6020 Innsbruck, Austria; Inst Pasteur, U325, INSERM, Dept Atherosclerose, F-59019 Lille, France	University of Innsbruck; University of Innsbruck; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Baier, G (corresponding author), Univ Innsbruck, Inst Med Biol & Human Genet, Schoepfstr 41, A-6020 Innsbruck, Austria.	Gottfried.Baier@uibk.ac.at	Baier, Gottfried/E-8755-2012; Parson, Walther/AAD-6845-2020	Parson, Walther/0000-0002-5692-2392; Baier, Gottfried/0000-0002-2085-8325				ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; ANGLESCANO E, 1994, CHEM PHYS LIPIDS, V67-8, P353, DOI 10.1016/0009-3084(94)90157-0; Boonmark NW, 1997, J CLIN INVEST, V100, P558, DOI 10.1172/JCI119565; BRUNNER C, 1993, P NATL ACAD SCI USA, V90, P11643, DOI 10.1073/pnas.90.24.11643; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DIEPLINGER H, 1995, J LIPID RES, V36, P813; EDELBERG JM, 1990, THROMB RES, V57, P155, DOI 10.1016/0049-3848(90)90203-O; ERNST A, 1995, J BIOL CHEM, V270, P6227, DOI 10.1074/jbc.270.11.6227; Fless GM, 1996, BIOCHEMISTRY-US, V35, P2289, DOI 10.1021/bi951792q; Fless GM, 2000, BIOCHEMISTRY-US, V39, P2740, DOI 10.1021/bi991961x; FRANK S, 1994, BIOCHEM J, V304, P27, DOI 10.1042/bj3040027; FRANK S, 1994, BIOCHEMISTRY-US, V33, P12329, DOI 10.1021/bi00206a041; GABEL B, 1994, FEBS LETT, V350, P77, DOI 10.1016/0014-5793(94)00737-3; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; GUEVARA J, 1992, PROTEINS, V12, P188, DOI 10.1002/prot.340120212; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; HARPEL PC, 1989, P NATL ACAD SCI USA, V86, P3847, DOI 10.1073/pnas.86.10.3847; Hobbs HH, 1999, CURR OPIN LIPIDOL, V10, P225, DOI 10.1097/00041433-199906000-00005; Klezovitch O, 1996, ARTERIOSCL THROM VAS, V16, P392, DOI 10.1161/01.ATV.16.3.392; Klezovitch O, 1996, J CLIN INVEST, V98, P185, DOI 10.1172/JCI118765; Kochl S, 1997, BLOOD, V90, P1482, DOI 10.1182/blood.V90.4.1482.1482_1482_1489; KOJIMA S, 1991, J CELL BIOL, V113, P1439, DOI 10.1083/jcb.113.6.1439; KOSCHINSKY ML, 1990, BIOCHEMISTRY-US, V29, P640, DOI 10.1021/bi00455a007; Kraft HG, 1996, EUR J HUM GENET, V4, P74; LACKNER C, 1991, J CLIN INVEST, V87, P2153, DOI 10.1172/JCI115248; Liu JN, 1998, BIOCHEMISTRY-US, V37, P3949, DOI 10.1021/bi972585o; Lou XJ, 1998, P NATL ACAD SCI USA, V95, P12591, DOI 10.1073/pnas.95.21.12591; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MILES LA, 1995, THROMB HAEMOSTASIS, V73, P458; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; Nielsen LB, 1996, CIRC RES, V78, P615, DOI 10.1161/01.RES.78.4.615; Ogorelkova M, 1999, HUM MOL GENET, V8, P2087, DOI 10.1093/hmg/8.11.2087; PALABRICA TM, 1995, NAT MED, V1, P256, DOI 10.1038/nm0395-256; Papagrigorakis E, 1997, CLIN GENET, V52, P262; PEPIN JM, 1991, J LIPID RES, V32, P317; Romanic AM, 1998, CIRC RES, V83, P264, DOI 10.1161/01.RES.83.3.264; ROUY D, 1991, ARTERIOSCLER THROMB, V11, P629, DOI 10.1161/01.ATV.11.3.629; ROUY D, 1992, BIOCHEMISTRY-US, V31, P6333, DOI 10.1021/bi00142a024; SCANU AM, 1994, BBA-MOL BASIS DIS, V1227, P41, DOI 10.1016/0925-4439(94)90104-X; SIMON DI, 1991, BIOCHEMISTRY-US, V30, P6671, DOI 10.1021/bi00241a006; Spraggon G, 1997, NATURE, V389, P455, DOI 10.1038/38947; SUTER M, 1986, IMMUNOL LETT, V13, P313, DOI 10.1016/0165-2478(86)90064-7; TAM JP, 1983, J AM CHEM SOC, V105, P6442, DOI 10.1021/ja00359a014; Tang LP, 1996, J CLIN INVEST, V97, P1329, DOI 10.1172/JCI118549; TROMMSDORFF M, 1995, J CLIN INVEST, V96, P150, DOI 10.1172/JCI118015; Ugarova TP, 1998, J BIOL CHEM, V273, P22519, DOI 10.1074/jbc.273.35.22519; UTERMANN G, 1987, J CLIN INVEST, V80, P458, DOI 10.1172/JCI113093; UTERMANN G, 1995, METABOLIC MOL BASES; VARADI A, 1983, BIOCHEMISTRY-US, V22, P2440, DOI 10.1021/bi00279a021; WINN ES, 1980, EUR J BIOCHEM, V104, P579, DOI 10.1111/j.1432-1033.1980.tb04461.x; Yano Y, 1997, J HISTOCHEM CYTOCHEM, V45, P559, DOI 10.1177/002215549704500408; Yee VC, 1997, STRUCTURE, V5, P125, DOI 10.1016/S0969-2126(97)00171-8	52	9	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38206	38212		10.1074/jbc.M003640200	http://dx.doi.org/10.1074/jbc.M003640200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10980194	hybrid			2022-12-25	WOS:000165739800012
J	Lotharius, J; O'Malley, KL				Lotharius, J; O'Malley, KL			The Parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation - A novel mechanism of toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; CEREBELLAR GRANULE CELLS; MOUSE STRIATAL MEMBRANES; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE MPTP; NEUROTOXIN 1-METHYL-4-PHENYLPYRIDINIUM; BRAIN MITOCHONDRIA; NADH DEHYDROGENASE; AMPHETAMINE ACTION; HYDROGEN-PEROXIDE; SUPEROXIDE ANION	Uptake of the Parkinsonism-inducing toxin, 1-methyl-4-phenylpyridinium (MPP+), into dopaminergic terminals is thought to block Complex I activity leading to ATP loss and overproduction of reactive oxygen species (ROS). The present study indicates that MPP+-induced ROS formation is not mitochondrial in origin but results from intracellular dopamine (DA) oxidation. Although a mean lethal dose of MPP+ led to ROS production in identified dopaminergic neurons, toxic doses of the Complex I inhibitor rotenone did not. Concurrent with ROS formation, MPP+ redistributed vesicular DA to the cytoplasm prior to its extrusion from the cell by reverse transport via the DA transporter. MPP+-induced DA redistribution was also associated with cell death. Depleting cells of newly synthesized and/or stored DA significantly attenuated both superorxide production and cell death, whereas enhancing intracellular DA content exacerbated dopaminergic sensitivity to MPP+. Lastly, depleting cells of DA in the presence of succinate completely abolished MPP+-induced cell death. Thus, MPP+ neurotoxicity is a multi-component process involving both mitochondrial dysfunction and ROS generated by vesicular DA displacement. These results suggest that in the presence of a Complex I defect, misregulation of DA storage could lead to the loss of nigrostriatal neurons in Parkinson's disease.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Washington University (WUSTL)	O'Malley, KL (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, Box 8108,660 S Euclid Ave, St Louis, MO 63110 USA.	omalleyk@pcg.wustl.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS039084, R01NS039084] Funding Source: NIH RePORTER; NIMH NIH HHS [MH45330] Funding Source: Medline; NINDS NIH HHS [NS39084] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKANEYA Y, 1995, NEUROSCI LETT, V193, P53, DOI 10.1016/0304-3940(95)11668-M; Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; Barrientos A, 1999, J BIOL CHEM, V274, P16188, DOI 10.1074/jbc.274.23.16188; Benov L, 1998, FREE RADICAL BIO MED, V25, P826, DOI 10.1016/S0891-5849(98)00163-4; Berman SB, 1999, J NEUROCHEM, V73, P1127, DOI 10.1046/j.1471-4159.1999.0731127.x; Bindokas VP, 1996, J NEUROSCI, V16, P1324; BOWLING AC, 1995, LIFE SCI, V56, P1151, DOI 10.1016/0024-3205(95)00055-B; Budd SL, 1996, J NEUROCHEM, V67, P2282; Budd SL, 1997, FEBS LETT, V415, P21, DOI 10.1016/S0014-5793(97)01088-0; Cassarino DS, 1999, BBA-MOL BASIS DIS, V1453, P49, DOI 10.1016/S0925-4439(98)00083-0; CHAN P, 1991, J NEUROCHEM, V57, P348, DOI 10.1111/j.1471-4159.1991.tb02134.x; CHANG GD, 1986, BRAIN RES, V368, P134, DOI 10.1016/0006-8993(86)91050-4; Chinopoulos C, 1999, J NEUROCHEM, V73, P220, DOI 10.1046/j.1471-4159.1999.0730220.x; CLARKE PBS, 1995, BRIT J PHARMACOL, V114, P315, DOI 10.1111/j.1476-5381.1995.tb13229.x; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; DANIELS AJ, 1988, J BIOL CHEM, V263, P5034; DELZOMPO M, 1991, EUR J PHARMACOL, V202, P293, DOI 10.1016/0014-2999(91)90309-E; DELZOMPO M, 1992, BRAIN RES, V571, P354, DOI 10.1016/0006-8993(92)90677-2; DELZOMPO M, 1993, BRIT J PHARMACOL, V109, P411; DENTON T, 1987, J NEUROCHEM, V49, P622, DOI 10.1111/j.1471-4159.1987.tb02909.x; Dugan LL, 1997, P NATL ACAD SCI USA, V94, P9434, DOI 10.1073/pnas.94.17.9434; DUGAN LL, 1995, J NEUROSCI, V15, P6377; FILLOUX F, 1993, EXP NEUROL, V119, P79, DOI 10.1006/exnr.1993.1008; FISCHER JF, 1979, J PHARMACOL EXP THER, V208, P203; Fon EA, 1997, NEURON, V19, P1271, DOI 10.1016/S0896-6273(00)80418-3; FORNSTEDT B, 1990, ACTA NEUROL SCAND, V82, P12; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Gainetdinov RR, 1998, J NEUROCHEM, V70, P1973; Gerlach M, 1996, J NEURAL TRANSM, V103, P987, DOI 10.1007/BF01291788; GLUCK MR, 1994, J BIOL CHEM, V269, P3167; GRAHAM DG, 1978, MOL PHARMACOL, V14, P633; HASEGAWA E, 1990, BIOCHEM BIOPH RES CO, V170, P1049, DOI 10.1016/0006-291X(90)90498-C; Hastings TG, 1996, P NATL ACAD SCI USA, V93, P1956, DOI 10.1073/pnas.93.5.1956; HEIKKILA RE, 1973, SCIENCE, V181, P456, DOI 10.1126/science.181.4098.456; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; Jones SR, 1999, J NEUROCHEM, V73, P2406, DOI 10.1046/j.1471-4159.1999.0732406.x; Jones SR, 1998, J NEUROSCI, V18, P1979; Klivenyi P, 1998, NEUROBIOL DIS, V5, P253, DOI 10.1006/nbdi.1998.0191; Kristal BS, 1997, J NEUROCHEM, V69, P524; KRUEGER MJ, 1990, BIOCHEM BIOPH RES CO, V169, P123, DOI 10.1016/0006-291X(90)91442-U; Li H, 1997, J NEUROCHEM, V69, P1530; LIANG NY, 1982, BIOCHEM PHARMACOL, V31, P983, DOI 10.1016/0006-2952(82)90332-X; LIU Y, 1992, P NATL ACAD SCI USA, V89, P9074, DOI 10.1073/pnas.89.19.9074; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; Loeffler M, 2000, EXP CELL RES, V256, P19, DOI 10.1006/excr.2000.4833; Lotharius J, 1999, J NEUROSCI, V19, P1284; MAKER HS, 1981, J NEUROCHEM, V36, P589, DOI 10.1111/j.1471-4159.1981.tb01631.x; MARKSTEIN R, 1984, EUR J PHARMACOL, V106, P301, DOI 10.1016/0014-2999(84)90717-9; MICHEL PP, 1990, J NEUROSCI RES, V26, P428, DOI 10.1002/jnr.490260405; MOKHOVA EN, 1986, J BIOENERG BIOMEMBR, V18, P265, DOI 10.1007/BF00743047; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; NICKLAS WJ, 1985, LIFE SCI, V36, P2503, DOI 10.1016/0024-3205(85)90146-8; Obata T, 1999, BRAIN RES, V828, P68, DOI 10.1016/S0006-8993(99)01329-3; OBATA T, 1992, J NEURAL TRANSM-GEN, V89, P139, DOI 10.1007/BF01245361; OWENS GC, 1991, J NEUROCHEM, V56, P1030, DOI 10.1111/j.1471-4159.1991.tb02025.x; Packer MA, 1996, BIOCHEM PHARMACOL, V51, P267, DOI 10.1016/0006-2952(95)02165-5; PETER D, 1994, J BIOL CHEM, V269, P7231; PILEBLAD E, 1985, NEUROPHARMACOLOGY, V24, P689, DOI 10.1016/0028-3908(85)90114-5; PILEBLAD E, 1984, J NEURAL TRANSM, V60, P199, DOI 10.1007/BF01249093; Przedborski S, 1996, P NATL ACAD SCI USA, V93, P4565, DOI 10.1073/pnas.93.10.4565; Przedborski S, 1998, MOVEMENT DISORD, V13, P35; PRZEDBORSKI S, 1992, J NEUROSCI, V12, P1658; RAMSAY RR, 1986, BIOCHEM BIOPH RES CO, V134, P743, DOI 10.1016/S0006-291X(86)80483-1; RAMSAY RR, 1991, J NEUROCHEM, V56, P1184, DOI 10.1111/j.1471-4159.1991.tb11409.x; REINHARD JF, 1990, J NEUROCHEM, V55, P311, DOI 10.1111/j.1471-4159.1990.tb08853.x; REINHARD JF, 1987, P NATL ACAD SCI USA, V84, P8160, DOI 10.1073/pnas.84.22.8160; Reynolds IJ, 1999, ANN NY ACAD SCI, V893, P33, DOI 10.1111/j.1749-6632.1999.tb07816.x; RICAURTE GA, 1985, NEUROSCI LETT, V59, P259, DOI 10.1016/0304-3940(85)90141-7; RICHTER C, 1995, BBA-MOL BASIS DIS, V1271, P67, DOI 10.1016/0925-4439(95)00012-S; ROLLEMA H, 1986, EUR J PHARMACOL, V126, P345, DOI 10.1016/0014-2999(86)90071-3; Rottenberg H, 1998, BBA-MOL CELL RES, V1404, P393, DOI 10.1016/S0167-4889(98)00088-3; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; SANCHEZRAMOS J, 1986, NEUROSCI LETT, V72, P215, DOI 10.1016/0304-3940(86)90083-2; SCHMIDT CJ, 1984, EUR J PHARMACOL, V103, P255, DOI 10.1016/0014-2999(84)90485-0; SCOTT ID, 1980, BIOCHEM J, V186, P21, DOI 10.1042/bj1860021; Shen XM, 1997, CHEM RES TOXICOL, V10, P147, DOI 10.1021/tx960145c; Simbula G, 1997, AM J PHYSIOL-CELL PH, V273, pC479, DOI 10.1152/ajpcell.1997.273.2.C479; SINGER TP, 1990, FEBS LETT, V274, P1, DOI 10.1016/0014-5793(90)81315-F; SIRINATHSINGHJI DJS, 1988, BRAIN RES, V443, P101, DOI 10.1016/0006-8993(88)91603-4; Sonders MS, 1997, J NEUROSCI, V17, P960; SULZER D, 1995, J NEUROSCI, V15, P4102; Takahashi N, 1997, P NATL ACAD SCI USA, V94, P9938, DOI 10.1073/pnas.94.18.9938; TAKESHIGE K, 1979, BIOCHEM J, V180, P129, DOI 10.1042/bj1800129; TANG L, 1994, J PHARMACOL EXP THER, V270, P475; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; Wang YM, 1997, NEURON, V19, P1285, DOI 10.1016/S0896-6273(00)80419-5	86	263	270	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38581	38588		10.1074/jbc.M005385200	http://dx.doi.org/10.1074/jbc.M005385200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10969076	hybrid			2022-12-25	WOS:000165739800060
J	Lampio, A; Kilpelainen, I; Pesonen, S; Karhi, K; Auvinen, P; Somerharju, P; Kaariainen, L				Lampio, A; Kilpelainen, I; Pesonen, S; Karhi, K; Auvinen, P; Somerharju, P; Kaariainen, L			Membrane binding mechanism of an RNA virus-mapping enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; PROTEIN SECONDARY STRUCTURE; PHOSPHOLIPASE A(2); PHOSPHATIDYLCHOLINE VESICLES; TRYPTOPHAN FLUORESCENCE; ESCHERICHIA-COLI; MODEL MEMBRANES; CAPPING ENZYME; BHK CELLS; PEPTIDE	The RNA replication complex of Semliki Forest virus is bound to cytoplasmic membranes via the mRNA-capping enzyme Nsp1. Here we have studied the structure and liposome interactions of a synthetic peptide (245)GSTLYTESRKLLRSWHLPSV(264) corresponding to the membrane binding domain of Nsp1. The peptide interacted with liposomes only if negatively charged lipids were present that induced a structural change in the peptide from a random coil to a partially cu-helical conformation. NMR structure shows that the Lu-helix is amphipathic, the hydrophobic surface consisting of several leucines, a valine, and a tryptophan moiety (Trp-259). Fluorescence studies revealed that this tryptophan intercalates in the bilayer to the depth of the ninth and tenth carbons of lipid acyl chains. Mutation W259A altered the mode of bilayer association of the peptide and abolished its ability to compete for membrane association of intact Nsp1, demonstrating its crucial role in the membrane association and function of Nsp1.	Viikki Bioctr, Program Cellular Biotechnol, FIN-00014 Helsinki, Finland; Viikki Bioctr, Inst Biotechnol, NMR Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biomed, Dept Med Chem, FIN-00014 Helsinki, Finland	University of Helsinki	Kaariainen, L (corresponding author), Viikki Bioctr, Program Cellular Biotechnol, POB 56, FIN-00014 Helsinki, Finland.		Auvinen, Petri/D-5044-2009; Auvinen, Petri/AAP-8117-2021	Auvinen, Petri/0000-0002-3947-4778; 				ACHESON NH, 1967, VIROLOGY, V32, P128, DOI 10.1016/0042-6822(67)90261-9; Ahola T, 1999, EMBO J, V18, P3164, DOI 10.1093/emboj/18.11.3164; Ahola T, 1997, J VIROL, V71, P392, DOI 10.1128/JVI.71.1.392-397.1997; Ahola T, 2000, J VIROL, V74, P6725, DOI 10.1128/JVI.74.15.6725-6733.2000; AHOLA T, 1995, P NATL ACAD SCI USA, V92, P507, DOI 10.1073/pnas.92.2.507; Allan D, 1996, MOL MEMBR BIOL, V13, P81, DOI 10.3109/09687689609160580; Baker SF, 1998, BIOCHEMISTRY-US, V37, P13203, DOI 10.1021/bi981223t; BERKHOUT TA, 1987, BIOCHIM BIOPHYS ACTA, V897, P1, DOI 10.1016/0005-2736(87)90308-7; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BOLEN EJ, 1990, BIOCHEMISTRY-US, V29, P9638, DOI 10.1021/bi00493a019; CLAGUE MJ, 1991, BIOCHEMISTRY-US, V30, P5491, DOI 10.1021/bi00236a023; Dunne SJ, 1996, BIOCHEMISTRY-US, V35, P11975, DOI 10.1021/bi960821+; FROSHAUER S, 1988, J CELL BIOL, V107, P2075, DOI 10.1083/jcb.107.6.2075; Gelb MH, 1999, CURR OPIN STRUC BIOL, V9, P428, DOI 10.1016/S0959-440X(99)80059-1; GRIMLEY PM, 1968, J VIROL, V2, P1326, DOI 10.1128/JVI.2.11.1326-1338.1968; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; JOHNSON JE, 1994, BIOCHEMISTRY-US, V33, P4327, DOI 10.1021/bi00180a029; Johnson JE, 1998, BIOCHEMISTRY-US, V37, P9509, DOI 10.1021/bi980340l; KILLIAN JA, 1990, BIOCHEMISTRY-US, V29, P8131, DOI 10.1021/bi00487a021; KUGE O, 1989, BIOCHIM BIOPHYS ACTA, V986, P61, DOI 10.1016/0005-2736(89)90272-1; Kujala P, 1999, J VIROL, V73, P7805, DOI 10.1128/JVI.73.9.7805-7811.1999; LAAKKONEN P, 1994, J VIROL, V68, P7418, DOI 10.1128/JVI.68.11.7418-7425.1994; Laakkonen P, 1998, J VIROL, V72, P10265, DOI 10.1128/JVI.72.12.10265-10269.1998; Laakkonen P, 1996, J BIOL CHEM, V271, P28567, DOI 10.1074/jbc.271.45.28567; LEAR JD, 1987, J BIOL CHEM, V262, P6500; Macedo-Ribeiro S, 1999, NATURE, V402, P434, DOI 10.1038/46594; Magliano D, 1998, VIROLOGY, V240, P57, DOI 10.1006/viro.1997.8906; MARKELLO T, 1985, BIOCHEMISTRY-US, V24, P2895, DOI 10.1021/bi00333a012; PERANEN J, 1995, VIROLOGY, V208, P610, DOI 10.1006/viro.1995.1192; PERANEN J, 1991, J VIROL, V65, P1623; PERANEN J, 1993, J HISTOCHEM CYTOCHEM, V41, P447, DOI 10.1177/41.3.8429208; PICOT D, 1994, FEBS LETT, V346, P21, DOI 10.1016/0014-5793(94)00314-9; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Pratt KP, 1999, NATURE, V402, P439, DOI 10.1038/46601; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROZANOV MN, 1992, J GEN VIROL, V73, P2129, DOI 10.1099/0022-1317-73-8-2129; Saleh MT, 1996, BIOCHEMISTRY-US, V35, P9325, DOI 10.1021/bi960177z; SOMERHARJU PJ, 1985, BIOCHEMISTRY-US, V24, P2773, DOI 10.1021/bi00332a027; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; Sumandea M, 1999, BIOCHEMISTRY-US, V38, P16290, DOI 10.1021/bi9921384; TEALE FWJ, 1960, BIOCHEM J, V76, P381, DOI 10.1042/bj0760381; TENNYSON J, 1986, J BIOL CHEM, V261, P14196; VAUHKONEN M, 1989, EUR J BIOCHEM, V186, P465, DOI 10.1111/j.1432-1033.1989.tb15230.x; White SH, 1998, BBA-REV BIOMEMBRANES, V1376, P339, DOI 10.1016/S0304-4157(98)00021-5; Wutrich K., 1986, NMR PROTEINS NUCL AC	47	73	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37853	37859		10.1074/jbc.M004865200	http://dx.doi.org/10.1074/jbc.M004865200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10984480	hybrid			2022-12-25	WOS:000165618700074
J	Tchan, MC; Choy, KJ; Mackay, JP; Lyons, ATL; Bains, NPS; Weiss, AS				Tchan, MC; Choy, KJ; Mackay, JP; Lyons, ATL; Bains, NPS; Weiss, AS			Interfacial asparagine residues within an amide tetrad contribute to Max helix-loop-helix leucine zipper homodimer stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARALLEL COILED-COIL; SECONDARY STRUCTURE; ESCHERICHIA-COLI; B/HLH/Z DOMAIN; MYC; PROTEIN; DNA; INSIGHTS; HETERODIMERIZATION; TRANSFORMATION	The transcription factor Max is the obligate dimerization partner of the Myc oncoprotein. The pivotal role of Max within the Myc regulatory network is dependent upon its ability to dimerize via the helix-loop-helix leucine zipper domain. The Max homodimer contains a tetrad of polar residues at the interface of the leucine zipper domain. A conserved interfacial Asn residue at an equivalent position in two other leucine zipper proteins has been shown to decrease homodimer stability. The unusual arrangement of this Gln-Asn/Gln'-Asn' tetrad prompted us to investigate whether Asn(92) plays a similar role in destabilizing the Max homodimer. This residue was sequentially replaced with aliphatic and charged residues. Thermal denaturation, redox time course and analytical ultracentrifugation studies show that the N92V mutation does not increase homodimer stability. Replacing this residue with negatively charged side chains in N92D and N92E destabilizes the mutant homodimer. Further replacement of Gln(91) indicated that H bonding between Gln(91) and Asn(92) residues is not significant to the stability of the native protein. These data collectively demonstrate the central role of Asn(92) in homodimer interactions. Molecular modelling studies illustrate the favorable packing of the native Asn residue at the dimer interface compared with that of the mutant Max peptides.	Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia; Univ Connecticut, Ctr Hlth, Dept Biochem, Farmington, CT 06030 USA	University of Sydney; University of Connecticut	Weiss, AS (corresponding author), Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia.		Weiss, Anthony S/GYV-0157-2022; Weiss, Anthony S/F-8103-2010; Mackay, Joel/D-6834-2011	Weiss, Anthony S/0000-0002-8106-4836; Mackay, Joel/0000-0001-7508-8033				Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; *BIOS TECHN, 1993, INS US GUID VERS 2 3; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Brownlie P, 1997, STRUCTURE, V5, P509, DOI 10.1016/S0969-2126(97)00207-4; CADWELL RC, 1994, PCR METH APPL, V3, P136; DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Fairman R, 1997, PROTEIN SCI, V6, P175; FERREDAMARE AR, 1994, STRUCTURE, V2, P357, DOI 10.1016/S0969-2126(00)00037-X; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; Gupta MP, 1997, MOL CELL BIOL, V17, P3924, DOI 10.1128/MCB.17.7.3924; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Hayes D. B., 1995, SEDNTERP; Horiuchi M, 1997, J BIOCHEM-TOKYO, V122, P711; Hurlin PJ, 1997, CURR TOP MICROBIOL, V224, P115; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; JUNIUS FK, 1995, BIOCHEMISTRY-US, V34, P6164, DOI 10.1021/bi00018a020; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Lavigne P, 1998, J MOL BIOL, V281, P165, DOI 10.1006/jmbi.1998.1914; LAVIGNE P, 1995, J MOL BIOL, V254, P505, DOI 10.1006/jmbi.1995.0634; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LUMB KJ, 1995, BIOCHEMISTRY-US, V34, P8642, DOI 10.1021/bi00027a013; MARTIN SL, 1995, GENE, V154, P159, DOI 10.1016/0378-1119(94)00848-M; MERELO JJ, 1994, NEUROCOMPUTING, V6, P443, DOI 10.1016/0925-2312(94)90021-3; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; MUHLEGOLL C, 1995, BIOCHEMISTRY-US, V34, P13554, DOI 10.1021/bi00041a035; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Wendt H, 1998, J BIOL CHEM, V273, P5735, DOI 10.1074/jbc.273.10.5735; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	37	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37454	37461		10.1074/jbc.M004264200	http://dx.doi.org/10.1074/jbc.M004264200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10978321	hybrid			2022-12-25	WOS:000165618700022
J	Andley, UP; Song, Z; Wawrousek, EF; Fleming, TP; Bassnett, S				Andley, UP; Song, Z; Wawrousek, EF; Fleming, TP; Bassnett, S			Differential protective activity of alpha A- and alpha B-crystallin in lens epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; CHAPERONE ACTIVITY; HUMAN HSP27; TNF-ALPHA; EXPRESSION; GENE; RESISTANCE; REGULATORS; STABILITY; APOPTOSIS	alphaA- and alphaB-crystallins are molecular chaperones expressed at low levels in lens epithelial cells, and their expression increases dramatically during differentiation to lens fibers. However, the functions of alphaA- and alphaB-crystallins in lens epithelial cells have not been studied in detail. In this study, the relative ability of alphaA- and alphaB-crystallin, in protecting lens epithelial cells from apoptotic cell death was determined, The introduction of alphaA-crystallin in the transformed human lens epithelial (HLE) B-3 lens epithelial cell line (which expresses low endogenous levels of alphaB-crystallin) led to a nearly complete protection of cell death induced by staurosporine, Fas monoclonal antibody, or the cytokine tumor necrosis factor cu. To further study the relative protective activities of alphaA- and alphaB-crystallins, we created a cell line derived from alphaA-/-alphaB-/- double knockout mouse lens epithelia by infecting primary cells with Ad12-SV40 hybrid virus. The transformed cell line alpha AYBKO1 derived from alphaA/alphaB double knockout cells was transfected with alphaA- or alphaB-crystallin cDNA contained in pCIneo mammalian expression vector. Cells expressing different amounts of either alphaA-crystallin or alphaB-crystallin were isolated. The ability of alphaA- or aB-crystallin to confer protection from apoptotic cell death was determined by annexin labeling and flow cytometry of staurosporine- or UVA- treated cells. The results indicate that the anti-apoptotic activity of alphaA-crystallin was two to threefold higher than that of alphaB-crystallin, Our work suggests that comparing the in vitro annexin labeling of lens epithelial cells is an effective way to measure the protective activity of alphaA- and alphaB-crystallin. Since the expression of alphaA-crystallin is largely restricted to the lens, its greater protective effect against apoptosis suggests that it may play a significant role in protecting lens epithelial cells from stress.	Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; NEI, NIH, Bethesda, MD 20892 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Andley, UP (corresponding author), Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, 660 S Euclid Ave,Campus Box 8096, St Louis, MO 63110 USA.	andley@vision.wustl.edu	Wawrousek, Eric/A-4547-2008	Andley, Usha/0000-0001-7049-7591; Bassnett, Steven/0000-0002-8337-2760	NEI NIH HHS [EY02687, P30 EY002687, R01-EY05681, EY09852] Funding Source: Medline; NATIONAL EYE INSTITUTE [Z01EY000286, R01EY009852, P30EY002687, R01EY005681] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Andley UP, 1998, J BIOL CHEM, V273, P31252, DOI 10.1074/jbc.273.47.31252; ANDLEY UP, 1994, INVEST OPHTH VIS SCI, V35, P3094; ANDLEY UP, 2000, IN PRESS FASEB J; Arrigo AP, 1994, BIOL HEAT SHOCK PROT, P335; Bhat SP, 1999, EUR J CELL BIOL, V78, P143, DOI 10.1016/S0171-9335(99)80016-8; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; Brady JP, 1997, P NATL ACAD SCI USA, V94, P884, DOI 10.1073/pnas.94.3.884; Cobb BA, 2000, J BIOL CHEM, V275, P6664, DOI 10.1074/jbc.275.9.6664; Datta SA, 1999, J BIOL CHEM, V274, P34773, DOI 10.1074/jbc.274.49.34773; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; Fleming TP, 1998, INVEST OPHTH VIS SCI, V39, P1387; GaleaLauri J, 1996, J IMMUNOL, V157, P4109; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Horwitz J, 1999, EYE, V13, P403, DOI 10.1038/eye.1999.114; Horwitz J, 1998, METHOD ENZYMOL, V290, P365, DOI 10.1016/S0076-6879(98)90032-5; Iwaki A, 1997, GENOMICS, V45, P386, DOI 10.1006/geno.1997.4956; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; KANTOROW M, 1994, P NATL ACAD SCI USA, V91, P3112, DOI 10.1073/pnas.91.8.3112; KLEMENZ R, 1991, MOL CELL BIOL, V11, P803, DOI 10.1128/MCB.11.2.803; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; MEHLEN P, 1995, J CELL BIOCHEM, V58, P248, DOI 10.1002/jcb.240580213; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Muchowski PJ, 1999, INVEST OPHTH VIS SCI, V40, P951; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; Reddy GB, 2000, J BIOL CHEM, V275, P4565, DOI 10.1074/jbc.275.7.4565; Robinson ML, 1996, INVEST OPHTH VIS SCI, V37, P2276; Samali A, 1998, CELL STRESS CHAPERON, V3, P228, DOI 10.1054/csac.1998.0129; SAX CM, 1993, ADV ENZYMOL RAMB, V69, P155; Sun TX, 1999, J BIOL CHEM, V274, P34067, DOI 10.1074/jbc.274.48.34067; Sun TX, 1998, J BIOL CHEM, V273, P286, DOI 10.1074/jbc.273.1.286; van Boekel MAM, 1999, BBA-PROTEIN STRUCT M, V1434, P114, DOI 10.1016/S0167-4838(99)00178-8; VANDENIJSSEL PRLA, 1994, FEBS LETT, V355, P54, DOI 10.1016/0014-5793(94)01175-3; VANNOORT JM, 1995, NATURE, V375, P798, DOI 10.1038/375798a0; VERMORKEN AJM, 1978, J CELL BIOL, V76, P175, DOI 10.1083/jcb.76.1.175; Wawrousek E. F., 1998, IOVS, V39, pS523	37	135	149	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36823	36831		10.1074/jbc.M004233200	http://dx.doi.org/10.1074/jbc.M004233200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10967101	hybrid			2022-12-25	WOS:000165577700055
J	Kurland, IJ; Alcivar, A; Bassilian, S; Lee, WNP				Kurland, IJ; Alcivar, A; Bassilian, S; Lee, WNP			Loss of [C-13]glycerol carbon via the pentose cycle - Implications for gluconeogenesis measurement by mass isotoper distribution analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER 6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE; HEPATOMA-CELLS; MESSENGER-RNA; GLUCOSE; HEPATOCYTES; LIMITATIONS; EXPRESSION; INSULIN; FLUX; RATS	Whereas many reports substantiated the suitability of using [2-C-13]glycerol and Mass Isotoper Distribution Analysis for gluconeogenesis, the use of [C-13]glycerol had been shown to give lower estimates of gluconeogenesis (GNG). The reason for the underestimation has been attributed to asymmetric isotope incorporation during gluconeogenesis as well as zonation of gluconeogenic enzymes and a [C-13]glycerol gradient across the liver. Since the cycling of glycerol carbons through the pentose cycle pathways can introduce asymmetry in glucose labeling pattern and tracer dilution, we present here a study of the role of the pentose cycle in gluconeogenesis in Fao cells. The metabolic regulation of glucose release and gluconeogenesis by insulin was also studied. Serum-starved cells were incubated for 24 h in Dulbecco's modified Eagle's media containing 1.5 mM [U-C-13]glycerol. Mass isotopomers of whole glucose from medium or glycogen and those of the C-1-C-4 fragment were highly asymmetrical, typical of that resulting from the cycling of glucose carbon through the pentose cycle. Substantial exchange of tracer between hexose and pentose intermediates was observed. Our results offer an alternative mechanism for the asymmetrical labeling of glucose carbon from triose phosphate, The scrambling of C-13 in hexose phosphate via the pentose phosphate cycle prior to glucose release into the medium is indistinguishable from dilution of labeled glucose by glycogen using MIDA and probably accounts for the underestimation of GNG using C-13 tracer methods.	Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Med, Div Endocrinol, Diabet Metab Signaling Lab, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Los Angeles Cty Harbor Med Ctr, Dept Pediat, Torrance, CA 90502 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Kurland, IJ (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90024 USA.	ikurland@mednet.ucla.edu						ARGAUD D, 1995, J BIOL CHEM, V270, P24229, DOI 10.1074/jbc.270.41.24229; Argaud D, 1997, J BIOL CHEM, V272, P12854, DOI 10.1074/jbc.272.19.12854; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAWFORD JM, 1983, BIOCHEM J, V212, P595, DOI 10.1042/bj2120585; CRETTAZ M, 1983, ENDOCRINOLOGY, V113, P1201, DOI 10.1210/endo-113-4-1201; ESPINET C, 1993, BIOCHEM J, V293, P173, DOI 10.1042/bj2930173; Hellerstein MK, 1999, AM J PHYSIOL-ENDOC M, V276, pE1146, DOI 10.1152/ajpendo.1999.276.6.E1146; KAHN CR, 1989, MOL ENDOCRINOL, V3, P840, DOI 10.1210/mend-3-5-840; KATZ J, 1967, BIOCHEMISTRY-US, V6, P2227, DOI 10.1021/bi00859a046; KATZ J, 1989, J BIOL CHEM, V264, P12994; LEE WNP, 1991, BIOL MASS SPECTROM, V20, P451, DOI 10.1002/bms.1200200804; Lee WNP, 1998, AM J PHYSIOL-ENDOC M, V274, pE843, DOI 10.1152/ajpendo.1998.274.5.E843; MOORE EE, 1982, J CELL PHYSIOL, V111, P1, DOI 10.1002/jcp.1041110102; NEESE RA, 1995, J BIOL CHEM, V270, P14452, DOI 10.1074/jbc.270.24.14452; PERONI O, 1995, AM J PHYSIOL-ENDOC M, V269, pE516, DOI 10.1152/ajpendo.1995.269.3.E516; Previs SF, 1998, J BIOL CHEM, V273, P16853, DOI 10.1074/jbc.273.27.16853; PREVIS SF, 1995, J BIOL CHEM, V270, P19806, DOI 10.1074/jbc.270.34.19806; SZAFRANECK J, 1974, CARBOHYD RES, V38, P97, DOI 10.1016/S0008-6215(00)82341-1; TSERNG KY, 1984, ANAL CHEM, V56, P517, DOI 10.1021/ac00267a049	20	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36787	36793		10.1074/jbc.M004739200	http://dx.doi.org/10.1074/jbc.M004739200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10960476	hybrid			2022-12-25	WOS:000165577700050
J	Schepens, I; Ruelland, E; Miginiac-Maslow, M; Le Marechal, P; Decottignies, P				Schepens, I; Ruelland, E; Miginiac-Maslow, M; Le Marechal, P; Decottignies, P			The role of active site arginines of sorghum NADP-malate dehydrogenase in thioredoxin-dependent activation and activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; SUBSTRATE-SPECIFICITY; CHLOROPLAST ENZYME; ARGINYL RESIDUES; REGULATORY SITE; AUTOINHIBITION; REDUCTION; PROTEINS; RELIEF	The activation of sorghum NADP-malate dehydrogenase is initiated by thiol/disulfide interchanges with reduced thioredoxin followed by the release of the C-terminal autoinhibitory extension and a structural modification shaping the active site into a high efficiency and high affinity for oxaloacetate conformation. In the present study, the role of the active site arginines in the activation and catalysis was investigated by site-directed mutagenesis and arginyl-specific chemical derivatization using butanedione, Sequence and mass spectrometry analysis were used to identify the chemically modified groups. Taken together, our data reveal the involvement of Arg-134 and Arg-204 in oxaloacetate coordination, suggest an indirect role for Arg-140 in substrate binding and catalysis, and clearly confirm that Arg-87 is implicated in cofactor binding. In contrast with NAD-malate dehydrogenase, no lactate dehydrogenase activity could be promoted by the R134Q mutation. The decreased susceptibility of the activation of the R204K mutant to NADP and its increased sensitivity to the histidine-specific reagent diethylpyrocarbonate indicated that Arg-204 is involved in the locking of the active site. These results are discussed in relation with the,recently published NADP-MDH three-dimensional structures and the previously established three-dimensional structures of NAD-malate dehydrogenase and lactate dehydrogenase.	Univ Paris Sud, Inst Biotechnol Plantes, UMR 8618 CNRS, Orsay, France; Univ Paris Sud, Inst Biochim & Biol Mol & Cellulaire, UMR 8619, Orsay, France	UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay	Miginiac-Maslow, M (corresponding author), Univ Paris Sud, Inst Biotechnol Plantes, UMR 8618 CNRS, Batiment 630, Orsay, France.		Ruelland, Eric/D-4863-2012	Schepens, Isabelle/0000-0002-6718-9608				BOERNKE WE, 1995, ARCH BIOCHEM BIOPHYS, V322, P43, DOI 10.1006/abbi.1995.1434; Carr PD, 1999, STRUCTURE, V7, P461, DOI 10.1016/S0969-2126(99)80058-6; CRETIN C, 1990, EUR J BIOCHEM, V192, P299, DOI 10.1111/j.1432-1033.1990.tb19227.x; DECOTTIGNIES P, 1988, J BIOL CHEM, V263, P11780; GOWARD CR, 1994, PROTEIN SCI, V3, P1883, DOI 10.1002/pro.5560031027; HALL MD, 1992, J MOL BIOL, V226, P867, DOI 10.1016/0022-2836(92)90637-Y; ISSAKIDIS E, 1994, J BIOL CHEM, V269, P3511; Issakidis E, 1996, FEBS LETT, V392, P121, DOI 10.1016/0014-5793(96)00801-0; ISSAKIDIS E, 1992, J BIOL CHEM, V267, P21577; Johansson K, 1999, BIOCHEMISTRY-US, V38, P4319, DOI 10.1021/bi982876c; KITZ R, 1962, J BIOL CHEM, V237, P3245; Krimm I, 1999, J BIOL CHEM, V274, P34539, DOI 10.1074/jbc.274.49.34539; LEMAIRE M, 1994, J BIOL CHEM, V269, P27291; NICHOLLS DJ, 1992, BIOCHEM BIOPH RES CO, V189, P1057, DOI 10.1016/0006-291X(92)92311-K; RIORDAN JF, 1979, MOL CELL BIOCHEM, V26, P71; RIORDAN JF, 1973, BIOCHEMISTRY-US, V12, P3915, DOI 10.1021/bi00744a020; Ruelland E, 1998, J BIOL CHEM, V273, P33482, DOI 10.1074/jbc.273.50.33482; Ruelland E, 1999, TRENDS PLANT SCI, V4, P136, DOI 10.1016/S1360-1385(99)01391-6; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schepens I, 2000, J BIOL CHEM, V275, P20996, DOI 10.1074/jbc.M002066200; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WILKS HM, 1988, SCIENCE, V242, P1541, DOI 10.1126/science.3201242	22	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35792	35798		10.1074/jbc.M006526200	http://dx.doi.org/10.1074/jbc.M006526200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10958800	hybrid			2022-12-25	WOS:000165382000023
J	Tobaben, S; Sudhof, TC; Stahl, B				Tobaben, S; Sudhof, TC; Stahl, B			The G protein-coupled receptor CL1 interacts directly with proteins of the Shank family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-EFFICIENCY TRANSFORMATION; POSTSYNAPTIC DENSITY PROTEINS; ALPHA-LATROTOXIN RECEPTOR; SYNAPTIC PROTEINS; ESCHERICHIA-COLI; BINDING-PROTEIN; PDZ DOMAINS; BRAIN; PURIFICATION; EXOCYTOSIS	PDZ domains play a pivotal role in the synaptic localization of ion channels, receptors, signaling enzymes, and cell adhesion molecules. These domains mediate protein-protein interactions via the recognition of a conserved sequence motif at the extreme C terminus of their: target proteins. By means of a yeast two-hybrid screen using the C terminus of the G protein-coupled Lu-latrotoxin receptor CL1 as bait, three PDZ domain proteins of the Shank family were identified. These proteins belong to a single protein family characterized by a common domain organization. The PDZ domain is highly conserved among the family members, significantly different from other known PDZ domains, and specifically binds to the C terminus of CL1. Shank1 and CL1:are expressed primarily in brain, and both proteins co-enrich in the postsynaptic density. Furthermore, Shank1 induces a clustering of CL1 in transfected cells, strongly supporting an interaction of both proteins in vivo.	Max Planck Inst Expt Med, D-37075 Gottingen, Germany; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	Max Planck Society; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Stahl, B (corresponding author), Max Planck Inst Expt Med, Hermann Rein Str 3, D-37075 Gottingen, Germany.							Boeckers TM, 1999, BIOCHEM BIOPH RES CO, V264, P247, DOI 10.1006/bbrc.1999.1489; Boeckers TM, 1999, J NEUROSCI, V19, P6506; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; DAVLETOV BA, 1995, J BIOL CHEM, V270, P23903, DOI 10.1074/jbc.270.41.23903; Du YR, 1998, MOL CELL BIOL, V18, P5838, DOI 10.1128/MCB.18.10.5838; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; GRASSO A, 1993, NEUROSCIENCE, V54, P595, DOI 10.1016/0306-4522(93)90231-4; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hata Y, 1996, J NEUROSCI, V16, P2488; Ichtchenko K, 1998, EMBO J, V17, P6188, DOI 10.1093/emboj/17.21.6188; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lim S, 1999, J BIOL CHEM, V274, P29510, DOI 10.1074/jbc.274.41.29510; Naisbitt S, 1999, NEURON, V23, P569, DOI 10.1016/S0896-6273(00)80809-0; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Rose MD., 1990, METHODS YEAST GENETI; ROSENTHAL L, 1989, PHARMACOL THERAPEUT, V42, P115, DOI 10.1016/0163-7258(89)90024-7; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHNITTLER HJ, 1993, AM J PHYSIOL, V265, P289; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Sugita S, 1998, J BIOL CHEM, V273, P32715, DOI 10.1074/jbc.273.49.32715; Thanos CD, 1999, SCIENCE, V283, P833, DOI 10.1126/science.283.5403.833; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARD AC, 1990, NUCLEIC ACIDS RES, V18, P5319, DOI 10.1093/nar/18.17.5319; Xu QL, 1996, NATURE, V381, P319, DOI 10.1038/381319a0; Yao I, 1999, J BIOL CHEM, V274, P27463, DOI 10.1074/jbc.274.39.27463; Zitzer H, 1999, J BIOL CHEM, V274, P32997, DOI 10.1074/jbc.274.46.32997	41	53	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36204	36210		10.1074/jbc.M006448200	http://dx.doi.org/10.1074/jbc.M006448200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10958799	hybrid			2022-12-25	WOS:000165382000079
J	Whitman, SC; Daugherty, A; Post, SR				Whitman, SC; Daugherty, A; Post, SR			Macrophage colony-stimulating factor rapidly enhances beta-migrating very low density lipoprotein metabolism in macrophages through activation of a G(i/o) protein signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCAVENGER RECEPTOR EXPRESSION; GTP-BINDING PROTEIN; GROWTH-FACTOR; PERTUSSIS TOXIN; HUMAN-MONOCYTES; FACTOR CSF-1; PHOSPHATIDYLINOSITOL 3-KINASE; CHOLESTEROL-METABOLISM; ADP-RIBOSYLATION; MEMBRANE-PROTEIN	Previous studies have examined lipoprotein metabolism by macrophages following prolonged exposure (>24 h) to macrophage colony-stimulating factor (M-CSF). Because M-CSF activates several, signaling pathways that could rapidly affect lipoprotein metabolism, we examined whether acute exposure of macrophages to M-CSF alters the metabolism of either native or modified lipoproteins, Acute incubation of cultured J774 macrophages and resident mouse peritoneal macrophages with M-CSF markedly enhanced low density lipoproteins (LDL) and beta -migrating very low density lipoproteins (beta -VLDL) stimulated cholesteryl [H-3]oleate deposition. In parallel, M-CSF treatment increased the association and degradation of I-125-labeled LDL or beta -VLDL without altering the amount of lipoprotein bound to the cell surface. The increase in LDL and beta -VLDL metabolism did not reflect a generalized effect on lipoprotein endocytosis and metabolism because M-CSF did not alter cholesterol deposition during incubation with acetylated LDL, Moreover, M-CSF did not augment beta -VLDL cholesterol deposition in macrophages from LDL receptor (-/-) mice, indicating that the effect of M-CSF was mediated by the LDL receptor. Incubation of macrophages with pertussis toxin, a specific inhibitor of G(i/o) protein signaling, had no effect on cholesterol deposition during incubation with beta -VLDL alone, but completely blocked the augmented response promoted by M-CSF. In addition, incubation of macrophages with the direct G(i/o) protein activator, mastoparan, mimicked the effect of M-CSF by enhancing cholesterol deposition in cells incubated with beta -VLDL, but not acetylated LDL, In summary, M-CSF rapidly enhances LDL receptor-mediated metabolism of native lipoproteins by macrophages through activation of a G(i/o), protein signaling pathway. Together, these findings describe a novel pathway for regulating lipoprotein metabolism.	Univ Kentucky, Med Ctr, Dept Pharmacol, Atherosclerosis Res Grp,Linda & Jack Gill Heart I, Lexington, KY 40536 USA; Univ Kentucky, Div Cardiovasc Med, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Post, SR (corresponding author), Univ Kentucky, Med Ctr, Dept Pharmacol, Atherosclerosis Res Grp,Linda & Jack Gill Heart I, MS305, Lexington, KY 40536 USA.		Daugherty, Alan/C-8282-2009	Daugherty, Alan/0000-0003-2093-3775; Post, Steven/0000-0002-4711-1723	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055487] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55487] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; CLINTON SK, 1992, AM J PATHOL, V140, P301; CORRE I, 1995, BLOOD, V86, P1776, DOI 10.1182/blood.V86.5.1776.bloodjournal8651776; de Villiers WJS, 1998, ARTERIOSCL THROM VAS, V18, P631, DOI 10.1161/01.ATV.18.4.631; DEVILLIERS WJS, 1994, IMMUNOL LETT, V43, P73, DOI 10.1016/0165-2478(94)00148-0; DEVILLIERS WJS, 1994, J EXP MED, V180, P705, DOI 10.1084/jem.180.2.705; Goretzki L, 1998, BIOCHEM J, V336, P381, DOI 10.1042/bj3360381; HALLET MM, 1991, BLOOD, V77, P780; Hamilton JA, 1997, J LEUKOCYTE BIOL, V62, P145, DOI 10.1002/jlb.62.2.145; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HE YX, 1988, BLOOD, V71, P1187; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HUME DA, 1989, IMMUNOL CELL BIOL, V67, P243, DOI 10.1038/icb.1989.37; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; IMAMURA K, 1990, EMBO J, V9, P2423, DOI 10.1002/j.1460-2075.1990.tb07418.x; IMAMURA K, 1988, J BIOL CHEM, V263, P14093; INABA T, 1992, J BIOL CHEM, V267, P5693; INOUE I, 1992, ATHEROSCLEROSIS, V93, P245, DOI 10.1016/0021-9150(92)90261-E; ISHIBASHI S, 1990, J BIOL CHEM, V265, P14109; ISHII I, 1994, BBA-LIPID LIPID MET, V1212, P278, DOI 10.1016/0005-2760(94)90201-1; Jessup W, 1997, ARTERIOSCL THROM VAS, V17, P18, DOI 10.1161/01.ATV.17.1.18; KATADA T, 1982, J BIOL CHEM, V257, P7210; KATADA T, 1982, P NATL ACAD SCI-BIOL, V79, P3129, DOI 10.1073/pnas.79.10.3129; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Qiao JH, 1997, AM J PATHOL, V150, P1687; RACOOSIN EL, 1992, J CELL SCI, V102, P867; RACOOSIN EL, 1989, J EXP MED, V170, P1635, DOI 10.1084/jem.170.5.1635; Rajavashisth T, 1998, J CLIN INVEST, V101, P2702, DOI 10.1172/JCI119891; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; RAMBALDI A, 1987, BLOOD, V69, P1409; ROSENFELD ME, 1992, AM J PATHOL, V140, P291; SACCA R, 1986, P NATL ACAD SCI USA, V83, P3331, DOI 10.1073/pnas.83.10.3331; Sano H, 1998, J BIOL CHEM, V273, P8630, DOI 10.1074/jbc.273.15.8630; SHERR CJ, 1988, BIOCHIM BIOPHYS ACTA, V948, P225, DOI 10.1016/0304-419X(88)90011-X; SHERR CJ, 1988, COLD SPRING HARB SYM, V53, P521, DOI 10.1101/SQB.1988.053.01.060; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SIEFF CA, 1988, BLOOD, V72, P1316; SILVERSTEIN SC, 1977, ANNU REV BIOCHEM, V46, P669, DOI 10.1146/annurev.bi.46.070177.003321; SMITH JD, 1995, P NATL ACAD SCI USA, V92, P8264, DOI 10.1073/pnas.92.18.8264; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; STOPECK AT, 1993, J BIOL CHEM, V268, P17489; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P89, DOI 10.1016/S0962-8924(00)88956-4; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; Whitman SC, 2000, J LIPID RES, V41, P807; XIE Y, 1993, BRIT J HAEMATOL, V84, P392, DOI 10.1111/j.1365-2141.1993.tb03092.x; YANO H, 1995, BIOCHEM J, V312, P145, DOI 10.1042/bj3120145	51	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35807	35813		10.1074/jbc.M001797200	http://dx.doi.org/10.1074/jbc.M001797200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10964909	hybrid			2022-12-25	WOS:000165382000025
J	Hayette, S; Tigaud, I; Vanier, A; Martel, S; Corbo, L; Charrin, C; Beillard, E; Deleage, G; Magaud, JP; Rimokh, R				Hayette, S; Tigaud, I; Vanier, A; Martel, S; Corbo, L; Charrin, C; Beillard, E; Deleage, G; Magaud, JP; Rimokh, R			AF15q14, a novel partner gene fused to the MLL gene in an acute myeloid leukaemia with a t(11;15)(q23;q14)	ONCOGENE			English	Article						t(11;15)(q23;q14); 11q23; MLL; AF15q14; leukaemogenesis	DROSOPHILA-TRITHORAX; ACUTE LEUKEMIAS; ALL-1 GENE; TRANSLOCATION; PROTEIN; FUSION; REARRANGEMENTS; INVOLVEMENT; BREAKPOINT; PRODUCTS	In haematopoietic malignancies the MLL gene, located on chromosome 11q23, is frequently disrupted by chromosome rearrangement, generally resulting in fusion to various partner genes. We have previously reported a t(11;15)(q23;q14) in a case of acute myeloblastic leukaemia. Here, we report the cloning of a novel MLL partner, AF15q14, at chromosome 15q14, In this translocation, the breakpoint occurred in exon 8 of MLL and exon 10 of AF15q14. The normal AF15q14 transcripts of approximately 8.5 kb in size, are expressed in different tumoral cell lines, in variety of normal tissues, and in all the foetal tissues tested. Sequencing of AF15q14 cDNA revealed a putative open reading frame of 1833 amino acids that had no homology with any other known protein. The C-terminal end of the putative AF15q14 contained a bipartite nuclear localization site. The translocation t(11;15) preserved the open reading frame between MLL and the 3' end of AF15q14. The contribution of AF15q14 to the fusion protein was only 85 amino acids, Immunofluorescence staining experiments with expression vectors encoding these 85 amino acids confirmed the functionality of the predicted nuclear localization site.	Ctr Leon Berard, INSERM, U453, F-69373 Lyon 08, France; Fac Med Nord, Lab Biochim & Biol Mol, F-13916 Marseille, France; IBCP, UMR 5086, F-69367 Lyon 07, France; Hop Edouard Herriot, Lab Cytogenet Mol, F-69437 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); CHU Lyon	Rimokh, R (corresponding author), Ctr Leon Berard, INSERM, U453, F-69373 Lyon 08, France.		HAYETTE, sandrine/Z-2283-2019; Rimokh, Ruth/G-7506-2014; Deléage, Gilbert/F-7163-2010	Deléage, Gilbert/0000-0003-1939-1614				Archimbaud E, 1998, LEUKEMIA, V12, P25, DOI 10.1038/sj.leu.2400853; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DiMartino JF, 1999, BRIT J HAEMATOL, V106, P614, DOI 10.1046/j.1365-2141.1999.01439.x; Dobson CL, 2000, EMBO J, V19, P843, DOI 10.1093/emboj/19.5.843; Fidanza V, 1996, CANCER RES, V56, P1179; GEOURJON C, 1995, J MOL GRAPHICS, V13, P209, DOI 10.1016/0263-7855(95)00035-5; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GU Y, 1994, CANCER RES, V54, P2326; Harrison CJ, 1998, LEUKEMIA, V12, P811, DOI 10.1038/sj.leu.2401017; HERNANDEZ JM, 1995, LEUKEMIA, V9, P1162; HUNGER SP, 1993, BLOOD, V81, P3197; Joh T, 1997, ONCOGENE, V15, P1681, DOI 10.1038/sj.onc.1201332; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Marschalek R, 1997, LEUKEMIA LYMPHOMA, V27, P417, DOI 10.3109/10428199709058308; Rogaia D, 1997, CANCER RES, V57, P799; Rouault JP, 1998, J BIOL CHEM, V273, P22563, DOI 10.1074/jbc.273.35.22563; ROWLEY JD, 1992, GENE CHROMOSOME CANC, V5, P264, DOI 10.1002/gcc.2870050316; RUBNITZ JE, 1994, BLOOD, V84, P570; Schreiner SA, 1999, LEUKEMIA, V13, P1525, DOI 10.1038/sj.leu.2401534; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	21	37	42	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4446	4450		10.1038/sj.onc.1203789	http://dx.doi.org/10.1038/sj.onc.1203789			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980622				2022-12-25	WOS:000089271900017
J	Blanchard, DA; Mouhamad, S; Auffredou, MT; Pesty, A; Bertoglio, J; Leca, G; Vazquez, A				Blanchard, DA; Mouhamad, S; Auffredou, MT; Pesty, A; Bertoglio, J; Leca, G; Vazquez, A			Cdk2 associates with MAP kinase in vivo and its nuclear translocation is dependent on MAP Kinase activation in IL-2-dependent Kit 225 T lymphocytes	ONCOGENE			English	Article						cell cycle; lymphocyte; IL-2; cdk2; MAP kinase; nuclear localization	CELL-CYCLE CONTROL; PROTEIN-KINASE; NUCLEOCYTOPLASMIC TRANSPORT; SUBCELLULAR-LOCALIZATION; G(1)/S TRANSITION; GROWTH-FACTORS; GENE-PRODUCT; IN-VIVO; S-PHASE; PHOSPHORYLATION	Cell proliferation is controlled by cdk2 which in association with cyclin E and a regulates G1/S transition and S phase progression. cdk2 activation is dependent on its localization in the nucleus where regulatory mediators are found, We report that activation of cdk2 is associated with the formation of cdk2/MAP kinase complexes, cdk2 associates with both inactive and activated MAP Kinase. Prevention of MAP Kinase activation ba the MEK inhibitor PD98059 inhibits both activation and nuclear localization of cdk2 and S phase entry. These findings indicate that the nuclear translocation of cdk2 is associated with the formation of molecular complexes containing active MAP Kinase and is dependent on MAP Kinase activation.	IPSC, INSERM U131, F-92140 Clamart, France; Claude Bernard Res Ctr, F-92140 Clamart, France; IPSC, INSERM U355, F-92140 Clamart, France; Fac Pharm Chatenay Malabry, INSERM U461, F-92296 Chatenay Malabry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Vazquez, A (corresponding author), IPSC, INSERM U131, 32 Rue des Carnets, F-92140 Clamart, France.							ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; Bresnahan WA, 1996, CELL GROWTH DIFFER, V7, P1283; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ETTEHADIEH E, 1992, SCIENCE, V255, P853, DOI 10.1126/science.1311128; Fisher RP, 1997, CURR OPIN GENET DEV, V7, P32, DOI 10.1016/S0959-437X(97)80106-2; Fotedar A, 1996, J BIOL CHEM, V271, P31627, DOI 10.1074/jbc.271.49.31627; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HARPER JW, 1993, CELL, V75, P805; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HONDA R, 1993, FEBS LETT, V318, P331, DOI 10.1016/0014-5793(93)80540-B; HORI T, 1987, BLOOD, V70, P1069; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LABBE JC, 1994, EMBO J, V13, P5155, DOI 10.1002/j.1460-2075.1994.tb06845.x; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; Mahony D, 1998, ONCOGENE, V16, P603, DOI 10.1038/sj.onc.1201570; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; Prosperi E, 1997, EUR J HISTOCHEM, V41, P161; Reed SI, 1997, CANCER SURV, V29, P7; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; Ruckdeschel K, 1997, J BIOL CHEM, V272, P15920, DOI 10.1074/jbc.272.25.15920; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; TAIEB J, 1995, J IMMUNOL, V155, P5623; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131	54	30	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2000	19	36					4184	4189		10.1038/sj.onc.1203761	http://dx.doi.org/10.1038/sj.onc.1203761			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962581				2022-12-25	WOS:000088955100014
J	Ohki, G; Miyoshi, T; Murata, M; Ishibashi, K; Imai, M; Suzuki, M				Ohki, G; Miyoshi, T; Murata, M; Ishibashi, K; Imai, M; Suzuki, M			A calcium-activated cation current by an alternatively spliced form of Trp3 in the heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CA2+ ENTRY; ENDOTHELIAL-CELLS; PURKINJE-FIBERS; CHANNEL; EXPRESSION; CLONING; RECEPTOR; HOMOLOG; RAT; MEMBRANE	To investigate a cDNA encoding cation current, we isolated an alternatively spliced form of a rat Trp3, designated Trp3sv, Trp3sv encodes 736 amino acids with a unique N terminus and six transmembrane segments. Expression of the cRNA in Xenopus oocytes was successfully performed. The cation selective current appeared after the addition of ionomycin or induced by prolonged depolarization but not by hyperpolarization. This induction was not observed by a treatment with thapsigargin, phorbol ester, or ATP, Na+, K+, tetraethylammonium, and divalent cations were permeable, while N-methyl-glucamine and chloride were nominally impermeable ions, The currents were not inhibited by flufenamate ruthenium red but nonspecifically by 2 mM Gd3+. Northern as well as Western blot suggested lower levels of the expression observed in some organs, while reverse transcriptase-polymerase chain reaction suggested that it widely spread among various organs. Therefore, we may conclude that N-terminal spliced valiant of Trp3, Trp3sv, encodes a calcium-activated cation channel in various organs.	Jichi Med Sch, Dept Pharmacol, Minami Kawachi, Tochigi 3290498, Japan	Jichi Medical University	Suzuki, M (corresponding author), Jichi Med Sch, Dept Pharmacol, 3311-1 Yakushiji, Minami Kawachi, Tochigi 3290498, Japan.							Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Carmeliet E, 1999, PHYSIOL REV, V79, P917, DOI 10.1152/physrev.1999.79.3.917; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; CHAMPIGNY G, 1991, BIOCHEM BIOPH RES CO, V176, P1196, DOI 10.1016/0006-291X(91)90412-Z; COLQUHOUN D, 1981, NATURE, V294, P752, DOI 10.1038/294752a0; Eguiguren AL, 1996, BIOCHEM BIOPH RES CO, V225, P505, DOI 10.1006/bbrc.1996.1203; EHARA T, 1988, J PHYSIOL-LONDON, V403, P117, DOI 10.1113/jphysiol.1988.sp017242; Freichel M, 1999, CELL PHYSIOL BIOCHEM, V9, P270, DOI 10.1159/000016321; Groschner K, 1998, FEBS LETT, V437, P101, DOI 10.1016/S0014-5793(98)01212-5; HILL JA, 1988, CIRC RES, V62, P411, DOI 10.1161/01.RES.62.2.411; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Ishibashi K, 1997, J BIOL CHEM, V272, P20782, DOI 10.1074/jbc.272.33.20782; Kamouchi M, 1999, J PHYSIOL-LONDON, V518, P345, DOI 10.1111/j.1469-7793.1999.0345p.x; KASS RS, 1978, J PHYSIOL-LONDON, V281, P187, DOI 10.1113/jphysiol.1978.sp012416; Lan L, 1996, BIOCHEM J, V316, P793, DOI 10.1042/bj3160793; MARCUS DC, 1992, AM J PHYSIOL, V262, pC1423, DOI 10.1152/ajpcell.1992.262.6.C1423; Mizuno N, 1999, MOL BRAIN RES, V64, P41, DOI 10.1016/S0169-328X(98)00296-4; Mori Y, 1998, NEUROREPORT, V9, P507; PETERSEN CCH, 1995, BIOCHEM J, V311, P41, DOI 10.1042/bj3110041; Preuss KD, 1997, BIOCHEM BIOPH RES CO, V240, P167, DOI 10.1006/bbrc.1997.7528; ROUSSEAU E, 1986, BIOPHYS J, V50, P1009, DOI 10.1016/S0006-3495(86)83543-3; SAUNDERS JH, 1973, CIRC RES, V32, P610; Schumacher MA, 2000, J BIOL CHEM, V275, P2756, DOI 10.1074/jbc.275.4.2756; Suzuki M, 1999, J BIOL CHEM, V274, P6330, DOI 10.1074/jbc.274.10.6330; TEULON J, 1987, BIOCHIM BIOPHYS ACTA, V905, P125, DOI 10.1016/0005-2736(87)90016-2; Tomita Y, 1998, NEUROSCI LETT, V248, P195, DOI 10.1016/S0304-3940(98)00362-0; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333	30	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39055	39060		10.1074/jbc.M003606200	http://dx.doi.org/10.1074/jbc.M003606200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10984475	hybrid			2022-12-25	WOS:000165953100017
J	Bridges, JP; Davis, HW; Damodarasamy, M; Kuroki, Y; Howles, G; Hui, DY; McCormack, FX				Bridges, JP; Davis, HW; Damodarasamy, M; Kuroki, Y; Howles, G; Hui, DY; McCormack, FX			Pulmonary surfactant proteins A and D are potent endogenous inhibitors of lipid peroxidation and oxidative cellular injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID AGGREGATION; CALCIUM; DOMAINS; BINDING; ANTIOXIDANTS; HOMEOSTASIS; ROLES; CELLS; A(2)	The lung is composed of a series of branching conducting airways that terminate in grape-like clusters of delicate gas-exchanging airspaces called pulmonary alveoli. Maintenance of alveolar patency at end expiration requires pulmonary surfactant, a mixture of phospholipids and proteins that coats the epithelial surface and reduces surface tension. The surfactant lining is exposed to the highest ambient oxygen tension of any internal interface and encounters a variety of oxidizing toxicants including ozone and trace metals contained within the 10 kl of air that is respired daily. The pathophysiological consequences of surfactant oxidation in humans and experimental animals include airspace collapse, reduced lung compliance, and impaired gas exchange. me now report that the hydrophilic surfactant proteins A (SP-A) and D (SP-D) directly protect surfactant phospholipids and macrophages from oxidative damage. Both proteins block accumulation of thiobarbituric acid-reactive substances and conjugated dienes during copper-induced oxidation of surfactant lipids or low density lipoprotein particles by a mechanism that does not involve metal chelation or oxidative modification of the proteins. Low density lipoprotein oxidation is instantaneously arrested upon SP-A or SP-D addition, suggesting direct interference with free radical formation or propagation. The antioxidant activity of SP-A maps to the carboxyl-terminal domain of the protein, which, like SP-D, contains a C-type lectin carbohydrate recognition domain. These results indicate that SP-A and SP-D, which are ubiquitous among air breathing organisms, could contribute to the protection of the lung from oxidative stresses due to atmospheric or supplemental oxygen, air pollutants, and lung inflammation.	Univ Cincinnati, Dept Med, Div Pulm & Crit Care, Cincinnati, OH 45267 USA; Univ Cincinnati, Dept Pathobiol & Mol Med, Cincinnati, OH 45267 USA; Sapporo Med Univ, Sch Med, Dept Biochem, Sapporo, Hokkaido 0608556, Japan	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Sapporo Medical University	McCormack, FX (corresponding author), POB 670564, Cincinnati, OH 45267 USA.	frank.mccormack@uc.edu	McCormack, Francis X./ABE-8398-2020	McCormack, Francis X./0000-0001-7168-9464; Bridges, James P./0000-0002-4815-117X	PHS HHS [06096, 61332, 61612] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Botas C, 1998, P NATL ACAD SCI USA, V95, P11869, DOI 10.1073/pnas.95.20.11869; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074; COCKSHUTT AM, 1990, BIOCHEMISTRY-US, V29, P8424, DOI 10.1021/bi00488a032; CROUCH E, 1994, J BIOL CHEM, V269, P15808; Crouch EC, 1998, AM J RESP CELL MOL, V19, P177, DOI 10.1165/ajrcmb.19.2.140; DETHLOFF LA, 1986, BIOCHEM J, V233, P111, DOI 10.1042/bj2330111; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; EFRATI H, 1987, BIOCHEMISTRY-US, V26, P7986, DOI 10.1021/bi00398a066; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; FISHER AB, 1994, AM J PHYSIOL, V267, pL335, DOI 10.1152/ajplung.1994.267.3.L335; GELVAN D, 1990, BIOCHIM BIOPHYS ACTA, V1035, P353, DOI 10.1016/0304-4165(90)90100-B; Goerke J, 1998, BBA-MOL BASIS DIS, V1408, P79, DOI 10.1016/S0925-4439(98)00060-X; Gutteridge JMC, 1996, BIOCHEM BIOPH RES CO, V220, P1024, DOI 10.1006/bbrc.1996.0518; HAAGSMAN HP, 1990, BIOCHEMISTRY-US, V29, P8894, DOI 10.1021/bi00490a003; Hakansson K, 1999, STRUCTURE, V7, P255, DOI 10.1016/S0969-2126(99)80036-7; HAWGOOD S, 1985, BIOCHEMISTRY-US, V24, P184, DOI 10.1021/bi00322a026; HAYEK T, 1994, BIOCHEM BIOPH RES CO, V201, P1567, DOI 10.1006/bbrc.1994.1883; Korfhagen TR, 1998, J BIOL CHEM, V273, P28438, DOI 10.1074/jbc.273.43.28438; Korfhagen TR, 1996, P NATL ACAD SCI USA, V93, P9594, DOI 10.1073/pnas.93.18.9594; KUROKI Y, 1994, J BIOL CHEM, V269, P29793; KUROKI Y, 1991, J BIOL CHEM, V266, P3068; Lawson PR, 2000, IMMUNOL REV, V173, P66, DOI 10.1034/j.1600-065X.2000.917308.x; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; MacNee W, 1999, AM J RESP CRIT CARE, V160, pS58, DOI 10.1164/ajrccm.160.supplement_1.15; MATALON S, 1987, J APPL PHYSIOL, V62, P756, DOI 10.1152/jappl.1987.62.2.756; McCormack FX, 1997, J BIOL CHEM, V272, P27971, DOI 10.1074/jbc.272.44.27971; McCormack FX, 1997, BIOCHEMISTRY-US, V36, P13963, DOI 10.1021/bi970745q; MCCORMACK FX, 1994, J BIOL CHEM, V269, P29801; McCormack FX, 1999, J BIOL CHEM, V274, P3173, DOI 10.1074/jbc.274.5.3173; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; OGASAWARA Y, 1994, J BIOL CHEM, V269, P29785; Patel RP, 1997, BIOCHEM J, V322, P425, DOI 10.1042/bj3220425; Postle AD, 1999, AM J RESP CELL MOL, V20, P90, DOI 10.1165/ajrcmb.20.1.3253; Qin XF, 1998, AM J PHYSIOL-HEART C, V274, pH1836, DOI 10.1152/ajpheart.1998.274.5.H1836; Sestili P, 1999, FEBS LETT, V457, P139, DOI 10.1016/S0014-5793(99)01027-3; Sullivan LC, 1998, J MOL EVOL, V46, P131, DOI 10.1007/PL00006287; Suwabe A, 1996, ARCH BIOCHEM BIOPHYS, V327, P285, DOI 10.1006/abbi.1996.0123; SUZUKI Y, 1989, AM REV RESPIR DIS, V140, P75, DOI 10.1164/ajrccm/140.1.75; Touqui L, 1999, MOL MED TODAY, V5, P244, DOI 10.1016/S1357-4310(99)01470-7; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2; Wert SE, 2000, P NATL ACAD SCI USA, V97, P5972, DOI 10.1073/pnas.100448997; Wright JR, 1997, PHYSIOL REV, V77, P931, DOI 10.1152/physrev.1997.77.4.931	42	124	131	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38848	38855		10.1074/jbc.M005322200	http://dx.doi.org/10.1074/jbc.M005322200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10969075	hybrid			2022-12-25	WOS:000165739800096
J	Wielowieyski, PA; Sevinc, S; Guzzo, R; Salih, M; Wigle, JT; Tuana, BS				Wielowieyski, PA; Sevinc, S; Guzzo, R; Salih, M; Wigle, JT; Tuana, BS			Alternative splicing, expression, and genomic structure of the 3 ' region of the gene encoding the sarcolemmal-associated proteins (SLAPs) defines a novel class of coiled-coil tail-anchored membrane proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTOBREVIN; SYNTAXIN; DOCKING; PATHWAY; FUSION; YEAST; SNARE	The sarcolemmal associated proteins (SLAPs) are encoded by multiple mRNAs that are presumably generated by alternative splicing mechanisms. The amino acid sequence of the SLAP1 isoform exhibited 76% identity with TOP,, a topographically graded antigen of the chick visual system. The regions of coiled-coil structure including an Il-heptad acidic amphipathic alpha -helical segment was conserved with a major divergence in sequence noted in the hydrophobic C termini predicted to be transmembrane domains in the two polypeptides. The genomic organization of the 3' region of the SLAP gene indicated that SLAP1 and TOP, are generated by alternative splicing mechanisms, which are conserved among mammalian and avian species. SLAP1/TOPAP were encoded by II exons distributed over a minimum of 35 kilobase pairs of continuous DNA; 9 of the exons were constitutively expressed, and 2 were alternatively spliced. The exons range in size from 60 to 321 base pairs, and the predicted functional domains within the polypeptides were encompassed by single exons, The introns vary from 0.2 to 10 kilobase pairs and conform to consensus dinucleotide splicing signals. Reverse transcriptase-polymerase chain reaction studies demonstrated that alternative exons (IV and X) of SLAP were expressed in a tissue-specific fashion and developmentally regulated. The alternatively spliced exon X, which encodes the putative transmembrane anchor in TOPAP, and a constitutively expressed exon XI, which encodes the putative transmembrane domain in SLAP, were found to target these polypeptides to membrane structures. The presence and conservation of termination codons in exons X and XI render expression of the two SLAP1/TOPAP transmembrane domains mutually exclusive. These data reveal that TOP, and SLAP are alternatively spliced products of a single gene that encodes a unique class of tail-anchored membrane proteins.	Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada	University of Ottawa	Tuana, BS (corresponding author), Univ Ottawa, Dept Cellular & Mol Med, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.		Guzzo, Raquel Souza Lobo/E-6730-2019; Wigle, J.t./G-2005-2014	Guzzo, Raquel Souza Lobo/0000-0002-7029-2913; Wigle, J.t./0000-0002-4985-7684				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; SAVITT JW, 1995, NEURON, V14, P253, DOI 10.1016/0896-6273(95)90283-X; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SPRING J, 1993, TRENDS BIOCHEM SCI, V18, P124, DOI 10.1016/0968-0004(93)90018-I; Wigle JT, 1997, J BIOL CHEM, V272, P32384, DOI 10.1074/jbc.272.51.32384; ZHANG P, 1997, BIOCHEMISTRY-US, V36, P4317	16	23	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38474	38481		10.1074/jbc.M007682200	http://dx.doi.org/10.1074/jbc.M007682200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10986292	hybrid			2022-12-25	WOS:000165739800046
J	Yang, Y; Hwang, CK; Junn, E; Lee, G; Mouradian, MM				Yang, Y; Hwang, CK; Junn, E; Lee, G; Mouradian, MM			ZIC2 and Sp3 repress Sp1-induced activation of the human D-1A dopamine receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS; BINDING-SITES; CELL LINEAGE; SP FAMILY; EXPRESSION; PROMOTER; ENHANCEMENT; AMPHETAMINE; MODULATION; AGONISTS	The human D-1A dopamine receptor is transcribed from a tissue-specific regulated gene under the control of two promoters. An activator region (AR1) located between nucleotides -1154 and -1136 (relative to the first ATG) enhances transcription from the upstream promoter that is active in the brain. In this investigation, we sought to identify the nuclear factors that regulate the D-1A gene through their binding to AR1 using yeast one-hybrid screening. Sp3 and Zic2 were among the positive clones isolated. Although Sp1 was not isolated from this screening and purified Sp1 alone does not bind to AR1 in gel shift experiments, this general transcription factor binds to AR1 in the presence of D-1A expressing NS20Y nuclear extract and activates the D-1A promoter. Thus, Sp1 appears to require an unknown factor(s) or post-translational modification to interact with AR1. On the other hand, Zic2 and Sp3 inhibit Sp1-induced activation of the D-1A gene in an AR1-dependent manner. Zic2 and D-1A genes have reciprocal brain regional distributions; Zic2 is expressed primarily in the cerebellum, and D-1A is highly expressed in corpus striatum. These observations collectively suggest that one of the physiologic functions of Zic2 is repression of D-1A gene transcription and that the intracellular balance among Sp1, Sp3 and Zic2 is important for regulating the tissue-specific expression of this dopamine receptor.	NINDS, Genet Pharmacol Unit, Expt Therapeut Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Mouradian, MM (corresponding author), NINDS, Genet Pharmacol Unit, Expt Therapeut Branch, NIH, 10 Ctr Dr,MSC 1406, Bethesda, MD 20892 USA.			Mouradian, M. Maral/0000-0002-9937-412X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002826] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aruga J, 1998, J NEUROSCI, V18, P284; ARUGA J, 1994, J NEUROCHEM, V63, P1880; Aruga J, 1996, J BIOL CHEM, V271, P1043, DOI 10.1074/jbc.271.2.1043; Baker DL, 1996, J BIOL CHEM, V271, P5921, DOI 10.1074/jbc.271.10.5921; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; Brown SA, 1998, NAT GENET, V20, P180, DOI 10.1038/2484; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; COUREY AJ, 1993, TRANSCRIPTIONAL REGU, P743; DAngelo DD, 1996, J BIOL CHEM, V271, P19696, DOI 10.1074/jbc.271.33.19696; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; Ding H, 1999, J BIOL CHEM, V274, P19573, DOI 10.1074/jbc.274.28.19573; GINGRICH JA, 1993, ANNU REV NEUROSCI, V16, P299, DOI 10.1146/annurev.ne.16.030193.001503; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hata Y, 1998, J BIOL CHEM, V273, P19294, DOI 10.1074/jbc.273.30.19294; Hussain T, 1998, HYPERTENSION, V32, P187, DOI 10.1161/01.HYP.32.2.187; Imafuku I, 1996, BIOCHEM BIOPH RES CO, V222, P736, DOI 10.1006/bbrc.1996.0813; Jung AB, 1996, DEV BRAIN RES, V94, P109, DOI 10.1016/0165-3806(96)00033-8; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Lee SH, 1996, J BIOL CHEM, V271, P25292, DOI 10.1074/jbc.271.41.25292; Lee SH, 1999, NEUROSCI RES, V34, P225, DOI 10.1016/S0168-0102(99)00055-3; Liang YX, 1996, J BIOL CHEM, V271, P11792, DOI 10.1074/jbc.271.20.11792; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MINOWA MT, 1993, J BIOL CHEM, V268, P23544; Morris ED, 1999, J CEREBR BLOOD F MET, V19, P218, DOI 10.1097/00004647-199902000-00013; Muller S, 1999, BIOCHEM BIOPH RES CO, V259, P364, DOI 10.1006/bbrc.1999.0677; Okazawa H, 1996, P NATL ACAD SCI USA, V93, P11933, DOI 10.1073/pnas.93.21.11933; PHILLIPS GD, 1994, PSYCHOPHARMACOLOGY, V114, P477, DOI 10.1007/BF02249339; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; Ritchie S, 2000, J BIOL CHEM, V275, P847, DOI 10.1074/jbc.275.2.847; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; Self DW, 1996, SCIENCE, V271, P1586, DOI 10.1126/science.271.5255.1586; Tsai CN, 1999, VIROLOGY, V261, P288, DOI 10.1006/viro.1999.9851; Vanderschuren LJMJ, 1999, J NEUROSCI, V19, P9579, DOI 10.1523/jneurosci.19-21-09579.1999; WADDINGTON JL, 1986, CLIN NEUROPHARMACOL, V9, P20; WADDINGTON JL, 1989, PHARMACOL THERAPEUT, V43, P1, DOI 10.1016/0163-7258(89)90046-6; Wang Y, 1998, SYNAPSE, V30, P56, DOI 10.1002/(SICI)1098-2396(199809)30:1<56::AID-SYN7>3.0.CO;2-J; WHITE NM, 1991, BEHAV NEURAL BIOL, V55, P255, DOI 10.1016/0163-1047(91)90609-T; WHITE NM, 1993, BEHAV NEURAL BIOL, V59, P230, DOI 10.1016/0163-1047(93)90998-W; Yajima S, 1998, DNA CELL BIOL, V17, P471, DOI 10.1089/dna.1998.17.471; Yokota N, 1996, CANCER RES, V56, P377; Zheng XL, 2000, J BIOL CHEM, V275, P31747, DOI 10.1074/jbc.M000621200	43	53	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38863	38869		10.1074/jbc.M007906200	http://dx.doi.org/10.1074/jbc.M007906200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10984499	hybrid			2022-12-25	WOS:000165739800098
J	Bae, SH; Seo, YS				Bae, SH; Seo, YS			Characterization of the enzymatic properties of the yeast Dna2 helicase/endonuclease suggests a new model for Okazaki fragment processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; SINGLE-STRANDED-DNA; PROKARYOTIC RNASE HII; REPLICATION FACTOR-C; SACCHAROMYCES-CEREVISIAE; SV40 ORIGIN; SCHIZOSACCHAROMYCES-POMBE; ENDONUCLEASE ACTIVITY; HELICASE; RAD27	The Saccharomyces cerevisiae Dna2, which contains single-stranded DNA-specific endonuclease activity, interacts genetically and physically with Fen-l, a structure-specific endonuclease implicated in Okazaki fragment maturation during lagging strand synthesis. In this report, we investigated the properties of the Dna2 helicase/endonuclease activities in search of their in vivo physiological functions in eukaryotes. We found that the Dnaa helicase activity translocates in the 5' to 3' direction and uses DNA with free ends as the preferred substrate. Furthermore, the endonucleolytic cleavage activity of Dna2 was markedly stimulated, by the presence of an RNA segment at the 5'-end of single-stranded DNA and occurred within the DNA, ensuring the complete removal of the initiator RNA segment on the Okazaki fragment. In addition, we demonstrated that the removal of pre-existing initiator 5'-terminal RNA segments depended on a displacement reaction carried out during the DNA polymerase delta -catalyzed elongation of the upstream Okazaki fragments. These properties indicate that Dna2 is well suited to remove the primer RNA on the Okazaki fragment. Based op this information, we propose a new model in which Dna2 plays a direct role in Okazaki fragment maturation in conjunction with Fen-l.	Sungkyunkwan Univ, Sch Med, Natl Creat Res Initiat Ctr Cell Cycle Control, Samsung Biomed Res Inst,Changan Ku, Suwon 440746, Kyunggi Do, South Korea	Sungkyunkwan University (SKKU)	Seo, YS (corresponding author), Sungkyunkwan Univ, Sch Med, Natl Creat Res Initiat Ctr Cell Cycle Control, Samsung Biomed Res Inst,Changan Ku, 300 Chunchun Dong, Suwon 440746, Kyunggi Do, South Korea.	ysseo@med.skku.ac.kr	Seo, Yeonsoo/C-1605-2011					AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; Bae SH, 1998, J BIOL CHEM, V273, P26880, DOI 10.1074/jbc.273.41.26880; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BUDD ME, 1995, P NATL ACAD SCI USA, V92, P7642, DOI 10.1073/pnas.92.17.7642; Budd ME, 2000, J BIOL CHEM, V275, P16518, DOI 10.1074/jbc.M909511199; BUDD ME, 1995, J BIOL CHEM, V270, P26766, DOI 10.1074/jbc.270.45.26766; Budd ME, 1997, MOL CELL BIOL, V17, P2136, DOI 10.1128/MCB.17.4.2136; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; DeMott MS, 1996, J BIOL CHEM, V271, P30068, DOI 10.1074/jbc.271.47.30068; DeMott MS, 1998, J BIOL CHEM, V273, P27492, DOI 10.1074/jbc.273.42.27492; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; Fiorentino DF, 1997, MOL BIOL CELL, V8, P2519, DOI 10.1091/mbc.8.12.2519; Formosa T, 1999, GENETICS, V151, P1459; Frank P, 1998, P NATL ACAD SCI USA, V95, P12872, DOI 10.1073/pnas.95.22.12872; Frank P, 1998, FEBS LETT, V421, P23, DOI 10.1016/S0014-5793(97)01528-7; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Gary R, 1999, MOL CELL BIOL, V19, P5373; Gerik KJ, 1997, J BIOL CHEM, V272, P1256, DOI 10.1074/jbc.272.2.1256; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Holmes AM, 1999, CELL, V96, P415, DOI 10.1016/S0092-8674(00)80554-1; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; Kang HY, 2000, GENETICS, V155, P1055; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kornberg A., 1992, DNA REPLICATION; Lee KH, 2000, NUCLEIC ACIDS RES, V28, P2873, DOI 10.1093/nar/28.15.2873; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Mossi R, 1998, J BIOL CHEM, V273, P14322, DOI 10.1074/jbc.273.23.14322; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; Murante RS, 1998, P NATL ACAD SCI USA, V95, P2244, DOI 10.1073/pnas.95.5.2244; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; NASMYTH KA, 1977, CELL, V12, P1109, DOI 10.1016/0092-8674(77)90173-8; Parenteau J, 1999, MOL CELL BIOL, V19, P4143; Park JS, 1997, J BIOL CHEM, V272, P18910, DOI 10.1074/jbc.272.30.18910; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; VALLEN EA, 1995, MOL CELL BIOL, V15, P4291; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; Wu XT, 1999, P NATL ACAD SCI USA, V96, P1303, DOI 10.1073/pnas.96.4.1303; Zuo SJ, 2000, J BIOL CHEM, V275, P5153, DOI 10.1074/jbc.275.7.5153	52	153	154	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					38022	38031		10.1074/jbc.M006513200	http://dx.doi.org/10.1074/jbc.M006513200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10984490	hybrid			2022-12-25	WOS:000165618700096
J	Hallstrom, TC; Moye-Rowley, WS				Hallstrom, TC; Moye-Rowley, WS			Multiple signals from dysfunctional mitochondria activate the pleiotropic drug resistance pathway in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST MULTIDRUG-RESISTANCE; BETA-SUBUNIT PRECURSOR; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; TRANSPORTER GENES; OXIDATIVE STRESS; METAL RESISTANCE; REGULATORY GENE; INNER MEMBRANE; PROTEIN	Multiple or pleiotropic drug resistance most often occurs in Saccharomyces cerevisiae due to substitution mutations within the Cys(6)-Zn(II) transcription factors Pdr1p and Pdr3p. These dominant transcriptional regulatory proteins cause elevated drug resistance and overexpression of the ATP-binding cassette transporter-encoding gene, PDR5. We have carried out a genetic screen to identify negative regulators of PDR5 expression and found that loss of the mitochondrial genome (rho (o) cells) causes up-regulation of Pdr3p but not Pdr1p function. Additionally, loss of the mitochondrial inner membrane protein Oxa1p generates a signal that results in increased Pdr3p activity. Both of these mitochondrial defects lead to increased expression of the PDR3 structural gene. Importantly, the signaling pathway used to enhance Pdr3p function in rho (o) cells is not the same as in oral cells. Loss of previously described nuclear-mitochondrial signaling genes like RTG1 reduce the level of PDR5 expression and drug resistance seen in rho (o) cells but has no effect on oxa1-induced phenotypes. These data uncover a new regulatory pathway connecting expression of multidrug resistance genes with mitochondrial function.	Univ Iowa, Mol Biol Program, Iowa City, IA 52242 USA; Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Moye-Rowley, WS (corresponding author), Univ Iowa, Mol Biol Program, Iowa City, IA 52242 USA.	moyerowl@blue.weeg.uiowa.edu	Moye-Rowley, Scott/AFL-7135-2022	Moye-Rowley, Scott/0000-0002-7163-1120	NIGMS NIH HHS [GM49825] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altamura N, 1996, FEBS LETT, V382, P111, DOI 10.1016/0014-5793(96)00165-2; BALZI E, 1987, J BIOL CHEM, V262, P16871; BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; BALZI E, 1994, J BIOL CHEM, V269, P2206; BALZI E, 1991, BIOCHIM BIOPHYS ACTA, V1073, P241, DOI 10.1016/0304-4165(91)90128-4; BISSINGER PH, 1994, J BIOL CHEM, V269, P4180; Bomer U, 1997, EMBO J, V16, P2205, DOI 10.1093/emboj/16.9.2205; BONNEFOY N, 1994, J MOL BIOL, V239, P201, DOI 10.1006/jmbi.1994.1363; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; Carvajal E, 1997, MOL GEN GENET, V256, P406, DOI 10.1007/s004380050584; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Coleman ST, 1999, MOL CELL BIOL, V19, P8302; DELAHODDE A, 1995, MOL CELL BIOL, V15, P4043; DELAVEAU T, 1994, MOL GEN GENET, V244, P501, DOI 10.1007/BF00583901; Dujon B., 1981, MOL BIOL YEAST SACCH, P505; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; FOGEL S, 1982, P NATL ACAD SCI-BIOL, V79, P5342, DOI 10.1073/pnas.79.17.5342; FOX TD, 1991, METHOD ENZYMOL, V194, P149; FRIDEN P, 1989, MOL CELL BIOL, V9, P4056, DOI 10.1128/MCB.9.9.4056; FRIDEN P, 1987, MOL CELL BIOL, V7, P2708, DOI 10.1128/MCB.7.8.2708; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRANT CE, 1994, CANCER RES, V54, P357; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Hallstrom TC, 1998, MOL CELL BIOL, V18, P1147, DOI 10.1128/MCB.18.3.1147; HARTIG A, 1986, EUR J BIOCHEM, V160, P487, DOI 10.1111/j.1432-1033.1986.tb10065.x; Hell K, 1997, FEBS LETT, V418, P367, DOI 10.1016/S0014-5793(97)01412-9; Hermann GJ, 1998, J CELL BIOL, V143, P359, DOI 10.1083/jcb.143.2.359; Herrmann JM, 1997, EMBO J, V16, P2217, DOI 10.1093/emboj/16.9.2217; HIRATA D, 1994, CURR GENET, V26, P285, DOI 10.1007/BF00310491; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jia YK, 1997, MOL CELL BIOL, V17, P1110, DOI 10.1128/MCB.17.3.1110; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; KATZMANN DJ, 1995, MOL CELL BIOL, V15, P6875; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; Katzmann DJ, 1996, J BIOL CHEM, V271, P23049, DOI 10.1074/jbc.271.38.23049; KIM KS, 1986, MOL CELL BIOL, V6, P1936, DOI 10.1128/MCB.6.6.1936; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; Lemaire C, 2000, J BIOL CHEM, V275, P23471, DOI 10.1074/jbc.M002045200; LIAO XS, 1993, CELL, V72, P61, DOI 10.1016/0092-8674(93)90050-Z; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; MAARSE AC, 1994, FEBS LETT, V349, P215, DOI 10.1016/0014-5793(94)00669-5; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; MEYERS S, 1992, CURR GENET, V21, P431, DOI 10.1007/BF00351651; Miyahara K, 1996, CURR GENET, V29, P103, DOI 10.1007/s002940050023; Morgan BA, 1997, EMBO J, V16, P1035, DOI 10.1093/emboj/16.5.1035; Nourani A, 1997, MOL GEN GENET, V256, P397, DOI 10.1007/s004380050583; Poch O, 1997, GENE, V184, P229, DOI 10.1016/S0378-1119(96)00602-6; PRAEKELT UM, 1990, MOL GEN GENET, V223, P97, DOI 10.1007/BF00315801; Schmitt AP, 1996, P NATL ACAD SCI USA, V93, P5777, DOI 10.1073/pnas.93.12.5777; SEWELL AK, 1995, J BIOL CHEM, V270, P25079, DOI 10.1074/jbc.270.42.25079; Sherman F, 1979, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Stephen DWS, 1997, MOL MICROBIOL, V23, P203, DOI 10.1046/j.1365-2958.1997.2081572.x; STONE G, 1993, EMBO J, V12, P1375, DOI 10.1002/j.1460-2075.1993.tb05782.x; SZE JY, 1992, SCIENCE, V258, P1143, DOI 10.1126/science.1439822; TAKEDA M, 1985, J BIOL CHEM, V260, P5458; TAMAI KT, 1994, MOL CELL BIOL, V14, P8155, DOI 10.1128/MCB.14.12.8155; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WU AL, 1993, J BIOL CHEM, V268, P18850; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832; ZALKIN H, 1982, J BIOL CHEM, V257, P1491; ZHOU K, 1987, NUCLEIC ACIDS RES, V15, P5261, DOI 10.1093/nar/15.13.5261	63	144	147	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37347	37356		10.1074/jbc.M007338200	http://dx.doi.org/10.1074/jbc.M007338200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10980204	hybrid			2022-12-25	WOS:000165618700008
J	Harvey, TJ; Hooper, JD; Myers, SA; Stephenson, SA; Ashworth, LK; Clements, JA				Harvey, TJ; Hooper, JD; Myers, SA; Stephenson, SA; Ashworth, LK; Clements, JA			Tissue-specific expression patterns and fine mapping of the human kallikrein (KLK) locus on proximal 19q13.4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-SPECIFIC ANTIGEN; SERINE-PROTEASE GENE; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; FAMILY; RAT; CDNA; ANDROGEN; BREAST; CANCER	The tissue or glandular kallikreins (KLK) are members of a highly conserved multigene family encoding serine proteases that are central to many biological processes. The rodent KLK families are large, highly conserved and clustered at one locus. The human KLK gene family is clustered on chromosome 19q13.3-13.4, and until recently consisted of just three members. However, recent studies have identified up to II new members of the KLK family that are less conserved than their rodent counterparts. Using a Southern blot and sequence analysis of 10 BACs and cosmids spanning approximately 400 kilobases (kb) either side of the original KLK 60-kb locus, we demonstrated that these genes also lie adjacent to this. We have also clarified the position of several microsatellite markers in relation to the extended KLK locus. Moreover, from Southern blot analysis of the cosmids and BACs with a degenerate oligonucleotide probe to the histidine-encoding region of serine proteases, we have shown that there are no other serine protease genes approximately 400 kb centromeric and 220 kb telomeric of the extended locus. We performed an extensive analysis of the expression patterns of these genes by poly(A)' RNA dot blot and reverse transcriptase-polymerase chain reaction analysis, and demonstrated a diverse pattern of expression. Of interest are clusters of genes with high prostate (KLK2-4) and pancreatic (KLK6-13) expression suggesting evolutionary conservation of elements conferring tissue specificity. From these findings, it is likely that the human KLK gene family consists of just 14 clustered genes within 300 kb and thus is of a comparable size to the rodent families (13-24 genes within 310 and 480 kb, respectively). In contrast to the rodent families, the newest members of the human KLK family are much less conserved in sequence (23-44% at the protein level) and appear to consist of at least four subfamilies. In addition, like the rat, these genes are expressed at varying levels in a diverse range of tissues although they exhibit quite distinct patterns of expression.	Queensland Univ Technol, Sch Life Sci, Ctr Mol Biotechnol, Brisbane, Qld 4001, Australia; Lawrence Livermore Natl Lab, Livermore, CA 94551 USA	Queensland University of Technology (QUT); United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Clements, JA (corresponding author), Queensland Univ Technol, Sch Life Sci, Ctr Mol Biotechnol, GPO Box 2434, Brisbane, Qld 4001, Australia.	j.clements@qut.edu.au	Hooper, John/C-1481-2016; Stephenson, Sally-Anne/I-9801-2012; Harvey, Tracey/P-4305-2016	Hooper, John/0000-0003-1054-8486; Harvey, Tracey/0000-0001-5388-0337; Stephenson, Sally-Anne/0000-0003-3227-2476; Clements, Judith/0000-0001-6026-1964; Myers, Stephen/0000-0003-4793-3820				Anisowicz A, 1996, MOL MED, V2, P624, DOI 10.1007/BF03401646; Berg T, 1992, Agents Actions Suppl, V38 ( Pt 1), P19; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; BOULET AM, 1986, P NATL ACAD SCI USA, V83, P3599, DOI 10.1073/pnas.83.11.3599; Carroll VA, 1999, SEMIN THROMB HEMOST, V25, P183, DOI 10.1055/s-2007-994920; CHAPDELAINE P, 1988, FEBS LETT, V236, P205, DOI 10.1016/0014-5793(88)80315-6; CHEN ZL, 1995, J NEUROSCI, V15, P5088; CLEMENTS J, 1997, KININ SYSTEM, P71; CLEMENTS JA, 1989, ENDOCR REV, V10, P393, DOI 10.1210/edrv-10-4-393; COHEN P, 1992, J CLIN ENDOCR METAB, V75, P1046, DOI 10.1210/jc.75.4.1046; DeClerck YA, 1997, ADV EXP MED BIOL, V425, P89; Diamandis EP, 2000, TRENDS ENDOCRIN MET, V11, P54, DOI 10.1016/S1043-2760(99)00225-8; DIAMANDIS EP, 2000, IN PRESS CLIN CHEM; DRINKWATER CC, 1988, TRENDS BIOCHEM SCI, V13, P169, DOI 10.1016/0968-0004(88)90144-2; EVANS BA, 1987, J BIOL CHEM, V262, P8027; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; Frenette G, 1997, INT J CANCER, V71, P897, DOI 10.1002/(SICI)1097-0215(19970529)71:5<897::AID-IJC31>3.0.CO;2-2; FUKUSHIMA D, 1985, BIOCHEMISTRY-US, V24, P8037, DOI 10.1021/bi00348a030; Goyal J, 1998, CANCER RES, V58, P4782; GRIESBACHER T, 1977, KININ SYSTEM, P197; KURTZ TW, 1992, J AM SOC NEPHROL, V3, P28; LIN FK, 1993, BIOCHIM BIOPHYS ACTA, V1173, P325, DOI 10.1016/0167-4781(93)90131-V; Little SP, 1997, J BIOL CHEM, V272, P25135, DOI 10.1074/jbc.272.40.25135; Liu XL, 1996, CANCER RES, V56, P3371; LUNDSTROM A, 1991, ACTA DERM-VENEREOL, V71, P471; MacDonald RJ, 1996, J BIOL CHEM, V271, P13684, DOI 10.1074/jbc.271.23.13684; MURRAY SR, 1990, J CARDIOVASC PHARM, V15, pS7, DOI 10.1097/00005344-199000156-00003; Nelson PS, 1999, P NATL ACAD SCI USA, V96, P3114, DOI 10.1073/pnas.96.6.3114; REIGMAN PHJ, 1989, BIOCHEM BIOPH RES CO, V159, P95, DOI 10.1016/0006-291X(89)92409-1; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; RIEGMAN PHJ, 1992, GENOMICS, V14, P6, DOI 10.1016/S0888-7543(05)80275-7; Rittenhouse HG, 1998, CRIT REV CL LAB SCI, V35, P275, DOI 10.1080/10408369891234219; SCHEDLICH LJ, 1987, DNA-J MOLEC CELL BIO, V6, P429, DOI 10.1089/dna.1987.6.429; SOUTHARDSMITH M, 1994, GENOMICS, V22, P404, DOI 10.1006/geno.1994.1402; Stephenson SA, 1999, J BIOL CHEM, V274, P23210, DOI 10.1074/jbc.274.33.23210; SWIFT GH, 1984, J BIOL CHEM, V259, P4271; Underwood LJ, 1999, CANCER RES, V59, P4435; WINES DR, 1989, J BIOL CHEM, V264, P7653; WINES DR, 1991, J MOL EVOL, V32, P476, DOI 10.1007/BF02102650; WOLF DA, 1992, MOL ENDOCRINOL, V6, P753, DOI 10.1210/me.6.5.753; Yamashiro K, 1997, BBA-GENE STRUCT EXPR, V1350, P11, DOI 10.1016/S0167-4781(96)00187-X; Yoshida S, 1998, BBA-GENE STRUCT EXPR, V1399, P225, DOI 10.1016/S0167-4781(98)00116-X; Yoshida S, 1998, GENE, V213, P9, DOI 10.1016/S0378-1119(98)00232-7; Yousef GM, 2000, GENOMICS, V65, P184, DOI 10.1006/geno.2000.6159; Yousef GM, 2000, J BIOL CHEM, V275, P11891, DOI 10.1074/jbc.275.16.11891; Yousef GM, 1999, CANCER RES, V59, P4252; Yousef GM, 1999, GENOMICS, V62, P251, DOI 10.1006/geno.1999.6012; Yousef GM, 1999, J BIOL CHEM, V274, P37511, DOI 10.1074/jbc.274.53.37511; Yousef GM, 1999, ANTICANCER RES, V19, P2843	49	137	142	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37397	37406		10.1074/jbc.M004525200	http://dx.doi.org/10.1074/jbc.M004525200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10969073	Green Published, hybrid			2022-12-25	WOS:000165618700014
J	Suzuki, H; Okazawa, Y; Komiya, T; Saeki, K; Mekada, E; Kitada, S; Ito, A; Mihara, K				Suzuki, H; Okazawa, Y; Komiya, T; Saeki, K; Mekada, E; Kitada, S; Ito, A; Mihara, K			Characterization of rat TOM40, a central component of the preprotein translocase of the mitochondrial outer membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; PROTEIN IMPORT RECEPTOR; INNER MEMBRANE; CYTOPLASMIC CHAPERONES; PRECURSOR PROTEINS; COMPLEX; IDENTIFICATION; INSERTION; YEAST; PORE	We cloned a 38-kDa rat mitochondrial outer membrane protein (OM38) with structural homology to the central component of preprotein translocase of the fungal mitochondrial outer membrane, Tom40. Although it has no predictable alpha -helical transmembrane segments, OM38 is resistant to alkaline carbonate extraction and is inaccessible to proteases and polyclonal antibodies added from outside the mitochondria, suggesting that it is embedded in the membrane, probably in a beta -barrel structure, as has been similarly speculated for fungal Tom40. Immunoprecipitation demonstrated that OM38 is associated with the major import receptors rTOM20 and rTOM22, and several other unidentified components with molecular masses of 5-10 kDa in digitonin-solubilized membrane: OM10, OM7.5, and OM5. Blue native polyacrylamide gel electrophoresis revealed that OM38 is a component of a similar to 400-kDa complex, firmly associating with rTOM22 and loosely associating with rTOM20. The preprotein in transit to the matrix interacted with the TOM complex containing OM38, and immunodepletion of OM38 resulted in the loss of preprotein import activity of the detergent-solubilized and reconstituted outer membrane vesicles. Taken together, these results indicate that OM38 is a structural and functional homolog of fungal Tom40 and functions as a component of the preprotein import machinery of the rat mitochondrial outer membrane.	Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8120054, Japan; Kurume Univ, Inst Life Sci, Kurume, Fukuoka 8390861, Japan; Kyushu Univ, Fac Sci, Dept Chem, Fukuoka 8128581, Japan	Kyushu University; Kurume University; Kyushu University	Mihara, K (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8120054, Japan.			Mekada, Eisuke/0000-0001-8858-4781				Ahting U, 1999, J CELL BIOL, V147, P959, DOI 10.1083/jcb.147.5.959; Armstrong LC, 1997, J BIOL CHEM, V272, P6510, DOI 10.1074/jbc.272.10.6510; Bauer MF, 2000, TRENDS CELL BIOL, V10, P25, DOI 10.1016/S0962-8924(99)01684-0; Davis AJ, 1998, MOL BIOL CELL, V9, P2577, DOI 10.1091/mbc.9.9.2577; Dekker PJT, 1998, MOL CELL BIOL, V18, P6515, DOI 10.1128/MCB.18.11.6515; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; GOPING IS, 1995, FEBS LETT, V373, P45; HACHIYA N, 1994, EMBO J, V13, P5246; Hanson B, 1996, EUR J BIOCHEM, V235, P750, DOI 10.1111/j.1432-1033.1996.t01-1-00750.x; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; Ishihara N, 1998, J BIOCHEM-TOKYO, V123, P722; ISHIHARA S, 1990, J BIOCHEM-TOKYO, V108, P899, DOI 10.1093/oxfordjournals.jbchem.a123310; IWAHASHI J, 1994, J BIOCHEM-TOKYO, V116, P156, DOI 10.1093/oxfordjournals.jbchem.a124488; Iwahashi J, 1997, J BIOL CHEM, V272, P18467, DOI 10.1074/jbc.272.29.18467; Jansch L, 1998, J BIOL CHEM, V273, P17251, DOI 10.1074/jbc.273.27.17251; Kerscher O, 2000, MOL BIOL CELL, V11, P103, DOI 10.1091/mbc.11.1.103; Kerscher O, 1997, J CELL BIOL, V139, P1663, DOI 10.1083/jcb.139.7.1663; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Koehler CM, 1999, P NATL ACAD SCI USA, V96, P2141, DOI 10.1073/pnas.96.5.2141; Komiya T, 1996, EMBO J, V15, P399, DOI 10.1002/j.1460-2075.1996.tb00370.x; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; MATSUMOTO T, 1986, J BIOCHEM-TOKYO, V100, P1359, DOI 10.1093/oxfordjournals.jbchem.a121842; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; Mayer A, 1995, METHOD ENZYMOL, V260, P252, DOI 10.1016/0076-6879(95)60143-0; Mihara K, 1996, TRENDS CELL BIOL, V6, P104, DOI 10.1016/0962-8924(96)81000-2; MIHARA K, 1990, J BIOCHEM-TOKYO, V108, P1022, DOI 10.1093/oxfordjournals.jbchem.a123301; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Nuttall SD, 1997, DNA CELL BIOL, V16, P1067, DOI 10.1089/dna.1997.16.1067; Pfanner N, 1997, ANNU REV CELL DEV BI, V13, P25, DOI 10.1146/annurev.cellbio.13.1.25; Rapaport D, 1997, J BIOL CHEM, V272, P18725, DOI 10.1074/jbc.272.30.18725; Rassow J, 1999, J MOL BIOL, V286, P105, DOI 10.1006/jmbi.1998.2455; Saeki K, 2000, J BIOL CHEM, V275, P31996, DOI 10.1074/jbc.M004794200; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SEKI N, 1995, FEBS LETT, V375, P307, DOI 10.1016/0014-5793(95)01229-8; Shimokata K, 1998, J BIOL CHEM, V273, P25158, DOI 10.1074/jbc.273.39.25158; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; Tokatlidis K, 1999, J BIOL CHEM, V274, P35285, DOI 10.1074/jbc.274.50.35285; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; Voos W, 1999, BBA-REV BIOMEMBRANES, V1422, P235, DOI 10.1016/S0304-4157(99)00007-6	43	71	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37930	37936		10.1074/jbc.M006558200	http://dx.doi.org/10.1074/jbc.M006558200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10980201	hybrid			2022-12-25	WOS:000165618700084
J	Wisniewski, M; Balakrishnan, M; Palaniappan, C; Fay, PJ; Bambara, RA				Wisniewski, M; Balakrishnan, M; Palaniappan, C; Fay, PJ; Bambara, RA			The sequential mechanism of HIV reverse transcriptase RNase H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MURINE LEUKEMIA-VIRUS; DNA STRAND TRANSFER; POLYPURINE TRACT PRIMER; AVIAN-MYELOBLASTOSIS; CLEAVAGE SPECIFICITY; ANGSTROM RESOLUTION; FEATURES IMPORTANT; CRYSTAL-STRUCTURE; TYPE-1	Synthesis of the minus strand of viral DNA by human immunodeficiency virus, type 1 (HIV-1) reverse transcriptase is accompanied by RNase H degradation of the viral RNA genome. RNA fragments remain after synthesis and are degraded by the polymerase-independent mode of RNase H cleavage, Recently, we showed that this mode of cleavage occurs by a specific ordered mechanism in which primary cuts are first, secondary and 5-nucleotide cuts are next, and second primary cuts oc cur last (Wisniewski, Ri,, Balakrishnan, M., Palaniappan, C., Fay, P., J., and Bambara, R., A. (2000) Proc. Natl. Acad. Sci. U.S.A. 97, 11978-11983), Ultimately the RNAs are cleaved into small fragments that can dissociate from the DNA template. Because the cleavage mechanism is an ordered series of events, we determined in this study whether any earlier cut is required for a later cut, By precisely inhibiting cleavage at each site, we examined the dependence of later cuts on cleavage at that site, We found that each cut is independent of the other cuts, demonstrating that the order of this stepwise mechanism is based on the rates of each cut. A mechanism for unlinked ordered cleavage consistent with these results is presented.	Univ Rochester, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Ctr Canc, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Bambara, RA (corresponding author), Univ Rochester, Dept Biochem & Biophys, Box 712,601 Elmwood Ave, Rochester, NY 14642 USA.				NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049573] Funding Source: NIH RePORTER; NCI NIH HHS [CA11198] Funding Source: Medline; NIDCR NIH HHS [T32DE07207-09] Funding Source: Medline; NIGMS NIH HHS [GM49573] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLAIN SW, 1995, J VIROL, V69, P5113, DOI 10.1128/JVI.69.8.5113-5116.1995; Blain SW, 1996, J BIOL CHEM, V271, P1448, DOI 10.1074/jbc.271.3.1448; CHAMPOUX JJ, 1984, J VIROL, V49, P686, DOI 10.1128/JVI.49.3.686-691.1984; CHAMPOUX JJ, 1993, REVERSE TRANSCRIPTAS, P103; DESTEFANO JJ, 1993, BIOCHEMISTRY-US, V32, P6908, DOI 10.1021/bi00078a014; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P7423; DESTEFANO JJ, 1994, NUCLEIC ACIDS RES, V22, P3793, DOI 10.1093/nar/22.18.3793; DESTEFANO JJ, 1995, NUCLEIC ACIDS RES, V23, P3901, DOI 10.1093/nar/23.19.3901; DESTEFANO JJ, 1993, NUCLEIC ACIDS RES, V21, P4330, DOI 10.1093/nar/21.18.4330; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P24295; FINSTON WI, 1984, J VIROL, V51, P26, DOI 10.1128/JVI.51.1.26-33.1984; FU TB, 1992, J VIROL, V66, P4271, DOI 10.1128/JVI.66.7.4271-4278.1992; Fuentes GM, 1996, NUCLEIC ACIDS RES, V24, P1719, DOI 10.1093/nar/24.9.1719; FURFINE ES, 1991, J BIOL CHEM, V266, P406; Gabbara S, 1999, BIOCHEMISTRY-US, V38, P13070, DOI 10.1021/bi991085n; Gao HQ, 1999, J MOL BIOL, V294, P1097, DOI 10.1006/jmbi.1999.3325; Ghosh M, 1997, BIOCHEMISTRY-US, V36, P5758, DOI 10.1021/bi963045e; Ghosh M, 1996, BIOCHEMISTRY-US, V35, P8553, DOI 10.1021/bi952773j; GHOSH M, 1995, J BIOL CHEM, V270, P7068, DOI 10.1074/jbc.270.13.7068; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; Gotte M, 1998, J BIOL CHEM, V273, P10139, DOI 10.1074/jbc.273.17.10139; GUO JH, 1995, BIOCHEMISTRY-US, V34, P5018, DOI 10.1021/bi00015a013; JACOBOMOLINA A, 1991, P NATL ACAD SCI USA, V88, P10895, DOI 10.1073/pnas.88.23.10895; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kelleher CD, 1998, J BIOL CHEM, V273, P9976, DOI 10.1074/jbc.273.16.9976; Kelleher CD, 2000, J BIOL CHEM, V275, P13061, DOI 10.1074/jbc.275.17.13061; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; OYAMA F, 1989, J BIOL CHEM, V264, P18808; Palaniappan C, 1997, J BIOL CHEM, V272, P11157, DOI 10.1074/jbc.272.17.11157; Palaniappan C, 1996, J BIOL CHEM, V271, P2063, DOI 10.1074/jbc.271.47.29605; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; Powell MD, 1999, J BIOL CHEM, V274, P19885, DOI 10.1074/jbc.274.28.19885; Powell MD, 1997, J BIOL CHEM, V272, P13262, DOI 10.1074/jbc.272.20.13262; PULLEN KA, 1992, J VIROL, V66, P367, DOI 10.1128/JVI.66.1.367-373.1992; PULLEN KA, 1993, J BIOL CHEM, V268, P6221; PULLEN KA, 1990, J VIROL, V64, P6274, DOI 10.1128/JVI.64.12.6274-6277.1990; RATTRAY AJ, 1989, J MOL BIOL, V208, P445, DOI 10.1016/0022-2836(89)90508-1; RATTRAY AJ, 1987, J VIROL, V61, P2843, DOI 10.1128/JVI.61.9.2843-2851.1987; SCHULTZ SJ, 1995, J BIOL CHEM, V270, P24135, DOI 10.1074/jbc.270.41.24135; Schultz SJ, 2000, J BIOL CHEM, V275, P32299, DOI 10.1074/jbc.M000021200; Schultz SJ, 1999, J BIOL CHEM, V274, P34547, DOI 10.1074/jbc.274.49.34547; Smith CM, 1998, J VIROL, V72, P6805, DOI 10.1128/JVI.72.8.6805-6812.1998; SMITH JS, 1994, J VIROL, V68, P5721, DOI 10.1128/JVI.68.9.5721-5729.1994; TANESE N, 1991, J VIROL, V65, P4387, DOI 10.1128/JVI.65.8.4387-4397.1991; TELESNITSKY A, 1993, EMBO J, V12, P4433, DOI 10.1002/j.1460-2075.1993.tb06128.x; TELESNITSKY A, 1993, P NATL ACAD SCI USA, V90, P1276, DOI 10.1073/pnas.90.4.1276; Wisniewski M, 2000, P NATL ACAD SCI USA, V97, P11978, DOI 10.1073/pnas.210392297; WOHRL BM, 1991, BEHRING I MITT, V89, P100	51	49	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37664	37671		10.1074/jbc.M007381200	http://dx.doi.org/10.1074/jbc.M007381200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10956669	hybrid			2022-12-25	WOS:000165618700050
J	Zeghouf, M; Fontecave, M; Coves, J				Zeghouf, M; Fontecave, M; Coves, J			A simplifed functional version of the Escherichia coli sulfite reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAVIN ADENINE-DINUCLEOTIDE; FLAVOPROTEIN COMPONENT; PROSTHETIC GROUPS; RIBONUCLEOTIDE REDUCTASE; CATALYTIC PARAMETERS; HEMOPROTEIN SUBUNIT; HEMOFLAVOPROTEIN; MONONUCLEOTIDE; ENTEROBACTERIA; EXPRESSION	Escherichia coli sulfite reductase (SiR) is a large and soluble enzyme with an alpha (8)beta (4) quaternary structure, Protein alpha (or sulfite reductase flavoprotein) contains both FAD and FMN, whereas protein beta (or sulfite reductase hemoprotein (SiR-HP)) contains an iron-sulfur cluster coupled to a siroheme, The enzyme is set up to arrange the redox cofactors in a FAD-FMN-Fe4S4-Heme sequence to make an electron pathway between NADPH and sulfite. Whereas alpha spontaneously polymerizes, we have been able to produce SiR-FP60, a monomeric but fully active truncated version of it, lacking the N-terminal part (Zeghouf, M., Fontecave, M,, Macherel, D., and Coves, J. (1998) Biochemistry 37, 6114-6123). Here we report the cloning, overproduction, and characterization of the beta subunit. Pure recombinant SiR-HP behaves as a monomer in solution and is identical to the native protein in all its characteristics. Moreover, we demonstrate that the combination of SiR-FP60 and SiR-HP produces a functional 1:1 complex with tight interactions retaining about 20% of the activity of the native SiR, In addition, fully active SiR can be reconstituted by incubation of the octameric sulfite reductase flavoprotein with recombinant SiR-HP. Titration experiments and spectroscopic properties strongly suggest that the holoenzyme should be described as an alpha (8)beta (4) with equal amounts of alpha and beta subunits and that the alpha (8)beta (4) structure is probably not correct.	Univ Grenoble 1, CEA, CNRS 5047, UMR,DBMS,CB,Lab Chim & Biochim,Ctr Redox Biol, F-38054 Grenoble 9, France	CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Fontecave, M (corresponding author), Univ Grenoble 1, CEA, CNRS 5047, UMR,DBMS,CB,Lab Chim & Biochim,Ctr Redox Biol, 17 Ave Martyrs, F-38054 Grenoble 9, France.			Zeghouf, Mahel/0000-0003-3686-2510				AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; BEINERT H, 1983, ANAL BIOCHEM, V78, P248; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CLIMENT I, 1991, BIOCHEMISTRY-US, V30, P5164, DOI 10.1021/bi00235a008; COVES J, 1993, J BIOL CHEM, V268, P18604; Coves J, 1997, BIOCHEMISTRY-US, V36, P5921, DOI 10.1021/bi9623744; Crane BR, 1997, BIOCHEMISTRY-US, V36, P12120, DOI 10.1021/bi971066i; CRANE BR, 1995, SCIENCE, V270, P59, DOI 10.1126/science.270.5233.59; ESCHENBRENNER M, 1995, FEBS LETT, V374, P82, DOI 10.1016/0014-5793(95)01081-O; ESCHENBRENNER M, 1995, J BIOL CHEM, V270, P20550, DOI 10.1074/jbc.270.35.20550; FAEDER EJ, 1973, ANAL BIOCHEM, V53, P332, DOI 10.1016/0003-2697(73)90442-9; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; Gruez A, 2000, J MOL BIOL, V299, P199, DOI 10.1006/jmbi.2000.3748; JANICK PA, 1982, BIOCHEMISTRY-US, V21, P3538, DOI 10.1021/bi00258a003; Jelesarov Ilian, 1996, Methods (Orlando), V9, P533, DOI 10.1006/meth.1996.0061; KARPLUS PA, 1994, J BIOENERG BIOMEMBR, V26, P89, DOI 10.1007/BF00763221; KREDICH NM, 1971, J BIOL CHEM, V246, P3474; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; Siegel L M, 1978, Methods Enzymol, V52, P436; SIEGEL LM, 1982, J BIOL CHEM, V257, P6343; SIEGEL LM, 1974, J BIOL CHEM, V249, P1587; SIEGEL LM, 1973, J BIOL CHEM, V248, P251; SIEGEL LM, 1974, J BIOL CHEM, V249, P1572; SIEGEL LM, 1971, FLAVINS FLAVOPROTEIN, P523; WU JY, 1991, J BACTERIOL, V173, P325, DOI 10.1128/jb.173.1.325-333.1991; YONEDA F, 1976, J CHEM SOC PERK T 1, P1805, DOI 10.1039/p19760001805; Zeghouf M, 1998, BIOCHEM BIOPH RES CO, V246, P602, DOI 10.1006/bbrc.1998.8671; Zeghouf M, 1998, BIOCHEMISTRY-US, V37, P6114, DOI 10.1021/bi9728699	31	26	29	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37651	37656		10.1074/jbc.M005619200	http://dx.doi.org/10.1074/jbc.M005619200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10984484	hybrid			2022-12-25	WOS:000165618700048
J	He, W; Lu, LS; Zhang, X; El-Hodiri, HM; Chen, CK; Slep, KC; Simon, MI; Jamrich, M; Wensel, TG				He, W; Lu, LS; Zhang, X; El-Hodiri, HM; Chen, CK; Slep, KC; Simon, MI; Jamrich, M; Wensel, TG			Modules in the photoreceptor RGS9-1 center dot G(beta 5L) GTPase-accelerating protein complex control effector coupling, GTPase acceleration, protein folding, and stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RGS PROTEINS; BETA-SUBUNIT; TARGET ENZYME; GAMMA; TRANSDUCIN; DOMAIN; DEACTIVATION; EXPRESSION; REGULATORS; DISTINCT	RGS (regulators of G protein signaling proteins regulate G protein signaling by accelerating GTP hydrolysis, but little is known about regulation of GTPase-accelerating protein (GAP) activities or roles of domains and subunits outside the catalytic cores. RGS9-1 is the GAP required for rapid recovery of light responses in vertebrate photoreceptors and the only mammalian RGS protein with a defined physiological function. It belongs to an RGS subfamily whose members have multiple domains, including G gamma -like domains that bind G(beta5) proteins. Members of this subfamily play important roles in neuronal signaling, Within the GAP complex organized around the RGS domain of RGS9-1, we have identified a functional role for the G gamma -like-G(beta 5L) complex in regulation of GAP activity by an effector subunit, cGMP phosphodiesterase gamma and in protein folding and stability of RGS9-1, The C-terminal domain of RGS9-1 also plays a major role in conferring effector stimulation. The sequence of the RGS domain determines whether the sign of the effector effect will be positive or negative. These roles were observed in, vitro using full-length proteins or fragments for RGS9-1, RGS7, G(beta 5S), and G(beta 5s), The dependence of RGS9-1 on Gp, co-expression for folding, stability, and function has been confirmed in vivo using transgenic Xenopus laevis, These results reveal how multiple domains and regulatory polypeptides work together to fine tune G(t alpha) inactivation.	Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA; Yale Univ, Dept Biochem & Mol Biophys, New Haven, CT 06511 USA	Baylor College of Medicine; Baylor College of Medicine; California Institute of Technology; Yale University	Wensel, TG (corresponding author), Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA.	twensel@bcm.tmc.edu	El-hodiri, Heithem/E-3019-2011	Wensel, Theodore/0000-0003-3518-9352				ANGLESON JK, 1993, NEURON, V11, P939, DOI 10.1016/0896-6273(93)90123-9; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARSHAVSKY VY, 1994, J BIOL CHEM, V269, P19882; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; Cowan CW, 2001, PROG NUCLEIC ACID RE, V65, P341; Cowan CW, 1998, P NATL ACAD SCI USA, V95, P5351, DOI 10.1073/pnas.95.9.5351; Cowan CW, 2000, METHOD ENZYMOL, V315, P524; Fletcher JE, 1998, J BIOL CHEM, V273, P636, DOI 10.1074/jbc.273.1.636; HARPER JW, 1993, CELL, V75, P805; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Kovoor A, 2000, J BIOL CHEM, V275, P3397, DOI 10.1074/jbc.275.5.3397; Kroll KL, 1996, DEVELOPMENT, V122, P3173; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Levay K, 1999, P NATL ACAD SCI USA, V96, P2503, DOI 10.1073/pnas.96.5.2503; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; McEntaffer RL, 1999, BIOCHEMISTRY-US, V38, P4931, DOI 10.1021/bi982636x; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; PENG HB, 1991, METHOD CELL BIOL, V36, P657; Posner BA, 1999, J BIOL CHEM, V274, P31087, DOI 10.1074/jbc.274.43.31087; Rahman Z, 1999, J NEUROSCI, V19, P2016; SCHMIDT CJ, 1991, J BIOL CHEM, V266, P4538; Shuey DJ, 1998, J NEUROCHEM, V70, P1964; Siderovski DP, 1999, CRIT REV BIOCHEM MOL, V34, P215, DOI 10.1080/10409239991209273; Skiba NP, 1999, J BIOL CHEM, V274, P8770, DOI 10.1074/jbc.274.13.8770; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Snow BE, 1999, P NATL ACAD SCI USA, V96, P6489, DOI 10.1073/pnas.96.11.6489; Sowa ME, 2000, P NATL ACAD SCI USA, V97, P1483, DOI 10.1073/pnas.030409597; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tsang SH, 1998, SCIENCE, V282, P117, DOI 10.1126/science.282.5386.117; Watson AJ, 1996, J BIOL CHEM, V271, P28154, DOI 10.1074/jbc.271.45.28154; Witherow DS, 2000, J BIOL CHEM, V275, P24872, DOI 10.1074/jbc.M001535200; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; Zhang JH, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-03-j0004.2000; Zhang K, 1999, GENE, V240, P23, DOI 10.1016/S0378-1119(99)00393-5	38	76	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37093	37100		10.1074/jbc.M006982200	http://dx.doi.org/10.1074/jbc.M006982200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10978345	hybrid, Green Accepted			2022-12-25	WOS:000165577700089
J	Maestri-El Kouhen, O; Wang, GL; Solberg, J; Erickson, LJ; Law, PY; Loh, HH				Maestri-El Kouhen, O; Wang, GL; Solberg, J; Erickson, LJ; Law, PY; Loh, HH			Hierarchical phosphorylation of delta-opioid receptor regulates agonist-induced receptor desensitization and internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIN-DEPENDENT ENDOCYTOSIS; G-PROTEIN; BETA(2)-ADRENERGIC RECEPTOR; CARBOXYL-TERMINUS; OPIATE RECEPTOR; DOWN-REGULATION; C-TERMINUS; KINASE; INVOLVEMENT; CELLS	Treatment of HEK293 cells expressing the delta -opioid re ceptor with agonist [D-Pen(2,5)]enkephalin (DPDPE) resulted in the rapid phosphorylation of the receptor, We constructed several mutants of the potential phosphorylation sites (Ser/Thr) at the carboxyl tail of the receptor in order to delineate the receptor phosphorylation sites and the agonist-induced desensitization and internalization. The Ser and Thr were substituted to alanine, and the corresponding mutants were transiently and stably expressed in HEK293 cells. We found that only two residues, i.e. Thr(358) and Ser(363), were phosphorylated, with Ser(363) being critical for the DPDPE-induced phosphorylation of the receptor. Furthermore, using alanine and aspartic acid substitutions, we found that the phosphorylation of the receptor is hierarchical, with Ser(363) as the primary phosphorylation site. Here, we demonstrated that DPDPE-induced rapid receptor desensitization, as measured by adenylyl cyclase activity, and receptor internalization are intimately related to phosphorylation of Thr(358) and Ser(363), with Thr(358) being involved in the receptor internalization.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Maestri-El Kouhen, O (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	elkou002@tc.umn.edu		Law, Ping-Yee/0000-0002-5364-1093	NATIONAL INSTITUTE ON DRUG ABUSE [R56DA000564, R37DA001583, R01DA007339, R01DA001583, R01DA000564, P50DA011806] Funding Source: NIH RePORTER; NIDA NIH HHS [P50 DA011806, DA07339, R01 DA007339, R56 DA000564, DA00564, DA01583, R01 DA000564, R01 DA001583] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Appleyard SM, 1997, J NEUROCHEM, V69, P2405; ARDEN JR, 1995, J NEUROCHEM, V65, P1636; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; Burd AL, 1998, J BIOL CHEM, V273, P34488, DOI 10.1074/jbc.273.51.34488; Chu P, 1997, J BIOL CHEM, V272, P27124, DOI 10.1074/jbc.272.43.27124; Cvejic S, 1996, J BIOL CHEM, V271, P4073; El Kouhen R, 1999, J BIOL CHEM, V274, P9207, DOI 10.1074/jbc.274.14.9207; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FANTOZZI R, 1981, MOL PHARMACOL, V20, P8; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Gabilondo AM, 1997, P NATL ACAD SCI USA, V94, P12285, DOI 10.1073/pnas.94.23.12285; Hasbi A, 1998, J NEUROCHEM, V70, P2129; HASHI A, 2000, J PHARMACOL EXP THER, V293, P237; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; Ko JL, 1999, MOL BRAIN RES, V69, P171, DOI 10.1016/S0169-328X(99)00094-7; Koch T, 1997, J NEUROCHEM, V69, P1767; Kovoor A, 1997, J BIOL CHEM, V272, P27605, DOI 10.1074/jbc.272.44.27605; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Law PY, 2000, MOL PHARMACOL, V58, P388, DOI 10.1124/mol.58.2.388; Law PY, 2000, J BIOL CHEM, V275, P32057, DOI 10.1074/jbc.M002395200; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Murray SR, 1998, J BIOL CHEM, V273, P24987, DOI 10.1074/jbc.273.39.24987; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; Pak Y, 1996, MOL PHARMACOL, V50, P1214; PEI G, 1995, MOL PHARMACOL, V48, P173; Polakiewicz RD, 1998, J BIOL CHEM, V273, P12402, DOI 10.1074/jbc.273.20.12402; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P1130, DOI 10.1074/jbc.270.3.1130; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; Wang CH, 1998, BIOCHEM BIOPH RES CO, V249, P321, DOI 10.1006/bbrc.1998.9080; YANG J, 1995, MOL PHARMACOL, V48, P477; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang L, 1996, J BIOL CHEM, V271, P11449, DOI 10.1074/jbc.271.19.11449; Zhao J, 1997, BIOCHEM BIOPH RES CO, V238, P71, DOI 10.1006/bbrc.1997.7242	37	68	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36659	36664		10.1074/jbc.M006788200	http://dx.doi.org/10.1074/jbc.M006788200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973976	hybrid, Green Accepted			2022-12-25	WOS:000165577700030
J	Scherle, PA; Ma, WG; Lim, H; Dey, SK; Trzaskos, JM				Scherle, PA; Ma, WG; Lim, H; Dey, SK; Trzaskos, JM			Regulation of cyclooxygenase-2 induction in the mouse uterus during decidualization - An event of early pregnancy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE-2; GRANULOSA-CELLS; GENE DISRUPTION; GROWTH-FACTOR; KINASE; INHIBITOR; IMPLANTATION; BINDING; MICE; IDENTIFICATION	The infertility phenotype of cyclooxygenase-2 (Cox-2)deficient female mice establishes the important role of Cox-8 in pregnancy. Cox-2 deficiency results in defective ovulation, fertilization, implantation, and decidualization; the latter of which can be restored in part by the prostacyclin analog carbaprostacyclin. Uterine Cox-g expression during early pregnancy shows distinct focalization and kinetics in the uterine luminal epithelium and underlying stromal cells, suggesting that expression is tightly regulated. Several intracellular signaling cascades including ERK, p38, and JNK are implicated in vitro as critical components of regulated Cox-8 expression in response to mitogens, growth factors, and cytokines. We investigated the involvement of these signaling pathways during Cox-2 induction in vivo by monitoring uterine kinase activity after intraluminal application of a deciduogenic stimulus. Our results show that the ERK and p38 pathways are activated in uterine preparations as early as 5-min post-stimulation, ERK activation was sustained for several hours with a return to baseline levels by 4 h. p38 activation was rapid with a peak at 5-min post-stimulation and returned to near baseline levels after 45 min. Systemic administration of a MEK inhibitor completely inhibited ERK activation, but did not affect early (2 h) luminal epithelial or late (24 h) stromal Cox-2 expression and only modestly affected decidualization. In contrast, administration of a p38 inhibitor modestly inhibited early Cox-2 expression in the luminal epithelium, while dramatically diminishing late stromal expression. In parallel, induced stromal peroxisomal proliferator activated receptor-delta (PPAR delta) expression is blunted by p38 inhibition. p38 inhibition also significantly inhibited decidualization. These results suggest that p38, but not ERK activation is required for induced Cox-2 and PPAR delta expression during decidualization. In addition, inhibition of p38 led to decreased decidualization suggesting that an intracrine prostanoid pathway consisting of Cox-a, prostacyclin, and PPAR delta is required for maintenance of early pregnancy.	DuPont Pharmaceut Co, Res Lab, Wilmington, DE 19880 USA; Univ Kansas, Med Ctr, Ralph L Smith Res Ctr, Dept Mol & INtegrat Physiol, Kansas City, KS 66160 USA	DuPont; University of Kansas; University of Kansas Medical Center	Trzaskos, JM (corresponding author), DuPont Pharmaceut Co, Res Lab, POB 80400, Wilmington, DE 19880 USA.		Lim, Hyunjung J/D-5343-2011	Lim, Hyunjung J/0000-0003-2191-666X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD012304, U01HD022968, R01HD012304] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 12304, HD 22968, HD 33994] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CHAKRABORTY I, 1995, J ENDOCRINOL, V147, P339, DOI 10.1677/joe.0.1470339; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAS SK, 1994, DEVELOPMENT, V120, P1071; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DEWITT D, 1995, CELL, V83, P345, DOI 10.1016/0092-8674(95)90109-4; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Frantz B, 1998, BIOCHEMISTRY-US, V37, P13846, DOI 10.1021/bi980832y; GALLIN JI, 1992, INFLAMMATION BASIC P, P11227; Herschman HR, 1997, ADV EXP MED BIOL, V407, P61; HUETHUDSON YM, 1989, ENDOCRINOLOGY, V125, P1638; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; OGRADY JP, 1972, PROSTAGL, V1, P97, DOI 10.1016/0090-6980(72)90072-X; PARIA BC, 1993, P NATL ACAD SCI USA, V90, P10159, DOI 10.1073/pnas.90.21.10159; PSYCHOYOS A, 1973, HDB PHYSL, P187; Scherle PA, 1998, J IMMUNOL, V161, P5681; SIROIS J, 1992, J BIOL CHEM, V267, P6382; SIROIS J, 1993, J BIOL CHEM, V268, P21931; SIROIS J, 1993, J BIOL CHEM, V268, P12199; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259	26	86	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37086	37092		10.1074/jbc.M006168200	http://dx.doi.org/10.1074/jbc.M006168200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10969080	hybrid			2022-12-25	WOS:000165577700088
J	Tan, J; Town, T; Mullan, M				Tan, J; Town, T; Mullan, M			CD45 inhibits CD40L-induced microglial activation via negative regulation of the Src/p44/42 MAPK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; GERMINAL CENTER FORMATION; FAMILY TYROSINE KINASES; IMMATURE B-CELLS; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; DEFICIENT MICE; T-LYMPHOCYTES; LYN KINASE; LIGAND	It has been reported that Ligation of CD40 with CD40 ligand (CD40L) results in microglial activation as evidenced by p44/42 mitogen-activated protein kinase (MAPK) dependent tumor necrosis factor alpha (TNF-alpha) production. Previous studies have shown that CD45, a functional transmembrane protein-tyrosine phosphatase, is constitutively expressed at moderate levels on microglial cells and this expression is greatly elevated on activated microglia. To investigate the possibility that CD45 might modulate CD40L-induced microglial activation, we treated primary cultured microglial cells with CD40L and anti-CD45 antibody. Data show that crosslinking of CD45 markedly inhibits CD40L-induced activity of the Src family kinases Lck and Lyn. Further, cotreatment of microglia with CD40L and anti-CD45 antibody results in significant inhibition of microglial TNF-alpha production through inhibition of p44/42 MAPK activity, a downstream signaling event resulting from Src activation. Accordingly, primary cultured microglial cells from mice deficient in CD45 demonstrate hyper-responsiveness to ligation of CD40, as evidenced by increased p44/42 MAPK activation and TNF-alpha production. Taken together, these results show that CD45 plays a novel role in suppressing CD40L-induced microglial activation via negative regulation of the Src/p44/42 MAPK cascade.	Univ S Florida, Dept Psychiat, Roskamp Inst, Tampa, FL 33613 USA	State University System of Florida; University of South Florida	Tan, J (corresponding author), Univ S Florida, Dept Psychiat, Roskamp Inst, 3515 E Fletcher Ave, Tampa, FL 33613 USA.		Tan, Jun/I-5339-2012	Mullan, Michael/0000-0002-1473-7527				Aloisi F, 1998, J IMMUNOL, V160, P4671; Ashwell JD, 1999, IMMUNOL TODAY, V20, P412, DOI 10.1016/S0167-5699(99)01505-4; Bhat NR, 1998, J NEUROSCI, V18, P1633; Brenner B, 1997, BIOCHEM BIOPH RES CO, V239, P11, DOI 10.1006/bbrc.1997.7415; Brenner B, 1997, FEBS LETT, V417, P301, DOI 10.1016/S0014-5793(97)01306-9; BURNS CM, 1994, J BIOL CHEM, V269, P13594; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; Carson MJ, 1998, GLIA, V22, P72, DOI 10.1002/(SICI)1098-1136(199801)22:1<72::AID-GLIA7>3.0.CO;2-A; CHENG HC, 1992, J BIOL CHEM, V267, P9248; Combs CK, 1999, J NEUROSCI, V19, P928; Daulhac L, 1999, J BIOL CHEM, V274, P20657, DOI 10.1074/jbc.274.29.20657; Diehl L, 1999, NAT MED, V5, P774, DOI 10.1038/10495; Downen M, 1999, GLIA, V28, P114, DOI 10.1002/(SICI)1098-1136(199911)28:2<114::AID-GLIA3>3.0.CO;2-O; Foy TM, 1996, ANNU REV IMMUNOL, V14, P591, DOI 10.1146/annurev.immunol.14.1.591; Gebicke-Haerter PJ, 1998, NERVENARZT, V69, P752, DOI 10.1007/s001150050339; Gulbins E, 1997, P NATL ACAD SCI USA, V94, P7661, DOI 10.1073/pnas.94.14.7661; Gulbins E, 1996, J IMMUNOL, V157, P2844; Iciek LA, 1997, J IMMUNOL, V158, P4769; Imbert V, 1996, J INFLAMM, V46, P65; Jeohn GH, 1998, J NEUROIMMUNOL, V85, P1, DOI 10.1016/S0165-5728(97)00204-X; Justement LB, 1997, ADV IMMUNOL, V66, P1, DOI 10.1016/S0065-2776(08)60595-7; Kalaria R N, 1999, Curr Opin Hematol, V6, P15, DOI 10.1097/00062752-199901000-00004; KATAGIRI T, 1995, J BIOL CHEM, V270, P27987; Katagiri T, 1999, J IMMUNOL, V163, P1321; Kato J, 1998, J IMMUNOL, V160, P4788; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; LOH RKS, 1995, IMMUNOL LETT, V45, P99, DOI 10.1016/0165-2478(94)00233-H; Mach F, 1997, P NATL ACAD SCI USA, V94, P1931, DOI 10.1073/pnas.94.5.1931; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; MCGEER PL, 1993, GLIA, V7, P84, DOI 10.1002/glia.440070114; Meng FY, 1997, J EXP MED, V185, P1661, DOI 10.1084/jem.185.9.1661; Nguyen VT, 1998, EUR J IMMUNOL, V28, P2537, DOI 10.1002/(SICI)1521-4141(199808)28:08<2537::AID-IMMU2537>3.0.CO;2-1; Orlicek SL, 1999, SHOCK, V12, P350, DOI 10.1097/00024382-199911000-00004; Purkerson JM, 1998, J IMMUNOL, V160, P2121; Pyo H, 1998, NEUROREPORT, V9, P871, DOI 10.1097/00001756-199803300-00020; REN CL, 1994, J EXP MED, V179, P673, DOI 10.1084/jem.179.2.673; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; Suttles J, 1999, J BIOL CHEM, V274, P5835, DOI 10.1074/jbc.274.9.5835; Tan J, 1999, SCIENCE, V286, P2352, DOI 10.1126/science.286.5448.2352; Tan J, 1999, J NEUROIMMUNOL, V97, P77, DOI 10.1016/S0165-5728(99)00053-3; Tan J, 1999, J IMMUNOL, V163, P6614; Thomas ML, 1999, IMMUNOL TODAY, V20, P406, DOI 10.1016/S0167-5699(99)01506-6; TsujiTakayama K, 1997, BIOCHEM BIOPH RES CO, V237, P126, DOI 10.1006/bbrc.1997.7099; van der Bruggen T, 1999, INFECT IMMUN, V67, P3824, DOI 10.1128/IAI.67.8.3824-3829.1999; Wang JY, 1996, J EXP MED, V184, P831, DOI 10.1084/jem.184.3.831; YOSJIMOTO T, 1997, EUR J IMMUNOL, V27, P3461; Zhou L, 1999, CLIN IMMUNOL, V93, P232, DOI 10.1006/clim.1999.4796	47	74	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37224	37231		10.1074/jbc.M002006200	http://dx.doi.org/10.1074/jbc.M002006200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10978311	hybrid			2022-12-25	WOS:000165577700105
J	Kapahi, P; Takahashi, T; Natoli, G; Adams, SR; Chen, Y; Tsien, RY; Karin, M				Kapahi, P; Takahashi, T; Natoli, G; Adams, SR; Chen, Y; Tsien, RY; Karin, M			Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of I kappa B kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IKK-BETA SUBUNIT; TRANSCRIPTION FACTOR; PHOSPHORYLATION; COMPLEX; ALPHA; AP-1; JNK	Arsenite is a potent environmental toxin that causes various pathologies including cancers and skin disorders. Arsenite is believed to exert its biological effects through reaction with exposed sulfhydryl groups, especially pairs of adjacent thiols. Here, we describe the mechanism by which arsenite affects the NF-kappaB signaling pathway. Activation of transcription factor NF-kappaB depends on the integrity of the I kappaB kinase (IKK) complex. We found that arsenite potently inhibits NF-kappaB and IKK activation by binding to Cys-179 in the activation loop of the IKK catalytic subunits, IKK alpha/beta. The affinity of IKK beta for trivalent arsenic was verified in vitro by the ability of IKK beta to enhance the fluorescence of an arsenic-substituted fluorescein dye. The addition of 1,2-dithiol antidotes or replacement of Cys-179 with an alanine residue abolished dye binding to and arsenite inhibition of IKK beta. Overexpression of IKK beta (C179A) protects NF-kappaB from inhibition by arsenite, indicating that despite the involvement of a large number of distinct gene products in this activation pathway, the critical target for inhibition by arsenite is on the IKK catalytic subunits.	Univ Calif San Diego, Dept Pharmacol 0636, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst 0647, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Karin, M (corresponding author), Univ Calif San Diego, Dept Pharmacol 0636, Lab Gene Regulat & Signal Transduct, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Natoli, gioacchino/J-2100-2018; Natoli, gioacchino/ABB-8679-2020	Natoli, Gioacchino/0000-0003-0711-2411	NIEHS NIH HHS [ES 04151] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES004151, R01ES004151] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abernathy CO, 1999, ENVIRON HEALTH PERSP, V107, P593, DOI 10.2307/3434403; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; CUZICK J, 1982, BRIT J CANCER, V45, P904, DOI 10.1038/bjc.1982.143; DAS D, 1995, ANALYST, V120, P917, DOI 10.1039/an9952000917; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FARBER EM, 1992, J AM ACAD DERMATOL, V27, P640, DOI 10.1016/0190-9622(92)70232-5; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; GRIFFIN B, 2000, IN PRESS METHODS ENZ; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; NEVENS F, 1990, J HEPATOL, V11, P80, DOI 10.1016/0168-8278(90)90276-W; Node K, 1999, SCIENCE, V285, P1276, DOI 10.1126/science.285.5431.1276; PIONTEK M, 1989, DEUT MED WOCHENSCHR, V114, P1653, DOI 10.1055/s-2008-1066810; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; ROTHWARF DM, 1999, SCIENCE; Rudolph D, 2000, GENE DEV, V14, P854; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; SNOW ET, 1992, PHARMACOL THERAPEUT, V53, P31, DOI 10.1016/0163-7258(92)90043-Y; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	29	296	313	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36062	36066		10.1074/jbc.M007204200	http://dx.doi.org/10.1074/jbc.M007204200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10967126	hybrid			2022-12-25	WOS:000165382000060
J	Li, XH; Shimada, K; Showalter, LA; Weinman, SA				Li, XH; Shimada, K; Showalter, LA; Weinman, SA			Biophysical properties of ClC-3 differentiate it from swelling-activated chloride channels in Chinese hamster ovary-K1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY VOLUME DECREASE; P-GLYCOPROTEIN; CL CHANNEL; EXPRESSION; IDENTIFICATION; CURRENTS	ClC-3 is a highly conserved voltage-gated chloride channel, which together with ClC-4 and ClC-5 belongs to one subfamily of the larger group of ClC chloride channels, Whereas ClC-5 is localized intracellularly, ClC-3 has:been reported to be a swelling-activated plasma membrane channel, However, recent studies have shown that native ClC-3 in hepatocytes is primarily intracellular, Therefore, we reexamined the properties of ClC-3 in a mammalian cell expression system and compared them with the properties of endogenous swelling-activated channels. Chinese hamster ovary (CHO)-K1 cells;were transiently transfected with rat ClC-3, The resulting chloride currents were Cl- > I- selective, showed extreme outward rectification, and lacked inactivation at positive voltages, In addition, they were insensitive to the chloride channel blockers, 5-nitro-2-(3-phenylpropylamino)-benzoic acid (NPPB) and 4,4'diisothiocyanostilbene-2,2'-disulfonic acid (DIDS) and were not inhibited by phorbol esters or activated by osmotic swelling. These properties are identical to those of ClC-5 but differ from those previously attributed to ClC-3, In contrast, nontransfected CHO-K1 cells displayed an endogenous swelling-activated chloride current, which was weakly outward rectifying, inactivated at positive voltages, sensitive to NPPB and DIDS, and inhibited by phorbol esters, These properties are identical to those previously attributed to ClC-3, Therefore, we conclude that when expressed in CHO-K1 cells, ClC-3 is an extremely outward rectifying channel with similar properties to ClC-5 and is neither activated by cell swelling nor identical to the endogenous swelling-activated channel. These data suggest that ClC-3 cannot be responsible for the swelling-activated chloride channel under all circumstances.	Univ Texas, Med Branch, Dept Physiol & Biophys, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Internal Med, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Weinman, SA (corresponding author), Univ Texas, Med Branch, Dept Physiol & Biophys, 301 Univ Blvd, Galveston, TX 77555 USA.		Weinman, Steven/E-7012-2011		NIDDK NIH HHS [DK42917] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042917, R01DK042917] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Begenisich T, 1998, J MEMBRANE BIOL, V163, P77, DOI 10.1007/s002329900372; Bond TD, 1998, J PHYSIOL-LONDON, V508, P333, DOI 10.1111/j.1469-7793.1998.333bq.x; Buyse G, 1997, J BIOL CHEM, V272, P3615, DOI 10.1074/jbc.272.6.3615; Duan D, 1999, J GEN PHYSIOL, V113, P57, DOI 10.1085/jgp.113.1.57; Duan D, 1997, NATURE, V390, P417, DOI 10.1038/37151; Friedrich T, 1999, J BIOL CHEM, V274, P896, DOI 10.1074/jbc.274.2.896; GSCHWENTNER M, 1995, PFLUG ARCH EUR J PHY, V430, P464, DOI 10.1007/BF00373882; HIGGINS CF, 1995, J BIOENERG BIOMEMBR, V27, P63, DOI 10.1007/BF02110332; Jentsch TJ, 1999, PFLUG ARCH EUR J PHY, V437, P783, DOI 10.1007/s004240050847; KAWASAKI M, 1995, NEURON, V14, P1285, DOI 10.1016/0896-6273(95)90275-9; KAWASAKI M, 1994, NEURON, V12, P597, DOI 10.1016/0896-6273(94)90215-1; Laich A, 1997, KIDNEY INT, V51, P477, DOI 10.1038/ki.1997.65; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Meng XJ, 1996, AM J PHYSIOL-CELL PH, V271, pC112, DOI 10.1152/ajpcell.1996.271.1.C112; Sakamoto H, 1996, J BIOL CHEM, V271, P10210, DOI 10.1074/jbc.271.17.10210; Shimada K, 2000, AM J PHYSIOL-GASTR L, V279, pG268, DOI 10.1152/ajpgi.2000.279.2.G268; Strange K, 1996, AM J PHYSIOL-CELL PH, V270, pC711, DOI 10.1152/ajpcell.1996.270.3.C711; Strange K, 1998, J GEN PHYSIOL, V111, P617, DOI 10.1085/jgp.111.5.617; Vanoye CG, 1997, J PHYSIOL-LONDON, V502, P249, DOI 10.1111/j.1469-7793.1997.249bk.x; Waldegger S, 2000, J AM SOC NEPHROL, V11, P1331, DOI 10.1681/ASN.V1171331; Wang LW, 2000, J PHYSIOL-LONDON, V524, P63, DOI 10.1111/j.1469-7793.2000.t01-1-00063.x; Weinman SA, 1998, J BIOL CHEM, V273, P34691, DOI 10.1074/jbc.273.52.34691; Xiong H, 1999, J MEMBRANE BIOL, V167, P215, DOI 10.1007/s002329900485	23	115	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35994	35998		10.1074/jbc.M002712200	http://dx.doi.org/10.1074/jbc.M002712200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10973952	hybrid			2022-12-25	WOS:000165382000050
J	Mahmmoud, YA; Vorum, H; Cornelius, F				Mahmmoud, YA; Vorum, H; Cornelius, F			Identification of a phospholemman-like protein from shark rectal glands - Evidence for indirect regulation of Na,K-ATPase by protein kinase C via a novel member of the FXYDY family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SUBUNIT; NA+/K+-ATPASE; ALPHA-1 SUBUNIT; INTACT-CELLS; SIDED ACTION; PHOSPHORYLATION; PHOSPHOLAMBAN; K+; NA+,K+-ATPASE; INHIBITION	The Na,K-ATPase provides the driving force for many ion transport processes through control of Na+ and K+ concentration gradients across the plasma membranes of animal cells. It is composed of two subunits, cu and beta, In many tissues, predominantly in kidney, it is associated with a small ancillary component, the gamma -subunit that plays a modulatory role. A novel 15-kDa protein, sharing considerable homology to the gamma -subunit and to phospholemman (PLM) was identified in purified Na,K-ATPase preparations from rectal glands of the shark Squalus acanthias, but was absent in pig kidney preparations. This PLM-like protein from shark (PLMS) was found to be a substrate for both PKA and PKC, Antibodies to the Na,K-ATPase or subunit coimmunoprecipitated PLMS, Purified PLMS also coimmunoprecipitated with the ol-subunit of pig kidney Na,K-ATPase, indicating specific association with different alpha -isoforms. Finally, PLMS and the alpha -subunit were expressed in stoichiometric amounts in rectal gland membrane preparations. Incubation of membrane bound Na,K-ATPase with non-solubilizing concentrations of C12E8 resulted in functional dissociation of PLMS from Na,K-ATPase and increased the hydrolytic activity. The same effects were observed after PKC phosphorylation of Na,K-ATPase membrane preparations. Thus, PLMS may function as a modulator of shark Na,K-ATPase in a way resembling the phospholamban regulation of the Ca-ATPase.	Aarhus Univ, Dept Biophys, DK-8000 Aarhus C, Denmark	Aarhus University	Cornelius, F (corresponding author), Aarhus Univ, Dept Biophys, Ole Worms Alle 185, DK-8000 Aarhus C, Denmark.	fc@biophys.au.dk	Cornelius, Flemming/C-1912-2019	Cornelius, Flemming/0000-0003-1566-0020				Arystarkhova E, 1999, J BIOL CHEM, V274, P33183, DOI 10.1074/jbc.274.47.33183; ATTALI B, 1995, P NATL ACAD SCI USA, V92, P6092, DOI 10.1073/pnas.92.13.6092; Beggah AT, 1999, J BIOL CHEM, V274, P8217, DOI 10.1074/jbc.274.12.8217; BEGUIN P, 1994, J BIOL CHEM, V269, P24437; Beguin P, 1997, EMBO J, V16, P4250, DOI 10.1093/emboj/16.14.4250; Celis JE, 1998, CELL BIOLOGY - A LABOARATORY HANDBOOK, 2ND EDITION, VOL 4, P404; CELIS JE, 1994, CELL BIOL LABORATORY, V3, P222; Chen LSK, 1997, GENOMICS, V41, P435, DOI 10.1006/geno.1997.4665; Chen ZH, 1998, CIRC RES, V82, P367, DOI 10.1161/01.RES.82.3.367; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P188; CORNELIUS F, 1987, BIOCHIM BIOPHYS ACTA, V904, P353, DOI 10.1016/0005-2736(87)90385-3; CORNELIUS F, 1988, BIOCHIM BIOPHYS ACTA, V944, P223, DOI 10.1016/0005-2736(88)90435-X; Cornelius F, 1996, FEBS LETT, V380, P277, DOI 10.1016/0014-5793(96)00032-4; CORNELIUS F, 2000, IN PRESS INT C SER; Feschenko MS, 1997, J BIOL CHEM, V272, P17726, DOI 10.1074/jbc.272.28.17726; FESCHENKO MS, 1995, J BIOL CHEM, V270, P14072, DOI 10.1074/jbc.270.23.14072; FISONE G, 1994, J BIOL CHEM, V269, P9368; FORBUSH B, 1978, BIOCHEMISTRY-US, V17, P3667, DOI 10.1021/bi00610a037; Fu XY, 1997, MOL CELL BIOL, V17, P1503, DOI 10.1128/MCB.17.3.1503; GORG A, 1988, ELECTROPHORESIS, V9, P531, DOI 10.1002/elps.1150090913; Hansen O, 1999, PFLUG ARCH EUR J PHY, V437, P517, DOI 10.1007/s004240050812; HARDWICKE PMD, 1981, BIOCHEM BIOPH RES CO, V102, P250, DOI 10.1016/0006-291X(81)91514-X; HUANG WH, 1985, J BIOL CHEM, V260, P7356; JONES LR, 1979, J BIOL CHEM, V254, P530; KOVACS RJ, 1988, J BIOL CHEM, V263, P18364; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBERG O, 1956, METHODS BIOCHEMICAL, V3, P1; Logvinenko NS, 1996, P NATL ACAD SCI USA, V93, P9132, DOI 10.1073/pnas.93.17.9132; LU YZ, 1994, BIOCHEMISTRY-US, V33, P5056, DOI 10.1021/bi00183a008; MERCER RW, 1993, J CELL BIOL, V121, P579, DOI 10.1083/jcb.121.3.579; Middleton JP, 1996, MINER ELECTROL METAB, V22, P293; MIDDLETON JP, 1993, J BIOL CHEM, V268, P15958; Minor NT, 1998, P NATL ACAD SCI USA, V95, P6521, DOI 10.1073/pnas.95.11.6521; MOORMAN JR, 1995, NATURE, V377, P737, DOI 10.1038/377737a0; Moorman JR, 1998, ADV EXP MED BIOL, V442, P219; MOORMAN JR, 1992, J BIOL CHEM, V267, P14551; MORRISON BW, 1995, J BIOL CHEM, V270, P2176, DOI 10.1074/jbc.270.5.2176; NAKADATE T, 1987, J BIOL CHEM, V262, P11507; Nishi A, 1999, J NEUROCHEM, V73, P1492, DOI 10.1046/j.1471-4159.1999.0731492.x; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PLESNER IW, 1986, BIOCHEM J, V239, P175, DOI 10.1042/bj2390175; Ramjeesingh M, 1999, BIOCHEM J, V342, P119, DOI 10.1042/0264-6021:3420119; Shi YL, 1996, BIOCHEMISTRY-US, V35, P13393, DOI 10.1021/bi9614085; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; Therien AG, 1999, J BIOL CHEM, V274, P12252, DOI 10.1074/jbc.274.18.12252; TUNON P, 1984, J BIOCHEM BIOPH METH, V9, P171, DOI 10.1016/0165-022X(84)90008-3; TURI A, 1988, BIOCHIM BIOPHYS ACTA, V940, P77, DOI 10.1016/0005-2736(88)90010-7; TURI A, 1985, BIOCHIM BIOPHYS ACTA, V818, P123, DOI 10.1016/0005-2736(85)90555-3; Vasilets LA, 1999, FEBS LETT, V455, P8, DOI 10.1016/S0014-5793(99)00851-0; VASILETS LA, 1992, J MEMBRANE BIOL, V125, P119; WALAAS SI, 1988, BIOCHIM BIOPHYS ACTA, V968, P127, DOI 10.1016/0167-4889(88)90052-3; Yang L, 1996, BIOCHEMISTRY-US, V35, P13966, DOI 10.1021/bi9610008; Zhai J, 2000, J BIOL CHEM, V275, P10538, DOI 10.1074/jbc.275.14.10538	54	106	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35969	35977		10.1074/jbc.M005168200	http://dx.doi.org/10.1074/jbc.M005168200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10961995	hybrid			2022-12-25	WOS:000165382000047
J	Mazurek, N; Conklin, J; Byrd, JC; Raz, A; Bresalier, RS				Mazurek, N; Conklin, J; Byrd, JC; Raz, A; Bresalier, RS			Phosphorylation of the beta-galactoside-binding protein galectin-3 modulates binding to its ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANIMAL LECTIN; HUMAN NEUTROPHILS; MESSENGER-RNA; CELL-ADHESION; COLON-CANCER; EPSILON-BP; EXPRESSION; IGE; METASTASIS; SEQUENCE	The beta -galactoside-binding protein galectin-3 has pleiotropic biological functions and has been implicated in cell growth, differentiation, adhesion, RNA processing, apoptosis, and malignant transformation. Galectin-3 may be phosphorylated at N-terminal Ser(6), but the role of phosphorylation in determining interactions of this endogenous lectin with its ligands remains to be elucidated. We therefore studied the effect of phosphorylation on binding of galectin-3 to two of its reported ligands, laminin and purified colon cancer mucin, Human recombinant galectin-3 was phosphorylated in vitro by casein kinase I, and separated from the native species by isoelectric focusing for use in solid phase binding assays. Non-phosphorylated galectin-3 bound to laminin and asialomucin in a dose-dependent manner with half-maximal binding at 1.5 mug/ml. Phosphorylation reduced saturation binding to each ligand by >85%. Ligand binding could be fully restored by dephosphorylation with protein phosphatase type 1. Mutation of galectin-3 at Ser(6) (Ser to Glu) did not alter galectin ligand binding. Metabolic labeling or separation by isoelectric focusing confirmed the presence of phosphorylated galectin-8 species in vivo in the cytosol of human colon cancer cells from which ligand mucin was purified. Phosphorylation significantly reduces the interaction of galectin-3 with its ligands. The process by which phosphorylation modulates protein-carbohydrate interactions has important implications for understanding the biological functions of this protein, and may serve as an "on/off" switch for its sugar binding capabilities.	Henry Ford Hlth Sci Ctr K7, Gastrointestinal Canc Res Lab, Detroit, MI 48202 USA; Univ Michigan, Sch Med, Dept Med, Ann Arbor, MI 48109 USA; Wayne State Univ, Sch Med, Karmanos Canc Inst, Metastasis Res Program, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA	University of Michigan System; University of Michigan; Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne State University	Bresalier, RS (corresponding author), Henry Ford Hlth Sci Ctr K7, Gastrointestinal Canc Res Lab, 2799 W Grand Blvd, Detroit, MI 48202 USA.			Bresalier, Robert/0000-0002-9740-281X	NATIONAL CANCER INSTITUTE [R01CA046120, R01CA069480] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA 46120, R01CA 69480] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akahani S, 1997, CANCER RES, V57, P5272; ALBRANDT K, 1987, P NATL ACAD SCI USA, V84, P6859, DOI 10.1073/pnas.84.19.6859; BAO Q, 1995, J CELL SCI, V108, P2791; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; Bresalier RS, 1996, CANCER RES, V56, P4354; Bresalier RS, 1998, GASTROENTEROLOGY, V115, P287, DOI 10.1016/S0016-5085(98)70195-7; Bresalier RS, 1997, CANCER, V80, P776; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; COWLES EA, 1990, J BIOL CHEM, V265, P17706; DAGHER SF, 1995, P NATL ACAD SCI USA, V92, P1213, DOI 10.1073/pnas.92.4.1213; Dudas SP, 2000, GASTROENTEROLOGY, V118, pA273, DOI 10.1016/S0016-5085(00)83173-X; Dyer KD, 1997, GENOMICS, V40, P217, DOI 10.1006/geno.1996.4590; FRIGERI LG, 1993, BIOCHEMISTRY-US, V32, P7644, DOI 10.1021/bi00081a007; GITT MA, 1995, J BIOL CHEM, V270, P5032, DOI 10.1074/jbc.270.10.5032; Gong HC, 1999, CANCER RES, V59, P6239; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; HAMANN KK, 1991, EXP CELL RES, V196, P82, DOI 10.1016/0014-4827(91)90458-7; HERRMANN J, 1993, J BIOL CHEM, V268, P26704; HSU DK, 1992, J BIOL CHEM, V267, P14167; HUFLEJT ME, 1993, J BIOL CHEM, V268, P26712; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; INOHARA H, 1994, BIOCHEM BIOPH RES CO, V201, P1366, DOI 10.1006/bbrc.1994.1854; INOHARA H, 1995, CANCER RES, V55, P3267; IRIMURA T, 1991, CANCER RES, V51, P387; JIA SH, 1988, J BIOL CHEM, V263, P6009; Kasai K, 1996, J BIOCHEM-TOKYO, V119, P1; Kuwabara I, 1996, J IMMUNOL, V156, P3939; LIU FT, 1995, AM J PATHOL, V147, P1016; MADSEN P, 1995, J BIOL CHEM, V270, P5823, DOI 10.1074/jbc.270.11.5823; MEHUL B, 1994, J BIOL CHEM, V269, P18250; MORSA SM, 1993, BIOCHEMISTRY-US, V32, P260; MOUTSATSOS IK, 1987, P NATL ACAD SCI USA, V84, P6452, DOI 10.1073/pnas.84.18.6452; Nakamura M, 1999, INT J ONCOL, V15, P143; NANGIAMAKKER P, 1995, INT J ONCOL, V7, P1079; OCHIENG J, 1992, BIOCHEM BIOPH RES CO, V186, P1674, DOI 10.1016/S0006-291X(05)81601-8; OCHIENG J, 1993, BIOCHEMISTRY-US, V32, P4455, DOI 10.1021/bi00067a038; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; RAZ A, 1990, INT J CANCER, V46, P871, DOI 10.1002/ijc.2910460520; RAZ A, 1987, CANCER METAST REV, V6, P433, DOI 10.1007/BF00144274; RAZ A, 1991, CANCER RES, V51, P2173; RAZ A, 1986, CANCER RES, V46, P3367; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; SATO S, 1993, EXP CELL RES, V207, P8, DOI 10.1006/excr.1993.1157; SCHOEPPNER HL, 1995, CANCER, V75, P2818, DOI 10.1002/1097-0142(19950615)75:12<2818::AID-CNCR2820751206>3.0.CO;2-#; Seetharaman J, 1998, J BIOL CHEM, V273, P13047, DOI 10.1074/jbc.273.21.13047; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; TRUONG MJ, 1993, J EXP MED, V177, P243, DOI 10.1084/jem.177.1.243; VASS PG, 1994, GLYCOCONJ J, V11, P353; Wada J, 1997, J BIOL CHEM, V272, P6078, DOI 10.1074/jbc.272.9.6078; YAMAOKA A, 1995, J IMMUNOL, V154, P3479; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737; Yoshida M, 1998, J IMMUNOL, V161, P933; ZHANG ZJ, 1992, J BIOL CHEM, V267, P1484; ZUBERI RI, 1994, CELL IMMUNOL, V156, P1, DOI 10.1006/cimm.1994.1148	55	98	103	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36311	36315		10.1074/jbc.M003831200	http://dx.doi.org/10.1074/jbc.M003831200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10961987	hybrid			2022-12-25	WOS:000165382000094
J	Xavier, GD; Varadi, A; Ainscow, EK; Rutter, GA				Xavier, GD; Varadi, A; Ainscow, EK; Rutter, GA			Regulation of gene expression by glucose in pancreatic beta-cells (MIN6) via insulin secretion and activation of phosphatidylinositol 3 '-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-KINASE GENE; UPSTREAM STIMULATORY FACTOR; ACETYL-COA CARBOXYLASE; PROTEIN-KINASE; METABOLIC-REGULATION; CA2+ CONCENTRATION; RESPONSE ELEMENT; TRANSCRIPTIONAL REGULATION; CARBOHYDRATE REGULATION; TRANSPORTER ISOFORMS	Increases in glucose concentration control the transcription of the preproinsulin (PPI) gene and several other genes in the pancreatic islet beta -cell. Although recent data have demonstrated that secreted insulin may regulate the PPT gene (Leibiger, I. B., Leibiger, B., Moede, T,, and Berggren, P, O, (1998) Mel. Cell 1, 933-938), the role of insulin in the control of other beta -cell genes is unexplored. To study the importance of insulin secretion in the regulation of the PPI and liver-type pyruvate kinase (L-PK) genes by glucose, we have used intranuclear microinjection of promoter-luciferase constructs into MING beta -cells and photon-counting imaging. The activity of each promoter was increased either by 30 (versus 3) mM glucose or by 1-20 nM insulin. These effects of insulin were not due to enhanced glucose metabolism since culture with the hormone had no impact on the stimulation of increases in intracellular ATP concentration caused by 30 mM glucose. Furthermore, the islet-specific glucokinase promoter and cellular glucokinase immunoreactivity were unaffected by 30 mM glucose or 20 nM insulin. Inhibition of insulin secretion with the Ca2+ channel blocker verapamil, the ATP-sensitive K+ channel opener diazoxide, or the alpha (2)-adrenergic agonist clonidine blocked the effects of glucose on L-PK gene transcription. Similarly, 30 mM glucose failed to induce the promoter after inhibition of phosphatidylinositol 3'-kinase activity with LY294002 and the expression of dominant negative-acting phosphatidylinositol 3'-kinase (Delta p85) or the phosphoinositide 3'-phosphatase PTEN (phosphatase and tensin homologue), LY294002 also diminished the activation of the L-PK gene caused by inhibition of 5'-AMP-activated protein kinase with anti-5'-AMP-activated protein kinase alpha2 antibodies. Conversely, stimulation of insulin secretion with 13 mM KCI or 10 muM tolbutamide strongly activated the PPI and L-PK promoters. These data indicate that, in MING beta -cells, stimulation of insulin secretion is important for the activation by glucose of L-PK as well as the PPI promoter, but does not cause increases in glucokinase gene expression or glucose metabolism.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol	Rutter, GA (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Univ Walk, Bristol BS8 1TD, Avon, England.	g.a.rutter@bris.ac.uk		da Silva Xavier, Gabriela/0000-0002-0678-012X; Rutter, Guy/0000-0001-6360-0343	Diabetes UK [13/0004672] Funding Source: Medline	Diabetes UK(Diabetes UK)		Ainscow EK, 2000, DIABETES, V49, P1149, DOI 10.2337/diabetes.49.7.1149; Aspinwall CA, 2000, J BIOL CHEM, V275, P22331, DOI 10.1074/jbc.M909647199; Becker TC, 1996, J BIOL CHEM, V271, P390, DOI 10.1074/jbc.271.1.390; Berman HK, 1998, BIOCHEMISTRY-US, V37, P4543, DOI 10.1021/bi9726133; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUN T, 1993, J BIOL CHEM, V268, P18905; Bryan J, 1997, CURR OPIN CELL BIOL, V9, P553, DOI 10.1016/S0955-0674(97)80033-6; Buteau J, 1999, DIABETOLOGIA, V42, P856, DOI 10.1007/s001250051238; Cuif MH, 1997, FEBS LETT, V417, P81, DOI 10.1016/S0014-5793(97)01260-X; CUIF MH, 1993, J BIOL CHEM, V268, P13769; deVargas LM, 1997, J BIOL CHEM, V272, P26573, DOI 10.1074/jbc.272.42.26573; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DOCHERTY K, 1994, FASEB J, V8, P20, DOI 10.1096/fasebj.8.1.8299887; DOIRON B, 1994, J BIOL CHEM, V269, P10213; Doiron B, 1996, J BIOL CHEM, V271, P5321, DOI 10.1074/jbc.271.10.5321; EFRAT S, 1991, J BIOL CHEM, V266, P11141; Emmanouilidou E, 1999, CURR BIOL, V9, P915, DOI 10.1016/S0960-9822(99)80398-4; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Foretz M, 1998, J BIOL CHEM, V273, P14767, DOI 10.1074/jbc.273.24.14767; GERMAN M, 1995, DIABETES, V44, P1002, DOI 10.2337/diab.44.8.1002; GERMAN MS, 1990, J BIOL CHEM, V265, P22063; GILON P, 1992, J BIOL CHEM, V267, P20713; GOODISON S, 1992, BIOCHEM J, V285, P563, DOI 10.1042/bj2850563; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Harvey J, 2000, J BIOL CHEM, V275, P4660, DOI 10.1074/jbc.275.7.4660; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; IYNEDJIAN PB, 1989, P NATL ACAD SCI USA, V86, P7838, DOI 10.1073/pnas.86.20.7838; IYNEDJIAN PB, 1993, BIOCHEM J, V293, P1; Kahn A, 1997, BIOCHIMIE, V79, P113, DOI 10.1016/S0300-9084(97)81501-5; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kaytor EN, 1997, J BIOL CHEM, V272, P7525, DOI 10.1074/jbc.272.11.7525; Kennedy HJ, 1999, BIOCHEM J, V342, P275, DOI 10.1042/0264-6021:3420275; Kennedy HJ, 1997, J BIOL CHEM, V272, P20636, DOI 10.1074/jbc.272.33.20636; Kennedy HJ, 1999, J BIOL CHEM, V274, P13281, DOI 10.1074/jbc.274.19.13281; KILO C, 1967, DIABETES, V16, P377, DOI 10.2337/diab.16.6.377; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Leclerc I, 1998, FEBS LETT, V431, P180, DOI 10.1016/S0014-5793(98)00745-5; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; LIANG Y, 1990, J BIOL CHEM, V265, P16863; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; LUO XC, 1990, NUCLEIC ACIDS RES, V18, P3249, DOI 10.1093/nar/18.11.3249; Macfarlane WM, 1997, J BIOL CHEM, V272, P20936, DOI 10.1074/jbc.272.33.20936; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; MARIE S, 1993, J BIOL CHEM, V268, P23881; Mater MK, 1999, J BIOL CHEM, V274, P32725, DOI 10.1074/jbc.274.46.32725; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Moriizumi S, 1998, GENE EXPRESSION, V7, P103; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Pauli-Magnus C, 2000, J PHARMACOL EXP THER, V293, P376; Prentki M, 1997, DIABETOLOGIA, V40, pS32, DOI 10.1007/s001250051395; Qian J, 1999, BIOCHEM J, V341, P315, DOI 10.1042/0264-6021:3410315; Rafiq I, 2000, J BIOL CHEM, V275, P15977, DOI 10.1074/jbc.275.21.15977; Rafiq I, 1998, J BIOL CHEM, V273, P23241, DOI 10.1074/jbc.273.36.23241; Rutter CA, 2000, NEWS PHYSIOL SCI, V15, P149; RUTTER GA, 1993, J BIOL CHEM, V268, P22385; Rutter GA, 1998, CHEM BIOL, V5, pR285, DOI 10.1016/S1074-5521(98)90287-3; Rutter GA, 1999, CURR BIOL, V9, pR443, DOI 10.1016/S0960-9822(99)80277-2; Rutter GA, 1996, P NATL ACAD SCI USA, V93, P5489, DOI 10.1073/pnas.93.11.5489; Salt IP, 1998, BIOCHEM J, V335, P533, DOI 10.1042/bj3350533; SHIH HM, 1994, J BIOL CHEM, V269, P9380; Su HS, 2000, J NUTR, V130, p315S, DOI 10.1093/jn/130.2.315S; Thornton C, 1998, J BIOL CHEM, V273, P12443, DOI 10.1074/jbc.273.20.12443; Tiedge M, 1999, DIABETES, V48, P514, DOI 10.2337/diabetes.48.3.514; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; VAULONT S, 1986, J BIOL CHEM, V261, P7621; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; Wang HY, 1997, P NATL ACAD SCI USA, V94, P4372, DOI 10.1073/pnas.94.9.4372; Webb GC, 2000, P NATL ACAD SCI USA, V97, P5773, DOI 10.1073/pnas.100126597; WELSH M, 1985, J BIOL CHEM, V260, P3590; Wu H, 1999, BIOCHEM J, V344, P813, DOI 10.1042/0264-6021:3440813; Xavier GD, 2000, P NATL ACAD SCI USA, V97, P4023, DOI 10.1073/pnas.97.8.4023; Yamada K, 1999, BIOCHEM J, V337, P1, DOI 10.1042/0264-6021:3370001; YASUDA K, 1992, DIABETES, V41, P76, DOI 10.2337/diabetes.41.1.76; ZHANG S, 1995, J ENDOCRINOL, V147, P33, DOI 10.1677/joe.0.1470033	76	59	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36269	36277		10.1074/jbc.M006597200	http://dx.doi.org/10.1074/jbc.M006597200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10967119	hybrid, Green Published			2022-12-25	WOS:000165382000089
J	Kim, WJ; Lee, S; Park, MS; Jang, YK; Kim, JB; Park, SD				Kim, WJ; Lee, S; Park, MS; Jang, YK; Kim, JB; Park, SD			Rad22 protein, a Rad52 homologue in Schizosaccharomyces pombe, binds to DNA double-strand breaks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FISSION YEAST; RECOMBINATION; REPAIR; PATHWAYS	DNA double-strand breaks can be introduced by exogenous agents or during normal cellular processes. Genes belonging to the RAD52 epistasis group are known to repair these breaks in budding yeast. Among these genes, RAD52 plays a central role in homologous recombination and DNA double-strand break repair. Despite its importance, its mechanism of action is not yet clear. It is known, however, that the human homologue of Rad52 is capable of binding to DNA ends in vitro. Herein, we show that Rad22 protein, a Rad52 homologue in the fission yeast Schizosaccharomyces pombe, can similarly bind to DNA ends at double-strand breaks. This end-binding ability was demonstrated in vitro by electron microscopy and by protection from exonuclease attack. We also showed that Rad22 specifically binds near double-strand break associated with mating type switching in vivo by chromatin immunoprecipitation analysis. This is the first evidence that a recombinational protein directly binds to DNA double-strand breaks in vivo.	Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; CHA Gen Hosp, Pochon CHA Med Sch, Genet Lab, Tokyo 135081, Japan; Los Alamos Natl Lab, Div Biosci, Los Alamos, NM 87545 USA	Seoul National University (SNU); United States Department of Energy (DOE); Los Alamos National Laboratory	Park, SD (corresponding author), Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea.	sdpark@plaza.snu.ac.kr	Park, Min Sung/HCH-2207-2022; Song, Minsun/I-5701-2015	KIM, Jae Bum/0000-0003-2337-6935				Ayoub N, 1999, GENETICS, V152, P495; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Benson FE, 1998, NATURE, V391, P401, DOI 10.1038/34937; Ekwall K, 1997, CELL, V91, P1021, DOI 10.1016/S0092-8674(00)80492-4; Fortunato EA, 1996, MUTAT RES-DNA REPAIR, V364, P147, DOI 10.1016/S0921-8777(96)00022-5; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; Haber JE, 1999, NATURE, V398, P665, DOI 10.1038/19423; Hecht A, 1999, METHOD ENZYMOL, V304, P399; HEIM L, 1990, CURR GENET, V17, P13, DOI 10.1007/BF00313243; Kanaar R, 1998, NATURE, V391, P335, DOI 10.1038/34790; Malkova A, 1996, P NATL ACAD SCI USA, V93, P7131, DOI 10.1073/pnas.93.14.7131; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; Muris DFR, 1997, CURR GENET, V31, P248, DOI 10.1007/s002940050202; Nasim A., 1989, MOL BIOL FISSION YEA; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; OSTERMANN K, 1993, NUCLEIC ACIDS RES, V21, P5940, DOI 10.1093/nar/21.25.5940; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Rijkers T, 1998, MOL CELL BIOL, V18, P6423, DOI 10.1128/MCB.18.11.6423; SCHLAKE C, 1993, MUTAT RES, V294, P59, DOI 10.1016/0921-8777(93)90058-O; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P387, DOI 10.1016/S0968-0004(00)89085-4; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; Sugiyama T, 1998, P NATL ACAD SCI USA, V95, P6049, DOI 10.1073/pnas.95.11.6049; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; Suto K, 1999, MOL BIOL CELL, V10, P3331, DOI 10.1091/mbc.10.10.3331; Van Dyck E, 1999, NATURE, V398, P728, DOI 10.1038/43942; Wilson S, 1999, NUCLEIC ACIDS RES, V27, P2655, DOI 10.1093/nar/27.13.2655; Yamaguchi-Iwai Y, 1998, MOL CELL BIOL, V18, P6430, DOI 10.1128/MCB.18.11.6430	28	25	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35607	35611		10.1074/jbc.M007060200	http://dx.doi.org/10.1074/jbc.M007060200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10956666	hybrid			2022-12-25	WOS:000165422800102
J	Laser, M; Willey, CD; Jiang, WJ; Cooper, G; Menick, DR; Zile, MR; Kuppuswamy, D				Laser, M; Willey, CD; Jiang, WJ; Cooper, G; Menick, DR; Zile, MR; Kuppuswamy, D			Integrin activation and focal complex formation in cardiac hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; CELL-CYCLE PROGRESSION; ADHESION KINASE FAK; SRC FAMILY KINASES; MYOCYTES IN-VITRO; PROTEIN-KINASE; C-SRC; FIBRONECTIN RECEPTOR; TYROSINE PHOSPHORYLATION; CONTRACTILE DYSFUNCTION	Cardiac hypertrophy is characterized by both remodeling of the extracellular matrix (ECM) and hypertrophic growth of the cardiocytes. Here we show increased expression and cytoskeletal association of the ECM: proteins fibronectin and vitronectin in pressure-overloaded feline myocardium. These changes are accompanied by cytoskeletal binding and phosphorylation of focal adhesion kinase (FAK) at Tyr-397 and Tyr-925, c-Src at Tyr-416, recruitment of the adapter proteins p130(Cas), Shc, and Nck, and activation of the extracellular-regulated: kinases ERK1/2. A synthetic peptide containing the Arg-Gly-Asp (RGD) motif of fibronectin and vitronectin was used to stimulate adult feline cardiomyocytes cultured on laminin or within a type-1 collagen matrix. Whereas cardiocytes under both conditions showed RGD-stimulated ERK1/2 activation, only collagen-embedded cells exhibited cytoskeletal assembly of FAK, c-Src, Nck, and Shc. In ROD-stimulated collagen-embedded cells, FAK was phosphorylated only at Tyr-397 and; c-Src association occurred without Tyr-416 phosphorylation and p130(Cas) association. Therefore, c-Src activation is not required for its cytoskeletal binding:but may be important for additional phosphorylation of:FAK. Overall, our study suggests that multiple signaling pathways originate in pressure-overloaded heart following integrin engagement with ECM proteins, including focal complex formation and ERK1/2 activation, and many of these pathways can be activated in cardiomyocytes via RGD-stimulated integrin activation.	Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Cell Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Physiol, Charleston, SC 29425 USA; Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Div Cardiol, Charleston, SC 29425 USA; Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Kuppuswamy, D (corresponding author), Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Cell Biol, 114 Doughty St, Charleston, SC 29425 USA.	kuppusd@musc.edu		Willey, Christopher/0000-0001-9953-0279; Zile, Michael/0000-0001-7076-221X	NHLBI NIH HHS [HL-48788] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048788] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; Belkin AM, 1996, J CELL BIOL, V132, P211, DOI 10.1083/jcb.132.1.211; BLATTI SP, 1988, P NATL ACAD SCI USA, V85, P1119, DOI 10.1073/pnas.85.4.1119; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; Cary LA, 1999, HISTOL HISTOPATHOL, V14, P1001, DOI 10.14670/HH-14.1001; COOPER G, 1987, ANNU REV PHYSIOL, V49, P501, DOI 10.1146/annurev.ph.49.030187.002441; COOPER G, 1973, CIRC RES, V33, P213, DOI 10.1161/01.RES.33.2.213; DANEN EHJ, 1995, J BIOL CHEM, V270, P21612, DOI 10.1074/jbc.270.37.21612; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; Farhadian F, 1996, CARDIOVASC RES, V32, P433, DOI 10.1016/S0008-6363(96)00119-8; Fassler R, 1996, J CELL SCI, V109, P2989; FRANCIS GS, 1994, CURR OPIN CARDIOL, V9, P280, DOI 10.1097/00001573-199405000-00004; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; Green LJ, 1998, INT J BIOCHEM CELL B, V30, P179, DOI 10.1016/S1357-2725(97)00107-6; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; Hefti MA, 1997, J MOL CELL CARDIOL, V29, P2873, DOI 10.1006/jmcc.1997.0523; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Horwitz AR, 1999, SCIENCE, V286, P1102, DOI 10.1126/science.286.5442.1102; Jaffe R, 1997, ADV EXP MED BIOL, V430, P257; Kasi VS, 1999, MOL CELL BIOL, V19, P6858; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kuppuswamy D, 1997, J BIOL CHEM, V272, P4500, DOI 10.1074/jbc.272.7.4500; Laser M, 1998, J BIOL CHEM, V273, P24610, DOI 10.1074/jbc.273.38.24610; LASER M, 2000, HYPERTROPHIED HEART, P143; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; MANN DL, 1991, CIRC RES, V68, P402, DOI 10.1161/01.RES.68.2.402; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MULLER JG, 1998, SCIENCE, V282, pA1007; Nagai T, 1999, AM J CARDIOL, V83, p38H; Ogawa E, 2000, J MOL CELL CARDIOL, V32, P765, DOI 10.1006/jmcc.2000.1119; Page C, 1996, MOL CELL BIOCHEM, V157, P49; Pasqualini R, 1996, BRAZ J MED BIOL RES, V29, P1151; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; Ross RS, 1998, CIRC RES, V82, P1160, DOI 10.1161/01.RES.82.11.1160; ROZICH JD, 1995, J MOL CELL CARDIOL, V27, P485, DOI 10.1016/S0022-2828(08)80044-2; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RYSECK RP, 1989, EXP CELL RES, V180, P537, DOI 10.1016/0014-4827(89)90080-3; SADOSHIMA J, 1995, CIRC RES, V77, P1040, DOI 10.1161/01.RES.77.6.1040; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SAMUEL JL, 1991, J CLIN INVEST, V88, P1737, DOI 10.1172/JCI115492; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwarzbauer JE, 1999, CURR OPIN CELL BIOL, V11, P622, DOI 10.1016/S0955-0674(99)00017-4; Sechler JL, 1997, MOL BIOL CELL, V8, P2563, DOI 10.1091/mbc.8.12.2563; Sieg DJ, 1999, J CELL SCI, V112, P2677; Smilenov LB, 1999, SCIENCE, V286, P1172, DOI 10.1126/science.286.5442.1172; TSUTSUI H, 1993, SCIENCE, V260, P682, DOI 10.1126/science.8097594; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Yang JT, 1996, MOL BIOL CELL, V7, P1737, DOI 10.1091/mbc.7.11.1737; YAZAKI Y, 1992, BASIC RES CARDIOL, V87, P11; Zou YZ, 1998, CIRC RES, V82, P337, DOI 10.1161/01.RES.82.3.337	59	101	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35624	35630		10.1074/jbc.M006124200	http://dx.doi.org/10.1074/jbc.M006124200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10958798	hybrid			2022-12-25	WOS:000165422800105
J	Thompson, JE; Fahnestock, S; Farrall, L; Liao, DI; Valent, B; Jordan, DB				Thompson, JE; Fahnestock, S; Farrall, L; Liao, DI; Valent, B; Jordan, DB			The second naphthol reductase of fungal melanin biosynthesis in Magnaporthe grisea - Tetrahydroxynaphthalene reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCYTALONE DEHYDRATASE INHIBITORS; RICE BLAST FUNGICIDES; ACTIVE-SITE; 1,3,8-TRIHYDROXYNAPHTHALENE REDUCTASE; CRYSTAL-STRUCTURE; COMPLEX; DESIGN; MUTAGENESIS; PENETRATION; RESOLUTION	Mutants of Magnaporthe grisea harboring a defective gene for 1,3,8-trihydroxynaphthalene reductase retain the capability to produce scytalone, thus suggesting the existence of a second naphthol reductase that can catalyze the reduction of 1,3,6,8-tetrahydroxynaphthalene to scytalone within the fungal melanin biosynthetic pathway. The second naphthol reductase gene was cloned from M. grisea by identification of cDNA fragments with weak homology to the cDNA of trihydroxynaphthalene reductase. The amino acid sequence for the second naphthol reductase is 46% identical to that of trihydroxynaphthalene reductase. The second naphthol reductase was produced in Esherichia coli and purified to homogeneity. Substrate competition experiments indicate that the second reductase prefers tetrahydroxynaphthalene over trihydroxynaphthalene by a factor of 310; trihydroxynaphthalene reductase prefers trihydroxynaphthalene over tetrahydroxynaphthalene by a factor of 4.2. On the basis of the 1300-fold difference in substrate specificities between the two reductases, the second reductase is designated tetrahydroxynaphthalene reductase, Tetrahydroxynaphthalene reductase has a 200-fold larger K-i for the fungicide tricyclazole than that of trihydroxynaphthalene reductase, and this accounts for the latter enzyme being the primary physiological target of the fungicide. M. grisea mutants lacking activities for both trihydroxynaphthalene and tetrahydroxynaphthalene reductases do not produce scytalone, indicating that there are no other metabolic routes to scytalone.	Dupont Merck Pharmaceut Co, Expt Stn, Wilmington, DE 19880 USA; DuPont Agr Prod, Wilmington, DE 19880 USA; Dupont Co, Cent Res & Dev, Wilmington, DE 19880 USA; DuPont Agr Prod, Stine Haskell Res Ctr, Newark, DE 19714 USA	DuPont; DuPont; DuPont; DuPont	Jordan, DB (corresponding author), Dupont Merck Pharmaceut Co, Expt Stn, Rt 141 & Henry Clay Rd, Wilmington, DE 19880 USA.			Valent, Barbara/0000-0002-5088-3345				Andersson A, 1996, PROTEINS, V24, P525, DOI 10.1002/(SICI)1097-0134(199604)24:4<525::AID-PROT14>3.0.CO;2-N; Andersson A, 1997, FEBS LETT, V400, P173, DOI 10.1016/S0014-5793(96)01382-8; Andersson A, 1996, STRUCTURE, V4, P1161, DOI 10.1016/S0969-2126(96)00124-4; Basarab GS, 1999, BIOORG MED CHEM LETT, V9, P1613, DOI 10.1016/S0960-894X(99)00247-4; Basarab GS, 1999, BIOCHEMISTRY-US, V38, P6012, DOI 10.1021/bi982952b; Bechinger C, 1999, SCIENCE, V285, P1896, DOI 10.1126/science.285.5435.1896; BELL AA, 1986, ANNU REV PHYTOPATHOL, V24, P411, DOI 10.1146/annurev.py.24.090186.002211; Chen JM, 1998, BIOCHEMISTRY-US, V37, P17735, DOI 10.1021/bi981848r; CHUMLEY FG, 1990, MOL PLANT MICROBE IN, V3, P135, DOI 10.1094/MPMI-3-135; FERSHT A, 1984, ENZYME STRUCTURE MEC, P109; Guncar G, 1998, STRUCTURE, V6, P51; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HOWARD RJ, 1989, EXP MYCOL, V13, P403, DOI 10.1016/0147-5975(89)90036-4; Howard RJ, 1996, ANNU REV MICROBIOL, V50, P491, DOI 10.1146/annurev.micro.50.1.491; ISHIDA M, 1975, NOYAKU KAGAKU, V3, P10; Jennings LD, 1999, BIOORG MED CHEM LETT, V9, P2509, DOI 10.1016/S0960-894X(99)00424-2; Jordan DB, 2000, BIOCHEMISTRY-US, V39, P8593, DOI 10.1021/bi000467m; Jordan DB, 2000, BIOCHEMISTRY-US, V39, P2276, DOI 10.1021/bi991839y; Jordan DB, 1999, BIOORG MED CHEM LETT, V9, P1607, DOI 10.1016/S0960-894X(99)00246-2; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Jornvall H, 1999, FEBS LETT, V445, P261, DOI 10.1016/S0014-5793(99)00130-1; Kurahashi Y, 1997, J PESTIC SCI, V22, P108; Liao DI, 2000, BIOORG MED CHEM LETT, V10, P491, DOI 10.1016/S0960-894X(00)00037-8; MINOR W, 1993, BIOCHEMISTRY-US, V32, P6320, DOI 10.1021/bi00076a003; Nakasako M, 1998, BIOCHEMISTRY-US, V37, P9931, DOI 10.1021/bi980321b; PERRY KM, 1993, BIOCHEMISTRY-US, V32, P7116, DOI 10.1021/bi00079a007; SAMBROOK J, 1989, MOL CLONGING LAB MAN; SCHONER BE, 1990, METHOD ENZYMOL, V185, P94; Sweigard JA, 1998, MOL PLANT MICROBE IN, V11, P404, DOI 10.1094/MPMI.1998.11.5.404; Thompson JE, 1998, ANAL BIOCHEM, V256, P7, DOI 10.1006/abio.1997.2490; Thompson JE, 1997, BIOCHEMISTRY-US, V36, P1852, DOI 10.1021/bi962355u; Thompson JE, 1998, ANAL BIOCHEM, V256, P1, DOI 10.1006/abio.1997.2489; TOKOUSBALIDES MC, 1978, PESTIC BIOCHEM PHYS, V8, P26, DOI 10.1016/0048-3575(78)90089-5; Tsuji G, 1997, PESTIC BIOCHEM PHYS, V57, P211, DOI 10.1006/pest.1997.2272; VIDALCROS A, 1994, EUR J BIOCHEM, V219, P985, DOI 10.1111/j.1432-1033.1994.tb18581.x; VIVIANI F, 1992, NEW J CHEM, V16, P81; VIVIANI F, 1993, B SOC CHIM FR, V136, P395; VOET D, 1995, BIOCHEMISTRY-US, P617; Ward WHJ, 1999, BIOCHEMISTRY-US, V38, P12514, DOI 10.1021/bi9907779; Wawrzak Z, 1999, PROTEINS, V35, P425, DOI 10.1002/(SICI)1097-0134(19990601)35:4<425::AID-PROT6>3.3.CO;2-T; WOLOSHUK CP, 1981, PESTIC SCI, V12, P86, DOI 10.1002/ps.2780120113; YASUEDA H, 1991, APPL MICROBIOL BIOT, V36, P211, DOI 10.1007/BF00164422	42	113	124	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					34867	34872		10.1074/jbc.M006659200	http://dx.doi.org/10.1074/jbc.M006659200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10956664	hybrid			2022-12-25	WOS:000165422800008
J	Hua, XX; Miller, ZA; Benchabane, H; Wrana, JL; Lodish, HF				Hua, XX; Miller, ZA; Benchabane, H; Wrana, JL; Lodish, HF			Synergism between transcription factors TFE3 and Smad3 in transforming growth factor-beta-induced transcription of the Smad7 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR INHIBITOR-1 GENE; TGF-BETA; PROTEINS; COOPERATION; PROMOTER; COACTIVATOR; ANTAGONIST; RESPONSES; RECEPTOR; FAST-1	Activation of transforming growth factor-beta (TGF-beta) receptors triggers phosphorylation of Smad2 and Smad3. After binding to Smad4, the complex enters the nucleus and interacts with other transcription factors to activate gene transcription. Unlike other Smads, Smad7 inhibits phosphorylation of Smad2 and Smad3, and its transcription is induced by TGF-beta, suggesting a negative feedback loop. Here, we show that TFE3 and Smad3 synergistically mediate TGF-beta -induced transcription from the Smad7 promoter by binding to an E-box and two adjacent Smad binding elements (SBEs ), respectively. A precise 3-base pair spacer between one SEE and the E-box is essential. Previously, me showed that a similar arrangement between a SEE and an E-box of an element is essential for TGF-beta -dependent transcription of the plasminogen activator inhibitor-1 gene (PAI-1) and that TGF-beta -induced phosphorylation of Smad3 triggers its association with TFE3. Thus, TFE3-Smad3 response elements may represent a common target for TGF-beta -induced gene expression.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Lodish, HF (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	lodish@wi.mit.edu	Wrana, Jeffrey/F-8857-2013		NATIONAL CANCER INSTITUTE [R01CA063260, K01CA078592] Funding Source: NIH RePORTER; NCI NIH HHS [CA78592-02, CA63260] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; Brodin G, 2000, J BIOL CHEM, V275, P29023, DOI 10.1074/jbc.M002815200; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Denissova NG, 2000, P NATL ACAD SCI USA, V97, P6397, DOI 10.1073/pnas.090099297; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Ishisaki A, 1998, J BIOL CHEM, V273, P24293, DOI 10.1074/jbc.273.38.24293; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kleeff J, 1999, ONCOGENE, V18, P5363, DOI 10.1038/sj.onc.1202909; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1999, J CLIN INVEST, V104, P5, DOI 10.1172/JCI6094; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Sambrook J, 1989, MOL CLONING; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Stopa M, 2000, MAMM GENOME, V11, P169, DOI 10.1007/s003350010032; Stopa M, 2000, J BIOL CHEM, V275, P29308, DOI 10.1074/jbc.M003282200; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Wong C, 1999, MOL CELL BIOL, V19, P1821; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	31	57	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33205	33208		10.1074/jbc.C000568200	http://dx.doi.org/10.1074/jbc.C000568200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10973944	hybrid			2022-12-25	WOS:000090104600006
J	Harms, C; Lautenschlager, M; Bergk, A; Freyer, D; Weih, M; Dirnagl, U; Weber, JR; Hortnagl, H				Harms, C; Lautenschlager, M; Bergk, A; Freyer, D; Weih, M; Dirnagl, U; Weber, JR; Hortnagl, H			Melatonin is protective in necrotic but not in caspase-dependent, free radical-independent apoptotic neuronal cell death in primary neuronal cultures	FASEB JOURNAL			English	Article						ethylcholine aziridinium (AF64A); staurosporine; oxygen-glucose deprivation; cortex; oxidative stress	ETHYLCHOLINE AZIRIDINIUM AF64A; RAT CORTICAL-NEURONS; NF-KAPPA-B; HIPPOCAMPAL-NEURONS; OXIDATIVE STRESS; CHOLINERGIC HYPOFUNCTION; DOPAMINERGIC-NEURONS; EMBRYONIC NEURONS; HYDROGEN-PEROXIDE; AMYLOID PEPTIDE	To assess the neuroprotective potential of melatonin in apoptotic neuronal cell death, we investigated the efficacy of melatonin in serum-free primary neuronal cultures of rat cortex by using three different models of caspase-dependent apoptotic, excitotoxin-independent neurodegeneration and com pared it to that in necrotic neuronal damage. Neuronal apoptosis was induced by either staurosporine or the neurotoxin ethylcholine aziridinium (AF64A) with a delayed occurrence of apoptotic cell death (within 72 h). The apoptotic component of oxygen-glucose deprivation (OGD) unmasked by glutamate antagonists served as a third model. As a model for necrotic cell death, OGD was applied. Neuronal injury was quantified by LDH release and loss of metabolic activity. Although melatonin (0.5 mM) partly protected cortical neurons from OGD-induced necrosis, as measured by a significant reduction in LDH release, it was not effective in all three models of apoptotic cell death. In contrast, exaggeration of neuronal damage by melatonin was observed in native cultures as well as after induction of apoptosis. The present data suggest that the neuroprotectiveness of melatonin strongly depends on the model of neuronal cell death applied. As demonstrated in three different models of neuronal apoptosis, the progression of the apoptotic type of neuronal cell death cannot be withhold or is even exaggerated by melatonin, in contrast to its beneficial effect in the necrotic type of cell death.	Humboldt Univ, Fac Med Charite, Inst Pharmacol & Toxicol, D-10098 Berlin, Germany; Humboldt Univ, Fac Med Charite, Dept Neurol, D-10098 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Hortnagl, H (corresponding author), Humboldt Univ, Fac Med Charite, Inst Pharmacol & Toxicol, Dorotheensr 94, D-10098 Berlin, Germany.	heide.hoertnagl@charite.de	Harms, Christoph/AAD-7895-2021; Harms, Christoph/HIK-2989-2022	Harms, Christoph/0000-0002-2063-2860; Dirnagl, Ulrich/0000-0003-0755-6119				ACUNACASTROVIEJ.D, 1997, LIFE SCI, V60, P23; Ahlemeyer B, 1998, NEUROSCI LETT, V246, P93, DOI 10.1016/S0304-3940(98)00242-0; Antolin I, 1996, FASEB J, V10, P882, DOI 10.1096/fasebj.10.8.8666165; Barsacchi R, 1998, FREE RADICAL BIO MED, V24, P1187, DOI 10.1016/S0891-5849(97)00431-0; Behan WMH, 1999, BRIT J PHARMACOL, V128, P1754, DOI 10.1038/sj.bjp.0702940; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BENITEZKING G, 1993, EXPERIENTIA, V49, P635; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; BREWER GJ, 1995, J NEUROSCI RES, V42, P674, DOI 10.1002/jnr.490420510; Bruer U, 1997, FEBS LETT, V414, P117, DOI 10.1016/S0014-5793(97)00954-X; Cazevieille C, 1997, BRAIN RES, V768, P120, DOI 10.1016/S0006-8993(97)00611-2; Chen ST, 1999, EXP BRAIN RES, V124, P241, DOI 10.1007/s002210050619; Cho S, 1997, BRAIN RES, V755, P335, DOI 10.1016/S0006-8993(97)00188-1; COHEN G, 1974, J BIOL CHEM, V249, P2447; COPANI A, 1995, MOL PHARMACOL, V47, P890; Copin JC, 1998, BRAIN RES, V784, P25, DOI 10.1016/S0006-8993(97)00972-4; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; Dodel RC, 1999, MOL BRAIN RES, V64, P141, DOI 10.1016/S0169-328X(98)00318-0; FALCIERI E, 1993, BIOCHEM BIOPH RES CO, V193, P19, DOI 10.1006/bbrc.1993.1584; FISHER A, 1982, J PHARMACOL EXP THER, V222, P140; Floreani M, 1997, FASEB J, V11, P1309, DOI 10.1096/fasebj.11.14.9409550; Gibb JW, 1997, J PHARMACOL EXP THER, V283, P630; Gilad E, 1998, FASEB J, V12, P685, DOI 10.1096/fasebj.12.9.685; Giusti P, 1996, FASEB J, V10, P891, DOI 10.1096/fasebj.10.8.8666166; Gottron FJ, 1997, MOL CELL NEUROSCI, V9, P159, DOI 10.1006/mcne.1997.0618; GSCHWIND M, 1995, J NEUROCHEM, V65, P292; Gulyaeva NV, 1996, BRAIN RES, V726, P174; Hanin I, 1996, LIFE SCI, V58, P1955, DOI 10.1016/0024-3205(96)00185-3; HORTNAGL H, 1991, N-S ARCH PHARMACOL, V344, P213, DOI 10.1007/BF00167221; HUERTODELGADILLO L, 1994, J PINEAL RES, V17, P55, DOI 10.1111/j.1600-079X.1994.tb00114.x; Iacovitti L, 1997, BRAIN RES, V768, P317, DOI 10.1016/S0006-8993(97)00668-9; IANAS O, 1991, ROM J ENDOCRINOL, V29, P147; Jin BK, 1998, NEUROSCI LETT, V245, P61, DOI 10.1016/S0304-3940(98)00170-0; Kabuto H, 1998, EPILEPSIA, V39, P237, DOI 10.1111/j.1528-1157.1998.tb01367.x; Kim YS, 1998, NEUROREPORT, V9, P2387, DOI 10.1097/00001756-199807130-00043; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; Lapin IP, 1998, J PINEAL RES, V24, P215; Lautenschlager M, 1998, ADV BEHAV BIOL, V49, P681; Lautenschlager M, 2000, NEUROSCIENCE, V97, P383, DOI 10.1016/S0306-4522(99)00599-0; Lezoualch F, 1996, NEUROREPORT, V7, P2071, DOI 10.1097/00001756-199609020-00003; Lotharius J, 1999, J NEUROSCI, V19, P1284; Manev H, 1996, FASEB J, V10, P1546, DOI 10.1096/fasebj.10.13.8940301; Mayo JC, 1999, BRAIN RES, V818, P221, DOI 10.1016/S0006-8993(98)01262-1; Medina-Navarro R, 1999, ENDOCR RES, V25, P263, DOI 10.1080/07435809909066147; MELCHIORRI D, 1995, FASEB J, V9, P1205, DOI 10.1096/fasebj.9.12.7672513; Mevissen M, 1998, NEUROSCI LETT, V257, P13, DOI 10.1016/S0304-3940(98)00790-3; Mohan N, 1995, BIOCHEM MOL BIOL INT, V37, P1063; Nathan L, 1998, SEMIN REPROD ENDOCR, V16, P309, DOI 10.1055/s-2007-1016289; Paolini M, 1999, LIFE SCI, V64, pPL273, DOI 10.1016/S0024-3205(99)00167-8; Pappolla M, 1998, J BIOL CHEM, V273, P7185, DOI 10.1074/jbc.273.13.7185; Pappolla MA, 1997, J NEUROSCI, V17, P1683; POLLARD H, 1994, NEUROSCIENCE, V63, P7, DOI 10.1016/0306-4522(94)90003-5; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Reiter R, 1997, LIFE SCI, V60, P2255, DOI 10.1016/S0024-3205(97)00030-1; Reiter RJ, 1998, PROG NEUROBIOL, V56, P359, DOI 10.1016/S0301-0082(98)00052-5; REITER RJ, 1995, FASEB J, V9, P526, DOI 10.1096/fasebj.9.7.7737461; Rinner WA, 1997, NEUROSCIENCE, V79, P535, DOI 10.1016/S0306-4522(96)00687-2; Sheldon SH, 1998, LANCET, V351, P1254, DOI 10.1016/S0140-6736(05)79321-1; Skaper SD, 1998, FASEB J, V12, P725, DOI 10.1096/fasebj.12.9.725; Southgate GS, 1998, J CHEM NEUROANAT, V14, P151, DOI 10.1016/S0891-0618(98)00026-X; Tan DX, 1998, J NEUROSCI RES, V54, P382, DOI 10.1002/(SICI)1097-4547(19981101)54:3<382::AID-JNR9>3.0.CO;2-Y; Uz T, 1996, NEUROSCIENCE, V73, P631, DOI 10.1016/0306-4522(96)00155-8; Wiesner DA, 1996, J NEUROCHEM, V66, P1418; WONG SHY, 1987, CLIN CHEM, V33, P214	65	50	54	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2000	14	12					1814	1824		10.1096/fj.99-0899com	http://dx.doi.org/10.1096/fj.99-0899com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973931				2022-12-25	WOS:000089212400021
J	Si-Hoe, SL; De Bree, FM; Nijenhuis, M; Davies, JE; Howell, LMC; Tinley, H; Waller, SJ; Zeng, Q; Zalm, R; Sonnemans, M; Van Leeuwen, FW; Burbach, JPH; Murphy, D				Si-Hoe, SL; De Bree, FM; Nijenhuis, M; Davies, JE; Howell, LMC; Tinley, H; Waller, SJ; Zeng, Q; Zalm, R; Sonnemans, M; Van Leeuwen, FW; Burbach, JPH; Murphy, D			Endoplasmic reticulum derangement in hypothalamic neurons of rats expressing a familial neurohypophyseal diabetes insipidus mutant vasopressin transgene	FASEB JOURNAL			English	Article									Univ Bristol, Bristol Royal Infirm, Dept Med, Mol Neuroendocrinol Res Grp, Bristol BS2 8HW, Avon, England; Natl Univ Singapore, Inst Mol & Cell Biol, Neuropeptide Lab, Singapore 117609, Singapore; Rudolf Magnus Inst Neurosci, Dept Med Pharmacol, NL-3584 CG Utrecht, Netherlands; Netherlands Inst Brain Res, NL-1105 AZ Amsterdam, Netherlands	Bristol Royal Infirmary; University of Bristol; Agency for Science Technology & Research (ASTAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Utrecht University; Utrecht University Medical Center; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW)	Murphy, D (corresponding author), Univ Bristol, Bristol Royal Infirm, Dept Med, Mol Neuroendocrinol Res Grp, Marlborough St, Bristol BS2 8HW, Avon, England.		Murphy, David/C-3967-2012; ZENG, Qi/E-9812-2010	Murphy, David/0000-0003-2946-0353; 					0	41	41	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2000	14	12					1680	1684						5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973916				2022-12-25	WOS:000089212400006
J	Boone, E; Vanden Berghe, T; Van Loo, G; De Wilde, G; De Wael, N; Vercammen, D; Fiers, W; Haegeman, G; Vandenabeele, P				Boone, E; Vanden Berghe, T; Van Loo, G; De Wilde, G; De Wael, N; Vercammen, D; Fiers, W; Haegeman, G; Vandenabeele, P			Structure/function analysis of p55 tumor necrosis factor receptor and Fas-associated death domain - Effect on necrosis in L929sA cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TNF RECEPTOR; SIGNALING COMPLEX; INDUCED APOPTOSIS; CD95 FAS/APO-1; PROTEIN; CYTOTOXICITY; INVOLVEMENT; INTERACTS; MEMBRANE; PATHWAYS	Tumor necrosis factor (TNF) induces a typical apoptotic cell death program in various cell lines by interacting with the p55 tumor necrosis factor receptor (TNF-R55), In contrast, triggering of the fibrosarcoma cell line L929sA gives rise to characteristic cellular changes resulting in necrosis, The intracellular domain of TNF-R55 can be subdivided into two parts: a membrane-proximal domain (amino acids 202-325) and a C-terminal death domain (DD) (amino acids 326-413), which has been shown to be necessary and sufficient for apoptosis, Structure/function analysis of TNF-R55-mediated necrosis in L929sA cells demonstrated that initiation of necrotic cell death, as defined by swelling of the cells, rapid membrane permeabilization, absence of nuclear condensation, absence of DNA hypoploidy, and generation of mitochondrial reactive oxygen intermediates, is also confined to the DD, The striking synergistic effect of the caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone on TNF-induced necrosis was also observed with receptors solely containing the DD, TNF-R55-mediated necrosis is not affected by the dominant negative deletion mutant of the Fas-associated death domain (FADD-(80-205)) that lacks the N-terminal death effector domain. Moreover, overexpression of FADD-(80-205) in L929sA is cytotoxic and insensitive to CrmA, while the cytotoxicity due to over-expression of the deletion mutant FADD-(1-111) lacking the DD is prevented by CrmA These results demonstrate that the death domain of FADD can elicit an active necrotic cell death pathway.	Flanders Interuniv Inst Biotechnol, Dept Mol Biol, B-9000 Ghent, Belgium; State Univ Ghent, B-9000 Ghent, Belgium	Ghent University	Vandenabeele, P (corresponding author), Flanders Interuniv Inst Biotechnol, Dept Mol Biol, KL Ledeganckstr 35, B-9000 Ghent, Belgium.		Vercammen, Dominique/A-4237-2008; , van Loo Geert/AAD-1220-2019; Vanden Berghe, Tom/C-4916-2009; Berghe, Tom Vanden/N-2902-2019; Vandenabeele, Peter/C-8597-2009; van Loo, Geert/C-1505-2009; Vandenabeele, Peter/AAD-5793-2022	, van Loo Geert/0000-0002-8427-4775; Vanden Berghe, Tom/0000-0002-1633-0974; Berghe, Tom Vanden/0000-0002-1633-0974; Vandenabeele, Peter/0000-0002-6669-8822				Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Boone E, 1998, FEBS LETT, V441, P275, DOI 10.1016/S0014-5793(98)01567-1; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; De Vos K, 1998, J BIOL CHEM, V273, P9673, DOI 10.1074/jbc.273.16.9673; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Fiers W, 1996, J INFLAMM, V47, P67; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; FONES E, 1989, BIOCHEM PHARMACOL, V38, P3443, DOI 10.1016/0006-2952(89)90113-5; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; GROOTEN J, 1993, CYTOKINE, V5, P546, DOI 10.1016/S1043-4666(05)80003-1; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Jones SJ, 1999, J IMMUNOL, V162, P1042; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Khwaja A, 1999, J BIOL CHEM, V274, P36817, DOI 10.1074/jbc.274.51.36817; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; LASTER SM, 1988, J IMMUNOL, V141, P2629; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Lemasters JJ, 1998, BIOFACTORS, V8, P283, DOI 10.1002/biof.5520080316; Luschen S, 2000, J BIOL CHEM, V275, P24670, DOI 10.1074/jbc.M003280200; Martinon F, 2000, FEBS LETT, V468, P134, DOI 10.1016/S0014-5793(00)01212-6; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Van de Craen M, 1997, FEBS LETT, V403, P61, DOI 10.1016/S0014-5793(97)00026-4; VANDENABEELE P, 1995, J IMMUNOL, V154, P2904; VANHAESEBROECK B, 1991, CANCER RES, V51, P2469; Varfolomeev EE, 1996, J EXP MED, V183, P1271, DOI 10.1084/jem.183.3.1271; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Vercammen D, 1997, CYTOKINE, V9, P801, DOI 10.1006/cyto.1997.0252; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	48	28	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37596	37603		10.1074/jbc.M007166200	http://dx.doi.org/10.1074/jbc.M007166200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10988295	hybrid			2022-12-25	WOS:000165618700041
J	Barberis, L; Wary, KK; Fiucci, G; Liu, F; Hirsch, E; Brancaccio, M; Altruda, F; Tarone, G; Giancotti, FG				Barberis, L; Wary, KK; Fiucci, G; Liu, F; Hirsch, E; Brancaccio, M; Altruda, F; Tarone, G; Giancotti, FG			Distinct roles of the adaptor protein Shc and focal adhesion kinase in integrin signaling to ERK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED CELL-ADHESION; JUN NH2-TERMINAL KINASE; MAP KINASE; TYROSINE PHOSPHORYLATION; C-SRC; B-RAF; GROWTH-FACTOR; ACTIVATION; FIBRONECTIN; PATHWAYS	It has been proposed that integrins activate ERK through the adaptor protein She independently of focal adhesion kinase (FAK) or through FAK acting on multiple target effecters, including She. We show that disrupt ion of the actin cytoskeleton by cytochalasin D causes a complete inhibition of FAK. but does not inhibit She signaling and activation of ERK. We have then generated primary fibroblasts carrying a targeted deletion of the segment of beta (1) subunit cytoplasmic domain required for activation of FAK Analysis of these cells indicates that FAK is not necessary for efficient tyrosine phosphorylation of She, association of She with Grb2, and activation of ERK in response to matrix adhesion. In addition, integrin-mediated activation of FAK does not appear to be required for signaling to ERK following growth factor stimulation. To examine if FAK could contribute to the activation of ERK in a cell type-specific manner through the Rap1/B-Raf pathway, we have used Swiss-3T3 cells, which in contrast to primary fibroblasts express B-Raf. Dominant negative studies indicate that She mediates the early phase and peak, whereas FAK, p130(CAS), Crk, and Rap1 contribute to the late phase of integrin-dependent activation of ERK in these cells. In addition, introduction of B-Raf enhances and sustains integrin-mediated activation of ERK in wild-type primary fibroblasts but not in those carrying the targeted deletion of the beta (1) cytoplasmic domain. Thus, the She and FAK pathways are activated independently and function in a parallel fashion. Although not necessary for signaling to ERK in primary fibroblasts, FAH may enhance and prolong integrin-mediated activation of ERK through p130(CAS), Crk, and Rap1 in cells expressing B-Raf.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Univ Turin, Dipartimento Genet Biol & Chim Med, I-10100 Turin, Italy	Memorial Sloan Kettering Cancer Center; University of Turin	Giancotti, FG (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave,Box 216, New York, NY 10021 USA.	F-Giancotti@ski.mskcc.org	Hirsch, Emilio/F-4848-2013	Hirsch, Emilio/0000-0002-9073-6024; Tarone, Guido/0000-0003-4805-086X; Wary, Kishore/0000-0001-8851-8565	NCI NIH HHS [P30 CA08748, R01 CA78901] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078901, P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; Buensuceso CS, 2000, J BIOL CHEM, V275, P13118, DOI 10.1074/jbc.275.17.13118; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Clark EA, 1997, BBA-REV CANCER, V1333, pR9, DOI 10.1016/S0304-419X(97)00028-0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; de Jong R, 1998, ONCOGENE, V17, P2805, DOI 10.1038/sj.onc.1202207; DEFILIPPI P, 1995, EXP CELL RES, V221, P141, DOI 10.1006/excr.1995.1361; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; Giancotti FG, 2000, NAT CELL BIOL, V2, pE13, DOI 10.1038/71397; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Howe AK, 1998, J BIOL CHEM, V273, P27268, DOI 10.1074/jbc.273.42.27268; Huang S, 1999, NAT CELL BIOL, V1, pE131, DOI 10.1038/13043; Ichiba T, 1999, J BIOL CHEM, V274, P14376, DOI 10.1074/jbc.274.20.14376; Igishi T, 1999, J BIOL CHEM, V274, P30738, DOI 10.1074/jbc.274.43.30738; ILLC D, 1995, NATURE, V377, P539; Ishimaru S, 1999, EMBO J, V18, P145, DOI 10.1093/emboj/18.1.145; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Lai KMV, 2000, GENE DEV, V14, P1132; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEWIS JM, 1995, MOL BIOL CELL, V6, P151, DOI 10.1091/mbc.6.2.151; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Lock P, 1998, EMBO J, V17, P4346, DOI 10.1093/emboj/17.15.4346; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; Miranti CK, 1999, J BIOL CHEM, V274, P10571, DOI 10.1074/jbc.274.15.10571; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; Murgia C, 1998, EMBO J, V17, P3940, DOI 10.1093/emboj/17.14.3940; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Patil S, 1999, J BIOL CHEM, V274, P28575, DOI 10.1074/jbc.274.40.28575; Pozzi M, 1998, J CELL BIOL, V142, P587; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; Renshaw MW, 1999, J CELL BIOL, V147, P611, DOI 10.1083/jcb.147.3.611; Retta SF, 1999, METH MOL B, V96, P119; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; SAMPATH P, 1991, BIOCHEMISTRY-US, V30, P1973, DOI 10.1021/bi00221a034; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; SPINARDI L, 1995, J CELL BIOL, V129, P473, DOI 10.1083/jcb.129.2.473; Syu LJ, 1997, J CELL BIOCHEM, V67, P367, DOI 10.1002/(SICI)1097-4644(19971201)67:3<367::AID-JCB8>3.3.CO;2-N; Tomatis D, 1999, EXP CELL RES, V246, P421, DOI 10.1006/excr.1998.4315; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	64	148	151	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36532	36540		10.1074/jbc.M002487200	http://dx.doi.org/10.1074/jbc.M002487200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10976102	hybrid			2022-12-25	WOS:000165577700012
J	Stewart, RJ; Fredenburgh, JC; Rischke, JA; Bajzar, L; Weitz, JI				Stewart, RJ; Fredenburgh, JC; Rischke, JA; Bajzar, L; Weitz, JI			Thrombin-activable fibrinolysis inhibitor attenuates (DD)E-mediated stimulation of plasminogen activation by reducing the affinity of (DD)E for tissue plasminogen activator - A potential mechanism for enhancing the fibrin specificity of tissue plasminogen activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA CARBOXYPEPTIDASE; LYS-PLASMINOGEN; FACTOR-VA; ONE-CHAIN; COMPLEX; TAFI; KINETICS; BINDING; THROMBOMODULIN; PURIFICATION	A complex of D-dimer noncovalently associated with fragment E ((DD)E), a degradation product of crosslinked fibrin that binds tissue plasminogen activator (t-PA) and plasminogen (Pg) with affinities similar to those of fibrin, compromises the fibrin specificity of t-PA by stimulating systemic Pg activation. In this study, we examined the effect of thrombin-activable fibrinolysis inhibitor (TAFI), a latent carboxypeptidase B (CPB)-like enzyme, on the stimulatory activity of (DD)E. Incubation of (DD)E with activated TAFI (TAFIa) or CPB (a) produces a 96% reduction in the capacity of (DD)E to stimulate t-PA-mediated activation of Glu- or Lys-Pg by reducing k(cat) and increasing K-m for the reaction; (b) induces the release of 8 mol of lysine/mol of (DD)E, although most of the stimulatory activity is lost after release of only 4 mol of lysine/mol (DD)E; and (c) reduces the affinity of (DD)E for Glu-Pg, Lys-Pg, and t-PA. by 2-, 4-, and 160-fold, respectively. Because TAFIa- or CPB-exposed (DD)E produces little stimulation of Glu-Pg activation by t-PA, (DD)E is not degraded into fragment E and D-dimer, the latter of which has been reported to impair fibrin polymerization. These data suggest a novel role for TAFIa. By attenuating systemic Pg activation by (DD)E, TAFIa renders t-PA more fibrin-specific.	Hamilton Civ Hosp Res Ctr, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Hamilton, ON L8V 1C3, Canada	McMaster University; McMaster University	Weitz, JI (corresponding author), Hamilton Civ Hosp Res Ctr, 711 Concess St, Hamilton, ON L8V 1C3, Canada.		Weitz, Jeffrey/AAD-1929-2019	Weitz, Jeffrey/0000-0002-1092-7550				Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; Blanchoin L, 1996, J BIOL CHEM, V271, P12380, DOI 10.1074/jbc.271.21.12380; BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; Boffa MB, 2000, J BIOL CHEM, V275, P12868, DOI 10.1074/jbc.275.17.12868; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; BRINGMANN P, 1995, J BIOL CHEM, V270, P25596, DOI 10.1074/jbc.270.43.25596; BUDZYNSKI AZ, 1979, BIOCHIM BIOPHYS ACTA, V584, P284, DOI 10.1016/0304-4165(79)90273-3; CASTELLINO FJ, 1981, METHOD ENZYMOL, V80, P365; COLLEN D, 1986, HAEMOSTASIS, V16, P25; DELLENBACK RJ, 1970, P SOC EXP BIOL MED, V134, P353; DEVRIES C, 1989, J BIOL CHEM, V264, P12604; EATON DL, 1991, J BIOL CHEM, V266, P21833; FLEURY V, 1991, BIOCHEMISTRY-US, V30, P7630, DOI 10.1021/bi00244a035; FREDENBURGH JC, 1992, J BIOL CHEM, V267, P26150; GAEDE G, 1974, ANAL BIOCHEM, V66, P393; GAFFNEY PJ, 1979, THROMB RES, V15, P673, DOI 10.1016/0049-3848(79)90177-4; HIGGINS DL, 1987, BIOCHEMISTRY-US, V26, P7786, DOI 10.1021/bi00398a038; HIGGINS DL, 1986, ARCH BIOCHEM BIOPHYS, V249, P418, DOI 10.1016/0003-9861(86)90018-4; Horrevoets AJG, 1997, J BIOL CHEM, V272, P2183; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; HUSAIN SS, 1989, J BIOL CHEM, V264, P11414; Marx PF, 2000, J BIOL CHEM, V275, P12410, DOI 10.1074/jbc.275.17.12410; Mosesson MW, 1998, THROMB HAEMOSTASIS, V79, P796; MOSKOWITZ KA, 1994, BIOCHEMISTRY-US, V33, P12937, DOI 10.1021/bi00248a001; NAKATANI Y, 1972, ANAL BIOCHEM, V49, P225, DOI 10.1016/0003-2697(72)90261-8; NESHEIM M, 1990, J BIOL CHEM, V265, P21541; Nesheim M, 1997, THROMB HAEMOSTASIS, V78, P386; Nesheim ME, 1999, FIBRINOLYSIS PROTEOL, V13, P72, DOI 10.1016/S0268-9499(99)90082-6; NIEUWENHUIZEN W, 1988, EUR J BIOCHEM, V174, P163, DOI 10.1111/j.1432-1033.1988.tb14077.x; OLEXA SA, 1979, BIOCHEMISTRY-US, V18, P991, DOI 10.1021/bi00573a009; OLEXA SA, 1979, J BIOL CHEM, V254, P4925; OLEXA SA, 1981, BIOCHEMISTRY-US, V20, P6139, DOI 10.1021/bi00524a035; OLEXA SA, 1980, P NATL ACAD SCI-BIOL, V77, P1374, DOI 10.1073/pnas.77.3.1374; RYAN CA, 1974, J BIOL CHEM, V249, P5495; Sakharov DV, 1997, J BIOL CHEM, V272, P14477, DOI 10.1074/jbc.272.22.14477; Stewart R. J., 1998, Blood Coagulation and Fibrinolysis, V9, P691, DOI 10.1097/00001721-199810000-00065; Stewart RJ, 2000, J BIOL CHEM, V275, P10112, DOI 10.1074/jbc.275.14.10112; Stewart RJ, 1998, J BIOL CHEM, V273, P18292, DOI 10.1074/jbc.273.29.18292; Walker JB, 1999, J BIOL CHEM, V274, P5201, DOI 10.1074/jbc.274.8.5201; Wang W, 1998, J BIOL CHEM, V273, P27176, DOI 10.1074/jbc.273.42.27176; WANG W, 1994, J BIOL CHEM, V269, P15937; Weitz JI, 1999, THROMB HAEMOSTASIS, V82, P974; WEITZ JI, 1991, J CLIN INVEST, V87, P1082, DOI 10.1172/JCI115069	44	24	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36612	36620		10.1074/jbc.M005483200	http://dx.doi.org/10.1074/jbc.M005483200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10970891	hybrid			2022-12-25	WOS:000165577700023
J	Yin, L; Hubbard, AK; Giardina, C				Yin, L; Hubbard, AK; Giardina, C			NF-kappa B regulates transcription of the mouse telomerase catalytic subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSE-TRANSCRIPTASE; C-MYC; GENE; PROMOTER; CANCER; CELLS; PROLIFERATION; EXPRESSION; PROTEINS; RECEPTOR	Expression of the telomerase catalytic subunit (TERT) is the rate-limiting determinant of telomerase activity in most cells. Analysis of the mouse TERT promoter revealed a potential NF-kappaB binding site 350 base pairs upstream from the translational start site. An oligonucleotide from this region of the TERT promoter bound to proteins in a nuclear extract prepared from a mouse hepatoma cell line. These proteins were identified as NF-kappaB by a number of criteria: 1) the protein complex formed on the TERT oligonucleotide had an electrophoretic mobility similar to that formed on an NF-kappaB consensus oligonucleotide; 2) protein binding to this site was enhanced by NF-kappaB activators tumor necrosis factor-alpha, phorbol 12-myristate 13-acetate, and interleukin-1 beta; and 3) the complex was specific and could be supershifted with antibodies against the p50 or p65 NF-kappaB subunits. The NF-kappaB binding site from the mouse TERT promoter activated transcription when fused to a basal SV40 promoter and enhanced the activity of the native TERT promoter in mouse hepatoma cells stimulated with phorbol 12-myristate 13-acetate. Transcriptional activation by the TERT NF-kappaB site could also be enhanced by co-transfection with an NF-kappa B1 expression vector. NF-kappaB may therefore contribute to the activation of TERT expression observed in mouse tissue.	Univ Connecticut, Dept Mol & Cell Biol, Storrs, CT 06269 USA; Univ Connecticut, Dept Pharmaceut Sci, Storrs, CT 06269 USA	University of Connecticut; University of Connecticut	Giardina, C (corresponding author), Univ Connecticut, Dept Mol & Cell Biol, 75 N Eagleville Rd,U-125, Storrs, CT 06269 USA.							Avilion AA, 1996, CANCER RES, V56, P645; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Cerni C, 2000, MUTAT RES-REV MUTAT, V462, P31, DOI 10.1016/S1383-5742(99)00091-5; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; GRILLI M, 1993, INT REV CYTOL, V143, P1; Herrera E, 1999, EMBO J, V18, P2950, DOI 10.1093/emboj/18.11.2950; Holt SE, 1999, J CELL PHYSIOL, V180, P10, DOI 10.1002/(SICI)1097-4652(199907)180:1<10::AID-JCP2>3.0.CO;2-D; Horikawa I, 1999, CANCER RES, V59, P826; Igarashi H, 1997, BLOOD, V89, P1299, DOI 10.1182/blood.V89.4.1299; Inan MS, 2000, GASTROENTEROLOGY, V118, P724, DOI 10.1016/S0016-5085(00)70142-9; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Kyo S, 1999, CANCER RES, V59, P5917; Liu JP, 1999, FASEB J, V13, P2091, DOI 10.1096/fasebj.13.15.2091; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Schauer SL, 1996, J IMMUNOL, V157, P81; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Ueda M, 1997, CANCER RES, V57, P370; Ulaner GA, 1998, CANCER RES, V58, P4168; Ulaner GA, 2000, INT J CANCER, V85, P330, DOI 10.1002/(SICI)1097-0215(20000201)85:3<330::AID-IJC6>3.0.CO;2-U; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wick M, 1999, GENE, V232, P97, DOI 10.1016/S0378-1119(99)00108-0; Yuan XM, 1999, GENES CELLS, V4, P563, DOI 10.1046/j.1365-2443.1999.00284.x	29	100	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36671	36675		10.1074/jbc.M007378200	http://dx.doi.org/10.1074/jbc.M007378200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10970902	hybrid			2022-12-25	WOS:000165577700032
J	Jelacic, TM; Kennedy, ME; Wickman, K; Clapham, DE				Jelacic, TM; Kennedy, ME; Wickman, K; Clapham, DE			Functional and biochemical evidence for G-protein-gated inwardly rectifying K+ (GIRK) channels composed of GIRK2 and GIRK3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; RECTIFIER POTASSIUM CHANNELS; SODIUM-DEPENDENT ACTIVATION; MESSENGER-RNAS; ACH CHANNEL; RAT-BRAIN; EXPRESSION; IDENTIFICATION; LOCALIZATION; REGIONS	G-protein-gated inwardly rectifying K+ (GIRK) channels are widely expressed in the brain and are activated by at least eight different neurotransmitters. As Kt channels, they drive the transmembrane potential toward E-K when open and thus dampen neuronal excitability. There are four mammalian GIRK subunits (GIRK1-4 or Kir 3.1-4), with GIRK1 being the most unique of the four by possessing a long carboxyl-terminal tail. Early studies suggested that GIRK1 was an integral component of native GIRK channels. However, more recent data indicate that native channels can be either homo- or heterotetrameric complexes composed of several GIRK subunit combinations. The functional implications of subunit composition are poorly understood at present. The purpose of this study was to examine the functional and biochemical properties of GIRK channels formed by the co-assembly of GIRK2 and GIRK3, the most abundant GIRK subunits found in the mammalian brain. To examine the properties of a channel composed of these two subunits, we co-transfected GIRK2 and GIRK3 in CHO-K1 cells and assayed the cells for channel activity by patch clamp. The most significant difference between the putative GIRK2/GIRK3 heteromultimeric channel and GIRK1/GIRKx channels at the single channel level was an similar to5-fold lower sensitivity to activation by G beta gamma. Complexes containing only GIRK2 and GIRK3 could be immunoprecipitated from transfected cells and could be purified from native brain tissue. These data indicate that functional GIRK channels composed of GIRK2 and GIRK3 subunits exist in brain.	Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Mayo Clin & Mayo Fdn, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Mayo Clinic	Clapham, DE (corresponding author), Childrens Hosp, Howard Hughes Med Inst, Enders 1309,320 Longwood Ave, Boston, MA 02115 USA.		Clapham, David/R-5974-2019; Jelacic, Tanya/S-3173-2019; Clapham, David/S-1123-2019	Jelacic, Tanya/0000-0002-1584-5300; Clapham, David/0000-0002-4459-9428; Wickman, Kevin/0000-0002-5179-9540				Chan KW, 1997, J BIOL CHEM, V272, P6548, DOI 10.1074/jbc.272.10.6548; Chan KW, 1996, P NATL ACAD SCI USA, V93, P14193, DOI 10.1073/pnas.93.24.14193; Chen SC, 1997, BRAIN RES, V778, P251, DOI 10.1016/S0006-8993(97)00896-2; Corey S, 1998, J BIOL CHEM, V273, P27499, DOI 10.1074/jbc.273.42.27499; Dascal N, 1997, CELL SIGNAL, V9, P551, DOI 10.1016/S0898-6568(97)00095-8; Dissmann E, 1996, BIOCHEM BIOPH RES CO, V223, P474, DOI 10.1006/bbrc.1996.0918; He C, 1999, J BIOL CHEM, V274, P12517, DOI 10.1074/jbc.274.18.12517; Ho IHM, 1999, J PHYSIOL-LONDON, V520, P645, DOI 10.1111/j.1469-7793.1999.00645.x; Ho IHM, 1999, J BIOL CHEM, V274, P8639, DOI 10.1074/jbc.274.13.8639; Huang CL, 1997, FEBS LETT, V405, P291, DOI 10.1016/S0014-5793(97)00197-X; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Isomoto S, 1996, BIOCHEM BIOPH RES CO, V218, P286, DOI 10.1006/bbrc.1996.0050; Jelacic TM, 1999, J MEMBRANE BIOL, V169, P123, DOI 10.1007/s002329900524; Karschin C, 1996, J NEUROSCI, V16, P3559; Kennedy ME, 1996, NEUROPHARMACOLOGY, V35, P831, DOI 10.1016/0028-3908(96)00132-3; Kennedy ME, 1999, J BIOL CHEM, V274, P2571, DOI 10.1074/jbc.274.4.2571; KOBAYASHI T, 1995, BIOCHEM BIOPH RES CO, V208, P1166, DOI 10.1006/bbrc.1995.1456; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P28777, DOI 10.1074/jbc.270.48.28777; Krapivinsky G, 1998, J BIOL CHEM, V273, P16946, DOI 10.1074/jbc.273.27.16946; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUNKEL MT, 1995, CELL, V83, P443, DOI 10.1016/0092-8674(95)90122-1; LESAGE F, 1995, J BIOL CHEM, V270, P28660, DOI 10.1074/jbc.270.48.28660; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; Navarro B, 1996, SCIENCE, V272, P1950, DOI 10.1126/science.272.5270.1950; Petit-Jacques J, 1999, J GEN PHYSIOL, V114, P673, DOI 10.1085/jgp.114.5.673; Schoots O, 1999, CELL SIGNAL, V11, P871, DOI 10.1016/S0898-6568(99)00059-5; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; Spauschus A, 1996, J NEUROSCI, V16, P930; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; VELIMIROVIC BM, 1996, FEBS LETT, V379, P91; Vivaudou M, 1997, J BIOL CHEM, V272, P31553, DOI 10.1074/jbc.272.50.31553; Wei JJ, 1998, GENOMICS, V51, P379, DOI 10.1006/geno.1998.5369; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; Wischmeyer E, 1997, MOL CELL NEUROSCI, V9, P194, DOI 10.1006/mcne.1997.0614	35	85	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36211	36216		10.1074/jbc.M007087200	http://dx.doi.org/10.1074/jbc.M007087200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10956667	hybrid			2022-12-25	WOS:000165382000080
J	Prigent, M; Barlat, I; Langen, H; Dargemont, C				Prigent, M; Barlat, I; Langen, H; Dargemont, C			I kappa B alpha and I kappa B alpha/NF-kappa B complexes are retained in the cytoplasm through interaction with a novel partner, RasGAP SH3-binding protein 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT SIGNAL; DNA-BINDING SUBUNIT; TRANSCRIPTION FACTOR; KINASE COMPLEX; PORE COMPLEX; TYROSINE PHOSPHORYLATION; INDUCED DEGRADATION; P50 PRECURSOR; P62 COMPLEX; ACTIVATION	I kappaB alpha inhibits the transcriptional activity of NF-kappaB both in the cytoplasm by preventing the nuclear translocation of NF-kappaB and in the nucleus where it dissociates NF-kappaB from DNA and transports it back to the cytoplasm, Cytoplasmic localization of inactive NF-kappaB/I kappaB alpha complexes is controlled by mutual masking of nuclear import sequences of NF-kappaB p65 and I kappaB alpha and active CRM1-mediated nuclear export. Here, we describe an additional mechanism accounting for the cytoplasmic anchoring of I kappaB alpha or NF-kappaB/I kappaB alpha complexes. The N-terminal domain of I kappaB alpha contains a sequence responsible for the cytoplasmic retention of I kappaB alpha that is specifically recognized by G3BP2, a cytoplasmic protein that interacts with both IKB alpha and I kappaB alpha /NF-kappaB complexes. G3BP2 is composed of an N-terminal domain homologous to the NTF2 protein, followed by an acidic domain sufficient for the interaction with the I kappaB alpha cytoplasmic retention sequence, a region containing five PXXP motifs and a C-terminal domain containing RNA-binding motifs. Overexpression of G3BP2 directly promotes retention of I kappaB alpha in the cytoplasm, indicating that subcellular distribution of I kappaB alpha and NF-kappaB/I kappaB alpha complexes likely results from a equilibrium between nuclear import, nuclear export, and cytoplasmic retention. The molecular organization of G3BP2 suggests that this putative scaffold protein might connect the NF-kappaB signal transduction cascade with cellular functions such as nuclear transport or RNA metabolism.	Inst Curie, CNRS UMR144, Lab Transport Nucleoytoplasm, F-75248 Paris 05, France; Avantis Pharma, F-94403 Vitry, France; Hoffmann La Roche Ag, PRPN G, CH-4070 Basel, Switzerland	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Roche Holding	Dargemont, C (corresponding author), Inst Jacques Monod, CNRS UMR 7592, Lab Transport Nucleoytoplasm, Tour 43,2 Pl Jussieu, F-75251 Paris 05, France.							ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Bachelerie F, 1997, J CELL SCI, V110, P2883; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bauerle PA, 1996, CELL, V87, P13; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Cheng JD, 1998, J EXP MED, V188, P1055, DOI 10.1084/jem.188.6.1055; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Costa M, 1999, NUCLEIC ACIDS RES, V27, P817, DOI 10.1093/nar/27.3.817; de Lera TL, 1999, ONCOGENE, V18, P1581, DOI 10.1038/sj.onc.1202455; DeFranco DB, 1995, VITAM HORM, V51, P315, DOI 10.1016/S0083-6729(08)61043-2; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fritz CC, 1996, CURR BIOL, V6, P848, DOI 10.1016/S0960-9822(02)00608-5; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gallouzi IE, 1998, MOL CELL BIOL, V18, P3956, DOI 10.1128/MCB.18.7.3956; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GUAN TL, 1995, MOL BIOL CELL, V6, P1591, DOI 10.1091/mbc.6.11.1591; HANKE T, 1992, J GEN VIROL, V73, P653, DOI 10.1099/0022-1317-73-3-653; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; Hirano F, 1998, MOL CELL BIOL, V18, P2596, DOI 10.1128/MCB.18.5.2596; Hu TH, 1996, J CELL BIOL, V134, P589, DOI 10.1083/jcb.134.3.589; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Kehlenbach RH, 1998, J CELL BIOL, V141, P863, DOI 10.1083/jcb.141.4.863; Kennedy D, 1996, Biomed Pept Proteins Nucleic Acids, V2, P93; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOONG AC, 1994, CANCER RES, V54, P5278; LABAIL O, 1993, EMBO J, V12, P5043; Latimer M, 1998, MOL CELL BIOL, V18, P2640, DOI 10.1128/MCB.18.5.2640; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; Liu JM, 2000, MOL ENDOCRINOL, V14, P40, DOI 10.1210/me.14.1.40; Love DC, 1998, P NATL ACAD SCI USA, V95, P10608, DOI 10.1073/pnas.95.18.10608; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; MERCURIO F, 1992, DNA CELL BIOL, V11, P523, DOI 10.1089/dna.1992.11.523; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; Ossareh-Nazari B, 1999, EXP CELL RES, V252, P236, DOI 10.1006/excr.1999.4599; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Parker F, 1996, MOL CELL BIOL, V16, P2561; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; RODRIGUEZ MS, 1996, ONCOGENE, V12, P369; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; Sachdev S, 2000, MOL CELL BIOL, V20, P1571, DOI 10.1128/MCB.20.5.1571-1582.2000; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Singh S, 1996, J BIOL CHEM, V271, P31049, DOI 10.1074/jbc.271.49.31049; Smith A, 1998, CURR BIOL, V8, P1403, DOI 10.1016/S0960-9822(98)00023-2; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Tam WF, 2000, MOL CELL BIOL, V20, P2269, DOI 10.1128/MCB.20.6.2269-2284.2000; Turpin P, 1999, J BIOL CHEM, V274, P6804, DOI 10.1074/jbc.274.10.6804; Weil R, 1997, J BIOL CHEM, V272, P9942; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; WILHELMSEN KC, 1984, J VIROL, V49, P521, DOI 10.1128/JVI.49.2.521-529.1984; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	84	87	95	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36441	36449		10.1074/jbc.M004751200	http://dx.doi.org/10.1074/jbc.M004751200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10969074	hybrid			2022-12-25	WOS:000165382000111
J	Bausek, N; Waclawek, M; Schneider, WJ; Wohlrab, F				Bausek, N; Waclawek, M; Schneider, WJ; Wohlrab, F			The major chicken egg envelope protein ZP1 is different from ZPB and is synthesized in the liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN ZONA-PELLUCIDA; MOLECULAR-CLONING; COORDINATE EXPRESSION; STRUCTURAL-ANALYSIS; RADIATA-PROTEINS; GRANULOSA-CELLS; GENE-EXPRESSION; CDNA CLONING; INNER-EAR; IDENTIFICATION	The extracellular matrix surrounding vertebrate oocytes is called the zona pellucida in mammals and perivitelline membrane (pvm) in birds. We have analyzed this structure in chicken follicles and laid eggs and have identified a 95-kDa component of the pvm, which, by protein sequencing, shows homology to mammalian zona pellucida proteins. Surprisingly, we could not detect this protein in ovarian granulosa cells or oocytes but instead found high levels in the liver of the laying hen. In contrast, it is absent in rooster liver but can be efficiently induced by estrogen treatment of the animal. An immunoscreen of a liver lambda-ZAP library yielded a cDNA coding for a protein of 934 amino acids. It displayed significant homology to members of the ZP1/ZPB family from other species, notably to mouse and rat ZP1, and was therefore designated chkZP1, It is clearly different from a protein designated chkZPB that had been deposited in the data base previously. Alignment of the known members of the ZP1/ZPB family demonstrated the existence of at least three subgroups, with representatives of both the ZP1 and the ZPB sequence homology group occurring in vertebrates. Northern blot analysis of liver extracts revealed the presence of a single 3.2-kilobase mRNA coding for chkZP1, distinct from the chkZPB transcript detectable in follicles, Immunohistochemical analysis of follicle sections demonstrates that chkZP1 can be found in the blood vessels of the theca cell layer as well as in the pvm surrounding the oocyte, Thus, in the chicken, at least one of the major pvm components is synthesized in the liver and is transported via the bloodstream to the follicle.	Univ Vienna, Dept Mol Genet, Inst Med Biochem, A-1030 Vienna, Austria; Bioctr Vienna, A-1030 Vienna, Austria	University of Vienna; Vienna Biocenter (VBC)	Wohlrab, F (corresponding author), Univ Vienna, Dept Mol Genet, Inst Med Biochem, Dr Bohr Gasse 9-2, A-1030 Vienna, Austria.	wohlrab@mol.univie.ac.at		Bausek, Nina/0000-0003-2415-1463				BACK JF, 1982, BIOCHIM BIOPHYS ACTA, V705, P12, DOI 10.1016/0167-4838(82)90329-6; Barros C, 1996, CELL BIOL INT, V20, P33, DOI 10.1006/cbir.1996.0006; BELLAIRS RUTH, 1963, JOUR ULTRASTRUCTURE RES, V8, P339, DOI 10.1016/S0022-5320(63)90012-1; BORK P, 1992, FEBS LETT, V300, P237, DOI 10.1016/0014-5793(92)80853-9; Chang YS, 1997, MOL REPROD DEV, V46, P258, DOI 10.1002/(SICI)1098-2795(199703)46:3&lt;258::AID-MRD4&gt;3.0.CO;2-O; COTELLI F, 1988, J ULTRA MOL STRUCT R, V99, P70, DOI 10.1016/0889-1605(88)90034-1; Coutinho P, 1999, HEARING RES, V130, P62, DOI 10.1016/S0378-5955(98)00213-5; Del Giacco L, 2000, DEV GENES EVOL, V210, P41, DOI 10.1007/PL00008187; DelGiacco L, 1998, MOL REPROD DEV, V49, P58, DOI 10.1002/(SICI)1098-2795(199801)49:1&lt;58::AID-MRD7&gt;3.0.CO;2-N; Dumont J N, 1985, Dev Biol (N Y 1985), V1, P235; EPIFANO O, 1995, DEVELOPMENT, V121, P1947; GILBERT AB, 1977, J REPROD FERTIL, V50, P179, DOI 10.1530/jrf.0.0500179; GREVE JM, 1985, J MOL BIOL, V181, P253, DOI 10.1016/0022-2836(85)90089-0; Haines BP, 1999, MOL REPROD DEV, V52, P174, DOI 10.1002/(SICI)1098-2795(199902)52:2<174::AID-MRD8>3.0.CO;2-7; HARRIS JD, 1994, DNA SEQUENCE, V4, P361, DOI 10.3109/10425179409010186; HESSION C, 1987, SCIENCE, V237, P1479, DOI 10.1126/science.3498215; HOFFMANN W, 1993, TRENDS BIOCHEM SCI, V18, P239, DOI 10.1016/0968-0004(93)90170-R; HOOPS TC, 1991, J BIOL CHEM, V266, P4257; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; Hughes DC, 1999, BBA-GENE STRUCT EXPR, V1447, P303, DOI 10.1016/S0167-4781(99)00181-5; KIDO S, 1992, BIOCHEM J, V286, P17, DOI 10.1042/bj2860017; KILLICK R, 1995, J CELL BIOL, V129, P535, DOI 10.1083/jcb.129.2.535; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Legan PK, 1997, J BIOL CHEM, V272, P8791, DOI 10.1074/jbc.272.13.8791; Liang LF, 1997, DEVELOPMENT, V124, P4939; LIU DY, 1993, BIOL REPROD, V48, P340, DOI 10.1095/biolreprod48.2.340; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LYONS CE, 1993, J BIOL CHEM, V268, P21351; Martinez ML, 1996, J REPROD FERTIL, P35; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Moore DD, 1995, GLOB MOB SURV; Murata K, 1997, P NATL ACAD SCI USA, V94, P2050, DOI 10.1073/pnas.94.5.2050; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OPPENBERNTSEN DO, 1992, J ENDOCRINOL, V135, P293, DOI 10.1677/joe.0.1350293; OPPENBERNTSEN DO, 1992, INT J DEV BIOL, V36, P247; ORAND MG, 1988, GAMETE RES, V19, P315, DOI 10.1002/mrd.1120190402; PENNICA D, 1987, SCIENCE, V236, P83, DOI 10.1126/science.3453112; Prasad SV, 1996, MOL REPROD DEV, V43, P519, DOI 10.1002/(SICI)1098-2795(199604)43:4&lt;519::AID-MRD15&gt;3.0.CO;2-U; Prasad SV, 1997, I C S S, V12, P129; Sambrook J, 1989, MOL CLONING; Stockinger W, 1998, J BIOL CHEM, V273, P32213, DOI 10.1074/jbc.273.48.32213; Sugiyama H, 1998, DEV GROWTH DIFFER, V40, P35; Takeuchi Y, 1999, EUR J BIOCHEM, V260, P736, DOI 10.1046/j.1432-1327.1999.00203.x; Waclawek M, 1998, BIOL REPROD, V59, P1230, DOI 10.1095/biolreprod59.5.1230; Wassarman P, 1999, J EXP ZOOL, V285, P251, DOI 10.1002/(SICI)1097-010X(19991015)285:3&lt;251::AID-JEZ8&gt;3.0.CO;2-1; WASSARMAN PM, 1990, J REPROD FERTIL, P79; Yonezawa N, 1997, EUR J BIOCHEM, V248, P86, DOI 10.1111/j.1432-1033.1997.00086.x; YONEZAWA N, 1995, EUR J BIOCHEM, V233, P35, DOI 10.1111/j.1432-1033.1995.035_1.x; Yurewicz EC, 1998, J BIOL CHEM, V273, P7488, DOI 10.1074/jbc.273.13.7488	49	97	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28866	28872		10.1074/jbc.275.37.28866	http://dx.doi.org/10.1074/jbc.275.37.28866			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10979984	hybrid			2022-12-25	WOS:000089330700070
J	Rossmeisl, M; Syrovy, I; Baumruk, F; Flachs, P; Janovska, P; Kopecky, J				Rossmeisl, M; Syrovy, I; Baumruk, F; Flachs, P; Janovska, P; Kopecky, J			Decreased fatty acid synthesis due to mitochondrial uncoupling in adipose tissue	FASEB JOURNAL			English	Article						UCP; lipogenesis; C57BL/6J mice; 3T3-L1; obesity	MESSENGER-RNA EXPRESSION; BROWN ADIPOCYTES; WHITE ADIPOCYTES; PROTEIN HOMOLOG; GENE-EXPRESSION; METABOLIC-RATE; OBESITY; HUMANS; LIPOGENESIS; INSULIN	Synthesis of fatty acid (FA) in adipose tissue requires cooperation of mitochondrial and cytoplasmic enzymes, Mitochondria are required for the production of ATP and they also support the formation of acetyl-CoA and NADPH in cytoplasm, Since cellular levels of all these metabolites depend on the efficiency of mitochondrial energy conversion, mitochondrial proton leak via uncoupling proteins (UCPs) could modulate FA synthesis. In 3T3-L1 adipocytes, 2,4-dinitrophenol depressed the synthesis of FA 4-fold while increasing FA oxidation 1.5-fold and the production of lactate 14-fold. Inhibition of FA synthesis in 3T3-L1 adipocytes was proportional to the decrease in mitochondrial membrane potential, FA synthesis from D-[U-C-14] glucose was reduced up to fourfold by ectopic UCP1 in the white fat of transgenic aP2-Ucp1 mice, reflecting the magnitude of UCP1 expression in different fat depots and the reduction of adiposity, Transcript levels for Lipogenic enzymes were lower in the white fat of the transgenic mice than in the control animals. Our results show that uncoupling of oxidative phosphorylation depresses FA synthesis in white fat, Reduction of adiposity via mitochondrial uncoupling in white fat not only reflects increased energy expenditure, but also decreased in situ lipogenesis.	Acad Sci Czech Republ, Inst Physiol, Dept Adipose Tissue Biol, CZ-14220 Prague, Czech Republic	Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences	Kopecky, J (corresponding author), Acad Sci Czech Republ, Inst Physiol, Dept Adipose Tissue Biol, Videnska 1083, CZ-14220 Prague, Czech Republic.	kopecky@biomed.cas.cz	Kopecky, Jan/B-8244-2012; Rossmeisl, Martin/CAF-0060-2022; Janovska, Petra/E-7160-2013; Flachs, Pavel/A-5341-2012; Rossmeisl, Martin/C-1892-2012	Kopecky, Jan/0000-0001-8072-2035; Rossmeisl, Martin/0000-0001-8534-4002; Janovska, Petra/0000-0002-6154-2175; Rossmeisl, Martin/0000-0001-8534-4002				ARNER P, 1987, AM J PHYSIOL, V253, pE193, DOI 10.1152/ajpendo.1987.253.2.E193; BARBER MC, 1991, HORM METAB RES, V23, P143, DOI 10.1055/s-2007-1003636; BASHAN N, 1993, AM J PHYSIOL, V264, pC430, DOI 10.1152/ajpcell.1993.264.2.C430; Baumruk F, 1999, FEBS LETT, V444, P206, DOI 10.1016/S0014-5793(99)00053-8; BELFIORE F, 1976, METABOLISM, V25, P483, DOI 10.1016/0026-0495(76)90001-9; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Bouchard C, 1997, HUM MOL GENET, V6, P1887, DOI 10.1093/hmg/6.11.1887; BUCKLEY MG, 1987, BIOCHEM J, V243, P437, DOI 10.1042/bj2430437; CHASCIONE C, 1987, AM J PHYSIOL, V253, pE664, DOI 10.1152/ajpendo.1987.253.6.E664; Digby JE, 1998, DIABETES, V47, P138, DOI 10.2337/diabetes.47.1.138; EVANS RM, 1977, BIOCHIM BIOPHYS ACTA, V489, P48, DOI 10.1016/0005-2760(77)90230-2; FLATT JP, 1970, J LIPID RES, V11, P131; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Gimble JM, 1996, MOL PHARMACOL, V50, P1087; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; Guerra C, 1998, J CLIN INVEST, V102, P412, DOI 10.1172/JCI3155; Iritani N, 1996, J BIOCHEM, V120, P242, DOI 10.1093/oxfordjournals.jbchem.a021405; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; KATZ J, 1974, BIOCHIM BIOPHYS ACTA, V337, P313, DOI 10.1016/0005-2760(74)90105-2; Klingenberg M, 1999, BBA-BIOMEMBRANES, V1415, P271, DOI 10.1016/S0005-2736(98)00232-6; Kopecky J, 1995, J CLIN INVEST, V96, P2914, DOI 10.1172/JCI118363; Kopecky J, 1996, AM J PHYSIOL-ENDOC M, V270, pE768, DOI 10.1152/ajpendo.1996.270.5.E768; Kopecky J, 1996, AM J PHYSIOL-ENDOC M, V270, pE776, DOI 10.1152/ajpendo.1996.270.5.E776; KOPECKY J, 1997, KEYST S AD CELL PARK, P18; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Lee FYJ, 1999, HEPATOLOGY, V29, P677, DOI 10.1002/hep.510290320; MARTIN BR, 1971, BIOCHEM J, V125, P105, DOI 10.1042/bj1250105; Millet L, 1997, J CLIN INVEST, V100, P2665, DOI 10.1172/JCI119811; Oberkofler H, 1997, J LIPID RES, V38, P2125; Oberkofler H, 1998, DIABETOLOGIA, V41, P940, DOI 10.1007/s001250051011; PATEL MS, 1970, J BIOL CHEM, V245, P1302; PORTER RK, 1993, NATURE, V362, P628, DOI 10.1038/362628a0; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; ROGNSTAD R, 1969, BIOCHEM J, V111, P431, DOI 10.1042/bj1110431; SAGGERSON ED, 1988, BIOCHEM J, V251, P701, DOI 10.1042/bj2510701; SHILLABEER G, 1990, J LIPID RES, V31, P623; SIBILLE B, 1995, EUR J BIOCHEM, V231, P498, DOI 10.1111/j.1432-1033.1995.tb20724.x; Soloveva V, 1997, MOL ENDOCRINOL, V11, P27, DOI 10.1210/me.11.1.27; STANSBIE D, 1976, BIOCHEM J, V160, P413, DOI 10.1042/bj1600413; Stefl B, 1998, AM J PHYSIOL-ENDOC M, V274, pE527, DOI 10.1152/ajpendo.1998.274.3.E527; Surwit RS, 1998, P NATL ACAD SCI USA, V95, P4061, DOI 10.1073/pnas.95.7.4061; Valverde AM, 1998, ENDOCRINOLOGY, V139, P1229, DOI 10.1210/en.139.3.1229; Vidal-Puig A, 1999, OBES RES, V7, P133, DOI 10.1002/j.1550-8528.1999.tb00694.x; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; Yoshida T, 1998, AM J PHYSIOL-ENDOC M, V274, pE469, DOI 10.1152/ajpendo.1998.274.3.E469; Yoshida T, 1999, INT J OBESITY, V23, P570, DOI 10.1038/sj.ijo.0800870; Zhou YT, 1999, P NATL ACAD SCI USA, V96, P2391, DOI 10.1073/pnas.96.5.2391; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P6386, DOI 10.1073/pnas.94.12.6386	51	71	73	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2000	14	12					1793	1800		10.1096/fj.99-0965com	http://dx.doi.org/10.1096/fj.99-0965com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973929				2022-12-25	WOS:000089212400019
J	Wang, YX; Dhulipala, PK; Kotlikoff, MI				Wang, YX; Dhulipala, PK; Kotlikoff, MI			Hypoxia inhibits the Na+/Ca2+ exchanger pulmonary artery smooth muscle cells	FASEB JOURNAL			English	Article						smooth muscle; ion channel; cytosolic calcium; reverse transcriptase polymerase chain reaction hypoxic pulmonary vasoconstriction	SODIUM-CALCIUM EXCHANGE; TISSUE-SPECIFIC EXPRESSION; SINGLE VENTRICULAR CELLS; NA+-CA2+ EXCHANGER; RAT PULMONARY; GUINEA-PIG; CA2+ RELEASE; SARCOPLASMIC-RETICULUM; ION CHANNELS; K+ CHANNELS	The cellular mechanisms underlying hypoxic pulmonary vasoconstriction are not fully understood. We examined the effect of hypoxia on Ca2+ efflux from the cytosol in single Fura-2-loaded pulmonary artery myocytes, During mild hypoxia (pO(2)=50-60 Torr), peak [Ca2+](i) was increased and the rate of Ca2+ removal from the cytosol was markedly slowed after stimuli that elevated [Ca2+](i), Removal of extracellular Na+ potentiated the peak [Ca2+](i) rise and slowed the Ca2+ decay rate in cells recorded under normoxic conditions; it did not further slow the Ca2+ decay rate or potentiate the [Ca2+](i) increase in hypoxic cells. An Na+/Ca2+ exchange current was recorded in isolated pulmonary artery myocytes, Switching from Li+ to Na+ (130 mM) revealed an inward current with reversal potential consistent with the Na+/Ca2+ exchange current in cells in which [Ca2+](i) was clamped at 1 mu M; similar currents, although smaller, were observed with normal resting [Ca2+](i) using the perforated patch clamp technique. The Na+/Ca2+ exchange current was markedly inhibited in myocytes exposed to mild hypoxia, RT-PCR revealed the expression of specific alternatively spliced RNAs of NCX1 in rat pulmonary arteries. These findings provide an enhanced understanding of the molecular mechanisms underlying hypoxic sensing in pulmonary arteries.	Univ Penn, Dept Anim Biol, Sch Vet Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Kotlikoff, MI (corresponding author), Univ Penn, Dept Anim Biol, Sch Vet Med, 3800 Spruce St, Philadelphia, PA 19104 USA.	mik@vet.upenn.edu			NHLBI NIH HHS [HL41084, HL64043, HL45239] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041084, R01HL064043, R01HL045239, R29HL041084] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARCHER SL, 1993, CIRC RES, V73, P1100, DOI 10.1161/01.RES.73.6.1100; Archer SL, 1998, J CLIN INVEST, V101, P2319, DOI 10.1172/JCI333; Archer SL, 1996, CIRC RES, V78, P431, DOI 10.1161/01.RES.78.3.431; ASHIDA T, 1987, J PHYSIOL-LONDON, V392, P617, DOI 10.1113/jphysiol.1987.sp016800; BLAUSTEIN MP, 1992, JPN J PHARMACOL, V58, pP107; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; BRIGHT RT, 1995, AM J PHYSIOL-LUNG C, V269, pL203, DOI 10.1152/ajplung.1995.269.2.L203; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOERING AE, 1993, J PHYSIOL-LONDON, V466, P481; EARM YE, 1986, JPN HEART J, V27, P153; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; Gelband CH, 1997, CIRCULATION, V96, P3647; Jabr RI, 1997, BRIT J PHARMACOL, V122, P21, DOI 10.1038/sj.bjp.0701326; Juhaszova M, 1996, ANN NY ACAD SCI, V779, P318, DOI 10.1111/j.1749-6632.1996.tb44804.x; KIMURA J, 1987, J PHYSIOL-LONDON, V384, P199, DOI 10.1113/jphysiol.1987.sp016450; KOZLOWSKI RZ, 1995, CARDIOVASC RES, V30, P318; LEE SL, 1994, J BIOL CHEM, V269, P14849; LI ZP, 1994, J BIOL CHEM, V269, P17434; MADDEN JA, 1992, AM J PHYSIOL, V263, pL384, DOI 10.1152/ajplung.1992.263.3.L384; Marin J, 1998, LIFE SCI, V64, P279, DOI 10.1016/S0024-3205(98)00393-2; NAKASAKI Y, 1993, J BIOCHEM-TOKYO, V114, P528, DOI 10.1093/oxfordjournals.jbchem.a124211; Nazer MA, 1998, CELL CALCIUM, V24, P275, DOI 10.1016/S0143-4160(98)90051-3; Nazer MA, 1998, AM J PHYSIOL-HEART C, V274, pH123, DOI 10.1152/ajpheart.1998.274.1.H123; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; Orallo F, 1996, PHARMACOL THERAPEUT, V69, P153, DOI 10.1016/0163-7258(95)02042-X; Perez GJ, 1999, J GEN PHYSIOL, V113, P229, DOI 10.1085/jgp.113.2.229; Perez-Garcia MT, 1999, J GEN PHYSIOL, V113, P897, DOI 10.1085/jgp.113.6.897; POST JM, 1995, CIRC RES, V77, P131, DOI 10.1161/01.RES.77.1.131; POST JM, 1992, AM J PHYSIOL, V262, pC882, DOI 10.1152/ajpcell.1992.262.4.C882; Quednau BD, 1997, AM J PHYSIOL-CELL PH, V272, pC1250, DOI 10.1152/ajpcell.1997.272.4.C1250; SALVATERRA CG, 1989, AM REV RESPIR DIS, V139, P933, DOI 10.1164/ajrccm/139.4.933; SEKI S, 1995, AM J PHYSIOL-HEART C, V268, pH1045, DOI 10.1152/ajpheart.1995.268.3.H1045; Shigematsu S, 1999, J MOL CELL CARDIOL, V31, P895, DOI 10.1006/jmcc.1998.0929; SLAUGHTER RS, 1989, BIOCHEMISTRY-US, V28, P3995, DOI 10.1021/bi00435a055; Slodzinski MK, 1998, AM J PHYSIOL-CELL PH, V275, pC251, DOI 10.1152/ajpcell.1998.275.1.C251; SLODZINSKI MK, 1995, AM J PHYSIOL-CELL PH, V269, pC1340, DOI 10.1152/ajpcell.1995.269.5.C1340; VADULA MS, 1993, AM J PHYSIOL, V265, pL591, DOI 10.1152/ajplung.1993.265.6.L591; VANBREEMEN C, 1995, TRENDS PHARMACOL SCI, V16, P98, DOI 10.1016/S0165-6147(00)88990-7; Vandier C, 1998, AM J PHYSIOL-LUNG C, V275, pL145, DOI 10.1152/ajplung.1998.275.1.L145; VOELKEL NF, 1981, J CLIN INVEST, V67, P238, DOI 10.1172/JCI110019; Wang J, 1997, J CLIN INVEST, V100, P2347, DOI 10.1172/JCI119774; Wang Q, 1997, AM J PHYSIOL-CELL PH, V273, pC520, DOI 10.1152/ajpcell.1997.273.2.C520; Wang YX, 1997, P NATL ACAD SCI USA, V94, P14918, DOI 10.1073/pnas.94.26.14918; Weir EK, 1998, CHEST, V114, p17S, DOI 10.1378/chest.114.1_Supplement.17S-a; YUAN XJ, 1994, AM J PHYSIOL, V267, pL52, DOI 10.1152/ajplung.1994.267.1.L52; YUAN XJ, 1993, AM J PHYSIOL, V264, pL116, DOI 10.1152/ajplung.1993.264.2.L116; ZHU ZM, 1994, AM J PHYSIOL, V266, pC794, DOI 10.1152/ajpcell.1994.266.3.C794	48	35	35	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2000	14	12					1731	1740		10.1096/fj.99-0859com	http://dx.doi.org/10.1096/fj.99-0859com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973922				2022-12-25	WOS:000089212400012
J	Kang, BS; French, OG; Sando, JJ; Hahn, CS				Kang, BS; French, OG; Sando, JJ; Hahn, CS			Activation-dependent degradation of protein kinase C eta	ONCOGENE			English	Article						protein kinase C; down-regulation; proteolysis; phorbol ester; ubiquitin; proteasome	MOUSE THYMOMA CELLS; DOWN-REGULATION; EXPRESSION VECTORS; COUPLED RECEPTOR; UP-REGULATION; BETA-II; PHOSPHORYLATION; APOPTOSIS; INACTIVATION; PATHWAY	Prolonged activation of protein kinase Cs (PKCs) by long-term treatment of cells with phorbol ester tumor promoters down-regulates the expression of many PKCs, To investigate the molecular mechanisms involved in the down-regulation of PKC eta, we expressed the novel PKCs eta and theta and various mutant forms in baby hamster kidney cells. Upon overexpression, constitutively active PKC eta, but not wild type or kinase-dead PKC eta, underwent rapid degradation to generate several lower molecular weight polypeptides. When co-expressed with active kinases, kinase-dead PKC eta with a pseudosubstrate site mutation designed to give an active conformation was dawn-regulated while the wild type PKC eta was not. These results suggest requirements for kinase activity and an active conformation for down-regulation of PKC eta. Treatment with the proteasome inhibitors N-Ac-Leu-Leu-norleucinal and lactacystin led to accumulation of PKC eta proteolytic products and potentially ubiquitinated forms, While wild type PKC eta localizes mostly to the detergent-soluble fraction of the cell, a significant portion of full-length constitutively active PKC eta and of kinase-dead, active conformation PKC eta were found in the detergent-insoluble fraction. Several proteolytic fragments of constitutively active PKC eta also were found in the detergent insoluble fraction. These full-length and proteolytic fragments of PKC eta in the detergent-insoluble fraction accumulated further in the presence of proteasome inhibitors. These data suggest that active conformation PKC eta accumulates in the detergent-insoluble compartment, is degraded by proteolysis in the presence of kinase activity, and that the cleavage products undergo further degradation via ubiquitin-mediated degradation in the proteasome.	Univ Virginia, Hlth Sci Ctr, Beirne Carter Ctr Immunol Res, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Beirne Carter Ctr Immunol Res, Dept Anesthesiol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Hahn, CS (corresponding author), Univ Virginia, Hlth Sci Ctr, Beirne Carter Ctr Immunol Res, Dept Microbiol, Box MR4-4012, Charlottesville, VA 22908 USA.				NIGMS NIH HHS [GM54572, GM31184] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054572, R01GM031184] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bobak D, 1997, ONCOGENE, V15, P2179, DOI 10.1038/sj.onc.1201396; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; BREDENBEEK PJ, 1993, J VIROL, V67, P6439, DOI 10.1128/JVI.67.11.6439-6446.1993; Chen CC, 1997, FEBS LETT, V412, P30, DOI 10.1016/S0014-5793(97)00697-2; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; Feng X, 1998, J BIOL CHEM, V273, P26870, DOI 10.1074/jbc.273.41.26870; Feng X, 1998, J BIOL CHEM, V273, P10755, DOI 10.1074/jbc.273.17.10755; FREISEWINKEL I, 1991, FEBS LETT, V280, P262, DOI 10.1016/0014-5793(91)80307-O; GOODE NT, 1994, MOL BIOL CELL, V5, P907, DOI 10.1091/mbc.5.8.907; GOODE NT, 1995, J BIOL CHEM, V270, P2669, DOI 10.1074/jbc.270.6.2669; GREIF H, 1992, MOL CELL BIOL, V12, P1304, DOI 10.1128/MCB.12.3.1304; HAHN CS, 1992, P NATL ACAD SCI USA, V89, P2679, DOI 10.1073/pnas.89.7.2679; Hansra G, 1999, BIOCHEM J, V342, P337, DOI 10.1042/0264-6021:3420337; HONG DH, 1995, BBA-MOL CELL RES, V1267, P45, DOI 10.1016/0167-4889(95)00024-M; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; Lee HW, 1996, AM J PHYSIOL-CELL PH, V271, pC304, DOI 10.1152/ajpcell.1996.271.1.C304; Lee HW, 1997, MOL PHARMACOL, V51, P439; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Moorman JP, 1999, ONCOGENE, V18, P47, DOI 10.1038/sj.onc.1202262; Moorman JP, 1996, J IMMUNOL, V156, P4146; Murakami A, 1996, J INVEST DERMATOL, V106, P790, DOI 10.1111/1523-1747.ep12346391; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; PARKER PJ, 1995, BIOCHEM SOC T, V23, P153, DOI 10.1042/bst0230153; PEARS C, 1991, FEBS LETT, V284, P120, DOI 10.1016/0014-5793(91)80776-Y; PONTREMOLI S, 1988, J BIOL CHEM, V263, P1915; Resnick MS, 1998, J BIOL CHEM, V273, P27654, DOI 10.1074/jbc.273.42.27654; Resnick MS, 1997, CANCER RES, V57, P2209; Roth AF, 1996, J CELL BIOL, V134, P661, DOI 10.1083/jcb.134.3.661; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9	37	32	33	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 31	2000	19	37					4263	4272		10.1038/sj.onc.1203779	http://dx.doi.org/10.1038/sj.onc.1203779			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980600				2022-12-25	WOS:000089032900009
J	Reddy, TR; Xu, WD; Wong-Staal, F				Reddy, TR; Xu, WD; Wong-Staal, F			General effect of Sam68 on Rev/Rex regulated expression of complex retroviruses	ONCOGENE			English	Article						Sam68; HTLV-1; EIA V; Rev-MS2; transactivation	INFECTIOUS-ANEMIA VIRUS; FELINE IMMUNODEFICIENCY VIRUS; NUCLEAR EXPORT SIGNALS; HIV-1 REV PROTEIN; I REX; MESSENGER-RNA; LEPTOMYCIN-B; TYPE-1 REV; VIRAL-RNA; IDENTIFICATION	We have previously demonstrated that overexpression of Sam68 functionally substitutes for, as well as synergizes with, HIV-1 Rev in RRE-mediated gene expression and virus replication. In addition, C-terminal deletion mutants of Sam68 exhibit a transdominant negative phenotype in HIV replication. We now report that Sam68 also enhances the activities of Rev-like proteins of other complex retroviruses (e.g. HTLV-1 and EIAV) on their respective RNA targets. Furthermore, we demonstrate that Sam68 can function alone as well as synergize with Rev-MS2 and/or Rex-MS2 chimeric proteins on expression mediated by the corresponding RRE-MS2 fusion RNA element. Additionally, dominant negative mutants of Sam68 also repressed the synergistic activation of Sam68 with Rex, E-Rev, and/or Rev-MS2/ Rex-MS2 on their corresponding RNA targets. Thus, Sam68 may play an important role in the post-transcriptional regulation of all complex retroviruses.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Reddy, TR (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.				NIAID NIH HHS [AI46240] Funding Source: Medline; NIGMS NIH HHS [GM56089] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046240] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; Cullen BR, 1998, VIROLOGY, V249, P203, DOI 10.1006/viro.1998.9331; FELBER B K, 1989, New Biologist, V1, P318; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; FRIDELL RA, 1993, J VIROL, V67, P7317, DOI 10.1128/JVI.67.12.7317-7323.1993; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; HANLY SM, 1989, GENE DEV, V3, P1534, DOI 10.1101/gad.3.10.1534; Hope TJ, 1997, CHEM BIOL, V4, P335, DOI 10.1016/S1074-5521(97)90124-1; KATAHIRA J, 1995, J VIROL, V69, P3125, DOI 10.1128/JVI.69.5.3125-3133.1995; LEWIS N, 1990, J VIROL, V64, P1690, DOI 10.1128/JVI.64.4.1690-1697.1990; LUO Y, 1994, J VIROL, V68, P3850, DOI 10.1128/JVI.68.6.3850-3856.1994; MANCUSO VA, 1994, J VIROL, V68, P1998, DOI 10.1128/JVI.68.3.1998-2001.1994; MARTARANO L, 1994, J VIROL, V68, P3102, DOI 10.1128/JVI.68.5.3102-3111.1994; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MCDONALD D, 1992, J VIROL, V66, P7232, DOI 10.1128/JVI.66.12.7232-7238.1992; Meyer BE, 1996, J VIROL, V70, P2350, DOI 10.1128/JVI.70.4.2350-2359.1996; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; Otero GC, 1998, J VIROL, V72, P7593, DOI 10.1128/JVI.72.9.7593-7597.1998; Reddy TR, 2000, ONCOGENE, V19, P3110, DOI 10.1038/sj.onc.1203637; Reddy TR, 1999, NAT MED, V5, P635, DOI 10.1038/9479; RIMSKY L, 1988, NATURE, V335, P738, DOI 10.1038/335738a0; UNGE T, 1991, P NATL ACAD SCI USA, V88, P7145, DOI 10.1073/pnas.88.16.7145; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Xu Yuan, 1996, Journal of Biomedical Science, V3, P82, DOI 10.1007/BF02255535	24	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2000	19	35					4071	4074		10.1038/sj.onc.1203749	http://dx.doi.org/10.1038/sj.onc.1203749			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962565				2022-12-25	WOS:000088825300014
J	Wu, CJ; Chen, ZJ; Ullrich, A; Greene, MI; O'Rourke, DM				Wu, CJ; Chen, ZJ; Ullrich, A; Greene, MI; O'Rourke, DM			Inhibition of EGFR-mediated phosphoinositide-3-OH kinase (PI3-K) signaling and glioblastoma phenotype by Signal-Regulatory Proteins (SIRPs)	ONCOGENE			English	Article						apoptosis; erbB; EGFR; phosphoinositide-3-OH kinase (PI3-K); SHP2; Signal-Regulatory Proteins (SIRPs)	EPIDERMAL GROWTH-FACTOR; TYROSINE-PHOSPHATASE SHP-2; CONFERS ENHANCED TUMORIGENICITY; PHOSPHORYLATED 100-KDA PROTEIN; SRC HOMOLOGY-2 DOMAINS; TUMOR-SUPPRESSOR PTEN; FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; GLIOMA-CELLS; ERBB FAMILY	Several growth factors and cytokines, including EGF, are known to induce tyrosine phosphorylation of Signal Regulatory Proteins (SIRPs). Consistent with the idea that increased phosphorylation activates SIRP function, we overexpressed human SIRP alpha 1 in U87MG glioblastoma cells in order to examine how SIRP alpha 1 modulates EGFR signaling pathways. Endogenous EGFR proteins are overexpressed in U87MG cells and these cells exhibit survival and motility phenotypes that are influenced by EGFR kinase activity. Overexpression of the SIRP alpha 1 cDNA diminished EGF-induced phosphoinositide-3-OH kinase (PI3-K) activation in U87MG cells. Reduced EGF-stimulated activation of PI3-K was mediated by interactions between carboxyl terminus of SIRP alpha 1 and the Src homology-2 (SH2)-containing phosphotyrosine phosphatase, SHP2. SIRP alpha 1 overexpression also reduced the EGF-induced association between SHP2 and the p85 regulatory subunit of PI3-K. Inhibition of transformation and enhanced apoptosis following gamma-irradiation were observed in SIRP alpha 1-overexpressing U87MG cells, and enhanced apoptosis was associated with reduced levels of bcl-x(L) protein. Furthermore, SIRP alpha 1-overexpressing U87MG cells displayed reduced cell migration and cell spreading that was mediated by association between SIRP alpha 1 and SHP2. However, SIRP alpha 1-overexpressing U87MG clonal derivatives exhibited no differences in cell growth or levels of mitogen-activated protein kinase (MAPK) activation. These data reveal a pathway that negatively regulates EGFR-induced PI3-K activation in glioblastoma cells and involves interactions between SHP2 and tyrosine phosphorylated SIRP alpha 1. These results also suggest that negative regulation of PI3-K pathway activation by the SIRP family of transmembrane receptors may diminish EGFR-mediated motility and survival phenotypes that contribute to transformation of glioblastoma cells.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Canc Ctr, Philadelphia, PA 19104 USA; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Anhui, Peoples R China; Univ Penn, Sch Med, Abramson Family Canc Inst, Philadelphia, PA 19104 USA; Philadelphia Vet Adm Med Ctr, Dept Surg Neurosurg, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Max Planck Society; Chinese Academy of Sciences; University of Science & Technology of China, CAS; University of Pennsylvania	O'Rourke, DM (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 502 Stemmler Hall,36th & Hamilton Walk, Philadelphia, PA 19104 USA.		O'Rourke, Donald/AAC-3376-2021	O'Rourke, Donald/0000-0002-8479-7314				Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Cambier JC, 1997, P NATL ACAD SCI USA, V94, P5993, DOI 10.1073/pnas.94.12.5993; Carlberg K, 1997, J BIOL CHEM, V272, P15943, DOI 10.1074/jbc.272.25.15943; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Coggeshall KM, 1999, IMMUNOL RES, V19, P47, DOI 10.1007/BF02786476; Craddock BL, 1997, J BIOL CHEM, V272, P29281, DOI 10.1074/jbc.272.46.29281; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Davies MA, 1998, CANCER RES, V58, P5285; Deb TB, 1998, J BIOL CHEM, V273, P16643, DOI 10.1074/jbc.273.27.16643; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; Gesbert F, 1998, J BIOL CHEM, V273, P18273, DOI 10.1074/jbc.273.29.18273; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Inagaki K, 2000, ONCOGENE, V19, P75, DOI 10.1038/sj.onc.1203204; Jiang PH, 1999, J BIOL CHEM, V274, P559, DOI 10.1074/jbc.274.2.559; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Manes S, 1999, MOL CELL BIOL, V19, P3125; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Moscatello DK, 1996, ONCOGENE, V13, P85; Nagane M, 1996, CANCER RES, V56, P5079; Nagane M, 1998, P NATL ACAD SCI USA, V95, P5724, DOI 10.1073/pnas.95.10.5724; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; O'Rourke DM, 1998, ONCOGENE, V16, P1197, DOI 10.1038/sj.onc.1201635; O'Rourke DM, 1998, P NATL ACAD SCI USA, V95, P10842, DOI 10.1073/pnas.95.18.10842; Ochi F, 1997, BIOCHEM BIOPH RES CO, V239, P483, DOI 10.1006/bbrc.1997.7489; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Ohnishi H, 1996, J BIOL CHEM, V271, P25569, DOI 10.1074/jbc.271.41.25569; Okada N, 1996, BIOCHEM BIOPH RES CO, V229, P607, DOI 10.1006/bbrc.1996.1851; ORourke DM, 1997, P ASSOC AM PHYSICIAN, V109, P209; ORourke DM, 1997, P NATL ACAD SCI USA, V94, P3250, DOI 10.1073/pnas.94.7.3250; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; Qian XL, 1999, J BIOL CHEM, V274, P574, DOI 10.1074/jbc.274.2.574; Qian XL, 1996, ONCOGENE, V13, P2149; Qu CK, 1999, P NATL ACAD SCI USA, V96, P8528, DOI 10.1073/pnas.96.15.8528; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; Rodeck U, 1997, P NATL ACAD SCI USA, V94, P5067, DOI 10.1073/pnas.94.10.5067; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Takada T, 1998, J BIOL CHEM, V273, P9234, DOI 10.1074/jbc.273.15.9234; Takahashi Y, 1999, J CELL PHYSIOL, V178, P69, DOI 10.1002/(SICI)1097-4652(199901)178:1<69::AID-JCP9>3.0.CO;2-Z; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tan M, 1999, CANCER RES, V59, P1620; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; Tanowitz M, 1999, J NEUROSCI, V19, P9426; Tsuda M, 1998, J BIOL CHEM, V273, P13223, DOI 10.1074/jbc.273.21.13223; Veillette A, 1998, J BIOL CHEM, V273, P22719, DOI 10.1074/jbc.273.35.22719; Vely F, 1997, EUR J IMMUNOL, V27, P1994, DOI 10.1002/eji.1830270825; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Wick W, 1999, ONCOGENE, V18, P3936, DOI 10.1038/sj.onc.1202774; Wu CJ, 1999, DNA CELL BIOL, V18, P731, DOI 10.1089/104454999314872; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Yamada M, 1999, J NEUROCHEM, V73, P41, DOI 10.1046/j.1471-4159.1999.0730041.x; Yamao T, 1997, BIOCHEM BIOPH RES CO, V231, P61, DOI 10.1006/bbrc.1996.6047; YAMAUCHI K, 1995, J BIOL CHEM, V270, P14871, DOI 10.1074/jbc.270.25.14871; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zhang SL, 1999, BIOCHEM BIOPH RES CO, V254, P440, DOI 10.1006/bbrc.1998.9959	70	56	59	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 17	2000	19	35					3999	4010		10.1038/sj.onc.1203748	http://dx.doi.org/10.1038/sj.onc.1203748			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962556				2022-12-25	WOS:000088825300005
J	Davare, MA; Horne, MC; Hell, JW				Davare, MA; Horne, MC; Hell, JW			Protein phosphatase 2A is associated with class C L-type calcium channels (Ca(v)1.2) and antagonizes channel phosphorylation by cAMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE PHOSPHATASES; D-ASPARTATE RECEPTOR; NEURONAL CLASS-C; CA2+ CHANNELS; HIPPOCAMPAL-NEURONS; DIFFERENTIAL PHOSPHORYLATION; BETA(2)-ADRENERGIC RECEPTORS; CHANNEL-ALPHA-1 SUBUNITS; CATALYTIC SUBUNIT; SIGNALING COMPLEX	Phosphorylation by cAMP-dependent protein kinase (PKA) regulates a vast number of cellular functions. An important target for PKA in brain and heart is the class C L-type Ca2+ channel (Ca(v)1.2). PKA phosphorylates serine 1928 in the central, pore-forming alpha (1C) subunit of this channel. Regulation of channel activity by PRA requires a proper balance between phosphorylation and dephosphorylation. For hat and specific signaling, PKA is recruited to this channel by an protein kinase A anchor protein (Davare, M. A, Dong, F., Rubin, C. S., and Hell, J.W (1999) J. Biol. Chem. 274, 39280-39287), A phosphatase may be associated with the channel to effectively balance serine 1928 phosphorylation by channel-bound PKA Dephosphorylation of this site is mediated by a serine/threonine phosphatase that is inhibited by okadaic acid and microcystin. We show that immunoprecipitation of the channel complex hom rat brain results in coprecipitation of PP2A Stoichiometric: analysis indicates that about 80% of the channel complexes contain PP2A PP2A directly and stably binds to the C-terminal 557 amino acids of alpha (1C). This interaction does not depend on serine 1928 phosphorylation and is not altered by PP2A catalytic site inhibitors. These results indicate that the PP2A-alpha (1C) interaction constitutively recruits PP2A to the channel complex rather than being a transient substrate-catalytic site interaction. Functional assays with the immunoisolated class C channel complex showed that channel-associated PP2A effectively reverses serine 1928 phosphorylation by endogenous PHA. Our findings demonstrate that both PKA and PP2A are integral components of the class C L-type Ca2+ channel that determine the phosphorylation level of serine 1928 and thereby channel activity.	Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Hell, JW (corresponding author), Univ Wisconsin, Dept Pharmacol, 3770 MSC,1300 Univ Ave, Madison, WI 53706 USA.	jwhell@facstaff.wisc.edu	Hell, Johannes W./P-5085-2019	Davare, Monika/0000-0003-1802-7597; Horne, Mary/0000-0002-2799-3212	NIA NIH HHS [R01-AG17502] Funding Source: Medline; NIGMS NIH HHS [R01-GM56900] Funding Source: Medline; NINDS NIH HHS [R01-NS35563] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056900] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017502] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Baharians Z, 1998, J BIOL CHEM, V273, P19019, DOI 10.1074/jbc.273.30.19019; BEAN BP, 1984, NATURE, V307, P371, DOI 10.1038/307371a0; BOLSHAKOV VY, 1994, SCIENCE, V264, P1148, DOI 10.1126/science.7909958; Bunemann M, 1999, J BIOL CHEM, V274, P33851, DOI 10.1074/jbc.274.48.33851; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Cheng Q, 1996, BIOCHEMISTRY-US, V35, P15593, DOI 10.1021/bi960709b; Christie BR, 1997, J NEUROPHYSIOL, V77, P1651, DOI 10.1152/jn.1997.77.3.1651; COEN DM, 1997, CURRENT PROTOCOLS MO, V2; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1991, METHOD ENZYMOL, V201, P389; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; Davare MA, 1999, J BIOL CHEM, V274, P30280, DOI 10.1074/jbc.274.42.30280; DeJongh KS, 1996, BIOCHEMISTRY-US, V35, P10392, DOI 10.1021/bi953023c; Edwards AS, 2000, CURR OPIN CELL BIOL, V12, P217, DOI 10.1016/S0955-0674(99)00085-X; Fraser IDC, 2000, CURR BIOL, V10, P409, DOI 10.1016/S0960-9822(00)00419-X; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; Gerhardstein BL, 2000, J BIOL CHEM, V275, P8556, DOI 10.1074/jbc.275.12.8556; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Gray PC, 1998, CURR OPIN NEUROBIOL, V8, P330, DOI 10.1016/S0959-4388(98)80057-3; Groschner K, 1996, BIOCHEM J, V318, P513, DOI 10.1042/bj3180513; GROVER LM, 1990, NATURE, V347, P477, DOI 10.1038/347477a0; Gupta V, 1997, J MED CHEM, V40, P3199, DOI 10.1021/jm960873x; HELL JW, 1995, EMBO J, V14, P3036, DOI 10.1002/j.1460-2075.1995.tb07306.x; HELL JW, 1993, J CELL BIOL, V123, P949, DOI 10.1083/jcb.123.4.949; Hell JW, 1996, P NATL ACAD SCI USA, V93, P3362, DOI 10.1073/pnas.93.8.3362; HELL JW, 1993, J BIOL CHEM, V268, P19451; HELL JW, 1994, ANN NY ACAD SCI, V747, P282; HESS P, 1984, NATURE, V311, P538, DOI 10.1038/311538a0; HONKANEN RE, 1990, J BIOL CHEM, V265, P19401; JOHNSON BD, 1994, P NATL ACAD SCI USA, V91, P11492, DOI 10.1073/pnas.91.24.11492; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; Kamp TJ, 2000, AM J PHYSIOL-HEART C, V278, pH126, DOI 10.1152/ajpheart.2000.278.1.H126; KINGSTON RE, 1997, CURRENT PROTOCOLS MO; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; Leonard AS, 1999, P NATL ACAD SCI USA, V96, P3239, DOI 10.1073/pnas.96.6.3239; Li Y, 1996, J BIOL CHEM, V271, P16862, DOI 10.1074/jbc.271.28.16862; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; Marrion NV, 1998, NATURE, V395, P900, DOI 10.1038/27674; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Moreno CS, 2000, J BIOL CHEM, V275, P5257, DOI 10.1074/jbc.275.8.5257; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; OMALLEY RP, 1986, CELL, V44, P391, DOI 10.1016/0092-8674(86)90460-5; ONO K, 1993, J PHYSIOL-LONDON, V470, P73, DOI 10.1113/jphysiol.1993.sp019848; ONO K, 1992, J PHYSIOL-LONDON, V454, P673, DOI 10.1113/jphysiol.1992.sp019286; PITCHER JA, 1995, P NATL ACAD SCI USA, V92, P8343, DOI 10.1073/pnas.92.18.8343; REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569a0; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SCULPTOREANU A, 1993, P NATL ACAD SCI USA, V90, P10135, DOI 10.1073/pnas.90.21.10135; Seibold A, 1998, J BIOL CHEM, V273, P7637, DOI 10.1074/jbc.273.13.7637; SHENOLIKAR S, 1984, METHOD ENZYMOL, V107, P102; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; Shih ML, 1999, J BIOL CHEM, V274, P1588, DOI 10.1074/jbc.274.3.1588; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; USUI H, 1988, J BIOL CHEM, V263, P3752; VALLEE RB, 1981, J CELL BIOL, V90, P568, DOI 10.1083/jcb.90.3.568; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; WADZINSKI BE, 1992, J BIOL CHEM, V267, P16883; Walker D, 1998, TRENDS NEUROSCI, V21, P148, DOI 10.1016/S0166-2236(97)01200-9; WEI XY, 1994, J BIOL CHEM, V269, P1635; WERA S, 1995, J BIOL CHEM, V270, P21374, DOI 10.1074/jbc.270.36.21374; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; WIECHEN K, 1995, J PHYSIOL-LONDON, V484, P583, DOI 10.1113/jphysiol.1995.sp020688; Yan Z, 1999, NAT NEUROSCI, V2, P13, DOI 10.1038/4516	70	138	139	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39710	39717		10.1074/jbc.M005462200	http://dx.doi.org/10.1074/jbc.M005462200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10984483	hybrid			2022-12-25	WOS:000165953100100
J	Votsch, W; Templin, MF				Votsch, W; Templin, MF			Characterization of a beta-N-acetylglucosaminidase of Escherichia coli and elucidation of its role in muropeptide recycling and beta-lactamase induction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL PEPTIDES; LYTIC TRANSGLYCOSYLASE; MUREIN SACCULUS; MOLECULAR-CLONING; D-GLUCOSAMINIDASE; GENE; GROWTH; AMPD; IDENTIFICATION; PROTEIN-7/8	Using the known mapping position the gene encoding a beta -1,4-N-acetylglucosaminidase needed for the degradation of muropeptides could be identified, nagZ encodes a cytosolic enzyme active on N-actylglucosamyl-beta -1,4-(1,6)-anhydromuramic acid containing muropeptides. These degradation products of the peptidoglycan are formed during the enlargement of the murein sacculus as a consequence of a growth mechanism, which couples the controlled degradation of the cell wall polymer with the insertion of new material. NagZ is needed for the formation of monosaccharides from the released disaccharides during the cytosolic steps of the muropeptide-recycling pathway. The formation of intracellular 1,6-anhydro-N-acetylmuramyl-peptides is important for the expression control of the inducible beta -lactamases of the AmpC type. A mutant lacking active NagZ cannot establish AmpC mediated beta -lactam resistance. The biochemical characterization of the enzyme showed its activity on different muropeptides and inhibitors of enzyme activity could be identified, This observation might be important for designing inhibitors of NagZ that could prevent the establishment of beta -lactam resistance of Enterobacteria possessing inducible beta -lactamases.	Max Planck Inst Entwicklungsbiol, Biochem Abt, D-72076 Tubingen, Germany	Max Planck Society	Templin, MF (corresponding author), Univ Tubingen, NMI, Markwiesenstr 55, D-72770 Reutlingen, Germany.	Templin@nmi.de						Altschul SF, 1998, TRENDS BIOCHEM SCI, V23, P444, DOI 10.1016/S0968-0004(98)01298-5; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BISSWANGER H, 1994, ENZYMKINETIK; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Chitlaru E, 1996, J BIOL CHEM, V271, P33433, DOI 10.1074/jbc.271.52.33433; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; GLAUNER B, 1988, ANAL BIOCHEM, V172, P451, DOI 10.1016/0003-2697(88)90468-X; GOODELL EW, 1985, J BACTERIOL, V162, P391, DOI 10.1128/JB.162.1.391-397.1985; GOODELL EW, 1987, J BACTERIOL, V169, P3861, DOI 10.1128/jb.169.8.3861-3865.1987; GOODELL EW, 1985, J BACTERIOL, V163, P305, DOI 10.1128/JB.163.1.305-310.1985; Holtje JV, 1996, MICROBIOL-SGM, V142, P1911, DOI 10.1099/13500872-142-8-1911; Holtje JV, 1998, MICROBIOL MOL BIOL R, V62, P181; HOLTJE JV, 1975, J BACTERIOL, V124, P1067; HOLTJE JV, 1994, FEMS MICROBIOL LETT, V122, P159, DOI 10.1111/j.1574-6968.1994.tb07159.x; HOLTJE JV, 1995, ARCH MICROBIOL, V164, P243, DOI 10.1007/s002030050261; HREBENDA J, 1979, ACTA MICROBIOL POL, V28, P53; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; Jacobs C, 1997, CELL, V88, P823, DOI 10.1016/S0092-8674(00)81928-5; JACOBS C, 1995, MOL MICROBIOL, V15, P553, DOI 10.1111/j.1365-2958.1995.tb02268.x; JACOBS C, 1994, EMBO J, V13, P4684, DOI 10.1002/j.1460-2075.1994.tb06792.x; Jacobs C, 1997, SCIENCE, V278, P1731, DOI 10.1126/science.278.5344.1731b; KECK W, 1990, MOL MICROBIOL, V4, P209, DOI 10.1111/j.1365-2958.1990.tb00588.x; KOHLRAUSCH U, 1991, J BACTERIOL, V173, P3425, DOI 10.1128/jb.173.11.3425-3431.1991; KOPP U, 1993, ANTIMICROB AGENTS CH, V37, P224, DOI 10.1128/AAC.37.2.224; KORAT B, 1991, MOL MICROBIOL, V5, P675, DOI 10.1111/j.1365-2958.1991.tb00739.x; Kraft AR, 1999, J BACTERIOL, V181, P7192, DOI 10.1128/JB.181.23.7192-7198.1999; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; MenginLecreulx D, 1996, J BACTERIOL, V178, P5347, DOI 10.1128/jb.178.18.5347-5352.1996; OCALLAGHAN CH, 1972, ANTIMICROB AGENTS CH, V1, P283, DOI 10.1128/AAC.1.4.283; PARK JT, 1993, J BACTERIOL, V175, P7, DOI 10.1128/JB.175.1.7-11.1993; PARK JT, 1995, MOL MICROBIOL, V17, P421, DOI 10.1111/j.1365-2958.1995.mmi_17030421.x; Park JT, 1996, MICROB DRUG RESIST, V2, P105, DOI 10.1089/mdr.1996.2.105; Park JT, 1998, J BACTERIOL, V180, P1215, DOI 10.1128/JB.180.5.1215-1223.1998; ROMEIS T, 1994, J BIOL CHEM, V269, P21603; ROMEIS T, 1994, EUR J BIOCHEM, V224, P597, DOI 10.1111/j.1432-1033.1994.00597.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU, V2; TEMPLIN MF, 1992, J BIOL CHEM, V267, P20039; Templin MF, 1999, EMBO J, V18, P4108, DOI 10.1093/emboj/18.15.4108; THUNNISSEN AMWH, 1995, PROTEINS, V22, P245, DOI 10.1002/prot.340220305; Vocadlo DJ, 2000, BIOCHEMISTRY-US, V39, P117, DOI 10.1021/bi991958d; Vollmer W, 1999, J BIOL CHEM, V274, P6726, DOI 10.1074/jbc.274.10.6726; WEIDEL W, 1964, ADV ENZYMOL REL S BI, V26, P193; Wiedemann B, 1998, CLIN INFECT DIS, V27, pS42, DOI 10.1086/514921; Yang M, 1996, MICROBIOL-SGM, V142, P1659, DOI 10.1099/13500872-142-7-1659; YEM DW, 1976, J BACTERIOL, V125, P324, DOI 10.1128/JB.125.1.324-331.1976; YEM DW, 1976, J BACTERIOL, V125, P372, DOI 10.1128/JB.125.1.372-373.1976	48	102	103	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39032	39038		10.1074/jbc.M004797200	http://dx.doi.org/10.1074/jbc.M004797200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10978324	hybrid			2022-12-25	WOS:000165953100014
J	Brinkman, AB; Dahlke, I; Tuininga, JE; Lammers, T; Dumay, V; de Heus, E; Lebbink, JHG; Thomm, M; de Vos, WM; van der Oost, J				Brinkman, AB; Dahlke, I; Tuininga, JE; Lammers, T; Dumay, V; de Heus, E; Lebbink, JHG; Thomm, M; de Vos, WM; van der Oost, J			An Lrp-like transcriptional regulator from the archaeon Pyrococcus furiosus is negatively autoregulated	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE TRANSCRIPTION; INTEGRATION HOST FACTOR; ESCHERICHIA-COLI; TATA-BOX; CRYSTAL-STRUCTURE; SULFOLOBUS-SOLFATARICUS; METHANOCOCCUS-VANNIELII; REPRESSOR BINDING; GLOBAL REGULATOR; DNA INTERACTIONS	The archaeal transcriptional initiation machinery closely resembles core elements of the eukaryal polymerase II system. However, apart from the established basal archaeal transcription system, little is known about the modulation of gene expression in archaea, At present, no obvious eukaryal-like transcriptional regulators have been identified in archaea. Instead, we have previously isolated an archaeal gene, the Pyrococcus furiosus lrpA, that potentially encodes a bacterial-like transcriptional regulator, In the present study, we have for the first time addressed the actual involvement of an archaeal Lrp homologue in transcription modulation, For that purpose, we have produced LrpA in Escherichia coli, In a cell-free P. furiosus transcription system we used wild-type and mutated lrpA promoter fragments to demonstrate that the purified LrpA negatively regulates its own transcription. In addition, gel retardation analyses revealed a single protein-DNA complex, in which LrpA appeared to be present in (at least) a tetrameric conformation. The location of the LrpA binding site was further identified by DNaseI and hydroxyl radical footprinting, indicating that LrpA binds to a 46-base pair sequence that overlaps the transcriptional start site of its own promoter. The molecular basis of the transcription inhibition by LrpA is discussed.	Univ Wageningen & Res Ctr, Microbiol Lab, Dept Agrotechnol & Food Sci, NL-6703 CT Wageningen, Netherlands; Univ Kiel, Inst Allgemeine Mikrobiol, D-24118 Kiel, Germany	Wageningen University & Research; University of Kiel	Brinkman, AB (corresponding author), Univ Wageningen & Res Ctr, Microbiol Lab, Dept Agrotechnol & Food Sci, Hesselink van Suchtelenweg 4, NL-6703 CT Wageningen, Netherlands.		van+der+Oost, John/Y-2548-2019; Brinkman, Arie/V-1533-2018; Lammers, Twan/U-2794-2018	Brinkman, Arie/0000-0002-9875-1835; Lammers, Twan/0000-0002-1090-6805				Bell SD, 1999, MOL CELL, V4, P971, DOI 10.1016/S1097-2765(00)80226-9; Bell SD, 1998, TRENDS MICROBIOL, V6, P222, DOI 10.1016/S0966-842X(98)01281-5; Bell SD, 1999, P NATL ACAD SCI USA, V96, P13662, DOI 10.1073/pnas.96.24.13662; Bernues J, 1996, NUCLEIC ACIDS RES, V24, P2950, DOI 10.1093/nar/24.15.2950; CALVO JM, 1994, MICROBIOL REV, V58, P466, DOI 10.1128/MMBR.58.3.466-490.1994; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CHAPON C, 1983, J BACTERIOL, V156, P1135, DOI 10.1128/JB.156.3.1135-1143.1983; Charlier D, 1997, GENE, V201, P63, DOI 10.1016/S0378-1119(97)00428-9; Cohen-Kupiec R, 1999, J BACTERIOL, V181, P256, DOI 10.1128/JB.181.1.256-261.1999; CohenKupiec R, 1997, P NATL ACAD SCI USA, V94, P1316, DOI 10.1073/pnas.94.4.1316; Cui YH, 1996, J BIOL CHEM, V271, P6611, DOI 10.1074/jbc.271.12.6611; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; DEWIND N, 1985, NUCLEIC ACIDS RES, V13, P8797, DOI 10.1093/nar/13.24.8797; DODD IB, 1990, NUCLEIC ACIDS RES, V18, P5019, DOI 10.1093/nar/18.17.5019; EGGEN RIL, 1993, GENE, V132, P143, DOI 10.1016/0378-1119(93)90527-A; FERRARIO M, 1995, J BACTERIOL, V177, P103, DOI 10.1128/jb.177.1.103-113.1995; FREY G, 1990, NUCLEIC ACIDS RES, V18, P1361, DOI 10.1093/nar/18.6.1361; Galasinski SK, 2000, MOL CELL BIOL, V20, P1923, DOI 10.1128/MCB.20.6.1923-1930.2000; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; GASTON K, 1992, NUCLEIC ACIDS RES, V20, P3391, DOI 10.1093/nar/20.13.3391; GAZEAU M, 1994, J MOL BIOL, V241, P378, DOI 10.1006/jmbi.1994.1514; HAUSNER W, 1991, J MOL BIOL, V222, P495, DOI 10.1016/0022-2836(91)90492-O; Hausner W, 1996, J BIOL CHEM, V271, P30144, DOI 10.1074/jbc.271.47.30144; Hethke C, 1996, NUCLEIC ACIDS RES, V24, P2369, DOI 10.1093/nar/24.12.2369; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hochheimer A, 1999, MOL MICROBIOL, V31, P641, DOI 10.1046/j.1365-2958.1999.01204.x; HOCHSEHILD A, 1991, METHOD ENZYMOL, V208, P434; Huang N, 1996, BIOCHEM BIOPH RES CO, V223, P315, DOI 10.1006/bbrc.1996.0891; Jafri S, 1999, J MOL BIOL, V288, P811, DOI 10.1006/jmbi.1999.2715; Kawarabayasi Y, 1998, DNA Res, V5, P147, DOI 10.1093/dnares/5.2.147; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; KELLEY WL, 1991, J BIOL CHEM, V266, P15924; KEUNTJE B, 1995, J BACTERIOL, V177, P6432, DOI 10.1128/jb.177.22.6432-6439.1995; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KOLLING R, 1985, J BACTERIOL, V164, P310; Kruger K, 1998, J MOL BIOL, V279, P761, DOI 10.1006/jmbi.1998.1795; KYRPIDES NC, 1995, TRENDS BIOCHEM SCI, V20, P140, DOI 10.1016/S0968-0004(00)88988-4; Kyrpides NC, 1999, P NATL ACAD SCI USA, V96, P8545, DOI 10.1073/pnas.96.15.8545; LILJELUND P, 1993, MOL GEN GENET, V241, P694, DOI 10.1007/BF00279913; Littlefield O, 1999, P NATL ACAD SCI USA, V96, P13668, DOI 10.1073/pnas.96.24.13668; MADHUSUDHAN KT, 1995, J BACTERIOL, V177, P636, DOI 10.1128/jb.177.3.636-641.1995; Mathew E, 1996, J BACTERIOL, V178, P7234, DOI 10.1128/jb.178.24.7234-7240.1996; Morgan RM, 1997, J BACTERIOL, V179, P889, DOI 10.1128/jb.179.3.889-898.1997; Napoli A, 1999, J BACTERIOL, V181, P1474, DOI 10.1128/JB.181.5.1474-1480.1999; NEWMAN EB, 1995, ANNU REV MICROBIOL, V49, P747, DOI 10.1146/annurev.mi.49.100195.003531; Nolling J, 1997, J BACTERIOL, V179, P899; NOU XW, 1995, EMBO J, V14, P5785, DOI 10.1002/j.1460-2075.1995.tb00267.x; PLUMBRIDGE J, 1991, J MOL BIOL, V217, P661, DOI 10.1016/0022-2836(91)90524-A; Rhee KY, 1996, J BIOL CHEM, V271, P26499, DOI 10.1074/jbc.271.43.26499; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; Rink R, 1997, J BIOL CHEM, V272, P14650, DOI 10.1074/jbc.272.23.14650; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SIRKO A, 1993, J BACTERIOL, V175, P5769, DOI 10.1128/JB.175.18.5769-5777.1993; Soppa J, 1999, MOL MICROBIOL, V31, P1589, DOI 10.1046/j.1365-2958.1999.01274.x; Soppa J, 1999, MOL MICROBIOL, V31, P1295, DOI 10.1046/j.1365-2958.1999.01273.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Thomm M, 1996, FEMS MICROBIOL REV, V18, P159; TRAVERS AA, 1989, ANNU REV BIOCHEM, V58, P427, DOI 10.1146/annurev.biochem.58.1.427; TSAI MM, 1990, J BACTERIOL, V172, P4603, DOI 10.1128/jb.172.8.4603-4609.1990; Voorhorst WGB, 1999, J BACTERIOL, V181, P3777, DOI 10.1128/JB.181.12.3777-3783.1999; WANG Q, 1993, J MOL BIOL, V229, P306, DOI 10.1006/jmbi.1993.1036; WANG Q, 1993, EMBO J, V12, P2495, DOI 10.1002/j.1460-2075.1993.tb05904.x; WANG Q, 1994, J BACTERIOL, V176, P1831, DOI 10.1128/jb.176.7.1831-1839.1994; Ward DE, 2000, J BACTERIOL, V182, P2559, DOI 10.1128/JB.182.9.2559-2566.2000; WEBSTER C, 1988, GENE, V68, P297, DOI 10.1016/0378-1119(88)90032-7; Wiese DE, 1997, J MOL BIOL, V270, P152, DOI 10.1006/jmbi.1997.1057; WILLINS DA, 1991, J BIOL CHEM, V266, P10768	69	72	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38160	38169		10.1074/jbc.M005916200	http://dx.doi.org/10.1074/jbc.M005916200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10973967	hybrid			2022-12-25	WOS:000165739800006
J	Perdomo, J; Holmes, M; Chong, E; Crossley, M				Perdomo, J; Holmes, M; Chong, E; Crossley, M			Eos and Pegasus, two members of the Ikaros family of proteins with distinct DNA binding activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; TRANSCRIPTION FACTOR; HISTONE DEACETYLASE; CENTROMERIC HETEROCHROMATIN; LYMPHOCYTE DEVELOPMENT; GENE; EXPRESSION; REPRESSION; COMPLEXES; ISOFORMS	Members of the Ikaros family of transcription factors, Ikaros, Aiolos, and Hellos, are expressed in lymphocytes and have been implicated in controlling lymphoid development. These proteins contain two characteristic clusters of zinc fingers, an N-terminal domain important for DNA recognition, and a C-terminal domain that mediates homo- and heterotypic associations between family members. The conservation of these domains is such that all three proteins recognize related DNA sequences, and all are capable of dimerizing with other family members. Here we describe two additional Ikaros family proteins, Eos and Pegasus. Eos is most highly related to Hellos and shares its DNA binding and protein association properties. Pegasus is related to other Ikaros proteins in its C-terminal dimerization domain but contains a divergent N-terminal zinc finger domain, Pegasus self-associates and binds to other family members but recognizes distinct DNA-binding sites, Eos and Pegasus repress the expression of reporter genes containing their recognition elements. Our results suggest that these proteins may associate with previously described Ikaros family proteins in lymphoid cells and play additional roles in other tissues.	Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia; Univ New S Wales, Sch Pathol, Ctr Thrombosis & Vasc Res, Sydney, NSW 2052, Australia	University of Sydney; University of New South Wales Sydney	Crossley, M (corresponding author), Univ Sydney, Dept Biochem, G08, Sydney, NSW 2006, Australia.		Crossley, Merlin/D-7888-2011; Perdomo, Jose/H-8871-2019	Crossley, Merlin/0000-0003-2057-3642; Perdomo, Jose/0000-0002-1554-708X; Holmes, Melissa/0000-0001-5894-6649				Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; Georgopoulos K, 1997, ANNU REV IMMUNOL, V15, P155, DOI 10.1146/annurev.immunol.15.1.155; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; Hahm K, 1998, GENE DEV, V12, P782, DOI 10.1101/gad.12.6.782; HAHM KM, 1994, MOL CELL BIOL, V14, P7111, DOI 10.1128/MCB.14.11.7111; Honma Y, 1999, FEBS LETT, V447, P76, DOI 10.1016/S0014-5793(99)00265-3; Hosokawa Y, 1999, IMMUNOGENETICS, V50, P106, DOI 10.1007/s002510050696; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; Kelley CM, 1998, CURR BIOL, V8, P508, DOI 10.1016/S0960-9822(98)70202-7; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; KLEVIT RE, 1991, SCIENCE, V253, P1367, DOI 10.1126/science.1896847; KLEVIT RE, 1991, SCIENCE, V253, P1393; Klug CA, 1998, P NATL ACAD SCI USA, V95, P657, DOI 10.1073/pnas.95.2.657; Koipally J, 2000, J BIOL CHEM, V275, P19594, DOI 10.1074/jbc.M000254200; Koipally J, 1999, EMBO J, V18, P3090, DOI 10.1093/emboj/18.11.3090; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; Momeni P, 2000, NAT GENET, V24, P71, DOI 10.1038/71717; Morgan B, 1997, EMBO J, V16, P2004, DOI 10.1093/emboj/16.8.2004; Nietfeld W, 1996, IMMUNOL LETT, V49, P139, DOI 10.1016/0165-2478(95)02479-4; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; Sambrook J., 2002, MOL CLONING LAB MANU; Schreiber-Agus N, 1998, BIOESSAYS, V20, P808, DOI 10.1002/(SICI)1521-1878(199810)20:10<808::AID-BIES6>3.0.CO;2-U; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; Sun L, 1999, P NATL ACAD SCI USA, V96, P680, DOI 10.1073/pnas.96.2.680; Sun L, 1999, J CLIN ONCOL, V17, P3753, DOI 10.1200/JCO.1999.17.12.3753; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wang JH, 1996, IMMUNITY, V5, P537, DOI 10.1016/S1074-7613(00)80269-1; Wang JH, 1998, IMMUNITY, V9, P543, DOI 10.1016/S1074-7613(00)80637-8; WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4; ZweidlerMcKay PA, 1996, MOL CELL BIOL, V16, P4024	36	92	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38347	38354		10.1074/jbc.M005457200	http://dx.doi.org/10.1074/jbc.M005457200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10978333	hybrid			2022-12-25	WOS:000165739800030
J	Xiao, KH; Yu, L; Yu, CA				Xiao, KH; Yu, L; Yu, CA			Confirmation of the involvement of protein domain movement during the catalytic cycle of the cytochrome bc1 complex by the formation of an intersubunit disulfide bond between cytochrome b and the iron-sulfur protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WATER-SOLUBLE FRAGMENT; BC(1) COMPLEX; RHODOBACTER-SPHAEROIDES; BOVINE HEART; ELECTRON-TRANSFER; Q0 SITE; MITOCHONDRIAL; UBIQUINONE; CAPSULATUS; BINDING	To study the essentiality of head domain movement of the Rieske iron-sulfur protein (ISP) during bc(1) catalysis, Rhodobacter sphaeroides mutants expressing His-tagged cytochrome be, complexes with three pairs of cysteines engineered (one cysteine each) on the interface between cytochrome b and ISP, A185C(cytb)/K70C(ISP), I326C(cytb)/G165C(ISP), and T386C(cytb)/K164C(ISP), were generated and characterized. Formation of an intersubunit disulfide bond between cytochrome b and ISP is detected in membrane (intracytoplasmic membrane and air-aged chromatophore), and purified be, complex was prepared from the A185C(cytb)/K70C(ISP) mutant cells. Formation of the intersubunit disulfide bond in this cysteine pair mutant complex is concurrent with the loss of its be, activity. Reduction of this disulfide bond by P-mercaptoethanol restores activity, indicating that mobility of the head domain of ISP is functionally important in the cytochrome be, complex. The rate of intramolecular electron transfer, between 2Fe2S and heme c(1), in the A185C(cytb)/K70C(ISP) mutant complex is much lower than that in the wild type or in their respective single cysteine mutant complexes, indicating that formation of an intersubunit disulfide bond between cytochrome b and ISP arrests the head domain of ISP in the "fixed state" position, which is too far for electron transfer to heme c(1).	Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA	Oklahoma State University System; Oklahoma State University - Stillwater	Yu, CA (corresponding author), Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA.		Xiao, Kunhong/AAG-4275-2020	Xiao, Kunhong/0000-0002-1069-1226	NIGMS NIH HHS [GM30721] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030721, R37GM030721] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS KM, 1990, BIOCHEMISTRY-US, V29, P2645, DOI 10.1021/bi00463a004; ATTAASAFOADJEI E, 1991, P NATL ACAD SCI USA, V88, P492, DOI 10.1073/pnas.88.2.492; BERDEN JA, 1970, BIOCHIM BIOPHYS ACTA, V216, P237, DOI 10.1016/0005-2728(70)90215-X; DAVIDSON E, 1992, BIOCHEMISTRY-US, V31, P3342, DOI 10.1021/bi00128a006; DING HG, 1992, BIOCHEMISTRY-US, V31, P3144, DOI 10.1021/bi00127a015; GRAY KA, 1992, BIOCHEMISTRY-US, V31, P11864, DOI 10.1021/bi00162a027; Guergova-Kuras M, 1999, PROTEIN EXPRES PURIF, V15, P370, DOI 10.1006/prep.1998.1018; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Iwata S, 1996, STRUCTURE, V4, P567, DOI 10.1016/S0969-2126(96)00062-7; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Link TA, 1996, EUR J BIOCHEM, V237, P71, DOI 10.1111/j.1432-1033.1996.0071n.x; Link TA, 1996, BIOCHEMISTRY-US, V35, P7546, DOI 10.1021/bi960004+; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATHER MW, 1995, J BIOL CHEM, V270, P28668, DOI 10.1074/jbc.270.48.28668; MCCURLEY JP, 1990, BIOCHIM BIOPHYS ACTA, V1020, P176, DOI 10.1016/0005-2728(90)90049-A; MEINHARDT SW, 1987, J BIOL CHEM, V262, P8702; ROBERTSON DE, 1990, BIOCHEMISTRY-US, V29, P11249, DOI 10.1021/bi00503a014; Tian H, 1999, J BIOL CHEM, V274, P7146, DOI 10.1074/jbc.274.11.7146; Tian H, 1998, J BIOL CHEM, V273, P27953, DOI 10.1074/jbc.273.43.27953; Tian H, 1997, J BIOL CHEM, V272, P23722, DOI 10.1074/jbc.272.38.23722; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; Tso SC, 2000, J BIOL CHEM, V275, P15287, DOI 10.1074/jbc.M907367199; Ugulava NB, 1998, FEBS LETT, V440, P409, DOI 10.1016/S0014-5793(98)01493-8; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; YU CA, 1982, BIOCHEMISTRY-US, V21, P4096, DOI 10.1021/bi00260a028; YU L, 1986, BIOCHIM BIOPHYS ACTA, V852, P203, DOI 10.1016/0005-2728(86)90225-2; YU L, 1992, J BIOL CHEM, V267, P24508; Zhang L, 2000, J BIOL CHEM, V275, P7656, DOI 10.1074/jbc.275.11.7656; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	30	62	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38597	38604		10.1074/jbc.M007444200	http://dx.doi.org/10.1074/jbc.M007444200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10978350	hybrid			2022-12-25	WOS:000165739800062
J	Graversen, JH; Jacobsen, C; Sigurskjold, BW; Lorentsen, RH; Moestrup, SK; Thogersen, HC; Etzerodt, M				Graversen, JH; Jacobsen, C; Sigurskjold, BW; Lorentsen, RH; Moestrup, SK; Thogersen, HC; Etzerodt, M			Mutational analysis of affinity and selectivity of kringle-tetranectin interaction - Grafting novel kringle affinity onto the tetranectin lectin scaffold	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE LECTIN; CARBOHYDRATE-RECOGNITION DOMAIN; HUMAN-PLASMINOGEN; BINDING-SITE; PLASMA-TETRANECTIN; HOMOLOGOUS DOMAINS; CRYSTAL-STRUCTURE; GENE-EXPRESSION; PROTEIN; ANGIOSTATIN	C-type lectin-like domains are found in many proteins, where they mediate binding to a wide diversity of compounds, including carbohydrates, lipids, and proteins. The binding of a C-type lectin-like domain to a ligand is often influenced by calcium. Recently, we have identified a site in the C-type lectin-like domain of tetranectin, involving Lys-148, Glu-150, and Asp-165, which mediates calcium-sensitive binding to plasminogen kringle 4. Here, we investigate the effect of conservative substitutions of these and a neighboring amino acid residue. Substitution of Thr-149 in tetranectin with a tyrosine residue considerably increases the affinity for plasminogen kringle 4, and, in addition, confers affinity for plasminogen kringle 2. As shown by isothermal titration calorimetry analysis, this new interaction is stronger than the binding of wild-type tetranectin to plasminogen kringle 4. This study provides further insight into molecular determinants of importance for binding selectivity and affinity of C-type lectin kringle interactions.	Aarhus Univ, Dept Biol Mol & Struct, Lab Gene Express, DK-8000 Aarhus C, Denmark; Aarhus Univ, Dept Biochem Med, DK-8000 Aarhus, Denmark; Univ Copenhagen, August Krogh Inst, DK-2100 Copenhagen O, Denmark	Aarhus University; Aarhus University; University of Copenhagen	Etzerodt, M (corresponding author), Sci Pk Aarhus,Gustav Wieds Vej 10C, DK-8000 Aarhus C, Denmark.		Moestrup, Søren Kragh/A-1403-2014; Moestrup, Søren Kragh/AAD-1735-2019	Moestrup, Søren Kragh/0000-0003-3862-2107; Graversen, Jonas Heilskov/0000-0002-2411-9933; Graversen, Jonas Heilskov/0000-0001-7119-2108				Aspberg A, 1999, J BIOL CHEM, V274, P20444, DOI 10.1074/jbc.274.29.20444; Aspberg A, 1997, P NATL ACAD SCI USA, V94, P10116, DOI 10.1073/pnas.94.19.10116; Cao YH, 1997, J BIOL CHEM, V272, P22924, DOI 10.1074/jbc.272.36.22924; Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; CHRISTENSEN L, 1991, HISTOCHEMISTRY, V95, P427, DOI 10.1007/BF00315737; CHRISTENSEN L, 1989, HISTOCHEMISTRY, V92, P29, DOI 10.1007/BF00495012; CLEMMENSEN I, 1989, SCAND J CLIN LAB INV, V49, P719, DOI 10.3109/00365518909091550; CLEMMENSEN I, 1986, EUR J BIOCHEM, V156, P327, DOI 10.1111/j.1432-1033.1986.tb09586.x; deVries TJ, 1996, J PATHOL, V179, P260, DOI 10.1002/(SICI)1096-9896(199607)179:3<260::AID-PATH586>3.0.CO;2-T; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; Ellgaard L, 1997, EUR J BIOCHEM, V244, P544, DOI 10.1111/j.1432-1033.1997.00544.x; Ewart KV, 1998, BIOCHEMISTRY-US, V37, P4080, DOI 10.1021/bi972503w; FUHLENDORFF J, 1987, BIOCHEMISTRY-US, V26, P6757, DOI 10.1021/bi00395a027; Graversen JH, 1998, J BIOL CHEM, V273, P29241, DOI 10.1074/jbc.273.44.29241; Graversen JH, 2000, BIOCHEMISTRY-US, V39, P7414, DOI 10.1021/bi000155j; Hogdall C K, 1998, APMIS Suppl, V86, P1; Holtet TL, 1997, PROTEIN SCI, V6, P1511, DOI 10.1002/pro.5560060715; JENSEN BA, 1988, CANCER, V62, P869, DOI 10.1002/1097-0142(19880901)62:5<869::AID-CNCR2820620503>3.0.CO;2-6; Ji WDR, 1998, FASEB J, V12, P1731, DOI 10.1096/fasebj.12.15.1731; Kastrup JS, 1998, ACTA CRYSTALLOGR D, V54, P757, DOI 10.1107/S0907444997016806; LERCH PG, 1980, EUR J BIOCHEM, V107, P7, DOI 10.1111/j.1432-1033.1980.tb04617.x; LORENTSEN RH, 2000, BIOCHEM J, V347, P33; MacDonald NJ, 1999, BIOCHEM BIOPH RES CO, V264, P469, DOI 10.1006/bbrc.1999.1486; MARTI D, 1994, EUR J BIOCHEM, V219, P455, DOI 10.1111/j.1432-1033.1994.tb19959.x; Marti DN, 1999, BIOCHEMISTRY-US, V38, P15741, DOI 10.1021/bi9917378; Marti DN, 1997, BIOCHEMISTRY-US, V36, P11591, DOI 10.1021/bi971316v; Natarajan K, 1999, IMMUNITY, V11, P591, DOI 10.1016/S1074-7613(00)80134-X; Nielsen BB, 1997, FEBS LETT, V412, P388, DOI 10.1016/S0014-5793(97)00664-9; OREILLY MS, 1994, COLD SPRING HARB SYM, V59, P471, DOI 10.1101/SQB.1994.059.01.052; PONTING CP, 1992, BLOOD COAGUL FIBRIN, V3, P605, DOI 10.1097/00001721-199210000-00012; Sano H, 1998, J BIOL CHEM, V273, P4783, DOI 10.1074/jbc.273.8.4783; Sohndel S, 1996, BIOCHEMISTRY-US, V35, P2357, DOI 10.1021/bi9520949; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; Tormo J, 1999, NATURE, V402, P623, DOI 10.1038/45170; VERCELLI D, 1989, NATURE, V338, P649, DOI 10.1038/338649a0; Wewer UM, 1998, DEV BIOL, V200, P247, DOI 10.1006/dbio.1998.8962; WEWER UM, 1994, J CELL BIOL, V127, P1767, DOI 10.1083/jcb.127.6.1767; WEWER UM, 1992, LAB INVEST, V67, P253; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; WU TP, 1991, BIOCHEMISTRY-US, V30, P10589, DOI 10.1021/bi00107a030	40	10	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37390	37396		10.1074/jbc.M004873200	http://dx.doi.org/10.1074/jbc.M004873200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10964919	hybrid			2022-12-25	WOS:000165618700013
J	Lijnen, HR; Arza, B; Van Hoef, B; Collen, D; Declerck, PJ				Lijnen, HR; Arza, B; Van Hoef, B; Collen, D; Declerck, PJ			Inactivation of plasminogen activator inhibitor-1 by specific proteolysis with stromelysin-1 (MMP-3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UROKINASE RECEPTOR; HUMAN-PLASMA; ALPHA-1-PROTEINASE INHIBITOR; CONFORMATIONAL-CHANGES; BINDING-PROTEIN; GENE-EXPRESSION; CELL-MIGRATION; U-PA; VITRONECTIN; TYPE-1	Matrix metalloproteinase-3 (MMP-3 or stromelysin-1) specifically hydrolyzes the Ser(337)-Ser(338) (P10-P9) and Val(341)-Ile(342) (P6-P5) peptide bonds in human plasminogen activator inhibitor-1 (PAI-1). Cleavage is completely abolished in the presence of the metal chelators EDTA or 1,10-phenanthroline. A stabilized active PAI-1 variant was also cleaved by MMP-3. At an enzyme/substrate ratio of 1/10 at 37 degreesC, PAI-1 protein cleavage occurred with half-lives of 27 or 14 min for active or stable PAI-1 and was associated with rapid loss of inhibitory activity toward tissue-type plasminogen activator with half-lives of 15 or 13 min, respectively. A substrate-like variant of PAI-1, lacking inhibitory activity but with exposed reactive site loop, was cleaved with a half-life of 23 min, whereas latent PAI-1 in which a major part of the reactive site loop is inserted into the molecule, was resistant to cleavage, Biospecific interaction analysis indicated comparable binding of active, stable, and substrate PAI-1 to both proMMP-3 and MMP-3 (K-A of 12-22 x 10(6) M-1), whereas binding of latent PAI-1 occurred with lower affinity (1.7-2.3 x 10(6) M-1). Stable PAI-1 bound to vitronectin was cleaved and inactivated by MMP-3 in a manner comparable with that of free PAI-1; however, the cleaved protein did not bind to vitronectin. Cleavage and inactivation of PAI-1 by MMP-3 may thus constitute a mechanism decreasing the antiproteolytic activity of PAI-1 and impairing the potential inhibitory effect of vitronectin-bound PAI-1 on cell adhesion and/or migration.	Katholieke Univ Leuven, Ctr Mol & Vasc Biol, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Lab Pharmaceut Biol & Phytopharmacol, B-3000 Louvain, Belgium	KU Leuven; KU Leuven	Lijnen, HR (corresponding author), Katholieke Univ Leuven, Ctr Mol & Vasc Biol, Campus Gasthuisberg O&N,Herestr 49, B-3000 Louvain, Belgium.	roger.lijnen@med.kuleuven.ac.be	Declerck, Paul J/A-2330-2017; Lijnen, Roger/AAA-4085-2020	Declerck, Paul J/0000-0003-1259-9105; 				AERTGEERTS K, 1995, NAT STRUCT BIOL, V2, P891, DOI 10.1038/nsb1095-891; AUDENAERT AM, 1994, J BIOL CHEM, V269, P19559; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Bini A, 1996, BIOCHEMISTRY-US, V35, P13056, DOI 10.1021/bi960730c; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; CARRELL RW, 1985, NATURE, V317, P730, DOI 10.1038/317730a0; COLUCCI M, 1985, J CLIN INVEST, V75, P818, DOI 10.1172/JCI111777; DECLERCK PJ, 1995, THROMB HAEMOSTASIS, V74, P1305; DECLERCK PJ, 1988, BLOOD, V71, P220; DECLERCK PJ, 1992, J BIOL CHEM, V267, P11693; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; DESROCHERS PE, 1991, J CLIN INVEST, V87, P2258, DOI 10.1172/JCI115262; DESROCHERS PE, 1992, J BIOL CHEM, V267, P5005; Ehnebom J, 2000, FIBRINOLYSIS PROTEOL, V14, P47, DOI 10.1054/fipr.2000.0052; EHRLICH HJ, 1991, J CELL BIOL, V115, P1773, DOI 10.1083/jcb.115.6.1773; FA M, 1995, BIOCHEMISTRY-US, V34, P13833, DOI 10.1021/bi00042a015; FEINBERG RF, 1989, LAB INVEST, V61, P20; Gibson A, 1997, J BIOL CHEM, V272, P5112, DOI 10.1074/jbc.272.8.5112; Gils A, 1997, J BIOL CHEM, V272, P12662, DOI 10.1074/jbc.272.19.12662; Gils A, 1998, THROMB HAEMOSTASIS, V80, P531; GINSBURG D, 1986, J CLIN INVEST, V78, P1673, DOI 10.1172/JCI112761; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JuhanVague I, 1997, THROMB HAEMOSTASIS, V78, P656; JUHANVAGUE I, 1995, BAILLIERE CLIN HAEM, V8, P329, DOI 10.1016/S0950-3536(05)80271-9; Kanse SM, 1996, EXP CELL RES, V224, P344, DOI 10.1006/excr.1996.0144; Kjoller L, 1997, EXP CELL RES, V232, P420, DOI 10.1006/excr.1997.3540; KNAUPER V, 1990, FEBS LETT, V263, P355, DOI 10.1016/0014-5793(90)81412-H; Kuhn W, 1999, BRIT J CANCER, V79, P1746, DOI 10.1038/sj.bjc.6690278; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LI XK, 1992, BLOOD, V79, P417; Lijnen HR, 1999, THROMB HAEMOSTASIS, V82, P837; LIJNEN HR, 1994, EUR J BIOCHEM, V224, P567, DOI 10.1111/j.1432-1033.1994.00567.x; LIJNEN HR, 1995, BAILLIERE CLIN HAEM, V8, P277, DOI 10.1016/S0950-3536(05)80268-9; Lijnen HR, 1998, BIOCHEMISTRY-US, V37, P4699, DOI 10.1021/bi9731798; LINDAHL TL, 1990, BIOCHEM J, V265, P109, DOI 10.1042/bj2650109; Loskutoff DJ, 1999, APMIS, V107, P54, DOI 10.1111/j.1699-0463.1999.tb01526.x; MAREY MI, 1991, BIOCHEMISTRY-US, V30, P6476; MARSHALL CJ, 1993, PHILOS T ROY SOC B, V342, P101, DOI 10.1098/rstb.1993.0141; MAST AE, 1991, J BIOL CHEM, V266, P15810; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; Murphy G, 1995, ACTA ORTHOP SCAND, V66, P55, DOI 10.3109/17453679509157648; Nar H, 2000, J MOL BIOL, V297, P683, DOI 10.1006/jmbi.2000.3604; NASKI MC, 1993, J BIOL CHEM, V268, P12367; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; PANNEKOEK H, 1986, EMBO J, V5, P2539, DOI 10.1002/j.1460-2075.1986.tb04532.x; PEI DQ, 1994, J BIOL CHEM, V269, P25849; SALOMAA V, 1995, CIRCULATION, V91, P284, DOI 10.1161/01.CIR.91.2.284; Samad F, 1999, THROMB HAEMOSTASIS, V82, P742, DOI 10.1055/s-0037-1615906; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHNEIDERMAN J, 1992, P NATL ACAD SCI USA, V89, P6998, DOI 10.1073/pnas.89.15.6998; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stefansson S, 1998, TRENDS CARDIOVAS MED, V8, P175, DOI 10.1016/S1050-1738(98)00003-6; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; Ugwu F, 1998, BIOCHEMISTRY-US, V37, P7231, DOI 10.1021/bi9728708; Vleugels N, 1998, FIBRINOLYSIS PROTEOL, V12, P277, DOI 10.1016/S0268-9499(98)80020-9; Waltz DA, 1997, J CLIN INVEST, V100, P58, DOI 10.1172/JCI119521; Wiman B, 1999, SCAND J CLIN LAB INV, V59, P23; WINYARD PG, 1991, FEBS LETT, V279, P91, DOI 10.1016/0014-5793(91)80258-5	62	52	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37645	37650		10.1074/jbc.M006475200	http://dx.doi.org/10.1074/jbc.M006475200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10967118	hybrid			2022-12-25	WOS:000165618700047
J	Bogdanovic, A; Bruckert, F; Morio, T; Satre, M				Bogdanovic, A; Bruckert, F; Morio, T; Satre, M			A syntaxin 7 homologue is present in Dictyostelium discoideum endosomes and controls their homotypic fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TRANSPORT; SNARE COMPLEX; MAGNETIC FRACTIONATION; LYSOSOMAL-ENZYMES; MEMBRANE-FUSION; IN-VITRO; T-SNARE; YEAST; VACUOLE; ENDOCYTOSIS	Endo-phagocytic activity is prominent in Dictyostelium discoideum and makes it a good model organism to study the molecular organization of membrane traffic in this pathway. We have identified a syntaxin 7 homologue (26% identity and 54% similarity to human syntaxin 7) in Dictyostelium cDNA and genomic data banks. In addition to the Habc and H3 helices and the C-terminal transmembrane domain characteristic of syntaxins, this protein contains a repetitive N-terminal extension of 68 amino acids. We first showed that Dictyostelium syntaxin 7 was able to form a complex with N-ethylmaleimide-sensitive fusion protein and alpha- and gamma -soluble Nethylmaleimide-sensitive fusion protein attachment protein. Its intracellular localization was then studied by cell fractionation techniques and magnetic purification of the endocytic compartments. Most of D. discoideum syntaxin 7 is contained in endosomes. Finally, an in vitro endosome homotypic fusion assay (Laurent, O., Bruckert, F., Adessi, C., and Satre, M. (1998) J. Biol Chem. 273, 793-799) was used to study a possible role for syntaxin 7 in this process. Purified anti-syntaxin 7 antibodies and a recombinant soluble fragment of syntaxin 7 both strongly inhibited fusion activity, indicating that this protein was necessary for endosome-endosome fusion. These results demonstrate the importance of this syntaxin 7 homologue in the early phases of Dictyostelium endo-phagocytic pathway.	CEA Grenoble, UMR5092, BBSI, DBMS,Lab Biochim & Biophys Syst Integres, F-38054 Grenoble 09, France; Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 3050006, Japan	CEA; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); University of Tsukuba	Bogdanovic, A (corresponding author), CEA Grenoble, UMR5092, BBSI, DBMS,Lab Biochim & Biophys Syst Integres, 17 Rue Martyrs, F-38054 Grenoble 09, France.	abogdanovic@cea.fr		MORIO, Takahiro/0000-0002-4007-881X				ADESSI C, 1995, J CELL SCI, V108, P3331; AUBRY L, 1993, J CELL SCI, V105, P861; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; Becherer KA, 1996, MOL BIOL CELL, V7, P579, DOI 10.1091/mbc.7.4.579; Beinert H, 1978, Methods Enzymol, V54, P435; Bruckert F, 2000, PROTOPLASMA, V210, P108, DOI 10.1007/BF01276850; Buczynski G, 1997, MOL BIOL CELL, V8, P1343, DOI 10.1091/mbc.8.7.1343; Bush J, 1996, MOL BIOL CELL, V7, P1623, DOI 10.1091/mbc.7.10.1623; CARDELLI JA, 1990, DEV GENET, V11, P454, DOI 10.1002/dvg.1020110522; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; Darsow T, 1998, J CELL BIOL, V142, P913, DOI 10.1083/jcb.142.4.913; Dembinsky A, 1997, J BIOL CHEM, V272, P828, DOI 10.1074/jbc.272.2.828; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; Gotte M, 1997, FEBS LETT, V411, P48, DOI 10.1016/S0014-5793(97)00575-9; Hackam DJ, 1996, J IMMUNOL, V156, P4377; Hacker U, 1997, J CELL SCI, V110, P105; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; HARLOW H, 1988, ANTIBODIES LAB MANUA, P313; Holthuis JCM, 1998, EMBO J, V17, P113, DOI 10.1093/emboj/17.1.113; Journet A, 1999, J CELL SCI, V112, P3833; Laurent O, 1998, J BIOL CHEM, V273, P793, DOI 10.1074/jbc.273.2.793; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Nakamura N, 2000, J BIOL CHEM, V275, P6523, DOI 10.1074/jbc.275.9.6523; NOLTA KV, 1994, J BIOL CHEM, V269, P2225; NOLTA KV, 1991, J BIOL CHEM, V266, P18318; NOLTA KV, 1994, BBA-MOL CELL RES, V1224, P237, DOI 10.1016/0167-4889(94)90196-1; PADH H, 1993, J BIOL CHEM, V268, P6742; Parlati F, 1999, P NATL ACAD SCI USA, V96, P12565, DOI 10.1073/pnas.96.22.12565; Pelham HRB, 1999, EXP CELL RES, V247, P1, DOI 10.1006/excr.1998.4356; Perriere G, 1996, BIOCHIMIE, V78, P364, DOI 10.1016/0300-9084(96)84768-7; PITT A, 1992, METHOD ENZYMOL, V219, P21; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Prekeris R, 1999, MOL BIOL CELL, V10, P3891, DOI 10.1091/mbc.10.11.3891; Prekeris R, 1998, J CELL BIOL, V143, P957, DOI 10.1083/jcb.143.4.957; RODRIGUEZPARIS JM, 1993, J BIOL CHEM, V268, P9110; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sanderfoot AA, 1998, P NATL ACAD SCI USA, V95, P9920, DOI 10.1073/pnas.95.17.9920; Sato MH, 1997, J BIOL CHEM, V272, P24530, DOI 10.1074/jbc.272.39.24530; Seron K, 1998, MOL BIOL CELL, V9, P2873, DOI 10.1091/mbc.9.10.2873; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Subramaniam VN, 2000, J CELL SCI, V113, P997; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; THILO L, 1980, P NATL ACAD SCI-BIOL, V77, P1015, DOI 10.1073/pnas.77.2.1015; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Valdez AC, 1999, J CELL SCI, V112, P845; Wada Y, 1997, J CELL SCI, V110, P1299; Ward DM, 2000, MOL BIOL CELL, V11, P2327, DOI 10.1091/mbc.11.7.2327; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; Weber T, 2000, J CELL BIOL, V149, P1063, DOI 10.1083/jcb.149.5.1063; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weidenhaupt M, 2000, EUR J BIOCHEM, V267, P2062, DOI 10.1046/j.1432-1327.2000.01212.x; Wickner W, 2000, ANNU REV BIOCHEM, V69, P247, DOI 10.1146/annurev.biochem.69.1.247; Wong SH, 1998, J BIOL CHEM, V273, P375, DOI 10.1074/jbc.273.1.375	57	18	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36691	36697		10.1074/jbc.M006710200	http://dx.doi.org/10.1074/jbc.M006710200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10978342	hybrid			2022-12-25	WOS:000165577700035
J	Smith, SB; Watada, H; Scheel, DW; Mrejen, C; German, MS				Smith, SB; Watada, H; Scheel, DW; Mrejen, C; German, MS			Autoregulation and maturity onset diabetes of the young transcription factors control the human PAX4 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC TRANSCRIPTION; PANCREATIC BETA-CELLS; DOMAIN-DNA COMPLEX; INSULIN GENE; PAIRED DOMAIN; CRYSTAL-STRUCTURE; BINDING PROTEINS; MICE LACKING; FACTOR HNF-4; FACTOR STF-1	Duping pancreatic development, the paired homeodomain transcription factor PAX4 is required for the differentiation of the insulin-producing beta cells and somatostatin-producing delta cells. To establish the position of PAX4 in the hierarchy of factors controlling islet cell development, we examined the control of the humanPAX4 gene promoter. In both cell Lines and transgenic animals, a 4.9-kilobase pair region directly upstream of the human PAX4 gene transcriptional start site acts as a potent pancreas-specific promoter. Deletion mapping experiments demonstrate that a 118-base pair region lying approximately 1.9 kilobase pairs upstream of the transcription start site is both necessary and sufficient to direct pancreas-specific expression. Serial deletions through this region reveal the presence of positive elements that bind several pancreatic transcription factors as follows: the POU homeodomain factor HNF1 alpha, the orphan nuclear receptor HNF4 alpha, the homeodomain factor PDX1, and a heterodimer composed of two basic helix-loop-helix factors. Interestingly, mutations in the genes encoding four of these factors cause a dominantly inherited form of human diabetes called Maturity Onset Diabetes of the Young. In addition, PAX4 itself has at least two high affinity binding sites within the promoter through which it exerts a strong negative autoregulatory effect. Together, these results suggest a model in which PAX4 expression is activated during pancreatic development by a combination of pancreas-specific factors but is then switched off once PAX4 protein reaches sufficient levels.	Univ Calif San Francisco, Hormone Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	German, MS (corresponding author), Univ Calif San Francisco, Hormone Res Inst, San Francisco, CA 94143 USA.			Watada, Hirotaka/0000-0001-5961-1816	NIDDK NIH HHS [DK55340, DK21344, R01 DK021344] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055340, R01DK021344, R37DK021344, R56DK021344] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; ARONHEIM A, 1991, NUCLEIC ACIDS RES, V19, P3893, DOI 10.1093/nar/19.14.3893; Campbell SC, 1999, FEBS LETT, V463, P53, DOI 10.1016/S0014-5793(99)01584-7; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; CZERNY T, 1995, MOL CELL BIOL, V15, P2858; Danilov V, 1998, J BIOL CHEM, V273, P627, DOI 10.1074/jbc.273.1.627; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Dukes ID, 1998, J BIOL CHEM, V273, P24457, DOI 10.1074/jbc.273.38.24457; DUNCAN SA, 1994, P NATL ACAD SCI USA, V91, P7598, DOI 10.1073/pnas.91.16.7598; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; EMENS LA, 1992, P NATL ACAD SCI USA, V89, P7300, DOI 10.1073/pnas.89.16.7300; Fujitani Y, 1999, MOL CELL BIOL, V19, P8281; GERMAN MS, 1994, GENOMICS, V24, P403, DOI 10.1006/geno.1994.1639; GERMAN MS, 1992, MOL CELL BIOL, V12, P1777, DOI 10.1128/MCB.12.4.1777; GERMAN MS, 1991, MOL ENDOCRINOL, V5, P292, DOI 10.1210/mend-5-2-292; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; Gradwohl G, 2000, P NATL ACAD SCI USA, V97, P1607, DOI 10.1073/pnas.97.4.1607; Harrison KA, 1999, NAT GENET, V23, P71, DOI 10.1038/12674; Huang HP, 2000, MOL CELL BIOL, V20, P3292, DOI 10.1128/MCB.20.9.3292-3307.2000; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KARLSSON O, 1989, MOL CELL BIOL, V9, P823, DOI 10.1128/MCB.9.2.823; Li H, 1999, NAT GENET, V23, P67; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; MIQUEROL L, 1994, J BIOL CHEM, V269, P8944; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; Offield MF, 1996, DEVELOPMENT, V122, P983; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; PEERS B, 1995, MOL CELL BIOL, V15, P7091; PETERSEN HV, 1994, P NATL ACAD SCI USA, V91, P10465, DOI 10.1073/pnas.91.22.10465; PEYTON M, 1994, J BIOL CHEM, V269, P25936; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; Schwitzgebel VM, 2000, DEVELOPMENT, V127, P3533; Sharma S, 1997, MOL CELL BIOL, V17, P2598, DOI 10.1128/MCB.17.5.2598; SHEIH S, 1991, J BIOL CHEM, V266, P16708; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Sladek FM, 1999, MOL CELL BIOL, V19, P6509; Smith KM, 1997, INT IMMUNOL, V9, P1355, DOI 10.1093/intimm/9.9.1355; Smith SB, 1999, MOL CELL BIOL, V19, P8272; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; Stoffel M, 1997, P NATL ACAD SCI USA, V94, P13209, DOI 10.1073/pnas.94.24.13209; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Sussel L, 1998, DEVELOPMENT, V125, P2213; Tao M, 1998, DIABETES, V47, P1650, DOI 10.2337/diabetes.47.10.1650; Tokuyama Y, 1998, BIOCHEM BIOPH RES CO, V248, P153, DOI 10.1006/bbrc.1998.8925; Wu KL, 1997, MOL CELL BIOL, V17, P6002, DOI 10.1128/MCB.17.10.6002; Xu HE, 1999, GENE DEV, V13, P1263, DOI 10.1101/gad.13.10.1263; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0	53	63	63	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36910	36919		10.1074/jbc.M005202200	http://dx.doi.org/10.1074/jbc.M005202200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10967107	hybrid			2022-12-25	WOS:000165577700066
J	Bell, DR; Poland, A				Bell, DR; Poland, A			Binding of aryl hydrocarbon receptor (AhR) to AhR-interacting protein - The role of hsp90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE; PROGESTERONE-RECEPTOR; DIOXIN RECEPTOR; CORE COMPLEX; IN-VIVO; DOMAIN; IDENTIFICATION; GELDANAMYCIN; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN; HEAT-SHOCK-PROTEIN-90	The aryl hydrocarbon receptor (AhR) has been shown to interact with an immunophilin-like molecule known as AhR-interacting protein (AIP) and to enhance AhR function. We show here that AIP associates with AhR homologues from mouse and fish, which can bind ligands such as dioxin, but nonligand binding homologues from Caenorhabditis elegans or Drosophila do not bind to AIP. However, a minimal ligand-binding domain of the AhR is incapable of binding AIP. The binding of AIP to AhR in reticulocyte lysate shows several of the characteristics of an hsp90-dependent process, including sensitivity to geldanamycin and temperature and a requirement for ATP or nonhydrolyzable analogues. Purified AIP binds to the C terminus of hsp90, and mutation of a conserved basic residue in the tetratricopeptide repeats of AIP (K266A, analogous to K97A in protein phosphatase 5) abolishes binding to hsp90. Mutation of K266A in AIP reduces binding to AhR by 75-80%; the geldanamycin sensitivity of this complex shows that AhR stabilizes the AIP-hsp90-AhR complex. The alpha -helical C terminus of AIP, which is outside the tetratricopeptide repeat domain, is absolutely required for binding to AhR as shown by deletions of the C-terminal 5 amino acids or alanine-scanning mutagenesis, but it is not required for binding of AIP to hsp90. The data support a model where 1) AIP binds to both hsp90 and AhR; 2) hsp90 is required for AhR-AIP binding; and 3) the binding of AhR to AIP stabilizes the AIP-hsp90-AhR complex.	NIOSH, Hlth Effects Lab Div, Ctr Dis Control, Morgantown, WV 26505 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	Bell, DR (corresponding author), Univ Nottingham, Sch Biol Sci, Nottingham NG7 2RD, England.	david.bell@nottingham.ac.uk						Barent RL, 1998, MOL ENDOCRINOL, V12, P342, DOI 10.1210/me.12.3.342; Carrello A, 1999, J BIOL CHEM, V274, P2682, DOI 10.1074/jbc.274.5.2682; Carver LA, 1997, J BIOL CHEM, V272, P11452; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; Chen HS, 1997, ARCH BIOCHEM BIOPHYS, V348, P190, DOI 10.1006/abbi.1997.0398; COUMAILLEAU P, 1995, J BIOL CHEM, V270, P25291, DOI 10.1074/jbc.270.42.25291; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Duncan DM, 1998, GENE DEV, V12, P1290, DOI 10.1101/gad.12.9.1290; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; Giannone JV, 1998, BIOCHEM PHARMACOL, V55, P489, DOI 10.1016/S0006-2952(97)00493-0; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; Karchner SI, 1999, J BIOL CHEM, V274, P33814, DOI 10.1074/jbc.274.47.33814; Kuzhandaivelu N, 1996, NUCLEIC ACIDS RES, V24, P4741, DOI 10.1093/nar/24.23.4741; Ma Q, 2000, J BIOL CHEM, V275, P8432, DOI 10.1074/jbc.275.12.8432; Ma Q, 1997, J BIOL CHEM, V272, P8878; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Meyer BK, 1999, BIOCHEMISTRY-US, V38, P8907, DOI 10.1021/bi982223w; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1994, MOL PHARMACOL, V46, P915; Powell-Coffman JA, 1998, P NATL ACAD SCI USA, V95, P2844, DOI 10.1073/pnas.95.6.2844; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Ratajczak T, 1996, J BIOL CHEM, V271, P2961, DOI 10.1074/jbc.271.6.2961; Roberts BJ, 1999, J BIOL CHEM, V274, P36351, DOI 10.1074/jbc.274.51.36351; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; Russell LC, 1999, J BIOL CHEM, V274, P20060, DOI 10.1074/jbc.274.29.20060; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; SCHERRER LC, 1992, BIOCHEMISTRY-US, V31, P10879, DOI 10.1021/bi00159a031; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; Shimizu Y, 2000, P NATL ACAD SCI USA, V97, P779, DOI 10.1073/pnas.97.2.779; SMITH DF, 1992, J BIOL CHEM, V267, P1350; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Young JC, 1998, J BIOL CHEM, V273, P18007, DOI 10.1074/jbc.273.29.18007	36	130	132	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36407	36414		10.1074/jbc.M004236200	http://dx.doi.org/10.1074/jbc.M004236200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10961990	hybrid			2022-12-25	WOS:000165382000106
J	Huang, THJ; Yang, DS; Fraser, PE; Chakrabartty, A				Huang, THJ; Yang, DS; Fraser, PE; Chakrabartty, A			Alternate aggregation pathways of the Alzheimer beta-amyloid peptide - An in vitro model of preamyloid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN FIBRILLOGENESIS; FIBRIL FORMATION; DOWNS-SYNDROME; DISEASE; PRECURSOR; REQUIRES; PLAQUES	Deposition of amyloid-beta (A beta) aggregates in the brain is a defining characteristic of Alzheimer's disease (AD), Fibrillar amyloid, found in the cores of senile plaques, is surrounded by dystrophic neurites, In contrast, the amorphous A beta (also called preamyloid) in diffuse plaques: is ndt associated with neurodegeneration. Depending on the conditions, A beta will also form fibrillar or amorphous aggregates in vitro, In this present study, we sought to characterize the properties of the amorphous aggregate and determine whether we could establish an in vitro model for amorphous A beta, CD data indicated that A beta 40 assembled to form either a beta -structured aggregate or an unfolded aggregate with the structured aggregate forming at high peptide concentrations and the unstructured aggregate forming at low A beta 40 levels. The critical concentration separating these two pathways was 10 muM. Fluorescence emission and polarization showed the structured aggregate was tightly packed containing peptides that were not accessible to water. Peptides in the unstructured aggregate were loosely packed, mobile, and accessible to water. When examined by electron microscopy, the structured aggregate appeared as protofibrillar structures and formed classic amyloid fibrils over a period of several weeks. The unstructured aggregate was not visible by electron microscopy and did not generate fibrils, These findings suggest that the unstructured aggregate shares many properties with the amorphous A beta of AD and that conditions can be established to form amorphous A beta in vitro. This would allow for investigations to better understand the relationship between fibrillar and amorphous A beta and could have significant impact upon efforts to find therapies for AD.	Univ Toronto, Ontario Canc Inst, Div Mol & Struct Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	Chakrabartty, A (corresponding author), Univ Toronto, Ontario Canc Inst, Div Mol & Struct Biol, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.			Chakrabartty, Avi/0000-0001-7002-8381				CHANTLER PD, 1978, BIOCHEMISTRY-US, V17, P5440, DOI 10.1021/bi00618a018; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; GIACCONE G, 1989, NEUROSCI LETT, V97, P232, DOI 10.1016/0304-3940(89)90169-9; Huang THJ, 2000, J MOL BIOL, V297, P73, DOI 10.1006/jmbi.2000.3559; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; JARRETT JT, 1992, BIOCHEMISTRY-US, V31, P12345, DOI 10.1021/bi00164a008; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIRSCHNER DA, 1986, P NATL ACAD SCI USA, V83, P503, DOI 10.1073/pnas.83.2.503; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MANN DMA, 1989, NEUROBIOL AGING, V10, P397, DOI 10.1016/0197-4580(89)90073-0; PIKE CJ, 1993, J NEUROSCI, V13, P1676; PUCHTLER H, 1962, J HISTOCHEM CYTOCHEM, V10, P355, DOI 10.1177/10.3.355; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SIMMONS LK, 1994, MOL PHARMACOL, V45, P373; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; WISNIEWSKI KE, 1985, NEUROLOGY, V35, P957, DOI 10.1212/WNL.35.7.957; YAMAGUCHI H, 1989, AM J PATHOL, V135, P593; Yang DS, 1999, J BIOL CHEM, V274, P32970, DOI 10.1074/jbc.274.46.32970	20	64	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36436	36440		10.1074/jbc.M005698200	http://dx.doi.org/10.1074/jbc.M005698200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10961999	hybrid			2022-12-25	WOS:000165382000110
J	Petersen, DN; Tkalcevic, GT; Mansolf, AL; Rivera-Gonzalez, R; Brown, TA				Petersen, DN; Tkalcevic, GT; Mansolf, AL; Rivera-Gonzalez, R; Brown, TA			Identification of osteoblast/osteocyte factor 45 (OF45), a bone-specific cDNA encoding an RGD-containing protein that is highly expressed in osteoblasts and osteocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STROMAL CELL-CULTURES; IMPERFECTA TYPE-II; MATRIX ACIDIC PHOSPHOPROTEIN; OSTEOCALCIN-DEFICIENT MICE; ADULT HUMAN BONE; PROGRESSIVE DEVELOPMENT; EXTRACELLULAR-MATRIX; MESSENGER-RNA; IN-VITRO; MARROW	We describe the cloning and characterization of a novel bone-specific cDNA predicted to encode an extracellular matrix protein. This cDNA was identified by subtractive hybridization based upon its high expression in bone marrow-derived osteoblasts. By Northern blot analysis, we detected a single a-kilobase mRNA transcript in bone, whereas no expression was detected in Other tissues. Immunohistochemistry revealed that the protein was expressed highly in osteocytes within trabecular and cortical bone. RNA and protein expression analysis using in vivo marrow ablation as a model of bone remodeling demonstrated that this gene was expressed only in cells that were embedded within bone matrix in contrast to the earlier expression of known osteoblast markers. The cDNA was predicted to encode a serine/glycine-rich secreted peptide containing numerous potential phosphorylation sites and one RGD sequence motif. The interaction of RGD domain-containing peptides with integrins has been shown previously to regulate bone remodeling by promoting recruitment, attachment, and differentiation of osteoblasts and osteoclasts,: Secretion of this RGD-containing protein from osteocytes has the potential to regulate cellular activities within-the bone environment and thereby may impact bone homeostasis. We propose the name OF45 (osteoblast/osteocyte factor of 45 kDa) for this novel cDNA.	Pfizer Inc, Global Res & Dev, Dept Cardiovasc & Metab Dis, Groton, CT 06340 USA	Pfizer	Brown, TA (corresponding author), Pfizer Inc, Global Res & Dev, Dept Cardiovasc & Metab Dis, Box 8118W-215,Eastern Point Rd, Groton, CT 06340 USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; APLIN HM, 1995, GENOMICS, V30, P347, DOI 10.1006/geno.1995.9867; Aubin JE, 1999, J CELL BIOCHEM, V72, P396, DOI 10.1002/(SICI)1097-4644(19990301)72:3<396::AID-JCB9>3.3.CO;2-Y; BAB IA, 1995, BONE, V17, pA437; BERESFORD JN, 1992, J CELL SCI, V102, P341; Bodine PVN, 1999, BONE, V25, P535, DOI 10.1016/S8756-3282(99)00213-6; Boskey AL, 1998, BONE, V23, P187, DOI 10.1016/S8756-3282(98)00092-1; Boskey AL, 1996, CONNECT TISSUE RES, V35, P357, DOI 10.3109/03008209609029212; Burger EH, 1999, FASEB J, V13, pS101, DOI 10.1096/fasebj.13.9001.s101; Butler W T, 1995, Connect Tissue Res, V33, P59, DOI 10.3109/03008209509016983; Butler WT, 1997, CIBA F SYMP, V205, P107; BUTLER WT, 1995, INT J DEV BIOL, V39, P169; CHEN TL, 1983, ENDOCRINOLOGY, V112, P1739, DOI 10.1210/endo-112-5-1739; CHOMCZYNSKI P, 1995, BIOTECHNIQUES, V19, P942; DSouza RN, 1997, J BONE MINER RES, V12, P2040, DOI 10.1359/jbmr.1997.12.12.2040; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Erdmann J, 1999, MECH AGEING DEV, V110, P73, DOI 10.1016/S0047-6374(99)00043-3; FROHMAN MA, 1994, PCR METH APPL, V4, P540; GENOVESE C, 1984, BIOCHEMISTRY-US, V23, P6210, DOI 10.1021/bi00320a049; George A, 1995, Connect Tissue Res, V33, P67, DOI 10.3109/03008209509016984; GEORGE A, 1993, J BIOL CHEM, V268, P12624; Harlow E., 1988, ANTIBODIES LAB MANUA; Herbertson A, 1997, BONE, V21, P491, DOI 10.1016/S8756-3282(97)00197-X; Hirst KL, 1997, GENOMICS, V42, P38, DOI 10.1006/geno.1997.4700; INGRAM RT, 1993, J BONE MINER RES, V8, P1019; Katzburg S, 1999, BONE, V25, P667, DOI 10.1016/S8756-3282(99)00225-2; Lanyon L.E., 1993, CALCIFIED TISSUE INT, V53, P102; LEBOY PS, 1991, J CELL PHYSIOL, V146, P370, DOI 10.1002/jcp.1041460306; Lozupone E, 1996, CLIN RHEUMATOL, V15, P563, DOI 10.1007/BF02238545; MacDougall M, 1998, J BONE MINER RES, V13, P422, DOI 10.1359/jbmr.1998.13.3.422; MacDougall M, 1998, EUR J ORAL SCI, V106, P227, DOI 10.1111/j.1600-0722.1998.tb02180.x; MacDougall M, 1996, CYTOGENET CELL GENET, V74, P189, DOI 10.1159/000134410; Malaval L, 1999, J CELL BIOCHEM, V74, P616; MANIATOPOULOS C, 1988, CELL TISSUE RES, V254, P317; MCGEOCH DJ, 1985, VIRUS RES, V3, P271, DOI 10.1016/0168-1702(85)90051-6; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; PALUMBO C, 1990, ACTA ANAT, V137, P350; PARFITT AM, 1994, J CELL BIOCHEM, V55, P273, DOI 10.1002/jcb.240550303; RICKARD DJ, 1994, DEV BIOL, V161, P218, DOI 10.1006/dbio.1994.1022; Rickard DJ, 1996, J BONE MINER RES, V11, P312; Rivera-Gonzalez R, 1998, J STEROID BIOCHEM, V64, P13, DOI 10.1016/S0960-0760(97)00142-8; Robey PG, 1996, CONNECT TISSUE RES, V35, P131, DOI 10.3109/03008209609029183; Rodriguez JP, 1999, J CELL BIOCHEM, V75, P414, DOI 10.1002/(SICI)1097-4644(19991201)75:3<414::AID-JCB7>3.0.CO;2-C; ROHOLL PJM, 1994, J BONE MINER RES, V9, P355; Sambrook J., 2002, MOL CLONING LAB MANU; STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424; SUVA LJ, 1993, J BONE MINER RES, V8, P379; THIEDE MA, 1994, ENDOCRINOLOGY, V135, P929, DOI 10.1210/en.135.3.929; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WANG Z, 1991, P NATL ACAD SCI USA, V88, P11505, DOI 10.1073/pnas.88.24.11505; WLODARSKI KH, 1990, CLIN ORTHOP RELAT R, P276; YAO KL, 1994, J BONE MINER RES, V9, P231	53	94	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36172	36180		10.1074/jbc.M003622200	http://dx.doi.org/10.1074/jbc.M003622200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10967096	hybrid			2022-12-25	WOS:000165382000075
J	Turner, FB; Taylor, SM; Moran, RG				Turner, FB; Taylor, SM; Moran, RG			Expression patterns of the multiple transcripts from the folylpolyglutamate synthetase gene in human leukemias and normal differentiated tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMATE SYNTHETASE; ORGANIZATION; CELLS	Folylpoly-gamma -glutamate synthetase (FPGS) catalyzes the activation of folate antimetabolites in mammalian tissues and tumors. We have determined the sequence, abundance, and function of human FPGS transcripts and found some striking differences to transcription of the mouse gene that allow production of FPGS isoforms in mouse liver and dividing tissues. Multiple human transcripts were identified, including the homolog of the mouse transcripts that initiate at two upstream exons. However, the human FPGS upstream promoter is infrequently used, and transcripts from this promoter include sequences homologous with only one of the upstream exons found in the mouse, The downstream promoter generates an array of transcripts, some of which do not produce active enzyme, a phenomenon not seen in the mouse, Hence, the dual promoter mechanism directing expression of FPGS isozymes in mouse tissues is not conserved in humans, and, unlike the mouse downstream promoter, the human downstream promoter is active in both dividing and differentiated tissues. This study raises questions about the differences in function served by the two mouse FPGS isozymes and how, or if, human tissues fulfill these functions. How humans and mice-produce FPGS in only a subset of tissues using such different promoter structures also becomes a central issue.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Immunol & Microbiol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Moran, RG (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA.	rmoran@hsc.vcu.edu			NATIONAL CANCER INSTITUTE [R01CA039687] Funding Source: NIH RePORTER; NCI NIH HHS [CA-39687] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chen J, 2000, GENE, V242, P257, DOI 10.1016/S0378-1119(99)00507-7; Chen L, 1996, J BIOL CHEM, V271, P13077, DOI 10.1074/jbc.271.22.13077; Freemantle SJ, 1997, J BIOL CHEM, V272, P25373, DOI 10.1074/jbc.272.40.25373; FREEMANTLE SJ, 1995, J BIOL CHEM, V270, P9579, DOI 10.1074/jbc.270.16.9579; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Longo GSA, 1997, BLOOD, V90, P1241, DOI 10.1182/blood.V90.3.1241.1241_1241_1245; MCBURNEY MW, 1974, CELL, V2, P173, DOI 10.1016/0092-8674(74)90091-9; MCGUIRE JJ, 1986, BIOCHEM PHARMACOL, V35, P2607, DOI 10.1016/0006-2952(86)90060-2; MORAN RG, 1984, ANAL BIOCHEM, V140, P326, DOI 10.1016/0003-2697(84)90174-X; Roy K, 1997, J BIOL CHEM, V272, P5587, DOI 10.1074/jbc.272.9.5587; Roy K, 1996, J BIOL CHEM, V271, P23820, DOI 10.1074/jbc.271.39.23820; SHANE B, 1989, VITAM HORM, V45, P263; SIROTNAK FM, 1988, BIOCHEM PHARMACOL, V37, P4239, DOI 10.1016/0006-2952(88)90122-0; TAYLOR SM, 1995, CANCER RES, V55, P6030; Turner FB, 1999, CANCER RES, V59, P6074	15	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35960	35968		10.1074/jbc.M005228200	http://dx.doi.org/10.1074/jbc.M005228200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10964921	hybrid			2022-12-25	WOS:000165382000046
J	Yoo, BC; Aoki, K; Xiang, Y; Campbell, LR; Hull, RJ; Xoconostle-Cazares, B; Monzer, J; Lee, JY; Ullman, DE; Lucas, WJ				Yoo, BC; Aoki, K; Xiang, Y; Campbell, LR; Hull, RJ; Xoconostle-Cazares, B; Monzer, J; Lee, JY; Ullman, DE; Lucas, WJ			Characterization of Cucurbita maxima phloem serpin-1 (CmPS-1) - A developmentally regulated elastase inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-TO-CELL; PROTEINASE-INHIBITORS; PROTEASE INHIBITORS; RICINUS-COMMUNIS; MESSENGER-RNA; ACYRTHOSIPHON-PISUM; PLANT DEFENSE; MANDUCA-SEXTA; INSECTS; EXUDATE	We report on the molecular, biochemical, and functional characterization of Cucurbita maxima phloem serpin-1 (CmPS-1), a novel 42-kDa serine proteinase inhibitor,that is developmentally regulated and has anti-elastase properties. CmPS-1 was purified to near homogeneity from C. maxima (pumpkin) phloem exudate and, based on microsequence analysis, the cDNA encoding CmPS-1 was cloned. The association rate constant (k(a)) of phloem-purified and recombinant His(6)-tagged CmPS-1 for elastase was 3.5 +/- 1.6 x 10(5) and 2.7 +/- 0.4 x 10(5) M-1 s(-1), respectively. The fraction of complex-forming CmPS-1 X-inh, was estimated at 79%. CmPS-1 displayed no detectable inhibitory properties against chymotrypsin, trypsin, or thrombin. The elastase cleavage sites within the reactive center loop of CmPS-1 were determined to be Val(347)-Gly(348) and Val(350)-Ser(351) With a 3:2 molar ratio. In vivo feeding assays conducted with the piercing-sucking aphid, Myzus persicae, established a close correlation between the developmentally regulated increase in CmPS-1 within the phloem sap and the reduced ability of these insects to survive and reproduce on C. maxima. However, in vitro feeding experiments, using purified phloem CmPS-1, failed to demonstrate a direct effect on aphid survival. Likely roles of this novel phloem serpin in defense against insects/pathogens are discussed.	Univ Calif Davis, Div Biol Sci, Plant Biol Sect, Coll Agr & Environm Sci, Davis, CA 95616 USA; Univ Calif Davis, Dept Entomol, Coll Agr & Environm Sci, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Lucas, WJ (corresponding author), Univ Calif Davis, Div Biol Sci, Plant Biol Sect, Coll Agr & Environm Sci, 1 Shields Ave, Davis, CA 95616 USA.			Lee, Jinkee/0000-0001-5590-0549; Lee, Jung-Youn/0000-0003-4604-7974				Balachandran S, 1997, P NATL ACAD SCI USA, V94, P14150, DOI 10.1073/pnas.94.25.14150; BEATTY K, 1980, J BIOL CHEM, V255, P3931; BODE W, 1989, BIOCHEMISTRY-US, V28, P1951, DOI 10.1021/bi00431a001; BORKOVEC V, 1994, PLANT GROWTH REGUL, V15, P137, DOI 10.1007/BF00024103; BRANDT A, 1990, EUR J BIOCHEM, V194, P499, DOI 10.1111/j.1432-1033.1990.tb15644.x; BROADWAY RM, 1986, ENTOMOL EXP APPL, V41, P33, DOI 10.1007/BF00343486; Caillaud CM, 1996, EXPERIENTIA, V52, P927, DOI 10.1007/BF01938882; Carrell RW, 1996, BIOL CHEM H-S, V377, P1; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; Chino M, 1991, RECENT ADV PHLOEM TR, P64; Christeller JT, 1998, EUR J BIOCHEM, V254, P160, DOI 10.1046/j.1432-1327.1998.2540160.x; CHRISTELLER JT, 1992, INSECT BIOCHEM MOLEC, V22, P735, DOI 10.1016/0965-1748(92)90052-G; Dahl SW, 1996, FEBS LETT, V394, P165, DOI 10.1016/0014-5793(96)00940-4; Dahl SW, 1996, J BIOL CHEM, V271, P25083, DOI 10.1074/jbc.271.41.25083; Duffey SS, 1996, ARCH INSECT BIOCHEM, V32, P3, DOI 10.1002/(SICI)1520-6327(1996)32:1&lt;3::AID-ARCH2&gt;3.0.CO;2-1; FISHER DB, 1992, PLANT PHYSIOL, V100, P1433, DOI 10.1104/pp.100.3.1433; Golecki B, 1999, PLANT CELL, V11, P127, DOI 10.1105/tpc.11.1.127; Habu Y, 1996, PLANT MOL BIOL, V32, P1209, DOI 10.1007/BF00041408; Ishiwatari Y, 1998, PLANTA, V205, P12, DOI 10.1007/s004250050291; Jiang HB, 1997, J BIOL CHEM, V272, P1082, DOI 10.1074/jbc.272.2.1082; Jongsma MA, 1997, J INSECT PHYSIOL, V43, P885, DOI 10.1016/S0022-1910(97)00040-1; Jorgensen RA, 1998, SCIENCE, V279, P1486, DOI 10.1126/science.279.5356.1486; Kamboj JS, 1998, PLANT GROWTH REGUL, V25, P123, DOI 10.1023/A:1006016023707; KANOST MR, 1989, J BIOL CHEM, V264, P965; Khadhair AH, 2000, MICROBIOL RES, V155, P53, DOI 10.1016/S0944-5013(00)80023-3; Klingler J, 1998, ENTOMOL EXP APPL, V86, P79, DOI 10.1023/A:1003153410049; Koiwa H, 1997, TRENDS PLANT SCI, V2, P379, DOI 10.1016/S1360-1385(97)90052-2; Kuhn C, 1997, SCIENCE, V275, P1298, DOI 10.1126/science.275.5304.1298; Lherminier J, 1999, MOL CELL PROBE, V13, P41, DOI 10.1006/mcpr.1998.0213; MACGIBBON DB, 1986, J SCI FOOD AGR, V37, P515, DOI 10.1002/jsfa.2740370602; MURRAY C, 1995, BIOL CHEM H-S, V376, P281, DOI 10.1515/bchm3.1995.376.5.281; RAHBE Y, 1993, ENTOMOL EXP APPL, V67, P149, DOI 10.1007/BF02386520; RAHBE Y, 1995, ENTOMOL EXP APPL, V76, P143, DOI 10.1007/BF02383212; RASMUSSEN SK, 1993, BIOCHIM BIOPHYS ACTA, V1172, P151, DOI 10.1016/0167-4781(93)90282-I; Rasmussen SK, 1996, PLANT MOL BIOL, V30, P673, DOI 10.1007/BF00049343; Ruiz-Medrano R, 1999, DEVELOPMENT, V126, P4405; Ryals JA, 1996, PLANT CELL, V8, P1809, DOI 10.1105/tpc.8.10.1809; Ryan CA, 1998, ANNU REV CELL DEV BI, V14, P1, DOI 10.1146/annurev.cellbio.14.1.1; RYAN CA, 1990, ANNU REV PHYTOPATHOL, V28, P425, DOI 10.1146/annurev.py.28.090190.002233; Sasaki T, 1998, PLANT CELL PHYSIOL, V39, P895, DOI 10.1093/oxfordjournals.pcp.a029451; Schaller A, 1996, BIOESSAYS, V18, P27, DOI 10.1002/bies.950180108; Simpson AJ, 1999, FEBS LETT, V452, P309, DOI 10.1016/S0014-5793(99)00670-5; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TIEDEMANN R, 1994, J PLANT PHYSIOL, V143, P189, DOI 10.1016/S0176-1617(11)81685-8; WIECZOREK M, 1985, BIOCHEM BIOPH RES CO, V126, P646, DOI 10.1016/0006-291X(85)90233-5; Xoconostle-Cazares B, 1999, SCIENCE, V283, P94, DOI 10.1126/science.283.5398.94; ZIMMERMANN HM, 1975, ENCY PLANT PHYSL NEW, V1	48	66	70	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35122	35128		10.1074/jbc.M006060200	http://dx.doi.org/10.1074/jbc.M006060200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10960478	hybrid			2022-12-25	WOS:000165422800041
J	Roth, W; Wild-Bode, C; Platten, M; Grimmel, C; Melkonyan, HS; Dichgans, J; Weller, M				Roth, W; Wild-Bode, C; Platten, M; Grimmel, C; Melkonyan, HS; Dichgans, J; Weller, M			Secreted Frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells	ONCOGENE			English	Article						sFRP; Wnt signaling; migration; MMP-2; beta-catenin; malignant glioma	CADHERIN-CATENIN COMPLEX; CENTRAL-NERVOUS-SYSTEM; BETA-CATENIN; FACTOR RECEPTOR; IN-VITRO; TYROSINE-PHOSPHATASE; SPEMANN ORGANIZER; CARCINOMA-CELLS; CD95 LIGAND; MIGRATION	Cellular resistance to multiple proapoptotic stimuli and invasion of surrounding brain tissue by migrating tumor cells are main obstacles to an effective therapy for human malignant glioma. Here, we report that the Wnt family of embryonic differentiation genes modulate growth of malignant glioma cells in vitro and in ville and inhibit cellular migration in vitro. sFRPs (soluble Frizzled-related proteins) are soluble proteins that bind to Wnt and interfere with Wnt signaling. We find that sFRP-1 and sFRP-2 are produced by the majority of longterm and ex vivo malignant glioma cell lines. Glioma cells that ectopically express sFRPs exhibit increased clonogenicity and enhanced resistance to serum starvation. In contrast, sFRPs do not modulate glioma cell susceptibility to apoptosis induced by the cytotoxic cytokines, CD95 (Fas/APO-1) ligand (CD95L) or Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL), or various cytotoxic drugs. sFRP-2 strongly promotes the growth of intracranial glioma xenografts in nude mice. In contrast, enhanced expression of sFRPs inhibits the motility of glioma cells in vitro. sFRP-mediated effects on glioma cells are accompanied by decreased expression and activity of matrix metalloproteinase-2 (MMP-2) and decreased tyrosine phosphorylation of beta-catenin. Thus, sFRPs promote survival under non-supportive conditions and inhibit the migration of glioma cells. We suggest that the regulation of these cellular processes involves expression of MMP-2: and tyrosine phosphorylation of beta-catenin. These data support a function for Wnt signaling and its modulation by sFRPs in the biology of human gliomas.	Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, D-72076 Tubingen, Germany; LXR Biotechnol Inc, Richmond, CA 94804 USA	Eberhard Karls University of Tubingen	Weller, M (corresponding author), Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.		Platten, Michael/F-2902-2013	Platten, Michael/0000-0002-4746-887X; Weller, Michael/0000-0002-1748-174X				Amberger VR, 1998, CANCER RES, V58, P149; Aoki M, 1999, P NATL ACAD SCI USA, V96, P139, DOI 10.1073/pnas.96.1.139; APODACA G, 1990, CANCER RES, V50, P2322; Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Dennis S, 1999, J CELL SCI, V112, P3815; Deryugina EI, 1997, J CELL SCI, V110, P2473; Dierick H, 1999, CURR TOP DEV BIOL, V43, P153, DOI 10.1016/S0070-2153(08)60381-6; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Friedlander DR, 1996, CANCER RES, V56, P1939; Garcia-Rostan G, 1999, CANCER RES, V59, P1811; Giese A, 1996, NEUROSURGERY, V39, P235, DOI 10.1097/00006123-199608000-00001; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Hueber A, 1998, FEBS LETT, V432, P155, DOI 10.1016/S0014-5793(98)00855-2; Jawhari AU, 1999, J PATHOL, V187, P155, DOI 10.1002/(SICI)1096-9896(199901)187:2<155::AID-PATH193>3.0.CO;2-E; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Lin KM, 1997, P NATL ACAD SCI USA, V94, P11196, DOI 10.1073/pnas.94.21.11196; Liu D, 1997, LAB INVEST, V77, P557; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; MERZAK A, 1994, CANCER RES, V54, P3988; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Ogawa K, 1999, CANCER RES, V59, P1830; PAULUS W, 1994, J NEUROSURG, V80, P515, DOI 10.3171/jns.1994.80.3.0515; Platten M, 2000, BIOCHEM BIOPH RES CO, V268, P607, DOI 10.1006/bbrc.2000.2176; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; Roth W, 1999, BIOCHEM BIOPH RES CO, V265, P479, DOI 10.1006/bbrc.1999.1693; Roth W, 1999, CELL MOL LIFE SCI, V56, P481, DOI 10.1007/s000180050447; Roth W, 1997, CANCER IMMUNOL IMMUN, V44, P55, DOI 10.1007/s002620050355; Roth W, 2000, BRAIN PATHOL, V10, P223, DOI 10.1111/j.1750-3639.2000.tb00256.x; Roth W, 1998, BRIT J CANCER, V77, P404, DOI 10.1038/bjc.1998.64; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; WELLER M, 1995, CANCER RES, V55, P2936; Weller M, 1998, INT J CANCER, V79, P640; Wick W, 1998, FEBS LETT, V440, P419, DOI 10.1016/S0014-5793(98)01494-X; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Wong MH, 1998, J CELL BIOL, V141, P765, DOI 10.1083/jcb.141.3.765; Yamamoto M, 1996, CANCER RES, V56, P384; Zhou ZJ, 1998, INT J CANCER, V78, P95, DOI 10.1002/(SICI)1097-0215(19980925)78:1<95::AID-IJC15>3.0.CO;2-4; Zurawel RH, 1998, CANCER RES, V58, P896	49	140	148	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 31	2000	19	37					4210	4220		10.1038/sj.onc.1203783	http://dx.doi.org/10.1038/sj.onc.1203783			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980594				2022-12-25	WOS:000089032900003
J	Zeng, HW; Phang, T; Song, YS; Ji, I; Ji, TH				Zeng, HW; Phang, T; Song, YS; Ji, I; Ji, TH			The role of the hinge region of the luteinizing hormone receptor in hormone interaction and signal generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; LUTROPIN-CHORIOGONADOTROPIN RECEPTOR; AMINO-TERMINAL REGION; LEUCINE-RICH REPEATS; EXTRACELLULAR DOMAIN; HIGH-AFFINITY; SECONDARY-STRUCTURE; BINDING; PROTEIN; ACTIVATION	Luteinizing hormone receptor, a G protein-coupled receptor, consists of two halves, the N-terminal extracellular hormone binding domain (exodomain) and the C-terminal membrane-associated, signal-generating domain (endodomain). The exodomain has seven to nine Leu-rich repeats, which are generally thought to form a 1/3 donut-like structure and interact with human choriogonadotropin (hCG), The resulting hCG-exodomain complex adjusts the structure and its association with the endodomain, which results in signal generation in the endodomain. It is unclear whether the rigid 1/3 donut structure could provide the agility and versatility of this dynamic action. In addition, there is no clue as to where the endodomain contact point (the signal modulator) in the exodomain is. To address these issues, the exodomain was examined by Ala scan and multiple substitutions, while receptor peptides were used for photoaffinity labeling and affinity cross-linking. Our results show that the C-flanking sequence (hinge region), Thr(250)-Gln(268), Of the Leu-rich repeats (LRRs) specifically interacts with hCG, preferentially hCG alpha. This interaction is inhibited by exoloop 2 of the endodomain but not by exoloops 1 and 3, suggesting an intimate relationship between Thg(250)-Gln(268), exoloop a, and hCG, Taken together, our observations in this article suggest a new paradigm that the LRRs contact the front of hCG, while both flanking regions of the LRRs interact with the sides of hCG. This would trap hCG in the 1/3 donut structure of the LRRs and enhance the binding affinity. In addition, mutations of conserved Ser(255) in the sequence can constitutively activate the receptor. This provides a clue for the signal modulator in the exodomain. In contrast, a phenyl or phenolic group is necessary at conserved Tyr(253) for targeting the receptor to the surface.	Univ Kentucky, Dept Chem, Lexington, KY 40506 USA; Seoul Natl Univ, Coll Med, Canc Res Ctr, Seoul 110744, South Korea	University of Kentucky; Seoul National University (SNU)	Ji, TH (corresponding author), Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.		Song, Yong Sang/E-7824-2012	SONG, YONGSANG/0000-0001-7115-4021	NICHD NIH HHS [HD-18702] Funding Source: Medline; NIDDK NIH HHS [DK-51469] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051469] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abell A, 1996, J BIOL CHEM, V271, P4518; Angelova K, 2000, MOL ENDOCRINOL, V14, P459, DOI 10.1210/me.14.4.459; Bhowmick N, 1996, MOL ENDOCRINOL, V10, P1147, DOI 10.1210/me.10.9.1147; Bhowmick N, 1999, ENDOCRINOLOGY, V140, P4558, DOI 10.1210/en.140.10.4558; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Cwirla SE, 1997, SCIENCE, V276, P1696, DOI 10.1126/science.276.5319.1696; Dias JA, 1998, BIOL REPROD, V58, P1331, DOI 10.1095/biolreprod58.6.1331; Dufau ML, 1998, ANNU REV PHYSIOL, V60, P461, DOI 10.1146/annurev.physiol.60.1.461; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Hong SH, 1998, J BIOL CHEM, V273, P13835, DOI 10.1074/jbc.273.22.13835; Huhtaniemi I, 1999, MOL CELL ENDOCRINOL, V151, P89, DOI 10.1016/S0303-7207(99)00015-5; JANIN J, 1990, J BIOL CHEM, V265, P16027; Jeoung MK, 2001, J BIOL CHEM, V276, P3443, DOI 10.1074/jbc.M003774200; JI I, 1993, J BIOL CHEM, V268, P20851; JI I, 1991, J BIOL CHEM, V266, P13076; JI I, 1981, P NATL ACAD SCI-BIOL, V78, P5465, DOI 10.1073/pnas.78.9.5465; JI IH, 1991, ENDOCRINOLOGY, V128, P2648, DOI 10.1210/endo-128-5-2648; Ji IH, 1995, ENDOCRINE, V3, P907, DOI 10.1007/BF02738896; JI IH, 1995, J BIOL CHEM, V270, P15970, DOI 10.1074/jbc.270.27.15970; JI L, 1980, P NATL ACAD SCI USA, V77, P7167; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; JI TH, 1995, ENDOCRINE, V3, P187, DOI 10.1007/BF02994442; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOO YB, 1991, ENDOCRINOLOGY, V128, P2297, DOI 10.1210/endo-128-5-2297; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LIU XX, 1994, ENDOCRINOLOGY, V135, P682, DOI 10.1210/en.135.2.682; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; Lobel LI, 1997, ENDOCRINOLOGY, V138, P1232, DOI 10.1210/en.138.3.1232; Lustbader JW, 1998, RECENT PROG HORM RES, V53, P395; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; Nakabayashi K, 2000, J BIOL CHEM, V275, P30264, DOI 10.1074/jbc.M005568200; Osuga Y, 1997, MOL ENDOCRINOL, V11, P1659, DOI 10.1210/me.11.11.1659; Papageorgiou AC, 1997, EMBO J, V16, P5162, DOI 10.1093/emboj/16.17.5162; Phang T, 1998, J BIOL CHEM, V273, P13841, DOI 10.1074/jbc.273.22.13841; REMY JJ, 1993, BIOCHEM BIOPH RES CO, V193, P1023, DOI 10.1006/bbrc.1993.1727; ROCHE PC, 1992, ENDOCRINOLOGY, V131, P268, DOI 10.1210/en.131.1.268; ROCHE PC, 1985, LUTEINIZING HORMONE, P17; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Ryu K, 1998, J BIOL CHEM, V273, P28953, DOI 10.1074/jbc.273.44.28953; Ryu KS, 1998, J BIOL CHEM, V273, P6285, DOI 10.1074/jbc.273.11.6285; Ryu KS, 1996, J BIOL CHEM, V271, P7301, DOI 10.1074/jbc.271.13.7301; Song YS, 2001, J BIOL CHEM, V276, P3426, DOI 10.1074/jbc.M003772200; Song YS, 2001, J BIOL CHEM, V276, P3436, DOI 10.1074/jbc.M003773200; Struthers MD, 1996, SCIENCE, V271, P342, DOI 10.1126/science.271.5247.342; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; TSAIMORRIS CH, 1991, J BIOL CHEM, V266, P11355; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; XIE YB, 1990, J BIOL CHEM, V265, P21411; Zhang R, 1996, J BIOL CHEM, V271, P5755, DOI 10.1074/jbc.271.10.5755	55	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3451	3458		10.1074/jbc.M007488200	http://dx.doi.org/10.1074/jbc.M007488200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	10964934	hybrid			2022-12-25	WOS:000166784900061
J	Ingram, AJ; James, L; Cai, L; Thai, K; Ly, H; Scholey, JW				Ingram, AJ; James, L; Cai, L; Thai, K; Ly, H; Scholey, JW			NO inhibits stretch-induced MAPK activity by cytoskeletal disruption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; ACTIVATED PROTEIN-KINASES; FOCAL ADHESION KINASE; RAT MESANGIAL CELLS; GLOMERULAR INJURY; EXTRACELLULAR-MATRIX; DIETARY SUPPLEMENTATION; SIGNAL-TRANSDUCTION; MECHANICAL STRAIN; ACTIN-FILAMENTS	Mesangial cells (MC) grown on extracellular matrix protein-coated plates and exposed to cyclic strain/relaxation proliferate and produce extracellular matrix protein, providing an in vitro model of signaling in stretched MC, Intracellular transduction of mechanical strain involves mitogen-activated protein kinases, and we have shown that p42/44 mitogen-activated protein kinase (extracellular signal-regulated kinase (ERK)) is activated by cyclic strain in MC,ln vivo studies show that increased production of nitric oxide (NO) in the remnant kidney limits glomerular injury without reducing glomerular capillary pressure, and we have observed that NO attenuates stretch-induced ERK activity in MC via generation of cyclic guanosine monophosphate (cGMP), Accordingly, we sought to determine whether NO affects strain-induced ERK activity after strain and how this is mediated. Strain-induced ERK activity was dependent on time and magnitude of stretch and was maximal after 10 min at -27 kilopascals, Actin cytoskeleton disruption with cytochalasin D abrogated this. The non-metabolizable cGMP analogue 8-bromo cyclic GMP (8-Br-cGMP) dose-dependently attenuated strain-induced ERK activity. Cytoskeletal stabilization with jas-plakinolide prevented this inhibitory effect of 8-Br-cGMP, Cyclic strain increased nuclear translocation of phospho-ERK by immunofluorescent microscopy, again attenuated by 8-Br-cGMP. Jasplakinolide prevented the inhibitory effect of 8-Br-cGMP on activated ERK nuclear translocation after strain. Strain increased ERK-dependent AP-1 nuclear protein binding, which was attenuated by cytochalasin D and 8-Br-cGMP, These data indicate that cGMP can inhibit cyclic strain-induced ERK activity, nuclear translocation, and AP-1 nuclear protein binding. Cytoskeletal disruption leads to the same effect, whereas cytoskeleton stabilization reverses the effect of 8-Br-cGMP, Thus, NO inhibits strain-induced ERK activity by cytoskeletal destabilization.	McMaster Univ, Dept Med, Hamilton, ON L8N 1Y2, Canada; Univ Toronto, Dept Med, Toronto, ON M5C 1A1, Canada	McMaster University; University of Toronto	Ingram, AJ (corresponding author), 500-25 Charlton Ave E, Hamilton, ON L8N 1Y2, Canada.			James, Leighton/0000-0002-7613-705X				AKAI Y, 1994, AM J PHYSIOL, V267, pC482, DOI 10.1152/ajpcell.1994.267.2.C482; ANDERSON S, 1985, J CLIN INVEST, V76, P612, DOI 10.1172/JCI112013; Arnautov A M, 1998, Tsitologiia, V40, P639; Bubb MR, 2000, J BIOL CHEM, V275, P5163, DOI 10.1074/jbc.275.7.5163; BUBB MR, 1994, J BIOL CHEM, V269, P14869; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; DWORKIN LD, 1986, J CLIN INVEST, V77, P797, DOI 10.1172/JCI112377; DWORKIN LD, 1984, J CLIN INVEST, V73, P1448, DOI 10.1172/JCI111349; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gorodeski GI, 2000, AM J PHYSIOL-CELL PH, V278, pC942, DOI 10.1152/ajpcell.2000.278.5.C942; Gruden G, 1997, P NATL ACAD SCI USA, V94, P12112, DOI 10.1073/pnas.94.22.12112; Hamaguchi A, 1998, J AM SOC NEPHROL, V9, P372; HAMASAKI K, 1995, BIOCHEM BIOPH RES CO, V212, P544, DOI 10.1006/bbrc.1995.2004; HARRIS RC, 1994, KIDNEY INT, V45, pS17; HARRIS RC, 1992, LAB INVEST, V66, P548; HEIDECKER M, 1995, BIOCHEMISTRY-US, V34, P11017, DOI 10.1021/bi00035a007; Hirakata M, 1997, KIDNEY INT, V51, P1028, DOI 10.1038/ki.1997.144; Hirshman CA, 1999, AM J PHYSIOL-LUNG C, V277, pL653, DOI 10.1152/ajplung.1999.277.3.L653; INGRAM A, 1995, KIDNEY INT, V48, P1857, DOI 10.1038/ki.1995.484; Ingram AJ, 2000, CURR OPIN NEPHROL HY, V9, P49, DOI 10.1097/00041552-200001000-00009; Ingram AJ, 1999, KIDNEY INT, V55, P476, DOI 10.1046/j.1523-1755.1999.00276.x; Ingram AJ, 2000, KIDNEY INT, V58, P1067, DOI 10.1046/j.1523-1755.2000.00264.x; Jalali S, 1998, ARTERIOSCL THROM VAS, V18, P227, DOI 10.1161/01.ATV.18.2.227; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kawata Y, 1998, BBA-MOL CELL RES, V1401, P195, DOI 10.1016/S0167-4889(97)00112-2; Kawata Y, 1998, J BIOL CHEM, V273, P16905, DOI 10.1074/jbc.273.27.16905; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Komuro I, 1996, FASEB J, V10, P631, DOI 10.1096/fasebj.10.5.8621062; Leinweber BD, 1999, BIOCHEM J, V344, P117, DOI 10.1042/0264-6021:3440117; Li CH, 1999, J BIOL CHEM, V274, P25273, DOI 10.1074/jbc.274.36.25273; MEYER TW, 1985, AM J MED, V79, P31, DOI 10.1016/0002-9343(85)90077-4; Numaguchi K, 1999, CIRC RES, V85, P5; REYES AA, 1992, AM J KIDNEY DIS, V20, P168, DOI 10.1016/S0272-6386(12)80546-4; RISER BL, 1992, J CLIN INVEST, V90, P1932, DOI 10.1172/JCI116071; Sauzeau V, 2000, J BIOL CHEM, V275, P21722, DOI 10.1074/jbc.M000753200; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; TOGASHI H, 1998, AM J PHYSIOL, V274, pL808; WILSON E, 1995, J CLIN INVEST, V96, P2364, DOI 10.1172/JCI118293; Xu QB, 1996, J CLIN INVEST, V97, P508, DOI 10.1172/JCI118442; Yao J, 1998, KIDNEY INT, V53, P598, DOI 10.1046/j.1523-1755.1998.00793.x; Yasuda T, 1996, CONTRIB NEPHROL, V118, P222; Yasuda T, 1996, J CLIN INVEST, V98, P1991, DOI 10.1172/JCI119003	45	51	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40301	40306		10.1074/jbc.M007018200	http://dx.doi.org/10.1074/jbc.M007018200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10984494	hybrid			2022-12-25	WOS:000166039500069
J	Tang, YY; Shi, JX; Zhang, LN; Davis, A; Bravo, J; Warren, AJ; Speck, NA; Bushweller, JH				Tang, YY; Shi, JX; Zhang, LN; Davis, A; Bravo, J; Warren, AJ; Speck, NA; Bushweller, JH			Energetic and functional contribution of residues in the core binding factor beta (CBF beta) subunit to heterodimerization with CBF alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; FETAL LIVER HEMATOPOIESIS; DNA-BINDING; RUNT DOMAIN; CLEIDOCRANIAL DYSPLASIA; AML1 GENE; PROTEIN INTERFACES; HOT-SPOT	Core-binding factors (CBFs) are a small family of heterodimeric transcription factors that play critical roles in several developmental pathways, including hematopoiesis and bone development. Mutations in CBF genes are found in leukemias and bone disorders. CBFs consist of a DNA-binding CBF alpha subunit (Runx1, Runx2, or Runx3) and a non-DNA-binding CEF beta subunit. CBF alpha binds DNA in a sequence-specific manner, whereas CBF beta enhances DNA binding by CBF alpha. Recent structural analyses of the DNA-binding Runt domain of CBF alpha and the CBF beta subunit identified the heterodimerization surfaces on each subunit. Here we identify amino acids in CBF beta that mediate binding to CBF alpha. We determine the energy contributed by each of these amino acids to heterodimerization and the importance of these residues for in vivo function. These data refine the structural analyses and further support the hypothesis that CBF beta enhances DNA binding by inducing a conformational change in the Runt domain.	Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA; Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22906 USA; 3MRC, Mol Biol Lab, Cambridge CB2 2QH, England	Dartmouth College; University of Virginia; MRC Laboratory Molecular Biology	Tang, YY (corresponding author), Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA.	Yen-Yee.Tang@dartmouth.edu	Bravo, Jeronimo/K-9103-2014	Bravo, Jeronimo/0000-0001-6695-2846; Bushweller, John/0000-0002-5386-1758	NCI NIH HHS [R01-CA75611, R01-CA58343] Funding Source: Medline; NIAID NIH HHS [T32-AI07363] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075611, R01CA058343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007363] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAE SC, 1993, ONCOGENE, V8, P809; Berardi MJ, 1999, STRUCT FOLD DES, V7, P1247, DOI 10.1016/S0969-2126(00)80058-1; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; Chen CZ, 1999, BIOCHEMISTRY-US, V38, P9273, DOI 10.1021/bi990762a; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Crute BE, 1996, J BIOL CHEM, V271, P26251, DOI 10.1074/jbc.271.42.26251; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; Goger M, 1999, NAT STRUCT BIOL, V6, P620; Golling G, 1996, MOL CELL BIOL, V16, P932; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Gu TL, 2000, MOL CELL BIOL, V20, P91, DOI 10.1128/MCB.20.1.91-103.2000; HAWLEY RG, 1994, GENE THER, V1, P136; Huang XM, 1998, J BIOL CHEM, V273, P2480, DOI 10.1074/jbc.273.4.2480; Huang XM, 1999, NAT STRUCT BIOL, V6, P624; Huang XM, 1998, J BIOMOL NMR, V12, P459, DOI 10.1023/A:1008306026814; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; Kagoshima H, 1996, J BIOL CHEM, V271, P33074, DOI 10.1074/jbc.271.51.33074; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KELLER HU, 1993, ADV SPACE RES, V13, P73; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nagata T, 1999, NAT STRUCT BIOL, V6, P615; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Perez-Alvarado GC, 2000, FEBS LETT, V470, P125, DOI 10.1016/S0014-5793(00)01296-5; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Roulston D, 1998, BLOOD, V92, P2879, DOI 10.1182/blood.V92.8.2879.420k22_2879_2885; Rubnitz J E, 1998, Curr Opin Hematol, V5, P264; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHURTLEFF SA, 1995, BLOOD, V85, P3695, DOI 10.1182/blood.V85.12.3695.bloodjournal85123695; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Tang YY, 2000, FEBS LETT, V470, P167, DOI 10.1016/S0014-5793(00)01312-0; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Warren AJ, 2000, EMBO J, V19, P3004, DOI 10.1093/emboj/19.12.3004; WEBER C, 1991, BIOCHEMISTRY-US, V30, P6563, DOI 10.1021/bi00240a029; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; Zhou G, 1999, HUM MOL GENET, V8, P2311, DOI 10.1093/hmg/8.12.2311	53	51	54	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39579	39588		10.1074/jbc.M007350200	http://dx.doi.org/10.1074/jbc.M007350200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10984496	hybrid			2022-12-25	WOS:000165953100084
J	Voit, R; Feldmaier-Fuchs, G; Schweikardt, T; Decker, H; Burmester, T				Voit, R; Feldmaier-Fuchs, G; Schweikardt, T; Decker, H; Burmester, T			Complete sequence of the 24-mer hemocyanin of the tarantula Eurypelma californicum - Structure and intramolecular evolution of the subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ARTHROPOD HEMOCYANINS; CRYSTAL-STRUCTURE; QUATERNARY STRUCTURE; MOLECULAR-CLONING; SPIDERS; HETEROGENEITY; HEXAMERINS; RESOLUTION	Hemocyanins are large oligomeric respiratory proteins found in many arthropods and molluscs. The hemocyanin of the tarantula Eurypelma californicum is a 24-mer protein complex with molecular mass of 1,726,459 Da that consists of seven different polypeptides (a-g); each occupying a distinct position within the native molecule, Here we report the complete molecular structure of the E. californicum hemocyanin as deduced from the corresponding cDNAs, This represents the first complex arthropod hemocyanin to be completely sequenced. The different subunits display 52-66% amino acid sequence identity. Within the subunits, the central domain, which bears the active center with the copper-binding sites A and B, displays the highest degree of identity. Using a homology modeling approach, the putative three-dimensional structure of individual subunits was deduced and compared. Phylogenetic analyses suggest that differentiation of the individual subunits occurred 400-550 million years ago. The hemocyanin of the stemline Chelicerata was probably a hexamer built up of six distinct subunit types a, b/c, d, e, f, and g, whereas that of the early Arachnida was originally a 24-mer that emerged after the differentiation of subunits b and c.	German Canc Res Ctr, Div Mol Biol Cell 2, D-69120 Heidelberg, Germany; Univ Munich, Inst Zool, D-80333 Munich, Germany; Johannes Gutenberg Univ Mainz, Inst Biophys, D-55099 Mainz, Germany; Johannes Gutenberg Univ Mainz, Inst Zool, D-55099 Mainz, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); University of Munich; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Voit, R (corresponding author), German Canc Res Ctr, Div Mol Biol Cell 2, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	R.Voit@dkfz-heidelberg.de	Burmester, Thorsten/I-7225-2013	Burmester, Thorsten/0000-0002-5772-7863; Schweikardt, Thorsten/0000-0002-1304-7970				BASYONY M, 1991, THESIS MUNCHEN GERMA; BEINTEMA JJ, 1994, MOL BIOL EVOL, V11, P493; Burmester T, 1998, J MOL EVOL, V47, P93, DOI 10.1007/PL00006366; Burmester T, 1996, J MOL EVOL, V42, P713, DOI 10.1007/BF02338804; Burmester T, 1999, J BIOL CHEM, V274, P13217, DOI 10.1074/jbc.274.19.13217; Cuff ME, 1998, J MOL BIOL, V278, P855, DOI 10.1006/jmbi.1998.1647; DAYHOFF MO, 1979, ATLAS PROTEIN SEQ S3, V5; DECKER H, 1979, H-S Z PHYSIOL CHEM, V360, P1505; Decker H, 1998, J BIOL CHEM, V273, P25889, DOI 10.1074/jbc.273.40.25889; Decker H, 2000, ANGEW CHEM INT EDIT, V39, P1591, DOI 10.1002/(SICI)1521-3773(20000502)39:9<1591::AID-ANIE1591>3.0.CO;2-H; Decker H, 1996, FEBS LETT, V393, P226, DOI 10.1016/0014-5793(96)00887-3; Dunlop J.A., 1998, Systematics Association Special Volume Series, V55, P221; Felsenstein J., 1985, EVOLUTION 1985, V39, P783; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; GAYKEMA WPJ, 1984, NATURE, V309, P23, DOI 10.1038/309023a0; HAZES B, 1993, PROTEIN SCI, V2, P597; KEMPTER B, 1985, BIOL CHEM H-S, V366, P77, DOI 10.1515/bchm3.1985.366.1.77; KEMPTER B, 1983, NATURWISSENSCHAFTEN, V70, P255, DOI 10.1007/BF00405449; LAMY J, 1979, H-S Z PHYSIOL CHEM, V360, P889, DOI 10.1515/bchm2.1979.360.2.889; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LINZEN B, 1985, SCIENCE, V229, P519, DOI 10.1126/science.4023698; LOEWE R, 1973, HOPPESEYLERS Z PHYSL, V324, P182; MARKL J, 1981, H-S Z PHYSIOL CHEM, V362, P1631, DOI 10.1515/bchm2.1981.362.2.1631; MARKL J, 1979, J COMP PHYSIOL, V130, P283, DOI 10.1007/BF00689845; MARKL J, 1981, H-S Z PHYSIOL CHEM, V362, P185; Markl J., 1992, Advances in Comparative and Environmental Physiology, V13, P325; MARKL J, 1986, BIOL BULL, V171, P90, DOI 10.2307/1541909; MARKL J, 1980, H-S Z PHYSIOL CHEM, V361, P649, DOI 10.1515/bchm2.1980.361.1.649; MARKL J, 1981, H-S Z PHYSIOL CHEM, V362, P429, DOI 10.1515/bchm2.1981.362.1.429; MARKL J, 1982, H-S Z PHYSIOL CHEM, V363, P73, DOI 10.1515/bchm2.1982.363.1.73; MORRIS SC, 1993, NATURE, V361, P219, DOI 10.1038/361219a0; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALVATO B, 1990, LIFE CHEM REPORTS, V8, P1; SCHARTAU W, 1983, H-S Z PHYSIOL CHEM, V364, P1383, DOI 10.1515/bchm2.1983.364.2.1383; Schartau W., 1986, P177; SCHARTAU W, 1990, BIOL CHEM H-S, V371, P557, DOI 10.1515/bchm3.1990.371.2.557; SCHNEIDER HJ, 1983, H-S Z PHYSIOL CHEM, V364, P1357, DOI 10.1515/bchm2.1983.364.2.1357; SCHNEIDER HJ, 1977, H-S Z PHYSIOL CHEM, V358, P1133, DOI 10.1515/bchm2.1977.358.2.1133; SONNER P, 1990, THESIS MUNCHEN GERMA; Valentine JW, 1999, DEVELOPMENT, V126, P851; VANHEEL M, 1994, MICRON, V25, P387, DOI 10.1016/0968-4328(94)90007-8; vanHolde KE, 1995, ADV PROTEIN CHEM, V47, P1, DOI 10.1016/S0065-3233(08)60545-8; VOIT R, 1990, J BIOL CHEM, V265, P19447; VOIT R, 1986, EUR J BIOCHEM, V159, P23, DOI 10.1111/j.1432-1033.1986.tb09828.x; VOLBEDA A, 1989, J MOL BIOL, V209, P249, DOI 10.1016/0022-2836(89)90276-3; VOLL W, 1990, P NATL ACAD SCI USA, V87, P5312, DOI 10.1073/pnas.87.14.5312; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V	47	57	63	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39339	39344		10.1074/jbc.M005442200	http://dx.doi.org/10.1074/jbc.M005442200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10961996	hybrid			2022-12-25	WOS:000165953100056
J	Iwamoto, T; Uehara, A; Imanaga, I; Shigekawa, M				Iwamoto, T; Uehara, A; Imanaga, I; Shigekawa, M			The Na+/Ca2+ exchanger NCX1 has oppositely oriented reentrant loop domains that contain conserved aspartic acids whose mutation alters its apparent Ca2+ affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOLEMMAL NA+-CA2+ EXCHANGER; PROTEIN-KINASE-C; FUNCTIONAL EXPRESSION; TRANSMEMBRANE SEGMENTS; DEPENDENT REGULATION; MOLECULAR-CLONING; POTASSIUM CHANNEL; GATED CHANNEL; PHOSPHORYLATION; SELECTIVITY	We examined the membrane topology and functional importance of residues in regions of the Na+/Ca2+ exchanger NCX1 encompassing the conserved internal a repeats by substituted cysteine scanning analysis and kinetic analysis of site directed mutants. The results suggest that both the alpha -1 repeat and a region encompassing the a-a repeat and its immediately C-terminal segment contain reentrant loop domains, each oriented in an opposite direction with respect to the membrane, We found that single or multiple mutations of six residues including Asn-125 and conserved aspartates Asp-130, Asp-825, and Asp-829 in the a repeat reentrant domains reduce the apparent affinity of the exchanger for extracellular Ca2+ by up to g-fold, In contrast, the triple cysteine mutation D130C/D825C/D829C did not influence the current-voltage (I-V) relationship of the exchange current. Cysteine accessibility scanning with different thiol modifiers suggested that N125C, D130C, and D825C may be located in a restricted aqueous space in the membrane accessible only to ions when examined with external probes, although N125C and D825C were previously shown to be internally accessible during exchange reaction. The results suggest that these reentrant domains in the a repeats may participate in the formation of the ion transport pathway in the exchanger with some of the aspartates possibly lining it or located close to it.	Natl Cardiovasc Ctr, Res Inst, Dept Mol Physiol, Suita, Osaka 5658565, Japan; Fukuoka Univ, Sch Med, Dept Physiol, Fukuoka 8140180, Japan	National Cerebral & Cardiovascular Center - Japan; Fukuoka University	Shigekawa, M (corresponding author), Natl Cardiovasc Ctr, Res Inst, Dept Mol Physiol, Fujishiro Dai 5, Suita, Osaka 5658565, Japan.	shigekaw@ri.ncvc.go.jp						Agre P, 1998, J BIOL CHEM, V273, P14659, DOI 10.1074/jbc.273.24.14659; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; Dingledine R, 1999, PHARMACOL REV, V51, P7; Doering AE, 1998, J BIOL CHEM, V273, P778, DOI 10.1074/jbc.273.2.778; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Durell SR, 1999, BIOPHYS J, V77, P775, DOI 10.1016/S0006-3495(99)76931-6; EISMANN E, 1994, P NATL ACAD SCI USA, V91, P1109, DOI 10.1073/pnas.91.3.1109; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; Iwamoto T, 1999, J BIOL CHEM, V274, P23094, DOI 10.1074/jbc.274.33.23094; Iwamoto T, 1998, EUR J CELL BIOL, V76, P228, DOI 10.1016/S0171-9335(98)80038-1; Iwamoto T, 1999, FEBS LETT, V446, P264, DOI 10.1016/S0014-5793(99)00218-5; Iwamoto T, 1998, AM J PHYSIOL-CELL PH, V275, pC423, DOI 10.1152/ajpcell.1998.275.2.C423; Iwamoto T, 1998, BIOCHEMISTRY-US, V37, P17230, DOI 10.1021/bi981521q; Iwamoto T, 1996, J BIOL CHEM, V271, P13609, DOI 10.1074/jbc.271.23.13609; Karlin A, 1998, METHOD ENZYMOL, V293, P123; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; LI ZP, 1994, J BIOL CHEM, V269, P17434; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; Nicoll DA, 1999, J BIOL CHEM, V274, P910, DOI 10.1074/jbc.274.2.910; Nicoll DA, 1996, J BIOL CHEM, V271, P13385, DOI 10.1074/jbc.271.23.13385; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; REILANDER H, 1992, EMBO J, V11, P1689, DOI 10.1002/j.1460-2075.1992.tb05219.x; ROOT MJ, 1993, NEURON, V11, P459, DOI 10.1016/0896-6273(93)90150-P; SCHREMPF H, 1995, EMBO J, V14, P5170, DOI 10.1002/j.1460-2075.1995.tb00201.x; Schwarz EM, 1997, P NATL ACAD SCI USA, V94, P10249, DOI 10.1073/pnas.94.19.10249; Shaul O, 1999, EMBO J, V18, P3973, DOI 10.1093/emboj/18.14.3973; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Uehara A, 1997, PFLUG ARCH EUR J PHY, V434, P335, DOI 10.1007/s004240050405; Wakabayashi S, 2000, J BIOL CHEM, V275, P7942, DOI 10.1074/jbc.275.11.7942; WO ZG, 1995, TRENDS NEUROSCI, V18, P161; WOOD MW, 1995, P NATL ACAD SCI USA, V92, P4882, DOI 10.1073/pnas.92.11.4882	36	84	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38571	38580		10.1074/jbc.M003788200	http://dx.doi.org/10.1074/jbc.M003788200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10967097	hybrid			2022-12-25	WOS:000165739800059
J	Joseph, JD; Means, AR				Joseph, JD; Means, AR			Identification and characterization of two Ca2+/CaM-dependent protein kinases required for normal nuclear division in Aspergillus nidulans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIH 3T3 CELLS; CA2+/CALMODULIN-DEPENDENT KINASE; CDNA CLONING; CAMK-II; CALMODULIN; CALCIUM; EXPRESSION; ACTIVATION; CYCLE; G(1)	We utilized an expression screen to identify two novel Ca2+/calmodulin (CaM)-regulated protein kinases in Aspergillus nidulans. The two kinases, CMKB and CMKC, possess high sequence identity with mammalian CaM kinases (CaMKs) I/IV and CaMKK alpha/beta, respectively. In vitro CMKC phosphorylates and increases the activity of CMKB, indicating they are biochemical homologues of CaMKK alpha/beta and CaMKI/IV. The disruption of CMKB is lethal; however, when protein expression is postponed, the spores germinate with delayed kinetics. The observed lag corresponds to a delay in the G(1)-phase activation of the cyclin-dependent kinase NIMXcdc2. Disruption of cmkC is not lethal, but spores lacking CMKC also germinate with delayed kinetics and a lag in the activation of NIMXcdc2. Analysis of Delta cmkC suggests a role for CMKC in regulating the first and subsequent nuclear division cycles. We conclude that both CMKB and CMKC are required for the proper temporal activation of NIMXcdc2 as spores enter the cell cycle hom quiescence and suggest that this relationship exists during the G(1)/S transition of subsequent cell divisions.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Means, AR (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27710 USA.				NIGMS NIH HHS [GM33976] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033976] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson KA, 1998, J BIOL CHEM, V273, P31880, DOI 10.1074/jbc.273.48.31880; CHAFOULEAS JG, 1984, CELL, V36, P73, DOI 10.1016/0092-8674(84)90075-8; Dayton JS, 1997, J BIOL CHEM, V272, P3223, DOI 10.1074/jbc.272.6.3223; Dayton JS, 1996, MOL BIOL CELL, V7, P1511, DOI 10.1091/mbc.7.10.1511; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; HARLOW E, 1988, ANTIBODIES LAB MANUA, P92; HARRIS SD, 1994, GENETICS, V136, P517; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; HIDAKA H, 1996, INTRACELLULAR SIGNAL, P193; Hook SS, 1999, J BIOL CHEM, V274, P20215, DOI 10.1074/jbc.274.29.20215; LU KP, 1993, J CELL BIOL, V121, P621, DOI 10.1083/jcb.121.3.621; LU KP, 1993, METH MOL G, V2, P255; Means AR, 1999, CALCIUM AS A CELLULAR REGULATOR, P512; Morris TA, 1998, EXP CELL RES, V240, P218, DOI 10.1006/excr.1997.3925; OSMANI AH, 1994, J CELL SCI, V107, P1519; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; RASMUSSEN C, 1994, EMBO J, V13, P3917, DOI 10.1002/j.1460-2075.1994.tb06703.x; RASMUSSEN CD, 1990, J BIOL CHEM, V265, P13767; Rasmussen CD, 2000, J BIOL CHEM, V275, P685, DOI 10.1074/jbc.275.1.685; RASMUSSEN G, 1995, BIOCHEM CELL BIOL, V73, P201, DOI 10.1139/o95-024; S~anchez O, 1996, FUNGAL GENET REP, V43, P21; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SEBERT MA, 1995, J BIOL CHEM, V270, P17616; STIRLING DA, 1992, MOL MICROBIOL, V6, P703, DOI 10.1111/j.1365-2958.1992.tb01519.x; Taules M, 1998, J BIOL CHEM, V273, P33279, DOI 10.1074/jbc.273.50.33279; TOMBES RM, 1995, CELL GROWTH DIFFER, V6, P1063; WARING RB, 1989, GENE, V79, P119, DOI 10.1016/0378-1119(89)90097-8; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147	28	62	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38230	38238		10.1074/jbc.M006422200	http://dx.doi.org/10.1074/jbc.M006422200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10988293	hybrid			2022-12-25	WOS:000165739800015
J	Goto, T; Kato, N; Ono-Nita, SK; Yoshida, H; Otsuka, M; Shiratori, Y; Omata, M				Goto, T; Kato, N; Ono-Nita, SK; Yoshida, H; Otsuka, M; Shiratori, Y; Omata, M			Large isoform of hepatitis delta antigen activates serum response factor-associated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-X-PROTEIN; TERNARY COMPLEX FACTORS; IMMEDIATE-EARLY GENES; RNA-POLYMERASE-II; C-FOS PROMOTER; B VIRUS; ABERRANT INDUCTION; NUCLEAR TRANSPORT; BINDING-ACTIVITY; GROWTH-FACTORS	Hepatitis delta virus infection sometimes causes severe and fulminant hepatitis as a coinfection or superinfection along with the hepatitis B virus. To elucidate the underlying mechanism of injury caused by hepatitis delta virus, we examined whether two isoforms of the hepatitis delta antigen (HDAg) had any effect on five well defined intracellular signal transduction pathways: serum response factor (SRF)-, serum response element (SRE)-, nuclear factor kappaB-, activator protein 1-, and cyclic AMP response element-dependent pathways. Reporter assays revealed that large HDAg (LIDDAg) activated the SRF- and SRE-dependent pathways. In contrast, small HDAg (LHDAg) did not activate any of five pathways. LHDAg enhanced the transcriptional ability of SRF without changing its DNA binding affinity in an electrophoretic mobility shift assay. In addition, LHDAg activated a rat SM22 alpha promoter containing SRF binding site and a human c-fos promoter containing SRE. In conclusion, LHDAg, but not SHDAg, enhances SRF-associated transcriptions. Despite structural similarities be tween the two HDAgs, there are significant differences in their effects on intracellular signal transduction pathways. These results may provide clues that will aid in the clarification of functional differences between LHDAg and SHDAg and the pathogenesis of delta hepatitis.	Univ Tokyo, Fac Med, Dept Gastroenterol, Bunkyo Ku, Tokyo 1138655, Japan	University of Tokyo	Kato, N (corresponding author), Univ Tokyo, Fac Med, Dept Gastroenterol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.		Otsuka, Motoyuki/H-9067-2019; Ono, Suzane K/I-3107-2012	Otsuka, Motoyuki/0000-0003-2869-2881; 				AVANTAGGIATI ML, 1993, ONCOGENE, V8, P1567; BERGMANN KF, 1986, J INFECT DIS, V154, P702, DOI 10.1093/infdis/154.4.702; Bichko V, 1997, J VIROL, V71, P512, DOI 10.1128/JVI.71.1.512-518.1997; Brazas R, 1996, SCIENCE, V274, P90, DOI 10.1126/science.274.5284.90; CHANG FL, 1991, P NATL ACAD SCI USA, V88, P8490, DOI 10.1073/pnas.88.19.8490; CHANG MF, 1988, J VIROL, V62, P2403, DOI 10.1128/JVI.62.7.2403-2410.1988; CHANG MF, 1992, J VIROL, V66, P6019, DOI 10.1128/JVI.66.10.6019-6027.1992; CHAO M, 1990, J VIROL, V64, P5066, DOI 10.1128/JVI.64.10.5066-5069.1990; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chin MT, 1998, J BIOL CHEM, V273, P9755, DOI 10.1074/jbc.273.16.9755; Chou HC, 1998, J VIROL, V72, P3684, DOI 10.1128/JVI.72.5.3684-3690.1998; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; FU TB, 1993, J VIROL, V67, P6965, DOI 10.1128/JVI.67.12.6965-6972.1993; FUJII M, 1995, ONCOGENE, V11, P7; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; GAUTHIERROUVIERE C, 1995, MOL CELL BIOL, V15, P433, DOI 10.1128/MCB.15.1.433; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Ginisty H, 1999, J CELL SCI, V112, P761; GLENN JS, 1992, SCIENCE, V256, P1331, DOI 10.1126/science.1598578; Hautmann MB, 1997, CIRC RES, V81, P600, DOI 10.1161/01.RES.81.4.600; Haviv I, 1996, EMBO J, V15, P3413, DOI 10.1002/j.1460-2075.1996.tb00707.x; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HOOFNAGLE JH, 1989, JAMA-J AM MED ASSOC, V261, P1321, DOI 10.1001/jama.261.9.1321; IMAZEKI F, 1990, J VIROL, V64, P5594, DOI 10.1128/JVI.64.11.5594-5599.1990; Ishikawa T, 1999, BIOCHEM BIOPH RES CO, V254, P566, DOI 10.1006/bbrc.1998.9979; KEMP PR, 1995, BIOCHEM J, V310, P1037, DOI 10.1042/bj3101037; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KUO MYP, 1989, J VIROL, V63, P1945, DOI 10.1128/JVI.63.5.1945-1950.1989; KUO MYP, 1988, J VIROL, V62, P1855, DOI 10.1128/JVI.62.6.1855-1861.1988; LATINKIC BV, 1994, J BIOL CHEM, V269, P23163; Lee CH, 1998, J BIOL CHEM, V273, P7650, DOI 10.1074/jbc.273.13.7650; Liao JF, 1997, J BIOL CHEM, V272, P25951, DOI 10.1074/jbc.272.41.25951; LIN JH, 1990, J VIROL, V64, P4051, DOI 10.1128/JVI.64.9.4051-4058.1990; Lin Y, 1997, CANCER RES, V57, P5137; Lin Y, 1998, J BIOL CHEM, V273, P27097, DOI 10.1074/jbc.273.42.27097; Lo K, 1998, VIROLOGY, V247, P178, DOI 10.1006/viro.1998.9253; MACNAUGHTON TB, 1991, VIROLOGY, V184, P387, DOI 10.1016/0042-6822(91)90855-6; MACNAUGHTON TB, 1990, VIROLOGY, V177, P692, DOI 10.1016/0042-6822(90)90535-Y; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MAKINO S, 1987, NATURE, V329, P343, DOI 10.1038/329343a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MIN BH, 1990, J BIOL CHEM, V265, P16667; MUSCAT GE, 1988, MOL CELL BIOL, V8, P4120, DOI 10.1128/MCB.8.10.4120; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OLIVERI F, 1991, PROG CLIN BIOL RES, V364, P217; RIZZETTO M, 1977, GUT, V18, P997, DOI 10.1136/gut.18.12.997; RIZZETTO M, 1983, HEPATOLOGY, V3, P906; Sambrook J., 1989, MOL CLONING, pA1; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Taylor J, 1993, Prog Clin Biol Res, V382, P1; Togo G, 1996, CANCER RES, V56, P5620; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Treisman R, 1992, CURR OPIN GENET DEV, V2, P221, DOI 10.1016/S0959-437X(05)80277-1; Urich M, 1997, ONCOGENE, V14, P1235, DOI 10.1038/sj.onc.1200982; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191; WANG JG, 1993, J VIROL, V67, P446, DOI 10.1128/JVI.67.1.446-454.1993; WANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0; Wei Y, 1998, J VIROL, V72, P2089, DOI 10.1128/JVI.72.3.2089-2096.1998; WU JC, 1991, J VIROL, V65, P1099, DOI 10.1128/JVI.65.3.1099-1104.1991; XIA YP, 1992, J VIROL, V66, P914, DOI 10.1128/JVI.66.2.914-921.1992; YANG TH, 1994, MOL CELL BIOL, V14, P6068, DOI 10.1128/MCB.14.9.6068; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20	63	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37311	37316		10.1074/jbc.M002947200	http://dx.doi.org/10.1074/jbc.M002947200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10961986	hybrid			2022-12-25	WOS:000165618700003
J	Heaton, D; Nittis, T; Srinivasan, C; Winge, DR				Heaton, D; Nittis, T; Srinivasan, C; Winge, DR			Mutational analysis of the mitochondrial copper metallochaperone Cox17	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; SACCHAROMYCES-CEREVISIAE; INTERMEMBRANE SPACE; TARGETING SIGNAL; YEAST; PROTEIN; SCO1; GENE; COMPLEMENTATION; LOCALIZATION	The copper metallochaperone Cox17 is proposed to shuttle Cu(I) ions to the mitochondrion for the assembly of cytochrome c oxidase, The Cu(I) ions are liganded by cysteinyl thiolates, Mutational analysis on the yeast Cox17 reveals three of the seven cysteinyl residues to be critical for Cox17 function, and these three residues are present in a Cys-Cys-Xaa-Cys sequence motif. Single substitution of any of these three cysteines with serines results in a nonfunctional cytochrome oxidase complex. Cells harboring such a mutation fail to grow on nonfermentable carbon sources and have no cytochrome c oxidase activity in isolated mitochondria, Wild-type Cox17 purified as untagged protein binds three Cu(I) ions/molecule. Mutant proteins lacking only one of these critical Cys residues retain the ability to bind three Cu(I) ions and are imported within the mitochondria, In contrast, Cox17 molecules with a double Cys --> Ser mutation exhibit no Cu(I) binding but are still localized to the mitochondria, Thus, mitochondrial uptake of Cox17 is not restricted to the Cu(I) conformer of Cox17, COX17 was originally cloned by virtue of complementation of a mutant containing a nonfunctional Cys --> Tyr substitution at codon 57, The mutant C57Y Cox17 fails to accumulate within the mitochondria but retains the ability to bind three Cu(I) ions. A C57S Cox17 variant is functional, and a quadruple Cox17 mutant with C16S/C36S/C47S/C57S substitutions binds three Cu(I) ions. Thus, only three cysteinyl residues are important for the ligation of three Cu(I) ions. A novel mode of Cu(I) binding is predicted.	Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84132 USA; Univ Utah, Hlth Sci Ctr, Dept Biochem, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Winge, DR (corresponding author), Univ Utah, Hlth Sci Ctr, Dept Med, 50 N Med Dr, Salt Lake City, UT 84132 USA.		Winge, Dennis/G-3611-2010		NCI NIH HHS [5P30CA42014] Funding Source: Medline; NIEHS NIH HHS [ES03817] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES003817, R01ES003817] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSSON SGE, 1990, MICROBIOL REV, V54, P198, DOI 10.1128/MMBR.54.2.198-210.1990; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHWALD P, 1991, MOL GEN GENET, V229, P413, DOI 10.1007/BF00267464; Diekert K, 1999, P NATL ACAD SCI USA, V96, P11752, DOI 10.1073/pnas.96.21.11752; Glerum DM, 1997, J BIOL CHEM, V272, P19088, DOI 10.1074/jbc.272.30.19088; GLERUM DM, 1994, P NATL ACAD SCI USA, V91, P8452, DOI 10.1073/pnas.91.18.8452; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; GLERUM DM, 1995, J BIOL CHEM, V270, P15585, DOI 10.1074/jbc.270.26.15585; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Hiser L, 2000, J BIOL CHEM, V275, P619, DOI 10.1074/jbc.275.1.619; Lee CM, 1999, J BIOL CHEM, V274, P20937, DOI 10.1074/jbc.274.30.20937; Leuenberger D, 1999, EMBO J, V18, P4816, DOI 10.1093/emboj/18.17.4816; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Papadopoulou LC, 1999, NAT GENET, V23, P333; Paret C, 1999, FEBS LETT, V447, P65, DOI 10.1016/S0014-5793(99)00266-5; Poyton RO, 1995, METHOD ENZYMOL, V260, P97, DOI 10.1016/0076-6879(95)60133-3; Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Rentzsch A, 1999, CURR GENET, V35, P103, DOI 10.1007/s002940050438; SCHULZE M, 1988, MOL GEN GENET, V211, P492, DOI 10.1007/BF00425706; Srinivasan C, 1998, BIOCHEMISTRY-US, V37, P7572, DOI 10.1021/bi980418y; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; TZAGOLOFF A, 1990, EMBO J, V9, P2759, DOI 10.1002/j.1460-2075.1990.tb07463.x; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990	28	82	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37582	37587		10.1074/jbc.M006639200	http://dx.doi.org/10.1074/jbc.M006639200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10970896	hybrid			2022-12-25	WOS:000165618700039
J	Harada, Y; Sanada, K; Fukada, Y				Harada, Y; Sanada, K; Fukada, Y			Circadian activation of bullfrog retinal mitogen-activated protein kinase associates with oscillator function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLTRANSFERASE ACTIVITY; ENDOGENOUS DOPAMINE RELEASE; DROSOPHILA CLOCK GENE; CHICKEN PINEAL-GLAND; MAP KINASE; PERIOD PROTEIN; IN-VITRO; SUPRACHIASMATIC NUCLEI; TYROSINE-HYDROXYLASE; BEHAVIORAL RHYTHMS	The vertebrate retina retains a circadian oscillator, and its oscillation is self-sustained with a period close to 24 h under constant environmental conditions. Here we show that bullfrog retinal mitogen-activated protein kinase (MAPK) exhibits an in vivo circadian rhythm in phosphorylation with a peak at night in a light/dark cycle. The phosphorylation rhythm of MAPK persists in constant darkness with a peak at subjective night, and this self-sustained rhythm is also observed in cultured retinas, indicating its close interaction with the retinal oscillator. The rhythmically phosphorylated MAPK. is detected only in a discrete subset of amacrine cells despite ubiquitous distribution of MAPK throughout the retinal layers. Treatment of the cultured retinas with MAPK kinase (MEK) inhibitor PD98059 suppresses MAPK phosphorylation during the subjective night, and this pulse perturbation of MEK activity induces a significant phase delay (4-8 h) of the retinal circadian rhythm in MAPK and MEK phosphorylation. These observations strongly suggest that the site-specific and time-of-day-specific activation of MAPK contributes to the circadian time-keeping mechanism of the retinal clock system.	Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan; Japan Sci & Technol Corp, CREST, Tokyo 1130033, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Fukada, Y (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.		SANADA, YOSHIKADO/G-5014-2014; 吉孝, 深田/G-5090-2014	Sanada, Kamon/0000-0002-0280-8957				Adachi A, 1998, BRAIN RES, V792, P361, DOI 10.1016/S0006-8993(98)00206-6; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; Belvin MP, 1999, NEURON, V22, P777, DOI 10.1016/S0896-6273(00)80736-9; BESHARSE JC, 1983, EXP EYE RES, V36, P567, DOI 10.1016/0014-4835(83)90051-9; BOATRIGHT JH, 1994, VISUAL NEUROSCI, V11, P1013, DOI 10.1017/S0952523800003941; BOATRIGHT JH, 1994, VISUAL NEUROSCI, V11, P1003, DOI 10.1017/S095252380000393X; CAHILL GM, 1993, NEURON, V10, P573, DOI 10.1016/0896-6273(93)90160-S; CAHILL GM, 1990, J NEUROCHEM, V54, P716, DOI 10.1111/j.1471-4159.1990.tb01932.x; CROOKS J, 1992, J COMP NEUROL, V315, P287, DOI 10.1002/cne.903150305; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; DEGUCHI T, 1979, SCIENCE, V203, P1245, DOI 10.1126/science.424750; DJAMGOZ MBA, 1992, NEUROCHEM INT, V20, P139, DOI 10.1016/0197-0186(92)90166-O; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Dunlap JC, 1999, GENES CELLS, V4, P1, DOI 10.1046/j.1365-2443.1999.00239.x; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; Greve P, 1996, BIOCHEM J, V319, P761, DOI 10.1042/bj3190761; Harada Y, 1998, BIOL RHYTHM RES, V29, P30, DOI 10.1076/brhm.29.1.30.3043; Hardin PE, 1999, SCIENCE, V286, P2460, DOI 10.1126/science.286.5449.2460; KASAL CA, 1979, SCIENCE, V203, P656, DOI 10.1126/science.569904; KAZULA A, 1993, VISUAL NEUROSCI, V10, P621, DOI 10.1017/S0952523800005320; KEMALI M, 1983, EXP BRAIN RES, V53, P193, DOI 10.1007/BF00239412; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Kolb H, 1997, EYE, V11, P904, DOI 10.1038/eye.1997.230; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; LAM DMK, 1979, NATURE, V278, P565, DOI 10.1038/278565a0; Lee CG, 1998, NEURON, V21, P857, DOI 10.1016/S0896-6273(00)80601-7; Liu C, 1997, NEURON, V19, P91, DOI 10.1016/S0896-6273(00)80350-5; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; Myers MP, 1996, SCIENCE, V271, P1736, DOI 10.1126/science.271.5256.1736; Naidoo N, 1999, SCIENCE, V285, P1737, DOI 10.1126/science.285.5434.1737; Nakahara K, 1997, BRAIN RES, V774, P242, DOI 10.1016/S0006-8993(97)81713-1; Obrietan K, 1998, NAT NEUROSCI, V1, P693, DOI 10.1038/3695; Obrietan K, 1999, J BIOL CHEM, V274, P17748, DOI 10.1074/jbc.274.25.17748; OSBORNE NN, 1984, HISTOCHEMISTRY, V80, P389, DOI 10.1007/BF00495423; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Reppert SM, 1998, NEURON, V21, P1, DOI 10.1016/S0896-6273(00)80234-2; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; Sanada K, 2000, J NEUROSCI, V20, P986, DOI 10.1523/JNEUROSCI.20-03-00986.2000; Sassone-Corsi P, 1998, NATURE, V392, P871, DOI 10.1038/31821; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; Tosini G, 1998, BRAIN RES, V789, P221, DOI 10.1016/S0006-8993(97)01446-7; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; Whitmore D, 1998, NAT NEUROSCI, V1, P701, DOI 10.1038/3703; WIRZJUSTICE A, 1984, NEUROSCI LETT, V45, P21, DOI 10.1016/0304-3940(84)90323-9; WITKOVSKY P, 1991, VISUAL NEUROSCI, V7, P113, DOI 10.1017/S0952523800010981; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Young MW, 1998, ANNU REV BIOCHEM, V67, P135, DOI 10.1146/annurev.biochem.67.1.135; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	63	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37078	37085		10.1074/jbc.M004706200	http://dx.doi.org/10.1074/jbc.M004706200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10978323	hybrid			2022-12-25	WOS:000165577700087
J	Sadasivan, C; Yee, VC				Sadasivan, C; Yee, VC			Interaction of the factor XIII activation peptide with alpha-thrombin - Crystal structure of its enzyme-substrate analog complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-XIII; PRO-ARG CHLOROMETHYLKETONE; MYOCARDIAL-INFARCTION; COMMON POLYMORPHISM; VENOUS THROMBOSIS; TRYPSIN COMPLEX; BOVINE THROMBIN; BINDING-SITE; A-SUBUNIT; ASSOCIATION	The serine protease thrombin proteolytically activates blood coagulation factor XIII by cleavage at residue Arg(37); factor XIII in turn cross-links fibrin molecules and gives mechanical stability to the blood clot. The 2.0-Angstrom resolution x-ray crystal structure of human cy-thrombin bound to the factor XII-(28-37) decapeptide has been determined. This structure reveals the detailed atomic level interactions between the factor XIII activation peptide and thrombin and provides the first high resolution view of this functionally important part of the factor XIII molecule. A comparison of this structure with the crystal structure of fibrinopeptide A complexed with thrombin highlights several important determinants of thrombin substrate interaction. First, the P1 and P2 residues must be compatible with the geometry and chemistry of the SI and S2 specificity sites in thrombin. Second, a glycine in the P5 position is necessary for the conserved substrate conformation seen in both factor XIII-(28-37) and fibrinopeptide A. Finally, the hydrophobic residues, which occupy the aryl binding site of thrombin determine the substrate conformation further away from the catalytic residues. In the case of factor XII-(28-37), the aryl binding site is shared by hydrophobic residues P4 (Val(34)) and P9 (Val(29)). A bulkier residue in either of these sites may alter the substrate peptide conformation.	Cleveland Clin Fdn, Lerner Res Inst, Dept Med Cardiol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Struct Biol Ctr, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Yee, VC (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Med Cardiol, 9500 Euclid Ave,NB 20, Cleveland, OH 44195 USA.	yee@pierre.lerner.ccf.org	Chittalakkottu, Sadasivan/AAR-1786-2020					Ariens RAS, 2000, BLOOD, V96, P988, DOI 10.1182/blood.V96.3.988.015k57_988_995; Balogh I, 2000, BLOOD, V96, P2479; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1990, EUR J BIOCHEM, V193, P175, DOI 10.1111/j.1432-1033.1990.tb19320.x; BODE W, 1992, PROTEIN SCI, V1, P426; BRUNGER AT, 1992, XPLOR VERSION 3 1; Catto AJ, 1998, STROKE, V29, P813, DOI 10.1161/01.STR.29.4.813; Catto AJ, 1999, BLOOD, V93, P906, DOI 10.1182/blood.V93.3.906.403k24_906_908; CHEN ZG, 1995, ARCH BIOCHEM BIOPHYS, V322, P198, DOI 10.1006/abbi.1995.1452; Chirgadze NY, 1997, PROTEIN SCI, V6, P1412, DOI 10.1002/pro.5560060705; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; Elbaz A, 2000, BLOOD, V95, P586, DOI 10.1182/blood.V95.2.586; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fenton J W 2nd, 1981, Ann N Y Acad Sci, V370, P468, DOI 10.1111/j.1749-6632.1981.tb29757.x; FENTON JW, 1988, BIOCHEMISTRY-US, V27, P7106, DOI 10.1021/bi00418a066; FENTON JW, 1986, SEMIN THROMB HEMOST, V12, P200, DOI 10.1055/s-2007-1003551; FOLK JE, 1973, ADV ENZYMOL RAMB, V38, P109; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; Fox BA, 1999, J BIOL CHEM, V274, P4917, DOI 10.1074/jbc.274.8.4917; Franco RF, 2000, HAEMATOLOGICA, V85, P67; Franco RF, 1999, THROMB HAEMOSTASIS, V81, P676; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; HORNYAK TJ, 1989, BIOCHEMISTRY-US, V28, P7326, DOI 10.1021/bi00444a027; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kangsadalampai S, 1998, BLOOD, V92, P2766, DOI 10.1182/blood.V92.8.2766.420k26_2766_2770; Kohler HP, 1998, THROMB HAEMOSTASIS, V79, P8, DOI 10.1055/s-0037-1614250; Kohler HP, 1998, THROMB HAEMOSTASIS, V80, P704; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krishnan R, 1998, BIOCHEMISTRY-US, V37, P12094, DOI 10.1021/bi980840e; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LORAND L, 1986, ANN NY ACAD SCI, V485, P144, DOI 10.1111/j.1749-6632.1986.tb34577.x; Malkowski MG, 1997, BIOCHEM J, V326, P815, DOI 10.1042/bj3260815; MARTIN PD, 1992, J BIOL CHEM, V267, P7911; MATSUZAKI T, 1989, J BIOCHEM-TOKYO, V105, P949, DOI 10.1093/oxfordjournals.jbchem.a122785; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Muszbek L, 1996, CRIT REV CL LAB SCI, V33, P357, DOI 10.3109/10408369609084691; Muszbek L, 1999, THROMB RES, V94, P271, DOI 10.1016/S0049-3848(99)00023-7; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; REHSE PH, 1995, BIOCHEMISTRY-US, V34, P11537, DOI 10.1021/bi00036a029; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; TOLLEFSEN DM, 1974, J BIOL CHEM, V249, P2646; Trumbo TA, 2000, J BIOL CHEM, V275, P20627, DOI 10.1074/jbc.M000209200; TURK D, 1991, FEBS LETT, V287, P133, DOI 10.1016/0014-5793(91)80033-Y; van den Akker F, 1999, ACTA CRYSTALLOGR D, V55, P206, DOI 10.1107/S0907444998007161; Wartiovaara U, 1999, ATHEROSCLEROSIS, V142, P295, DOI 10.1016/S0021-9150(98)00241-X; Weir MP, 1998, BIOCHEMISTRY-US, V37, P6645, DOI 10.1021/bi972499o; YEE VC, 1995, THROMB RES, V78, P389, DOI 10.1016/0049-3848(95)00072-Y; YEE VC, 1994, P NATL ACAD SCI USA, V91, P7296, DOI 10.1073/pnas.91.15.7296; Zhang EL, 1997, BIOPHYS CHEM, V63, P185, DOI 10.1016/S0301-4622(96)02227-2	56	51	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36942	36948		10.1074/jbc.M006076200	http://dx.doi.org/10.1074/jbc.M006076200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10956659	hybrid			2022-12-25	WOS:000165577700070
J	Jones, EA; Conover, J; Symes, AJ				Jones, EA; Conover, J; Symes, AJ			Identification of a novel gp130-responsive site in the vasoactive intestinal peptide cytokine response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CILIARY NEUROTROPHIC FACTOR; LEUKEMIA INHIBITORY FACTOR; TYROSINE-PHOSPHATASE SHP-2; ACTIVATED PROTEIN-KINASE; CENTRAL-NERVOUS-SYSTEM; SIGNALING PATHWAYS; GENE-EXPRESSION; CHOLINERGIC DIFFERENTIATION; SYMPATHETIC NEURONS; STAT PROTEINS	The neuropoietic cytokine ciliary neurotrophic factor (CNTF) potently induces transcription of the vasoactive intestinal peptide (VIP) gene through a 180-base pair (bp) cytokine response element (CyRE) in the VIP promoter. We have previously shown that CNTF induction of STAT and AP-1 protein binding within the CyRE is necessary to mediate CNTF induction of VIP gene transcription. We now show that a third, previously uncharacterized site at the S'-end of the CyRE is also critical to CNTF induction of CyRE transcription. A 4-bp mutation in this 3'-region reduced CNTF-mediated induction of transcription similar to 80%. Whereas mutations in both the STAT and AP-1 sites substantially reduced CNTF induction of transcription, mutations in these sites together with the novel 3'-site completely abolished the ability of CNTF to induce CyRE-mediated transcription. Gel shift analysis indicated that a complex in neuroblastoma cells bound specifically to this 3'-site. This complex was not altered by CNTF treatment. Mutations in an 8-bp sequence (TTACTGGA) eliminated binding of this protein complex and markedly reduced transcriptional activation of the CyRE by CNTF. Thus, we have identified a protein complex binding to a novel DNA sequence that is necessary for full CNTF induction of VIP gene transcription.	Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA	Symes, AJ (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Pharmacol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	Asymes@usuhs.mil	Symes, Aviva J/S-7471-2016	Symes, Aviva J/0000-0003-2557-9939	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS035839] Funding Source: NIH RePORTER; NINDS NIH HHS [R29 NS035839, R29 NS-35839] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Bjorbaek C, 1999, J BIOL CHEM, V274, P30059, DOI 10.1074/jbc.274.42.30059; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; Bousquet C, 1999, J CLIN INVEST, V104, P1277, DOI 10.1172/JCI7924; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; Bugno M, 1995, NUCLEIC ACIDS RES, V23, P5041, DOI 10.1093/nar/23.24.5041; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; Carpenter LR, 1999, ADV PROTEIN CHEM, V52, P109; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; Choi I, 1998, IMMUNOL LETT, V61, P103, DOI 10.1016/S0165-2478(98)00005-4; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DESERIO A, 1995, J MOL BIOL, V254, P795, DOI 10.1006/jmbi.1995.0655; ERNSBERGER U, 1989, NEURON, V2, P1275, DOI 10.1016/0896-6273(89)90312-7; FAN GP, 1993, DEVELOPMENT, V118, P83; Frank DA, 1996, PERSPECT DEV NEUROBI, V4, P3; Giordano V, 1997, J IMMUNOL, V158, P4097; GOZES I, 1988, NEUROENDOCRINOLOGY, V47, P27, DOI 10.1159/000124886; GOZES I, 1987, MOL BRAIN RES, V2, P137, DOI 10.1016/0169-328X(87)90007-6; Hahm SH, 1998, J BIOL CHEM, V273, P17086, DOI 10.1074/jbc.273.27.17086; Hahm SH, 1996, J NEUROCHEM, V67, P1872; Hahm SH, 1999, J BIOL CHEM, V274, P25588, DOI 10.1074/jbc.274.36.25588; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; JOHNSON JA, 1994, J BIOL CHEM, V269, P18856; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kim H, 1999, MOL CELL BIOL, V19, P5326; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEWIS SE, 1994, J NEUROCHEM, V63, P429; MARTINOU JC, 1992, NEURON, V8, P737, DOI 10.1016/0896-6273(92)90094-T; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Nakashima K, 1999, J NEUROSCI, V19, P5429; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; PATTERSON PH, 1993, CELL, V72, P123, DOI 10.1016/S0092-8674(05)80032-7; RAO MS, 1992, DEV BIOL, V150, P281, DOI 10.1016/0012-1606(92)90242-9; SAADAT S, 1989, J CELL BIOL, V108, P1807, DOI 10.1083/jcb.108.5.1807; SCHIEMANN WP, 1994, J BIOL CHEM, V269, P6376; Schiemann WP, 1997, J BIOL CHEM, V272, P16631, DOI 10.1074/jbc.272.26.16631; SCHWARZSCHILD MA, 1994, J NEUROCHEM, V63, P1246; SENA M, 1994, DNA SEQUENCE, V5, P25, DOI 10.3109/10425179409039701; STAHL N, 1994, J NEUROBIOL, V25, P1454, DOI 10.1002/neu.480251111; Starr R, 1999, BIOESSAYS, V21, P47, DOI 10.1002/(SICI)1521-1878(199901)21:1<47::AID-BIES6>3.0.CO;2-N; SYMES A, 1994, MOL ENDOCRINOL, V8, P1750, DOI 10.1210/me.8.12.1750; Symes A, 1997, J BIOL CHEM, V272, P9648; Symes A, 1997, CURR BIOL, V7, P697, DOI 10.1016/S0960-9822(06)00298-3; SYMES AJ, 1993, P NATL ACAD SCI USA, V90, P572, DOI 10.1073/pnas.90.2.572; SYMES AJ, 1995, J BIOL CHEM, V270, P8068, DOI 10.1074/jbc.270.14.8068; SYMES AJ, 1995, J NEUROCHEM, V65, P1926; SYMES AJ, 1998, LUNG BIOL HEALTH DIS, V112, P293; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; THANOS D, 1993, COLD SPRING HARB SYM, V58, P73, DOI 10.1101/SQB.1993.058.01.011; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; WINTER CG, 1995, P NATL ACAD SCI USA, V92, P5865, DOI 10.1073/pnas.92.13.5865; Yie JM, 1999, P NATL ACAD SCI USA, V96, P13108, DOI 10.1073/pnas.96.23.13108; Yie JM, 1999, EMBO J, V18, P3074, DOI 10.1093/emboj/18.11.3074; YOSHIDA T, 1993, DEV BRAIN RES, V76, P147, DOI 10.1016/0165-3806(93)90132-T	65	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36013	36020		10.1074/jbc.M007373200	http://dx.doi.org/10.1074/jbc.M007373200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10964933	hybrid			2022-12-25	WOS:000165382000053
J	Gopalkrishnan, RV; Roberts, T; Tuli, S; Kang, D; Christiansen, KA; Fisher, PB				Gopalkrishnan, RV; Roberts, T; Tuli, S; Kang, D; Christiansen, KA; Fisher, PB			Molecular characterization of prostate carcinoma tumor antigen-1, PCTA-1, a human Galectin-8 related gene	ONCOGENE			English	Article						prostate; genomic structure; chromosomal localization; 1q42-43; SEM	BINDING PROTEIN GALECTIN-3; SURFACE-EPITOPE MASKING; ANIMAL LECTINS; CELL-ADHESION; SUPPRESSOR GENE; T-CELLS; EXPRESSION; GROWTH; CANCER; DIFFERENTIATION	The galectin family of proteins has been associated with several diverse cellular processes. More than 30 years since the discovery of the first member, precise biological functions for the family as a whole, or for individual members has pro, cn elusive. The isolation of Prostate Carcinoma Tumor Antigen-1 (PCTA-1), a cDNA closely related to rat and human Galectin-8, as a surface marker associated with prostate cancer was achieved using a previously described immunological subtraction approach, Surface Epitope Masking (SEM) approach, in combination,with expression screening. It appears that PCTA-1 expression is almost ubiquitous in normal human tissues and could alter in specific contests such as transformation or metastasis. Multiple expression isoforms of PCTA-1 at the mRNA level are observed. PCTA-1 maps to 1q42-43, a locus associated with predisposition to prostate cancer. We have determined the genomic structure of PCTA-1 to account for the several observed isoforms, performed expression analysis to determine distribution in normal and transformed contests at the RNA and protein level and conducted over-expression studies to determine effects on cellular phenotype.	Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Urol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Neurosurg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Fisher, PB (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, BB-1501,603 W 168th St, New York, NY 10032 USA.		Roberts, Terry/A-8211-2014					Akahani S, 1997, CANCER RES, V57, P5272; Arata Y, 1997, J BIOCHEM-TOKYO, V121, P1002, DOI 10.1093/oxfordjournals.jbchem.a021686; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Bassen R, 1999, ANTICANCER RES, V19, P5429; Berthon P, 1998, AM J HUM GENET, V62, P1416, DOI 10.1086/301879; Blaser C, 1998, EUR J IMMUNOL, V28, P2311, DOI 10.1002/(SICI)1521-4141(199808)28:08<2311::AID-IMMU2311>3.0.CO;2-G; Bresalier RS, 1996, CANCER RES, V56, P4354; Bresalier RS, 1997, CANCER, V80, P776; Chadli A, 1997, J NEUROCHEM, V68, P1640; Chammas R, 1996, BRAZ J MED BIOL RES, V29, P1141; CHO MJ, 1995, J BIOL CHEM, V270, P5198, DOI 10.1074/jbc.270.10.5198; CHO MJ, 1995, J BIOL CHEM, V270, P5207, DOI 10.1074/jbc.270.10.5207; Colnot C, 1996, BIOCHEM SOC T, V24, P141, DOI 10.1042/bst0240141; Cooper DNW, 1999, GLYCOBIOLOGY, V9, P979, DOI 10.1093/glycob/9.10.979; Cooper DNW, 1997, J BIOL CHEM, V272, P1514, DOI 10.1074/jbc.272.3.1514; Cortegano I, 1998, J IMMUNOL, V161, P385; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; DAGHER SF, 1995, P NATL ACAD SCI USA, V92, P1213, DOI 10.1073/pnas.92.4.1213; Ellerhorst J, 1999, INT J ONCOL, V14, P217; FEICHTINGER W, 1989, HUM GENET, V83, P145, DOI 10.1007/BF00286707; FEINSTEIN E, 1995, GENOMICS, V29, P305, DOI 10.1006/geno.1995.1255; Gillenwater A, 1996, HEAD NECK-J SCI SPEC, V18, P422, DOI 10.1002/(SICI)1097-0347(199609/10)18:5<422::AID-HED5>3.3.CO;2-S; Gitt MA, 1998, J BIOL CHEM, V273, P2961, DOI 10.1074/jbc.273.5.2961; GITT MA, 1995, J BIOL CHEM, V270, P5032, DOI 10.1074/jbc.270.10.5032; Gitt MA, 1998, J BIOL CHEM, V273, P2954, DOI 10.1074/jbc.273.5.2954; Gopalkrishnan RV, 1996, ONCOGENE, V13, P2671; Gopalkrishnan RV, 1999, NUCLEIC ACIDS RES, V27, P4775, DOI 10.1093/nar/27.24.4775; Greenhalgh CJ, 1999, MOL BIOCHEM PARASIT, V98, P285, DOI 10.1016/S0166-6851(98)00167-4; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; Hebert E, 1996, CR ACAD SCI III-VIE, V319, P871; Hsu DK, 1999, INT J CANCER, V81, P519, DOI 10.1002/(SICI)1097-0215(19990517)81:4<519::AID-IJC3>3.3.CO;2-S; Hughes D, 1997, DRUG DISCOV TODAY, V2, P2, DOI 10.1016/S1359-6446(97)81331-1; Iglesias MM, 1998, GLYCOBIOLOGY, V8, P59, DOI 10.1093/glycob/8.1.59; INOHARA H, 1995, CANCER RES, V55, P3267; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; Kaltner H, 1998, ACTA ANAT, V161, P162; Kasai K, 1996, J BIOCHEM-TOKYO, V119, P1; Li YS, 1995, CANCER GENET CYTOGEN, V84, P46, DOI 10.1016/0165-4608(95)00065-8; LOTAN R, 1994, GLYCOCONJUGATE J, V11, P462, DOI 10.1007/BF00731282; Lu Y, 1999, BBA-GENE STRUCT EXPR, V1444, P85, DOI 10.1016/S0167-4781(98)00257-7; Lu Y, 1998, BIOL CHEM, V379, P1323, DOI 10.1515/bchm.1998.379.11.1323; Lutomski D, 1997, GLYCOBIOLOGY, V7, P1193, DOI 10.1093/glycob/7.8.1193; Maldonado CA, 1999, INVEST OPHTH VIS SCI, V40, P2971; Maquoi E, 1997, PLACENTA, V18, P433, DOI 10.1016/S0143-4004(97)80044-6; Mehul B, 1997, J CELL SCI, V110, P1169; MURTY VVVS, 1994, CANCER RES, V54, P3983; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Puch S, 1999, UROLOGY, V53, P848, DOI 10.1016/S0090-4295(98)00619-0; Remmelink M, 1999, J CANCER RES CLIN, V125, P275, DOI 10.1007/s004320050274; RINI JM, 1995, CURR OPIN STRUC BIOL, V5, P617, DOI 10.1016/0959-440X(95)80053-0; Sahraoui YH, 1996, J CELL BIOCHEM, V62, P529, DOI 10.1002/(SICI)1097-4644(19960915)62:4<529::AID-JCB10>3.0.CO;2-A; Sarafian V, 1998, INT J CANCER, V75, P105, DOI 10.1002/(SICI)1097-0215(19980105)75:1<105::AID-IJC16>3.3.CO;2-L; SCHOEPPNER HL, 1995, CANCER, V75, P2818, DOI 10.1002/1097-0142(19950615)75:12<2818::AID-CNCR2820751206>3.0.CO;2-#; SHEN RQ, 1994, J NATL CANCER I, V86, P91, DOI 10.1093/jnci/86.2.91; Su ZZ, 1996, P NATL ACAD SCI USA, V93, P7252, DOI 10.1073/pnas.93.14.7252; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Vyakarnam A, 1998, EXP CELL RES, V242, P419, DOI 10.1006/excr.1998.4111; Vyakarnam A, 1997, MOL CELL BIOL, V17, P4730, DOI 10.1128/MCB.17.8.4730; Wada J, 1997, J BIOL CHEM, V272, P6078, DOI 10.1074/jbc.272.9.6078; WagnerHulsmann C, 1996, GLYCOBIOLOGY, V6, P785, DOI 10.1093/glycob/6.8.785-d; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; WELCH DR, 1994, ONCOGENE, V9, P255; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737	64	46	49	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4405	4416		10.1038/sj.onc.1203767	http://dx.doi.org/10.1038/sj.onc.1203767			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980616				2022-12-25	WOS:000089271900011
J	Morris, DP; Greenleaf, AL				Morris, DP; Greenleaf, AL			The splicing factor, Prp40, binds the phosphorylated carboxyl-terminal domain of RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; UBIQUITIN-PROTEIN LIGASE; SACCHAROMYCES-CEREVISIAE; LARGEST SUBUNIT; CAPPING ENZYME; IN-VIVO; 3'-END FORMATION; NUCLEAR MATRIX; WW DOMAINS; TRANSCRIPTION	We showed previously that the WW domain of the prolyl isomerase, Ess1, can bind the phosphorylated carboxyl-terminal domain (phospho-CTD) of the largest subunit of RNA Polymerase II. Analysis of phospho-CTD binding by four other WW domain-containing Saccharomyces cerevisiae proteins indicates the splicing factor, Prp40, and the RNA polymerase II ubiquitin ligase, Rsp5, can also bind the phospho-CTD. The identification of Prp40 as a phospho-CTD binding protein represents the first demonstration of direct interaction between a documented splicing factor and the phospho-CTD. Domain dissection studies reveal that phospho-CTD binding occurs at multiple locations in Prp40, including sites in both the WW and FF domain regions. Because the conserved repeats of the CTD make it an ideal ligand for multi-site binding events, the implications of multi-site binding are discussed. Our data suggest a mechanism by which the phospho-CTD of elongating RNA polymerase II facilitates commitment complex formation by juxtaposing the 5' and 3' splice sites.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Greenleaf, AL (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.							Abovich N, 1997, CELL, V89, P403, DOI 10.1016/S0092-8674(00)80221-4; Beaudenon SL, 1999, MOL CELL BIOL, V19, P6972; Bedford MT, 1999, TRENDS BIOCHEM SCI, V24, P264, DOI 10.1016/S0968-0004(99)01417-6; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; Bentley D, 1999, CURR OPIN CELL BIOL, V11, P347, DOI 10.1016/S0955-0674(99)80048-9; Burge CB, 1999, RNA WORLD, P525; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CAGAS PM, 1995, PROTEINS, V21, P149, DOI 10.1002/prot.340210209; Carty SM, 2000, P NATL ACAD SCI USA, V97, P9015, DOI 10.1073/pnas.160266597; Cho EJ, 1998, GENE DEV, V12, P3482, DOI 10.1101/gad.12.22.3482; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; Du L, 1997, J CELL BIOL, V136, P5, DOI 10.1083/jcb.136.1.5; Greenblatt J, 1997, CURR OPIN CELL BIOL, V9, P310, DOI 10.1016/S0955-0674(97)80002-6; GREENLEAF AL, 1993, TRENDS BIOCHEM SCI, V18, P117, DOI 10.1016/0968-0004(93)90016-G; Hani J, 1999, J BIOL CHEM, V274, P108, DOI 10.1074/jbc.274.1.108; HANI J, 1995, FEBS LETT, V365, P198, DOI 10.1016/0014-5793(95)00471-K; Hirose Y, 1999, GENE DEV, V13, P1234, DOI 10.1101/gad.13.10.1234; Hirose Y, 2000, GENE DEV, V14, P1415; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; Huibregtse JM, 1997, P NATL ACAD SCI USA, V94, P3656, DOI 10.1073/pnas.94.8.3656; JENCKS WP, 1981, P NATL ACAD SCI USA, V78, P4056; Kao HY, 1996, MOL CELL BIOL, V16, P960; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; Linn H, 1997, BIOL CHEM, V378, P531, DOI 10.1515/bchm.1997.378.6.531; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Misteli T, 1999, MOL CELL, V3, P697, DOI 10.1016/S1097-2765(01)80002-2; Morris DP, 1997, METHODS, V12, P264, DOI 10.1006/meth.1997.0478; Morris DP, 1999, J BIOL CHEM, V274, P31583, DOI 10.1074/jbc.274.44.31583; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; Neubauer G, 1997, P NATL ACAD SCI USA, V94, P385, DOI 10.1073/pnas.94.2.385; Neugebauer KM, 1997, GENE DEV, V11, P3279, DOI 10.1101/gad.11.24.3279; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Snaar SP, 1999, J HISTOCHEM CYTOCHEM, V47, P245, DOI 10.1177/002215549904700213; Steinmetz EJ, 1997, CELL, V89, P491, DOI 10.1016/S0092-8674(00)80230-5; Tanner S, 1997, BIOL CHEM, V378, P565; Vincent M, 1996, NUCLEIC ACIDS RES, V24, P4649, DOI 10.1093/nar/24.23.4649; Wang GL, 1999, MOL CELL BIOL, V19, P342; WEEKS JR, 1993, GENE DEV, V7, P2329, DOI 10.1101/gad.7.12a.2329; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975	45	147	148	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39935	39943		10.1074/jbc.M004118200	http://dx.doi.org/10.1074/jbc.M004118200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10978320	hybrid			2022-12-25	WOS:000166039500022
J	Kim, TH; Zhao, YG; Barber, MJ; Kuharsky, DK; Yin, XM				Kim, TH; Zhao, YG; Barber, MJ; Kuharsky, DK; Yin, XM			Bid-induced cytochrome c release is mediated by a pathway independent of mitochondrial permeability transition pore and bax	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY-MEMBERS; LIVER-MITOCHONDRIA; OUTER-MEMBRANE; DEFICIENT MICE; CELL-DEATH; APOPTOSIS; ACTIVATION; PROTEINS; CHANNEL; TRANSIENT	Bid, a pro-apoptosis "BH3-only" member of the Bcl-2 family, can be cleaved by caspase-8 after Fas/TNF-R1 engagement. The p15 form of truncated Bid (tBid) translocates to mitochondria and induces cytochrome c release, leading to the activation of downstream caspases and apoptosis. In the current study, we investigated the mechanism by which tBid regulated cytochrome c release in terms of its relationship to mitochondrial permeability transition and Bax, another Bcl-2 family protein. We employed an in vitro reconstitution system as well as cell cultures and an animal model to reflect the physiological environment where Bid could be functional. We found that induction of cytochrome c release by tBid was not accompanied by a permeability transition even at high doses. Indeed, inhibition of permeability transition did not suppress the activity of tBid in vitro nor could they block Pas activation-induced, Bid-dependent hepatocyte apoptosis in cultures. Furthermore, Mg2+, although inhibiting permeability transition, actually enhanced the ability of tBid to induce cytochrome c release. We also found that tBid did not require Bax to induce cytochrome c release in vitro. In addition, mice deficient in bat were still highly susceptible to anti-Fas-induced hepatocyte apoptosis, in which cytochrome c release was unaffected. Moreover, although Bax-induced cytochrome c release was not dependent on tBid, the two proteins could function synergistically. We conclude that Bid possesses the biochemical activity to induce cytochrome c release through a mechanism independent of mitochondrial permeability transition pore and Bax.	Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; State University System of Florida; University of South Florida	Yin, XM (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, 200 Lothrop St, Pittsburgh, PA 15261 USA.	xmyin@pitt.edu			NATIONAL CANCER INSTITUTE [K01CA074885] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032696] Funding Source: NIH RePORTER; NCI NIH HHS [K01-CA74885] Funding Source: Medline; NIGMS NIH HHS [GM-32696] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrams JM, 1999, TRENDS CELL BIOL, V9, P435, DOI 10.1016/S0962-8924(99)01646-3; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bernardi P, 1996, J BIOENERG BIOMEMBR, V28, P131, DOI 10.1007/BF02110643; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; ELLIS RE, 1991, GENETICS, V129, P79; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Feldmann G, 2000, HEPATOLOGY, V31, P674, DOI 10.1002/hep.510310318; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HASHIMOTO K, 1983, BIOCHEMISTRY-US, V22, P5738, DOI 10.1021/bi00294a010; Hatano E, 2000, J BIOL CHEM, V275, P11814, DOI 10.1074/jbc.275.16.11814; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kantrow SP, 1997, BIOCHEM BIOPH RES CO, V232, P669, DOI 10.1006/bbrc.1997.6353; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KLAUNIG JE, 1981, IN VITRO CELL DEV B, V17, P913; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Lemasters JJ, 1998, BIOFACTORS, V8, P283, DOI 10.1002/biof.5520080316; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Martinou JC, 2000, NAT CELL BIOL, V2, pE41, DOI 10.1038/35004069; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; NI R, 1994, EXP CELL RES, V215, P332, DOI 10.1006/excr.1994.1349; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; ROBERTSON DE, 1983, J BIOL CHEM, V258, P1039; ROTTENBERG H, 1984, J MEMBRANE BIOL, V81, P127, DOI 10.1007/BF01868977; Scarlett JL, 1997, FEBS LETT, V418, P282, DOI 10.1016/S0014-5793(97)01391-4; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1997, BRIT MED BULL, V53, P478; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	52	156	165	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39474	39481		10.1074/jbc.M003370200	http://dx.doi.org/10.1074/jbc.M003370200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10982793	hybrid			2022-12-25	WOS:000165953100073
J	Janssen, JWH; Bovee-Geurts, PHM; Peeters, ZPA; Bowmaker, JK; Cooper, HM; David-Gray, ZA; Nevo, E; DeGrip, WJ				Janssen, JWH; Bovee-Geurts, PHM; Peeters, ZPA; Bowmaker, JK; Cooper, HM; David-Gray, ZA; Nevo, E; DeGrip, WJ			A fully functional rod visual pigment in a blind mammal - A case for adaptive functional reorganization?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE-SCALE PRODUCTION; RAT SPALAX-EHRENBERGI; MOLE-RAT; BOVINE RHODOPSIN; IONIC-STRENGTH; PINEAL ORGAN; PURIFICATION; PHOTORECEPTORS; LOCALIZATION; EVOLUTION	In the blind subterranean mole rat Spalax ehrenbergi superspecies complete ablation of the visual image-forming capability has been accompanied by an expansion of the bilateral projection from the retina to the suprachiasmatic nucleus. We have cloned the open reading frame of a visual pigment from Spalax that shows >90% homology with mammalian rod pigments. Baculovirus expression yields a membrane protein with all functional characteristics of a rod visual pigment (lambda (max) = 497 +/- 2 nm; pK(alpha) of meta I/meta II equilibrium = 6.5; rapid activation of transducin in the light). We not only provide evidence that this Spalax rod pigment is fully functional in vitro but also show that all requirements for a functional pigment are present in vivo. The physiological consequences of this unexpected finding are discussed. One attractive option is that during adaptation to a subterranean lifestyle, the visual system of this mammal has undergone mosaic reorganization, and the visual pigments have adapted to a function in circadian photoreception.	Univ Nijmegen, Inst Cellular Signalling, Dept Biochem UMC 160, NL-6500 HB Nijmegen, Netherlands; UCL, Inst Ophthalmol, Dept Visual Sci, London EC1V 9EL, England; Cerveau & Vis, INSERM U 371, F-69500 Bron, France; Univ London Imperial Coll Sci Technol & Med, Dept Biol, London SW7 2AZ, England; Univ Haifa, Inst Evolut, IL-31905 Haifa, Israel	Radboud University Nijmegen; University of London; University College London; Institut National de la Sante et de la Recherche Medicale (Inserm); Imperial College London; University of Haifa	DeGrip, WJ (corresponding author), Univ Nijmegen, Inst Cellular Signalling, Dept Biochem UMC 160, POB 9101, NL-6500 HB Nijmegen, Netherlands.	WDeGrip@baserv.uci.kun.nl	COOPER, HOWARD/M-7304-2014; DeGrip, Willem/L-4335-2015	DeGrip, Willem/0000-0001-7637-4920				Archer SN, 1999, ADAPTIVE MECH ECOLOG, DOI [10.1007/978-94-017-0619-3, DOI 10.1007/978-94-017-0619-3]; COOPER HM, 1993, NATURE, V361, P156, DOI 10.1038/361156a0; Crandall KA, 1997, NATURE, V387, P667, DOI 10.1038/42628; DARTNALL HJA, 1983, PROC R SOC SER B-BIO, V220, P115, DOI 10.1098/rspb.1983.0091; David-Gray ZK, 1998, NAT NEUROSCI, V1, P655, DOI 10.1038/3656; DeGrip WJ, 1998, BIOCHEM J, V330, P667; DEGRIP WJ, 1992, SIGNAL TRANSDUCTION, P42; DeLange F, 1997, EUR J BIOCHEM, V243, P174, DOI 10.1111/j.1432-1033.1997.0174a.x; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P9165, DOI 10.1021/bi00086a023; FOSTER RG, 1987, CELL TISSUE RES, V248, P161, DOI 10.1007/BF01239977; FOSTER RG, 1993, J COMP PHYSIOL A, V172, P33, DOI 10.1007/BF00214713; FOSTER RG, 1991, J COMP PHYSIOL A, V169, P39, DOI 10.1007/BF00198171; Freedman MS, 1999, SCIENCE, V284, P502, DOI 10.1126/science.284.5413.502; GROOS G, 1982, EXPERIENTIA, V38, P929; JANSSEN JJM, 1995, J BIOL CHEM, V270, P11222, DOI 10.1074/jbc.270.19.11222; Klaassen CHW, 1999, BIOCHEM J, V342, P293, DOI 10.1042/0264-6021:3420293; KORF HW, 1994, ANN NY ACAD SCI, V719, P13, DOI 10.1111/j.1749-6632.1994.tb56818.x; LEWIS JW, 1991, BIOCHEMISTRY-US, V30, P11372, DOI 10.1021/bi00112a003; Lupi D, 1999, NEUROSCIENCE, V89, P363, DOI 10.1016/S0306-4522(98)00353-4; Menaker M, 1997, BRAZ J MED BIOL RES, V30, P305, DOI 10.1590/S0100-879X1997000300003; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; NECKER R, 1992, NEUROREPORT, V3, P505, DOI 10.1097/00001756-199206000-00012; Neitz M., 1998, COLOR VISION PERSPEC, P101, DOI [10.1515/9783110806984.101, DOI 10.1515/9783110806984.101]; NELSON DE, 1991, J PHYSIOL-LONDON, V439, P115, DOI 10.1113/jphysiol.1991.sp018660; Nevo, 1999, MOSAIC EVOLUTION SUB; Okano T, 1997, J PINEAL RES, V22, P145, DOI 10.1111/j.1600-079X.1997.tb00316.x; PEVET P, 1984, J EXP ZOOL, V232, P41, DOI 10.1002/jez.1402320106; REHKAMPER G, 1994, J COMP NEUROL, V347, P570, DOI 10.1002/cne.903470408; SANYAL S, 1990, INVEST OPHTH VIS SCI, V31, P1398; SPIEGEL AM, 1990, BIOL COUN S, P31; Springer MS, 1997, P NATL ACAD SCI USA, V94, P13754, DOI 10.1073/pnas.94.25.13754; TAKAHASHI JS, 1989, RECENT PROG HORM RES, V45, P279; Vigh B, 1998, BIOL CELL, V90, P653, DOI 10.1016/S0248-4900(99)80022-7; Vissers PMAM, 1998, BIOCHEM J, V330, P1201, DOI 10.1042/bj3301201; YOKOYAMA S, 1995, MOL BIOL EVOL, V12, P527	35	35	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38674	38679		10.1074/jbc.M008254200	http://dx.doi.org/10.1074/jbc.M008254200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10984500	hybrid, Green Published			2022-12-25	WOS:000165739800073
J	Ohmori, Y; Hamilton, TA				Ohmori, Y; Hamilton, TA			Interleukin-4/STAT6 represses STAT1 and NF-kappa B-dependent transcription through distinct mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PERITONEAL-MACROPHAGES; GERMLINE EPSILON-PROMOTER; NECROSIS-FACTOR-ALPHA; CREB-BINDING PROTEIN; MONOCYTIC CELL-LINES; GENE-EXPRESSION; IFN-GAMMA; NUCLEAR FACTOR; INTERFERON-GAMMA; DNA-BINDING	STAT6 mediates interleukin-4 (IL-4)-dependent positive and negative regulation of inflammatory gene expression. In the present report we examined the molecular mechanisms involved in IL-4-induced repression of reporter gene transcription driven by STAT1 and/or NF-kappaB. Transient expression of STAT6 in a STAT6-deficient cell line (HEK 293) conferred sensitivity to IL-4 for STAT6-dependent transcription and for repression of interferon-gamma (IFN gamma)/STAT1- and/or tumor necrosis factor-alpha (TNF alpha)/NF-kappaB driven reporter gene expression. In cells transfected with a deletion mutant of STAT6 lacking its transactivating domain, IL-4 could not mediate either positive or negative control of reporter gene expression. Overexpression of CREB-binding protein dramatically enhanced IL-4/STAT6-stimulated transcription and overcame IL-4-mediated repression of TNF alpha /NF-kappaB-dependent but not IFN gamma /STAT1-dependent transcription. A single amino acid change in the DNA-binding domain of STAT6 (H415A) selectively reduced the affinity of STAT6 for IL-4-responsive STAT sequence motifs (N4) without affecting the affinity for IFN gamma -responsive (GAS) sequences (N3) and, accordingly, eliminated transcription from an IL-4-responsive promoter. Interestingly, this mutation eliminated IL-4-mediated suppression of reporter gene transcription stimulated by TNF alpha /NF-kappaB but retained nearly full capacity to suppress IFN gamma /STAT1-stimulated transcription. Taken together these results demonstrate that STAT6 mediates suppression of STAT1 and NF-kappaB-dependent transcription by distinct mechanisms. Both processes are dependent upon the STAT6 transactivation domain and may involve sequestration of necessary but different transcriptional coactivator proteins. These two suppressive mechanisms are controlled differentially by the nature of the STAT6 DNA-binding site (i.e. N3 versus N4).	Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Ohmori, Y (corresponding author), Meikai Univ, Sch Dent, Ctr Biol Mol, 1-1 Keyakidai, Kawagoe, Saitama 3500283, Japan.	ohmori@dent.meikai.ac.jp		Hamilton, Thomas/0000-0002-9817-242X; Ohmori, Yoshihiro/0000-0002-6069-357X	NATIONAL CANCER INSTITUTE [P01CA062220] Funding Source: NIH RePORTER; NCI NIH HHS [CA62220] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; Bennett BL, 1997, J BIOL CHEM, V272, P10212; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BOGDAN C, 1994, J LEUKOCYTE BIOL, V55, P227, DOI 10.1002/jlb.55.2.227; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DELPHIN S, 1995, J EXP MED, V181, P181, DOI 10.1084/jem.181.1.181; DENG WL, 1994, J IMMUNOL, V153, P2130; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dokter WHA, 1996, LEUKEMIA, V10, P1308; DOKTER WHA, 1993, BLOOD, V81, P337; DONNELLY RP, 1993, J IMMUNOL, V151, P5603; DONNELLY RP, 1991, J IMMUNOL, V146, P3431; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; ESSNER R, 1989, J IMMUNOL, V142, P3857; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; GAUTAM S, 1992, J IMMUNOL, V148, P1725; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Gingras S, 1999, NUCLEIC ACIDS RES, V27, P2722, DOI 10.1093/nar/27.13.2722; Goenka S, 1999, J IMMUNOL, V163, P4663; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; Ihle JN, 1998, ANN NY ACAD SCI, V865, P1, DOI 10.1111/j.1749-6632.1998.tb11157.x; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; Kotanides H, 1996, J BIOL CHEM, V271, P25555, DOI 10.1074/jbc.271.41.25555; LARNER AC, 1993, J IMMUNOL, V150, P1944; Luo GY, 2000, MOL ENDOCRINOL, V14, P114, DOI 10.1210/me.14.1.114; Manna SK, 1998, J BIOL CHEM, V273, P33333, DOI 10.1074/jbc.273.50.33333; MARFAINGKOKA A, 1995, J IMMUNOL, V154, P1870; McDonald C, 1999, J INTERF CYTOK RES, V19, P711, DOI 10.1089/107999099313550; Mikita T, 1998, J IMMUNOL, V161, P1822; Mikita T, 1996, MOL CELL BIOL, V16, P5811; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; OHMORI Y, 1994, J IMMUNOL, V153, P2204; Ohmori Y, 1997, J IMMUNOL, V159, P5474; OHMORI Y, 1994, PHARMACOL THERAPEUT, V63, P235, DOI 10.1016/0163-7258(94)90026-4; Ohmori Y, 1996, J IMMUNOL, V157, P2058; Ohmori Y, 1998, J BIOL CHEM, V273, P29202, DOI 10.1074/jbc.273.44.29202; OHMORI Y, 1994, J BIOL CHEM, V269, P17684; Ohmori Y, 1997, J BIOL CHEM, V272, P14899, DOI 10.1074/jbc.272.23.14899; Pine R, 1997, NUCLEIC ACIDS RES, V25, P4346, DOI 10.1093/nar/25.21.4346; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; RENKONEN R, 1992, SCAND J IMMUNOL, V35, P525; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SEDER RA, 1999, FUNDAMENTAL IMMUNOLO, P879; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Shen CH, 1998, MOL CELL BIOL, V18, P3395, DOI 10.1128/MCB.18.6.3395; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Sidhu JS, 1998, J BIOL CHEM, V273, P4769, DOI 10.1074/jbc.273.8.4769; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; Takeshita S, 1996, J IMMUNOL, V156, P2591; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; VANNIER E, 1992, P NATL ACAD SCI USA, V89, P4076, DOI 10.1073/pnas.89.9.4076; VELDE AAT, 1990, J IMMUNOL, V144, P3046; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	66	87	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					38095	38103		10.1074/jbc.M006227200	http://dx.doi.org/10.1074/jbc.M006227200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10982806	hybrid			2022-12-25	WOS:000165618700105
J	Cardinale, F; Jonak, C; Ligterink, W; Niehaus, K; Boller, T; Hirt, H				Cardinale, F; Jonak, C; Ligterink, W; Niehaus, K; Boller, T; Hirt, H			Differential activation of four specific MAPK pathways by distinct elicitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENYLALANINE AMMONIA-LYASE; PROTEIN-KINASE-ACTIVITY; TOMATO CELLS; TRANSIENT ACTIVATION; TOBACCO CELLS; EXTRACELLULAR ALKALINIZATION; SUBNANOMOLAR CONCENTRATIONS; GLYCOPEPTIDE ELICITOR; CHITIN FRAGMENTS; RESISTANCE GENE	Plant cells respond to elicitors by inducing a variety of defense responses. Some of these reactions are dependent on the activity of protein kinases. Recently, mitogen-activated protein kinases (MAPKs) have been identified to be activated by fungal and bacterial elicitors as well as by pathogen infection. In gel kinase assays of alfalfa cells treated with yeast cell wall-derived elicitor (YE) revealed that 44- and 46-kDa MAPKs are rapidly and transiently activated. Immunokinase assays with specific MAPK antibodies revealed that YE mainly activated the 46-kDa SIMK and the 44-kDa MMK3 and to a lesser extent the 44-kDa MMK2 and SAMK. When cells mere treated with chemically defined elicitors potentially contained in the YE (chitin and N-acetylglucosamine oligomers, beta -glucan, and ergosterol), the four MAPKs were found to be activated to different levels and with different kinetics, Whereas SIMK and SAMK have been found to be activated by a number of diverse stimuli, MMK3 is activated during mitosis and was therefore assumed to participate in cell division (22). No physiological, process could be associated with MMK2 activity so far. This is the first report that MMK2 and MMK3 can be activated by external stimuli. Overall, our findings indicate that plant cells can sense different cues of a given microorganism through the activation of multiple MAPKs.	Univ Vienna, Vienna Bioctr, Inst Microbiol & Genet, A-1030 Vienna, Austria; Univ Bielefeld, D-33501 Bielefeld, Germany; Friedrich Miescher Inst, CH-4002 Basel, Switzerland	University of Vienna; Vienna Biocenter (VBC); University of Bielefeld; Friedrich Miescher Institute for Biomedical Research	Hirt, H (corresponding author), Univ Vienna, Vienna Bioctr, Inst Microbiol & Genet, Dr Bohrgasse 9, A-1030 Vienna, Austria.	hehi@gem.univie.ac.at	Niehaus, Karsten/A-3966-2010; Ligterink, Wilco/C-8103-2009; Jonak, Claudia/G-1362-2016; Cardinale, Francesca/B-9758-2013; Hirt, Heribert/A-2061-2013; Boller, Thomas/G-3500-2012	Ligterink, Wilco/0000-0002-0228-169X; Boller, Thomas/0000-0001-6768-7503; Cardinale, Francesca/0000-0001-9892-9325; Jonak, Claudia/0000-0001-9605-6751				Adam AL, 1997, PLANT PHYSIOL, V115, P853, DOI 10.1104/pp.115.2.853; Baier R, 1999, PLANTA, V210, P157, DOI 10.1007/s004250050665; BASSE CW, 1992, J BIOL CHEM, V267, P10258; BASSE CW, 1993, J BIOL CHEM, V268, P14724; Bogre L, 1999, PLANT CELL, V11, P101, DOI 10.1105/tpc.11.1.101; Bogre L, 1997, PLANT CELL, V9, P75, DOI 10.1105/tpc.9.1.75; Bogre L, 1996, NATURE, V383, P489, DOI 10.1038/383489a0; Desikan R, 1999, PLANTA, V210, P97, DOI 10.1007/s004250050658; DIETRICH A, 1990, J BIOL CHEM, V265, P6360; FELIX G, 1991, P NATL ACAD SCI USA, V88, P8831, DOI 10.1073/pnas.88.19.8831; Felix G, 1998, PLANT PHYSIOL, V117, P643, DOI 10.1104/pp.117.2.643; FELIX G, 1993, PLANT J, V4, P307, DOI 10.1046/j.1365-313X.1993.04020307.x; GRANADO J, 1995, PLANT PHYSIOL, V107, P485, DOI 10.1104/pp.107.2.485; GROSS P, 1993, EMBO J, V12, P1735, DOI 10.1002/j.1460-2075.1993.tb05821.x; GROSSKOPF DG, 1991, J PLANT PHYSIOL, V138, P741, DOI 10.1016/S0176-1617(11)81325-8; GROSSKOPF DG, 1990, FEBS LETT, V275, P177, DOI 10.1016/0014-5793(90)81466-2; He CZ, 1999, MOL PLANT MICROBE IN, V12, P1064, DOI 10.1094/MPMI.1999.12.12.1064; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Hirt H, 2000, RES PRO CEL, V27, P85; Hirt H, 2000, RES PRO CEL, V27, P1; Inui H, 1997, BIOSCI BIOTECH BIOCH, V61, P975, DOI 10.1271/bbb.61.975; Jonak C, 1999, CELL MOL LIFE SCI, V55, P204, DOI 10.1007/s000180050285; Jonak C, 1996, P NATL ACAD SCI USA, V93, P11274, DOI 10.1073/pnas.93.20.11274; JONAK C, 1995, MOL GEN GENET, V248, P686, DOI 10.1007/BF02191708; Lebrun-Garcia A, 1998, PLANT J, V15, P773, DOI 10.1046/j.1365-313X.1998.00269.x; Ligterink W, 1997, SCIENCE, V276, P2054, DOI 10.1126/science.276.5321.2054; Mizoguchi T, 1996, P NATL ACAD SCI USA, V93, P765, DOI 10.1073/pnas.93.2.765; Munnik T, 1999, PLANT J, V20, P381, DOI 10.1046/j.1365-313x.1999.00610.x; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Nuhse TS, 2000, J BIOL CHEM, V275, P7521, DOI 10.1074/jbc.275.11.7521; Romeis T, 1999, PLANT CELL, V11, P273, DOI 10.1105/tpc.11.2.273; Seo S, 1999, PLANT CELL, V11, P289, DOI 10.1105/tpc.11.2.289; Stratmann JW, 1997, P NATL ACAD SCI USA, V94, P11085, DOI 10.1073/pnas.94.20.11085; SUZUKI K, 1995, PLANT CELL PHYSIOL, V36, P281, DOI 10.1093/oxfordjournals.pcp.a078760; SUZUKI K, 1995, PLANT CELL, V7, P639, DOI 10.1105/tpc.7.5.639; USAMI S, 1995, P NATL ACAD SCI USA, V92, P8660, DOI 10.1073/pnas.92.19.8660; VIARD MP, 1994, PLANT PHYSIOL, V104, P1245, DOI 10.1104/pp.104.4.1245; Zhang SQ, 2000, RES PRO CEL, V27, P65; Zhang SQ, 1998, PLANT CELL, V10, P435, DOI 10.1105/tpc.10.3.435; Zhang SQ, 1998, P NATL ACAD SCI USA, V95, P7433, DOI 10.1073/pnas.95.13.7433; Zhang SQ, 1998, P NATL ACAD SCI USA, V95, P7225, DOI 10.1073/pnas.95.12.7225; Zhang SQ, 1997, PLANT CELL, V9, P809, DOI 10.1105/tpc.9.5.809	42	119	130	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36734	36740		10.1074/jbc.M007418200	http://dx.doi.org/10.1074/jbc.M007418200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973984	hybrid			2022-12-25	WOS:000165577700042
J	Cowan, KJ; Law, DA; Phillips, DR				Cowan, KJ; Law, DA; Phillips, DR			Identification of Shc as the primary protein binding to the tyrosine-phosphorylated beta(3) subunit of alpha(IIb)beta(3) during outside-in integrin platelet signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN; ALPHA(6)BETA(4) INTEGRIN; PHOSPHOLIPASE A(2); THROMBIN RECEPTOR; CELL-ADHESION; MAP KINASE; ACTIVATION; GROWTH; TRANSDUCTION; ASSOCIATION	Outside-in signaling mediated by the integrin alpha (IIb)beta (3) (GPIIbIIIa) is critical to platelet function and has been shown to involve the phosphorylation of tyrosine residues on the cytoplasmic tail of beta (3). To identify proteins that bind directly to phosphorylated beta (3), we utilized an affinity column consisting of a peptide modeled on the tyrosine-phosphorylated cytoplasmic domain of beta (3). Tandem mass spectrometric sequencing and immunoblotting demonstrated that She was the primary protein binding to phosphorylated beta (3). To determine the involvement of Shc in outside-in alpha (IIb)beta (3) signaling, the phosphorylation of Shc during platelet aggregation was examined; transient She phosphorylation was observed when thrombin-stimulated platelets were allowed to aggregate or when aggregation was induced by an LIBS (ligand-induced binding site) antibody, D3. Moreover, She was co-immunoprecipitated with tyrosine-phosphorylated beta (3) in detergent lysates of aggregated platelets. Using purified, recombinant protein, it was found that the binding of Shc to monophosphorylated (C-terminal tyrosine) and diphosphorylated beta (3) peptides was direct, demonstrating She recognition motifs on phospho-beta (3). Aggregation-induced She phosphorylation was also observed to be robust in platelets from wild-type mice, but not in those from mice expressing (Y747F,Y759F) beta (3), which are defective in outside-in alpha (IIb)beta (3) signaling. Thus, Shc is the primary downstream signaling partner of beta (3) in its tyrosine phosphorylation outside-in signaling pathway.	COR Therapeut Inc, San Francisco, CA 94080 USA		Phillips, DR (corresponding author), COR Therapeut Inc, 256 E Grand Ave, San Francisco, CA 94080 USA.	dphillips@corr.com						Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; BorschHaubold AG, 1997, EUR J BIOCHEM, V245, P751, DOI 10.1111/j.1432-1033.1997.t01-1-00751.x; Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393; Chung J, 1997, J BIOL CHEM, V272, P14740, DOI 10.1074/jbc.272.23.14740; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK EA, 1994, J BIOL CHEM, V269, P28859; Clements JL, 1999, J CLIN INVEST, V103, P925, DOI 10.1172/JCI6562; DEFRANCO AL, 1995, CURR OPIN CELL BIOL, V7, P163, DOI 10.1016/0955-0674(95)80024-7; Eigenthaler R, 1997, J BIOL CHEM, V272, P7693, DOI 10.1074/jbc.272.12.7693; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FOX JEB, 1982, J BIOL CHEM, V257, P4120; FRACKELTON AR, 1984, J BIOL CHEM, V259, P7909; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; Jenkins AL, 1998, J BIOL CHEM, V273, P13878, DOI 10.1074/jbc.273.22.13878; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Knezevic I, 1996, J BIOL CHEM, V271, P16416, DOI 10.1074/jbc.271.27.16416; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; Law DA, 1999, NATURE, V401, P808, DOI 10.1038/44599; Law DA, 1999, BLOOD, V93, P2645, DOI 10.1182/blood.V93.8.2645.408k13_2645_2652; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; LINDBERG FP, 1994, J BIOL CHEM, V269, P1567; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; MAINIERO F, 1995, EMBO J, V14, P4470, DOI 10.1002/j.1460-2075.1995.tb00126.x; Mauro L, 1999, EXP CELL RES, V252, P439, DOI 10.1006/excr.1999.4639; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; NAKAMURA S, 1989, J BIOL CHEM, V264, P7089; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; ROSS AH, 1981, NATURE, V294, P654, DOI 10.1038/294654a0; Sato T, 1999, J BIOCHEM, V125, P96, DOI 10.1093/oxfordjournals.jbchem.a022275; SAXTON TM, 1994, J IMMUNOL, V153, P623; Shattil SJ, 1999, THROMB HAEMOSTASIS, V82, P318; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; Shock DD, 1997, BIOCHEM J, V321, P525, DOI 10.1042/bj3210525; Shock DD, 1999, BIOCHEM J, V342, P729, DOI 10.1042/0264-6021:3420729; THOMAS D, 1995, J BIOL CHEM, V270, P28924, DOI 10.1074/jbc.270.48.28924; Tridandapani S, 1999, J IMMUNOL, V162, P1408; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WILLIAMS LT, 1991, COLD SH Q B, V56, P243; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; Zhang J, 1996, J BIOL CHEM, V271, P6265, DOI 10.1074/jbc.271.11.6265	51	82	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36423	36429		10.1074/jbc.M004068200	http://dx.doi.org/10.1074/jbc.M004068200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10964917	hybrid			2022-12-25	WOS:000165382000108
J	Kong, M; Mounier, C; Wu, J; Posner, BI				Kong, M; Mounier, C; Wu, J; Posner, BI			Epidermal growth factor-induced phosphatidylinositol 3-kinase activation and DNA synthesis - Identification of Grb2-associated binder 2 as the major mediator in rat hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATED 100-KDA PROTEIN; INSULIN-RECEPTOR SUBSTRATE-1; PLECKSTRIN HOMOLOGY DOMAIN; PHOSPHOINOSITIDE 3-KINASE; TYROSINE PHOSPHORYLATION; ADAPTER PROTEIN; HEMATOPOIETIC-CELLS; P85 SUBUNIT; SH2 DOMAIN; S6 KINASE	In previous work we showed that the phosphatidylinositol S-kinase (PI3-kinase), not the mitogen-activated protein kinase, pathway is necessary and sufficient to account for insulin- and epidermal growth factor (EGF)induced DNA synthesis in rat hepatocytes. Here, using a dominant-negative p85, we confirmed the key role of EGF-induced PI3-kinase activation and sought to identify the mechanism by which this is effected. Our results show that EGF activates PI3-kinase with a time course similar to that of the association of p85 with three principal phosphotyrosine proteins (i.e. PY180, PY105, and PY52), We demonstrated that each formed a distinct p85-associated complex. PY180 and PY52 each constituted about 10% of EGF-activated PI3-kinase, whereas PY105 was responsible for 80%. PY105 associated with Grb2 and SHP-2, and although it behaved like Gab1, none of the latter was detected in rat liver. We therefore cloned a cDNA from rat liver, which was found to be 95% homologous to the mouse Grb2-associated binder 2 (Gab2) cDNA sequence. Using a specific Gab2 antibody, we demonstrated its expression in and association with p85, SHP-2, and Grb2 upon EGF treatment of rat hepatocytes, Gab2 accounted for most if not all of the PY105 species, since immunoprecipitation of Gab2 with specific antibodies demonstrated parallel immunodepletion of Gab2 and PY105 from the residual supernatants, We also found that the PI3-kinase activity associated with Gaba was totally abolished by dominant negative p85. Thus, Gab2 appears to be the principal EGF-induced PY protein recruiting and activating PI3-kinase and mitogenesis.	McGill Univ, Fac Med, Polypeptide Hormone Lab, Montreal, PQ H3A 2B2, Canada	McGill University	Posner, BI (corresponding author), McGill Univ, Fac Med, Polypeptide Hormone Lab, Strathocona Anat Bldg 3640 Univ St, Montreal, PQ H3A 2B2, Canada.		Posner, Barry/B-6733-2008; Mounier, Catherine/D-3690-2011	Mounier, Catherine/0000-0003-3608-4229				ANDO A, 1994, EMBO J, V13, P3033, DOI 10.1002/j.1460-2075.1994.tb06602.x; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Band CJ, 1999, ENDOCRINOLOGY, V140, P5626, DOI 10.1210/en.140.12.5626; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; Carlberg K, 1997, J BIOL CHEM, V272, P15943, DOI 10.1074/jbc.272.25.15943; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Carver RS, 1996, J BIOL CHEM, V271, P13491, DOI 10.1074/jbc.271.23.13491; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Derossi D, 1998, BIOCHEM BIOPH RES CO, V251, P148, DOI 10.1006/bbrc.1998.9444; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Eder AM, 1998, J BIOL CHEM, V273, P28025, DOI 10.1074/jbc.273.43.28025; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; Gadina M, 1999, J IMMUNOL, V162, P2081; Gesbert F, 1998, J BIOL CHEM, V273, P18273, DOI 10.1074/jbc.273.29.18273; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; HADARI YR, 1992, J BIOL CHEM, V267, P17483; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HOLGADOMADRUGA M, 1996, NATURE, V379, P8560; HOLT KH, 1994, MOL CELL BIOL, V14, P42, DOI 10.1128/MCB.14.1.42; Ingham RJ, 1998, J BIOL CHEM, V273, P30630, DOI 10.1074/jbc.273.46.30630; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; Kanagasundaram V, 1996, BIOCHEM J, V320, P69, DOI 10.1042/bj3200069; KHAN MN, 1989, J BIOL CHEM, V264, P12931; KIM HH, 1994, J BIOL CHEM, V269, P24747; KLIPPEL A, 1993, MOL CELL BIOL, V13, P5560, DOI 10.1128/MCB.13.9.5560; Korhonen JM, 1999, J BIOL CHEM, V274, P37307, DOI 10.1074/jbc.274.52.37307; Laffargue M, 1999, J BIOL CHEM, V274, P32835, DOI 10.1074/jbc.274.46.32835; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; LEE CC, 1995, J BIOL CHEM, V270, P507, DOI 10.1074/jbc.270.2.507; Maroun CR, 1999, J BIOL CHEM, V274, P31719, DOI 10.1074/jbc.274.44.31719; McIlroy J, 1997, MOL CELL BIOL, V17, P248, DOI 10.1128/MCB.17.1.248; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Takahashi Y, 1999, J CELL PHYSIOL, V178, P69, DOI 10.1002/(SICI)1097-4652(199901)178:1<69::AID-JCP9>3.0.CO;2-Z; THOMPSON DM, 1985, J BIOL CHEM, V260, P8824; TOBE K, 1995, J BIOL CHEM, V270, P5698, DOI 10.1074/jbc.270.11.5698; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; Wong L, 1996, J BIOL CHEM, V271, P20981, DOI 10.1074/jbc.271.35.20981; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Zhang SL, 1999, BIOCHEM BIOPH RES CO, V254, P440, DOI 10.1006/bbrc.1998.9959; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649	53	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36035	36042		10.1074/jbc.M005621200	http://dx.doi.org/10.1074/jbc.M005621200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10973965	hybrid			2022-12-25	WOS:000165382000056
J	Boese, A; Sauter, M; Galli, U; Best, B; Herbst, H; Mayer, J; Kremmer, E; Roemer, K; Mueller-Lantzsch, N				Boese, A; Sauter, M; Galli, U; Best, B; Herbst, H; Mayer, J; Kremmer, E; Roemer, K; Mueller-Lantzsch, N			Human endogenous retrovirus protein cORF supports cell transformation and associates with the promyelocytic leukemia zinc finger protein	ONCOGENE			English	Article						endogenous retroviruses; germ cell tumor; spermatogenesis	ACID RECEPTOR-ALPHA; OPEN READING FRAMES; PLZF-RAR-ALPHA; RETINOIC ACID; GERM-CELL; HISTONE DEACETYLASE; TROPHOBLASTIC TUMORS; FUSION PARTNERS; HTDV/HERV-K; TRANSLOCATION	Human endogenous retrovirus sequences (HERVs) reside in the genomes of primates and humans for several million years, The majority of HERVs is non-coding but a limited set is intact and can express proteins, We have recently identified an almost intact HERV-K(HML-2) provirus on chromosome 7 and have documented that most patients with germ cell tumors (GCTs) display antibodies directed against proteins of HERV-K(HML-2), To address whether these proteins merely represent tumor markers or contribute to neoplastic transformation, we examined the transforming potential of various HERV sequences and studied physical interactions between HERV and cellular proteins by yeast two-hybrid and biochemical assays. cORF, a protein encoded by the C-terminal open reading frame within the cnv gene, supports tumor growth in nude mice and associates with the promyelocytic leukemia zinc finger protein (PLZF), The interaction domains map between amino acid residues 21 and 87 of cORF, and between residues 245 and 543 of PLZF, PLZF is critical for spermatogenesis in mice. Abnormal spermatogenesis or maturation of gonocytes is thought to predispose humans to the development of germ cell tumors. Thus, cORF of human endogenous retroviruses may contribute to tumor development by interfering,vith processes during spermatogenesis that involve PLZF.	Univ Saarland, Sch Med, Dept Virol, D-66421 Homburg, Germany; Gerhard Domagk Inst Pathol, D-48149 Munster, Germany; GSF Forschungszentrum Umwelt & Gesundheit, Inst Mol Immunol, D-81377 Munich, Germany	Saarland University; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Mueller-Lantzsch, N (corresponding author), Univ Saarland, Sch Med, Dept Virol, Bldg 47, D-66421 Homburg, Germany.		Mayer, Jens/B-8506-2013; Mayer, Jens/P-4777-2019	Mayer, Jens/0000-0002-1090-5765; Mayer, Jens/0000-0002-1090-5765; Boese, Annette Sophia/0000-0002-5166-7425				Arnould C, 1999, HUM MOL GENET, V8, P1741, DOI 10.1093/hmg/8.9.1741; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Boese A, 2000, FEBS LETT, V468, P65, DOI 10.1016/S0014-5793(00)01197-2; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GUIDEZ F, 1994, LEUKEMIA, V8, P312; Hawe N., 1996, Blood, V88, p291A; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Heimdal K, 1997, BRIT J CANCER, V75, P1084, DOI 10.1038/bjc.1997.185; Herbst H, 1998, APMIS, V106, P216, DOI 10.1111/j.1699-0463.1998.tb01338.x; Herbst H, 1996, AM J PATHOL, V149, P1727; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Hyman J, 2000, J CELL BIOL, V149, P537, DOI 10.1083/jcb.149.3.537; Koken MHM, 1999, ONCOGENE, V18, P1113, DOI 10.1038/sj.onc.1202414; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; LOWER R, 1995, J VIROL, V69, P141; LOWER R, 1993, P NATL ACAD SCI USA, V90, P4480, DOI 10.1073/pnas.90.10.4480; Magin C, 1999, J VIROL, V73, P9496, DOI 10.1128/JVI.73.11.9496-9507.1999; Mangeney M, 1998, P NATL ACAD SCI USA, V95, P14920, DOI 10.1073/pnas.95.25.14920; Mayer J, 1999, NAT GENET, V21, P257, DOI 10.1038/6766; Mayer J, 1997, CYTOGENET CELL GENET, V78, P1, DOI 10.1159/000134614; Mayer J, 1997, CYTOGENET CELL GENET, V79, P157, DOI 10.1159/000134709; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; MUELLERLANTZSCH N, 1993, AIDS RES HUM RETROV, V9, P343, DOI 10.1089/aid.1993.9.343; Ravnik SE, 1999, DEV BIOL, V207, P408, DOI 10.1006/dbio.1998.9156; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; SAUTER M, 1995, J VIROL, V69, P414, DOI 10.1128/JVI.69.1.414-421.1995; Sauter M, 1996, CANCER RES, V56, P4362; SKAKKEBAEK NE, 1972, LANCET, V2, P516; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; Yang J, 1999, P NATL ACAD SCI USA, V96, P13404, DOI 10.1073/pnas.96.23.13404; YEE JK, 1994, METHOD CELL BIOL, V43, P99; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375; Zhang T, 1999, P NATL ACAD SCI USA, V96, P11422, DOI 10.1073/pnas.96.20.11422	41	98	103	1	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4328	4336		10.1038/sj.onc.1203794	http://dx.doi.org/10.1038/sj.onc.1203794			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980608				2022-12-25	WOS:000089271900003
J	Milner, J; Fuks, F; Hughes-Davies, L; Kouzarides, T				Milner, J; Fuks, F; Hughes-Davies, L; Kouzarides, T			The BRCA2 activation domain associates with and is phosphorylated by a cellular protein kinase	ONCOGENE			English	Article						BRCA2; protein kinase; phosphorylation	GENE; RAD51; ACETYLTRANSFERASE; IDENTIFICATION; INTERACT; MOUSE; BINDS; JNK	A substantial proportion of familiar breast cancers have mutations within the BRCA2 gene. The product of this gene has been implicated in DNA repair and in the regulation of transcription. We have previously identified at the amino-terminus of BRCA2 a transcriptional activation domain whose importance is highlighted by the presence of predisposing mutations and in-frame deletions in breast cancer families. This activation domain shows sequence similarity to a region of c-Jun which has been defined as a binding site for the c-Jun N-terminal kinase, Here, we show that the analogous region in BRCA2 is also a binding site for a cellular kinase, although this kinase is distinct from JNK, The BRCA2 associated enzyme Is able to phosphorylate residues within the BRCA2 activation domain. Consistent with this observation, we find that the activation domain of BRCA2 is phosphorylated in vivo. Our results indicate that the BRCA2 activation domain possesses a binding site for a kinase that may regulate BRCA2 activity by phosphorylation.	Univ Cambridge, Wellcome CRC Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Pathol, Cambridge CB2 1QR, England; Addenbrookes Hosp, CRC, Human Canc Genet Res Grp, Cambridge, England	University of Cambridge; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Kouzarides, T (corresponding author), Univ Cambridge, Wellcome CRC Inst, Tennis Court Rd, Cambridge CB2 1QR, England.			Kouzarides, Tony/0000-0002-8918-4162				Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Connor F, 1997, HUM MOL GENET, V6, P291, DOI 10.1093/hmg/6.2.291; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Fuks F, 1998, ONCOGENE, V17, P2531, DOI 10.1038/sj.onc.1202475; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; May GHW, 1999, GENE CHROMOSOME CANC, V25, P407, DOI 10.1002/(SICI)1098-2264(199908)25:4<407::AID-GCC16>3.0.CO;2-I; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Nordling M, 1998, CANCER RES, V58, P1372; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	19	19	19	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4441	4445		10.1038/sj.onc.1203793	http://dx.doi.org/10.1038/sj.onc.1203793			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980621				2022-12-25	WOS:000089271900016
J	Durante, W; Liao, L; Reyna, SV; Peyton, KJ; Schafer, AI				Durante, W; Liao, L; Reyna, SV; Peyton, KJ; Schafer, AI			Physiological cyclic stretch directs L-arginine transport and metabolism to collagen synthesis in vascular smooth muscle	FASEB JOURNAL			English	Article						biomechanical strain; L-proline; cationic amino acid transporter; arginase; vascular cells	NITRIC-OXIDE SYNTHASE; AMINO-ACID TRANSPORTER; NECROSIS-FACTOR-ALPHA; RAT-LIVER ARGINASE; GENE-EXPRESSION; GROWTH-FACTOR; MECHANICAL STIMULATION; CELL-PROLIFERATION; ANGIOTENSIN-II; INDUCTION	Application of cyclic stretch (10% at 1 hertz) to vascular smooth muscle cells (SMC) increased L-arginine uptake and this was associated with a specific increase in cationic amino acid transporter-2 (CAT-2) mRNA. In addition, cyclic stretch stimulated L-arginine metabolism by inducing arginase I mRNA and arginase activity. In contrast, cyclic stretch inhibited the catabolism of L-arginine to nitric oxide (NO) by blocking inducible NO synthase expression. Exposure of SMC to cyclic stretch markedly increased the capacity of SMC to generate L-proline from L-arginine while inhibiting the formation of polyamines. The stretch-mediated increase in L-proline production was reversed by methyl-L-arginine, a competitive inhibitor of L-arginine transport, by hydroxy-L-arginine, an arginase inhibitor, or by the ornithine aminotransferase inhibitor L-canaline. Finally, cyclic stretch stimulated collagen synthesis and the accumulation of type I collagen, which was inhibited by L-canaline. These results demonstrate that cyclic stretch coordinately stimulates L-proline synthesis by regulating the genes that modulate the transport and metabolism of L-arginine. In addition, they show that stretch-stimulated collagen production is dependent on L-proline formation. The ability of hemodynamic forces to up-regulate L-arginine transport and direct its metabolism to L-proline may play an important role in stabilizing vascular lesions by promoting SMC collagen synthesis.	Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Durante, W (corresponding author), Vet Adm Med Ctr, Bldg 109,Room 130,2002 Holcombe Blvd, Houston, TX 77030 USA.	wdurante@bcm.tmc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062467, R01HL059976, R01HL036045] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36045, HL-62467, HL-59976] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; AWOLESI MA, 1995, J CLIN INVEST, V96, P1449, DOI 10.1172/JCI118181; BENES AJ, 1985, J CELL SCI, V75, P35; BUNTIN CM, 1990, ANN BIOMED ENG, V18, P549, DOI 10.1007/BF02364617; BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T; Chapman GB, 2000, AM J PHYSIOL-HEART C, V278, pH748, DOI 10.1152/ajpheart.2000.278.3.H748; CLOSS EI, 1993, J BIOL CHEM, V268, P20796; CLOSS EI, 1993, J BIOL CHEM, V268, P7538; DAGHIGH F, 1994, BIOCHEM BIOPH RES CO, V202, P174, DOI 10.1006/bbrc.1994.1909; DARTSCH PC, 1986, EUR J CELL BIOL, V41, P339; Dethlefsen SM, 1996, J VASC RES, V33, P405, DOI 10.1159/000159169; DIZIKES GJ, 1986, BIOCHEM BIOPH RES CO, V141, P53, DOI 10.1016/S0006-291X(86)80333-3; DOBRIN PB, 1978, PHYSIOL REV, V58, P397, DOI 10.1152/physrev.1978.58.2.397; Durante W, 1996, CIRC RES, V78, P1075, DOI 10.1161/01.RES.78.6.1075; DURANTE W, 1995, AM J PHYSIOL-HEART C, V268, pH1158; DURANTE W, 1993, AM J PHYSIOL, V264, pH617, DOI 10.1152/ajpheart.1993.264.2.H617; Durante W, 1996, P ASSOC AM PHYSICIAN, V108, P356; Durante W, 1996, J BIOL CHEM, V271, P11838, DOI 10.1074/jbc.271.20.11838; Durante W, 1998, CIRC RES, V83, P217, DOI 10.1161/01.RES.83.2.217; Durante W, 1997, J BIOL CHEM, V272, P30154, DOI 10.1074/jbc.272.48.30154; ENDEAN ED, 1991, J SURG RES, V50, P634, DOI 10.1016/0022-4804(91)90054-P; Geng YJ, 1996, ARTERIOSCL THROM VAS, V16, P19, DOI 10.1161/01.ATV.16.1.19; Gill DJ, 1996, J BIOL CHEM, V271, P11280, DOI 10.1074/jbc.271.19.11280; Gotoh T, 1996, FEBS LETT, V395, P119, DOI 10.1016/0014-5793(96)01015-0; Hosokawa H, 1997, J BIOL CHEM, V272, P8717, DOI 10.1074/jbc.272.13.8717; Iwashina M, 1998, CIRCULATION, V98, P1212, DOI 10.1161/01.CIR.98.12.1212; Jenkinson CP, 1996, COMP BIOCHEM PHYS B, V114, P107, DOI 10.1016/0305-0491(95)02138-8; JONES ME, 1985, J NUTR, V115, P509, DOI 10.1093/jn/115.4.509; KAWAMOTO S, 1987, J BIOL CHEM, V262, P6280; KIM HR, 1994, ANAL BIOCHEM, V223, P205, DOI 10.1006/abio.1994.1574; KITO K, 1978, J BIOCHEM-TOKYO, V83, P201, DOI 10.1093/oxfordjournals.jbchem.a131892; KOLPAKOV V, 1995, CIRC RES, V76, P305, DOI 10.1161/01.RES.76.2.305; KULIK TJ, 1993, J CELL PHYSIOL, V157, P615, DOI 10.1002/jcp.1041570322; Lee RT, 1997, ARTERIOSCL THROM VAS, V17, P1859, DOI 10.1161/01.ATV.17.10.1859; LEUNG DYM, 1976, SCIENCE, V191, P475; Li Q, 1998, J VASC RES, V35, P93, DOI 10.1159/000025570; LOW BC, 1995, J BIOL CHEM, V270, P27577, DOI 10.1074/jbc.270.46.27577; LOW BC, 1993, J CELL PHYSIOL, V156, P626, DOI 10.1002/jcp.1041560323; MACLEOD CL, 1990, MOL CELL BIOL, V10, P3663, DOI 10.1128/MCB.10.7.3663; Mills I, 1997, J CELL PHYSIOL, V170, P228, DOI 10.1002/(SICI)1097-4652(199703)170:3<228::AID-JCP2>3.0.CO;2-Q; PETERKOFSKY B, 1971, BIOCHEMISTRY-US, V10, P988, DOI 10.1021/bi00782a009; Reusch P, 1996, CIRC RES, V79, P1046, DOI 10.1161/01.RES.79.5.1046; SPECTOR EB, 1994, INT J DEV NEUROSCI, V12, P337, DOI 10.1016/0736-5748(94)90083-3; STRECKER HJ, 1965, J BIOL CHEM, V240, P1225; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; THYBERG J, 1987, EXP CELL RES, V170, P160, DOI 10.1016/0014-4827(87)90125-X; WHITE MF, 1985, BIOCHIM BIOPHYS ACTA, V822, P355, DOI 10.1016/0304-4157(85)90015-2; WILSON E, 1993, J CELL BIOL, V123, P741, DOI 10.1083/jcb.123.3.741; Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001; Yamamoto K, 1998, J BIOL CHEM, V273, P11862, DOI 10.1074/jbc.273.19.11862; Yang JH, 1998, J BIOL CHEM, V273, P6550, DOI 10.1074/jbc.273.11.6550	51	65	66	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2000	14	12					1775	1783		10.1096/fj.99-0960com	http://dx.doi.org/10.1096/fj.99-0960com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973927				2022-12-25	WOS:000089212400017
J	Pons, S; Torres-Aleman, I				Pons, S; Torres-Aleman, I			Insulin-like growth factor-I stimulates dephosphorylation of I kappa B through the serine phosphatase calcineurin (protein phosphatase 2B)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; TNF-ALPHA; ACTIVATION; KINASE; RECEPTOR; SURVIVAL; ASTROCYTES; PATHWAY; AKT; NEURODEGENERATION	Astrocytes represent the most abundant cell type of the adult nervous system. Under normal conditions, astrocytes participate in neuronal feeding and detoxification. However, following brain injury, local increases in inflammatory cytokines trigger a reactive phenotype in astrocytes during which these cells produce their own inflammatory cytokines and neurotoxic free radicals. Indeed, progression of this inflammatory reaction is responsible for most neurological damage associated with brain trauma. Insulin-Like growth factor-I (IGF-I) protects neurons against a variety of brain pathologies associated with glial overproduction of proinflammatory cytokines. Here, we demonstrate that in astrocyte cultures IGF-I regulates NF kappaB, a transcription factor known to play a key role in the inflammatory reaction. IGF-I induces a site-specific dephosphorylation of I kappaB alpha (phospho-Ser(32)) in astrocytes. Moreover, IGF-I-mediated dephosphorylation of I kappaB alpha protects this molecule from tumor necrosis factor cu (TNF alpha)-stimulated degradation; therefore, IGF-I also inhibits the nuclear translocation of NF kappaB (p65) induced by TNF alpha exposure. Finally, we show that dephosphorylation of I kappaB alpha by IGF-I pathways requires activation of calcineurin. Activation of this phosphatase is independent of phosphatidylinositol 3-kinase and mitogen-activated protein kinase. Thus, these data suggest that the therapeutic benefits associated with IGF-I treatment of brain injury are derived from both its positive effects on neuronal survival and inhibition of the glial inflammatory reaction.	CSIC, Inst Cajal Neurobiol, Cellular & Mol Neuroendocrinol Lab, E-28002 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC)	Pons, S (corresponding author), CSIC, Inst Cajal Neurobiol, Cellular & Mol Neuroendocrinol Lab, Av Doctor Arce 37, E-28002 Madrid, Spain.	pons@cajal.csic.es	Torres-Aleman, Ignacio/A-1613-2008; Pons, Sebastian/K-7794-2014	Torres-Aleman, Ignacio/0000-0001-8107-7947; Pons, Sebastian/0000-0003-1027-0621				Akama KT, 2000, J BIOL CHEM, V275, P7918, DOI 10.1074/jbc.275.11.7918; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bence-Hanulec KK, 2000, NEURON, V27, P121, DOI 10.1016/S0896-6273(00)00014-3; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Dore S, 1997, TRENDS NEUROSCI, V20, P326; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Feldman EL, 1997, NEUROBIOL DIS, V4, P201, DOI 10.1006/nbdi.1997.0156; Fernandez AM, 1999, EUR J NEUROSCI, V11, P2019, DOI 10.1046/j.1460-9568.1999.00623.x; Fernandez AM, 1997, NEUROSCIENCE, V76, P117; Heck S, 1999, J BIOL CHEM, V274, P9828, DOI 10.1074/jbc.274.14.9828; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Le Roith D, 1998, INT CONGR SER, V1151, P285; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; MOYNAGH PN, 1993, BIOCHEM J, V294, P343, DOI 10.1042/bj2940343; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Okubo Y, 1998, J BIOL CHEM, V273, P25961, DOI 10.1074/jbc.273.40.25961; Ozes ON, 1999, NATURE, V401, P82; Peraldi P, 1996, J BIOL CHEM, V271, P13018, DOI 10.1074/jbc.271.22.13018; Perry SW, 1998, J BIOL CHEM, V273, P17660, DOI 10.1074/jbc.273.28.17660; PONS S, 1992, ENDOCRINOLOGY, V131, P2271, DOI 10.1210/en.131.5.2271; PONS S, 1995, MOL CELL BIOL, V15, P4453; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Semsarian C, 1999, NATURE, V400, P576, DOI 10.1038/23054; SPARACIO SM, 1992, J NEUROIMMUNOL, V39, P231, DOI 10.1016/0165-5728(92)90257-L; Venters HD, 1999, P NATL ACAD SCI USA, V96, P9879, DOI 10.1073/pnas.96.17.9879; Venters HD, 2000, TRENDS NEUROSCI, V23, P175, DOI 10.1016/S0166-2236(99)01533-7; White MF, 1998, RECENT PROG HORM RES, V53, P119; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355	33	78	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38620	38625		10.1074/jbc.M004531200	http://dx.doi.org/10.1074/jbc.M004531200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10973957	hybrid			2022-12-25	WOS:000165739800065
J	Raussens, V; Mah, MKH; Kay, CM; Sykes, BD; Ryan, RO				Raussens, V; Mah, MKH; Kay, CM; Sykes, BD; Ryan, RO			Structural characterization of a low density lipoprotein receptor-active apolipoprotein E peptide, ApoE3-(126-183)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL DOMAIN; CELL-SURFACE RECEPTORS; LDL-RECEPTOR; SYNTHETIC PEPTIDES; APOLIPOPHORIN-III; ALPHA-HELIX; PLASMA-LIPOPROTEINS; AQUEOUS-SOLUTION; BINDING DOMAIN; PROTEIN	Apolipoprotein E (apoE) plays a critical role in lipoprotein particle clearance from blood plasma through its interaction with the low density lipoprotein (LDL) receptor and other related receptors, Here, we studied a 58-residue peptide encompassing the receptor binding region of apoE, ApoE3-(126-183) was generated by cyanogen bromide cleavage of recombinant apoE3-(1-183), purified by reversed-phase high pressure liquid chromatography, and characterized by mass spectrometry, Far UV CD spectroscopy of the peptide showed that it is unstructured in aqueous solution, The addition of trifluoroethanol or dodecylphosphocholine induces the peptide to adopt an alpha -helical conformation, ApoE3-(126-183) efficiently transforms dimyristoylphosphatidyl-glycerol (DMPG) vesicles into peptide-lipid complexes. Analysis of apoE3-(126-183) DMPG; complexes by electron microscopy revealed disc-shaped particles with an average diameter of 13 +/- 3 nm, Flotation equilibrium analysis yielded a particle molecular mass of 252 kDa. Far UV CD analysis of apoE3-(126-183) DMPG discs provided evidence that the peptide adopts a helical conformation. Competition binding experiments with I-125-labeled low density lipoprotein (LDL) were conducted to assess the ability of apoE3-(126-183).DMPG complexes to bind to the LDL receptor. Both N-terminal apoE and the peptide, when complexed with DMPG, competed with I-125-LDL for binding sites on the surface of cultured human skin fibroblasts, Under the conditions employed, apoE3-(126-183).DMPG complexes were similar to apoE3-(1-183).DMPG discs in their ability to bind to the receptor, demonstrating that the peptide represents a good model to study the interaction between apoE and the LDL receptor. Preliminary NMR results indicated that a high resolution structure of the apoE3-(126-183) peptide is obtainable.	Univ Alberta, Dept Biochem, Lipid Biol Res Grp, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Biochem, Prot Engn Network Ctr Excellence, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta	Raussens, V (corresponding author), Univ Alberta, Dept Biochem, Lipid Biol Res Grp, 327 HMRC, Edmonton, AB T6G 2S2, Canada.				NHLBI NIH HHS [HL64159] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064159, R37HL064159] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; Benzinger TLS, 1998, BIOCHEMISTRY-US, V37, P13222, DOI 10.1021/bi980482f; Braddock DT, 1996, BIOCHEMISTRY-US, V35, P13975, DOI 10.1021/bi960006u; Brown MS, 1997, NATURE, V388, P629, DOI 10.1038/41672; BUCH M, 1995, BIOCHEMISTRY-US, V34, P13219; Clayton D, 1999, PROTEIN SCI, V8, P1797, DOI 10.1110/ps.8.9.1797; Dominguez SR, 1999, J LIPID RES, V40, P753; Dong LM, 1996, NAT STRUCT BIOL, V3, P718, DOI 10.1038/nsb0896-718; DYER CA, 1995, J LIPID RES, V36, P80; DYER CA, 1991, J BIOL CHEM, V266, P22803; FAN P, 1993, BIOCHEMISTRY-US, V32, P1573, DOI 10.1021/bi00057a023; Fisher CA, 1999, J LIPID RES, V40, P93; Fisher CA, 1997, BIOCHEM CELL BIOL, V75, P45, DOI 10.1139/bcb-75-1-45; HENRY GD, 1994, METHOD ENZYMOL, V239, P515; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; Kumaran S, 1999, J PEPT RES, V53, P284, DOI 10.1034/j.1399-3011.1999.00027.x; LALAZAR A, 1989, J BIOL CHEM, V264, P8447; LANGER T, 1972, J CLIN INVEST, V51, P1528, DOI 10.1172/JCI106949; LAUTERWEIN J, 1979, BIOCHIM BIOPHYS ACTA, V556, P244, DOI 10.1016/0005-2736(79)90046-4; Luo PZ, 1997, BIOCHEMISTRY-US, V36, P8413, DOI 10.1021/bi9707133; LUO PZ, 1994, BIOCHEMISTRY-US, V33, P12367, DOI 10.1021/bi00207a003; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MAHLEY RW, 1977, J BIOL CHEM, V252, P7279; MIMS MP, 1994, J BIOL CHEM, V269, P20539; Morrow JA, 2000, J BIOL CHEM, V275, P2576, DOI 10.1074/jbc.275.4.2576; NELSON CA, 1974, ANAL BIOCHEM, V59, P69, DOI 10.1016/0003-2697(74)90010-4; NELSON JW, 1989, BIOCHEMISTRY-US, V28, P5256, DOI 10.1021/bi00438a050; Nikoulin IR, 1998, J CLIN INVEST, V101, P223, DOI 10.1172/JCI1099; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; POWNALL HJ, 1978, BIOCHEMISTRY-US, V17, P1183, DOI 10.1021/bi00600a008; RYAN RO, 1993, J BIOL CHEM, V268, P1525; SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155; SEGREST JP, 1994, ADV PROTEIN CHEM, V45, P303; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; SPARROW JT, 1992, BIOCHEMISTRY-US, V31, P1065, DOI 10.1021/bi00119a015; SPARROW JT, 1985, BIOCHEMISTRY-US, V24, P6984, DOI 10.1021/bi00345a035; Wang GS, 1996, BIOCHEMISTRY-US, V35, P10358, DOI 10.1021/bi960934t; Weers PMM, 1999, J BIOL CHEM, V274, P21804, DOI 10.1074/jbc.274.31.21804; WEISGRABER KH, 1978, J BIOL CHEM, V253, P9053; WEISGRABER KH, 1990, J LIPID RES, V31, P1503; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WEISGRABER KH, 1992, HIGH DENSITY LIPOPRO, V3, P175; WESTERLUND JA, 1993, J BIOL CHEM, V268, P15745; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WIENTZEK M, 1994, J BIOL CHEM, V269, P4605; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	48	15	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38329	38336		10.1074/jbc.M005732200	http://dx.doi.org/10.1074/jbc.M005732200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10986285	hybrid			2022-12-25	WOS:000165739800028
J	Matsushita, T; Fujii-Taira, I; Tanaka, Y; Homma, KJ; Natori, S				Matsushita, T; Fujii-Taira, I; Tanaka, Y; Homma, KJ; Natori, S			Male-specific IDGF, a novel gene encoding a membrane-bound extracellular signaling molecule expressed exclusively in testis of Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEREGRINA FLESH FLY; CDC25 HOMOLOG TWINE; MEIOTIC CELL-CYCLE; SPERMATID DIFFERENTIATION; PROTEIN; SPERMATOGENESIS; PROLIFERATION; MEIOSIS; COORDINATE; LINE	We identified a novel gene of Drosophila melanogaster, Male-specific IDGF (MSI), encoding a transmembrane signaling molecule with exclusive expression in the testis. This molecule (MSI) contains a single transmembrane domain and has 35% amino acid identity with insect-derived growth factor (IDGF), a soluble growth factor for embryonic cells of the flesh fly, Sarcophaga peregrina. When MSI was exogenously expressed in Schneiders's line 2 cells, it was shown to be localized on the cell surface and exhibits growth factor activity, suggesting that MSI is a membrane-bound extracellular signaling molecule. Gene expression studies revealed that MSI mRNA was restricted to mature primary spermatocytes, whereas MSI was detected in the cells at the later developmental stages. Analysis using four meiotic arrest mutants, aly, can, mia, and sa suggested that MSI is involved in spermiogenesis, the final differentiation step of spermatogenesis. These results suggest that MSI is an extracellular signaling molecule participating in spermatogenesis and is a new member of the IDGF family.	Inst Phys & Chem Res, Natori Special Lab, Wako, Saitama 3510198, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan	RIKEN; University of Tokyo	Natori, S (corresponding author), Inst Phys & Chem Res, Natori Special Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.							ALPHEY L, 1992, EUR J CELL BIOL, V56, P151; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; Cooper K. W, 1965, BIOL DROSOPHILA, P1; COURTOT C, 1992, DEVELOPMENT, V116, P405; Eberhart CG, 1996, NATURE, V381, P783, DOI 10.1038/381783a0; ENDO K, 1996, CELL, V90, P121; Fuller Margaret T., 1993, P71; Gonczy P, 1996, DEVELOPMENT, V122, P2437; GOULDSOMERO M, 1974, ROUX ARCH DEV BIOL, V174, P133, DOI 10.1007/BF00573626; HACKSTEIN JHP, 1991, EUR J CELL BIOL, V56, P151; Hales KG, 1997, CELL, V90, P121, DOI 10.1016/S0092-8674(00)80319-0; HARDY RW, 1979, J ULTRA MOL STRUCT R, V69, P180, DOI 10.1016/S0022-5320(79)90108-4; Hisahara S, 1998, J CELL SCI, V111, P667; Homma K, 1996, J BIOL CHEM, V271, P13770, DOI 10.1074/jbc.271.23.13770; Hori S, 1997, BIOCHEM BIOPH RES CO, V236, P497, DOI 10.1006/bbrc.1997.6918; KEMPHUES KJ, 1982, CELL, V31, P655, DOI 10.1016/0092-8674(82)90321-X; KOMANO H, 1991, FEBS LETT, V289, P167, DOI 10.1016/0014-5793(91)81061-C; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIFSCHYTZ E, 1987, INT REV CYTOL, V109, P211, DOI 10.1016/S0074-7696(08)61723-4; Lin TY, 1996, DEVELOPMENT, V122, P1331; Lindsley D.L., 1980, Genetics and Biology of Drosophila, V2d, P225; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; OLIVIERI G, 1965, MUTAT RES, V2, P366, DOI 10.1016/0027-5107(65)90072-2; Santel A, 1997, MECH DEVELOP, V64, P19, DOI 10.1016/S0925-4773(97)00031-2; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SOSSIN WS, 1989, J BIOL CHEM, V264, P16933; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; White-Cooper H, 1998, DEVELOPMENT, V125, P125; WHITECOOPER H, 1993, J CELL SCI, V106, P1035	33	21	21	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36934	36941		10.1074/jbc.M003455200	http://dx.doi.org/10.1074/jbc.M003455200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10967093	hybrid			2022-12-25	WOS:000165577700069
J	Oda, T; Morikawa, N; Saito, Y; Masuho, Y; Matsumoto, S				Oda, T; Morikawa, N; Saito, Y; Masuho, Y; Matsumoto, S			Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-3 RECEPTOR; COUPLED RECEPTORS; CELLS; CLOZAPINE; IDENTIFICATION; RESPONSES; AFFINITY; RELEASE	Recently cDNA encoding the histamine H3 receptor was isolated after 15 years of considerable research. However, several studies have proposed heterogeneity of the H3 receptor. We report here the molecular cloning and characterization of a novel type of histamine receptor. A novel orphan G-protein-coupled receptor named GPRv53 was obtained through a search of the human genomic DNA data base and analyzed by rapid amplification of cDNA ends (RACE), GPRv53 possessed the features of biologic amine receptors and had the highest homology with H3 receptor among known G-protein-coupled receptors. Mammalian cells expressing GPRv53 were demonstrated to bind and respond to histamine in a concentration-dependent manner. In functional assays, not only an H3 receptor agonist, R-(alpha)-methylhistamine, but also a H3 receptor antagonist, clobenpropit, and a neuroleptic, clozapine, activated GPRv53-expressing cells. Tissue distribution analysis revealed that expression of GPRv53 is localized in the peripheral blood leukocytes, spleen, thymus, and colon, which was totally different from the H3 receptor, whose expression was restricted to the brain. The discovery of the GPRv53 receptor will open a new phase of research on the physiological role of histamine.	Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Mol Med Lab, Tsukuba, Ibaraki 3058585, Japan; Helix Res Inst Inc, Chiba 2920812, Japan; Fujisawa Pharmaceut Co Ltd, Adv Technol Platform Res Lab, Tsukuba, Ibaraki 3002698, Japan	Astellas Pharmaceuticals; Astellas Pharmaceuticals	Matsumoto, S (corresponding author), Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Mol Med Lab, 21 Miyukigaoka, Tsukuba, Ibaraki 3058585, Japan.	matsumot@yamanouchi.co.jp	Beldar, Sagar V/C-8542-2011					Alphs LD, 1999, J CLIN PSYCHIAT, V60, P39; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; ARRANG JM, 1983, NATURE, V302, P832, DOI 10.1038/302832a0; CASTANON MJ, 1994, BIOCHEM BIOPH RES CO, V198, P626, DOI 10.1006/bbrc.1994.1091; CLARK MA, 1993, AGENTS ACTIONS, V40, P129, DOI 10.1007/BF01984051; ENDOU M, 1994, J PHARMACOL EXP THER, V269, P221; Fitzgerald LR, 1999, ANAL BIOCHEM, V275, P54, DOI 10.1006/abio.1999.4295; FUKUI H, 1994, BIOCHEM BIOPH RES CO, V201, P894, DOI 10.1006/bbrc.1994.1786; George SE, 1997, J NEUROCHEM, V69, P1278; GESPACH C, 1982, FEBS LETT, V149, P85, DOI 10.1016/0014-5793(82)81077-6; Hill SJ, 1997, PHARMACOL REV, V49, P253; HILL SJ, 1990, PHARMACOL REV, V42, P45; HIMMLER A, 1993, J RECEPTOR RES, V13, P79, DOI 10.3109/10799899309073647; JOHNSON CL, 1979, MOL PHARMACOL, V16, P417; KATHMANN M, 1994, PSYCHOPHARMACOLOGY, V116, P464, DOI 10.1007/BF02247479; KRUPP P, 1992, BRIT J PSYCHIAT, V160, P38, DOI 10.1192/S0007125000296906; Laitinen JT, 1998, J NEUROCHEM, V71, P808; LEURS R, 1995, PHARMACOL THERAPEUT, V66, P413, DOI 10.1016/0163-7258(95)00006-3; Leurs R, 1996, J PHARMACOL EXP THER, V276, P1009; Leurs R, 2000, TRENDS PHARMACOL SCI, V21, P11, DOI 10.1016/S0165-6147(99)01411-X; Lovenberg TW, 1999, MOL PHARMACOL, V55, P1101, DOI 10.1124/mol.55.6.1101; Matsumoto SI, 1997, BBA-GENE STRUCT EXPR, V1354, P159, DOI 10.1016/S0167-4781(97)00120-6; Minneman KP, 2000, J NEUROCHEM, V74, P2392, DOI 10.1046/j.1471-4159.2000.0742392.x; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; RAIBLE DG, 1994, AM J RESP CRIT CARE, V149, P1506, DOI 10.1164/ajrccm.149.6.8004306; RODRIGUES AA, 1995, BRIT J PHARMACOL, V114, P1523, DOI 10.1111/j.1476-5381.1995.tb14934.x; Schlicker E, 1996, N-S ARCH PHARMACOL, V353, P482; SCHWORER H, 1994, N-S ARCH PHARMACOL, V350, P375; SOLL AH, 1979, ANNU REV PHYSIOL, V41, P35, DOI 10.1146/annurev.ph.41.030179.000343; TRAIFFORT E, 1995, BIOCHEM BIOPH RES CO, V211, P570, DOI 10.1006/bbrc.1995.1851; WEST RE, 1990, MOL PHARMACOL, V38, P610; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049	34	512	581	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36781	36786		10.1074/jbc.M006480200	http://dx.doi.org/10.1074/jbc.M006480200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973974	hybrid			2022-12-25	WOS:000165577700049
J	Wakimoto, K; Kobayashi, K; Kuro-o, M; Yao, A; Iwamoto, T; Yanaka, N; Kita, S; Nishida, A; Azuma, S; Toyoda, Y; Omori, K; Imahie, H; Oka, T; Kudoh, S; Kohmoto, O; Yazaki, Y; Shigekawa, M; Imai, Y; Nabeshima, Y; Komuro, I				Wakimoto, K; Kobayashi, K; Kuro-o, M; Yao, A; Iwamoto, T; Yanaka, N; Kita, S; Nishida, A; Azuma, S; Toyoda, Y; Omori, K; Imahie, H; Oka, T; Kudoh, S; Kohmoto, O; Yazaki, Y; Shigekawa, M; Imai, Y; Nabeshima, Y; Komuro, I			Targeted disruption of Na+/Ca2+ exchanger gene leads to cardiomyocyte apoptosis and defects in heartbeat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC NA+-CA2+ EXCHANGER; SODIUM-CALCIUM EXCHANGER; PROTEIN-KINASE-C; DEPENDENT REGULATION; CA2+-BINDING DOMAIN; MOLECULAR-CLONING; GUINEA-PIG; PHOSPHORYLATION; MYOCYTES; MUSCLE	Ca2+, which enters cardiac myocytes through voltage dependent Ca2+ channels during excitation, is extruded from myocytes primarily by the Na+/Ca2+ exchanger (NCX1) during relaxation. The increase in intracellular Ca2+ concentration in myocytes by digitalis treatment and after ischemia/reperfusion is also thought to result from the reverse mode of the Na+/Ca2+ exchange mechanism. However, the precise roles of the NCX1 are still unclear because of the lack of its specific inhibitors. We generated Ncx1-deficient mice by gene targeting to determine the in vivo function of the exchanger. Homozygous Ncx1-deficient mice died between embryonic days 9 and 10. Their hearts did not beat, and cardiac myocytes showed apoptosis. No forward mode or reverse mode of the Na+/Ca2+ exchange activity was detected in null mutant hearts. The Na+-dependent Ca2+ exchange activity as well as protein content of NCX1 were decreased by similar to 50% in the heart, kidney, aorta, and smooth muscle cells of the heterozygous mice, and tension development of the aortic ring in Na+-free solution was markedly impaired in heterozygous mice. These findings suggest that NCX1 is required for heartbeats and survival of cardiac myocytes in embryos and plays critical roles in Na+-dependent Ca2+ handling in the heart and aorta.	Tanabe Seiyaku Co Ltd, Adv Med Res Dept, Yodogawa Ku, Osaka 5328505, Japan; Tanabe Seiyaku Co Ltd, Discovery Res Lab, Yodogawa Ku, Osaka 5328505, Japan; Natl Inst Neurosci, Div Mol Genet, Kodaira, Tokyo 1870000, Japan; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA; Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo Ku, Tokyo 1138655, Japan; Natl Cardiovasc Ctr, Res Inst, Dept Mol Physiol, Suita, Osaka 5658565, Japan; Mitsubishi Kasei Inst Life Sci, Machida, Tokyo 1948511, Japan; Obihiro Univ Agr & Vet Med, Res Ctr Protozoan Mol Immunol, Obihiro, Hokkaido 0808555, Japan; Saitama Med Sch, Dept Med 2, Moroyama, Saitama 3500495, Japan; Kyoto Univ, Fac Med, Grad Sch Med, Dept Pathol & Tumor Biol,Sakyo Ku, Kyoto 6068501, Japan	Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation; National Center for Neurology & Psychiatry - Japan; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Tokyo; National Cerebral & Cardiovascular Center - Japan; Obihiro University of Agriculture & Veterinary Medicine; Saitama Medical University; Kyoto University	Nabeshima, Y (corresponding author), Tanabe Seiyaku Co Ltd, Adv Med Res Dept, Yodogawa Ku, 3-16-89 Kashima, Osaka 5328505, Japan.		Andoh, Akira/AAB-9303-2022; Yanaka, Noriyuki/P-9096-2016					Bader BL, 1998, CELL, V95, P507, DOI 10.1016/S0092-8674(00)81618-9; BERS DM, 1993, CARDIOVASC RES, V27, P1772, DOI 10.1093/cvr/27.10.1772; BRIDGE JHB, 1990, SCIENCE, V248, P376, DOI 10.1126/science.2158147; CALLEWAERT G, 1989, AM J PHYSIOL, V257, P147; CHAPMAN RA, 1976, J PHYSIOL-LONDON, V258, P1; CONDRESCU M, 1995, J BIOL CHEM, V270, P9137, DOI 10.1074/jbc.270.16.9137; DOERING AE, 1994, J PHYSIOL-LONDON, V480, P9, DOI 10.1113/jphysiol.1994.sp020336; GADSBY DC, 1991, ANN NY ACAD SCI, V639, P140, DOI 10.1111/j.1749-6632.1991.tb17297.x; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P905, DOI 10.1085/jgp.100.6.905; HILGEMANN DW, 1990, NATURE, V344, P242, DOI 10.1038/344242a0; IWAMOTO T, 1995, J BIOL CHEM, V270, P8996, DOI 10.1074/jbc.270.15.8996; Iwamoto T, 1998, BIOCHEMISTRY-US, V37, P17230, DOI 10.1021/bi981521q; Iwamoto T, 1996, J BIOL CHEM, V271, P13609, DOI 10.1074/jbc.271.23.13609; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KIMURA J, 1986, NATURE, V319, P596, DOI 10.1038/319596a0; KLEBER AG, 1983, CIRC RES, V52, P442, DOI 10.1161/01.RES.52.4.442; KOFUJI P, 1994, J BIOL CHEM, V269, P5145; KOMURO I, 1992, P NATL ACAD SCI USA, V89, P4769, DOI 10.1073/pnas.89.10.4769; Kraev A, 1996, GENOMICS, V37, P105, DOI 10.1006/geno.1996.0526; Ladilov Y, 1999, AM J PHYSIOL-HEART C, V276, pH1868, DOI 10.1152/ajpheart.1999.276.6.H1868; LEVITSKY DO, 1994, J BIOL CHEM, V269, P22847; LI ZP, 1994, J BIOL CHEM, V269, P17434; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; MOTLEY ED, 1993, AM J PHYSIOL, V264, pH1028, DOI 10.1152/ajpheart.1993.264.4.H1028; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; REEVES JP, 1984, J BIOL CHEM, V259, P7733; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; RUGH R, 1994, MOUSE ITS REPROD DEV; Sambrook J., 2002, MOL CLONING LAB MANU; SCHULZE D, 1993, CARDIOVASC RES, V27, P1726, DOI 10.1093/cvr/27.10.1726; Tsuda M, 1997, J NEUROSCI, V17, P6678; Yao AS, 1998, CIRC RES, V82, P657, DOI 10.1161/01.RES.82.6.657	33	173	180	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36991	36998		10.1074/jbc.M004035200	http://dx.doi.org/10.1074/jbc.M004035200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10967099	hybrid			2022-12-25	WOS:000165577700076
J	Okazaki, Y; Ohno, H; Takase, K; Ochiai, T; Saito, T				Okazaki, Y; Ohno, H; Takase, K; Ochiai, T; Saito, T			Cell surface expression of calnexin, a molecular chaperone in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; UNFOLDED-PROTEIN RESPONSE; IMMATURE THYMOCYTES; SIGNALING PATHWAY; BINDING PROTEIN; CALRETICULIN; RETENTION; MEMBRANE; IDENTIFICATION; GLYCOPROTEIN	The folding and assembly of nascent proteins in the endoplasmic reticulum are assisted by the molecular chaperone calnexin, which is itself retained within the endoplasmic reticulum, It was up to now assumed that calnexin was selectively expressed on the surface of immature thymocytes because of a particular characteristic of the protein sorting machinery in these cells. We now report that a small fraction of calnexin is normally expressed on the surface of various cells such as mastocytoma cells, murine splenocytes, fibroblast cells, and human HeLa cells. Surface biotinylation followed by chase culture of living cells revealed that calnexin is continuously delivered to the cell surface and then internalized for lysosomal degradation. These results suggest that there is continuous exocytosis and endocytosis of calnexin, and the amount of calnexin on the plasma membrane results from the balance of the rates of these two events, To study the structural requirement of calnexin for surface expression, we created deletion mutants of calnexin and found that the luminal domain, particularly the glycoprotein binding domain, is necessary. These findings suggest that the surface expression of calnexin depends on the association with glycoproteins and that calnexin may play a certain role as a chaperone on the plasma membrane as well.	Chiba Univ, Grad Sch Med, Dept Mol Genet, Chuo Ku, Chiba 2608670, Japan; Kanazawa Univ, Inst Canc Res, Div Mol Membrane Biol, Kanazawa, Ishikawa 9200934, Japan; Chiba Univ, Sch Med, Dept Surg 2, Chuo Ku, Chiba 2608670, Japan	Chiba University; Kanazawa University; Chiba University	Saito, T (corresponding author), Chiba Univ, Grad Sch Med, Dept Mol Genet, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.		Ohno, Hiroshi/L-7899-2014; Saito, Takashi/C-9684-2009	Ohno, Hiroshi/0000-0001-8776-9661; Saito, Takashi/0000-0001-9495-3547				Altmeyer A, 1996, INT J CANCER, V69, P340, DOI 10.1002/(SICI)1097-0215(19960822)69:4<340::AID-IJC18>3.0.CO;2-9; Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; ARASE H, 1993, J IMMUNOL, V151, P546; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; Coppolino MG, 1999, BIOCHEM J, V340, P41, DOI 10.1042/0264-6021:3400041; Coppolino MG, 1997, NATURE, V386, P843, DOI 10.1038/386843a0; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; ESSEX DW, 1995, BLOOD, V86, P2168, DOI 10.1182/blood.V86.6.2168.bloodjournal8662168; FEBBRAIO M, 1990, J BIOL CHEM, V265, P18531; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HORN M, 1994, BIOCHEM J, V301, P69, DOI 10.1042/bj3010069; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LEUNGHAGESTEIJN CY, 1994, J CELL SCI, V107, P589; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Nagata K, 1997, IMMUNITY, V7, P559, DOI 10.1016/S1074-7613(00)80377-5; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; PUNT JA, 1991, J EXP MED, V174, P775, DOI 10.1084/jem.174.4.775; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; Roquemore EP, 1998, MOL BIOL CELL, V9, P2125, DOI 10.1091/mbc.9.8.2125; Sarafian V, 1998, INT J CANCER, V75, P105, DOI 10.1002/(SICI)1097-0215(19980105)75:1<105::AID-IJC16>3.3.CO;2-L; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; Takase K, 1997, J IMMUNOL, V159, P741; TJOELKER LW, 1994, BIOCHEMISTRY-US, V33, P3229, DOI 10.1021/bi00177a013; VANBUSKIRK AM, 1991, J IMMUNOL, V146, P500; WADA I, 1991, J BIOL CHEM, V266, P19599; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WHITE TK, 1995, J BIOL CHEM, V270, P15926, DOI 10.1074/jbc.270.27.15926; WHITNEY JA, 1995, CELL, V83, P703; Wiest DL, 1997, P NATL ACAD SCI USA, V94, P1884, DOI 10.1073/pnas.94.5.1884; WIEST DL, 1995, EMBO J, V14, P3425, DOI 10.1002/j.1460-2075.1995.tb07348.x; Xiao GQ, 1999, MOL BRAIN RES, V72, P121, DOI 10.1016/S0169-328X(99)00188-6; Yeates LC, 1997, BIOCHEM BIOPH RES CO, V238, P66, DOI 10.1006/bbrc.1997.7238	38	101	102	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35751	35758		10.1074/jbc.M007476200	http://dx.doi.org/10.1074/jbc.M007476200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10956670	hybrid			2022-12-25	WOS:000165382000018
J	Sitterlin, D; Bergametti, F; Tiollais, P; Tennant, BC; Transy, C				Sitterlin, D; Bergametti, F; Tiollais, P; Tennant, BC; Transy, C			Correct binding of viral X protein to UVDDB-p127 cellular protein is critical for efficient infection by hepatitis B viruses	ONCOGENE			English	Article						hepatitis B virus; X protein; UV-damaged DNA binding protein; virus-host interaction; therapeutic target	NUCLEOTIDE-SEQUENCE; GENE PRODUCT; IN-VIVO; REPLICATION; MUTATIONS; CELLS	A fully effective treatment of chronic human hepatitis B virus (I-IBV) infection is still missing and HBV remains the first etiological agent of liver cancer. Although the viral regulatory X protein is essential for infection, its mode of action remains obscure, due the lark of an in vitro infection system. In the accompanying study, we showed the functional importance of interaction between X and the host protein UVDDB-p127, in the transactivation and apoptotic properties of the viral protein, Here, we addressed the biological role of X-UVDDB interaction in the infectious process using a genetic approach in the woodchuck virus closely related to HBV. We show that (i) mutations in X, which markedly affect UVDDB-binding, also abolished productive infection in woodchucks, (ii) in the few cases where mutant viruses led to infection, compensatory mutations had occurred in the X gene of the viral progeny, which restored correct UVDDB-binding. We conclude that efficient viral replication in vivo requires proper X-UVDDB interaction. The interaction may thus provide a novel therapeutic target for the treatment of hepatitis B.	Inst Pasteur, Unite Recombinais & Express Genet, INSERM, U163, F-75724 Paris 15, France; Cornell Univ, Coll Vet Med, Dept Clin Sci, Vet Med Ctr C2 005, Ithaca, NY 14853 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Cornell University	Transy, C (corresponding author), Inst Pasteur, Unite Recombinais & Express Genet, INSERM, U163, 28 Rue Dr Roux, F-75724 Paris 15, France.							BEASLEY RP, 1981, LANCET, V2, P1129; Bergametti F, 1999, ONCOGENE, V18, P2860, DOI 10.1038/sj.onc.1202643; BLUM HE, 1992, J VIROL, V66, P1223, DOI 10.1128/JVI.66.2.1223-1227.1992; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Fourel G, 1996, J VIROL, V70, P8571, DOI 10.1128/JVI.70.12.8571-8583.1996; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GIRONES R, 1989, P NATL ACAD SCI USA, V86, P1846, DOI 10.1073/pnas.86.6.1846; Ho S, 1996, CLIN IMMUNOL IMMUNOP, V80, pS40, DOI 10.1006/clin.1996.0140; Kane MA, 1998, VACCINE, V16, pS104, DOI 10.1016/S0264-410X(98)00308-9; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Krogsgaard K, 1998, J VIRAL HEPATITIS, V5, P389, DOI 10.1046/j.1365-2893.1998.00118.x; Kumar V, 1996, P NATL ACAD SCI USA, V93, P5647, DOI 10.1073/pnas.93.11.5647; Nassal M, 1996, J VIRAL HEPATITIS, V3, P217, DOI 10.1111/j.1365-2893.1996.tb00047.x; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; SCHODEL F, 1989, ADV VIRAL ONCOL, V8, P73; Sitterlin D, 2000, ONCOGENE, V19, P4417, DOI 10.1038/sj.onc.1203771; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Wei Y, 1998, J VIROL, V72, P6608, DOI 10.1128/JVI.72.8.6608-6613.1998; Zoulim F, 1998, J HEPATOL, V29, P151, DOI 10.1016/S0168-8278(98)80191-8; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	21	57	60	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4427	4431		10.1038/sj.onc.1203770	http://dx.doi.org/10.1038/sj.onc.1203770			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980618				2022-12-25	WOS:000089271900013
J	Deshpande, SS; Angkeow, P; Kuang, JP; Ozaki, M; Irani, K				Deshpande, SS; Angkeow, P; Kuang, JP; Ozaki, M; Irani, K			Rac1 inhibits TNF-alpha-induced endothelial cell apoptosis: dual regulation by reactive oxygen species	FASEB JOURNAL			English	Article						apoptosis; ROS; Rac1; nuclear factor-kappa B; caspase-3	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; SMOOTH-MUSCLE CELLS; NADPH OXIDASE; NITRIC-OXIDE; SIGNAL-TRANSDUCTION; PROTEIN-SYNTHESIS; ANGIOTENSIN-II; ACTIVATION; PATHWAY	Reactive oxygen species (ROS) have been implicated as mediators of tumor necrosis factor-alpha (TNF) -induced apoptosis. In addition to leading to cell death, ROS can also promote cell growth and/or survival. We investigated these two roles of ROS in TNF-induced endothelial cell apoptosis. Human umbilical vein endothelial cells (HUVECs) stimulated with TNF produced an intracellular burst of ROS. Adenoviral-mediated gene transfer of a dominant negative form of the small GTPase Rad (Rac1N17) partially suppressed the TNF-induced oxidative burst without affecting TNF-induced mitochondrial ROS production. HUVECs were protected from TNF-induced apoptosis. Expression of Rac1N17 blocked TNF-induced activation of nuclear factor-kappa B (NF-kappa B), increased activity of caspase-3, and markedly augmented endothelial cell susceptibility to TNF-induced apoptosis. Direct inhibition of NF-kappa B through adenoviral expression of the super repressor form of inhibitor of kappa B alpha (I-kappa B S32/36A) also increased susceptibility of HUVECs to TNF-induced apoptosis. Rotenone, a mitochondrial electron transport chain inhibitor, suppressed TNF-induced mitochondrial ROS production, proteolytic cleavage of procaspase-3, and apoptosis. These findings show that Rad is an important regulator of TNF-induced ROS production in endothelial cells. Moreover, they suggest that Rad-dependent ROS, directly or indirectly, lead to protection against TNF-induced death, whereas mitochondrial-derived ROS promote TNF-induced apoptosis.	Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21205 USA	Johns Hopkins University	Irani, K (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Ross 1023,720 Rutland Ave, Baltimore, MD 21205 USA.		Ozaki, Michitaka/A-4549-2012	Irani, Kaikobad/0000-0001-9194-7387				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BELLAS RE, 1995, J CLIN INVEST, V96, P2521, DOI 10.1172/JCI118313; Bombeli T, 1997, BLOOD, V89, P2429, DOI 10.1182/blood.V89.7.2429; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Clement MV, 1996, EMBO J, V15, P216, DOI 10.1002/j.1460-2075.1996.tb00352.x; COLLINS T, 1993, LAB INVEST, V68, P499; Crawford LE, 1996, J BIOL CHEM, V271, P26863, DOI 10.1074/jbc.271.43.26863; DAVIES MJ, 1988, BRIT HEART J, V60, P459; Del Bello B, 1999, FASEB J, V13, P69; FENG L, 1995, J CLIN INVEST, V95, P1669, DOI 10.1172/JCI117842; FRIEDL HP, 1989, FASEB J, V3, P2512, DOI 10.1096/fasebj.3.13.2806779; GENG YJ, 1995, AM J PATHOL, V147, P251; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Gulbins E, 1996, J BIOL CHEM, V271, P26389, DOI 10.1074/jbc.271.42.26389; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hu XL, 1998, BLOOD, V92, P2759, DOI 10.1182/blood.V92.8.2759.420k29_2759_2765; Iimuro Y, 1998, J CLIN INVEST, V101, P1541; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Krieg RM, 1995, J URBAN TECHNOL, V3, P1; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Li DY, 1998, AM J PHYSIOL-HEART C, V275, pH568, DOI 10.1152/ajpheart.1998.275.2.H568; Li JR, 1999, J BIOL CHEM, V274, P17325, DOI 10.1074/jbc.274.24.17325; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; MATTHEWS N, 1987, IMMUNOLOGY, V62, P153; MEIER B, 1993, BIOCHEM J, V289, P481, DOI 10.1042/bj2890481; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Ozes ON, 1999, NATURE, V401, P82; POHLMAN TH, 1989, CELL IMMUNOL, V119, P41, DOI 10.1016/0008-8749(89)90222-0; POLUNOVSKY VA, 1994, EXP CELL RES, V214, P584, DOI 10.1006/excr.1994.1296; Pracyk JB, 1998, J CLIN INVEST, V102, P929, DOI 10.1172/JCI2552; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; RICHARDSON BC, 1994, EUR J IMMUNOL, V24, P2640, DOI 10.1002/eji.1830241111; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROTHE G, 1991, J IMMUNOL METHODS, V138, P133, DOI 10.1016/0022-1759(91)90074-P; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	50	199	214	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2000	14	12					1705	1714		10.1096/fj.99-0910com	http://dx.doi.org/10.1096/fj.99-0910com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973919				2022-12-25	WOS:000089212400009
J	Scanga, SE; Ruel, L; Binari, RC; Snow, B; Stambolic, V; Bouchard, D; Peters, M; Calvieri, B; Mak, TW; Woodgett, JR; Manoukian, AS				Scanga, SE; Ruel, L; Binari, RC; Snow, B; Stambolic, V; Bouchard, D; Peters, M; Calvieri, B; Mak, TW; Woodgett, JR; Manoukian, AS			The conserved PI3 ' K/PTEN/Akt signaling pathway regulates both cell size and survival in Drosophila	ONCOGENE			English	Article						Drosophila; PKB; PI3K; PTEN; cell size; cell survival	PROTEIN-KINASE B/AKT; B C-AKT; PHOSPHOINOSITIDE 3-KINASE; GROWTH; TRANSFORMATION; ACTIVATION; APOPTOSIS; DEATH	Akt (or PKB) is an oncogene involved in the regulation of cell survival. Akt is regulated by phosphatidylinositol 3-OH kinase (P13'K) signaling and has shown to be hyperactivated through the loss of the PTEN tumor suppressor. In Drosophila, insulin signaling as studied using the Drosophila IRS-4 homolog (Chico) has been shown to be a crucial regulator of cell size. We have studied Drosophila Akt (Dakt1) and have shown that it is also involved in the regulation of cell size. Furthermore me have performed genetic epistasis tests to demonstrate that in Drosophila, PI3'K, PTEN and Akt comprise a signaling cassette that is utilized during multiple stages of development. In addition, we show that this signaling cassette is also involved in the regulation of cell survival during embryogenesis. This study therefore establishes the evolutionary conservation of this signaling pathway in Drosophila.	Univ Toronto, Princess Margaret Hosp, Univ Hlth Network,Dept Med Biophys, Div Cell & Mol Biol,Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Princess Margaret Hosp, Univ Hlth Network,Dept Med Biophys, Div Expt Therapeut,Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Fac Med, Electron Microscopy Unit, Toronto, ON M5S 1A8, Canada; Amgen Res Inst, Toronto, ON M5G 2C1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto	Manoukian, AS (corresponding author), Univ Toronto, Princess Margaret Hosp, Univ Hlth Network,Dept Med Biophys, Div Cell & Mol Biol,Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.		Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797; Stambolic, Vuk/0000-0001-8853-3239				ABRAMS JM, 1993, DEVELOPMENT, V117, P29; Abrams JM, 1999, TRENDS CELL BIOL, V9, P435, DOI 10.1016/S0962-8924(99)01646-3; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; ANJELKOVIC M, 1996, P NATL ACAD SCI USA, V93, P5699; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Coffer PJ, 1998, BIOCHEM J, V335, P1; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; CULLEN CF, 1991, TISSUE CELL, V23, P29, DOI 10.1016/0040-8166(91)90064-Z; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Goberdhan DCI, 1999, GENE DEV, V13, P3244, DOI 10.1101/gad.13.24.3244; Huang H, 1999, DEVELOPMENT, V126, P5365; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Lehner CF, 1999, NAT CELL BIOL, V1, pE129, DOI 10.1038/12961; MANOUKIAN AS, 1997, MRNA FORMATION FUNCT, P361; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Staveley BE, 1998, CURR BIOL, V8, P599, DOI 10.1016/S0960-9822(98)70231-3; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; Weinkove D, 1999, CURR BIOL, V9, P1019, DOI 10.1016/S0960-9822(99)80450-3; XU T, 1994, METHOD CELL BIOL, V44, P655, DOI 10.1016/S0091-679X(08)60937-1; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087	29	149	153	10	22	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 17	2000	19	35					3971	3977		10.1038/sj.onc.1203739	http://dx.doi.org/10.1038/sj.onc.1203739			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962553				2022-12-25	WOS:000088825300002
J	Guzey, M; Takayama, S; Reed, JC				Guzey, M; Takayama, S; Reed, JC			BAG1L enhances trans-activation function of the vitamin D receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOTIC PROTEIN BAG-1; PROSTATE-CANCER CELLS; HEAT-SHOCK PROTEINS; RETINOIC ACID; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; GLUCOCORTICOID RECEPTOR; ANDROGEN RECEPTOR; DNA; GROWTH; LINES	The vitamin D receptor (VDR) is a member of the steroid/retinoid receptor superfamily of nuclear receptors that has potential tumor-suppressive functions. We show here that VDR interacts with and is regulated by BAG1L, a nuclear protein that binds heat shock 70-kDa (Hsp70) family molecular chaperones. Endogenous BAG1L can be eo-immunoprecipitated with VDR from prostate cancer cells (ALVA31; LNCaP) in a ligand-dependent manner. BAG1L, but not shorter non-nuclear isoforms of this protein (BAG1; BAG1M/Rap46), markedly enhanced, in a ligand-dependent manner, the ability of VDR to trans-activate reporter gene plasmids containing a vitamin D response element in transient transfection assays. Mutant BAG1L lacking the C-terminal Hsc70-binding domain suppressed tin a concentration-dependent fashion) VDR-mediated trans-activation of vitamin D response element-containing reporter gene plasmids, without altering levels of VDR or endogenous BAG1L protein, suggesting that it operates as a trans-dominant inhibitor of BAG1L. Gene transfer-mediated elevations in BAG1L protein levels in a prostate cancer cell line (PC3), which is moderately responsive to VDR ligands, increased the ability of natural (1 alpha ,25(OH)(2) vitamin D-3) and synthetic (1 alpha ,25-dihydroxy19-nor-22(E)-vitamin D-3) VDR ligands to induce expression of the VDR target gene, p21(Waf1), and suppress DNA synthesis. Thus, BAG1L is a direct regulator of VDR, which enhances its trans-activation function and improves tumor cell responses to growth-suppressive VDR ligands.	Burnham Inst, La Jolla, CA 92037 USA; RIGEB, MAM TUBITAK, TR-41470 Kocaeli, Turkey	Sanford Burnham Prebys Medical Discovery Institute; Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)	Reed, JC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		güzey, meral/AAW-4124-2020					Agadir A, 1999, CARCINOGENESIS, V20, P577, DOI 10.1093/carcin/20.4.577; Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; Cohen Michael B., 2000, American Journal of Pathology, V156, P355, DOI 10.1016/S0002-9440(10)64737-2; DAME MC, 1986, BIOCHEMISTRY-US, V25, P4523, DOI 10.1021/bi00364a011; Darwish HM, 1996, PROG NUCLEIC ACID RE, V53, P321, DOI 10.1016/S0079-6603(08)60149-X; DELUCA HF, 1988, FASEB J, V2, P224, DOI 10.1096/fasebj.2.3.3280376; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Feldman D, 1997, VITAMIN D, P3; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GLASS CK, 2000, INTRO MOL CELLULAR R, P83; Graumann K, 2000, BIOCHEM J, V345, P627, DOI 10.1042/0264-6021:3450627; Gross C., 1997, Vitamin D., P1125; Guzey M, 1997, RES COMMUN MOL PATH, V98, P3; Hedlund TE, 1999, PROSTATE, V41, P154; KOSHIYAMA M, 1995, J CLIN ENDOCR METAB, V80, P1106, DOI 10.1210/jc.80.4.1106; Kullmann M, 1998, J BIOL CHEM, V273, P14620, DOI 10.1074/jbc.273.23.14620; LANDEL CC, 1994, MOL ENDOCRINOL, V8, P1407, DOI 10.1210/me.8.10.1407; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Leeuwen J. P. T. M. van, 1997, Vitamin D., P1089; Liu R, 1998, J BIOL CHEM, V273, P16985, DOI 10.1074/jbc.273.27.16985; Luders J, 2000, J BIOL CHEM, V275, P4613, DOI 10.1074/jbc.275.7.4613; Ly LH, 1999, ENDOCRINOLOGY, V140, P2071, DOI 10.1210/en.140.5.2071; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; PERLMAN KL, 1990, TETRAHEDRON LETT, V31, P1823, DOI 10.1016/S0040-4039(00)98795-1; Prost S, 1998, FEBS LETT, V425, P499, DOI 10.1016/S0014-5793(98)00296-8; Rochel N, 2000, MOL CELL, V5, P173, DOI 10.1016/S1097-2765(00)80413-X; SCHRADER M, 1993, J BIOL CHEM, V268, P17830; SILBERSTEIN GB, 1987, SCIENCE, V237, P291, DOI 10.1126/science.3474783; SRINIVASAN G, 1994, MOL ENDOCRINOL, V8, P189, DOI 10.1210/me.8.2.189; Stuart JK, 1998, J BIOL CHEM, V273, P22506, DOI 10.1074/jbc.273.35.22506; Takayama S, 1996, GENOMICS, V35, P494, DOI 10.1006/geno.1996.0389; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Takayama S, 1998, CANCER RES, V58, P3116; WU Q, 1997, EMBO J, V16, P1658; Zeiner M, 1999, P NATL ACAD SCI USA, V96, P10194, DOI 10.1073/pnas.96.18.10194; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483; Zhao XY, 1999, ENDOCRINOLOGY, V140, P1205, DOI 10.1210/en.140.3.1205	38	44	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40749	40756		10.1074/jbc.M004977200	http://dx.doi.org/10.1074/jbc.M004977200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10967105	hybrid			2022-12-25	WOS:000166114600014
J	Hsu, HY; Twu, YC				Hsu, HY; Twu, YC			Tumor necrosis factor-alpha-mediated protein kinases in regulation of scavenger receptor and foam cell formation on macrophage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; SIGNAL-TRANSDUCTION PATHWAYS; SMOOTH-MUSCLE CELLS; FACTOR-KAPPA-B; TNF-RECEPTOR; TRANSCRIPTIONAL ACTIVATION; ATHEROSCLEROTIC LESIONS; OXIDATIVE STRESS; JNK ACTIVATION; IN-VITRO	We previously reported tumor necrosis factor-cr (TNF) modulates transcriptional and post-transcriptional down-regulation of macrophage scavenger receptor (MSR) (Hsu, H. Y., Nicholson, A. C., and Hajjar, D. P. (1996) J. Biol. Chem. 271, 7767-7773); however, TNF-mediated signaling mechanisms are unknown. Here, we demonstrate that ligation of TNF receptor stimulates activity of pal-activated protein kinase (PAK and mitogen-activated protein kinases (MAPK) as follows: ERK, JNK, and p38 in murine macrophage J774A.1 cells. Upon activation of protein kinases (PK), TNF rapidly increases MSR message and protein; later it markedly reduces MSR expression. Studies using PK inhibitors and dominant negative constructs demonstrate phosphatidylinositol 3-kinase/Rac1/PAK/JNK and phosphatidylinositol 3-kinase/Rac1/PAK/p38 pathways contribute to important roles in the late stage of TNF down-regulation of MSR expression and taking up of OxLDL. Alternatively, the PKC/MEK1/ERK pathway in the early stage plays a significant role in up-regulation of the MSR gene. By using anti-TNF-R1 agonist antibody, we further confirm TNF-R1-mediated MAPK in regulation of MSR. Furthermore, in MSR gene promoter-driven luciferase reporter assays with TNF, PKC activator increases, but antioxidant N-acetylcysteine, PK inhibitors, and dominant negative constructs decrease luciferase activity in MSR gene promoter-transfected cells. Our current results show the first evidence of crucial roles for TMF-mediated MAPK pathways in the transcriptional regulation of MSR gene and increase MSR expression; in contrast, with TNF longer treatment the pathways down-regulate MSR and foam cell formation probably via post-transcriptional process.	Natl Yang Ming Univ, Inst Biotechnol Med, Fac Med Technol, Taipei 112, Taiwan; Mackay Mem Hosp, Dept Med Res, Transfus Med Lab, Taipei 251, Taiwan	National Yang Ming Chiao Tung University; Mackay Memorial Hospital	Hsu, HY (corresponding author), Natl Yang Ming Univ, Inst Biotechnol Med, Fac Med Technol, 115 Li Nong St, Taipei 112, Taiwan.	hyhsu@ym.edu.tw						AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BASU SK, 1977, J CELL BIOL, V74, P119, DOI 10.1083/jcb.74.1.119; Bazzoni F, 1996, NEW ENGL J MED, V334, P1717, DOI 10.1056/NEJM199606273342607; Benigni F, 1996, J IMMUNOL, V157, P5563; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; Chan ED, 1999, J IMMUNOL, V162, P415; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; Fitzgerald ML, 2000, J IMMUNOL, V164, P2692, DOI 10.4049/jimmunol.164.5.2692; GENG YJ, 1995, ARTERIOSCL THROM VAS, V15, P1995, DOI 10.1161/01.ATV.15.11.1995; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Goebeler M, 1999, BLOOD, V93, P857, DOI 10.1182/blood.V93.3.857.403k03_857_865; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GONG QQ, 1995, J BIOL CHEM, V270, P21672, DOI 10.1074/jbc.270.37.21672; GOWN AM, 1986, AM J PATHOL, V125, P191; Han JH, 1998, AM J PATHOL, V152, P1647; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hsu HY, 1998, J BIOL CHEM, V273, P1240, DOI 10.1074/jbc.273.2.1240; Hsu HY, 1996, J BIOL CHEM, V271, P7767, DOI 10.1074/jbc.271.13.7767; HSU HY, 1994, J BIOL CHEM, V269, P9213; Huh HY, 1996, BLOOD, V87, P2020; JONASSON L, 1986, ARTERIOSCLEROSIS, V6, P131, DOI 10.1161/01.ATV.6.2.131; Jovinge S, 1996, ARTERIOSCL THROM VAS, V16, P1573, DOI 10.1161/01.ATV.16.12.1573; KAKAR SS, 1994, CANCER LETT, V87, P85, DOI 10.1016/0304-3835(94)90413-8; Kanaly ST, 1999, J IMMUNOL, V163, P3883; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KRONKE M, 1990, CELL SIGNAL, V2, P1, DOI 10.1016/0898-6568(90)90027-8; KULL FC, 1985, P NATL ACAD SCI USA, V82, P5756, DOI 10.1073/pnas.82.17.5756; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LI HM, 1995, J CLIN INVEST, V95, P122, DOI 10.1172/JCI117628; Li YS, 1996, MOL CELL BIOL, V16, P5947; Lin JK, 1997, J CELL BIOCHEM, P39; Liu RY, 1999, J BIOL CHEM, V274, P13877, DOI 10.1074/jbc.274.20.13877; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; Mietus-Snyder M, 1998, ARTERIOSCL THROM VAS, V18, P1440, DOI 10.1161/01.ATV.18.9.1440; MietusSnyder M, 1997, ARTERIOSCL THROM VAS, V17, P969, DOI 10.1161/01.ATV.17.5.969; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; MOULTON KS, 1992, P NATL ACAD SCI USA, V89, P8102, DOI 10.1073/pnas.89.17.8102; MUNRO JM, 1988, LAB INVEST, V58, P249; NAITO M, 1992, AM J PATHOL, V141, P591; Natoli G, 1997, J BIOL CHEM, V272, P26079, DOI 10.1074/jbc.272.42.26079; Nishimura N, 1998, J BIOL CHEM, V273, P1562, DOI 10.1074/jbc.273.3.1562; NUNNARI JJ, 1989, EXP MOL PATHOL, V51, P1, DOI 10.1016/0014-4800(89)90002-6; OKADA T, 1994, J BIOL CHEM, V269, P3563; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Peppelenbosch M, 1999, J IMMUNOL, V162, P837; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; Peschon JJ, 1998, J IMMUNOL, V160, P943; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Sakaguchi H, 1998, LAB INVEST, V78, P423; Schreyer SA, 1996, J BIOL CHEM, V271, P26174, DOI 10.1074/jbc.271.42.26174; SHINOHARA C, 1993, BIOCHIM BIOPHYS ACTA, V1167, P303, DOI 10.1016/0005-2760(93)90233-Y; Steinberg D, 1999, JAMA-J AM MED ASSOC, V282, P2043, DOI 10.1001/jama.282.21.2043; STEINBERG D, 1989, CIRCULATION, V80, P719, DOI 10.1161/01.CIR.80.3.719; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; Teupser D, 1999, ATHEROSCLEROSIS, V144, P109, DOI 10.1016/S0021-9150(99)00040-4; TIPPING PG, 1993, AM J PATHOL, V142, P1721; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; VANLENTEN BJ, 1985, J IMMUNOL, V134, P3718; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	75	52	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41035	41048		10.1074/jbc.M003464200	http://dx.doi.org/10.1074/jbc.M003464200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10969071	hybrid			2022-12-25	WOS:000166114600052
J	Lake, MW; Temple, CA; Rajagopalan, KV; Schindelin, H				Lake, MW; Temple, CA; Rajagopalan, KV; Schindelin, H			The crystal structure of the Escherichia coli MobA protein provides insight into molybdopterin guanine dinucleotide biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIMETHYL-SULFOXIDE REDUCTASE; MOLYBDENUM COFACTOR BIOSYNTHESIS; ANGSTROM RESOLUTION; FERREDOXIN OXIDOREDUCTASE; RHODOBACTER-CAPSULATUS; NITRATE REDUCTASE; DMSO REDUCTASE; DEHYDROGENASE; REFINEMENT; PRODUCT	The molybdenum cofactor (Moco) is found in a variety of enzymes present in all phyla and comprises a family of related molecules containing molybdopterin (MPT), a tricyclic pyranopterin with a cis-dithiolene group, as the invariant essential moiety, MPT biosynthesis involves a conserved pathway, but some organisms perform additional reactions that modify MPT. In eubacteria, the cofactor is often present in a dinucleotide form combining MPT and a purine or pyrimidine nucleotide via a pyrophosphate linkage. In Escherichia coli, the MobA protein links a guanosine 5'-phosphate to MPT forming molybdopterin guanine dinucleotide. This reaction requires GTP, MgCl2,, and the MPT form of the cofactor and can efficiently reconstitute Rhodobacter sphaeroides apo-DMSOR, an enzyme that requires molybdopterin guanine dinucleotide for activity. In this paper, we present the crystal structure of MobA, a protein containing 194 amino acids. The MobA monomer has an alpha/beta architecture in which the N-terminal half of the molecule adopts a Rossman fold. The structure of MobA has striking similarity to Bacillus subtilis SpsA, a nucleotide-diphospho-sugar transferase involved in sporulation, The cocrystal structure of MobA and GTP reveals that the GTP-binding site is located in the N-terminal half of the molecule. Conserved residues located primarily in three signature sequence motifs form crucial interactions with the bound nucleotide, The binding site for MPT is located adjacent to the GTP-binding site in the C-terminal half of the molecule, which contains another set of conserved residues presumably involved in MPT binding.	SUNY Stony Brook, Dept Biochem, Stony Brook, NY 11794 USA; SUNY Stony Brook, Ctr Struct Biol, Stony Brook, NY 11794 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Duke University	Schindelin, H (corresponding author), SUNY Stony Brook, Dept Biochem, Stony Brook, NY 11794 USA.	hermann.schindelin@sunysb.edu	Schindelin, Hermann/Q-2697-2019		NIDDK NIH HHS [DK54835] Funding Source: Medline; NIGMS NIH HHS [GM00091] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054835] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Boyington JC, 1997, SCIENCE, V275, P1305, DOI 10.1126/science.275.5304.1305; CHAN MK, 1995, SCIENCE, V267, P1463, DOI 10.1126/science.7878465; Charnock SJ, 1999, BIOCHEMISTRY-US, V38, P6380, DOI 10.1021/bi990270y; Christopher JA, 1998, J MOL GRAPH MODEL, V16, P285; Czjzek M, 1998, J MOL BIOL, V284, P435, DOI 10.1006/jmbi.1998.2156; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dias JM, 1999, STRUCTURE, V7, P65, DOI 10.1016/S0969-2126(99)80010-0; Dobbek H, 1999, P NATL ACAD SCI USA, V96, P8884, DOI 10.1073/pnas.96.16.8884; Eaves DJ, 1997, EUR J BIOCHEM, V246, P690, DOI 10.1111/j.1432-1033.1997.t01-1-00690.x; Hanzelmann P, 1998, EUR J BIOCHEM, V255, P755, DOI 10.1046/j.1432-1327.1998.2550755.x; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Hu YL, 1999, J MOL BIOL, V286, P899, DOI 10.1006/jmbi.1998.2488; HUNT JB, 1985, ANAL BIOCHEM, V146, P150, DOI 10.1016/0003-2697(85)90409-9; HUTCHINSON EG, 1994, PROTEIN SCI, V3, P2207, DOI 10.1002/pro.5560031206; JOHNSON JL, 1991, J BIOL CHEM, V266, P12140; JOHNSON JL, 1990, P NATL ACAD SCI USA, V87, P3190, DOI 10.1073/pnas.87.8.3190; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kisker C, 1997, ANNU REV BIOCHEM, V66, P233, DOI 10.1146/annurev.biochem.66.1.233; Kisker C, 1997, CELL, V91, P973, DOI 10.1016/S0092-8674(00)80488-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li HK, 2000, J AM CHEM SOC, V122, P7673, DOI 10.1021/ja000643e; MASUI H, 1994, J BACTERIOL, V176, P1624, DOI 10.1128/jb.176.6.1624-1629.1994; McAlpine AS, 1997, J BIOL INORG CHEM, V2, P690, DOI 10.1007/s007750050185; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MEYER O, 1993, MOLYBDENUM ENZYMES C; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Palmer T, 1996, MOL MICROBIOL, V20, P875, DOI 10.1111/j.1365-2958.1996.tb02525.x; PALMER T, 1994, EUR J BIOCHEM, V222, P687, DOI 10.1111/j.1432-1033.1994.tb18913.x; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; Rajagopalan KV, 1997, BIOCHEM SOC T, V25, P757, DOI 10.1042/bst0250757; Rajagopalan KV, 1996, ESCHERICHIA COLI SAL, P674; RAJAGOPALAN KV, 1991, ADV ENZYMOL RAMB, V64, P215; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; ROTHERY RA, 1995, J BACTERIOL, V177, P2057, DOI 10.1128/jb.177.8.2057-2063.1995; Rothery RA, 1998, J BIOL CHEM, V273, P7462, DOI 10.1074/jbc.273.13.7462; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schindelin H, 1996, SCIENCE, V272, P1615, DOI 10.1126/science.272.5268.1615; Schneider F, 1996, J MOL BIOL, V263, P53, DOI 10.1006/jmbi.1996.0555; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; Temple CA, 2000, J BIOL CHEM, V275, P40202, DOI 10.1074/jbc.M007407200; Vetter IR, 1999, Q REV BIOPHYS, V32, P1, DOI 10.1017/S0033583599003480	48	63	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40211	40217		10.1074/jbc.M007406200	http://dx.doi.org/10.1074/jbc.M007406200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10978347	hybrid			2022-12-25	WOS:000166039500058
J	Ravindranath, RMH; Tam, WY; Nguyen, P; Fincham, AG				Ravindranath, RMH; Tam, WY; Nguyen, P; Fincham, AG			The enamel protein amelogenin binds to the N-acetyl-D-glucosamine-mimicking peptide motif of cytokeratins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; MATRIX PROTEINS; DNA-SEQUENCE; BOVINE; CONSERVATION; EXPRESSION; CLEAVAGE; CDNA; RAT	Amelogenins bind to GlcNAc of the dentine-enamel matrix proteins (Ravindranath, R. M. H., Moradian-Oldak, J., Fincham, A. G. (1999) J. Biol Chem, 274, 2464-2471). The hypothesis that amelogenins may interact with the peptides that mimic GlcNAc is tested. GlcNAc-mimicking peptide (SFGSGFGGGY) but not its variants with single amino acid substitution at serine, tyrosine, or phenylalanine residues inhibited hemagglutination of amelogenins and the terminal, tyrosine-rich amelogenin polypeptide (TRAP). The binding affinity of SFGSGFGGGY to amelogenins was confirmed by dosimetric binding of amelogenins or TRAP with [H-3]peptide, specific binding in varying concentrations of the peptide, Scatchard plot analysis, and competitive inhibition with the unlabeled peptide. The ability of the peptide or GlcNAc to stoichiometrically inhibit TRAP binding of [C-14]GlcNAc or [H-3]peptide indicated that both the peptide and GlcNAc compete for a single binding site. Using different fragments of amelogenins, we have identified the peptide-binding motif in amelogenin to be the same as the GlcNAc-binding "amelogenin trityrosyl motif peptide." The GlcNAc-mimicking peptide failed to bind to the amelogenin trityrosyl moth peptide when the tyrosyl residues were substituted with phenylalanine or when the third proline was replaced with threonine, as in some cases of human X-linked amelogenesis imperfecta. This study documents that molecular mimicry may play a role in stability and organization of amelogenin during amelogenesis.	Univ So Calif, Sch Dent, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA	University of Southern California	Ravindranath, RMH (corresponding author), Univ So Calif, Sch Dent, Ctr Craniofacial Mol Biol, 2250 Alcazar St, Los Angeles, CA 90033 USA.	rravindr@hsc.usc.edu			NIDCR NIH HHS [DE-03660] Funding Source: Medline	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AKITA H, 1992, ARCH ORAL BIOL, V37, P953, DOI 10.1016/0003-9969(92)90067-I; BONA CA, 1992, MOL IMMUNOBIOLOGY SE, P239; BONASS WA, 1994, BIOCHEM BIOPH RES CO, V198, P755, DOI 10.1006/bbrc.1994.1109; Collier PM, 1997, ARCH ORAL BIOL, V42, P235, DOI 10.1016/S0003-9969(96)00099-4; CUNNINGHAM MW, 1991, MICROBIAL ADHESION I, P150; Domingues MG, 2000, EUR J ORAL SCI, V108, P43, DOI 10.1034/j.1600-0722.2000.00717.x; EASTOE JE, 1979, J DENT RES, V58, P753, DOI 10.1177/00220345790580022701; EASTOE JE, 1963, ARCH ORAL BIOL, V8, P633, DOI 10.1016/0003-9969(63)90078-5; FINCHAM AG, 1995, J STRUCT BIOL, V115, P50, DOI 10.1006/jsbi.1995.1029; FINCHAM AG, 1994, J STRUCT BIOL, V112, P103, DOI 10.1006/jsbi.1994.1011; FINCHAM AG, 1981, BIOSCIENCE REP, V1, P771, DOI 10.1007/BF01114799; FINCHAM AG, 1992, INT CONGR SER, V1002, P187; FINCHAM AG, 1982, CARIES RES, V16, P64, DOI 10.1159/000260578; FINCHAM AG, 1991, ARCH ORAL BIOL, V36, P305, DOI 10.1016/0003-9969(91)90101-Y; FINCHAM AG, 1990, CALCIFIED TISSUE INT, V47, P105, DOI 10.1007/BF02555993; FINCHAM AG, 1983, BIOCHEM J, V211, P149, DOI 10.1042/bj2110149; FINCHAM AG, 1993, BIOCHEM BIOPH RES CO, V197, P248, DOI 10.1006/bbrc.1993.2468; Foisner R, 1991, CURR OPIN CELL BIOL, V3, P75, DOI 10.1016/0955-0674(91)90168-X; HANUKOGLU I, 1982, CELL, V31, P243, DOI 10.1016/0092-8674(82)90424-X; HOESS R, 1993, GENE, V128, P43, DOI 10.1016/0378-1119(93)90151-R; KASPER M, 1989, DIFFERENTIATION, V40, P207, DOI 10.1111/j.1432-0436.1989.tb00600.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU EC, 1992, BIOCHEM BIOPH RES CO, V188, P1253, DOI 10.1016/0006-291X(92)91366-X; Luo P, 2000, J BIOL CHEM, V275, P16146, DOI 10.1074/jbc.M909121199; MARCHUK D, 1984, CELL, V39, P491, DOI 10.1016/0092-8674(84)90456-2; MERRIFIELD B, 1986, SCIENCE, V232, P341, DOI 10.1126/science.3961484; OGATA C, 1987, NATURE, V328, P739, DOI 10.1038/328739a0; OLDENBURG KR, 1992, P NATL ACAD SCI USA, V89, P5393, DOI 10.1073/pnas.89.12.5393; Paine ML, 1997, J BONE MINER RES, V12, P221, DOI 10.1359/jbmr.1997.12.2.221; Ravindranath RMH, 1999, J BIOL CHEM, V274, P2464, DOI 10.1074/jbc.274.4.2464; RAVINDRANATH RMH, 1992, VIROLOGY, V188, P143, DOI 10.1016/0042-6822(92)90743-9; RAVINDRANATH RMH, 1990, J VIROL, V64, P5430, DOI 10.1128/JVI.64.11.5430-5440.1990; Robinson C, 1989, Connect Tissue Res, V22, P93; RUGG EL, 1994, GENE DEV, V8, P2563, DOI 10.1101/gad.8.21.2563; Ryu OH, 1999, J DENT RES, V78, P743, DOI 10.1177/00220345990780030601; Sasaki S, 1991, MECH PHYLOGENY MINER, P79; SCOTT JK, 1992, P NATL ACAD SCI USA, V89, P5398, DOI 10.1073/pnas.89.12.5398; SHIKHMAN AR, 1994, J IMMUNOL, V153, P5593; SIMMER JP, 1994, CALCIFIED TISSUE INT, V54, P312, DOI 10.1007/BF00295956; SNEAD ML, 1985, BIOCHEM BIOPH RES CO, V129, P812, DOI 10.1016/0006-291X(85)91964-3; Tabata MJ, 1996, ARCH ORAL BIOL, V41, P1019, DOI 10.1016/S0003-9969(96)00087-8; TAKAGI T, 1984, BIOCHEM BIOPH RES CO, V121, P592, DOI 10.1016/0006-291X(84)90223-7; Tan J, 1998, J DENT RES, V77, P1388, DOI 10.1177/00220345980770060301; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Woessner JF, 1998, CONNECT TISSUE RES, V39, P69, DOI 10.3109/03008209809023913; WRIGHT CS, 1984, J MOL BIOL, V178, P91, DOI 10.1016/0022-2836(84)90232-8; Wright John Timothy, 1992, Pediatric Dentistry, V14, P331; WRIGHT JT, 1993, ORAL SURG ORAL MED O, V76, P192, DOI 10.1016/0030-4220(93)90204-H; Wright JT, 1997, ARCH ORAL BIOL, V42, P149, DOI 10.1016/S0003-9969(96)00096-9; YAMAMOTO K, 1992, J BIOCHEM-TOKYO, V111, P436, DOI 10.1093/oxfordjournals.jbchem.a123775; ZEICHNERDAVID M, 1995, INT J DEV BIOL, V39, P69	51	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39654	39661		10.1074/jbc.M006471200	http://dx.doi.org/10.1074/jbc.M006471200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10980199	hybrid			2022-12-25	WOS:000165953100093
J	Brandon, NJ; Delmas, P; Kittler, JT; McDonald, BJ; Sieghart, W; Brown, DA; Smart, TG; Moss, SJ				Brandon, NJ; Delmas, P; Kittler, JT; McDonald, BJ; Sieghart, W; Brown, DA; Smart, TG; Moss, SJ			GABA(A) receptor phosphorylation and functional modulation in cortical neurons by a protein kinase C-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED ION CHANNELS; A RECEPTORS; INTRACELLULAR DOMAINS; SUBUNIT COMPOSITION; MICE LACKING; BETA-SUBUNIT; ACTIVATION; EXPRESSION; CURRENTS; SITES	GABA(A) receptors are critical mediators of fast synaptic inhibition in the brain, and the predominant receptor subtype in the central nervous system is believed to be a pentamer composed of alpha, beta, and gamma subunits. Previous studies on recombinant receptors have shown that protein kinase C (PRC) and PHA directly phosphorylate intracellular serine residues within the receptor beta subunit and modulate receptor function. However, the relevance of this regulation for neuronal receptors remains poorly characterized. To address this critical issue, we have studied phosphorylation and functional modulation of GABA(A) receptors in cultured cortical neurons. Here we show that the neuronal beta3 subunit is basally phosphorylated on serine residues by a PHC-dependent pathway. PKC inhibitors abolish basal phosphorylation, increasing receptor activity, whereas activators of PKC enhance beta3 phosphorylation with a concomitant decrease in receptor activity. PKA activators were shown to increase the phosphorylation of the beta3 subunit only in the presence of PKC inhibitors, We also show that the main sites of phosphorylation within the neuronal beta3 subunit are likely to include Ser-408 and Ser-409, residues that are important for the functional modulation of beta3-containing recombinant receptors, Furthermore, PHC activation did not change the total number of GABA(A) receptors in the plasma membrane, suggesting that the effects of PKC activation are on the gating or conductance of the channel. Together, these results illustrate that cell-signaling pathways that activate PKC may have profound effects on the efficacy of synaptic inhibition by directly modulating GABA(A) receptor function.	UCL, MRC, Lab Mol Cell Biol, London WC1E 6BT, England; UCL, Dept Pharmacol, London WC1E 6BT, England; UCL, Wellcome Lab Mol Pharmacol, London WC1E 6BT, England; Univ Vienna, Psychiat Clin, A-1090 Vienna, Austria; Univ London, Sch Pharm, Dept Pharmacol, London WC1N 1AX, England	University of London; University College London; University of London; University College London; University of London; University College London; University of Vienna; University of London; University College London; University of London School of Pharmacy	Moss, SJ (corresponding author), UCL, MRC, Lab Mol Cell Biol, Gower St, London WC1E 6BT, England.	steve.moss@ucl.ac.uk	Brown, David A/J-9019-2012; Sieghart, Werner/A-4877-2013; Kittler, Josef T/E-9113-2010; Kittler, Josef/N-7589-2019	Sieghart, Werner/0000-0002-0443-0302; Kittler, Josef T/0000-0002-3437-9456; Kittler, Josef/0000-0002-3437-9456; Brandon, Nicholas/0000-0002-3917-0096				BENKE D, 1994, J BIOL CHEM, V269, P27100; Bonnert TP, 1999, P NATL ACAD SCI USA, V96, P9891, DOI 10.1073/pnas.96.17.9891; Brandon NJ, 1999, J NEUROSCI, V19, P9228; BROWNING MD, 1993, NEUROCHEM RES, V18, P95, DOI 10.1007/BF00966927; BROWNING MD, 1990, P NATL ACAD SCI USA, V87, P1315, DOI 10.1073/pnas.87.4.1315; Brunig I, 1999, P NATL ACAD SCI USA, V96, P2456, DOI 10.1073/pnas.96.5.2456; Chapell R, 1998, J BIOL CHEM, V273, P32595, DOI 10.1074/jbc.273.49.32595; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; Connolly CN, 1999, J BIOL CHEM, V274, P36565, DOI 10.1074/jbc.274.51.36565; Cooper ST, 1999, J BIOL CHEM, V274, P27145, DOI 10.1074/jbc.274.38.27145; Davies PA, 1997, NATURE, V385, P820, DOI 10.1038/385820a0; Essrich C, 1998, NAT NEUROSCI, V1, P563, DOI 10.1038/2798; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARRIS RA, 1995, P NATL ACAD SCI USA, V92, P3658, DOI 10.1073/pnas.92.9.3658; Hodge CW, 1999, NAT NEUROSCI, V2, P997, DOI 10.1038/14795; Jechlinger M, 1998, J NEUROSCI, V18, P2449; Jones MV, 1997, J NEUROSCI, V17, P7626; KIRKNESS EF, 1989, BIOCHEM J, V259, P613, DOI 10.1042/bj2590613; KRISHEK BJ, 1994, NEURON, V12, P1081, DOI 10.1016/0896-6273(94)90316-6; LEIDENHEIMER NJ, 1992, MOL PHARMACOL, V41, P1116; Lin YF, 1996, MOL PHARMACOL, V50, P185; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; McDonald BJ, 1997, NEUROPHARMACOLOGY, V36, P1377, DOI 10.1016/S0028-3908(97)00111-1; McDonald BJ, 1998, NAT NEUROSCI, V1, P23, DOI 10.1038/223; MOSS SJ, 1995, NATURE, V377, P344, DOI 10.1038/377344a0; MOSS SJ, 1992, J BIOL CHEM, V267, P14470; MOSS SJ, 1992, SCIENCE, V257, P661, DOI 10.1126/science.1323140; Moss SJ, 1996, INT REV NEUROBIOL, V39, P1, DOI 10.1016/S0074-7742(08)60662-5; Nusser Z, 1999, J PHYSIOL-LONDON, V521, P421, DOI 10.1111/j.1469-7793.1999.00421.x; Poisbeau P, 1999, J NEUROSCI, V19, P674; RABOW LE, 1995, SYNAPSE, V21, P189, DOI 10.1002/syn.890210302; Smart TG, 1997, CURR OPIN NEUROBIOL, V7, P358, DOI 10.1016/S0959-4388(97)80063-3; Tretter V, 1997, J NEUROSCI, V17, P2728; VALENZUELA CF, 1995, MOL BRAIN RES, V31, P165, DOI 10.1016/0169-328X(95)00048-W; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; WISDEN W, 1992, J NEUROSCI, V12, P1040	36	153	159	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38856	38862		10.1074/jbc.M004910200	http://dx.doi.org/10.1074/jbc.M004910200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10978327	hybrid			2022-12-25	WOS:000165739800097
J	Dale, LB; Bhattacharya, M; Anborgh, PH; Murdoch, B; Bhatia, M; Nakanishi, S; Ferguson, SSG				Dale, LB; Bhattacharya, M; Anborgh, PH; Murdoch, B; Bhatia, M; Nakanishi, S; Ferguson, SSG			G protein coupled receptor kinase-mediated desensitization of metabotropic glutamate receptor 1A protects against cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; RAPID DESENSITIZATION; HORMONE RECEPTOR; PHOSPHORYLATION; RAT; GLUTAMATE-RECEPTOR-1; INTERNALIZATION; MECHANISM; MUTATIONS	Metabotropic glutamate receptors (mGluRs) constitute a unique subclass of G protein-coupled receptors (GPCRs) that bear little sequence homology to other members of the G;PCR superfamily. The mGluR subtypes that are coupled to the hydrolysis of phosphoinositide contribute to both synaptic plasticity and glutamate-mediated excitotoxicity in neurons. In the present study, the expression of mGluR1a in HEK 293 cells led to agonist-independent cell death. Since G protein-coupled receptor kinases (GRKs) desensitize a diverse variety of GPCRs, we explored whether GRKs contributed to the regulation of both constitutive and agonist-stimulated mGluR1a activity and thereby may prevent mGluR1a-mediated excitotoxicity associated with mGluR1a overactivation. We find that the co-expression of mGluR1a with GRK2 and GRK5, but not GRK4 and GRK6, reduced both constitutive and agonist-stimulated mGluR1a activity. Agonist-stimulated mGluR1a phosphorylation was enhanced by the co-expression of GRK2 and was blocked by two different GRK2 dominant-negative mutants. Furthermore, GRK2-dependent mGluR1a desensitization protected against mGluR1a-mediated cell death, at least in part by blocking mGluR1a-stimulated apoptosis. Our data indicate that as with other members of the GPCR superfamily, a member of the structurally distinct mGluR family (mGluR1a) serves as a substrate for GRK-mediated phosphorylation and that GRK-dependent "feedback" modulation of mGluR1a responsiveness protects against pathophysiological mGluR1a signaling.	John P Robarts Res Inst, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Pharmacol & Toxicol, London, ON, Canada; Univ Western Ontario, Dept Physiol, London, ON, Canada; Univ Western Ontario, Dept Microbiol & Immunol, London, ON, Canada; Kyoto Univ, Sch Med, Kyoto 606, Japan	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Kyoto University	Ferguson, SSG (corresponding author), John P Robarts Res Inst, 100 Perth Dr,POB 5015, London, ON N6A 5K8, Canada.							Ankarcrona M, 1998, PROG BRAIN RES, V116, P265, DOI 10.1016/S0079-6123(08)60442-2; ARRIZA JL, 1992, J NEUROSCI, V12, P4045; Bordi F, 1999, PROG NEUROBIOL, V59, P55, DOI 10.1016/S0301-0082(98)00095-1; Bruno V, 1998, PROG BRAIN RES, V116, P209, DOI 10.1016/S0079-6123(08)60439-2; Calabresi P, 1999, EXP NEUROL, V158, P97, DOI 10.1006/exnr.1999.7092; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; Desai MA, 1996, BRIT J PHARMACOL, V118, P1558, DOI 10.1111/j.1476-5381.1996.tb15574.x; Dicker F, 1999, P NATL ACAD SCI USA, V96, P5476, DOI 10.1073/pnas.96.10.5476; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; Gereau RW, 1998, NEURON, V20, P143, DOI 10.1016/S0896-6273(00)80442-0; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; HERRERO I, 1994, EUR J NEUROSCI, V6, P115, DOI 10.1111/j.1460-9568.1994.tb00253.x; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KONG GH, 1994, J BIOL CHEM, V269, P13084; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Loo DT, 1998, METHOD CELL BIOL, V57, P251; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; Nicoletti F, 1996, TRENDS NEUROSCI, V19, P267, DOI 10.1016/S0166-2236(96)20019-0; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; Ozawa K, 1999, J BIOL CHEM, V274, P6397, DOI 10.1074/jbc.274.10.6397; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PEI G, 1994, P NATL ACAD SCI USA, V91, P2699, DOI 10.1073/pnas.91.7.2699; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; Prezeau L, 1996, MOL PHARMACOL, V49, P422; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; REN Q, 1993, J BIOL CHEM, V268, P16483; Riedel G, 1996, TRENDS NEUROSCI, V19, P219; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SHIGEMOTO R, 1992, J COMP NEUROL, V322, P121, DOI 10.1002/cne.903220110; Thomas WG, 2000, J BIOL CHEM, V275, P2893, DOI 10.1074/jbc.275.4.2893; WATSON S, 1994, G PROTEIN LINHED REC, P131; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	39	104	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38213	38220		10.1074/jbc.M006075200	http://dx.doi.org/10.1074/jbc.M006075200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10982802	hybrid			2022-12-25	WOS:000165739800013
J	Longenecker, KL; Zhang, BL; Derewenda, U; Sheffield, PJ; Dauter, Z; Parsons, JT; Zheng, Y; Derewenda, ZS				Longenecker, KL; Zhang, BL; Derewenda, U; Sheffield, PJ; Dauter, Z; Parsons, JT; Zheng, Y; Derewenda, ZS			Structure of the BH domain from Graf and its implications for Rho GTPase recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; ACTIVATING-PROTEIN; CRYSTAL-STRUCTURE; P50RHOGAP; COMPLEX; BINDING; P190; P85	Cellular signaling by small G-proteins is down-regulated by GTPase-activating proteins (GAPs), which increase the rate of GTP hydrolysis, The GTPase regulator associated with focal adhesion kinase (Graf) exhibits GAP activity toward the RhoA and Cdc42 GTPases, but is only weakly active toward the closely related Rad. We determined the crystal structure of a 231-residue fragment of Graf (GrafGAP), a domain containing the GAP activity, at 2.4-Angstrom resolution The structure clarifies the boundaries of the functional domain and yields insight to the mechanism of substrate recognition. Modeling its interaction with substrate suggested that a favorable interaction with Glu-95 of Cdc42 (Glu-97 of RhoA) would be absent with the corresponding Ala-95 of Rad. Indeed, GrafGAP activity is diminished similar to 40-fold toward a Cdc42 E95A mutant, whereas a similar to 10-fold increase is observed for a Rad A95E mutant. The GrafGAP epitope that apparently interacts with Glu-95(Glu-97) contains Asn-225, which was recently found mutated in some myeloid leukemia patients. We conclude that position 95 of the GTPase is an important determinant for GrafGAP specificity in cellular function and tumor suppression.	Univ Virginia Hlth Syst, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA; NCI, Frederick, MD 21702 USA; Brookhaven Natl Lab, Upton, NY 11973 USA; Univ Virginia, Ctr Canc, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Tennessee System; University of Tennessee Health Science Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Energy (DOE); Brookhaven National Laboratory; University of Virginia	Derewenda, ZS (corresponding author), Univ Virginia Hlth Syst, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA.	ZSD4N@virginia.edu	Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048807] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060523] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48807] Funding Source: Medline; NIGMS NIH HHS [GM60523] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; Billuart P, 1998, NATURE, V392, P923, DOI 10.1038/31940; Borkhardt A, 2000, P NATL ACAD SCI USA, V97, P9168, DOI 10.1073/pnas.150079597; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Gamblin SJ, 1998, CURR OPIN STRUC BIOL, V8, P195, DOI 10.1016/S0959-440X(98)80038-9; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P208, DOI 10.1016/S0076-6879(97)77013-7; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li R, 1997, J BIOL CHEM, V272, P32830, DOI 10.1074/jbc.272.52.32830; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Musacchio A, 1996, P NATL ACAD SCI USA, V93, P14373, DOI 10.1073/pnas.93.25.14373; Nassar N, 1998, NAT STRUCT BIOL, V5, P1047, DOI 10.1038/4156; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Sheffield PJ, 1999, ACTA CRYSTALLOGR D, V55, P356, DOI 10.1107/S0907444998009032; Sheldrick GM, 1998, NATO ADV SCI I C-MAT, V507, P401; Taylor JM, 1999, J CELL SCI, V112, P231; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Zhang BL, 1998, BIOCHEMISTRY-US, V37, P5249, DOI 10.1021/bi9718447; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	27	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38605	38610		10.1074/jbc.M007574200	http://dx.doi.org/10.1074/jbc.M007574200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10982819	hybrid			2022-12-25	WOS:000165739800063
J	Sousa, MM; Norden, AGW; Jacobsen, C; Willnow, TE; Christensen, EI; Thakker, RV; Verroust, PJ; Moestrup, SK; Saraiva, MJ				Sousa, MM; Norden, AGW; Jacobsen, C; Willnow, TE; Christensen, EI; Thakker, RV; Verroust, PJ; Moestrup, SK; Saraiva, MJ			Evidence for the role of megalin in renal uptake of transthyretin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT PROTEINURIA; DENTS-DISEASE; RECEPTOR; BINDING; PLASMA; RETINOL; ENDOCYTOSIS; FAMILY; GP330; MICE	The kidney is a major organ for uptake of the thyroid hormone thyroxine (T-4) and its conversion to the active form, triiodothyronine. In the plasma, one of the T-4 carriers is transthyretin (TTR). In the present study we observed that TTR, the transporter of both T-4 and retinol-binding protein, binds to megalin, the multiligand receptor expressed on the luminal surface of various epithelia including the renal proximal tubules. In the kidney, megalin plays an important role in tubular uptake of macromolecules filtered through the glomerulus. To evaluate the importance of megalin for renal uptake of TTR, we performed binding/uptake assays using immortalized rat yolk sac cells with high expression levels of megalin. Radiolabeled TTR, free as well as in complex with thyroxine or retinol-binding protein, was rapidly taken up by the cells, and the uptake was strongly inhibited by a polyclonal megalin antibody and by the receptor-associated protein, a chaperone-like protein inhibiting ligand binding to megalin. In cell culture, different TTR mutations presented different levels of cell association and degradation, suggesting that the structure of TTR is important for megalin recognition. Both the apo form and the T-4-bound form were taken up by the cells. Analysis of urine from patients with Dent's disease, a renal tubular disorder that alters receptor-mediated endocytic reabsorption of proteins, identified TTR as an abundant excreted protein. Furthermore, analysis of kidney sections of megalin-deficient mice revealed no immunohistochemical TTR labeling in intracellular vesicles in the proximal tubule cells when compared with wild type control littermates. Taken together, the present data indicate that TTR represents a novel megalin Ligand of importance in the thyroid hormone homeostasis.	Univ Porto, Amyloid Unit, Inst Biol Mol & Celular, P-4150 Porto, Portugal; Univ Porto, Inst Ciencias Biomed Abel Salazar, P-4150 Porto, Portugal; Addenbrookes Hosp, Dept Clin Biochem, Cambridge CB2 2QR, England; Aarhus Univ, Dept Med Biochem, DK-8000 Aarhus C, Denmark; Aarhus Univ, Dept Cell Biol, DK-8000 Aarhus C, Denmark; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Univ Oxford, Mol Endocrinol Grp, Nuffield Dept Med, Oxford OX3 9DU, England; Hop Tenon, INSERM, U489, F-75020 Paris, France	Universidade do Porto; Universidade do Porto; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Aarhus University; Aarhus University; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Oxford; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Saraiva, MJ (corresponding author), Univ Porto, Amyloid Unit, Inst Biol Mol & Celular, Rua Campo Alegre 823, P-4150 Porto, Portugal.		Sousa, Monica/K-4367-2013; Saraiva, Maria João/K-3907-2013; Moestrup, Søren Kragh/AAD-1735-2019; Moestrup, Søren Kragh/A-1403-2014	Sousa, Monica/0000-0002-4524-2260; Saraiva, Maria João/0000-0002-3360-6899; Moestrup, Søren Kragh/0000-0003-3862-2107; Willnow, Thomas/0000-0001-9515-7921; Thakker, Rajesh/0000-0002-1438-3220				Alves IL, 1997, EUR J BIOCHEM, V249, P662, DOI 10.1111/j.1432-1033.1997.00662.x; ANDRADE C, 1952, BRAIN, V75, P408, DOI 10.1093/brain/75.3.408; Birn H, 2000, J AM SOC NEPHROL, V11, P191, DOI 10.1681/ASN.V112191; BOOMSMA F, 1991, J PHARMACOL EXP THER, V259, P551; Cheek AO, 1999, ENVIRON HEALTH PERSP, V107, P273, DOI 10.2307/3434593; CHRISTENSEN EI, 1992, J HISTOCHEM CYTOCHEM, V40, P1481, DOI 10.1177/40.10.1382088; Christensen EI, 1999, J AM SOC NEPHROL, V10, P685; Christensen EI, 1998, INT REV CYTOL, V180, P237; CHRISTENSEN EI, 1995, EUR J CELL BIOL, V66, P349; Devuyst O, 1999, HUM MOL GENET, V8, P247, DOI 10.1093/hmg/8.2.247; DIVINO CM, 1990, J BIOL CHEM, V265, P1425; EPISKOPOU V, 1993, P NATL ACAD SCI USA, V90, P2375, DOI 10.1073/pnas.90.6.2375; ERNSTROM U, 1995, FEBS LETT, V360, P177, DOI 10.1016/0014-5793(95)00095-Q; GRAY HDA, 1985, VIRCHOWS ARCH A, V406, P463, DOI 10.1007/BF00710237; Green M. H., 1994, Vitamin A in health and disease., P119; HERZ J, 1991, J BIOL CHEM, V266, P21232; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; KATO M, 1985, P NATL ACAD SCI USA, V82, P2488, DOI 10.1073/pnas.82.8.2488; Leheste JR, 1999, AM J PATHOL, V155, P1361, DOI 10.1016/S0002-9440(10)65238-8; MAKOVER A, 1989, J LIPID RES, V30, P171; MAKOVER A, 1988, J BIOL CHEM, V263, P8598; MARTONE R, 1996, J RHEUMATOL, V20, P176; Moestrup SK, 1998, J CLIN INVEST, V102, P902, DOI 10.1172/JCI3772; Moestrup SK, 1996, P NATL ACAD SCI USA, V93, P8612, DOI 10.1073/pnas.93.16.8612; Moestrup SK, 1998, J BIOL CHEM, V273, P5235, DOI 10.1074/jbc.273.9.5235; Nykjaer A, 1999, CELL, V96, P507, DOI 10.1016/S0092-8674(00)80655-8; Palha JA, 1997, AM J PHYSIOL-ENDOC M, V272, pE485, DOI 10.1152/ajpendo.1997.272.3.E485; RAZ A, 1970, J BIOL CHEM, V245, P1903; SARAIVA MJM, 1985, J CLIN INVEST, V76, P2171, DOI 10.1172/JCI112224; SARAIVA MJM, 1995, HUM MUTAT, V5, P191; SMITH TJ, 1994, BBA-GEN SUBJECTS, V1199, P76, DOI 10.1016/0304-4165(94)90099-X; Willnow TE, 1998, BIOL CHEM, V379, P1025; Willnow TE, 1996, P NATL ACAD SCI USA, V93, P8460, DOI 10.1073/pnas.93.16.8460; WRONG OM, 1994, Q J MED, V87, P473; ZHENG G, 1994, J HISTOCHEM CYTOCHEM, V42, P531, DOI 10.1177/42.4.7510321	35	94	100	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38176	38181		10.1074/jbc.M002886200	http://dx.doi.org/10.1074/jbc.M002886200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10982792	hybrid			2022-12-25	WOS:000165739800008
J	Gautier, T; Masson, D; de Barros, JPP; Athias, A; Gambert, P; Aunis, D; Metz-Boutigue, MH; Lagrost, L				Gautier, T; Masson, D; de Barros, JPP; Athias, A; Gambert, P; Aunis, D; Metz-Boutigue, MH; Lagrost, L			Human apolipoprotein C-I accounts for the ability of plasma nigh density lipoproteins to inhibit the cholesteryl ester transfer protein activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID TRANSFER; TRANSGENIC MICE; A-I; HDL; ACYLTRANSFERASE; TRIGLYCERIDE; PARTICLES; LECITHIN; HYPERLIPIDEMIA; PEPTIDES	The aim of the present study was to identify the protein that accounts for the cholesteryl ester transfer protein (CETP)-inhibitory activity that is specifically associated with human plasma high density lipoproteins (HDL). To this end, human HDL apolipoproteins were fractionated by preparative polyacrylamide gradient gel electrophoresis, and 30 distinct protein fractions with molecular masses ranging from 80 down to 2 kDa were tested for their ability to inhibit CETP activity. One single apolipoprotein fraction was able to completely inhibit CETP activity. The N-terminal sequence of the 6-kDa protein inhibitor matched the N-terminal sequence of human apoC-I, the inhibition was completely blocked by specific anti-apolipoprotein C-I antibodies, and mass spectrometry analysis confirmed the identity of the isolated inhibitor with full-length human apoC-I. Pure apoC-I was able to abolish CETP activity in a concentration-dependent manner and with a high efficiency (IC50 = 100 nmol/liter). The inhibitory potency of total delipidated HDL apolipoproteins completely disappeared after a treatment with anti-apolipoprotein C-I antibodies, and the apoC-I deprivation of native plasma HDL by immunoaffinity chromatography produced a mean 43% rise in cholesteryl ester transfer rates. The main localization of apoC-I in HDL and not in low density lipoprotein in normolipidemic plasma provides further support for the specific property of HDL in inhibiting CETP activity.	Hop Bocage, INSERM U498, Lab Biochim Lipoprot, F-21034 Dijon, France; CNRS, Ctr Neurochim, INSERM U338, Lab Biol Commun Cellulaire, F-67084 Strasbourg, France	CHU Dijon Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Lagrost, L (corresponding author), Hop Bocage, INSERM U498, Lab Biochim Lipoprot, BP1542, F-21034 Dijon, France.	laurent.lagrost@u-bourgogne.fr	MASSON, David/AAC-8896-2022; Gautier, Thomas/Q-5371-2018; Masson, David/R-6633-2019; MASSON, David/R-4557-2017; Dominique, Aunis/W-1419-2019	MASSON, David/0000-0003-1692-0699; Gautier, Thomas/0000-0003-1119-7382; MASSON, David/0000-0003-1692-0699; 				BARTER PJ, 1980, J LIPID RES, V21, P238; CHEUNG MC, 1984, J BIOL CHEM, V259, P2201; Cho KH, 1998, BBA-LIPID LIPID MET, V1391, P133, DOI 10.1016/S0005-2760(97)00197-5; Connolly DT, 1996, BBA-LIPID LIPID MET, V1304, P145, DOI 10.1016/S0005-2760(96)00115-4; Goumon Y, 1998, J BIOL CHEM, V273, P29847, DOI 10.1074/jbc.273.45.29847; Guyard-Dangremont V, 1998, COMP BIOCHEM PHYS B, V120, P517, DOI 10.1016/S0305-0491(98)10038-X; GUYARDDANGREMONT V, 1994, J LIPID RES, V35, P982; HA YC, 1982, COMP BIOCHEM PHYS B, V71, P265, DOI 10.1016/0305-0491(82)90252-8; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; IHM J, 1982, J LIPID RES, V23, P1328; JACKSON RL, 1986, METHOD ENZYMOL, V128, P288; JONAS A, 1984, J BIOL CHEM, V259, P6369; Jong MC, 1998, J CLIN INVEST, V101, P145, DOI 10.1172/JCI791; KINNUNEN PKJ, 1976, FEBS LETT, V65, P354, DOI 10.1016/0014-5793(76)80145-7; KUSHWAHA RS, 1993, J LIPID RES, V34, P1285; LAGROST L, 1994, J BIOL CHEM, V269, P3189; LAGROST L, 1994, BBA-LIPID LIPID MET, V1215, P209, DOI 10.1016/0005-2760(94)90047-7; LAGROST L, 1991, BIOCHIM BIOPHYS ACTA, V1085, P209, DOI 10.1016/0005-2760(91)90096-Z; LAGROST L, 1994, J LIPID RES, V35, P825; MALMENDIER CL, 1986, ATHEROSCLEROSIS, V62, P167, DOI 10.1016/0021-9150(86)90063-8; Masson D, 1997, J BIOL CHEM, V272, P24287, DOI 10.1074/jbc.272.39.24287; MERRIL CR, 1990, METHOD ENZYMOL, V182, P477; METZBOUTIGUE MH, 1984, EUR J BIOCHEM, V145, P659, DOI 10.1111/j.1432-1033.1984.tb08607.x; MORTON RE, 1994, J LIPID RES, V35, P836; MORTON RE, 1993, ARTERIOSCLER THROMB, V13, P1843, DOI 10.1161/01.ATV.13.12.1843; MORTON RE, 1981, J BIOL CHEM, V256, P1992; MOULIN P, 1994, J LIPID RES, V35, P793; NISHIDA HI, 1990, J BIOL CHEM, V265, P4876; NISHIDE T, 1989, J LIPID RES, V30, P149; NISHIKAWA O, 1988, J BIOCHEM, V103, P188, DOI 10.1093/oxfordjournals.jbchem.a122229; PATTNAIK NM, 1979, J BIOL CHEM, V254, P2782; POENSGEN J, 1990, BIOCHIM BIOPHYS ACTA, V1042, P188, DOI 10.1016/0005-2760(90)90006-J; SEHAYEK E, 1991, J BIOL CHEM, V266, P18259; Shachter NS, 1996, J CLIN INVEST, V98, P846, DOI 10.1172/JCI118857; SHULMAN RS, 1975, J BIOL CHEM, V250, P182; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SON YSC, 1984, BIOCHIM BIOPHYS ACTA, V795, P473; SPARKS DL, 1989, J LIPID RES, V30, P1491; STEYRER E, 1988, BIOCHIM BIOPHYS ACTA, V958, P484, DOI 10.1016/0005-2760(88)90235-4; SWANEY JB, 1994, J LIPID RES, V35, P134; TOLLEFSON JH, 1988, AM J PHYSIOL, V255, pE894, DOI 10.1152/ajpendo.1988.255.6.E894; TOURNIER JF, 1984, BIOCHIM BIOPHYS ACTA, V804, P216, DOI 10.1016/0167-4889(84)90152-6; VANREE JH, 1995, BIOCHEM J, V305, P905, DOI 10.1042/bj3050905; Wang XX, 1999, J BIOL CHEM, V274, P1814, DOI 10.1074/jbc.274.3.1814; WEISGRABER KH, 1990, J BIOL CHEM, V265, P22453; ZHONG SB, 1994, J CLIN INVEST, V94, P2457, DOI 10.1172/JCI117614	46	106	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37504	37509		10.1074/jbc.M007210200	http://dx.doi.org/10.1074/jbc.M007210200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10978346	hybrid			2022-12-25	WOS:000165618700029
J	Loo, DDF; Eskandari, S; Boorer, KJ; Sarkar, HK; Wright, EM				Loo, DDF; Eskandari, S; Boorer, KJ; Sarkar, HK; Wright, EM			Role of Cl- in electrogenic Na+-coupled cotransporters GAT1 and SGLT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRIC-ACID; GLUCOSE COTRANSPORTER; RAT-BRAIN; TRANSPORT; SODIUM; NA+/GLUCOSE; STOICHIOMETRY; CURRENTS; STATE; BIOENERGETICS	We have investigated the functional role of Cl- in the human Na+/Cl-/gamma -aminobutyric acid (GABA) and Na+/glucose cotransporters (GAT1 and SGLT1, respectively) expressed in Xenopus laevis oocytes, Substrate-evoked steady-state inward currents were examined in the presence and absence of external Cl-. Replacement of Cl- by gluconate or 2-(N-morpholino)ethanesulfonic acid decreased the apparent affinity of GAT1 and SGLT1 for Na+ and the organic substrate. In the absence of substrate, GAT1 and SGLT1 exhibited charge movements that manifested as pre-steady-state current transients. Removal of Cl- shifted the voltage dependence of charge movements to more negative potentials, with apparent affinity constants (K-0.5) for Cl- of 21 and 115 mM for SGLT1 and GAT1, respectively. The maximum charge moved and the apparent valence were not altered. GAT1 stoichiometry was determined by measuring GABA-evoked currents and the unidirectional influx of Cl-36(-), Na-22(+), or [H-3]GABA. Uptake of each GABA molecule was accompanied by inward movement of 2 positive charges, which was entirely accounted for by the influx of Naf in the presence or absence of Cl-. Thus, the GAT1 stoichiometry was 2Na(+):1GABA, However, Cl- was transported by GAT1 because the inward movement of 2 positive charges was accompanied by the influx of one Cl- ion, suggesting unidirectional influx of 2Na(+):1Cl(-):1GABA per transport cycle. Activation of forward Na+/Cl-/GABA transport evoked Cl-36(-) efflux and was blocked by the inhibitor SKF 89976A. These data suggest a Cl-/Cl- exchange mechanism during the GAT1 transport cycle. In contrast, Cl- was not transported by SGLT1. Thus, in both GAT1 and SGLT1, Cl- modulates the kinetics of cotransport by altering Na+ affinity, but does not contribute to net charge transported per transport cycle, We conclude that Cl- dependence per se is not a useful criterion to classify Na+ cotransporters.	Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Baylor College of Medicine	Loo, DDF (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Physiol, 10833 Le Conte Ave,53-317 CHS, Los Angeles, CA 90095 USA.	dloo@mednet.ucla.edu			NIDDK NIH HHS [DK19567] Funding Source: Medline; NIGMS NIH HHS [GM99004] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019567] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BORDEN LA, 1992, J BIOL CHEM, V267, P21098; CAMMACK JN, 1994, NEURON, V13, P949, DOI 10.1016/0896-6273(94)90260-7; Eskandari S, 1997, J BIOL CHEM, V272, P27230, DOI 10.1074/jbc.272.43.27230; Eskandari S, 2000, P NATL ACAD SCI USA, V97, P8641, DOI 10.1073/pnas.97.15.8641; Fairman WA, 1999, AM J PHYSIOL-RENAL, V277, pF481, DOI 10.1152/ajprenal.1999.277.4.F481; Forster I, 1998, J GEN PHYSIOL, V112, P1, DOI 10.1085/jgp.112.1.1; Forster IC, 1999, AM J PHYSIOL-RENAL, V276, pF644, DOI 10.1152/ajprenal.1999.276.4.F644; Forster IC, 1997, J MEMBRANE BIOL, V160, P9, DOI 10.1007/s002329900291; Hazama A, 1997, J MEMBRANE BIOL, V155, P175, DOI 10.1007/s002329900169; HEDIGER MA, 1989, P NATL ACAD SCI USA, V86, P5748, DOI 10.1073/pnas.86.15.5748; Hilgemann DW, 1999, J GEN PHYSIOL, V114, P459, DOI 10.1085/jgp.114.3.459; KANNER BI, 1983, BIOCHIM BIOPHYS ACTA, V726, P293, DOI 10.1016/0304-4173(83)90013-7; KATAYAMA Y, 1991, J PHYSIOL-LONDON, V443, P587, DOI 10.1113/jphysiol.1991.sp018853; KAVANAUGH MP, 1992, J BIOL CHEM, V267, P22007; KEYNAN S, 1988, BIOCHEMISTRY-US, V27, P12, DOI 10.1021/bi00401a003; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; LAM DMK, 1993, MOL BRAIN RES, V19, P227, DOI 10.1016/0169-328X(93)90032-K; LESTER HA, 1994, ANNU REV PHARMACOL, V34, P219; Li M, 2000, J GEN PHYSIOL, V115, P491, DOI 10.1085/jgp.115.4.491; Loo DDF, 1998, P NATL ACAD SCI USA, V95, P7789, DOI 10.1073/pnas.95.13.7789; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; Loo DDF, 1999, J PHYSIOL-LONDON, V518, P195, DOI 10.1111/j.1469-7793.1999.0195r.x; Lu CC, 1999, J GEN PHYSIOL, V114, P429, DOI 10.1085/jgp.114.3.429; Lu CC, 1999, J GEN PHYSIOL, V114, P445, DOI 10.1085/jgp.114.3.445; Mackenzie B, 1998, J MEMBRANE BIOL, V162, P101, DOI 10.1007/s002329900347; Mager S, 1996, J NEUROSCI, V16, P5405; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; Nelson N, 1998, J NEUROCHEM, V71, P1785; OHRUI T, 1994, AM J PHYSIOL, V266, pC1586; Okuda T, 2000, NAT NEUROSCI, V3, P120, DOI 10.1038/72059; Pajor AM, 1999, ANNU REV PHYSIOL, V61, P663, DOI 10.1146/annurev.physiol.61.1.663; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; PARENT L, 1992, J MEMBRANE BIOL, V125, P63; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; PASTUSZKO A, 1982, J BIOL CHEM, V257, P7514; RADIAN R, 1983, BIOCHEMISTRY-US, V22, P1236, DOI 10.1021/bi00274a038; Risso S, 1996, J PHYSIOL-LONDON, V490, P691, DOI 10.1113/jphysiol.1996.sp021178; Rudnick G, 1998, J BIOENERG BIOMEMBR, V30, P173, DOI 10.1023/A:1020573325823; Turk E, 1997, J MEMBRANE BIOL, V159, P1, DOI 10.1007/s002329900264; UMBACH JA, 1990, BIOPHYS J, V57, P1217, DOI 10.1016/S0006-3495(90)82640-0; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; Wright EM, 1996, CURR OPIN CELL BIOL, V8, P468, DOI 10.1016/S0955-0674(96)80022-6; ZAMPIGHI GA, 1995, J MEMBRANE BIOL, V148, P65	43	100	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37414	37422		10.1074/jbc.M007241200	http://dx.doi.org/10.1074/jbc.M007241200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10973981	hybrid			2022-12-25	WOS:000165618700016
J	Leffers, G; Rao, VB				Leffers, G; Rao, VB			Biochemical characterization of an ATPase activity associated with the large packaging subunit gp17 from bacteriophage T4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED DNA; DEFINED SYSTEM; TERMINASE; PROTEINS; INVITRO; LAMBDA; PHAGE-T4; PROHEAD; ENDONUCLEASE; MOLECULES	Double-stranded DNA-packaging in icosahedral bacteriophages is believed to be driven by a packaging "machine" constituted by the portal protein and the two packaging/terminase proteins assembled at the unique portal vertex of the empty prohead shell. Although ATP hydrolysis is evidently the principal driving force, which component of the packaging machinery functions as the translocating ATPase has not been elucidated. Evidence suggests that the large packaging subunit is a strong candidate for the translocating ATPase. We have constructed new phage T4 terminase recombinants under the control of phage T7 promoter and overexpressed the packaging/terminase proteins gp16 and gp17 in various configurations. The hexahistidine-tagged-packaging proteins were purified to near homogeneity by Ni2+-agarose chromatography and were shown to be highly active for packaging DNA in, vitro. The large packaging subunit gp17 but not the small subunit gp16 exhibited an ATPase activity. Although gp16 lacked ATPase activity, it enhanced the gp17-associated ATPase activity by >50-fold, The gp16 enhancement was specific and was due to an increased catalytic rate for ATP hydrolysis. A phosphorylated gp17 was demonstrated under conditions of low catalytic rates but not under high catalytic rates in the presence of gp16. The data are consistent with the hypothesis that a weak ATPase is transformed into a translocating ATPase of high catalytic capacity after assembly of the packaging machine.	Catholic Univ Amer, Dept Biol, Washington, DC 20064 USA	Catholic University of America	Rao, VB (corresponding author), Catholic Univ Amer, Dept Biol, Washington, DC 20064 USA.			Rao, Venigalla/0000-0002-0777-6587				Andrew SM, 1997, CURRENT PROTOCOLS IM; BHATTACHARYYA SP, 1993, VIROLOGY, V196, P34, DOI 10.1006/viro.1993.1452; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLACK LW, 1981, VIROLOGY, V113, P336, DOI 10.1016/0042-6822(81)90160-4; BLACK LW, 1978, J VIROL, V28, P643, DOI 10.1128/JVI.28.2.643-655.1978; BLACK LW, 1995, BIOESSAYS, V17, P1052; BLACK LW, 1988, BACTERIOPHAGES, V2, P321; CATALANO CE, 1995, MOL MICROBIOL, V16, P1075, DOI 10.1111/j.1365-2958.1995.tb02333.x; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; EARNSHAW WC, 1980, CELL, V21, P319, DOI 10.1016/0092-8674(80)90468-7; FEISS M, 1986, TRENDS GENET, V2, P100, DOI 10.1016/0168-9525(86)90193-9; Franklin JL, 1998, J MOL BIOL, V277, P541, DOI 10.1006/jmbi.1998.1619; Fujisawa H, 1997, GENES CELLS, V2, P537, DOI 10.1046/j.1365-2443.1997.1450343.x; Golz S, 1999, J MOL BIOL, V285, P1131, DOI 10.1006/jmbi.1998.2399; GUO PX, 1987, J MOL BIOL, V197, P229, DOI 10.1016/0022-2836(87)90121-5; HENDRIX RW, 1978, P NATL ACAD SCI USA, V75, P4779, DOI 10.1073/pnas.75.10.4779; Hwang Y, 1996, BIOCHEMISTRY-US, V35, P2796, DOI 10.1021/bi952322z; HWANG Y, 1995, VIROLOGY, V211, P367, DOI 10.1006/viro.1995.1419; Kuebler D, 1998, J MOL BIOL, V281, P803, DOI 10.1006/jmbi.1998.1952; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leffers G, 1996, J MOL BIOL, V258, P839, DOI 10.1006/jmbi.1996.0291; LEFFERS G, 1997, THESIS CATHOLIC U AM; Lin H, 1997, J BIOL CHEM, V272, P3495, DOI 10.1074/jbc.272.6.3495; Lin HC, 1998, VIROLOGY, V242, P118, DOI 10.1006/viro.1997.9019; Maniatis T., 1982, MOL CLONING LAB MANU; MANNE V, 1982, J BIOL CHEM, V257, P13223; MOORE JT, 1993, PROTEIN EXPRES PURIF, V4, P160, DOI 10.1006/prep.1993.1022; MORITA M, 1994, J MOL BIOL, V235, P248, DOI 10.1016/S0022-2836(05)80031-2; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P186, DOI 10.1016/0968-0004(87)90090-9; POWELL D, 1990, NUCLEIC ACIDS RES, V18, P4005, DOI 10.1093/nar/18.13.4005; RAO VB, 1994, ANAL BIOCHEM, V216, P1, DOI 10.1006/abio.1994.1001; RAO VB, 1988, J MOL BIOL, V200, P475, DOI 10.1016/0022-2836(88)90537-2; RAO VB, 1985, J MOL BIOL, V185, P565, DOI 10.1016/0022-2836(85)90072-5; RAO VB, 1992, GENE, V113, P25, DOI 10.1016/0378-1119(92)90666-D; SERWER P, 1988, BIOPOLYMERS, V27, P165, DOI 10.1002/bip.360270113; SHIBATA H, 1987, J MOL BIOL, V196, P845, DOI 10.1016/0022-2836(87)90409-8; Soultanas P, 1999, J MOL BIOL, V290, P137, DOI 10.1006/jmbi.1999.2873; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P61; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURNQUIST S, 1992, P NATL ACAD SCI USA, V89, P10479, DOI 10.1073/pnas.89.21.10479; VALPUESTA JM, 1994, Q REV BIOPHYS, V27, P107, DOI 10.1017/S0033583500004510; Yap NL, 1996, J MOL BIOL, V263, P539, DOI 10.1006/jmbi.1996.0597	43	81	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37127	37136		10.1074/jbc.M003357200	http://dx.doi.org/10.1074/jbc.M003357200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10967092	hybrid			2022-12-25	WOS:000165577700093
J	Lim, KB; Walker, CRB; Guo, L; Pellett, S; Shabanowitz, J; Hunt, DF; Hewlett, EL; Ludwig, A; Goebel, W; Welch, RA; Hackett, M				Lim, KB; Walker, CRB; Guo, L; Pellett, S; Shabanowitz, J; Hunt, DF; Hewlett, EL; Ludwig, A; Goebel, W; Welch, RA; Hackett, M			Escherichia coli alpha-hemolysin (HlyA) is heterogeneously acylated in vivo with 14-, 15-, and 17-carbon fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERTUSSIS ADENYLATE-CYCLASE; TARGET-CELL SPECIFICITY; CHROMOSOMAL HEMOLYSIN; BORDETELLA-PERTUSSIS; MASS-SPECTROMETRY; NUCLEOTIDE-SEQUENCE; TOXIN FUNCTION; ACTIVATION; PROHAEMOLYSIN; PEPTIDES	alpha -Hemolysin (HlyA) is a secreted protein virulence factor observed in certain uropathogenic strains of Escherichia coli. The active, mature form of HlyA is produced by posttranslational modification of the protoxin that is mediated by acyl carrier protein and an acyltransferase, HlyC. We have now shown using mass spectrometry that these modifications, when observed in protein isolated in vivo, consist of acylation at the E-amino groups of two internal lysine residues, at positions 564 and 690, with saturated 14- (68%), 15- (26%), and 17- (6%) carbon amide-linked side chains. Thus, HlyA activated in vivo consists of a heterogeneous family of up to nine different covalent structures, and the substrate specificity of the HlyC acyltransferase appears to differ from that of the closely related CyaC acyltransferase expressed by Bordetella pertussis.	Univ Washington, Dept Med Chem, Seattle, WA 98195 USA; Univ Virginia, Dept Chem, Charlottesville, VA 22901 USA; Univ Virginia, Dept Med & Pharmacol, Charlottesville, VA 22901 USA; Univ Virginia, Dept Pathol, Charlottesville, VA 22901 USA; Univ Wisconsin, Dept Med Microbiol & Immunol, Madison, WI 53706 USA; Univ Wurzburg, Lehrstuhl Mikrobiol, D-97074 Wurzburg, Germany	University of Washington; University of Washington Seattle; University of Virginia; University of Virginia; University of Virginia; University of Wisconsin System; University of Wisconsin Madison; University of Wurzburg	Hackett, M (corresponding author), Univ Washington, Dept Med Chem, Box 357610, Seattle, WA 98195 USA.	mhackett@u.washington.edu	Hunt, Donald F/I-6936-2012; Bazemore-Walker, Carthene/I-1879-2013	Hunt, Donald F/0000-0003-2815-6368; 	NIAID NIH HHS [AI18000, AI20323] Funding Source: Medline; NIDDK NIH HHS [R01 DK063250] Funding Source: Medline; NIGMS NIH HHS [GM37537] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018000, R01AI020323] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063250] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037537] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Basar T, 1999, J BIOL CHEM, V274, P10777, DOI 10.1074/jbc.274.16.10777; BETSOU F, 1993, INFECT IMMUN, V61, P3583, DOI 10.1128/IAI.61.9.3583-3589.1993; BIEMANN K, 1992, ANNU REV BIOCHEM, V61, P977, DOI 10.1146/annurev.bi.61.070192.004553; Cronan JE, 1996, ESCHERICHIA COLI SAL, V1, P612; FELMLEE T, 1985, J BACTERIOL, V163, P94, DOI 10.1128/JB.163.1.94-105.1985; FORESTIER C, 1991, INFECT IMMUN, V59, P4212, DOI 10.1128/IAI.59.11.4212-4220.1991; GULDEN PH, 1996, MASS SPECTROMETRY BI, P281; HACKETT M, 1994, SCIENCE, V266, P433, DOI 10.1126/science.7939682; HACKETT M, 1995, J BIOL CHEM, V270, P20250, DOI 10.1074/jbc.270.35.20250; HARDIE KR, 1991, MOL MICROBIOL, V5, P1669, DOI 10.1111/j.1365-2958.1991.tb01914.x; HESS J, 1986, FEMS MICROBIOL LETT, V34, P1, DOI 10.1016/0378-1097(86)90261-2; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; HUNT DF, 1991, TECHNIQUES PROTEIN C, V2, P441; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; JOSEPH M, 1995, J BIOL CHEM, V270, P16749, DOI 10.1074/jbc.270.28.16749; KENNEDY RT, 1989, ANAL CHEM, V61, P1128, DOI 10.1021/ac00185a016; KERWIN JL, 1994, ACS SYM SER, V562, P163; Lally ET, 1997, J BIOL CHEM, V272, P30463, DOI 10.1074/jbc.272.48.30463; LEPAGE G, 1986, J LIPID RES, V27, P114; Ludwig A, 1996, J BACTERIOL, V178, P5422, DOI 10.1128/jb.178.18.5422-5430.1996; Moayeri M, 1997, INFECT IMMUN, V65, P2233, DOI 10.1128/IAI.65.6.2233-2239.1997; MOSELEY MA, 1991, ANAL CHEM, V63, P1467, DOI 10.1021/ac00014a023; NEIDHARDT FC, 1996, ESCHERICHIA COLI SAL, P13; Pellett S, 1996, INFECT IMMUN, V64, P3081, DOI 10.1128/IAI.64.8.3081-3087.1996; STANLEY P, 1994, SCIENCE, V266, P1992, DOI 10.1126/science.7801126; Stanley P, 1998, MICROBIOL MOL BIOL R, V62, P309, DOI 10.1128/MMBR.62.2.309-333.1998; Swenson DL, 1996, INFECT IMMUN, V64, P3736, DOI 10.1128/IAI.64.9.3736-3743.1996; Wang HL, 1997, ANAL BIOCHEM, V250, P162, DOI 10.1006/abio.1997.2214; WELCH RA, 1983, INFECT IMMUN, V42, P178, DOI 10.1128/IAI.42.1.178-186.1983; WELCH RA, 1981, NATURE, V294, P665, DOI 10.1038/294665a0; WELCH RA, 1991, MOL MICROBIOL, V5, P521, DOI 10.1111/j.1365-2958.1991.tb00723.x; Welch RA, 1995, INFECT AGENT DIS, V4, P254	32	40	40	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36698	36702		10.1074/jbc.C000544200	http://dx.doi.org/10.1074/jbc.C000544200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10978310	hybrid			2022-12-25	WOS:000165577700036
J	Werner, F; Jain, MK; Feinberg, MW; Sibinga, NES; Pellacani, A; Wiesel, P; Chin, MT; Topper, JN; Perrella, MA; Lee, ME				Werner, F; Jain, MK; Feinberg, MW; Sibinga, NES; Pellacani, A; Wiesel, P; Chin, MT; Topper, JN; Perrella, MA; Lee, ME			Transforming growth factor-beta 1 inhibition of macrophage activation is mediated via Smad3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; TGF-BETA SUPERFAMILY; DNA-BINDING PROTEIN; SMOOTH-MUSCLE CELLS; TRANSCRIPTIONAL ACTIVATION; TARGETED DISRUPTION; INFLAMMATORY RESPONSE; RHEUMATOID-ARTHRITIS; PULMONARY FIBROSIS	Activated macrophages are critical cellular participants in inflammatory disease states. Transforming growth factor (TGF)-beta1 is a growth factor with pleiotropic effects including inhibition of immune cell activation. Although the pathway of gene activation by TGF-beta1 via Smad proteins has recently been elucidated, suppression of gene expression by TGF-beta1 remains poorly understood. We found that of Smad1-Smad7, Smad3 alone was able to inhibit expression of markers of macrophage activation (inducible nitric-oxide synthase and matrix metalloproteinase-12 following lipopolysaccharide treatment in gene reporter assays. Transient and constitutive overexpression of a dominant negative Smad3 opposed the inhibitory effect of TGF-beta1. Domain swapping experiments suggest that both the Smad MH-1 and MH-2 domains are required for inhibition. Mutation of a critical amino acid residue required for DNA binding in the MH-1 of Smad3 (R74A) resulted in the loss of inhibition. Transient overexpression of p300, an interactor of the Smad MH-2 domain, partially alleviated the inhibition by TGF-beta1/Smad3, suggesting that inhibition of gene expression may be due to increased competition for limiting amounts of this coactivator. Our results have implications for the understanding of gene suppression by TGF-beta1 and for the regulation of activated macrophages by TGF-beta1.	Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Program Dev Cardiovasc Biol, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Pulm & Crit Care, Boston, MA 02115 USA; Stanford Univ, Sch Med, Dept Med, Div Cardiovasc, Stanford, CA 94305 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Stanford University	Jain, MK (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St,Thorn 11, Boston, MA 02115 USA.		Sibinga, Nicholas/GOJ-8544-2022	Feinberg, Mark/0000-0001-9523-3859; Sibinga, Nicholas/0000-0003-4838-910X	NHLBI NIH HHS [HL03274, HL03747, HL03194] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; AUSUBEL FM, 1993, SHORT PROTOCOLS MOL; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BARNARD JA, 1990, BIOCHIM BIOPHYS ACTA, V1032, P79, DOI 10.1016/0304-419X(90)90013-Q; Biggs JR, 1999, J BIOL CHEM, V274, P36987, DOI 10.1074/jbc.274.52.36987; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; BOTTALICO LA, 1991, J BIOL CHEM, V266, P22866; BRODY AR, 1981, EXP LUNG RES, V2, P207, DOI 10.3109/01902148109052316; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Curci JA, 1998, J CLIN INVEST, V102, P1900, DOI 10.1172/JCI2182; Datto MB, 1999, MOL CELL BIOL, V19, P2495; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; ESPEVIK T, 1987, J EXP MED, V166, P571, DOI 10.1084/jem.166.2.571; Feinberg MW, 2000, J BIOL CHEM, V275, P25766, DOI 10.1074/jbc.M002664200; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; FORSTERMANN U, 1992, EUR J PHARM-MOLEC PH, V225, P161, DOI 10.1016/0922-4106(92)90096-E; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Halpert I, 1996, P NATL ACAD SCI USA, V93, P9748, DOI 10.1073/pnas.93.18.9748; HAMILTON JA, 1993, CELL IMMUNOL, V152, P7, DOI 10.1006/cimm.1993.1263; HARRIS ED, 1990, NEW ENGL J MED, V322, P1277, DOI 10.1056/nejm199005033221805; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kon A, 1999, ONCOGENE, V18, P1837, DOI 10.1038/sj.onc.1202495; KUHN C, 1989, AM REV RESPIR DIS, V140, P1693, DOI 10.1164/ajrccm/140.6.1693; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBBY P, 1991, LAB INVEST, V64, P5; Lukacs NW, 1996, ADV IMMUNOL, V62, P257, DOI 10.1016/S0065-2776(08)60432-0; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; PERRELLA MA, 1994, J BIOL CHEM, V269, P14595; Perrella MA, 1996, J BIOL CHEM, V271, P13776, DOI 10.1074/jbc.271.23.13776; Rich JN, 1999, J BIOL CHEM, V274, P35053, DOI 10.1074/jbc.274.49.35053; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sambrook J., 2002, MOL CLONING LAB MANU; SARLES H, 1989, ANNU REV MED, V40, P453; SATO K, 1995, J LEUKOCYTE BIOL, V57, P36, DOI 10.1002/jlb.57.1.36; SEWELL KL, 1993, LANCET, V341, P283, DOI 10.1016/0140-6736(93)92627-6; SHAPIRO SD, 1994, AM J RESP CRIT CARE, V150, pS160, DOI 10.1164/ajrccm/150.6_Pt_2.S160; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUNAWAKI S, 1988, NATURE, V334, P260, DOI 10.1038/334260a0; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	62	140	155	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36653	36658		10.1074/jbc.M004536200	http://dx.doi.org/10.1074/jbc.M004536200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973958	hybrid			2022-12-25	WOS:000165577700029
J	Matter, N; Marx, M; Weg-Remers, S; Ponta, H; Herrlich, P; Konig, H				Matter, N; Marx, M; Weg-Remers, S; Ponta, H; Herrlich, P; Konig, H			Heterogeneous ribonucleoprotein A1 is part of an exon-specific splice-silencing complex controlled by oncogenic signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; CD44 VARIANT ISOFORMS; HNRNP A/B PROTEINS; IN-VIVO; NUCLEAR RIBONUCLEOPROTEINS; PREMESSENGER RNA; SITE SELECTION; EXPRESSION; CDC42; CELL	Regulation of alternative pre-mRNA splicing, recognized as increasingly important in causing human disease, was studied using the CD44 gene, whose splice variants have been implicated in tumor progression. We identified heterogeneous ribonucleoprotein (hnRNP) Al as a protein interacting in vitro and in vivo with regulatory splice elements in CD44 variant exon v5, Transient overexpression of hnRNP Al prevented v5 exon inclusion, dependent on the exonic elements. HnRNP Al-dependent repression was exon-specific and could be relieved by coexpression of oncogenic forms of Ras and Cdc42, The results define hnRNP Al as a decisive part of an oncogene-regulated splice-silencing complex, which can select between multiple alternatively spliced exons.	Forschungszentrum Karlsruhe, Inst Toxikol & Genet, D-76021 Karlsruhe, Germany; Univ Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany	Helmholtz Association; Karlsruhe Institute of Technology; Helmholtz Association; Karlsruhe Institute of Technology	Konig, H (corresponding author), Forschungszentrum Karlsruhe, Inst Toxikol & Genet, Postfach 3640, D-76021 Karlsruhe, Germany.			Konig, Harald/0000-0002-0117-0939				Adams MD, 1996, CURR OPIN CELL BIOL, V8, P331, DOI 10.1016/S0955-0674(96)80006-8; ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; Bai YD, 1999, NUCLEIC ACIDS RES, V27, P1126, DOI 10.1093/nar/27.4.1126; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BENDAVID Y, 1992, MOL CELL BIOL, V12, P4449, DOI 10.1128/MCB.12.10.4449; Blanchette M, 1999, EMBO J, V18, P1939, DOI 10.1093/emboj/18.7.1939; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; COOPER DL, 1995, NAT MED, V1, P635, DOI 10.1038/nm0795-635; Cooper TA, 1997, AM J HUM GENET, V61, P259, DOI 10.1086/514856; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Del Gatto-Konczak F, 1999, MOL CELL BIOL, V19, P251; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FU XD, 1995, RNA, V1, P663; Ghigna C, 1998, CANCER RES, V58, P5818; Hanamura A, 1998, RNA, V4, P430; Herrlich P, 1998, CELL ADHES COMMUN, V6, P141, DOI 10.3109/15419069809004470; HOROWITZ DS, 1994, TRENDS GENET, V10, P100, DOI 10.1016/0168-9525(94)90233-X; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; KAMMA H, 1995, EXP CELL RES, V221, P187, DOI 10.1006/excr.1995.1366; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Konig H, 1996, EMBO J, V15, P4030, DOI 10.1002/j.1460-2075.1996.tb00776.x; Konig H, 1998, EMBO J, V17, P2904, DOI 10.1093/emboj/17.10.2904; KOOPMAN G, 1993, J EXP MED, V177, P897, DOI 10.1084/jem.177.4.897; KRAWCZAK M, 1992, HUM GENET, V90, P41; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lin CLG, 1998, NEURON, V20, P589, DOI 10.1016/S0896-6273(00)80997-6; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; MACKAY CR, 1994, J CELL BIOL, V124, P71, DOI 10.1083/jcb.124.1.71; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MAYEDA A, 1993, MOL CELL BIOL, V13, P2993, DOI 10.1128/MCB.13.5.2993; MAYEDA A, 1994, EMBO J, V13, P5483, DOI 10.1002/j.1460-2075.1994.tb06883.x; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Moore M., 1993, RNA WORLD, P303; MUNICIO MM, 1995, J BIOL CHEM, V270, P15884, DOI 10.1074/jbc.270.26.15884; Philips AV, 1998, SCIENCE, V280, P737, DOI 10.1126/science.280.5364.737; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; RIO DC, 1993, CURR OPIN GENET DEV, V3, P574, DOI 10.1016/0959-437X(93)90093-5; ROTH MB, 1990, J CELL BIOL, V111, P2217, DOI 10.1083/jcb.111.6.2217; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; Sherman L, 1996, CURR TOP MICROBIOL, V213, P249; Stam JC, 1998, EMBO J, V17, P4066, DOI 10.1093/emboj/17.14.4066; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; Wang J, 1997, CURR OPIN GENET DEV, V7, P205, DOI 10.1016/S0959-437X(97)80130-X; Weighardt F, 1996, BIOESSAYS, V18, P747, DOI 10.1002/bies.950180910; Weiss JM, 1997, J CELL BIOL, V137, P1137, DOI 10.1083/jcb.137.5.1137; Wu WJ, 1998, J BIOL CHEM, V273, P16655, DOI 10.1074/jbc.273.27.16655; XU RS, 1993, MOL CELL BIOL, V13, P3660, DOI 10.1128/MCB.13.6.3660; YANG XM, 1994, P NATL ACAD SCI USA, V91, P6924, DOI 10.1073/pnas.91.15.6924	56	84	87	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35353	35360		10.1074/jbc.M004692200	http://dx.doi.org/10.1074/jbc.M004692200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10958793	hybrid			2022-12-25	WOS:000165422800070
J	Bartoli, M; Gu, XL; Tsai, NT; Venema, RC; Brooks, SE; Marrero, MB; Caldwell, RB				Bartoli, M; Gu, XL; Tsai, NT; Venema, RC; Brooks, SE; Marrero, MB; Caldwell, RB			Vascular endothelial growth factor activates STAT proteins in aortic endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; SMOOTH-MUSCLE CELLS; II AT(1) RECEPTOR; SIGNAL-TRANSDUCTION; TRANSCRIPTION FACTOR; NUCLEAR TRANSLOCATION; NITRIC-OXIDE; FACTOR VEGF; PATHWAY; PHOSPHORYLATION	Vascular endothelial growth factor (VEGF) intracellular signaling in endothelial cells is initiated by the activation of distinct tyrosine kinase receptors, VEGFR1 (Flt-1) and VEGFR2 (Flk-1/KDR). Because the tyrosine kinase-dependent transcription factors known as STAT (signal transducers and activators of transcription) proteins are important modulators of cell growth responses induced by other growth factor receptors, we have determined the effects VEGF of on STAT activation in BAEC (bovine aortic endothelial cells). Here, we show that VEGF induces tyrosine phosphorylation and nuclear translocation of STAT1 and STAT6. VEGF also stimulates STAT3 tyrosine phosphorylation, but nuclear translocation does not occur. We found that placenta growth factor, which selectively activates VEGFR1, has no effect on the STATs. However, upon VEGF stimulation, STAT1 associates with the VEGFR2 in a tyrosine kinase-dependent manner, indicating that VEGF-induced STAT1 activation is mediated primarily by VEGFR2. Thus, our study shows for the first time that VEGF activates the STAT pathway through VEGFR2. Because the growth-promoting activity of VEGF depends upon VEGFR2 activation, these findings suggest a role for the STATs in the regulation of gene expression associated with the angiogenic effects of VEGF.	Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA; Med Coll Georgia, Dept Anat & Cellular Biol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pediat, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Ophthalmol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University	Caldwell, RB (corresponding author), Med Coll Georgia, Vasc Biol Ctr, 1120 15 St, Augusta, GA 30912 USA.			Caldwell, Ruth/0000-0003-0168-0354	NEI NIH HHS [EY11766, EY04618] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011766, R01EY004618] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ali MS, 1997, J BIOL CHEM, V272, P23382, DOI 10.1074/jbc.272.37.23382; Behzadian MA, 1995, GLIA, V15, P480, DOI 10.1002/glia.440150411; Decker T, 1999, CELL MOL LIFE SCI, V55, P1535, DOI 10.1007/s000180050393; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dumler I, 1999, ARTERIOSCL THROM VAS, V19, P290, DOI 10.1161/01.ATV.19.2.290; Feng YY, 1999, BIOCHEM BIOPH RES CO, V256, P192, DOI 10.1006/bbrc.1998.9790; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Ferrara N, 1999, KIDNEY INT, V56, P794, DOI 10.1046/j.1523-1755.1999.00610.x; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Frank DA, 1999, NAT MED, V5, P444, DOI 10.1038/7445; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; Johnson HM, 1998, BIOCHEM BIOPH RES CO, V244, P607, DOI 10.1006/bbrc.1998.8254; Korpelainen EI, 1999, ONCOGENE, V18, P1, DOI 10.1038/sj.onc.1202288; Landgren E, 1998, ONCOGENE, V16, P359, DOI 10.1038/sj.onc.1201545; LAWRENCE M, 1997, SCIENCE, V276, P1418; Levy DE, 1999, CELL MOL LIFE SCI, V55, P1559, DOI 10.1007/s000180050395; Liang HY, 1999, J BIOL CHEM, V274, P19846, DOI 10.1074/jbc.274.28.19846; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Marrero MB, 1997, J BIOL CHEM, V272, P24684, DOI 10.1074/jbc.272.39.24684; Mui ALF, 1999, CELL MOL LIFE SCI, V55, P1547, DOI 10.1007/s000180050394; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Ortega Nathalie, 1999, Frontiers in Bioscience, V4, pD141, DOI 10.2741/Ortega; Park OK, 1996, P NATL ACAD SCI USA, V93, P13704, DOI 10.1073/pnas.93.24.13704; Patel BKR, 1996, J BIOL CHEM, V271, P22175, DOI 10.1074/jbc.271.36.22175; Paukku K, 2000, BIOCHEM J, V345, P759, DOI 10.1042/0264-6021:3450759; Schindler C, 1999, CELL MOL LIFE SCI, V55, P1509, DOI 10.1007/s000180050391; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEETHARAM L, 1995, ONCOGENE, V10, P135; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Struman I, 1999, P NATL ACAD SCI USA, V96, P1246, DOI 10.1073/pnas.96.4.1246; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; Yamamoto H, 1996, EXP CELL RES, V222, P125, DOI 10.1006/excr.1996.0016; Yeh TC, 1999, CELL MOL LIFE SCI, V55, P1523, DOI 10.1007/s000180050392	41	121	126	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33189	33192		10.1074/jbc.C000318200	http://dx.doi.org/10.1074/jbc.C000318200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10961983	hybrid			2022-12-25	WOS:000090104600002
J	Lonart, G; Sudhof, TC				Lonart, G; Sudhof, TC			Assembly of SNARE core complexes prior to neurotransmitter release sets the readily releasable pool of synaptic vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; METABOTROPIC GLUTAMATE RECEPTORS; MEMBRANE-FUSION; HIPPOCAMPAL SYNAPSES; IN-VITRO; TRANSMISSION; EXOCYTOSIS; DOCKING; SIZE; PHOSPHORYLATION	Precise regulation of neurotransmitter release is essential for the normal function of neural networks, but the mechanisms involved are largely unclear. Using superfused synaptosomes, we have studied the readily releasable pool of synaptic vesicles, measured as the amount of release triggered by hypertonic sucrose, We show that activation of presynaptic metabotropic glutamate receptors by dihydroxyphenylglycine and stimulation of protein kinase C by phorbol esters enhance the readily releasable pool of glutamate, Although the molecular nature of the readily releasable pool is unknown, one possibility is that during its generation, SNARE proteins form full core complexes, and that core complex formation occurs prior to neurotransmitter release. To test this possibility, we employed N-ethylmaleimide (NEM), an inhibitor of the ATPase N-ethylmaleimide-sensitive factor that dissociates core complexes, to study the relation of the readily releasable pool to core complex assembly in synaptosomes. NEM induced a dose-dependent increase in the readily releasable pool of neurotransmitters but by itself did not trigger release. Direct measurements of core complexes confirmed that NEM caused an increase in the levels of SNARE core complexes under these conditions. Our data suggest that in the readily releasable pool of synaptic vesicles, SNARE proteins are fully assembled into core complexes, and that SNARE complex assembly is a target of presynaptic regulation.	Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Ctr Basic Neurosci, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	Tsudho@mednet.swmed.edu			NIMH NIH HHS [5K01-MH02505-02] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH002505] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Banerjee A, 1996, J BIOL CHEM, V271, P20227, DOI 10.1074/jbc.271.34.20227; BIT RA, 1993, J MED CHEM, V36, P21, DOI 10.1021/jm00053a003; Calakos N, 1996, PHYSIOL REV, V76, P1; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; de Vries KJ, 2000, EUR J NEUROSCI, V12, P385, DOI 10.1046/j.1460-9568.2000.00931.x; Dobrunz LE, 1997, NEURON, V18, P995, DOI 10.1016/S0896-6273(00)80338-4; Dobrunz LE, 1999, NEURON, V22, P157, DOI 10.1016/S0896-6273(00)80687-X; FATT P, 1952, J PHYSIOL-LONDON, V117, P109; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; Goda Y, 1998, P NATL ACAD SCI USA, V95, P1283, DOI 10.1073/pnas.95.3.1283; HAJOS F, 1975, J NEUROCHEM, V24, P1277, DOI 10.1111/j.1471-4159.1975.tb03913.x; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Herrero I, 1998, J BIOL CHEM, V273, P1951, DOI 10.1074/jbc.273.4.1951; LIU GS, 1995, NATURE, V375, P404, DOI 10.1038/375404a0; Lonart G, 1998, J NEUROSCI, V18, P634; Lonart G, 1998, NEURON, V21, P1141, DOI 10.1016/S0896-6273(00)80631-5; Montecucco C, 1995, Q REV BIOPHYS, V28, P423, DOI 10.1017/S0033583500003292; Murthy VN, 1997, NEURON, V18, P599, DOI 10.1016/S0896-6273(00)80301-3; NAGY A, 1984, J NEUROCHEM, V43, P1114, DOI 10.1111/j.1471-4159.1984.tb12851.x; Robinson LJ, 1998, CURR OPIN CELL BIOL, V10, P483, DOI 10.1016/S0955-0674(98)80063-X; Rodriguez-Moreno A, 1998, NEURON, V21, P1477, DOI 10.1016/S0896-6273(00)80665-0; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; Scanziani M, 1998, P NATL ACAD SCI USA, V95, P12004, DOI 10.1073/pnas.95.20.12004; Schneggenburger R, 1999, NEURON, V23, P399, DOI 10.1016/S0896-6273(00)80789-8; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Stevens CF, 1998, NEURON, V21, P885, DOI 10.1016/S0896-6273(00)80603-0; STEVENS CF, 1995, P NATL ACAD SCI USA, V92, P846, DOI 10.1073/pnas.92.3.846; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUDHOF TC, 1993, CELL, V75, P1; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; TERRIAN DM, 1988, BRAIN RES BULL, V21, P343, DOI 10.1016/0361-9230(88)90146-3; Turner JP, 1999, J PHYSIOL-LONDON, V519, P481, DOI 10.1111/j.1469-7793.1999.0481m.x; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; vonGersdorff H, 1997, J NEUROSCI, V17, P1919; Wang LY, 1998, NATURE, V394, P384, DOI 10.1038/28645; Whittaker VP, 1969, HDB NEUROCHEMISTRY, VII, P327, DOI DOI 10.1007/978-1-4899-7321-4_14; Wu LG, 1999, NEURON, V23, P821, DOI 10.1016/S0896-6273(01)80039-8; Xu T, 1999, CELL, V99, P713, DOI 10.1016/S0092-8674(00)81669-4; Zhang L, 1996, NEURON, V17, P287, DOI 10.1016/S0896-6273(00)80160-9	39	101	104	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27703	27707						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10970903				2022-12-25	WOS:000089197100025
J	Shimizu, S; Shinohara, Y; Tsujimoto, Y				Shimizu, S; Shinohara, Y; Tsujimoto, Y			Bax and Bcl-x(L) independently regulate apoptotic changes of yeast mitochondria that require VDAC but not adenine nucleotide translocator	ONCOGENE			English	Article						ANT; VDAC; Bax; mitochondria; yeast	PERMEABILITY TRANSITION PORE; CYTOCHROME-C RELEASE; ADP/ATP CARRIER; PROTEASE CASCADE; BCL-2; EXPRESSION; MEMBRANE; PROTEINS; CHANNEL; FAMILY	Mitochondria play an essential role in apoptosis by releasing apoptogenic molecules such as cytochrome c and AlF, and some caspases, which are all regulated by Bcl-2 family proteins. Pro-apoptotic Pas and Bah have been shown to induce cytochrome c release and loss of membrane potential (Delta psi) leading to AIF release in the isolated mitochondria. We have previously shown that Bas and Bah open the voltage-dependent anion channel (VDAC) allowing cytochrome c to pass through the channel, and Bcl-x(L) closes the channel. However, it has been reported that it is adenine nucleotide translocator (ANT) with which Bax/Bcl-x(L) interacts that modulate the channel activity. Here, we investigated the role of ANT and VDAC in the changes of isolated mitochondria triggered by Bas and by chemicals that induce permeability transition (PT), In rat and yeast mitochondria, Bas did not affect the ADP/ATP exchange activity of ANT. VDAC-deficient but not ANT-deficient feast mitochondria showed resistance to cytochrome c release, Delta psi loss, and swelling caused by Bas and PT inducers. Bcl-x(L) showed similar inhibition of all these changes in ANT-deficient and wild type yeast mitochondria, Furthermore, Bas induces cytochrome c release in wild type yeast cells but not VDAC1-deficient yeast cells. These data indicate that VDAC, but not ANT, is essential for apoptotic mitochondrial changes. The data also indicate that Bcl-xL acid Bas possess an ability to regulate mitochondrial membrane permeability independently of other Bcl-2 family members.	Osaka Univ, Grad Sch Med, Biomed Res Ctr, Dept Med Genet, Osaka 5650871, Japan; Univ Tokushima, Fac Pharmaceut Sci, Tokushima 7708505, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci, Osaka, Japan	Osaka University; Tokushima University; Japan Science & Technology Agency (JST)	Tsujimoto, Y (corresponding author), Osaka Univ, Grad Sch Med, Biomed Res Ctr, Dept Med Genet, 2-2 Yamadaoka, Osaka 5650871, Japan.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BLANCHLYDYSON E, 1997, MOL CELL BIOL, V17, P5727; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; COLOMBINI M, 1989, J MEMBRANE BIOL, V111, P103, DOI 10.1007/BF01871775; DAUM G, 1982, J BIOL CHEM, V257, P3028; DRGON T, 1992, FEBS LETT, V304, P277, DOI 10.1016/0014-5793(92)80637-V; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Greenhalf W, 1996, FEBS LETT, V380, P169, DOI 10.1016/0014-5793(96)00044-0; Gross A, 2000, MOL CELL BIOL, V20, P3125, DOI 10.1128/MCB.20.9.3125-3136.2000; Harris MH, 2000, MOL CELL BIOL, V20, P3590, DOI 10.1128/MCB.20.10.3590-3596.2000; Hashimoto M, 1999, BBA-BIOENERGETICS, V1409, P113, DOI 10.1016/S0005-2728(98)00155-8; Jung DW, 1997, J BIOL CHEM, V272, P21104, DOI 10.1074/jbc.272.34.21104; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; KAWAGOE K, 1994, GENOMICS, V23, P566, DOI 10.1006/geno.1994.1544; KLINGENBERG M, 1994, BBA-BIOENERGETICS, V1187, P241, DOI 10.1016/0005-2728(94)90119-8; Lee AC, 1998, J MEMBRANE BIOL, V161, P173, DOI 10.1007/s002329900324; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; NELSON DR, 1993, J MOL BIOL, V230, P1159, DOI 10.1006/jmbi.1993.1233; Nouraini S, 2000, MOL CELL BIOL, V20, P1604, DOI 10.1128/MCB.20.5.1604-1615.2000; Priault M, 1999, FEBS LETT, V456, P232, DOI 10.1016/S0014-5793(99)00957-6; Priault M, 1999, EUR J BIOCHEM, V260, P684, DOI 10.1046/j.1432-1327.1999.00198.x; Roucou X, 2000, FEBS LETT, V471, P235, DOI 10.1016/S0014-5793(00)01404-6; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; Shimizu S, 1996, ONCOGENE, V12, P2251; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	39	134	143	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4309	4318		10.1038/sj.onc.1203788	http://dx.doi.org/10.1038/sj.onc.1203788			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980606				2022-12-25	WOS:000089271900001
J	Zainal, TA; Oberley, TD; Allison, DB; Szweda, LI; Weindruch, R				Zainal, TA; Oberley, TD; Allison, DB; Szweda, LI; Weindruch, R			Caloric restriction of rhesus monkeys lowers oxidative damage in skeletal muscle	FASEB JOURNAL			English	Article						aging; free radicals; immunogold; lipid peroxidation; reactive oxygen species; sarcopenia	PROTEIN-TURNOVER; DIETARY RESTRICTION; SARCOPLASMIC-RETICULUM; TYROSINE NITRATION; SERCA2A ISOFORM; NITRIC-OXIDE; CA-ATPASE; RAT; GROWTH; ANTIOXIDANT	In laboratory rodents, caloric restriction (CR) retards several age-dependent physiological and biochemical changes in skeletal muscle, including increased steady-state levels of oxidative damage to lipids, DNA, and proteins. We used immunogold electron microscopic (EM) techniques with antibodies raised against 4-hydroxy-2-nonenal (HNE) -modified proteins, dinitrophenol, and nitrotyrosine to quantify and localize the age-dependent accrual of oxidative damage in rhesus monkey vastus lateralis skeletal muscle, Using immunogold EM analysis of muscle from rhesus monkeys ranging in age from 2 to 34 years old, a fourfold maximal increase in levels of HNE-modified proteins was observed. Likewise, carbonyl levels increased twofold with aging, Comparing 17- to 23-year-old normally fed to age-matched monkeys subjected to CR for 10 years, levels of HNE-modified proteins, carbonyls, and nitrotyrosine in skeletal muscle from the CR group were significantly less than control group values. Oxidative damage largely localized to myofibrils, with lesser labeling in other subcellular compartments. Accumulation of lipid peroxidation-derived aldehydes, such as malondialdehyde and 4-hydroxy-2-alkenals, and protein carbonyls were measured biochemically and confirmed the morphological data. Our study is the first to quantify morphologically and localize the age-dependent accrual of oxidative damage in mammalian skeletal muscle and to demonstrate that oxidative damage in primates is lowered by CR.	William S Middleton Mem Vet Hosp, Pathol & Lab Med Serv, Madison, WI 53705 USA; William S Middleton Mem Vet Hosp, Ctr Geriatr Res Educ & Clin, Madison, WI 53705 USA; Univ Wisconsin, Dept Nutr Sci, Madison, WI 53705 USA; Univ Wisconsin, Dept Lab Med & Pathol, Madison, WI 53705 USA; Univ Wisconsin, Dept Med, Madison, WI 53705 USA; Univ Wisconsin, Wisconsin Reg Primate Res Ctr, Madison, WI 53705 USA; Columbia Univ Coll Phys & Surg, St Lukes Roosevelt Hosp, Obes Res Ctr, New York, NY 10032 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Columbia University; Mount Sinai St. Luke's; Mount Sinai West; Case Western Reserve University	Oberley, TD (corresponding author), William S Middleton Mem Vet Hosp, Pathol & Lab Med Serv, 2500 Overlook Terrace,Room A35, Madison, WI 53705 USA.			Allison, David/0000-0003-3566-9399				Aspnes LE, 1997, FASEB J, V11, P573, DOI 10.1096/fasebj.11.7.9212081; Balagopal P, 1997, AM J PHYSIOL-ENDOC M, V273, pE790, DOI 10.1152/ajpendo.1997.273.4.E790; BATES PC, 1983, BIOCHEM J, V214, P587, DOI 10.1042/bj2140587; Chambon-Savanovitch C, 1999, EUR J CLIN INVEST, V29, P504, DOI 10.1046/j.1365-2362.1999.00469.x; Dutta C, 1997, J NUTR, V127, pS992, DOI 10.1093/jn/127.5.992S; ELHAJ AJ, 1986, COMP BIOCHEM PHYS A, V85, P281, DOI 10.1016/0300-9629(86)90251-3; Felgines C, 1999, JPEN-PARENTER ENTER, V23, P32, DOI 10.1177/014860719902300132; Ferrington DA, 1998, J BIOL CHEM, V273, P5885, DOI 10.1074/jbc.273.10.5885; Fruhbeck G, 1996, J PHYSIOL BIOCHEM, V52, P207; GOLDSPINK DF, 1987, EXP GERONTOL, V22, P67, DOI 10.1016/0531-5565(87)90016-7; GOLDSPINK DF, 1986, CARDIOVASC RES, V20, P672, DOI 10.1093/cvr/20.9.672; Gorsuch R., 1983, FACTOR ANAL; HOLLOSZY JO, 1995, J GERONTOL A-BIOL, V50, P1; INGRAM DK, 1990, J GERONTOL, V45, P148; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; JI LL, 1990, AM J PHYSIOL, V258, pR918, DOI 10.1152/ajpregu.1990.258.4.R918; KELLY FJ, 1984, MUSCLE NERVE, V7, P235, DOI 10.1002/mus.880070309; KEMNITZ JW, 1993, J GERONTOL, V48, pB17, DOI 10.1093/geronj/48.1.B17; KEMNITZ JW, 1994, AM J PHYSIOL, V266, pE540, DOI 10.1152/ajpendo.1994.266.4.E540; Lass A, 1998, FREE RADICAL BIO MED, V25, P1089, DOI 10.1016/S0891-5849(98)00144-0; LAWLER JM, 1993, AM J PHYSIOL, V265, pR1344, DOI 10.1152/ajpregu.1993.265.6.R1344; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Leeuwenburgh C, 1997, ARCH BIOCHEM BIOPHYS, V346, P74, DOI 10.1006/abbi.1997.0297; LEEUWENBURGH C, 1994, AM J PHYSIOL, V267, pR439, DOI 10.1152/ajpregu.1994.267.2.R439; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; LEWIS SEM, 1985, EXP GERONTOL, V20, P253, DOI 10.1016/0531-5565(85)90050-6; LEWIS SEM, 1984, BIOCHEM J, V217, P517, DOI 10.1042/bj2170517; Marechal G, 1999, CELL MOL LIFE SCI, V55, P1088, DOI 10.1007/s000180050359; Mecocci P, 1999, FREE RADICAL BIO MED, V26, P303, DOI 10.1016/S0891-5849(98)00208-1; Millward DJ, 1997, AM J CLIN NUTR, V66, P774, DOI 10.1093/ajcn/66.4.774; Pansarasa O, 1999, FREE RADICAL BIO MED, V27, P617, DOI 10.1016/S0891-5849(99)00108-2; PURI ML, 1969, ANN MATH STAT, V40, P1325, DOI 10.1214/aoms/1177697505; Reid MB, 1998, ACTA PHYSIOL SCAND, V162, P401, DOI 10.1046/j.1365-201X.1998.0303f.x; Smith K, 1996, BAILLIERE CLIN ENDOC, V10, P469, DOI 10.1016/S0950-351X(96)80651-3; Smith MA, 1998, J HISTOCHEM CYTOCHEM, V46, P731, DOI 10.1177/002215549804600605; Smith MA, 1996, NATURE, V382, P120, DOI 10.1038/382120b0; SOHAL RS, 1994, MECH AGEING DEV, V74, P121, DOI 10.1016/0047-6374(94)90104-X; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; SOHAL RS, 1994, MECH AGEING DEV, V76, P215, DOI 10.1016/0047-6374(94)91595-4; STARNES JW, 1989, J APPL PHYSIOL, V67, P69, DOI 10.1152/jappl.1989.67.1.69; Toothaker LE, 1991, MULTIPLE COMP RES; UAUY R, 1978, J GERONTOL, V33, P663, DOI 10.1093/geronj/33.5.663; UCHIDA K, 1993, P NATL ACAD SCI USA, V90, P8742, DOI 10.1073/pnas.90.18.8742; Uchida K, 1995, ARCH BIOCHEM BIOPHYS, V324, P241, DOI 10.1006/abbi.1995.0036; Viera L, 1999, METHOD ENZYMOL, V301, P373; Viner RI, 1997, BBA-BIOMEMBRANES, V1329, P321, DOI 10.1016/S0005-2736(97)00125-9; Viner RI, 1996, FEBS LETT, V379, P286, DOI 10.1016/0014-5793(95)01530-2; Viner RI, 1999, BIOCHEM J, V340, P657, DOI 10.1042/0264-6021:3400657; Waterlow J. C., 1978, PROTEIN TURNOVER MAM; WEINDRUCH R, 1995, J GERONTOL A-BIOL, V50, P157; WEINDRUCH R, 1988, RETARDATION AGING DI; WELLE S, 1993, AM J PHYSIOL, V264, pE693, DOI 10.1152/ajpendo.1993.264.5.E693; YARASHESKI KE, 1993, AM J PHYSIOL, V265, pE210, DOI 10.1152/ajpendo.1993.265.2.E210; Ye YZ, 1996, METHOD ENZYMOL, V269, P201; Yu BP, 1996, FREE RADICAL BIO MED, V21, P651, DOI 10.1016/0891-5849(96)00162-1; Zainal TA, 1999, FREE RADICAL BIO MED, V26, P1181, DOI 10.1016/S0891-5849(98)00312-8	56	159	169	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2000	14	12					1825	1836		10.1096/fj.99-0881com	http://dx.doi.org/10.1096/fj.99-0881com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973932				2022-12-25	WOS:000089212400022
J	Koga, H; Deppert, W				Koga, H; Deppert, W			Identification of genomic DNA sequences bound by mutant p53 protein (Gly(245)-> Ser) in vivo	ONCOGENE			English	Article						mutant p53; CHIP; PCR-EMSA; microinjection; repetitive DNA elements	CROSS-LINKING; BINDING; TRANSCRIPTION; ELEMENTS; GENE; MUTATIONS; REGIONS; COMPLEX; MURINE	Mutant p53 proteins were shown to exert complex DNA-interactions interactions in vitro, like binding to MAR-DNA, but so far it is unknown whether such interactions also occur in vivo. Therefore we analysed the binding of mutant (mut) p53 (Gly(245)-->Ser) in Onda 11 glioma cells to cellular DNA in vivo, using p53-specific chromatin immunoprecipitation (CHIP) after in vivo cross-linking of mut p53 to genomic DNA with cisplatin, We identified genomic DNA fragments to which mut p53 (Gly(245)-->Ser) could be cross-linked in vivo. Purified recombinant mut p53 (Gly(245)-->Ser) was able to bind specifically to such elements in PCR-EMSA in vitro, supporting the idea that this mut p53 protein interacts with genomic DNA in vivo. The genomic DNA fragments identified are vastly different in sequence, but display as a common feature a high likelihood to adopt a non B-DNA conformation. Therefore we propose that structural determinants within these DNA elements are important for their interaction with mut p53 (Gly(245)-->Ser) in vivo.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Deppert, W (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.							Beroud C, 1998, NUCLEIC ACIDS RES, V26, P200, DOI 10.1093/nar/26.1.200; Bode J, 1996, CRIT REV EUKAR GENE, V6, P115, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.20; Bode J, 1995, INT REV CYTOL, V162A, P389; Boulikas T, 1995, INT REV CYTOL, V162A, P279; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Chesnokov I, 1996, MOL CELL BIOL, V16, P7084; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Deppert W, 1996, J CELL BIOCHEM, V62, P172, DOI 10.1002/(SICI)1097-4644(199608)62:2<172::AID-JCB5>3.0.CO;2-P; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FLOROS J, 1995, BIOCHEM J, V305, P583, DOI 10.1042/bj3050583; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; Hart CM, 1998, CURR OPIN GENET DEV, V8, P519, DOI 10.1016/S0959-437X(98)80005-1; HERNANDEZBOUSSA.T, 1999, IARC SCI PUBL, V146, P43; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kim E, 1997, ONCOGENE, V15, P857, DOI 10.1038/sj.onc.1201412; Koga H, 1996, Noshuyo Byori, V13, P1; LEMAIRE MA, 1991, P NATL ACAD SCI USA, V88, P1982, DOI 10.1073/pnas.88.5.1982; Levine AJ, 1995, ANN NY ACAD SCI, V768, P111, DOI 10.1111/j.1749-6632.1995.tb12115.x; Muller BF, 1996, ONCOGENE, V12, P1941; Murphy TD, 1998, CELL, V93, P317, DOI 10.1016/S0092-8674(00)81158-7; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Roemer K, 1999, BIOL CHEM, V380, P879, DOI 10.1515/BC.1999.108; Samuel SK, 1998, CANCER RES, V58, P3004; Shimajiri S, 1999, FEBS LETT, V455, P70, DOI 10.1016/S0014-5793(99)00863-7; TRIPATHI J, 1991, J BIOMOL STRUCT DYN, V9, P387, DOI 10.1080/07391102.1991.10507919; WEISSKER SN, 1992, ONCOGENE, V7, P1921; Will K, 1998, J CELL BIOCHEM, V69, P260, DOI 10.1002/(SICI)1097-4644(19980601)69:3<260::AID-JCB4>3.0.CO;2-P; Will K, 1998, P NATL ACAD SCI USA, V95, P13681, DOI 10.1073/pnas.95.23.13681; Zhang SJ, 1996, JPN J CANCER RES, V87, P900, DOI 10.1111/j.1349-7006.1996.tb02118.x	31	30	30	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2000	19	36					4178	4183		10.1038/sj.onc.1203745	http://dx.doi.org/10.1038/sj.onc.1203745			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962580	Bronze			2022-12-25	WOS:000088955100013
J	Xu, Y; Gurusiddappa, S; Rich, RL; Owens, RT; Keene, DR; Mayne, R; Hook, A; Hook, M				Xu, Y; Gurusiddappa, S; Rich, RL; Owens, RT; Keene, DR; Mayne, R; Hook, A; Hook, M			Multiple binding sites in collagen type I for the integrins alpha(1)beta(1) and alpha(2)beta(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; A-DOMAIN; ALPHA-2-BETA-1 VLA-2; PLATELET-ADHESION; IDENTIFICATION; SEQUENCE; SUBUNIT; INTEGRIN-ALPHA-2-BETA-1; ALPHA-1-BETA-1; SPECIFICITY	Integrins alpha (1)beta (1) and alpha (2)beta (1) are two major collagen receptors on the surface of eukaryotic cells. Binding to collagen is primarily due to an A-domain near the N terminus of the alpha chains. Previously, we reported that recombinant A-domain of alpha (1)beta (1) (alpha (1)A) had at least two affinity classes of binding sites in type I collagen (Rich, R. L., ct al. (1999) J. Biol. Chem. 274, 24906-24913), Here, we compared the binding of the recombinant A-domain of alpha (2)beta (1) (alpha (2)A) to type I collagen with that of alpha (1)A using surface plasmon resonance and showed that alpha (2)A exhibited only one detectable class of binding sites in type I collagen, with a K-D of similar to 10 muM at similar to3 binding sites per collagen molecule. We further demonstrated that alpha (1)A and alpha (2)A competed with each other for binding to type I collagen in enzyme-linked immunosorbent assay (ELISA), suggesting that the binding sites in collagen for the two A-domains overlap or are adjacent to each other. By using rotary shadowing, the complexes of alpha (1)A- and alpha (2)A-procollagen were visualized. Morphometric analyses indicated three major binding regions (near the N terminus, in the central part, and near the C terminus) along the type I procollagen molecule for both A-domains. The positions of the respective binding regions for alpha (1)A and alpha (2)A were overlapping with or adjacent to each other, consistent with the ELISA results. Analysis of the sequences of type I collagen revealed that GER or GER-like motifs are present at each of the binding regions, and notably, the central region contains the GFOGER sequence, which was previously identified as a high affinity site for both alpha (1)A and alpha (2)A (Knight, C. G., ct al. (2000) J. Biol. Chem. 275, 35-40). Peptides containing GLOGERGRO (peptide I, near the N terminus), GFOGERGVQ (peptide II, central), and GASGERGPO (peptide III, near the C terminus) were synthesized. Peptides I and II effectively inhibited the binding of cli,A and alpha (2)A to type I collagen, while peptide III did so moderately, The N-terminal site in type I collagen has the sequence GLOGER in all three chains. Thus, it seems that peptide I represents a newly discovered native high affinity site for alpha (1)A and alpha (2)A.	Texas A&M Univ, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA; Shriners Hosp Children, Portland, OR 97201 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA	Texas A&M University System; University of Alabama System; University of Alabama Birmingham	Hook, M (corresponding author), Texas A&M Univ, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044415, R01AR030481, R37AR030481] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR30481, AR44415] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BIEKOWSKA J, 1997, J BIOL CHEM, V272, P25162; BRODSKY B, 1992, BIOPOLYMERS, V32, P447, DOI 10.1002/bip.360320423; Calderwood DA, 1997, J BIOL CHEM, V272, P12311, DOI 10.1074/jbc.272.19.12311; Camper L, 1998, J BIOL CHEM, V273, P20383, DOI 10.1074/jbc.273.32.20383; Dickeson SK, 1998, CELL MOL LIFE SCI, V54, P556, DOI 10.1007/s000180050184; Dickeson SK, 1999, J BIOL CHEM, V274, P32182, DOI 10.1074/jbc.274.45.32182; Dickeson SK, 1997, J BIOL CHEM, V272, P7661, DOI 10.1074/jbc.272.12.7661; EBLE JA, 1993, EMBO J, V12, P4795, DOI 10.1002/j.1460-2075.1993.tb06168.x; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; FIELDS C G, 1991, Peptide Research, V4, P95; Golbik R, 2000, J MOL BIOL, V297, P501, DOI 10.1006/jmbi.2000.3575; GULLBERG D, 1992, EMBO J, V11, P3865, DOI 10.1002/j.1460-2075.1992.tb05479.x; HIGHBERGER JH, 1982, BIOCHEMISTRY-US, V21, P2048, DOI 10.1021/bi00538a011; Humphries MJ, 2000, TRENDS PHARMACOL SCI, V21, P29, DOI 10.1016/S0165-6147(99)01410-8; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; Kamata T, 1999, J BIOL CHEM, V274, P32108, DOI 10.1074/jbc.274.45.32108; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; Kapyla J, 2000, J BIOL CHEM, V275, P3348, DOI 10.1074/jbc.275.5.3348; Kern A, 1998, J CELL PHYSIOL, V176, P634, DOI 10.1002/(SICI)1097-4652(199809)176:3<634::AID-JCP20>3.3.CO;2-J; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Knight CG, 1998, J BIOL CHEM, V273, P33287, DOI 10.1074/jbc.273.50.33287; KRAMER RH, 1989, J BIOL CHEM, V264, P4684; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Li R, 1998, J CELL BIOL, V143, P1523, DOI 10.1083/jcb.143.6.1523; Loftus JC, 1997, J CLIN INVEST, V99, P2302, DOI 10.1172/JCI119408; Messent AJ, 1998, J CELL SCI, V111, P1127; MORRIS NP, 1986, J BIOL CHEM, V261, P5638; MORTON LF, 1994, BIOCHEM J, V299, P791, DOI 10.1042/bj2990791; Nolte M, 1999, FEBS LETT, V452, P379, DOI 10.1016/S0014-5793(99)00666-3; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; Rich RL, 1999, J BIOL CHEM, V274, P26939, DOI 10.1074/jbc.274.38.26939; Rich RL, 1999, J BIOL CHEM, V274, P24906, DOI 10.1074/jbc.274.35.24906; Rich RL, 1998, BIOCHEMISTRY-US, V37, P15423, DOI 10.1021/bi981773r; SAELMAN EUM, 1993, BLOOD, V82, P3029; SARANTAKIS D, 1976, BIOCHEM BIOPH RES CO, V73, P336, DOI 10.1016/0006-291X(76)90712-9; Smith C, 2000, J BIOL CHEM, V275, P4205, DOI 10.1074/jbc.275.6.4205; SWASDISON S, 1992, MATRIX, V12, P56, DOI 10.1016/S0934-8832(11)80105-8; Symersky J, 1997, NAT STRUCT BIOL, V4, P833, DOI 10.1038/nsb1097-833; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TUCKWELL D, 1995, J CELL SCI, V108, P1629; Velling T, 1999, J BIOL CHEM, V274, P25735, DOI 10.1074/jbc.274.36.25735; VISAI L, 2000, IN PRESS J BIOL CHEM, V275	48	204	212	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					38981	38989		10.1074/jbc.M007668200	http://dx.doi.org/10.1074/jbc.M007668200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10986291	hybrid			2022-12-25	WOS:000165953100007
J	Chen, DX; Stetler, RA; Cao, GD; Pei, W; O'Horo, C; Yin, XM; Chen, J				Chen, DX; Stetler, RA; Cao, GD; Pei, W; O'Horo, C; Yin, XM; Chen, J			Characterization of the rat DNA fragmentation factor 35/inhibitor of caspase-activated DNase (short form) - The endogenous inhibitor of caspase-dependent DNA fragmentation in neuronal apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; CHROMATIN CONDENSATION; NEURODEGENERATIVE DISEASES; PROTEASES; NUCLEASE; FAMILY; INDUCTION; ISCHEMIA; EXTRACTS; PROTEIN	Nuclear changes, including internucleosomal DNA fragmentation, are classical manifestations of apoptosis for which the biochemical mechanisms have not been fully elucidated, particularly in neuronal cells. We have cloned the rat DNA fragmentation factor 35/inhibitor of caspase-activated DNase (short form) (DFF35/ICAD(S)) and found it to be the predominant form of ICAD present in rodent brain cells as well as in many other types of cells. DFF35/ICAD(S) forms a functional complex with DFF40/caspase-activated DNase (CAD) in the nucleus, and when its caspase-resistant mutant is over-expressed, it inhibits the nuclease activity, internucleosomal DNA fragmentation and nuclear fragmentation but not the shrinkage and condensation of the nucleus, in neuron-differentiated PC12 cells in response to apoptosis inducers. DFF40/CAD is found to be localized mainly in the nucleus, and during neuronal apoptosis, there is no evidence of further nuclear translocation of this molecule. It is further suggested that inactivation of DFF40/CAD-bound DFF35 and subsequent activation of DFF40/CAD during apoptosis of neuronal cells may not occur in the cytosol but rather in the nucleus through a novel mechanism that requires nuclear translocation of caspases. These results establish that DFF35/ICAD(S) is the endogenous inhibitor of DFF40/CAD and caspase-dependent apoptotic DNA fragmentation in neurons.	Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Pittsburgh Inst Neurodegenerat Disorders, Pittsburgh, PA 15213 USA; Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System	Chen, J (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurol, S-506 Biomed Sci Tower, Pittsburgh, PA 15213 USA.			Chen, Jun/0000-0002-8077-3403	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS035965, R01NS036736, R01NS038560] Funding Source: NIH RePORTER; NINDS NIH HHS [NS35965, NS36736, NS38560] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; Chen J, 1998, J NEUROSCI, V18, P4914; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Gu JJ, 1999, J BIOL CHEM, V274, P20759, DOI 10.1074/jbc.274.30.20759; Hajimohamadreza I, 1997, Prog Drug Res, V48, P55; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Inohara N, 1999, J BIOL CHEM, V274, P270, DOI 10.1074/jbc.274.1.270; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1999, J BIOL CHEM, V274, P13836, DOI 10.1074/jbc.274.20.13836; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Mukae N, 1998, P NATL ACAD SCI USA, V95, P9123, DOI 10.1073/pnas.95.16.9123; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Sakahira H, 1999, J BIOL CHEM, V274, P15740, DOI 10.1074/jbc.274.22.15740; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Samejima K, 2000, EXP CELL RES, V255, P314, DOI 10.1006/excr.2000.4801; Schulz JB, 1999, ANN NEUROL, V45, P421, DOI 10.1002/1531-8249(199904)45:4<421::AID-ANA2>3.0.CO;2-Q; Wolf BB, 1999, J BIOL CHEM, V274, P30651, DOI 10.1074/jbc.274.43.30651; WOOD ER, 1990, J CELL BIOL, V111, P2839, DOI 10.1083/jcb.111.6.2839; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zamzami N, 1999, NATURE, V401, P127, DOI 10.1038/43591; Zhang JH, 1999, J BIOL CHEM, V274, P37450, DOI 10.1074/jbc.274.52.37450; Zhang JH, 1998, P NATL ACAD SCI USA, V95, P12480, DOI 10.1073/pnas.95.21.12480	33	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38508	38517		10.1074/jbc.M003906200	http://dx.doi.org/10.1074/jbc.M003906200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10984476	hybrid			2022-12-25	WOS:000165739800051
J	Kato, M; Miyazawa, K; Kitamura, N				Kato, M; Miyazawa, K; Kitamura, N			A deubiquitinating enzyme UBPY interacts with the Src homology 3 domain of Hrs-binding protein via a novel binding motif PX(V/I)(D/N)RXXKP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSDUCING ADAPTER MOLECULE; LIGAND-INDUCED POLYUBIQUITINATION; GROWTH-FACTOR RECEPTOR; ZINC-FINGER DOMAIN; SH3 DOMAINS; CELL-GROWTH; UBIQUITIN; GRB2; SIGNAL; DEGRADATION	Hrs-binding protein (Hbp) is a Src homology 3 (SH3) domain-containing protein that tightly associates with Hrs. Hbp together with Hrs is thought to play a regulatory role in endocytic trafficking of growth factor-receptor complexes through early endosomes. Association of Hbp with a binding partner(s) via the SH3 domain seems to be essential for Hbp to exert its function. In this study, we searched for Hbp-binding proteins by a far Western screening and isolated a mouse cDNA clone encoding a deubiquitinating enzyme mUBPY as an Hbp SH3-binding protein, mUBPY has two Hbp-SH3 domain binding sites. Mutagenic analysis identified a consensus sequence PX(V/I)(D/N)RXXKP as the Hbp-SH3 domain binding motif. It is a novel SH3-binding motif and does not contain the canonical proline-rich consensus binding motif, PXXP. Ubiquitination of growth factor receptors is thought to regulate their intracellular degradation. Thus, UBPY may play a regulatory role in the degradation by interaction with the SH3 domain of Hbp via the novel SH3-binding motif.	Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biol Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology	Kitamura, N (corresponding author), Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biol Sci, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.	nkitamur@bio.titech.ac.jp	MIYAZAWA, KEIJI/I-9713-2014					Amerik AY, 1997, EMBO J, V16, P4826; Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; GalchevaGargova Z, 1995, ONCOGENE, V11, P2649; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HADARI T, 1992, J BIOL CHEM, V267, P719; Hofmann K, 1998, J MOL BIOL, V282, P195, DOI 10.1006/jmbi.1998.1998; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; KOMADA M, 1995, MOL CELL BIOL, V15, P6213; Komada M, 1997, J BIOL CHEM, V272, P20538, DOI 10.1074/jbc.272.33.20538; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; MORI S, 1992, J BIOL CHEM, V267, P6429; MORI S, 1995, BIOCHEM BIOPH RES CO, V213, P32, DOI 10.1006/bbrc.1995.2094; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Naviglio S, 1998, EMBO J, V17, P3241, DOI 10.1093/emboj/17.12.3241; Okkenhaug K, 1998, J BIOL CHEM, V273, P21194, DOI 10.1074/jbc.273.33.21194; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; She HY, 1997, MOL BIOL CELL, V8, P1709, DOI 10.1091/mbc.8.9.1709; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Swaminathan S, 1999, MOL BIOL CELL, V10, P2583, DOI 10.1091/mbc.10.8.2583; Takata H, 2000, GENES CELLS, V5, P57, DOI 10.1046/j.1365-2443.2000.00303.x; Takeshita T, 1997, IMMUNITY, V6, P449, DOI 10.1016/S1074-7613(00)80288-5; Takeshita T, 1996, BIOCHEM BIOPH RES CO, V225, P1035, DOI 10.1006/bbrc.1996.1290; Tanaka N, 1999, J BIOL CHEM, V274, P19129, DOI 10.1074/jbc.274.27.19129; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543	39	183	188	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37481	37487		10.1074/jbc.M007251200	http://dx.doi.org/10.1074/jbc.M007251200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10982817	hybrid			2022-12-25	WOS:000165618700026
J	Lee, M; Goodall, J; Verastegui, C; Ballotti, R; Goding, CR				Lee, M; Goodall, J; Verastegui, C; Ballotti, R; Goding, CR			Direct regulation of the Microphthalmia promoter by Sox10 links Waardenburg-Shah syndrome (WS4)-associated hypopigmentation and deafness to WS2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZIPPER TRANSCRIPTION FACTOR; ENDOTHELIN-B RECEPTOR; HIRSCHSPRUNG-DISEASE; BETA-CATENIN; SYNDROME TYPE-2; MELANOMA-CELLS; FACTOR LEF-1; MOUSE MODEL; IN-VIVO; GENE	The transcription factor Sox10 is genetically linked with Waardenburg syndrome 4 (WS4) in humans and the Dominant megacolon (Dom) mouse model for this disease. The pigmentary defects observed in the Dom mouse and WS4 are reminiscent of those associated with mutations in the microphthalmia (Mitf) gene, which encodes a transcription factor essential for the development of the melanocyte lineage. We demonstrate here that wild type Sox10 directly binds and activates transcription of the MITF promoter, whereas a mutant form of the Sox10 protein genetically linked with WS4 acts as a dominant-negative repressor of MITF expression and can reduce endogenous MITF protein levels. The ability of Sox10 to activate transcription of the MITF promoter implicates Sox10 in the regulation of melanocyte development and provides a molecular basis for the hypopigmentation and deafness associated with WS4.	Marie Curie Res Inst, Eukaryot Transcript Lab, Oxted RH8 0TL, Surrey, England; Fac Med Nice, INSERM, U385, F-06107 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Goding, CR (corresponding author), Marie Curie Res Inst, Eukaryot Transcript Lab, The Chart, Oxted RH8 0TL, Surrey, England.		BALLOTTI, Robert/F-8825-2013	BALLOTTI, Robert/0000-0002-7322-4908; Goding, Colin/0000-0002-1614-3909				Aksan I, 1998, MOL CELL BIOL, V18, P6930, DOI 10.1128/MCB.18.12.6930; ATTIE T, 1995, HUM MOL GENET, V4, P2407, DOI 10.1093/hmg/4.12.2407; BALDWIN CT, 1994, HUM MUTAT, V3, P205, DOI 10.1002/humu.1380030306; BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BENNETT DC, 1983, CELL, V34, P445, DOI 10.1016/0092-8674(83)90378-1; Bertolotto C, 1996, J CELL BIOL, V134, P747, DOI 10.1083/jcb.134.3.747; Bertolotto C, 1998, MOL CELL BIOL, V18, P694, DOI 10.1128/MCB.18.2.694; Carreira S, 1998, MOL CELL BIOL, V18, P5099, DOI 10.1128/MCB.18.9.5099; Dorsky RI, 2000, GENE DEV, V14, P158; Edery P, 1996, NAT GENET, V12, P442, DOI 10.1038/ng0496-442; Fuse N, 1996, BIOCHEM BIOPH RES CO, V219, P702, DOI 10.1006/bbrc.1996.0298; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; Herbarth B, 1998, P NATL ACAD SCI USA, V95, P5161, DOI 10.1073/pnas.95.9.5161; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Hofstra RMW, 1996, NAT GENET, V12, P445, DOI 10.1038/ng0496-445; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; HUGHES MJ, 1993, J BIOL CHEM, V268, P20687; Kuhlbrodt K, 1998, J BIOL CHEM, V273, P23033, DOI 10.1074/jbc.273.36.23033; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; LEVENSON R, 1981, CELL, V25, P5, DOI 10.1016/0092-8674(81)90225-7; Lister JA, 1999, DEVELOPMENT, V126, P3757; Liu Q, 1999, J NEUROSCI, V19, P9747; LOWINGS P, 1992, MOL CELL BIOL, V12, P3653, DOI 10.1128/MCB.12.8.3653; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MOORE KJ, 1995, TRENDS GENET, V11, P442, DOI 10.1016/S0168-9525(00)89143-X; Opdecamp K, 1997, DEVELOPMENT, V124, P2377; Pingault V, 1998, NAT GENET, V18, P171, DOI 10.1038/ng0298-171; Planque N, 1999, CELL GROWTH DIFFER, V10, P525; Southard-Smith EM, 1998, NAT GENET, V18, P60, DOI 10.1038/ng0198-60; Tachibana M, 1996, NAT GENET, V14, P50, DOI 10.1038/ng0996-50; Takeda K, 2000, J BIOL CHEM, V275, P14013, DOI 10.1074/jbc.C000113200; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; TASSABEHJI M, 1993, NAT GENET, V3, P26, DOI 10.1038/ng0193-26; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; Watanabe A, 1998, NAT GENET, V18, P283, DOI 10.1038/ng0398-283; Zorn AM, 1999, MOL CELL, V4, P487, DOI 10.1016/S1097-2765(00)80200-2	39	141	144	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37978	37983		10.1074/jbc.M003816200	http://dx.doi.org/10.1074/jbc.M003816200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10973953	hybrid			2022-12-25	WOS:000165618700090
J	Steele-Mortimer, O; Knodler, LA; Marcus, SL; Scheid, MP; Goh, B; Pfeifer, CG; Duronio, V; Finlay, BB				Steele-Mortimer, O; Knodler, LA; Marcus, SL; Scheid, MP; Goh, B; Pfeifer, CG; Duronio, V; Finlay, BB			Activation of Akt/protein kinase B in epithelial cells by the Salmonella typhimurium effector SigD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; BACTERIAL INVASION; NUCLEAR RESPONSES; HOST-CELLS; APOPTOSIS; VIRULENCE; AKT; INHIBITION	The serine-threonine kinase Akt is a protooncogene involved in the regulation of cell proliferation and survival. Activation of Abt is initiated by binding to the phospholipid products of phosphoinositide 3-kinase at the inner leaflet of the plasma membranes followed by phosphorylation at Ser(473) and Thr(308). We have found that Akt is activated by Salmonella enterica serovar Typhimurium in epithelial cells. A bacterial effector protein, SigD, which is translocated into host cells via the specialized type III secretion system, is essential for Akt activation. In HeLa cells, wild type S. typhimurium induced translocation of Akt to membrane ruffles and phosphorylation at residues Thr(308) and Ser(473) and increased kinase activity. In contrast, infection with a SigD deletion mutant did not induce phosphorylation or activity although Akt was translocated to membrane ruffles. Complementation of the SigD deletion strain with a mutant containing a single Cys to Ser mutation (C462S), did not restore the Akt activation phenotype, This residue has previously been shown to be essential for inositol phosphatase activity of the SigD homologue, SopB, Our data indicate a novel mechanism of Akt activation in which the endogenous cellular pathway does not convert membrane-associated Akt into its active form. SigD is also the first bacterial effector to be identified as an activator of Akt.	Univ British Columbia, Biotechnol Lab, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Med, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Steele-Mortimer, O (corresponding author), Washington Univ, Dept Cell Biol & Physiol, Box 8228,660 S Euclid, St Louis, MO 63110 USA.	osteelem@cellbio.wustl.edu		Pfeifer, Cheryl/0000-0001-8584-228X; Knodler, Leigh/0000-0002-3028-2198				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Clifton DR, 1998, P NATL ACAD SCI USA, V95, P4646, DOI 10.1073/pnas.95.8.4646; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Eaves-Pyles T, 1999, INFECT IMMUN, V67, P800, DOI 10.1128/IAI.67.2.800-804.1999; Eckmann L, 1997, P NATL ACAD SCI USA, V94, P14456, DOI 10.1073/pnas.94.26.14456; Edwards RA, 1998, GENE, V207, P149, DOI 10.1016/S0378-1119(97)00619-7; Elewaut D, 1999, J IMMUNOL, V163, P1457; Fan T, 1998, J EXP MED, V187, P487, DOI 10.1084/jem.187.4.487; FINLAY BB, 1991, J CELL SCI, V99, P283; FRANCIS CL, 1993, NATURE, V364, P639, DOI 10.1038/364639a0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Fu YX, 1998, MOL MICROBIOL, V27, P359, DOI 10.1046/j.1365-2958.1998.00684.x; Galan JE, 1999, CURR OPIN MICROBIOL, V2, P46, DOI 10.1016/S1369-5274(99)80008-3; GALAN JE, 1992, J BACTERIOL, V174, P4338; Galyov EE, 1997, MOL MICROBIOL, V25, P903, DOI 10.1111/j.1365-2958.1997.mmi525.x; GARCIADELPORTILLO F, 1994, J CELL SCI, V107, P2005; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; Hersh D, 1999, P NATL ACAD SCI USA, V96, P2396, DOI 10.1073/pnas.96.5.2396; Hilbi H, 1998, J BIOL CHEM, V273, P32895, DOI 10.1074/jbc.273.49.32895; Hobbie S, 1997, J IMMUNOL, V159, P5550; Hong KH, 1998, J BACTERIOL, V180, P1793, DOI 10.1128/JB.180.7.1793-1802.1998; Ireton K, 1996, SCIENCE, V274, P780, DOI 10.1126/science.274.5288.780; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; JONES BD, 1993, P NATL ACAD SCI USA, V90, P10390, DOI 10.1073/pnas.90.21.10390; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; KANIGA K, 1995, J BACTERIOL, V177, P3965, DOI 10.1128/jb.177.14.3965-3971.1995; Marcus SL, 2000, MICROBES INFECT, V2, P145, DOI 10.1016/S1286-4579(00)00273-2; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; Monack DM, 2000, J EXP MED, V192, P249, DOI 10.1084/jem.192.2.249; NORRIS FA, 1994, J BIOL CHEM, V269, P8716; Norris FA, 1998, P NATL ACAD SCI USA, V95, P14057, DOI 10.1073/pnas.95.24.14057; Ozes ON, 1999, NATURE, V401, P82; Pfeifer CG, 1999, INFECT IMMUN, V67, P5690, DOI 10.1128/IAI.67.11.5690-5698.1999; Steele-Mortimer O, 1999, CELL MICROBIOL, V1, P33, DOI 10.1046/j.1462-5822.1999.00003.x; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4	45	154	158	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37718	37724		10.1074/jbc.M008187200	http://dx.doi.org/10.1074/jbc.M008187200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10978351	hybrid			2022-12-25	WOS:000165618700057
J	Lee, SL; Dickson, RB; Lin, CY				Lee, SL; Dickson, RB; Lin, CY			Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-DEGRADING PROTEASE; BREAST-CANCER CELLS; PLASMINOGEN-ACTIVATOR; SCATTER FACTOR; PRO-UROKINASE; RECEPTOR; TISSUE; FORM; IDENTIFICATION; PROUROKINASE	Matriptase is an epithelial-derived, integral membrane serine protease. The enzyme was initially isolated from human breast cancer cells and has been implicated in breast cancer invasion and metastasis. In the current study, using active matriptase isolated from human milk we demonstrate that matriptase is able to cleave various synthetic substrates with arginine or lysine as their P1 sites and prefers small side chain amino acids, such as Ala and Gly, at P2 sites. For the most reactive substrates, N-tert-butoxycarbonyl (N-t-Boc)-gamma -benzyl-Glu-Ala-Arg-7-amino-4-methylcoumarin (AMC) and N-t-Boc-Gln-Ala-Arg-AMC, the K-m values were determined to be 3.81 and 4.89 muM respectively. We further demonstrated that matriptase can convert hepatocyte growth factor/scattering factor to its active form, which can induce scatter of Madin-Darby canine kidney epithelial cells and can activate c-Met tyrosine phosphorylation in A549 human lung carcinoma cells. In addition, we noted that matriptase can activate urokinase plasminogen activator but has no affect on plasminogen. These results suggest that matriptase could act as an epithelial, upstream membrane activator to recruit and activate stromal-derived downstream effecters important for extracellular matrix degradation and epithelial migration, two major events of tissue remodeling, cancer invasion, and metastasis.	Georgetown Univ, Ctr Med, Vincent T Lombardi Canc Res Ctr, Dept Oncol, Washington, DC 20007 USA	Georgetown University	Lin, CY (corresponding author), Georgetown Univ, Ctr Med, Vincent T Lombardi Canc Res Ctr, Dept Oncol, 3970 Reservoir Rd NW, Washington, DC 20007 USA.				NCI NIH HHS [R21-CA80897, 1P50CA58158] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R44CA058158, R21CA080897, R43CA058158] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRUNNER G, 1992, BLOOD, V79, P2099; BUGGE TH, 1995, GENE DEV, V9, P794, DOI 10.1101/gad.9.7.794; Dano K, 1999, APMIS, V107, P120, DOI 10.1111/j.1699-0463.1999.tb01534.x; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; GORETZKI L, 1992, FEBS LETT, V297, P112, DOI 10.1016/0014-5793(92)80339-I; ICHINOSE A, 1986, J BIOL CHEM, V261, P3486; KAWABATA SI, 1988, EUR J BIOCHEM, V172, P17, DOI 10.1111/j.1432-1033.1988.tb13849.x; Kim MG, 1999, IMMUNOGENETICS, V49, P420, DOI 10.1007/s002510050515; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; KOIVUNEN E, 1989, J BIOL CHEM, V264, P14095; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; Lin CY, 1997, J BIOL CHEM, V272, P9147; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; NAKA D, 1992, J BIOL CHEM, V267, P20114; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; RONG S, 1993, CELL GROWTH DIFFER, V4, P563; SHI YE, 1993, CANCER RES, V53, P1409; Shimomura T, 1997, J BIOL CHEM, V272, P6370, DOI 10.1074/jbc.272.10.6370; STACK MS, 1994, J BIOL CHEM, V269, P9416; Stewart F, 1996, Rev Reprod, V1, P144, DOI 10.1530/ror.0.0010144; STOKER M, 1985, J CELL SCI, V77, P209; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Takeuchi T, 1999, P NATL ACAD SCI USA, V96, P11054, DOI 10.1073/pnas.96.20.11054; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WOLF BB, 1993, J BIOL CHEM, V268, P16327; Yoshida E, 1995, INT J CANCER, V63, P863, DOI 10.1002/ijc.2910630618	28	347	376	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36720	36725		10.1074/jbc.M007802200	http://dx.doi.org/10.1074/jbc.M007802200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10962009	hybrid			2022-12-25	WOS:000165577700040
J	Maya-Monteiro, CM; Daffre, S; Logullo, C; Lara, FA; Alves, EW; Capurro, ML; Zingali, R; Almeida, IC; Oliveira, PL				Maya-Monteiro, CM; Daffre, S; Logullo, C; Lara, FA; Alves, EW; Capurro, ML; Zingali, R; Almeida, IC; Oliveira, PL			HeLp, a heme lipoprotein from the hemolymph of the cattle tick, Boophilus microplus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; DENSITY LIPOPROTEINS; POLYACRYLAMIDE GELS; LIPID TRANSPORT; INSECT EGG; APOLIPOPROTEIN; PROTECTION; MECHANISMS; LIPOPHORIN; HEMOGLOBIN	The main protein of the hemolymph of the cattle tick Boophilus microplus has been isolated and shown to be a heme lipoprotein (HeLp). HeLp has an apparent molecular mass of 354,000 and contains two apoproteins (103 and 92 kDa) found in equal amounts. HeLp presents a pi of 5.8 and a density of 1.28 g/ml and contains 33% Lipids, containing both neutral lipids and phospholipids, and 3% of sugars. A remarkable feature of Help is the abundance of cholesterol ester (35% of total lipids), a lipid not previously reported in invertebrate lipoproteins. Western blot analysis showed Help in hemolymph from adult females and males, but not in eggs. Although Help contains 2 heme molecules, it is capable of binding 6 additional molecules of heme. Boophilus feeds large amount of blood, and we recently showed that this tick is unable to perform de novo synthesis of heme (Braz, G, R. C., Coelho, H. S. L., Masuda, H., and Oliveira, P. L. (1999) Curr. Biol. 9, 703-706). Injection of tick females with Fe-55-labeled heme-HeLp indicated that this protein transports heme from hemolymph to tissues. Help is suggested to be an essential adaptation to the loss of the heme synthesis pathway.	Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil; Univ Sao Paulo, Inst Ciencias Biomed, Dept Parasitol, BR-05508900 Sao Paulo, Brazil; Univ Fed Fluminense, Inst Biol, Dept Cellular & Mol Biol, BR-24001970 Niteroi, RJ, Brazil; Univ Estadual Norte Fluminense, Ctr Biociencias & Biotecnol, BR-28015620 Rio De Janeiro, Brazil; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	Universidade Federal do Rio de Janeiro; Universidade de Sao Paulo; Universidade Federal Fluminense; Universidade Estadual do Norte Fluminense; University of California System; University of California Irvine	Maya-Monteiro, CM (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil.		maya-monteiro, clarissa/A-9091-2010; Logullo de Oliveira, Carlos Jorge/G-3436-2013; Capurro, Margareth L/F-8679-2012; Lara, Flavio Alves/L-1861-2013; Almeida, Igor C./AAF-9409-2019; Daffre, Sirlei/M-4233-2013; Capurro, Margareth/M-5286-2019; Zingali, Russolina/G-4862-2012; L. Oliveira, Pedro/A-9438-2010	Capurro, Margareth L/0000-0002-7480-2116; Almeida, Igor C./0000-0002-2443-8213; Daffre, Sirlei/0000-0002-9966-0433; Zingali, Russolina/0000-0003-3156-6923; L. Oliveira, Pedro/0000-0003-0307-354X				[Anonymous], 1991, BIOL BLOOD SUCKING I; BEAVEN GH, 1974, EUR J BIOCHEM, V41, P530; BLANCHE PJ, 1981, BIOCHIM BIOPHYS ACTA, V665, P408, DOI 10.1016/0005-2760(81)90253-8; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Braz GRC, 1999, CURR BIOL, V9, P703, DOI 10.1016/S0960-9822(99)80312-1; CANNON JB, 1984, BIOCHEMISTRY-US, V23, P3715, DOI 10.1021/bi00311a022; CHAPMAN MJ, 1986, METHOD ENZYMOL, V128, P70; DANSAPETRETSKI M, 1995, J BIOL CHEM, V270, P10893, DOI 10.1074/jbc.270.18.10893; Doolittle R. F., 1986, URFS ORFS PRIMER ANA; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; DUBOIS M, 1956, ANAL CHEM, V28, P356; Duffin K, 2000, ANAL BIOCHEM, V279, P179, DOI 10.1006/abio.1999.4452; El Hafidi M, 1999, CHEM PHYS LIPIDS, V100, P127, DOI 10.1016/S0009-3084(99)00049-3; Eskew JD, 1999, J BIOL CHEM, V274, P638, DOI 10.1074/jbc.274.2.638; FALK JE, 1964, PORPHYRINS METALLOPO; GALBRAITH RA, 1985, J BIOL CHEM, V260, P2198; GEORGE R, 1987, J BIOL CHEM, V262, P16838; GUTTERIDGE JMC, 1988, BIOCHEM J, V256, P861, DOI 10.1042/bj2560861; HALLIWELL B, 1990, ARCH BIOCHEM BIOPHYS, V280, P1, DOI 10.1016/0003-9861(90)90510-6; HORWITZ J, 1987, METHOD ENZYMOL, V141, P169; IWAHARA S, 1995, BIOCHEMISTRY-US, V34, P13398, DOI 10.1021/bi00041a017; JONAS A, 1993, J BIOL CHEM, V268, P1596; Kanost M.R., 1990, Advances in Insect Physiology, V22, P299, DOI 10.1016/S0065-2806(08)60008-9; KAWOOYA JK, 1988, J BIOL CHEM, V263, P8748; KAWOOYA JK, 1988, J BIOL CHEM, V263, P8740; KAWOOYA JK, 1989, BIOCHEMISTRY-US, V28, P6658, DOI 10.1021/bi00442a019; KERWIN JL, 1994, J LIPID RES, V35, P1102; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE BC, 1995, MOL MICROBIOL, V18, P383, DOI 10.1111/j.1365-2958.1995.mmi_18030383.x; Lovry O.H., 1951, J BIOL CHEM, V193, P265; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MILLER YI, 1995, BBA-MOL BASIS DIS, V1272, P119, DOI 10.1016/0925-4439(95)00075-F; MONTEIRO CM, 1997, BIOCHEMISTRY-US, V36, P11216; Morris K., 1972, TECHNIQUES LIPIDOLOG; MOURAO PAS, 1995, J BIOL CHEM, V270, P3132, DOI 10.1074/jbc.270.7.3132; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; Noyer CM, 1998, HEPATOLOGY, V28, P150, DOI 10.1002/hep.510280120; OLIVEIRA PL, 1995, J BIOL CHEM, V270, P10897, DOI 10.1074/jbc.270.18.10897; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; Ponka P, 1999, AM J MED SCI, V318, P241, DOI 10.1097/00000441-199910000-00004; Ponka P, 1997, BLOOD, V89, P1; SADRZADEH SMH, 1987, J CLIN INVEST, V79, P662, DOI 10.1172/JCI112865; SADRZADEH SMH, 1984, J BIOL CHEM, V259, P4354; SHIPMAN BA, 1986, BIOCHEMISTRY-US, V26, P1885; SOLAR I, 1989, BIOCHIM BIOPHYS ACTA, V983, P199, DOI 10.1016/0005-2736(89)90234-4; Sonenshine D.E., 1993, ECOLOGY NIDICOLOUS T, V2; SOULAGES JL, 1994, ADV PROTEIN CHEM, V45, P371; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; TIPPING E, 1976, BIOCHEM J, V157, P461, DOI 10.1042/bj1570461; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VINCENT SH, 1988, ARCH BIOCHEM BIOPHYS, V265, P539, DOI 10.1016/0003-9861(88)90159-2; VINCENT SH, 1989, SEMIN HEMATOL, V26, P105	52	80	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36584	36589		10.1074/jbc.M007344200	http://dx.doi.org/10.1074/jbc.M007344200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10964932	hybrid			2022-12-25	WOS:000165577700019
J	Ovide-Bordeaux, S; Ventura-Clapier, R; Veksler, V				Ovide-Bordeaux, S; Ventura-Clapier, R; Veksler, V			Do modulators of the mitochondrial K-ATP channel change the mitochondria in situ?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ACTION-POTENTIAL DURATION; POTASSIUM CHANNEL; LIVER-MITOCHONDRIA; RAT-LIVER; CARDIOPROTECTION; OPENER; ACTIVATION; DIAZOXIDE; MEMBRANE	Pharmacological opening of mitochondrial cardiac ATP-sensitive potassium (K-ATP) channels has the chance to be a promising but still controversial cardioprotective mechanism. Physiological roles of mitochondrial K-ATP, channels in the myocardium remain unclear. We studied the effects of diazoxide, a specific opener of these channels, on the function of rat mitochondria in. situ in saponin-permeabilized fibers using an ionic medium that mimics the cytosol, In the presence of NADH-producing substrates (malate + glutamate), neither 100 muM diazoxide nor 100 muM glibenclamide (a K-ATP channel blocker) changed the mitochondrial respiration in the absence or presence of ADP, Because the K-ATP channel function could be modified by changes in adenine nucleotide concentrations near the mitochondria, we studied the effects of diazoxide and glibenclamide on the functional activity of mitochondrial kinases, Both diazoxide and glibenclamide did not change the in situ ADP sensitivity in the presence or absence of creatine (apparent IE,values for ADP were, respectively, 59 +/- 9 and 379 +/- 45 muM) Similarly, stimulation of the mitochondrial respiration with AMP in the presence of ATP due to adenylate kinase activity was not affected by the modulators of K-ATP channels, However, when succinate was used as substrate, diazoxide significantly inhibited basal respiration by 22% and maximal respiration by 24%. Thus, at a cardioprotective dose, the main functional effect of diazoxide depends on respiratory substrates and seems not to be related to K-ATP channel activity.	Univ Paris Sud, Fac Pharm, INSERM U446, Lab Cardiol Cellulaire & Mol, F-92296 Chatenay Malabry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Veksler, V (corresponding author), Univ Paris Sud, Fac Pharm, INSERM U446, Lab Cardiol Cellulaire & Mol, F-92296 Chatenay Malabry, France.			Ventura-Clapier, Renee/0000-0002-7488-4123; Veksler, Vladimir/0000-0002-8869-9594				Baines CP, 1999, J CARDIOVASC ELECTR, V10, P741, DOI 10.1111/j.1540-8167.1999.tb00251.x; Baines CP, 1999, AM J PHYSIOL-HEART C, V276, pH1361, DOI 10.1152/ajpheart.1999.276.4.H1361; Dzeja PP, 1998, FASEB J, V12, P523, DOI 10.1096/fasebj.12.7.523; Garlid KD, 1997, CIRC RES, V81, P1072; Garlid KD, 1996, BBA-BIOENERGETICS, V1275, P123, DOI 10.1016/0005-2728(96)00061-8; Garlid KD, 1996, J BIOL CHEM, V271, P8796, DOI 10.1074/jbc.271.15.8796; Grigoriev SM, 1999, BBA-BIOENERGETICS, V1410, P91, DOI 10.1016/S0005-2728(98)00179-0; Grimmsmann T, 1998, BRIT J PHARMACOL, V123, P781, DOI 10.1038/sj.bjp.0701663; Gross GJ, 1999, CIRC RES, V84, P973, DOI 10.1161/01.RES.84.9.973; GROVER GJ, 1995, J CARDIOVASC PHARM, V26, P145, DOI 10.1097/00005344-199507000-00023; Han J, 1996, J MOL CELL CARDIOL, V28, P2043, DOI 10.1006/jmcc.1996.0197; Holmuhamedov EL, 1999, J PHYSIOL-LONDON, V519, P347, DOI 10.1111/j.1469-7793.1999.0347m.x; Holmuhamedov EL, 1998, AM J PHYSIOL-HEART C, V275, pH1567, DOI 10.1152/ajpheart.1998.275.5.H1567; INOUE I, 1991, NATURE, V352, P244, DOI 10.1038/352244a0; Jaburek M, 1998, J BIOL CHEM, V273, P13578; Jovanovic A, 1998, CIRCULATION, V98, P1548, DOI 10.1161/01.CIR.98.15.1548; Liu YG, 1998, CIRCULATION, V97, P2463, DOI 10.1161/01.CIR.97.24.2463; MCDONALD MJ, 1984, BIOCH INT, V8, P771; MOORE PF, 1968, ANN NY ACAD SCI, V150, P256, DOI 10.1111/j.1749-6632.1968.tb19050.x; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; PAUCEK P, 1992, J BIOL CHEM, V267, P26062; Ribalet B, 1996, J GEN PHYSIOL, V107, P231, DOI 10.1085/jgp.107.2.231; Sato T, 1998, CIRC RES, V83, P110, DOI 10.1161/01.RES.83.1.110; SCHAFER G, 1971, BIOCHEM PHARMACOL, V20, P1271, DOI 10.1016/0006-2952(71)90358-3; SELLERS EM, 1974, BIOCHEM PHARMACOL, V23, P553, DOI 10.1016/0006-2952(74)90620-0; SZEWCZYK A, 1995, BIOCHEM BIOPH RES CO, V207, P126, DOI 10.1006/bbrc.1995.1162; Takashi E, 1999, CIRC RES, V85, P1146; VEKSLER VI, 1995, J BIOL CHEM, V270, P19921, DOI 10.1074/jbc.270.34.19921; VEKSLER VI, 1987, BIOCHIM BIOPHYS ACTA, V892, P191, DOI 10.1016/0005-2728(87)90174-5; Wang YG, 1999, CIRC RES, V85, P731, DOI 10.1161/01.RES.85.8.731; YAO ZH, 1994, CIRCULATION, V89, P1769, DOI 10.1161/01.CIR.89.4.1769	31	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37291	37295		10.1074/jbc.M005772200	http://dx.doi.org/10.1074/jbc.M005772200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10970894	hybrid			2022-12-25	WOS:000165577700115
J	Gitter, AH; Bendfeldt, K; Schulzke, JD; Fromm, M				Gitter, AH; Bendfeldt, K; Schulzke, JD; Fromm, M			Leaks in the epithelial barrier caused by spontaneous and TNF-alpha-induced single-cell apoptosis	FASEB JOURNAL			English	Article						cell death; conductance scanning; intestine; tight junction; permeability	TUMOR-NECROSIS-FACTOR; INFLAMMATORY BOWEL-DISEASE; SMALL-INTESTINE; GASTROINTESTINAL-TRACT; TIGHT JUNCTIONS; HUMAN COLON; TRANSPORT; PERMEABILITY; CONDUCTANCE; MAINTENANCE	Current opinion assumes epithelial integrity during spontaneous apoptotic cell death. We measured, for the first time, the local conductances associated with apoptoses and show leaks of up to 280 nS (mean 48 +/- 19 nS) in human intestinal epithelium, The results disprove the dogma that isolated cell apoptosis occurs without affecting the epithelial cell permeability barrier, After induction by tumor necrosis factor alpha (TNF-alpha) the apoptotic leaks were dramatically enhanced: not only was the frequency increased by threefold, but the mean conductance also increased by 12-fold (597+/-98 nS), Thus, apoptosis accounted for about half (56%) of the TNF-alpha-induced permeability increase whereas the other half was caused by degradation of tight junctions in nonapoptotic areas. Hence, spontaneous and induced apoptosis hollow out the intestinal barrier and may facilitate loss of solutes and uptake of noxious agents.	Free Univ Berlin, Klinikum Benjamin Franklin, Inst Klin Physiol, D-12200 Berlin, Germany; Free Univ Berlin, Univ Hosp Benjamin Franklin, Inst Clin Physiol, D-1000 Berlin, Germany; Free Univ Berlin, Univ Hosp Benjamin Franklin, Dept Gastroenterol, D-1000 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Gitter, AH (corresponding author), Free Univ Berlin, Klinikum Benjamin Franklin, Inst Klin Physiol, D-12200 Berlin, Germany.	gitter@medizin.fu-berlin.de	bendfeldt, kerstin/AAZ-2197-2020; Fromm, Michael/K-6203-2013	Fromm, Michael/0000-0003-4497-7983				ANDERSON JM, 1995, AM J PHYSIOL-GASTR L, V269, pG467, DOI 10.1152/ajpgi.1995.269.4.G467; BARON DA, 1990, J ELECTRON MICR TECH, V16, P15, DOI 10.1002/jemt.1060160104; BREESE EJ, 1994, GASTROENTEROLOGY, V106, P1455, DOI 10.1016/0016-5085(94)90398-0; FROMTER E, 1972, NATURE-NEW BIOL, V235, P9, DOI 10.1038/newbio235009a0; Gitter AH, 1997, PFLUG ARCH EUR J PHY, V434, P830, DOI 10.1007/s004240050472; Goodenough DA, 1999, P NATL ACAD SCI USA, V96, P319, DOI 10.1073/pnas.96.2.319; HALL PA, 1994, J CELL SCI, V107, P3569; HEYMAN M, 1994, GASTROENTEROLOGY, V106, P1514, DOI 10.1016/0016-5085(94)90405-7; HUDSPETH AJ, 1975, P NATL ACAD SCI USA, V72, P2711, DOI 10.1073/pnas.72.7.2711; HUDSPETH AJ, 1982, EXP CELL RES, V138, P331, DOI 10.1016/0014-4827(82)90182-3; IWANAGA T, 1993, GASTROENTEROLOGY, V105, P1089, DOI 10.1016/0016-5085(93)90953-A; JINGUJI Y, 1992, CELL STRUCT FUNCT, V17, P27, DOI 10.1247/csf.17.27; Jones BA, 1997, AM J PHYSIOL-GASTR L, V273, pG1174, DOI 10.1152/ajpgi.1997.273.6.G1174; KANDIL HM, 1994, GUT, V35, P934, DOI 10.1136/gut.35.7.934; KOTLER DP, 1993, DIGEST DIS SCI, V38, P1119, DOI 10.1007/BF01295730; KREUSEL KM, 1991, AM J PHYSIOL, V261, pC574, DOI 10.1152/ajpcell.1991.261.4.C574; Ksontini R, 1998, ARCH SURG-CHICAGO, V133, P558, DOI 10.1001/archsurg.133.5.558; Kunstle G, 1997, IMMUNOL LETT, V55, P5, DOI 10.1016/S0165-2478(96)02642-9; LASTER SM, 1988, J IMMUNOL, V141, P2629; MADARA JL, 1990, J MEMBRANE BIOL, V116, P177, DOI 10.1007/BF01868675; Marano CW, 1998, J MEMBRANE BIOL, V161, P263, DOI 10.1007/s002329900333; Mayhew TM, 1999, HISTOL HISTOPATHOL, V14, P257, DOI 10.14670/HH-14.257; McKay DM, 1997, J IMMUNOL, V159, P2382; MERRITT AJ, 1994, CANCER RES, V54, P614; MULLIN JM, 1992, AM J PHYSIOL, V263, pF915, DOI 10.1152/ajprenal.1992.263.5.F915; MURCH SH, 1993, GUT, V34, P1705, DOI 10.1136/gut.34.12.1705; Potten CS, 1997, AM J PHYSIOL-GASTR L, V273, pG253, DOI 10.1152/ajpgi.1997.273.2.G253; RODRIGUEZ P, 1995, CYTOKINE, V7, P441, DOI 10.1006/cyto.1995.0060; RUGGIERO V, 1986, J IMMUNOL, V136, P2445; RUSSELL RG, 1993, J INFECT DIS, V168, P210, DOI 10.1093/infdis/168.1.210; SANDLE GI, 1990, GASTROENTEROLOGY, V99, P97, DOI 10.1016/0016-5085(90)91235-X; SARTOR RB, 1994, GASTROENTEROLOGY, V106, P533, DOI 10.1016/0016-5085(94)90614-9; Sategna-Guidetti Carla, 1993, Recenti Progressi in Medicina, V84, P93; Schmitz H, 1996, AM J PHYSIOL-GASTR L, V271, pG669, DOI 10.1152/ajpgi.1996.271.4.G669; Schmitz H, 1999, J CELL SCI, V112, P137; Soler AP, 1996, AM J PHYSIOL-RENAL, V270, pF869, DOI 10.1152/ajprenal.1996.270.5.F869	36	214	222	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2000	14	12					1749	1753		10.1096/fj.99-0898com	http://dx.doi.org/10.1096/fj.99-0898com			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973924				2022-12-25	WOS:000089212400014
J	Holcik, M; Yeh, C; Korneluk, RG; Chow, T				Holcik, M; Yeh, C; Korneluk, RG; Chow, T			Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death	ONCOGENE			English	Article						IAP; radiation induced cell death; IRES; translation	CANCER; SURVIVIN; GENE; THERAPY	Inhibitory regulators of apoptosis play a critical role in the responsiveness of tumour cells to cytotoxic agents. The X-linked inhibitor of apoptosis protein (XIAP) is a member of a novel family of Inhibitor of Apoptosis (IAP) proteins. Here we show that acute lon dose ionizing irradiation results in the translational upregulation of XIAP that correlates with an increased resistance to radiation in non-small cell lung carcinoma. This upregulation is mediated by an internal ribosome binding mechanism, ia an IRES element located within a XIAP 5' UTR. Transient overexpression of XIAP rendered human carcinoma cells resistant to low dose gamma-irradiation. By contrast, the antisense targeting of XIAP resulted in increased cell death following irradiation advocating a distinct role for XIAP in radiation resistant phenotype of human cancers.	Childrens Hosp Eastern Ontario, Inst Res, Solange Gauthier Karsh Mol Genet Lab, Ottawa, ON K1H 8L1, Canada; Apoptogen Inc, Ottawa, ON K1H 8L1, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8L1, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1A4, Canada	University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; McGill University	Korneluk, RG (corresponding author), Childrens Hosp Eastern Ontario, Inst Res, Solange Gauthier Karsh Mol Genet Lab, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.		Holcik, Martin/A-9768-2008; Holcik, Martin/AAC-6660-2019; Holcik, Martin/E-5372-2011	Holcik, Martin/0000-0002-1922-5299; 				Adida C, 1998, LANCET, V351, P882, DOI 10.1016/S0140-6736(05)70294-4; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Bold RJ, 1997, SURG ONCOL, V6, P133, DOI 10.1016/S0960-7404(97)00015-7; Cohen-Jonathan E, 1999, CURR OPIN CHEM BIOL, V3, P77, DOI 10.1016/S1367-5931(99)80014-3; Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Kawasaki H, 1998, CANCER RES, V58, P5071; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Lu CD, 1998, CANCER RES, V58, P1808; Macgregor G R, 1991, Methods Mol Biol, V7, P217, DOI 10.1385/0-89603-178-0:217; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Withers HR, 1999, CANCER RES, V59, p1676S; Yount GL, 1998, CANCER RES, V58, P3819; Zhivotovsky B, 1999, EXP CELL RES, V248, P10, DOI 10.1006/excr.1999.4452	20	217	233	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2000	19	36					4174	4177		10.1038/sj.onc.1203765	http://dx.doi.org/10.1038/sj.onc.1203765			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962579				2022-12-25	WOS:000088955100012
J	Davies, C; White, SW; Nicholas, RA				Davies, C; White, SW; Nicholas, RA			Crystal structure of a deacylation-defective mutant of penicillin-binding protein 5 at 2.3-angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALANINE CARBOXYPEPTIDASE IA; SITE-DIRECTED MUTAGENESIS; ACYL-ENZYME INTERMEDIATE; A BETA-LACTAMASE; ESCHERICHIA-COLI; STREPTOMYCES R61; TRANSPEPTIDASE; PURIFICATION; MECHANISM; FORM	Penicillin-binding protein 5 (PBP 5) of Escherichia coli functions as a D-alanine carboxypeptidase, cleaving the C-terminal D-alanine residue from cell wall peptides, Like all PBPs, PBP 5 forms a covalent acyl-enzyme complex with p-lactam antibiotics; however, PBP 5 is distinguished by its high rate of deacylation of the acyl-enzyme complex (t(1/2) similar to 9 min). A Gly-105 --> Asp mutation in PBP 5 markedly impairs this beta -lactamase activity (deacylation), with only minor effects on acylation, and promotes accumulation of a covalent complex with peptide substrates, To gain further insight into the catalytic mechanism of PBP 5, we determined the three-dimensional structure of the G105D mutant form of soluble PBP 5 (termed sPBP 5') at 2.3 Angstrom resolution. The structure is composed of two domains, a penicillin binding domain with a striking similarity to Class A beta -lactamases (TEM-1-like) and a domain of unknown function. In addition, the penicillin-binding domain contains an active site loop spatially equivalent to the Omega loop of beta -lactamases. In beta -lactamases, the Omega loop contains two amino acids involved in catalyzing deacylation, This similarity may explain the high beta -lactamase activity of wild-type PBP 5. Because of the low rate of deacylation of the G105D mutant, visualization of peptide substrates bound to the active site may be possible.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA; St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA; Univ Sussex, Sch Biol Sci, Brighton BN1 9QG, E Sussex, England	University of North Carolina; University of North Carolina Chapel Hill; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; University of Sussex	Nicholas, RA (corresponding author), Univ N Carolina, Dept Pharmacol, CB 7365 Mary Ellen Jones Bldg, Chapel Hill, NC 27599 USA.	nicholas@med.unc.edu	White, Stephen W/N-8164-2018					Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ADACHI H, 1991, J BIOL CHEM, V266, P3186; AMANUMA H, 1980, J BIOL CHEM, V255, P1173; AMANUMA H, 1984, J BIOL CHEM, V259, P1294; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRANNIGAN J, 1991, BIOCHEM J, V278, P673, DOI 10.1042/bj2780673; BUSH K, 1984, ANTIMICROBIAL DRUG R, P1; CURTIS SJ, 1978, J BIOL CHEM, V253, P2584; Davies C, 2000, STRUCTURE, V8, P185, DOI 10.1016/S0969-2126(00)00094-0; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; ELLERBY LM, 1990, BIOCHEMISTRY-US, V29, P5797, DOI 10.1021/bi00476a022; FERSHT AR, 1985, ENZYME STRUCTURE MEC, P406; Fonze E, 1999, J BIOL CHEM, V274, P21853, DOI 10.1074/jbc.274.31.21853; FRERE JM, 1975, EUR J BIOCHEM, V57, P353, DOI 10.1111/j.1432-1033.1975.tb02308.x; GHUYSEN JM, 1991, ANNU REV MICROBIOL, V45, P37, DOI 10.1146/annurev.mi.45.100191.000345; GHUYSEN JM, 1988, REV INFECT DIS, V10, P726; GHUYSEN JM, 1994, BACTERIAL CELL WALL, P103; Guillaume G, 1997, J BIOL CHEM, V272, P5438, DOI 10.1074/jbc.272.9.5438; HERZBERG O, 1987, SCIENCE, V236, P694, DOI 10.1126/science.3107125; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; JELSCH C, 1993, PROTEINS, V16, P364, DOI 10.1002/prot.340160406; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORIS B, 1988, BIOCHEM J, V250, P313, DOI 10.1042/bj2500313; KELLY JA, 1986, SCIENCE, V231, P1429, DOI 10.1126/science.3082007; KELLY JA, 1985, J BIOL CHEM, V260, P6449; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUSTU SG, 1974, J BIOL CHEM, V249, P6976; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MALHOTRA KT, 1992, J BIOL CHEM, V267, P11386; MARTIN MT, 1988, BIOCHEM J, V254, P923, DOI 10.1042/bj2540923; Massova I, 1998, ANTIMICROB AGENTS CH, V42, P1; Matagne A, 1998, BIOCHEM J, V330, P581, DOI 10.1042/bj3300581; MATSUHASHI M, 1979, J BACTERIOL, V137, P644, DOI 10.1128/JB.137.1.644-647.1979; Nelson DE, 2000, J BACTERIOL, V182, P1714, DOI 10.1128/JB.182.6.1714-1721.2000; NICHOLAS RA, 1988, REV INFECT DIS, V10, P733; NICHOLAS RA, 1988, J BIOL CHEM, V263, P2034; NICHOLAS RA, 1985, J BIOL CHEM, V260, P6394; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pares S, 1996, NAT STRUCT BIOL, V3, P284, DOI 10.1038/nsb0396-284; PRATT JM, 1986, EMBO J, V5, P2399, DOI 10.1002/j.1460-2075.1986.tb04510.x; PRATT RF, 1984, P NATL ACAD SCI-BIOL, V81, P1302, DOI 10.1073/pnas.81.5.1302; Rhazi N, 1999, BIOCHEM J, V341, P409, DOI 10.1042/0264-6021:3410409; SAMRAOUI B, 1986, NATURE, V320, P378, DOI 10.1038/320378a0; SPRATT BG, 1975, P NATL ACAD SCI USA, V72, P2999, DOI 10.1073/pnas.72.8.2999; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; TIPPER DJ, 1965, P NATL ACAD SCI USA, V54, P1133, DOI 10.1073/pnas.54.4.1133; VANDERLINDEN MPG, 1994, BIOCHEM J, V303, P357, DOI 10.1042/bj3030357; VANDERLINDEN MPG, 1993, BIOCHEM J, V289, P593, DOI 10.1042/bj2890593; VANDERLINDEN MPG, 1992, EUR J BIOCHEM, V204, P197	49	78	80	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					616	623		10.1074/jbc.M004471200	http://dx.doi.org/10.1074/jbc.M004471200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	10967102	hybrid, Green Published			2022-12-25	WOS:000166280700083
J	Borges, E; Jan, YW; Ruoslahti, E				Borges, E; Jan, YW; Ruoslahti, E			Platelet-derived growth factor receptor beta and vascular endothelial growth factor receptor 2 bind to the beta(3) integrin through its extracellular domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; ALPHA(V)BETA(3) INTEGRIN; GLYCOPROTEIN-IIB; ACTIVATION; ADHESION; PROTEIN; PDGF; VITRONECTIN; APOPTOSIS; INSULIN	Integrin-mediated cell attachment and growth factor stimulation often act synergistically on cell proliferation, differentiation, migration, and survival. Some of these synergistic effects depend on the physical interaction of integrins with growth factor receptors, Here we examine the nature of the physical interaction between the alpha (v)beta (3) integrin and two receptor tyrosine kinases (RTKs), the platelet-derived growth factor receptor beta (PDGF-R beta) and the vascular endothelial growth factor receptor 2 (VEGF-R2, also known as KDR and flk-1). Both of these RTKs associate with the alpha (v)beta (3), integrin but do not associate with beta (1) integrins, Furthermore, growth factor stimulation of these RTKs promotes increased cell proliferation and migration when cells are attached to the alpha (v)beta (3) ligand, vitronectin. We show that alpha (v)beta (3) in which the beta (3) cytoplasmic domain is deleted or replaced with the beta (1) cytoplasmic domain coimmunoprecipitates with PDGF-R beta and VEGF-R2, The beta (3) extracellular domain alone was sufficient for the PDGF-R beta association whereas the VEGF-R2 association required the presence of the cu, subunit, Activation of the RTKs by their ligands was not required for them to associate with the integrin, Cell migration to PDGF was enhanced in the cells transfected with the chimeric subunit containing the beta (3) extracellular domain but not when that domain came from the beta (1) subunit, These results show that the interactions that lead to the association of the alpha (v)beta (3) integrin with PDGF-R beta and VEGF-R2 and enhancement of RTK activity take place outside the cell.	Burnham Inst, Ctr Canc Res, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Ruoslahti, E (corresponding author), Burnham Inst, Ctr Canc Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NCI NIH HHS [CA67224, CA30199] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA030199, R01CA067224] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAJT ML, 1992, J BIOL CHEM, V267, P22211; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CLARK EA, 1995, SCIENCE, V268, P223; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; KOVALENKO M, 1994, CANCER RES, V54, P6106; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Schaffner-Reckinger E, 1998, J BIOL CHEM, V273, P12623, DOI 10.1074/jbc.273.20.12623; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Sundberg C, 1996, J CELL BIOL, V132, P741, DOI 10.1083/jcb.132.4.741; SUZUKI S, 1986, P NATL ACAD SCI USA, V83, P8614, DOI 10.1073/pnas.83.22.8614; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; Woodard AS, 1998, J CELL SCI, V111, P469; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yancopoulos GD, 1998, CELL, V93, P661, DOI 10.1016/S0092-8674(00)81426-9	23	231	238	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39867	39873		10.1074/jbc.M007040200	http://dx.doi.org/10.1074/jbc.M007040200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10964931	hybrid			2022-12-25	WOS:000166039500013
J	Karandikar, M; Xu, SC; Cobb, MH				Karandikar, M; Xu, SC; Cobb, MH			MEKK1 binds Raf-1 and the ERK2 cascade components	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOGEN-ACTIVATED PROTEIN; PHEROMONE RESPONSE PATHWAY; MAP KINASE CASCADE; BETA-GAMMA COMPLEX; SIGNAL-TRANSDUCTION; SACCHAROMYCES-CEREVISIAE; XENOPUS OOCYTES; YEAST; PHOSPHORYLATION; SCAFFOLD	Mitogen-activated protein (MAP) kinase cascades are involved in transmitting signals that are generated at the cell surface into the cytosol and nucleus and consist of three sequentially acting enzymes: a MAP kinase, an upstream MAP/extracellular signal-regulated protein kinase (ERK) kinase (MEK), and a MEK kinase (MEKK), Protein-protein interactions within these cascades provide a mechanism to control the localization and function of the proteins. MEKK1 is implicated in activation of the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) and ERK1/2 MAP kinase pathways. We showed previously that MEKK1 binds directly to JNR/SAPK. In this study we demonstrate that endogenous MEKK1 binds to endogenous ERK2, MEK1, and another MEKK level kinase, Raf-1, suggesting that it can assemble all three proteins of the ERK2 MAP kinase module.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75216 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75216 USA.			Cobb, Melanie/0000-0003-0833-5473	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034128, R01DK034128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056498] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34128] Funding Source: Medline; NIGMS NIH HHS [GM56498] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akada R, 1996, GENETICS, V143, P103; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; Chen Z, 1999, J BIOL CHEM, V274, P28803, DOI 10.1074/jbc.274.40.28803; Cheng JK, 2000, MOL CELL BIOL, V20, P2334, DOI 10.1128/MCB.20.7.2334-2342.2000; Cheng M, 1996, J BIOL CHEM, V271, P8951, DOI 10.1074/jbc.271.15.8951; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; CHOI KY, 1994, CELL, V78, P499; Christerson LB, 1999, CELL MOTIL CYTOSKEL, V43, P186, DOI 10.1002/(SICI)1097-0169(1999)43:3<186::AID-CM2>3.0.CO;2-1; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; English JM, 1998, J BIOL CHEM, V273, P3854, DOI 10.1074/jbc.273.7.3854; ERREDE B, 1995, MOL REPROD DEV, V42, P477, DOI 10.1002/mrd.1080420416; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Feng YY, 1998, CURR BIOL, V8, P267, DOI 10.1016/S0960-9822(98)70108-3; Ferrell JE, 1998, SCIENCE, V280, P895, DOI 10.1126/science.280.5365.895; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; GARDNER AM, 1994, MOL BIOL CELL, V5, P193, DOI 10.1091/mbc.5.2.193; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Hutchison M, 1998, J BIOL CHEM, V273, P28625, DOI 10.1074/jbc.273.44.28625; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Leeuw T, 1998, NATURE, V391, P191, DOI 10.1038/34448; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Mochly-Rosen D, 2000, SEMIN IMMUNOL, V12, P55, DOI 10.1006/smim.2000.0207; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; Nishina H, 1999, DEVELOPMENT, V126, P505; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; PRINTEN JA, 1994, GENETICS, V138, P609; Pryciak PM, 1998, GENE DEV, V12, P2684, DOI 10.1101/gad.12.17.2684; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Robinson MJ, 1996, J BIOL CHEM, V271, P29734, DOI 10.1074/jbc.271.47.29734; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; SPRAGUE GF, 1993, MOL BIOL YEAST SACCH; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu BE, 2000, J BIOL CHEM, V275, P16795, DOI 10.1074/jbc.275.22.16795; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; Xu SC, 1997, J BIOL CHEM, V272, P32056, DOI 10.1074/jbc.272.51.32056; YAN MH, 1994, NATURE, V372, P798; YAN MH, 1994, J BIOL CHEM, V269, P19067; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; YASHAR B, 1995, MOL CELL BIOL, V15, P6545; Yujiri T, 1999, J BIOL CHEM, V274, P12605, DOI 10.1074/jbc.274.18.12605; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; Zanke BW, 1996, J BIOL CHEM, V271, P29876, DOI 10.1074/jbc.271.47.29876	69	93	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40120	40127		10.1074/jbc.M005926200	http://dx.doi.org/10.1074/jbc.M005926200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10969079	hybrid			2022-12-25	WOS:000166039500045
J	Sandoval, IV; Martinez-Arca, S; Valdueza, J; Palacios, S; Holman, GD				Sandoval, IV; Martinez-Arca, S; Valdueza, J; Palacios, S; Holman, GD			Distinct reading of different structural determinants modulates the dileucine-mediated transport steps of the lysosomal membrane protein LIMPII and the insulin-sensitive glucose transporter GLUT4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DI-LEUCINE MOTIF; MANNOSE 6-PHOSPHATE RECEPTOR; FACTOR-II RECEPTOR; LEU-LEU SEQUENCE; DOWN-REGULATION; CARBOXYL-TERMINUS; CYTOPLASMIC DOMAIN; TRAFFICKING KINETICS; SORTING SIGNALS; HIV-1 NEF	Leucine-based motifs mediate the sorting of membrane proteins at such cellular sites as the trans-Golgi network, endosomes, and plasma membrane. A Leu paired with a second Leu, He, or Met, while itself lacking the ability to mediate transport, is the key structural feature in these motifs, Here we have studied the structural differences between the leucine-based motifs contained in the COOH tails of LIMPII and GLUT4, two membrane proteins that are transported through the secretory pathway and are targeted to lysosomes (1-3) and to a perinuclear compartment adjacent to the Golgi complex (4), respectively. LIMPII and GLUT4 display negatively (Asp(470)/Glu(471)) and positively (Arg(484)/Ar-485) charged residues, respectively, at positions -4 and -5 upstream from the critical Leu residue. The change in the charge sign of residues -4 and -5 results in missorting of LIMPII and GLUT4. We note that the acidic Glu residue at position -4 is critical for efficient intracellular sorting of LIMPII to lysosomes, but is dispensable for its surface internalization by endocytosis. Efficient intracellular sorting and endocytosis of GLUT4 require an Arg pair between positions -4 and -7. These results are consistent with the existence of distinct leucine-based motifs and provide evidence of their different readings at different cellular sites.	Univ Autonoma Madrid, Fac Ciencias, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; Univ Bath, Dept Biochem, Bath BA2 7AY, Avon, England	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); University of Bath	Sandoval, IV (corresponding author), Univ Autonoma Madrid, Fac Ciencias, CSIC, Ctr Biol Mol Severo Ochoa, Cantoblanco, E-28049 Madrid, Spain.	isandoval@cbm.uam.es		Holman, Geoffrey/0000-0001-7045-1358				Abe H, 1998, J VET MED SCI, V60, P769, DOI 10.1292/jvms.60.769; Araki S, 1996, BIOCHEM J, V315, P153, DOI 10.1042/bj3150153; BARRIOCANAL JG, 1986, J BIOL CHEM, V261, P6755; Bremnes T, 1998, J BIOL CHEM, V273, P8638, DOI 10.1074/jbc.273.15.8638; Bresnahan PA, 1998, CURR BIOL, V8, P1235, DOI 10.1016/S0960-9822(07)00517-9; Brodsky FM, 1997, TRENDS CELL BIOL, V7, P175, DOI 10.1016/S0962-8924(97)01038-6; CAMPS M, 1994, ENDOCRINOLOGY, V134, P924, DOI 10.1210/en.134.2.924; CARLSSON SR, 1992, ARCH BIOCHEM BIOPHYS, V296, P630, DOI 10.1016/0003-9861(92)90619-8; CHEN HJ, 1993, J BIOL CHEM, V268, P22338; CLAESSON L, 1983, P NATL ACAD SCI-BIOL, V80, P7395, DOI 10.1073/pnas.80.24.7395; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; Darsow T, 1998, J CELL BIOL, V142, P913, DOI 10.1083/jcb.142.4.913; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; delMarmol V, 1996, FEBS LETT, V381, P165, DOI 10.1016/0014-5793(96)00109-3; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; Dittrich E, 1996, J BIOL CHEM, V271, P5487, DOI 10.1074/jbc.271.10.5487; Garippa RJ, 1996, J BIOL CHEM, V271, P20660, DOI 10.1074/jbc.271.34.20660; Geisler C, 1998, J BIOL CHEM, V273, P21316, DOI 10.1074/jbc.273.33.21316; Gillingham AK, 1999, J CELL SCI, V112, P4793; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; Greenberg M, 1998, CURR BIOL, V8, P1239, DOI 10.1016/S0960-9822(07)00518-0; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; Haft CR, 1998, ENDOCRINOLOGY, V139, P1618, DOI 10.1210/en.139.4.1618; HANEY PM, 1995, J CELL BIOL, V129, P641, DOI 10.1083/jcb.129.3.641; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; Hein C, 1997, MOL MICROBIOL, V24, P607, DOI 10.1046/j.1365-2958.1997.3771735.x; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; HRESKO RC, 1994, J BIOL CHEM, V269, P32110; Johnson AO, 1998, J BIOL CHEM, V273, P17968, DOI 10.1074/jbc.273.28.17968; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; Karlsson K, 1998, J BIOL CHEM, V273, P18966, DOI 10.1074/jbc.273.30.18966; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Koumanov F, 1998, BIOCHEM J, V330, P1209, DOI 10.1042/bj3301209; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KWON BS, 1995, NUCLEIC ACIDS RES, V23, P154, DOI 10.1093/nar/23.1.154; Le Borgne R, 1998, J BIOL CHEM, V273, P29451, DOI 10.1074/jbc.273.45.29451; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Martinez-Arca S, 2000, J CELL SCI, V113, P1705; Melvin DR, 1999, BIOCHEMISTRY-US, V38, P1456, DOI 10.1021/bi980988y; OGATA S, 1994, J BIOL CHEM, V269, P5210; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; Petersen CM, 1997, J BIOL CHEM, V272, P3599, DOI 10.1074/jbc.272.6.3599; Petris MJ, 1998, HUM MOL GENET, V7, P2063, DOI 10.1093/hmg/7.13.2063; PIPER RC, 1991, AM J PHYSIOL, V247, pE726; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; Ralston E, 1996, J CELL SCI, V109, P2967; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Robinson MS, 1997, TRENDS CELL BIOL, V7, P99, DOI 10.1016/S0962-8924(96)10048-9; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; Ross SA, 1997, BIOCHEM BIOPH RES CO, V239, P247, DOI 10.1006/bbrc.1997.7459; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; Sheikh H, 1996, J BIOL CHEM, V271, P12185, DOI 10.1074/jbc.271.21.12185; SHIN JY, 1991, J BIOL CHEM, V266, P10658; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; Sumitani S, 1997, ENDOCRINOLOGY, V138, P1029, DOI 10.1210/en.138.3.1029; Tan PK, 1998, J BIOL CHEM, V273, P17351, DOI 10.1074/jbc.273.28.17351; Traub LM, 1997, TRENDS CELL BIOL, V7, P43, DOI 10.1016/S0962-8924(96)20042-X; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VERHEY KJ, 1994, J BIOL CHEM, V269, P2353; VIJAYASARADHI S, 1995, J CELL BIOL, V130, P807, DOI 10.1083/jcb.130.4.807; Vowels JJ, 1998, EMBO J, V17, P2482, DOI 10.1093/emboj/17.9.2482	71	70	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39874	39885		10.1074/jbc.M006261200	http://dx.doi.org/10.1074/jbc.M006261200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10973972	hybrid			2022-12-25	WOS:000166039500014
J	Zhu, JH; Zhang, SZ; Jiang, JY; Chen, XB				Zhu, JH; Zhang, SZ; Jiang, JY; Chen, XB			Definition of the p53 functional domains necessary for inducing apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; TUMOR-SUPPRESSOR P53; DNA-BINDING FUNCTION; CELL-CYCLE ARREST; C-TERMINAL DOMAIN; TRANSCRIPTIONAL ACTIVATION; PROTEOLYTIC CLEAVAGE; GROWTH SUPPRESSION; MUTANT P53; P53-MEDIATED APOPTOSIS	The p53 protein contains several functional domains necessary for inducing cell cycle arrest and apoptosis. The C-terminal basic domain within residues 364-393 and the proline-rich domain within residues 64-91 are required for apoptotic activity. In addition, activation domain 2 within residues 43-63 is necessary for apoptotic activity when the N-terminal activation domain 1 within residues 1-42 is deleted (Delta AD1) or mutated (AD1(-)). Here we have discovered that an activation domain 2 mutation at residues 53-54 (AD2(-)) abrogates the apoptotic activity but has no significant effect on cell cycle arrest. We have also found that p53-(Delta AD2), which lacks activation domain 2, is inert in inducing apoptosis. p53-(AD2(-)Delta BD), which is defective in activation domain 2 and lacks the C-terminal basic domain, p53-(Delta AD2 Delta BD), which lacks both activation domain 2 and the C-terminal basic domain, and p53-(Delta PRD Delta BD), which lacks both the proline-rich domain and the C-terminal basic domain, are also inert in inducing apoptosis. All four mutants are still capable of inducing cell cycle arrest, albeit to a lesser extent than wild-type p53. Interestingly, we have found that deletion of the N-terminal activation domain 1 alleviates the requirement of the C-terminal basic domain for apoptotic activity. Thus, we have generated a small but potent p53-(Delta AD1 Delta BD) molecule. Furthermore, we have determined that at least two of the three domains (activation domain 1, activation domain 2, and the proline-rich domain), are required for inducing cell cycle arrest. Taken together, our results suggest that activation domain 2 and the proline-rich domain form an activation domain for inducing pro-apoptotic genes or inhibiting antiapoptotic genes. The C-terminal basic domain is required for maintaining this activation domain competent for transactivation or transrepression.	Med Coll Georgia, Inst Mol Biol & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Chen, XB (corresponding author), Med Coll Georgia, Inst Mol Biol & Genet, CB-2803, Augusta, GA 30912 USA.				NATIONAL CANCER INSTITUTE [R29CA076069, R01CA076069] Funding Source: NIH RePORTER; NCI NIH HHS [CA76069] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Blander G, 1999, J BIOL CHEM, V274, P29463, DOI 10.1074/jbc.274.41.29463; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; Chen J, 1996, ONCOGENE, V13, P1395; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; CHEN YQ, 1995, CANCER RES, V55, P4536; Clayman GL, 1998, J CLIN ONCOL, V16, P2221, DOI 10.1200/JCO.1998.16.6.2221; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu L, 1999, MOL CELL BIOL, V19, P1202; Mee T, 1999, BRIT J CANCER, V81, P212, DOI 10.1038/sj.bjc.6690679; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Molinari M, 1996, ONCOGENE, V13, P2077; Muller-Tiemann BF, 1998, P NATL ACAD SCI USA, V95, P6079, DOI 10.1073/pnas.95.11.6079; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Okorokov AL, 1997, ONCOL RES, V9, P267; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Sekiguchi T, 1998, ONCOGENE, V16, P369, DOI 10.1038/sj.onc.1201539; Selivanova G, 1999, MOL CELL BIOL, V19, P3395; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHEIKH MS, 1995, ONCOGENE, V11, P1899; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; Swisher SG, 1999, J NATL CANCER I, V91, P763, DOI 10.1093/jnci/91.9.763; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; Venot C, 1999, ONCOGENE, V18, P2405, DOI 10.1038/sj.onc.1202539; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Zhou XL, 1999, CANCER RES, V59, P843; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533	65	95	100	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39927	39934		10.1074/jbc.M005676200	http://dx.doi.org/10.1074/jbc.M005676200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10982799	hybrid			2022-12-25	WOS:000166039500021
J	Bagheri-Yarmand, R; Vadlamudi, RK; Wang, RA; Mendelsohn, J; Kumar, R				Bagheri-Yarmand, R; Vadlamudi, RK; Wang, RA; Mendelsohn, J; Kumar, R			Vascular endothelial growth factor up-regulation via p21-activated kinase-1 signaling regulates heregulin-beta 1-mediated angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; RECEPTOR TYROSINE KINASES; DIFFERENTIATION FACTOR; ERBB RECEPTORS; TUMOR-CELLS; EXPRESSION; MICE; GLYCOPROTEIN; ACTIVATION; INDUCTION	Heregulin-beta1 promotes the activation of p21-activated kinase 1 (Pak1) and the motility and invasiveness of breast cancer cells. In this study, we identified vascular endothelial growth factor (VEGF) as a gene product induced by heregulin-beta1, The stimulation by heregulin-beta1 of breast cancer epithelial cells induced the expression of the VEGF mRNA and protein and its promoter activity. Heregulin-beta1 also stimulated angiogenesis in a VEGF-dependent manner. Herceptin, an anti-HER2 antibody inhibited heregulin-beta1-mediated stimulation of both VEGF expression in epithelial cells and angiogenesis in endothelial cells. Because the activation of Pak1 and VEGF expression are positively regulated by heregulin-beta1, we hypothesized that Pak1 regulates VEGF expression, and hence explored the role of Pak1 in angiogenesis,We provide new evidence to implicate Pak1 signaling in VEGF expression. Overexpression of a kinase-dead K299R Pak1 leads to suppression of VEGF promoter activity, as well as VEGF mRNA expression and secretion of VEGF protein. Conversely, kinase-active T423E Pak1 promotes the expression and secretion of VEGF. Furthermore, expression of the heregulin-beta1 transgene, HRG, in harderian tumors in mice enhances the activation of Pak1 as well as expression of VEGF and angiogenic marker CD34 antigen. These results suggest that heregulin-beta1 regulates angiogenesis via up-regulation of VEGF expression and that Pak1 plays an important role in controlling VEGF expression and, consequently, VEGF secretion and function.	Univ Texas, MD Anderson Canc Ctr 108, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr 108, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Wang, Brian/HGA-9535-2022	Bagheri-Yarmand, Rozita/0000-0001-5139-6381	NCI NIH HHS [CA80066, CA65746] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA065746, R01CA065746, R01CA080066] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 2000, J BIOL CHEM, V275, P12041, DOI 10.1074/jbc.275.16.12041; Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Bagheri-Yarmand R, 1999, CANCER RES, V59, P507; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; DVORAK HF, 1995, AM J PATHOL, V146, P1029; FIDLER IJ, 1995, J NATL CANCER I, V87, P1588, DOI 10.1093/jnci/87.21.1588; FINA L, 1990, BLOOD, V75, P2417; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; ITO A, 1995, LAB INVEST, V72, P532; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Kramer R, 1996, P NATL ACAD SCI USA, V93, P4833, DOI 10.1073/pnas.93.10.4833; Krane IM, 1996, ONCOGENE, V12, P1781; Kumar R, 1996, CLIN CANCER RES, V2, P1215; KUMAR R, 2000, IN PRESS SEMIN ONCOL; KUMAR R, 1995, J CELL BIOCHEM, V62, P102; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; Petit AMV, 1997, AM J PATHOL, V151, P1523; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; RAK J, 1995, CANCER RES, V55, P4575; Russell KS, 1999, AM J PHYSIOL-HEART C, V277, pH2205, DOI 10.1152/ajpheart.1999.277.6.H2205; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Tang CK, 1996, CANCER RES, V56, P3350; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Vadlamudi R, 1999, ONCOGENE, V18, P305, DOI 10.1038/sj.onc.1202307; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; Wang DG, 1999, CANCER RES, V59, P1464; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M	35	99	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39451	39457		10.1074/jbc.M006150200	http://dx.doi.org/10.1074/jbc.M006150200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10967114	hybrid			2022-12-25	WOS:000165953100070
J	Lin, CY; Huang, PH; Liao, WL; Cheng, HJ; Huang, CF; Kuo, JC; Patton, WA; Massenburg, D; Moss, J; Lee, FJS				Lin, CY; Huang, PH; Liao, WL; Cheng, HJ; Huang, CF; Kuo, JC; Patton, WA; Massenburg, D; Moss, J; Lee, FJS			ARL4, an ARF-like protein that is developmentally regulated and localized to nuclei and nucleoli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; SACCHAROMYCES-CEREVISIAE; CHOLERA-TOXIN; DIFFERENTIAL EXPRESSION; BINDING-PROTEINS; PHOSPHOLIPASE-D; CELLS; FAMILY; IDENTIFICATION; SEGMENTATION	ADP-ribosylation factors (ARFs) are highly conserved similar to 20-kDa guanine nucleotide-binding proteins that participate in both exocytic and endocytic vesicular transport pathways via mechanisms that are only partially understood. Although several ARF-like proteins (ARLs) are known, their biological functions remain unclear. To characterize its molecular properties, we cloned mouse and human ARL4 (mARL4 and hARL4) cDNA. The appearance of mouse ARL4 mRNA during embryonic development coincided temporally with the sequential formation of somites and the establishment of brain compartmentation. Using ARL4-specific antibody for immunofluorescence microscopy, we observed that endogenous mARL4 in cultured Sertoli and neuroblastoma cells was mainly concentrated in nuclei. When expressed in COS7 cells, ARL4-T34N mutant, predicted to exist with GDP bound, was concentrated in nucleoli. Yeast two-hybrid screening and in vitro protein-interaction assays showed that hARL4 interacted with importin-alpha through its C-terminal NLS region and that the interaction was not nucleotide-dependent. Like ARL2 and -3, recombinant hARL4 did not enhance cholera toxin-catalyzed auto-ADP-ribosylation. Its binding of guanosine 5'-O-(thiotriphosphate) was modified by phospholipid and detergent, and the N terminus of hARL4, like that of ARF, was myristoylated. Our findings suggest that ARL4, with its distinctive nuclear/nucleolar localization and pattern of developmental expression, may play a unique role(s) in neurogenesis and somitogenesis during embryonic development and in the early stages of spermatogenesis in adults.	Natl Taiwan Univ, Coll Med, Inst Mol Med, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Inst Pathol, Taipei, Taiwan; NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	National Taiwan University; National Taiwan University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Lee, FJS (corresponding author), 7 Chung Shan S Rd, Taipei, Taiwan.		Cheng, Hwai-Jong/AAY-5067-2021	Cheng, Hwai-Jong/0000-0003-0647-0567; HUANG, PEI-HSIN/0000-0002-2414-1487; LEE, FANG-JEN/0000-0002-2167-2426	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000638] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; CARSON DD, 1984, J BIOL CHEM, V259, P3117; CAVENAGH MM, 1994, J BIOL CHEM, V269, P18937; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CLARK J, 1993, P NATL ACAD SCI USA, V90, P8952, DOI 10.1073/pnas.90.19.8952; CONLON RA, 1995, DEVELOPMENT, V121, P1533; CUOMO CA, 1994, P NATL ACAD SCI USA, V91, P6156, DOI 10.1073/pnas.91.13.6156; DASCHER C, 1994, J BIOL CHEM, V269, P1437; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; Durbin L, 1998, GENE DEV, V12, P3096, DOI 10.1101/gad.12.19.3096; Gant TM, 1997, ANNU REV CELL DEV BI, V13, P669, DOI 10.1146/annurev.cellbio.13.1.669; Gant TM, 1997, EUR J CELL BIOL, V74, P10; Garcia SN, 1999, CELL, V97, P825, DOI 10.1016/S0092-8674(00)80794-1; Harlow E., 1988, ANTIBODIES LAB MANUA; HAUN RS, 1993, J BIOL CHEM, V268, P7064; Heald R, 2000, TRENDS CELL BIOL, V10, P1, DOI 10.1016/S0962-8924(99)01691-8; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Hong JX, 1998, J BIOL CHEM, V273, P15872, DOI 10.1074/jbc.273.25.15872; HONG JX, 1994, J BIOL CHEM, V269, P9743; Huang CF, 1999, J BIOL CHEM, V274, P3819, DOI 10.1074/jbc.274.6.3819; INO H, 1993, BRAIN RES, V614, P131, DOI 10.1016/0006-8993(93)91026-O; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; Jacobs S, 1998, BIOCHEM J, V335, P259, DOI 10.1042/bj3350259; Jacobs S, 1999, FEBS LETT, V456, P384, DOI 10.1016/S0014-5793(99)00759-0; LEE FJS, 1994, J BIOL CHEM, V269, P20931; Lee FJS, 1997, J BIOL CHEM, V272, P30998, DOI 10.1074/jbc.272.49.30998; Lowe SL, 1996, J CELL SCI, V109, P209; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P6572, DOI 10.1073/pnas.93.13.6572; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; NORTHUP JK, 1983, J BIOL CHEM, V258, P1361; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; Palmeirim I, 1997, CELL, V91, P639, DOI 10.1016/S0092-8674(00)80451-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHURMANN A, 1994, J BIOL CHEM, V269, P15683; Visintin R, 2000, CURR OPIN CELL BIOL, V12, P372, DOI 10.1016/S0955-0674(00)00102-2; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Yang CZ, 1998, J BIOL CHEM, V273, P4006, DOI 10.1074/jbc.273.7.4006; ZHANG GF, 1995, J BIOL CHEM, V270, P21, DOI 10.1074/jbc.270.1.21	42	41	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37815	37823		10.1074/jbc.M002470200	http://dx.doi.org/10.1074/jbc.M002470200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10980193	hybrid			2022-12-25	WOS:000165618700069
J	Charsky, CMH; Schumann, NJ; Kane, PM				Charsky, CMH; Schumann, NJ; Kane, PM			Mutational analysis of subunit G (Vma10p) of the yeast vacuolar H+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; V-TYPE ATPASE; ESCHERICHIA-COLI; B-SUBUNIT; ADENOSINE-TRIPHOSPHATASES; SACCHAROMYCES-CEREVISIAE; NEUROSPORA-CRASSA; SYNTHASE; F1-ATPASE; ROTATION	The G subunit of V-ATPases is a soluble subunit that shows homology with the b subunit of F-ATPases and may be part of the "stator'' stalk connecting the peripheral V-1 and membrane V-0 sectors. When the N-terminal half of the G subunit is modeled as an or helix, most of the conserved residues fall on one face of the helix (Hunt, I. E., and Bowman, B. J. (1997) J. Bioenerg. Biomembr. 29, 533-540). We probed the function of this region by site-directed mutagenesis of the yeast VMA10 gene. Stable Gr subunits were produced in the presence of Y46A and K55A mutations, but subunit E was destabilized, resulting in loss of the V-ATPase assembly. Mutations E14A and K50A allowed wild-type growth and assembly of V-ATPase complexes, but the complexes formed were unstable. Mutations R25A and R25L stabilized V-ATPase complexes relative to wild-type and partially inhibited disassembly of V, from V, in response to glucose deprivation even though the mutant enzymes were fully active. A 2-amino acid deletion in the middle of the predicted N-terminal helix (Delta Q29D30) allowed assembly of a functional V-ATPase. The results indicate that, although the N-terminal half of the G subunit is essential for V-ATPase activity, either this region is not a rigid helix or the presence of a continuous, conserved face of the helix is not essential.	SUNY, Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; SUNY Maritime College	Kane, PM (corresponding author), SUNY, Upstate Med Univ, Dept Biochem & Mol Biol, 750 E Adams St, Syracuse, NY 13210 USA.	kanepm@mail.upstate.edu			NIGMS NIH HHS [R01 GM050322, R01-GM50322] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050322] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Boekema EJ, 1999, NATURE, V401, P37, DOI 10.1038/43369; Boekema EJ, 1997, P NATL ACAD SCI USA, V94, P14291, DOI 10.1073/pnas.94.26.14291; Bottcher B, 2000, J MOL BIOL, V296, P449, DOI 10.1006/jmbi.1999.3435; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Dunn SD, 2000, BBA-BIOENERGETICS, V1458, P356, DOI 10.1016/S0005-2728(00)00086-4; DUNN SD, 1992, J BIOL CHEM, V267, P7630; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Graf R, 1996, J BIOL CHEM, V271, P20908, DOI 10.1074/jbc.271.34.20908; HALLBERG EM, 1993, MOL CELL BIOL, V13, P3050, DOI 10.1128/MCB.13.5.3050; HO MN, 1993, J BIOL CHEM, V268, P221; Hunt IE, 1997, J BIOENERG BIOMEMBR, V29, P533, DOI 10.1023/A:1022474816665; Kane PM, 2000, FEBS LETT, V469, P137, DOI 10.1016/S0014-5793(00)01265-5; KANE PM, 1995, J BIOL CHEM, V270, P17025; KANE PM, 1992, J BIOL CHEM, V267, P447; Karrasch S, 1999, J MOL BIOL, V290, P379, DOI 10.1006/jmbi.1999.2897; Liu JZ, 1996, BIOCHEMISTRY-US, V35, P10938, DOI 10.1021/bi9608065; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4128, DOI 10.1021/bi00313a018; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Margolles-Clark E, 1999, J BIOENERG BIOMEMBR, V31, P29, DOI 10.1023/A:1005440412633; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Parra KJ, 2000, J BIOL CHEM, V275, P21761, DOI 10.1074/jbc.M002305200; Parra KJ, 1998, MOL CELL BIOL, V18, P7064, DOI 10.1128/MCB.18.12.7064; Rastogi VK, 1999, NATURE, V402, P263, DOI 10.1038/46224; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; SHERMAN F, 1982, METHODS YEAST GENETI, P177; SIKORSKI RS, 1989, GENETICS, V122, P19; Sorgen PL, 1998, BIOCHEMISTRY-US, V37, P923, DOI 10.1021/bi972309+; Sorgen PL, 1999, J BIOL CHEM, V274, P36261, DOI 10.1074/jbc.274.51.36261; Sorgen PL, 1998, J BIOL CHEM, V273, P27873, DOI 10.1074/jbc.273.43.27873; STEVENS TH, 1986, J CELL BIOL, V102, P1551, DOI 10.1083/jcb.102.5.1551; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Supekova L, 1996, J EXP BIOL, V199, P1147; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; Tsunoda SP, 2000, FEBS LETT, V470, P244, DOI 10.1016/S0014-5793(00)01336-3; Wieczorek H, 1999, BIOESSAYS, V21, P637, DOI 10.1002/(SICI)1521-1878(199908)21:8<637::AID-BIES3>3.3.CO;2-N; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; Wilkens S, 1998, BBA-BIOENERGETICS, V1365, P93, DOI 10.1016/S0005-2728(98)00048-6; Xie XS, 1996, J BIOL CHEM, V271, P30980; Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909	49	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37232	37239		10.1074/jbc.M006640200	http://dx.doi.org/10.1074/jbc.M006640200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10969085	hybrid			2022-12-25	WOS:000165577700106
J	Singh, BB; Liu, XB; Ambudkar, IS				Singh, BB; Liu, XB; Ambudkar, IS			Expression of truncated transient receptor potential protein 1 alpha (Trp1 alpha) - Evidence that the Trp1 C terminus modulates store-operated Ca2+ entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; HTRP3 CHANNELS; CELLS; ACTIVATION	Transient receptor potential protein 1 (Trp1) has been proposed as a component of the store-operated Ca2+ entry (SOCE) channel. However, the exact mechanism by which Trp1 is regulated by store depletion is not known. Here, we examined the role of the Trpl C-terminal domain in SOCE by expressing hTrp1 alpha lacking amino acids 664-793 (Delta Trp1 alpha) or full-length hTrp1 alpha in the HSG (human submandibular gland) cell line. Both carbachol (CCh) and thapsigargin (Tg) activated sustained Ca2+ influx in control (nontransfected), Delta Trp1 alpha-, and Trp1 alpha -expressing cells. Sustained [Ca2+](i), following stimulation with either Tg or CCh in Delta Trp1 alpha -expressing cells, was about 1.5-2-fold higher than in Trp1 alpha -expressing cells and 4-fold higher than in control cells. Importantly, (i) basal Ca2+ influx and (ii) Tg- or CCh-stimulated internal Ca2+ release were similar in all the cells. A similar increase in Tg-stimulated Ca2+ influx was seen in cells expressing Delta 2Tr1 alpha, lacking the C-terminal domain amino acid 649-793, which includes the EWKFAR sequence. Further, both inositol 1,4,5-trisphosphate receptor-3 and caveolin-1 were immunoprecipitated with Delta Trp1 alpha and Trp1 alpha. In aggregate, these data suggest that (i) the EWKFAR sequence does not contribute significantly to the Trp1-associated increase in SOCE, and (ii) the Trpl C-terminal region, amino acids 664-793, is involved in the modulation of SOCE.	NIDCR, Secretory Physiol Sect, Gene Therapy & Therapeut Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Ambudkar, IS (corresponding author), NIDCR, Secretory Physiol Sect, Gene Therapy & Therapeut Branch, NIH, Bldg 10,Rm 1N-113, Bethesda, MD 20892 USA.			Singh, Brij/0000-0003-0535-5997	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000438] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000438] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ambudkar IS, 2000, CRIT REV ORAL BIOL M, V11, P4, DOI 10.1177/10454411000110010301; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Kamouchi M, 1999, J PHYSIOL-LONDON, V518, P345, DOI 10.1111/j.1469-7793.1999.0345p.x; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Liu XB, 1998, J BIOL CHEM, V273, P33295, DOI 10.1074/jbc.273.50.33295; Liu XB, 1998, AM J PHYSIOL-CELL PH, V275, pC571, DOI 10.1152/ajpcell.1998.275.2.C571; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; Putney JW, 1999, CELL, V99, P5, DOI 10.1016/S0092-8674(00)80056-2; Wang WC, 1999, AM J PHYSIOL-CELL PH, V276, pC969, DOI 10.1152/ajpcell.1999.276.4.C969; WEI XY, 1994, J BIOL CHEM, V269, P1635; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; Zhu X, 1998, NEWS PHYSIOL SCI, V13, P211; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333	22	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36483	36486		10.1074/jbc.C000529200	http://dx.doi.org/10.1074/jbc.C000529200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10980191	hybrid			2022-12-25	WOS:000165577700002
J	MacDonald, MJ; Fahien, LA				MacDonald, MJ; Fahien, LA			Glutamate is not a messenger in insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC-ISLETS; AMINO-ACID; METHYL SUCCINATE; L-LEUCINE; RELEASE; METABOLISM; DEHYDROGENASE; GLUCOSE; PYRUVATE; SECRETAGOGUES	Experiments do not support a recent claim that glutamate formed from the amination of citric acid cycle-derived alpha -ketoglutarate is a messenger in glucose-induced insulin secretion (Maechler, P., and Wollheim, C. (1999) Nature 402, 685-689), Glucose, leucine, succinic acid methyl ester, and alpha -ketoisocaproic acid all markedly stimulate insulin release but do not increase glutamate levels in pancreatic islets, Increasing the intracellular glutamate levels to 10-fold higher than basal levels by adding glutamine to islets does not stimulate insulin release. When leucine, in addition to glutamine, is applied to islets, insulin release is almost as high as with glucose alone. This is consistent with the known ability of leucine to allosterically activate glutamate deamination by glutamate dehydrogenase, which can supply alpha -ketoglutarate to the citric acid cycle. Experiments with mitochondria from pancreatic islets suggest that flux through the glutamate dehydrogenase reaction is quiescent during glucose-induced insulin secretion. These experiments support the traditional idea that when insulin release is associated with flux through glutamate dehydrogenase, the flux is in the direction of alpha -ketoglutarate.	Univ Wisconsin, Sch Med, Childrens Diabet Ctr, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	MacDonald, MJ (corresponding author), Med Sci Ctr, Rm 3459,1300 Univ Ave, Madison, WI 53706 USA.				NIDDK NIH HHS [DK28438] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		DANIELSSON B, 1970, HORM METAB RES, V2, P28; FAHIEN LA, 1990, MOL PHARMACOL, V37, P943; FAHIEN LA, 1992, J BIOL CHEM, V267, P10411; FAHIEN LA, 1988, J BIOL CHEM, V263, P13610; Farfari S, 2000, DIABETES, V49, P718, DOI 10.2337/diabetes.49.5.718; Frieden C., 1963, ENZYMES 7, P3; Gao Z, 1999, DIABETES, V48, P1535, DOI 10.2337/diabetes.48.8.1535; GYLFE E, 1976, ACTA DIABETOL LAT, V13, P20, DOI 10.1007/BF02591577; Khan A, 1996, J BIOL CHEM, V271, P2539, DOI 10.1074/jbc.271.5.2539; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD MJ, 1991, J BIOL CHEM, V266, P1335; MACDONALD MJ, 1993, ARCH BIOCHEM BIOPHYS, V300, P201, DOI 10.1006/abbi.1993.1028; MACDONALD MJ, 1990, AM J PHYSIOL, V259, pE548, DOI 10.1152/ajpendo.1990.259.4.E548; MACDONALD MJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P205, DOI 10.1006/abbi.1993.1413; MACDONALD MJ, 1995, J BIOL CHEM, V270, P20051; Maechler P, 1999, NATURE, V402, P685, DOI 10.1038/45280; MALAISSE WJ, 1984, BIOCHIM BIOPHYS ACTA, V797, P194, DOI 10.1016/0304-4165(84)90122-3; MALAISSE WJ, 1982, J BIOL CHEM, V257, P8731; PACE CS, 1975, DIABETES, V24, P476, DOI 10.2337/diabetes.24.5.476; PANTEN U, 1984, BIOCHEM J, V219, P189, DOI 10.1042/bj2190189; Passonneau J.V., 1993, ENZYMATIC ANAL PRACT; SENER A, 1981, P NATL ACAD SCI-BIOL, V78, P5460, DOI 10.1073/pnas.78.9.5460; Stanley CA, 2000, DIABETES, V49, P667, DOI 10.2337/diabetes.49.4.667; TRUS M, 1980, DIABETES, V29, P1, DOI 10.2337/diabetes.29.1.1; Williamson D. H., 1974, METHODS ENZYMATIC AN, P2266, DOI [10.1016/B978-0-12-091304-6.50093-8, DOI 10.1016/B978-0-12-091304-6.50093-8]; WILLIAMSON DH, 1967, BIOCHEM J, V103, P514, DOI 10.1042/bj1030514	26	122	125	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34025	34027		10.1074/jbc.C000411200	http://dx.doi.org/10.1074/jbc.C000411200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10967090	hybrid			2022-12-25	WOS:000165095300005
J	Ingram-Smith, C; Barber, RD; Ferry, JG				Ingram-Smith, C; Barber, RD; Ferry, JG			The role of histidines in the acetate kinase from Methanosarcina thermophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFICATION; PROTEINS; SYSTEM; GENES	The role of histidine in the catalytic mechanism of acetate kinase from Methanosarcina thermophila was investigated by diethylpyrocarbonate inactivation and site-directed mutagenesis, Inactivation was accompanied by an increase in absorbance at 240 nm with no change in absorbance at 280 nm, and treatment of the inactivated enzyme with hydroxylamine restored 95% activity, results that indicated diethylpyrocarbonate inactivates the enzyme by the specific modification of histidine, The substrates ATP, ADP, acetate, and acetyl phosphate protected against inactivation suggesting at least one active site where histidine is modified. Correlation of residual activity with the number of histidines modified, as determined by absorbance at 240 nm, indicated that a maximum of three histidines are modified per subunit, two of which are essential for full inactivation. Comparison of the M, thermophila acetate kinase sequence with 56 putative acetate kinase sequences revealed eight highly conserved histidines, three of which (His-123, His-180, and His-208) are perfectly conserved. Diethylpyrocarbonate inactivation of the eight histidine --> alanine variants indicated that His-180 and His-123 are in the active site and that the modification of both is necessary for full inactivation. Kinetic analyses of the eight variants showed that no other histidines are important for activity. Analysis of additional His-180 variants indicated that phosphorylation of His-180 is not essential for catalysis, Possible functions of His-180 are discussed.	Penn State Univ, Eberly Coll Sci, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Ferry, JG (corresponding author), Penn State Univ, Eberly Coll Sci, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.			Ingram-Smith, Cheryl/0000-0002-6752-6678	NIGMS NIH HHS [GM19720] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACETI DJ, 1988, J BIOL CHEM, V263, P15444; ALLEN SHG, 1964, J BACTERIOL, V87, P171, DOI 10.1128/JB.87.1.171-187.1964; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Altschul Stephen F., J MOL BIOL, V215, P403, DOI [10.1016/S0022-2836(05)80360-2, DOI 10.1016/S0022-2836(05)80360-2]; ANDERSON CM, 1979, SCIENCE, V204, P375, DOI 10.1126/science.220706; ANTHONY RS, 1972, J BIOL CHEM, V247, P2120; ANTHONY RS, 1971, J BIOL CHEM, V246, P6129; ANTHONY RS, 1970, J BIOL CHEM, V245, P6739; BLATTLER WA, 1979, BIOCHEMISTRY-US, V18, P3927, DOI 10.1021/bi00585a013; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Ferry JG, 1997, BIOFACTORS, V6, P25, DOI 10.1002/biof.5520060104; FOX DK, 1986, J BIOL CHEM, V261, P3487; KAHANE I, 1979, J BACTERIOL, V137, P764, DOI 10.1128/JB.137.2.764-772.1979; KIM YS, 1988, BIOCHIM BIOPHYS ACTA, V956, P103, DOI 10.1016/0167-4838(88)90255-5; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATIMER MT, 1993, J BACTERIOL, V175, P6822, DOI 10.1128/jb.175.21.6822-6829.1993; LIPMANN F, 1945, J BIOL CHEM, V159, P21; LUNDBLAD RL, 1984, CHEM REAGENTS PROTEI, P101; LUNDBLAD RL, 1995, TECHNIQUES PROTEIN M, P105; MELCHIOR WB, 1970, BIOCHEMISTRY-US, V9, P251, DOI 10.1021/bi00804a010; Miles E W, 1977, Methods Enzymol, V47, P431; NAKAJIMA H, 1978, J BIOCHEM, V84, P193, DOI 10.1093/oxfordjournals.jbchem.a132108; NISHIMURA JS, 1981, METHOD ENZYMOL, V71, P311; ROMANIUK PJ, 1981, J BIOL CHEM, V256, P7322; ROSE IA, 1954, J BIOL CHEM, V211, P737; Rosenthal A, 1992, DNA Seq, V3, P61, DOI 10.3109/10425179209039697; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAUPP A, 1974, ARCH MICROBIOL, V100, P121, DOI 10.1007/BF00446312; Singh-Wissmann K, 2000, BIOCHEMISTRY-US, V39, P3671, DOI 10.1021/bi991998h; SPECTOR LB, 1980, P NATL ACAD SCI-BIOL, V77, P2626, DOI 10.1073/pnas.77.5.2626; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TODHUNTER JA, 1974, BIOCHEM BIOPH RES CO, V60, P273, DOI 10.1016/0006-291X(74)90201-0; TSOU C, 1962, SCI SINICA, V11, P1535; VIGENSCHOW H, 1986, BIOL CHEM H-S, V367, P951, DOI 10.1515/bchm3.1986.367.2.951; WEBB BC, 1976, ARCH BIOCHEM BIOPHYS, V173, P282, DOI 10.1016/0003-9861(76)90261-7	37	22	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33765	33770		10.1074/jbc.M005303200	http://dx.doi.org/10.1074/jbc.M005303200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10958794	hybrid			2022-12-25	WOS:000090104600081
J	Majone, F; Jeang, KT				Majone, F; Jeang, KT			Clastogenic effect of the human T-cell leukemia virus type I tax oncoprotein correlates with unstabilized DNA breaks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICRONUCLEI; PROTEIN; REPAIR; GENE; IDENTIFICATION; CHROMOSOMES; INDUCTION	Expression of the human T-cell leukemia virus type I (HTLV-I) Tax oncoprotein rapidly engenders DNA damage as reflected in a significant increase of micronuclei (MN) in cells, To understand better this phenomenon, we have investigated the DNA content of MN induced by Tax. Using an approach that we termed FISHI, fluorescent in situ hybridization and incorporation, we attempted to characterize MN with centric or acentric DNA fragments for the presence or absence of free 3'-OH ends. Free 3'-OH ends were defined as those ends accessible to in situ addition of digoxigenin-dUTP using terminal deoxynucleotidyl transferase. MN were also assessed for centromeric sequences using standard fluorescent in situ hybridization (FISH). Combining these results, we determined that Tax oncoprotein increased the frequency of MN containing centric DNA with free 3'-OH and decreased the frequency of MN containing DNA fragments that had incorporation-inaccessible 3'-ends. Recently, it has been suggested that intracellular DNA breaks without detectable 3'-OH ends are stabilized by the protective addition of telomeric caps, while breaks with freely detectable 3'-OH are uncapped and are labile to degradation, incomplete replication, and loss during cell division. Accordingly, based on increased detection of free 3'-OH-containing DNA fragments, we concluded that HTLV-I Tax interferes with protective cellular mechanism(s) used normally for stabilizing DNA breaks.	Univ Padua, Dept Biol, I-35131 Padua, Italy; NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA	University of Padua; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Majone, F (corresponding author), Univ Padua, Dept Biol, Viale G Colombo 3, I-35131 Padua, Italy.	majone@civ.bio.unipd.it	Jeang, Kuan-Teh/A-2424-2008					Driller L, 2000, J BIOL CHEM, V275, P24921, DOI 10.1074/jbc.M002588200; Fiumicino S, 2000, INT J CANCER, V85, P590, DOI 10.1002/(SICI)1097-0215(20000215)85:4<590::AID-IJC23>3.0.CO;2-O; GILLEY D, 1988, MOL CELL BIOL, V8, P4765, DOI 10.1128/MCB.8.11.4765; Jeang KT, 1997, J VIROL, V71, P6277, DOI 10.1128/JVI.71.9.6277-6278.1997; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; KAMPER J, 1989, MOL CELL BIOL, V9, P3931; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; Kibler KV, 1999, JNCI-J NATL CANCER I, V91, P903, DOI 10.1093/jnci/91.11.903; Li RH, 2000, P NATL ACAD SCI USA, V97, P3236, DOI 10.1073/pnas.040529797; Loeb KR, 2000, CARCINOGENESIS, V21, P379, DOI 10.1093/carcin/21.3.379; MAJONE F, 1992, TERATOGEN CARCIN MUT, V12, P155, DOI 10.1002/tcm.1770120402; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; MAJONE F, 1990, MUTAT RES, V244, P147, DOI 10.1016/0165-7992(90)90064-Q; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; MATERA AG, 1992, HUM MOL GENET, V1, P535, DOI 10.1093/hmg/1.7.535; MATSUMOTO T, 1987, MOL CELL BIOL, V7, P4424, DOI 10.1128/MCB.7.12.4424; MILLER BM, 1993, MUTAGENESIS, V8, P35, DOI 10.1093/mutage/8.1.35; Miyake H, 1999, VIROLOGY, V253, P155, DOI 10.1006/viro.1998.9500; Perucho M, 1996, BIOL CHEM, V377, P675; Philpott SM, 1999, J NATL CANCER I, V91, P933, DOI 10.1093/jnci/91.11.933; POLOGE LG, 1988, CELL, V55, P869, DOI 10.1016/0092-8674(88)90142-0; Semmes OJ, 1996, VIROLOGY, V217, P373, DOI 10.1006/viro.1996.0126; SOKAL P, 1991, BIOMETRY; YU GL, 1991, CELL, V67, P823, DOI 10.1016/0092-8674(91)90077-C	25	65	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32906	32910		10.1074/jbc.C000538200	http://dx.doi.org/10.1074/jbc.C000538200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10969065	hybrid			2022-12-25	WOS:000090003800073
J	Robertson, JD; Gogvadze, V; Zhivotovsky, B; Orrenius, S				Robertson, JD; Gogvadze, V; Zhivotovsky, B; Orrenius, S			Distinct pathways for stimulation of cytochrome c release by etoposide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TOPOISOMERASE; INDUCED APOPTOSIS; CELL-DEATH; MITOCHONDRIA; ACTIVATION; BCL-2; CASPASE-2; HOMOLOGY; SEQUENCE; REGIONS	Induction of apoptosis by DNA-damaging agents, such as etoposide, is known to involve the release of mitochondrial cytochrome c, although the mechanism responsible for this event is unclear. In the present study, using Jurkat T-lymphocytes, a reconstituted cell-free system, or isolated liver mitochondria, we demonstrate the ability of etoposide to induce cytochrome c release via two distinct pathways. Caspase inhibition by either benzyloxycarbonyl-val-Alwa-Asp-fluoromethyl ketone (z-VAD-fmk) or benzyloxycarbonyl-val-Asp-Val-Ala-Asp-fluoromethyl ketone (z-VDVAD-fmk) attenuates cytochrome c release triggered by a low dose of etoposide via an apparent inhibition of nuclear events involving the release of protein factor(s) that is (are) able to interact with mitochondria. In contrast, caspase inhibition has no effect on cytochrome c release induced by a higher dose of etoposide. Moreover, the higher dose of etoposide heightens the sensitivity of Ca2+-loaded isolated mitochondria to mitochondrial permeability transition, an effect that is completely abolished by cyclosporin A. Interestingly, cyclosporin A is ineffective at preventing similar mitochondrial damage in Jurkat cells treated with etoposide. We propose that lower doses of etoposide predominantly target the nucleus and stimulate the release of caspase-sensitive protein factor(s) that interact with mitochondria to trigger cytochrome c release, whereas higher doses of the drug impart a more direct effect on mitochondria and thus are not mitigated by caspase inhibition.	Karolinska Inst, Inst Environm Med, Div Toxicol, SE-17177 Stockholm, Sweden	Karolinska Institutet	Robertson, JD (corresponding author), Karolinska Inst, Inst Environm Med, Div Toxicol, Box 210, SE-17177 Stockholm, Sweden.	john.robertson@imm.ki.se	Gogvadze, Vladimir/A-4392-2014; Zhivotovsky, Boris/A-4346-2014	Zhivotovsky, Boris/0000-0002-2238-3482				BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; Butt AJ, 1998, J BIOL CHEM, V273, P6763, DOI 10.1074/jbc.273.12.6763; Chen Q, 2000, CELL DEATH DIFFER, V7, P227, DOI 10.1038/sj.cdd.4400629; Crabtree HG, 1929, BIOCHEM J, V23, P536, DOI 10.1042/bj0230536; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Davies KJA, 1999, IUBMB LIFE, V48, P41, DOI 10.1080/152165499307404; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; Harvey NL, 1997, J BIOL CHEM, V272, P13134, DOI 10.1074/jbc.272.20.13134; HSIEH TS, 1980, CELL, V21, P115, DOI 10.1016/0092-8674(80)90119-1; Kaufmann SH, 1998, BBA-GENE STRUCT EXPR, V1400, P195, DOI 10.1016/S0167-4781(98)00136-5; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; LYNN R, 1986, SCIENCE, V233, P647, DOI 10.1126/science.3014661; Martinou I, 1999, J CELL BIOL, V144, P883, DOI 10.1083/jcb.144.5.883; Mesner PW, 1999, J BIOL CHEM, V274, P22635, DOI 10.1074/jbc.274.32.22635; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Robertson JD, 2000, CRIT REV TOXICOL, V30, P609, DOI 10.1080/10408440008951122; SANDER M, 1987, J MOL BIOL, V194, P219, DOI 10.1016/0022-2836(87)90370-6; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; WYCKOFF E, 1989, J MOL BIOL, V205, P1, DOI 10.1016/0022-2836(89)90361-6; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5; Zhivotovsky B, 1999, EXP CELL RES, V248, P10, DOI 10.1006/excr.1999.4452; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536; Zhuang JG, 1998, TOXICOL LETT, V103, P121, DOI 10.1016/S0378-4274(98)00296-3; Zhuang JG, 1998, CELL DEATH DIFFER, V5, P953, DOI 10.1038/sj.cdd.4400440; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	30	133	137	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32438	32443		10.1074/jbc.C000518200	http://dx.doi.org/10.1074/jbc.C000518200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10961984	hybrid			2022-12-25	WOS:000090003800010
J	Verselis, SJ; Rheinwald, JG; Fraumeni, JF; Li, FP				Verselis, SJ; Rheinwald, JG; Fraumeni, JF; Li, FP			Novel p53 splice site mutations in three families with Li-Fraumeni syndrome	ONCOGENE			English	Article						p53; germline mutation; Li-Fraumeni syndrome; alternate splicing	CANCER-PRONE FAMILY; CELL-LINES; GENE; TP53; DATABASE; PATIENT; POLYMORPHISM; DEFICIENCY; PROTEIN; TUMORS	Germline mutations in the p53 tumor suppressor gene predispose to a variety of cancers in families with Li-Fraumeni syndrome. Most germline p53 mutations observed to date cause amino acid substitutions in the protein's central sequence-specific DNA binding domain. Outside this conserved core region, however, we found novel alterations in sequences that regulate precursor mRNA splicing in three Li-Fraumeni syndrome families. Two splice site mutations affected the consensus sequence at the splice donor sites of introns 1 and 9, and produced unstable variant transcripts in normal cells. A third mutation at the splice acceptor site of intron 9 generated splicing at a cryptic acceptor site in intron 9, These splice site alterations emphasize the need to examine both noncoding and untranslated regions of the p53 gene for germline mutations in Li-Fraumeni syndrome families.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Skin Dis Res Ctr, Boston, MA 02115 USA; NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Li, FP (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA.							Antonarakis SE, 1998, HUM MUTAT, V11, P1; ARA S, 1990, NUCLEIC ACIDS RES, V18, P4961, DOI 10.1093/nar/18.16.4961; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; Beroud C, 1998, NUCLEIC ACIDS RES, V26, P200, DOI 10.1093/nar/26.1.200; BIRCH JM, 1994, CANCER RES, V54, P1298; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Darling TN, 1998, J INVEST DERMATOL, V110, P165, DOI 10.1046/j.1523-1747.1998.00103.x; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; FELIX CA, 1993, ONCOGENE, V8, P1203; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; FREBOURG T, 1995, AM J HUM GENET, V56, P608; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; ISHIOKA C, 1995, ONCOGENE, V10, P1485; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; JOLLY KW, 1994, ONCOGENE, V9, P97; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Maquat LE, 1996, AM J HUM GENET, V59, P279; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; Sedlacek Z, 1998, NUCLEIC ACIDS RES, V26, P214, DOI 10.1093/nar/26.1.214; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Soria JM, 1996, THROMB HAEMOSTASIS, V75, P870; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; Varley JM, 1998, BRIT J CANCER, V78, P1081, DOI 10.1038/bjc.1998.631; Varley JM, 1998, ONCOGENE, V16, P3291, DOI 10.1038/sj.onc.1201878; Varley JM, 1997, CANCER RES, V57, P3245; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839; Wilson A, 1998, AM J HUM GENET, V63, P409, DOI 10.1086/301976	33	25	28	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 31	2000	19	37					4230	4235		10.1038/sj.onc.1203758	http://dx.doi.org/10.1038/sj.onc.1203758			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980596				2022-12-25	WOS:000089032900005
J	Clarke, PA; Hostein, I; Banerji, U; Di Stefano, F; Maloney, A; Walton, M; Judson, I; Workman, P				Clarke, PA; Hostein, I; Banerji, U; Di Stefano, F; Maloney, A; Walton, M; Judson, I; Workman, P			Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of hsp90 molecular chaperone	ONCOGENE			English	Article						gene array; cancer therapy; hsp90 chaperone; 17-allylamino-17-demethoxygeldanamycin	ROUS-SARCOMA VIRUS; RAT-KIDNEY CELLS; IN-VIVO; HEAT-SHOCK; GLUCOCORTICOID RECEPTOR; CDNA MICROARRAY; DT-DIAPHORASE; GELDANAMYCIN; KINASE; PROTEIN	A number of molecular therapeutic agents, derived from exploiting our knowledge of the oncogenic pathways that are frequently deregulated in cancer, are now entering clinical trials. One of these is the novel agent 17-allylamino-17-demethoxygeldanamycin that acts to inhibit the hsp90 molecular chaperone. Treatment of four human colon cancer cell lines with iso-effective concentrations of this agent resulted in depletion of c-raf-1 and akt and inhibition of signal transduction. We have used gene expression array analysis to identify genes responsive to treatment with this drug. The expression of hsp90 client protein genes was not affected, but hsc hsp70, hsp90 beta, keratin 8, keratin 18 and caveolin-1 were deregulated following treatment. These observations were consistent with inhibition of signal transduction and suggested a possible mechanism of resistance or recovery from 17-allylamino-17-demethoxygeldanamycin treatment. The results shed light on the molecular mode of action of the hsp90 inhibitors, and suggest possible molecular markers of drug action for use in hypothesis testing clinical trials.	Inst Canc Res, Canc Res Campaign, Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England	University of London; Institute of Cancer Research - UK	Workman, P (corresponding author), Inst Canc Res, Canc Res Campaign, Ctr Canc Therapeut, E Block,15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.			Clarke, Paul/0000-0001-9342-1290; Banerji, Udai/0000-0003-1503-3123				Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Brunton VG, 1998, CANCER CHEMOTH PHARM, V41, P417, DOI 10.1007/s002800050760; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Byrd CA, 1999, P NATL ACAD SCI USA, V96, P5645, DOI 10.1073/pnas.96.10.5645; Chavany C, 1996, J BIOL CHEM, V271, P4974; DeRisi J, 1996, NAT GENET, V14, P457; Egorin MJ, 1998, CANCER RES, V58, P2385; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Galigniana MD, 1998, MOL ENDOCRINOL, V12, P1903, DOI 10.1210/me.12.12.1903; Garrett MD, 1999, EUR J CANCER, V35, P2010, DOI 10.1016/S0959-8049(99)00280-4; Gelmon KA, 1999, J NATL CANCER I, V91, P1281, DOI 10.1093/jnci/91.15.1281; GIBBS JB, 1994, CELL, V79, P193, DOI 10.1016/0092-8674(94)90189-9; HANSEN LK, 1991, EXP CELL RES, V192, P587, DOI 10.1016/0014-4827(91)90080-E; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Hilsenbeck SG, 1999, J NATL CANCER I, V91, P453, DOI 10.1093/jnci/91.5.453; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Kelland LR, 1999, J NATL CANCER I, V91, P1940, DOI 10.1093/jnci/91.22.1940; Khan J, 1998, CANCER RES, V58, P5009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Martin S, 1998, EUR PHYS J D, V4, P1, DOI 10.1007/s100530050178; MILLER P, 1994, CANCER RES, V54, P2724; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; MURAKAMI Y, 1991, EXP CELL RES, V195, P338, DOI 10.1016/0014-4827(91)90382-5; MURAKAMI Y, 1991, BIOCHEM J, V301, P63; Oshima RG, 1996, CANCER METAST REV, V15, P445, DOI 10.1007/BF00054012; Pawson T, 1999, CELL, V97, P675, DOI 10.1016/S0092-8674(00)80779-5; Price MA, 1996, PHILOS T ROY SOC B, V351, P551, DOI 10.1098/rstb.1996.0054; ROLLINS BJ, 1989, ADV CANCER RES, V53, P1; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; SCHNUR RC, 1995, J MED CHEM, V38, P3806, DOI 10.1021/jm00019a010; Schulte TW, 1998, CANCER CHEMOTH PHARM, V42, P273, DOI 10.1007/s002800050817; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sebti SM, 1997, PHARMACOL THERAPEUT, V74, P103, DOI 10.1016/S0163-7258(97)00014-4; Sgroi DC, 1999, CANCER RES, V59, P5656; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Strawn L M, 1998, Expert Opin Investig Drugs, V7, P553, DOI 10.1517/13543784.7.4.553; SUPKO JG, 1995, CANCER CHEMOTH PHARM, V36, P305, DOI 10.1007/BF00689048; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; UEHARA Y, 1985, JPN J CANCER RES, V76, P672; Vasilevskaya IA, 1999, CANCER RES, V59, P3935; Vlahos Chris J., 1995, Drugs of the Future, V20, P165; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; ZOU J, 1996, CELL, V94, P471	51	168	176	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2000	19	36					4125	4133		10.1038/sj.onc.1203753	http://dx.doi.org/10.1038/sj.onc.1203753			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962573				2022-12-25	WOS:000088955100006
J	Lee, C; Miura, K; Liu, XP; Zweier, JL				Lee, C; Miura, K; Liu, XP; Zweier, JL			Biphasic regulation of leukocyte superoxide generation by nitric oxide and peroxynitrite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FREE-RADICAL GENERATION; HUMAN-NEUTROPHILS; NADPH OXIDASE; TYROSINE PHOSPHORYLATION; POLYMORPHONUCLEAR LEUKOCYTES; COMPONENT P47(PHOX); SIGNAL-TRANSDUCTION; POSTISCHEMIC HEART; SUBUNIT P47(PHOX)	Activation of the NADPH oxidase-derived oxidant burst of polymorphonuclear leukocytes (PMNs) is of critical importance in inflammatory disease, PMN-derived superoxide (O-2(.-)) can be scavenged by nitric oxide (NO.) with the formation of peroxynitrite (ONOO-); however, questions remain regarding the effects and mechanisms by which NO. and ONOO- modulate the PMN oxidative burst. Therefore, we directly measured the dose-dependent effects of NO. and ONOO- on O-2(.-) generation from human PMNs stimulated with phorbol 12-myristate 13-acetate using EPR spin trapping. Pretreatment with low physiological (muM) concentrations of NO. from NO. gas had no effect on PMN O-2(.-) generation, whereas high levels (greater than or equal to 50 muM) exerted inhibition. With ONOO- pretreatment, however, a biphasic modulation of O-2(.-) generation was seen with stimulation by muM levels, but inhibition at higher levels. With the NO. donor NOR-1, which provides more sustained release of NO. persisting at the time of O(2)(.-)generation, a similar biphasic modulation of O-2(.-) generation was seen, and this was inhibited by ONOO- scavengers. The enhancement of O-2(.-) generation by low concentrations of ONOO- or NOR-1 was associated with activation of the ERR MAPKs and was blocked by their inhibition, Thus, low physiological levels of NO. present following PMN activation are converted to ONOO-, which enhances O-2(.-) generation through activation of the ERK MAPK pathway, whereas higher levels of NO. or ONOO- feed back and inhibit O-2(.-) generation. This biphasic concentration-dependent regulation of the PMN oxidant burst by NO.-derived ONOO- may be of critical importance in regulating the process of inflammation.	Johns Hopkins Med Inst, Dept Med, Div Cardiol, Mol & Cellular Biophys Labs, Baltimore, MD 21224 USA; Johns Hopkins Med Inst, Elect Paramagnet Resonance Ctr, Baltimore, MD 21224 USA; Johns Hopkins Med Inst, Dept Med, Div Clin Immunol, Baltimore, MD 21224 USA; Kanagawa Dent Coll, Dept Pharmacol, Yokosuka, Kanagawa 2380003, Japan; Kanagawa Dent Coll, Electron Spin Resonance Ctr, Yokosuka, Kanagawa 2380003, Japan	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Kanagawa Dental College; Kanagawa Dental College	Zweier, JL (corresponding author), Johns Hopkins Asthma & Allergy Ctr, EPR Ctr, 5501 Johns Hopkins Bayview Circle, Baltimore, MD 21224 USA.	jzweier@welch.jhu.edu	Liu, Xiaoping/A-4516-2008		NHLBI NIH HHS [R01 HL063744, HL-38324, HL-63744, R01 HL038324] Funding Source: Medline; NIBIB NIH HHS [R01 EB004900] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063744, R29HL038324, R01HL038324] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB004900] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Babior B M, 1995, Curr Opin Hematol, V2, P55; BABIOR BM, 1981, J BIOL CHEM, V256, P2321; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CLANCY RM, 1992, J CLIN INVEST, V90, P1116, DOI 10.1172/JCI115929; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CURNUTTE JT, 1994, J BIOL CHEM, V269, P10813; Dana R, 1998, J BIOL CHEM, V273, P441, DOI 10.1074/jbc.273.1.441; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Downey GP, 1996, J BIOL CHEM, V271, P21005, DOI 10.1074/jbc.271.35.21005; Downey GP, 1998, J IMMUNOL, V160, P434; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ElBenna J, 1996, ARCH BIOCHEM BIOPHYS, V334, P395; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; Fujii H, 1997, J BIOL CHEM, V272, P32773, DOI 10.1074/jbc.272.52.32773; GRINSTEIN S, 1990, J BIOL CHEM, V265, P318; GRINSTEIN S, 1994, J BIOL CHEM, V269, P19313; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Inanami O, 1998, ARCH BIOCHEM BIOPHYS, V350, P36, DOI 10.1006/abbi.1997.0484; Inanami O, 1998, J BIOL CHEM, V273, P9539, DOI 10.1074/jbc.273.16.9539; KELM M, 1990, CIRC RES, V66, P1561, DOI 10.1161/01.RES.66.6.1561; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; Lander HM, 1996, J BIOL CHEM, V271, P19705, DOI 10.1074/jbc.271.33.19705; Liu XP, 1998, J BIOL CHEM, V273, P18709, DOI 10.1074/jbc.273.30.18709; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; MATHEIS G, 1992, AM J PHYSIOL, V262, pH616, DOI 10.1152/ajpheart.1992.262.2.H616; McLeish KR, 1998, J LEUKOCYTE BIOL, V64, P537, DOI 10.1002/jlb.64.4.537; MCPHAIL LC, 1984, J BIOL CHEM, V259, P5768; Miura K, 1999, J IMMUNOL, V162, P4198; Nick JA, 1996, J IMMUNOL, V156, P4867; RADI R, 1991, J BIOL CHEM, V266, P4244; Rohn TT, 1999, J LEUKOCYTE BIOL, V65, P59, DOI 10.1002/jlb.65.1.59; Roubaud V, 1997, ANAL BIOCHEM, V247, P404, DOI 10.1006/abio.1997.2067; ROWE GT, 1984, J MOL CELL CARDIOL, V16, P1075, DOI 10.1016/S0022-2828(84)80020-6; Schieke SM, 1999, FEBS LETT, V448, P301, DOI 10.1016/S0014-5793(99)00372-5; SCHLEIMER RP, 1986, J IMMUNOL, V136, P649; SCHULZ R, 1995, CARDIOVASC RES, V30, P432; SHANDELYA SML, 1993, CIRCULATION, V88, P2812, DOI 10.1161/01.CIR.88.6.2812; SHANDELYA SML, 1993, CIRCULATION, V87, P536, DOI 10.1161/01.CIR.87.2.536; SZABO C, 1995, FEBS LETT, V372, P229, DOI 10.1016/0014-5793(95)00984-H; TARPEY MM, 1995, FEBS LETT, V364, P314, DOI 10.1016/0014-5793(95)00413-4; TORRES M, 1993, J IMMUNOL, V150, P1563; WADDELL TK, 1995, J BIOL CHEM, V270, P15403, DOI 10.1074/jbc.270.25.15403; Wang PH, 1996, J BIOL CHEM, V271, P29223, DOI 10.1074/jbc.271.46.29223; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401; ZHENG CF, 1993, J BIOL CHEM, V268, P23933; Zu YL, 1996, BLOOD, V87, P5287, DOI 10.1182/blood.V87.12.5287.bloodjournal87125287; ZWEIER JL, 1995, NAT MED, V1, P804, DOI 10.1038/nm0895-804; ZWEIER JL, 1988, J BIOL CHEM, V263, P1353; ZWEIER JL, 1988, P NATL ACAD SCI USA, V85, P4046, DOI 10.1073/pnas.85.11.4046; ZWEIER JL, 1995, J BIOL CHEM, V270, P304, DOI 10.1074/jbc.270.1.304; ZWEIER JL, 1989, J BIOL CHEM, V264, P18890	56	106	114	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					38965	38972		10.1074/jbc.M006341200	http://dx.doi.org/10.1074/jbc.M006341200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10976106	hybrid			2022-12-25	WOS:000165953100005
J	Seisenberger, C; Specht, V; Welling, A; Platzer, J; Pfeifer, A; Kuhbandner, S; Striessnig, J; Klugbauer, N; Feil, R; Hofmann, F				Seisenberger, C; Specht, V; Welling, A; Platzer, J; Pfeifer, A; Kuhbandner, S; Striessnig, J; Klugbauer, N; Feil, R; Hofmann, F			Functional embryonic cardiomyocytes after disruption of the L-type alpha(1C) (Ca(v)1.2) calcium channel gene in the mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STATIONARY NIGHT BLINDNESS; BETA-ADRENERGIC MODULATION; CA2+ CHANNEL; ION CHANNELS; MICE LACKING; DEVELOPMENTAL-CHANGES; DRUG-BINDING; SUBUNIT; HEART; EXPRESSION	The L-type alpha (1c) (Ca(V)1.2) calcium channel is the major calcium entry pathway in cardiac and smooth muscle. We inactivated the Ca(nu)1.2 gene in two independent mouse lines that had indistinguishable phenotypes. Homozygous knockout embryos (Ca(V)1.2-/-) died before day 14.5 postcoitum (p.c.), At day 12.5 p.c., the embryonic heart contracted with identical frequency in wild type (+/+), heterozygous (+/-), and homozygous (-/-) Ca(V)1.2 embryos. Beating of isolated embryonic cardiomyocytes depended on extracellular calcium and was blocked by 1 muM nisoldipine, In (+/+), (+/-), and (-/-) cardiomyocytes, an L-type Ba2+ inward current (I-Ba) was present that was stimulated by Bay K 8644 in all genotypes. At a holding potential of -80 mV, nisoldipine blocked I-Ba of day 12.5 p.c. (+/+) and (+/-) cells with two IC50 values of approximate to0.1 and approximate to1 muM. Inhibition of I-Ba of (-/-) camdiomyocytes was monophasic with an IC50 of approximate to1 mum. The low affinity I-Ba was also present in cardiomyocytes of homozygous alpha (1D) (Ca(V)1.3) knockout embryos at day 12.5 p.c. These results indicate that, up to day 14 p.c., contraction of murine embryonic hearts requires an unidentified, low affinity L-type like calcium channel.	Tech Univ Munich, Inst Pharmakol & Toxikol, D-80802 Munich, Germany; Univ Innsbruck, Inst Biochem Pharmacol, A-6020 Innsbruck, Austria	Technical University of Munich; University of Innsbruck	Hofmann, F (corresponding author), Tech Univ Munich, Inst Pharmakol & Toxikol, Biedersteiner Str 29, D-80802 Munich, Germany.	pharma@ipt.med.tu-muenchen.de	Feil, Susanne/AAF-7032-2019; Feil, Robert/B-8918-2014; Striessnig, Joerg/S-9334-2017; Welling, Andrea/K-6674-2017	Feil, Robert/0000-0002-7335-4841; Striessnig, Joerg/0000-0002-9406-7120; Welling, Andrea/0000-0002-5364-4980				An RH, 1996, CIRC RES, V78, P371, DOI 10.1161/01.RES.78.3.371; BEAM KG, 1986, NATURE, V320, P168, DOI 10.1038/320168a0; Bech-Hansen NT, 1998, NAT GENET, V19, P264, DOI 10.1038/947; Davies MP, 1996, CIRC RES, V78, P15, DOI 10.1161/01.RES.78.1.15; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; HAASE H, 1994, RECEPTOR CHANNEL, V2, P41; Hockerman GH, 1997, ANNU REV PHARMACOL, V37, P361, DOI 10.1146/annurev.pharmtox.37.1.361; Hofmann F, 1999, REV PHYSIOL BIOCH P, V139, P33, DOI 10.1007/BFb0033648; Jun K, 1999, P NATL ACAD SCI USA, V96, P15245, DOI 10.1073/pnas.96.26.15245; KATZ AM, 1993, NEW ENGL J MED, V328, P1244; Klugbauer N, 1999, PFLUG ARCH EUR J PHY, V437, P710, DOI 10.1007/s004240050836; Lacinova L, 2000, PFLUG ARCH EUR J PHY, V440, P50, DOI 10.1007/s004240051021; LACINOVA L, 1995, FEBS LETT, V373, P103, DOI 10.1016/0014-5793(95)01013-5; LACINOVA L, 2000, NEUROPHARMACOLOGY, V12, P1217; Littleton JT, 2000, NEURON, V26, P35, DOI 10.1016/S0896-6273(00)81135-6; Liu W, 1999, AM J PHYSIOL-HEART C, V276, pH608, DOI 10.1152/ajpheart.1999.276.2.H608; MA WJ, 1992, J BIOL CHEM, V267, P22728; MEJIAALVAREZ R, 1994, J PHYSIOL-LONDON, V478, P315, DOI 10.1113/jphysiol.1994.sp020252; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Morel N, 1998, BRIT J PHARMACOL, V125, P1005, DOI 10.1038/sj.bjp.0702162; Perchenet L, 2000, N-S ARCH PHARMACOL, V361, P590, DOI 10.1007/s002100000238; Platzer J, 2000, CELL, V102, P89, DOI 10.1016/S0092-8674(00)00013-1; REUTER H, 1984, ANNU REV PHYSIOL, V46, P473; Saegusa H, 2000, P NATL ACAD SCI USA, V97, P6132, DOI 10.1073/pnas.100124197; Santana LF, 1998, SCIENCE, V279, P1027, DOI 10.1126/science.279.5353.1027; Satin J, 2000, CIRC RES, V86, P636, DOI 10.1161/01.RES.86.6.636; Schuster A, 1996, EMBO J, V15, P2365, DOI 10.1002/j.1460-2075.1996.tb00592.x; SOLDATOV NM, 1995, J BIOL CHEM, V270, P10540, DOI 10.1074/jbc.270.18.10540; SOLDATOV NM, 1994, GENOMICS, V22, P77, DOI 10.1006/geno.1994.1347; Striessnig J, 1999, CELL PHYSIOL BIOCHEM, V9, P242, DOI 10.1159/000016320; Striessnig J, 1998, TRENDS PHARMACOL SCI, V19, P108, DOI 10.1016/S0165-6147(98)01171-7; Strom TM, 1998, NAT GENET, V19, P260, DOI 10.1038/940; Takimoto K, 1997, J MOL CELL CARDIOL, V29, P3035, DOI 10.1006/jmcc.1997.0532; VASSORT G, 1994, J CARDIOVASC ELECTR, V5, P376, DOI 10.1111/j.1540-8167.1994.tb01175.x; Viatchenko-Karpinski S, 1999, P NATL ACAD SCI USA, V96, P8259, DOI 10.1073/pnas.96.14.8259; Welling A, 1997, CIRC RES, V81, P526, DOI 10.1161/01.RES.81.4.526; WELLING A, 1993, CIRC RES, V73, P974, DOI 10.1161/01.RES.73.5.974; Wyatt CN, 1997, J PHYSIOL-LONDON, V502, P307, DOI 10.1111/j.1469-7793.1997.307bk.x; YANEY GC, 1992, MOL ENDOCRINOL, V6, P2143, DOI 10.1210/me.6.12.2143; Zuhlke RD, 1998, FEBS LETT, V427, P220, DOI 10.1016/S0014-5793(98)00425-6	40	208	216	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39193	39199		10.1074/jbc.M006467200	http://dx.doi.org/10.1074/jbc.M006467200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10973973	hybrid			2022-12-25	WOS:000165953100035
J	Shimono, Y; Murakami, H; Hasegawa, Y; Takahashi, M				Shimono, Y; Murakami, H; Hasegawa, Y; Takahashi, M			RET finger protein is a transcriptional repressor and interacts with enhancer of polycomb that has dual transcriptional functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITION-EFFECT VARIEGATION; NUCLEAR-BODIES; DROSOPHILA-MELANOGASTER; TRANSFORMING GENE; BINDING-PROTEIN; RAR-ALPHA; ENCODES; PML; RING; COMPLEXES	RET finger protein (RFP) belongs to the large B-box RING; finger protein family and is known to become oncogenic by fusion with RET tyrosine kinase. Although RFP is reported to be a nuclear protein that is present in the nuclear matrix, its function is largely unknown. Here we show that REP interacts with Enhancer of Polycomb (EPC) and strongly represses the gene transcription. Yeast two-hybrid assays revealed that the coiled-coil domain of RFP was associated with the EPcA domain and the carboxyl-terminal region of EPC. In addition, both proteins were co-precipitated from the lysates of human cells and mostly colocalized in the nucleus. Using the luciferase reporter-gene assay, we found that they repress the gene transcription activity independent of the differences of enhancers and promoters used, although the repressive activity of RFP was much stronger than that of EPC. The coiled-coil domain of RFP and the carboxyl-terminal region of EPC were most important for the repressive activity of each protein, whereas the EPcA domain had the transcription activating ability that is unique as the Polycomb group protein function. These results suggested that RFP may be involved in the epigenetic gene silencing mechanism cooperating with Polycomb group proteins and that EPC is a unique molecule with both repressive and transactivating activities.	Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Internal Med 1, Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University; Nagoya University	Takahashi, M (corresponding author), Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.		Takahashi, Masahide/AAN-4770-2020; Hasegawa, Yoshinori/I-1277-2012; TAKAHASHI, Masahide/I-7244-2014	Takahashi, Masahide/0000-0002-2803-2683; Shimono, Yohei/0000-0002-6256-4704				ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; Bardos JI, 2000, J BIOL CHEM, V275, P28785, DOI 10.1074/jbc.M001835200; BERG JM, 1990, J BIOL CHEM, V265, P6513; Boisvert FM, 2000, J CELL BIOL, V148, P283, DOI 10.1083/jcb.148.2.283; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; Borden KLB, 1998, BIOCHEM CELL BIOL, V76, P351, DOI 10.1139/bcb-76-2-3-351; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BUNKER CA, 1994, MOL CELL BIOL, V14, P1721, DOI 10.1128/MCB.14.3.1721; CAMPBELL RB, 1995, MOL GEN GENET, V246, P291, DOI 10.1007/BF00288601; Cao TY, 1998, J CELL SCI, V111, P1319; Cao TY, 1997, J CELL SCI, V110, P1563; Carrington EA, 1996, DEVELOPMENT, V122, P4073; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; CHENG NSN, 1994, GENETICS, V138, P1151; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; Gould A, 1997, CURR OPIN GENET DEV, V7, P488, DOI 10.1016/S0959-437X(97)80075-5; Grande MA, 1996, J CELL BIOCHEM, V63, P280, DOI 10.1002/(SICI)1097-4644(19961201)63:3<280::AID-JCB3>3.0.CO;2-T; Gunster MJ, 1997, MOL CELL BIOL, V17, P2326, DOI 10.1128/MCB.17.4.2326; GUTJAHR T, 1995, EMBO J, V14, P4296, DOI 10.1002/j.1460-2075.1995.tb00104.x; Hasegawa N, 1996, BIOCHEM BIOPH RES CO, V225, P627, DOI 10.1006/bbrc.1996.1221; Henry J, 1998, MOL BIOL EVOL, V15, P1696, DOI 10.1093/oxfordjournals.molbev.a025896; ISOMURA T, 1992, NUCLEIC ACIDS RES, V20, P5305, DOI 10.1093/nar/20.20.5305; Iwata Y, 1999, BIOCHEM BIOPH RES CO, V261, P381, DOI 10.1006/bbrc.1999.1037; Jones CA, 1998, MOL CELL BIOL, V18, P2825, DOI 10.1128/MCB.18.5.2825; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KANNO M, 1995, EMBO J, V14, P5672, DOI 10.1002/j.1460-2075.1995.tb00254.x; Laible G, 1997, EMBO J, V16, P3219, DOI 10.1093/emboj/16.11.3219; LaJeunesse D, 1996, DEVELOPMENT, V122, P2189; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Morris-Desbois C, 1999, J CELL SCI, V112, P3331; MULLER J, 1995, EMBO J, V14, P1209, DOI 10.1002/j.1460-2075.1995.tb07104.x; Pirrotta V, 1997, CURR OPIN GENET DEV, V7, P249, DOI 10.1016/S0959-437X(97)80135-9; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; Satijn DPE, 1999, BBA-GENE STRUCT EXPR, V1447, P1, DOI 10.1016/S0167-4781(99)00130-X; Satijn DPE, 1999, MOL CELL BIOL, V19, P57; Satijn DPE, 1997, MOL CELL BIOL, V17, P4105, DOI 10.1128/MCB.17.7.4105; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SHEARN A, 1989, GENETICS, V121, P517; Sinclair DAR, 1998, GENETICS, V148, P211; Stankunas K, 1998, DEVELOPMENT, V125, P4055; Sternsdorf T, 1997, IMMUNOBIOLOGY, V198, P307, DOI 10.1016/S0171-2985(97)80051-4; STUURMAN N, 1992, J CELL SCI, V101, P773; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; Tetsu O, 1998, IMMUNITY, V9, P439, DOI 10.1016/S1074-7613(00)80627-5; Tezel G, 1999, PATHOL INT, V49, P881, DOI 10.1046/j.1440-1827.1999.00957.x; Topcu Z, 1999, ONCOGENE, V18, P7091, DOI 10.1038/sj.onc.1203201; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602	53	83	90	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39411	39419		10.1074/jbc.M006585200	http://dx.doi.org/10.1074/jbc.M006585200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10976108	hybrid			2022-12-25	WOS:000165953100065
J	Meetei, AR; Ullas, KS; Rao, MRS				Meetei, AR; Ullas, KS; Rao, MRS			Identification of two novel zinc finger modules and nuclear localization signal in rat spermatidal protein TP2 by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOLAR LOCALIZATION; TRANSITION PROTEIN-2; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; SPERM CHROMATIN; GENE-EXPRESSION; DNA RECOGNITION; SEQUENCE; COMPLEX; CDNA	Spermatidal protein TP2, which appears transiently during stages 12-16 of mammalian spermiogenesis, is a DNA condensing zinc metalloprotein with a preference to GC-rich DNA. We have carried out a detailed site-directed mutagenesis analysis of rat spermatidal protein TP2 to delineate the amino acid residues involved in coordination with two atoms of zinc. Two zinc fingers modules have been identified involving 4 histidine and 4 cysteine residues, respectively. The modular structure of the two zinc fingers identified in TP2 define a new class of zinc finger proteins that do not fall into any of the known classes of zinc fingers. Transfection experiments with COS-7 cells using wild type and the two zinc finger pocket mutants have shown that TP2 preferentially localizes to nucleolus. The nuclear localization signal in TP2 was identified to be (87)GKVSKRKAV(95) present in the C-terminal third of TP2 as a part of an extended NoLS sequence.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Rao, MRS (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.							Akama K, 1999, FEBS LETT, V442, P189, DOI 10.1016/S0014-5793(98)01649-4; Akama K, 1997, BIOCHEM MOL BIOL INT, V42, P865; Annilo T, 1998, BIOCHEM BIOPH RES CO, V249, P759, DOI 10.1006/bbrc.1998.9187; BASKARAN R, 1990, J BIOL CHEM, V265, P21039; BASKARAN R, 1991, BIOCHEM BIOPH RES CO, V179, P1491, DOI 10.1016/0006-291X(91)91741-T; BUSCH H, 1970, NUCLEUS, P161; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Donaldson IM, 2000, J BIOL CHEM, V275, P13780, DOI 10.1074/jbc.275.18.13780; FALKNER FG, 1988, VIROLOGY, V164, P450, DOI 10.1016/0042-6822(88)90559-4; GATEWOOD JM, 1987, SCIENCE, V236, P962, DOI 10.1126/science.3576213; KEIME S, 1992, ANIM GENET, V23, P373, DOI 10.1111/j.1365-2052.1992.tb00161.x; KLEENE KC, 1987, J BIOL CHEM, V262, P17272; Klug A, 1999, J MOL BIOL, V293, P215, DOI 10.1006/jmbi.1999.3007; KUNDU TK, 1994, FEBS LETT, V351, P6, DOI 10.1016/0014-5793(94)00799-3; KUNDU TK, 1995, BIOCHEMISTRY-US, V34, P5143, DOI 10.1021/bi00015a027; Kundu TK, 1999, J BIOCHEM, V125, P217, DOI 10.1093/oxfordjournals.jbchem.a022276; Kundu TK, 1996, BIOCHEMISTRY-US, V35, P15626, DOI 10.1021/bi961271i; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu JL, 1997, J VIROL, V71, P3188, DOI 10.1128/JVI.71.4.3188-3196.1997; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MEARS WE, 1995, J VIROL, V69, P935, DOI 10.1128/JVI.69.2.935-947.1995; Meetei AR, 1996, PROTEIN EXPRES PURIF, V8, P409, DOI 10.1006/prep.1996.0118; Meetei AR, 1998, PROTEIN EXPRES PURIF, V13, P184, DOI 10.1006/prep.1998.0887; Meetei AR, 1998, ANAL BIOCHEM, V264, P288; Meistrich M., 1989, HISTONES OTHER BASIC, P165; NELSON JE, 1993, J BIOL CHEM, V268, P2932; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Pittoggi C, 1999, J CELL SCI, V112, P3537; RIKKONEN M, 1992, VIROLOGY, V189, P462, DOI 10.1016/0042-6822(92)90570-F; Sato H, 1999, PROTEIN EXPRES PURIF, V16, P454, DOI 10.1006/prep.1999.1095; SINGH J, 1987, J BIOL CHEM, V262, P734; SINGH J, 1988, BIOCHEM INT, V17, P701; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; VALDEZ BC, 1994, J BIOL CHEM, V269, P23776; Wolfe SA, 1999, J MOL BIOL, V285, P1917, DOI 10.1006/jmbi.1998.2421; Yu YE, 2000, P NATL ACAD SCI USA, V97, P4683, DOI 10.1073/pnas.97.9.4683	38	25	27	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38500	38507		10.1074/jbc.M002734200	http://dx.doi.org/10.1074/jbc.M002734200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10961985	hybrid			2022-12-25	WOS:000165739800050
J	Davis, PJ; Shih, A; Lin, HY; Martino, LJ; Davis, FB				Davis, PJ; Shih, A; Lin, HY; Martino, LJ; Davis, FB			Thyroxine promotes association of mitogen-activated protein kinase and nuclear thyroid hormone receptor (TR) and causes serine phosphorylation of TR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X RECEPTOR; CULTURED-CELLS; IN-VITRO; BINDING; ACID; DNA; TRANSCRIPTION; ANALOGS; COACTIVATORS; STIMULATION	Activated nongenomically by L-thyroxine (T-4), mitogen-activated protein kinase (MAPK) complexed in 10-20 min with endogenous nuclear thyroid hormone receptor (TR beta1 or TR) in nuclear fractions of 293T cells, resulting in serine phosphorylation of TR, Treatment of cells with the MAPK kinase inhibitor, PD 98059, prevented both T-4-induced nuclear MAPK-TR co-immunoprecipitation and serine phosphorylation of TR. T-4 treatment caused dissociation of TR and SMRT (silencing mediator of retinoid and thyroid hormone receptor), an effect also inhibited by PD 98059 and presumptively a result of association of nuclear MAPK with TR, Transfection into CV-1 cells of TR gene constructs in which one or both zinc fingers in the TR DNA-binding domain were replaced with those from the glucocorticoid receptor localized the site of TR phosphorylation by T-4-activated MAPK to a serine in the second zinc finger of the TR DNA-binding domain. In an in vitro cell- and hormone-free system, purified activated MAPK phosphorylated recombinant human TR beta1 (102-461). Thus, T-4 activates MAPK and causes MAPK-mediated serine phosphorylation of TR beta1 and dissociation of TR and the co-repressor SMRT.	Albany Med Coll, Dept Med, Albany, NY 12208 USA; Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; Albany Med Coll, Samuel S Stratton Vet Affairs Med Ctr, Albany, NY 12208 USA; Albany Med Coll, Mol & Cellular Med Program, Albany, NY 12208 USA	Albany Medical College; Albany Medical College; Albany Medical College; Albany Medical College	Davis, PJ (corresponding author), Albany Med Coll, Dept Med, MC-16, Albany, NY 12208 USA.							BHAT MK, 1994, P NATL ACAD SCI USA, V91, P7927, DOI 10.1073/pnas.91.17.7927; Castoria G, 1999, EMBO J, V18, P2500, DOI 10.1093/emboj/18.9.2500; Ceresa BP, 1997, ENDOCRINOLOGY, V138, P4131, DOI 10.1210/en.138.10.4131; CHIN WW, 1997, CONT ENDOCRINOLOGY D, P17; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAVIS FB, 1995, METABOLISM, V44, P865, DOI 10.1016/0026-0495(95)90238-4; DAVIS FB, 1993, J CLIN ENDOCR METAB, V77, P1427, DOI 10.1210/jc.77.5.1427; DAVIS PJ, 1982, LIFE SCI, V30, P675, DOI 10.1016/0024-3205(82)90283-1; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Han XB, 1999, ENDOCRINOLOGY, V140, P2241, DOI 10.1210/en.140.5.2241; JONES KE, 1994, ENDOCRINOLOGY, V134, P543, DOI 10.1210/en.134.2.543; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KATZ D, 1995, MOL CELL BIOL, V15, P2341; Krstic MD, 1997, MOL CELL BIOL, V17, P3947, DOI 10.1128/MCB.17.7.3947; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; Leitman DC, 1996, J BIOL CHEM, V271, P21950, DOI 10.1074/jbc.271.36.21950; Lin HY, 1999, AM J PHYSIOL-CELL PH, V276, pC1014, DOI 10.1152/ajpcell.1999.276.5.C1014; Lin HY, 1997, AM J PHYSIOL-CELL PH, V273, pC1225, DOI 10.1152/ajpcell.1997.273.4.C1225; Lin HY, 1996, J CELL PHYSIOL, V167, P269, DOI 10.1002/(SICI)1097-4652(199605)167:2<269::AID-JCP10>3.0.CO;2-3; Lin HY, 1998, J IMMUNOL, V161, P843; Lin HY, 1999, BIOCHEM J, V338, P427, DOI 10.1042/0264-6021:3380427; LIN KH, 1992, P NATL ACAD SCI USA, V89, P7737, DOI 10.1073/pnas.89.16.7737; Nagaya T, 1996, BIOCHEM BIOPH RES CO, V222, P524, DOI 10.1006/bbrc.1996.0777; OPPENHEIMER JH, 1973, BIOCHEM BIOPH RES CO, V55, P544, DOI 10.1016/0006-291X(73)91177-7; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; Safer JD, 1998, J BIOL CHEM, V273, P30175, DOI 10.1074/jbc.273.46.30175; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SCHUELER PA, 1990, MOL ENDOCRINOL, V4, P227, DOI 10.1210/mend-4-2-227; SELMI S, 1991, J BIOL CHEM, V266, P11589; SMITH TJ, 1992, BIOCHEM J, V284, P583, DOI 10.1042/bj2840583; SUGAWARA A, 1994, J BIOL CHEM, V269, P433; Tagami T, 1998, MOL ENDOCRINOL, V12, P1888, DOI 10.1210/me.12.12.1888; Ting YT, 1997, J BIOL CHEM, V272, P4129, DOI 10.1074/jbc.272.7.4129; Ting YT, 1997, THYROID, V7, P463, DOI 10.1089/thy.1997.7.463; Tzagarakis-Foster C, 1998, J BIOL CHEM, V273, P10926, DOI 10.1074/jbc.273.18.10926; WEINSTEIN SP, 1990, ENDOCRINOLOGY, V126, P1421, DOI 10.1210/endo-126-3-1421; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yamazaki T, 1997, CIRCULATION, V95, P1260; Yang XY, 1998, J BIOL CHEM, V273, P29879, DOI 10.1074/jbc.273.45.29879; YEN PM, 1992, J BIOL CHEM, V267, P23248; Zhu XG, 1998, J BIOL CHEM, V273, P27058, DOI 10.1074/jbc.273.42.27058	42	171	199	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					38032	38039		10.1074/jbc.M002560200	http://dx.doi.org/10.1074/jbc.M002560200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10982791	hybrid			2022-12-25	WOS:000165618700097
J	Howorka, S; Sara, M; Wang, YJ; Kuen, B; Sleytr, UB; Lubitz, W; Bayley, H				Howorka, S; Sara, M; Wang, YJ; Kuen, B; Sleytr, UB; Lubitz, W; Bayley, H			Surface-accessible residues in the monomeric and assembled forms of a bacterial surface layer protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCAL ALPHA-HEMOLYSIN; BACILLUS-STEAROTHERMOPHILUS STRAINS; CYSTEINE SCANNING MUTAGENESIS; CELL-WALL POLYMER; N-TERMINAL PART; S-LAYER; ESCHERICHIA-COLI; OUTER-MEMBRANE; CAULOBACTER-CRESCENTUS; AEROMONAS-SALMONICIDA	The S-layer protein SbsB of the thermophilic, Grampositive organism Bacillus stearothermophilus PV72/p2 forms a crystalline, porous array constituting the outermost component of the cell envelope. SbsB has a molecular mass of 98 kDa, and the corresponding S-layer exhibits an oblique lattice symmetry. To investigate the molecular structure and assembly of SbsB, we replaced 75 residues (mainly serine, threonine, and alanine), located throughout the primary sequence, with cysteine, which is not found in the wild-type protein. As determined by electron microscopy, 72 out of 75 mutants formed regularly-structured self-assembly products identical to wild-type, thereby proving that the replacement of most of the selected amino acids by cysteine does not dramatically alter the structure of the protein. The three defective mutants, which showed a greatly reduced ability to self-assemble, were, however, successfully incorporated into S-layers of wild-type protein. Monomeric SbsB mutants and SbsB mutants assembled into S-layers were subjected to a surface accessibility screen by targeted chemical modification with a 5-kDa hydrophilic cysteine-reactive polyethylene glycol conjugate. In the monomeric form of SbsB, 34 of the examined residues were not surface accessible, while 23 were classified as very accessible, and 18 were of intermediate surface accessibility. By contrast, in the assembled Slayers, 57 of the mutated residues were not accessible, six were very accessible, and 12 of intermediate accessibility. Together with other structural information, the results suggest a model for SbsB in which functional domains are segregated along the length of the polypeptide chain.	Texas A&M Univ Syst, Hlth Sci Ctr, Dept Med Biochem & Genet, College Stn, TX 77843 USA; Univ Agr Sci, Ctr Ultrastruct Res, A-1180 Vienna, Austria; Univ Agr Sci, Ludwig Boltzmann Inst Mol Nanotechnol, A-1180 Vienna, Austria; Univ Vienna, Inst Genet & Microbiol, A-1030 Vienna, Austria; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Natural Resources & Life Sciences, Vienna; Ludwig Boltzmann Institute; University of Natural Resources & Life Sciences, Vienna; University of Vienna; Texas A&M University System; Texas A&M University College Station	Howorka, S (corresponding author), Texas A&M Univ Syst, Hlth Sci Ctr, Dept Med Biochem & Genet, 440 Reynolds Med Bldg, College Stn, TX 77843 USA.			Howorka, Stefan/0000-0002-6527-2846; Bayley, Hagan/0000-0003-2499-6116				AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; BEVERIDGE TJ, 1994, CURR OPIN STRUC BIOL, V4, P204, DOI 10.1016/S0959-440X(94)90309-3; Bingle WH, 1997, MOL MICROBIOL, V26, P277, DOI 10.1046/j.1365-2958.1997.5711932.x; Bingle WH, 1997, J BACTERIOL, V179, P601, DOI 10.1128/jb.179.3.601-611.1997; Boot HJ, 1996, MOL MICROBIOL, V21, P1117, DOI 10.1046/j.1365-2958.1996.711442.x; Chami M, 1997, MOL MICROBIOL, V23, P483, DOI 10.1046/j.1365-2958.1997.d01-1868.x; Cheley S, 1997, PROTEIN ENG, V10, P1433, DOI 10.1093/protein/10.12.1433; CHU S, 1991, J BIOL CHEM, V266, P15258; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; Demchick P, 1996, J BACTERIOL, V178, P768, DOI 10.1128/jb.178.3.768-773.1996; DOIG P, 1993, J MOL BIOL, V233, P753, DOI 10.1006/jmbi.1993.1550; DWORKIN J, 1995, J BACTERIOL, V177, P1734, DOI 10.1128/jb.177.7.1734-1741.1995; Engelhardt H, 1998, J STRUCT BIOL, V124, P276, DOI 10.1006/jsbi.1998.4070; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; Howorka S, 1998, BIOTECHNIQUES, V25, P764, DOI 10.2144/98255bm03; HUFF JP, 1990, BIOTECHNIQUES, V9, P570; Jones Douglas H., 1995, P591; Kleinschmidt JH, 1999, PROTEIN SCI, V8, P2065, DOI 10.1110/ps.8.10.2065; KLOSE M, 1988, J BIOL CHEM, V263, P13291; KRISHNASASTRY M, 1994, FEBS LETT, V356, P66, DOI 10.1016/0014-5793(94)01240-7; Kuen B, 1997, J BACTERIOL, V179, P1664, DOI 10.1128/jb.179.5.1664-1670.1997; KURFURST MM, 1992, ANAL BIOCHEM, V200, P244, DOI 10.1016/0003-2697(92)90460-O; LUPAS A, 1994, J BACTERIOL, V176, P1224, DOI 10.1128/jb.176.5.1224-1233.1994; Mesnage S, 1999, MOL MICROBIOL, V31, P927, DOI 10.1046/j.1365-2958.1999.01232.x; MESSNER P, 1984, INT J SYST BACTERIOL, V34, P202, DOI 10.1099/00207713-34-2-202; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; NAKAMURA K, 1976, J BIOCHEM, V80, P1411, DOI 10.1093/oxfordjournals.jbchem.a131414; NEUBAUER A, 2000, P 4 SEM QUANT MICR Q, P118; Olabarria G, 1996, J BACTERIOL, V178, P4765, DOI 10.1128/jb.178.16.4765-4772.1996; PUM D, 1989, J BACTERIOL, V171, P5296, DOI 10.1128/jb.171.10.5296-5303.1989; REST B, 1994, PROTEINS, V20, P216; Ries W, 1997, J BACTERIOL, V179, P3892, DOI 10.1128/jb.179.12.3892-3898.1997; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; Sambrook J., 2002, MOL CLONING LAB MANU; Sara M, 1996, J BACTERIOL, V178, P2108, DOI 10.1128/jb.178.7.2108-2117.1996; Sara M, 1998, J BACTERIOL, V180, P6780; SARA M, 1994, J BACTERIOL, V176, P7182; Sara M, 2000, J BACTERIOL, V182, P859, DOI 10.1128/JB.182.4.859-868.2000; SCHERRER R, 1971, J BACTERIOL, V107, P718, DOI 10.1128/JB.107.3.718-735.1971; Sleytr U.B., 1996, CRYSTALLINE BACTERIA; Sleytr UB, 1999, TRENDS MICROBIOL, V7, P253, DOI 10.1016/S0966-842X(99)01513-9; THOMAS S, 1992, J MOL BIOL, V228, P652, DOI 10.1016/0022-2836(92)90847-D; Tsai CJ, 1997, PROTEIN SCI, V6, P53; WALKER B, 1995, J BIOL CHEM, V270, P23065, DOI 10.1074/jbc.270.39.23065; WEI J, 1995, BIOCHEMISTRY-US, V34, P6408, DOI 10.1021/bi00019a021; WIEDER KJ, 1979, J BIOL CHEM, V254, P2579	47	48	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37876	37886		10.1074/jbc.M003838200	http://dx.doi.org/10.1074/jbc.M003838200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10969072	hybrid			2022-12-25	WOS:000165618700077
J	Ji, Y; Lalli, MJ; Babu, GJ; Xu, YF; Kirkpatrick, DL; Liu, LH; Chiamvimonvat, N; Walsh, RA; Shull, GE; Periasamy, M				Ji, Y; Lalli, MJ; Babu, GJ; Xu, YF; Kirkpatrick, DL; Liu, LH; Chiamvimonvat, N; Walsh, RA; Shull, GE; Periasamy, M			Disruption of a single copy of the SERCA2 gene results in altered Ca2+ homeostasis and cardiomyocyte function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; ENHANCED MYOCARDIAL-CONTRACTILITY; CARDIAC NA+-CA2+ EXCHANGER; SODIUM-CALCIUM EXCHANGE; VENTRICULAR MYOCYTES; TRANSGENIC MICE; PROTEIN-LEVELS; HEART-FAILURE; PHOSPHOLAMBAN; PHOSPHORYLATION	A mouse model carrying a null mutation in one copy of the sarcoplasmic reticulum (SR) Ca2+-ATPase isoform 2 (SERCA2) gene, in which SERCA2 protein levels are reduced by similar to 35%, was used to investigate the effects of decreased SERCA2 level on intracellular Ca2+ homeostasis and contractile properties in isolated cardiomyocytes, When compared with wild-type controls, SR Ca2+ stores and Ca2+ release in myocytes of SERCA2 heterozygous mice were decreased by similar to 40-60% and similar to 30-40%, respectively, and the rate of myocyte shortening and relengthening were each decreased by similar to 40%. However, the rate of Ca2+ transient decline (tau) was not altered significantly, suggesting that compensation was occurring in the removal of Ca2+ from the cytosol, Phospholamban, which inhibits SERCA2, was decreased by similar to 40% in heterozygous hearts, and basal phosphorylation of Ser-16 and Thr-17, which relieves the inhibition, was increased similar to2- and 2.1-fold. These results indicate that reduced expression and increased phosphorylation of phospholamban provides compensation for decreased SERCA2 protein levels in heterozygous heart. Furthermore, both expression and current density of the sarcolemmal Na+-Ca2+ exchanger were up-regulated, These results demonstrate that a decrease in SERCA2 levels can directly modify intracellular Ca2+ homeostasis and myocyte contractility. However, the resulting deficit is partially compensated by alterations in phospholamban/SERCA2 interactions and by up-regulation of the Na+-Ca2+ exchanger.	Univ Cincinnati, Coll Med, Div Cardiol, Dept Internal Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Case Western Reserve University; University Hospitals of Cleveland	Periasamy, M (corresponding author), Univ Cincinnati, Coll Med, Div Cardiol, Dept Internal Med, 231 Bethesda Ave,ML 0542, Cincinnati, OH 45267 USA.	muthu.periasamy@UC.edu	Babu, Gopal/AAB-7787-2021	Babu, Gopal/0000-0001-7833-5300; Periasamy, Muthu/0000-0001-8834-5975	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061974, P50HL052318, R01HL068507, R01HL064140] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL64140-01, HL52318, R01 HL068507, HL61974] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AdachiAkahane S, 1997, J GEN PHYSIOL, V109, P717, DOI 10.1085/jgp.109.6.717; ARAI M, 1994, CIRC RES, V74, P555, DOI 10.1161/01.RES.74.4.555; Autry JM, 1997, J BIOL CHEM, V272, P15872, DOI 10.1074/jbc.272.25.15872; Baker DL, 1998, CIRC RES, V83, P1205, DOI 10.1161/01.RES.83.12.1205; BARRY WH, 1993, CIRCULATION, V87, P1806, DOI 10.1161/01.CIR.87.6.1806; BASSANI JWM, 1994, J PHYSIOL-LONDON, V476, P279, DOI 10.1113/jphysiol.1994.sp020130; BERS DM, 1991, EXCITATION CONTRACTI; BEUCKELMANN DJ, 1989, J PHYSIOL-LONDON, V414, P499, DOI 10.1113/jphysiol.1989.sp017700; Bhogal MS, 1998, P NATL ACAD SCI USA, V95, P1484, DOI 10.1073/pnas.95.4.1484; Cernohorsky J, 1998, AM J PHYSIOL-HEART C, V275, pH264, DOI 10.1152/ajpheart.1998.275.1.H264; Chu GX, 1996, CIRC RES, V79, P1064, DOI 10.1161/01.RES.79.6.1064; Cornea RL, 1997, BIOCHEMISTRY-US, V36, P2960, DOI 10.1021/bi961955q; Dipla K, 1999, CIRC RES, V84, P435, DOI 10.1161/01.RES.84.4.435; DRAGO GA, 1994, BIOCHEM J, V269, P20573; EGGERMONT JA, 1990, BIOCHEM J, V271, P649, DOI 10.1042/bj2710649; GIAS AU, 2000, CIRC RES, V86, P558; Greene AL, 2000, J BIOL CHEM, V275, P24722, DOI 10.1074/jbc.M001783200; Guo W, 1996, J BIOL CHEM, V271, P458, DOI 10.1074/jbc.271.1.458; HARRER JM, 1995, BIOTECHNIQUES, V18, P995; Hasenfuss G, 1999, CIRCULATION, V99, P641, DOI 10.1161/01.CIR.99.5.641; Ji Y, 1999, AM J PHYSIOL-HEART C, V276, pH89, DOI 10.1152/ajpheart.1999.276.1.H89; Ji Y, 1999, ANAL BIOCHEM, V269, P236, DOI 10.1006/abio.1999.4059; Jones LR, 1998, J CLIN INVEST, V101, P1385, DOI 10.1172/JCI1362; Kadambi VJ, 1996, J CLIN INVEST, V97, P533, DOI 10.1172/JCI118446; Kimura Y, 1997, J BIOL CHEM, V272, P15061, DOI 10.1074/jbc.272.24.15061; Koss KL, 1996, CIRC RES, V79, P1059, DOI 10.1161/01.RES.79.6.1059; Li L, 1998, AM J PHYSIOL-HEART C, V274, pH1335, DOI 10.1152/ajpheart.1998.274.4.H1335; LINDEMANN JP, 1983, J BIOL CHEM, V258, P464; Litwin S, 1996, ANN NY ACAD SCI, V779, P451, DOI 10.1111/j.1749-6632.1996.tb44820.x; Loukianov E, 1998, CIRC RES, V83, P889; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; Mattiello JA, 1998, CARDIOVASC RES, V37, P424, DOI 10.1016/S0008-6363(97)00271-X; NADALGINARD B, 1989, J CLIN INVEST, V84, P1693, DOI 10.1172/JCI114351; NEGRETTI N, 1993, CARDIOVASC RES, V27, P1826, DOI 10.1093/cvr/27.10.1826; Pawloski-Dahm CM, 1998, CIRCULATION, V97, P1508; Periasamy M, 1999, J BIOL CHEM, V274, P2556, DOI 10.1074/jbc.274.4.2556; Reddy LG, 1999, BIOCHEMISTRY-US, V38, P3954, DOI 10.1021/bi981795d; Reed TD, 2000, J MOL CELL CARDIOL, V32, P453, DOI 10.1006/jmcc.1999.1095; ROBERTSON S, 1984, METHOD PHARMACOL, V5, P63, DOI DOI 10.1007/978-1-4684-4778-1_6; Sato Y, 1998, J BIOL CHEM, V273, P28470, DOI 10.1074/jbc.273.43.28470; SCHWARTZ K, 1981, J MOL CELL CARDIOL, V13, P1071, DOI 10.1016/0022-2828(81)90297-2; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; SMITH GL, 1988, J GEN PHYSIOL, V92, P351, DOI 10.1085/jgp.92.3.351; STUDER R, 1994, CIRC RES, V75, P443, DOI 10.1161/01.RES.75.3.443; TADA M, 1974, J BIOL CHEM, V249, P6174; TAKESHIMA H, 1995, EMBO J, V14, P2999, DOI 10.1002/j.1460-2075.1995.tb07302.x; Vikstrom KL, 1998, CIRC RES, V82, P773, DOI 10.1161/01.RES.82.7.773; WEGENER AD, 1989, J BIOL CHEM, V264, P11468; Yao AS, 1998, CIRC RES, V82, P657, DOI 10.1161/01.RES.82.6.657; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389	50	104	108	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					38073	38080		10.1074/jbc.M004804200	http://dx.doi.org/10.1074/jbc.M004804200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10970890	hybrid			2022-12-25	WOS:000165618700102
J	Sanders, MA; Basson, MD				Sanders, MA; Basson, MD			Collagen IV-dependent ERK activation in human Caco-2 intestinal epithelial cells requires focal adhesion kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX PROTEINS; INTEGRIN-MEDIATED ACTIVATION; IN-VITRO MODEL; TYROSINE PHOSPHORYLATION; ENTEROCYTIC DIFFERENTIATION; UROKINASE RECEPTOR; SIGNALING PATHWAYS; DOWN-REGULATION; GROWTH-FACTOR; MAP KINASE	Integrin-initiated extracellular signal-regulated kinase (ERK) activation by matrix adhesion may require focal adhesion kinase (FAK) or be FAK-independent via caveolin and Shc. This remains controversial for fibroblast and endothelial cell adhesion to fibronectin and is less understood for other matrix proteins and cells. We investigated Caco-2 intestinal epithelial cell ERK activation by collagen I and TV, laminin, and fibronectin. Collagens or laminin, but not fibronectin, stimulated tyrosine phosphorylation of FAK, paxillin, and p130(cas) and activated ERK1/2. Shc, tyrosine-phosphorylated by matrix adhesion in many cells, was not phosphorylated in Caco-2 cells in response to any matrix. Caveolin expression did not affect Caco-2 Shc phosphorylation in response to fibronectin. FAK, ERK, and p130(cas) tyrosine phosphorylation were activated after 10-min adhesion to collagen TV. FAK activity increased for 45 min after collagen TV adhesion and persisted for 2 h, while p130(cas) phosphorylation increased only slightly after 10 min. ERK activity peaked at 10 min, declined after 30 min, and returned to base line after 1 h. Transfection with FAK-related nonkinase, but not substrate domain deleted p130(cas), strongly inhibited ERK2 activation in response to collagen TV, indicating Caco-2 ERK activation is at least partly regulated by FAK.	Yale Univ, Sch Med, Dept Surg, New Haven, CT 06520 USA; Connecticut Vet Affairs Hlth Care SYst, W Haven, CT 06516 USA	Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	Basson, MD (corresponding author), Yale Univ, Sch Med, Dept Surg, 333 Cedar St,POB 208062, New Haven, CT 06520 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK047051] Funding Source: NIH RePORTER; NIDDK NIH HHS [R29DK47051] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asthagiri AR, 1999, J BIOL CHEM, V274, P27119, DOI 10.1074/jbc.274.38.27119; Basson MD, 1998, CLIN EXP PHARMACOL P, V25, P280, DOI 10.1111/j.1440-1681.1998.t01-10-.x; Basson MD, 1996, EXP CELL RES, V225, P301, DOI 10.1006/excr.1996.0180; BASSON MD, 1992, J CLIN INVEST, V90, P15, DOI 10.1172/JCI115828; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Camper L, 1998, J BIOL CHEM, V273, P20383, DOI 10.1074/jbc.273.32.20383; CHANTRET I, 1988, CANCER RES, V48, P1936; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; De Arcangelis A, 1996, J CELL BIOL, V133, P417, DOI 10.1083/jcb.133.2.417; DIPERSIO CM, 1995, J CELL SCI, V108, P2321; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Field FJ, 1998, J LIPID RES, V39, P1938; FORSBERG E, 1994, EXP CELL RES, V213, P183, DOI 10.1006/excr.1994.1189; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Gibson PR, 1999, CARCINOGENESIS, V20, P539, DOI 10.1093/carcin/20.4.539; Hakak Y, 1999, MOL CELL BIOL, V19, P6953; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Heath JP, 1996, CELL BIOL INT, V20, P139, DOI 10.1006/cbir.1996.0018; KRAMER RH, 1989, J BIOL CHEM, V264, P4684; Levy P, 1998, J CELL PHYSIOL, V177, P618, DOI 10.1002/(SICI)1097-4652(199812)177:4<618::AID-JCP12>3.0.CO;2-R; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Lotz MM, 2000, AM J PATHOL, V156, P985, DOI 10.1016/S0002-9440(10)64966-8; Lotz MM, 1997, AM J PATHOL, V150, P747; MADRI JA, 1988, AM J PATHOL, V132, P18; Mirre C, 1996, AM J PHYSIOL-CELL PH, V271, pC887, DOI 10.1152/ajpcell.1996.271.3.C887; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; Nakamoto T, 1997, MOL CELL BIOL, V17, P3884, DOI 10.1128/MCB.17.7.3884; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; PETERSON MD, 1993, J CELL SCI, V105, P461; PETERSON MD, 1993, J CELL SCI, V105, P445; Podolsky DK, 1997, J GASTROENTEROL, V32, P122, DOI 10.1007/BF01213309; Pozzi M, 1998, J CELL BIOL, V142, P587; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; SIMONASSMANN P, 1995, EXPERIENTIA, V51, P883, DOI 10.1007/BF01921739; Takeuchi Y, 1997, J BIOL CHEM, V272, P29309, DOI 10.1074/jbc.272.46.29309; VACHON PH, 1995, AM J PHYSIOL-GASTR L, V268, pG857, DOI 10.1152/ajpgi.1995.268.5.G857; Velling T, 1999, J BIOL CHEM, V274, P25735, DOI 10.1074/jbc.274.36.25735; Vogel U, 1998, J CELL SCI, V111, P825; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; Wilson AJ, 1997, CLIN SCI, V93, P97, DOI 10.1042/cs0930097; Wolpert S, 1996, AM J SURG, V171, P109, DOI 10.1016/S0002-9610(99)80083-X; Yu CF, 2000, AM J PHYSIOL-GASTR L, V278, pG952, DOI 10.1152/ajpgi.2000.278.6.G952; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	59	70	70	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					38040	38047		10.1074/jbc.M003871200	http://dx.doi.org/10.1074/jbc.M003871200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10986280	hybrid			2022-12-25	WOS:000165618700098
J	Bennett, RG; Duckworth, WC; Hamel, FG				Bennett, RG; Duckworth, WC; Hamel, FG			Degradation of amylin by insulin-degrading enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISLET-AMYLOID POLYPEPTIDE; TRANSGENIC MICE; DIABETES-MELLITUS; OVERPRODUCTION; HYPERGLYCEMIA; PURIFICATION; EXPRESSION; SUBSTRATE; PROTEIN	A pathological feature of Type 2 diabetes is deposits in the pancreatic islets primarily composed of amylin (islet amyloid polypeptide). Although much attention has been paid to the expression and secretion of amylin, little is known about the enzymes involved in amylin turnover. Recent reports suggest that insulin-degrading enzyme (IDE) may have specificity for amyloidogenic proteins, and therefore we sought to determine whether amylin is an IDE substrate. Amylin-degrading activity co-purified with IDE from rat muscle through several chromatographic steps. Metalloproteinase inhibitors inactivated amylin-degrading activity with a pattern consistent with the enzymatic properties of IDE, whereas inhibitors of acid and serine proteases, calpains, and the proteasome were ineffective. Amylin degradation was inhibited by insulin in a dose-dependent manner, whereas insulin degradation was inhibited by amylin. Other substrates of IDE such as atrial natriuretic peptide and glucagon also competitively inhibited amylin degradation. Radiolabeled amylin and insulin were both covalently cross-linked to a protein of 110 kDa, and the binding was competitively inhibited by either unlabeled insulin or amylin. Finally, a monoclonal anti-IDE antibody immunoprecipitated both insulin- and amylin-degrading activities. The data strongly suggest that IDE is an amylin-degrading enzyme and plays an important role in the clearance of amylin and the prevention of islet amyloid formation.	Vet Affairs Med Ctr, Med Res Serv 151, Omaha, NE 68105 USA; Univ Nebraska, Med Ctr, Dept Internal Med, Omaha, NE 68105 USA; Carl T Hayden Vet Affairs Med Ctr, Endocrinol Sect, Phoenix, AZ 85012 USA; Arizona State Univ, Dept Mol & Cellular Biol, Tempe, AZ 85287 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Nebraska System; University of Nebraska Medical Center; Arizona State University; Arizona State University-Tempe	Bennett, RG (corresponding author), Vet Affairs Med Ctr, Med Res Serv 151, 4101 Woolworth Ave, Omaha, NE 68105 USA.		chene, genevieve/H-8665-2014	chene, genevieve/0000-0002-8368-6460				BENNETT RG, 2000, END SOC 82 ANN M END, P89; BHATHENA SJ, 1985, DIABETES, V34, P121, DOI 10.2337/diabetes.34.2.121; DALESSIO DA, 1994, DIABETES, V43, P1457, DOI 10.2337/diabetes.43.12.1457; DUCKWORT.WC, 1972, P NATL ACAD SCI USA, V69, P3698, DOI 10.1073/pnas.69.12.3698; Duckworth WC, 1998, ENDOCR REV, V19, P608, DOI 10.1210/er.19.5.608; DUCKWORTH WC, 1974, DIABETES, V23, P536, DOI 10.2337/diab.23.6.536; FOX N, 1993, FEBS LETT, V323, P40, DOI 10.1016/0014-5793(93)81444-5; HOPPENER JWM, 1993, DIABETOLOGIA, V36, P1258, DOI 10.1007/BF00400803; Janson J, 1996, P NATL ACAD SCI USA, V93, P7283, DOI 10.1073/pnas.93.14.7283; JOHNSON KH, 1989, NEW ENGL J MED, V321, P513; Kahn SE, 1999, DIABETES, V48, P241, DOI 10.2337/diabetes.48.2.241; Kurochkin IV, 1998, FEBS LETT, V427, P153, DOI 10.1016/S0014-5793(98)00422-0; KUROCHKIN IV, 1994, FEBS LETT, V345, P33, DOI 10.1016/0014-5793(94)00387-4; McDermott JR, 1997, NEUROCHEM RES, V22, P49, DOI 10.1023/A:1027325304203; MULLER D, 1991, EUR J BIOCHEM, V202, P285, DOI 10.1111/j.1432-1033.1991.tb16374.x; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; ROTH RA, 1984, ENDOCR RES, V10, P101, DOI 10.3109/07435808409035411; SHII K, 1986, DIABETES, V35, P675, DOI 10.2337/diabetes.35.6.675; SIPE JD, 1992, ANNU REV BIOCHEM, V61, P947, DOI 10.1146/annurev.bi.61.070192.004503; Vekrellis K, 2000, J NEUROSCI, V20, P1657; Verchere CB, 1996, P NATL ACAD SCI USA, V93, P3492, DOI 10.1073/pnas.93.8.3492; Verchere CB, 1997, HORM METAB RES, V29, P311, DOI 10.1055/s-2007-979042; WESTERMARK P, 1990, P NATL ACAD SCI USA, V87, P5036, DOI 10.1073/pnas.87.13.5036; YAGUI K, 1995, EUR J ENDOCRINOL, V132, P487, DOI 10.1530/eje.0.1320487	24	133	141	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36621	36625		10.1074/jbc.M006170200	http://dx.doi.org/10.1074/jbc.M006170200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973971	hybrid			2022-12-25	WOS:000165577700024
J	Chau, KY; Chen, SM; Zack, DJ; Ono, SJ				Chau, KY; Chen, SM; Zack, DJ; Ono, SJ			Functional domains of the cone-rod homeobox (CRX) transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTORECEPTOR-SPECIFIC EXPRESSION; LEBER CONGENITAL AMAUROSIS; BINDING PROTEIN GENE; TRUNCATION MUTATIONS; HOMEODOMAIN PROTEIN; MAMMALIAN BRAIN; FACTOR NRL; OTX; DISSECTION; DYSTROPHY	The paired-like homeodomain transcription factor CRX (cone-rod homeobox) is involved in regulating photoreceptor gene expression and rod outer segment development. Mutations in CRX have been associated with several retinal degenerative diseases. These conditions range from Leber congenital amaurosis (a severe cone and rod degeneration of childhood onset) to adult onset cone-rod dystrophy and retinitis pigmentosa tan adult onset condition that primarily affects rods). The goal of this study is to better understand the molecular basis of CRX function and to provide insight into how mutations in CRX cause such a variety of clinical phenotypes. We performed deletion analysis in conjunction with DNA binding and transient transfection-based transactivation studies to identify the functional domains within CRX. DNA binding requires a complete homeodomain. Furthermore, truncated proteins that did not contain an intact homeodomain failed to demonstrate detectable expression in tissue culture upon transfection. Transactivation analysis indicated that both the OTX tail and the WSP domain are important for controlling positive regulatory activity of CRX interestingly, the mapped CRX transactivation domains were also critical when coexpressed with NRL, Specifically, the synergy between CRX and NRL was constant regardless of which CRX variant was used.	Harvard Univ, Sch Med, Schepens Eye Res Inst, Dept Ophthalmol, Boston, MA 02114 USA; Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA; Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA; Brigham & Womens Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Comm Immunol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Schepens Eye Research Institute; Washington University (WUSTL); Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Ono, SJ (corresponding author), Harvard Univ, Sch Med, Schepens Eye Res Inst, Dept Ophthalmol, 20 Staniford St, Boston, MA 02114 USA.	sjono@vision.eri.harvard.edu	Chau, Kai-Yin (David)/C-2845-2011; Chau, David/P-8335-2019	Chau, David/0000-0002-5797-2922; Zack, Don/0000-0002-7966-1973	NATIONAL EYE INSTITUTE [R01EY009769, R01EY012543] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049661] Funding Source: NIH RePORTER; NEI NIH HHS [EY09769, R01 EY012543] Funding Source: Medline; NIGMS NIH HHS [GM49661] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boatright J H, 1997, Mol Vis, V3, P15; Bobola N, 1999, MECH DEVELOP, V82, P165, DOI 10.1016/S0925-4773(98)00162-2; Chau KY, 2000, J NEUROSCI, V20, P7317; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; Fei YJ, 1999, J BIOCHEM, V125, P1189, DOI 10.1093/oxfordjournals.jbchem.a022403; FINKELSTEIN R, 1994, TRENDS GENET, V10, P310, DOI 10.1016/0168-9525(94)90033-7; Fong SL, 1999, CURR EYE RES, V18, P283, DOI 10.1076/ceyr.18.4.283.5360; Freund CL, 1998, NAT GENET, V18, P311, DOI 10.1038/ng0498-311; Freund CL, 1997, CELL, V91, P543, DOI 10.1016/S0092-8674(00)80440-7; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; Furukawa T, 1999, NAT GENET, V23, P466, DOI 10.1038/70591; Hessabi B, 1999, EUR J BIOCHEM, V263, P170, DOI 10.1046/j.1432-1327.1999.00481.x; Hirth F, 1999, BIOESSAYS, V21, P677, DOI 10.1002/(SICI)1521-1878(199908)21:8<677::AID-BIES7>3.3.CO;2-#; Jacobson SG, 1998, INVEST OPHTH VIS SCI, V39, P2417; Kimura A, 2000, J BIOL CHEM, V275, P1152, DOI 10.1074/jbc.275.2.1152; Kumar R, 1996, J BIOL CHEM, V271, P29612, DOI 10.1074/jbc.271.47.29612; Li XD, 1998, P NATL ACAD SCI USA, V95, P1876, DOI 10.1073/pnas.95.4.1876; Livesey FJ, 2000, CURR BIOL, V10, P301, DOI 10.1016/S0960-9822(00)00379-1; Mitton KP, 2000, J BIOL CHEM, V275, P29794, DOI 10.1074/jbc.M003658200; Morrow EM, 1998, TRENDS CELL BIOL, V8, P353, DOI 10.1016/S0962-8924(98)01341-5; Rehemtulla A, 1996, P NATL ACAD SCI USA, V93, P191, DOI 10.1073/pnas.93.1.191; Sakamoto K, 1999, NEUROSCI LETT, V261, P101, DOI 10.1016/S0304-3940(99)00008-7; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Silva E, 2000, INVEST OPHTH VIS SCI, V41, P2076; Simeone A, 1998, EMBO J, V17, P6790, DOI 10.1093/emboj/17.23.6790; Singh S, 1998, J BIOL CHEM, V273, P21531, DOI 10.1074/jbc.273.34.21531; Sohocki MM, 1998, AM J HUM GENET, V63, P1307, DOI 10.1086/302101; Swain PK, 1997, NEURON, V19, P1329, DOI 10.1016/S0896-6273(00)80423-7; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; Swaroop A, 1999, HUM MOL GENET, V8, P299, DOI 10.1093/hmg/8.2.299; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Tang HK, 1998, J BIOL CHEM, V273, P7210, DOI 10.1074/jbc.273.13.7210; Yanagi Y, 2000, BIOCHEM BIOPH RES CO, V269, P410, DOI 10.1006/bbrc.2000.2304; Zhu XM, 2000, MOL CELL BIOL, V20, P5216, DOI 10.1128/MCB.20.14.5216-5226.2000; Zhu XM, 2000, BIOCHEM BIOPH RES CO, V270, P504, DOI 10.1006/bbrc.2000.2414	35	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37264	37270		10.1074/jbc.M002763200	http://dx.doi.org/10.1074/jbc.M002763200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10984472	hybrid			2022-12-25	WOS:000165577700111
J	Sakurai, H; Fukasawa, T				Sakurai, H; Fukasawa, T			Functional connections between mediator components and general transcription factors of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CARBOXYL-TERMINAL DOMAIN; FACTOR TF IIE; CTD KINASE; IN-VIVO; FINGER PROTEIN; LARGE SUBUNIT; YEAST GAL11; HOLOENZYME; PROMOTER	The yeast Gal11 protein is an important component of the Mediator complex in RNA polymerase II-directed transcription. Gal11 and the general transcription factor (TF) IIE are involved in regulation of the protein kinase activity of TFIIH that phosphorylates the carboxyl-terminal domain of RNA polymerase II. We have previously shown that Gal11 binds the small and large subunits of TFIIE at two Gal11 domains, A and B, respectively, which are important for normal function of Gal11 in vivo. Here we demonstrate that Gal11 binds directly to TFIIH through domain A in vitro. A null mutation in GAL11 caused lethality of cells when combined with temperature-sensitive mutations in the genes encoding TFIIE or the carboxyl-terminal domain kinase, indicating the presence of genetic interactions between Gal11 and these proteins. Mutational depletion of Gal11 or TFIIE caused inefficient opening of the transcription initiation region, but had no significant effect on TATA-binding protein occupancy of the TATA sequence in vivo. These results suggest that the functions of Gal11 and TFIIE are necessary after recruitment of TATA-binding protein to the TATA box presumably at the step of stable preinitiation complex formation and/or promoter melting. We illustrate genetic interactions between Gal11 and other Mediator components such as Med2 and Pgd1/Hrs1/Med3.	Kanazawa Univ, Fac Med, Sch Hlth Sci, Kanazawa, Ishikawa 9200942, Japan; Keio Univ, Sch Med, Dept Microbiol, Shinjyuku Ku, Tokyo 1608582, Japan	Kanazawa University; Keio University	Sakurai, H (corresponding author), Kanazawa Univ, Fac Med, Sch Hlth Sci, 5-11-80 Kodatsuno, Kanazawa, Ishikawa 9200942, Japan.							Asturias FJ, 1997, J MOL BIOL, V272, P536, DOI 10.1006/jmbi.1997.1273; Bjorklund S, 1999, CELL, V96, P759, DOI 10.1016/S0092-8674(00)80586-3; Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; BROHL S, 1994, YEAST, V10, P719, DOI 10.1002/yea.320100604; Bushnell DA, 1996, J BIOL CHEM, V271, P20170, DOI 10.1074/jbc.271.33.20170; CHEN S, 1993, GENETICS, V134, P701; CHEN SM, 1993, MOL CELL BIOL, V13, P831, DOI 10.1128/MCB.13.2.831; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; Faye G, 1997, MOL GEN GENET, V255, P460, DOI 10.1007/s004380050518; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; GIARDINA C, 1993, SCIENCE, V261, P759, DOI 10.1126/science.8342041; GIARDINA C, 1992, GENE DEV, V6, P2190, DOI 10.1101/gad.6.11.2190; GIARDINA C, 1995, MOL CELL BIOL, V15, P2737; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Guzman E, 1999, MOL CELL BIOL, V19, P5652; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; JIANG YW, 1992, MOL CELL BIOL, V12, P4503, DOI 10.1128/MCB.12.10.4503; JIANG YW, 1995, GENETICS, V140, P47; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Koh SS, 1998, MOL CELL, V1, P895, DOI 10.1016/S1097-2765(00)80088-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; Kuldell NH, 1997, MOL CELL BIOL, V17, P5288, DOI 10.1128/MCB.17.9.5288; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Lee YC, 1999, MOL CELL BIOL, V19, P2967; Lee YC, 1998, MOL CELL BIOL, V18, P5364, DOI 10.1128/MCB.18.9.5364; Leuther KK, 1996, CELL, V85, P773, DOI 10.1016/S0092-8674(00)81242-8; Li XY, 1999, NATURE, V399, P605, DOI 10.1038/21232; Myers LC, 1999, P NATL ACAD SCI USA, V96, P67, DOI 10.1073/pnas.96.1.67; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Parvin JD, 1998, CURR OPIN GENET DEV, V8, P565, DOI 10.1016/S0959-437X(98)80012-9; Piruat JI, 1997, GENETICS, V147, P1585; Roberts SM, 1997, GENETICS, V147, P451; Sakurai H, 1997, J BIOL CHEM, V272, P15936, DOI 10.1074/jbc.272.25.15936; Sakurai H, 1996, P NATL ACAD SCI USA, V93, P9488, DOI 10.1073/pnas.93.18.9488; Sakurai H, 1998, J BIOL CHEM, V273, P9534, DOI 10.1074/jbc.273.16.9534; Sakurai H, 1997, J BIOL CHEM, V272, P32663, DOI 10.1074/jbc.272.51.32663; SERIZAWA H, 1994, J BIOL CHEM, V269, P20750; Song WJ, 1996, MOL CELL BIOL, V16, P115; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; VALAY JG, 1995, J MOL BIOL, V249, P535, DOI 10.1006/jmbi.1995.0316; VALLIER LG, 1991, GENETICS, V129, P675	48	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37251	37256		10.1074/jbc.M004364200	http://dx.doi.org/10.1074/jbc.M004364200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973956	hybrid			2022-12-25	WOS:000165577700109
J	Kashiwagi, K; Kuraishi, A; Tomitori, H; Igarashi, A; Nishimura, K; Shirahata, A; Igarashi, K				Kashiwagi, K; Kuraishi, A; Tomitori, H; Igarashi, A; Nishimura, K; Shirahata, A; Igarashi, K			Identification of the putrescine recognition site on polyamine transport protein PotE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; ORNITHINE DECARBOXYLASE; DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; LACTOSE PERMEASE; SYSTEM; SPERMIDINE; BINDING; MECHANISM; GENE	The PotE protein can catalyze both uptake and excretion of putrescine. The K-m, values of putrescine for uptake and excretion are 1.8 and 73 muM respectively. Uptake of putrescine is dependent on the membrane potential, whereas excretion involves putrescine-ornithine antiporter activity. Amino acids involved in both activities were identified using mutated PotE proteins. It was found that Cys(62), Trp(201), Trp(292),,d Tyr(425) were strongly involved in both activities, and that Tyr(92), Cys(210) Cys(285), and Cys(286) were moderately involved in the activities. Mutations of Tyr(78), Trp(90), and Trp(422) mainly affected uptake activity, and the K-m, values for putrescine uptake by these PotE mutants increased greatly, indicating that these amino acids are involved in the high affinity uptake of putrescine by PotE. Mutations of Lys(301) and Tyr(308) mainly affected excretion activity (putrescine-ornithine antiporter activity), and excretion by these mutants was not stimulated by ornithine, indicating that these amino acids are involved in the recognition of ornithine. It was found that the putrescine and ornithine recognition site on PotE is located at the cytoplasmic surface and the vestibule of the pore consisting of 12 transmembrane segments. Based on the results of competition experiments with various putrescine analogues and the disulfide cross-linking of PotE between cytoplasmic loops and the COOH terminus, a model of the putrescine recognition site on PotE consisting of the identified amino acids is presented.	Chiba Univ, Fac Pharmaceut Sci, Inage Ku, Chiba 2638522, Japan; Niigata Univ, Sch Dent, Niigata 9518514, Japan; Josai Univ, Fac Pharmaceut Sci, Sakado, Saitama 3500295, Japan	Chiba University; Niigata University; Josai University	Igarashi, K (corresponding author), Chiba Univ, Fac Pharmaceut Sci, Inage Ku, 1-33 Yayoi Cho, Chiba 2638522, Japan.			Nishimura, Kazuhiro/0000-0002-6209-5522; Igarashi, Kazuei/0000-0003-3751-3187				AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; CUNNINGHAMRUNDLES S, 1975, J BACTERIOL, V124, P791, DOI 10.1128/JB.124.2.791-799.1975; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; FURUCHI T, 1991, J BIOL CHEM, V266, P20928; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; Hu LA, 1998, J BIOL CHEM, V273, P20162, DOI 10.1074/jbc.273.32.20162; Igarashi K, 1999, BIOCHEM J, V344, P633, DOI 10.1042/0264-6021:3440633; KABACK HR, 1987, BIOCHEMISTRY-US, V26, P2071, DOI 10.1021/bi00382a001; KASHIWAGI K, 1990, J BIOL CHEM, V265, P8387; KASHIWAGI K, 1994, BIOCHEM BIOPH RES CO, V200, P591, DOI 10.1006/bbrc.1994.1489; KASHIWAGI K, 1990, J BIOL CHEM, V265, P20893; KASHIWAGI K, 1991, J BIOL CHEM, V266, P20922; Kashiwagi K, 1997, J BIOL CHEM, V272, P6318, DOI 10.1074/jbc.272.10.6318; KASHIWAGI K, 1992, P NATL ACAD SCI USA, V89, P4529, DOI 10.1073/pnas.89.10.4529; Kashiwagi K, 1996, J BIOL CHEM, V271, P12205, DOI 10.1074/jbc.271.21.12205; KASHIWAGI K, 1988, J BACTERIOL, V170, P3131, DOI 10.1128/jb.170.7.3131-3135.1988; Kubo Y, 2000, J BIOL CHEM, V275, P5270, DOI 10.1074/jbc.275.8.5270; LEE JI, 1992, J BIOL CHEM, V267, P20758; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NIELSEN PJ, 1982, J BIOL CHEM, V257, P2316; PEGG AE, 1988, CANCER RES, V48, P759; PISTOCCHI R, 1993, J BIOL CHEM, V268, P146; POOLMAN B, 1992, J BIOL CHEM, V267, P9150; SAHINTOTH M, 1994, P NATL ACAD SCI USA, V91, P5421, DOI 10.1073/pnas.91.12.5421; Sambrook J., 1989, MOL CLONING LAB MANU, pA9; SAYERS JR, 1992, BIOTECHNIQUES, V13, P592; SHIRAHATA A, 1991, BIOCHEM PHARMACOL, V41, P205, DOI 10.1016/0006-2952(91)90478-N; Sugiyama S, 1996, J BIOL CHEM, V271, P9519, DOI 10.1074/jbc.271.16.9519; Sugiyama S, 1996, PROTEIN SCI, V5, P1984, DOI 10.1002/pro.5560051004; Sun JZ, 1997, BIOCHEMISTRY-US, V36, P11959, DOI 10.1021/bi971172k; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Tomitori H, 1999, J BIOL CHEM, V274, P3265, DOI 10.1074/jbc.274.6.3265; Vassylyev DG, 1998, J BIOL CHEM, V273, P17604, DOI 10.1074/jbc.273.28.17604; Wu JH, 1997, J MOL BIOL, V270, P285, DOI 10.1006/jmbi.1997.1099; YAMAGUCHI A, 1992, BIOCHEMISTRY-US, V31, P8344, DOI 10.1021/bi00150a031	36	53	55	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36007	36012		10.1074/jbc.M006083200	http://dx.doi.org/10.1074/jbc.M006083200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10964926	hybrid			2022-12-25	WOS:000165382000052
J	Sakamoto, Y; Taguchi, T; Honke, K; Korekane, H; Watanabe, H; Tano, Y; Dohmae, N; Takio, K; Horii, A; Taniguchi, N				Sakamoto, Y; Taguchi, T; Honke, K; Korekane, H; Watanabe, H; Tano, Y; Dohmae, N; Takio, K; Horii, A; Taniguchi, N			Molecular cloning and expression of cDNA encoding chicken UDP-N-acetyl-D-glucosamine (GlcNAc): GlcNAc beta 1-6(GlcNAc beta 1-2)-Man alpha 1-R[GlcNAc to Man]beta 1,4N-acetylglucosaminyltransferase VI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN UDP-N-ACETYLGLUCOSAMINE-ALPHA-1,3-D-MANNOSIDE BETA-1,4-N-ACETYLGLUCOSAMINY; ACETYLGLUCOSAMINYLTRANSFERASE-V; GLYCOPROTEIN-SYNTHESIS; ORYZIAS-LATIPES; SUGAR CHAINS; RAT-KIDNEY; PURIFICATION; IV; ENZYME; LIVER	A cDNA that encodes UDP-N-acetyl-D-glucosamine (GlcNAc):GlcNAc beta1-6(GlcNAc beta1-2)Man alpha1-R[GlcNAc to Man]beta1,4N-acetylglucosaminyltransferase VI (GnT VI), which is responsible for the formation of pentaantennary asparagine-linked oligosaccharides (N-glycans), has been cloned from a hen oviduct cDNA library based on the partial amino acid sequences of the purified enzyme. The isolated cDNA clone contained an open reading frame encoding 464 amino acids, including all of the peptides that were sequenced. The deduced amino acid sequence predicts a type II transmembrane topology and contains two potential N-glycosylation sites. The primary structure was found to be significantly similar to human GnT IV-homologue, the gene for which was cloned from the deleted region in pancreatic cancer, and to human and bovine GnT IVs, Chicken GnT VI-transfected COS-1 cells showed a high GnT VI activity (26.8 pmol/h/mg protein), whereas nontransfected, mock-transfected, or human GnT IV-homologue-transfected COS-l cells had no activity. Northern blot analysis using poly(A)(+) RNA from hen oviduct indicated that the size of GnT VT mRNA is 2.1 kilobases, Reverse transcription-polymerase chain reaction analysis showed that GnT VI mRNA was relatively highly expressed in oviduct, spleen, lung, and colon.	Osaka Univ, Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Ophthalmol, Suita, Osaka 5650871, Japan; RIKEN, Inst Phys & Chem Res, Synthet Cellular Chem Lab, Wako, Saitama 3510198, Japan; RIKEN, Inst Phys & Chem Res, Div Biomol Characterizat, Wako, Saitama 3510198, Japan; Tohoku Univ, Sch Med, Dept Mol Pathol, Aoba Ku, Sendai, Miyagi 9808575, Japan	Osaka University; Osaka University; RIKEN; RIKEN; Tohoku University	Taniguchi, N (corresponding author), Osaka Univ, Sch Med, Dept Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Horii, Akira/AAW-2839-2021; Taniguchi, Naoyuki/A-7086-2016; Taguchi, Tomohiko/I-5014-2019; Taniguchi, Naoyuki/I-4182-2014; Dohmae, Naoshi/C-2040-2011	Horii, Akira/0000-0002-3967-3291; Taguchi, Tomohiko/0000-0003-0464-6370; Taniguchi, Naoyuki/0000-0001-5889-5968; Dohmae, Naoshi/0000-0002-5242-9410				BENDIAK B, 1987, J BIOL CHEM, V262, P5775; BROCKHAUSEN I, 1989, J BIOL CHEM, V264, P11211; Buckhaults P, 1997, J BIOL CHEM, V272, P19575, DOI 10.1074/jbc.272.31.19575; DAGOSTARO GAF, 1995, J BIOL CHEM, V270, P15211, DOI 10.1074/jbc.270.25.15211; Dennis JW, 1999, BBA-GEN SUBJECTS, V1473, P21, DOI 10.1016/S0304-4165(99)00167-1; Furukawa T, 1999, J HUM GENET, V44, P397, DOI 10.1007/s100380050186; GU J, J BIOCH TOKYO, V113, P614; Ihara Y, 1997, J BIOL CHEM, V272, P9629; IHARA Y, 1993, J BIOCHEM-TOKYO, V113, P692, DOI 10.1093/oxfordjournals.jbchem.a124105; KITAJIMA K, 1989, DEV BIOL, V132, P544, DOI 10.1016/0012-1606(89)90249-2; KOBATA A, 1988, J CELL BIOCHEM, V37, P79, DOI 10.1002/jcb.240370108; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P44, DOI 10.1016/0005-2744(81)90106-6; Minowa MT, 1998, J BIOL CHEM, V273, P11556, DOI 10.1074/jbc.273.19.11556; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; NISHIKAWA A, 1990, BIOCHIM BIOPHYS ACTA, V1035, P313, DOI 10.1016/0304-4165(90)90094-D; NISHIKAWA Y, 1988, J BIOL CHEM, V263, P8270; Oguri S, 1997, J BIOL CHEM, V272, P22721, DOI 10.1074/jbc.272.36.22721; OPPENHEIMER CL, 1981, J BIOL CHEM, V256, P799; PARENTE JP, 1982, J BIOL CHEM, V257, P13173; SAITO H, 1994, BIOCHEM BIOPH RES CO, V198, P318, DOI 10.1006/bbrc.1994.1045; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SCHACHTER H, 1991, Glycobiology, V1, P453, DOI 10.1093/glycob/1.5.453; SHOREIBAH M, 1993, J BIOL CHEM, V268, P15381; SHOREIBAH MG, 1992, J BIOL CHEM, V267, P2920; Taguchi T, 1997, BIOCHEM BIOPH RES CO, V230, P533, DOI 10.1006/bbrc.1996.6013; Taguchi T, 1998, ANAL BIOCHEM, V255, P155, DOI 10.1006/abio.1997.2465; Taguchi T, 2000, J BIOL CHEM, V275, P32598, DOI 10.1074/jbc.M004673200; TAGUCHI T, 1995, GLYCOBIOLOGY, V5, P611, DOI 10.1093/glycob/5.6.611; Xu NX, 1997, J AM SOC MASS SPECTR, V8, P116, DOI 10.1016/S1044-0305(96)00233-4; YAMASHITA K, 1982, J BIOL CHEM, V257, P2809; Yoshida A, 1998, GLYCOCONJUGATE J, V15, P1115, DOI 10.1023/A:1006951519522; Yoshida A, 1999, GLYCOBIOLOGY, V9, P303, DOI 10.1093/glycob/9.3.303	34	9	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36029	36034		10.1074/jbc.M005860200	http://dx.doi.org/10.1074/jbc.M005860200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10962001	hybrid			2022-12-25	WOS:000165382000055
J	Silva, AM; Reis, LFL				Silva, AM; Reis, LFL			Sodium salicylate induces the expression of the immunophilin FKBP51 and Biglycan genes and inhibits p34(cdc2) mRNA both in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ACETYLSALICYLIC-ACID; C-KROX; TRANSCRIPTIONAL ACTIVATION; ALPHA PHOSPHORYLATION; ALZHEIMERS-DISEASE; ENDOTHELIAL-CELLS; PROTEIN-KINASE; ASPIRIN	One of the mechanisms proposed to explain the antiinflammatory, activity of sodium salicylate (NaSal) is based, at least in part, on its ability to inhibit nuclear factor-kappaB activation and inhibition of nuclear factor-kappaB-dependent gene expression. On the other hand, little is known about the ability of NaSal to activate gene expression. By differential display reverse transcription polymerase chain reaction, we identified several genes that are modulated upon treatment of mouse fibroblasts with NaSal. From the various cDNA fragments recovered from autoradiograms, we found that NaSal can increase the levels of mRNA for biglycan, the mouse homologue of the human eIF-3 p47 unit, and immunophilin FRBP51. NaSal-induced expression of these genes was time- and dose-dependent. Moreover, FKBP51 gene expression was augmented in vivo, in mice treated orally or intraperitoneally with NaSal, We also found that treating,cells with NaSal can inhibit the expression of the p34(cdc2) kinase. The impact this inhibition on cell cycle was evaluated by measuring the content of DNA during the cell cycle. Treatment of cells with NaSal led to a G(2)/M arrest. By investigating the signaling events that regulate the expression of these genes and their biological activities, we can contribute to the understanding of the mechanism of NaSal.	Ludwig Inst Canc Res, Lab Inflammat, BR-01509010 Sao Paulo, SP, Brazil; Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, BR-31270901 Belo Horizonte, MG, Brazil	Ludwig Institute for Cancer Research; Universidade Federal de Minas Gerais	Reis, LFL (corresponding author), Ludwig Inst Canc Res, Lab Inflammat, Rua Prof Antonio Prudente 109-4th Floor Liberdade, BR-01509010 Sao Paulo, SP, Brazil.		Reis, Luiz F. L./C-4556-2013; Silva, Aristóbolo/AAA-2239-2021; Silva, Aristobolo/CAF-4874-2022; Silva, Aristobolo AMS/F-7326-2016	Silva, Aristóbolo/0000-0001-7473-7433; Reis, Luiz/0000-0002-4040-2456				ABRAMSON S, 1989, CLIN EXP RHEUMATOL, V7, pS163; ALTMEYER A, 1995, J BIOL CHEM, V270, P25584, DOI 10.1074/jbc.270.43.25584; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BAUGHMAN G, 1995, MOL CELL BIOL, V15, P4395; BAUGHMAN G, 1991, MOL ENDOCRINOL, V5, P637, DOI 10.1210/mend-5-5-637; Bitko V, 1997, VIROLOGY, V232, P369, DOI 10.1006/viro.1997.8582; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CRONSTEIN BN, 1994, INFLAMMATION, V18, P323, DOI 10.1007/BF01534273; Damme B, 1996, TOXICOLOGY, V106, P99, DOI 10.1016/0300-483X(95)03168-F; Elder DJE, 1996, CANCER RES, V56, P2273; Farivar RS, 1996, CIRC RES, V78, P759; FISHER LW, 1989, J BIOL CHEM, V264, P4571; GALERA P, 1994, P NATL ACAD SCI USA, V91, P9372, DOI 10.1073/pnas.91.20.9372; Galera P, 1996, J BIOL CHEM, V271, P21331, DOI 10.1074/jbc.271.35.21331; GAUTAM SC, 1995, BLOOD, V86, P2541; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Heegaard AM, 1997, J BONE MINER RES, V12, P2050, DOI 10.1359/jbmr.1997.12.12.2050; Housby JN, 1999, CYTOKINE, V11, P347, DOI 10.1006/cyto.1998.0437; JURIVICH DA, 1995, J BIOL CHEM, V270, P24489, DOI 10.1074/jbc.270.41.24489; Kagawa A, 1999, J BIOL CHEM, V274, P34111, DOI 10.1074/jbc.274.48.34111; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIU RY, 1994, J CELL SCI, V107, P2209; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; MoogLutz C, 1997, INT J CANCER, V71, P183, DOI 10.1002/(SICI)1097-0215(19970410)71:2<183::AID-IJC10>3.0.CO;2-J; OETH P, 1995, BLOOD, V86, P4144, DOI 10.1182/blood.V86.11.4144.bloodjournal86114144; OHMORI Y, 1995, J IMMUNOL, V155, P3593; PANKOW D, 1994, ARCH TOXICOL, V68, P261, DOI 10.1007/s002040050066; Perugini RA, 2000, J GASTROINTEST SURG, V4, P24, DOI 10.1016/S1091-255X(00)80029-3; Pierce JW, 1996, J IMMUNOL, V156, P3961; RICH JB, 1995, NEUROLOGY, V45, P51, DOI 10.1212/WNL.45.1.51; ROSENKRANZ B, 1986, BRIT J CLIN PHARMACO, V21, P309, DOI 10.1111/j.1365-2125.1986.tb05195.x; Schwenger P, 1998, MOL CELL BIOL, V18, P78, DOI 10.1128/MCB.18.1.78; Shiff SJ, 1996, EXP CELL RES, V222, P179, DOI 10.1006/excr.1996.0023; SPURR NK, 1990, J DNA SEQUENCING MAP, V1, P49; Stevenson MA, 1999, J IMMUNOL, V163, P5608; Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626; Ungefroren H, 1998, J BIOL CHEM, V273, P29230, DOI 10.1074/jbc.273.44.29230; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; WEGROWSKI Y, 1995, GENOMICS, V30, P8, DOI 10.1006/geno.1995.0002; WEISSMANN G, 1991, SCI AM, V264, P84, DOI 10.1038/scientificamerican0191-84; WU KK, 1991, P NATL ACAD SCI USA, V88, P2384, DOI 10.1073/pnas.88.6.2384; Xia LJ, 1998, BLOOD, V91, P1625, DOI 10.1182/blood.V91.5.1625.1625_1625_1632; YEH WC, 1995, P NATL ACAD SCI USA, V92, P11081, DOI 10.1073/pnas.92.24.11081; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948	46	8	8	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36388	36393		10.1074/jbc.M005887200	http://dx.doi.org/10.1074/jbc.M005887200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10962002	hybrid			2022-12-25	WOS:000165382000103
J	Sueoka, N; Lee, HY; Wiehle, S; Cristiano, RJ; Fang, BL; Ji, L; Roth, JA; Hong, WK; Cohen, P; Kurie, JM				Sueoka, N; Lee, HY; Wiehle, S; Cristiano, RJ; Fang, BL; Ji, L; Roth, JA; Hong, WK; Cohen, P; Kurie, JM			Insulin-like growth factor binding protein-6 activates programmed cell death in non-small cell lung cancer cells	ONCOGENE			English	Article						apoptosis; tumor; growth inhibition	FACTOR-I RECEPTOR; BREAST-CANCER; EXPRESSION; APOPTOSIS; DIFFERENTIATION; IDENTIFICATION; INHIBITION; INDUCTION; LINES; RISK	Insulin-like growth factor binding proteins (IGFBPs) are secreted into the extra-cellular matrix and inhibit cell growth through IGF-dependent and -independent mechanisms. In this study, we investigated the role of IGFBP-6, a relatively unexplored member of the IGFBP family, in the proliferation of non-small cell lung cancer (NSCLC) cells. Infection of NSCLC cell lints in vitro with an adenovirus expressing human IGFBP-6 under the control of a CMV promoter (Ad5CMV-BP6) reduced NSCLC cell number through activation of programmed cell death, as shown by cell staining with Hoechst 33342 or DIVA end-labeling with bromodeoxyuridine triphosphate, The growth regulatory effect of IGFBP-6 was investigated in vivo by intratumoral injection of Ad5CMV-BP6 in NSCLC xenografts established in nu/nu mice. A single injection of Ad5CMV-BP6 reduced the size of NSCLC xenografts by 45%. These findings indicate that IGFBP-6 is a potent inducer of programmed cell death in cancer cells and support investigations into IGFBP-6 as a potential target in cancer therapeutics.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA; Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90095 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California Los Angeles	Kurie, JM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Box 80,1515 Holcombe Blvd, Houston, TX 77030 USA.			Lee, Ho-Young/0000-0001-7556-9312	NATIONAL CANCER INSTITUTE [R29CA067353, P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA70907, R29 CA67353] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLOC F, 1994, CYTOMETRY, V17, P59, DOI 10.1002/cyto.990170108; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CARMICHAEL J, 1987, CANCER RES, V47, P936; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; CollettSolberg PF, 1996, ENDOCRIN METAB CLIN, V25, P591, DOI 10.1016/S0889-8529(05)70342-X; Dunn SE, 1998, CANCER RES, V58, P3353; Fang BL, 1997, ANAL BIOCHEM, V254, P139, DOI 10.1006/abio.1997.2417; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Grellier P, 1998, CANCER RES, V58, P1670; Gucev ZS, 1996, CANCER RES, V56, P1545; HAVEMANN K, 1990, J STEROID BIOCHEM, V37, P877, DOI 10.1016/0960-0760(90)90436-O; Hongo A, 1998, CANCER RES, V58, P2477; Huynh H, 1996, CELL GROWTH DIFFER, V7, P1501; HWANG CC, 1995, CANCER LETT, V94, P157, DOI 10.1016/0304-3835(95)03845-N; Kaliman P, 1998, MOL ENDOCRINOL, V12, P66, DOI 10.1210/mend.12.1.0047; Kim HS, 1997, P NATL ACAD SCI USA, V94, P12981, DOI 10.1073/pnas.94.24.12981; Leal SM, 1997, J BIOL CHEM, V272, P20572, DOI 10.1074/jbc.272.33.20572; Lee CT, 1996, CANCER RES, V56, P3038; Liu YM, 1998, CANCER RES, V58, P570; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; Milasincic DJ, 1996, MOL CELL BIOL, V16, P5964; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; Porras A, 1998, MOL ENDOCRINOL, V12, P825, DOI 10.1210/me.12.6.825; Quinn KA, 1996, J BIOL CHEM, V271, P11477, DOI 10.1074/jbc.271.19.11477; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Scotlandi K, 1998, CANCER RES, V58, P4127; SHIMASAKI S, 1991, MOL ENDOCRINOL, V5, P938, DOI 10.1210/mend-5-7-938; SIEGFRIED JM, 1992, P NATL ACAD SCI USA, V89, P8107, DOI 10.1073/pnas.89.17.8107; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; VAVERDE AM, 1998, MOL ENDOCRINOL, V12, P688; Yu H, 1999, JNCI-J NATL CANCER I, V91, P151, DOI 10.1093/jnci/91.2.151	31	63	70	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4432	4436		10.1038/sj.onc.1203813	http://dx.doi.org/10.1038/sj.onc.1203813			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980619				2022-12-25	WOS:000089271900014
J	Lefterov, IM; Koldamova, RP; Lazo, JS				Lefterov, IM; Koldamova, RP; Lazo, JS			Human bleomycin hydrolase regulates the secretion of amyloid precursor protein	FASEB JOURNAL			English	Article						Alzheimer disease; protease; beta-amyloid	FAMILIAL ALZHEIMERS-DISEASE; BETA-PROTEIN; CYSTEINE PROTEASE; ENDOPLASMIC-RETICULUM; CRYSTAL-STRUCTURE; GENE; PEPTIDE; CLEAVAGE; CELLS; BINDS	Human bleomycin hydrolase (hBH) is a neutral cysteine protease genetically associated with increased risk for Alzheimer disease, We show here that ectopic expression of hBH in 293APPwt and CHOAPPsw cells altered the processing of amyloid precursor protein (APP) and increased significantly the release of its proteolytic fragment, beta amyloid (A beta), We also found that hBH interacted and colocalized with APP as determined by subcellular fractionation, in vitro binding assay, and confocal immunolocalization. Metabolic labeling and pulse-chase experiments showed that ectopic hBH expression increased secretion of soluble APP alpha/beta products without changing the half-life of cellular APP, We also observed that this increased A beta secretion was independent of hBH isoforms, Our finding suggest a regulatory role for hBH in APP processing pathways.	Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lazo, JS (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol, Biomed Sci Tower E1340, Pittsburgh, PA 15261 USA.		Lefterov, Iliya/B-4767-2008	Lefterov, Iliya/0000-0002-0249-0280; Koldamova, Radosveta/0000-0002-6761-0984	NATIONAL CANCER INSTITUTE [R01CA043917] Funding Source: NIH RePORTER; NCI NIH HHS [CA43917] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM C R, 1990, Peptide Research, V3, P211; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Chang TE, 1996, ANN NY ACAD SCI, V777, P183, DOI 10.1111/j.1749-6632.1996.tb34417.x; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Emilien G, 2000, ARCH NEUROL-CHICAGO, V57, P176, DOI 10.1001/archneur.57.2.176; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Farrer LA, 1998, ANN NEUROL, V44, P808, DOI 10.1002/ana.410440515; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Greenfield JP, 1999, P NATL ACAD SCI USA, V96, P742, DOI 10.1073/pnas.96.2.742; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1994, J BIOL CHEM, V269, P17741; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; HSIAO KK, 1995, NEURON, V15, P1203, DOI 10.1016/0896-6273(95)90107-8; Ikezu T, 1998, J BIOL CHEM, V273, P10485, DOI 10.1074/jbc.273.17.10485; JOSHUATOR L, 1995, SCIENCE, V269, P945, DOI 10.1126/science.7638617; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; Koldamova RP, 1998, MOL PHARMACOL, V54, P954, DOI 10.1124/mol.54.6.954; Koldamova RP, 1998, BIOCHEMISTRY-US, V37, P2282, DOI 10.1021/bi9722204; Koldamova RP, 1999, BIOCHEMISTRY-US, V38, P7111, DOI 10.1021/bi990135l; MAGDOLEN U, 1993, BIOCHIM BIOPHYS ACTA, V1171, P299, DOI 10.1016/0167-4781(93)90069-P; Masliah E, 1996, J NEUROSCI, V16, P5795; Montoya SE, 1998, NAT GENET, V18, P211, DOI 10.1038/ng0398-211; Namba Y, 1999, BRAIN RES, V830, P200, DOI 10.1016/S0006-8993(99)01435-3; O'Farrell PA, 1999, STRUCT FOLD DES, V7, P619, DOI 10.1016/S0969-2126(99)80083-5; Raina AK, 1999, NEUROREPORT, V10, P1355, DOI 10.1097/00001756-199904260-00036; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; Sambamurti K, 1999, J BIOL CHEM, V274, P26810, DOI 10.1074/jbc.274.38.26810; Sastre M, 1998, J BIOL CHEM, V273, P22351, DOI 10.1074/jbc.273.35.22351; SEBTI SM, 1987, BIOCHEMISTRY-US, V26, P4213, DOI 10.1021/bi00388a006; SEBTI SM, 1988, PHARMACOL THERAPEUT, V38, P321, DOI 10.1016/0163-7258(88)90009-5; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Skern T, 1998, J GEN VIROL, V79, P301, DOI 10.1099/0022-1317-79-2-301; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; Thome J, 1999, NEUROSCI LETT, V274, P37, DOI 10.1016/S0304-3940(99)00662-X; Turner RS, 1996, J BIOL CHEM, V271, P8966, DOI 10.1074/jbc.271.15.8966; VAN BROECKHOVEN C, 1990, SCIENCE, V248, P1120, DOI 10.1126/science.1971458; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436; Zhang W, 1997, BBA-MOL CELL RES, V1359, P110, DOI 10.1016/S0167-4889(97)00082-7; Zheng WJ, 1998, CELL, V93, P103, DOI 10.1016/S0092-8674(00)81150-2	49	31	31	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2000	14	12					1837	1847		10.1096/fj.99-0938com	http://dx.doi.org/10.1096/fj.99-0938com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973933				2022-12-25	WOS:000089212400023
J	Lane, TF; Lin, CW; Brown, MA; Solomon, E; Leder, P				Lane, TF; Lin, CW; Brown, MA; Solomon, E; Leder, P			Gene replacement with the human BRCA1 locus: tissue specific expression and rescue of embryonic lethality in mice	ONCOGENE			English	Article						transgenic; BRCA1; tumor suppressor; gene transfer	OVARIAN-CANCER; BRCA1-DEFICIENT MICE; BREAST CARCINOMAS; MEIOTIC CELLS; DNA-REPAIR; MUTATIONS; P53; REGION; SUSCEPTIBILITY; METHYLATION	We have generated transgenic mice that harbor a 140 kb genomic fragment of the human BRCA1 locus (TgN.BRCA1(GEN)). We find that the transgene directs appropriate expression of human BRCA1 transcripts in multiple mouse tissues, and that human BRCA1 protein is expressed and stabilized following exposure to DIVA damage, Such mice are completely normal, with no overt signs of BRCA1 toxicity commonly observed when BRCA1 is expressed from heterologous promoters. Most importantly, however, the transgene rescues the otherwise lethal phenotype associated with the targeted hypomorphic allele (Brca1(Delta exIISA)). Brca1(-/-); TgN.BRCA1(GEN) bigenic animals develop normally and can be maintained as a distinct line. These results show that a 140 kb fragment of chromosome 17 contains all elements necessary for the correct expression, localization, and function of the BRCA1 protein, Further, the model provides evidence that function and regulation of the human BRCA1 gene can be studied and manipulated in a genetically tractable mammalian system.	Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; Guys Hosp, Div Med & Mol Genet, GKT, Sch Med, London SE1 9RT, England; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Melbourne; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Lane, TF (corresponding author), Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr, 10833 Le Conte Ave,27-139 CHS, Los Angeles, CA 90095 USA.		Brown, Melissa A/F-1451-2010	Lane, Timothy F./0000-0002-0210-970X; Brown, Melissa/0000-0002-2830-9259	Medical Research Council [G9600577] Funding Source: Medline; MRC [G9600577] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; *BIC, 1999, BREAST CANC INF COR; BIESECKER BB, 1993, JAMA-J AM MED ASSOC, V269, P1970, DOI 10.1001/jama.269.15.1970; BROWN MA, 1995, P NATL ACAD SCI USA, V92, P4362, DOI 10.1073/pnas.92.10.4362; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; CHEN JJ, 1999, CANCER RES, V59, P1752; Cressman VL, 1999, MOL CELL BIOL, V19, P7061; Cressman VL, 1999, CELL GROWTH DIFFER, V10, P1; Crook T, 1998, ONCOGENE, V17, P1681, DOI 10.1038/sj.onc.1202106; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Lane TF, 1997, ONCOGENE, V15, P2133, DOI 10.1038/sj.onc.1201593; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; Maul GG, 1998, CELL GROWTH DIFFER, V9, P743; Phillips KA, 1999, J NATL CANCER I, V91, P469, DOI 10.1093/jnci/91.5.469; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shao NS, 1996, ONCOGENE, V13, P1; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Snouwaert JN, 1999, ONCOGENE, V18, P7900, DOI 10.1038/sj.onc.1203334; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Whittemore AS, 1997, AM J HUM GENET, V60, P496; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; WILSON CA, 1997, ONCOGENE, V9, P1; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zabludoff SD, 1996, ONCOGENE, V13, P649; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	35	20	21	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2000	19	36					4085	4090		10.1038/sj.onc.1203760	http://dx.doi.org/10.1038/sj.onc.1203760			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962568				2022-12-25	WOS:000088955100001
J	Piatigorsky, J; Kozmik, Z; Horwitz, J; Ding, LL; Carosa, E; Robison, WG; Steinbach, PJ; Tamm, ER				Piatigorsky, J; Kozmik, Z; Horwitz, J; Ding, LL; Carosa, E; Robison, WG; Steinbach, PJ; Tamm, ER			Omega-crystallin of the scallop lens - A dimeric aldehyde dehydrogenase class 1/2 enzyme-crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-B-CRYSTALLIN; MULTIPLE-SEQUENCE ALIGNMENT; MAJOR SOLUBLE-PROTEIN; CORNEAL EPITHELIUM; EYE LENS; BINDING-PROTEIN; ACTIVE-SITE; GENE; RECRUITMENT; EXPRESSION	While many of the diverse crystallins of the transparent lens of vertebrates are related or identical to metabolic enzymes, much less is known about the lens crystallins of invertebrates. Here we investigate the complex eye of scallops. Electron microscopic inspection revealed that the anterior, single layered corneal epithelium overlying the cellular lens contains a regular array of microvilli that we propose might contribute to its optical properties. The sole crystallin of the scallop eye lens was found to be homologous to Omega -crystallin, a minor crystallin in cephalopods related to aldehyde dehydrogenase (ALDH) class 1/2. Scallop Omega -crystallin (officially designated ALDH1A9) is 55-56% identical to its cephalopod homologues, while it is 67 and 64% identical to human ALDH 2 and 1, respectively, and 61% identical to retinaldehyde dehydrogenase/eta -crystallin of elephant shrews.:like other enzyme-crystallins, scallop Omega -crystallin appears to be present in low amounts in nonocular tissues. Within the scallop eye, immunofluorescence tests indicated that Omega -crystallin expression is confined to the lens and cornea, Although it has conserved the critical residues required for activity in other ALDHs and appears by homology modeling to have a structure very similar to human ALDH2, scallop Omega -crystallin was enzymatically inactive with diverse substrates and did not bind NAD or NADP, In contrast to mammalian ALDH1 and -2 and other cephalopod Omega -crystallins, which are tetrameric proteins, scallop Omega -crystallin is a dimeric protein. Thus, ALDH is the most diverse lens enzyme-crystallin identified so far, having been used as-a lens crystallin in at least two classes of molluscs as well as elephant shrews.	NEI, Mol & Dev Biol Lab, NIH, Bethesda, MD 20892 USA; NEI, Lab Mechanisms Ocular Dis, NIH, Bethesda, MD 20892 USA; NIH, Ctr Mol Modeling, Ctr Informat Technol, Bethesda, MD 20892 USA; Acad Sci Czech Republ, Inst Mol Genet, Lab Transcript Regulat, Prague 6, Czech Republic; Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH Center for Information Technology (CIT); Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Piatigorsky, J (corresponding author), NEI, Mol & Dev Biol Lab, NIH, Bldg 6,Rm 201, Bethesda, MD 20892 USA.	joramp@intra.nei.nih.gov	Tamm, Ernst/AAB-9772-2019; Kozmik, Zbynek/G-3581-2014; Kozmik, Zbynek/I-8807-2014	Tamm, Ernst/0000-0002-6679-8743; CAROSA, Eleonora/0000-0002-6593-6833; Kozmik, Zbynek/0000-0002-5850-2105	CENTER FOR INFORMATION TECHNOLOGY [Z01CT000265, ZIACT000265] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [Z01EY000126, Z01EY000149] Funding Source: NIH RePORTER	CENTER FOR INFORMATION TECHNOLOGY(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Center for Information Technology (CIT)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABEDINIA M, 1990, EXP EYE RES, V51, P419, DOI 10.1016/0014-4835(90)90154-M; ALEXANDER RJ, 1981, EXP EYE RES, V32, P205, DOI 10.1016/0014-4835(81)90009-9; BARBER VC, 1967, Z ZELLFORSCH MIK ANA, V76, P295, DOI 10.1007/BF00339290; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BOSTIAN KA, 1978, BIOCHEM J, V173, P787, DOI 10.1042/bj1730787; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CHIOU SH, 1988, FEBS LETT, V241, P261, DOI 10.1016/0014-5793(88)81073-1; COOPER DL, 1991, GENE, V98, P201, DOI 10.1016/0378-1119(91)90174-A; CUTHBERTSON RA, 1992, P NATL ACAD SCI USA, V89, P4004, DOI 10.1073/pnas.89.9.4004; DEJONG WW, 1989, TRENDS BIOCHEM SCI, V14, P365, DOI 10.1016/0968-0004(89)90009-1; DEJONG WW, 1994, PROG RETIN EYE RES, V13, P391, DOI 10.1016/1350-9462(94)90018-3; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; DOHLMAN CH, 1971, INVEST OPHTH VISUAL, V10, P383; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; FARRES J, 1995, BIOCHEMISTRY-US, V34, P2592, DOI 10.1021/bi00008a025; FARRES J, 1994, J BIOL CHEM, V269, P13854; Felsentein J, 1993, PHYLIP PHYLOGENY INF; GORMAN ALF, 1969, SCIENCE, V165, P309, DOI 10.1126/science.165.3890.309; Graham C, 1996, J BIOL CHEM, V271, P15623, DOI 10.1074/jbc.271.26.15623; HAZLETT LD, 1984, SCAN ELECTRON MICROS, P1379; HAZLETT LD, 1981, EXP EYE RES, V32, P97, DOI 10.1016/S0014-4835(81)80043-7; HEMPEL J, 1993, PROTEIN SCI, V2, P1890, DOI 10.1002/pro.5560021111; Hickson RE, 2000, MOL BIOL EVOL, V17, P530, DOI 10.1093/oxfordjournals.molbev.a026333; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; HURLEY TD, 1999, ENZYMOLOGY MOL BIOL, V7, P15; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; INOUE J, 1995, J BACTERIOL, V177, P1196, DOI 10.1128/jb.177.5.1196-1201.1995; IWAKI T, 1990, J HISTOCHEM CYTOCHEM, V38, P31, DOI 10.1177/38.1.2294148; Jester JV, 1999, J CELL SCI, V112, P613; Johnsen S, 1999, J THEOR BIOL, V199, P181, DOI 10.1006/jtbi.1999.0948; Johnsen S, 2000, SCI AM, V282, P80, DOI 10.1038/scientificamerican0200-80; KIM RY, 1992, P NATL ACAD SCI USA, V89, P9292, DOI 10.1073/pnas.89.19.9292; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krupenko SA, 1997, J BIOL CHEM, V272, P10266; KUZAK JR, 1994, PRINCIPLES PRACTICE, P82; LAND MF, 1965, J PHYSIOL-LONDON, V179, P138, DOI 10.1113/jphysiol.1965.sp007653; LAND MF, 1988, CONTEMP PHYS, V29, P435, DOI 10.1080/00107518808222601; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEVITT M, 1992, J MOL BIOL, V226, P507, DOI 10.1016/0022-2836(92)90964-L; Liu ZJ, 1997, NAT STRUCT BIOL, V4, P317, DOI 10.1038/nsb0497-317; LUBSEN NH, 1988, PROG BIOPHYS MOL BIO, V51, P47, DOI 10.1016/0079-6107(88)90010-7; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MONTGOMERY MK, 1992, J BIOL CHEM, V267, P20999; NICHOLS B, 1983, INVEST OPHTH VIS SCI, V24, P570; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEREIRA F, 1991, BIOCHEM BIOPH RES CO, V175, P831, DOI 10.1016/0006-291X(91)91640-X; Perozich J, 1999, PROTEIN SCI, V8, P137, DOI 10.1110/ps.8.1.137; PFISTER RR, 1973, INVEST OPHTH VISUAL, V12, P654; PIATIGORSKY J, 1988, P NATL ACAD SCI USA, V85, P3479, DOI 10.1073/pnas.85.10.3479; Piatigorsky J, 1998, PROG RETIN EYE RES, V17, P145, DOI 10.1016/S1350-9462(97)00004-9; PIATIGORSKY J, 1989, CELL, V57, P197, DOI 10.1016/0092-8674(89)90956-2; PIATIGORSKY J, 1992, J BIOL CHEM, V267, P4277; PIATIGORSKY J, 1989, J COMP PHYSIOL A, V164, P577, DOI 10.1007/BF00614500; Sax CM, 1996, J BIOL CHEM, V271, P33568, DOI 10.1074/jbc.271.52.33568; SAX CM, 1993, ADV ENZYMOL RAMB, V69, P155; SILVERMAN B, 1981, EXP EYE RES, V33, P19, DOI 10.1016/S0014-4835(81)80078-4; Steinmetz CG, 1997, STRUCTURE, V5, P701, DOI 10.1016/S0969-2126(97)00224-4; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Sun LJ, 1999, J BIOL CHEM, V274, P17334, DOI 10.1074/jbc.274.24.17334; TAKAHASHI K, 1980, J BIOL CHEM, V255, P8206; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOMAREV SI, 1992, J BIOL CHEM, V267, P8604; TOMAREV SI, 1988, NATURE, V336, P86, DOI 10.1038/336086a0; Tomarev SI, 1996, EUR J BIOCHEM, V235, P449, DOI 10.1111/j.1432-1033.1996.00449.x; Vasiliou V, 1999, PHARMACOGENETICS, V9, P421, DOI 10.1097/00008571-199910000-00004; VERHAGEN C, 1991, EXP EYE RES, V53, P283, DOI 10.1016/0014-4835(91)90085-S; Vie MP, 1997, MOL ENDOCRINOL, V11, P1728, DOI 10.1210/me.11.11.1728; WANG XP, 1995, BIOCHEMISTRY-US, V34, P237, DOI 10.1021/bi00001a028; Werten PJL, 2000, P NATL ACAD SCI USA, V97, P3282, DOI 10.1073/pnas.050500597; WISTOW G, 1987, SCIENCE, V236, P1554, DOI 10.1126/science.3589669; WISTOW G, 1991, J MOL EVOL, V32, P262, DOI 10.1007/BF02342749; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; XIAO Q, 1995, J CLIN INVEST, V96, P2180, DOI 10.1172/JCI118272; Xu YS, 2000, J BIOL CHEM, V275, P24645, DOI 10.1074/jbc.M001159200; Yamauchi K, 1999, J BIOL CHEM, V274, P8460, DOI 10.1074/jbc.274.13.8460; Yoshida A, 1998, EUR J BIOCHEM, V251, P549, DOI 10.1046/j.1432-1327.1998.2510549.x; Zhou JZ, 1997, EUR J BIOCHEM, V245, P123, DOI 10.1111/j.1432-1033.1997.00123.x; ZINOVIEVA RD, 1993, J BIOL CHEM, V268, P11449	79	39	39	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41064	41073		10.1074/jbc.M005625200	http://dx.doi.org/10.1074/jbc.M005625200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10961997	hybrid			2022-12-25	WOS:000166114600055
J	Li, M; Kondo, T; Zhao, QL; Li, FJ; Tanabe, K; Arai, Y; Zhou, ZC; Kasuya, M				Li, M; Kondo, T; Zhao, QL; Li, FJ; Tanabe, K; Arai, Y; Zhou, ZC; Kasuya, M			Apoptosis induced by cadmium in human lymphoma U937 cells through Ca2+-calpain and caspase-mitochondria dependent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; CYTOCHROME-C RELEASE; DNA FRAGMENTATION; T-CELLS; BCL-X; CALCIUM; DEATH; ACTIVATION; INDUCTION; PROTEIN	Apoptosis induced by cadmium has been shown in many tissues in vivo and in cultured cells in vitro. However, its molecular mechanism is not fully understood. When the human histiocytic lymphoma cell line U937 was treated with cadmium for 12 h, evidence of apoptotic features, including change in nuclear morphology, DNA fragmentation, formation of DNA ladder in agarose gel electrophoresis, and phosphatidylserine externalization, were obtained. Moreover, loss of the mitochondrial membrane potential (Delta psi (m)) was observed in the cadmium-treated cells and was inhibited by a broad caspase inhibitor (Z-VAD-FMK). Caspase inhibitors suppressed the DNA fragmentation in the order of Z-VAD-FMK > caspase-8 inhibitor > caspase-3 inhibitor. Expression of Bcl-x(L) and Bid decreased significantly in the cadmium-treated cells, although no apparent change in Bcl-2 and Bax expression was found. Tetrakis-(2-pyridylmethyl) ethylendiamine, a cell-permeable heavy metal chelator, partially reversed the increase of fluorescence of Fura-a in the cadmium-treated cells. In addition, verapamil (70 muM), a voltage-dependent Ca2+ channel blocker, inhibited the DNA fragmentation induced by cadmium less than 100 muM and decreased the fluorescence of Fura-8. Cadmium up-regulated the expression of type 1 inositol 1,4,5-trisphosphate receptor (IP3R) but not type 2 or type 3 IP3R Calpain inhibitors I and II partially prevented DNA fragmentation. No effects of Z-VAD-FMK on the expression of type 1 IP3R or of calpain inhibitors on the loss of Delta psi (m) were observed. These results suggest that cadmium possibly induced apoptosis in U937 cells through two independent pathways, the Ca2+-calpain-dependent pathway and the caspase-mitochondria-dependent pathway.	Toyama Med & Pharmaceut Univ, Fac Med, Dept Radiol Sci, Sugitani, Toyama 9300197, Japan; Toyama Med & Pharmaceut Univ, Fac Med, Dept Publ Hlth, Sugitani, Toyama 9300197, Japan; Beijing Med Univ, Sch Publ Hlth, Dept Toxicol, Beijing 100083, Peoples R China; China Med Univ, Sch Publ Hlth, Dept Ind Hyg & Occupat Dis, Shenyang 110001, Peoples R China	University of Toyama; University of Toyama; Peking University; China Medical University	Kondo, T (corresponding author), Toyama Med & Pharmaceut Univ, Fac Med, Dept Radiol Sci, Sugitani, Toyama 9300197, Japan.							Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Beyersmann D, 1997, TOXICOL APPL PHARM, V144, P247, DOI 10.1006/taap.1997.8125; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bossy-Wetzel E, 1999, MUTAT RES-DNA REPAIR, V434, P243, DOI 10.1016/S0921-8777(99)00032-4; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Caricchio R, 1998, J IMMUNOL, V161, P241; Denecker G, 2000, FEBS LETT, V465, P47, DOI 10.1016/S0014-5793(99)01702-0; ELAZZOUZI B, 1994, TOXICOLOGY, V88, P127; Fadeel B, 1999, BIOCHEM BIOPH RES CO, V266, P699, DOI 10.1006/bbrc.1999.1888; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Fulda S, 1997, CANCER RES, V57, P4956; Fulda S, 1997, CANCER RES, V57, P3823; Habeebu SSM, 1998, TOXICOL APPL PHARM, V149, P203, DOI 10.1006/taap.1997.8334; Hamada T, 1996, BIOCHEM BIOPH RES CO, V219, P829, DOI 10.1006/bbrc.1996.0318; HARNICK DJ, 1995, J BIOL CHEM, V270, P2833, DOI 10.1074/jbc.270.6.2833; Hart BA, 1999, TOXICOLOGY, V133, P43, DOI 10.1016/S0300-483X(99)00013-X; Harwood FG, 2000, J BIOL CHEM, V275, P10023, DOI 10.1074/jbc.275.14.10023; Haugland R., 1996, HDB FLUORESCENT PROB; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; Jones MM, 1997, TOXICOLOGY, V116, P169, DOI 10.1016/S0300-483X(96)03541-X; Kato M, 2000, J BIOCHEM, V127, P297, DOI 10.1093/oxfordjournals.jbchem.a022607; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Khodarev NN, 1998, INT J RADIAT BIOL, V73, P455; Kimura C, 1998, EXP CELL RES, V239, P411, DOI 10.1006/excr.1997.3912; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KONDO T, 1993, CELL CALCIUM, V14, P621, DOI 10.1016/0143-4160(93)90087-M; KOSTRZEWSKA A, 1990, FEBS LETT, V263, P381, DOI 10.1016/0014-5793(90)81419-O; Kuo TH, 1998, ONCOGENE, V17, P1903, DOI 10.1038/sj.onc.1202110; Li HL, 1999, CURR OPIN CELL BIOL, V11, P261, DOI 10.1016/S0955-0674(99)80035-0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Long GJ, 1997, TOXICOL LETT, V91, P91, DOI 10.1016/S0378-4274(97)03880-0; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; McConkey DJ, 1997, BIOCHEM BIOPH RES CO, V239, P357, DOI 10.1006/bbrc.1997.7409; MORSELT AFW, 1991, TOXICOLOGY, V70, P1; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Ono Y, 1998, BIOCHEM BIOPH RES CO, V245, P289, DOI 10.1006/bbrc.1998.8085; OTLVAI ZN, 1993, CELL, V74, P609; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; RICKAN LE, 2000, J BIOCHEM MOL TOXIC, V14, P110; SELLINS KS, 1987, J IMMUNOL, V139, P3199; Somji S, 1999, ENVIRON HEALTH PERSP, V107, P545, DOI 10.2307/3434396; Squier MKT, 1997, J IMMUNOL, V158, P3690; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; SWANDULLA D, 1989, P NATL ACAD SCI USA, V86, P1736, DOI 10.1073/pnas.86.5.1736; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsangaris GT, 1998, TOXICOLOGY, V128, P143, DOI 10.1016/S0300-483X(98)00032-8; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; VERBOST PM, 1987, BIOCHIM BIOPHYS ACTA, V902, P247, DOI 10.1016/0005-2736(87)90302-6; VISSER GJ, 1993, BIOCHIM BIOPHYS ACTA, V1152, P26, DOI 10.1016/0005-2736(93)90227-Q; Wang Z, 1998, J BIOL CHEM, V273, P73, DOI 10.1074/jbc.273.1.73; WHO, 1992, ENV HLTH CRIT, V134; Xu CY, 1996, TOXICOLOGY, V107, P1, DOI 10.1016/0300-483X(95)03195-L; Yang CF, 1997, ENVIRON HEALTH PERSP, V105, P712, DOI 10.1289/ehp.97105712; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZHANG GH, 1990, J BIOL CHEM, V265, P2184; Zhao QL, 1999, INT J RADIAT BIOL, V75, P493, DOI 10.1080/095530099140429; Zhou T, 1999, TOXICOLOGY, V142, P1, DOI 10.1016/S0300-483X(99)00115-8	64	207	220	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39702	39709		10.1074/jbc.M007369200	http://dx.doi.org/10.1074/jbc.M007369200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10970901	hybrid			2022-12-25	WOS:000165953100099
J	Chu, GX; Lester, JW; Young, KB; Luo, WS; Zhai, J; Kranias, EG				Chu, GX; Lester, JW; Young, KB; Luo, WS; Zhai, J; Kranias, EG			A single site (Ser(16)) phosphorylation in phospholamban is sufficient in mediating its maximal cardiac responses to beta-agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-DEPENDENT PHOSPHORYLATION; RETICULUM CALCIUM-TRANSPORT; SARCOPLASMIC-RETICULUM; PROTEIN-KINASE; ADRENERGIC STIMULATION; INTACT HEART; MYOCARDIAL-CONTRACTILITY; IN-VIVO; MECHANISMS; THR(17)	Phospholamban (PLB) can be phosphorylated at Ser(16) by cyclic AMP-dependent protein kinase and at Thr(17) by Ca2+-calmodulin-dependent protein kinase during beta -agonist stimulation. A previous study indicated that mutation of S16A in PLB resulted in lack of Thr(17) phosphorylation and attenuation of the beta -agonist stimulatory effects in perfused mouse hearts. To further delineate the functional interplay between dual-site PLB phosphorylation, we generated transgenic mice expressing the T17A mutant PLB in the cardiac compartment of the null background. Lines expressing similar levels of T17A mutant, S16A mutant, or wild-type PLB in the null background mere characterized in parallel. Cardiac myocyte basal mechanics and Ca2+ kinetics were similar among the three groups. Isoproterenol stimulation was associated with phosphorylation of both Ser(16) and Thr(17) in wild-type PLB and Ser(16) phosphorylation in T17A mutant PLB, whereas there was no detectable phosphorylation of S16A mutant PLB. Phosphorylation of Ser(16) alone in T17A mutant PLB resulted in responses of the mechanical and Ca2+ kinetic parameters to isoproterenol similar to those in wild-type myocytes, which exhibited dual-site PLB phosphorylation. However, those parameters were significantly attenuated in the S16A mutant myocytes. Thus, Ser(16) in PLB can be phosphorylated independently of Thr(17) in vivo, and phosphorylation of Ser(16) is sufficient for mediating the maximal cardiac responses to beta -adrenergic stimulation.	Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Kranias, EG (corresponding author), Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, 231 Bethesda Ave, Cincinnati, OH 45267 USA.				NCRR NIH HHS [P40RR12358] Funding Source: Medline; NHLBI NIH HHS [HL26057, HL52318] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P40RR012358] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026057, P50HL052318, R37HL026057] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASSANI RA, 1995, AM J PHYSIOL-HEART C, V268, pH703, DOI 10.1152/ajpheart.1995.268.2.H703; Calaghan SC, 1998, PFLUG ARCH EUR J PHY, V436, P948, DOI 10.1007/s004240050728; Chu GX, 1997, CIRC RES, V81, P485, DOI 10.1161/01.RES.81.4.485; Chu GX, 1998, J BIOL CHEM, V273, P33674, DOI 10.1074/jbc.273.50.33674; COLYER J, 1991, J BIOL CHEM, V266, P17486; Colyer J, 1998, ANN NY ACAD SCI, V853, P79, DOI 10.1111/j.1749-6632.1998.tb08258.x; DAVIS BA, 1983, J BIOL CHEM, V258, P3587; Hagemann D, 2000, J BIOL CHEM, V275, P22532, DOI 10.1074/jbc.C000253200; HOIT BD, 1995, CIRC RES, V77, P632, DOI 10.1161/01.RES.77.3.632; Hulme JT, 1997, PFLUG ARCH EUR J PHY, V434, P475, DOI 10.1007/s004240050423; Hussain M, 1997, AM J PHYSIOL-HEART C, V273, pH695, DOI 10.1152/ajpheart.1997.273.2.H695; Jackson WA, 1996, BIOCHEM J, V316, P201, DOI 10.1042/bj3160201; Kadambi VJ, 1996, J CLIN INVEST, V97, P533, DOI 10.1172/JCI118446; Kimura Y, 1996, J BIOL CHEM, V271, P21726, DOI 10.1074/jbc.271.36.21726; Kiss E, 1997, AM J PHYSIOL-HEART C, V272, pH785, DOI 10.1152/ajpheart.1997.272.2.H785; Koss KL, 1996, CIRC RES, V79, P1059, DOI 10.1161/01.RES.79.6.1059; Kranias E.G., 1998, AM J PHYSIOL, V274, P1335; KRANIAS EG, 1985, BIOCHIM BIOPHYS ACTA, V844, P193, DOI 10.1016/0167-4889(85)90090-4; Kuschel M, 1999, AM J PHYSIOL-HEART C, V276, pH1625, DOI 10.1152/ajpheart.1999.276.5.H1625; LEPEUCH CJ, 1979, BIOCHEMISTRY-US, V18, P5150, DOI 10.1021/bi00590a019; LINDEMANN JP, 1985, J BIOL CHEM, V260, P4516; Luo WS, 1996, CIRC RES, V78, P839, DOI 10.1161/01.RES.78.5.839; Luo WS, 1998, J BIOL CHEM, V273, P4734, DOI 10.1074/jbc.273.8.4734; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; MacLennan DH, 1998, ANN NY ACAD SCI, V853, P31, DOI 10.1111/j.1749-6632.1998.tb08254.x; MATTIAZZI A, 1994, AM J PHYSIOL, V267, pH812, DOI 10.1152/ajpheart.1994.267.2.H812; MOVSESIAN MA, 1984, J BIOL CHEM, V259, P8029; MundinaWeilenmann C, 1996, J BIOL CHEM, V271, P33561, DOI 10.1074/jbc.271.52.33561; NAPOLITANO R, 1992, J MOL CELL CARDIOL, V24, P387, DOI 10.1016/0022-2828(92)93193-N; RAEYMAEKERS L, 1988, BIOCHEM J, V252, P269, DOI 10.1042/bj2520269; Santana LF, 1997, J PHYSIOL-LONDON, V503, P21, DOI 10.1111/j.1469-7793.1997.021bi.x; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; TADA M, 1983, J MOL CELL CARDIOL, V15, P335, DOI 10.1016/0022-2828(83)91345-7; TALOSI L, 1993, AM J PHYSIOL, V264, pH791; Vittone L, 1998, J BIOL CHEM, V273, P9804, DOI 10.1074/jbc.273.16.9804; WEGENER AD, 1989, J BIOL CHEM, V264, P11468; Wolska BM, 1996, AM J PHYSIOL-CELL PH, V271, pC391, DOI 10.1152/ajpcell.1996.271.1.C391	37	125	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38938	38943		10.1074/jbc.M004079200	http://dx.doi.org/10.1074/jbc.M004079200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10988285	hybrid			2022-12-25	WOS:000165739800108
J	Barnett, ME; Zolkiewska, A; Zolkiewski, M				Barnett, ME; Zolkiewska, A; Zolkiewski, M			Structure and activity of ClpB from Escherichia coli - Role of the amino- and carboxyl-terminal domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONE SYSTEM; PROTEIN; MECHANISM; PROTEASES; HSP104; FAMILY; ASSAY; DNAK; GRPE	ClpB is a member of a protein-disaggregating multi-chaperone system in Escherichia coli, The mechanism of protein-folding reactions mediated by ClpB is currently unknown, and the functional role of different sequence regions in ClpB is under discussion. We have expressed and purified the full-length ClpB and three truncated variants with the N-terminal, C terminal, and a double N- and C-terminal deletion. We studied the protein concentration-dependent and ATP-induced oligomerization of ClpB, casein-induced activation of ClpB ATPase, and ClpB-assisted reactivation of denatured firefly luciferase, We found that both the N- and C-terminal truncation of ClpB strongly inhibited its chaperone activity. The reasons for such inhibition were different, however, for the N- and C-terminal truncation. Deletion of the C-terminal domain inhibited the self-association of ClpB, which led to decreased affinity for ATP and to decreased ATPase and chaperone activity of the C terminally truncated variants. In contrast, deletion of the N-terminal domain did not inhibit the self-association of ClpB and its basal ATPase activity but decreased the ability of casein to activate ClpB ATPase, These results indicate that the N-terminal region of ClpB may contain a functionally significant protein-binding site, whereas the main role of the C-terminal region is to support oligomerization of ClpB.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA	Kansas State University	Barnett, ME (corresponding author), Kansas State Univ, Dept Biochem, 104 Willard Hall, Manhattan, KS 66506 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058626] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58626, R01 GM058626, R01 GM058626-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HESS HH, 1975, ANAL BIOCHEM, V63, P607, DOI 10.1016/0003-2697(75)90388-7; Kessel M, 1996, FEBS LETT, V398, P274, DOI 10.1016/S0014-5793(96)01261-6; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Levchenko I, 1997, CELL, V91, P939, DOI 10.1016/S0092-8674(00)80485-7; Maurizi MR, 1998, BIOCHEMISTRY-US, V37, P7778, DOI 10.1021/bi973093e; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; PARK SK, 1993, J BIOL CHEM, V268, P20170; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Smith CK, 1999, P NATL ACAD SCI USA, V96, P6678, DOI 10.1073/pnas.96.12.6678; SQUIRES CL, 1991, J BACTERIOL, V173, P4254, DOI 10.1128/JB.173.14.4254-4262.1991; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Stafford WF, 1994, MODERN ANAL ULTRACEN, P119; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WOO KM, 1992, J BIOL CHEM, V267, P20429; WYMAN J, 1990, BINDING LINKAGE FUNC, P206; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083; Zolkiewski M, 1999, PROTEIN SCI, V8, P1899, DOI 10.1110/ps.8.9.1899	23	94	96	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37565	37571		10.1074/jbc.M005211200	http://dx.doi.org/10.1074/jbc.M005211200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10982797	Green Accepted, hybrid			2022-12-25	WOS:000165618700037
J	Cunha, RA; Almeida, T; Ribeiro, JA				Cunha, RA; Almeida, T; Ribeiro, JA			Modification by arachidonic acid of extracellular adenosine metabolism and neuromodulatory action in the rat hippocampus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBER NERVE-ENDINGS; CULTURED CHROMAFFIN CELLS; LONG-TERM POTENTIATION; GLUTAMATE RELEASE; FATTY-ACIDS; ACETYLCHOLINE-RELEASE; SYNAPTIC-TRANSMISSION; ECTO-NUCLEOTIDASES; SERUM-ALBUMIN; BRAIN	Adenosine and arachidonate (AA) fulfil opposite modulatory roles, arachidonate facilitating and adenosine inhibiting cellular responses. To understand if there is an inter-play between these two neuromodulatory systems, we investigated the effect of AA on extracellular adenosine metabolism in hippocampal nerve terminals. AA (30 muM) facilitated by 67% adenosine evoked release and by 45% ATP evoked release. These effects were not significantly modified upon blockade of lipooxygenase or cyclooxygenase and were attenuated (52-61%) by the protein kinase C inhibitor, chelerythrine (6 muM). The ecto-5'-nucleotidase inhibitor, alpha,beta -methylene ADP (100 muM), caused a larger inhibition (54%) of adenosine release in the presence of AA (30 muM) compared with control (37% inhibition) indicating that the AA-induced extracellular adenosine accumulation is mostly originated from an increased release and extracellular catabolism of ATP. This AA-induced extracellular adenosine accumulation is further potentiated by an AA-induced decrease (48%) of adenosine transporters capacity. AA (30 muM) increased by 36-42% the tonic inhibition by endogenous extracellular adenosine of adenosine A(1) receptors in the modulation of acetylcholine release and of CA1 hippocampal synaptic transmission in hippocampal slices. These results indicate that AA increases tonic adenosine modulation as a possible feedback loop to limit AA facilitation of neuronal excitability.	Univ Lisbon, Fac Med, Neurosci Lab, P-1649028 Lisbon, Portugal; Univ Lisbon, Fac Sci, Dept Chem & Biochem, P-1649028 Lisbon, Portugal	Universidade de Lisboa; Universidade de Lisboa	Cunha, RA (corresponding author), Univ Lisbon, Fac Med, Neurosci Lab, Av Prof Egas Moniz, P-1649028 Lisbon, Portugal.	racunha@neurociencias.pt	Cunha, Rodrigo A/E-7475-2015	Cunha, Rodrigo A/0000-0003-2550-6422; Ribeiro, Joaquim/0000-0002-9330-3507				ADESUYI SA, 1985, J NEUROCHEM, V45, P770, DOI 10.1111/j.1471-4159.1985.tb04059.x; Almeida T, 1999, BRAIN RES, V826, P104, DOI 10.1016/S0006-8993(99)01267-6; Ambrosio AF, 1997, EUR J PHARMACOL, V340, P301, DOI 10.1016/S0014-2999(97)01451-9; ANDERSON WW, 1997, NEUR ABST, V23, P665; BAZAN NG, 1989, ANN NY ACAD SCI, V559, P1; BIRKLE DL, 1987, J NEUROCHEM, V48, P1768, DOI 10.1111/j.1471-4159.1987.tb05735.x; BRADFORD PG, 1983, J NEUROCHEM, V41, P1684, DOI 10.1111/j.1471-4159.1983.tb00881.x; Breukel AIM, 1997, BRAIN RES, V773, P90, DOI 10.1016/S0006-8993(97)00918-9; CHAN PH, 1983, J NEUROCHEM, V41, P1550, DOI 10.1111/j.1471-4159.1983.tb00863.x; Chen WC, 1998, GLIA, V22, P360, DOI 10.1002/(SICI)1098-1136(199804)22:4<360::AID-GLIA5>3.0.CO;2-7; CLEMENTS MP, 1991, NEUROSCIENCE, V45, P379, DOI 10.1016/0306-4522(91)90235-G; Collins DR, 1995, EUR J PHARMACOL, V294, P147, DOI 10.1016/0014-2999(95)00523-4; Cunha RA, 2001, NEUROCHEM INT, V38, P107, DOI 10.1016/S0197-0186(00)00034-6; Cunha RA, 1998, J NEUROSCI, V18, P1987; Cunha RA, 1996, J NEUROCHEM, V67, P2180; CUNHA RA, 1992, J NEUROCHEM, V59, P657, DOI 10.1111/j.1471-4159.1992.tb09420.x; CUNHA RA, 1994, J NEUROCHEM, V63, P207; Cunha RA, 1999, EUR J NEUROSCI, V11, P2171, DOI 10.1046/j.1460-9568.1999.00661.x; DAMRON DS, 1993, NEUROCHEM RES, V18, P1231, DOI 10.1007/BF00975040; DELICADO EG, 1991, BIOCHEM J, V279, P651, DOI 10.1042/bj2790651; deMendonca A, 1996, LIFE SCI, V60, P245, DOI 10.1016/S0024-3205(96)00544-9; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DOMANSKAJANIK K, 1993, NEUROREPORT, V4, P451, DOI 10.1097/00001756-199304000-00029; DRAGUNOW M, 1988, PROG NEUROBIOL, V31, P85, DOI 10.1016/0301-0082(88)90028-7; DUMAN RS, 1986, J NEUROCHEM, V47, P800; DUNWIDDIE TV, 1990, BRAIN RES, V527, P76, DOI 10.1016/0006-8993(90)91062-L; FREDHOLM BB, 1994, J NEUROCHEM, V62, P563; Fredholm BB, 1997, INT REV NEUROBIOL, V40, P259; FREEMAN EJ, 1990, NEUROCHEM RES, V15, P743, DOI 10.1007/BF00973656; FREEMAN EJ, 1991, J NEUROCHEM, V56, P1079, DOI 10.1111/j.1471-4159.1991.tb02032.x; Gonzalez L, 1997, NEUROCHEM RES, V22, P189, DOI 10.1023/A:1027319708321; GU JG, 1993, J NEUROCHEM, V60, P2232, DOI 10.1111/j.1471-4159.1993.tb03509.x; HENKE DC, 1984, ANAL BIOCHEM, V140, P87, DOI 10.1016/0003-2697(84)90137-4; JAMES S, 1993, J NEUROCHEM, V60, P219, DOI 10.1111/j.1471-4159.1993.tb05841.x; KENAKIN TP, 1987, PHARM ANAL DRUG RECE; Kitakaze M, 1997, BIOCHEM BIOPH RES CO, V239, P171, DOI 10.1006/bbrc.1997.7445; KOIDE T, 1986, J NEUROCHEM, V46, P235, DOI 10.1111/j.1471-4159.1986.tb12952.x; KRAGHHANSEN U, 1981, PHARMACOL REV, V33, P17; LINDGREN JA, 1984, P NATL ACAD SCI-BIOL, V81, P6212, DOI 10.1073/pnas.81.19.6212; LUPICA CR, 1990, J PHARMACOL EXP THER, V252, P1134; LYNCH MA, 1990, J NEUROCHEM, V55, P215, DOI 10.1111/j.1471-4159.1990.tb08841.x; LYNCH MA, 1991, BIOCHEM SOC T, V19, P391, DOI 10.1042/bst0190391; Masino SA, 1999, J NEUROSCI, V19, P1932; MITCHELL JB, 1993, J NEUROSCI, V13, P3439; ORDWAY RW, 1991, TRENDS NEUROSCI, V14, P96, DOI 10.1016/0166-2236(91)90069-7; Pankratov Y, 1998, EUR J NEUROSCI, V10, P3898, DOI 10.1046/j.1460-9568.1998.00419.x; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; PIOMELLI D, 1989, P NATL ACAD SCI USA, V86, P8550, DOI 10.1073/pnas.86.21.8550; REHNCRONA S, 1982, J NEUROCHEM, V38, P84, DOI 10.1111/j.1471-4159.1982.tb10857.x; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; SAMPLES DR, 1989, AM J PHYSIOL, V257, pC1166; SEN RP, 1993, J NEUROCHEM, V60, P613, DOI 10.1111/j.1471-4159.1993.tb03192.x; SHEARMAN MS, 1991, FEBS LETT, V279, P261, DOI 10.1016/0014-5793(91)80163-W; SPECTOR T, 1978, ANAL BIOCHEM, V86, P142, DOI 10.1016/0003-2697(78)90327-5; VERNON LP, 1992, PHARMACOL THERAPEUT, V54, P269, DOI 10.1016/0163-7258(92)90003-I; VOLTERRA A, 1992, ADV EXP MED BIOL, V318, P147; Wieraszko A, 1996, ACTA NEUROBIOL EXP, V56, P637; Wildman SS, 1997, BRIT J PHARMACOL, V120, P221, DOI 10.1038/sj.bjp.0700903; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; Zimmermann H, 1996, PROG NEUROBIOL, V49, P589, DOI 10.1016/0301-0082(96)00026-3	60	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37572	37581		10.1074/jbc.M003011200	http://dx.doi.org/10.1074/jbc.M003011200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10978314	hybrid			2022-12-25	WOS:000165618700038
J	Poyet, JL; Srinivasula, SM; Lin, JH; Fernandes-Alnemri, T; Yamaoka, S; Tsichlis, PN; Alnemri, ES				Poyet, JL; Srinivasula, SM; Lin, JH; Fernandes-Alnemri, T; Yamaoka, S; Tsichlis, PN; Alnemri, ES			Activation of the I kappa B kinases by RIP via IKK gamma/NEMO-mediated oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-RECEPTOR; SIGNALING COMPLEX; CONTAINS 2; ALPHA; PROTEIN; PHOSPHORYLATION; TNF; BETA; APOPTOSIS; PATHWAY	To understand the mechanism of activation of the I kappaB kinase (IKK) complex in the tumor necrosis factor (TNF) receptor 1 pathway, we examined the possibility that oligomerization of the IKK complex triggered by ligand-induced trimerization of the TNF receptor 1 complex is responsible for activation of the IKKs. Gel filtration analysis of the IKK complex revealed that TNF alpha stimulation induces a large increase in the size of this complex, suggesting oligomerization. Substitution of the C-terminal region of IKK gamma, which interacts with RIP, with a truncated DR4 lacking its cytoplasmic death domain, produced a molecule that could induce IKK and NF-kappaB activation in cells in response to TRAIL. Enforced oligomerization of the N terminus of IKK gamma or truncated IKK alpha or IKK beta lacking their serine-cluster domains can also induce IKK and NF-kappaB activation. These data suggest that IKK gamma functions as a signaling adaptor between the upstream regulators such as RIP and the IKKs and that oligomerization of the IKK complex by upstream regulators is a critical step in activation of this complex.	Thomas Jefferson Univ, Ctr Apoptosis Res, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Tokyo Med & Dent Univ, Sch Med, Dept Microbiol, Bunkyo Ku, Tokyo 1138519, Japan	Jefferson University; Jefferson University; Tokyo Medical & Dental University (TMDU)	Alnemri, ES (corresponding author), Thomas Jefferson Univ, Ctr Apoptosis Res, Philadelphia, PA 19107 USA.		Poyet, Jean-Luc/G-7114-2017	Poyet, Jean-Luc/0000-0002-3747-255X	NCI NIH HHS [CA38047, CA78890, CA85421] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078890, R01CA038047, R01CA085421] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Burke JR, 1998, J BIOL CHEM, V273, P12041, DOI 10.1074/jbc.273.20.12041; Cha SS, 1999, IMMUNITY, V11, P253, DOI 10.1016/S1074-7613(00)80100-4; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; Chin AID, 1999, MOL CELL BIOL, V19, P6665; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hymowitz SG, 2000, BIOCHEMISTRY-US, V39, P633, DOI 10.1021/bi992242l; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Ozes ON, 1999, NATURE, V401, P82; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Relaix F, 1998, NAT GENET, V18, P287, DOI 10.1038/ng0398-287; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rudolph D, 2000, GENE DEV, V14, P854; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; SPENCER DM, 1993, SCIENCE, V262, P119; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; WIRTH T, 1988, EMBO J, V7, P3109, DOI 10.1002/j.1460-2075.1988.tb03177.x; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Ye JJ, 2000, J BIOL CHEM, V275, P9882, DOI 10.1074/jbc.275.13.9882; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	52	142	151	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37966	37977		10.1074/jbc.M006643200	http://dx.doi.org/10.1074/jbc.M006643200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10980203	hybrid			2022-12-25	WOS:000165618700089
J	Ueoka, C; Kaneda, N; Okazaki, I; Nadanaka, S; Muramatsu, T; Sugahara, K				Ueoka, C; Kaneda, N; Okazaki, I; Nadanaka, S; Muramatsu, T; Sugahara, K			Neuronal cell adhesion, mediated by the heparin-binding neuroregulatory factor midkine, is specifically inhibited by chondroitin sulfate E - Structural and functional implications of the over-sulfated chondroitin sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; GROWTH-ASSOCIATED MOLECULE; CENTRAL-NERVOUS-SYSTEM; HIGH-AFFINITY BINDING; NEURITE OUTGROWTH; HB-GAM; DERMATAN SULFATE; ZETA/RPTP-BETA; RAT-BRAIN; 6B4 PROTEOGLYCAN/PHOSPHACAN	The heparin-binding neurotrophic factor midkine (MK) has been proposed to mediate neuronal cell adhesion and neurite outgrowth promotion by interacting with cell-surface heparan sulfate. We have observed that over-sulfated chondroitin sulfate (CS) D and CS-E show neurite outgrowth-promoting activity in embryonic day (E) 18 rat hippocampal neurons (Nadanaka, S., Clement, A., Masayama, K., Faissner, A., and Sugahara, K. (1998) J. Biol. Chem. 273, 3296-3307). In the present study, various CS isoforms were examined for their ability to inhibit the MK-mediated cell. adhesion of cortical neuronal cells in comparison with heparin from porcine intestine and heparan sulfate from bovine kidney. E17-18 rat cortical neuronal cells were cultured on plates coated with recombinant MK in a grid pattern. The cells attached to and extended their neurites along the MK substratum. Cell adhesion was inhibited by squid cartilage over-sulfated CS-E as well as by heparin, but not by heparan sulfate or other CS isoforms. Direct interactions of MH with various glycosaminoglycans were then evaluated using surface plasmon resonance, showing that CS-E bound MK as strongly as heparin, followed by other over-sulfated CS isoforms, CS-H and CS K. Furthermore, E18 rat brain extracts showed an E disaccharide unit, GlcUA beta1-3GalNAc(4,6-O-disulfate). These findings indicate that CS chains containing the E unit as well as heparin-like glycosaminoglycans may be involved in the expression and/or modulation of the multiple neuroregulatory functions of MK such as neuronal adhesion and migration and promotion of neurite outgrowth.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan; Meijo Univ, Fac Pharm, Dept Analyt Neurobiol, Nagoya, Aichi 4688503, Japan; Nagoya Univ, Sch Med, Dept Biochem, Nagoya, Aichi 4660065, Japan; Biacore Kabushiki Kaisha, Minato Ku, Tokyo 1050011, Japan	Kobe Pharmaceutical University; Meijo University; Nagoya University	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan.							ANNO K, 1971, BIOCHIM BIOPHYS ACTA, V237, P173, DOI 10.1016/0304-4165(71)90046-8; BARNEA G, 1994, J BIOL CHEM, V269, P14349; BRITTIS PA, 1992, SCIENCE, V255, P733, DOI 10.1126/science.1738848; Clement AM, 1999, NEUROSCI LETT, V269, P125, DOI 10.1016/S0304-3940(99)00432-2; Clement AM, 1998, J BIOL CHEM, V273, P28444, DOI 10.1074/jbc.273.43.28444; Engel M, 1996, J COMP NEUROL, V366, P34; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; FERNAUDESPINOSA I, 1994, J CELL SCI, V107, P1437; Garwood J, 1999, J NEUROSCI, V19, P3888; HERNDON ME, 1990, NEURON, V4, P949, DOI 10.1016/0896-6273(90)90148-9; Horiba M, 2000, J CLIN INVEST, V105, P489, DOI 10.1172/JCI7208; IWANE M, 1987, BIOCHEM BIOPH RES CO, V146, P470, DOI 10.1016/0006-291X(87)90553-5; Iwasaki W, 1997, EMBO J, V16, P6936, DOI 10.1093/emboj/16.23.6936; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; Kaneda N, 1996, J BIOCHEM-TOKYO, V119, P1150; Kaneda N, 1996, BIOCHEM BIOPH RES CO, V220, P108, DOI 10.1006/bbrc.1996.0365; KARLSSON R, 1995, ANAL BIOCHEM, V228, P274, DOI 10.1006/abio.1995.1350; KATOHSEMBA R, 1995, EUR J NEUROSCI, V7, P613, DOI 10.1111/j.1460-9568.1995.tb00665.x; Kinnunen T, 1996, J BIOL CHEM, V271, P2243, DOI 10.1074/jbc.271.4.2243; Kinnunen T, 1998, J BIOL CHEM, V273, P10702, DOI 10.1074/jbc.273.17.10702; Kinoshita A, 1997, J BIOL CHEM, V272, P19656, DOI 10.1074/jbc.272.32.19656; Kinoshita A, 1999, ANAL BIOCHEM, V269, P367, DOI 10.1006/abio.1999.4027; KINOSHITA A, 1998, ABSTR 19 INT CARB S; KINOSHITA A, 1997, SEIKAGAKU, V69, P794; Kitagawa H, 1997, J BIOL CHEM, V272, P31377, DOI 10.1074/jbc.272.50.31377; KOJIMA S, 1995, J BIOL CHEM, V270, P9590, DOI 10.1074/jbc.270.16.9590; Kojima T, 1996, J BIOL CHEM, V271, P5914, DOI 10.1074/jbc.271.10.5914; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; LAFONT F, 1992, DEVELOPMENT, V114, P17; Lander A D, 1993, Curr Opin Neurobiol, V3, P716, DOI 10.1016/0959-4388(93)90143-M; LEVY JB, 1993, J BIOL CHEM, V268, P10573; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; Lindahl U., 1989, HEPARIN, P159; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; MAEDA N, 1995, NEUROSCIENCE, V67, P23, DOI 10.1016/0306-4522(94)00069-H; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MATSUMOTO K, 1994, DEV BRAIN RES, V79, P229, DOI 10.1016/0165-3806(94)90127-9; MERENMIES J, 1990, J BIOL CHEM, V265, P16721; Milev P, 1998, J BIOL CHEM, V273, P6998, DOI 10.1074/jbc.273.12.6998; Munakata H, 1999, GLYCOBIOLOGY, V9, P1023, DOI 10.1093/glycob/9.10.1023; MURAMATSU H, 1991, BIOCHEM BIOPH RES CO, V177, P652, DOI 10.1016/0006-291X(91)91838-4; MURAMATSU H, 1994, BIOCHEM BIOPH RES CO, V203, P1131, DOI 10.1006/bbrc.1994.2300; Nadanaka S, 1998, J BIOL CHEM, V273, P3296, DOI 10.1074/jbc.273.6.3296; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; OOHIRA A, 1988, J BIOL CHEM, V263, P10240; OOHIRA A, 1991, J NEUROSCI, V11, P822; RAUCH U, 1991, J BIOL CHEM, V266, P14785; RAULO E, 1994, J BIOL CHEM, V269, P12999; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; SAIGO K, 1970, J NEUROCHEM, V17, P633, DOI 10.1111/j.1471-4159.1970.tb00543.x; SENO N, 1982, CARBOHYD RES, V103, P190; SNOW DM, 1990, DEV BIOL, V138, P359, DOI 10.1016/0012-1606(90)90203-U; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; SNOW DM, 1991, DEVELOPMENT, V113, P1473; Snyder SE, 1996, MOL BRAIN RES, V40, P79; STALLCUP WB, 1981, DEV BIOL, V83, P154, DOI 10.1016/S0012-1606(81)80018-8; STREIT A, 1993, J CELL BIOL, V120, P799, DOI 10.1083/jcb.120.3.799; SUGAHARA K, 1994, CARBOHYD RES, V255, P145, DOI 10.1016/S0008-6215(00)90976-5; Sugahara K, 1996, J BIOL CHEM, V271, P26745, DOI 10.1074/jbc.271.43.26745; SUGAHARA K, 1989, BIOCHEM BIOPH RES CO, V162, P189, DOI 10.1016/0006-291X(89)91980-3; SUZUKI S, 1968, J BIOL CHEM, V243, P1543; Ueoka C, 1999, GLYCOCONJUGATE J, V16, P291, DOI 10.1023/A:1007022229813; UEOKA C, 1997, ABSTR 4 BIA S JAP OS, P62; WATANABE E, 1995, J BIOL CHEM, V270, P26876, DOI 10.1074/jbc.270.45.26876; YAMADA H, 1994, J BIOL CHEM, V269, P10119; Yamada S, 1998, EUR J BIOCHEM, V258, P775, DOI 10.1046/j.1432-1327.1998.2580775.x; Yamane Y, 1998, J BIOL CHEM, V273, P7375, DOI 10.1074/jbc.273.13.7375; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; Zou K, 2000, EUR J BIOCHEM, V267, P4046, DOI 10.1046/j.1432-1327.2000.01440.x	71	130	130	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37407	37413		10.1074/jbc.M002538200	http://dx.doi.org/10.1074/jbc.M002538200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10978312	hybrid			2022-12-25	WOS:000165618700015
J	Bertolotto, C; Maulon, L; Filippa, N; Baier, G; Auberger, P				Bertolotto, C; Maulon, L; Filippa, N; Baier, G; Auberger, P			Protein kinase C theta and epsilon promote T-cell survival by a rsk-dependent phosphorylation and inactivation of BAD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED APOPTOSIS; SIGNALING PATHWAY; DEATH; SUPPRESSION; ACTIVATION; INHIBITION; CLEAVAGE; RAS	Both MAPK and protein kinase C (PKC) signaling pathways promote cell survival and protect against cell death. Here, we show that 12-O-tetradecanoylphorbol-13-acetate (TPA) prevents Fas-induced apoptosis in T lymphocytes. The effect of TPA was specifically abolished by the PKC inhibitor GF109203X and by dominant negative PKC theta, PKC is an element of, and PKC alpha, suggesting that novel and conventional PKC isoforms mediate phorbol ester action. Moreover, TPA stimulated phosphorylation of BAD at serine 112, an effect abrogated by GF109203X but not by the MEK inhibitor PD98059. Expression of constitutively active PKC increased the phosphorylation of BAD at serine 112 but not at serine 136. Additionally, Fas-mediated cell death was enhanced by overexpression of a catalytically inactive form of p90Rsk (Rsk2-KN). Finally, Rsk2-KN abolished the protective effect of constitutively active PKC and totally blocked phosphorylation of BAD on serine 112. Thus, novel PKC theta and PKC is an element of rescue T lymphocytes from Fas-mediated apoptosis via a p90Rsk-dependent phosphorylation and inactivation of BAD.	Equipe Labelisee Ligue, INSERM, U526, F-06107 Nice 2, France; INSERM, U145, F-06107 Nice 2, France; Univ Innsbruck, Inst Med Biol & Human Genet, A-6020 Innsbruck, Austria	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; University of Innsbruck	Auberger, P (corresponding author), Equipe Labelisee Ligue, INSERM, U526, IFR 50,28 Ave Valombrose, F-06107 Nice 2, France.	auberger@unice.fr	AUBERGER, Patrick/G-1491-2013; Bertolotto-Ballotti, Corine/O-2155-2016; Bertolotto, Corine/AAF-6634-2021; Baier, Gottfried/E-8755-2012	AUBERGER, Patrick/0000-0002-2481-8275; Bertolotto, Corine/0000-0001-6971-7753; Baier, Gottfried/0000-0002-2085-8325				BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; Bertolotto C, 2000, J BIOL CHEM, V275, P12941, DOI 10.1074/jbc.275.17.12941; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Chen CY, 1999, J BIOL CHEM, V274, P15320, DOI 10.1074/jbc.274.22.15320; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Datta SR, 1998, HORM SIGNALING, V1, P257; DEL PL, 1997, SCIENCE, V278, P687; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; Gray MO, 1997, J BIOL CHEM, V272, P30945, DOI 10.1074/jbc.272.49.30945; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Holmstrom TH, 1998, J IMMUNOL, V160, P2626; JARVIS WD, 1994, CANCER RES, V54, P1707; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; MARQUARDT B, 1994, ONCOGENE, V9, P3213; Mayne GC, 1998, J BIOL CHEM, V273, P24115, DOI 10.1074/jbc.273.37.24115; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Savickiene J, 1999, CELL DEATH DIFFER, V6, P698, DOI 10.1038/sj.cdd.4400541; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Soh JW, 1999, MOL CELL BIOL, V19, P1313; SOZERI O, 1992, ONCOGENE, V7, P2259; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yeh JH, 1998, J EXP MED, V188, P1795, DOI 10.1084/jem.188.10.1795; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	30	125	131	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37246	37250		10.1074/jbc.M007732200	http://dx.doi.org/10.1074/jbc.M007732200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10976111	hybrid			2022-12-25	WOS:000165577700108
J	Brunet, A; Samaan, A; Deshaies, F; Kindt, TJ; Thibodeau, J				Brunet, A; Samaan, A; Deshaies, F; Kindt, TJ; Thibodeau, J			Functional characterization of a lysosomal sorting motif in the cytoplasmic tail of HLA-DO beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-II MOLECULES; INVARIANT CHAIN EXPRESSION; INTRACELLULAR-TRANSPORT; MICE LACKING; DR MOLECULES; HISTOCOMPATIBILITY ANTIGENS; CELL-SURFACE; MONOCLONAL-ANTIBODIES; ENDOCYTIC PATHWAY; TARGETING SIGNALS	HLA-DO is an intracellular non-classical class II major histocompatibility complex molecule expressed in the endocytic pathway of B lymphocytes, which regulates the loading of antigenic peptides onto classical class II molecules such as HLA-DR. The activity of HLA-DO is mediated through its interaction with the peptide editor HLA-DM. Here, our results demonstrate that although HLA-DO is absolutely dependent on its association with DM: to egress the endoplasmic reticulum, the cytoplasmic portion of its beta chain encodes a functional lysosomal sorting signal, By confocal microscopy and flow cytometry analysis, we show that reporter transmembrane molecules fused to the cytoplasmic tail of HLA-DO beta accumulated in Lamp-1(+) vesicles of transfected HeLa cells. Mutagenesis of a leucine-leucine motif abrogated lysosomal accumulation and resulted in cell surface redistribution of reporter molecules. Finally, we show that mutation of the di-leucine sequence in DO beta did not alter its lysosomal sorting when associated with DM molecules. Taken together, these results demonstrate that lysosomal expression of the DO-DM complex is mediated primarily by the tyrosine-based motif of HLA-DM and suggest that the DO beta -encoded motif is involved in the fine-tuning of the intracellular sorting.	Univ Montreal, Dept Microbiol & Immunol, Lab Immunol Mol, Montreal, PQ H3C 3J7, Canada; NIAID, Immunogenet Lab, NIH, Bethesda, MD 20892 USA	Universite de Montreal; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Thibodeau, J (corresponding author), Univ Montreal, Dept Microbiol & Immunol, Lab Immunol Mol, CP 6128,Succ Ctr Ville, Montreal, PQ H3C 3J7, Canada.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000180] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BENAROCH P, 1995, EMBO J, V14, P37, DOI 10.1002/j.1460-2075.1995.tb06973.x; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; Busch R, 1996, EMBO J, V15, P418, DOI 10.1002/j.1460-2075.1996.tb00372.x; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; CHOUCHANE L, 1993, IMMUNOGENETICS, V38, P64, DOI 10.1007/BF00216394; Copier J, 1998, IMMUNOLOGY, V93, P505; Copier J, 1996, J IMMUNOL, V157, P1017; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; Denzin LK, 1997, SCIENCE, V278, P106, DOI 10.1126/science.278.5335.106; Denzin LK, 1996, J EXP MED, V184, P2153, DOI 10.1084/jem.184.6.2153; DENZIN LK, 1994, IMMUNITY, V1, P595, DOI 10.1016/1074-7613(94)90049-3; Douek DC, 1997, INT IMMUNOL, V9, P355, DOI 10.1093/intimm/9.3.355; ERICSON ML, 1994, J BIOL CHEM, V269, P26531; GORVEL JP, 1995, J BIOL CHEM, V270, P2741, DOI 10.1074/jbc.270.6.2741; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUY K, 1982, EUR J IMMUNOL, V12, P942, DOI 10.1002/eji.1830121109; Hammond C, 1998, J IMMUNOL, V161, P3282; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; Heilker R, 1999, BIOESSAYS, V21, P558, DOI 10.1002/(SICI)1521-1878(199907)21:7<558::AID-BIES4>3.0.CO;2-R; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hofmann MW, 1999, J BIOL CHEM, V274, P36153, DOI 10.1074/jbc.274.51.36153; JACOBSON S, 1989, J VIROL, V63, P1756, DOI 10.1128/JVI.63.4.1756-1762.1989; Jensen PE, 1999, IMMUNOL REV, V172, P229, DOI 10.1111/j.1600-065X.1999.tb01368.x; KARLSSON L, 1991, NATURE, V351, P485, DOI 10.1038/351485a0; KELLY AP, 1991, NATURE, V353, P571, DOI 10.1038/353571a0; Kropshofer H, 1996, EMBO J, V15, P6144, DOI 10.1002/j.1460-2075.1996.tb01002.x; Kropshofer H, 1998, EMBO J, V17, P2971, DOI 10.1093/emboj/17.11.2971; Kropshofer H, 1997, IMMUNITY, V6, P293, DOI 10.1016/S1074-7613(00)80332-5; KVIST S, 1982, CELL, V29, P61, DOI 10.1016/0092-8674(82)90090-3; LAMB CA, 1991, P NATL ACAD SCI USA, V88, P5998, DOI 10.1073/pnas.88.14.5998; LARHAMMAR D, 1985, J BIOL CHEM, V260, P4111; Lavoie PM, 1997, P NATL ACAD SCI USA, V94, P6892, DOI 10.1073/pnas.94.13.6892; Liljedahl M, 1996, EMBO J, V15, P4817, DOI 10.1002/j.1460-2075.1996.tb00862.x; Liljedahl M, 1998, IMMUNITY, V8, P233, DOI 10.1016/S1074-7613(00)80475-6; LINDSTEDT R, 1995, IMMUNITY, V3, P561, DOI 10.1016/1074-7613(95)90127-2; LOSS GE, 1993, J IMMUNOL, V150, P3187; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MARKS MS, 1995, J CELL BIOL, V131, P351, DOI 10.1083/jcb.131.2.351; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; MOTTA A, 1995, J BIOL CHEM, V270, P27165, DOI 10.1074/jbc.270.45.27165; Nakagawa TY, 1999, IMMUNOL REV, V172, P121, DOI 10.1111/j.1600-065X.1999.tb01361.x; Neefjes J, 1999, EUR J IMMUNOL, V29, P1421, DOI 10.1002/(SICI)1521-4141(199905)29:05<1421::AID-IMMU1421>3.3.CO;2-3; Nordeng TW, 1999, J BIOL CHEM, V274, P21139, DOI 10.1074/jbc.274.30.21139; Nordeng TW, 1998, CURR TOP MICROBIOL, V232, P179; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; PANINABORDIGNON P, 1992, J EXP MED, V176, P1779, DOI 10.1084/jem.176.6.1779; PIETERS J, 1993, J CELL SCI, V106, P831; Pinet VM, 1998, EUR J IMMUNOL, V28, P799, DOI 10.1002/(SICI)1521-4141(199803)28:03<799::AID-IMMU799>3.0.CO;2-5; Potter PK, 1999, EUR J IMMUNOL, V29, P3936, DOI 10.1002/(SICI)1521-4141(199912)29:12<3936::AID-IMMU3936>3.3.CO;2-B; RADKA SF, 1984, HUM IMMUNOL, V10, P177, DOI 10.1016/0198-8859(84)90038-7; Robadey C, 1997, J IMMUNOL, V159, P3238; ROBBINS AR, 1987, METHOD ENZYMOL, V138, P458; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1993, P NATL ACAD SCI USA, V90, P8581, DOI 10.1073/pnas.90.18.8581; ROMAGNOLI P, 1994, J EXP MED, V180, P1107, DOI 10.1084/jem.180.3.1107; ROMAGNOLI P, 1993, J EXP MED, V177, P583, DOI 10.1084/jem.177.3.583; ROSENBRONSON S, 1991, IMMUNOGENETICS, V33, P124; Rovere P, 1997, ADV EXP MED BIOL, V417, P195; Runnels HA, 1997, MOL IMMUNOL, V34, P471, DOI 10.1016/S0161-5890(97)00043-6; Salamero J, 1996, J BIOL CHEM, V271, P30318, DOI 10.1074/jbc.271.48.30318; Samaan A, 1999, INT IMMUNOL, V11, P99, DOI 10.1093/intimm/11.1.99; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SEKALY RP, 1986, J EXP MED, V164, P1490, DOI 10.1084/jem.164.5.1490; SHERMAN MA, 1995, IMMUNITY, V3, P197, DOI 10.1016/1074-7613(95)90089-6; SIMONSEN A, 1993, INT IMMUNOL, V5, P903, DOI 10.1093/intimm/5.8.903; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; Stumptner P, 1997, EMBO J, V16, P5807, DOI 10.1038/sj.emboj.7590555; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Thibodeau J, 1998, MOL IMMUNOL, V35, P885, DOI 10.1016/S0161-5890(98)00061-3; TONNELLE C, 1985, EMBO J, V4, P2839, DOI 10.1002/j.1460-2075.1985.tb04012.x; van Ham M, 2000, J EXP MED, V191, P1127, DOI 10.1084/jem.191.7.1127; vanHam SM, 1997, CURR BIOL, V7, P950, DOI 10.1016/S0960-9822(06)00414-3; vanHam SM, 1996, J EXP MED, V184, P2019, DOI 10.1084/jem.184.5.2019; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; Wang K, 1997, J BIOL CHEM, V272, P17055, DOI 10.1074/jbc.272.27.17055; Weber DA, 1996, SCIENCE, V274, P618, DOI 10.1126/science.274.5287.618; Wubbolts R, 1996, J CELL BIOL, V135, P611, DOI 10.1083/jcb.135.3.611; Zhong GM, 1997, J EXP MED, V185, P429, DOI 10.1084/jem.185.3.429; Zhong GM, 1996, J EXP MED, V184, P2061, DOI 10.1084/jem.184.5.2061	81	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37062	37071		10.1074/jbc.M005112200	http://dx.doi.org/10.1074/jbc.M005112200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10964920	hybrid			2022-12-25	WOS:000165577700085
J	Zobel-Thropp, P; Yang, MC; Machado, L; Clarke, S				Zobel-Thropp, P; Yang, MC; Machado, L; Clarke, S			A novel post-translational modification of yeast elongation factor 1A - Methylesterification at the C terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN CARBOXYL METHYLATION; AMINOACYL-TRANSFER-RNA; SACCHAROMYCES-CEREVISIAE; FACTOR 1-ALPHA; STE14 GENE; NUCLEOTIDE-SEQUENCE; BOVINE BRAIN; FACTOR-I; A-FACTOR; METHYLTRANSFERASE	Protein methylation reactions can play important roles in cell physiology. After labeling intact Saccharomyces cerevisiae cells with S-adenosyl-L-[methyl-H-3]methionine, we identified a major methylated 49-kDa polypeptide containing [H-3]methyl groups in two distinct types of linkages. Peptide sequence analysis of the purified methylated protein revealed that it is eukaryotic elongation factor 1A (eEF1A, formerly EF-1 alpha), the protein that forms a complex with GTP and aminoacyl-tRNAs for binding to the ribosomal A site during protein translation, Previous studies have shown that eEF1A is methylated on several internal lysine residues to give mono-, di-, and tri-N-epsilon -methyl-lysine derivatives. We confirm this finding but also detect methylation that is released as volatile methyl groups after base hydrolysis, characteristic of ester linkages. In cycloheximide-treated cells, methyl esterified eEF1A was detected largely in the ribosome and polysome fractions; little or no methylated protein was found in the soluble fraction. Because the base-labile, volatile [methyl-H-3]radioactivity of eEF1A could be released by trypsin treatment but not by carboxypeptidase Y or chymotrypsin treatment, we suggest that the methyl ester is present on the alpha -carboxyl group of its C-terminal lysine residue, From the results of pulse-chase experiments using radiolabeled intact yeast cells, we find that the N-methylated lysine residues of eEF1A. are stable over 4 h, whereas the eEF1A carboxyl methyl ester has a half-life of less than 10 min. The rapid turnover of the methyl ester suggests that the methylation/demethylation of eEF1A at the C-terminal carboxyl group may represent a novel mode of regulation of the activity of this protein in yeast.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Clarke, S (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 607 Charles E Young Dr E, Los Angeles, CA 90095 USA.				NIGMS NIH HHS [GM26020] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026020, R37GM026020] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES GFL, 1979, J BIOL CHEM, V254, P9947; AMONS R, 1983, FEBS LETT, V153, P37, DOI 10.1016/0014-5793(83)80115-X; BAI Y, 1975, J BIOCHEM-TOKYO, V78, P617, DOI 10.1093/oxfordjournals.jbchem.a130948; BERNHARD SA, 1955, BIOCHEM J, V59, P506, DOI 10.1042/bj0590506; Carr-Schmid A, 1999, J BIOL CHEM, V274, P30297, DOI 10.1074/jbc.274.42.30297; Cavallius J, 1997, BBA-GENE STRUCT EXPR, V1350, P345, DOI 10.1016/S0167-4781(96)00181-9; CAVALLIUS J, 1993, BIOCHIM BIOPHYS ACTA, V1163, P75, DOI 10.1016/0167-4838(93)90281-U; Cavallius J, 1998, J BIOL CHEM, V273, P28752, DOI 10.1074/jbc.273.44.28752; CLARKE S, 1984, METHOD ENZYMOL, V106, P330; Clarke S, 1993, CURR OPIN CELL BIOL, V5, P977, DOI 10.1016/0955-0674(93)90080-A; CONDEELIS J, 1995, TRENDS BIOCHEM SCI, V20, P169, DOI 10.1016/S0968-0004(00)88998-7; COTTRELLE P, 1985, J BIOL CHEM, V260, P3090; DEVER TE, 1989, J BIOL CHEM, V264, P20518; FAVRE B, 1994, J BIOL CHEM, V269, P16311; Gary JD, 1996, J BIOL CHEM, V271, P12585, DOI 10.1074/jbc.271.21.12585; Graves JD, 1999, PHARMACOL THERAPEUT, V82, P111, DOI 10.1016/S0163-7258(98)00056-4; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; GRUNWALD SK, 1995, J BACTERIOL, V177, P628, DOI 10.1128/jb.177.3.628-635.1995; HAN KK, 1993, INT J BIOCHEM, V25, P957, DOI 10.1016/0020-711X(93)90108-Q; HIATT WR, 1982, P NATL ACAD SCI-BIOL, V79, P3433, DOI 10.1073/pnas.79.11.3433; HRYCYNA CA, 1990, MOL CELL BIOL, V10, P5071, DOI 10.1128/MCB.10.10.5071; HRYCYNA CA, 1994, BIOCHEMISTRY-US, V33, P9806, DOI 10.1021/bi00198a053; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; JANSSEN GMC, 1994, J BIOL CHEM, V269, P31410; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITALIEN JJ, 1979, FEBS LETT, V107, P359, DOI 10.1016/0014-5793(79)80407-X; Liu G, 1996, TRENDS CELL BIOL, V6, P168, DOI 10.1016/0962-8924(96)20013-3; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MURPHY JT, 1972, J BACTERIOL, V109, P499, DOI 10.1128/JB.109.2.499-504.1972; Negrutskii BS, 1998, PROG NUCLEIC ACID RE, V60, P47, DOI 10.1016/S0079-6603(08)60889-2; Pintard L, 2000, MOL CELL BIOL, V20, P1370, DOI 10.1128/MCB.20.4.1370-1381.2000; RIIS B, 1990, TRENDS BIOCHEM SCI, V15, P420, DOI 10.1016/0968-0004(90)90279-K; SAHA SK, 1986, J BIOL CHEM, V261, P2599; SAPPERSTEIN S, 1994, MOL CELL BIOL, V14, P1438, DOI 10.1128/MCB.14.2.1438; Savitz AJ, 1997, J BIOL CHEM, V272, P13140, DOI 10.1074/jbc.272.20.13140; SCHIRMAIER F, 1984, EMBO J, V3, P3311, DOI 10.1002/j.1460-2075.1984.tb02295.x; SCHWERT GW, 1949, J BIOL CHEM, V179, P665; SHERMAN M, 1989, ARCH BIOCHEM BIOPHYS, V275, P371, DOI 10.1016/0003-9861(89)90384-6; THIELE D, 1985, J BIOL CHEM, V260, P3084; TOLEDO H, 1990, FEMS MICROBIOL LETT, V71, P241, DOI 10.1016/0378-1097(90)90227-H; VANDAMME HTF, 1992, EUR J BIOCHEM, V207, P1025; XIE HY, 1993, J BIOL CHEM, V268, P13364; XIE HY, 1994, J BIOL CHEM, V269, P1981; YOUNG SG, 2000, PROTEIN LIPIDATION E, V21, P155	44	39	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					37150	37158		10.1074/jbc.M001005200	http://dx.doi.org/10.1074/jbc.M001005200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973948	hybrid			2022-12-25	WOS:000165577700095
J	Cavalcante, MCM; Allodi, S; Valente, AP; Straus, AH; Takahashi, HK; Mourao, PAS; Pavao, MSG				Cavalcante, MCM; Allodi, S; Valente, AP; Straus, AH; Takahashi, HK; Mourao, PAS; Pavao, MSG			Occurrence of heparin in the invertebrate Styela plicata (Tunicata) is restricted to cell layers facing the outside environment - An ancient role in defense?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATED L-GALACTANS; ANTICOAGULANT ACTIVITY; DERMATAN SULFATE; MAST-CELLS; ANTIBODY ST-1; ASCIDIANS; GLYCOSAMINOGLYCANS; PROTEOGLYCANS; MECHANISM	Heparin is an intracellular product of vertebrate mast cell currently used as exogenous anticoagulant. Despite of the potent biological activities of exogenous heparin, its physiological function has not been clearly established yet. Here, a heparin with similar structure and anticoagulant properties to the mammalian counterpart was shown to occur as the intracellular product of test cells, a cell monolayer that surrounds egg of the invertebrate Styela plicata (Chordata-Tunicata). As in the case of mammalian mast cells, heparin from the ascidian test cells is removed from the intracellular granules after incubation with compound 48/80, Following fertilization, the test cells surrounding the developing larva still retain heparin as metachromatic granulation. In the adult invertebrate, heparin occurs as intracellular granules at the apical tip of epithelial cells surrounding the lumen of both intestine and pharynx, in close contact with the external environment. This is the first description of the presence of heparin in cytoplasmic granules of epithelial-like cells around the lumen of sites exposed to external agents. This arrangement may reflect the participation of heparin in defense mechanisms in this invertebrate.	Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, HOsp Clementino Fraga Filho, Lab Tecido Conjuntivo, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Dept Histol & Embriol, Inst Ciencias Biomed, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Ctr Nacl Ressonancia Magnet Nucl Macromol, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Sao Paulo, Escola Paulista Med, Dept Bioquim, BR-04023900 Sao Paulo, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal de Sao Paulo (UNIFESP)	Pavao, MSG (corresponding author), Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Dept Bioquim Med, Caixa Postal 68041, BR-21941590 Rio De Janeiro, Brazil.		Mourao, Paulo/AAA-5386-2020; Pavao, Mauro Sergio Goncalves/B-1979-2010; Straus, Anita H/K-7629-2013; Allodi, Silvana/G-1781-2012; Valente, Ana Paula/J-3010-2017; S, Allodi/AAR-7968-2020; Takahashi, Helio/J-1725-2012	Pavao, Mauro Sergio Goncalves/0000-0002-1336-4271; Allodi, Silvana/0000-0002-3053-3866; Valente, Ana Paula/0000-0001-7219-1123; 				BARWIG B, 1985, J COMP PHYSIOL B, V155, P135, DOI 10.1007/BF00685206; BJORK I, 1982, MOL CELL BIOCHEM, V48, P161, DOI 10.1007/BF00421226; Cavalcante MCM, 1999, BBA-GEN SUBJECTS, V1428, P77, DOI 10.1016/S0304-4165(99)00046-X; Chahdi A, 2000, J PHARMACOL EXP THER, V292, P122; CLONEY RA, 1990, ACTA ZOOL-STOCKHOLM, V71, P151, DOI 10.1111/j.1463-6395.1990.tb01190.x; Conrad H. E., 1998, HEPARIN BINDING PROT; DIETRICH CP, 1985, BIOCHIM BIOPHYS ACTA, V843, P1, DOI 10.1016/0304-4165(85)90041-8; DIETRICH CP, 1976, ANAL BIOCHEM, V70, P645, DOI 10.1016/0003-2697(76)90496-6; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; IWANAGA S, 1993, CURR OPIN IMMUNOL, V5, P74, DOI 10.1016/0952-7915(93)90084-6; JASEJA M, 1989, CAN J CHEM, V67, P1449, DOI 10.1139/v89-221; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; LANE DL, 1989, HEPARIN CHEM BIOL PR; LINDAHL U, 1979, P NATL ACAD SCI USA, V76, P3198, DOI 10.1073/pnas.76.7.3198; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; Mourao PAS, 1997, CARBOHYD RES, V300, P315, DOI 10.1016/S0008-6215(97)00061-X; MULLOY B, 1994, CARBOHYD RES, V255, P1, DOI 10.1016/S0008-6215(00)90968-6; OFUSO FA, 1989, HEPARIN RELATED POLY; Oliani SM, 1997, J HISTOCHEM CYTOCHEM, V45, P231, DOI 10.1177/002215549704500208; Pavao MSG, 1995, J BIOL CHEM, V270, P31027, DOI 10.1074/jbc.270.52.31027; PAVAO MSG, 1989, J BIOL CHEM, V264, P9972; PAVAO MSG, 1994, BBA-GEN SUBJECTS, V1199, P229, DOI 10.1016/0304-4165(94)90001-9; Pavao MSG, 1998, J BIOL CHEM, V273, P27848, DOI 10.1074/jbc.273.43.27848; PAVAO MSG, 1990, CARBOHYD RES, V208, P153, DOI 10.1016/0008-6215(90)80095-K; RATCLIFFE NA, 1985, INT REV CYTOL, V97, P183, DOI 10.1016/S0074-7696(08)62351-7; Rowley AF., 1981, INVERTEBRATE BLOOD C; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; STRAUS AH, 1982, BIOCHIM BIOPHYS ACTA, V717, P478, DOI 10.1016/0304-4165(82)90291-4; STRAUS AH, 1992, ANAL BIOCHEM, V201, P1, DOI 10.1016/0003-2697(92)90167-6; TAKAHASHI H, 1995, EUR J BIOCHEM, V233, P778, DOI 10.1111/j.1432-1033.1995.778_3.x; TOLLEFSEN DM, 1995, THROMB HAEMOSTASIS, V74, P1209; Wright R.K., 1981, INVERTEBR BLOOD CELL, V2, P565; YOUNG NS, 1972, J CLIN INVEST, V51, P1790, DOI 10.1172/JCI106980	37	53	55	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36189	36196		10.1074/jbc.M005830200	http://dx.doi.org/10.1074/jbc.M005830200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10956656	hybrid			2022-12-25	WOS:000165382000077
J	Miyahara, T; Schrum, L; Rippe, R; Xiong, SG; Yee, HF; Motomura, K; Anania, FA; Willson, TM; Tsukamoto, H				Miyahara, T; Schrum, L; Rippe, R; Xiong, SG; Yee, HF; Motomura, K; Anania, FA; Willson, TM; Tsukamoto, H			Peroxisome proliferator-activated receptors and hepatic stellate cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GENE-EXPRESSION; SMOOTH-MUSCLE CELLS; 9-CIS RETINOIC ACID; RAT-LIVER FIBROSIS; IN-VIVO; ENDOTHELIAL-CELLS; ALL-TRANS; ITO CELL; LIPOCYTES; BINDING	The present study examined the roles of peroxisome proliferator-activated receptors (PPAR) in activation of hepatic stellate cells (HSC), a pivotal event in liver fibrogenesis. RNase protection assay detected mRNA for PPAR gamma1 but not that for the adipocyte-specific gamma (2) isoform in HSC isolated from sham-operated rats, whereas the transcripts for neither isoforms were detectable in HSC from cholestatic liver fibrosis induced by bile duct ligation (BDL), Semi-quantitative reverse transcriptase-polymerase chain reaction confirmed a 70% reduction in PPAR gamma mRNA level in HSC from BDL, Nuclear extracts from BDL cells showed an expected diminution of binding to PPAR-responsive element, whereas NF-kappaB and AP-I binding were increased. Treatment of cultured-activated HSC with ligands for PPAR gamma (10 muM 15-deoxy-Delta (12,14)-PGJ(2) (15dPGJ(2)); 0.1 similar to 10 muM BRL49653) inhibited DNA and collagen synthesis without affecting the cell viability. Suppression of HSC collagen by 15dPGJ(2), was abrogated 70% by the concomitant treatment with a PPAR gamma antagonist (GW9662). HSC DNA and collagen synthesis were inhibited by WY14643 at the concentrations known to activate both PPAR alpha and gamma (>100 muM) but not at those that only activate PPARa (<10 <mu>M) Or by a synthetic PPAR alpha -selective agonist (GW9578). 15dPGJ(2), reduced Phi1(I) procollagen, smooth muscle alpha -actin, and monocyte chemotactic protein-1 mRNA levels while inducing matrix metalloproteinase-3 and CD36, 15dPGJ(2), and BRL49653 inhibited alpha1(I) procollagen promoter activity. Tumor necrosis factor or (10 ng/ml) reduced PPAR gamma mRNA, and this effect was prevented by the treatment with 15dPGJ(2),, These results demonstrate that HSC activation is associated with the reductions in PPAR gamma expression and PPAR-responsive element binding in vivo and is reversed by the treatment with PPAR gamma ligands in vitro. These findings implicate diminished PPAR gamma signaling in molecular mechanisms underlying activation of HSC in liver fibrogenesis and the potential therapeutic value of PPAR gamma ligands for liver fibrosis.	Univ So Calif, Keck Sch Med, Dept Med, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA; Dept Vet Affairs Greater Los Angeles Healthcare S, Sepulveda, CA 91343 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Surg, Chapel Hill, NC 27599 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90095 USA; Univ Maryland, Dept Med, College Pk, MD 21201 USA; Glaxo Wellcome Res & Dev Ltd, Dept Med Chem, Res Triangle Pk, NC 27709 USA	University of Southern California; University of Southern California; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University System of Maryland; University of Maryland College Park; GlaxoSmithKline	Miyahara, T (corresponding author), Univ So Calif, Keck Sch Med, Dept Med, 1333 San Pablo St,MMR-412, Los Angeles, CA 90033 USA.		feinstein, doug/M-9414-2019		NIAAA NIH HHS [AA10459, R37-AA06603] Funding Source: Medline; NIDDK NIH HHS [DK02450] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002450] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA006603, R01AA010459, R29AA010459] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; BACHEM MG, 1992, J CLIN INVEST, V89, P19, DOI 10.1172/JCI115561; BISSELL DM, 1990, SEMIN LIVER DIS, V10, P3; Camp HS, 1997, J BIOL CHEM, V272, P10811; Carloni V, 1997, GASTROENTEROLOGY, V112, P522, DOI 10.1053/gast.1997.v112.pm9024306; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS BH, 1990, J CLIN INVEST, V86, P2062, DOI 10.1172/JCI114943; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; DEVEHAND PR, 1996, NATURE, V384, P39; Fadok VA, 1998, J IMMUNOL, V161, P6250; FRIEDMAN SL, 1993, AM J PHYSIOL, V264, pG947, DOI 10.1152/ajpgi.1993.264.5.G947; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; FRIEDMAN SL, 1994, J BIOL CHEM, V269, P10551; Graf K, 1997, FEBS LETT, V400, P119, DOI 10.1016/S0014-5793(96)01371-3; Hautekeete ML, 1997, VIRCHOWS ARCH, V430, P195, DOI 10.1007/BF01324802; Hellemans K, 1999, GUT, V45, P134, DOI 10.1136/gut.45.1.134; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Imai S, 1997, FEBS LETT, V411, P102, DOI 10.1016/S0014-5793(97)00673-X; IREDALE JP, 1995, CLIN SCI, V89, P75, DOI 10.1042/cs0890075; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; Lin M, 1997, AM J PHYSIOL-GASTR L, V272, pG1355; MAHER JJ, 1990, J CLIN INVEST, V86, P1641, DOI 10.1172/JCI114886; Mangelsdorf David J., 1994, P319; MATSUOKA M, 1990, HEPATOLOGY, V11, P173, DOI 10.1002/hep.1840110204; NAKATSUKASA H, 1990, J CLIN INVEST, V85, P1833, DOI 10.1172/JCI114643; Ohata M, 1997, AM J PHYSIOL-GASTR L, V272, pG589, DOI 10.1152/ajpgi.1997.272.3.G589; Okuno M, 1997, HEPATOLOGY, V26, P913, DOI 10.1053/jhep.1997.v26.pm0009328313; PAN LY, 1995, J CELL BIOCHEM, V57, P575, DOI 10.1002/jcb.240570402; Parola M, 1998, J CLIN INVEST, V102, P1942, DOI 10.1172/JCI1413; PEKTOVICH M, 1987, NATURE, V330, P444; Potter JJ, 1998, BIOCHEM BIOPH RES CO, V244, P178, DOI 10.1006/bbrc.1997.8193; Poulos JE, 1997, AM J PHYSIOL-GASTR L, V273, pG804, DOI 10.1152/ajpgi.1997.273.4.G804; Qi Z, 1999, P NATL ACAD SCI USA, V96, P2345, DOI 10.1073/pnas.96.5.2345; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; RIPPE RA, 1995, HEPATOLOGY, V22, P241, DOI 10.1016/0270-9139(95)90378-X; Rockey DC, 1996, J CLIN INVEST, V98, P1381, DOI 10.1172/JCI118925; ROCKEY DC, 1992, J SUBMICR CYTOL PATH, V24, P193; ROCKEY DC, 1993, J CLIN INVEST, V92, P1795, DOI 10.1172/JCI116769; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Su CG, 1999, J CLIN INVEST, V104, P383, DOI 10.1172/JCI7145; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Tsukamoto H, 1999, ALCOHOL CLIN EXP RES, V23, P911, DOI 10.1111/j.1530-0277.1999.tb04202.x; Tsukamoto H, 1996, AM J PHYSIOL-GASTR L, V270, pG581, DOI 10.1152/ajpgi.1996.270.4.G581; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; Wang SC, 1998, J BIOL CHEM, V273, P302, DOI 10.1074/jbc.273.1.302; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; WONG L, 1994, J CLIN INVEST, V94, P1563, DOI 10.1172/JCI117497; Yee HF, 1998, HEPATOLOGY, V28, P843, DOI 10.1002/hep.510280336; Zhang B, 1996, MOL ENDOCRINOL, V10, P1457, DOI 10.1210/me.10.11.1457	55	396	423	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35715	35722		10.1074/jbc.M006577200	http://dx.doi.org/10.1074/jbc.M006577200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10969082	hybrid, Green Published			2022-12-25	WOS:000165382000012
J	Kihara, M; Nakai, W; Asano, S; Suzuki, A; Kitada, K; Kawasaki, Y; Johnston, LH; Sugino, A				Kihara, M; Nakai, W; Asano, S; Suzuki, A; Kitada, K; Kawasaki, Y; Johnston, LH; Sugino, A			Characterization of the yeast Cdc7p/Dbf4p complex purified from insect cells - Its protein kinase activity is regulated by Rad53p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE CDC7; S-PHASE; DNA-REPLICATION; BUDDING YEAST; MCM PROTEINS; FISSION YEAST; CHROMOSOMAL REPLICATION; CDC7-RELATED KINASE; CHECKPOINT PATHWAY; G(1)/S TRANSITION	The yeast Saccharomyces cerevisiae Cdc7p/Dbf4p protein kinase complex was purified to near homogeneity from insect cells. The complex efficiently phosphorylated yeast Mcm2p and less efficiently the remaining Mcm proteins or other replication proteins. Significantly, when pretreated with alkaline phosphatase, Mcm2p became completely inactive as a substrate, suggesting that it must be phosphorylated by other protein kinase(s) to be a substrate for the Cdc7p/Dbf4p complex. Mutant Cdc7p/Dbf4p complexes containing either Cdc7-1p or Dbf4-1 similar to 5p were also partially purified from insect cells and characterized in vitro. Furthermore, the autonomously replicating sequence binding activity of various dbf4 mutants was also analyzed. These studies suggest that the autonomously replicating sequence-binding and Cdc7p protein kinase activation domains of Dbf4p collaborate to form an active Cdc7p/Dbf4p complex and function during S phase in S. cerevisiae, It is shown that Rad53p phosphorylates the Cdc7p/Dbf4p complex in vitro and that this phosphorylation greatly inhibits the kinase activity of Cdc7p/Dbf4p, This result suggests that Rad53p controls the initiation of chromosomal DNA replication by regulating the protein kinase activity associated with the Cdc7p/Dbf4p complex.	Osaka Univ, Dept Biochem & Mol Biol, Microbial Dis Res Inst, Suita, Osaka 5650871, Japan; Nippon Roche Res Ctr, Kanagawa 2470063, Japan; Natl Inst Med Res, Div Yeast Genet, London NW7 1AA, England	Osaka University; Roche Holding; MRC National Institute for Medical Research	Sugino, A (corresponding author), Osaka Univ, Dept Biochem & Mol Biol, Microbial Dis Res Inst, 3-1 Yamada Oka, Suita, Osaka 5650871, Japan.							Adachi Y, 1997, GENES CELLS, V2, P467, DOI 10.1046/j.1365-2443.1997.1350333.x; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Bousset K, 1998, GENE DEV, V12, P480, DOI 10.1101/gad.12.4.480; Brown GW, 1998, J BIOL CHEM, V273, P22083, DOI 10.1074/jbc.273.34.22083; CHAPMAN JW, 1989, EXP CELL RES, V180, P419, DOI 10.1016/0014-4827(89)90068-2; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; Detweiler CS, 1997, J CELL SCI, V110, P753; Dohrmann PR, 1999, GENETICS, V151, P965; Donaldson AD, 1998, MOL CELL, V2, P173, DOI 10.1016/S1097-2765(00)80127-6; Donaldson AD, 1998, GENE DEV, V12, P491, DOI 10.1101/gad.12.4.491; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; DOWELL SJ, 1994, SCIENCE, V265, P1243, DOI 10.1126/science.8066465; Feng L, 1998, J BIOL CHEM, V273, P1298, DOI 10.1074/jbc.273.3.1298; Fujita M, 1997, J BIOL CHEM, V272, P10928; HAMATAKE RK, 1990, J BIOL CHEM, V265, P4072; Hardy CFJ, 1997, P NATL ACAD SCI USA, V94, P3151, DOI 10.1073/pnas.94.7.3151; Hardy CFJ, 1996, MOL CELL BIOL, V16, P6775; HARTWELL LH, 1973, J BACTERIOL, V115, P966, DOI 10.1128/JB.115.3.966-974.1973; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; Hashimoto K, 1998, NUCLEIC ACIDS RES, V26, P477, DOI 10.1093/nar/26.2.477; Hess GF, 1998, GENE, V211, P133, DOI 10.1016/S0378-1119(98)00094-8; JACKSON AL, 1993, MOL CELL BIOL, V13, P2899, DOI 10.1128/MCB.13.5.2899; Jiang W, 1997, P NATL ACAD SCI USA, V94, P14320, DOI 10.1073/pnas.94.26.14320; Johnston LH, 1999, TRENDS CELL BIOL, V9, P249, DOI 10.1016/S0962-8924(99)01586-X; JOHNSTON LH, 1982, MOL GEN GENET, V186, P445, DOI 10.1007/BF00729467; Kamimura Y, 1998, MOL CELL BIOL, V18, P6102, DOI 10.1128/MCB.18.10.6102; Kim JM, 1998, J BIOL CHEM, V273, P23248, DOI 10.1074/jbc.273.36.23248; KITADA K, 1992, GENETICS, V131, P21; Kumagai H, 1999, MOL CELL BIOL, V19, P5083; Lei M, 1996, MOL CELL BIOL, V16, P5081; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; MASAI H, 1995, EMBO J, V14, P3094, DOI 10.1002/j.1460-2075.1995.tb07312.x; Oshiro G, 1999, MOL CELL BIOL, V19, P4888; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; Sambrook J., 2002, MOL CLONING LAB MANU; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Sato N, 1997, EMBO J, V16, P4340, DOI 10.1093/emboj/16.14.4340; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Sugimoto K, 1997, MOL CELL BIOL, V17, P5905, DOI 10.1128/MCB.17.10.5905; Takeda T, 1999, MOL CELL BIOL, V19, P5535; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Tye BK, 2000, P NATL ACAD SCI USA, V97, P2399, DOI 10.1073/pnas.97.6.2399; Weinert T, 1998, CURR OPIN GENET DEV, V8, P185, DOI 10.1016/S0959-437X(98)80140-8; Weinreich M, 1999, EMBO J, V18, P5334, DOI 10.1093/emboj/18.19.5334; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593	51	61	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35051	35062		10.1074/jbc.M003491200	http://dx.doi.org/10.1074/jbc.M003491200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10964916	hybrid			2022-12-25	WOS:000165422800032
J	Skiba, NP; Hopp, JA; Arshavsky, VY				Skiba, NP; Hopp, JA; Arshavsky, VY			The effector enzyme regulates the duration of G protein signaling in vertebrate photoreceptors by increasing the affinity between transducin and RGS protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE ACCELERATING PROTEIN; CGMP PHOSPHODIESTERASE; INHIBITORY SUBUNIT; ROD PHOTORECEPTORS; TRANSITION-STATE; TARGET ENZYME; GAMMA-SUBUNIT; IN-VIVO; HYDROLYSIS; BINDING	The photoreceptor-specific G protein transducin acts as a molecular switch, stimulating the activity of its downstream effector in its GTP-bound form and inactivating the effector upon GTP hydrolysis, This activity makes the rate of transducin GTPase an essential factor in determining the duration of photoresponse in vertebrate rods and cones. In photoreceptors, the slow intrinsic rate of transducin GTPase is accelerated by the complex of the ninth member of the regulators of G protein signaling family with the long splice variant of type 5 G protein beta subunit (RGS9-G beta 5L). However, physiologically rapid GTPase is observed only when transducin forms a complex with its effector, the gamma subunit of cGMP phosphodiesterase (PDE gamma), In this study, we addressed the mechanism by which PDE gamma regulates the rate of transducin GTPase, We found that RGS9-G beta 5L alone has a significant ability to activate transducin GTPase, but its affinity for transducin is low. PDEy acts by enhancing the affinity between activated transducin and RGS9-G beta 5L by more than 15-fold, which is evident both from kinetic measurements of transducin GTPase rate and from protein binding assays with immobilized transducin. Furthermore, our data indicate that a single RGS9-G beta 5L molecule is capable of accelerating the GTPase activity of similar to 100 transducin molecules/s. This rate is faster than the rates reported previously for any RGS protein and is sufficient for timely photoreceptor recovery in both rod and cone photoreceptors.	Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol,Howe Lab Ophthalmol, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary	Arshavsky, VY (corresponding author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol,Howe Lab Ophthalmol, 243 Charles St, Boston, MA 02114 USA.	vadim_arshavsky@meei.harvard.edu			NATIONAL EYE INSTITUTE [R01EY012859] Funding Source: NIH RePORTER; NEI NIH HHS [EY-12859] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANANT JS, 1992, J BIOL CHEM, V267, P687; ANGLESON JK, 1994, J BIOL CHEM, V269, P16290; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARSHAVSKY VY, 1994, J BIOL CHEM, V269, P19882; Arshavsky VY, 1998, NEURON, V20, P11, DOI 10.1016/S0896-6273(00)80430-4; Artemyev NO, 1997, BIOCHEMISTRY-US, V36, P4188, DOI 10.1021/bi963002y; BAYLOR DA, 1984, J PHYSIOL-LONDON, V357, P575, DOI 10.1113/jphysiol.1984.sp015518; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BOWNDS D, 1971, J GEN PHYSIOL, V58, P225, DOI 10.1085/jgp.58.3.225; BOWNDS MD, 1995, BEHAV BRAIN SCI, V18, P415, DOI 10.1017/S0140525X00039170; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; Cowan CW, 1998, P NATL ACAD SCI USA, V95, P5351, DOI 10.1073/pnas.95.9.5351; Cowan CW, 2000, METHOD ENZYMOL, V315, P524; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lyubarsky AL, 1996, J NEUROSCI, V16, P563, DOI 10.1523/jneurosci.16-02-00563.1996; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; McDowell J. H., 1993, PHOTORECEPTOR CELLS, V15, P123; McEntaffer RL, 1999, BIOCHEMISTRY-US, V38, P4931, DOI 10.1021/bi982636x; MORRISON DF, 1989, J BIOL CHEM, V264, P11671; Mukhopadhyay S, 1999, P NATL ACAD SCI USA, V96, P9539, DOI 10.1073/pnas.96.17.9539; Nekrasova ER, 1997, BIOCHEMISTRY-US, V36, P7638, DOI 10.1021/bi970427r; PEPPERBERG DR, 1992, VISUAL NEUROSCI, V8, P9, DOI 10.1017/S0952523800006441; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; RIPPS H, 1976, EYE A, V2, P185; Skiba NP, 1999, J BIOL CHEM, V274, P8770, DOI 10.1074/jbc.274.13.8770; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; SLEPAK VZ, 1995, J BIOL CHEM, V270, P14319, DOI 10.1074/jbc.270.24.14319; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; TING TD, 1993, METH NEUROSCI, V15, P180; Tsang SH, 1998, SCIENCE, V282, P117, DOI 10.1126/science.282.5386.117; YAMAZAKI A, 1993, J BIOL CHEM, V268, P8899	37	58	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32716	32720		10.1074/jbc.C000413200	http://dx.doi.org/10.1074/jbc.C000413200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10973941	hybrid			2022-12-25	WOS:000090003800048
J	Shao, ZM; Nguyen, M; Barsky, SH				Shao, ZM; Nguyen, M; Barsky, SH			Human breast carcinoma desmoplasia is PDGF initiated	ONCOGENE			English	Article						PDGF; desmoplasia; breast carcinoma; paracrine growth factors; dominant-negative mutants; c-ras(H)	GROWTH-FACTOR-II; DOMINANT-NEGATIVE MUTANTS; MESSENGER-RNA EXPRESSION; MCF-7 CELLS; TUMOR-GROWTH; NUDE-MICE; IN-VIVO; CANCER; RECEPTOR; GENE	The desmoplastic response to human breast carcinoma is a host myofibroblast-mediated collagenous response exhibiting synergistic effects on tumor progression. Although many paracrine interactions between breast carcinoma cells and myofibroblasts have been characterized, the event(s) which initiate desmoplasia have remained undefined. Our studies utilized c-ras(H) transfected MCF-7 cells which overexpress ras p21 and which are weakly tumorigenic in ovariectomized nude mice. The xenografts are desmoplastic and comprised of 30% myofibroblasts and 60 mg/g of interstitial collagen. III sits hybridization studies of these xenografts reveal a stromal gene expression pattern (stromelysin-3, IGF-II and TIMP-1) identical to that observed in human tumor desmoplasia. 17-beta estradiol increases c-ras(H) MCF-7 growth but abolishes desmoplasia. c-ras(H) MCF-7 in vitro constitutively produce myofibroblast mitogenic activity which competes with PDGF in a receptor binding assay. This myofibroblast mitogenic activity is unaltered by 17-beta estradiol/tamoxifen pretreatment irt vitro. Transfection of c-ras(H) MCF-7,vith a PDGF-A dominant negative mutant, 1308, produced by site-directed mutagenesis (serine -->cystcine(129)) reduces both homo- and heterodimer secretion of PDGF by as much as 90% but does not interfere with the secretion of other growth factors. Clones with low PDGF, though tumorigenic, are nondesmoplastic. Our results suggest that breast carcinoma-secreted PDGF is the major initiator of tumor desmoplasia.	Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Surg, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Revlon Breast Ctr, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Barsky, SH (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90024 USA.				NCI NIH HHS [CA01351, CA40225, CA71195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA071195, R01CA040225] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS EF, 1988, BREAST CANCER RES TR, V11, P165, DOI 10.1007/BF01805840; ARTEAGA CL, 1989, CANCER RES, V49, P6237; BARSKY SH, 1987, CANCER RES, V47, P1663; BARSKY SH, 1987, BIOCHEM BIOPH RES CO, V149, P1125, DOI 10.1016/0006-291X(87)90525-0; BARSKY SH, 1984, AM J PATHOL, V115, P329; Barsky SH, 1997, ONCOGENE, V15, P2077, DOI 10.1038/sj.onc.1201379; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BERGMAN I, 1963, ANAL CHEM, V35, P1961, DOI 10.1021/ac60205a053; BRONZERT DA, 1987, P NATL ACAD SCI USA, V84, P5763, DOI 10.1073/pnas.84.16.5763; CULLEN KJ, 1991, CANCER RES, V51, P4978; DICKSON RB, 1987, P NATL ACAD SCI USA, V84, P837, DOI 10.1073/pnas.84.3.837; DVORAK HF, 1979, JNCI-J NATL CANCER I, V62, P1459; DVORAK HF, 1981, J NATL CANCER I, V67, P335; DVORAK HF, 1981, SCIENCE, V212, P923, DOI 10.1126/science.7195067; GOUSTIN AS, 1986, CANCER RES, V46, P1015; HART CE, 1990, BIOCHEMISTRY-US, V29, P166, DOI 10.1021/bi00453a022; HELDIN CH, 1981, P NATL ACAD SCI-BIOL, V78, P3664, DOI 10.1073/pnas.78.6.3664; HORGAN K, 1987, BRIT J SURG, V74, P227, DOI 10.1002/bjs.1800740326; KASID A, 1985, SCIENCE, V228, P725, DOI 10.1126/science.4039465; LIEUBEAU B, 1994, CANCER RES, V54, P6526; MALIK R, 1991, CANCER RES, V51, P5626; MANNI A, 1994, CANCER RES, V54, P2934; MERCOLA M, 1990, GENE DEV, V4, P2333, DOI 10.1101/gad.4.12b.2333; MIURA M, 1994, CANCER RES, V54, P2472; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; NAUNDORF H, 1992, J CANCER RES CLIN, V119, P35, DOI 10.1007/BF01209485; NOGUCHI M, 1993, MOL CELL ENDOCRINOL, V92, P69, DOI 10.1016/0303-7207(93)90076-V; O'Connell JT, 1998, HUM PATHOL, V29, P1517, DOI 10.1016/S0046-8177(98)90024-7; OSBORNE CK, 1990, BREAST CANCER RES TR, V15, P3, DOI 10.1007/BF01811884; OSBORNE CK, 1989, MOL ENDOCRINOL, V3, P1701, DOI 10.1210/mend-3-11-1701; PERES R, 1987, CANCER RES, V47, P3425; Povlsen C O, 1980, Antibiot Chemother (1971), V28, P15; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; SINGER C, 1995, CANCER RES, V55, P2448; SOMMERS CL, 1990, CANCER RES, V50, P67; Sternlicht MD, 1997, CLIN CANCER RES, V3, P1949; Tomlinson J, 1999, CLIN CANCER RES, V5, P3516; YEE D, 1988, CANCER RES, V48, P6691; YEE D, 1989, MOL ENDOCRINOL, V3, P509, DOI 10.1210/mend-3-3-509	40	178	182	0	12	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4337	4345		10.1038/sj.onc.1203785	http://dx.doi.org/10.1038/sj.onc.1203785			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980609	Bronze			2022-12-25	WOS:000089271900004
J	Corvi, R; Berger, N; Balczon, R; Romeo, G				Corvi, R; Berger, N; Balczon, R; Romeo, G			RET/PCM-1: a novel fusion gene in papillary thyroid carcinoma	ONCOGENE			English	Article						RET rearrangement; oncogene; PTC; interphase FISH; RET; PCM-1; fusion gene	TYROSINE KINASE; ONCOGENE REARRANGEMENTS; RET PROTOONCOGENE; AUTOANTIGEN; CENTROSOME; ACTIVATION; CHERNOBYL; DELETION; CHILDREN; CHROMOSOME-10	The RET proto-oncogene is often activated through somatic rearrangements in papillary thyroid carcinomas (PTCs). Three main rearranged forms of RET have been described: RET/PTC1 and RET/PTC3, which arise from a paracentric inversion and RET/PTC2, which originates from a 10:17 translocation. We previously developed a dual-color FISH test to detect these RET rearrangements in interphase nuclei of thyroid lesions. This approach allowed us to detect a novel translocation involving the RET region, which was not detectable by RT-PCR with specific primers for known rearrangements. A combination of RT-PCR and RACE analyses finally led to the identification of the fusion gene, which involves the 5' portion of PCM-I, a gene coding for a centrosomal protein with distinct cell cycle distribution, and the RET tyrosine kinase (TK) domain. FISH analysis confirmed the chromosomal localization of PCM-I on chromosome 8p21-22, a region commonly deleted in several tumors. Immunohistochemistry, using an antibody specific for the C-terminal portion of PCM-1 showed that the protein level is drastically decreased and its subcellular localization is altered in thyroid tumor tissue with respect to normal thyroid. However, heterozygosity is retained for seven microsatellite markers in the 8p21-22 region, suggesting that the nonrearranged PCM-1 allele is not lost and that the translocation is balanced.	Int Agcy Res Canc, F-69372 Lyon, France; Hop Antiquaille Lyon, Clin Endocrinol, F-69005 Lyon, France; Univ S Alabama, Dept Cell Biol & Neurosci, Mobile, AL 36688 USA	World Health Organization; International Agency for Research on Cancer (IARC); CHU Lyon; University of South Alabama	Corvi, R (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.							Alen P, 1999, MOL ENDOCRINOL, V13, P117, DOI 10.1210/me.13.1.117; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Balczon R, 1999, CELL MOTIL CYTOSKEL, V42, P60, DOI 10.1002/(SICI)1097-0169(1999)42:1<60::AID-CM6>3.0.CO;2-7; BALCZON R, 1994, J CELL BIOL, V124, P783, DOI 10.1083/jcb.124.5.783; Bao LM, 1998, MOL BIOL REP, V25, P111, DOI 10.1023/A:1006814217037; BARKER PE, 1993, METHODS MOL GENETICS, V2, P129; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; Bongarzone I, 1996, J CLIN ENDOCR METAB, V81, P2006, DOI 10.1210/jc.81.5.2006; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; Chinen K, 1996, CYTOGENET CELL GENET, V75, P190, DOI 10.1159/000134480; Cinti R, 2000, CYTOGENET CELL GENET, V88, P56, DOI 10.1159/000015485; CORVI R, 1994, P NATL ACAD SCI USA, V91, P5523, DOI 10.1073/pnas.91.12.5523; DURICK K, 1995, J BIOL CHEM, V270, P24642, DOI 10.1074/jbc.270.42.24642; EMI M, 1992, CANCER RES, V52, P5368; Engelender S, 1997, HUM MOL GENET, V6, P2205, DOI 10.1093/hmg/6.13.2205; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Klugbauer S, 1996, ONCOGENE, V13, P1099; Klugbauer S, 1999, ONCOGENE, V18, P4388, DOI 10.1038/sj.onc.1202824; Klugbauer S, 1998, CANCER RES, V58, P198; KNOWLES MA, 1993, ONCOGENE, V8, P1357; LANGER PR, 1981, P NATL ACAD SCI-BIOL, V78, P6633, DOI 10.1073/pnas.78.11.6633; Nakata T, 1999, GENE CHROMOSOME CANC, V25, P97, DOI 10.1002/(SICI)1098-2264(199906)25:2<97::AID-GCC4>3.0.CO;2-L; Nikiforov YE, 1997, CANCER RES, V57, P1690; OHATA H, 1994, GENOMICS, V24, P404, DOI 10.1006/geno.1994.1640; PASINI B, 1995, ONCOGENE, V11, P1737; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; Raynaud S, 1996, BLOOD, V87, P2891, DOI 10.1182/blood.V87.7.2891.bloodjournal8772891; Scarpato R, 1997, CYTOGENET CELL GENET, V79, P153, DOI 10.1159/000134708; Sugg SL, 1996, J CLIN ENDOCR METAB, V81, P3360, DOI 10.1210/jc.81.9.3360; Sugg SL, 1998, J CLIN ENDOCR METAB, V83, P4116, DOI 10.1210/jc.83.11.4116; Tallini G, 1998, CLIN CANCER RES, V4, P287; Tong Q, 1997, J BIOL CHEM, V272, P9043	33	66	84	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 31	2000	19	37					4236	4242		10.1038/sj.onc.1203772	http://dx.doi.org/10.1038/sj.onc.1203772			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980597				2022-12-25	WOS:000089032900006
J	Galvez, T; Prezeau, L; Milioti, G; Franek, M; Joly, C; Froestl, W; Bettler, B; Bertrand, HO; Blahos, J; Pin, JP				Galvez, T; Prezeau, L; Milioti, G; Franek, M; Joly, C; Froestl, W; Bettler, B; Bertrand, HO; Blahos, J; Pin, JP			Mapping the agonist-binding site of GABA(B) type 1 subunit sheds light on the activation process of GABA(B) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; PUTATIVE PHEROMONE RECEPTORS; CALCIUM-SENSING RECEPTOR; AMINO-TERMINAL DOMAIN; LIGAND-BINDING; MGLUR4 SUBTYPE; PROTEIN; IDENTIFICATION; EXPRESSION; CLONING	The gamma -amino-n-butyric acid type B (GABA(B)) receptor is composed of two subunits, GABA(B)1 and GABA(B)2, belonging to the family 3 heptahelix receptors. These proteins possess two domains, a seven transmembrane core and an extracellular domain containing the agonist binding site. This binding domain is likely to fold like bacterial periplasmic binding proteins that are constituted of two lobes that close upon ligand binding. Here, using molecular modeling and site-directed mutagenesis, we have identified residues in the GABA(B)1 subunit that are critical for agonist binding and activation of the heteromeric receptor. Our data suggest that two residues (Ser(246) and Asp(471)) located within lobe I form H bonds and a salt bridge with carboxylic and amino groups of GABA, respectively, demonstrating the pivotal role of lobe I in agonist binding. Interestingly, our data also suggest that a residue within lobe II (Tyr(366)) interacts with the agonists in a closed form model of the binding domain, and its mutation into Ala converts the agonist baclofen into an antagonist. These data demonstrate the pivotal role played by the GABA(B)1 subunit in the activation of the heteromeric GABA(B) receptor and are-consistent with the idea that a closed state of the binding domain of family 3 receptors is required for their activation.	CNRS, UPR9023, CCIPE, F-34094 Montpellier 5, France; Charles Univ, Lab Mol Physiol, Med Sch 3, Prague 2, Czech Republic; Acad Sci Czech Republ, Prague 2, Czech Republic; Novartis Pharma AG, TA Nervous Syst, CH-4002 Basel, Switzerland; Mol Simulat Inc, F-91893 Orsay, France	Centre National de la Recherche Scientifique (CNRS); Charles University Prague; Czech Academy of Sciences; Novartis	Galvez, T (corresponding author), CNRS, UPR9023, CCIPE, 141 Rue Cardonille, F-34094 Montpellier 5, France.		Pin, Jean-Philippe/Y-6668-2019; bettler, bernhard/AAO-8018-2020; Blahos, Jaroslav/G-4397-2014; Blahos, Jaroslav/G-8325-2017	Pin, Jean-Philippe/0000-0002-1423-345X; galvez, thierry/0000-0003-2800-3732; Bettler, Bernhard/0000-0003-0842-8207; Blahos, Jaroslav/0000-0003-3355-1469; Blahos, Jaroslav/0000-0001-9803-0061				Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Bai M, 1999, P NATL ACAD SCI USA, V96, P2834, DOI 10.1073/pnas.96.6.2834; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Brauner-Osborne H, 1999, J BIOL CHEM, V274, P18382, DOI 10.1074/jbc.274.26.18382; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Costantino G, 1996, J MED CHEM, V39, P3998, DOI 10.1021/jm9601718; Couve A, 1998, J BIOL CHEM, V273, P26361, DOI 10.1074/jbc.273.41.26361; Franek M, 1999, NEUROPHARMACOLOGY, V38, P1657, DOI 10.1016/S0028-3908(99)00135-5; FROESTL W, 1995, J MED CHEM, V38, P3297, DOI 10.1021/jm00017a015; Galvez T, 1999, J BIOL CHEM, V274, P13362, DOI 10.1074/jbc.274.19.13362; Galvez T, 2000, MOL PHARMACOL, V57, P419, DOI 10.1124/mol.57.3.419; Gomeza J, 1996, MOL PHARMACOL, V50, P923; Hampson DR, 1999, J BIOL CHEM, V274, P33488, DOI 10.1074/jbc.274.47.33488; Han GM, 1999, J BIOL CHEM, V274, P10008, DOI 10.1074/jbc.274.15.10008; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; Hoon MA, 1999, CELL, V96, P541, DOI 10.1016/S0092-8674(00)80658-3; Isomoto S, 1998, BIOCHEM BIOPH RES CO, V253, P10, DOI 10.1006/bbrc.1998.9706; Jensen AA, 2000, EUR J PHARMACOL, V397, P247, DOI 10.1016/S0014-2999(00)00283-1; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; Kaupmann K., 1997, WO 97/46675, Patent No. 9746675; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Malitschek B, 1999, MOL PHARMACOL, V56, P448, DOI 10.1124/mol.56.2.448; Malitschek B, 1998, MOL CELL NEUROSCI, V12, P56, DOI 10.1006/mcne.1998.0698; Martin SC, 1999, MOL CELL NEUROSCI, V13, P180, DOI 10.1006/mcne.1999.0741; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; Ng GYK, 1999, J BIOL CHEM, V274, P7607, DOI 10.1074/jbc.274.12.7607; O'Hara BP, 2000, PROTEIN ENG, V13, P129, DOI 10.1093/protein/13.2.129; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; PEARL L, 1994, EMBO J, V13, P5810, DOI 10.1002/j.1460-2075.1994.tb06924.x; Pfaff T, 1999, EUR J NEUROSCI, V11, P2874, DOI 10.1046/j.1460-9568.1999.00704.x; Pin JP, 1999, EUR J PHARMACOL, V375, P277, DOI 10.1016/S0014-2999(99)00258-7; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Speca DJ, 1999, NEURON, V23, P487, DOI 10.1016/S0896-6273(00)80802-8; Sullivan R, 2000, J PHARMACOL EXP THER, V293, P460; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; YAO NH, 1994, BIOCHEMISTRY-US, V33, P4769, DOI 10.1021/bi00182a004	45	108	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					41166	41174		10.1074/jbc.M007848200	http://dx.doi.org/10.1074/jbc.M007848200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10986293	hybrid			2022-12-25	WOS:000166114600069
J	Hassan, H; Reis, CA; Bennett, EP; Mirgorodskaya, E; Roepstorff, P; Hollingsworth, MA; Burchell, J; Taylor-Papadimitriou, J; Clausen, H				Hassan, H; Reis, CA; Bennett, EP; Mirgorodskaya, E; Roepstorff, P; Hollingsworth, MA; Burchell, J; Taylor-Papadimitriou, J; Clausen, H			The lectin domain of UDP-N-acetyl-D-galactosamine : polypeptide N-acetylgalactosaminyltransferase-T4 directs its glycopeptide specificities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-D-GALACTOSAMINE; O-LINKED GLYCOSYLATION; MUC1 TANDEM REPEAT; CDNA CLONING; GALNAC-TRANSFERASES; CANCER-CELLS; HT-29 CELLS; ACETYLGALACTOSAMINYLTRANSFERASE; PEPTIDE; EXPRESSION	The initiation step of mucin-type O-glycosylation is controlled by a large family of homologous UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferases (GalNAc-transferases), Differences in kinetic properties, substrate specificities, and expression patterns of these isoenzymes provide for differential regulation of O-glycan attachment sites and density, Recently, it has emerged that some GalNAc-transferase isoforms in, vitro selectively function with partially GalNAc O-glycosylated acceptor peptides rather than with the corresponding unglycosylated peptides, O-Glycan attachment to selected sites, most notably two sites in the MUC1 tandem repeat, is entirely dependent on the glycosylation-dependent function of GalNAc-T4. Here we present data that a putative lectin domain found in the C terminus of GalNAc-T4 functions as a GalNAc lectin and confers its glycopeptide specificity. A single amino acid substitution in the lectin domain of a secreted form of GalNAc-T4 selectively blocked GalNAc-glycopeptide activity, while the general activity to peptides exerted by this enzyme was unaffected. Furthermore, the GalNAc-glycopeptide activity of wild-type secreted GalNAc-T4 was selectively inhibited by free GalNAc, while the activity with peptides was unaffected.	Fac Hlth Sci, Sch Dent, DK-2200 Copenhagen, Denmark; Univ Porto, Inst Mol Pathol & Immunol, P-4200 Oporto, Portugal; Odense Univ, Dept Biochem & Mol Biol, Univ So Denmark, DK-5230 Odense, Denmark; Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Imperial Canc Res Fund, London WC2A 3PX, England	Universidade do Porto; University of Southern Denmark; University of Nebraska System; University of Nebraska Medical Center; Cancer Research UK	Clausen, H (corresponding author), Fac Hlth Sci, Sch Dent, DK-2200 Copenhagen, Denmark.		Bennett, Eric/AAG-6120-2020; clausen, henrik/AAD-8016-2021; Burchell, Joy/G-4560-2012; REIS, Celso A/B-9969-2008	Bennett, Eric/0000-0002-4976-0647; REIS, Celso A/0000-0002-0286-6639; Burchell, Joy/0000-0003-0413-3823; Clausen, Henrik/0000-0002-0915-5055	NATIONAL CANCER INSTITUTE [R01CA066234] Funding Source: NIH RePORTER; NCI NIH HHS [1RO1CA66234] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appenzeller C, 1999, NAT CELL BIOL, V1, P330, DOI 10.1038/14020; BAECKSTROM D, 1991, J BIOL CHEM, V266, P21537; Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; Bennett EP, 1998, J BIOL CHEM, V273, P30472, DOI 10.1074/jbc.273.46.30472; Bennett EP, 1999, J BIOL CHEM, V274, P25362, DOI 10.1074/jbc.274.36.25362; Bennett EP, 1999, FEBS LETT, V460, P226, DOI 10.1016/S0014-5793(99)01268-5; Breton C, 1999, CURR OPIN STRUC BIOL, V9, P563, DOI 10.1016/S0959-440X(99)00006-8; Buschiazzo A, 2000, EMBO J, V19, P16, DOI 10.1093/emboj/19.1.16; Clausen H, 1996, GLYCOBIOLOGY, V6, P635, DOI 10.1093/glycob/6.6.635; Day PJ, 1996, BIOCHEMISTRY-US, V35, P11098, DOI 10.1021/bi960880n; Elhammer AP, 1999, GLYCOCONJUGATE J, V16, P171, DOI 10.1023/A:1026465232149; FARQUHAR MG, 1997, GOLGI APPARATUS, P63; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; GENDLER SJ, 1991, AM REV RESPIR DIS, V144, P42; Gobom J, 1999, J MASS SPECTROM, V34, P105, DOI 10.1002/(SICI)1096-9888(199902)34:2<105::AID-JMS768>3.0.CO;2-4; Hagen FK, 1999, J BIOL CHEM, V274, P6797, DOI 10.1074/jbc.274.10.6797; Hagen FK, 1998, J BIOL CHEM, V273, P8268, DOI 10.1074/jbc.273.14.8268; Hagen FK, 1997, J BIOL CHEM, V272, P13843, DOI 10.1074/jbc.272.21.13843; Hanisch FG, 1999, J BIOL CHEM, V274, P9946, DOI 10.1074/jbc.274.15.9946; HASSAN H, 2000, OLIGOSACCHARIDES CHE, P273; Hazes B, 1996, PROTEIN SCI, V5, P1490, DOI 10.1002/pro.5560050805; Hennebicq-Reig S, 1998, BIOCHEM J, V334, P283, DOI 10.1042/bj3340283; HOMA FL, 1993, J BIOL CHEM, V268, P12609; Huet G, 1998, J CELL BIOL, V141, P1311, DOI 10.1083/jcb.141.6.1311; Imberty A, 1997, PROTEIN ENG, V10, P1353, DOI 10.1093/protein/10.12.1353; KUAN SF, 1989, J BIOL CHEM, V264, P19271; Lugemwa FN, 1996, J BIOL CHEM, V271, P19159, DOI 10.1074/jbc.271.32.19159; Mirgorodskaya E, 1999, ANAL BIOCHEM, V269, P54, DOI 10.1006/abio.1998.3089; Monlauzeur L, 1998, J BIOL CHEM, V273, P30263, DOI 10.1074/jbc.273.46.30263; Muller S, 1997, J BIOL CHEM, V272, P24780, DOI 10.1074/jbc.272.40.24780; Muller S, 1999, J BIOL CHEM, V274, P18165, DOI 10.1074/jbc.274.26.18165; NISHIMORI I, 1994, CANCER RES, V54, P3738; ROTH J, 1994, P NATL ACAD SCI USA, V91, P8935, DOI 10.1073/pnas.91.19.8935; Rottger S, 1998, J CELL SCI, V111, P45; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; Taylor-Papadimitriou J, 1999, BBA-MOL BASIS DIS, V1455, P301, DOI 10.1016/S0925-4439(99)00055-1; Ten Hagen BG, 1998, J BIOL CHEM, V273, P27749; Ten Hagen KG, 1999, J BIOL CHEM, V274, P27867; Wandall HH, 1997, J BIOL CHEM, V272, P23503, DOI 10.1074/jbc.272.38.23503; White KE, 2000, GENE, V246, P347, DOI 10.1016/S0378-1119(00)00050-0; WHITE T, 1995, J BIOL CHEM, V270, P24156, DOI 10.1074/jbc.270.41.24156; Zanetta JP, 2000, GLYCOBIOLOGY, V10, P565, DOI 10.1093/glycob/10.6.565	42	132	160	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38197	38205		10.1074/jbc.M005783200	http://dx.doi.org/10.1074/jbc.M005783200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10984485	hybrid			2022-12-25	WOS:000165739800011
J	Jin, TC; Gu, YP; Zanusso, G; Sy, MS; Kumar, A; Cohen, M; Gambetti, P; Singh, N				Jin, TC; Gu, YP; Zanusso, G; Sy, MS; Kumar, A; Cohen, M; Gambetti, P; Singh, N			The chaperone protein BiP binds to a mutant prion protein and mediates its degradation by the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; QUALITY-CONTROL; MOLECULAR CHAPERONES; APOLIPOPROTEIN-B; RETENTION; PRECURSOR; PATHWAY; TRANSPORT; DISEASES; CELLS	Familial prion diseases are thought to result from a change in structure of the mutant prion protein (PrP), which takes a pathogenic conformation. We have examined the role of molecular chaperones in the folding of normal and mutant PrP Q217R (PrP217) in transfected neuroblastoma cells. In a previous report we showed that, although most of the PrP217 forms escape the endoplasmic reticulum quality control system and aggregate in post-Golgi compartments, a significant proportion of PrP217 retains the C-terminal glycosylphos-phatidyl inositol signal peptide (PrP32), and does not exit the endoplasmic reticulum (Singh, N., Zanusso, G., Chen, S, G., Fujioka, H., Richardson, S., Gambetti, P., and Petersen, R, B, (1997) J. Biol Chem. 272, 28461-28470), We have now studied the folding and turnover of PrP32 to understand the mechanism by which abnormal PrP forms cause cellular toxicity in our cell culture model and in the human brain carrying the Gerstmann-Straussler-Scheinker disease Q217R mutation. In this report, we show that PrP32 remains associated with the chaperone BiP for an abnormally prolonged period of time and is degraded by the proteasomal pathway. This study is the first demonstration that BiP is chaperoning the folding of PrP and plays a role in maintaining the quality control in the PrP maturation pathway. Our data provide new insight into the diverse pathways of mutant PrP metabolism and neurotoxicity.	Case Western Reserve Univ, Inst Pathol, Div Neuropathol, Cleveland, OH 44106 USA	Case Western Reserve University	Singh, N (corresponding author), Case Western Reserve Univ, Inst Pathol, Div Neuropathol, 2085 Adelbert Rd, Cleveland, OH 44106 USA.		Zanusso, Gianluigi/K-2823-2018; Kumar, Anil/B-6909-2008	Zanusso, Gianluigi/0000-0001-5199-6264; 				Beggah A, 1996, J BIOL CHEM, V271, P20895, DOI 10.1074/jbc.271.34.20895; Bennett MC, 1999, J BIOL CHEM, V274, P33855, DOI 10.1074/jbc.274.48.33855; Brodsky JL, 1999, J BIOL CHEM, V274, P3453, DOI 10.1074/jbc.274.6.3453; Chesebro B, 1999, NEURON, V24, P503, DOI 10.1016/S0896-6273(00)81105-8; Clark HB, 2000, J NEUROPATH EXP NEUR, V59, P265, DOI 10.1093/jnen/59.4.265; COTNER T, 1995, J BIOL CHEM, V270, P2379, DOI 10.1074/jbc.270.5.2379; DebBurman SK, 1997, P NATL ACAD SCI USA, V94, P13938, DOI 10.1073/pnas.94.25.13938; DELAHUNTY MD, 1993, J BIOL CHEM, V268, P12017; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; FIELD MC, 1994, J BIOL CHEM, V269, P10830; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; Gambetti P., 1999, PRION BIOL DIS; Hellman R, 1999, J CELL BIOL, V144, P21, DOI 10.1083/jcb.144.1.21; Imamura T, 1998, J BIOL CHEM, V273, P11183, DOI 10.1074/jbc.273.18.11183; Kaytor MD, 1999, J BIOL CHEM, V274, P37507, DOI 10.1074/jbc.274.53.37507; KNITTLER MR, 1995, P NATL ACAD SCI USA, V92, P1764, DOI 10.1073/pnas.92.5.1764; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Krobitsch S, 2000, P NATL ACAD SCI USA, V97, P1589, DOI 10.1073/pnas.97.4.1589; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Linnik KM, 1998, J BIOL CHEM, V273, P21368, DOI 10.1074/jbc.273.33.21368; Matlack KES, 1999, CELL, V97, P553, DOI 10.1016/S0092-8674(00)80767-9; Meerovitch K, 1998, J BIOL CHEM, V273, P21025, DOI 10.1074/jbc.273.33.21025; Newnam GP, 1999, MOL CELL BIOL, V19, P1325; Oda K, 1996, BIOCHEM J, V316, P623, DOI 10.1042/bj3160623; Oda K, 1996, BIOCHEM BIOPH RES CO, V219, P800, DOI 10.1006/bbrc.1996.0314; PAULY PC, 1995, BIOCHEM J, V306, P643, DOI 10.1042/bj3060643; Perlmutter DH, 1999, LAB INVEST, V79, P623; PIMPLIKAR SW, 1994, J CELL BIOL, V125, P1025, DOI 10.1083/jcb.125.5.1025; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Plemper RK, 1998, J BIOL CHEM, V273, P32848, DOI 10.1074/jbc.273.49.32848; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; Ruddon RW, 1997, J BIOL CHEM, V272, P3125, DOI 10.1074/jbc.272.6.3125; Sakata N, 1999, J BIOL CHEM, V274, P17068, DOI 10.1074/jbc.274.24.17068; Schirmer EC, 1997, P NATL ACAD SCI USA, V94, P13932, DOI 10.1073/pnas.94.25.13932; Shtilerman M, 1999, SCIENCE, V284, P822, DOI 10.1126/science.284.5415.822; Singh N, 1997, J BIOL CHEM, V272, P28461, DOI 10.1074/jbc.272.45.28461; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Weissmann C, 1999, J BIOL CHEM, V274, P3, DOI 10.1074/jbc.274.1.3; Welch WJ, 1998, NATURE, V392, P23, DOI 10.1038/32049; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Wilbourn B, 1998, BIOCHEM J, V332, P111, DOI 10.1042/bj3320111; Zanusso G, 1999, J BIOL CHEM, V274, P23396, DOI 10.1074/jbc.274.33.23396	43	136	141	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38699	38704		10.1074/jbc.M005543200	http://dx.doi.org/10.1074/jbc.M005543200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10970892	hybrid			2022-12-25	WOS:000165739800077
J	Yi, JZ; Arthur, JW; Dunbrack, RL; Skalka, AM				Yi, JZ; Arthur, JW; Dunbrack, RL; Skalka, AM			An inhibitory monoclonal antibody binds at the turn of the helix-turn-helix motif in the N-terminal domain of HIV-1 integrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DEPENDENT ROTAMER LIBRARY; TYPE-1 INTEGRASE; CATALYTIC DOMAIN; ACTIVE-SITE; DNA-BINDING; RETROVIRAL INTEGRASE; DIVALENT-CATIONS; IN-VITRO; PROTEIN	With the increase in our understanding of its structure and enzymatic mechanism, HIV-1 integrase (IN) ha, become a promising target for designing drugs to treat patients with AIDS, To investigate the structure and function of IN, a panel of monoclonal antibodies (mAbs) directed against HIV-1 IN was raised and characterized previously in this laboratory, Among them, mAbs17, -4, and -33 were found to inhibit IN activity in vitro. In this study, we investigated the interaction of N-terminal-specific mAb17 and its isolated Fab fragment with full-length HIV-1 IN(1-288) and its isolated N-terminal, Zn2+ binding domain IN(1-49). Our results show that binding of Zn2+ to IN(1-49) stabilizes the mAb17-IN complex and that dimer dissociation is not required for binding of the Fab. To identify the epitope recognized by mAb17, we developed a protein footprinting technique based on controlled proteolysis and matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Binding was mapped to a region within amino acids Asp(25)-Glu(35). This peptide corresponds to the end of a helix-turn-helix motif in the IN(1-55) NMR structure and contributes to the dimerization of the N-terminal domain. Antibody binding also appears to destabilize the N-terminal helix in this domain. A molecular model of the [IN(1-49)](2).(Fab)(1) complex shows Fab binding across the dimer protein and suggests a potential target for drug design. These data also suggest that mAb17 inhibits integrase activity by blocking critical protein-protein interactions and/or by distorting the orientation of the N-terminal alpha -helix, The relevance of our results to an understanding of IN function is discussed.	Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Skalka, AM (corresponding author), Fox Chase Canc Ctr, Inst Canc Res, 7701 Burholme Ave, Philadelphia, PA 19111 USA.		Dunbrack, Roland/ABG-7141-2020; Arthur, Jonathan/A-5367-2009	Arthur, Jonathan/0000-0003-3615-7352; Dunbrack, Roland/0000-0001-7674-6667	NATIONAL CANCER INSTITUTE [P30CA006927, R01CA071515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040385] Funding Source: NIH RePORTER; NCI NIH HHS [CA06927, CA71515] Funding Source: Medline; NIAID NIH HHS [AI40385] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andrake MD, 1996, J BIOL CHEM, V271, P19633, DOI 10.1074/jbc.271.33.19633; Asante-Appiah E, 1998, J BIOL CHEM, V273, P35078, DOI 10.1074/jbc.273.52.35078; Asante-Appiah E, 1997, ANTIVIR RES, V36, P139, DOI 10.1016/S0166-3542(97)00046-6; AsanteAppiah E, 1997, J BIOL CHEM, V272, P16196, DOI 10.1074/jbc.272.26.16196; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BIZUBBENDER D, 1994, AIDS RES HUM RETROV, V10, P1105, DOI 10.1089/aid.1994.10.1105; Bower MJ, 1997, J MOL BIOL, V267, P1268, DOI 10.1006/jmbi.1997.0926; Buchbinder JL, 1998, J MOL BIOL, V282, P1033, DOI 10.1006/jmbi.1998.2025; Bujacz G, 1997, J BIOL CHEM, V272, P18161, DOI 10.1074/jbc.272.29.18161; Bujacz G, 1996, STRUCTURE, V4, P89, DOI 10.1016/S0969-2126(96)00012-3; BUSHMAN FD, 1994, J VIROL, V68, P2215, DOI 10.1128/JVI.68.4.2215-2223.1994; Cai ML, 1997, NAT STRUCT BIOL, V4, P567, DOI 10.1038/nsb0797-567; Chen ZG, 2000, J MOL BIOL, V296, P521, DOI 10.1006/jmbi.1999.3451; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; DRELICH M, 1992, VIROLOGY, V188, P459, DOI 10.1016/0042-6822(92)90499-F; DUNBRACK RL, 1993, J MOL BIOL, V230, P543, DOI 10.1006/jmbi.1993.1170; Dunbrack RL, 1997, PROTEIN SCI, V6, P1661, DOI 10.1002/pro.5560060807; Dunbrack RL, 1999, PROTEINS, P81; EIJKELENBOOM AP, 1997, CURR BIOL, V7, P7398; Eijkelenboom APAM, 1999, PROTEINS, V36, P556, DOI 10.1002/(SICI)1097-0134(19990901)36:4<556::AID-PROT18>3.0.CO;2-6; EIJKELENBOOM APAM, 1995, NAT STRUCT BIOL, V2, P807, DOI 10.1038/nsb0995-807; ELLISON V, 1995, J BIOL CHEM, V270, P3320, DOI 10.1074/jbc.270.7.3320; ENGELMAN A, 1993, EMBO J, V12, P3269, DOI 10.1002/j.1460-2075.1993.tb05996.x; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; Goldgur Y, 1999, P NATL ACAD SCI USA, V96, P13040, DOI 10.1073/pnas.96.23.13040; Goldgur Y, 1998, P NATL ACAD SCI USA, V95, P9150, DOI 10.1073/pnas.95.16.9150; Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646; Hindmarsh P, 1999, MICROBIOL MOL BIOL R, V63, P836, DOI 10.1128/MMBR.63.4.836-843.1999; JEFFREY PD, 1995, J MOL BIOL, V248, P344, DOI 10.1016/S0022-2836(95)80055-7; Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712; Kaminski MJ, 1999, J BIOL CHEM, V274, P5597, DOI 10.1074/jbc.274.9.5597; Katz RA, 1996, VIROLOGY, V217, P178, DOI 10.1006/viro.1996.0105; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; KHAN E, 1991, NUCLEIC ACIDS RES, V19, P851, DOI 10.1093/nar/19.4.851; Koehl Patrice, 1999, Nature Structural Biology, V6, P108, DOI 10.1038/5794; Lee SP, 1996, BIOCHEMISTRY-US, V35, P3837, DOI 10.1021/bi952056p; Lee SP, 1997, BIOCHEMISTRY-US, V36, P173, DOI 10.1021/bi961849o; LevyMintz P, 1996, J VIROL, V70, P8821, DOI 10.1128/JVI.70.12.8821-8832.1996; LODI PJ, 1995, BIOCHEMISTRY-US, V34, P9826, DOI 10.1021/bi00031a002; Lubkowski J, 1998, P NATL ACAD SCI USA, V95, P4831, DOI 10.1073/pnas.95.9.4831; Maignan S, 1998, J MOL BIOL, V282, P359, DOI 10.1006/jmbi.1998.2002; Mazumder A, 1996, BIOCHEMISTRY-US, V35, P13762, DOI 10.1021/bi960541u; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Pommier Y, 1999, ADV VIRUS RES, V52, P427, DOI 10.1016/S0065-3527(08)60310-3; Ritchie DW, 2000, PROTEINS, V39, P178, DOI 10.1002/(SICI)1097-0134(20000501)39:2<178::AID-PROT8>3.3.CO;2-Y; STEVENSON M, 1990, J VIROL, V64, P2421, DOI 10.1128/JVI.64.5.2421-2425.1990; VANGENT DC, 1992, P NATL ACAD SCI USA, V89, P9598, DOI 10.1073/pnas.89.20.9598; VINCENT KA, 1993, J VIROL, V67, P425, DOI 10.1128/JVI.67.1.425-437.1993; Yang ZN, 2000, J MOL BIOL, V296, P535, DOI 10.1006/jmbi.1999.3463; Yi JZ, 1999, BIOCHEMISTRY-US, V38, P8458, DOI 10.1021/bi982870n; Zheng RL, 1996, P NATL ACAD SCI USA, V93, P13659, DOI 10.1073/pnas.93.24.13659	53	22	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38739	38748		10.1074/jbc.M005499200	http://dx.doi.org/10.1074/jbc.M005499200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10969077	hybrid			2022-12-25	WOS:000165739800083
J	Fuller, W; Cuthbert, AW				Fuller, W; Cuthbert, AW			Post-translational disruption of the Delta F508 cystic fibrosis transmembrane conductance regulator (CFTR)-molecular chaperone complex with geldanamycin stabilizes Delta F508 CFTR in the rabbit reticulocyte lysate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONE; ANTITUMOR AGENT; HERBIMYCIN-A; IN-VITRO; DEGRADATION; PROTEIN; HSP90; RECEPTOR	The Delta F508 mutation of cystic fibrosis transmembrane conductance regulator (CFTR) is a trafficking mutant, which is retained and degraded in the endoplasmic reticulum by the ubiquitin-proteasome pathway. The mutant protein fails to reach a completely folded conformation that is no longer a substrate for ubiquitination ("stable B"). Wild type protein reaches this state with 25% efficiency. In this study the rabbit reticulocyte lysate with added microsomal membranes has been used to reproduce the post-translational events in the folding of wild type and Delta F508 CFTR. In this system wild type CFTR does not reach the stable B form if the post-translational temperature is 37 degreesC, whereas at 30 degreesC the behavior of both wild type and mutant proteins mimics that observed in the cell. Geldanamycin stabilizes Delta F508 CFTR with respect to ubiquitination only when added post-translationally. The interaction of wild type and mutant CFTR with the molecular chaperones heat shock cognate 70 (hsc70) and heat shock protein 90 (hsp90) has been assessed. Release of wild type protein from hsc70 coincides with the cessation of ubiquitination and formation of stable B. Geldanamycin immediately prevents the binding of hsp90 to Delta F508 CFTR, and after a delay releases it from hsc70. Release of mutant protein from hsc70 also coincides with the formation of stable B Delta F508 CFTR.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1QJ, England	University of Cambridge	Cuthbert, AW (corresponding author), Addenbrookes Hosp, Dept Med, Level 5,Box 157,Hills Rd, Cambridge CB2 2QQ, England.			Fuller, William/0000-0002-5883-4433				ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; Bercovich B, 1997, J BIOL CHEM, V272, P9002; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; Gilmore R, 1998, J BIOL CHEM, V273, P15227, DOI 10.1074/jbc.273.24.15227; GROSS M, 1980, MOL CELL BIOCHEM, V31, P25, DOI 10.1007/BF00817888; HAAS AL, 1981, P NATL ACAD SCI-BIOL, V78, P6845, DOI 10.1073/pnas.78.11.6845; Hartson SD, 1996, BIOCHEMISTRY-US, V35, P13451, DOI 10.1021/bi961332c; HUTCHISON KA, 1994, J BIOL CHEM, V269, P27894; Imamura T, 1998, J BIOL CHEM, V273, P11183, DOI 10.1074/jbc.273.18.11183; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Jiang CW, 1998, AM J PHYSIOL-CELL PH, V275, pC171, DOI 10.1152/ajpcell.1998.275.1.C171; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; Lu Y, 1998, J BIOL CHEM, V273, P568, DOI 10.1074/jbc.273.1.568; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; MURAKAMI Y, 1994, BIOCHEM J, V301, P57, DOI 10.1042/bj3010057; PIND S, 1994, J BIOL CHEM, V269, P12784; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; Sato S, 1998, J BIOL CHEM, V273, P7189, DOI 10.1074/jbc.273.13.7189; Sawa T, 1996, BIOCHEM BIOPH RES CO, V218, P449, DOI 10.1006/bbrc.1996.0080; Scheibel T, 1998, BIOCHEM PHARMACOL, V56, P675, DOI 10.1016/S0006-2952(98)00120-8; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Schulte TW, 1998, CANCER CHEMOTH PHARM, V42, P273, DOI 10.1007/s002800050817; Schumacher RJ, 1996, BIOCHEMISTRY-US, V35, P14889, DOI 10.1021/bi961825h; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; SUPKO JG, 1995, CANCER CHEMOTH PHARM, V36, P305, DOI 10.1007/BF00689048; UEHARA Y, 1989, CANCER RES, V49, P780; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WHITESELL L, 1992, CANCER RES, V52, P1721; Whitesell L, 1997, ONCOGENE, V14, P2809, DOI 10.1038/sj.onc.1201120; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480	43	48	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37462	37468		10.1074/jbc.M006278200	http://dx.doi.org/10.1074/jbc.M006278200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10982807	hybrid			2022-12-25	WOS:000165618700023
J	Halaszovich, CR; Zitt, C; Jungling, E; Luckhoff, A				Halaszovich, CR; Zitt, C; Jungling, E; Luckhoff, A			Inhibition of TRP3 channels by lanthanides - Block from the cytosolic side of the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; OPERATED HTRP3 CHANNELS; ENDOTHELIAL-CELLS; MAST-CELLS; CA2+ ENTRY; EXPRESSION; GADOLINIUM; DEPLETION; PROTEINS; RECEPTOR	The lanthanide ions La3+ and Gd3+ block Ca2+-permeable cation channels and have been used as important tools to characterize channels of the transient receptor potential (TRP) family, However, widely different concentrations of La3+ and Gd3+ have reportedly been required for block of TRP3 channels in Various expression systems. The present study provides a possible explanation for this discrepancy. After overexpression of TRP3 in Chinese hamster ovary cells, whole-cell currents through TRP3 were reversibly inhibited by La3+ with an EC50 of 4 mum. For comparison, the organic blocker SKF96365 required an EC50 of 8 mum. Gd3+ blocked with an EC50 of 0.1 mum, but this block was slow in onset and was not reversible after wash-out. When the two lanthanides were added to the cytosolic side of inside-out patches, block was achieved with considerably lower concentrations (EC50 for La3+, 0.02 mum; EC50 for Gd3+, 0.02 mum). Uptake of La3+ into the cytosol of Chinese hamster ovary cells was demonstrated with intracellular fura a. We conclude that lanthanides block TRP3 more potently from the cytosolic than from the extracellular side of the plasma membrane and that uptake of lanthanides will largely affect the apparent EC50 values after extracellular application.	Univ Klinikum Aachen, Rhein Westfal TH Aachen, Inst Physiol, D-52074 Aachen, Germany	RWTH Aachen University; RWTH Aachen University Hospital	Luckhoff, A (corresponding author), Univ Klinikum Aachen, Rhein Westfal TH Aachen, Inst Physiol, Pauwelsstr 30, D-52074 Aachen, Germany.		Halaszovich, Christian/I-7231-2012					Aussel C, 1996, BIOCHEM J, V313, P909, DOI 10.1042/bj3130909; Balzer M, 1999, CARDIOVASC RES, V42, P543, DOI 10.1016/S0008-6363(99)00025-5; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Caldwell RA, 1998, AM J PHYSIOL-CELL PH, V275, pC619, DOI 10.1152/ajpcell.1998.275.2.C619; Cheng Y, 1999, J BIOL INORG CHEM, V4, P447, DOI 10.1007/s007750050331; Dippel E, 1996, P NATL ACAD SCI USA, V93, P1391, DOI 10.1073/pnas.93.4.1391; EVANS CH, 1990, BIOCHEMISTRY LANTHAN; FRANZIUS D, 1994, PFLUG ARCH EUR J PHY, V428, P433, DOI 10.1007/BF00374562; Groschner K, 1998, FEBS LETT, V437, P101, DOI 10.1016/S0014-5793(98)01212-5; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANSEN DE, 1991, CIRC RES, V69, P820, DOI 10.1161/01.RES.69.3.820; Hofmann T, 2000, J MOL MED, V78, P14, DOI 10.1007/s001090050378; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Hongo K, 1997, EXP PHYSIOL, V82, P647, DOI 10.1113/expphysiol.1997.sp004053; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Kamouchi M, 1999, J PHYSIOL-LONDON, V518, P345, DOI 10.1111/j.1469-7793.1999.0345p.x; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; KWAN CY, 1990, J BIOL CHEM, V265, P678; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; MARTELL AE, 1976, CRITICAL STABILITY C; PEETERS GA, 1989, AM J PHYSIOL, V256, pC351, DOI 10.1152/ajpcell.1989.256.2.C351; Philipp S, 2000, J BIOL CHEM, V275, P23965, DOI 10.1074/jbc.M003408200; Preuss KD, 1997, BIOCHEM BIOPH RES CO, V240, P167, DOI 10.1006/bbrc.1997.7528; Putney JW, 1999, BIOESSAYS, V21, P38; STACY GP, 1992, AM J PHYSIOL, V263, pH613, DOI 10.1152/ajpheart.1992.263.2.H613; TAKANO H, 1995, CIRCULATION, V91, P1575, DOI 10.1161/01.CIR.91.5.1575; Wu XY, 2000, AM J PHYSIOL-CELL PH, V278, pC526, DOI 10.1152/ajpcell.2000.278.3.C526; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	34	111	117	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37423	37428		10.1074/jbc.M007010200	http://dx.doi.org/10.1074/jbc.M007010200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10970899	hybrid			2022-12-25	WOS:000165618700017
J	Hughes, AL; Gollapudi, L; Sladek, TL; Neet, KE				Hughes, AL; Gollapudi, L; Sladek, TL; Neet, KE			Mediation of nerve growth factor-driven cell cycle arrest in PC12 cells by p53 simultaneous - Differentiation and proliferation subsequent to p53 functional inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; CDK INHIBITOR P21(WAF1/CIP1); NEURONAL DIFFERENTIATION; NUCLEAR-LOCALIZATION; TYROSINE PHOSPHORYLATION; PHEOCHROMOCYTOMA CELLS; NITRIC-OXIDE; PROTEIN; GENE; NGF	Upon stimulation with nerve growth factor (NGF), PC12 cells extend neurites and cease to proliferate by influencing cell cycle proteins. Previous studies have shown that neuritogenesis and a block at the G(1)/S checkpoint correlate with the nuclear translocation of and an increase in the p53 tumor suppressor protein. This study was designed to determine if p53 plays a direct role in mediating NGF-driven G(1) arrest. A retroviral vector that overexpresses a temperature-sensitive p53 mutant protein (p53ts) was used to extinguish the function of endogenous p53 in PC12 cells in a dominant-negative manner at the nonpermissive temperature. NGF treatment led to transactivation of a p53 response element in a luciferase reporter construct in PC12 cells, whereas this response to NGF was absent in PC12(p53ts) cells at the nonpermissive temperature. With p53 functionally inactivated, NGF failed to activate growth arrest, as measured by bromodeoxyuridine incorporation, and also failed to induce p21/WAF1 expression, as measured by Western blotting. Since neurite outgrowth proceeded unharmed, 50% of the cells simultaneously demonstrated neurite morphology and were in S phase. Both PC12 cells expressing SV40 T antigen and PC12 cells treated with p53 antisense oligonucleotides continued through the cell cycle, confirming the dependence of the NGF growth arrest signal on a p53 pathway. Activation of Ras in a dexamethasone-inducible PC12 cell line (GSRas1) also caused p53 nuclear translocation and growth arrest, Therefore, wild-type p53 is indispensable in mediating the NGF antiproliferative signal through the Ras/MAPK pathway that regulates the cell cycle of PC12 cells.	Finch Univ Hlth Sci Chicago Med Sch, Dept Biochem & Mol Biol, N Chicago, IL 60064 USA; Finch Univ Hlth Sci Chicago Med Sch, Dept Microbiol & Immunol, N Chicago, IL 60064 USA	Chicago Medical School; Chicago Medical School	Neet, KE (corresponding author), Finch Univ Hlth Sci Chicago Med Sch, Dept Biol Chem, 3333 Green Bay Rd, N Chicago, IL 60064 USA.				NINDS NIH HHS [NS24380] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024380] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALONIGRINSTEIN R, 1993, ONCOGENE, V8, P3297; BELL JC, 1986, MOL CELL BIOL, V6, P617, DOI 10.1128/MCB.6.2.617; Billon N, 1999, ONCOGENE, V18, P2872, DOI 10.1038/sj.onc.1202712; Billon N, 1996, ONCOGENE, V13, P2047; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHEN J, 1990, CELL GROWTH DIFFER, V1, P79; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DAVIES AM, 1994, NEUROSCI LETT, V182, P112, DOI 10.1016/0304-3940(94)90219-4; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erhardt JA, 1998, ONCOGENE, V16, P443, DOI 10.1038/sj.onc.1201577; FIELDS AP, 1988, J BIOL CHEM, V263, P8253; FUKUI Y, 1987, METHOD CELL BIOL, V28, P347; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; Gollapudi L, 1997, J NEUROSCI RES, V49, P461, DOI 10.1002/(SICI)1097-4547(19970815)49:4<461::AID-JNR7>3.3.CO;2-6; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; GUNNING PW, 1981, J NEUROSCI, V1, P368; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOSANG M, 1987, EMBO J, V6, P1197, DOI 10.1002/j.1460-2075.1987.tb02354.x; IGNATIUS MJ, 1985, J NEUROSCI, V5, P343; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; Knippschild U, 1996, ONCOGENE, V12, P1755; LEROUX I, 1993, P NATL ACAD SCI USA, V90, P9120, DOI 10.1073/pnas.90.19.9120; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LUO Y, 1992, J BIOL CHEM, V267, P12275; MARTINOU I, 1995, J CELL BIOL, V128, P201, DOI 10.1083/jcb.128.1.201; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MONTANO X, 1987, MOL CELL BIOL, V7, P1782, DOI 10.1128/MCB.7.5.1782; Poluha W, 1997, J BIOL CHEM, V272, P24002, DOI 10.1074/jbc.272.38.24002; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; RYDEL RE, 1987, J NEUROSCI, V7, P3639; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHAULSKY G, 1991, CELL GROWTH DIFFER, V2, P661; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; SLADEK TL, 1992, J VIROL, V66, P1059, DOI 10.1128/JVI.66.2.1059-1065.1992; Sladek TL, 1996, CELL PROLIFERAT, V29, P579, DOI 10.1111/j.1365-2184.1996.tb00973.x; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Troy CM, 1996, J NEUROSCI, V16, P253; TSUJI K, 1994, MOL CARCINOGEN, V9, P167, DOI 10.1002/mc.2940090308; TSUKADA T, 1993, ONCOGENE, V8, P3313; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; Urdiales JL, 1998, J NEUROSCI, V18, P6767; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WOODRUFF NR, 1986, BIOCHEMISTRY-US, V25, P7967, DOI 10.1021/bi00372a027; Yan GZ, 1997, J NEUROSCI, V17, P6122; YAN GZ, 1995, J NEUROSCI, V15, P6200; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	65	57	59	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37829	37837		10.1074/jbc.M003146200	http://dx.doi.org/10.1074/jbc.M003146200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10978315	hybrid			2022-12-25	WOS:000165618700071
J	Liu, L; Sazonova, IY; Turner, RB; Chowdhry, SA; Tsai, J; Houng, AK; Reed, GL				Liu, L; Sazonova, IY; Turner, RB; Chowdhry, SA; Tsai, J; Houng, AK; Reed, GL			Leucine 42 in the fibronectin motif of streptokinase plays a critical role in fibrin-independent plasminogen activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBOLYTIC THERAPY; BINDING REGION; COMPLEX; MECHANISM; CONVERSION; DOMAINS; ACID	The NH2 terminus (residues 1-59) of streptokinase (SK) is a molecular switch that permits fibrin-independent plasminogen activation. Targeted mutations were made in recombinant (r) SK1-59 to identify structural interactions required for this process. Mutagenesis established the functional roles of Phe-37and Glu-39, which were projected to interact with microplasmin in the activator complex. Mutation of Leu-42 (rSK1-59(L42A)), a conserved residue in the SK fibronectin motif that lacks interactions with microplasmin, strongly reduced plasminogen activation (k(cat) decreased 50-fold) but not amidolysis (k(cat) decreased 1.5-fold). Otherwise rSK1-59(L42A) and native rSK1-59 were indistinguishable in several parameters. Both displayed saturable and specific binding to Glu-plasminogen or the remaining SK fragment (rSK Delta 59), Similarly rSK1-59 and rSK1-59(L42A) bound simultaneously to two different plasminogen molecules, indicating that both plasminogen binding sites were intact. However, when bound to SK1-59, rSK1-59(L42A) was less effective than rSK1-59 in restructuring the native conformation of the SK A domain, as detected by conformation-dependent monoclonal antibodies. In the light of previous studies, these data provide evidence that SK1-59 contributes to fibrin-independent plasminogen activation through 1) intermolecular interactions with the plasmin in the activator complex, 2) binding interactions with the plasminogen substrate, and 3) intramolecular interactions that structure the A domain of SK for Pg substrate processing.	Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital	Reed, GL (corresponding author), Cardiovasc Biol Lab, HSHP 2-127,677 Huntington Ave, Boston, MA 02115 USA.	reed@cvlab.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057314] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57314] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROCKWAY WJ, 1974, BIOCHEMISTRY-US, V13, P2063, DOI 10.1021/bi00707a010; Caballero RR, 1999, INFECT IMMUN, V67, P6478; CAMIOLO SM, 1971, P SOC EXP BIOL MED, V138, P277; Conejero-Lara F, 1998, PROTEIN SCI, V7, P2190, DOI 10.1002/pro.5560071017; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GONZALEZGRONOW M, 1993, BIOCHIM BIOPHYS ACTA, V1180, P283, DOI 10.1016/0925-4439(93)90051-2; Hirst JD, 1996, PROTEIN ENG, V9, P657, DOI 10.1093/protein/9.8.657; Lin LF, 1996, BIOCHEMISTRY-US, V35, P16879, DOI 10.1021/bi961531w; Lin LF, 2000, BIOCHEMISTRY-US, V39, P4740, DOI 10.1021/bi992028x; LUKACOVA D, 1991, BIOCHEMISTRY-US, V30, P10164, DOI 10.1021/bi00106a013; MARDER VJ, 1988, NEW ENGL J MED, V318, P1585, DOI 10.1056/NEJM198806163182406; MARDER VJ, 1988, NEW ENGL J MED, V318, P1512, DOI 10.1056/NEJM198806093182306; MARKUS G, 1976, J BIOL CHEM, V251, P6495; MCCLINTOCK DK, 1971, BIOCHEM BIOPH RES CO, V43, P694, DOI 10.1016/0006-291X(71)90670-X; Moitra J, 1997, BIOCHEMISTRY-US, V36, P12567, DOI 10.1021/bi971424h; Nihalani D, 1997, PROTEIN SCI, V6, P1284, DOI 10.1002/pro.5560060616; Nihalani D, 1998, PROTEIN SCI, V7, P637, DOI 10.1002/pro.5560070313; Pace CN, 1996, FASEB J, V10, P75, DOI 10.1096/fasebj.10.1.8566551; ParhamiSeren B, 1997, J MOL BIOL, V271, P333, DOI 10.1006/jmbi.1997.1174; Parrado J, 1996, PROTEIN SCI, V5, P693; Parry MAA, 1998, NAT STRUCT BIOL, V5, P917, DOI 10.1038/2359; REDDY KNN, 1972, J BIOL CHEM, V247, P1683; REED GL, 1995, BIOCHEMISTRY-US, V34, P10266, DOI 10.1021/bi00032a021; Reed GL, 1999, P NATL ACAD SCI USA, V96, P8879, DOI 10.1073/pnas.96.16.8879; REED GL, 1993, J IMMUNOL, V150, P4407; RODRIGUEZ P, 1995, EUR J BIOCHEM, V229, P83, DOI 10.1111/j.1432-1033.1995.tb20441.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Serrano RL, 1996, BIOCHEM J, V313, P171, DOI 10.1042/bj3130171; SIEFRING GE, 1976, J BIOL CHEM, V251, P3913; SUMMARIA L, 1967, J BIOL CHEM, V242, P4279; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Wang SG, 1999, BIOCHEMISTRY-US, V38, P5232, DOI 10.1021/bi981915h; Wang XQ, 1998, SCIENCE, V281, P1662, DOI 10.1126/science.281.5383.1662; WOHL RC, 1980, J BIOL CHEM, V255, P2005; WULF RJ, 1969, CAN J BIOCHEM CELL B, V47, P927, DOI 10.1139/o69-145	35	13	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37686	37691		10.1074/jbc.M003963200	http://dx.doi.org/10.1074/jbc.M003963200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10961989	hybrid			2022-12-25	WOS:000165618700053
J	Peiro, S; Comella, JX; Enrich, C; Martin-Zanca, D; Rocamora, N				Peiro, S; Comella, JX; Enrich, C; Martin-Zanca, D; Rocamora, N			PC12 cells have caveolae that contain TrkA - Caveolae-disrupting drugs inhibit nerve growth factor-induced, but not epidermal growth factor-induced, MAPK phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; IN-VIVO; MEDIATED TRANSPORT; MEMBRANE DOMAINS; PLASMA-MEMBRANE; GENE FAMILY; CHOLESTEROL; PROTEIN; TYROSINE; KINASE	Nerve growth factor (NGF) induces survival and differentiation of the neural crest-derived PC12 cell line. Caveolae are cholesterol-enriched, caveolin-containing plasma membrane microdomains involved in vesicular transport and signal transduction. Here we demonstrate the presence of caveolae in PC12 cells and their involvement in NGF signaling. Our results showed the expression of caveolin-1 by Western blot and confocal immuno-microscopy. The presence of plasma membrane caveolae was directly shown by rapid-freeze deep-etching electron microscopy. Moreover, combined deep-etching and immunogold techniques revealed the presence of the NGF receptor TrkA in the caveolae of PC12 cells. These data together with the cofractionation of Shc, Ras, caveolin, and TrkA in the caveolae fraction supported a role for these plasma membrane microdomains in NGF signaling. To approach this hypothesis, caveolae were disrupted by treatment of PC12 cells with cholesterol binding drugs. Either filipin or cyclodextrin treatment increased basal levels of MAPK phosphorylation. in contrast, pretreatment of PC12 cells with these drugs inhibited the NGF- but not the epidermal growth factor-induced MAPK phosphorylation without affecting the TrkA autophosphorylation. Taken together, our results demonstrate the presence of caveolae in PC12 cells, which contain the high affinity NGF receptor TrkA, and the specific involvement of these cholesterol-enriched plasma membrane microdomains in the propagation of the NGF-induced signal.	Inst Catala Oncol, Lab Biol Mol, Barcelona 08907, Spain; Univ Barcelona, Fac Med, IDIBAPS, Inst Invest Biomed August Pi & Sunyer,Dept Biol C, Barcelona 08036, Spain; Univ Lleida, Fac Med, Dept Ciencias Med Basiques, Grp Neurobiol Mol, Lleida 25198, Spain; Univ Salamanca, CSIC, Inst Microbiol Bioquim, Salamanca 37007, Spain	Catalan Institute of Oncology; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Universitat de Lleida; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca	Rocamora, N (corresponding author), Inst Catala Oncol, Lab Biol Mol, Avda Gran Via S-N,Km 2-7, Barcelona 08907, Spain.	rocamora@ico.scs.es	Comella, Joan/GQA-4279-2022; Comella, Joan X/D-7333-2012	Comella, Joan X/0000-0002-6218-0786; Enrich, Carlos/0000-0003-0382-2993				ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Baorto DM, 1997, NATURE, V389, P636, DOI 10.1038/39376; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; Barrett GL, 1996, J NEUROSCI RES, V45, P117, DOI 10.1002/(SICI)1097-4547(19960715)45:2<117::AID-JNR4>3.0.CO;2-D; Bilderback TR, 1997, J BIOL CHEM, V272, P10922; Bilderback TR, 1999, J BIOL CHEM, V274, P257, DOI 10.1074/jbc.274.1.257; Cameron PL, 1997, J NEUROSCI, V17, P9520; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; Chao M, 1998, BRAIN RES REV, V26, P295, DOI 10.1016/S0165-0173(97)00036-2; CLARY DO, 1994, MOL BIOL CELL, V5, P549, DOI 10.1091/mbc.5.5.549; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; ESCAIG J, 1982, J MICROSC-OXFORD, V126, P221, DOI 10.1111/j.1365-2818.1982.tb00379.x; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Galbiati F, 1998, P NATL ACAD SCI USA, V95, P10257, DOI 10.1073/pnas.95.17.10257; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Grimes ML, 1997, P NATL ACAD SCI USA, V94, P9909, DOI 10.1073/pnas.94.18.9909; Grimes ML, 1996, J NEUROSCI, V16, P7950; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; Monier S, 1996, FEBS LETT, V388, P143, DOI 10.1016/0014-5793(96)00519-4; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Oh P, 1999, J BIOL CHEM, V274, P23144, DOI 10.1074/jbc.274.33.23144; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; PALADE GE, 1953, J APPL PHYS, V24, P1424; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; QUINTANA C, 1994, MICRON, V25, P63, DOI 10.1016/0968-4328(94)90056-6; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; Schnitzer JE, 1996, SCIENCE, V274, P239, DOI 10.1126/science.274.5285.239; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Taglialatela G, 1997, J NEUROSCI RES, V47, P155; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Waugh MG, 1999, BIOCHEM J, V337, P591, DOI 10.1042/0264-6021:3370591; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962	52	82	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37846	37852		10.1074/jbc.M000487200	http://dx.doi.org/10.1074/jbc.M000487200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10982788	hybrid			2022-12-25	WOS:000165618700073
J	Schulz, A; Bruns, K; Henklein, P; Krause, G; Schubert, M; Gudermann, T; Wray, V; Schultz, G; Schoneberg, T				Schulz, A; Bruns, K; Henklein, P; Krause, G; Schubert, M; Gudermann, T; Wray, V; Schultz, G; Schoneberg, T			Requirement of specific intrahelical interactions for stabilizing the inactive conformation of glycoprotein hormone receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3RD INTRACELLULAR LOOP; HUMAN LUTROPIN/CHORIOGONADOTROPIN RECEPTOR; HUMAN THYROTROPIN RECEPTOR; CARBOXYL-TERMINAL REGION; G-PROTEIN RECEPTOR; CYTOPLASMIC LOOP; ALPHA-HELIX; CONSTITUTIVE ACTIVATION; SECONDARY STRUCTURE; CIRCULAR-DICHROISM	Systematic analysis of structural changes induced by activating mutations has been frequently utilized to study activation mechanisms of G-protein-coupled receptors (GPCRs). In the thyrotropin receptor and the lutropin receptor (LHR), a large number of naturally occurring mutations leading to constitutive receptor activation were identified. Saturating mutagenesis studies of a highly conserved Asp in the junction of the third intracellular loop and transmembrane domain 6 suggested a participation of this anionic residue in a salt bridge stabilizing the inactive receptor conformation. However, substitution of all conserved cationic residues at the cytoplasmic receptor surface did not support this hypothesis. Asp/Glu residues are a common motif at the N-terminal ends of alpha -helices terminating and stabilizing the helical structure (helix capping). Since Asp/Glu residues in the third intracellular loop/transmembrane domain 6 junction are not only preserved in glycoprotein hormone receptors but also in other GPCRs we speculated that this residue probably participates in an N-terminal helix-capping structure. Poly-Ala stretches are known to form and stabilize alpha -helices. Herein, we show that the function of the highly conserved Asp can be mimicked by poly-Ala substitutions in the LHR and thyrotropin receptor. CD and NMR studies of peptides derived from the juxtamembrane portion of the LHR confirmed the helix extension by the poly-Ala substitution and provided further evidence for an involvement of Asp in a helix-capping structure. Our data implicate that in addition to well established interhelical interactions the inactive conformation of GPCRs is also stabilized by specific intrahelical structures.	Free Univ Berlin, Inst Pharmakol, Klinikum Benjamin Franklin, D-14195 Berlin, Germany; Gesell Biotechnol Forsch GmbH, Dept Mol Struct Res, D-38124 Braunschweig, Germany; Humboldt Univ, Charite, Fak Med, Inst Biochem, D-10098 Berlin, Germany; Inst Mol Pharmakol, D-10315 Berlin, Germany; Univ Marburg, Fachberiech Humanmed, Inst Pharmakol & Toxikol, D-35033 Marburg, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Gesellschaft fur Biotechnologische Forschung mbH; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Philipps University Marburg	Schoneberg, T (corresponding author), Free Univ Berlin, Inst Pharmakol, Klinikum Benjamin Franklin, Thielallee 69-73, D-14195 Berlin, Germany.		Schubert, Mario/B-3972-2008	Schubert, Mario/0000-0003-0278-4091				Abell AN, 1997, J BIOL CHEM, V272, P14586, DOI 10.1074/jbc.272.23.14586; Abell AN, 1998, MOL ENDOCRINOL, V12, P1857, DOI 10.1210/me.12.12.1857; Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; Arshava B, 1998, BIOPOLYMERS, V46, P343, DOI 10.1002/(SICI)1097-0282(199811)46:6<343::AID-BIP1>3.0.CO;2-L; Aurora R, 1998, PROTEIN SCI, V7, P21, DOI 10.1002/pro.5560070103; Biebermann H, 1998, FASEB J, V12, P1461, DOI 10.1096/fasebj.12.14.1461; Blondelle SE, 1997, BIOCHEMISTRY-US, V36, P8393, DOI 10.1021/bi963015b; Boice JA, 1997, J BIOL CHEM, V272, P24825, DOI 10.1074/jbc.272.40.24825; BRUNGER AT, 1992, X PLOR SYSTEM XRAY C; CHAZENBALK GD, 1991, MOL ENDOCRINOL, V5, P1523, DOI 10.1210/mend-5-10-1523; Chopra A, 2000, BBA-BIOMEMBRANES, V1463, P1, DOI 10.1016/S0005-2736(99)00212-6; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; ELMASRY NF, 1994, PROTEIN ENG, V7, P777, DOI 10.1093/protein/7.6.777; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; FOROOD B, 1993, P NATL ACAD SCI USA, V90, P838, DOI 10.1073/pnas.90.3.838; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HEINZ DW, 1992, P NATL ACAD SCI USA, V89, P3751, DOI 10.1073/pnas.89.9.3751; HENKLEIN P, 1993, PEPTIDE RES, V6, P79; HENRY GD, 1994, METHOD ENZYMOL, V239, P515; Higuchi R., 1989, PCR TECHNOLOGY, P61; HITT M, 1995, VIRAL GENE TECHNIQUE, P13; HOGGER P, 1995, J BIOL CHEM, V270, P7405; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JUNG H, 1995, FEBS LETT, V358, P133, DOI 10.1016/0014-5793(94)01409-T; Jung H, 1996, BIOCHEMISTRY-US, V35, P6399, DOI 10.1021/bi952575s; KILLIAN JA, 1994, FEBS LETT, V348, P161, DOI 10.1016/0014-5793(94)00594-X; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; Kosugi S, 1998, MOL PHARMACOL, V53, P894; Kosugi S, 1996, J BIOL CHEM, V271, P31813, DOI 10.1074/jbc.271.50.31813; Krause G, 2000, MOL PHARMACOL, V57, P232; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lin ZL, 1997, PROTEIN ENG, V10, P501, DOI 10.1093/protein/10.5.501; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; Porter JE, 1996, J BIOL CHEM, V271, P28318, DOI 10.1074/jbc.271.45.28318; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; Rigby AC, 1998, BBA-BIOMEMBRANES, V1371, P241, DOI 10.1016/S0005-2736(98)00020-0; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SERRANO L, 1989, NATURE, V342, P296, DOI 10.1038/342296a0; Soulie S, 1999, BIOCHEMISTRY-US, V38, P5813, DOI 10.1021/bi983039d; Thapar R, 1996, BIOCHEMISTRY-US, V35, P11268, DOI 10.1021/bi960349s; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; WALLIN E, 1995, PROTEIN ENG, V8, P693, DOI 10.1093/protein/8.7.693; Wan WY, 1999, J MOL BIOL, V286, P1633, DOI 10.1006/jmbi.1999.2552; WANG HY, 1993, MOL ENDOCRINOL, V7, P1437, DOI 10.1210/me.7.11.1437; Wang Z, 1996, MOL ENDOCRINOL, V10, P748, DOI 10.1210/me.10.6.748; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wonerow P, 1998, J BIOL CHEM, V273, P7900, DOI 10.1074/jbc.273.14.7900; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yeagle PL, 1997, BIOCHEMISTRY-US, V36, P9649, DOI 10.1021/bi970908a; YEAGLE PL, 1995, BIOCHEMISTRY-US, V34, P14621, DOI 10.1021/bi00045a002; YEAGLE PL, 1995, NAT STRUCT BIOL, V2, P832, DOI 10.1038/nsb1095-832; Yeagle PL, 1997, BIOCHEMISTRY-US, V36, P3864, DOI 10.1021/bi962403a; ZHANG XJ, 1991, BIOCHEMISTRY-US, V30, P2012, DOI 10.1021/bi00222a001; ZHU X, 1993, J BIOL CHEM, V268, P1723	63	28	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37860	37869		10.1074/jbc.M006709200	http://dx.doi.org/10.1074/jbc.M006709200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10967122	hybrid			2022-12-25	WOS:000165618700075
J	Yang, TX; Park, JM; Arend, L; Huang, YN; Topaloglu, R; Pasumarthy, A; Praetorius, H; Spring, K; Briggs, JP; Schnermann, J				Yang, TX; Park, JM; Arend, L; Huang, YN; Topaloglu, R; Pasumarthy, A; Praetorius, H; Spring, K; Briggs, JP; Schnermann, J			Low chloride stimulation of prostaglandin E-2 release and cyclooxygenase-2 expression in a mouse macula densa cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; THICK ASCENDING LIMB; CYTOSOLIC PHOSPHOLIPASE A(2); ACTIVATED PROTEIN-KINASE; MESSENGER-RNA; RAT-KIDNEY; RENIN SECRETION; PHOSPHORYLATION; COTRANSPORTER; LOCALIZATION	Reducing luminal NaCl concentration in the macula densa region of the nephron stimulates renin secretion, and this response is blocked by a specific inhibitor of cyclooxygenase-2 (COX-2) (Traynor, T. R., Smart, A., Briggs, J. P., and Schnermann, J. (1999) Am. J. Physiol. Renal Physiol, 277, F706-710), To study whether low NaCl activates COX-2 activity or expression we clonally derived a macula densa cell line (MMDD1 cells) from SV-40 transgenic mice using fluorescence-activated cell sorting of renal tubular cells labeled with segment-specific fluorescent lectins, MMDD1 cells express COX-2, bNOS, NKCC2, and ROMK, but not Tamm-Horsfall protein, and showed rapid Rb-86(+) uptake that was inhibited by a reduction in NaCl concentration and by bumetanide or furosemide. Isosmotic exposure of MMDD1 cells to low NaCl (60 mM) caused a prompt and time-dependent stimulation of prostaglandin E-2 (PGE(2)) release that was prevented by the COX-2 specific inhibitor NS-398 (10 muM). Reducing NaCl to 60 and 6 mM for 16 h increased COX-2 expression in a chloride-dependent fashion. Low NaCl phosphorylated p38 kinase within 30 min and ERK1/2 kinases within 15 min without changing total MAP kinase levels. Low NaCl-stimulated PGE(2) release and COX-2 expression was inhibited by SE 203580 and PD 98059 (10 muM), inhibitors of p38 and ERK kinase pathways. We conclude that low chloride stimulates PGE(2) release and COX-2 expression in MMDD1 cells through activation of MAP kinases.	NIDDK, NIH, Bethesda, MD 20892 USA; NHLBI, NIH, Bethesda, MD 20892 USA; Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA; Univ Rochester, Dept Pathol & Lab Med, Rochester, NY 14642 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Michigan System; University of Michigan; University of Rochester	Schnermann, J (corresponding author), NIDDK, NIH, Bldg 10,Rm 4D51,10 Ctr Dr,MSC 1370, Bethesda, MD 20892 USA.	jurgens@intra.niddk.nih.gov	TOPALOGLU, Rezan/I-9095-2013; Briggs, Josephine P/B-9394-2009; Arend, Lois/ABE-2002-2020	Briggs, Josephine P/0000-0003-0798-1190; Arend, Lois/0000-0001-5434-7630; Topaloglu, Rezan/0000-0002-6423-0927; Praetorius, Helle/0000-0002-0970-5061	NIDDK NIH HHS [DK37448, DK39255, DK40042] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040042, P50DK039255, Z01DK043407, R01DK037448] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atherfold PA, 1999, MOL IMMUNOL, V36, P543, DOI 10.1016/S0161-5890(99)00076-0; Bell PD, 1997, CLIN EXP PHARMACOL P, V24, P541, DOI 10.1111/j.1440-1681.1997.tb01243.x; Borsch-Haubold AG, 1999, EUR J BIOCHEM, V265, P195, DOI 10.1046/j.1432-1327.1999.00722.x; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Ecelbarger CA, 1996, AM J PHYSIOL-RENAL, V271, pF619, DOI 10.1152/ajprenal.1996.271.3.F619; ECELBARGER CA, 2001, IN PRESS J AM SOC NE; FOWLER BC, 1995, KIDNEY INT, V47, P746, DOI 10.1038/ki.1995.114; FRANCISCO LL, 1982, AM J PHYSIOL, V243, pF537, DOI 10.1152/ajprenal.1982.243.6.F537; Gillen CM, 1999, AM J PHYSIOL-CELL PH, V276, pC328, DOI 10.1152/ajpcell.1999.276.2.C328; GREENBERG SG, 1993, AM J PHYSIOL, V265, pF578, DOI 10.1152/ajprenal.1993.265.4.F578; GREGER R, 1985, PHYSIOL REV, V65, P760, DOI 10.1152/physrev.1985.65.3.760; HARRIS RC, 1994, J CLIN INVEST, V94, P2504, DOI 10.1172/JCI117620; Hartner A, 1998, HYPERTENSION, V31, P201, DOI 10.1161/01.HYP.31.1.201; Hiller G, 1999, CELL SIGNAL, V11, P863, DOI 10.1016/S0898-6568(99)00058-3; Jensen BL, 1996, AM J PHYSIOL-RENAL, V271, pF659, DOI 10.1152/ajprenal.1996.271.3.F659; KIZER NL, 1995, AM J PHYSIOL-RENAL, V268, pF347, DOI 10.1152/ajprenal.1995.268.2.F347; Lapointe JY, 1998, KIDNEY INT, V54, pS58, DOI 10.1046/j.1523-1755.1998.06712.x; Lee SA, 2000, MOL BRAIN RES, V75, P16, DOI 10.1016/S0169-328X(99)00280-6; LORENZ JN, 1991, AM J PHYSIOL, V260, pF486, DOI 10.1152/ajprenal.1991.260.4.F486; Marais R, 1996, CANCER SURV, V27, P101; MUNDEL P, 1992, KIDNEY INT, V42, P1017, DOI 10.1038/ki.1992.382; Naidu PS, 1999, AM J PHYSIOL-HEART C, V277, pH1061, DOI 10.1152/ajpheart.1999.277.3.H1061; Nielsen S, 1998, AM J PHYSIOL-RENAL, V275, pF885, DOI 10.1152/ajprenal.1998.275.6.F885; Oberbaumer I, 1998, BIOL CHEM, V379, P913; OKUDA T, 1989, J CLIN INVEST, V84, P1866, DOI 10.1172/JCI114373; Parfenova H, 1999, AM J PHYSIOL-CELL PH, V277, pC728, DOI 10.1152/ajpcell.1999.277.4.C728; Parfenova H, 1998, AM J PHYSIOL-CELL PH, V274, pC72, DOI 10.1152/ajpcell.1998.274.1.C72; Peti-Peterdi J, 1999, AM J PHYSIOL-RENAL, V277, pF472, DOI 10.1152/ajprenal.1999.277.3.F472; RAUCHMAN MI, 1993, AM J PHYSIOL, V265, pF416, DOI 10.1152/ajprenal.1993.265.3.F416; RIELLE JC, 1987, ANAT RECORD, V218, P243, DOI 10.1002/ar.1092180304; SCHNERMANN J, 1976, PFLUG ARCH EUR J PHY, V362, P229, DOI 10.1007/BF00581175; SCHNERMANN J, 1982, KIDNEY INT, pS82; SCHULTE BA, 1983, AM J ANAT, V168, P345, DOI 10.1002/aja.1001680308; Singh I, 1996, AM J PHYSIOL-RENAL, V270, pF1027, DOI 10.1152/ajprenal.1996.270.6.F1027; SKOTT O, 1987, SCIENCE, V237, P1618, DOI 10.1126/science.3306925; STOOS BA, 1991, KIDNEY INT, V39, P1168, DOI 10.1038/ki.1991.148; Traynor TR, 1999, AM J PHYSIOL-RENAL, V277, pF706, DOI 10.1152/ajprenal.1999.277.5.F706; VANDER AJ, 1967, PHYSIOL REV, V47, P359, DOI 10.1152/physrev.1967.47.3.359; Wang J.-L., 1999, Journal of the American Society of Nephrology, V10, p464A; Wang JL, 1999, HYPERTENSION, V34, P96, DOI 10.1161/01.HYP.34.1.96; WILCOX CS, 1992, P NATL ACAD SCI USA, V89, P11993, DOI 10.1073/pnas.89.24.11993; Xia P, 1998, BIOPHYS J, V74, P3302, DOI 10.1016/S0006-3495(98)78037-3; Xu JZ, 1997, AM J PHYSIOL-RENAL, V273, pF739, DOI 10.1152/ajprenal.1997.273.5.F739; Yang TX, 2000, J BIOL CHEM, V275, P23281, DOI 10.1074/jbc.M910237199; Yang TX, 1999, AM J PHYSIOL-RENAL, V277, pF1, DOI 10.1152/ajprenal.1999.277.1.F1; Yang TX, 1998, AM J PHYSIOL-RENAL, V274, pF481, DOI 10.1152/ajprenal.1998.274.3.F481	46	125	129	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37922	37929		10.1074/jbc.M006218200	http://dx.doi.org/10.1074/jbc.M006218200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10982805	hybrid			2022-12-25	WOS:000165618700083
J	Chen, FS; Yang, DS; Petanceska, S; Yang, A; Tandon, A; Yu, G; Rozmahel, R; Ghiso, J; Nishimura, M; Zhang, DM; Kawara, T; Levesque, G; Mills, J; Levesque, L; Song, YQ; Rogaeva, E; Westaway, D; Mount, H; Gandy, S; St George-Hyslop, P; Fraser, PE				Chen, FS; Yang, DS; Petanceska, S; Yang, A; Tandon, A; Yu, G; Rozmahel, R; Ghiso, J; Nishimura, M; Zhang, DM; Kawara, T; Levesque, G; Mills, J; Levesque, L; Song, YQ; Rogaeva, E; Westaway, D; Mount, H; Gandy, S; St George-Hyslop, P; Fraser, PE			Carboxyl-terminal fragments of Alzheimer beta-amyloid precursor protein accumulate in restricted and unpredicted intracellular compartments in presenilin 1-deficient cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; ENDOPLASMIC-RETICULUM; SECRETASE CLEAVAGE; MUTANT PRESENILIN-1; MISSENSE MUTATIONS; PEPTIDE VARIANTS; PRE-GOLGI; DISEASE; MEMBRANE; PHOSPHORYLATION	Absence of functional presenilin 1 (PS1) protein leads to loss of gamma -secretase cleavage of the amyloid precursor protein (beta APP), resulting in a dramatic reduction in amyloid beta peptide (A beta) production and accumulation of alpha- or beta -secretase-cleaved COOH-terminal fragments of PAPP (alpha- or beta -CTFs). The major COOH-terminal fragment (CTF) in brain was identified as PAPP-CTF-(11-98), which is consistent with the observation that cultured neurons generate primarily A beta-(11-40). In PS1(-/-) murine neurons and fibroblasts expressing the loss-of-function PS1(D385A) mutant, CTFs accumulated in the endoplasmic reticulum, Golgi, and lysosomes, but not late endosomes. There were some subtle differences in the subcellular distribution of CTFs in PS1(-/-) neurons as compared with PS1(D385A) mutant fibroblasts. However, there was no obvious redistribution of full-length beta APP or of markers of other organelles in either mutant. Blockade of endoplasmic reticulum-to-Golgi trafficking indicated that in PS1-/- neurons las in normal cells) trafficking of beta APP to the Golgi compartment is necessary before alpha- and beta -secretase cleavages occur. Thus, although we cannot exclude a specific role for PS1 in trafficking of CTFs, these data argue against a major role in general protein trafficking. These results are more compatible with a role for PS1 either as the actual gamma -secretase catalytic activity or in other functions indirectly related to gamma -secretase catalysis (e,g. an activator of gamma -secretase, a substrate adaptor for gamma -secretase, or delivery of gamma -secretase to beta APP-containing compartments).	Univ Toronto, Ctr Res Neurodegenerat Dis, Dept Lab Med & Pathobiol, Toronto, ON M5S 3H2, Canada; Univ Toronto, Ctr Res Neurodegenerat Dis, Dept Med Biophys, Toronto, ON M5S 3H2, Canada; Univ Toronto, Ctr Res Neurodegenerat Dis, Dept Med, Toronto, ON M5S 3H2, Canada; Toronto Hosp, Dept Med Neurol, Toronto, ON M5S 3H2, Canada; NYU, Sch Med, Nathan S Kline Inst Psychiat Res, Dept Psychiat, Orangeburg, NY 10962 USA; NYU, Sch Med, Nathan S Kline Inst Psychiat Res, Dept Pathol, Orangeburg, NY 10962 USA; Hosp Sick Children, Res Inst, Dept Pharmacol, Toronto, ON M5S 3H2, Canada; Hosp Sick Children, Res Inst, Dept Genet, Toronto, ON M5S 3H2, Canada; Hosp Sick Children, Dept Genet, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON M5S 3H2, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Nathan Kline Institute for Psychiatric Research; New York University; Nathan Kline Institute for Psychiatric Research; New York University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	St George-Hyslop, P (corresponding author), Univ Toronto, Ctr Res Neurodegenerat Dis, Dept Lab Med & Pathobiol, 6 Queens Pk Crescent W, Toronto, ON M5S 3H2, Canada.	p.hyslop@utoronto.ca	Song, You-qiang/C-4401-2009; Song, You-Qiang/E-5207-2011; Mount, Howard/B-4097-2013	Song, You-Qiang/0000-0001-9407-2256	Canadian Institutes of Health Research [37920] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Barelli HL, 1997, MOL MED, V3, P695, DOI 10.1007/BF03401708; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; Buxbaum JD, 1998, J NEUROSCI, V18, P9629; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; CAPORASO GL, 1994, J NEUROSCI, V14, P3122; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; GARDELLA JE, 1993, BIOCHEM J, V294, P667, DOI 10.1042/bj2940667; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Gouras GK, 1998, J NEUROCHEM, V71, P1920; Greenfield JP, 1999, P NATL ACAD SCI USA, V96, P742, DOI 10.1073/pnas.96.2.742; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; HILBICH C, 1992, J MOL BIOL, V228, P460, DOI 10.1016/0022-2836(92)90835-8; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; Iijima K, 2000, J NEUROCHEM, V75, P1085, DOI 10.1046/j.1471-4159.2000.0751085.x; Ikezu T, 1998, J BIOL CHEM, V273, P10485, DOI 10.1074/jbc.273.17.10485; JIN MJ, 1993, J BIOL CHEM, V268, P18390; KOO EH, 1994, J BIOL CHEM, V269, P17386; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; Levesque G, 1999, J NEUROCHEM, V72, P999, DOI 10.1046/j.1471-4159.1999.0720999.x; Levesque L, 1999, MOL MED, V5, P542, DOI 10.1007/BF03401981; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; Lupashin VV, 1996, J CELL BIOL, V132, P277, DOI 10.1083/jcb.132.3.277; Majoul IV, 1996, J CELL BIOL, V133, P777, DOI 10.1083/jcb.133.4.777; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; NASLUND J, 1994, P NATL ACAD SCI USA, V91, P8378, DOI 10.1073/pnas.91.18.8378; Nishimura M, 1999, NAT MED, V5, P164, DOI 10.1038/5526; NORDSTEDT C, 1993, J BIOL CHEM, V268, P608; Oishi M, 1997, MOL MED, V3, P111, DOI 10.1007/BF03401803; Parkin ET, 1997, J NEUROCHEM, V69, P2179; Peraus GC, 1997, J NEUROSCI, V17, P7714; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Petanceska SS, 2000, J NEUROCHEM, V74, P1878, DOI 10.1046/j.1471-4159.2000.0741878.x; PIKE CJ, 1995, J BIOL CHEM, V270, P23895, DOI 10.1074/jbc.270.41.23895; REFOLO LM, 1995, J NEUROSCI RES, V40, P694, DOI 10.1002/jnr.490400515; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; SAMBAMURTI K, 1992, J NEUROSCI RES, V33, P319, DOI 10.1002/jnr.490330216; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; Sciaky N, 1997, J CELL BIOL, V139, P1137, DOI 10.1083/jcb.139.5.1137; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; Stan RV, 1997, MOL BIOL CELL, V8, P595, DOI 10.1091/mbc.8.4.595; Storrie B, 1998, BBA-MOL CELL RES, V1404, P127, DOI 10.1016/S0167-4889(98)00053-6; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; SUZUKI T, 1994, EMBO J, V13, P1114, DOI 10.1002/j.1460-2075.1994.tb06360.x; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Thyberg J, 1999, EXP CELL RES, V246, P263, DOI 10.1006/excr.1998.4326; Tjelle TE, 1996, J CELL SCI, V109, P2905; Tjernberg LO, 1997, J BIOL CHEM, V272, P1870, DOI 10.1074/jbc.272.3.1870; Tomita S, 1998, J BIOL CHEM, V273, P6277, DOI 10.1074/jbc.273.11.6277; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; WATT CB, 1985, J NEUROSCI, V5, P857; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Xia WM, 1998, BIOCHEMISTRY-US, V37, P16465, DOI 10.1021/bi9816195; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yu G, 2000, J BIOL CHEM, V275, P27348; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	75	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36794	36802		10.1074/jbc.M006986200	http://dx.doi.org/10.1074/jbc.M006986200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10962005	hybrid			2022-12-25	WOS:000165577700051
J	De Gois, S; Houhou, L; Oda, Y; Corbex, M; Pajak, F; Thevenot, E; Vodjdani, G; Mallet, J; Berrard, S				De Gois, S; Houhou, L; Oda, Y; Corbex, M; Pajak, F; Thevenot, E; Vodjdani, G; Mallet, J; Berrard, S			Is RE1/NRSE a common cis-regulatory sequence for ChAT and VAChT genes?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR ACETYLCHOLINE TRANSPORTER; CHOLINE-ACETYLTRANSFERASE GENE; RESTRICTIVE SILENCER ELEMENT; NEURON-SPECIFIC EXPRESSION; SODIUM-CHANNEL GENE; TISSUE-SPECIFIC EXPRESSION; CELL-ADHESION MOLECULE; ZINC-FINGER PROTEIN; TRANSCRIPTIONAL REPRESSION; HISTONE DEACETYLASE	Choline acetyltransferase (ChAT), the biosynthetic enzyme of acetylcholine, and the vesicular acetylcholine transporter (VAChT) are both required for cholinergic neurotransmission. These proteins are encoded by two embedded genes, the VAChT gene lying within the first intron of the ChAT gene. In the nervous system, both ChAT and VAChT are synthesized only in cholinergic neurons, and it is therefore likely that the cell type-specific expression of their genes is coordinately regulated. It has been suggested that a. 2336-base pair genomic region upstream from the ChAT and VAChT coding sequences drives ChAT gene expression in cholinergic structures. We investigated whether this region also regulates VAChT gene transcription. Transfection assays showed that this region strongly represses the activity of the native VAChT promoters in non-neuronal cells, but has no major effect in neuronal cells whether or not they express the endogenous ChAT and VAChT genes. The silencer activity of this region is mediated solely by a repressor element 1 or neuron-restrictive silencer element (RE1/NRSE). Moreover, several proteins, including RE1-silencing transcription factor or neuron-restrictive silencer factor, are recruited by this regulatory sequence. These data suggest that this upstream region and RE1/NRSE co-regulate the expression of the ChAT and VAChT genes.	Hop La Pitie Salpetriere, CNRS, UMRC 9935, Lab Genet Mol Neurotransmiss & Proc, F-75013 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Mallet, J (corresponding author), Hop La Pitie Salpetriere, CNRS, UMRC 9935, Lab Genet Mol Neurotransmiss & Proc, Batiment CERVI,83 Blvd Hop, F-75013 Paris, France.	mallet@infobiogen.fr	VODJDANI, Guilan/GSN-1174-2022	CORBEX, Marilys/0000-0001-5755-7326; Thevenot, Etienne A./0000-0003-1019-4577				ALFONSO A, 1994, J MOL BIOL, V241, P627, DOI 10.1006/jmbi.1994.1538; Arvidsson U, 1997, J COMP NEUROL, V378, P454; BEJANIN S, 1992, J NEUROCHEM, V58, P1580, DOI 10.1111/j.1471-4159.1992.tb11383.x; BEJANIN S, 1994, J BIOL CHEM, V269, P21944; BERRARD S, 1995, J NEUROCHEM, V65, P939; Berse B, 1997, FEBS LETT, V410, P175, DOI 10.1016/S0014-5793(97)00568-1; BERSE B, 1995, J BIOL CHEM, V270, P22101, DOI 10.1074/jbc.270.38.22101; Bessis A, 1997, P NATL ACAD SCI USA, V94, P5906, DOI 10.1073/pnas.94.11.5906; BOULARAND S, 1995, J BIOL CHEM, V270, P3757, DOI 10.1074/jbc.270.8.3757; CERVINI R, 1995, J BIOL CHEM, V270, P24654, DOI 10.1074/jbc.270.42.24654; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; ERICKSON JD, 1994, J BIOL CHEM, V269, P21929; HIGASHIDA H, 1991, ANN NY ACAD SCI, V635, P153, DOI 10.1111/j.1749-6632.1991.tb36489.x; Huang YF, 1999, NAT NEUROSCI, V2, P867, DOI 10.1038/13165; IBANEZ CF, 1991, EUR J NEUROSCI, V3, P1309, DOI 10.1111/j.1460-9568.1991.tb00063.x; Ichikawa T, 1997, J CHEM NEUROANAT, V13, P23, DOI 10.1016/S0891-0618(97)00021-5; Kallunki P, 1998, P NATL ACAD SCI USA, V95, P3233, DOI 10.1073/pnas.95.6.3233; Kallunki P, 1997, J CELL BIOL, V138, P1343, DOI 10.1083/jcb.138.6.1343; Kaufer D, 1998, NATURE, V393, P373, DOI 10.1038/30741; KENGAKU M, 1993, MOL BRAIN RES, V18, P71, DOI 10.1016/0169-328X(93)90174-N; Kitamoto T, 1998, J BIOL CHEM, V273, P2706, DOI 10.1074/jbc.273.5.2706; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; Leichter M, 1999, EUR J NEUROSCI, V11, P1937, DOI 10.1046/j.1460-9568.1999.00617.x; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; LI YP, 1993, J NEUROCHEM, V61, P748; LI YP, 1995, MOL BRAIN RES, V30, P106, DOI 10.1016/0169-328X(94)00285-M; LONNERBERG P, 1995, P NATL ACAD SCI USA, V92, P4046, DOI 10.1073/pnas.92.9.4046; Lonnerberg P, 1996, J BIOL CHEM, V271, P33358, DOI 10.1074/jbc.271.52.33358; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; Millecamps S, 1999, NAT BIOTECHNOL, V17, P865, DOI 10.1038/12849; MISAWA H, 1993, J NEUROCHEM, V60, P1383, DOI 10.1111/j.1471-4159.1993.tb03299.x; MISAWA H, 1992, J BIOL CHEM, V267, P20392; MISAWA H, 1995, NEUROREPORT, V6, P965, DOI 10.1097/00001756-199505090-00004; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; Naciff JM, 1999, J NEUROCHEM, V72, P17, DOI 10.1046/j.1471-4159.1999.0720017.x; Naciff JM, 1997, NEUROREPORT, V8, P3467, DOI 10.1097/00001756-199711100-00011; Naruse Y, 1999, P NATL ACAD SCI USA, V96, P13691, DOI 10.1073/pnas.96.24.13691; Oosawa H, 1999, J NEUROSCI RES, V57, P381, DOI 10.1002/(SICI)1097-4547(19990801)57:3<381::AID-JNR10>3.3.CO;2-3; Palm K, 1998, J NEUROSCI, V18, P1280; PATHAK BG, 1994, NUCLEIC ACIDS RES, V22, P4748, DOI 10.1093/nar/22.22.4748; PU HF, 1993, MOL CELL NEUROSCI, V4, P131, DOI 10.1006/mcne.1993.1017; RAND JB, 1984, GENETICS, V106, P227; SCHAFER MKH, 1994, J MOL NEUROSCI, V5, P1, DOI 10.1007/BF02736691; Schafer MKH, 1995, J MOL NEUROSCI, V6, P225, DOI 10.1007/BF02736782; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; Scholl T, 1996, J IMMUNOL, V156, P1448; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shimojo M, 1998, J NEUROCHEM, V71, P1118; Tanaka H, 1998, J NEUROCHEM, V70, P1799; TapiaRamirez J, 1997, P NATL ACAD SCI USA, V94, P1177, DOI 10.1073/pnas.94.4.1177; Thiel G, 1998, J BIOL CHEM, V273, P26891, DOI 10.1074/jbc.273.41.26891; Tian XT, 1996, NEUROSCI LETT, V209, P134, DOI 10.1016/0304-3940(96)12629-X; Timmusk T, 1999, J BIOL CHEM, V274, P1078	54	16	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36683	36690		10.1074/jbc.M006895200	http://dx.doi.org/10.1074/jbc.M006895200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10973977	Green Published, hybrid			2022-12-25	WOS:000165577700034
J	Chen, J; Mitcheson, JS; Lin, M; Sanguinetti, MC				Chen, J; Mitcheson, JS; Lin, M; Sanguinetti, MC			Functional roles of charged residues in the putative voltage sensor of the HCN2 pacemaker channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHAKER K+ CHANNEL; POTASSIUM CHANNEL; XENOPUS-OOCYTES; ELECTROSTATIC INTERACTIONS; TRANSMEMBRANE SEGMENTS; SENSING RESIDUES; CATION CHANNELS; FAMILY; IDENTIFICATION; EXPRESSION	Hyperpolarization-activated, cyclic nucleotide-gated (HCN) channels contribute to pacemaking activity in specialized neurons and cardiac myocytes, HCN channels have a structure similar to voltage-gated K+ channels but have a much larger putative S4 transmembrane domain and open in response to membrane hyperpolarization instead of depolarization. As an initial attempt to define the structural basis of HCN channel gating, we have characterized the functional roles of the charged residues in the S2, S3, and S4 transmembrane domains. The nine basic residues and a single Ser in S4 were mutated individually to Gin, and the function of mutant channels was analyzed in Xenopus oocytes using two-microelectrode voltage clamp techniques, Surface membrane expression of hemagglutinin-epitope-tagged channel proteins was examined by chemiluminescence. Our results suggest that 1) Lys-291, Arg-294, Arg-297, and Arg-300 contribute to the voltage dependence of gating but not to channel folding or trafficking to the surface membrane; 2) Lys-303 and Ser-306 are essential for gating, but not for channel folding/trafficking; 3) Arg-312 is important for folding but not gating; and 4) Arg-309, Arg-315, and Arg-318 are crucial for normal protein folding/trafficking and may charge-pair with Asp residues located in the S2 and S3 domains.	Univ Utah, Eccles Inst Human Genet, Dept Med, Div Cardiol, Salt Lake City, UT 84112 USA; Univ Utah, Eccles Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Sanguinetti, MC (corresponding author), Univ Utah, Eccles Inst Human Genet, Dept Med, Div Cardiol, 15 N 2030 E,Rm 4220, Salt Lake City, UT 84112 USA.		Sanguinetti, Michael/AAN-2615-2020	Mitcheson, John/0000-0002-2683-2839	NHLBI NIH HHS [HL65299] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065299] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; Biel M, 1999, REV PHYSIOL BIOCH P, V136, P165, DOI 10.1007/BFb0032324; Cha A, 1999, NATURE, V402, P809, DOI 10.1038/45552; Clapham DE, 1998, NEURON, V21, P5, DOI 10.1016/S0896-6273(00)80508-5; DIFRANCESCO D, 1993, ANNU REV PHYSIOL, V55, P455, DOI 10.1146/annurev.physiol.55.1.455; Gauss R, 1998, NATURE, V393, P583, DOI 10.1038/31248; Glauner KS, 1999, NATURE, V402, P813, DOI 10.1038/45561; GOLDIN AL, 1991, METHOD CELL BIOL, V36, P487; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P279; Li-Smerin YY, 2000, J GEN PHYSIOL, V115, P33, DOI 10.1085/jgp.115.1.33; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Marten I, 1998, BIOPHYS J, V74, P2953, DOI 10.1016/S0006-3495(98)78002-6; Marten I, 1997, P NATL ACAD SCI USA, V94, P3448, DOI 10.1073/pnas.94.7.3448; Miller AG, 1996, NEURON, V16, P853, DOI 10.1016/S0896-6273(00)80105-1; Mitcheson JS, 2000, J GEN PHYSIOL, V115, P229, DOI 10.1085/jgp.115.3.229; PAPAZIAN DM, 1995, NEURON, V14, P1293, DOI 10.1016/0896-6273(95)90276-7; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PLANELLSCASES R, 1995, P NATL ACAD SCI USA, V92, P9422, DOI 10.1073/pnas.92.20.9422; Sanguinetti MC, 1999, J PHYSIOL-LONDON, V514, P667, DOI 10.1111/j.1469-7793.1999.667ad.x; Santoro B, 1999, ANN NY ACAD SCI, V868, P741, DOI 10.1111/j.1749-6632.1999.tb11353.x; Santoro B, 1998, CELL, V93, P717, DOI 10.1016/S0092-8674(00)81434-8; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Seoh SA, 1996, NEURON, V16, P1159, DOI 10.1016/S0896-6273(00)80142-7; SIGWORTH FJ, 1993, Q REV BIOPHYS, V27, P1; STUHMER W, 1992, METHOD ENZYMOL, V207, P319; Tiwari-Woodruff SK, 2000, J GEN PHYSIOL, V115, P123, DOI 10.1085/jgp.115.2.123; TiwariWoodruff SK, 1997, BIOPHYS J, V72, P1489, DOI 10.1016/S0006-3495(97)78797-6; Zei PC, 1998, J GEN PHYSIOL, V112, P679, DOI 10.1085/jgp.112.6.679; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	31	62	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36465	36471		10.1074/jbc.M007034200	http://dx.doi.org/10.1074/jbc.M007034200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10962006	hybrid			2022-12-25	WOS:000165382000114
J	Morelli, S; Buitrago, C; Vazquez, G; De Boland, AR; Boland, R				Morelli, S; Buitrago, C; Vazquez, G; De Boland, AR; Boland, R			Involvement of tyrosine kinase activity in 1 alpha,25(OH)(2)-vitamin D-3 signal transduction in skeletal muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; VITAMIN-D; C-ALPHA; PHOSPHOLIPASE-C; CALCIUM FLUXES; HERBIMYCIN-A; CA2+ INFLUX; PHOSPHORYLATION; D-3; STIMULATION	In cultured chick skeletal muscle cells loaded with Fura-a, the tyrosine kinase inhibitors herbimycin A and genistein abolished both the fast inositol 1,4,5-trisphosphatedependent Ca2+ release from internal stores and extracellular Ca2+ influx induced by 1 alpha ,25(OH)(2)-vitamin D-3 (1 alpha ,25(OH)(2)D-3). Daidzein, an inactive analog of genistein, was without effects. Tyrosine phosphatase inhibition by orthovanadate increased cytosolic Ca2+. Antiphosphotyrosine immunoblot analysis revealed that 1 alpha ,2S(OH)(2)D-3 rapidly (0.5-10 min) stimulates in a concentrationdependent fashion (0.1-10 nM) tyrosine phosphorylation of several myoblast proteins, among which the major targets of the hormone could be immunochemically identified as phospholipase C gamma (127 kDa), which mediates intracellular store Ca2+ mobilization and external Ca2+ influx, and the growth-related proteins mitogen-activated protein (MAP) kinase (42/44 kDa) and c-myc (65 kDa), Genistein suppressed the increase in phosphorylation and concomitant elevation of MAPK activity elicited by the sterol, Both genistein and the MAPK kinase (MEK) inhibitor PD98059 abolished stimulation of DNA synthesis by 1 alpha ,25(OH)(2)D-3. The sterol-induced increase in tyrosine phosphorylation of c-myc, a finding not reported before for cell growth regulators, was totally suppressed by the specific Src inhibitor PP1, These results demonstrate that tyrosine phosphorylation is a previously unrecognized mechanism involved in 1 alpha ,25(OH)(2)D-3 regulation of Ca2+ homeostasis in hormone target cells. In addition, the data involve tyrosine kinase cascades in the mitogenic effects of 1 alpha ,25(OH)(2)D-3 on skeletal muscle cells.	Univ Nacl Sur, Dept Biol Bioquim & Farm, RA-8000 Bahia Blanca, Buenos Aires, Argentina	National University of the South	Boland, R (corresponding author), Univ Nacl Sur, Dept Biol Bioquim & Farm, San Juan 670, RA-8000 Bahia Blanca, Buenos Aires, Argentina.	rboland@criba.edu.ar						AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BELLIDO T, 1993, MOL CELL ENDOCRINOL, V90, P231, DOI 10.1016/0303-7207(93)90156-E; BERRIDGE MJ, 1995, BIOESSAYS, V17, P491, DOI 10.1002/bies.950170605; BERS D, 1996, METHOD CELL BIOL, P21; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLUMER KJ, 1994, P NATL ACAD SCI USA, V91, P4925, DOI 10.1073/pnas.91.11.4925; BOLAND R, 1995, MOL CELL ENDOCRINOL, V114, P1, DOI 10.1016/0303-7207(95)03650-V; BOLAND R, 1986, ENDOCR REV, V7, P434, DOI 10.1210/edrv-7-4-434; BOLAND R, 1997, VITAMIN D CHEM BIOL, P361; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Buitrago C, 2000, J CELL BIOCHEM, V79, P274, DOI 10.1002/1097-4644(20001101)79:2<274::AID-JCB100>3.0.CO;2-R; Capiati DA, 1999, MOL CELL ENDOCRINOL, V153, P39, DOI 10.1016/S0303-7207(99)00093-3; Capiati DA, 1999, J CELL BIOCHEM, V74, P292, DOI 10.1002/(SICI)1097-4644(19990801)74:2<292::AID-JCB13>3.0.CO;2-M; Cataldi M, 1996, J BIOL CHEM, V271, P9441, DOI 10.1074/jbc.271.16.9441; Dang CV, 1999, MOL CELL BIOL, V19, P1; de Boland AR, 1998, J CELL BIOCHEM, V69, P470, DOI 10.1002/(SICI)1097-4644(19980615)69:4<470::AID-JCB8>3.0.CO;2-K; DEBOLAND AR, 1994, CELL SIGNAL, V6, P717, DOI 10.1016/0898-6568(94)00042-5; DEBOLAND AR, 1994, J BIOL CHEM, V269, P8675; DEBOLAND AR, 1995, BBA-LIPID LIPID MET, V1257, P274, DOI 10.1016/0005-2760(95)00083-O; DEBOLAND AR, 1998, 1 INT M RAP RESP STE, P90; DELUCA HF, 1988, FASEB J, V2, P224, DOI 10.1096/fasebj.2.3.3280376; DISALVO J, 1988, BIOCHEM BIOPH RES CO, V153, P388, DOI 10.1016/S0006-291X(88)81236-1; DRITTANTI L, 1989, BIOCHIM BIOPHYS ACTA, V1014, P112, DOI 10.1016/0167-4889(89)90022-0; EKBOM K, 1964, ACTA MED SCAND, V176, P493; FUKAZAWA H, 1991, BIOCHEM PHARMACOL, V42, P1661; GIULIANI DL, 1984, CALCIFIED TISSUE INT, V36, P200, DOI 10.1007/BF02405318; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hatakeyama N, 1996, AM J PHYSIOL-CELL PH, V270, pC1780, DOI 10.1152/ajpcell.1996.270.6.C1780; HAUSSLER MR, 1986, ANNU REV NUTR, V6, P527, DOI 10.1146/annurev.nu.06.070186.002523; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Hunter T, 1998, PHILOS T R SOC B, V353, P583, DOI 10.1098/rstb.1998.0228; Katsube Y, 1998, EUR J PHARMACOL, V345, P309, DOI 10.1016/S0014-2999(98)00010-7; Khare S, 1997, J CLIN INVEST, V99, P1831, DOI 10.1172/JCI119350; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE KM, 1993, J BIOL CHEM, V268, P9945; LIAO F, 1993, BIOCHEM BIOPH RES CO, V191, P1028, DOI 10.1006/bbrc.1993.1320; LIEBERHERR M, 1989, J BIOL CHEM, V264, P20403; Liu HY, 1997, CAN J PHYSIOL PHARM, V75, P1063, DOI 10.1139/cjpp-75-9-1063; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANOLAGAS SC, 1990, KIDNEY INT, V38, pS9; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; MINGHETTI PP, 1988, FASEB J, V2, P3043, DOI 10.1096/fasebj.2.15.2847948; MORELLI S, 1993, BIOCHEM J, V289, P675, DOI 10.1042/bj2890675; Morelli S, 1996, MOL CELL ENDOCRINOL, V122, P207, DOI 10.1016/0303-7207(96)03886-5; Morelli S, 1999, J BONE MINER RES, V14, pS423; Neary JT, 1997, NEWS PHYSIOL SCI, V12, P286; Nemere I, 1998, BIOCHEM BIOPH RES CO, V248, P443, DOI 10.1006/bbrc.1998.8492; NORMAN AW, 1982, ENDOCR REV, V3, P331, DOI 10.1210/edrv-3-4-331; NORMAN AW, 1992, J STEROID BIOCHEM, V41, P231, DOI 10.1016/0960-0760(92)90349-N; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; REICHEL H, 1989, ANNU REV MED, V40, P71; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; SARGEANT P, 1993, J BIOL CHEM, V268, P18151; Selbie LA, 1998, TRENDS PHARMACOL SCI, V19, P87, DOI 10.1016/S0165-6147(97)01166-8; SETH A, 1991, J BIOL CHEM, V266, P23521; Sharma NR, 1996, AM J PHYSIOL-HEART C, V270, pH267, DOI 10.1152/ajpheart.1996.270.1.H267; SMITH R, 1969, J NEUROL SCI, V8, P511, DOI 10.1016/0022-510X(69)90010-0; SMITH R, 1967, BRAIN, V90, P593, DOI 10.1093/brain/90.3.593; Snedecor G.W., 1967, STAT METHODS; Song XD, 1998, ENDOCRINOLOGY, V139, P457, DOI 10.1210/en.139.2.457; Takahashi R, 1997, JPN CIRC J, V61, P1030, DOI 10.1253/jcj.61.1030; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; VAZQUEZ G, 1993, BIOCHEM MOL BIOL INT, V31, P677; Vazquez G, 1997, BIOCHEM BIOPH RES CO, V234, P125, DOI 10.1006/bbrc.1997.6590; Vazquez G, 1996, BBA-MOL CELL RES, V1310, P157, DOI 10.1016/0167-4889(95)00158-1; Vazquez G, 1998, J BIOL CHEM, V273, P33954, DOI 10.1074/jbc.273.51.33954; Vazquez G, 1997, BIOCHEM BIOPH RES CO, V239, P562, DOI 10.1006/bbrc.1997.7501; WALTERS MR, 1992, ENDOCR REV, V13, P719, DOI 10.1210/er.13.4.719; Wehling M, 1997, ANNU REV PHYSIOL, V59, P365, DOI 10.1146/annurev.physiol.59.1.365	74	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					36021	36028		10.1074/jbc.M002025200	http://dx.doi.org/10.1074/jbc.M002025200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10964910	hybrid			2022-12-25	WOS:000165382000054
J	Routledge, EJ; White, R; Parker, MG; Sumpter, JP				Routledge, EJ; White, R; Parker, MG; Sumpter, JP			Differential effects of xenoestrogens on coactivator recruitment by estrogen receptor (ER) alpha and ER beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION FUNCTIONS; NUCLEAR HORMONE-RECEPTOR; RAT PITUITARY; MESSENGER-RNA; BINDING; LIGAND; PHYTOESTROGENS; IDENTIFICATION; ANTIESTROGENS; HETERODIMERS	It has been proposed that tissue-specific estrogenic and/or antiestrogenic actions of certain xenoestrogens may be associated with alterations in the tertiary structure of estrogen receptor (ER) alpha and/or ER beta following ligand binding; changes which are sensed by cellular factors (coactivators) required for normal gene expression. However, it is still unclear whether xenoestrogens affect the normal behavior of ER alpha and/or ER beta subsequent to receptor binding. In view of the wide range of structural forms now recognized to mimic the actions of the natural estrogens, we have assessed the ability of ER alpha and ER beta to recruit TIF2 and SRC-1a in the presence of 17 beta -estradiol, genistein, diethylstilbestrol, 4-tert-oc-tylphenol, 2',3',4',5' -tetrachlorobiphenyl-1, and bisphenol A. We show that ligand-dependent differences exist in the ability of ER alpha and ER beta to bind coactivator proteins in vitro, despite the similarity in binding affinity of the various ligands for both ER subtypes, The enhanced ability of ER beta (over ER alpha) to recruit coactivators in the presence of xenoestrogens was consistent with a greater ability of ERP to potentiate reporter gene activity in transiently transfected HeLa cells expressing SRC-1e and TIFS. We conclude that ligand-dependent differences in the ability of ER alpha and ER beta to recruit coactivator proteins may contribute to the complex tissue-dependent agonistic/antagonistic responses observed with certain xenoestrogens.	Brunel Univ, Dept Biol Sci, Uxbridge UB8 3PH, Middx, England; Imperial Canc Res Fund, Mol Endocrinol Lab, London WC2A 3PX, England	Brunel University; Cancer Research UK; University of London; Queen Mary University London	Routledge, EJ (corresponding author), Brunel Univ, Dept Biol Sci, Uxbridge UB8 3PH, Middx, England.	edwin.routledge@brunel.ac.uk	sumpter, john/HGB-7584-2022; Routledge, Edwin John/V-2336-2019; Routledge, Edwin/AGI-0283-2022	Routledge, Edwin/0000-0001-7695-364X				ADLERCREUTZ H, 1993, LANCET, V342, P1209, DOI 10.1016/0140-6736(93)92188-Y; ADLERCREUTZ H, 1995, ENVIRON HEALTH PERSP, V103, P103, DOI 10.2307/3432518; BROUWER A, 1995, EUR J PHARM-ENVIRON, V293, P1; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Collins BM, 1997, STEROIDS, V62, P365, DOI 10.1016/S0039-128X(96)00246-2; Connor K, 1997, TOXICOL APPL PHARM, V145, P111, DOI 10.1006/taap.1997.8169; Cowley SM, 1999, J STEROID BIOCHEM, V69, P165, DOI 10.1016/S0960-0760(99)00055-2; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; JANSEN HT, 1993, REPROD TOXICOL, V7, P237, DOI 10.1016/0890-6238(93)90230-5; JOBLING S, 1995, ENVIRON HEALTH PERSP, V103, P582, DOI 10.2307/3432434; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KALDAS RS, 1989, REPROD TOXICOL, V3, P81, DOI 10.1016/0890-6238(89)90042-7; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Klinge CM, 1996, STEROIDS, V61, P278, DOI 10.1016/0039-128X(95)00219-G; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Le Bail JC, 1998, CANCER LETT, V130, P209, DOI 10.1016/S0304-3835(98)00141-4; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; MADHABANANDA S, 1999, ENDOCRINOLOGY, V140, P963; McInerney EM, 1996, P NATL ACAD SCI USA, V93, P10069, DOI 10.1073/pnas.93.19.10069; METZGER D, 1992, NUCLEIC ACIDS RES, V20, P2813, DOI 10.1093/nar/20.11.2813; MIKSICEK RJ, 1993, MOL PHARMACOL, V44, P37; Mitchner NA, 1998, ENDOCRINOLOGY, V139, P3976, DOI 10.1210/en.139.9.3976; Nishikawa J, 1999, TOXICOL APPL PHARM, V154, P76, DOI 10.1006/taap.1998.8557; ONATE SA, 1995, SCIENCE, V270, P1354; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; Pennie WD, 1998, J ENDOCRINOL, V158, pR11, DOI 10.1677/joe.0.158R011; Pettersson K, 1997, MOL ENDOCRINOL, V11, P1486, DOI 10.1210/me.11.10.1486; RUH MF, 1995, BIOCHEM PHARMACOL, V50, P1485, DOI 10.1016/0006-2952(95)02061-6; SEIELSTAD DA, 1995, BIOCHEMISTRY-US, V34, P12605, DOI 10.1021/bi00039a016; Shughrue PJ, 1996, STEROIDS, V61, P678, DOI 10.1016/S0039-128X(96)00222-X; Shughure PJ, 1998, STEROIDS, V63, P498, DOI 10.1016/S0039-128X(98)00054-3; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; Sun J, 1999, ENDOCRINOLOGY, V140, P800, DOI 10.1210/en.140.2.800; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; VONBAUR E, 1996, EMBO J, V15, P110	49	271	278	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35986	35993		10.1074/jbc.M006777200	http://dx.doi.org/10.1074/jbc.M006777200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10964929	hybrid			2022-12-25	WOS:000165382000049
J	Uchiumi, T; Nomura, T; Shimizu, T; Katakai, Y; Mita, K; Koike, Y; Nakagaki, M; Taira, H; Hachimori, A				Uchiumi, T; Nomura, T; Shimizu, T; Katakai, Y; Mita, K; Koike, Y; Nakagaki, M; Taira, H; Hachimori, A			A covariant change of the two highly conserved bases in the GTPase-associated center of 28 S rRNA in silkworms and other moths	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							23-S RIBOSOMAL-RNA; FACTOR EF-G; ESCHERICHIA-COLI; FACTOR-II; THIOSTREPTON; BINDING; SITE; PROTEINS; AUTOANTIBODY; COMPLEX		Shinshu Univ, Fac Text Sci & Technol, Inst High Polymer Res, Ueda, Nagano 3868567, Japan; Shinshu Univ, Fac Text Sci & Technol, Dept Appl Biol Sci, Ueda, Nagano 3868567, Japan; Natl Inst Radiol Sci, Genome Res Grp, Chiba 2638555, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Agr & Environm Biol, Tokyo 1138657, Japan; Iwate Univ, Fac Agr, Dept Biosci & Technol, Morioka, Iwate 0208550, Japan	Shinshu University; Shinshu University; National Institutes for Quantum Science & Technology; University of Tokyo; Iwate University	Uchiumi, T (corresponding author), Shinshu Univ, Fac Text Sci & Technol, Inst High Polymer Res, Ueda, Nagano 3868567, Japan.							BLOBEL G, 1971, P NATL ACAD SCI USA, V68, P390, DOI 10.1073/pnas.68.2.390; Conn GL, 1998, BIOCHEMISTRY-US, V37, P11980, DOI 10.1021/bi980825+; Conn GL, 1999, SCIENCE, V284, P1171, DOI 10.1126/science.284.5417.1171; CUNDLIFFE E, 1986, STRUCTURE FUNCTION G; EGEBJERG J, 1989, EMBO J, V8, P607, DOI 10.1002/j.1460-2075.1989.tb03415.x; ELBARADI TTAL, 1987, J MOL BIOL, V195, P909, DOI 10.1016/0022-2836(87)90494-3; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUJIWARA H, 1986, NUCLEIC ACIDS RES, V14, P6393, DOI 10.1093/nar/14.16.6393; GUTELL RR, 1993, NUCLEIC ACIDS RES, V21, P3055, DOI 10.1093/nar/21.13.3055; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Huang SG, 1996, J MOL BIOL, V258, P308, DOI 10.1006/jmbi.1996.0252; Iwasaki K, 1979, Methods Enzymol, V60, P657; KJER KM, 1994, BBA-GENE STRUCT EXPR, V1217, P147, DOI 10.1016/0167-4781(94)90028-0; MADJAR JJ, 1981, MOL GEN GENET, V182, P273, DOI 10.1007/BF00269670; MANKIN AS, 1994, J MOL BIOL, V244, P151, DOI 10.1006/jmbi.1994.1715; McKnight S L, 1976, Prog Nucleic Acid Res Mol Biol, V19, P313; MITA K, 1994, J MOL EVOL, V38, P583; MITA K, 1999, RIKEN REV, V22, P63; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; Munishkin A, 1997, P NATL ACAD SCI USA, V94, P12280, DOI 10.1073/pnas.94.23.12280; MUSTERS W, 1991, P NATL ACAD SCI USA, V88, P1469, DOI 10.1073/pnas.88.4.1469; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; Rodnina MV, 1999, P NATL ACAD SCI USA, V96, P9586, DOI 10.1073/pnas.96.17.9586; ROSENDAHL G, 1993, J MOL BIOL, V234, P1013, DOI 10.1006/jmbi.1993.1655; RYAN PC, 1991, P NATL ACAD SCI USA, V88, P6308, DOI 10.1073/pnas.88.14.6308; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT FJ, 1981, J BIOL CHEM, V256, P2301; Schnare MN, 1996, J MOL BIOL, V256, P701, DOI 10.1006/jmbi.1996.0119; TAUTZ D, 1988, MOL BIOL EVOL, V5, P366; THOMPSON J, 1982, J BIOL CHEM, V257, P7915; THOMPSON J, 1993, EMBO J, V12, P1499, DOI 10.1002/j.1460-2075.1993.tb05793.x; UCHIUMI T, 1995, J BIOL CHEM, V270, P29889; UCHIUMI T, 1990, J BIOL CHEM, V265, P89; UCHIUMI T, 1986, EUR J BIOCHEM, V156, P37, DOI 10.1111/j.1432-1033.1986.tb09545.x; UCHIUMI T, 1994, EMBO J, V13, P3389, DOI 10.1002/j.1460-2075.1994.tb06641.x; UCHIUMI T, 1992, J BIOL CHEM, V267, P19179; UCHIUMI T, 1987, P NATL ACAD SCI USA, V84, P5580, DOI 10.1073/pnas.84.16.5580; UCHIUMI T, 1991, J BIOL CHEM, V266, P2054; Uchiumi T, 1997, J BIOL CHEM, V272, P3302, DOI 10.1074/jbc.272.6.3302; Wilson KS, 1998, CELL, V92, P131, DOI 10.1016/S0092-8674(00)80905-8; Wimberly BT, 1999, CELL, V97, P491, DOI 10.1016/S0092-8674(00)80759-X; XING YY, 1995, J MOL BIOL, V249, P319, DOI 10.1006/jmbi.1995.0299	43	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35116	35121		10.1074/jbc.M004596200	http://dx.doi.org/10.1074/jbc.M004596200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10960474	hybrid			2022-12-25	WOS:000165422800040
J	Zhang, QM; Miyabe, I; Matsumoto, Y; Kino, K; Sugiyama, H; Yonei, S				Zhang, QM; Miyabe, I; Matsumoto, Y; Kino, K; Sugiyama, H; Yonei, S			Identification of repair enzymes for 5-formyluracil in DNA - Nth, Nei, and MutM proteins of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC APYRIMIDINIC SITES; BASE-EXCISION-REPAIR; ENDONUCLEASE-III NTH; IONIZING-RADIATION; FPG PROTEIN; IN-VITRO; GLYCOSYLASE ACTIVITIES; IRRADIATED DNA; DAMAGE; THYMINE	5-Formyluracil (5-foU) is a potentially mutagenic lesion of thymine produced in DNA by ionizing radiation and various chemical oxidants. Although 5-foU has been reported to be removed from DNA by Escherichia coli AlkA protein in vitro, its repair mechanisms are not fully understood. In this study, we used the borohydride trapping assay to detect and characterize repair activities for 5-foU in E. cold extracts with site-specifically designed oligonucleotides containing a 5-foU at defined sites. The trapping assay revealed that there are three kinds of proteins that form covalent complexes with the 5-foU-containing oligonucleotides. Extracts from strains defective in the nth, nei, or mutM gene lacked one of the proteins. All of the trapped complexes were completely lost in extracts from the nth nei mutM triple mutant. The introduction of a plasmid carrying the nth, nei, or mutM gene into the E. coli triple mutant restored the formation of the corresponding protein-DNA complex. Purified Nth, Nei, and MutM proteins were trapped by the 5-foU-containing oligonucleotide to form the complex in the presence of NaBH4. Furthermore, the purified Nth, Nei, and MutM proteins efficiently cleaved the oligonucleotide at the 5-foU site. In addition, 5-foU was site-specifically incorporated into plasmid pSVK3, and the resulting plasmid was replicated in E. cold. The mutation frequency of the plasmid was significantly increased in the E. coli nth nei mutM alkA mutant, compared with the wild-type and alkA strains. From these results it is concluded that the Nth, Nei, and MutM proteins are involved in the repair pathways for 5-foU that serve to avoid mutations in E. coli.	Kyoto Univ, Grad Sch Sci, Radiat Biol Lab, Sakyo Ku, Kyoto 6068502, Japan; Tokyo Med & Dent Univ, Inst Biomat & Bioengn, Chiyoda Ku, Tokyo 1010062, Japan	Kyoto University; Tokyo Medical & Dental University (TMDU)	Yonei, S (corresponding author), Kyoto Univ, Grad Sch Sci, Radiat Biol Lab, Sakyo Ku, Kyoto 6068502, Japan.	yonei@kingyo.zool.kyoto-u.ac.jp	Miyabe, Izumi/K-7536-2017; Matsumoto, Yoichiro/M-4093-2014; Sugiyama, Hiroshi/C-7687-2011	Miyabe, Izumi/0000-0002-4546-2837; Sugiyama, Hiroshi/0000-0001-8923-5946				AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; ARMEL PR, 1978, NUCLEIC ACIDS RES, V5, P3347, DOI 10.1093/nar/5.9.3347; Asagoshi K, 2000, J BIOL CHEM, V275, P4956, DOI 10.1074/jbc.275.7.4956; BAILLY V, 1989, BIOCHEM J, V262, P581, DOI 10.1042/bj2620581; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; BJELLAND S, 1995, BIOCHEMISTRY-US, V34, P14758, DOI 10.1021/bi00045a017; BJELLAND S, 1994, J BIOL CHEM, V269, P30489; Blaisdell JO, 1999, J BACTERIOL, V181, P6396, DOI 10.1128/JB.181.20.6396-6402.1999; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; BREIMER LH, 1984, J BIOL CHEM, V259, P5543; Bruner SD, 1998, CURR BIOL, V8, P393, DOI 10.1016/S0960-9822(98)70158-7; Cadet J, 1999, MUTAT RES-FUND MOL M, V424, P9, DOI 10.1016/S0027-5107(99)00004-4; CUNNINGHAM RP, 1985, P NATL ACAD SCI USA, V82, P474, DOI 10.1073/pnas.82.2.474; D'Ham C, 1999, BIOCHEMISTRY-US, V38, P3335, DOI 10.1021/bi981982b; David SS, 1998, CHEM REV, V98, P1221, DOI 10.1021/cr980321h; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; Dizdaroglu M, 2000, BIOCHEMISTRY-US, V39, P5586, DOI 10.1021/bi9927787; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; Eisen JA, 1999, MUTAT RES-DNA REPAIR, V435, P171, DOI 10.1016/S0921-8777(99)00050-6; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Fujikawa K, 1998, NUCLEIC ACIDS RES, V26, P4582, DOI 10.1093/nar/26.20.4582; HATAHET Z, 1994, J BIOL CHEM, V269, P18814; Hazra TK, 2000, J BIOL CHEM, V275, P27762; HAZRA TK, 1998, NUCLEIC ACIDS RES, V226, P5116; Hilbert TP, 1997, J BIOL CHEM, V272, P6733, DOI 10.1074/jbc.272.10.6733; IDE H, 1985, NUCLEIC ACIDS RES, V13, P8035, DOI 10.1093/nar/13.22.8035; Ikeda S, 1998, J BIOL CHEM, V273, P21585, DOI 10.1074/jbc.273.34.21585; Jiang DY, 1997, J BACTERIOL, V179, P3773, DOI 10.1128/jb.179.11.3773-3782.1997; KASAI H, 1990, MUTAT RES, V243, P249, DOI 10.1016/0165-7992(90)90139-B; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KOW YW, 1987, BIOCHEMISTRY-US, V26, P8200, DOI 10.1021/bi00399a027; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Marnett LJ, 2000, CARCINOGENESIS, V21, P361, DOI 10.1093/carcin/21.3.361; Masaoka A, 1999, J BIOL CHEM, V274, P25136, DOI 10.1074/jbc.274.35.25136; MAZUMDER A, 1991, BIOCHEMISTRY-US, V30, P1119, DOI 10.1021/bi00218a033; McCullough AK, 1999, ANNU REV BIOCHEM, V68, P255, DOI 10.1146/annurev.biochem.68.1.255; MELAMEDE RJ, 1994, BIOCHEMISTRY-US, V33, P1255, DOI 10.1021/bi00171a028; Miller JH, 1972, EXPT MOL GENETICS, P201; Mol CD, 1999, ANNU REV BIOPH BIOM, V28, P101, DOI 10.1146/annurev.biophys.28.1.101; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; OCONNOR TR, 1989, P NATL ACAD SCI USA, V86, P5222, DOI 10.1073/pnas.86.14.5222; Purmal AA, 1998, J BIOL CHEM, V273, P10026, DOI 10.1074/jbc.273.16.10026; PURMAL AA, 1994, NUCLEIC ACIDS RES, V22, P72, DOI 10.1093/nar/22.1.72; Rabow LE, 1997, BIOCHEMISTRY-US, V36, P5084, DOI 10.1021/bi963005a; RADMAN M, 1976, J BIOL CHEM, V251, P1438; Saito Y, 1997, J BACTERIOL, V179, P3783, DOI 10.1128/jb.179.11.3783-3785.1997; Sambrook J., 1989, MOL CLONING, pA1; Sarker AH, 1998, J MOL BIOL, V282, P761, DOI 10.1006/jmbi.1998.2042; Sidorkina OM, 1998, NUCLEIC ACIDS RES, V26, P5351, DOI 10.1093/nar/26.23.5351; Sugiyama H, 1996, TETRAHEDRON LETT, V37, P9067, DOI 10.1016/S0040-4039(96)02130-2; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TEEBOR GW, 1988, INT J RADIAT BIOL, V54, P131, DOI 10.1080/09553008814551591; TOFIGH S, 1989, FREE RADICAL BIO MED, V7, P131, DOI 10.1016/0891-5849(89)90004-X; VONSONNTAG C, 1994, INT J RADIAT BIOL, V66, P485, DOI 10.1080/09553009414551501; Wagner JR, 1996, ANAL BIOCHEM, V233, P76, DOI 10.1006/abio.1996.0010; WALLACE SS, 1997, OXIDATIVE STRESS MOL, P49; WARNER HR, 1994, FREE RADICAL BIO MED, V17, P249, DOI 10.1016/0891-5849(94)90080-9; Yoshida M, 1997, NUCLEIC ACIDS RES, V25, P1570, DOI 10.1093/nar/25.8.1570; Zhang QM, 1995, INT J RADIAT BIOL, V68, P603, DOI 10.1080/09553009514551601; Zhang QM, 1997, NUCLEIC ACIDS RES, V25, P3969, DOI 10.1093/nar/25.20.3969; Zhang QM, 1999, INT J RADIAT BIOL, V75, P59, DOI 10.1080/095530099140816	62	42	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35471	35477		10.1074/jbc.M006125200	http://dx.doi.org/10.1074/jbc.M006125200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10956660	hybrid			2022-12-25	WOS:000165422800084
J	Hazlehurst, LA; Damiano, JS; Buyuksal, I; Pledger, WJ; Dalton, WS				Hazlehurst, LA; Damiano, JS; Buyuksal, I; Pledger, WJ; Dalton, WS			Adhesion to fibronectin via beta 1 integrins regulates p27(kip1) levels and contributes to cell adhesion mediated drug resistance (CAM-DR)	ONCOGENE			English	Article						beta 1 integrins; drug resistance; p27(kip1); cell adhesion; myeloma; CAM-DR	DEPENDENT KINASE INHIBITOR; HEMATOPOIETIC PROGENITOR PROLIFERATION; BALB/C 3T3 CELLS; CYCLE PROGRESSION; GROWTH-FACTOR; EXTRACELLULAR-MATRIX; CONTACT INHIBITION; HL-60 CELLS; IN-VIVO; APOPTOSIS	The tumor cell environment may influence drug response through interactions with the extracellular matrix (ECM). We recently reported that adhesion of myeloma cells to fibronectin (FN), via beta 1 integrins is associated with a cell adhesion mediated drug resistance (CAM-DR), Activation of beta 1 integrins is known to influence both apoptosis and cell growth. We hypothesized that the FN mediated cytoprotection mag be in part due to perturbations in cell cycle progression. In this report we demonstrate that adhesion of myeloma cells to FN results in a G(1) arrest associated,vith increased p27(kip1) protein levels and inhibition of cyclin A and E associated kinase activity. Disruption of cells from FN adhesion resulted in a rapid recruitment of cells into S phase, a decrease in p27(kip1) levels, and reversion to a drug sensitive phenotype. Treatment of cells with p27(Kip1) antisense oligonucleotides did not affect FN adhesion; however, p27(Kip1) protein levels were reduced and cells became sensitive to cytotoxic drugs. These studies demonstrate that beta 1 mediated adhesion of myeloma cells to FN regulates p27(Kip1) levels and that p27(kip1) levels are causally related to CAM-DR. Disruption of beta 1 integrin mediated FN adhesion may represent a potential target for the potentiation of drug induced apoptosis.	Univ S Florida, Dept Oncol, Tampa, FL 33612 USA; Univ S Florida, Clin Invest Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Dalton, WS (corresponding author), Univ S Florida, Dept Oncol, Tampa, FL 33612 USA.							Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Belkin AM, 1998, J BIOL CHEM, V273, P15234, DOI 10.1074/jbc.273.24.15234; BOHNSACK JF, 1994, BLOOD, V83, P543; Chiarle R, 2000, BLOOD, V95, P619, DOI 10.1182/blood.V95.2.619; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Cook G, 1997, ACTA HAEMATOL-BASEL, V97, P81; Damiano JS, 2000, LEUKEMIA LYMPHOMA, V38, P71, DOI 10.3109/10428190009060320; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Dong F, 1998, MOL BIOL CELL, V9, P2081, DOI 10.1091/mbc.9.8.2081; DURAND RE, 1972, EXP CELL RES, V71, P75, DOI 10.1016/0014-4827(72)90265-0; Erhardt JA, 1998, J BIOL CHEM, V273, P23517, DOI 10.1074/jbc.273.36.23517; Eymin B, 1999, ONCOGENE, V18, P1411, DOI 10.1038/sj.onc.1202437; Fornaro M, 1999, J CLIN INVEST, V103, P321, DOI 10.1172/JCI4585; FORNARO M, 1995, J BIOL CHEM, V270, P24666, DOI 10.1074/jbc.270.42.24666; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; Hiromura K, 1999, J CLIN INVEST, V103, P597, DOI 10.1172/JCI5461; Hoyt DG, 1996, CANCER RES, V56, P4146; Hurley RW, 1997, EXP HEMATOL, V25, P321; HURLEY RW, 1995, J CLIN INVEST, V96, P511, DOI 10.1172/JCI118063; JENSEN GS, 1993, AM J HEMATOL, V43, P29, DOI 10.1002/ajh.2830430108; Jiang YH, 2000, BLOOD, V95, P846, DOI 10.1182/blood.V95.3.846.003k31_846_854; Katayose Y, 1997, CANCER RES, V57, P5441; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kramer A, 1999, P NATL ACAD SCI USA, V96, P2087, DOI 10.1073/pnas.96.5.2087; Kudo Y, 2000, CANCER LETT, V151, P217, DOI 10.1016/S0304-3835(99)00419-X; Lee JW, 2000, MOL BIOL CELL, V11, P1973, DOI 10.1091/mbc.11.6.1973; Levenberg S, 1999, ONCOGENE, V18, P869, DOI 10.1038/sj.onc.1202396; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Liu DF, 1999, J CLIN LAB ANAL, V13, P291, DOI 10.1002/(SICI)1098-2825(1999)13:6<291::AID-JCLA7>3.0.CO;2-K; Lundell BI, 1996, BLOOD, V87, P2450, DOI 10.1182/blood.V87.6.2450.bloodjournal8762450; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; MEREDITH J, 1995, SCIENCE, V269, P1570, DOI 10.1126/science.7545312; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Naumann U, 1999, BIOCHEM BIOPH RES CO, V261, P890, DOI 10.1006/bbrc.1999.1126; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Pozzi M, 1998, J CELL BIOL, V142, P587; Ruan S, 1998, CANCER RES, V58, P1538; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; SOLARY E, 1993, BLOOD, V81, P1359; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; StCroix B, 1996, NAT MED, V2, P1204; TEICHER BA, 1990, SCIENCE, V247, P1457, DOI 10.1126/science.2108497; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Wang MWJ, 1998, CELL GROWTH DIFFER, V9, P105; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	56	293	317	1	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4319	4327		10.1038/sj.onc.1203782	http://dx.doi.org/10.1038/sj.onc.1203782			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980607				2022-12-25	WOS:000089271900002
J	Moren, A; Itoh, S; Moustakas, A; ten Dijke, P; Heldin, CH				Moren, A; Itoh, S; Moustakas, A; ten Dijke, P; Heldin, CH			Functional consequences of tumorigenic missense mutations in the amino-terminal domain of Smad4	ONCOGENE			English	Article						mutation; signal transduction; Smad; TGF-beta-transcription; tumor suppressor gene	GROWTH-FACTOR-BETA; COLON-CANCER CELLS; TGF-BETA; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; DPC4 SMAD4; PROTEINS; PROMOTER; RECEPTOR; GENE	Smads, the intracellular effecters of transforming growth factor-beta (TGF-beta) family members, are somatically mutated at high frequency in particular types of human cancers. Certain of these mutations affect the Smad amino-terminal domain, which, in the case of Smad3 and Smad4, binds DNA. We investigated the functional consequences of four missense mutations in the Smad4 amino-terminal domain found in human tumors. The mutant proteins were found to have impaired abilities to bind DNA although they were fully capable of forming complexes with Smad3, All four Smad4 mutants showed decreased protein stability compared to wild-type Smad3. Two of the Smad4 mutants (G65V and P130S) were translocated to the nucleus and were capable of transactivating a Smad-dependent promoter in a ligand-dependent manner. In contrast, the L43S and R100T mutants were not translocated efficiently to the nucleus and consequently resulted in severely defective transcriptional responses to TGF-beta. Moreover, we demonstrate here the critical importance of two basic residues in the beta-hairpin loop of Smad3 or Smad4 for DNA binding, consistent with predictions from the Smad3 crystal structure. In addition, our results reveal that in the TGF-beta-induced heteromeric signaling complex, loss of DNA binding of Smad4 can be compensated by Smad3, however, both Smad3 and Smad3 are needed for efficient DNA binding and signaling. In conclusion, mutations in the amino-terminal domain of Smad4, that are found in cancer, show loss of multiple functional properties which may contribute to tumorigenesis.	Ludwig Inst Canc Res, S-75124 Uppsala, Sweden; Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands	Ludwig Institute for Cancer Research; Netherlands Cancer Institute	Heldin, CH (corresponding author), Ludwig Inst Canc Res, Box 595, S-75124 Uppsala, Sweden.		Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X; Moustakas, Aristidis/0000-0001-9131-3827; Itoh, Susumu/0000-0002-7967-0730				Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; DECAESTECKER MP, 2000, IN PRESS J NATL CANC; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; deWinter JP, 1997, ONCOGENE, V14, P1891, DOI 10.1038/sj.onc.1201017; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Hata A, 1998, MOL MED TODAY, V4, P257, DOI 10.1016/S1357-4310(98)01247-7; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Howell M, 1999, DEV BIOL, V214, P354, DOI 10.1006/dbio.1999.9430; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Johnson K, 1999, J BIOL CHEM, V274, P20709, DOI 10.1074/jbc.274.29.20709; Jones JB, 2000, NUCLEIC ACIDS RES, V28, P2363, DOI 10.1093/nar/28.12.2363; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LEDAI J, 1998, CANCER RES, V58, P4592; LEDAI J, 1999, MOL CARCINOG, V26, P37; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; MacGrogan D, 1997, ONCOGENE, V15, P1111, DOI 10.1038/sj.onc.1201232; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; PARDALI K, 2000, IN PRESS J BIOL CHEM; Piek E, 1999, J CELL SCI, V112, P4557; ROBERTS AB, 1990, HDB EXPT PHARM PEPTI, V95, P3; Schutte M, 1996, CANCER RES, V56, P2527; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Sirard C, 2000, J BIOL CHEM, V275, P2063, DOI 10.1074/jbc.275.3.2063; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; Yagi K, 1999, J BIOL CHEM, V274, P703, DOI 10.1074/jbc.274.2.703; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 2000, J BIOL CHEM, V275, P16979, DOI 10.1074/jbc.M001526200; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou SB, 1998, P NATL ACAD SCI USA, V95, P2412, DOI 10.1073/pnas.95.5.2412	55	79	81	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4396	4404		10.1038/sj.onc.1203798	http://dx.doi.org/10.1038/sj.onc.1203798			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980615				2022-12-25	WOS:000089271900010
J	Tokunaga, F; Brostrom, C; Koide, T; Arvan, P				Tokunaga, F; Brostrom, C; Koide, T; Arvan, P			Endoplasmic reticulum (ER)-associated degradation of misfolded N-linked glycoproteins is suppressed upon inhibition of ER mannosidase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TCR-ALPHA PROTEINS; MOLECULAR CHAPERONES; SECRETORY PATHWAY; RAT-LIVER; SACCHAROMYCES-CEREVISIAE; CARBOXYPEPTIDASE YSCY; PROTEASOME PATHWAY; CONGENITAL GOITER; STORAGE DISEASES; QUALITY-CONTROL	To examine the role of early carbohydrate recognition/trimming reactions in targeting endoplasmic reticulum (ER)-retained, misfolded glycoproteins for ER-associated degradation (ERAD), we have stably expressed the cog thyroglobulin (Tg) mutant cDNA in Chinese hamster ovary cells. We found that inhibitors of ER mannosidase I (but not other glycosidases) acutely suppressed Cog Tg degradation and also perturbed the ERAD process for Tg reduced with dithiothreitol as well as for gamma -carboxylation-deficient protein C expressed in warfarin-treated baby hamster kidney cells. Kifunensine inhibition of ER mannosidase I also suppressed ERAD in castanospermine-treated cells; thus, suppression of ERAD does not require lectin-like binding of ER chaperones calnexin and calreticulin to monoglucosylated oligosaccharides. Notably, the undegraded protein fraction remained completely microsome-associated. In pulse-chase studies, kifunensine-sensitive degradation was still inhibitable even 1 h after Tg synthesis. Intriguingly, chronic treatment with kifunensine caused a 3-fold accumulation of Cog Tg in Chinese hamster ovary cells and did not lead to significant induction of the ER unfolded protein response. We hypothesize that, in a manner not requiring lectin-like activity of calnexin/ calreticulin, the recognition or processing of a specific branched N-linked mannose structure enhances the efficiency of glycoprotein retrotranslocation from the ER lumen.	Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol biol, Div Endocrinol, Bronx, NY 10461 USA; Univ Med & Dent New Jersey, Dept Pharmacol, Piscataway, NJ 08854 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Div Endocrinol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center; Yeshiva University; Albert Einstein College of Medicine	Arvan, P (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol biol, Div Endocrinol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.			Tokunaga, Fuminori/0000-0003-3626-9119	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040344, R29DK040344] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40344] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Bordallo J, 1998, MOL BIOL CELL, V9, P209, DOI 10.1091/mbc.9.1.209; Brodsky JL, 1999, J BIOL CHEM, V274, P3453, DOI 10.1074/jbc.274.6.3453; Brodsky JL, 1997, TRENDS CELL BIOL, V7, P151, DOI 10.1016/S0962-8924(97)01020-9; Chen Y, 1998, J BIOL CHEM, V273, P11887, DOI 10.1074/jbc.273.19.11887; de Virgilio M, 1999, MOL BIOL CELL, V10, P4059, DOI 10.1091/mbc.10.12.4059; de Virgilio M, 1998, J BIOL CHEM, V273, P9734, DOI 10.1074/jbc.273.16.9734; ELBEIN AD, 1990, J BIOL CHEM, V265, P15599; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hebert DN, 1996, EMBO J, V15, P2961, DOI 10.1002/j.1460-2075.1996.tb00659.x; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; Huppa JB, 1997, IMMUNITY, V7, P113, DOI 10.1016/S1074-7613(00)80514-2; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; Keller SH, 1998, J BIOL CHEM, V273, P17064, DOI 10.1074/jbc.273.27.17064; KIM PS, 1991, J BIOL CHEM, V266, P12412; Kim PS, 1996, J CELL BIOL, V133, P517, DOI 10.1083/jcb.133.3.517; Kim PS, 1998, P NATL ACAD SCI USA, V95, P9909, DOI 10.1073/pnas.95.17.9909; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; KIM PS, 1992, J CELL BIOL, V118, P541, DOI 10.1083/jcb.118.3.541; Kim PS, 1998, ENDOCR REV, V19, P173, DOI 10.1210/er.19.2.173; KNITTLER MR, 1995, P NATL ACAD SCI USA, V92, P1764, DOI 10.1073/pnas.92.5.1764; Knop M, 1996, YEAST, V12, P1229, DOI 10.1002/(SICI)1097-0061(19960930)12:12<1229::AID-YEA15>3.0.CO;2-H; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; Liu Y, 1997, J BIOL CHEM, V272, P7946, DOI 10.1074/jbc.272.12.7946; LODISH HF, 1993, J BIOL CHEM, V268, P20598; Marcus NY, 2000, J BIOL CHEM, V275, P1987, DOI 10.1074/jbc.275.3.1987; MCCLURE DB, 1992, J BIOL CHEM, V267, P19710; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; Parodi AJ, 1999, BBA-GEN SUBJECTS, V1426, P287, DOI 10.1016/S0304-4165(98)00130-5; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Pipe SW, 1998, J BIOL CHEM, V273, P8537, DOI 10.1074/jbc.273.14.8537; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Plemper RK, 1999, FEBS LETT, V443, P241, DOI 10.1016/S0014-5793(98)01724-4; Plemper RK, 1998, J BIOL CHEM, V273, P32848, DOI 10.1074/jbc.273.49.32848; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; Rodan AR, 1996, EMBO J, V15, P6921, DOI 10.1002/j.1460-2075.1996.tb01084.x; ROMAGNOLI P, 1995, J EXP MED, V182, P2027, DOI 10.1084/jem.182.6.2027; Romisch K, 1997, P NATL ACAD SCI USA, V94, P6730, DOI 10.1073/pnas.94.13.6730; Schubert U, 1998, J VIROL, V72, P2280, DOI 10.1128/JVI.72.3.2280-2288.1998; Selby M, 1999, J IMMUNOL, V162, P669; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; SU K, 1993, J BIOL CHEM, V268, P14301; Suzuki T, 1998, J BIOL CHEM, V273, P10083, DOI 10.1074/jbc.273.17.10083; Tatu U, 1997, J CELL BIOL, V136, P555, DOI 10.1083/jcb.136.3.555; TOKUNAGA F, 1995, BIOCHEMISTRY-US, V34, P1163, DOI 10.1021/bi00004a009; Tokunaga F, 2000, THROMB RES, V99, P511, DOI 10.1016/S0049-3848(00)00258-9; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; VanLeeuwen JEM, 1997, J BIOL CHEM, V272, P4179, DOI 10.1074/jbc.272.7.4179; Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x; WADA I, 1995, J BIOL CHEM, V270, P20298, DOI 10.1074/jbc.270.35.20298; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; Weng S, 1997, BIOCHEM J, V322, P655, DOI 10.1042/bj3220655; Weng S, 1996, GLYCOBIOLOGY, V6, P861, DOI 10.1093/glycob/6.8.861; WENG SA, 1993, J BIOL CHEM, V268, P25656; White AL, 1999, J LIPID RES, V40, P275; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3; ZHANG Q, 1995, J BIOL CHEM, V270, P3944, DOI 10.1074/jbc.270.8.3944	68	105	107	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40757	40764		10.1074/jbc.M001073200	http://dx.doi.org/10.1074/jbc.M001073200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	10984471	hybrid			2022-12-25	WOS:000166114600015
J	Howe, DL; Duewel, HS; Woodard, RW				Howe, DL; Duewel, HS; Woodard, RW			Histidine 268 in 3-deoxy-D-arabino-heptulosonic acid 7-phosphate synthase plays the same role as histidine 202 in 3-deoxy-D-manno-octulosonic acid 8-phosphate synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; CHEMICAL MODIFICATION; DIETHYL PYROCARBONATE; ESSENTIAL CYSTEINES; ACTIVE-SITE; SYNTHETASE; PURIFICATION; RESIDUE; STEREOCHEMISTRY	The enzyme 3-deoxy-D-arabino-heptulosonate 7-phosphate (DAH 7-P) synthase (Phe) is inactivated by diethyl pyrocarbonate (DEPC). The inactivation is first order with respect to enzyme and DEPC concentrations with a pseudo-second order rate constant of inactivation by DEPC of 4.9 +/- 0.8 M-1 s(-1) at pH 6.8 and 4 degreesC. The dependence of inactivation on pH and the spectral features of enzyme modified at specific pH values imply that both histidine and cysteine residues are modified, which is confirmed by site-directed mutagenesis. Analysis of the chemical modification data indicates that one histidine is essential for activity. DAH 7-P synthase (Phe) is protected against DEPC inactivation by phosphoenolpyruvate, whereas D-erythrose 4-phosphate offers only minimal protection. The conserved residues H-172, H-207, H-268, and H-304 were individually mutated to glycine. The H304G and H207G mutants retain some level of activity, whereas the H268G and H172G mutants are virtually inactive. A comparison of the circular dichroism spectra of wild-type enzyme and the various mutants demonstrates that H-172 may play a structural role. Comparison of the UV spectra of the H268G and wildtype enzymes saturated with Cu2+ indicates that the metal-binding site of the H268G mutant resembles that of the wild-type enzyme. The residue H-268 may play a catalytic role based on the site-directed mutagenesis and spectroscopic studies. Cysteine 61 appears to influence the pK(a) of H-268 in the wild-type enzyme. The pK(a), of H-268 increases from 6.0 to 7.0 following mutation of C-61 to glycine.	Univ Michigan, Coll Pharm, Dept Med Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Woodard, RW (corresponding author), Univ Michigan, Coll Pharm, Dept Med Chem, 428 Church St, Ann Arbor, MI 48109 USA.			Woodard, Ronald/0000-0002-7472-3653				AMINOFF D, 1961, BIOCHEM J, V81, P384, DOI 10.1042/bj0810384; BAASOV T, 1989, J BACTERIOL, V170, P5500; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURSTEIN Y, 1974, BIOCHEMISTRY-US, V13, P205, DOI 10.1021/bi00698a030; DELEO AB, 1968, BIOCHEM BIOPH RES CO, V32, P873, DOI 10.1016/0006-291X(68)90322-7; DELEO AB, 1973, J BIOL CHEM, V248, P2344; DOTSON GD, 1993, BIOCHEMISTRY-US, V32, P12392, DOI 10.1021/bi00097a017; DOY CH, 1967, BIOCHEM BIOPH RES CO, V26, P187, DOI 10.1016/0006-291X(67)90232-X; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; GOMI T, 1983, BIOCHEMISTRY-US, V22, P137, DOI 10.1021/bi00270a020; Haslam E., 1993, SHIKIMIC ACID METABO; HEDSTROM L, 1988, BIOCHEM BIOPH RES CO, V157, P816, DOI 10.1016/S0006-291X(88)80322-X; HORIIKE K, 1979, J BIOL CHEM, V254, P6638; HUISMAN OC, 1974, J BIOL CHEM, V249, P6842; HUYNH QK, 1987, ARCH BIOCHEM BIOPHYS, V258, P233, DOI 10.1016/0003-9861(87)90340-7; KOHEN A, 1993, BIOORG MED CHEM LETT, V3, P1577, DOI 10.1016/S0960-894X(00)80021-9; LEVIN DH, 1959, J BIOL CHEM, V234, P2532; MELCHIOR WB, 1970, BIOCHEMISTRY-US, V9, P251, DOI 10.1021/bi00804a010; Miles E W, 1977, Methods Enzymol, V47, P431; NAGANO H, 1970, ARCH BIOCHEM BIOPHYS, V138, P58, DOI 10.1016/0003-9861(70)90284-5; ONDERKA DK, 1969, BIOCHEM BIOPH RES CO, V35, P801, DOI 10.1016/0006-291X(69)90694-9; ONDERKA DK, 1969, J AM CHEM SOC, V91, P5894, DOI 10.1021/ja01049a046; Park OK, 1999, J BACTERIOL, V181, P1636, DOI 10.1128/JB.181.5.1636-1642.1999; Radaev S, 2000, J BIOL CHEM, V275, P9476, DOI 10.1074/jbc.275.13.9476; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAY PH, 1983, ACS SYM SER, V231, P141; RAY PH, 1980, J BACTERIOL, V141, P635, DOI 10.1128/JB.141.2.635-644.1980; Salleh HM, 1996, BIOCHEMISTRY-US, V35, P8942, DOI 10.1021/bi952373w; SALUJA AK, 1980, BIOCHEM BIOPH RES CO, V94, P1091, DOI 10.1016/0006-291X(80)90531-8; SCHONER R, 1976, J BIOL CHEM, V251, P5440; Sheflyan GY, 1999, BIOCHEMISTRY-US, V38, P14320, DOI 10.1021/bi9829884; Sheflyan GY, 1998, J AM CHEM SOC, V120, P11027, DOI 10.1021/ja9816281; Shumilin IA, 1999, STRUCTURE, V7, P865, DOI 10.1016/S0969-2126(99)80109-9; SIMPSON RJ, 1976, EUR J BIOCHEM, V70, P501, DOI 10.1111/j.1432-1033.1976.tb11041.x; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; SRINIVASAN PR, 1959, J BIOL CHEM, V234, P716; STAUB M, 1969, BIOCHIM BIOPHYS ACTA, V178, P588, DOI 10.1016/0005-2744(69)90227-7; STEPHENS CM, 1992, J BIOL CHEM, V267, P5762; STEPHENS CM, 1991, J BIOL CHEM, V266, P20810; Subramaniam PS, 1998, J BACTERIOL, V180, P119, DOI 10.1128/JB.180.1.119-127.1998; SUGIMOTO S, 1980, J BIOCHEM-TOKYO, V87, P881, DOI 10.1093/oxfordjournals.jbchem.a132818; Sundaram AK, 1998, FEBS LETT, V441, P195, DOI 10.1016/S0014-5793(98)01545-2; TAKEUCHI M, 1986, J BIOCHEM-TOKYO, V99, P1571, DOI 10.1093/oxfordjournals.jbchem.a135630; WEINER MP, 1994, GENE, V151, P119, DOI 10.1016/0378-1119(94)90641-6; WEINER MP, 1994, PCR METH APPL, V4, pS131	45	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40258	40265		10.1074/jbc.M003585200	http://dx.doi.org/10.1074/jbc.M003585200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10988284	hybrid			2022-12-25	WOS:000166039500064
J	Kugel, JF; Goodrich, JA				Kugel, JF; Goodrich, JA			A kinetic model for the early steps of RNA synthesis by human RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENERAL TRANSCRIPTION FACTORS; PROMOTER ESCAPE; ELONGATION COMPLEXES; MINIMAL SET; INITIATION; ATP; TFIIH; DNA; IDENTIFICATION; INVITRO	Eukaryotic mRNA synthesis is a highly regulated process involving numerous proteins acting in concert with RNA polymerase II to set levels of transcription from individual promoters. The transcription reaction consists of multiple steps beginning with preinitiation complex formation and ending in the production of a full-length primary transcript. We used pre-steady-state approaches to study the steps of human mRNA transcription at the adenovirus major late promoter in a minimal in vitro transcription system. These kinetic studies revealed an early transition in RNA polymerase II transcription, termed escape commitment, that occurs after initiation and prior to promoter escape. Escape commitment is rapid and is characterized by sensitivity to competitor DNA. Upon completion of escape commitment, ternary complexes are resistant to challenge by competitor DNA and slowly proceed forward through promoter escape. Escape commitment is stimulated by transcription factors TFIIE and TFIIH. We measured forward and reverse rate constants for discrete steps in transcription and present a kinetic model for the mechanism of RNA polymerase II transcription that describes five distinct steps (preinitiation complex formation, initiation, escape commitment, promoter escape, and transcript elongation) and clearly shows promoter escape is rate-limiting in this system.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Goodrich, JA (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.							BORUKHOV S, 1993, J BIOL CHEM, V268, P23477; Bradsher J, 2000, J BIOL CHEM, V275, P2532, DOI 10.1074/jbc.275.4.2532; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAI H, 1987, J BIOL CHEM, V262, P298; Cheetham GMT, 1999, SCIENCE, V286, P2305, DOI 10.1126/science.286.5448.2305; Cramer P, 2000, SCIENCE, V288, P640, DOI 10.1126/science.288.5466.640; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; Dvir A, 1996, J BIOL CHEM, V271, P23352, DOI 10.1074/jbc.271.38.23352; Dvir A, 1997, J BIOL CHEM, V272, P28175, DOI 10.1074/jbc.272.45.28175; Dvir A, 1997, P NATL ACAD SCI USA, V94, P9006, DOI 10.1073/pnas.94.17.9006; Fiedler U, 2000, BIOESSAYS, V22, P316, DOI 10.1002/(SICI)1521-1878(200004)22:4<316::AID-BIES2>3.0.CO;2-B; FLORES O, 1992, J BIOL CHEM, V267, P2786; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; Holstege FCP, 1997, EMBO J, V16, P7468, DOI 10.1093/emboj/16.24.7468; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; Jiang Y, 1996, MOL CELL BIOL, V16, P1614; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; Kim TK, 2000, SCIENCE, V288, P1418, DOI 10.1126/science.288.5470.1418; Kugel JF, 1998, P NATL ACAD SCI USA, V95, P9232, DOI 10.1073/pnas.95.16.9232; Kumar KP, 1998, P NATL ACAD SCI USA, V95, P9767, DOI 10.1073/pnas.95.17.9767; LUSE DS, 1987, J BIOL CHEM, V262, P14990; LUSE DS, 1987, J BIOL CHEM, V262, P289; Moreland RJ, 1999, J BIOL CHEM, V274, P22127, DOI 10.1074/jbc.274.32.22127; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; REINBERG D, 1987, J BIOL CHEM, V262, P3322; Reines D, 1999, CURR OPIN CELL BIOL, V11, P342, DOI 10.1016/S0955-0674(99)80047-7; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; TIMMERS HTM, 1994, EMBO J, V13, P391, DOI 10.1002/j.1460-2075.1994.tb06273.x; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; TYREE CM, 1993, GENE DEV, V7, P1254, DOI 10.1101/gad.7.7a.1254; Yan M, 1997, EMBO J, V16, P7457, DOI 10.1093/emboj/16.24.7457; Yan M, 1999, J BIOL CHEM, V274, P34819, DOI 10.1074/jbc.274.49.34819; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479	37	31	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					40483	40491		10.1074/jbc.M006401200	http://dx.doi.org/10.1074/jbc.M006401200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	10982810	hybrid			2022-12-25	WOS:000166039500092
J	Ryu, S; Kawabe, T; Nada, S; Yamaguchi, A				Ryu, S; Kawabe, T; Nada, S; Yamaguchi, A			Identification of basic residues involved in drug export function of human multidrug resistance-associated protein 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORGANIC ANION-TRANSPORTER; DUBIN-JOHNSON-SYNDROME; HUMAN P-GLYCOPROTEIN; KIDNEY MDCK CELLS; SUBSTRATE-SPECIFICITY; BINDING-SITE; TRANSMEMBRANE DOMAIN; LABELING SITES; CMOAT MRP2; GENE	Multidrurg resistance-associated protein 2 (MRPS)/canalicular multispecific organic anion transporter (cMOAT) is involved in the ATP-dependent export of organic anions across the bile canalicular membrane. To identify functional amino acid residues that play essential roles in the substrate transport, each of 13 basic residues around transmembrane regions (TMs) 6-17 were replaced with alanine. Wild type and mutant proteins were expressed in COS-7 cells, and the transport activity was measured as the excretion of glutathione-methylfluorescein. Four mutants, K324A (TM6), K483A (TM9), R1210A (TM16), and R1257A (TM17), showed decreased transport activity, and another mutant, K578A (TM11), showed decreased protein expression. These five mutants were normally delivered to the cell surface similar to the other fully active mutants and wild type MRP2. The importance of TM6, TM16, and TM17 in the transport function of MRP2 is consistent with the previous observation indicating the importance of the corresponding TMI, TM11, and TM12 on P-glycoprotein (Loo, T. W, and Clarke, D. M. (1999) J. Biol. Chem. 274, 35388-35392). Another observation that MRP2 inhibitor, cyclosporine A, failed to inhibit R1230A specifically, indicated the existence of its binding site within TM16.	Osaka Univ, Inst Sci & Ind Res, Dept Cell Membrane Biol, Ibaraki, Osaka 5670047, Japan; Osaka Univ, Fac Pharmaceut Sci, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, CREST, Osaka 5670047, Japan	Osaka University; Osaka University; Japan Science & Technology Agency (JST)	Yamaguchi, A (corresponding author), Osaka Univ, Inst Sci & Ind Res, Dept Cell Membrane Biol, 8-1 Mihogaoka, Ibaraki, Osaka 5670047, Japan.	akihito@sanken.osaka-u.ac.jp						Bakos E, 1998, J BIOL CHEM, V273, P32167, DOI 10.1074/jbc.273.48.32167; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; Buchler M, 1996, J BIOL CHEM, V271, P15091; Chen ZS, 1999, MOL PHARMACOL, V56, P1219, DOI 10.1124/mol.56.6.1219; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; ELFERINK RPJO, 1994, PHARMACOL THERAPEUT, V64, P77, DOI 10.1016/0163-7258(94)90034-5; ELFERINK RPJO, 1995, BBA-REV BIOMEMBRANES, V1241, P215, DOI 10.1016/0304-4157(95)00006-D; Evers R, 1998, J CLIN INVEST, V101, P1310, DOI 10.1172/JCI119886; Gao M, 1998, J BIOL CHEM, V273, P10733, DOI 10.1074/jbc.273.17.10733; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; GREENBERGER LM, 1991, J BIOL CHEM, V266, P20744; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; Ito K, 1998, J BIOL CHEM, V273, P1684, DOI 10.1074/jbc.273.3.1684; KAJIJI S, 1993, BIOCHEMISTRY-US, V32, P4185, DOI 10.1021/bi00067a005; Keppler D, 1996, Prog Liver Dis, V14, P55; Keppler D, 1997, FASEB J, V11, P509, DOI 10.1096/fasebj.11.7.9212074; Kinoshita S, 1998, PHARMACEUT RES, V15, P1851, DOI 10.1023/A:1011953906065; Klein I, 1999, BBA-BIOMEMBRANES, V1461, P237, DOI 10.1016/S0005-2736(99)00161-3; Kool M, 1997, CANCER RES, V57, P3537; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loo TW, 1999, J BIOL CHEM, V274, P35388, DOI 10.1074/jbc.274.50.35388; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; Loo TW, 2000, J BIOL CHEM, V275, P5253, DOI 10.1074/jbc.275.8.5253; LOO TW, 1994, BIOCHEMISTRY-US, V33, P14049, DOI 10.1021/bi00251a013; LOO TW, 1993, J BIOL CHEM, V268, P19965; MORRIS DI, 1994, MOL PHARMACOL, V46, P329; Muller M, 1996, J HEPATOL, V24, P100; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; Roelofsen H, 1998, J CELL SCI, V111, P1137; Smit JW, 1998, BRIT J PHARMACOL, V123, P361, DOI 10.1038/sj.bjp.0701606; Taguchi Y, 1997, BIOCHEMISTRY-US, V36, P8883, DOI 10.1021/bi970553v; Toh S, 1999, AM J HUM GENET, V64, P739, DOI 10.1086/302292; Wada M, 1998, HUM MOL GENET, V7, P203, DOI 10.1093/hmg/7.2.203; Yamazaki M, 1996, PHARMACEUT RES, V13, P497, DOI 10.1023/A:1016077517241; ZHANG XP, 1995, J BIOL CHEM, V270, P5441, DOI 10.1074/jbc.270.10.5441; Zheleznova EE, 2000, TRENDS BIOCHEM SCI, V25, P39, DOI 10.1016/S0968-0004(99)01514-5	39	70	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2000	275	50					39617	39624		10.1074/jbc.M005149200	http://dx.doi.org/10.1074/jbc.M005149200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	384PB	10978330	hybrid			2022-12-25	WOS:000165953100088
J	Bommakanti, RK; Vinayak, S; Simonds, WF				Bommakanti, RK; Vinayak, S; Simonds, WF			Dual regulation of Akt/protein kinase B by heterotrimeric G protein subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	American-Society-of-Biochemistry-and-Molecular-Biology Annual Meeting	MAY 15-20, 1998	WASHINGTON, D.C.	Amer Soc Biochem & Molec Biol			BETA-GAMMA-SUBUNITS; ACTIVATED PHOSPHATIDYLINOSITOL 3-KINASE; GLYCOGEN-SYNTHASE KINASE-3; PLECKSTRIN HOMOLOGY DOMAIN; FACTOR-I RECEPTOR; COUPLED RECEPTORS; PHOSPHOINOSITIDE 3-KINASE-GAMMA; MOLECULAR-CLONING; AKT PROTOONCOGENE; INSULIN	While positive regulation of c-Akt (also known as protein kinase B) by receptor tyrosine kinases is well documented, compounds acting through G protein-coupled receptors can also activate Akt and its downstream targets. We therefore explored the role of G protein subunits in the regulation of Akt in cultured mammalian cells,In HEK-293 and COS-7 cells transiently transfected with beta (2)-adrenergic or m2 muscarinic receptors, respectively, treatment with agonist-induced phosphorylation of Akt at serine 473 as evidenced by phosphoserine-specific immunoblots. This effect was blocked by the phosphatidylinositol-3-OH kinase inhibitor LY294002 and wild-type G alpha (il), and was not duplicated by co-transfection of the constitutively active G alpha (s)-Q227L or G alpha (i)-Q204L mutant, Co-transfection of G beta (1), G beta (2) but not G beta (5) together with G gamma (2) activated the kinase when assayed in vitro following immunoprecipitation of the epitope-tagged enzyme. In contrast, constitutively activated G protein subunits representing the four G alpha subfamilies were found unable to activate Akt in either cell line. The latter results are in disagreement with a report by Murga et al. (Murga, C., Laguinge, L., Wetzker, R., Cuadrado, A., and Gutkind, J. S. (1998) J, Biol. Chem. 273, 19080-19085) that described activation of Akt in response to mutationally activated G alpha (q) and G alpha (i) transfection in COS cells. To the contrary, in our experiments G alpha (q)-Q209L inhibited Akt activation resulting from beta gamma or mutationally activated H-Ras co-transfection in these cells. In HEK-293 cells G alpha (q)-Q209L transfection inhibited insulin-like growth factor-1 activation of epitope-tagged Akt. In m1 muscarinic receptor transfected HEK-293 cells, carbachol inhibited insulin-like growth factor-1 stimulated phosphorylation at Ser(473) of endogenous Akt in an atropine-reversible fashion. me conclude that G proteins can regulate Akt by two distinct and potentially opposing mechanisms: activation by G beta gamma heterodimers in a phosphatidylinositol-3-OH kinase-dependent fashion, and inhibition mediated by G alpha (q). This work identifies Akt as a novel point of convergence between disparate signaling pathways.	NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Simonds, WF (corresponding author), NIDDK, Metab Dis Branch, NIH, Bldg 10,Rm 8C-101,10 Ctr Dr,MSC 1752, Bethesda, MD 20892 USA.	wfs@helix.nih.gov						Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Barthel A, 1998, BIOCHEM BIOPH RES CO, V243, P509, DOI 10.1006/bbrc.1998.8134; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GARRITSEN A, 1994, J BIOL CHEM, V269, P24418; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; LEE CH, 1995, J BIOL CHEM, V270, P8779, DOI 10.1074/jbc.270.15.8779; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; Lindorfer MA, 1998, J BIOL CHEM, V273, P34429, DOI 10.1074/jbc.273.51.34429; Lopez-Ilasaca M, 1998, J BIOL CHEM, V273, P2505, DOI 10.1074/jbc.273.5.2505; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Maier U, 2000, J BIOL CHEM, V275, P13746, DOI 10.1074/jbc.275.18.13746; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; MURAKAMI T, 1992, BIOCHEMISTRY-US, V31, P2905, DOI 10.1021/bi00126a009; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Okada T, 1996, BIOCHEM J, V317, P475, DOI 10.1042/bj3170475; Philpott KL, 1997, J CELL BIOL, V139, P809, DOI 10.1083/jcb.139.3.809; Rubio I, 1997, BIOCHEM J, V326, P891, DOI 10.1042/bj3260891; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Tilton B, 1997, J BIOL CHEM, V272, P28096, DOI 10.1074/jbc.272.44.28096; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; YAMAMOTO K, 1992, J BIOL CHEM, V267, P11337; Zhang SY, 1996, J BIOL CHEM, V271, P33575, DOI 10.1074/jbc.271.52.33575; Zheng WH, 2000, J BIOL CHEM, V275, P13377, DOI 10.1074/jbc.275.18.13377; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	59	81	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38870	38876		10.1074/jbc.M007403200	http://dx.doi.org/10.1074/jbc.M007403200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	381AH	10986289	hybrid			2022-12-25	WOS:000165739800099
J	Ding, HF; Lin, YL; McGill, G; Juo, P; Zhu, H; Blenis, J; Yuan, JY; Fisher, DE				Ding, HF; Lin, YL; McGill, G; Juo, P; Zhu, H; Blenis, J; Yuan, JY; Fisher, DE			Essential role for caspase-8 in transcription-independent apoptosis triggered by p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; CELL-CYCLE ARREST; CYTOCHROME-C; DEATH DOMAIN; P53-DEPENDENT APOPTOSIS; CD95 FAS/APO-1; RECEPTOR/LIGAND SYSTEM; CANCER-THERAPY; ACTIVATION; PROTEIN	p53's dual regulation of arrest versus apoptosis may underlie tumor-selective effects of anti-cancer therapy. p53's apoptotic effect has been suggested to involve both transcription-dependent and -independent mechanisms. It is shown here that caspase-8 is activated early in cells undergoing p53-mediated apoptosis and in S100 cell-free extracts that recapitulate transcription-independent apoptosis, Depletion or inactivation of caspase-8 either in cells or cell-free extracts completely prevents this transcription-independent apoptosis and significantly attenuates overall death induced by wildtype p53. Importantly, caspase-8 activation appears to be independent of FADD, and caspase-8 is found in a novel 600-kDa complex following p53 activation. These findings highlight the roles of both transcription-dependent and -independent apoptosis by p53 and identify an essential role for caspase-8 in the transcription-independent pathway.	Dana Farber Canc Inst, Div Pediat Hematol Oncol, Dept Pediat Hematol Oncol, Boston, MA 02115 USA; Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Fisher, DE (corresponding author), Dana Farber Canc Inst, Div Pediat Hematol Oncol, Dept Pediat Hematol Oncol, D630,44 Binney St, Boston, MA 02115 USA.	david_fisher@dfci.harvard.edu	Juo, Peter/CJY-3695-2022	Juo, Peter/0000-0002-3039-2266; Zhu, Hong/0000-0002-2575-4031; Ding, Han-Fei/0000-0001-5702-3439	NATIONAL CANCER INSTITUTE [R01CA069531] Funding Source: NIH RePORTER; NCI NIH HHS [CA69531] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bissonnette N, 1997, BIOCHEM CELL BIOL, V75, P351, DOI 10.1139/bcb-75-4-351; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chandler JM, 1997, BIOCHEM J, V322, P19, DOI 10.1042/bj3220019; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Ding HF, 1998, J BIOL CHEM, V273, P28378, DOI 10.1074/jbc.273.43.28378; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Fukazawa T, 1999, ONCOGENE, V18, P2189, DOI 10.1038/sj.onc.1202561; Gao CF, 1999, JPN J CANCER RES, V90, P180, DOI 10.1111/j.1349-7006.1999.tb00731.x; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HARDENBERG PH, 1998, INT J RADIAT ONCOL, V43, P601; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hengartner M, 1998, SCIENCE, V281, P1298, DOI 10.1126/science.281.5381.1298; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; Kim AL, 1999, J BIOL CHEM, V274, P34924, DOI 10.1074/jbc.274.49.34924; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MIYASHITA T, 1995, CELL, V80, P293; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rakkar ANS, 1999, CELL DEATH DIFFER, V6, P326, DOI 10.1038/sj.cdd.4400498; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	76	119	125	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38905	38911		10.1074/jbc.M004714200	http://dx.doi.org/10.1074/jbc.M004714200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	10988287	Green Published, hybrid			2022-12-25	WOS:000165739800104
J	Busby, WH; Nam, TJ; Moralez, A; Smith, C; Jennings, M; Clemmons, DR				Busby, WH; Nam, TJ; Moralez, A; Smith, C; Jennings, M; Clemmons, DR			The complement component C1s is the protease that accounts for cleavage of insulin-like growth factor-binding protein-5 in fibroblast medium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGF BINDING; SERINE-PROTEASE; CELLS; IDENTIFICATION; PROTEOLYSIS; MECHANISMS; THROMBIN; TISSUE	Cultured fibroblasts secrete an 88-kDa serine protease that cleaves insulin-like growth factor binding protein-5 (IGFBP-5). Because IGFBP-5 has been shown to regulate IGF-I actions, understanding the chemical identity and regulation of this protease is important for understanding how IGF-I stimulates anabolic functions. The protease was purified from human fibroblast-conditioned medium by hydrophobic interaction, lectin affinity, and heparin Sepharose affinity chromatography followed by SDS polyacrylamide gel electrophoresis. An 88-kDa band was excised and digested with lysyl-endopeptidase. Sequencing of the high pressure liquid chromatography-purified peptides yielded the complement components C1r and C1s. To confirm that C1r/C1s accounted for the proteolytic activity in the medium, immunoaffinity chromatography was performed. Most of the protease activity adhered to the column, and the eluant was fully active in cleaving IGFBP-5. SDS-polyacrylamide gel electrophoresis with silver staining showed two bands, and IGFBP-5 zymography showed a single 88-kDa band. Amino acid sequencing confirmed that the 88-kDa band contained only Clr and Cls. Clr in the fibroblast medium underwent autoactivation, and the activated form cleaved Cls. Cls purified from the conditioned medium cleaved C-4, a naturally occurring substrate. The purified protease cleaved IGFBP-5 but had no activity against IGFBP-1 through -4. C1 inhibitor, a protein known to inhibit activated Cls, was shown to inhibit the cleavage of IGFBP-5 by the protease in the conditioned medium. In summary, human fibroblasts secrete Clr and Cls that actively cleave IGFBP-5. The findings define a mechanism for cleaving IGFBP-5 in the culture medium, thus allowing release of IGF-I to cell surface receptors.	Univ N Carolina, Div Endocrinol, Sch Med, Dept Med, Chapel Hill, NC 27599 USA; Monsanto Inc, Dept Prot Chem, Chesterfield, MO 63198 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Monsanto	Clemmons, DR (corresponding author), Univ N Carolina, Div Endocrinol, Sch Med, Dept Med, CB 7170,6111 Thurston Bowles, Chapel Hill, NC 27599 USA.	endo@med.unc.edu			NIA NIH HHS [AGO23331] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1991, INSULIN LIKE GROWTH; ARLAUD G, 1983, METHOD ENZYMOL, V223, P61; Bang Peter, 1995, Progress in Growth Factor Research, V6, P285, DOI 10.1016/0955-2235(96)00007-5; Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BINOUX M, 1994, INT CONGR SER, V1056, P217; Booth BA, 1996, AM J PHYSIOL-ENDOC M, V271, pE465, DOI 10.1152/ajpendo.1996.271.3.E465; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; CAMBELL PG, 1992, ENDOCRINOLOGY, V130, P1401; DAVIES AE, 1983, METHOD ENZYMOL, V223, P97; ERIKSSON H, 1990, BIOCHIM BIOPHYS ACTA, V1037, P2109; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; Imai Y, 1997, J CLIN INVEST, V100, P2596, DOI 10.1172/JCI119803; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KATZ Y, 1995, J CLIN ENDOCR METAB, V80, P2027, DOI 10.1210/jc.80.7.2027; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lang CH, 1996, AM J PHYSIOL-ENDOC M, V270, pE430, DOI 10.1152/ajpendo.1996.270.3.E430; Lawrence JB, 1999, P NATL ACAD SCI USA, V96, P3149, DOI 10.1073/pnas.96.6.3149; LOVELL AB, 1990, IMMUNOL METHODS, V129, P55; MOFFAT GJ, 1989, CLIN EXP IMMUNOL, V78, P54; MOHAN S, 1995, J BIOL CHEM, V270, P20424, DOI 10.1074/jbc.270.35.20424; Nam TJ, 1996, ENDOCRINOLOGY, V137, P5530, DOI 10.1210/en.137.12.5530; Nam TJ, 2000, ENDOCRINOLOGY, V141, P1100, DOI 10.1210/en.141.3.1100; NAM TJ, 1994, ENDOCRINOLOGY, V135, P1385, DOI 10.1210/en.135.4.1385; NISSEN MH, 1990, EUR J BIOCHEM, V189, P423, DOI 10.1111/j.1432-1033.1990.tb15505.x; Parker A, 1996, J BIOL CHEM, V271, P13523, DOI 10.1074/jbc.271.23.13523; RADLEY K, 1996, IMMUNOLOGY, V88, P648; Sakai H, 1998, GENE, V209, P87, DOI 10.1016/S0378-1119(98)00015-8; SAKIYAMA H, 1991, J IMMUNOL, V146, P183; SAKIYAWA H, 1994, CELL TISSUE RES, V227, P239; SCHASTEIN CS, 1997, MOL IMMUNOL, P17; VANAGRECHI K, 1990, FEBS LETT, V268, P206; Zheng B, 1998, ENDOCRINOLOGY, V139, P1708, DOI 10.1210/endo.139.4.5945; ZICCARDI RJ, 1976, J IMMUNOL, V116, P504	36	68	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37638	37644		10.1074/jbc.M006107200	http://dx.doi.org/10.1074/jbc.M006107200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10982804	hybrid			2022-12-25	WOS:000165618700046
J	Petrulis, JR; Hord, NG; Perdew, GH				Petrulis, JR; Hord, NG; Perdew, GH			Subcellular localization of the aryl hydrocarbon receptor is modulated by the immunophilin homolog hepatitis B virus X-associated protein 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; HEPA 1C1C7 CELLS; AH RECEPTOR; DIOXIN RECEPTOR; CORE COMPLEX; NUCLEAR; LIGAND; ROLES	The hepatitis B virus X-associated protein 2 (XAP2) is an immunophilin homolog and core component of the aryl hydrocarbon receptor (AhR). Immunophilins are components of many steroid receptor complexes, serving a largely unknown function, Transiently expressed AhR.YFP (yellow fluorescent protein) localized to the nuclei of COS-l and NIH-3T3 cells. Go-expression of AhR YFP with XAP2 restored cytoplasmic localization, which was reversed by 2,3,7,8-tetrachlorodibenzo-p-dioxin treatment (TCDD), The effect of XAP2 on AhR localization was specific involving a nuclear localization signal-mediated pathway. Examination of the ratio of AhR to XAP2 in the AhR complex revealed that similar to 25% of transiently expressed AhR was associated with XAP2, in contrast with similar to 100% when the AhR and XAP2 were coexpressed. Strikingly, TCDD did not influence these ratios, suggesting that ligand binding initiates nuclear translocation prior to complex dissociation. Analysis of endogenous AhR in Hepa-l cells revealed that similar to 40% of the AhR complex was associated with XAP2, predicting observed AhR localization to cytoplasm and nuclei. This study reveals a novel functional role for the immunophilin-like component of a soluble receptor complex and provides new insight into the mechanism of AhR-mediated signal transduction, demonstrating the existence of two structurally distinct and possibly functionally unique forms of the AhR.	Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, University Pk, PA 16802 USA; Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Perdew, GH (corresponding author), Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, University Pk, PA 16802 USA.	ghp2@psu.edu			NIEHS NIH HHS [ES04869] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES004869, R01ES004869] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABBOTT BD, 1995, DEV DYNAM, V204, P133, DOI 10.1002/aja.1002040204; ARMISTEAD DM, 1993, ANNU REP MED CHEM, V28, P207; Carver LA, 1997, J BIOL CHEM, V272, P11452; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; Chen HS, 1997, ARCH BIOCHEM BIOPHYS, V348, P190, DOI 10.1006/abbi.1997.0398; Denison MS, 1998, TARG ORG T, P3; Dogra SC, 1998, CLIN EXP PHARMACOL P, V25, P1, DOI 10.1111/j.1440-1681.1998.tb02135.x; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Fukunaga BN, 1996, J BIOL CHEM, V271, P3743; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Heid SE, 2000, MOL PHARMACOL, V57, P82; Ikuta T, 1998, J BIOL CHEM, V273, P2895, DOI 10.1074/jbc.273.5.2895; LaPres JJ, 2000, J BIOL CHEM, V275, P6153, DOI 10.1074/jbc.275.9.6153; Lees MJ, 1999, MOL CELL BIOL, V19, P5811; Ma Q, 1997, J BIOL CHEM, V272, P8878; Meyer BK, 2000, CELL STRESS CHAPERON, V5, P243, DOI 10.1379/1466-1268(2000)005<0243:AHARLA>2.0.CO;2; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Meyer BK, 1999, BIOCHEMISTRY-US, V38, P8907, DOI 10.1021/bi982223w; PERDEW GH, 1995, HYBRIDOMA, V14, P279, DOI 10.1089/hyb.1995.14.279; PERDEW GH, 1993, EXP CELL RES, V209, P350, DOI 10.1006/excr.1993.1320; PERDEW GH, 1991, ARCH BIOCHEM BIOPHYS, V291, P284, DOI 10.1016/0003-9861(91)90136-7; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Sabatini DM, 1997, MOL NEUROBIOL, V15, P223, DOI 10.1007/BF02740635; Singh SS, 1996, ARCH BIOCHEM BIOPHYS, V329, P47, DOI 10.1006/abbi.1996.0190; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174	28	81	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37448	37453		10.1074/jbc.M006873200	http://dx.doi.org/10.1074/jbc.M006873200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10986286	hybrid			2022-12-25	WOS:000165618700021
J	Takahara, T; Kanazu, S; Yanagisawa, S; Akanuma, H				Takahara, T; Kanazu, S; Yanagisawa, S; Akanuma, H			Heterogeneous Sp1 mRNAs in human HepG2 cells include a product of homotypic trans-splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SP1; MESSENGER-RNA PRECURSORS; MAMMALIAN-CELLS; DNA-BINDING; RAT-LIVER; ACTIVATION; GENE; EXON; SEQUENCES; PROMOTER	Spl is one of the well documented transcription factors, but the whole structure of human Spl has not been determined yet. In the present study, we isolated several cDNAs representing two forms of human Spl mRNA with different 5'-terminal structures in HepG2 cells. Isolation of a genomic clone established that one of the cDNAs represents the mRNA having consecutive alignment of exons, which allowed deducing the complete amino acid sequence for human Spl. Another cDNA clone had a surprising structure that possessed an alignment of exons 3-2-3. Both reverse transcriptase-polymerase chain reaction and RNase protection assays confirmed accumulation of the two forms of Spl mRNA in HepG2 cells. Because Southern blot analysis suggested that exon 3 is of a single copy in the genome, the cDNA clone having the duplicated sequences for exon 3 appeared to reflect the trans-splicing between pre-mRNAs of human Sp1.	Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci Chem, Meguro Ku, Tokyo 1538902, Japan	University of Tokyo	Yanagisawa, S (corresponding author), Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci Chem, Meguro Ku, Tokyo 1538902, Japan.							Akopian AN, 1999, FEBS LETT, V445, P177, DOI 10.1016/S0014-5793(99)00126-X; BONEN L, 1993, FASEB J, V7, P40, DOI 10.1096/fasebj.7.1.8422973; BRUZIK JP, 1992, NATURE, V360, P692, DOI 10.1038/360692a0; BRUZIK JP, 1995, P NATL ACAD SCI USA, V92, P7056, DOI 10.1073/pnas.92.15.7056; Caudevilla C, 1998, P NATL ACAD SCI USA, V95, P12185, DOI 10.1073/pnas.95.21.12185; CHAPDELAINE Y, 1991, CELL, V65, P465, DOI 10.1016/0092-8674(91)90464-A; CHIARA MD, 1995, NATURE, V375, P510, DOI 10.1038/375510a0; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; DIRKSEN WP, 1994, J BIOL CHEM, V269, P6431; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1986, NATURE, V319, P246, DOI 10.1038/319246a0; EUL J, 1995, EMBO J, V14, P3226, DOI 10.1002/j.1460-2075.1995.tb07325.x; Frantz SA, 1999, P NATL ACAD SCI USA, V96, P5400, DOI 10.1073/pnas.96.10.5400; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; JONES KA, 1985, NATURE, V317, P179, DOI 10.1038/317179a0; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KITADAI Y, 1992, BIOCHEM BIOPH RES CO, V189, P1342, DOI 10.1016/0006-291X(92)90221-6; KONARSKA MM, 1985, CELL, V42, P165, DOI 10.1016/S0092-8674(85)80112-4; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; Li BL, 1999, J BIOL CHEM, V274, P11060, DOI 10.1074/jbc.274.16.11060; MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Persengiev SP, 1996, ENDOCRINOLOGY, V137, P638, DOI 10.1210/en.137.2.638; Pink JJ, 1996, NUCLEIC ACIDS RES, V24, P962, DOI 10.1093/nar/24.5.962; SAMBROOK J, 1989, MOL CLONING, V2, P9; SHIMIZU A, 1993, FASEB J, V7, P149, DOI 10.1096/fasebj.7.1.7916698; SOLNICK D, 1985, CELL, V42, P157, DOI 10.1016/S0092-8674(85)80111-2; Su KH, 1999, J BIOL CHEM, V274, P15194, DOI 10.1074/jbc.274.21.15194; SULLIVAN PM, 1991, J BIOL CHEM, V266, P143; SUN Q, 1993, GENE DEV, V7, P2598, DOI 10.1101/gad.7.12b.2598; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; Vinals F, 1997, J BIOL CHEM, V272, P12913, DOI 10.1074/jbc.272.20.12913; WISSINGER B, 1991, CELL, V65, P473, DOI 10.1016/0092-8674(91)90465-B; XU RS, 1993, MOL CELL BIOL, V13, P3660, DOI 10.1128/MCB.13.6.3660	38	49	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					38067	38072		10.1074/jbc.M002010200	http://dx.doi.org/10.1074/jbc.M002010200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	10973950	hybrid			2022-12-25	WOS:000165618700101
J	Giannoukakis, N; Rudert, WA; Trucco, M; Robbins, PD				Giannoukakis, N; Rudert, WA; Trucco, M; Robbins, PD			Protection of human islets from the effects of interleukin-1 beta by adenoviral gene transfer of an I kappa B repressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE PRODUCTION; NECROSIS-FACTOR-ALPHA; DEPENDENT DIABETES-MELLITUS; RECEPTOR ANTAGONIST PROTEIN; BETA-CELL DESTRUCTION; PANCREATIC-ISLETS; INSULIN-SECRETION; DEATH PATHWAYS; NOD MICE; EXPRESSION	Interleukin-1 beta (IL-1 beta) is a pro-inflammatory cytokine that inhibits beta cell function and promotes Fas-triggered apoptosis. IL-IP is thought to act early in the initiation of the autoimmune destruction of pancreatic beta cells in type I diabetes. IL-1 beta promotes beta cell impairment, in part, by activating NF-KB transcription factor-dependent signaling pathways. We have examined whether beta cells could be protected from the effects of IL-1 beta by overexpressing an inhibitor of NF-kappaB activity, I kappaB alpha by adenoviral gene transfer to intact human islets in culture. Infection of islets with an adenoviral vector encoding a non-phosphorylatable, non-degradable variant of I kappaB alpha resulted in normal insulin responses to glucose in the presence of IL-1 beta. Furthermore, nitric oxide production was prevented and, more importantly, Fas-triggered apoptosis was inhibited following I kappaB alpha gene transfer. These results suggest that blocking the NF-KB pathway might prevent cytokine-induced beta cell impairment as a means of facilitating islet transplantation.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Robbins, PD (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, W1246 BST, Pittsburgh, PA 15261 USA.							Arnush M, 1998, J IMMUNOL, V160, P2684; Arnush M, 1998, J CLIN INVEST, V102, P516, DOI 10.1172/JCI844; BACH JF, 1994, ENDOCR REV, V15, P516, DOI 10.1210/er.15.4.516; Beckman JS, 1997, AM J RESP CELL MOL, V16, P495, DOI 10.1165/ajrcmb.16.5.9160830; Burcin MM, 1999, P NATL ACAD SCI USA, V96, P355, DOI 10.1073/pnas.96.2.355; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; Clesham GJ, 1998, GENE THER, V5, P174, DOI 10.1038/sj.gt.3300576; CORBETT JA, 1993, AUTOIMMUNITY, V15, P145, DOI 10.3109/08916939309043889; CORBETT JA, 1993, P NATL ACAD SCI USA, V90, P1731, DOI 10.1073/pnas.90.5.1731; CORBETT JA, 1992, J CLIN INVEST, V90, P2384, DOI 10.1172/JCI116129; CSETE ME, 1994, TRANSPLANT P, V26, P756; CSETE ME, 1995, TRANSPLANTATION, V59, P263, DOI 10.1097/00007890-199501270-00019; Darville MI, 1998, DIABETOLOGIA, V41, P1101, DOI 10.1007/s001250051036; De Vera ME, 1997, AM J PHYSIOL-GASTR L, V273, pG1290, DOI 10.1152/ajpgi.1997.273.6.G1290; DECRAEN MV, 1999, CELL DEATH DIFFER, V6, P1117; EIZIRIK DL, 1991, DIABETOLOGIA, V34, P445, DOI 10.1007/BF00403185; EIZIRIK DL, 1994, J CLIN INVEST, V93, P1968, DOI 10.1172/JCI117188; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Flodstrom M, 1997, ENDOCRINOLOGY, V138, P2747, DOI 10.1210/en.138.7.2747; Foo SY, 1999, TRENDS GENET, V15, P229; Foxwell B, 1998, P NATL ACAD SCI USA, V95, P8211, DOI 10.1073/pnas.95.14.8211; Freundlieb S, 1999, J GENE MED, V1, P4, DOI 10.1002/(SICI)1521-2254(199901/02)1:1<4::AID-JGM4>3.0.CO;2-Y; Freundlieb S, 1997, METHOD ENZYMOL, V283, P159; Giannoukakis N, 1999, DIABETES, V48, P1730, DOI 10.2337/diabetes.48.9.1730; Giannoukakis N, 1999, GENE THER, V6, P1545, DOI 10.1038/sj.gt.3300996; Haddad IY, 1997, AM J RESP CELL MOL, V16, P501, DOI 10.1165/ajrcmb.16.5.9160832; HANENBERG H, 1989, DIABETOLOGIA, V32, P126, DOI 10.1007/BF00505185; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Hellerbrand C, 1998, AM J PHYSIOL-GASTR L, V275, pG269, DOI 10.1152/ajpgi.1998.275.2.G269; Hostens K, 1999, J CLIN INVEST, V104, P67, DOI 10.1172/JCI6438; Hsu SC, 1999, EUR J IMMUNOL, V29, P2948, DOI 10.1002/(SICI)1521-4141(199909)29:09<2948::AID-IMMU2948>3.0.CO;2-0; Jobin C, 1998, J IMMUNOL, V160, P410; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; KASUGA A, 1993, DIABETOLOGIA, V36, P1252, DOI 10.1007/BF00400802; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; LACY PE, 1991, AM J PATHOL, V138, P1183; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Linetsky E, 1997, DIABETES, V46, P1120, DOI 10.2337/diabetes.46.7.1120; McDaniel ML, 1996, P SOC EXP BIOL MED, V211, P24; McIlroy D, 1999, ONCOGENE, V18, P4401, DOI 10.1038/sj.onc.1202868; Mittereder N, 1996, J VIROL, V70, P7498, DOI 10.1128/JVI.70.11.7498-7509.1996; Oligino T, 1998, GENE THER, V5, P491, DOI 10.1038/sj.gt.3300612; Ouaaz F, 1999, J EXP MED, V189, P999, DOI 10.1084/jem.189.6.999; RABINOVITCH A, 1994, J CLIN ENDOCR METAB, V79, P1058, DOI 10.1210/jc.79.4.1058; Rabinovitch A, 1998, BIOCHEM PHARMACOL, V55, P1139, DOI 10.1016/S0006-2952(97)00492-9; REDDY S, 1993, PANCREAS, V8, P602, DOI 10.1097/00006676-199309000-00012; Reddy S, 1997, HISTOCHEM J, V29, P53, DOI 10.1023/A:1026416918339; Renard P, 1999, CELL BIOL TOXICOL, V15, P341, DOI 10.1023/A:1007652414175; Renard P, 1997, BIOCHEM PHARMACOL, V53, P149, DOI 10.1016/S0006-2952(96)00645-4; Roebuck KA, 1999, J LEUKOCYTE BIOL, V66, P876, DOI 10.1002/jlb.66.6.876; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Sorli CH, 1998, P NATL ACAD SCI USA, V95, P1788, DOI 10.1073/pnas.95.4.1788; SOUTHERN C, 1990, FEBS LETT, V276, P42, DOI 10.1016/0014-5793(90)80502-A; Stephens LA, 1999, ENDOCRINOLOGY, V140, P3219, DOI 10.1210/en.140.7.3219; SuarezPinzon WL, 1997, DIABETES, V46, P907, DOI 10.2337/diabetes.46.5.907; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Weber M, 1997, J SURG RES, V69, P23, DOI 10.1006/jsre.1997.4995; WELSH N, 1991, ENDOCRINOLOGY, V129, P3167, DOI 10.1210/endo-129-6-3167; Wolf BB, 1999, J BIOL CHEM, V274, P30651, DOI 10.1074/jbc.274.43.30651; Yamada K, 1996, DIABETOLOGIA, V39, P1306, DOI 10.1007/s001250050574	62	186	192	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36509	36513		10.1074/jbc.M005943200	http://dx.doi.org/10.1074/jbc.M005943200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10967112	hybrid			2022-12-25	WOS:000165577700009
J	Kast, P; Grisostomi, C; Chen, IA; Li, SL; Krengel, U; Xue, YF; Hilvert, D				Kast, P; Grisostomi, C; Chen, IA; Li, SL; Krengel, U; Xue, YF; Hilvert, D			A strategically positioned cation is crucial for efficient catalysis by chorismate mutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE ANALOG; SITE-DIRECTED MUTAGENESIS; ELECTRON-DENSITY MAPS; BACILLUS-SUBTILIS; CLAISEN REARRANGEMENT; ACTIVE-SITE; CRYSTAL-STRUCTURES; ENZYME; PREPHENATE; MECHANISM	Combinatorial mutagenesis and in vivo selection experiments previously afforded functional variants of the AroH class Bacillus subtilis chorismate mutase lacking the otherwise highly conserved active site residue Arg(90). Here, we present a detailed kinetic and crystallographic study of several such variants. Removing the arginine side chain (R90G and R90A) reduced catalytic efficiency by more than 5 orders of magnitude. Reintroducing a positive charge to the active site through lysine substitutions restored more than a factor of a thousand in k(cat) Remarkably, the lysine could be placed at position 90 or at the more remote position 88 provided a sterically suitable residue was present at the partner site. Crystal structures of the double mutants C88S/R90K and C88K/R90S show that the lysine adopts an extended conformation that would place its E-ammonium group within hydrogen-bonding distance of the ether oxygen of bound chorismate in the transition state. These results provide support for the hypothesis that developing negative charge in the highly polarized transition state is stabilized electrostatically by a strategically placed cation. The implications of this finding for the mechanism of all natural chorismate mutases and for the design of artificial catalysts are discussed.	ETH Zurich, Swiss Fed Inst Technol, Organ Chem Lab, CH-8092 Zurich, Switzerland; Scripps Res Inst, Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Univ Gothenburg, Dept Biochem & Biophys, SE-90530 Gothenburg, Sweden; Univ Gothenburg, Dept Mol Biotechnol, SE-90530 Gothenburg, Sweden; Chalmers Univ Technol, SE-90530 Gothenburg, Sweden	Swiss Federal Institutes of Technology Domain; ETH Zurich; Scripps Research Institute; Scripps Research Institute; University of Gothenburg; University of Gothenburg; Chalmers University of Technology	Hilvert, D (corresponding author), ETH Zurich, Swiss Fed Inst Technol, Organ Chem Lab, Univ Str 16, CH-8092 Zurich, Switzerland.			Chen, Irene/0000-0001-6040-7927; Xue, Yafeng/0000-0002-7526-8672; Krengel, Ute/0000-0001-6688-8151	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038273, R29GM038273] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38273] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDADI L, 1983, BIOCHEMISTRY-US, V22, P4494, DOI 10.1021/bi00288a022; ANDREWS PR, 1973, BIOCHEMISTRY-US, V12, P3492, DOI 10.1021/bi00742a022; BARTLETT PA, 1985, J AM CHEM SOC, V107, P7792, DOI 10.1021/ja00311a111; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1993, XPLOR SYSTEM CRYSTAL; CHOOK YM, 1993, P NATL ACAD SCI USA, V90, P8600, DOI 10.1073/pnas.90.18.8600; CHOOK YM, 1994, J MOL BIOL, V240, P476, DOI 10.1006/jmbi.1994.1462; CHRISTIANSON DW, 1989, ACCOUNTS CHEM RES, V22, P62, DOI 10.1021/ar00158a003; Cload ST, 1996, J AM CHEM SOC, V118, P1787, DOI 10.1021/ja953152g; COPLEY SD, 1985, J AM CHEM SOC, V107, P5306, DOI 10.1021/ja00304a064; DAVIDSON MM, 1996, J CHEM SOC P1, V2, P525; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Fersht A, 1985, ENZYME STRUCTURE MEC, V2, P107; GAJEWSKI JJ, 1987, J AM CHEM SOC, V109, P1170, DOI 10.1021/ja00238a029; Galopin CC, 1996, TETRAHEDRON LETT, V37, P8675, DOI 10.1016/S0040-4039(96)02007-2; Ganem B., 1996, ANGEW CHEM INT EDIT, V35, P936, DOI [10.1002/anie.19960936, DOI 10.1002/ANIE.199609361]; GORISCH H, 1978, BIOCHEMISTRY-US, V17, P3700, DOI 10.1021/bi00611a004; GRAY JV, 1990, BIOCHEMISTRY-US, V29, P8872, DOI 10.1021/bi00489a051; Grisostomi C, 1997, BIOORG CHEM, V25, P297, DOI 10.1006/bioo.1997.1073; Gu W, 1997, Microb Comp Genomics, V2, P141, DOI 10.1089/omi.1.1997.2.141; Gustin DJ, 1999, J AM CHEM SOC, V121, P1756, DOI 10.1021/ja9841759; Haslam E., 1993, SHIKIMIC ACID METABO; HAYNES MR, 1994, SCIENCE, V263, P646, DOI 10.1126/science.8303271; HILVERT D, 1988, P NATL ACAD SCI USA, V85, P4953, DOI 10.1073/pnas.85.14.4953; HILVERT D, 1988, J AM CHEM SOC, V110, P5593, DOI 10.1021/ja00224a066; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kast P, 1996, TETRAHEDRON LETT, V37, P2691, DOI 10.1016/0040-4039(96)00338-3; Kast P, 1996, J AM CHEM SOC, V118, P3069, DOI 10.1021/ja953701i; Kast P, 1996, P NATL ACAD SCI USA, V93, P5043, DOI 10.1073/pnas.93.10.5043; Kast P, 1997, J PHYS CHEM B, V101, P10976, DOI 10.1021/jp972501l; Khanjin NA, 1999, J AM CHEM SOC, V121, P11831, DOI 10.1021/ja992453d; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE AY, 1995, CHEM BIOL, V2, P195, DOI 10.1016/1074-5521(95)90269-4; LEE AY, 1995, J AM CHEM SOC, V117, P3627, DOI 10.1021/ja00117a038; Liu DR, 1996, J AM CHEM SOC, V118, P1789, DOI 10.1021/ja953151o; LYNE PD, 1995, J AM CHEM SOC, V117, P11345, DOI 10.1021/ja00150a037; MacBeath G, 1998, BIOTECHNIQUES, V24, P789, DOI 10.2144/98245st02; MacBeath G, 1998, BIOCHEMISTRY-US, V37, P10062, DOI 10.1021/bi980449t; Mattei P, 1999, EUR J BIOCHEM, V261, P25, DOI 10.1046/j.1432-1327.1999.00169.x; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Miller J.H., 1992, SHORT COURSE BACTERI, P150; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OTWINOWSKI Z, 1993, DENZO OSCILLATION DA; PHILLIPS MA, 1990, J BIOL CHEM, V265, P20692; RADZICKA A, 1995, SCIENCE, V267, P90, DOI 10.1126/science.7809611; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5467; SCHIMMEL P, 1989, ACCOUNTS CHEM RES, V22, P232, DOI 10.1021/ar00163a001; SMITH WW, 1993, J ORG CHEM, V58, P7308, DOI 10.1021/jo00077a070; Strater N, 1997, STRUCTURE, V5, P1437, DOI 10.1016/S0969-2126(97)00294-3; TANG Y, 1991, P NATL ACAD SCI USA, V88, P8784, DOI 10.1073/pnas.88.19.8784; WIEST O, 1995, J AM CHEM SOC, V117, P11628, DOI 10.1021/ja00152a002; XUE YF, 1995, P NATL ACAD SCI USA, V92, P10595, DOI 10.1073/pnas.92.23.10595; XUE YF, 1994, P NATL ACAD SCI USA, V91, P10814, DOI 10.1073/pnas.91.23.10814; Zhang S, 1996, BIOORGAN MED CHEM, V4, P1015, DOI 10.1016/0968-0896(96)00099-5	57	58	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36832	36838		10.1074/jbc.M006351200	http://dx.doi.org/10.1074/jbc.M006351200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	10960481	hybrid			2022-12-25	WOS:000165577700056
J	Imai, Y; Soda, M; Takahashi, R				Imai, Y; Soda, M; Takahashi, R			Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECESSIVE JUVENILE PARKINSONISM; C-CBL; RING; APOPTOSIS; UBCH7	Autosomal recessive juvenile parkinsonism (AR-JP) is caused by mutations in the parkin gene. Parkin protein is characterized by a ubiquitin-like domain at its NH,terminus and two RING finger motifs and an IBR (in between RING: fingers) at its COOH terminus (RING-IBR-RING). Here, we show that Parkin is a RING-type E3 ubiquitin-protein ligase which binds to E2 ubiquitin-conjugating enzymes, including UbcH7 and UbcH8, through its RING-IBR-RING motif, Moreover, we found that unfolded protein stress induces up-regulation of both the mRNA and protein level of Parkin, Furthermore, overexpression of Parkin, but not a set of mutants without the E3 activity, specifically suppressed unfolded protein stress-induced cell death. These findings demonstrate that Parkin is an E3 enzyme and suggest that it is involved in the ubiquitination pathway for misfolded proteins derived from endoplasmic reticulum and contributes to protection from neurotoxicity induced by unfolded protein stresses.	RIKEN, BSI, Lab Motor Syst Neurodegenerat, Wako, Saitama 3510198, Japan	RIKEN	Takahashi, R (corresponding author), RIKEN, BSI, Lab Motor Syst Neurodegenerat, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.		Imai, Yuzuru/AAA-6472-2019	Imai, Yuzuru/0000-0003-2924-5231				ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Dawson TM, 2000, CELL, V101, P115, DOI 10.1016/S0092-8674(00)80629-7; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Moynihan TP, 1999, J BIOL CHEM, V274, P30963, DOI 10.1074/jbc.274.43.30963; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Niwa M, 1999, CELL, V99, P691, DOI 10.1016/S0092-8674(00)81667-0; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 1999, ANN NEUROL, V45, P668, DOI 10.1002/1531-8249(199905)45:5<668::AID-ANA19>3.0.CO;2-Z; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Tyers M, 1999, SCIENCE, V284, P601, DOI 10.1126/science.284.5414.601; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; YAMAMURA Y, 1973, NEUROLOGY, V23, P239, DOI 10.1212/WNL.23.3.239; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707	24	618	636	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35661	35664		10.1074/jbc.C000447200	http://dx.doi.org/10.1074/jbc.C000447200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10973942	hybrid			2022-12-25	WOS:000165382000002
J	Kato-Yamada, Y; Yoshida, M; Hisabori, T				Kato-Yamada, Y; Yoshida, M; Hisabori, T			Movement of the helical domain of the epsilon subunit is required for the activation of thermophilic F-1-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ATP SYNTHASE; ALPHA(3)BETA(3)GAMMA COMPLEX; ENDOGENOUS INHIBITOR; GAMMA-SUBUNIT; BETA-SUBUNITS; CROSS-LINKING; H+-ATPASE; IN-SITU; ROTATION	The inhibitory effect of epsilon subunit in F-1-ATPase from thermophilic Bacillus PS3 was examined focusing on the structure-function relationship. For this purpose, we designed: a mutant for epsilon subunit similar to the one constructed by Schulenberg and Capaldi (Schulenberg, B,, and Capaldi, R, A. (1999) J, Biol, Chem. 274, 28351-28355), We introduced two cysteine residues at the interface of N-terminal beta -sandwich domain (S48C) and C-terminal cu-helical domain (N125C) of epsilon subunit, The alpha (3)beta (3)gamma epsilon complex containing the reduced form of this mutant epsilon subunit showed suppressed ATPase activity and gradual activation during the measurement. This activation pattern was similar to the complex with the wild type epsilon subunit, The conformation of the mutant epsilon subunit must be fixed and similar to the reported three-dimensional structure of the isolated epsilon subunit, when the intramolecular disulfide bridge was formed on this subunit by oxidation. This oxidized mutant epsilon subunit could form the alpha (3)beta (3)gamma epsilon complex but did not show any inhibitory effect. The complex was converted to the activated state, and the cross-link in the mutant epsilon subunit in the complex was efficiently formed in the presence of ATP-Mg, whereas no cross-link was observed without ATP-Mg, suggesting the conformation of the oxidized mutant epsilon subunit must be similar to that in the activated state complex. A non-hydrolyzable analog of ATP, 5'-adenylyl-beta,gamma -imidodiphosphate, could stimulate the formation of the cross-link on the epsilon subunit, Furthermore, the cross-link formation was stimulated by nucleotides even when this mutant epsilon subunit was assembled with a mutant alpha (3)beta (3)gamma complex lacking non-catalytic sites. These results indicate that binding of ATP to the catalytic sites induces a conformational change in the epsilon subunit and triggers transition of the complex from the suppressed state to the activated state.	Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268503, Japan	Tokyo Institute of Technology	Hisabori, T (corresponding author), Tokyo Inst Technol, Chem Resources Lab, R-1,4259 Nagatsuta, Yokohama, Kanagawa 2268503, Japan.	thisabor@res.titech.ac.jp	Hisabori, Toru/E-5205-2014	Hisabori, Toru/0000-0003-2046-0277				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aggeler R, 1997, J BIOL CHEM, V272, P19621, DOI 10.1074/jbc.272.31.19621; Aggeler R, 1996, J BIOL CHEM, V271, P13888, DOI 10.1074/jbc.271.23.13888; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bulygin VV, 1998, J BIOL CHEM, V273, P31765, DOI 10.1074/jbc.273.48.31765; Capaldi RA, 2000, BBA-BIOENERGETICS, V1458, P263, DOI 10.1016/S0005-2728(00)00078-5; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; HASHIMOTO T, 1990, J BIOENERG BIOMEMBR, V22, P27, DOI 10.1007/BF00762843; HASHIMOTO T, 1996, SEIKAGAKU, V68, P775; Hisabori T, 1999, FEBS LETT, V463, P35, DOI 10.1016/S0014-5793(99)01602-6; Hisabori T, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P1711; Hisabori T, 1997, EUR J BIOCHEM, V247, P1158, DOI 10.1111/j.1432-1033.1997.01158.x; Jones PC, 2000, J BIOL CHEM, V275, P31340, DOI 10.1074/jbc.M003687200; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Kaibara C, 1996, J BIOL CHEM, V271, P2433, DOI 10.1074/jbc.271.5.2433; Kato Y, 1997, J BIOL CHEM, V272, P24906, DOI 10.1074/jbc.272.40.24906; Kato-Yamada Y, 1999, J BIOL CHEM, V274, P33991, DOI 10.1074/jbc.274.48.33991; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; KUKI M, 1988, J BIOL CHEM, V263, P17437; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGET PP, 1979, ARCH BIOCHEM BIOPHYS, V197, P83, DOI 10.1016/0003-9861(79)90222-4; MATSUI T, 1995, BBA-BIOENERGETICS, V1231, P139, DOI 10.1016/0005-2728(95)00070-Y; Matsui T, 1997, J BIOL CHEM, V272, P8215, DOI 10.1074/jbc.272.13.8215; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; ORT DR, 1992, ANNU REV PLANT PHYS, V43, P269, DOI 10.1146/annurev.pp.43.060192.001413; PULLMAN ME, 1963, J BIOL CHEM, V238, P3762; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Schulenberg B, 1999, J BIOL CHEM, V274, P28351, DOI 10.1074/jbc.274.40.28351; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; STERNWEIS PC, 1980, BIOCHEMISTRY-US, V19, P526, DOI 10.1021/bi00544a021; Stiggall D L, 1979, Methods Enzymol, V55, P308; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Tang CL, 1996, J BIOL CHEM, V271, P3018, DOI 10.1074/jbc.271.6.3018; Tsunoda SP, 2000, FEBS LETT, V470, P244, DOI 10.1016/S0014-5793(00)01336-3; Uhlin U, 1997, STRUCTURE, V5, P1219, DOI 10.1016/S0969-2126(97)00272-4; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; Wilkens S, 1998, J BIOL CHEM, V273, P26645, DOI 10.1074/jbc.273.41.26645; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; YOKOYAMA K, 1989, J BIOL CHEM, V264, P21837	46	43	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	2000	275	46					35746	35750		10.1074/jbc.M006575200	http://dx.doi.org/10.1074/jbc.M006575200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375CM	10958801	hybrid			2022-12-25	WOS:000165382000017
J	Ohira, M; Kageyama, H; Mihara, M; Furuta, S; Machida, T; Shishikura, T; Takayasu, H; Islam, A; Nakamura, Y; Takahashi, M; Tomioka, N; Sakiyama, S; Kaneko, Y; Toyoda, A; Hattori, M; Sakaki, Y; Ohki, M; Horii, A; Soeda, E; Inazawa, J; Seki, N; Kuma, H; Nozawa, I; Nakagawara, A				Ohira, M; Kageyama, H; Mihara, M; Furuta, S; Machida, T; Shishikura, T; Takayasu, H; Islam, A; Nakamura, Y; Takahashi, M; Tomioka, N; Sakiyama, S; Kaneko, Y; Toyoda, A; Hattori, M; Sakaki, Y; Ohki, M; Horii, A; Soeda, E; Inazawa, J; Seki, N; Kuma, H; Nozawa, I; Nakagawara, A			Identification and characterization of a 500-kb homozygously deleted region at 1p36.2-p36.3 in a neuroblastoma cell line	ONCOGENE			English	Article						neuroblastoma; homozygous deletion; 1p36; tumor suppressor gene	MESSENGER-RNA EXPRESSION; TUMOR-SUPPRESSOR GENES; CHROMOSOME 1P36.3; ALLELIC LOSS; N-MYC; DNA; APOPTOSIS; PROTEIN; CANCER; UBIQUITINATION	Loss of heterozygosity of the distal region of chromosome Ip where tumor suppressor gene(s) might harbor is frequently observed in many human cancers including neuroblastoma (NBL) with MYCN amplification and poor prognosis. We have identified for the first time a homozygously deleted region at the marker D1S244 within the smallest region of overlap at 1p36.2-p36.3 in two NBL cell lines, NB-1 and NB-C201 (MASS-NB-SCH1), although our genotyping has suggested the possibility that both lines are derived from the same origin. The 800-kb PAC contig covering the entire region of homozygous deletion was made and partially sequenced (about 60%). The estimated length of the deleted region was 500 kb. We have, thus far, identified sis genes within the region which include three known genes (DFF45, PGD, and CORT) as well as three other genes which have been reported during processing our present project for the last 31/2 years (HDNB1/UFD2, KIAA0591F/KIF1B-beta, and PEX14). They include the genes related to apoptosis, glucose metabolism, ubiquitin-proteasome pathway, a neuronal microtubule-associated motor molecule and biogenesis of peroxisome. At least three genes (HDNB1/UFD2, KIAA0591F/KIF1B-beta, and PEX14) were differentially expressed at high levels in favorable and at low levels in unfavorable subsets of primary neuroblastoma. Since the Ip distal region is reported to be imprinted, those differentially expressed genes could be the new members of the candidate NBL suppressor, although RT-PCR-SSCP analysis has demonstrated infrequent mutation of the genes so far identified. Full-sequencing and gene prediction for the region of homozygous deletion would elucidate more detailed structure of this region and might lead to discovery of additional candidate genes.	Chiba Canc Ctr, Res Inst, Div Biochem, Chiba 2608717, Japan; Saitama Canc Ctr Hosp, Dept Canc Chemotherapy, Ina, Saitama 3620806, Japan; RIKEN, Gen Sci Ctr, Sagamihara, Kanagawa 2288555, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, Tokyo 1088639, Japan; Natl Canc Ctr, Res Inst, Canc Gen Div, Chuoh Ku, Tokyo 1040045, Japan; Tohoku Univ, Sch Med, Dept Mol Pathol, Sendai, Miyagi 9808575, Japan; RIKEN Gene Bank, Tsukuba, Ibaraki 3050074, Japan; Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Div Genet,Bunkyo Ku, Tokyo 1138519, Japan; Helix Res Inst Inc, Biol Technol Lab, Chiba 2920812, Japan; Hisamitsu Pharmaceut Co Inc, Tsukuba Res Labs, Cent Res Ctr, New Technol Dev Dept, Tsukuba, Ibaraki 3050856, Japan	Chiba Cancer Center; RIKEN; University of Tokyo; National Cancer Center - Japan; Tohoku University; RIKEN; Tokyo Medical & Dental University (TMDU); Eisai Co Ltd; Hisamitsu Pharmaceutical Co Ltd	Nakagawara, A (corresponding author), Chiba Canc Ctr, Res Inst, Div Biochem, 666-2 Nitona, Chiba 2608717, Japan.		Horii, Akira/AAW-2839-2021; Hattori, Masahira/C-6958-2016; Hattori, Masahira/AAD-3785-2019	Horii, Akira/0000-0002-3967-3291; Hattori, Masahira/0000-0001-9467-0344; 				AMLER LC, 1995, ONCOGENE, V10, P1095; BOLANDE RP, 1974, HUM PATHOL, V5, P409, DOI 10.1016/S0046-8177(74)80021-3; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Carling T, 1999, INT J CANCER, V83, P80, DOI 10.1002/(SICI)1097-0215(19990924)83:1<80::AID-IJC15>3.0.CO;2-E; CARON H, 1995, MED PEDIATR ONCOL, V24, P215, DOI 10.1002/mpo.2950240402; CARON H, 1993, NAT GENET, V4, P187, DOI 10.1038/ng0693-187; CHEN FS, 1995, MICROW OPT TECHN LET, V10, P297, DOI 10.1002/mop.4650100512; deLecea L, 1997, GENOMICS, V42, P499, DOI 10.1006/geno.1997.4763; Diccianni MB, 1996, CANCER LETT, V104, P183, DOI 10.1016/0304-3835(96)04250-4; DRACOPOLI N C, 1988, Genomics, V3, P124, DOI 10.1016/0888-7543(88)90142-5; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; ENOMOTO H, 1994, ONCOGENE, V9, P2785; Fukusumi S, 1997, BIOCHEM BIOPH RES CO, V232, P157, DOI 10.1006/bbrc.1997.6252; Hattori M, 1997, NUCLEIC ACIDS RES, V25, P1802, DOI 10.1093/nar/25.9.1802; He LS, 1998, CANCER RES, V58, P4238; Hiraiwa H, 1997, CANCER, V79, P2036, DOI 10.1002/(SICI)1097-0142(19970515)79:10<2036::AID-CNCR27>3.3.CO;2-M; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; IMASHUKU S, 1973, J CLIN ENDOCR METAB, V36, P931, DOI 10.1210/jcem-36-5-931; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; LAHTI JM, 1994, NAT GENET, V7, P370, DOI 10.1038/ng0794-370; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MARTINSSON T, 1995, CANCER RES, V55, P5681; Martinsson T, 1997, CANCER GENET CYTOGEN, V95, P183, DOI 10.1016/S0165-4608(96)00259-2; Nagai M, 2000, INT J ONCOL, V16, P907; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; Pukatzki S, 1998, J BIOL CHEM, V273, P24131, DOI 10.1074/jbc.273.37.24131; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0; Sunahara M, 1998, INT J ONCOL, V13, P319; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; Takemura R, 1996, J NEUROSCI, V16, P31; THE I, 1993, NAT GENET, V3, P62, DOI 10.1038/ng0193-62; Tsui SKW, 1996, BIOCHEM GENET, V34, P367, DOI 10.1007/BF00554412; WHITE PS, 1993, GENE CHROMOSOME CANC, V7, P102, DOI 10.1002/gcc.2870070207; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520; Will GK, 1999, MOL CELL BIOL, V19, P2265; Wise CA, 1997, GENOME RES, V7, P10, DOI 10.1101/gr.7.1.10	43	71	77	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 31	2000	19	37					4302	4307		10.1038/sj.onc.1203786	http://dx.doi.org/10.1038/sj.onc.1203786			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980605				2022-12-25	WOS:000089032900014
J	Iglesias, M; Frontelo, P; Gamallo, C; Quintanilla, M				Iglesias, M; Frontelo, P; Gamallo, C; Quintanilla, M			Blockade of Smad4 in transformed keratinocytes containing a Ras oncogene leads to hyperactivation of the Ras-dependent Erk signalling pathway associated with progression to undifferentiated carcinomas	ONCOGENE			English	Article						TGF-beta(1); Smad4; Ras; Erk; urokinase; carcinoma	GROWTH-FACTOR-BETA; PROTEIN-KINASE KINASE; CELL-CYCLE ARREST; TGF-BETA; EPITHELIAL-CELLS; UROKINASE EXPRESSION; P21(WAF1) EXPRESSION; COLORECTAL CANCERS; INVASIVE PHENOTYPE; SIGNALING PATHWAY	Smad4 functions as a transcription factor in TGF-beta signalling. We have investigated the role of Smad4 in the TGF-beta(1) cell responses of transformed PDV keratinocytes, which contain a Ras oncogene, and of non-tumorigenic MCA3D keratinocytes, by transfecting both cell lines with a dominant-negative Smad4 construct. Smad4 mediates TGF-beta(1)-induced up-regulation of p21(Cip1) and growth arrest in MCA3D cells, However, in PDV keratinocytes, Smad4 is only partially involved in TGF-beta(1)-induced growth inhibition, and does not mediate enhancement of p21(Cip1) levels by the growth factor. TGF-beta(1) activates Ras/Erk signalling activity in both cell lines, PD098059, a specific inhibitor of MEK, disminishes TGF-beta(1)-induced p21(Cip1) levels in PDV but not in MCA3D cells, suggesting an involvement of Erk in upregulation of p21(Cip1) by TGF-beta(1) in PDV cells, PDV dominant-negative Smad4 cell transfectants, but not MCA3D transfectants, showed constitutive hyperactivation of the Ras/Erk signalling pathway, increased secretion of urokinase, higher motility properties, and a change to a fibroblastoid cell morphology associated in vivo with the transition from a well differentiated to a poorly differentiated tumour phenotype. infection of MCA3D control and dominant negative Smad4 cell transfectants with retroviruses carrying a Ras oncogene led to enhanced p21(Cip1) and urokinase secreted levels, independently of TGF-beta(1) stimulation, that were reduced by PD098059, These results suggest that Smad4 acts inhibiting Ras-dependent Erk signalling activity in Ras-transformed keratinocytes. Loss of Smad4 function in these cells results in hyperactivation of Erk signalling and progression to undifferentiated carcinomas.	UAM, CSIC, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain; UAM, Fac Med, Dept Anat Patol, Hosp Princesa, Madrid 28029, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; Hospital de La Princesa	Quintanilla, M (corresponding author), UAM, CSIC, Inst Invest Biomed Alberto Sols, Arturo Duperier 4, Madrid 28029, Spain.		Quintanilla, Miguel/K-9293-2017	Quintanilla, Miguel/0000-0002-2124-7657				Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; Akhurst RJ, 1999, J PATHOL, V187, P82, DOI 10.1002/(SICI)1096-9896(199901)187:1<82::AID-PATH248>3.0.CO;2-8; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BURMER GC, 1990, GASTROENTEROLOGY, V99, P416, DOI 10.1016/0016-5085(90)91024-Z; BURNS PA, 1991, ONCOGENE, V6, P2363; CAULIN C, 1995, CELL GROWTH DIFFER, V6, P1027; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; deWinter JP, 1997, ONCOGENE, V14, P1891, DOI 10.1038/sj.onc.1201017; Farina AR, 1998, INT J CANCER, V75, P721; Frontelo P, 1998, EXP CELL RES, V244, P420, DOI 10.1006/excr.1998.4219; Grau AM, 1997, CANCER RES, V57, P3929; HADDOW S, 1991, ONCOGENE, V6, P1465; Hahn SA, 1998, DIGESTION, V59, P493, DOI 10.1159/000007526; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hartsough MT, 1996, J BIOL CHEM, V271, P22368, DOI 10.1074/jbc.271.37.22368; Hartsough MT, 1997, PHARMACOL THERAPEUT, V75, P21, DOI 10.1016/S0163-7258(97)00020-X; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Hunt KK, 1998, CANCER RES, V58, P5656; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LAIHO M, 1992, Critical Reviews in Oncogenesis, V3, P1; Lloyd AC, 1998, CURR OPIN GENET DEV, V8, P43, DOI 10.1016/S0959-437X(98)80060-9; MacGrogan D, 1997, ONCOGENE, V15, P1111, DOI 10.1038/sj.onc.1201232; Malliri A, 1996, CELL GROWTH DIFFER, V7, P1291; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Min HY, 1996, CANCER RES, V56, P2428; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P3489, DOI 10.1073/pnas.88.8.3489; Montesano R, 1999, CELL GROWTH DIFFER, V10, P317; Mucsi I, 1996, J BIOL CHEM, V271, P16567, DOI 10.1074/jbc.271.28.16567; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Portella G, 1998, CELL GROWTH DIFFER, V9, P393; QUINTANILLA M, 1991, CARCINOGENESIS, V12, P1875, DOI 10.1093/carcin/12.10.1875; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Rozenblum E, 1997, CANCER RES, V57, P1731; Santibanez JF, 1999, J CELL BIOCHEM, V74, P61, DOI 10.1002/(SICI)1097-4644(19990701)74:1<61::AID-JCB7>3.3.CO;2-2; Santibanez JF, 2000, BIOCHEM BIOPH RES CO, V273, P521, DOI 10.1006/bbrc.2000.2946; Schwarte-Waldhoff I, 1999, ONCOGENE, V18, P3152, DOI 10.1038/sj.onc.1202641; Simon C, 1996, CANCER RES, V56, P5369; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Yue JB, 1998, ONCOGENE, V17, P47, DOI 10.1038/sj.onc.1201903; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2	53	63	68	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2000	19	36					4134	4145		10.1038/sj.onc.1203764	http://dx.doi.org/10.1038/sj.onc.1203764			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962574	Green Submitted			2022-12-25	WOS:000088955100007
